{"title": "PDF", "author": "PDF", "url": "https://www.socium.uni-bremen.de/uploads/News/2019/190930_Innovationsreport_2019_Kurzfassung.pdf", "hostname": "PDF", "description": "PDF", "sitename": "PDF", "date": "PDF", "id": "PDF", "license": "PDF", "body": "PDF", "comments": "PDF", "commentsbody": "PDF", "raw_text": "PDF", "text": "\u00a0\n\u00a0\u00a0\n\u00a0\nInnovationsreport\u00a02019 \u00a0\n\u00a0\n\u00a0\nAuswertungsergebnisse\u00a0von\u00a0Routinedaten\u00a0der\u00a0\nTechniker\u00a0Krankenkasse\u00a0aus\u00a0den\u00a0Jahren\u00a02016\u00a0bis\u00a02017\u00a0\n\u00a0\nHerausgeber:\u00a0Gerd\u00a0Glaeske\u00a0und\u00a0Wolf\u2010Dieter\u00a0Ludwig\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\nErstellt\u00a0mit\u00a0freundliche r\u00a0Unterst\u00fctzung\u00a0der\u00a0\u00a0\nTechniker\u00a0Krankenkasse\u00a0(TK)\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n \u00a0\n2\u00a0\u00a0\n\u00a03\u00a0\u00a0\nHerausgeber\u00a0\u00a0\nProf.\u00a0Dr.\u00a0Gerd\u00a0Glaeske\u00a0\u00a0\nProf.\u00a0Dr.\u00a0Wolf\u2010Dieter\u00a0Ludwig \u00a0\n\u00a0\n\u00a0\nExperten\u00a0f\u00fcr\u00a0ausgew\u00e4hlte\u00a0Kapitel\u00a0\u00a0\nProf.\u00a0Dr.\u00a0med.\u00a0Manfred\u00a0Anlauf,\u00a0Bremerhaven\u00a0\nProf.\u00a0Dr.\u00a0med.\u00a0Peter\u00a0Berlit,\u00a0Berlin\u00a0\nProf.\u00a0Dr.\u00a0med.\u00a0Winfried\u00a0V.\u00a0Kern,\u00a0Freiburg\u00a0\nProf.\u00a0Dr.\u00a0med.\u00a0Joachim\u00a0Labenz,\u00a0Siegen\u00a0\nProf.\u00a0Dr.\u00a0med.\u00a0Ulrich\u00a0A.\u00a0M\u00fcller,\u00a0MSc,\u00a0Jena\u00a0\nProf.\u00a0Dr.\u00a0med.\u00a0Bruno\u00a0M\u00fclle r\u2010Oerlinghausen,\u00a0Berlin\u00a0\nProf.\u00a0Dr.\u00a0med.\u00a0Wolfgang\u00a0Schramm,\u00a0M\u00fcnchen\u00a0\nProf.\u00a0Dr.\u00a0med.\u00a0Die ter\u00a0Ukena,\u00a0Bremen\u00a0\nPD\u00a0Dr.\u00a0med.\u00a0Tobias\u00a0Weberschock,\u00a0Frankfurt\u00a0am\u00a0Main\u00a0\n\u00a0\n\u00a0\nAutoren\u00a0der\u00a0Wirkstoffkapitel\u00a0\n\u00a0\nDr.\u00a0Stanislava\u00a0Dicheva\u2010Radev,\u00a0D\u00f6rte\u00a0Fuchs,\u00a0\nDr.\u00a0Iris\u00a0Hinneburg,\u00a0Anja\u00a0L\u00fcbs,\u00a0Andr\u00e9\u00a0S.\u00a0Morawetz,\u00a0\u00a0\nLutz\u00a0Muth,\u00a0Saskia\u00a0Ritter,\u00a0Dr.\u00a0Kristin\u00a0Sauer\u00a0\n\u00a0\nunter\u00a0Mitarbeit\u00a0von\u00a0\n\u00a0\nEleonora\u00a0Durakovic,\u00a0Friederike\u00a0H\u00f6fel,\u00a0\u00a0\nLinda\u00a0Jespersen,\u00a0Linda\u00a0Richter,\u00a0Marle\u00a0Wilhelm \u00a0\n\u00a0\n\u00a0\u00a0\n\u00a0\nAnschrift:\u00a0Universit\u00e4t\u00a0Bremen,\u00a0S OCIUM,\u00a0Mary\u2010Somerville\u2010Str.\u00a05,\u00a0 28359\u00a0Bremen\u00a0\n\u00a0\nAus\u00a0Gr\u00fcnden\u00a0der\u00a0besseren\u00a0Lesbarke it\u00a0wurde\u00a0auf\u00a0die\u00a0Nennung\u00a0beide r\u00a0\u00a0\ngeschlechtsspezifischer\u00a0Formen\u00a0verzichtet.\u00a0Im\u00a0Allgemeinen\u00a0ist\u00a0a ber\u00a0das\u00a0jeweils\u00a0\nandere\u00a0Geschlecht\u00a0ebenfalls\u00a0gemeint.\u00a0\n\u00a04\u00a0\u00a0 \u00a0\n\u00a05\u00a0Glossar\u00a0....................................................... ....................................\u00a06 \u00a0\nVorwort\u00a0zum\u00a0Innova tionsreport\u00a02019\u00a0............................ ...............\u00a013 \u00a0\nZweites\u00a0Vorwort\u00a0zum\u00a0In novationsreport\u00a02019\u00a0.................... ..........\u00a015\u00a0\n1\u00a0Einleitung\u00a0.................................................... ............................\u00a019 \u00a0\n2\u00a0Ziele\u00a0und\u00a0Methodik\u00a0............................................ .....................\u00a032 \u00a0\n3\u00a0Neue\u00a0Arzneimittel\u00a0 des\u00a0Jahres\u00a02016\u00a0............................. .............\u00a043 \u00a0\n4\u00a0Bewertungen\u00a0der\u00a0ne uen\u00a0Wirkstoffe\u00a0.............................. ...........\u00a055\u00a0\n\u00a0Albutrepenonacog\u00a0alfa.......................................... .............\u00a055 \u00a0 4.1\n\u00a0Brivaracetam\u00a0.................................................. ....................\u00a061 \u00a0 4.2\n\u00a0Daratumumab\u00a0................................................... .................\u00a068 \u00a0 4.3\n\u00a0Efmoroctocog\u00a0alfa\u00a0............................................. .................\u00a083 \u00a0 4.4\n\u00a0Eftrenonacog\u00a0alfa\u00a0............................................. ..................\u00a091 \u00a0 4.5\n\u00a0Elbasvir/Grazoprevir\u00a0.......................................... ................\u00a096 \u00a0 4.6\n\u00a0Elotuzumab\u00a0.................................................... ..................\u00a0102 \u00a0 4.7\n\u00a0HPV\u2010Impfstoff\u00a0................................................. .................\u00a0109 \u00a0 4.8\n\u00a0Mepolizumab\u00a0................................................... ................\u00a0118 \u00a0 4.9\n\u00a0Migalastat\u00a0.................................................... ....................\u00a0126 \u00a0 4.10\n\u00a0Olaratumab\u00a0.................................................... ..................\u00a0130 \u00a0 4.11\n\u00a0Opicapon\u00a0...................................................... ....................\u00a0140 \u00a0 4.12\n\u00a0Osimertinib\u00a0................................................... ...................\u00a0145 \u00a0 4.13\n\u00a0Palbociclib\u00a0................................................... .....................\u00a0155 \u00a0 4.14\n\u00a0Pitolisant\u00a0.................................................... ......................\u00a0163 \u00a0 4.15\n\u00a0Sacubitril/Valsartan\u00a0.......................................... ...............\u00a0167 \u00a0 4.16\n\u00a0Selexipag\u00a0..................................................... .....................\u00a0172 \u00a0 4.17\n\u00a0Sofosbuvir/Velpatasvir\u00a0........................................ .............\u00a0176 \u00a0 4.18\n\u00a0Talimogen\u00a0laherparepvec\u00a0....................................... .........\u00a0183\u00a0 4.19\n\u00a0Tenofoviralafenamid\u00a0(TAF)\u00a0..................................... .........\u00a0189\u00a0 4.20\n\u00a0Trifluridin/Tipiracil\u00a0......................................... ..................\u00a0198 \u00a0 4.21\n5\u00a0Diskussion\u00a0.................................................... .........................\u00a0205 \u00a0\n6\u00a0Impfen\u00a0und\u00a0Impfpflicht\u00a0........................................ ..................\u00a0217 \u00a0\n7\u00a0Keypoints\u00a0un d\u00a0Fazit\u00a0........................................... ....................\u00a0272\u00a06\u00a0Glossar\u00a0\n1st\u2010line\u00a0 Erstlinientherapie\u00a0\n2nd\u2010line\u00a0 Zweitlinientherapie\u00a03rd\u2010line\u00a0 Drittlinientherapie\u00a0\nAA\u00a0\u00a0\nAccelerated\u00a0 Assessmen t,\u00a0beschleunigte\u00a0Beurteilung:\u00a0\nEine\u00a0beschleunigte\u00a0Beurteilung\u00a0i m\u00a0zentralen\u00a0Zulassungsverfahren \u00a0\nerfolgt\u00a0f\u00fcr\u00a0Arzneimittel,\u00a0die\u00a0vo n\u00a0besonderer\u00a0Bedeutung\u00a0f\u00fcr\u00a0die\u00a0 \u00f6ffentli\u2010\nche\u00a0Gesundheit\u00a0sind,\u00a0insbesondere\u00a0 solchen,\u00a0die\u00a0therapeutische\u00a0I nnova\u2010\ntionen\u00a0darstellen.\u00a0Die\u00a0beschleuni gte\u00a0Beurteilung\u00a0wird\u00a0durch\u00a0die \u00a0Ver\u2010\nordnung\u00a0(EG)\u00a0Nr.\u00a0726/20 04,\u00a0Artikel\u00a014\u00a0(9)\u00a0g eregelt.\u00a0Der\u00a0Antrags teller\u00a0\nmuss\u00a0bereits\u00a0bei\u00a0Einreichen\u00a0des\u00a0Antrags\u00a0ein\u00a0beschleunigtes\u00a0Beur tei\u2010\nlungsverfahren\u00a0beantragen\u00a0und\u00a0au sreichend\u00a0begr\u00fcnden.\u00a0Bei\u00a0diesen \u00a0\nbeschleunigten\u00a0Beurteilungen\u00a0verk \u00fcrzt\u00a0sich\u00a0die\u00a0Zeit,\u00a0die\u00a0dem\u00a0CH MP\u00a0\nhierf\u00fcr\u00a0zur\u00a0Verf\u00fcgung\u00a0steht ,\u00a0von\u00a0210\u00a0auf\u00a0150\u00a0Tage.\u00a0\nAIDS\u00a0 Acquired\u00a0Immune\u00a0Deficiency\u00a0Syndrome ,\u00a0erworbenes\u00a0Immun\u2010\nschw\u00e4chesyndrom\u00a0\nAE\u00a0 Adverse\u00a0Even t,\u00a0unerw\u00fcnschtes\u00a0Arzneimittelereignis\u00a0\nAGI\u00a0 Arbeitsgemeinschaft\u00a0Influe nza\u00a0des\u00a0Robert\u2010Koch\u2010Instituts\u00a0\nAMB\u00a0 Der\u00a0Arzneimittelbrief\u00a0\nAMNOG\u00a0 Arzneimittelmarktneuordnungsgesetz\u00a0\nARNI\u00a0 Angiotensin\u2010Rezepto r\u2010Neprilysin\u2010Inhibitor\u00a0\nASZT\u00a0 Autologe\u00a0Stammz elltransplantation\u00a0\na\u2010t\u00a0 arznei\u2010telegramm\u00ae\u00a0\nAT1\u2010Rezeptor\u00a0 Angiotensin\u2010 II\u2010Rezeptor\u00a0Subtyp\u00a01\u00a0\nATC\u2010Code\u00a0 Anatomisch\u2010Therapeutisch\u2010Chemischer\u00a0Code\u00a0\natd\u00a0 Arzneimitteldatenbank \u00a0zum\u00a0arznei\u2010telegramm\u00ae\u00a0\nATP\u00a0 Adenosintriphosphat\u00a0\nATMP\u00a0 Advanced\u00a0Therapy\u00a0Medicina l\u00a0Products, \u00a0Arzneimittel\u00a0f\u00fcr\u00a0neuartige\u00a0\nTherapien:\u00a0Gentherapeutika\u00a0bzw.\u00a0 somatische\u00a0Zelltherapeutika\u00a0\u00a0\nAV\u00a0 au\u00dfer\u00a0Vertrieb\u00a0\nAVK\u00a0 Apothekenverkaufspreis\u00a0brutto\u00a0\nAWMF\u00a0 Arbeitsgemeinschaft\u00a0der\u00a0Wi ssenschaftlichen\u00a0Medizinischen\u00a0F achgesell\u2010\nschaften\u00a0e.V.\u00a0\nBfArM\u00a0 Bundesinstitut\u00a0f\u00fcr\u00a0Arzn eimittel\u00a0und\u00a0Medizinprodukte\u00a0\nBRAF\u2010Gen\u00a0 Onkogen,\u00a0das\u00a0f\u00fcr\u00a0die\u00a0Se rin\u2010Threonin\u2010Proteinkinase\u00a0BRAF \u00a0kodiert\u00a0\nBRAF\u2010V600\u00a0(+)\u00a0 infolge\u00a0Genmutati on\u00a0ver\u00e4nderte\u00a0BRAF\u2010Kinase\u00a0mit\u00a0ei ner\u00a0anderen\u00a0Ami\u2010\nnos\u00e4ure\u00a0anstelle\u00a0von\u00a0Valin\u00a0(V)\u00a0an\u00a0Position\u00a0600\u00a0der\u00a0AS\u2010Sequenz\u00a0\nBRAF\u2010V600\u00a0(w)\u00a0 BRAF\u2010V600\u2010W ildtyp\u00a0(ohne\u00a0Mutation)\u00a0\nbreakthrough\u00a0therap y\u00a0Therapiedurchbruch,\u00a0Kategorie\u00a0der \u00a0FDA\u00a0zur\u00a0beschleunigten\u00a0Zulass ung\u00a0\nBSC\u00a0 Best\u00a0Supportive\u00a0Care,\u00a0 bestm\u00f6gliche\u00a0unterst\u00fctzende\u00a0Behandlung\u00a0\nBZgA\u00a0 Bundeszentrale\u00a0f\u00fcr\u00a0ge sundheitliche\u00a0Aufkl\u00e4rung\u00a0\nC\u00a0 Conditional\u00a0approva l,\u00a0auflagengebundene\u00a0Zulassung\u00a0der\u00a0EMA\u00a0\nCA\u00a0 Carcinoma ,\u00a0Karzinom\u00a0\nCADTH\u00a0 Canadian\u00a0Agency\u00a0for\u00a0Drugs\u00a0and\u00a0Technologies\u00a0in\u00a0Health\u00a0\nCAR\u2010T\u00a0 Chimeric\u00a0Antigen\u00a0Receptor\u2010T\u2010cell,\u00a0 CAR\u2010T\u2010Zell\u2010Therapie \u00a07\u00a0CAT\u00a0 Committee\u00a0for\u00a0Advanced\u00a0Therapies\u00a0\ncAMP\u00a0 cyclic\u00a0Adenosine\u00a0Monophosphate ,\u00a0zyklisches\u00a0Adenosinmonophosphat\u00a0\nCER\u00a0 Comparative\u00a0Effectiveness\u00a0Research\u00a0\nCDER\u00a0 Center\u00a0for\u00a0Drug\u00a0Evaluation\u00a0and\u00a0Research ,\u00a0Zentrum\u00a0f\u00fcr\u00a0Arzneimittelbe\u2010\nwertung\u00a0u.\u00a0Forschung\u00a0der\u00a0US\u2010amerik anischen\u00a0Zulassungsbeh\u00f6rde\u00a0FD A\u00a0\nCDK\u00a0 Cyclin\u2010Dependent\u00a0Kinases ,\u00a0Cyclin\u2010abh\u00e4ngige\u00a0Kinasen\u00a0\ncHCV\u00a0 chronisches\u00a0Hepatitis\u2010C\u2010Virus\u00a0\nCHMP\u00a0 Committee\u00a0for\u00a0Medicinal\u00a0Products\u00a0for\u00a0Human\u00a0Use,\u00a0 Ausschuss\u00a0der\u00a0EMA\u00a0\nf\u00fcr\u00a0Humanarzneimittel\u00a0\nCHO\u00a0 Chinese\u00a0Hamster\u00a0Ovar y,\u00a0Ovarzellen\u00a0des\u00a0chinesischen\u00a0Hamsters\u00a0\u00a0\nCIN\u00a0 Cervical\u00a0Intraepithelial\u00a0Neoplasia ,\u00a0zervikale\u00a0intraepi theliale\u00a0Neoplasie\u00a0\nCMA\u00a0 Conditional\u00a0Marketing\u00a0Authorisation ,\u00a0bedingte\u00a0Zulassung:\u00a0\nF\u00fcr\u00a0die\u00a0Erteilung\u00a0der\u00a0Zulassung\u00a0a uf\u00a0der\u00a0Grundlage\u00a0weniger\u00a0umfan grei\u2010\ncher\u00a0Daten,\u00a0als\u00a0dies\u00a0normalerwei se\u00a0der\u00a0Fall\u00a0ist,\u00a0wurde\u00a0mit\u00a0der\u00a0 Verord\u2010\nnung\u00a0(EG)\u00a0Nr.\u00a0507/2006\u00a0ein\u00a0Verfah ren\u00a0etabliert,\u00a0das\u00a0an\u00a0bestimmt e\u00a0\nAuflagen\u00a0gekn\u00fcpft\u00a0ist.\u00a0Diese\u00a0bed ingte\u00a0Zulassung\u00a0wird\u00a0f\u00fcr\u00a0Arznei mittel\u00a0\nmit\u00a0noch\u00a0unvollst\u00e4ndigen\u00a0klinisch en\u00a0Daten\u00a0erteilt,\u00a0die\u00a0zur\u00a0Beha ndlung,\u00a0\nVorbeugung\u00a0oder\u00a0\u00e4rztlichen\u00a0Diag nose\u00a0von\u00a0zu\u00a0schwerer\u00a0Invalidit\u00e4t \u00a0\nf\u00fchrenden\u00a0oder\u00a0lebensbedrohliche n\u00a0Krankheiten\u00a0bestimmt\u00a0sind,\u00a0f\u00fc r\u00a0\nOrphan\u2010Arzneimittel\u00a0oder\u00a0f\u00fcr\u00a0Arzneimi ttel,\u00a0die\u00a0in\u00a0Krisensituationen\u00a0\ngegen\u00a0eine\u00a0Bedrohung\u00a0der\u00a0\u00f6ffent lichen\u00a0Gesundheit\u00a0eingesetzt\u00a0wer den\u00a0\nsollen.\u00a0Bedingungen\u00a0sind\u00a0weiterhi n,\u00a0dass\u00a0umfangreiche\u00a0Daten\u00a0zu\u00a0 Wirk\u2010\nsamkeit\u00a0und\u00a0Sicherheit\u00a0sp\u00e4ter\u00a0nach \u00a0der\u00a0Zulassung\u00a0eingereicht\u00a0we rden\u00a0\nund\u00a0ein\u00a0ungedeckter\u00a0med izinischer\u00a0Bedarf\u00a0(\u201e unmet\u00a0medical\u00a0need \u201c)\u00a0\nbesteht.\u00a0\nCOMT\u00a0 Catcheol\u2010O\u2010Methyltransferase\u00a0\nCOMP\u00a0 Committee\u00a0for\u00a0Orphan\u00a0Medicinal\u00a0Products ,\u00a0Ausschuss\u00a0f\u00fcr\u00a0Arzneimittel\u00a0\ngegen\u00a0seltene\u00a0Krankheiten\u00a0der\u00a0EMA\u00a0\nCPT\u00a0 Child\u2010Pugh\u2010Turcotte\u00a0\nCR\u00a0 Complete\u00a0Remission ,\u00a0vollst\u00e4ndige\u00a0Remission \u00a0\nCrossover\u00a0 Wechsel\u00a0von\u00a0Patienten\u00a0in\u00a0einen\u00a0a nderen\u00a0Therapie\u2010Arm\u00a0im\u00a0Rahmen\u00a0\neiner\u00a0klinischen\u00a0Studie\u00a0\nCTCAE\u00a0 Common\u00a0Terminology\u00a0Criteria\u00a0for\u00a0Adverse\u00a0Events, \u00a0Allgemeine\u00a0Termino\u2010\nlogie\u00a0und\u00a0Merkmale\u00a0schwerer\u00a0unerw\u00fcnschter\u00a0Ereignisse\u00a0\nCYP\u00a0 Cytochrom\u2010P450\u2010Enzym\u00a0\nCYP3A4\u00a0 Cytochrom\u2010P450\u2010Isoenzym\u00a03A4\u00a0\nCYP3A5\u00a0 Cytochrom\u2010P450\u2010Isoenzym\u00a03A5\u00a0\nDAA\u00a0 Direkt\u00a0wirkende\u00a0antivirale\u00a0Arzneimittel\u00a0\nDDD\u00a0 Defined\u00a0Daily\u00a0Dose,\u00a0 definierte\u00a0Tagesdosis\u00a0\nDEGS\u00a0 Studie\u00a0zur\u00a0Gesundheit\u00a0Erwachsener\u00a0in\u00a0Deutschland\u00a0DIMDI\u00a0 Deutsches\u00a0Institut\u00a0f\u00fcr\u00a0Med izinische\u00a0Dokumentation\u00a0und\u00a0Inf ormation\u00a0\nDNA\u00a0 Deoxyribonucleic\u00a0Aci\nd,\u00a0Desoxyribonukleins\u00e4ure\u00a0\nDoR\u00a0 Duration\u00a0of\u00a0Response, \u00a0Ansprechdauer\u00a0\nDRR\u00a0 Durable\u00a0response\u00a0rate,\u00a0 Dauerhafte\u00a0Ansprechrate \u00a0\nEbM\u00a0 Evidenzbasierte\u00a0Medizin\u00a0\n\u00a0\u00a08\u00a0EC\u00a0 Exceptional\u00a0 Circumstances ,\u00a0Zulassung\u00a0unter\u00a0au\u00dfergew\u00f6hnlichen\u00a0Um\u2010\nst\u00e4nden:\u00a0\nEin\u00a0Verfahren\u00a0der\u00a0beschleunigten \u00a0Zulassung,\u00a0das\u00a0bereits\u00a0seit\u00a019 95\u00a0\nexistiert\u00a0und\u00a0durch\u00a0die\u00a0Verordnung\u00a0( EG)\u00a0Nr.\u00a0726/2004\u00a0geregelt\u00a0w ird.\u00a0Sie\u00a0\nwird\u00a0erteilt,\u00a0wenn\u00a0es\u00a0prinzipie ll\u00a0unm\u00f6glich\u00a0ist,\u00a0die\u00a0f\u00fcr\u00a0eine\u00a0Z ulassung\u00a0\ngew\u00f6hnlich\u00a0geforderten\u00a0Studienda ten\u00a0vorzulegen.\u00a0Bedingungen\u00a0sin d,\u00a0\ndass\u00a0das\u00a0Anwendungsgebiet\u00a0so\u00a0selt en\u00a0ist,\u00a0dass\u00a0keine\u00a0umfangreich e\u00a0\nEvidenz\u00a0vorliegen\u00a0kann,\u00a0dass\u00a0es \u00a0aufgrund\u00a0des\u00a0wissenschaftlichen \u00a0\nKenntnisstands\u00a0nicht\u00a0gen\u00fcgend\u00a0In formationen\u00a0gibt\u00a0und\u00a0es\u00a0nicht\u00a0d en\u00a0\nPrinzipien\u00a0der\u00a0medizinischen\u00a0Eth ik\u00a0entsprechen\u00a0w\u00fcrde,\u00a0derartige \u00a0\nInformationen\u00a0in\u00a0klinischen\u00a0Studien\u00a0zu\u00a0generieren.\u00a0\nECDC\u00a0 European\u00a0Centre\u00a0for\u00a0Disease\u00a0Prevention\u00a0and\u00a0Contro l,\u00a0Europ\u00e4isches\u00a0\nZentrum\u00a0f\u00fcr\u00a0die\u00a0Pr\u00e4vention\u00a0und\u00a0 die\u00a0Kontrolle\u00a0von\u00a0Krankheiten\u00a0\nECOG\u00a0 Eastern\u00a0Cooperative\u00a0Oncology\u00a0Group\u00a0\nECOG\u2010PS\u00a0 Eastern\u00a0Cooperative\u00a0Oncology\u00a0Group\u2010Performance\u00a0Status,\u00a0 Index\u00a0der\u00a0\nECOG\u00a0zur\u00a0Einsch\u00e4tzung\u00a0der\u00a0Aktivit \u00e4t\u00a0bzw.\u00a0des\u00a0Allgemeinzustands\u00a0 \u00a0\nEG\u00a0 Europ\u00e4ische\u00a0Gemeinschaft\u00a0\nEGFR\u00a0 Epidermal\u00a0Growth\u00a0Factor\u00a0Receptor ,\u00a0epidermaler\u00a0Wachstumsfaktor\u2010\nRezeptor\u00a0\nEGFRm\u00a0 Epidermal\u00a0Growth\u00a0Factor\u00a0Receptor\u00a0Mutan t,\u00a0epidermaler\u00a0Wachstums\u2010\nfaktor\u2010Rezeptor\u00a0Mutationsstatus\u00a0\nEMA\u00a0 European\u00a0Medicines\u00a0Agenc y,\u00a0Europ\u00e4ische\u00a0Arzneimittelagentur,\u00a0Zulas\u2010\nsungsbeh\u00f6rde\u00a0der\u00a0EU\u00a0\nEORTC\u00a0 European\u00a0Organisation\u00a0for\u00a0Research\u00a0and\u00a0Treatment\u00a0of\u00a0Cancer ,\u00a0Europ\u00e4\u2010\nische\u00a0Organisation\u00a0f\u00fcr\u00a0Kre bsforschung\u00a0und\u00a0\u2010behandlung \u00a0\nEORTC\u00a0QL Q\u2010C30\u00a0 EORTC\u00a0 Quality\u00a0of\u00a0Life\u00a0Questionnaire,\u00a0 Fragebogen\u00a0der\u00a0EORTC\u00a0zur\u00a0Beur\u2010\nteilung\u00a0der\u00a0Lebensqualit\u00e4t\u00a0o nkologischer\u00a0Patienten\u00a0\nEORTC\u00a0QL Q\u2010LC13\u00a0 Modulare\u00a0Erg\u00e4nzung\u00a0des\u00a0C30\u2010 Fragebogens\u00a0f\u00fcr\u00a0Lungenkarzinom \u00a0\nEPAR\u00a0 European\u00a0Public\u00a0Assessment\u00a0Repor t,\u00a0Europ\u00e4ischer\u00a0\u00f6ffentlicher\u00a0Beurteilungs\u2010\nbericht\u00a0\nEPhMRA\u00a0 European\u00a0Pharmaceutical\u00a0Market\u00a0Research\u00a0Association ,\u00a0Europ\u00e4ische\u00a0\nVereinigung\u00a0f\u00fcr\u00a0Pharmazeutische\u00a0Marktforschung\u00a0\nEQ\u20105D\u00a0 EuroQol\u00a0Group\u00a05\u00a0Dimensions ;\u00a0kurzer\u00a0Fragebogen\u00a0mit\u00a05\u00a0Items\u00a0zur\u00a0Erfas\u2010\nsung\u00a0der\u00a0gesundheitsbe zogenen\u00a0Lebensqualit\u00e4t\u00a0\nESS\u00a0 Epworth\u00a0Sleepiness\u00a0Scale ,\u00a0Epworth\u2010Schl\u00e4frigkeitsskala \u00a0\nEU\u00a0 Europ\u00e4ische\u00a0Union\u00a0\nFACT\u2010B\u00a0 Functional\u00a0Assessmen t\u00a0of\u00a0Cancer\u00a0Therap y\u2010Breast\u00a0Cancer,\u00a0Fragebogen\u00a0\nzur\u00a0Messung\u00a0der\u00a0Lebensqualit\u00e4t \u00a0bei\u00a0Brustkrebspatientinnen \u00a0\nFAM\u00a0 Fertigarzneimittel\u00a0\nFDA\u00a0 Food\u00a0and\u00a0Drug\u00a0Administration ,\u00a0US\u2010Amerikanische\u00a0Arzneimittelzulas\u2010\nsungsbeh\u00f6rde\u00a0\nfollow\u2010up\u00a0 Nachverfolgung \u00a0\nG\u2010BA\u00a0 Gemeinsamer\u00a0Bundesausschuss\u00a0\nGEJ\u00a0 Gastro\u00a0Esophageal\u00a0Junction ,\u00a0gastro\u2010\u00f6sophagealer\u00a0\u00dcbergang\u00a0\nGFR\u00a0 Glomerul\u00e4re\u00a0Filtrationsrate\u00a0\n\u00a0\u00a09\u00a0GHS/Qol\u00a0\u00a0 Global\u00a0Health\u00a0Status/Qualit y\u2010of\u2010Life,\u00a0Skala\u00a0des\u00a0EORTC\u00a0zur\u00a0Messung\u00a0der\u00a0\nLebensqualit\u00e4t\u00a0\nGIST\u00a0 Gastrointestinale\u00a0Stromatumore\u00a0\nGKV\u00a0 Gesetzliche\u00a0Krankenversicherung\u00a0GLA\u00a0 \u03b1\u2010Galaktosidase\u00a0A\u00a0(Synon ym:\u00a0AGLA\u00a0bzw.\u00a0Melibidase)\u00a0\nGLP\u20101\u00a0 Glucagon\u2010Like\u00a0Peptide\u00a0 1\u00a0\nGMG\u00a0 GKV\u2010Modernisierungsgesetz\u00a0\nGM\u2010CSF\u00a0 Humaner\u00a0Granulozyten\u2010\u00a0und\u00a0 Makrophagen\u2010koloniestimulieren der\u00a0\nFaktor\u00a0\nGSAV\u00a0 Gesetz\u00a0f\u00fcr\u00a0mehr\u00a0Sicherheit\u00a0 in\u00a0der\u00a0Arzneimittelversorgung\u00a0\nGT\u00a0 Genotyp\u00a0\nHb\u00a0 H\u00e4moglobin\u00a0\nHbA1c\u00a0 Glykiertes\u00a0H\u00e4moglobin,\u00a0Langzeitblutzuckerwert\u00a0\nHCV\u00a0 Hepatitis\u2010C\u2010Virus\u00a0\nhea\nd\u2010to\u2010head\u00a0 im\u00a0direkten\u00a0Vergleich\u00a0\nHER2\u00a0 Human\u00a0Epidermal\u00a0growth\u00a0factor\u00a0Receptor\u00a02 ,\u00a0Humaner\u00a0epidermaler\u00a0\nWachstumsfaktor\u00a0Rezeptor\u00a02\u00a0\nHib\u00a0 Haemophilus\u00a0influenzae\u00a0Typ\u00a0b\u00a0\nHIV\u00a0 Humanes\u00a0Immunodefizienz\u2010Virus\u00a0HPV\u00a0 Human\u00a0Papillomavirus ,\u00a0Humaner\u00a0Papillomvirus\u00a0\nHR\u00a0 Hazard\u00a0Ratio \u00a0\nHR\u2010positiv\u00a0 hormonrezeptorpositiv\u00a0\nHRQoL\u00a0 Health\u00a0Relate\nd\u00a0Quality\u00a0of\u00a0Life ,\u00a0Gesundheitsbezogene\u00a0Lebensqualit\u00e4t\u00a0\nHSV\u20101\u00a0 Herpes\u2010Simple x\u2010Virus\u00a0Typ\u00a01\u00a0\nICD\u00a0 International\u00a0Statistical\u00a0Classification\u00a0of\u00a0Diseases\u00a0and\u00a0Relate d\u00a0Health\u00a0\nProblems ,\u00a0amtliche\u00a0Klassifikation\u00a0zur\u00a0V erschl\u00fcsselung\u00a0von\u00a0Diagnosen\u00a0\nIfSG\u00a0 Infektionsschutzgesetz,\u00a0Ges etz\u00a0zur\u00a0Verh\u00fctung\u00a0und\u00a0Bek\u00e4mpfun g\u00a0von\u00a0\nInfektionskrankheiten\u00a0beim\u00a0Menschen\u00a0\nIGeL\u00a0 Individuelle\u00a0Gesundheitsleistungen\u00a0ILD\u00a0 Interstitial\u00a0Lung\u00a0Disease ,\u00a0interstitielle\u00a0Lungenerkrankung\u00a0\nIMiD\u00a0 Immunomodulatory\u00a0drug ,\u00a0immunmodulierende\u00a0Arzneimittel \u00a0\nIQWiG\u00a0 Institut\u00a0f\u00fcr\u00a0Qualit\u00e4t\u00a0und\u00a0 Wirtschaftlichkeit\u00a0im\u00a0Gesundhei tswesen\u00a0\nISS\u00a0 International\u00a0Staging\u00a0System ;\u00a0Stadieneinteilung\u00a0nac h\u00a0der\u00a0International\u00a0\nMyeloma\u00a0Working\u00a0Group\u00a0\nITT\u00a0 Intention\u00a0To\u00a0Trea\nt,\u00a0Studienanalyseverfahren,\u00a0bei\u00a0dem\u00a0alle\u00a0Teilnehmer\u00a0\nin\u00a0ihrer\u00a0Gruppe\u00a0ausgewertet\u00a0wer den,\u00a0unabh\u00e4ngig\u00a0von\u00a0Protokollver \u2010\nletzungen,\u00a0Compliance\u00a0oder\u00a0verfr \u00fchtem\u00a0Abbruch\u00a0der\u00a0Studienteilna hme\u00a0\nKCCQ\u00a0 Kansas\u00a0City\u00a0Cardiomyopathy\u00a0Questionnaire ,\u00a0Fragebogen\u00a0zur\u00a0Erfassung\u00a0\nder\u00a0Lebensqualit\u00e4t\u00a0bei\u00a0chron ischer\u00a0Herzinsuffizienz\u00a0\u00a0\nkg\u00a0 Kilogramm\u00a0KG\u00a0 K\u00f6rpergewicht\u00a0\nKI\u00a0 Konfidenzintervall\u00a0\nKiGGS\u00a0 Studie\u00a0zur\u00a0Gesundheit\u00a0von\u00a0 Kindern\u00a0und\u00a0Jugendlichen\u00a0in\u00a0Deu tschland\u00a0\nKOF\u00a0 K\u00f6rperoberfl\u00e4che\u00a0\nKRAS\u00a0 Kirsten\u00a0RAt\u00a0Sarcoma\u00a0viral\u00a0oncogene\u00a0homolog\u00a010\u00a0KRK\u00a0 Kolorektalkarzinom\u00a0\nLHRH\u2010Agonist\u00a0 Luteinizing\u00a0Hormone\u00a0Releasing\u00a0Hormone\u2010 Agonist,\u00a0Luteinisierungshor\u2010\nmon\u2010Releasinghormon\u00a0\nMAO\u2010B\u00a0 Monoaminooxidase\u00a0B\u00a0MCV\u00a0 Measles\u00a0Containing\u00a0V accine,\u00a0Masernimpfung\u00a0\nmKRK\u00a0 metastasiertes\u00a0 Kolorektalkarzinom\u00a0\nMM\u00a0 Multiples\u00a0Myelom\u00a0\nMMR\u00a0 Masern,\u00a0Mumps,\u00a0R\u00f6teln\u00a0\nMMRV\u00a0 Masern,\u00a0Mumps,\u00a0R\u00f6teln\u00a0 und\u00a0Varizellen\u00a0(Windpocken)\u00a0\nMS\u00a0 Multiple\u00a0Sklerose\u00a0\nNAVKO\u00a0 Nationale\u00a0Verifizierung skommission\u00a0Masern/R\u00f6teln\u00a0\nNBW\u00a0 Nutzenbewertung\u00a0\nNICE\u00a0 National\u00a0Institute\u00a0for\u00a0Health\u00a0and\u00a0Care\u00a0Excellence,\u00a0 britische\u00a0Arzneimittelzu\u2010\nlassungsbeh\u00f6rde \u00a0\nNNRTI\u00a0 Nicht\u2010nukleosidischer\u00a0Rev erse\u2010Transkriptase\u2010Inhibitor\u00a0\nNRTI\u00a0 Nukleotidischer\u00a0Hemmer\u00a0der\u00a0Reversen\u00a0Transkriptase\u00a0\nNS5A\u00a0 Non\u2010structural\u00a0protein\u00a05A ,\u00a0Nichtstrukturprotein\u20105A\u00a0des\u00a0Hepatitis\u2010C\u2010\nVirus\u00a0\nNSCLC\u00a0 Non\u2010Small\u00a0Cell\u00a0Lung\u00a0Cancer ,\u00a0nicht\u2010kleinzellige s\u00a0Lungenkarzinom\u00a0\nNYHA\u00a0classification\u00a0 New\u00a0York\u00a0Heart\u00a0Association \u00a0functional\u00a0classification ,\u00a0Klassifika\u2010\ntionsmodell\u00a0der\u00a0Herzinsuffizienz\u00a0nach\u00a0NYHA\u00a0\no.g.\u00a0 oben\u00a0genannt\u00a0\nOR\u00a0 Overall\u00a0Response ,\u00a0Gesamtansprechen\u00a0\nOrphan\u2010Arzneimittel\u00a0 Orphan\u00a0Drugs \u00a0\nArzneimittel,\u00a0die\u00a0zur\u00a0Behandlung\u00a0f \u00fcr\u00a0seltene\u00a0Leiden\u00a0eingesetzt\u00a0 werden.\u00a0\nAls\u00a0selten\u00a0gilt\u00a0innerhalb\u00a0der\u00a0EU\u00a0e ine\u00a0Krankheit,\u00a0wenn\u00a0sie\u00a0nicht \u00a0mehr\u00a0als\u00a0\n5\u00a0pro\u00a010.000\u00a0EU\u2010Einwohner\u00a0betri fft.\u00a0Mit\u00a0der\u00a0Verordnung\u00a0(EG)\u00a0Nr. \u00a0\n141/2000\u00a0hat\u00a0das\u00a0Europ\u00e4ische\u00a0Par lament\u00a0und\u00a0der\u00a0Rat\u00a0versucht\u00a0Anr eize\u00a0\nf\u00fcr\u00a0die\u00a0pU\u00a0zu\u00a0schaffen\u00a0Arzneimitte l\u00a0f\u00fcr\u00a0seltene\u00a0Leiden\u00a0zu\u00a0entwi ckeln.\u00a0Zu\u00a0\nden\u00a0Anreizen\u00a0z\u00e4hlt\u00a0u.a.\u00a0das\u00a0besc hleunigte\u00a0Zulassungsverfahren.\u00a0 Bevor\u00a0\nein\u00a0Orphan\u2010Arzneimittel\u00a0von\u00a0der\u00a0EU\u00a0zugel assen\u00a0wird,\u00a0muss\u00a0der\u00a0pU\u00a0beim\u00a0\nhierf\u00fcr\u00a0zust\u00e4ndigen\u00a0Komitee\u00a0der\u00a0 EMA\u00a0(COMP)\u00a0eine\u00a0Zuerkennung\u00a0der \u00a0\nOrphan\u00a0Drug \u2010Status\u00a0beantragen.\u00a0Das\u00a0CO MP\u00a0ber\u00fccksichtigt\u00a0dabei\u00a0vor\u00a0\nallem\u00a0epidemiologische\u00a0Daten\u00a0und\u00a0 den\u00a0potenziellen\u00a0Nutzen\u00a0des\u00a0Ar z\u2010\nneimittels.\u00a0\nORR\u00a0 Overall\u00a0Response\u00a0Rate,\u00a0 Gesamtansprechrate\u00a0\nOS\u00a0 Overall\u00a0Surviva\nl,\u00a0Gesamt\u00fcberleben\u00a0\nPAH\u00a0 Pulmonal\u00a0arterielle\u00a0Hypertonie\u00a0\nPap\u2010Test\u00a0 Papanicolaou\u2010Test\u00a0\nPASS\u00a0 Post\u00a0Authorization\u00a0Safety\u00a0Stud y,\u00a0Unbedenklichkeitsstudie\u00a0nach\u00a0der\u00a0\nZulassung\u00a0\nPDD\u00a0 Prescribed\u00a0Daily\u00a0Dose ,\u00a0verordnete\u00a0Tagesdosis\u00a0\nPDE\u00a0 Phosphodiesterase\u00a0\nPDGFR\u03b1\u00a0 Platelet\u00a0Derived\u00a0Growth\u00a0Factor\u00a0Receptor\u00a0alpha ,\u00a0Wachstumsfaktorre\u2010\nzeptor\u00a0mit\u00a0zentraler\u00a0Funktion\u00a0in \u00a0der\u00a0Regulation\u00a0von\u00a0Zellwachstu m\u00a0und\u00a0\nDifferenzierung\u00a011\u00a0PEI\u00a0 Paul\u2010Ehrlich\u2010Institut\u00a0\nPFS\u00a0 Progression\u2010free\u00a0Survival,\u00a0 progressionsfreies\u00a0\u00dcberleben\u00a0\nPFU\u00a0 Plaque\u00a0Forming\u00a0Uni t,\u00a0Plaque\u2010bildende\u00a0Einheit \u00a0\nPGI2\u00a0 Prostaglandin\u00a0I 2\u00a0(Synonym:\u00a0Prostacyclin)\u00a0\nPost\u2010hoc\u2010Analyse\u00a0 Statistische\u00a0Auswertung ,\u00a0die\u00a0vor\u00a0Studienbeginn\u00a0noch\u00a0ni cht\u00a0vorgesehen\u00a0\nwar\u00a0\nPRIME\u00a0 PRIority\u00a0MEdicines \u00a0\nBeschleunigtes\u00a0Zulassungsverfahr en,\u00a0das\u00a0f\u00fcr\u00a0Erkrankungen\u00a0mit\u00a0un ge\u2010\ndecktem\u00a0medizinischen\u00a0Bedarf\u00a0(\u201e unmet\u00a0medical\u00a0need \u201c)\u00a0vorgesehen\u00a0ist,\u00a0\nbei\u00a0denen\u00a0Patienten\u00a0keine\u00a0wirksam en\u00a0Therapieoptionen\u00a0zur\u00a0Verf\u00fcg ung\u00a0\nstehen\u00a0bzw.\u00a0das\u00a0neue\u00a0Arzneimitte l\u00a0einen\u00a0therapeutischen\u00a0Vorteil \u00a0\ngegen\u00fcber\u00a0den\u00a0vorhandenen\u00a0Alternativen\u00a0bietet. \u00a0\npU\u00a0 pharmazeutischer\u00a0Unternehmer\u00a0\nPZ\u00a0 Pharmazeutische\u00a0Zeitung\u00a0\nQLQ\u2010...\u00a0 s.\u00a0EORTC\u2010QL Q\u00a0\nQT\u2010Zeit\u00a0 Messgr\u00f6\u00dfe\u00a0im\u00a0EKG,\u00a0repr\u00e4se ntiert\u00a0die\u00a0Gesamtdauer\u00a0der\u00a0Kam mer\u2010\nerregung,\u00a0d.h.\u00a0vom\u00a0QRS\u2010Komp lex\u00a0bis\u00a0Ende\u00a0der\u00a0T\u2010Welle\u00a0\nRHB\u00a0 Rote\u2010Hand\u2010Brief\u00a0\nRPSFTM\u00a0 Rank\u00a0Preserving\u00a0Structural\u00a0Failure\u00a0Time\u00a0Model,\u00a0 statistisches\u00a0Analyse\u2010\nverfahren\u00a0\nR/R\u2010MM\u00a0 Refrakt\u00e4res\u00a0multiples\u00a0Myelom\u00a0\nSAG\u2010O\u00a0 Scientific\u00a0Advisory\u00a0Group\u00a0on\u00a0Oncolog y,\u00a0Beratungsgruppe\u00a0der\u00a0EMA\u00a0im\u00a0\nBereich\u00a0Onkologie\u00a0\nSGB\u00a0 Sozialgesetzbuch\u00a0\nSGLT\u20102\u00a0 Sodium\u2010Glucose\u00a0Linked\u00a0Transporter\u00a02 ,\u00a0Natrium\u2010Glucose\u2010Cotransporter\u00a02 \u00a0\nSIKO\u00a0 S\u00e4chsische\u00a0Impfkommission\u00a0\nSSPE\u00a0 Subakute\u00a0sklerosierende\u00a0Panenzephalitis\u00a0\nSTIKO\u00a0 St\u00e4ndige\u00a0Impfkommission \u00a0beim\u00a0Robert\u00a0Koch\u2010Institut\u00a0\nSUAE\u00a0 Serious\u00a0Unexpected\u00a0Adverse\u00a0Even t,\u00a0schwerwiegendes\u00a0unerwartetes\u00a0\nunerw\u00fcnschtes\u00a0Ereignis\u00a0\nSUE\u00a0 Serious\u00a0Unexpected\u00a0Adverse\u00a0Even t,\u00a0schwerwiegendes\u00a0unerw\u00fcnschtes\u00a0\nEreignis\u00a0\nSVR\u00a0 Sustained\u00a0Virological\u00a0Response ,\u00a0anhaltendes\u00a0virologisches\u00a0Ansprechen\u00a0\nSV2A\u00a0 Synaptisches\u00a0Vesikelprotein\u00a02A\u00a0\nTAF\u00a0 Tenofoviralafenamid\u00a0\nTd\u2010Impfstoff\u00a0 Tetanus\u2010Diphtherie\u2010Impfstoff\u00a0\nTdap\u2010Impfung\u00a0 Diphtherie\u2010,\u00a0Te tanus\u2010\u00a0und\u00a0Pertussis\u2010Impfung\u00a0\nTDF\u00a0 Tenofovirdisoproxilfumarat\u00a0\nTdPa\u2010IPV\u2010Impfstoff\u00a0 Diphtherie\u2010,\u00a0 Tetanus\u2010,\u00a0Pertussis\u2010,\u00a0Poliomyel itis\u00a0(inaktiviert)\u2010,\u00a0Adsorbat\u2010\u00a0\nImpfstoff\u00a0\nTGA\u00a0 Therapeutic\u00a0Goods\u00a0 Administration ,\u00a0australische\u00a0Arzneimittelbeh\u00f6rde\u00a0\ntgl.\u00a0 t\u00e4glich\u00a0\nTK\u00a0 Techniker\u00a0Krankenkasse\u00a0TKI\u00a0 Tyrosinkinase\u2010Inhibitor\u00a0\nTsd.\u00a0 Tausend\u00a012\u00a0TTP\u00a0 Time\u00a0to\u00a0Disease\u00a0Progression\u00a0\nTVT\u00a0 Tiefe\u00a0Venenthrombose\u00a0\nT\u2010Vec\u00a0 Talimogen\u00a0laherparepvec\u00a0\nUAE\u00a0 Unerw\u00fcnschtes\u00a0Arzneimittelereignis\u00a0\nUAW\u00a0 Unerw\u00fcnschte\u00a0Arzneimittelwirkung\u00a0UC\u00a0 Uncommon\u00a0Mutations ,\u00a0ungew\u00f6hnliche\u00a0Mutationen\u00a0\nunmet\u00a0medical\u00a0nee\nd\u00a0 nicht\u00a0durch\u00a0derzeitige\u00a0Therapie m\u00f6glichkeiten\u00a0abgedeckter\u00a0mediz ini\u2010\nscher\u00a0Bedarf\u00a0\nVEGF\u00a0 Vascular\u00a0Endothelial\u00a0Growth\u00a0Factor,\u00a0 vaskul\u00e4rer\u00a0endothelialer\u00a0Wachs\u2010\ntumsfaktor\u00a0\nVEGFR\u00a0 Vascular\u00a0Endothelial\u00a0Growth\u00a0Factor\u00a0Receptor ,\u00a0vaskul\u00e4rer\u00a0endothelialer\u00a0\nWachstumsfaktor\u2010Rezeptor\u00a0\nVaIN2\u00a0oder\u00a03\u00a0 Vaginal\u00a0Intraepithelial\u00a0Neoplasia ,\u00a0hochgradigen\u00a0intraepithelialen\u00a0Neo\u2010\nplasien\u00a0der\u00a0Vagina\u00a0\nVIN2\u00a0oder\u00a03\u00a0 Vulval\u00a0Intraepithelial\u00a0Neoplasia ,\u00a0intraepitheliale\u00a0Neoplasien\u00a0der\u00a0Vulva\u00a0\nvs.\u00a0 versus,\u00a0gegen\u00a0\nWHO\u00a0 World\u00a0Health\u00a0Organization ,\u00a0Weltgesundheitsorganisation\u00a0\nw\u00f6ch.\u00a0 w\u00f6chentlich\u00a0ZN\u00a0 Zusatznutzen\u00a0\nZNS\u00a0 Zentrales\u00a0Nervensystem\u00a0\nzVT\u00a0 zweckm\u00e4\u00dfige\u00a0Vergleichstherapie\u00a0\nmg\u00a0 Milligramm\u00a0\n\u00b5g\u00a0 Mikrogramm\u00a0\n\u00a0\nDie\u00a0Begriffsbestimmungen\u00a0zu\u00a0den\u00a0beschleunigten\u00a0Zulassungsverfah ren\u00a0aus:\u00a0\nLudwig\u00a0WD\u00a0(2018).\u00a0Zulassungsverfahren\u00a0f\u00fcr\u00a0neue\u00a0Arzneimittel\u00a0in\u00a0 Europa.\u00a0Arzneiverordnungsreport\u00a02018.\u00a0In:\u00a0Schwabe\u00a0U,\u00a0Paffrath\u00a0\nD,\u00a0Ludwig\u00a0W\u2010D,\u00a0Klauber\u00a0J\u00a0(Hrsg.)\u00a0(2018).\u00a0Arzneiverordnungs\u2010Repo rt\u00a02018.\u00a0Berlin,\u00a0Heidelberg.\u00a0Springer:\u00a027\u201051.\u00a0\n\u00a0\u00a013\u00a0Vorwort\u00a0zum\u00a0Innovationsreport\u00a02019\u00a0\nDr.\u00a0Jens\u00a0Baas,\u00a0Vorsitzender\u00a0des\u00a0 Vorstands\u00a0der\u00a0Techniker\u00a0Kranken kasse\u00a0\nMit\u00a0dem\u00a0Innovationsreport\u00a0beglei tet\u00a0die\u00a0Techniker\u00a0Krankenkasse\u00a0 seit\u00a0nun\u00a0schon\u00a0\nsieben\u00a0Jahren\u00a0den\u00a0Prozess\u00a0der\u00a0fr\u00fchen\u00a0Nutzenbewertung\u00a0von\u00a0Arznei mitteln.\u00a0Der\u00a0\nReport\u00a0ist\u00a0wie\u00a0in\u00a0den\u00a0vergangenen\u00a0Jahren\u00a0unter\u00a0der\u00a0Leitung\u00a0der\u00a0 Herausgeber\u00a0\u00a0\nProfessor\u00a0Dr.\u00a0Gerd\u00a0Glaeske\u00a0vom\u00a0S OCIUM\u00a0\u2013\u00a0Forschungszentrum\u00a0Ungle ichheit\u00a0und\u00a0\nSo z i al po li ti k\u00a0an\u00a0der\u00a0U ni v ersi t\u00e4t\u00a0Brem en\u00a0und\u00a0Pro f esso r\u00a0Dr.\u00a0Wo l f \u2010 Dieter\u00a0Ludwig,\u00a0\nVorstandsvorsitzender\u00a0der\u00a0Arznei mittelkommission\u00a0der\u00a0deutschen\u00a0 \u00c4rzteschaft,\u00a0ent\u2010\nstanden.\u00a0In\u00a0diesem\u00a0Jahr\u00a0wurden\u00a021\u00a0neue\u00a0Wirkstoffe\u00a0des\u00a0Jahres\u00a020 16\u00a0in\u00a023\u00a0Arznei\u2010\nmitteln\u00a0nach\u00a0der\u00a0bew\u00e4hrten\u00a0Ampels ystematik\u00a0hinsichtlich\u00a0zur\u00a0Ver f\u00fcgung\u00a0stehen\u2010\nder\u00a0Therapiealternativen,\u00a0patien ten\u2010orientiertem\u00a0Zusatznutzen\u00a0u nd\u00a0Vergleichskos\u2010\nten\u00a0bewertet.\u00a0\u00a0\nDie\u00a0positive\u00a0Entwicklung\u00a0des\u00a0ver gangenen\u00a0Jahres\u00a0konnte\u00a0sich\u00a0lei der\u00a0nicht\u00a0fortset\u2010\nzen:\u00a0Die\u00a0Arzneimittel\u00a0des\u00a0Jahr es\u00a02016\u00a0sind\u00a0weniger\u00a0innovativ\u00a0un d\u00a0zus\u00e4tzlich\u00a0kos\u2010\ntenintensiver\u00a0als\u00a0die\u00a0aus\u00a02015.\u00a0Lediglich\u00a0f\u00fcnf\u00a0Arzneimittel\u00a0erh ielten\u00a0eine\u00a0gr\u00fcne\u00a0\nGesamtampel.\u00a0Dies\u00a0entspricht\u00a0zwar\u00a0wie\u00a0im\u00a0Vorjahr\u00a0etwa\u00a022\u00a0%\u00a0alle r\u00a0bewerteten\u00a0\nArzneimittel,\u00a0jedoch\u00a0hat\u00a0sich\u00a0der\u00a0Anteil\u00a0der\u00a0Pr\u00e4parate,\u00a0die\u00a0die \u00a0Herausgeber\u00a0nicht\u00a0\n\u00fcberzeugen\u00a0konnten,\u00a0fast\u00a0verdoppelt.\u00a0Mit\u00a014\u00a0von\u00a023\u00a0Arzneimittel n\u00a0wurde\u00a0f\u00fcr\u00a0mehr\u00a0\nals\u00a0die\u00a0H\u00e4lfte\u00a0aller\u00a0betrachtete n\u00a0Pr\u00e4parate\u00a0eine\u00a0rote\u00a0Gesamtamp el\u00a0vergeben.\u00a0\u00a0\nNachdem\u00a0 im\u00a0 vergangenen\u00a0 Jahr\u00a0 erfreulicherweise\u00a0 ein\u00a0 deutlicher\u00a0 R\u00fc ckgang\u00a0 des\u00a0\ndurchschnittlichen\u00a0Packungspreises\u00a0der\u00a0bewerteten\u00a0Arzneimittel\u00a0 auf\u00a01.048\u00a0\u20ac\u00a0zu\u00a0\nverzeichnen\u00a0war,\u00a0stieg\u00a0dieser\u00a0nun\u00a0wieder\u00a0um\u00a0gut\u00a025\u00a0%\u00a0auf\u00a01.298\u00a0 \u20ac\u00a0an.\u00a0Dies\u00a0ist\u00a0\numso\u00a0bemerkenswerter,\u00a0da\u00a040\u00a0%\u00a0der\u00a0verordneten\u00a0Packungen\u00a0auf\u00a0den \u00a0Impfstoff\u00a0\ngegen\u00a0humane\u00a0Papillomviren\u00a0(HPV)\u00a0Gardasil\u00ae\u00a09\u00a0entfielen,\u00a0der\u00a0mit \u00a0rund\u00a0160\u00a0\u20ac\u00a0pro\u00a0\nPackung\u00a0verh\u00e4ltnism\u00e4\u00dfig\u00a0kosteng \u00fcnstig\u00a0ist.\u00a0Allerdings\u00a0enth\u00e4lt\u00a0d er\u00a0Innovationsre\u2010\nport\u00a02019\u00a0auch\u00a0zwei\u00a0Pr\u00e4parate\u00a0zur\u00a0Behandlung\u00a0der\u00a0chronischen\u00a0He patitis\u00a0C\u00a0sowie\u00a0\nden\u00a0Wirkstoff\u00a0Migalastat,\u00a0die\u00a0jeweils\u00a0mit\u00a0Packungspreisen\u00a0im\u00a0f\u00fc nfstelligen\u00a0Bereich\u00a0\nzu\u00a0Buche\u00a0schlagen.\u00a0Obwohl\u00a0diese\u00a0Arzneimittel\u00a0insgesamt\u00a0nur\u00a0gut\u00a0 2\u00a0%\u00a0aller\u00a0Verord\u2010\nnungen\u00a0ausmachen,\u00a0treiben\u00a0sie\u00a0somit\u00a0den\u00a0durchschnittlichen\u00a0Pack ungspreis\u00a0nach\u00a0\noben.\u00a0\u00a0\nBislang\u00a0wurden\u00a0Impfstoffe\u00a0im\u00a0Innovationsreport\u00a0nicht\u00a0bewertet,\u00a0 da\u00a0sie\u00a0von\u00a0der\u00a0\nfr\u00fchen\u00a0Nutzenbewertung\u00a0nicht\u00a0erfasst\u00a0sind.\u00a0Aufgrund\u00a0der\u00a0Aktuali t\u00e4t\u00a0des\u00a0Themas\u00a0\nImpfen\u00a0haben\u00a0die\u00a0Verfasser\u00a0in\u00a0dem\u00a0nun\u00a0vorliegenden\u00a0Report\u00a0erstm als\u00a0einen\u00a0Impf\u2010\nstoff\u00a0bewertet.\u00a0Auch\u00a0das\u00a0diesj\u00e4hrige\u00a0Sonderkapitel\u00a0widmet\u00a0sich\u00a0 dem\u00a0Thema\u00a0Imp\u2010\nfen\u00a0am\u00a0Beispiel\u00a0der\u00a0HPV\u2010\u00a0und\u00a0Gri ppeimpfung\u00a0und\u00a0greift\u00a0zudem\u00a0das \u00a0aktuell\u00a0viel\u00a0\ndiskutierte\u00a0Thema\u00a0Impfpflicht\u00a0am\u00a0Beispiel\u00a0der\u00a0Masern\u00a0auf.\u00a014\u00a0Die\u00a0 Impfempfehlungen\u00a0 der\u00a0 STIKO\u00a0 w erden\u00a0 kontinuierlich\u00a0 aktualisie rt.\u00a0 J\u00fcngstes\u00a0\nBeispiel\u00a0ist\u00a0die\u00a0Ausweitung\u00a0der\u00a0Empfehlungen\u00a0zur\u00a0HPV\u2010Impfung\u00a0au ch\u00a0auf\u00a0Jungen,\u00a0\nmit\u00a0der\u00a0man\u00a0sich\u00a0das\u00a0Erreichen\u00a0e iner\u00a0Herdenimmunit\u00e4t\u00a0erhofft.\u00a0D iese\u00a0Empfehlung\u00a0\nberuht\u00a0allerdings\u00a0auf\u00a0im\u00a0Vergleich\u00a0zu\u00a0M\u00e4dchen\u00a0und\u00a0jungen\u00a0Frauen \u00a0unverh\u00e4ltnis\u2010\nm\u00e4\u00dfig\u00a0 kleineren\u00a0 Studienpopulatio n e n , \u00a0w i e \u00a0d i e \u00a0A u t o r e n \u00a0d e s \u00a0I n n o v a tionsreports\u00a0\nfeststellen.\u00a0Deshalb\u00a0ist\u00a0bislang \u00a0noch\u00a0unklar,\u00a0ob\u00a0die\u00a0Impfung\u00a0be i\u00a0Jungen\u00a0genauso\u00a0\neffektiv\u00a0ist\u00a0wie\u00a0bei\u00a0M\u00e4dchen\u00a0und\u00a0jungen\u00a0Frauen.\u00a0Auch\u00a0f\u00fcr\u00a0Impfun gen\u00a0sollte\u00a0daher\u00a0\nein\u00a0transparenter\u00a0Bewertungspro zess\u00a0\u00e4hnlich\u00a0dem\u00a0der\u00a0fr\u00fchen\u00a0Nutz enbewertung\u00a0\nvon\u00a0Arzneimitteln\u00a0geschaffen\u00a0werden.\u00a0\u00a0\nDas\u00a0Ph\u00e4nomen\u00a0der\u00a0Herdenimmunit\u00e4t\u00a0k\u00f6nnte\u00a0man\u00a0sich\u00a0zuk\u00fcnftig\u00a0auch \u00a0bei\u00a0der\u00a0\nGrippe\u00a0zunutze\u00a0machen.\u00a0Die\u00a0Impfung\u00a0ist\u00a0bei\u00a0\u00e4lteren\u00a0Menschen\u00a0auf grund\u00a0der\u00a0ein\u2010\ngeschr\u00e4nkten\u00a0Funktionsf\u00e4higkeit\u00a0ihres\u00a0Immunsystems\u00a0wenig\u00a0effekt iv.\u00a0Diese\u00a0k\u00f6nn\u2010\nten\u00a0aber\u00a0durch\u00a0eine\u00a0Immunisierung\u00a0von\u00a0Kindern\u00a0und\u00a0Jugendlichen\u00a0 zus\u00e4tzlich\u00a0ge\u2010\nsch\u00fctzt\u00a0werden.\u00a0Daher\u00a0empfehlen\u00a0verschiedene\u00a0L\u00e4nder\u00a0\u2013\u00a0anders\u00a0al s\u00a0Deutschland\u00a0\u2013\u00a0\nbereits\u00a0eine\u00a0Grippeschutzimpfung \u00a0f\u00fcr\u00a0Kinder\u00a0und\u00a0Jugendliche.\u00a0Ei ne\u00a0Ma\u00dfnahme,\u00a0\nwelche\u00a0die\u00a0Autoren\u00a0ebenfalls\u00a0in\u00a0 dem\u00a0Sonderkapitel\u00a0diskutieren.\u00a0 \u00a0\nDie\u00a0Effektivit\u00e4t\u00a0der\u00a0Masernimpfung\u00a0ist\u00a0demgegen\u00fcber\u00a0sehr\u00a0hoch.\u00a0 Trotzdem\u00a0rei\u2010\nchen\u00a0die\u00a0aktuellen\u00a0Impfquoten\u00a0derzeit\u00a0nicht\u00a0aus,\u00a0um\u00a0das\u00a0WHO\u2010Zie l\u00a0der\u00a0Maserneli\u2010\nminierung\u00a0in\u00a0Deutschland\u00a0zu\u00a0erreichen.\u00a0Immer\u00a0wieder\u00a0kommt\u00a0es\u00a0au ch\u00a0zu\u00a0gr\u00f6\u00dferen\u00a0\nAusbr\u00fcchen.\u00a0Daher\u00a0hat\u00a0Bundesgesundheitsminister\u00a0Jens\u00a0Spahn\u00a0nun\u00a0 ein\u00a0Gesetz\u00a0zur\u00a0\nEinf\u00fchrung\u00a0einer\u00a0Masernimpfpflicht\u00a0f\u00fcr\u00a0bestimmte\u00a0Bev\u00f6lkerungsgr uppen\u00a0vorge\u2010\nlegt.\u00a0Der\u00a0Report\u00a0beleuchtet\u00a0die\u00a0 Vor\u2010\u00a0und\u00a0Nachteile\u00a0dieser\u00a0Verpf lichtung\u00a0und\u00a0blickt\u00a0\nauch\u00a0in\u00a0L\u00e4nder,\u00a0in\u00a0denen\u00a0es\u00a0bereits\u00a0einschl\u00e4gige\u00a0Erfahrungen\u00a0mi t\u00a0Pflichtimpfungen\u00a0\ngibt.\u00a0Letztlich\u00a0kann\u00a0eine\u00a0Impfpflicht\u00a0immer\u00a0nur\u00a0der\u00a0letzte\u00a0Schr itt\u00a0sein.\u00a0Ihr\u00a0sollten\u00a0\nverbesserte\u00a0Aufkl\u00e4rungs\u2010\u00a0und\u00a0Inf ormationskampagnen\u00a0vorausgehen, \u00a0die\u00a0die\u00a0Be\u2010\ndenken\u00a0der\u00a0Impfskeptiker\u00a0zwar\u00a0ernst\u00a0nehmen,\u00a0ihnen\u00a0aber\u00a0evidenzb asiert\u00a0begeg\u2010\nnen.\u00a0Au\u00dferdem\u00a0sollten\u00a0die\u00a0M\u00f6glic hkeiten\u00a0der\u00a0Digitalisierung\u00a0z.B .\u00a0in\u00a0Form\u00a0eines\u00a0\ndigitalen\u00a0 Impfpasses\u00a0 st\u00e4rker\u00a0 genutzt\u00a0 werden,\u00a0 um\u00a0 Menschen\u00a0 auf\u00a0 be stehende\u00a0\nImpfl\u00fccken\u00a0aufmerksam\u00a0zu\u00a0mache n\u00a0und\u00a0an\u00a0notwendige\u00a0Auffrischunge n\u00a0zu\u00a0erin\u2010\nnern.\u00a0Solche\u00a0Ma\u00dfnahmen\u00a0k\u00f6nnen\u00a0aber\u00a0nur\u00a0greifen,\u00a0wenn\u00a0sie\u00a0fl\u00e4che ndeckend\u00a0zur\u00a0\nVerf\u00fcgung\u00a0stehen.\u00a0\n\u00a0 \u00a015\u00a0Zweites\u00a0Vorwort\u00a0zum\u00a0Innovationsreport\u00a02019\u00a0\nProf.\u00a0Dr.\u00a0Wolf\u2010Dieter\u00a0Ludwig,\u00a0Vorsitzender\u00a0der\u00a0Arzneimittelkomm ission\u00a0der\u00a0\ndeutschen\u00a0\u00c4rzteschaft\u00a0\nDie\u00a0im\u00a0Innovationsreport\u00a02019\u00a0bewerteten\u00a023\u00a0neuen\u00a0Arzneimittel\u00a0 des\u00a0Jahres\u00a02016\u00a0\nbest\u00e4tigen\u00a0die\u00a0in\u00a0den\u00a0letzten\u00a0Jahren\u00a0und\u00a0auch\u00a0aktuell\u00a0im\u00a0Jahr\u00a02 018\u00a0in\u00a0Europa\u00a0und\u00a0\nden\u00a0USA\u00a0zu\u00a0beobachtenden\u00a0Trends\u00a0i n\u00a0der\u00a0Arzneimittelentwicklung\u00a0 durch\u00a0pharma\u2010\nzeutische\u00a0 Unternehmer.\u00a0 Knapp\u00a0 ein\u00a0 Drittel\u00a0 der\u00a0 neuen\u00a0 Wirkstoffe\u00a0 s ind\u00a0Orphan\u2010\nArzneimittel,\u00a0die\u00a0nicht\u00a0nur\u00a0von\u00a0den\u00a0in\u00a0der\u00a0Verordnung\u00a0(EG)\u00a0Nr.\u00a0 141/2000\u00a0\u00fcber\u00a0\nArzneimittel\u00a0f\u00fcr\u00a0seltene\u00a0Leiden\u00a0 festgelegten\u00a0\u00f6konomischen\u00a0Anrei zen\u00a0(z.B.\u00a0kosten\u2010\nlose\u00a0wissenschaftliche\u00a0Beratung,\u00a0Befreiung\u00a0oder\u00a0Erm\u00e4\u00dfigung\u00a0von\u00a0 Geb\u00fchren\u00a0im\u00a0\nZulassungsverfahren,\u00a0zehnj\u00e4hrige\u00a0Marktexklusivit\u00e4t)\u00a0profitieren ,\u00a0sondern\u00a0mitunter\u00a0\nauch\u00a0von\u00a0beschleunigten\u00a0Zulassungsverfahren.\u00a0Diese\u00a0Entwicklung, \u00a0aber\u00a0auch\u00a0die\u00a0\nTatsache,\u00a0dass\u00a0derzeit\u00a0f\u00fcr\u00a0die\u00a0 Behandlung\u00a0von\u00a0nur\u00a0etwa\u00a01\u00a0%\u00a0der\u00a0 seltenen\u00a0Leiden\u00a0\nOrphan\u2010Arzneimittel\u00a0zur\u00a0Verf\u00fcgung\u00a0stehen,\u00a0wird\u00a0zu\u00a0Recht\u00a0kritisiert\u00a0\u2013\u00a0 so\u00a0auch\u00a0in\u00a0\neinem\u00a0aktuellen\u00a0Votum\u00a0des\u00a0Deutschen\u00a0Ethikrats\u00a0zu\u00a0den\u00a0\u201eHerausfor derungen\u00a0im\u00a0\nUmgang\u00a0mit\u00a0seltenen\u00a0Erkrankungen\u201c\u00a0(Deutscher\u00a0Ethikrat,\u00a02018).\u00a0A ngesichts\u00a0der\u00a0\n2019\u00a0prognostizierten\u00a0242\u00a0Mrd.\u00a0US\u2010Dollar,\u00a0die\u00a0im\u00a0Jahr\u00a02024\u00a0welt weit\u00a0f\u00fcr\u00a0die\u00a0Ver\u2010\nordnung\u00a0 von\u00a0 Orphan\u2010Arzneimitteln\u00a0 bezahlt\u00a0 werden\u00a0 m\u00fcssen\u00a0 (EvaluatePharma\u00ae,\u00a0\n2019),\u00a0sind\u00a0die\u00a0immer\u00a0h\u00e4ufiger\u00a0angemahnten\u00a0Reformen\u00a0in\u00a0der\u00a0Gese tzgebung\u00a0zu\u00a0\nOrphan\u2010Arzneimitteln\u00a0\u2013\u00a0sowohl\u00a0in\u00a0den\u00a0USA\u00a0als\u00a0auch\u00a0in\u00a0Europa\u00a0\u2013\u00a0sicher\u00a0 berechtigt\u00a0\n(Ludwig,\u00a02019;\u00a0Sarpatwari\u00a0&\u00a0Kesselheim,\u00a02019).\u00a0Es\u00a0gilt\u00a0deshalb, \u00a0jetzt\u00a0rasch\u00a0sinnvol\u2010\nle\u00a0 Ma\u00dfnahmen\u00a0 zu\u00a0 ergreifen,\u00a0 die\u00a0 den\u00a0 Missbrauch\u00a0 der\u00a0 bestehenden\u00a0 R egularien\u00a0\nbeenden\u00a0und\u00a0der\u00a0urspr\u00fcnglichen\u00a0Mission\u00a0der\u00a0Verordnung\u00a0f\u00fcr\u00a0 Orphan\u2010Arzneimittel\u00a0\nentsprechen,\u00a0und\u00a0zwar\u00a0die\u00a0Entwicklung\u00a0von\u00a0 Orphan\u2010Arzneimitteln\u00a0mit\u00a0gro\u00dfem\u00a0\nAufwand\u00a0f\u00fcr\u00a0die\u00a0klinische\u00a0Erforschung\u00a0und\u00a0geringer\u00a0Nachfrage\u00a0zu \u00a0f\u00f6rdern.\u00a0Es\u00a0ist\u00a0\nerfreulich,\u00a0dass\u00a0inzwischen\u00a0die\u00a0Europ\u00e4ische\u00a0Kommission\u00a0diese\u00a0En twicklung\u00a0\u2013\u00a0vor\u00a0\nallem\u00a0die\u00a0sehr\u00a0hohen\u00a0Preise\u00a0und\u00a0die\u00a0auch\u00a02019\u00a0sehr\u00a0geringe\u00a0Zahl \u00a0an\u00a0seltenen\u00a0\nKrankheiten,\u00a0die\u00a0mit\u00a0 Orphan\u2010Arzneimitteln\u00a0wirksam\u00a0und\u00a0sicher\u00a0behandelt\u00a0werden\u00a0\nk\u00f6nnen\u00a0\u2013\u00a0erkannt\u00a0hat\u00a0und\u00a0hoffentlich\u00a0bald\u00a0die\u00a0Verordnung\u00a0(EG)\u00a0N r.\u00a0141/2000\u00a0\nrevidiert.\u00a0\u00a0\nEin\u00a0weiterer\u00a0Trend\u00a0\u2013\u00a0die\u00a0Entwickl ung\u00a0zahlreicher\u00a0neuer\u00a0Wirkstof fe\u00a0f\u00fcr\u00a0die\u00a0Behand\u2010\nlung\u00a0onkologischer\u00a0bzw.\u00a0h\u00e4matolo gischer\u00a0Erkrankungen\u00a0\u2013\u00a0h\u00e4lt\u00a0ebe nfalls\u00a0an.\u00a0Dies\u00a0ist\u00a0\nkeineswegs\u00a0\u00fcberraschend\u00a0angesich ts\u00a0der\u00a0demographischen\u00a0Entwickl ung,\u00a0der\u00a0\u00f6ko\u2010\nnomischen\u00a0Lukrativit\u00e4t\u00a0dieser\u00a0Indikationen\u00a0und\u00a0der\u00a0Vielzahl\u00a0der \u00a0auch\u00a02019\u00a0meist\u00a0\nnur\u00a0mit\u00a0palliativer\u00a0Zielsetzung\u00a0zu \u00a0behandelnden\u00a0fortgeschritten en\u00a0Krebserkran\u2010\nkungen.\u00a0Die\u00a0bisher\u00a0nie\u00a0dagewesen e\u00a0Hoffnung\u00a0auf\u00a0Heilung\u00a0von\u00a0Kreb s,\u00a0ausgel\u00f6st\u00a0\nbeispielweise\u00a0durch\u00a0eine\u00a0Vielzah l\u00a0neuer,\u00a0sog.\u00a0zielgerichteter\u00a0W irkstoffe\u00a0und\u00a0vor\u00a0\nallem\u00a0Immuntherapien,\u00a0wurde\u00a0k\u00fcrzlich\u00a0in\u00a0JAMA\u00a0 Internal\u00a0Medicine \u00a0sehr\u00a0pr\u00e4zise\u00a0\nkommentiert\u00a0unter\u00a0dem\u00a0Titel:\u00a0\u201e The\u00a0Best\u00a0of\u00a0Times,\u00a0the\u00a0Worst\u00a0of\u00a0Times \u201c\u00a0(Lehman\u00a0&\u00a016\u00a0Gross,\u00a02019).\u00a0Positiv\u00a0zu\u00a0bewerten\u00a0ist\u00a0zweifelsfrei\u00a0der\u00a0Zuwachs\u00a0 an\u00a0medikament\u00f6sen\u00a0\nTherapieoptionen\u00a0f\u00fcr\u00a0die\u00a0Behandlung\u00a0von\u00a0Krebserkrankungen.\u00a0F\u00fcr\u00a0 onkologisch\u00a0t\u00e4ti\u2010\nge\u00a0\u00c4rzte\u00a0ist\u00a0es\u00a0heute\u00a0jedoch\u00a0fast\u00a0unm\u00f6glich,\u00a0Schritt\u00a0zu\u00a0halten\u00a0 mit\u00a0der\u00a0stetig\u00a0wachsen\u2010\nden\u00a0 Zahl\u00a0 neuer\u00a0 onkologischer\u00a0 Wir kstoffe\u00a0 \u2013\u00a0 eingesetzt\u00a0 als\u00a0 Monoth erapie,\u00a0 immer\u00a0\nh\u00e4ufiger\u00a0aber\u00a0auch\u00a0in\u00a0Kombinatio n\u00a0mit\u00a0anderen\u00a0onkologischen\u00a0Wir kstoffen\u00a0\u2013\u00a0und\u00a0\nst\u00e4ndig\u00a0sich\u00a0\u00e4ndernder\u00a0Klassifi kationen\u00a0aufgrund\u00a0der\u00a0(molekular genetischen)\u00a0Iden\u2010\ntifizierung\u00a0 neuer\u00a0 Subgruppen\u00a0 bei\u00a0 Krebserkrankungen.\u00a0 Dies\u00a0 wirkt\u00a0 sich\u00a0 nat\u00fcrlich\u00a0\nauch\u00a0negativ\u00a0aus\u00a0auf\u00a0die\u00a0heute\u00a0immer\u00a0wichtiger\u00a0werdenden\u00a0gemein samen\u00a0von\u00a0\nArzt\u00a0und\u00a0Patient\u00a0zu\u00a0treffenden\u00a0Entscheidungen\u00a0(\u201e shared\u00a0decision\u00a0making \u201c)\u00a0bei\u00a0\ndiesen\u00a0h\u00e4ufig\u00a0lebensbedrohlichen\u00a0Krankheiten,\u00a0da\u00a0bei\u00a0Zulassung\u00a0 meist\u00a0noch\u00a0erheb\u2010\nliche\u00a0Unsicherheit\u00a0hinsichtlich\u00a0Wirksamkeit\u00a0und\u00a0Sicherheit\u00a0der\u00a0 neuen\u00a0Arzneimittel\u00a0\nbesteht.\u00a0Viele\u00a0der\u00a0neuen\u00a0Krebsmedikamente\u00a0werden\u00a0heute\u00a0\u2013\u00a0sowohl \u00a0von\u00a0der\u00a0FDA\u00a0\nin\u00a0den\u00a0USA\u00a0als\u00a0auch\u00a0von\u00a0der\u00a0EMA\u00a0in\u00a0Europa\u00a0\u2013\u00a0nach\u00a0beschleunigten \u00a0Verfahren\u00a0zuge\u2010\nlassen.\u00a0H\u00e4ufig\u00a0basieren\u00a0diese\u00a0Zulassungen\u00a0auf\u00a0Surrogatendpunkte n\u00a0(z.B.\u00a0Ansprech\u2010\nrate\u00a0der\u00a0Tumorerkrankung,\u00a0progre ssionsfreies\u00a0\u00dcberleben),\u00a0die\u00a0ni cht\u00a0oder\u00a0nur\u00a0unzu\u2010\nreichend\u00a0korrelieren\u00a0mit\u00a0den\u00a0f\u00fcr\u00a0die\u00a0Patienten\u00a0sehr\u00a0relevanten\u00a0 Parametern\u00a0wie\u00a0\u00dcber\u2010\nlebenszeit\u00a0und\u00a0gesundheitsbezogene\u00a0Lebensqualit\u00e4t.\u00a0Besonders\u00a0na chdenklich\u00a0stim\u2010\nmen\u00a0sollten\u00a0aktuelle\u00a0Analysen,\u00a0die\u00a0anhand\u00a0der\u00a0in\u00a0den\u00a0USA\u00a0von\u00a0de r\u00a0FDA\u00a0zwischen\u00a0\n1992\u00a0und\u00a02017\u00a0beschleunigt\u00a0zugelasse nen\u00a0onkologischen\u00a0Wirkstoff e\u00a0nachwiesen,\u00a0\ndass\u00a0nur\u00a0bei\u00a0etwa\u00a020\u00a0%\u00a0dieser\u00a0Arzneimittel\u00a0in\u00a0Studien\u00a0nach\u00a0der\u00a0 Zulassung\u00a0eine\u00a0\nVerbesserung\u00a0im\u00a0Gesamt\u00fcberleben\u00a0g ezeigt\u00a0werden\u00a0konnte\u00a0(Gywali\u00a0e t\u00a0al.,\u00a02019).\u00a0\nDen\u00a0aktuellen\u00a0Herausforderunge n\u00a0in\u00a0der\u00a0Forschung\u00a0und\u00a0Entwicklun g\u00a0neuer\u00a0Arz\u2010\nneimittel\u00a0bzw.\u00a0in\u00a0der\u00a0Versorgung\u00a0von\u00a0Patienten\u00a0mit\u00a0innovativen, \u00a0einen\u00a0echten\u00a0\ntherapeutischen\u00a0Fortschritt\u00a0bedeutenden\u00a0Arzneimitteln\u00a0zu\u00a0angeme ssenen\u00a0Preisen\u00a0\nhaben\u00a0sich\u00a02018\u00a0verschiedene\u00a0Ste llungnahmen\u00a0und\u00a0Publikationen\u00a0g ewidmet,\u00a0an\u00a0\ndenen\u00a0renommierte\u00a0Experten\u00a0auf\u00a0d em\u00a0Gebiet\u00a0der\u00a0Gesundheitspoliti k,\u00a0Gesund\u2010\nheits\u00f6konomie\u00a0und\u00a0Pharmakologie\u00a0beteiligt\u00a0waren.\u00a0Als\u00a0wesentlich e\u00a0Herausforde\u2010\nrungen,\u00a0die\u00a0im\u00a0November\u00a02018\u00a0von\u00a0der\u00a0Organisation\u00a0f\u00fcr\u00a0wirtschaf tliche\u00a0Zusam\u2010\nmenarbeit\u00a0und\u00a0Entwicklung\u00a0( Organisation\u00a0for\u00a0Economic\u00a0Co\u2010operation\u00a0and\u00a0Develop\u2010\nment,\u00a0OECD)\u00a0in\u00a0einer\u00a0sehr\u00a0ausf\u00fchrlich en\u00a0Studie\u00a0(OECD,\u00a02018)\u00a0benannt \u00a0wurden,\u00a0\nz\u00e4hlt\u00a0vor\u00a0allem\u00a0die\u00a0Frage:\u00a0\u201eWie\u00a0 gelingt\u00a0es,\u00a0den\u00a0Arzneimittelmar kt\u00a0k\u00fcnftig\u00a0so\u00a0zu\u00a0\ngestalten,\u00a0dass\u00a0bessere\u00a0Ergebnisse\u00a0f\u00fcr\u00a0Patienten,\u00a0Kostentr\u00e4ger\u00a0 und\u00a0pharmazeuti\u2010\nsche\u00a0Unternehmer\u00a0generiert\u00a0werden\u00a0und\u00a0k\u00fcnftig\u00a0ein\u00a0System\u00a0etabli ert\u00a0wird,\u00a0das\u00a0die\u00a0\nrichtigen\u00a0Innovationen\u00a0f\u00fcr\u00a0die\u00a0richtigen\u00a0Patienten\u00a0zu\u00a0den\u00a0richt igen\u00a0Preisen\u00a0liefert?\u201c\u00a0\nIn\u00a0drei\u00a0Kapiteln\u00a0werden\u00a0die\u00a0neue n\u00a0medikament\u00f6sen\u00a0Therapien\u00a0besp rochen,\u00a0die\u00a0in\u00a0\nden\u00a0letzten\u00a020\u00a0Jahren\u00a0entwickelt\u00a0wurden,\u00a0ausf\u00fchrlich\u00a0auf\u00a0die\u00a0Ro lle\u00a0und\u00a0Bedeutung\u00a0\nder\u00a0biopharmazeutischen\u00a0Industrie \u00a0f\u00fcr\u00a0die\u00a0\u00f6konomische\u00a0Entwicklu ng\u00a0in\u00a0den\u00a0OECD\u2010\nMitgliedsstaaten\u00a0eingegangen\u00a0und\u00a0abschlie\u00dfend\u00a0auch\u00a016\u00a0strategis che\u00a0L\u00f6sungsan\u2010\ns\u00e4tze\u00a0vorgestellt,\u00a0um\u00a0die\u00a0aktue llen\u00a0Herausforderungen\u00a0besser\u00a0zu \u00a0meistern\u00a0als\u00a0in\u00a0\nder\u00a0Vergangenheit.\u00a0Einige\u00a0dieser\u00a0L\u00f6sungsans\u00e4tze,\u00a0die\u00a0auch\u00a0f\u00fcr\u00a0d ie\u00a0\u201eHeilung\u00a0eines\u00a017\u00a0kr\u00e4nkelnden\u00a0pharmazeutischen\u00a0Marktes\u00a0in\u00a0den\u00a0USA\u00a0bzw.\u00a0Kanada\u201c\u00a0al s\u00a0erforderlich\u00a0\nangesehen\u00a0werden\u00a0(Gaffney\u00a0&\u00a0Lexch in,\u00a02018),\u00a0seien\u00a0an\u00a0dieser\u00a0Ste lle\u00a0kurz\u00a0genannt:\u00a0\n\uf0b7 Es\u00a0bedarf\u00a0gemeinsamer\u00a0Anstrengungen\u00a0aller\u00a0in\u00a0unserem\u00a0Gesundheit s\u2010\nsystem\u00a0f\u00fcr\u00a0die\u00a0rationale\u00a0Arzneimittelversorgung\u00a0verantwortliche n\u00a0Ak\u2010\nteure,\u00a0um\u00a0die\u00a0Kosten\u00a0f\u00fcr\u00a0Forschung\u00a0und\u00a0Entwicklung\u00a0neuer\u00a0Arznei mittel\u00a0\nzu\u00a0reduzieren\u00a0und\u00a0das\u00a0viel\u00a0zu\u00a0h\u00e4ufige\u00a0Scheitern,\u00a0beispielsweise \u00a0von\u00a0on\u2010\nkologischen\u00a0 Wirkstoffen,\u00a0 im\u00a0 Rahmen\u00a0 der\u00a0 pr\u00e4klinischen\u00a0 Forschung\u00a0 zu\u00a0\nverhindern.\u00a0\n\uf0b7 Der\u00a0Wettbewerb\u00a0sollte\u00a0sowohl\u00a0im\u00a0Patentmarkt\u00a0als\u00a0auch\u00a0bei\u00a0patent freien\u00a0\nArzneimittel\u00a0(Generika,\u00a0Biosimilars)\u00a0st\u00e4rker\u00a0gef\u00f6rdert\u00a0werden.\u00a0 So\u00a0signali\u2010\nsiert\u00a0beispielweise\u00a0die\u00a0Verf\u00fcgbarkeit\u00a0von\u00a035\u00a0Biosimilars\u00a0zu\u00a013\u00a0 verschie\u2010\ndenen\u00a0Originalbiologika\u00a0(Ende\u00a02018)\u00a0ein\u00a0erhebliches\u00a0Einsparpote nzial\u00a0\nbei\u00a0rationaler\u00a0Verordnung\u00a0der\u00a0Biosimilars\u00a0durch\u00a0\u00c4rzte.\u00a0\u00a0\n\uf0b7 Die\u00a0Kriterien\u00a0f\u00fcr\u00a0Erstattung\u00a0und\u00a0Preissetzung\u00a0neuer\u00a0patentgesch \u00fctzter\u00a0\nArzneimittel\u00a0sollten\u00a0\u00fcberdacht\u00a0werden\u00a0und\u00a0vertragliche\u00a0Rabatte\u00a0 (sog.\u00a0\n\u201eManaged\u00a0Entry\u00a0Agreements \u201c)\u00a0an\u00a0Bedeutung\u00a0gewinnen.\u00a0\n\uf0b7 Die\u00a0gezielte\u00a0Entwicklung\u00a0neuer\u00a0A rzneimittel\u00a0f\u00fcr\u00a0Indikationen\u00a0mi t\u00a0heutzu\u2010\ntage\u00a0nur\u00a0unzureichend\u00a0wirksamen\u00a0 medikament\u00f6sen\u00a0Therapieoptionen \u00a0\nsollte\u00a0durch\u00a0geeignete\u00a0Anreize\u00a0und\u00a0Gelder\u00a0der\u00a0\u00f6ffentlichen\u00a0Hand \u00a0voran\u2010\ngetrieben\u00a0werden.\u00a0Dies\u00a0setzt\u00a0jed och\u00a0voraus,\u00a0dass\u00a0Begriffe\u00a0wie\u00a0u ngedeck\u2010\nter\u00a0medizinischer\u00a0Bedarf\u00a0(\u201e unmet\u00a0medical\u00a0need \u201c)\u00a0klarer\u00a0definiert\u00a0und\u00a0\nPriorit\u00e4ten\u00a0bei\u00a0der\u00a0Entwicklung\u00a0neuer\u00a0Wirkstoffe\u00a0durch\u00a0unabh\u00e4ng ige\u00a0Ex\u2010\nperten\u00a0festgesetzt\u00a0werden.\u00a0\n\uf0b7 Reformen\u00a0hinsichtlich\u00a0der\u00a0Anforderungen\u00a0an\u00a0die\u00a0Zulassung\u00a0neuer\u00a0 Arz\u2010\nneimittel\u00a0sind\u00a0dringend\u00a0erforderlich.\u00a0\u00a0\n\uf0b7 Die\u00a0Transparenz\u00a0hinsichtlich\u00a0der\u00a0Ausgaben\u00a0der\u00a0pharmazeutischen\u00a0 Un\u2010\nternehmer\u00a0f\u00fcr\u00a0Forschung\u00a0und\u00a0Entwicklung\u00a0bzw.\u00a0die\u00a0mit\u00a0ihren\u00a0Arzn eimit\u2010\nteln\u00a0erzielten\u00a0Gewinne\u00a0muss\u00a0verbessert\u00a0werden.\u00a0\u00a0\n\uf0b7 Gestoppt\u00a0werden\u00a0sollte\u00a0der\u00a0bereits\u00a0seit\u00a0mehreren\u00a0Jahren\u00a0zu\u00a0beob ach\u2010\ntende\u00a0Trend,\u00a0die\u00a0derzeit\u00a0existie renden\u00a0regulatorischen\u00a0Anreize\u00a0 (siehe\u00a0\nOrphan\u2010Arzneimittel)\u00a0in\u00a0erster\u00a0Linie\u00a0dazu\u00a0zu\u00a0nutzen,\u00a0hohe\u00a0Gewinne\u00a0zu\u00a0\nerzielen,\u00a0und\u00a0weniger\u00a0die\u00a0f\u00fcr\u00a0die\u00a0\u00f6ffentliche\u00a0Gesundheit\u00a0wichti gen\u00a0Ziele\u00a0\nin\u00a0Forschung\u00a0und\u00a0Entwicklung\u00a0ne uer\u00a0Wirkstoffe\u00a0zu\u00a0verfolgen.\u00a0\n\u00a0\u00a018\u00a0Quellen\u00a0\nDeutscher\u00a0Ethikrat\u00a0(2018).\u00a0Herausforderungen\u00a0im\u00a0Umgang\u00a0mit\u00a0selt enen\u00a0Erkrankungen.\u00a0Ad\u2010hoc\u00a0Empfehlung.\u00a0\nhttps://www.ethikrat.org/fileadmin/Publikationen/Ad\u2010hoc\u2010Empfehl ungen/deutsch/herausforderungen\u2010im\u2010umgang\u2010\nmit\u2010seltenen\u2010erkrankungen.pdf,\u00a0letzter\u00a0Zugriff:\u00a014.08.2019.\u00a0\nEvaluatePharma\u00ae\u00a0(2019).\u00a0Orphan\u00a0Dr ug\u00a0Report\u00a02019. \u00a0https://www.ev aluate.com/thought\u2010leadership/pharma/evaluatepharma\u2010\norphan\u2010drug\u2010report\u20102019,\u00a0letzter\u00a0Zugriff:\u00a014.08.2019.\u00a0\nLudwig\u00a0WD\u00a0(2019).\u00a0Orphan\u00a0Drugs\u00a0aus\u00a0Sicht\u00a0der\u00a0Arzneimittelkommis sion\u00a0der\u00a0deutschen\u00a0\u00c4rzteschaft.\u00a0Chancen\u00a0und\u00a0\nHerausforderungen.\u00a0Internist\u00a060:\u00a0399\u2010404.\u00a0\nSarpatwari\u00a0A,\u00a0Kesselheim\u00a0AS\u00a0(2019) .\u00a0Reforming\u00a0the\u00a0Orphan\u00a0Drug\u00a0A ct\u00a0for\u00a0the\u00a021st\u00a0Century.\u00a0NEJM\u00a0381:\u00a0106\u2010108.\u00a0\nLehman\u00a0R,\u00a0Gross\u00a0CP\u00a0(2019).\u00a0An\u00a0international\u00a0perspective\u00a0on\u00a0drug s\u00a0of\u00a0cancer.\u00a0The\u00a0best\u00a0of\u00a0times,\u00a0the\u00a0worst\u00a0of\u00a0times.\u00a0JAMA\u00a0Intern \u00a0\nMed\u00a0179:\u00a0913\u2010914.\u00a0\nGywali\u00a0B,\u00a0Hey\u00a0SP,\u00a0Kesselheim\u00a0AS\u00a0(2019).\u00a0Assessment\u00a0of\u00a0the\u00a0clini cal\u00a0benefit\u00a0of\u00a0cancer\u00a0drugs\u00a0receiving\u00a0accelerated\u00a0approval.\u00a0JAM A\u00a0\nIntern\u00a0Med\u00a0179:\u00a0906\u2010913.\u00a0\nOECD\u00a0\u2013\u00a0Organisation\u00a0for\u00a0Economic\u00a0Co\u2010operation\u00a0and\u00a0Development\u00a0( 2018).\u00a0Health\u00a0Policy\u00a0Studies:\u00a0Pharmaceutical\u00a0Innovation\u00a0and\u00a0\nAccess\u00a0to\u00a0Medicines.\u00a0https://rea d.oecd\u2010ilibrary.org/social\u2010issu es\u2010migration\u2010health/pharmaceutical\u2010innovation\u2010and\u2010\naccess\u2010to\u2010medicines_9789264307391\u2010en#page1,\u00a0letzter\u00a0Zugriff:\u00a014 .08.2019.\u00a0\nGaffney\u00a0A,\u00a0Lexchin\u00a0J\u00a0(2018).\u00a0Hea ling\u00a0an\u00a0ailing\u00a0pharmaceutical\u00a0s ystem:\u00a0prescription\u00a0for\u00a0reform\u00a0f or\u00a0United\u00a0States\u00a0and\u00a0Canada.\u00a0BM J\u00a0\n361:\u00a0k1039.\u00a0 \u00a019\u00a01 Einleitung\u00a0\nGerd\u00a0Glaeske\u00a0\nIm\u00a0Innovationsreport\u00a02019\u00a0werden\u00a0die\u00a0im\u00a0Jahr\u00a02016\u00a0neu\u00a0zugelasse nen\u00a0Arzneimit\u2010\ntel\u00a0bez\u00fcglich\u00a0ihrer\u00a0Verordnungsh \u00e4ufigkeit\u00a0und\u00a0der\u00a0publizierten\u00a0 wissenschaftlichen\u00a0\nErgebnisse\u00a0zum\u00a0Patientennutzen\u00a0und\u00a0zu\u00a0den\u00a0neu\u00a0aufgetretenen\u00a0une rw\u00fcnschten\u00a0\nEreignissen\u00a0im\u00a0Versorgungsalltag\u00a0analysiert\u00a0und\u00a0nach\u00a0den\u00a0Grunds \u00e4tzen\u00a0der\u00a0evi\u2010\ndenzbasierten\u00a0Medizin\u00a0einer\u00a0Gesa mtbewertung\u00a0unterzogen.\u00a0Der\u00a0Ver sorgungsalltag\u00a0\nwird\u00a0auf\u00a0der\u00a0Basis\u00a0von\u00a0Routineda ten\u00a0der\u00a0Techniker\u00a0Krankenkasse\u00a0 (TK)\u00a0aus\u00a0den\u00a0\nJahren\u00a02016\u00a0und\u00a02017\u00a0beschrieben. \u00a0F\u00fcr\u00a0die\u00a0jeweiligen\u00a0Kostenbere chnungen\u00a0der\u00a0\nBehandlung\u00a0mit\u00a0den\u00a0besprochenen\u00a0Arzneimitteln,\u00a0die\u00a0ebenfalls\u00a0in \u00a0die\u00a0Gesamtbe\u2010\nwertung\u00a0miteingehen,\u00a0wurden\u00a0die\u00a0Preise\u00a0mit\u00a0Stand\u00a0vom\u00a015.\u00a0Januar \u00a02019\u00a0herange\u2010\nzogen.\u00a0Auf\u00a0der\u00a0Basis\u00a0der\u00a0TK\u2010Rout inedaten\u00a0wurden\u00a0auch\u00a0regionale\u00a0 Verordnungscha\u2010\nrakteristika\u00a0ermittelt,\u00a0sowohl\u00a0f\u00fcr\u00a0die\u00a0neuen\u00a0Mittel\u00a0insgesamt\u00a0a ls\u00a0auch\u00a0gesondert\u00a0\nf\u00fcr\u00a0solche\u00a0Pr\u00e4parate,\u00a0die\u00a0nach\u00a0unseren\u00a0in\u00a0der\u00a0Methodik\u00a0beschrie benen\u00a0Bewertung\u00a0\nweder\u00a0einen\u00a0Zusatznutzen\u00a0f\u00fcr\u00a0Pati enten\u00a0noch\u00a0unter\u00a0Kostenaspekte n\u00a0Vorteil\u00a0ge\u2010\ngen\u00fcber\u00a0bew\u00e4hrten\u00a0therapeutischen\u00a0Interventionen\u00a0aufweisen\u00a0und\u00a0 die\u00a0daher\u00a0gar\u00a0\nnicht\u00a0erst\u00a0verordnet\u00a0werden\u00a0sollten.\u00a0\nUnter\u00a0den\u00a0in\u00a0diesem\u00a0Innovationsreport\u00a0betrachteten\u00a0neuen\u00a0Wirkst offen\u00a0des\u00a0Jahres\u00a0\n2016\u00a0befindet\u00a0sich\u00a0auch\u00a0der\u00a0HPV\u00a0(Humanen\u00a0Papillomvirus)\u2010Impfsto ff\u00a0Gardasil\u00ae\u00a09.\u00a0\nDies\u00a0ist\u00a0auch\u00a0der\u00a0Grund\u00a0f\u00fcr\u00a0die\u00a0Aufnahme\u00a0eines\u00a0Sonderkapitels\u00a0i n\u00a0diesen\u00a0Report\u00a0(s.\u00a0\nKapitel\u00a06),\u00a0das\u00a0insbesondere\u00a0d ie\u00a0aktuelle\u00a0und\u00a0bisher\u00a0publiziert e\u00a0Evidenz\u00a0f\u00fcr\u00a0die\u00a0\nHPV\u2010Impfung\u00a0referiert,\u00a0aber\u00a0zus\u00e4 tzlich\u00a0auch\u00a0die\u00a0Diskussion\u00a0\u00fcber \u00a0die\u00a0Impfung\u00a0all\u2010\ngemein\u00a0aufnimmt,\u00a0die\u00a0sich\u00a0derzei t\u00a0vor\u00a0allem\u00a0im\u00a0Zusammenhang\u00a0mit \u00a0der\u00a0Masern\u2010\nimpfung\u00a0und\u00a0einer\u00a0m\u00f6glichen\u00a0Impf pflicht\u00a0entwickelt\u00a0hat.\u00a0Ein\u00a0vor gelegter\u00a0Entwurf\u00a0\neines\u00a0Masernschutzgesetzes,\u00a0das\u00a0u .a.\u00a0die\u00a0Zwangsimpfung\u00a0von\u00a0\u00c4rzt en,\u00a0Gefl\u00fcchteten\u00a0\nin\u00a0Fl\u00fcchtlingsunterk\u00fcnften,\u00a0Lehrern\u00a0und\u00a0Betreuern\u00a0in\u00a0KITAS,\u00a0Kin derg\u00e4rten\u00a0oder\u00a0\nSchulen\u00a0und\u00a0ein\u00a0KITA\u2010Verbot\u00a0f\u00fcr\u00a0ungeimpfte\u00a0Kinder\u00a0sowie\u00a0Geldstr afen\u00a0f\u00fcr\u00a0Eltern\u00a0\noder\u00a0Erziehungsberechtigte\u00a0vorsieht,\u00a0die\u00a0ihre\u00a0Kinder\u00a0nicht\u00a0impf en\u00a0lassen,\u00a0wurde\u00a0\nam\u00a017.\u00a0Juli\u00a02019\u00a0im\u00a0Bundeskabinett\u00a0verabschiedet.\u00a0Nun\u00a0stehen\u00a0no ch\u00a0die\u00a0Beratun\u2010\ngen\u00a0im\u00a0Bundesrat\u00a0und\u00a0der\u00a0Beschluss\u00a0im\u00a0Bundestag\u00a0aus,\u00a0bevor\u00a0das\u00a0 Gesetz\u00a0im\u00a0M\u00e4rz\u00a0\n2020\u00a0in\u00a0Kraft\u00a0treten\u00a0soll\u00a0(BMG,\u00a02019).\u00a0In\u00a0diesem\u00a0Kapitel\u00a0werden \u00a0auch\u00a0Impfquoten\u00a0\naus\u00a0Deutschland\u00a0und\u00a0aus\u00a0anderen\u00a0L\u00e4ndern\u00a0verglichen,\u00a0in\u00a0denen,\u00a0w ie\u00a0bei\u00a0uns,\u00a0Impf\u2010\nempfehlungen,\u00a0bestehen\u00a0oder\u00a0eine\u00a0Impfplicht\u00a0eingef\u00fchrt\u00a0worden\u00a0i st.\u00a0Die\u00a0auf\u00a0die\u2010\nser\u00a0Basis\u00a0dargestellten\u00a0Analysen\u00a0sollen\u00a0letztlich\u00a0Pro\u2010\u00a0oder\u00a0Con tra\u2010Argumente\u00a0f\u00fcr\u00a0\neine\u00a0Impfpflicht\u00a0liefern.\u00a0Dass\u00a0Im pfempfehlungen\u00a0auch\u00a0einer\u00a0aktu ellen\u00a0Evidenzori\u2010\nentierung\u00a0folgen\u00a0sollten,\u00a0wird\u00a0schlie\u00dflich\u00a0am\u00a0Beispiel\u00a0der\u00a0Grip peimpfung\u00a0gezeigt,\u00a0\ndie\u00a0vor\u00a0allem\u00a0die\u00a0Kinder\u00a0und\u00a0Jugendlichen\u00a0st\u00e4rker\u00a0als\u00a0bisher\u00a0be r\u00fccksichtigen\u00a0sollte.\u00a0\nInsgesamt\u00a0kommen\u00a0wir\u00a0in\u00a0diesem\u00a0Kapitel\u00a0zu\u00a0dem\u00a0Ergebnis,\u00a0dass\u00a0di e\u00a0Transparenz\u00a020\u00a0f\u00fcr\u00a0die\u00a0Zulassungsbedingungen\u00a0und\u00a0die\u00a0Empfehlungen\u00a0f\u00fcr\u00a0Impfstof fe\u00a0sowie\u00a0die\u00a0\nInformation\u00a0\u00fcber\u00a0das\u00a0Ausma\u00df\u00a0des\u00a0Nutzens\u00a0einer\u00a0Impfung\u00a0im\u00a0Verh\u00e4l tnis\u00a0zu\u00a0m\u00f6gli\u2010\nchen\u00a0Sch\u00e4den\u00a0verst\u00e4ndlicher\u00a0form uliert\u00a0und\u00a0insgesamt\u00a0verbessert \u00a0werden\u00a0m\u00fcssen.\u00a0\nIm\u00a0Jahre\u00a02018\u00a0wurden,\u00a0ohne\u00a0die\u00a0Biosimilars\u00a0einzurechnen,\u00a036\u00a0neu e\u00a0Medikamente\u00a0\nauf\u00a0den\u00a0Markt\u00a0gebracht.\u00a0Ein\u00a0Dri ttel\u00a0aller\u00a0neuen\u00a0Arzneimittel,\u00a0i nsgesamt\u00a0zw\u00f6lf,\u00a0wird\u00a0\nzur\u00a0 Behandlung\u00a0 von\u00a0 Krebserkrankungen\u00a0 angeboten,\u00a0 zehn\u00a0 zur\u00a0 Behand lung\u00a0 von\u00a0\nStoffwechselerkrankungen.\u00a0 Gemessen\u00a0 an\u00a0 den\u00a0 Jahren\u00a0 zuvor\u00a0 ist\u00a0 die\u00a0 Anzahl\u00a0 von\u00a0\nneuen\u00a0Medikamenten\u00a0leicht\u00a0angewachsen\u00a0(s.\u00a0auch\u00a0Abbildung\u00a01.1),\u00a0 gleichgeblieben\u00a0\nist\u00a0aber\u00a0die\u00a0Dominanz\u00a0der\u00a0Mittel \u00a0zur\u00a0Anwendung\u00a0in\u00a0der\u00a0Onkologie .\u00a0\u00a0\nAbbildung\u00a01.1:\u00a0Neue\u00a0Wirkstoffe\u00a0im\u00a0Jahr\u00a02018\u00a0\n\u00a0\nQuelle\u00a0vfa,\u00a02019\u00a0\nNeben\u00a0den\u00a0neuen\u00a0Mitteln\u00a0zur\u00a0Beh andlung\u00a0von\u00a0Krebs\u2010\u00a0und\u00a0Stoffwech selerkrankun\u2010\ngen\u00a0sind\u00a0noch\u00a0jeweils\u00a0vier\u00a0Mi ttel\u00a0gegen\u00a0Entz\u00fcndungen\u00a0und\u00a0Infekt ionen\u00a0im\u00a0Jahre\u00a0\n2018\u00a0auf\u00a0den\u00a0Markt\u00a0gekommen.\u00a0Der\u00a0Rest\u00a0entf\u00e4llt\u00a0auf\u00a0Blutungskran kheiten\u00a0(zwei),\u00a0\nHerz\u2010Kreislauf\u2010\u00a0 und\u00a0 psychische\u00a0 Krankheiten\u00a0 (jeweils\u00a0 eins),\u00a0 musk elskelettale\u00a0 Er\u2010\nkrankungen\u00a0(eins)\u00a0und\u00a0Schmerzen\u00a0(eins)\u00a0(s.\u00a0auch\u00a0Abbildung\u00a01.2\u00a0b zw.\u00a0Tabelle\u00a01.1)\u00a0\n(vfa,\u00a02019).\u00a0\n\u00a0\n21\u00a0Abbildung\u00a01.2:\u00a0Anwendungsgebiete\u00a0der\u00a036\u00a0neuen\u00a0Wirkstoffe\u00a0des\u00a0Ja hres\u00a02018\u00a0\n\u00a0\nQuelle\u00a0vfa,\u00a02019\u00a0\nTabelle\u00a0 1.1:\u00a0 Anwendungsgebiete\u00a0 der\u00a0 2018\u00a0 in\u00a0 Deutschland\u00a0 neu\u00a0 zuge lassenen\u00a0\nArzneimittel\u00a0\nAnwendungsgebiet\u00a0 Wirkstoff\u00a0\nKrebserkrankungen\u00a0 Brustkrebs\u00a0 Abemaciclib\u00a0\n\u00a0Begleitbehandlung\u00a0bei\u00a0\nStammzelltransplantation\u00a0allogene,\u00a0rekombinante\u00a0T\u2010Zellen\u00a0\n\u00a0 DLBC,\u00a0PMBCL\u00a0 Axicabtagen\u00a0ciloleucel\u00a0\n\u00a0 Melanom\u00a0 Binimetinib\u00a0\n\u00a0 Lungenkrebs\u00a0(NSCLC)\u00a0 Durvalumab\u00a0\n\u00a0 Melanom\u00a0 Encorafenib\u00a0\n\u00a0 akute\u00a0myeloische\u00a0Leuk\u00e4mie\u00a0(AML)\u00a0 Gemtuzumab\u00a0ozogamin\u00a0\n\u00a0gastroenteropankreatische\u00a0neuroendokrine\u00a0\nTumore\u00a0Lutetium\u00a0(177\u00a0Lu)\u00a0oxodotreotid\u00a0\n\u00a0 Prostatakrebs\u00a0 Padeliporfin\u00a0\n\u00a0 Basalzellkarzinom\u00a0 Sonidegib\u00a0\n\u00a0Diagnostikum\u00a0zur\u00a0Lokalisation\u00a0von\u00a0\nW\u00e4chterlymphknoten\u00a0Tilmanocept\u00a0\n\u00a0 ALL,\u00a0DLBCL\u00a0 Tisagenlecleucel\u00a0\n22\u00a0Anwendungsgebiet\u00a0 Wirkstoff\u00a0\n\u00a0\u00a0 \u00a0\nStoffwechselkrankheiten\u00a0 Diabetes\u00a0mellitus\u00a0Typ\u00a02\u00a0 Ertugliflozin\u00a0/\u00a0Sitagliptin\u00a0\n\u00a0 Harnstoffzyklusst\u00f6rungen\u00a0 Glycerolphenylbutyrat\u00a0\n\u00a0Polyneuropathien\u00a0bei\u00a0ererbter\u00a0Transthyretin\u2010\nAmyloidose\u00a0Inotersen\u00a0\n\u00a0 Lipodystrophien\u00a0bei\u00a0Lep tinmangel\u00a0 Metreleptin\u00a0\n\u00a0Hyperkali\u00e4mie\u00a0bei\u00a0chronischer\u00a0\nNierenerkrankung\u00a0Patiromer\u00a0\n\u00a0 Transthyretin\u2010Amyloidose,\u00a0ererbte\u00a0 Patisiran\u00a0\n\u00a0 Diabetes\u00a0mellitus\u00a0Typ\u00a02\u00a0 Semaglutid\u00a0\n\u00a0Mukoviszidose\u00a0mit\u00a0bestimmten\u00a0Mutationen\u00a0\nim\u00a0CTFR\u2010Gen\u00a0Tezacaftor\u00a0/\u00a0Ivacaftor\u00a0\n\u00a0 Alpha\u2010Mannosidose\u00a0 Velmanase\u00a0alfa\u00a0\u00a0 Mukopolysacharidose\u00a0VII\u00a0 Vestronidase\u00a0alfa\u00a0\nEntz\u00fcndungskrankheiten\u00a0 eosinophiles\u00a0Asthma\u00a0 Benralizumab\u00a0\n\u00a0 Perianalfisteln\u00a0bei\u00a0Morbus\u00a0Crohn\u00a0 Darvadstrocel\u00a0\n\u00a0Multiple\u00a0Sklerose,\u00a0pri m\u00e4r\u00a0progredient\u00a0oder\u00a0\nschubf\u00f6rmig\u00a0Ocrelizumab\u00a0\n\u00a0 Plaque\u2010Psoriasis\u00a0 Tildrakizumab\u00a0\nInfektionskrankheiten\u00a0Pr\u00e4vention\u00a0einer\u00a0Re\u2010Infektion\u00a0mit\u00a0Clostridium\u00a0\ndifficile\u00a0Bezlotoxumab\u00a0\n\u00a0 HIV\u2010Infektion\u00a0Bictegravir\u00a0/\u00a0Emtricitabin\u00a0/\u00a0\nTenofoviralafenamid\u00a0\n\u00a0 G\u00fcrtelrose\u2010Pr\u00e4vention\u00a0 Impfstoff\u00a0gegen\u00a0Herpes\u00a0Zoster\u00a0\n\u00a0CMV\u2010Prophylaxe\u00a0bei\u00a0\nStammzelltransplantation\u00a0Letermovir\u00a0\nBlutungskrankheiten\u00a0H\u00e4mophilie\u00a0A\u00a0bei\u00a0Patienten\u00a0mit\u00a0\nHemmk\u00f6rpern\u00a0gegen\u00a0Faktor\u00a0VIII\u00a0Emicizumab\u00a0\n\u00a0 H\u00e4mophilie\u00a0A\u00a0 Rurioctocog\u00a0alfa\u00a0\nHerz\u2010Kreislauf\u00a0\nKrankheiten\u00a0erworbene\u00a0thrombotische\u00a0\nthrombozytopenische\u00a0Purpura\u00a0Caplacizumab\u00a0\nMuskuloskelettale\u00a0\nErkrankungen\u00a0Hypophosphat\u00e4mie,\u00a0X\u2010chromosomal,\u00a0mit\u00a0\nKnochenerkrankung\u00a0Burosumab\u00a0\nPsychische\u00a0Krankheiten\u00a0 Schizophrenie\u00a0 Cariprazin\u00a0\nSchmerzen\u00a0 Migr\u00e4neprophylaxe\u00a0 Erenumab\u00a0\nQuelle\u00a0vfa,\u00a02019\u00a0\n\u00a0 \u00a023\u00a0Die\u00a0Verteilung\u00a0der\u00a0Indikationen\u00a0b ei\u00a0den\u00a0neu\u00a0zugelassenen\u00a0Arznei mitteln\u00a0in\u00a0den\u00a0\nUSA\u00a0ist\u00a0\u00fcbrigens\u00a0ganz\u00a0\u00e4hnlich, \u00a0wie\u00a0die\u00a0folgende\u00a0Graphik\u00a0des\u00a0 Center\u00a0for\u00a0Drug\u00a0Evalu\u2010\nation\u00a0and\u00a0Research \u00a0(CDER)\u00a0zeigt.\u00a0Dies\u00a0ist\u00a0auch\u00a0wegen\u00a0der\u00a0global\u00a0agierenden\u00a0phar\u2010\nmazeutischen\u00a0Unternehmen\u00a0(pU)\u00a0 nicht\u00a0besonders\u00a0erstaunlich:\u00a0\nAbbildung\u00a01.3:\u00a0CDER\u2010Genehmigungen\u00a0in\u00a0den\u00a0USA\u00a0nach\u00a0Therapiegebie t\u00a02018\u00a0\n\u00a0\nQuelle:\u00a0Mullard,\u00a02019,\u00a0eigene\u00a0\u00dcbersetzung\u00a0\nUnter\u00a0den\u00a0neuen\u00a0Arzneimitteln\u00a0befinden\u00a0sich\u00a0im\u00a0Jahre\u00a02018\u00a0auch\u00a0 zwei\u00a0CAR\u2010T\u2010Zell\u2010\nTherapien.\u00a0Diese\u00a0Therapien\u00a0werden\u00a0mit\u00a0ver\u00e4nderten\u00a0T\u2010Zellen\u00a0durc hgef\u00fchrt,\u00a0die\u00a0\nzuvor\u00a0den\u00a0jeweiligen\u00a0Patienten\u00a0entnommen\u00a0werden\u00a0und\u00a0die\u00a0dann\u00a0na ch\u00a0einer\u00a0gen\u2010\ntechnischen\u00a0\u201eNachr\u00fcstung\u201c\u00a0im\u00a0Labor\u00a0zur\u00fcckinjiziert\u00a0werden\u00a0und\u00a0K rebszellen\u00a0auf\u2010\nsp\u00fcren\u00a0und\u00a0zerst\u00f6ren\u00a0sollen.\u00a0Eingesetzt\u00a0wird\u00a0diese\u00a0Therapie\u00a0bei \u00a0Patienten\u00a0mit\u00a0\nbestimmten\u00a0Leuk\u00e4mien\u00a0oder\u00a0Lympho men.\u00a0Da\u00a0gravierende\u00a0unerw\u00fcnscht e\u00a0Wirkun\u2010\ngen\u00a0vorkommen\u00a0k\u00f6nnen\u00a0und\u00a0auch\u00a0der\u00a0Patientennutzen\u00a0noch\u00a0besser\u00a0u ntersucht\u00a0\nund\u00a0belegt\u00a0werden\u00a0muss,\u00a0werden\u00a0solche\u00a0Therapien\u00a0nur\u00a0in\u00a0speziali sierten\u00a0Einrich\u2010\ntungen\u00a0angewendet.\u00a0Die\u00a0beiden\u00a0zu gelassenen\u00a0CAR\u2010T\u2010Zell\u2010Produkte\u00a0 Kymriah\u00ae\u00a0und\u00a0\nYescarta\u00ae\u00a0geh\u00f6ren\u00a0zu\u00a0den\u00a0derzeit \u00a0besonders\u00a0teuren\u00a0Therapien,\u00a0so \u00a0kostet\u00a0eine\u00a0\nBehandlung\u00a0 mit\u00a0 Kymriah\u00ae\u00a0 mehr\u00a0 als\u00a0 300.000\u00a0\u20ac.\u00a0 Beide\u00a0 wurden\u00a0 als\u00a0 Orphan\u2010\nArzneimittel\u00a0zugelassen\u00a0(s.\u00a0auch \u00a0weiter\u00a0unten).\u00a0Bei\u00a0einigen\u00a0and eren\u00a0der\u00a0neuen\u00a0\nKrebsarzneimittel\u00a0 werden\u00a0 bei\u00a0 den\u00a0 betreffenden\u00a0 Patienten\u00a0 zun\u00e4chs t\u00a0 Gentests\u00a0\ndurchgef\u00fchrt,\u00a0um\u00a0eine\u00a0Stratifizierung\u00a0bez\u00fcglich\u00a0der\u00a0\u201erichtigen\u201c \u00a0Patientengruppen\u00a0\n24\u00a0vornehmen\u00a0zu\u00a0k\u00f6nnen.\u00a0Auf\u00a0diese\u00a0Weise\u00a0kann\u00a0im\u00a0Vorhinein\u00a0erreicht \u00a0werden,\u00a0dass\u00a0\nkeine\u00a0Therapie\u00a0eingeleitet\u00a0wird,\u00a0bei\u00a0der\u00a0ein\u00a0Misserfolg\u00a0wahrsch einlich\u00a0ist,\u00a0aber\u00a0\nm\u00f6gliche\u00a0unerw\u00fcnschte\u00a0Wirkungen\u00a0die\u00a0Patienten\u00a0unn\u00f6tig\u00a0belasten. \u00a0Auf\u00a0eine\u00a0vor\u2010\nhandene\u00a0BRAF\u2010V600\u2010Mutation\u00a0soll\u00a0z.B.\u00a0getestet\u00a0werden,\u00a0bevor\u00a0die \u00a0neue\u00a0Haut\u2010\nkrebs\u2010Kombination\u00a0 Braftovi\u00ae\u00a0 (Encorafenib)\u00a0 und\u00a0 Mektovi\u00ae\u00a0 (Binimet inib)\u00a0 zur\u00a0 An\u2010\nwendung\u00a0kommt.\u00a0Beide\u00a0oral\u00a0anwendbaren\u00a0Tyrosinkinasehemmer\u00a0komme n\u00a0immer\u00a0\ndann\u00a0in\u00a0Betracht,\u00a0wenn\u00a0die\u00a0Patienten\u00a0unter\u00a0einem\u00a0nicht\u2010resezier baren\u00a0oder\u00a0meta\u2010\nstasierten\u00a0Melanom\u00a0leiden.\u00a0Auch\u00a0beim\u00a0Kinaseinhibitor\u00a0Verzenios\u00ae \u00a0(Abemaciclib),\u00a0\nder\u00a0bei\u00a0fortgeschrittenem\u00a0oder\u00a0m etastasiertem\u00a0Brustkrebs\u00a0einges etzt\u00a0wird,\u00a0sollte\u00a0\nzun\u00e4chst\u00a0mit\u00a0einem\u00a0Biomarker\u00a0gepr\u00fcft\u00a0werden,\u00a0ob\u00a0das\u00a0Karzinom\u00a0ho rmonrezeptor\u2010\npositiv\u00a0bzw.\u00a0negativ\u00a0bez\u00fcglich\u00a0de s\u00a0epidermalen\u00a0Wachstumsfaktors \u00a02\u00a0ist.\u00a0\u00a0\nBei\u00a0der\u00a0\u00fcberraschend\u00a0hohen\u00a0Anzahl\u00a0von\u00a0neuen\u00a0Arzneimitteln\u00a0bei\u00a0S toffwechseler\u2010\nkrankungen\u00a0geht\u00a0es\u00a0nicht\u00a0nur\u00a0um\u00a0Diabetes\u00a0mellitus\u00a0Typ\u00a02,\u00a0sonder n\u00a0auch\u00a0um\u00a0neue\u00a0\nBehandlungsm\u00f6glichkeiten\u00a0 von\u00a0 Sto ffwechselst\u00f6rungen,\u00a0 wie\u00a0 z.B.\u00a0 Mu koviszidose,\u00a0\nTransthyretin\u2010Amyloidose\u00a0oder\u00a0be stimmte\u00a0Lipodystrophien.\u00a0Bei\u00a0de n\u00a0neuen\u00a0Arz\u2010\nneimitteln\u00a0gegen\u00a0Entz\u00fcndungskrankheiten\u00a0handelt\u00a0es\u00a0sich\u00a0z.B.\u00a0um \u00a0Mittel\u00a0zur\u00a0Be\u2010\nhandlung\u00a0 der\u00a0 Darmkrankheit\u00a0 Morbus\u00a0 Crohn,\u00a0 der\u00a0 Hautkrankheit\u00a0 Psor iasis,\u00a0 des\u00a0\neosinophilen\u00a0Asthmas\u00a0und\u00a0der\u00a0Multiplen\u00a0Sklerose\u00a0(MS).\u00a0Unter\u00a0den \u00a0\u00fcbrigen\u00a0neuen\u00a0\nArzneimitteln\u00a0befindet\u00a0sich\u00a0auch\u00a0ein\u00a0neuer\u00a0Impfstoff\u00a0gegen\u00a0G\u00fcrt elrose\u00a0(Herpes\u00a0\nZoster)\u00a0oder\u00a0weitere\u00a0Arzneimittel\u00a0zur\u00a0Behandlung\u00a0von\u00a0HIV,\u00a0von\u00a0H \u00e4mophilie\u00a0A\u00a0(Ge\u2010\nrinnungsst\u00f6rungen\u00a0durch\u00a0Mangel\u00a0an\u00a0Gerinnungsfaktor\u00a0VIII)\u00a0und\u00a0vo n\u00a0Schizophrenie\u00a0\nsowie\u00a0zur\u00a0Vorbeugung\u00a0von\u00a0Migr\u00e4ne.\u00a0\u00a0\nDie\u00a0neuen\u00a0Medikamente\u00a0zur\u00a0Anwe ndung\u00a0bei\u00a0Diabetes\u00a0mellitus\u00a0Typ\u00a02 \u00a0kommen\u00a0alle\u00a0\naus\u00a0bekannten\u00a0Substanzgruppen,\u00a0ihre\u00a0Anwendung\u00a0wurde\u00a0aber\u00a0z.T.\u00a0d eutlich\u00a0verein\u2010\nfacht.\u00a0Semaglutid\u00a0(Ozempic\u00ae)\u00a0ist\u00a0z.B.\u00a0ein\u00a0Wirkstoff\u00a0aus\u00a0der\u00a0Gru ppe\u00a0der\u00a0Glucagon\u2010\nlike\u2010Peptid\u20101\u2010(GLP\u20101)\u2010Analoga,\u00a0 der\u00a0 sich\u00a0 durch\u00a0 eine\u00a0 besonders\u00a0 la nge\u00a0 Wirkdauer\u00a0\nauszeichnet\u00a0und\u00a0nur\u00a0einmal\u00a0pro\u00a0Woche\u00a0injiziert\u00a0werden\u00a0muss.\u00a0Wah rscheinlich\u00a0\nwegen\u00a0des\u00a0Erfolgs\u00a0von\u00a0Empagliflozin\u00a0gibt\u00a0es\u00a0nun\u00a0auch\u00a0ein\u00a0weiter es\u00a0Gliflozin,\u00a0eine\u00a0\nKombination\u00a0des\u00a0neuen\u00a0SGLT\u20102\u2010Hemmer\u00a0Ertugliflozin\u00a0und\u00a0des\u00a0schon \u00a0lange\u00a0bekann\u2010\nten\u00a0 DPP4\u2010Inhibitor\u00a0 Sitagliptin\u00a0 in \u00a0 Tablettenform\u00a0 (Steglujan\u00ae).\u00a0 S chlie\u00dflich\u00a0 wurde\u00a0\nGlibenclamid\u00a0zur\u00a0Behandlung\u00a0bei\u00a0n eonatalem\u00a0Diabetes\u00a0mellitus\u00a0zu gelassen.\u00a0Dieses\u00a0\nKrankheitsbild,\u00a0das\u00a0in\u00a0den\u00a0ersten\u00a0sechs\u00a0Lebensmonaten\u00a0und\u00a0genet isch\u00a0bedingt\u00a0\nauftritt,\u00a0ist\u00a0sehr\u00a0selten\u00a0(1:100.000\u00a0Geburten)\u00a0und\u00a0hat\u00a0nichts\u00a0m it\u00a0einem\u00a0Diabetes\u00a0\nmellitus\u00a0Typ\u00a01\u00a0zu\u00a0tun.\u00a0Mit\u00a0Amglidia\u00ae\u00a0wurde\u00a0nun\u00a0eine\u00a0Suspension\u00a0 zugelassen,\u00a0die\u00a0\ndie\u00a0bisherige\u00a0umst\u00e4ndliche\u00a0Aufl\u00f6 sung\u00a0von\u00a0Glibenclamid\u2010Tabletten \u00a0in\u00a0Wasser\u00a0\u201eab\u2010\nl\u00f6st\u201c\u00a0und\u00a0den\u00a0Vorteil\u00a0der\u00a0genaue ren\u00a0Dosierbarkeit\u00a0anbietet.\u00a0\u00a0\n\u00a025\u00a0Trotz\u00a0aller\u00a0Neuerungen:\u00a0Die\u00a0Domi nanz\u00a0der\u00a0Arzneimittel\u00a0gegen\u00a0Kre bserkrankungen\u00a0\nist\u00a0ungebrochen\u00a0und\u00a0spiegelt\u00a0sich\u00a0auch\u00a0in\u00a0den\u00a0Umsatzstatistiken \u00a0der\u00a0pU\u00a0wider.\u00a0Im\u00a0\nJahr\u00a02018\u00a0entf\u00e4llt\u00a0etwa\u00a0ein\u00a0Drittel\u00a0aller\u00a0umsatzstarken\u00a0Mittel\u00a0 auf\u00a0den\u00a0Bereich\u00a0der\u00a0\nArzneimittel\u00a0zur\u00a0Behandlung\u00a0von\u00a0Krebsbehandlungen.\u00a0\u00a0\nTabelle\u00a01.2:\u00a0Die\u00a020\u00a0f\u00fchrenden\u00a0Pr\u00e4parate\u00a0nach\u00a0Industrieumsatz\u00a0im \u00a0Jahr\u00a02018\u00a0\nRang\u00a0 Pr\u00e4parat\u00a0(Hersteller)\u00a0(Wirkstoff)\u00a0 Anwendungsgebiet\u00a0Umsatz\u00a0\u00a0\n2018\u00a0\u00a0\nin\u00a0Mio.\u00a0\u20ac\u00a0Gegen\u00fcber\u00a0\u00a0\n2017\u00a0\u00a0\nin\u00a0%\u00a0\n1\u00a0Humira\u00ae\u00a0(Abbott/Abbvie)\u00a0\u00a0\n(Adalimumab)\u00a0z.B.\u00a0Rheumatische\u00a0Arthritis\u00a0 756,7\u00a0 \u20103,3\u00a0\n2\u00a0Eliquis\u00ae\u00a0(Bristol\u2010Myers\u00a0Squibb/Pfizer)\u00a0\n(Apixaban)\u00a0Antikoagulanzien\u00a0 551,5\u00a0 +30,8\u00a0\n3\u00a0Revlimid\u00ae\u00a0(Celgene\u00a0Europe)\u00a0\u00a0\n(Lenalidomid)\u00a0z.B.\u00a0Myelom\u00a0 468,6\u00a0 +45,0\u00a0\n4\u00a0Xarelto\u00ae\u00a0(Bayer)\u00a0\u00a0\n(Rivaroxaban)\u00a0Antikoagulanzien\u00a0 419,7\u00a0 +2,2\u00a0\n5\u00a0Zytiga\u00ae\u00a0(Janssen\u2010Cilag)\u00a0\u00a0\n(Abirateronacetat)\u00a0Prostatakrebs\u00a0 288,3\u00a0 +35,5\u00a0\n6\u00a0Gilenya\u00ae\u00a0(Novartis)\u00a0\u00a0\n(Fingolimod)\u00a0MS\u00a0 264,1\u00a0 +2,5\u00a0\n7\u00a0Cosentyx\u00ae\u00a0(Novartis)\u00a0\u00a0\n(Secukinumab)\u00a0z.B.\u00a0Schuppenflechte\u00a0 259,4\u00a0 +24,6\u00a0\n8\u00a0Xtandi\u00ae\u00a0(Astellas)\u00a0\n(Enzalutamid)\u00a0\u00a0Prostatakrebs\u00a0 241,5\u00a0 +1,9\u00a0\n9\u00a0Lucentis\u00ae\u00a0(Novartis)\u00a0\u00a0\n(Ranibizumab)\u00a0Makuladegeneration\u00a0 232,9\u00a0 +3,1\u00a0\n10\u00a0Tecfidera\u00ae\u00a0(Biogen)\u00a0\u00a0\n(Dimethylfumarat)\u00a0MS\u00a0 220,5\u00a0 \u20100,5\u00a0\n11\u00a0Imbruvica\u00ae\u00a0(Janssen\u2010Cilag)\u00a0\n(Ibrutinib)\u00a0Blutkrebs\u00a0 220,4\u00a0 +34,0\u00a0\n12\u00a0Enbrel\u00ae\u00a0(Pfizer)\u00a0\u00a0\n(Etanercept)\u00a0z.B.\u00a0Rheumatische\u00a0Art hritis\u00a0 219,2\u00a0 \u201033,4\u00a0\n13\u00a0Copaxone\u00ae\u00a0(Teva)\u00a0\n(Glatirameracetat)\u00a0MS\u00a0 214,9\u00a0 \u20106,2\u00a0\n14\u00a0Eylea\u00ae\u00a0(Bayer)\u00a0\u00a0\n(Aflibercept)\u00a0Makuladegeneration\u00a0 211,4\u00a0 +11,8\u00a0\n15\u00a0Jakavi\u00ae\u00a0(Novartis)\u00a0\u00a0\n(Ruxolitinib)\u00a0Blutkrebs\u00a0 209,5\u00a0 +17,4\u00a0\n16\u00a0Ibrance\u00ae\u00a0(Pfizer)\u00a0\u00a0\n(Palbociclib)\u00a0Brustkrebs\u00a0 206,2\u00a0 \u20104,0\u00a0\n17\u00a0Stelara\u00ae\u00a0(Janssen\u2010Cilag)\u00a0\n(Ustekinumab)\u00a0entz\u00fcndliche\u00a0Erkrankungen,\u00a0\nz.B.\u00a0Plaque\u2010Psoriasis\u00a0200,2\u00a0 +36,1\u00a0\n18\u00a0Lantus\u00ae\u00a0(Sanofi\u2010Aventis)\u00a0\u00a0\n(Insulin\u00a0glargin)\u00a0Diabetes\u00a0mellitus\u00a0 187,3\u00a0 \u20104,3\u00a0\n19\u00a0Lixiana\u00ae\u00a0(Daiichi\u00a0Sankyo\u00a0Europe)\u00a0\u00a0\n(Edoxaban)\u00a0Antikoagulanzien\u00a0 180,7\u00a0 +65,3\u00a0\n20\u00a0Benepali\u00ae\u00a0(Biogen)\u00a0\u00a0\n(Etanercept)\u00a0z.B.\u00a0Rheumatische\u00a0Arthritis\u00a0 176,3\u00a0 +33,5\u00a0\n\u00a0Gesamtmarkt\u00a0 \u00a0 33.516,2\u00a0 +3,6\u00a0\nQuelle:\u00a0nach\u00a0IMS\u00a0Health,\u00a02018\u00a0 \u00a026\u00a0Immer\u00a0st\u00e4rker\u00a0im\u00a0Mittelpunkt:\u00a0 Orphan\u2010Arzneimittel\u00a0\nNeben\u00a0den\u00a0\u201eg\u00e4ngigen\u201c\u00a0Arzneimitte ln\u00a0wurden\u00a0im\u00a0Jahre\u00a02018\u00a0auch\u00a016 \u00a0Medikamente\u00a0\nals\u00a0Orphan\u2010Arzneimittel\u00a0zugelassen,\u00a0\u00fcberset zt\u00a0\u201eWaisenmedikamente\u201c.\u00a0Nach\u00a0d er\u00a0\nDefinition\u00a0in\u00a0der\u00a0EU\u00a0sind\u00a0diese\u00a0Arzneimittel\u00a0f\u00fcr\u00a0Menschen\u00a0mit\u00a0K rankheiten\u00a0indi\u2010\nziert,\u00a0an\u00a0denen\u00a0maximal\u00a0f\u00fcnf\u00a0von\u00a010.000\u00a0Einwohnern\u00a0in\u00a0der\u00a0EU\u00a0le iden,\u00a0es\u00a0sind\u00a0\ninsgesamt\u00a0rund\u00a0256.000\u00a0Menschen\u00a0betroffen.\u00a0Bislang\u00a0gibt\u00a0es,\u00a0so\u00a0 die\u00a0Sch\u00e4tzungen,\u00a0\nnoch\u00a06.000\u00a0bis\u00a08.000\u00a0Erkrankungen,\u00a0die\u00a0nicht\u00a0mit\u00a0Arzneimitteln\u00a0 behandelbar\u00a0sind,\u00a0\nviele\u00a0darunter\u00a0entfallen\u00a0auf\u00a0die\u00a0Seltenen\u00a0Krankheiten\u00a0( Orphan\u00a0Diseases).\u00a0Offen\u2010\nsichtlich\u00a0mit\u00a0Blick\u00a0auf\u00a0eine\u00a0bes sere\u00a0Versorgung\u00a0dieser\u00a0Menschen \u00a0wurde\u00a0im\u00a0Dezem\u2010\nber\u00a01999\u00a0in\u00a0der\u00a0EU\u00a0entschieden,\u00a0dass\u00a0ab\u00a0dem\u00a0Jahr\u00a02000\u00a0regulator ische\u00a0und\u00a0\u00f6ko\u2010\nnomische\u00a0Anreize\u00a0f\u00fcr\u00a0die\u00a0pU\u00a0die\u00a0Forschung\u00a0im\u00a0Bereich\u00a0der\u00a0 Orphan\u2010Arzneimittel,\u00a0\nalso\u00a0der\u00a0Arzneimittel\u00a0gegen\u00a0selt ene\u00a0Erkrankungen,\u00a0f\u00f6rdern\u00a0sollt en.\u00a0Ein\u00a0solches\u00a0\n\u201eF\u00f6rderprogramm\u201c\u00a0besteht\u00a0auch\u00a0in \u00a0den\u00a0USA,\u00a0in\u00a0Australien\u00a0oder\u00a0in \u00a0Japan.\u00a0Zu\u00a0den\u00a0\nVorteilen\u00a0geh\u00f6ren\u00a0z.B.\u00a0erm\u00e4\u00dfigte \u00a0Zulassungsgeb\u00fchren,\u00a0ein\u00a0zehnj\u00e4 hriges\u00a0Exklusiv\u2010\nrecht\u00a0f\u00fcr\u00a0die\u00a0Vermarktung\u00a0und\u00a0beschleunigte\u00a0Zulassungsverfahren .\u00a0Nicht\u00a0nur\u00a0diese\u00a0\nVorteile,\u00a0sondern\u00a0auch\u00a0die\u00a0M\u00f6glichkeiten,\u00a0hohe\u00a0Preise\u00a0im\u00a0Markt\u00a0 zu\u00a0erzielen,\u00a0weil\u00a0\ndie\u00a0 Akzeptanz\u00a0 der\u00a0 verschiedenen\u00a0 Gesundheitssysteme\u00a0 f\u00fcr\u00a0 Orphan\u2010Arzneimittel\u00a0\nhoch\u00a0ist,\u00a0haben\u00a0viele\u00a0pU\u00a0zur\u00a0Forschung\u00a0in\u00a0diesem\u00a0lukrativen\u00a0Mar kt\u00a0gebracht,\u00a0der\u00a0\nWachstumsraten\u00a0von\u00a0rund\u00a07\u00a0bis\u00a08\u00a0%\u00a0pro\u00a0Jahr\u00a0verspricht\u00a0und\u00a0schon \u00a0einen\u00a0Anteil\u00a0von\u00a0\nrund\u00a015\u00a0%\u00a0am\u00a0weltweiten\u00a0Arzneimittelumsatz\u00a0erreicht\u00a0hat.\u00a0Insofe rn\u00a0werden\u00a0nicht\u00a0\nnur\u00a0Indikationsbereiche\u00a0f\u00fcr\u00a0die\u00a0 Orphan\u2010Arzneimittel\u00a0genutzt,\u00a0die\u00a0auf\u00a0genetisch\u00a0\nbedingte\u00a0Erkrankungen\u00a0zur\u00fcckzuf\u00fchren\u00a0sind\u00a0(dies\u00a0war\u00a0das\u00a0urspr\u00fcn gliche\u00a0Einsatz\u2010\ngebiet\u00a0dieser\u00a0Mittel,\u00a0wie\u00a0z.B.\u00a0Krankheiten\u00a0des\u00a0Immunsystems\u00a0ode r\u00a0Enzymman\u2010\ngelerkrankungen),\u00a0sondern\u00a0auch\u00a0 durch\u00a0Biomarker\u00a0erkennbare\u00a0und\u00a0z u\u00a0differenzie\u2010\nrende\u00a0kleine\u00a0Gruppen\u00a0von\u00a0Patiente n\u00a0mit\u00a0onkologischen\u00a0Erkrankung en,\u00a0auf\u00a0die\u00a0sich\u00a0\nvor\u00a0allem\u00a0gro\u00dfe\u00a0pU\u00a0konzentrieren ,\u00a0weil\u00a0auch\u00a0dort\u00a0hohe\u00a0Preisvors tellungen\u00a0zu\u00a0reali\u2010\nsieren\u00a0sind\u00a0\u2013\u00a0es\u00a0ist\u00a0geradezu\u00a0\u201eunfein\u201c,\u00a0bei\u00a0Krebserkrankungen\u00a0\u00fc ber\u00a0Ausgaben\u00a0f\u00fcr\u00a0\neine\u00a0m\u00f6glicherweise\u00a0hilfreiche\u00a0Therapie\u00a0zu\u00a0sprechen.\u00a0Daher\u00a0werd en\u00a0diese\u00a0M\u00f6g\u2010\nlichkeiten\u00a0insbesondere\u00a0von\u00a0global\u00a0agierenden\u00a0pU\u00a0genutzt,\u00a0die\u00a0z .B.\u00a0zun\u00e4chst\u00a0eine\u00a0\nZulassung\u00a0in\u00a0den\u00a0USA\u00a0anstreben,\u00a0weil\u00a0dort\u00a0das\u00a0 Slicing\u00a0von\u00a0Indikationen,\u00a0also\u00a0das\u00a0\n\u201eZuschneiden\u201c\u00a0der\u00a0Patientenzahlen\u00a0auf\u00a0das\u00a0\u201eMa\u00df\u201c\u00a0der\u00a0seltenen\u00a0Kr ankheiten\u00a0durch\u00a0\ndie\u00a0Definition\u00a0von\u00a0Subgruppen\u00a0z.B.\u00a0im\u00a0Bereich\u00a0der\u00a0Onkologie,\u00a0du rchaus\u00a0akzeptiert\u00a0\nwird.\u00a0Und\u00a0wenn\u00a0einmal\u00a0eine\u00a0Zulassung\u00a0erreicht\u00a0wurde,\u00a0tun\u00a0sich\u00a0a ndere\u00a0Zulas\u2010\nsungsagenturen\u00a0wie\u00a0die\u00a0europ\u00e4isc he\u00a0EMA\u00a0schwer,\u00a0dieser\u00a0Zulassung sentscheidung\u00a0\nnicht\u00a0 zu\u00a0 folgen.\u00a0 Insofern\u00a0 ist\u00a0 der\u00a0 Eindruck\u00a0 un\u00fcbersehbar,\u00a0 dass\u00a0 g erade\u00a0Orphan\u2010\nArzneimittel\u00a0die\u00a0Therapiekosten\u00a0bei\u00a0einzelnen\u00a0Krankheiten\u00a0massi v\u00a0in\u00a0die\u00a0H\u00f6he\u00a0\ntreiben.\u00a0Daher\u00a0stehen\u00a0diese\u00a0Mittel\u00a0auch\u00a0derzeit\u00a0bei\u00a0vielen\u00a0pU\u00a0i m\u00a0Fokus\u00a0des\u00a0Interes\u2010\nses,\u00a0weil\u00a0die\u00a0Forschung\u00a0im\u00a0Bereic h\u00a0der\u00a0Waisenmedikamente,\u00a0die\u00a0s chon\u00a0vom\u00a0Begriff\u00a0\nher\u00a0Mitleid\u00a0signalisieren,\u00a0lohne nder\u00a0zu\u00a0sein\u00a0scheint\u00a0als\u00a0bei\u00a0de n\u00a0\u201e\u00fcblichen\u201c\u00a0Arznei\u2010\nmitteln:\u00a0Nach\u00a0einer\u00a0langen\u00a0Fors chungspause\u00a0im\u00a0Bereich\u00a0der\u00a0 Orphan\u2010Arzneimittel\u00a027\u00a0sind\u00a0nun\u00a0in\u00a0der\u00a0EU\u00a0108\u00a0Arzneimittel\u00a0mit\u00a0diesem\u00a0Status\u00a0im\u00a0Markt, \u00a052\u00a0hatten\u00a0ehe\u2010\nmals\u00a0diesen\u00a0Status\u00a0und\u00a0gesch\u00e4tzt\u00a01.900\u00a0Produkte\u00a0aus\u00a0dem\u00a0Bereich \u00a0der\u00a0Waisenarz\u2010\nneimittel\u00a0sind\u00a0in\u00a0der\u00a0Entwicklung .\u00a0Die\u00a0Pharmafirmen\u00a0haben\u00a0den\u00a0l ukrativen\u00a0Markt\u00a0\nerkannt\u00a0und\u00a0treiben\u00a0ihn\u00a0also\u00a0immer\u00a0weiter\u00a0voran.\u00a0Weltweit\u00a0wird\u00a0 der\u00a0Umsatz\u00a0f\u00fcr\u00a0\nsolche\u00a0Arzneimittel\u00a0auf\u00a0131\u00a0Mrd.\u00a0$\u00a0gesch\u00e4tzt,\u00a0schon\u00a02014\u00a0sollen \u00a0es\u00a0242\u00a0Mrd.\u00a0$\u00a0\nsein.\u00a0 Die\u00a0 j\u00e4hrlichen\u00a0 Wachstumsraten\u00a0 w\u00fcrden\u00a0 damit\u00a0 12\u00a0%\u00a0 betragen\u00a0 und\u00a0 liegen\u00a0\ndamit\u00a0doppelt\u00a0so\u00a0hoch\u00a0wie\u00a0bei\u00a0den\u00a0\u00fcblichen\u00a0Medikamenten.\u00a0F\u00fcr\u00a0di e\u00a0GKV\u00a0fielen\u00a0im\u00a0\nJahre\u00a02017\u00a0etwa\u00a03,3\u00a0Mrd.\u00a0\u20ac\u00a0an\u00a0Ausgaben\u00a0an,\u00a0immerhin\u00a08\u00a0%\u00a0der\u00a0Ges amtausgaben\u00a0\nf\u00fcr\u00a0Arzneimittel.\u00a0\nHohe\u00a0Preise,\u00a0auch\u00a0f\u00fcr\u00a0 Orphan\u2010Arzneimittel,\u00a0werden\u00a0h\u00e4ufig\u00a0mit\u00a0den\u00a0hohen\u00a0Entwick\u2010\nlungskosten\u00a0begr\u00fcndet.\u00a0Letztlich\u00a0ist\u00a0aber\u00a0die\u00a0Transparenz\u00a0der\u00a0F orschungskosten\u00a0\nbei\u00a0keinem\u00a0einzigen\u00a0pU\u00a0weltweit\u00a0gegeben.\u00a0Es\u00a0gibt\u00a0immer\u00a0wieder\u00a0S ch\u00e4tzungen,\u00a0die\u00a0\naber\u00a0auf\u00a0unsicheren\u00a0Annahmen\u00a0beruhen\u00a0und\u00a0die\u00a0auch\u00a0leicht\u00a0entkr\u00e4 ftet\u00a0werden\u00a0\nk\u00f6nnen.\u00a0So\u00a0weist\u00a0das\u00a0 Tufts\u00a0Center\u00a0for\u00a0Drug\u00a0Development \u00a0in\u00a0Boston\u00a0darauf\u00a0hin,\u00a0dass\u00a0\nderzeit\u00a02,6\u00a0Mrd.\u00a0$\u00a0von\u00a0einem\u00a0pU\u00a0investiert\u00a0werden\u00a0m\u00fcssten,\u00a0um\u00a0e in\u00a0neues\u00a0Arz\u2010\nneimittel\u00a0 auf\u00a0 den\u00a0 Markt\u00a0 zu\u00a0 bringen.\u00a0 Dieser\u00a0 Betrag\u00a0 wird\u00a0 auch\u00a0 von \u00a0e i n e m \u00a0U S \u2010\namerikanischen\u00a0Verbund\u00a0von\u00a0Pharmaunternehmen\u00a0(PhARMA)\u00a0best\u00e4tigt .\u00a0Dagegen\u00a0\nkommen\u00a0 Untersuchungen\u00a0 aus\u00a0 Portland\u00a0 und\u00a0 New\u00a0 York\u00a0 auf\u00a0 einen\u00a0 Betra g\u00a0 von\u00a0\u00a0\n648\u00a0Mio.\u00a0$,\u00a0die\u00a0aufgewendet\u00a0werden\u00a0m\u00fcssten,\u00a0um\u00a0ein\u00a0 Orphan\u2010Arzneimittel\u00a0auf\u00a0den\u00a0\nMarkt\u00a0zu\u00a0bringen.\u00a0Und\u00a0dieser\u00a0Bet rag\u00a0sei\u00a0gut\u00a0investiert,\u00a0weil\u00a0di e\u00a0Firma\u00a0bei\u00a0der\u00a0Ver\u2010\nmarktung\u00a0zweieinhalbmal\u00a0so\u00a0viel\u00a0an\u00a0Gewinn\u00a0erwarten\u00a0kann,\u00a0n\u00e4mlic h\u00a01.658\u00a0Mio.\u00a0$\u00a0\n(Witte,\u00a02019).\u00a0Dass\u00a0Pharmaverb\u00e4nde\u00a0diese\u00a0Rechnung\u00a0nicht\u00a0akzepti eren\u00a0k\u00f6nnen,\u00a0ist\u00a0\nin\u00a0diesem\u00a0Zusammenhang\u00a0keine\u00a0\u00dcbe rraschung.\u00a0Etwas\u00a0anderes\u00a0kommt\u00a0 hinzu:\u00a0Die\u00a0\nNew\u00a0Pharmaceutical\u00a0Research ,\u00a0wie\u00a0die\u00a0Entwicklung\u00a0gegen\u00fcber\u00a0den\u00a0fr\u00fcheren\u00a0\u201e In\u2010\nhouse\u2010Forschungsaktivit\u00e4ten\u201c\u00a0genannt\u00a0werden\u00a0kann,\u00a0n\u00e4mlich\u00a0der\u00a0fr\u00fcher \u00a0\u00fcblichen\u00a0\nOld\u00a0Pharmaceutical\u00a0Research \u00a0im\u00a0Bereich\u00a0der\u00a0chemisch\u00a0synthetisierten\u00a0Wirkstoffe,\u00a0\nl\u00e4uft\u00a0ja\u00a0in\u00a0der\u00a0Zwischenzeit\u00a0unter\u00a0Einbeziehung\u00a0von\u00a0\u201e Outhouse \u2010Forschung\u201c:\u00a0Bio\u2010\ntech\u2010Unternehmen\u00a0entwickeln\u00a0einen \u00a0vielversprechenden\u00a0Wirkstoff, \u00a0der\u00a0von\u00a0einem\u00a0\ngro\u00dfen\u00a0Unternehmen\u00a0gekauft\u00a0und\u00a0dann\u00a0zur\u00a0Marktreife\u00a0im\u00a0Rahmen\u00a0de r\u00a0Erstellung\u00a0\nvon\u00a0Zulassungsstudien\u00a0gebracht\u00a0wi rd.\u00a0Beispiel:\u00a0Der\u00a0Wirkstoff\u00a0Ra nibizumab\u00a0(Lucen\u2010\ntis\u00ae,\u00a0 ein\u00a0 Mittel\u00a0 gegen\u00a0 altersbedi ngte\u00a0 Makuladegeneration)\u00a0 wurde n\u00a0 f\u00fcr\u00a0 sch\u00e4t\u2010\nzungsweise\u00a012\u00a0Mrd.\u00a0$\u00a0von\u00a0dem\u00a0Biotech\u2010Unternehmen\u00a0Genentech\u00a0geka uft,\u00a0das\u00a0zur\u00a0\nRoche\u00a0Gruppe\u00a0geh\u00f6rt.\u00a0F\u00fcr\u00a0die\u00a0Marktreife,\u00a0die\u00a0Durchf\u00fchrung\u00a0von\u00a0Z ulassungsstudien\u00a0\nund\u00a0die\u00a0Zulassung\u00a0hat\u00a0Novartis\u00a0gesorgt,\u00a0die\u00a0dann\u00a0auch\u00a0das\u00a0Mitte l\u00a0zu\u00a0einem\u00a0hohen\u00a0\nPreis\u00a0in\u00a0den\u00a0Markt\u00a0gebracht\u00a0haben.\u00a0Es\u00a0geht\u00a0also\u00a0nicht\u00a0nur\u00a0um\u00a0Fo rschungs\u2010\u00a0oder\u00a0\nEntwicklungskosten,\u00a0sondern\u00a0auch\u00a0um\u00a0\u201eBeschaffungskosten\u201c\u00a0des\u00a0Wi rkstoffes\u00a0\u2013\u00a0das\u00a0\nalles\u00a0zusammengenommen\u00a0f\u00fchrt\u00a0dann\u00a0 letztlich\u00a0zu\u00a0den\u00a0in\u00a0der\u00a0Zwisc henzeit\u00a0z.T.\u00a0\nexorbitanten\u00a0Preisen\u00a0f\u00fcr\u00a0einzeln e\u00a0Arzneimittel.\u00a0\u00dcbrigens\u00a0werden \u00a0solche\u00a0erfolgrei\u2010\nchen\u00a0Biotech\u2010Firmen\u00a0sehr\u00a0oft\u00a0von\u00a0den\u00a0Firmen\u00a0aufgekauft,\u00a0die\u00a0bis \u00a0dahin\u00a0nur\u00a0einzel\u2010\nne\u00a0Wirkstoffe\u00a0erstanden\u00a0haben.\u00a0Die \u00a0hohen\u00a0Preise\u00a0sind\u00a0auch\u00a0ein\u00a0E rgebnis\u00a0der\u00a0man\u201028\u00a0gelnden\u00a0Produktivit\u00e4t\u00a0der\u00a0Forsc hungsabteilungen\u00a0gro\u00dfer\u00a0pU,\u00a0die\u00a0 sich\u00a0dann\u00a0bei\u00a0den\u00a0\nErgebnissen\u00a0anderer\u00a0kleiner,\u00a0a ber\u00a0wendigen\u00a0und\u00a0kreativen\u00a0Firmen \u00a0gegen\u00a0\u201eviel\u00a0\nGeld\u201c\u00a0bedienen\u00a0m\u00fcssen.\u00a0\nNat\u00fcrlich\u00a0 gibt\u00a0 es\u00a0 Forschungsergebnisse,\u00a0 z.B.\u00a0 bei\u00a0 Morbus\u00a0 Gaucher \u00a0 oder\u00a0 der\u00a0\nDuchenne\u2010Muskeldystrophie,\u00a0die\u00a0f\u00fcr\u00a0die\u00a0Patienten\u00a0ausgesprochen\u00a0 hilfreich\u00a0sind,\u00a0\neinen\u00a0therapeutischen\u00a0Fortschritt\u00a0bedeuten\u00a0und\u00a0die\u00a0vielfach\u00a0auc h\u00a0ein\u00a0l\u00e4ngeres\u00a0\n\u00dcberleben\u00a0sichern\u00a0\u2013\u00a0dies\u00a0sind\u00a0sinnvolle\u00a0Therapieangebote\u00a0mit\u00a0ei nem\u00a0Zusatznutzen\u00a0\nf\u00fcr\u00a0die\u00a0Patienten.\u00a0Bei\u00a0den\u00a0 Orphan\u2010Arzneimitteln\u00a0mit\u00a0onkologischen\u00a0Indikationen,\u00a0\ndie\u00a0auf\u00a0der\u00a0Basis\u00a0stratifizierte r\u00a0Patientengruppen\u00a0eine\u00a0Zulassu ng\u00a0erhielten\u00a0und\u00a0in\u00a0\nden\u00a0Markt\u00a0kommen,\u00a0sehen\u00a0wir\u00a0dagegen\u00a0allzu\u00a0oft\u00a0keine\u00a0wirklichen\u00a0 zus\u00e4tzlichen\u00a0\nNutzen\u00a0f\u00fcr\u00a0die\u00a0Patienten,\u00a0weil\u00a0beschleunigte\u00a0Zulassungen\u00a0oftmal s\u00a0auf\u00a0der\u00a0Basis\u00a0von\u00a0\nSurrogatparametern\u00a0(z.B.\u00a0Progessionsfreies\u00a0\u00dcberleben\u00a0und\u00a0nicht\u00a0 Overall\u00a0Survival )\u00a0\nausgesprochen\u00a0werden\u00a0und\u00a0die\u00a0Laufzeit\u00a0und\u00a0Gr\u00f6\u00dfe\u00a0der\u00a0Studien\u00a0nic ht\u00a0ausreicht,\u00a0um\u00a0\nausreichende\u00a0Daten\u00a0f\u00fcr\u00a0die\u00a0Sicherheit\u00a0in\u00a0der\u00a0Anwendung\u00a0zu\u00a0gewin nen.\u00a0Hier\u00a0steht\u00a0\nin\u00a0vielen\u00a0F\u00e4llen\u00a0die\u00a0Profitorientierung\u00a0im\u00a0Vordergrund,\u00a0die\u00a0auc h\u00a0auf\u00a0dem\u00a0oftmals\u00a0\nbeobachteten\u00a0 Off\u2010label\u2010use \u00a0nach\u00a0der\u00a0Zulassung\u00a0aufbaut,\u00a0weil\u00a0die\u00a0Mittel\u00a0dann\u00a0auch\u00a0\nin\u00a0anderen,\u00a0bisher\u00a0nicht\u00a0untersuchten\u00a0Indikationen\u00a0eingesetzt\u00a0w erden.\u00a0Daher\u00a0kann\u00a0\nes\u00a0 zudem\u00a0 nicht\u00a0 erstaunen,\u00a0 dass\u00a0 zwischen\u00a0 2011\u00a0 und\u00a0 2017\u00a0 bei\u00a0 insge samt\u00a0 64\u00a0\nAMNOG\u2010Verfahren\u00a0 bei\u00a0 33\u00a0 Orphan\u2010Arzneimitteln\u00a0 zur\u00a0 Behandlung\u00a0 onkologischer\u00a0\nund\u00a0h\u00e4matologischer\u00a0Erkrankungen\u00a0kein\u00a0quantifizierbarer\u00a0Zusatzn utzen\u00a0gefunden\u00a0\nwerden\u00a0konnte.\u00a0Dennoch:\u00a0 Orphan\u2010Arzneimittel\u00a0bleiben\u00a0aus\u00a0all\u00a0den\u00a0\u00f6konomischen\u00a0\nAnreizen\u00a0die\u00a0\u201eLieblinge\u00a0der\u00a0Pharmabranche\u201c\u00a0und\u00a0oft\u00a0genug\u00a0auch\u00a0d er\u00a0\u201eMilliarden\u2010\ntrick\u00a0der\u00a0Pharmariesen\u201c.\u00a0\nAuch\u00a0dieses\u00a0Ergebnis\u00a0ergibt\u00a0sich\u00a0u.a.\u00a0aus\u00a0den\u00a0Anreizen\u00a0der\u00a0F\u00f6rd erma\u00dfnahmen.\u00a0\nBeschleunigte\u00a0Zulassungen\u00a0und\u00a0Ver sprechen\u00a0der\u00a0Hersteller\u00a0auf\u00a0de r\u00a0Basis\u00a0von\u00a0Sur\u2010\nrogatparametern\u00a0m\u00fcssten\u00a0eine\u00a0weit\u00a0strengere\u00a0Konsequenz\u00a0in\u00a0der\u00a0B ewertung\u00a0der\u00a0\nMittel\u00a0nach\u00a0sich\u00a0ziehen\u00a0als\u00a0das\u00a0heute\u00a0der\u00a0Fall\u00a0ist.\u00a0Ein\u00a0oftmals \u00a0festgestellter\u00a0unklarer\u00a0\nZusatznutzen\u00a0spricht\u00a0auch\u00a0daf\u00fcr,\u00a0dass\u00a0es\u00a0keine\u00a0Ausnahmeregelung en\u00a0im\u00a0AMNOG\u00a0\nVerfahren\u00a0f\u00fcr\u00a0 Orphan\u2010Arzneimittel\u00a0geben\u00a0darf,\u00a0sie\u00a0m\u00fcssen\u00a0den\u00a0gleichen\u00a0Prozess\u00a0\ndurchlaufen\u00a0wie\u00a0alle\u00a0anderen\u00a0neuen\u00a0Arzneimittel.\u00a0Eine\u00a0Privilegi erung,\u00a0dass\u00a0alle\u00a0\nOrphan\u2010Arzneimittel\u00a0schon\u00a0allein\u00a0durch \u00a0die\u00a0Zulassung\u00a0mit\u00a0einem\u00a0Zusatz nutzen\u00a0f\u00fcr\u00a0\ndie\u00a0Patienten\u00a0\u201egeadelt\u201c\u00a0sind,\u00a0ist\u00a0nicht\u00a0gerechtfertigt,\u00a0schlie\u00df lich\u00a0bewertet\u00a0der\u00a0Ge\u2010\nmeinsame\u00a0 Bundesausschuss\u00a0 (G\u2010BA)\u00a0 nur\u00a0 noch\u00a0 das\u00a0 Ausma\u00df\u00a0 des\u00a0 Zusatzn utzens.\u00a0\nZulassungs\u2010\u00a0und\u00a0Bewertungsprozesse\u00a0haben\u00a0unterschiedliche\u00a0Ziele ,\u00a0bei\u00a0dem\u00a0einen\u00a0\ndie\u00a0efficacy,\u00a0also\u00a0eine\u00a0wie\u00a0auch\u00a0immer\u00a0definierte\u00a0Wirksamkeit,\u00a0beim\u00a0anderen \u00a0die\u00a0\neffectiveness ,\u00a0ein\u00a0klar\u00a0definierter\u00a0Patientennutzen:\u00a0Verminderte\u00a0Mortalit\u00e4t, \u00a0verrin\u2010\ngerte\u00a0Morbidit\u00e4tslast,\u00a0verringerte\u00a0Nebenwirkungen\u00a0und\u00a0erh\u00f6hte\u00a0L ebensqualit\u00e4t.\u00a0\nWenn\u00a0dies\u00a0nicht\u00a0f\u00fcr\u00a0die\u00a0 Orphan\u2010Arzneimittel\u00a0wie\u00a0f\u00fcr\u00a0allen\u00a0anderen\u00a0neuen\u00a0Arznei\u2010\nmittel\u00a0gepr\u00fcft\u00a0wird\u00a0\u2013\u00a0und\u00a0dies\u00a0is t\u00a0auf\u00a0der\u00a0Basis\u00a0vor\u00a0allem\u00a0besc hleunigter\u00a0Zulassun\u201029\u00a0gen\u00a0kaum\u00a0denkbar,\u00a0wie\u00a0jetzt\u00a0auch\u00a0das\u00a0Institut\u00a0f\u00fcr\u00a0Qualit\u00e4t\u00a0und\u00a0 Wirtschaftlichkeit\u00a0\n(IQWiG)\u00a0in\u00a0einer\u00a0bemerkenswerten\u00a0Publikation\u00a0festgestellt\u00a0hat\u00a0( Wieseler\u00a0et\u00a0al.,\u00a0\n2019)\u00a0\u2013\u00a0,\u00a0ist\u00a0dies\u00a0letztlich\u00a0zum\u00a0Schaden\u00a0der\u00a0Patienten\u00a0und\u00a0f\u00fchr t\u00a0zu\u00a0unn\u00f6tigen\u00a0und\u00a0\ndann\u00a0auch\u00a0noch\u00a0erheblichen\u00a0Belastungen\u00a0des\u00a0Gesundheitssystems.\u00a0 Zudem\u00a0muss\u00a0\nauch\u00a0bedacht\u00a0werden,\u00a0dass\u00a0die\u00a0F\u00f6rderung,\u00a0die\u00a0Anreize\u00a0und\u00a0die\u00a0Ge winnaussichten\u00a0\nbei\u00a0der\u00a0Forschung\u00a0im\u00a0Bereich\u00a0der\u00a0 seltenen\u00a0Krankheiten\u00a0leider\u00a0au ch\u00a0Gr\u00fcnde\u00a0darstel\u2010\nlen,\u00a0 warum\u00a0 die\u00a0 notwendige\u00a0 Forschung\u00a0 in\u00a0 anderen\u00a0 Indikationen\u00a0 ver nachl\u00e4ssigt\u00a0\nwird.\u00a0Forschungsentscheidungen\u00a0in\u00a0kapitalistischen\u00a0Systemen\u00a0wer den\u00a0sich\u00a0immer\u00a0\nauch\u00a0an\u00a0den\u00a0Profiterwartungen\u00a0orientieren.\u00a0Nat\u00fcrlich\u00a0bleibt\u00a0es\u00a0 in\u00a0einem\u00a0solchen\u00a0\nSystem\u00a0immer\u00a0den\u00a0Firmen\u00a0vorbehalten,\u00a0\u00fcber\u00a0ihre\u00a0Forschungsaktivi t\u00e4ten\u00a0und\u00a0deren\u00a0\nFinanzierung\u00a0selber\u00a0zu\u00a0entscheid en.\u00a0Diese\u00a0Abw\u00e4gungsprozesse\u00a0hab en\u00a0aber\u00a0z.B.\u00a0\ndazu\u00a0gef\u00fchrt,\u00a0dass\u00a0im\u00a0Bereich\u00a0Antibiotika,\u00a0neurologischer\u00a0und\u00a0p sychischer\u00a0Erkran\u2010\nkungen\u00a0(z.B.\u00a0mit\u00a0dem\u00a0Ziel,\u00a0neue\u00a0Antidepressiva\u00a0auf\u00a0den\u00a0Markt\u00a0zu \u00a0bringen\u00a0(Bschor,\u00a0\n2018))\u00a0kaum\u00a0noch\u00a0geforscht\u00a0wird,\u00a0weil\u00a0sich\u00a0die\u00a0sp\u00e4tere\u00a0Preisges taltung\u00a0im\u00a0Markt\u00a0\nwegen\u00a0der\u00a0derzeitigen\u00a0Dominanz\u00a0d er\u00a0Generikaversorgung\u00a0nicht\u00a0meh r\u00a0zu\u00a0lohnen\u00a0\nscheint.\u00a0M\u00f6glicherweise\u00a0m\u00fcssten\u00a0hier\u00a0\u00f6ffentlich\u00a0finanzierte\u00a0For schungsprogramme\u00a0\ndie\u00a0L\u00fccke\u00a0schlie\u00dfen,\u00a0die\u00a0dann\u00a0allerdings\u00a0mit\u00a0einem\u00a0gewissen\u00a0Pro fitanteil\u00a0der\u00a0Phar\u2010\nmaunternehmen\u00a0mitfinanziert\u00a0werden\u00a0m\u00fcssten\u00a0(in\u00a0Italien\u00a0m\u00fcssen\u00a0z .B.\u00a05\u00a0%\u00a0der\u00a0\nAusgaben\u00a0f\u00fcr\u00a0Werbung\u00a0und\u00a0Vertrieb\u00a0in\u00a0einen\u00a0solchen\u00a0Forschungsfo nds\u00a0eingezahlt\u00a0\nwerden).\u00a0\nUnd\u00a0der\u00a0Ausblick?\u00a0\nUmso\u00a0wichtiger\u00a0ist\u00a0es\u00a0daher\u00a0in\u00a0der\u00a0GKV,\u00a0unter\u00a0dem\u00a0Eindruck\u00a0stei gender\u00a0Preise\u00a0\neinzelner\u00a0Arzneimittel,\u00a0vor\u00a0allem\u00a0auch\u00a0im\u00a0 Orphan\u2010Arzneimittel\u2010Bereich,\u00a0erweiterte\u00a0\nPreisverhandlungen\u00a0auf\u00a0der\u00a0Basis\u00a0gesicherter\u00a0gesundheits\u00f6konomi scher\u00a0Evaluatio\u2010\nnen\u00a0durchzuf\u00fchren,\u00a0also\u00a0z.B.\u00a0auf\u00a0der\u00a0Basis\u00a0lebenslanger\u00a0Krankhe itskosten\u00a0(Gerber\u2010\nGrote,\u00a0Windeler\u00a02014).\u00a0Daran\u00a0mangelt\u00a0es\u00a0aber\u00a0in\u00a0unserem\u00a0Gesundh eitssystem.\u00a0Es\u00a0\nsollten\u00a0differenzierte\u00a0Vertr\u00e4ge\u00a0mit\u00a0den\u00a0Firmen\u00a0abgeschlossen\u00a0we rden,\u00a0die\u00a0auch\u00a0\nden\u00a0Nutzen\u00a0und\u00a0Erfolge\u00a0in\u00a0der\u00a0Be handlung\u00a0von\u00a0Patienten\u00a0als\u00a0Para meter\u00a0einf\u00fchren\u00a0\n(z.B.\u00a0im\u00a0Rahmen\u00a0von\u00a0Pay\u00a0for\u00a0Perf ormance/P4P\u2010Vertragskonzepten). \u00a0Ein\u00a0verhandel\u2010\nter\u00a0Preis\u00a0m\u00fcsste\u00a0dann\u00a0z.B.\u00a0nach\u00a0de m\u00a0individuellen\u00a0Erfolg\u00a0in\u00a0der \u00a0Therapie\u00a0abgestaf\u2010\nfelt\u00a0werden,\u00a0eine\u00a0Art\u00a0 risk\u2010sharing \u2010Vertrag\u00a0mit\u00a0 Pay\u2010back\u00a0oder\u00a0R\u00fcckversicherungs\u2010\nklausel.\u00a0Dar\u00fcber\u00a0hinaus\u00a0hat\u00a0das\u00a0Unternehmen\u00a0die\u00a0Verpflichtung,\u00a0 die\u00a0Begleitfor\u2010\nschung\u00a0eines\u00a0unabh\u00e4ngigen\u00a0Institutes\u00a0zu\u00a0finanzieren\u00a0und\u00a0bei\u00a0ein em\u00a0eingeschr\u00e4nk\u2010\nten\u00a0Nutzenergebnis\u00a0einen\u00a0Ausgle ich\u00a0an\u00a0die\u00a0Kassen\u00a0zu\u00a0zahlen.\u00a0\nDazu\u00a0passen\u00a0die\u00a0Vorschl\u00e4ge\u00a0des\u00a0G \u2010BA\u00a0zum\u00a0Thema\u00a0\u201eversorgungsbegle itende\u201c\u00a0For\u2010\nschung.\u00a0In\u00a0der\u00a0Stellungnahme\u00a0hei\u00dft\u00a0es\u00a0(G\u2010BA,\u00a02019,\u00a011\u00a0ff):\u00a0\n\u00a030\u00a0\u201eDie\u00a0hauptamtlichen\u00a0unparteiischen \u00a0Mitglieder\u00a0des\u00a0G\u2010BA\u00a0begr\u00fc\u00dfen \u00a0den\u00a0vorliegenden\u00a0\nEntwurf\u00a0und\u00a0die\u00a0M\u00f6glichkeit\u00a0des\u00a0G\u2010BA,\u00a0weitere\u00a0Datenerhebungen\u00a0n ach\u00a0der\u00a0Zulassung\u00a0\nzum\u00a0Zweck\u00a0der\u00a0Nutzenbewertung\u00a0zu \u00a0fordern,\u00a0da\u00a0dies\u00a0eine\u00a0wesentli che\u00a0Grundlage\u00a0f\u00fcr\u00a0\ndie\u00a0weitere\u00a0Evidenzgenerierung\u00a0f \u00fcr\u00a0Arzneimittel\u00a0w\u00e4hrend\u00a0der\u00a0Anw endung\u00a0in\u00a0der\u00a0klini\u2010\nschen\u00a0Praxis\u00a0schafft,\u00a0bei\u00a0denen\u00a0 die\u00a0Evidenzlage\u00a0zum\u00a0Zeitpunkt\u00a0d er\u00a0Nutzenbewertung\u00a0\nunzureichend\u00a0ist.\u00a0[Erg\u00e4nzung:\u00a0Di es\u00a0gilt\u00a0sowohl\u00a0f\u00fcr\u00a0den\u00a0ambulant en\u00a0wie\u00a0station\u00e4ren\u00a0\nBereich.\u00a0GG]\u00a0[\u2026]\u00a0Um\u00a0das\u00a0Instrument\u00a0der\u00a0begleitenden\u00a0Datenerhebu ng\u00a0in\u00a0zweckverwirk\u2010\nlichender\u00a0Weise\u00a0zukunftsoffen\u00a0und\u00a0 damit\u00a0hinreichend\u00a0entwicklung soffen\u00a0einsetzen\u00a0zu\u00a0\nk\u00f6nnen,\u00a0wird\u00a0es\u00a0daher\u00a0als\u00a0sachger echt\u00a0angesehen,\u00a0den\u00a0Begriff\u00a0\u201ea nwendungsbeglei\u2010\ntend\u201c\u00a0durch\u00a0den\u00a0Begriff\u00a0\u201eversorg ungsbegleitend\u201c\u00a0zu\u00a0ersetzen.\u00a0Ge m\u00e4\u00df\u00a0Gesetzesbegr\u00fcn\u2010\ndung\u00a0kann\u00a0es\u00a0sich\u00a0bei\u00a0den\u00a0Datenerhebungen\u00a0z.B.\u00a0um\u00a0Anwendungsbeo bachtungen,\u00a0Fall\u2010\nKontroll\u2010Studien\u00a0oder\u00a0Registerst udien\u00a0handeln,\u00a0solange\u00a0die\u00a0Date nerhebung\u00a0\u201eanwen\u2010\ndungsbegleitend\u201c\u00a0ist.\u00a0Aus\u00a0methodis cher\u00a0Sicht\u00a0k\u00f6nnten\u00a0auch\u00a0kontr ollierte\u00a0Studien\u00a0(zum\u00a0\nBeispiel\u00a0pragmatische\u00a0Studiende signs)\u00a0versorgungsbegleitend\u00a0dur chgef\u00fchrt\u00a0werden\u00a0\nund\u00a0sollten\u00a0von\u00a0den\u00a0m\u00f6glichen\u00a0Datenerhebungen\u00a0mit\u00a0umfasst\u00a0sein. \u00a0[\u2026]\u00a0Datenerhebun\u2010\ngen\u00a0ohne\u00a0wissenschaftlichen\u00a0Mehr wert\u00a0und\u00a0ohne\u00a0transparente\u00a0Ver\u00f6 ffentlichung\u00a0der\u00a0\nErgebnisse\u00a0m\u00fcssen\u00a0auch\u00a0im\u00a0Rahmen\u00a0der\u00a0begleitenden\u00a0Datenerhebung sforderung\u00a0ver\u2010\nmieden\u00a0werden.\u00a0[\u2026]\u00a0Zum \u00a0Beispiel\u00a0w\u00e4re\u00a0es\u00a0durch\u00a0die\u00a0Einrichtung\u00a0e iner\u00a0unabh\u00e4ngigen\u00a0\nzentralen\u00a0Datenerfassung,\u00a0z.B.\u00a0i m\u00a0Rahmen\u00a0eines\u00a0klinischen\u00a0Regis ters,\u00a0prinzipiell\u00a0m\u00f6g\u2010\nlich,\u00a0therapierelevante\u00a0Krankheit sverlaufsdaten\u00a0\u00fcberregional\u00a0pr oduktunabh\u00e4ngig\u00a0zu\u00a0\nerfassen\u00a0und\u00a0die\u00a0im\u00a0Regierungsent wurf\u00a0bezweckte\u00a0Verbesserung\u00a0de r\u00a0Evidenzgrundlage\u00a0\nim\u00a0Rahmen\u00a0der\u00a0Nutzenbewertung\u00a0zu\u00a0gew\u00e4hrleisten.\u00a0Die\u00a0\u00dcbermittlun g\u00a0pseudonymisier\u2010\nter\u00a0personenbezogener\u00a0Daten\u00a0aus\u00a0diesen\u00a0Datenerhebungen\u00a0an\u00a0den\u00a0G \u2010BA\u00a0zur\u00a0Bewer\u2010\ntung\u00a0der\u00a0Evidenz\u00a0sollte\u00a0nicht\u00a0au sgeschlossen\u00a0sein.\u00a0Bei\u00a0sp\u00e4terer \u00a0Zulassung\u00a0von\u00a0Arznei\u2010\nmitteln\u00a0mit\u00a0gleichgelagerter\u00a0Evidenzproblematik\u00a0in\u00a0selbiger\u00a0ode r\u00a0\u00e4hnlicher\u00a0Indikation\u00a0\nk\u00f6nnten\u00a0die\u00a0versorgungsbegleitende n\u00a0Daten\u00a0in\u00a0das\u00a0gleiche\u00a0Regist er,\u00a0ggf.\u00a0mit\u00a0angepass\u2010\nten\u00a0Modulen,\u00a0eingepflegt\u00a0werden,\u00a0ohne\u00a0dass\u00a0neue\u00a0Strukturen\u00a0aufg ebaut\u00a0werden\u00a0m\u00fcs\u2010\nsen.\u00a0Interoperabilit\u00e4tsproblemati ken,\u00a0die\u00a0mit\u00a0der\u00a0Etablierung\u00a0v erschiedener\u00a0Datener\u2010\nhebungen\u00a0entstehen,\u00a0w\u00fcrden\u00a0vermie den,\u00a0und\u00a0der\u00a0Aufbau\u00a0von\u00a0Parall elstrukturen\u00a0un\u2010\nterbunden.\u201c\u00a0\n\u00a0\nDiese\u00a0Ans\u00e4tze\u00a0aus\u00a0dem\u00a0Entwurf\u00a0ei nes\u00a0Gesetzes\u00a0f\u00fcr\u00a0mehr\u00a0Sicherhei t\u00a0in\u00a0der\u00a0Arznei\u2010\nmittelversorgung\u00a0(GSAV),\u00a0die\u00a0hier \u00a0vom\u00a0G\u2010BA\u00a0kommentiert\u00a0werden,\u00a0 k\u00f6nnen\u00a0auch\u00a0\nals\u00a0Hinwendung\u00a0zur\u00a0Methodik\u00a0einer\u00a0Sp\u00e4tbewertung\u00a0verstanden\u00a0werd en,\u00a0die\u00a0vor\u00a0\nallem\u00a0im\u00a0Zusammenhang\u00a0mit\u00a0den\u00a0beschleunigten\u00a0Zulassungen\u00a0mehr\u00a0u nd\u00a0mehr\u00a0\ngefordert\u00a0werden.\u00a0Das\u00a0AMNOG\u00a0als\u00a0 lernendes\u00a0System\u00a0wird\u00a0eben\u00a0nich t\u00a0umhinkom\u2010\nmen,\u00a0sich\u00a0den\u00a0neuen\u00a0Herausforder ungen\u00a0in\u00a0der\u00a0Arzneimittelbewert ung\u00a0zu\u00a0stellen\u00a0\u2013\u00a0\ndie\u00a0Schw\u00e4chen\u00a0einer\u00a0ausschlie\u00dflichen\u00a0Fr\u00fchbewertung,\u00a0die\u00a0sicherl ich\u00a0als\u00a0erfolgrei\u2010\ncher\u00a0Beginn\u00a0einer\u00a0Zugangspr\u00fcfung\u00a0f\u00fcr\u00a0den\u00a0GKV\u2010Markt\u00a0zu\u00a0betrachte n\u00a0ist,\u00a0werden\u00a0\nimmer\u00a0sichtbarer,\u00a0die\u00a0Erg\u00e4nzung\u00a0einer\u00a0Sp\u00e4tbewertung\u00a0aufgrund\u00a0ve rsorgungsbe\u2010\ngleitender\u00a0Daten\u00a0in\u00a0der\u00a0Patientenbehandlung\u00a0ist\u00a0daher\u00a0ein\u00a0vielv ersprechender\u00a0und\u00a0\nnotwendiger\u00a0Schritt.\u00a0\u00a031\u00a0Quellen\u00a0\nBMG\u00a0\u2013\u00a0Bundesministerium\u00a0f\u00fcr\u00a0Gesundheit\u00a0(2019).\u00a0Gesetzentwurf\u00a0de r\u00a0Bundesregierung:\u00a0Entwurf\u00a0eines\u00a0Gesetzes\u00a0f\u00fcr\u00a0den\u00a0Schutz\u00a0vor\u00a0\nMasern\u00a0und\u00a0zur\u00a0St\u00e4rkung\u00a0der\u00a0Impfpr\u00e4vention\u00a0(Masernschutzgesetz) .\u00a0https://www. bundesgesundheitsministeriu\u00a0\nm.de/impfpflicht.html,\u00a0letzter\u00a0Zugriff:\u00a018.07.2019.\u00a0\nBschor\u00a0T\u00a0(2018).\u00a0Antidepressiva.\u00a0Wie\u00a0man\u00a0sie\u00a0richtig\u00a0anwendet\u00a0u nd\u00a0wer\u00a0sie\u00a0nicht\u00a0nehmen\u00a0sollte.\u00a0M\u00fcnchen:\u00a0S\u00fcdwest\u2010Verlag.\u00a0\u00a0\nG\u2010BA\u00a0\u2013\u00a0Gemeinsamer\u00a0Bundesausschuss\u00a0(2019).\u00a0Stellungnahme\u00a0der\u00a0ha uptamtlichen\u00a0unparteiischen\u00a0Mitglieder\u00a0des\u00a0Gemeinsamen\u00a0\nBundesausschusses\u00a0(G\u2010BA)\u00a0vom\u00a004.04.2019\u00a0zur\u00a0\u00f6ffentlichen\u00a0Anh\u00f6ru ng\u00a0zum\u00a0Gesetzentwurf\u00a0eines\u00a0Gesetzes\u00a0f\u00fcr\u00a0mehr\u00a0\nSicherheit\u00a0in\u00a0der\u00a0Arzneimittelversorgung\u00a0(Drucksache\u00a019/8753).\u00a0 https://www.g\u2010ba.de/downloads/17\u201098\u20104779/2019\u2010\n04\u201004\u2010PA\u2010AfG\u2010SN\u2010GSAV\u2010G\u2010BA.pdf ,\u00a0letzter\u00a0Zugriff:\u00a014.07.2019.\u00a0\nGerber\u2010Grote\u00a0A,\u00a0Windeler\u00a0J\u00a0(2014).\u00a0What\u00a0is\u00a0the\u00a0contribution\u00a0of\u00a0 health\u00a0economic\u00a0evaluations\u00a0to\u00a0decision\u2010making\u00a0in\u00a0health\u00a0care?\u00a0\nExperiences\u00a0from\u00a07\u00a0selected\u00a0countries.\u00a0ZEFQ\u00a0108(7):\u00a0353\u2010450.\u00a0\nIMS\u00a0Health\u00a0\u2013\u00a0Institut\u00a0f\u00fcr\u00a0medi zinische\u00a0Statistik\u00a0(Hrsg.)\u00a0(2018) .\u00a0Der\u00a0pharmazeutische\u00a0Markt\u00a0in\u00a0Deutschland.\u00a0Stand\u00a0der\u00a0Informati on:\u00a0\nDezember\u00a02018,\u00a0Frankfurt\u00a0a.M.:\u00a0Im\u00a0Eigenverlag.\u00a0\nMullard\u00a0A\u00a0(2019).\u00a02018\u00a0FDA\u00a0drug\u00a0approvals.\u00a0nature\u00a0reviews\u00a0drug\u00a0 discovery.\u00a0https://www.nature.c om/articles/d41573\u2010019\u201000014\u2010\nx,\u00a0letzter\u00a0Zugriff:\u00a020.05.2019.\u00a0\nvfa\u00a0\u2013\u00a0Verband\u00a0der\u00a0forschenden\u00a0Pharma\u2010Unternehmen\u00a0(2019).\u00a0Innova tionsbilanz\u00a02018,\u00a011.\u00a0Januar\u00a02019:\u00a0Viele\u00a0Fortschritte\u00a0durch\u00a0\nneue\u00a0Medikamente.\u00a0Nature\u00a0Reviews\u00a0Drug\u00a0Discovery\u00a018(8):\u00a085\u201089.\u00a0\nWieseler\u00a0B,\u00a0McGauran\u00a0N,\u00a0Kaiser\u00a0T\u00a0(2019).\u00a0New\u00a0drugs:\u00a0where\u00a0did\u00a0w e\u00a0go\u00a0wrong\u00a0and\u00a0what\u00a0can\u00a0we\u00a0do\u00a0better?\u00a0BMJ \u00a0366:\u00a0l4340.\u00a0\nWitte\u00a0F\u00a0(2019).\u00a0Millionen\u00a0f\u00fcr\u00a0eine \u00a0Illusion.\u00a0Frankfurter\u00a0Allgem eine\u00a0Woche\u00a027:\u00a044\u201046.\u00a0\n\u00a0\u00a032\u00a02 Ziele\u00a0und\u00a0Methodik\u00a0\n2.1\u00a0\u00a0\u00a0Zielsetzung\u00a0\nDie\u00a0Ziele\u00a0des\u00a0vorliegenden\u00a0Innovationsreports\u00a0sind\u00a0zum\u00a0einen,\u00a0n eue\u00a0Arzneimittel\u00a0\nnach\u00a0der\u00a0Markteinf\u00fchrung\u00a0anhand\u00a0der\u00a0aktuellen\u00a0Studienlage\u00a0nach\u00a0 den\u00a0Kriterien\u00a0\nder\u00a0evidenzbasierten\u00a0Medizin\u00a0zu\u00a0bewerten\u00a0und\u00a0zum\u00a0anderen,\u00a0Veror dnungscharak\u2010\nteristika\u00a0dieser\u00a0Arzneimittel\u00a0na ch\u00a0ihrer\u00a0Markteinf\u00fchrung\u00a0auf\u00a0de r\u00a0Basis\u00a0von\u00a0Daten\u00a0\nder\u00a0Techniker\u00a0Krankenkasse\u00a0(TK)\u00a0darzustellen.\u00a0\u00a0\nIm\u00a0diesj\u00e4hrigen\u00a0Innovationsreport\u00a0stehen\u00a0schwerpunktm\u00e4\u00dfig\u00a0die\u00a0n euen\u00a0Wirkstoffe\u00a0\ndes\u00a0Jahres\u00a02016\u00a0im\u00a0Fokus.\u00a0Zur\u00a0Bewertung\u00a0werden\u00a0auch\u00a0Studien\u00a0ber \u00fccksichtigt,\u00a0\nderen\u00a0Ergebnisse\u00a0erst\u00a0nach\u00a0der\u00a0Markteinf\u00fchrung\u00a0der\u00a0jeweiligen\u00a0W irkstoffe\u00a0publi\u2010\nziert\u00a0worden\u00a0sind.\u00a0Ebenso\u00a0finden\u00a0neue\u00a0Erkenntnisse\u00a0zu\u00a0Sicherhei tsrisiken\u00a0Beach\u2010\ntung,\u00a0 die\u00a0 zum\u00a0 Zeitpunkt\u00a0 der\u00a0 Zulassung\u00a0 und\u00a0 zum\u00a0 Zeitpunkt\u00a0 der\u00a0 AMN OG\u2010\nNutzenbewertung\u00a0noch\u00a0nicht\u00a0bekannt\u00a0waren.\u00a0Unsere\u00a0Bewertungen\u00a0we rden\u00a0durch\u00a0\nAnalysen\u00a0der\u00a0Routinedaten\u00a0der\u00a0TK\u00a0aus\u00a0den\u00a0Jahren\u00a02016\u00a0und\u00a02017 \u00a0erg\u00e4nzt,\u00a0um\u00a0\nEinsichten\u00a0in\u00a0das\u00a0Versorgungsgeschehen\u00a0zu\u00a0gewinnen.\u00a0Im\u00a0R\u00fcckblic k\u00a0auf\u00a0die\u00a0im\u00a0\nInnovationsreport\u00a0 2018\u00a0 behandelten\u00a0 Arzneimittel\u00a0 (neue\u00a0 Wirkstoff e\u00a0 des\u00a0 Jahres\u00a0\n2015)\u00a0wird\u00a0auch\u00a0gezeigt,\u00a0wie\u00a0diese\u00a0sich\u00a0im\u00a0Markt\u00a0weiterentwicke lt\u00a0haben\u00a0und\u00a0ob\u00a0\nneue\u00a0Risiken\u00a0aufgetreten\u00a0sind,\u00a0d ie\u00a0die\u00a0Therapiesicherheit\u00a0gef\u00e4h rden.\u00a0\u00a0\nDas\u00a0Sonderkapitel\u00a0(Kapitel\u00a06)\u00a0diskutiert\u00a0die\u00a0Impfpflicht\u00a0in\u00a0Deu tschland.\u00a0Es\u00a0geht\u00a0\nzun\u00e4chst\u00a0um\u00a0gesellschaftliche\u00a0und\u00a0historische\u00a0Aspekte\u00a0der\u00a0Impfp flicht,\u00a0auch\u00a0im\u00a0\ninternationalen\u00a0Vergleich,\u00a0soda nn\u00a0um\u00a0die\u00a0pharmazeutischen\u00a0und\u00a0z ulassungsbe\u2010\ndingten\u00a0Besonderheiten\u00a0bez\u00fcglich\u00a0des\u00a0Nutzens\u00a0sowie\u00a0der\u00a0Evidenzg enerierung\u00a0bei\u00a0\nImpfstoffen.\u00a0Aus\u00a0diesem\u00a0Anlass\u00a0w urde\u00a0\u2013\u00a0anders\u00a0als\u00a0in\u00a0den\u00a0bisher igen\u00a0Reporten\u00a0\u2013\u00a0\nauch\u00a0ein\u00a0Impfstoff,\u00a0ein\u00a0neunvalentes\u00a0HPV\u2010Produkt,\u00a0im\u00a0diesj\u00e4hrig en\u00a0Innovationsre\u2010\nport\u00a0bewertet,\u00a0unter\u00a0Ber\u00fccksichtigung\u00a0der\u00a0zulassungsbezogenen\u00a0U nterschiede\u00a0zu\u00a0\nden\u00a0bisher\u00a0bewerteten\u00a0Arzneimitteln.\u00a0\u00a0\n2.2\u00a0\u00a0\u00a0Methodik\u00a0zur\u00a0Bewertung\u00a0der\u00a0neuen\u00a0Arzneimittel\u00a0\nF\u00fcr\u00a0den\u00a0vorliegenden\u00a0Report\u00a0wurde n\u00a0Medikamente\u00a0mit\u00a0neuen\u00a0Wirkst offen\u00a0bewer\u2010\ntet,\u00a0die\u00a0im\u00a0Jahr\u00a02016\u00a0erstmals\u00a0in\u00a0den\u00a0deutschen\u00a0Arzneimittelmar kt\u00a0eingef\u00fchrt\u00a0\nwurden.\u00a0Generell\u00a0wurden\u00a0keine\u00a0neuen\u00a0Arzneimittel\u00a0mit\u00a0bereits\u00a0in \u00a0anderen\u00a0zuge\u2010\nlassenen\u00a0Pr\u00e4paraten\u00a0verf\u00fcgbaren\u00a0Wirkstoffen\u00a0(z.B.\u00a0Generika)\u00a0ode r\u00a0neue\u00a0Kombina\u2010\ntionen\u00a0aus\u00a0bereits\u00a0bekannten\u00a0Wirkstoffen\u00a0ber\u00fccksichtigt.\u00a0Von\u00a0de n\u00a037\u00a0neuen\u00a0Arz\u2010\nneimitteln\u00a0des\u00a0Jahres\u00a02016\u00a0wurden \u00a014\u00a0Pr\u00e4parate\u00a0nicht\u00a0in\u00a0unsere\u00a0 Bewertung\u00a0mit\u2010\neinbezogen:\u00a0Dalbavancin\u00a0(Xydalba\u00ae),\u00a0Dinutuximab\u00a0(Unituxin\u00ae,\u00a0sei t\u00a0Juni\u00a02017\u00a0au\u00dfer\u00a0\nVertrieb),\u00a0Idarucizumab\u00a0(Praxbind\u00ae),\u00a0Necitumumab\u00a0(Portrazza\u00ae)\u00a0u nd\u00a0Susoctocog\u00a0\nalfa\u00a0(Obizur\u00ae)\u00a0sind\u00a0oder\u00a0waren\u00a0vor\u00fcbergehend\u00a0nur\u00a0von\u00a0krankenhau sversorgenden\u00a033\u00a0Apotheken\u00a0direkt\u00a0vom\u00a0Hersteller\u00a0zu\u00a0beziehen\u00a0und\u00a0spielten\u00a0in\u00a0der \u00a0ambulanten\u00a0\nVersorgung\u00a0keine\u00a0Rolle.\u00a0Ebenso\u00a0wurden\u00a0Afamelanotid\u00a0(Scenesse\u00ae)\u00a0 und\u00a0Tasimelte\u2010\non\u00a0(Hetlioz\u00ae)\u00a0aufgrund\u00a0ihrer\u00a0speziellen\u00a0und\u00a0seltenen\u00a0Indikation \u00a0nicht\u00a0in\u00a0unsere\u00a0\nBewertung\u00a0aufgenommen.\u00a0Das\u00a0am\u00a001.05.2016\u00a0eingef\u00fchrte\u00a0Arzneimitt el\u00a0Ospemi\u2010\nfem\u00a0(Senshio\u00ae)\u00a0ist\u00a0seit\u00a0April\u00a02017\u00a0nicht\u00a0mehr\u00a0im\u00a0Handel\u00a0und\u00a0fin det\u00a0daher\u00a0keine\u00a0\nBer\u00fccksichtigung.\u00a0Bei\u00a0den\u00a0Wirkstoffen\u00a0Daclizumab\u00a0(Zinbryta\u00ae),\u00a0E isen\u00a0(III)\u2010Maltol\u00a0\n(Feraccru\u00ae),\u00a0Guanfacin\u00a0(Intuniv\u00ae ),\u00a0Ivermectin\u00a0(Scabioral\u00ae),\u00a0Mil nacipran\u00a0(Milnaneu\u2010\nrax\u00ae)\u00a0und\u00a0Pivmecillinam\u00a0(X\u2010Systo\u00ae)\u00a0handelt\u00a0es\u00a0sich\u00a0um\u00a0bereits\u00a0l \u00e4nger\u00a0bekannte\u00a0\nArzneistoffe\u00a0ohne\u00a0Unterlagenschutz,\u00a0die\u00a0mit\u00a0neuen\u00a0Indikationen\u00a0 auf\u00a0den\u00a0deut\u2010\nschen\u00a0Markt\u00a0kamen\u00a0und\u00a0auch\u00a0vom\u00a0G\u2010BA\u00a0keiner\u00a0Nutzenbewertung\u00a0unte rzogen\u00a0\nwurden.\u00a0\u00a0\nDie\u00a0Bewertung\u00a0der\u00a0Studienlage\u00a0basiert\u00a0zum\u00a0einen\u00a0auf\u00a0den\u00a0Ergebni ssen\u00a0der\u00a0Zulas\u2010\nsungsstudien\u00a0sowie\u00a0dem\u00a0Beurteilungsbericht\u00a0der\u00a0verantwortlichen \u00a0Zulassungsbe\u2010\nh\u00f6rde\u00a0und\u00a0zum\u00a0anderen\u00a0auf\u00a0Litera turrecherchen,\u00a0welche\u00a0die\u00a0jewei ligen\u00a0Autoren\u00a0\nder\u00a0einzelnen\u00a0Kapitel\u00a0unabh\u00e4ngig \u00a0voneinander\u00a0durchf\u00fchrten.\u00a0Haup ts\u00e4chlich\u00a0wurde\u00a0\nin\u00a0 der\u00a0 Literaturdatenbank\u00a0 MEDLINE\u00a0 \u00fcber\u00a0 PubMed\u00a0 recherchiert.\u00a0 Zus \u00e4tzlich\u00a0 zur\u00a0\nSuche\u00a0\u00fcber\u00a0Literaturdatenbanken\u00a0wurden\u00a0Standardwerke\u00a0der\u00a0wissen schaftlichen\u00a0\nLiteratur\u00a0genutzt.\u00a0\nGem\u00e4\u00df\u00a0den\u00a0Grunds\u00e4tzen\u00a0der\u00a0Evidenzbasierten\u00a0Medizin\u00a0(EbM),\u00a0dem\u00a0M ethodenpa\u2010\npier\u00a0IQWiG,\u00a0analog\u00a0zum\u00a0Vorgehen\u00a0nach\u00a0\u00a7\u00a035\u00a0Absatz\u00a01b\u00a0Satz\u00a01\u00a0bis\u00a0 5\u00a0(SGB\u00a0V)\u00a0und\u00a0\nnach\u00a0\u00a7\u00a013\u00a0Absatz\u00a02\u00a0der\u00a0Verfahrensordnung\u00a0des\u00a0G\u2010BA\u00a0wurden\u00a0im\u00a0Wes entlichen\u00a0\nkontrollierte\u00a0und\u00a0bzw.\u00a0oder\u00a0versorgungsrelevante\u00a0klinische\u00a0Stud ien\u00a0mit\u00a0patienten\u2010\nrelevanten\u00a0Endpunkten\u00a0eingeschlo ssen,\u00a0insbesondere\u00a0zur\u00a0Mortalit \u00e4t,\u00a0Morbidit\u00e4t\u00a0\nund\u00a0Lebensqualit\u00e4t.\u00a0Bei\u00a0der\u00a0Extraktion\u00a0der\u00a0Ergebnisse\u00a0zu\u00a0prim\u00e4r en\u00a0und\u00a0sekund\u00e4ren\u00a0\nEndpunkten\u00a0der\u00a0Studien\u00a0wurde\u00a0auf\u00a0die\u00a0Verf\u00fcgbarkeit\u00a0von\u00a0Ergebnis sen\u00a0zur\u00a0Health\u00a0\nRelated\u00a0Quality\u00a0of\u00a0Life\u00a0 (HRQoL)\u00a0geachtet;\u00a0sofern\u00a0vorhanden,\u00a0wurden\u00a0sie\u00a0in\u00a0den\u00a0\nBericht\u00a0aufgenommen.\u00a0\u00a0\nUnsere\u00a0Bewertung\u00a0der\u00a0neuen\u00a0Arzne imittel\u00a0wird\u00a0durch\u00a0Sekund\u00e4rlite ratur\u00a0unter\u00a0dem\u00a0\nAspekt\u00a0\"Wie\u00a0bewerten\u00a0andere\"\u00a0erg\u00e4 nzt.\u00a0Dazu\u00a0geh\u00f6ren\u00a0die\u00a0Bewertun gen\u00a0des\u00a0Inno\u2010\nvationsgrades\u00a0A\u2010D\u00a0nach\u00a0der\u00a0Methode\u00a0von\u00a0Fricke\u00a0und\u00a0Klaus,\u00a0die\u00a0Be wertungen\u00a0des\u00a0\narznei\u2010telegramms\u00a0(a\u2010t)\u00a0und\u00a0seiner\u00a0Datenbank\u00a0(atd),\u00a0des\u00a0Arzneim ittelbriefes\u00a0(AMB)\u00a0\nsowie\u00a0die\u00a0sieben\u00a0Bewertungsstufen \u00a0von\u00a0Prescrire\u00a0International\u00a0z wischen\u00a0\u201eBRAVO\u201c\u00a0\nund\u00a0\u201enot\u00a0acceptable\u201c.\u00a0Die\u00a0Methode\u00a0von\u00a0Fricke\u00a0und\u00a0Kollegen\u00a0basie rt\u00a0auf\u00a0pharmako\u2010\nlogischen\u00a0Kriterien\u00a0und\u00a0beurteilt \u00a0prim\u00e4r\u00a0die\u00a0Neuartigkeit\u00a0des\u00a0W irkungsmechanis\u2010\nmus\u00a0der\u00a0Arzneistoffe\u00a0(Fricke\u00a0&\u00a0Schwabe,\u00a02001).\u00a0Das\u00a0Hauptgewicht \u00a0der\u00a0Bewertung\u00a0\nliegt\u00a0dabei\u00a0auf\u00a0dem\u00a0angestrebten\u00a0therapeutischen\u00a0Effekt:\u00a0\u201eF\u00fchrt \u00a0ein\u00a0neuartiger\u00a0\nWirkungsmechanismus\u00a0(A)\u00a0nicht\u00a0zu\u00a0der\u00a0entsprechenden\u00a0Verbesserun g\u00a0des\u00a0thera\u2010\npeutischen\u00a0Nutzens,\u00a0wird\u00a0die\u00a0unterschiedliche\u00a0Bewertung\u00a0der\u00a0kli nischen\u00a0Eigen\u201034\u00a0schaften\u00a0durch\u00a0eine\u00a0zus\u00e4tzliche\u00a0K ennzeichnung\u00a0her vorgehoben.\u00a0So lche\u00a0Doppelbe\u2010\nwertungen\u00a0ergeben\u00a0sich\u00a0aus\u00a0einer\u00a0unterschiedlichen\u00a0Beurteilung\u00a0 der\u00a0pharmakolo\u2010\ngischen\u00a0Aspekte\u00a0(z.\u00a0B.\u00a0neuartiges\u00a0Wirkprinzip)\u00a0und\u00a0der\u00a0klinisch en\u00a0Studiendaten,\u00a0\nwenn\u00a0ein\u00a0pharmakologisch\u00a0innovatives\u00a0Arzneimittel\u00a0keine\u00a0therape utische\u00a0\u00dcberle\u2010\ngenheit\u00a0gegen\u00fcber\u00a0bereits\u00a0verf\u00fcgbaren\u00a0Arzneimitteln\u00a0mit\u00a0gleiche r\u00a0Indikation\u00a0ge\u2010\nzeigt\u00a0hat\u00a0(A/C)\u201c\u00a0(Fricke,\u00a02016).\u00a0\nDie\u00a0anschlie\u00dfende\u00a0Beurteilung\u00a0der\u00a0Evidenz\u00a0nahmen\u00a0die\u00a0Autoren\u00a0im \u00a0Konsensver\u2010\nfahren\u00a0vor.\u00a0\nF\u00fcr\u00a0die\u00a0Leitlinienempfehlungen\u00a0zu\u00a0den\u00a0einzelnen\u00a0Arzneimitteln\u00a0u nd\u00a0ihren\u00a0jeweili\u2010\ngen\u00a0Indikationsgebieten\u00a0wurden\u00a0Leitlinien\u00a0genutzt,\u00a0die\u00a0im\u00a0Regis ter\u00a0der\u00a0Arbeitsge\u2010\nmeinschaft\u00a0der\u00a0Wissenschaftliche n\u00a0Medizinischen\u00a0Fachgesellschaf ten\u00a0e.V.\u00a0(AWMF)\u00a0\neingetragen\u00a0 sind.\u00a0 Wurde\u00a0 zu\u00a0 den\u00a0 en tsprechenden\u00a0 Indikationsgebiet en\u00a0 keine\u00a0\nAWMF\u2010Leitlinie\u00a0gefunden,\u00a0erfolgte\u00a0eine\u00a0Recherche\u00a0nach\u00a0anderen\u00a0n ationalen\u00a0oder\u00a0\ninternationalen\u00a0Handlungsempfehlungen.\u00a0\u00a0\nBei\u00a0den\u00a0einzelnen\u00a0Wirkstoffen\u00a0wurden\u00a0verschiedene\u00a0Aspekte\u00a0separ at\u00a0bewertet:\u00a0\nerstens\u00a0die\u00a0Verf\u00fcgbarkeit\u00a0bestehender\u00a0medikament\u00f6ser\u00a0Therapien, \u00a0zweitens\u00a0der\u00a0\npatientenorientierte\u00a0(Zusatz\u2010)Nutzen\u00a0und\u00a0drittens\u00a0die\u00a0Kosten\u00a0de s\u00a0neuen\u00a0Arzneimit\u2010\ntels\u00a0im\u00a0Vergleich\u00a0zu\u00a0bisher\u00a0verf \u00fcgbaren\u00a0Arzneimitteln.\u00a0Waren\u00a0bi s\u00a0dato\u00a0keine\u00a0medi\u2010\nkament\u00f6sen\u00a0Therapien\u00a0f\u00fcr\u00a0die\u00a0jeweilige\u00a0Erkrankung\u00a0verf\u00fcgbar,\u00a0wu rde\u00a0die\u00a0thera\u2010\npeutische\u00a0Wirksamkeit\u00a0des\u00a0neuen\u00a0Arzneimittels\u00a0\u201ef\u00fcr\u00a0sich\u201c\u00a0bewert et.\u00a0F\u00fcr\u00a0jeden\u00a0der\u00a0\ndrei\u00a0genannten\u00a0Punkte\u00a0wurde\u00a0ein\u00a0Ampelschema\u00a0genutzt,\u00a0wobei\u00a0die\u00a0 Farben\u00a0das\u00a0\nFolgende\u00a0bedeuten:\u00a0\nVerf\u00fcgbare\u00a0Therapien\u00a0\n\u2022 Rot:\u00a0Das\u00a0neue\u00a0Arzneimittel\u00a0stellt\u00a0l ediglich\u00a0eine\u00a0weitere\u00a0Therapieo pti\u2010\non\u00a0f\u00fcr\u00a0das\u00a0zugelassene\u00a0Anwendungsgebiet\u00a0dar,\u00a0es\u00a0gibt\u00a0f\u00fcr\u00a0die\u00a0Be \u2010\nhandlung\u00a0der\u00a0jeweiligen\u00a0Erkrankung(en)\u00a0bereits\u00a0zugelassene\u00a0Arzn ei\u2010\nmittel\u00a0mit\u00a0vergleichbaren\u00a0pharmakodynamischen\u00a0und\u00a0pharmakoki\u2010\nnetischen\u00a0Eigenschaften\u00a0au f\u00a0dem\u00a0deutschen\u00a0Markt.\u00a0\n\u2022 Gelb:\u00a0Das\u00a0neue\u00a0Arzneimittel\u00a0stellt\u00a0aufgrund\u00a0eines\u00a0neuartigen\u00a0Wir\u2010\nkungsmechanismus\u00a0 oder\u00a0 verbesserter\u00a0 pharmakokinetischer\u00a0 und\u00a0\ntechnologischer\u00a0Eigenschaften\u00a0(z .B.\u00a0einer\u00a0neuen\u00a0Applikationsfor m)\u00a0\neine\u00a0Novit\u00e4t\u00a0dar,\u00a0die\u00a0zumindest\u00a0f \u00fcr\u00a0eine\u00a0bestimmte\u00a0Untergruppe\u00a0 der\u00a0\nErkrankten\u00a0eine\u00a0zus\u00e4tzliche\u00a0Therapiem\u00f6glichkeit\u00a0bietet,\u00a0z.B.\u00a0we il\u00a0ge\u2010\ngen\u00a0bisher\u00a0zugelassene\u00a0Arzneim ittel\u00a0Resistenzen\u00a0vorliegen.\u00a035\u00a0\u2022 Gr\u00fcn:\u00a0Das\u00a0neue\u00a0Arzneimittel\u00a0bietet\u00a0e rstmals\u00a0die\u00a0M\u00f6glichkeit,\u00a0die\u00a0Er \u2010\nkrankung,\u00a0f\u00fcr\u00a0die\u00a0es\u00a0zugelassen\u00a0 ist,\u00a0medikament\u00f6s\u00a0zu\u00a0behandeln\u00a0 so\u2010\nwie\u00a0bessere\u00a0Therapieergebnisse\u00a0zu\u00a0erzielen\u00a0(therapeutische\u00a0Inno va\u2010\ntion).\u00a0\n\u2022 Wei\u00df:\u00a0Das\u00a0neue\u00a0Arzneimittel\u00a0wurde\u00a0vom\u00a0pU\u00a0vom\u00a0Markt\u00a0genommen\u00a0\nund\u00a0deshalb\u00a0nicht\u00a0bewertet.\u00a0\n(Zusatz\u2010)Nutzen\u00a0\n\u2022 Rot:\u00a0Das\u00a0neue\u00a0Arzneimittel\u00a0bietet\u00a0f \u00fcr\u00a0die\u00a0Behandlung\u00a0gegen\u00fcber\u00a0den \u00a0\nbisher\u00a0verf\u00fcgbaren\u00a0Arz neimitteln\u00a0keine\u00a0patientenrelevante\u00a0Verbe s\u2010\nserung\u00a0oder\u00a0weist\u00a0sogar\u00a0eine\u00a0sch lechtere\u00a0Nutzen\u2010Schaden\u2010Relatio n\u00a0\nauf\u00a0als\u00a0bisher\u00a0verf\u00fcgbare\u00a0Arznei mittel\u00a0(z.B.\u00a0mehr\u00a0Nebenwirkunge n).\u00a0\n\u2022 Gelb:\u00a0Das\u00a0neue\u00a0Arzneimittel\u00a0bietet\u00a0Verbesserungen\u00a0in\u00a0Bezug\u00a0auf\u00a0die\u00a0\ntherapeutische\u00a0Wirksamkeit\u00a0oder\u00a0die\u00a0Vertr\u00e4glichkeit\u00a0bzw.\u00a0Therap ie\u2010\nsicherheit,\u00a0wobei\u00a0die\u00a0Evidenz\u00a0ni cht\u00a0eindeutig\u00a0ist\u00a0(z.B.\u00a0heterog ene\u00a0\nStudienergebnisse)\u00a0oder\u00a0die\u00a0beoba chteten\u00a0Verbesserungen\u00a0eher\u00a0ge \u2010\nring\u00a0ausfallen.\u00a0\n\u2022 Gr\u00fcn:\u00a0Das\u00a0neue\u00a0Arzneimittel\u00a0bietet\u00a0f\u00fcr\u00a0die\u00a0zugelassene\u00a0Behandlung\u00a0\nder\u00a0jeweiligen\u00a0Erkrankung\u00a0bez\u00fcglich\u00a0klinisch\u00a0relevanter\u00a0Endpunk te\u00a0\neine\u00a0Verbesserung\u00a0gegen\u00fcber\u00a0den\u00a0bi sher\u00a0verf\u00fcgbaren\u00a0Arzneimittel n.\u00a0\nDer\u00a0erforderliche\u00a0Zusatzeffekt\u00a0wird\u00a0hier\u00a0in\u00a0Abh\u00e4ngigkeit\u00a0von\u00a0de r\u00a0je\u2010\nweiligen\u00a0Indikation\u00a0festgelegt,\u00a0so\u00a0dass\u00a0z.B.\u00a0auch\u00a0kleinere,\u00a0abe r\u00a0pati\u2010\nentenrelevante\u00a0Verbesserungen\u00a0bei \u00a0seltenen\u00a0Erkrankungen,\u00a0f\u00fcr\u00a0di e\u00a0\nes\u00a0noch\u00a0keine\u00a0Therapie\u00a0gibt,\u00a0an\u00a0Gewicht\u00a0gewinnen.\u00a0Ebenfalls\u00a0wur de\u00a0\nmit\u00a0\u201egr\u00fcn\u201c\u00a0bewertet,\u00a0wenn\u00a0es\u00a0eindeutige\u00a0Belege\u00a0daf\u00fcr\u00a0gibt,\u00a0dass \u00a0die\u00a0\nNutzen\u2010Schaden\u2010Bilanz\u00a0 gegen\u00fcber\u00a0 bisherigen\u00a0 Therapien,\u00a0 z.B.\u00a0 auf\u2010\ngrund\u00a0einer\u00a0Verminderung\u00a0schwere r\u00a0unerw\u00fcnschter\u00a0Wirkungen,\u00a0re\u2010\nduziert\u00a0ist.\u00a0 \u00a0\nKosten\u00a0\n\u2022 Rot:\u00a0Das\u00a0neue\u00a0Arzneimittel\u00a0ist\u00a0in\u00a0Bezug\u00a0auf\u00a0einen\u00a0vergleichbaren\u00a0A n\u2010\nwendungszeitraum\u00a0teurer\u00a0als\u00a0andere \u00a0bisher\u00a0f\u00fcr\u00a0das\u00a0jeweilige\u00a0An\u2010\nwendungsgebiet\u00a0 zugelassene\u00a0 Arzneim ittel\u00a0 bzw.\u00a0 die\u00a0 zweckm\u00e4\u00dfige\u00a0\nVergleichstherapie.\u00a0Bei\u00a0mehreren \u00a0Indikationen\u00a0ist\u00a0prim\u00e4r\u00a0die\u00a0In dika\u2010\ntion\u00a0f\u00fcr\u00a0die\u00a0Bewertung\u00a0relevant,\u00a0bei\u00a0welcher\u00a0aufgrund\u00a0epidemiol ogi\u2010\nscher\u00a0Daten\u00a0die\u00a0meisten\u00a0An wender\u00a0zu\u00a0erwarten\u00a0sind.\u00a036\u00a0\u2022 Gelb:\u00a0Das\u00a0neue\u00a0Arzneimittel\u00a0kostet\u00a0i n\u00a0Bezug\u00a0auf\u00a0einen\u00a0vergleichba\u2010\nren\u00a0Anwendungszeitraum\u00a0ungef\u00e4hr\u00a0gleich\u00a0viel\u00a0wie\u00a0bisher\u00a0f\u00fcr\u00a0das\u00a0 je\u2010\nweilige\u00a0 Anwendungsgebiet\u00a0 zugelasse ne\u00a0 Arzneimittel\u00a0 bzw.\u00a0 die\u00a0\nzweckm\u00e4\u00dfige\u00a0Vergleichstherapie.\u00a0Oder\u00a0einige\u00a0wichtige\u00a0Arzneimitt el\u2010\ngruppen\u00a0sind\u00a0g\u00fcnstiger,\u00a0w\u00e4hrend\u00a0a ndere\u00a0relevante\u00a0Alternativen\u00a0t eu\u2010\nrer\u00a0sind\u00a0als\u00a0das\u00a0neue\u00a0Arzneimitte l.\u00a0Nur\u00a0bei\u00a0einem\u00a0quantifizierb aren\u00a0\nZusatznutzen\u00a0wird\u00a0auch\u00a0ein\u00a0h\u00f6herer\u00a0Preis\u00a0akzeptiert.\u00a0Bei\u00a0mehrer en\u00a0\nIndikationen\u00a0ist\u00a0prim\u00e4r\u00a0die\u00a0Indikation\u00a0f\u00fcr\u00a0die\u00a0Bewertung\u00a0releva nt,\u00a0bei\u00a0\nwelcher\u00a0aufgrund\u00a0epidemiologisc her\u00a0Daten\u00a0die\u00a0meisten\u00a0Anwender\u00a0\nzu\u00a0erwarten\u00a0sind.\u00a0\u00a0\n\u2022 Gr\u00fcn:\u00a0Das\u00a0neue\u00a0Arzneimittel\u00a0ist\u00a0in\u00a0Bezug\u00a0auf\u00a0einen\u00a0vergleichbaren\u00a0\nAnwendungszeitraum\u00a0g\u00fcnstiger\u00a0als\u00a0bisher\u00a0f\u00fcr\u00a0das\u00a0jeweilige\u00a0Anwen \u2010\ndungsgebiet\u00a0zugelassene\u00a0Arzneimi ttel\u00a0bzw.\u00a0als\u00a0die\u00a0zweckm\u00e4\u00dfige\u00a0V er\u2010\ngleichstherapie.\u00a0Bei\u00a0mehreren\u00a0I ndikationen\u00a0ist\u00a0prim\u00e4r\u00a0die\u00a0Indik ation\u00a0\nf\u00fcr\u00a0die\u00a0Bewertung\u00a0relevant,\u00a0bei\u00a0welcher\u00a0aufgrund\u00a0epidemiologisc her\u00a0\nDaten\u00a0die\u00a0meisten\u00a0Anwender\u00a0zu\u00a0erwarten\u00a0sind.\u00a0\n\u2022 Wei\u00df:\u00a0Ein\u00a0aktueller\u00a0Kostenvergleich\u00a0mit\u00a0Arzneimitteln,\u00a0die\u00a0sich\u00a0be\u2010\nreits\u00a0l\u00e4nger\u00a0auf\u00a0dem\u00a0Markt\u00a0befinden,\u00a0ist\u00a0entweder\u00a0aufgrund\u00a0eine r\u00a0\nfehlenden\u00a0Markteinf\u00fchrung\u00a0bzw.\u00a0einer\u00a0Marktr\u00fccknahme\u00a0des\u00a0neuen\u00a0Arzneimittels\u00a0oder\u00a0aufgrund\u00a0des\u00a0Fe hlens\u00a0einer\u00a0zweckm\u00e4\u00dfigen\u00a0medi \u2010\nkament\u00f6sen\u00a0Vergleichsthe rapie\u00a0nicht\u00a0m\u00f6glich.\u00a0\nWenn\u00a0die\u00a0Ampel\u00a0bei\u00a0den\u00a0\u201everf\u00fcgbaren\u00a0Therapien\u201c\u00a0rot\u00a0gekennzeichn et\u00a0ist,\u00a0ist\u00a0dies\u00a0\nnicht\u00a0automatisch\u00a0negativ\u00a0zu\u00a0seh en.\u00a0Sofern\u00a0diese\u00a0neue\u00a0Substanz\u00a0 einen\u00a0therapeuti\u2010\nschen\u00a0Fortschritt\u00a0mit\u00a0sich\u00a0bringt,\u00a0also\u00a0eine\u00a0gr\u00fcne\u00a0Ampel\u00a0beim\u00a0\u201e (Zusatz\u2010)Nutzen\u201c\u00a0\naufweist,\u00a0kann\u00a0immer\u00a0noch\u00a0eine\u00a0relevante\u00a0therapeutische\u00a0Innovat ion\u00a0vorliegen.\u00a0In\u00a0\nder\u00a0Regel\u00a0ist\u00a0jedoch\u00a0bei\u00a0einem\u00a0nachgewiesenen\u00a0(Zusatz\u2010)Nutzen\u00a0d ie\u00a0Verf\u00fcgbar\u2010\nkeitsampel\u00a0mindestens\u00a0auf\u00a0\u201egelb\u201c\u00a0gestellt,\u00a0weil\u00a0mit\u00a0der\u00a0Anwendu g\u00a0des\u00a0Mittels\u00a0\nVorteile\u00a0verbunden\u00a0sein\u00a0k\u00f6nnen,\u00a0z.B.\u00a0f\u00fcr\u00a0definierte\u00a0kleine\u00a0Pati entengruppen.\u00a0Die\u00a0\nVerf\u00fcgbarkeit\u00a0bestehender\u00a0Therapien\u00a0orientiert\u00a0sich\u00a0hier\u00a0an\u00a0der \u00a0Situation\u00a0zum\u00a0\nZeitpunkt\u00a0des\u00a0Redaktionsschlusses\u00a0am\u00a001.05.2019,\u00a0ebenso\u00a0wird\u00a0de r\u00a0(Zusatz\u2010)Nutzen\u00a0\nauf\u00a0 Basis\u00a0 der\u00a0 aktuellen\u00a0 Literatu r\u00a0 zum\u00a0 Redaktionsschluss\u00a0 bestimm t . \u00a0D i e \u00a0Ko s t e n \u00a0\nwerden\u00a0auf\u00a0Basis\u00a0der\u00a0Preisst\u00e4nde\u00a0gem\u00e4\u00df\u00a0Lauer\u2010Taxe\u00a0mit\u00a0Stand\u00a0vom \u00a015.01.2019\u00a0\nbeurteilt.\u00a0Sollte\u00a0das\u00a0neue\u00a0Arzne imittel\u00a0f\u00fcr\u00a0mehrere\u00a0Anwendungsg ebiete\u00a0zugelas\u2010\nsen\u00a0sein,\u00a0wurde\u00a0unsere\u00a0Bewertung\u00a0durch\u00a0die\u00a0Haupt\u2010\u00a0bzw.\u00a0Erstindi kation\u00a0geleitet,\u00a0\nsofern\u00a0diese\u00a0identifizierbar\u00a0war.\u00a0\nIm\u00a0 Rahmen\u00a0 der\u00a0 klinischen\u00a0 Studien\u00a0 m\u00f6glicherweise\u00a0 auftretende\u00a0 une rw\u00fcnschte\u00a0\nEreignisse\u00a0bzw.\u00a0Nebenwirkungen\u00a0wurden\u00a0gem\u00e4\u00df\u00a0\u00a7\u00a03\u00a0Abs.\u00a06,\u00a07\u00a0und\u00a08 \u00a0der\u00a0\u201eVerord\u2010\nnung\u00a0\u00fcber\u00a0die\u00a0Anwendung\u00a0der\u00a0Guten\u00a0Klinischen\u00a0Praxis\u00a0bei\u00a0der\u00a0Dur chf\u00fchrung\u00a0von\u00a037\u00a0klinischen\u00a0 Pr\u00fcfungen\u00a0 mit\u00a0 Arzneimitteln\u00a0 zur\u00a0 Anwendung\u00a0 am\u00a0 Mensche n\u201c\u00a0 (GCP\u2010\nVerordnung)\u00a0wie\u00a0folgt\u00a0definiert\u00a0und\u00a0so\u00a0auch\u00a0in\u00a0den\u00a0Bewertungen\u00a0 dieses\u00a0Reports\u00a0\nbehandelt\u00a0(Bundesministerium\u00a0der\u00a0Justiz\u00a0und\u00a0f\u00fcr\u00a0Verbraucherschu tz,\u00a02012):\u00a0\u00a0\n\u2022 Unerw\u00fcnschtes\u00a0Ereignis \u00a0(Unerw\u00fcnschtes\u00a0Arzneimittelereignis,\u00a0UAE)\u00a0\nist\u00a0jedes\u00a0nachteilige\u00a0Vorkommnis,\u00a0 das\u00a0einer\u00a0betroffenen\u00a0Person\u00a0 wi\u2010\nderf\u00e4hrt,\u00a0 der\u00a0 ein\u00a0 Pr\u00fcfpr\u00e4parat\u00a0 verabreicht\u00a0 wurde,\u00a0 das\u00a0 aber\u00a0 nich t\u00a0\nnotwendigerweise\u00a0in\u00a0urs\u00e4chliche m\u00a0Zusammenhang\u00a0mit\u00a0diesem\u00a0Pr\u00e4\u2010\nparat\u00a0steht.\u00a0\n\u2022 Nebenwirkung\u00a0 (Synonym:\u00a0unerw\u00fcnschte\u00a0Arzneimittelwirkung,\u00a0UAW)\u00a0\nist\u00a0jede\u00a0nachteilige\u00a0und\u00a0unbeabsichtigte\u00a0Reaktion\u00a0auf\u00a0ein\u00a0Pr\u00fcfp r\u00e4pa\u2010\nrat,\u00a0unabh\u00e4ngig\u00a0von \u00a0dessen\u00a0Dosierung.\u00a0\n\u2022 Schwerwiegendes\u00a0 unerw\u00fcnschtes\u00a0 Ereignis \u00a0 oder\u00a0 schwerwiegende\u00a0\nNebenwirkung\u00a0ist\u00a0jedes\u00a0unerw\u00fcnschte\u00a0Ereignis\u00a0oder\u00a0jede\u00a0Nebenwir \u2010\nkung,\u00a0das\u00a0oder\u00a0die\u00a0t\u00f6dlich\u00a0oder\u00a0lebensbedrohend\u00a0ist,\u00a0eine\u00a0stati on\u00e4re\u00a0\nBehandlung\u00a0oder\u00a0deren\u00a0Verl\u00e4ngerung\u00a0erforderlich\u00a0macht\u00a0oder\u00a0zu\u00a0b lei\u2010\nbender\u00a0oder\u00a0schwerwiegender\u00a0Behinderung\u00a0oder\u00a0Invalidit\u00e4t\u00a0f\u00fchrt\u00a0 oder\u00a0\neine\u00a0kongenitale\u00a0Anomalie\u00a0oder\u00a0e inen\u00a0Geburtsfehler\u00a0zur\u00a0Folge\u00a0ha t.\u00a0\nDie\u00a0im\u00a0Rahmen\u00a0der\u00a0Wirkstoffportr\u00e4ts\u00a0angegebenen\u00a0Therapiekosten\u00a0 wurden\u00a0f\u00fcr\u00a0die\u00a0\nPackungsgr\u00f6\u00dfe\u00a0berechnet,\u00a0deren\u00a0Verordnung\u00a0f\u00fcr\u00a0die\u00a0angegebene\u00a0Be handlungs\u2010\ndauer\u00a0am\u00a0preisg\u00fcnstigsten\u00a0war.\u00a0Die\u00a0Berechnung\u00a0erfolgte\u00a0auf\u00a0Basi s\u00a0der\u00a0Brutto\u2010\nApothekenverkaufspreise\u00a0 zum\u00a0 Preisstand\u00a0 15.01.2019\u00a0 (Lauer\u2010Taxe). \u00a0R e i m p o r t e \u00a0\nsowie\u00a0m\u00f6gliche\u00a0Rabatte\u00a0(durch\u00a0pU\u00a0und\u00a0Apotheke)\u00a0wurden\u00a0nicht\u00a0ber \u00fccksichtigt,\u00a0so\u00a0\ndass\u00a0die\u00a0Preise\u00a0nur\u00a0als\u00a0Richtwert\u00a0betrachtet\u00a0werden\u00a0k\u00f6nnen.\u00a0Sof ern\u00a0das\u00a0jeweilige\u00a0\nArzneimittel\u00a0f\u00fcr\u00a0mehrere\u00a0Indika tionsgebiete\u00a0in\u00a0unterschiedliche r\u00a0Dosierung\u00a0zuge\u2010\nlassen\u00a0ist,\u00a0wurden\u00a0die\u00a0Therapieko sten\u00a0separat\u00a0f\u00fcr\u00a0jedes\u00a0Indikat ionsgebiet\u00a0berech\u2010\nnet.\u00a0Die\u00a0Dosierungen\u00a0wurden\u00a0den\u00a0Fachinformationen\u00a0der\u00a0pU\u00a0entnom men.\u00a0Gab\u00a0es\u00a0\nunterschiedliche\u00a0Dosierungsempfehlungen\u00a0(z.B.\u00a0Initialdosis,\u00a0Erh altungsdosis,\u00a0Ko\u2010\nmedikation),\u00a0wurden\u00a0die\u00a0definierten\u00a0Tagesdosen\u00a0zur\u00a0Dosisberechn ung\u00a0hinzugezo\u2010\ngen.\u00a0Abweichungen\u00a0in\u00a0den\u00a0Berechnungen\u00a0finden\u00a0explizit\u00a0Erw\u00e4hnung \u00a0bei\u00a0den\u00a0jewei\u2010\nligen\u00a0Wirkstoffportr\u00e4ts.\u00a0Bezog\u00a0sich\u00a0die\u00a0Wirkstoffmenge\u00a0auf\u00a0das\u00a0 K\u00f6rpergewicht\u00a0(KG)\u00a0\noder\u00a0die\u00a0K\u00f6rperoberfl\u00e4che\u00a0(KOF),\u00a0wurden\u00a0die\u00a0durchschnittlichen\u00a0 K\u00f6rperma\u00dfe\u00a0aus\u00a0\nder\u00a0amtlichen\u00a0Repr\u00e4sentativstatistik\u00a0\u201eMikrozensus\u00a02017\u00a0\u2013\u00a0K\u00f6rper ma\u00dfe\u00a0der\u00a0Bev\u00f6l\u2010\nkerung\u201c\u00a0zugrunde\u00a0gelegt\u00a0und\u00a0als\u00a0Standard\u00a077,0\u00a0kg\u00a0K\u00f6rpergewicht\u00a0 bzw.\u00a01,90\u00a0m2\u00a0als\u00a0\ndurchschnittliche\u00a0K\u00f6rperoberfl\u00e4che\u00a0(KOF)\u00a0angenommen\u00a0(Statistisc hes\u00a0Bundesamt,\u00a0\n2019).\u00a0Sind\u00a0die\u00a0neuen\u00a0Wirkstoffe\u00a0als\u00a0Tabletten,\u00a0Filmtabletten\u00a0o der\u00a0(Hart\u2010)Kapseln\u00a0\nzugelassen,\u00a0so\u00a0wurde\u00a0die\u00a0f\u00fcr\u00a0die\u00a0Therapiedauer\u00a0ben\u00f6tigte\u00a0St\u00fcckz ahl\u00a0in\u00a0die\u00a0Berech\u2010\nnungen\u00a0einbezogen,\u00a0gleiches\u00a0gilt\u00a0f \u00fcr\u00a0Ampullen\u00a0bzw.\u00a0Fertigspritz en\u00a0mit\u00a0Injektions\u2010\nsuspensionen.\u00a0\u00a038\u00a0Im\u00a0Hinblick\u00a0auf\u00a0die\u00a0Vergleichstherapie\u00a0orientierten\u00a0wir\u00a0uns\u00a0an\u00a0 den\u00a0Arzneimitteln,\u00a0\ndie\u00a0 der\u00a0 G\u2010BA\u00a0 als\u00a0 zweckm\u00e4\u00dfige\u00a0 Ver gleichstherapeutika\u00a0 festgelegt\u00a0 hatte,\u00a0 sofern\u00a0\ndiese\u00a0zum\u00a0Zeitpunkt\u00a0unserer\u00a0Bewertung\u00a0noch\u00a0als\u00a0solche\u00a0einzustuf en\u00a0waren;\u00a0gege\u2010\nbenenfalls\u00a0fanden\u00a0Anpassungen\u00a0statt.\u00a0Zuschl\u00e4ge\u00a0f\u00fcr\u00a0die\u00a0Herstell ung\u00a0(z.B.\u00a0bei\u00a0mo\u2010\nnoklonalen\u00a0Antik\u00f6rpern),\u00a0Hilfsmittel\u00a0f\u00fcr\u00a0Injektionen\u00a0oder\u00a0sonst ige\u00a0Kosten\u00a0im\u00a0Zu\u2010\nsammenhang\u00a0mit\u00a0der\u00a0Arzneimittela nwendung\u00a0fanden\u00a0keine\u00a0Ber\u00fccksic htigung.\u00a0\n2.3\u00a0\u00a0\u00a0Methodik\u00a0der\u00a0Routinedaten\u2010Analyse\u00a0\nF\u00fcr\u00a0die\u00a0Analyse\u00a0zur\u00a0Versorgung\u00a0mit\u00a0innovativen\u00a0Arzneimitteln\u00a0wu rden\u00a0Arzneimit\u2010\nteldaten\u00a0aus\u00a0der\u00a0ambulanten\u00a0Versorgung\u00a0von\u00a09,7\u00a0Mio.\u00a0Versicherte n\u00a0(im\u00a0Jahr\u00a02016)\u00a0\nund\u00a09,9\u00a0Mio.\u00a0Versicherten\u00a0(im\u00a0Jahr\u00a02017)\u00a0der\u00a0TK\u00a0aus\u00a0den\u00a0o.g.\u00a0Ja hren\u00a0genutzt.\u00a0Die\u00a0\nzur\u00a0Erstellung\u00a0des\u00a0Reports\u00a0ben\u00f6t igten\u00a0Daten\u00a0wurden\u00a0bereits\u00a0im\u00a0H aus\u00a0der\u00a0TK\u00a0selek\u2010\ntiert\u00a0und\u00a0anonymisiert\u00a0an\u00a0die\u00a0Universit\u00e4t\u00a0Bremen\u00a0weitergeleitet .\u00a0Die\u00a0Anonymisie\u2010\nrung\u00a0s\u00e4mtlicher\u00a0Daten\u00a0erfolgte\u00a0unter\u00a0Verwendung\u00a0einer\u00a0Fallnumme r,\u00a0die\u00a0es\u00a0er\u2010\nm\u00f6glicht,\u00a0anonymisierte\u00a0Datens\u00e4tze\u00a0miteinander\u00a0zu\u00a0verkn\u00fcpfen,\u00a0o hne\u00a0dass\u00a0die\u00a0\nIdentit\u00e4t\u00a0der\u00a0Versicherten\u00a0festgestellt\u00a0werden\u00a0kann.\u00a0Es\u00a0wurden\u00a0 f\u00fcr\u00a0die\u00a0allgemeinen\u00a0\nAuswertungen\u00a0nur\u00a0Daten\u00a0ber\u00fccksichtigt,\u00a0bei\u00a0denen\u00a0auch\u00a0Angaben\u00a0z u\u00a0Alter\u00a0und\u00a0\nGeschlecht\u00a0 der\u00a0 Versicherten\u00a0 vorl agen.\u00a0 Nach\u00a0 unserer\u00a0 Methodik\u00a0 ent sprach\u00a0 eine\u00a0\n\u00e4rztliche\u00a0 Verordnung\u00a0 analog\u00a0 zum\u00a0 Arzneiverordnungs\u2010Report\u00a0 2017\u00a0 g enau\u00a0 einer\u00a0\nArzneimittelpackung,\u00a0d.h.\u00a0zwei\u00a0au f\u00a0einem\u00a0Rezeptblatt\u00a0verordnete \u00a0Packungen\u00a0z\u00e4hl\u2010\nten\u00a0 als\u00a0 zwei\u00a0 Verordnungen.\u00a0 Bei\u00a0 den\u00a0 Verordnungsanalysen\u00a0 wurden\u00a0 n eben\u00a0 Fer\u2010\ntigarzneimitteln\u00a0auch\u00a0Rezepturen \u00a0mit\u00a0den\u00a0neuen\u00a0Wirkstoffen\u00a0(z.B .\u00a0bei\u00a0den\u00a0onkolo\u2010\ngischen\u00a0monoklonalen\u00a0Antik\u00f6rpern)\u00a0ber\u00fccksichtigt.\u00a0Hier\u00a0flossen\u00a0 die\u00a0Abrechnungs\u2010\ndaten\u00a0ein,\u00a0die\u00a0auf\u00a0dem\u00a0Rezept\u00a0ve rmerkt\u00a0waren\u00a0(Brutto\u2010Apothekena bgabepreis).\u00a0\nBei\u00a0der\u00a0Untersuchung\u00a0der\u00a0Arzneimittelverordnungsdaten\u00a0wurde\u00a0die \u00a0international\u00a0\ng\u00fcltige\u00a0ATC\u00a0( Anatomical\u00a0Therapeutical\u00a0Chemical )\u2010Codierung\u00a0genutzt,\u00a0die\u00a01976\u00a0von\u00a0\nder\u00a0European\u00a0Pharmaceutical\u00a0Market\u00a0Research\u00a0Association \u00a0(EPhMRA)\u00a0entwickelt\u00a0\nund\u00a01990\u00a0vom\u00a0 Collaborating\u00a0Centre\u00a0for\u00a0Drug\u00a0Statistics \u00a0der\u00a0Weltgesundheitsorgani\u2010\nsation\u00a0(WHO)\u00a0adaptiert\u00a0und\u00a0\u00fcbernom men\u00a0wurde.\u00a0In\u00a0Deutschland\u00a0gib t\u00a0das\u00a0Deut\u2010\nsche\u00a0Institut\u00a0f\u00fcr\u00a0medizinische\u00a0Dokumentation\u00a0und\u00a0Information\u00a0(D IMDI)\u00a0seit\u00a02004\u00a0\ndie\u00a0amtliche\u00a0und\u00a0j\u00e4hrlich\u00a0aktualisierte\u00a0Fassung\u00a0der\u00a0nach\u00a0ATC\u2010Co de\u00a0aufgelisteten\u00a0\nArzneimittel\u00a0heraus.\u00a0In\u00a0dem\u00a0Kla ssifikationssystem\u00a0werden\u00a0die\u00a0je weiligen\u00a0Wirkstof\u2010\nfe\u00a0entsprechend\u00a0dem\u00a0Organ\u00a0oder\u00a0Organsystem,\u00a0auf\u00a0das\u00a0sie\u00a0einwirk en,\u00a0sowie\u00a0nach\u00a0\nihren\u00a0chemischen,\u00a0pharmakologischen\u00a0und\u00a0therapeutischen\u00a0Eigensc haften\u00a0in\u00a014\u00a0\nHauptgruppen\u00a0(Ebene\u00a01)\u00a0mit\u00a0zwei\u00a0t herapeutisch\u2010pharmakologischen \u00a0Untergrup\u2010\npen\u00a0(Ebene\u00a02\u00a0und\u00a03)\u00a0gegliedert.\u00a0Eine\u00a0anatomisch\u2010therapeutisch\u2010c hemische\u00a0Unter\u2010\ngruppe\u00a0bildet\u00a0die\u00a04.\u00a0Ebene,\u00a0w\u00e4hrend\u00a0die\u00a05.\u00a0Ebene\u00a0den\u00a0chemischen \u00a0Wirkstoff\u00a0be\u2010\nnennt.\u00a039\u00a0Seit\u00a0dem\u00a0Inkrafttreten\u00a0des\u00a0GKV\u2010Modernisierungsgesetzes\u00a0(GMG)\u00a0zu m\u00a001.01.2004\u00a0\nsind\u00a0die\u00a0Kassen\u00e4rztlichen\u00a0Vereinigungen\u00a0gem\u00e4\u00df\u00a0\u00a7\u00a0295\u00a0SGB\u00a0V\u00a0zur\u00a0W eitergabe\u00a0am\u2010\nbulanter\u00a0Daten\u00a0an\u00a0die\u00a0GKV\u00a0verpflichtet.\u00a0So\u00a0muss\u00a0f\u00fcr\u00a0jeden\u00a0Patie nten\u00a0der\u00a0Behand\u2010\nlungsanlass,\u00a0das\u00a0Datum\u00a0der\u00a0Leistungserbringung\u00a0und\u00a0die\u00a0Art\u00a0der\u00a0 Leistungserbrin\u2010\ngung\u00a0genannt\u00a0werden,\u00a0wenn\u00a0die\u00a0Leistungen\u00a0abgerechnet\u00a0werden\u00a0sol len.\u00a0Die\u00a0von\u00a0\nder\u00a0WHO\u00a0entwickelte\u00a0internationale\u00a0Klassifikation\u00a0der\u00a0Krankheit en\u00a0International\u00a0\nClassification\u00a0of\u00a0Diseases \u00a0(ICD)\u00a0stellt\u00a0die\u00a0Grundlage\u00a0der\u00a0gesetzlich\u00a0vorgeschriebenen\u00a0\nDiagnoseverschl\u00fcsselung\u00a0im\u00a0ambulanten\u00a0und\u00a0station\u00e4ren\u00a0Sektor\u00a0da r.\u00a0In\u00a0Deutsch\u2010\nland\u00a0wird\u00a0die\u00a0Diagnose\u00a0als\u00a0Behandlungsanlass\u00a0nach\u00a0der\u00a0internati onalen\u00a0Klassifika\u2010\ntion\u00a0von\u00a0Krankheiten\u00a0in\u00a0der\u00a0deutschen\u00a0Fassung\u00a0(ICD\u2010GM;\u00a0 German\u00a0Modification )\u00a0\nverschl\u00fcsselt\u00a0und\u00a0\u00fcbermittelt.\u00a0Ei ne\u00a0Hierarchisierung\u00a0nach\u00a0Haupt \u2010\u00a0und\u00a0Nebendiag\u2010\nnosen\u00a0je\u00a0Behandlungsfall\u00a0ist\u00a0derz eit\u00a0nicht\u00a0m\u00f6glich,\u00a0weswegen\u00a0ei n\u00a0einzelner\u00a0Arztbe\u2010\nsuch,\u00a0 eine\u00a0 Arzneimittelverordnung\u00a0 bzw.\u00a0 eine\u00a0 therapeutische\u00a0 Ma\u00dfn ahme\u00a0 nicht\u00a0\neindeutig\u00a0einer\u00a0Diagnose\u00a0zugeordnet\u00a0werden\u00a0kann.\u00a0Werden\u00a0Diagnos en\u00a0in\u00a0mehre\u2010\nren\u00a0Quartalen\u00a0bzw.\u00a0von\u00a0unterschi edlichen\u00a0\u00c4rzten\u00a0wiederholt,\u00a0kan n\u00a0dies\u00a0als\u00a0Ma\u00df\u2010\nnahme\u00a0 betrachtet\u00a0 werden,\u00a0 m\u00f6glichst\u00a0 nur\u00a0 tats\u00e4chlich\u00a0 Erkrankte\u00a0 au szuw\u00e4hlen\u00a0\n(Windt,\u00a02010).\u00a0\u00a0\nZur\u00a0 Messung\u00a0 der\u00a0 Verordnungsvolumina\u00a0 wurden\u00a0 definierte\u00a0 Tagesdose n\u00a0 (DDD)\u00a0\nverwendet.\u00a0Es\u00a0handelt\u00a0sich\u00a0dabei\u00a0um\u00a0eine\u00a0international\u00a0gebr\u00e4uch liche\u00a0rein\u00a0rechne\u2010\nrische\u00a0Messgr\u00f6\u00dfe,\u00a0die\u00a0nicht\u00a0notwendigerweise\u00a0die\u00a0empfohlene\u00a0Dos ierung\u00a0oder\u00a0die\u00a0\ntats\u00e4chlich\u00a0angewendeten\u00a0Dosierungen\u00a0(PDD\u00a0\u2013\u00a0 Prescribed\u00a0Daily\u00a0Dose )\u00a0eines\u00a0Arz\u2010\nneimittels\u00a0wiedergibt\u00a0(Pfannkuche\u00a0et\u00a0al.,\u00a02009).\u00a0F\u00fcr\u00a0jeden\u00a0Wirk stoff\u00a0legt\u00a0die\u00a0WHO\u00a0\neine\u00a0Dosierung\u00a0fest,\u00a0die\u00a0f\u00fcr\u00a0de ssen\u00a0Hauptindikation\u00a0der\u00a0mittler en\u00a0t\u00e4glichen\u00a0Erhal\u2010\ntungsdosis\u00a0f\u00fcr\u00a0Erwachsene\u00a0entspricht\u00a0(Fricke\u00a0&\u00a0G\u00fcnther,\u00a02001).\u00a0 Angaben\u00a0zu\u00a0den\u00a0\nDDD\u00a0sind\u00a0in\u00a0der\u00a0vom\u00a0DIMDI\u00a0herausgegebenen\u00a0und\u00a0j\u00e4hrlich\u00a0aktualis ierten\u00a0ATC\u2010\nCode\u2010Liste\u00a0enthalten,\u00a0die\u00a0im\u00a0Internet\u00a0unter\u00a0http://www.dimdi.de /static/de/klassi/\u00a0\natcddd/\u00a0verf\u00fcgbar\u00a0ist.\u00a0\u00a0\nZus\u00e4tzliche\u00a0\u00dcberwachung \u00a0\u25bc\u00a0\nSeit\u00a0dem\u00a0Jahr\u00a02013\u00a0wird\u00a0in\u00a0der\u00a0EU\u00a0ein\u00a0Arzneimittel,\u00a0das\u00a0unter\u00a0z us\u00e4tzlicher\u00a0\u00dcberwa\u2010\nchung\u00a0steht,\u00a0durch\u00a0ein\u00a0auf\u00a0dem\u00a0Kopf\u00a0stehendes\u00a0schwarzes\u00a0Dreieck \u00a0gekennzeich\u2010\nnet.\u00a0Die\u00a0Markierung\u00a0befindet\u00a0sich\u00a0nicht\u00a0auf\u00a0der\u00a0Packung\u00a0oder\u00a0de m\u00a0Arzneimitteleti\u2010\nkett,\u00a0sondern\u00a0in\u00a0der\u00a0Packungsbeilage\u00a0und\u00a0in\u00a0der\u00a0Fachinformation .\u00a0Dies\u00a0soll\u00a0f\u00fcr\u00a0\nerh\u00f6hte\u00a0Aufmerksamkeit\u00a0bei\u00a0Patienten\u00a0und\u00a0Angeh\u00f6rigen\u00a0von\u00a0Gesund heitsberufen\u00a0\nsorgen.\u00a0Jeder\u00a0Verdachtsfall\u00a0eine r\u00a0Nebenwirkung\u00a0soll\u00a0gemeldet\u00a0we rden,\u00a0vor\u00a0allen\u00a0\nDingen\u00a0durch\u00a0die\u00a0Berufsgruppen,\u00a0die\u00a0dazu\u00a0laut\u00a0ihrer\u00a0Berufsordnu ng\u00a0verpflichtet\u00a0\nsind.\u00a0Das\u00a0schwarze\u00a0Dreieck\u00a0wird\u00a0z.B.\u00a0vergeben,\u00a0weil\u00a0das\u00a0Arzneim ittel\u00a0neu\u00a0auf\u00a0dem\u00a0\nMarkt\u00a0oder\u00a0in\u00a0der\u00a0Langzeitanwe ndung\u00a0ungepr\u00fcft\u00a0ist,\u00a0und\u00a0erm\u00f6glic ht\u00a0eine\u00a0beson\u2010\nders\u00a0engmaschige\u00a0Kontrolle\u00a0und\u00a0s chnelle\u00a0Erfassung\u00a0neuer\u00a0Erkennt nisse\u00a0\u00fcber\u00a0seine\u00a0\nSicherheit.\u00a040\u00a0Alle\u00a0von\u00a0uns\u00a0bewerteten\u00a0neuen\u00a0Wirkstoffe\u00a0des\u00a0Jahres\u00a02016\u00a0finden \u00a0sich\u00a0auf\u00a0der\u00a0\nEurop\u00e4ischen\u00a0Liste\u00a0der\u00a0unter\u00a0zus\u00e4tzlicher\u00a0\u00dcberwachung\u00a0stehenden \u00a0Arzneimittel\u00a0\n(EMA,\u00a02019).\u00a0\nBlaue\u00a0Hand\u00a0\nDas\u00a0Logo\u00a0der\u00a0\u201eBlauen\u00a0Hand\u201c,\u00a0das\u00a0dem\u00a0Logo\u00a0der\u00a0\u201eRoten\u00a0Hand\u201c\u00a0f\u00fcr\u00a0s icherheitsrele\u2010\nvante\u00a0Informationen\u00a0zu\u00a0Arzneimitteln\u00a0nachempfunden\u00a0ist,\u00a0kennzei chnet\u00a0seit\u00a0De\u2010\nzember\u00a02016\u00a0beh\u00f6rdlich\u00a0angeordnetes\u00a0und\u00a0genehmigtes\u00a0Schulungsma terial.\u00a0Sol\u2010\nches\u00a0Schulungsmaterial\u00a0wird\u00a0f\u00fcr\u00a0Arzneimittel\u00a0erstellt,\u00a0bei\u00a0dene n\u00a0die\u00a0Informationen\u00a0\nin\u00a0der\u00a0Packungsbeilage\u00a0allein\u00a0als\u00a0nicht\u00a0ausreichend\u00a0erachtet\u00a0we rden,\u00a0um\u00a0ein\u00a0m\u00f6gli\u2010\nches\u00a0Risiko\u00a0bei\u00a0der\u00a0Anwendung\u00a0zu\u00a0minimieren.\u00a0Das\u00a0BfArM\u00a0oder\u00a0das \u00a0PEI\u00a0k\u00f6nnen\u00a0\nden\u00a0pU\u00a0zur\u00a0Erstellung\u00a0dieser\u00a0erg\u00e4nzenden\u00a0Schulungsmaterialien\u00a0f \u00fcr\u00a0\u00c4rzte,\u00a0Apothe\u2010\nker\u00a0und\u00a0Patienten\u00a0(z.B.\u00a0Patientenpass\u00a0zur\u00a0Verlaufskontrolle,\u00a0Pa tientenbrosch\u00fcre)\u00a0\nmit\u00a0dem\u00a0Ziel\u00a0verpflichten,\u00a0die\u00a0Arzneimittelsicherheit\u00a0bei\u00a0der\u00a0b estimmungsgem\u00e4\u2010\n\u00dfen\u00a0Anwendung\u00a0der\u00a0betreffenden\u00a0Me dikamente\u00a0zu\u00a0verbessern.\u00a0Die\u00a0K ennzeich\u2010\nnung\u00a0mit\u00a0dem\u00a0Symbol\u00a0der\u00a0\u201eBlauen\u00a0 Hand\u201c\u00a0soll\u00a0gew\u00e4hrleisten,\u00a0dass\u00a0 die\u00a0entspre\u2010\nchenden\u00a0Zusatzinformationen\u00a0nicht\u00a0mit\u00a0Werbung\u00a0verwechselt\u00a0werde n\u00a0und\u00a0die\u00a0\nAdressaten\u00a0verl\u00e4sslich\u00a0erreiche n.\u00a0Das\u00a0beauflagte\u00a0Schulungsmater ial\u00a0kann\u00a0auch\u00a0auf\u00a0\nden\u00a0Internetseiten\u00a0von\u00a0BfArM\u00a0und\u00a0PEI\u00a0eingesehen\u00a0werden\u00a0(Akd\u00c4,\u00a02 019).\u00a0\nF\u00fcr\u00a0die\u00a0von\u00a0uns\u00a0bewerteten\u00a0Wirkstoffe\u00a0des\u00a0Jahres\u00a02016\u00a0Daratumum ab\u00a0und\u00a0Selexi\u2010\npag\u00a0ist\u00a0derartiges\u00a0Schulungsmaterial\u00a0verf\u00fcgbar.\u00a0\nTabelle\u00a0 2.1:\u00a0 Im\u00a0 Report\u00a0 bewertete\u00a0 neue\u00a0 Wirkstoffe\u00a0 des\u00a0 Jahres\u00a0 201 6\u00a0 und\u00a0 die\u00a0\nentsprechenden\u00a0ATC\u2010Codes\u00a0\nWirkstoff\u00a0 Besonderheiten\u00a0 ATC\u2010\nCode\u00a0\nAlbutrepenonacog\u00a0alfa\u00a0 \u25bc\u00a0O\u00a0 \u00a0 B02BD33\u00a0\nBrivaracetam\u00a0 \u25bc\u00a0\u00a0Zulassungserw.\u00a0Kinder\u00a0ab\u00a0\n01/2019\u00a0N03AX23\u00a0\nDaratumumab\u00a0 \u25bc\u00a0O,\u00a0C\u00a0Blaue\u00a0Hand,\u00a0\u00dcberschreitung\u00a0der\u00a0\u00a0\n50\u00a0Mio.\u00a0\u20ac\u2010Grenze,\u00a02\u00a0neue\u00a0Anwendungsgebiete,\u00a03\u00a0G\u2010BA\u2010\nBeschl\u00fcsse,\u00a02\u00a0davon\u00a0befristet\u00a0\u00a0L01XC24\u00a0\nEfmoroctocog\u00a0alfa\u00a0 \u25bc\u00a0\u00a0Europ\u00e4isches\u00a0\nRisikobewertungsverfahen\u00a0f\u00fcr\u00a0\nalle\u00a0Faktor\u2010VIII\u2010Pr\u00e4parate\u00a0B02BD32\u00a0\nEftrenonacog\u00a0alfa\u00a0 \u25bc\u00a0O\u00a0 \u00a0 B02BD34\u00a0\nElbasvir/Grazoprevir\u00a0 \u25bc \u00a02\u00a0Rote\u2010Hand\u2010Briefe\u00a0(RHB)\u00a0f\u00fcr\u00a0\nalle\u00a0DAA\u00a0J05AP54\u00a0\nJ05AX68\u00a041\u00a0Wirkstoff\u00a0 Besonderheiten\u00a0 ATC\u2010\nCode\u00a0\nElotuzumab\u00a0 \u25bc\u00a0\u00a0\u00a0 L01XC23\u00a0\nHPV\u2010St\u00e4mme\u00a0 \u25bc\u00a0\u00a0 Impfstoff\u00a0(neunvalenter\u00a0HPV)\u00a0 J07BM03\u00a0\nMepolizumab\u00a0 \u25bc\u00a0\u00a0Zulassungserw.\u00a0Kinder\u00a0ab\u00a0\n03/2019\u00a0R03DX09\u00a0\nMigalastat\u00a0 \u25bc\u00a0O\u00a0 \u00a0 A16AX14\u00a0\nOlaratumab\u00a0 \u25bc\u00a0O,\u00a0C\u00a0RHB\u00a0\nbefr.\u00a0G\u2010BA\u2010Beschluss\u00a0\nWiderruf\u00a0der\u00a0Zulassung\u00a0L01XC27\u00a0\nOpicapon\u00a0 \u25bc\u00a0\u00a0 \u00a0 N04BX04\u00a0\nOsimertinib\u00a0 \u25bc\u00a0\u00a03\u00a0G\u2010BA\u2010Beschl\u00fcsse\u00a0 L01XE35\u00a0\nPalbociclib \u00a0 \u25bc\u00a0\u00a0 2\u00a0G\u2010BA\u2010Beschl\u00fcsse\u00a0(1\u00a0befr.)\u00a0 L01XE33\u00a0\nPitolisant\u00a0 \u25bc O\u00a0\u00a0 N07XX11\u00a0\nSacubitril/Valsartan\u00a0 \u25bc\u00a0\u00a0\u00a0 C09DX04\u00a0\nSelexipag\u00a0 \u25bc \u00a0Blaue\u00a0Hand\u00a0B01AC27\nC02KX09\u00a0\nSofosbuvir/Velpatasvir\u00a0 \u25bc \u00a02\u00a0RHB\u00a0f\u00fcr\u00a0alle\u00a0DAA\u00a0J05AP55\u00a0\nJ05AX69\u00a0\nTalimogen\u00a0laherparepvec\u00a0 \u25bc\u00a0\u00a0\u00a0 L01XX51\u00a0\nTenofoviralafenamid/\u00a0\nElvitegravir/Cobicistat/\u00a0Emtricitabin\u00a0\u25bc \n\u00a0RHB,\u00a0Zulassungse rw.\u00a0Kinder\u00a0ab\u00a0\n07/2018,\u00a02\u00a0G\u2010BA\u2010Beschl.\u00a0J05AR18\u00a0\nTenofoviralafenamid/\u00a0\nEmtricitabin\u00a0\u25bc \u00a0\u00a0 J05AR17\u00a0\nTenofoviralafenamid/\u00a0\nEmtricitabin/Rilpivirin\u00a0\u00a0\u25bc \u00a0 \u00a0 J05AR19\u00a0\nTrifluridin/Tipiracil\u00a0 \u25bc\u00a0\u00a0befr.\u00a0G\u2010BA\u2010Beschluss\u00a0 L01BC59\u00a0\nO:\u00a0Orphan\u2010Arzneimittel,\u00a0C:\u00a0 Conditional\u00a0approval :\u00a0Bedingte\u00a0Zulassung\u00a0\n\u00a0 \u00a042\u00a0Quellen\u00a0\nAKd\u00c4\u00a0\u2013\u00a0Arzneimittelkommission\u00a0der\u00a0deutschen\u00a0\u00c4rzteschaft\u00a0(2019). \u00a0Schulungsmaterial\u00a0zu\u00a0Arzneimitteln:\u00a0Die\u00a0Blaue\u00a0Hand\u00a0\nkennzeichnet\u00a0Material,\u00a0das\u00a0von\u00a0den\u00a0Beh\u00f6rden\u00a0gepr\u00fcft\u00a0und\u00a0genehmi gt\u00a0wurde.\u00a0\nhttps://www.akdae.de/Arzneimitteltherapie/AVP/Artikel/201901\u20102/ 106h/index.php,\u00a0letzter\u00a0Zugriff:\u00a025.04.2019.\u00a0\nEMA\u00a0\u2013\u00a0European\u00a0Medicines\u00a0Agency\u00a0(2019).\u00a0List\u00a0of\u00a0medicinal\u00a0produ cts\u00a0under\u00a0additional\u00a0monitoring.\u00a0\nhttps://www.ema.europa.eu/en/human\u2010regulatory/post\u2010authorisatio n/pharmacovigilance/medicines\u2010under\u2010\nadditional\u2010monitoring/list\u2010medicines\u2010under\u2010additional\u2010monitorin g,\u00a0letzter\u00a0Zugriff:\u00a008.05.2019.\u00a0\nFricke\u00a0U,\u00a0G\u00fcnther\u00a0J\u00a0(2001).\u00a0Meth odik\u00a0der\u00a0ATC\u2010Klassifikation\u00a0und \u00a0DDD\u2010Festlegung\u00a0f\u00fcr\u00a0den\u00a0deutschen\u00a0Arzneimittelmarkt.\u00a0Bonn:\u00a0\nWIdO.\u00a0\nFricke\u00a0U,\u00a0Schwabe\u00a0U\u00a0(2001).\u00a0Neue \u00a0Arzneimittel.\u00a0In:\u00a0U.\u00a0Schwabe,\u00a0 D.\u00a0Paffrath\u00a0(Hrsg.)\u00a0Arzneiver ordnungsreport\u00a02000.\u00a0Berlin,\u00a0\nHeidelberg:\u00a0Springer.\u00a018\u201050.\u00a0\nFricke\u00a0U\u00a0(2016).\u00a0Pharmakologische\u00a0Bewertung\u00a0neuer\u00a0Arzneimittel\u00a0 2015.\u00a0InVo\u00a0\u2010\u00a0Information\u00a0zu\u00a0Verordnungen\u00a0in\u00a0der\u00a0GKV.\u00a0\nWestfalen\u2010Lippe:\u00a0Kassen\u00e4rztliche\u00a0Vereinigung\u00a0Westfalen\u00a0Lippe.\u00a0\nStatistisches\u00a0Bundesamt\u00a0(2019).\u00a0Gesellschaft\u00a0und\u00a0Umwelt\u00a0\u2010\u00a0Gesun dheitszustand\u00a0und\u00a0\u2010relevantes\u00a0Verhalten\u00a0\u2010\u00a0K\u00f6rperma\u00dfe\u00a0nach\u00a0\nAltersgruppen\u00a0und\u00a0Geschlecht.\u00a0https://www.destatis.de/DE/Themen /Gesellschaft\u2010\nUmwelt/Gesundheit/Gesundheitszustand\u2010Relevantes\u2010Verhalten/Tabel len/liste\u2010\nkoerpermasse.html;jsessionid=A44075FF94EE35A83D6B3EAA4030F78C.i nternet722,\u00a0letzter\u00a0Zugriff:\u00a025.04.2019.\u00a0\n\u00a0\n\u00a0 \u00a043\u00a03 Neue\u00a0Arzneimittel\u00a0des\u00a0Jahres\u00a02016\u00a0\u2013\u00a0\u00dcbersicht\u00a0\nIm\u00a0Jahr\u00a02016\u00a0kamen\u00a0in\u00a0Deutschland\u00a0insgesamt\u00a050\u00a0neue\u00a0nicht\u2010gener ische\u00a0Arznei\u2010\nmittel\u00a0auf\u00a0den\u00a0Markt.\u00a0Darunter\u00a0befanden\u00a0sich\u00a0mit\u00a0Cabozantinib,\u00a0 Daclizumab,\u00a0Gua\u2010\nnfacin,\u00a0Irinotecan,\u00a0Ivermectin,\u00a0Lenvatinib,\u00a0Pivmecillinam\u00a0und\u00a0U meclidinium\u00a0acht\u00a0\nbekannte\u00a0Wirkstoffe,\u00a0die\u00a0bereits\u00a0in\u00a0der\u00a0Vergangenheit\u00a0eine\u00a0Zula ssung\u00a0f\u00fcr\u00a0andere\u00a0\nIndikationen\u00a0erhalten\u00a0hatten.\u00a0Weitere\u00a0neun\u00a0Arzneimittel\u00a0entfiel en\u00a0auf\u00a0bekannte\u00a0\nWirkstoffe\u00a0in\u00a0neuen\u00a0Kombinationen.\u00a0Von\u00a0den\u00a0verbleibenden\u00a033\u00a0Arz neimitteln\u00a0mit\u00a0\nneuartigen\u00a0Wirkstoffen\u00a0enthielten\u00a0drei\u00a0Kombinationspr\u00e4parate\u00a0de nselben\u00a0neuen\u00a0\nWirkstoff\u00a0(Tenofoviralafenamid).\u00a0Im\u00a0Jahr\u00a02016\u00a0kamen\u00a0dementsprec hend\u00a031\u00a0neue\u00a0\nWirkstoffe\u00a0auf\u00a0den\u00a0Markt.\u00a0Im\u00a0Vergleich\u00a0zum\u00a0Vorjahr\u00a0mit\u00a037\u00a0neuen \u00a0Wirkstoffen\u00a0\nwaren\u00a0es\u00a016,2\u00a0%\u00a0weniger\u00a0(Abb.\u00a03. 1).\u00a0Unter\u00a0den\u00a0neuen\u00a0Wirkstoffen \u00a0befanden\u00a0sich\u00a0\nneun,\u00a0die\u00a0als\u00a0 Orphan\u2010Arzneimittel\u00a0zugelassen\u00a0wurden .\u00a0F\u00fcr\u00a0einen\u00a0dieser\u00a0Wirkstoffe\u00a0\n\u2013\u00a0Dinutuximab\u00a0\u2013\u00a0wurde\u00a0allerdings\u00a0die\u00a0Zulassung\u00a0auf\u00a0Antrag\u00a0des\u00a0Z ulassungsinhabers\u00a0\nwiderrufen.\u00a0Seit\u00a0Dezember\u00a02017\u00a0is t\u00a0mit\u00a0Dinutuximab\u00a0beta\u00a0ein\u00a0Ant ik\u00f6rper\u00a0verf\u00fcg\u2010\nbar,\u00a0der\u00a0denselben\u00a0Wirkmechanismus\u00a0aufweist,\u00a0jedoch\u00a0in\u00a0einer\u00a0an deren\u00a0Zelllinie\u00a0\nproduziert\u00a0wird.\u00a0\nAbbildung\u00a03.1:\u00a0Markteinf\u00fchrung\u00a0von\u00a0Arzneimitteln\u00a0mit\u00a0neuen\u00a0Wirk stoffen\u00a0\neingeteilt\u00a0in\u00a0innovative\u00a0und\u00a0verbesserte\u00a0Wirkstoffe\u00a0im\u00a0Zeitraum \u00a01995\u00a0\u2013\u00a02016\u00a0\n\u00a0\nEigene\u00a0Darstellung\u00a0nach\u00a0Schwabe\u00a0et\u00a0al.,\u00a02017\u00a0\n44\u00a0Basierend\u00a0auf\u00a0der\u00a0Klassifikation,\u00a0urspr\u00fcnglich\u00a0nach\u00a0Fricke\u00a0und\u00a0 Klaus,\u00a0bewerteten\u00a0\ndie\u00a0Autoren\u00a0des\u00a0Arzneiverordnung s\u2010Reports\u00a02017\u00a0den\u00a0Innovationsg rad\u00a0der\u00a0neuen\u00a0\nWirkstoffe\u00a0 bzw.\u00a0 Wirkstoffkombinationen\u00a0 (Schwabe\u00a0 et\u00a0 al.,\u00a0 2017).\u00a0 Sie\u00a0 vergaben\u00a0\ninsgesamt\u00a0dreizehnmal\u00a0ein\u00a0\u201eA\u201c\u00a0ohne\u00a0Doppelbewertung\u00a0f\u00fcr\u00a0innovati ve\u00a0Wirkprinzi\u2010\npien\u00a0mit\u00a0therapeutischer\u00a0Relevanz:\u00a0f\u00fcr\u00a0Afamelanotid\u00a0zur\u00a0Pr\u00e4vent ion\u00a0von\u00a0Phototo\u2010\nxizit\u00e4t\u00a0bei\u00a0erythropoetischer\u00a0Protoporphyrie,\u00a0Daratumumab\u00a0und\u00a0E lotuzumab\u00a0bei\u00a0\nmultiplem\u00a0Myelom,\u00a0Dinutuximab\u00a0(AV )\u00a0bei\u00a0Hochrisiko\u2010Neuroblastom, \u00a0Idarucizumab\u00a0\nals\u00a0Antidot\u00a0f\u00fcr\u00a0Dabigatran,\u00a0Mepolizumab\u00a0bei\u00a0schwerem\u00a0refrakt\u00e4re m\u00a0eosinophilem\u00a0\nAsthma,\u00a0Migalastat\u00a0bei\u00a0Morbus\u00a0Fabry,\u00a0Necitumumab1\u00a0bei\u00a0nicht\u2010kleinzelligem\u00a0Lun\u2010\ngenkarzinom\u00a0( Non\u2010Small\u2010Cell\u00a0Lung\u00a0Carcinoma ,\u00a0NSCLC),\u00a0Olaratumab2\u00a0bei\u00a0fortge\u2010\nschrittenem\u00a0 Weichgewebesarkom,\u00a0 Palbociclib\u00a0 bei\u00a0 Hormonrezeptor\u2010p ositivem,\u00a0\nHER2\u2010negativem,\u00a0 lokal\u00a0 fortgeschr ittenem\u00a0 oder\u00a0 metastasiertem\u00a0 Bru stkrebs,\u00a0 Sa\u2010\ncubitril/\u00a0Valsartan\u00a0bei\u00a0symptoma tischer\u00a0chronischer\u00a0Herzinsuffi zienz\u00a0mit\u00a0reduzier\u2010\nter\u00a0Ejektionsfraktion,\u00a0Talimogen \u00a0laherparepvec\u00a0bei\u00a0metastasiert em\u00a0Melanom\u00a0und\u00a0\nTasimelteon\u00a0beim\u00a0Nicht\u201024\u2010Stunden\u2010Schlaf\u2010Wach\u2010Syndrom.\u00a0Im\u00a0Vergl eich\u00a0zum\u00a0Vor\u2010\njahr\u00a0wurde\u00a0somit\u00a0ein\u00a0Wirkstoff\u00a0mehr\u00a0mit\u00a0\u201eA\u201c\u00a0bewertet.\u00a0Zus\u00e4tzlic h\u00a0erhielt\u00a0der\u00a0Wirk\u2010\nstoff\u00a0Pitolisant\u00a0die\u00a0Doppelbewert ung\u00a0\u201eA/C\u201c\u00a0als\u00a0Arzneimittel\u00a0mit \u00a0neuartigem\u00a0Wirk\u2010\nmechanismus,\u00a0aber\u00a0ohne\u00a0\u00dcberlege nheit\u00a0gegen\u00fcber\u00a0bereits\u00a0bekannte n\u00a0therapeuti\u2010\nschen\u00a0Alternativen.\u00a0Im\u00a0Vorjahr\u00a0bekamen\u00a0insgesamt\u00a0drei\u00a0Wirkstoff e\u00a0die\u00a0Bewertung\u00a0\n\u201eA/C\u201c\u00a0(Schwabe\u00a0&\u00a0Paffrath,\u00a02016).\u00a0Eine\u00a0Verbesserung\u00a0pharmakodyn amischer\u00a0oder\u00a0\npharmakokinetischer\u00a0 Eigenschaften\u00a0 attestierten\u00a0 die\u00a0 Autoren\u00a0 sech s\u00a0 der\u00a0 neuen\u00a0\nWirkstoffe\u00a0bzw.\u00a0Wirkstoffkombinationen\u00a0des\u00a0Jahres\u00a02016\u00a0(Kategor ie\u00a0\u201eB\u201c):\u00a0Osimer\u2010\ntinib\u00a0bei\u00a0NSCLC,\u00a0dem\u00a0neunvalenten\u00a0Humanen\u00a0Papillomvirus\u2010Impfsto ff\u00a0Gardasil\u00ae\u00a093,\u00a0\nSusoctocog\u00a0alpha\u00a0bei\u00a0erworbener\u00a0H\u00e4mophilie\u00a0durch\u00a0Faktor\u2010VIII\u2010An tik\u00f6rper,\u00a0Teno\u2010\nfoviralafenamid\u00a0in\u00a0verschiedenen \u00a0Kombinationen\u00a0bei\u00a0HIV\u2010Infektio n,\u00a0Trifluridin\u00a0plus\u00a0\nTipiracil\u00a0bei\u00a0metastasiertem\u00a0kol orektalem\u00a0Karzinom\u00a0und\u00a0Velpatas vir\u00a0in\u00a0Kombinati\u2010\non\u00a0mit\u00a0dem\u00a0bereits\u00a0bekannten\u00a0Sofosbuvir\u00a0bei\u00a0chronischer\u00a0Hepatit is\u00a0C.\u00a0F\u00fcr\u00a0elf\u00a0Wirk\u2010\nstoffe\u00a0sahen\u00a0sie\u00a0keine\u00a0oder\u00a0nur\u00a0marginale\u00a0Unterschiede\u00a0zu\u00a0berei ts\u00a0eingef\u00fchrten\u00a0\nPr\u00e4paraten\u00a0und\u00a0stuften\u00a0diese\u00a0als\u00a0 Analogpr\u00e4parate\u00a0in\u00a0Kategorie\u00a0\u201e C\u201c\u00a0ein.\u00a0Dazu\u00a0z\u00e4hlt\u00a0\nOspemifen,\u00a0welches\u00a0inzwische n\u00a0nicht\u00a0mehr\u00a0im\u00a0Handel\u00a0ist.\u00a0\u00a0\nTabelle\u00a03.1\u00a0gibt\u00a0f\u00fcr\u00a0die\u00a0im\u00a0Innovationsreport\u00a02019\u00a0untersuchten \u00a0Wirkstoffe\u00a0einen\u00a0\n\u00dcberblick\u00a0\u00fcber\u00a0die\u00a0Bewertungen\u00a0gem\u00e4\u00df\u00a0Arzneiverordnungs\u2010Report\u00a0u nd\u00a0die\u00a0Bewer\u2010\ntungen\u00a0durch\u00a0andere\u00a0Standardwerke.\u00a0Der\u00a0vom\u00a0G\u2010BA\u00a0festgestellte\u00a0Z usatznutzen\u00a0ist\u00a0\nebenfalls\u00a0aufgef\u00fchrt.\u00a0Fand\u00a0die\u00a0Nutzenbewertung\u00a0f\u00fcr\u00a0mehrere\u00a0Subg ruppen\u00a0statt,\u00a0ist\u00a0\nin\u00a0Klammern\u00a0angegeben,\u00a0welcher\u00a0Anteil\u00a0der\u00a0insgesamt\u00a0betrachtete n\u00a0Subgruppen\u00a0\nden\u00a0in\u00a0der\u00a0Tabelle\u00a0aufgef\u00fchrten\u00a0Zusatznutzen\u00a0aufwies.\u00a0\n\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 \u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n1\u00a0Necitumumab\u00a0(Portrazza\u00ae)\u00a0wurde\u00a02017\u00a0kurzfristig\u00a0vom\u00a0Markt\u00a0geno mmen,\u00a0ist\u00a0aber\u00a0jetzt\u00a0wieder\u00a0verf\u00fcgbar.\u00a0\n2\u00a0Olaratumab\u00a0(Lartruvo\u00ae)\u00a0ging\u00a0am\u00a008.05.2019\u00a0au\u00dfer\u00a0Handel.\u00a0\n3\u00a0Dieser\u00a0Impfstoff\u00a0wurde\u00a0anl\u00e4sslich\u00a0des\u00a0Sonderkapitels\u00a0in\u00a0die\u00a0Be wertungen\u00a0des\u00a0Innovationsreports\u00a02019\u00a0aufgenommen,\u00a0obwohl\u00a0\nImpfstoffe\u00a0sonst\u00a0aufgrund\u00a0ihrer\u00a0Zulassungsbedingungen\u00a0nicht\u00a0im\u00a0 Innovationsreport\u00a0beurteilt\u00a0werden.\u00a045\u00a0Die\u00a0Pharmazeutische\u00a0Zeitung\u00a0(PZ)\u00a0beurteilte\u00a019\u00a0der\u00a023\u00a0Wirkstoff e\u00a0bzw.\u00a0Wirkstoff\u2010\nkombinationen\u00a0des\u00a0diesj\u00e4hrigen\u00a0Innovationsreports.\u00a0Als\u00a0Sprungin novation\u00a0wurden\u00a0\nvorl\u00e4ufig\u00a0acht\u00a0Wirkstoffe\u00a0(Daratumumab,\u00a0Elotuzumab,\u00a0Mepolizumab ,\u00a0Olaratumab,\u00a0\nPalbociclib,\u00a0Pitolisant,\u00a0Sacubit ril/Valsartan\u00a0un d\u00a0Talimogen\u00a0lah erparepvec)\u00a0eingestuft.\u00a0\nNeun\u00a0der\u00a0Arzneistoffe,\u00a0die\u00a0zum\u00a0Teil\u00a0in\u00a0fixen\u00a0Kombinationen\u00a0ange boten\u00a0werden,\u00a0\nwurden\u00a0als\u00a0Schrittinnovation\u00a0dek lariert\u00a0(Albutrepenonacog\u00a0alfa, \u00a0Efmoroctocog\u00a0alfa,\u00a0\nEftrenonacog\u00a0alfa,\u00a0Migalastat,\u00a0Opicapon,\u00a0Osimertinib,\u00a0Selexipag ,\u00a0Trifluridin/Tipiracil\u00a0\nund\u00a0Velpatasvir/Sofosbuvir).\u00a0Nur\u00a0der\u00a0Wirkstoff\u00a0Brivaracetam\u00a0und \u00a0die\u00a0Kombination\u00a0\nElbasvir/Grazoprevir\u00a0wurden\u00a0als\u00a0 Analogpr\u00e4parate\u00a0gewertet\u00a0(PZ,\u00a02 016).\u00a0\nEine\u00a0Bewertung\u00a0allein\u00a0anhand\u00a0der\u00a0Nutzen\u2010Schaden\u2010Relation\u00a0und\u00a0de m\u00a0daraus\u00a0fol\u2010\ngenden\u00a0 therapeutischen\u00a0 Stellenwert\u00a0 trifft\u00a0 das\u00a0 arznei\u2010telegramm\u00a0 (a\u2010t)\u00a0 bzw.\u00a0 die\u00a0\nzugeh\u00f6rige\u00a0Arzneimitteldatenbank \u00a0(atd).\u00a0Von\u00a0den\u00a0acht\u00a0bewerteten \u00a0Wirkstoffen\u00a0\nbzw.\u00a0 Wirkstoffkombinationen\u00a0 wurden\u00a0 drei\u00a0 als\u00a0 \u201eMittel\u00a0 der\u00a0 Wahl\u201c\u00a0 e ingeordnet:\u00a0\nElbasvir/Grazoprevir\u00a0allerdings\u00a0nur\u00a0bei\u00a0Hepatitis\u00a0C\u00a0Genotyp\u00a01\u00a0u nd\u00a04\u00a0mit\u00a0schwerer\u00a0\noder\u00a0 dialysepflichtiger\u00a0 Niereninsuffizienz,\u00a0 Velpatasvir/Sofosbu vir\u00a0 in\u00a0 bestimmten\u00a0\nSituationen\u00a0(abh\u00e4ngig\u00a0vom\u00a0Genoty p\u00a0und\u00a0dem\u00a0Vorliegen\u00a0einer\u00a0Leber zirrhose)\u00a0und\u00a0\nder\u00a0HPV\u2010Impfstoff\u00a0Gardasil\u00ae\u00a09.\u00a0F\u00fcr\u00a0die\u00a0zugelassenen\u00a0Impfstoffe\u00a0 gegen\u00a0Humane\u00a0\nPapillomviren\u00a0 nimmt\u00a0 das\u00a0 arznei\u2010telegramm\u00a0 eine\u00a0 gemeinsame\u00a0 Bewert ung\u00a0 vor.\u00a0\nWelche\u00a0Vakzine\u00a0zu\u00a0bevorzugen\u00a0ist,\u00a0l\u00e4sst\u00a0sich\u00a0laut\u00a0atd\u00a0schwer\u00a0ei nsch\u00e4tzen,\u00a0f\u00fcr\u00a0Jun\u2010\ngen\u00a0ziehen\u00a0die\u00a0Autoren\u00a0jedoch\u00a0Gardasil\u00ae\u00a09\u00a0vor.\u00a0Als\u00a0\u201eMittel\u00a0der\u00a0 Reserve\u201c\u00a0werden\u00a0\nbei\u00a0 den\u00a0 \u00fcbrigen\u00a0 Pr\u00e4paraten\u00a0 Mepolizumab\u00a0 und\u00a0 Sacubitril/Valsartan \u00a0e i n g e s t u f t , \u00a0\nerstgenanntes\u00a0 jedoch\u00a0 nur\u00a0 mit\u00a0 Einschr\u00e4nkungen.\u00a0 \u201eVarianten\u00a0 ohne\u00a0 b esonderen\u00a0\nStellenwert\u201c\u00a0sind\u00a0f\u00fcr\u00a0das\u00a0a\u2010t\u00a0Brivaracetam\u00a0und\u00a0Opicapon.\u00a0Olarat umab\u00a0und\u00a0Talimogen\u00a0\nlaherparepvec\u00a0beurteilen\u00a0die\u00a0Autoren\u00a0als\u00a0\u201eumstrittenes\u00a0Therapie prinzip\u201c\u00a0(a\u2010t,\u00a02019).\u00a0\nDie\u00a0Zeitschrift\u00a0\u201eDer\u00a0Arzneimittelbrief\u00a0\u2013\u00a0Unabh\u00e4ngige\u00a0Arzneimitt elinformation\u201c\u00a0(AMB)\u00a0\n\u00e4u\u00dfert\u00a0sich\u00a0zu\u00a0sieben\u00a0der\u00a0neuen\u00a0 Wirkstoffe\u00a0bzw.\u00a0Wirkstoffkombin ationen.\u00a0F\u00fcr\u00a0\nDaratumumab\u00a0und\u00a0Elotuzumab\u00a0ist\u00a0eine\u00a0endg\u00fcltige\u00a0Bewertung\u00a0des\u00a0th erapeutischen\u00a0\nStellenwertes\u00a0laut\u00a0AMB\u00a0noch\u00a0nicht\u00a0m\u00f6glich.\u00a0Weitere\u00a0medizinische \u00a0Erkenntnisse\u00a0\nw\u00fcrden\u00a0dringend\u00a0ben\u00f6tigt,\u00a0auch\u00a0angesichts\u00a0der\u00a0sehr\u00a0hohen\u00a0Kosten .\u00a0Efmoroctocog\u00a0\nalfa\u00a0und\u00a0die\u00a0Fixkombination\u00a0Elvit egravir/Cobicistat/Emtricitabi n/Tenofoviralafena\u2010\nmid\u00a0wurden\u00a0nicht\u00a0gesondert\u00a0bewertet,\u00a0jedoch\u00a0weist\u00a0der\u00a0AMB\u00a0darau f\u00a0hin,\u00a0dass\u00a0vom\u00a0\nG\u2010BA\u00a0kein\u00a0Zusatznutzen\u00a0festgestellt\u00a0wurde.\u00a0Bei\u00a0Mepolizumab\u00a0wird \u00a0auf\u00a0die\u00a0Nationa\u2010\nle\u00a0VersorgungsLeitlinie\u00a0Asthma\u00a0ve rwiesen,\u00a0welche\u00a0den\u00a0Einsatz\u00a0de s\u00a0Antik\u00f6rpers\u00a0erst\u00a0\nin\u00a0der\u00a0letzten\u00a0Therapiestufe\u00a0und\u00a0nur\u00a0durch\u00a0einen\u00a0Pneumologen\u00a0vo rsieht.\u00a0Hinsicht\u2010\nlich\u00a0Sacubitril/Valsartan\u00a0sehen\u00a0die\u00a0Autoren\u00a0trotz\u00a0der\u00a0insgesamt \u00a0positiven\u00a0Bewer\u2010\ntung\u00a0(noch)\u00a0keine\u00a0Veranlassung,\u00a0 die\u00a0Wirkstoffkombination\u00a0als\u00a0ne uen\u00a0Standard\u00a0in\u00a0\nder\u00a0Therapie\u00a0der\u00a0Herzinsuffizienz\u00a0umzusetzen.\u00a0Zur\u00a0Kombination\u00a0S ofosbuvir/Velpa\u2010\ntasvir\u00a0stellt\u00a0der\u00a0AMB\u00a0fest,\u00a0dass\u00a0die\u00a0Therapie\u00a0der\u00a0chronischen\u00a0H epatitis\u00a0C\u00a0wirksamer\u00a0\nund\u00a0einfacher\u00a0geworden\u00a0ist\u00a0(Ludwig\u00a0&\u00a0Schuler,\u00a02019).\u00a046\u00a0Tabelle\u00a03.1:\u00a0Ausgew\u00e4hlte\u00a0neue\u00a0Wirkstoffe/Wirkstoffkombinationen \u00a0des\u00a0Jahres\u00a0\n2016\u00a0und\u00a0deren\u00a0Bewertungen\u00a0in\u00a0Standardwerken\u00a0\nWirkstoff\u00a0 Indikation\u00a0G\u2010BA\u00a0\nNutzenbewertung\u00a0Fricke\u00a0\net\u00a0al.\u00a0a\u2010t/\u00a0\natd\u00a0AMB\u2010\nBewertung\u00a0PZ\u2010\nBewertung\u00a0\nAlbutrepeno\u2010\nnacog\u00a0alfa\u00a0H\u00e4mophilie\u00a0B\u00a0Nicht\u00a0 quantifizierb.\u00a0\nZN\u00a0(1/1)\u00a0C\u00a0keine\u00a0 keine\u00a0Schritt\u2010\ninnovation\u00a0\nBrivaracetam\u00a0 Epilepsie\u00a0 ZN\u00a0nicht\u00a0belegt\u00a0(2/2)\u00a0 C\u00a0Variante\u00a0ohne\u00a0\nbes.\u00a0Stellenw.\u00a0keine\u00a0Analog\u2010\npr\u00e4parat\u00a0\nDaratumumab\u00a0 Multiples\u00a0Myelom\u00a0Hinweis\u00a0auf\u00a0\nbetr\u00e4chtl.\u00a0ZN\u00a0(1/3)\u00a0\nAnhaltspunkt\u00a0f\u00fcr\u00a0\nbetr\u00e4chtl.\u00a0ZN\u00a0(1/3)\u00a0\nZN\u00a0nicht\u00a0belegt\u00a0(1/3)\u00a0A\u00a0keine\u00a0als\u00a0Kombination\u00a0\nwirksamste\u00a0Op\u2010\ntion\u00a0zur\u00a0Verl\u00e4n\u2010\ngerung\u00a0des\u00a0PFS,\u00a0\nweitere\u00a0Studien\u00a0\nzum\u00a0CER\u00a0bei\u00a0\nMM\u00a0erforderl.,\u00a0\nauch\u00a0wgn.\u00a0der\u00a0\nexorbitanten\u00a0\nJahrestherapie\u2010\nkosten\u00a0Sprung\u2010\ninnovation\u00a0\nEfmoroctocog\u00a0\nalfa\u00a0H\u00e4mophilie\u00a0A\u00a0ZN\u00a0nicht\u00a0belegt\u00a0\n(1/1)\u00a0C\u00a0keine\u00a0 keine\u00a0Schritt\u2010\ninnovation\u00a0\nEftrenonacog\u00a0\nalfa\u00a0H\u00e4mophilie\u00a0B\u00a0Nicht\u00a0quantifizierb.\u00a0\nZN\u00a0(1/1)\u00a0C\u00a0keine\u00a0 keine\u00a0Schritt\u2010\ninnovation\u00a0\nElotuzumab\u00a0 Multiples\u00a0Myelom\u00a0Anhaltspunkt\u00a0f\u00fcr\u00a0\ngeringen\u00a0ZN\u00a0(1/1)\u00a0A\u00a0keine\u00a0weitere\u00a0Studien\u00a0\nzum\u00a0CER\u00a0beim\u00a0\nMM\u00a0erforderl.,\u00a0\nauch\u00a0wgn.\u00a0der\u00a0\nexorbitanten\u00a0\nJahrestherapie\u2010\nkosten\u00a0Sprung\u2010\ninnovation\u00a0\nElbasvir/\u00a0\nGrazoprevir\u00a0cHCV\u00a0ZN\u00a0nicht\u00a0belegt\u00a0\n(2/2)\u00a0C\u00a0Variante\u00a0ohne\u00a0\nbes.\u00a0Stellen\u2010\nwert\u00a0mit\u00a0m\u00f6gl.\u00a0\nPreisvorteil\u00a0\nMittel\u00a0der\u00a0\nWahl\u00a0nur\u00a0bei\u00a0\nGenotyp\u00a01&4\u00a0\nmit\u00a0schwerer\u00a0\nod.\u00a0dialyse\u2010\npflichtiger\u00a0Nie\u2010\nreninsuffizienz\u00a0keine\u00a0Analog\u2010\npr\u00e4parat\u00a0\nHumaner\u00a0\nPapillomvirus\u2010\nImpfstoff\u00a0\n(nonavalent)\u00a0HPV\u2010Impfstoff\u00a0 keine\u00a0NBW\u00a0 B\u00a0Mittel\u00a0der\u00a0\nWahl\u00a0\neinige\u00a0offene\u00a0\nFragen\u00a0wirksam\u00a0zur\u00a0\nVerhinderung\u00a0\nvon\u00a0Genital\u2010\nwarzen\u00a0und\u00a0\nVorstufen\u00a0des\u00a0\nZervix\u2010CA\u00a0keine\u00a0\nMepolizumab\u00a0 Asthma\u00a0bronchiale\u00a0Anhaltspunkt\u00a0f\u00fcr\u00a0\ngeringen\u00a0ZN\u00a0(1/3)\u00a0\nZN\u00a0nicht\u00a0belegt\u00a0(2/3)\u00a0A\u00a0Mittel\u00a0der\u00a0\nReserve\u00a0mit\u00a0\nEinschr\u00e4nkgn.\u00a0keine\u00a0Sprung\u2010\ninnovation\u00a0\nMigalastat\u00a0 Morbus\u00a0Fabry\u00a0Nicht\u00a0quantifizierb.\u00a0\nZN\u00a0(1/1)\u00a0A\u00a0keine\u00a0 keine\u00a0Schritt\u2010\ninnovation\u00a0\nOlaratumab\u00a0 Weichgewebesarkom\u00a0 Betr\u00e4chtl.\u00a0ZN\u00a0(1/1)\u00a0 A\u00a0Zweifelhaftes\u00a0\nTherapieprinzip\u00a0keine\u00a0Sprung\u2010\ninnovation\u00a047\u00a0Wirkstoff\u00a0 Indikation\u00a0G\u2010BA\u00a0\nNutzenbewertung\u00a0Fricke\u00a0\net\u00a0al.\u00a0a\u2010t/\u00a0\natd\u00a0AMB\u2010\nBewertung\u00a0PZ\u2010\nBewertung\u00a0\nOpicapon\u00a0 Morbus\u00a0Parkinson\u00a0ZN\u00a0nicht\u00a0belegt\u00a0\n(1/1)\u00a0C\u00a0Variante\u00a0ohne\u00a0\nbes.\u00a0Stellenw.\u00a0keine\u00a0Schritt\u2010\ninnovation\u00a0\nOsimertinib\u00a0nicht\u2010kleinzell.\u00a0\nLungen\u2010CA\u00a0\u00a0\nNSCLC\u00a0Anhaltspunkt\u00a0f\u00fcr\u00a0\nbetr\u00e4chtl.\u00a0ZN\u00a0(2/6)\u00a0\nZN\u00a0nicht\u00a0belegt\u00a0\n(4/6)\u00a0B\u00a0keine\u00a0 keine\u00a0Schritt\u2010\ninnovation\u00a0\nPalbociclib\u00a0HR\u2010positives,\u00a0HER2\u2010\nnegatives\u00a0Mamma\u2010\nCA\u00a0ZN\u00a0nicht\u00a0belegt\u00a0\n(4/4)\u00a0A\u00a0keine\u00a0 keine\u00a0Sprung\u2010\ninnovation\u00a0\nPitolisant\u00a0Narkolepsie\u00a0mit\u00a0oder\u00a0\nohne\u00a0Kataplexie\u00a0Nicht\u00a0quantifizierb.\u00a0\nZN\u00a0(1/1)\u00a0A/C\u00a0keine\u00a0 keine\u00a0Sprung\u2010\ninnovation\u00a0\nSacubitril/\u00a0\nValsartan\u00a0chronische\u00a0\nHerzinsuffizienz\u00a0mit\u00a0\nreduzierter\u00a0\nEjektionsfraktion\u00a0Anhaltspunkt\u00a0f\u00fcr\u00a0\nbetr\u00e4chtl.\u00a0ZN\u00a0(1/2)\u00a0\nAnhaltspunkt\u00a0f\u00fcr\u00a0\ngeringen\u00a0ZN\u00a0(1/2)\u00a0A\u00a0Mittel\u00a0der\u00a0\nReserve\u00a0noch\u00a0kein\u00a0\nParadigmen\u2010\nwechsel\u00a0Sprung\u2010\ninnovation\u00a0\nSelexipag\u00a0Pulmonal\u00a0arterielle\u00a0\nHypertonie\u00a0ZN\u00a0nicht\u00a0belegt\u00a0\n(1/1)\u00a0C\u00a0keine\u00a0 keine\u00a0Schritt\u2010\ninnovation\u00a0\nTalimogen\u00a0\nlaherparepvec\u00a0Melanom \u00a0ZN\u00a0nicht\u00a0belegt\u00a0\n(3/3)\u00a0A\u00a0Umstrittenes\u00a0\nTherapieprinzip\u00a0keine\u00a0Sprung\u2010\ninnovation\u00a0\nTenofoviral\u2010\nafenamid/\u00a0\nElvitegravir/\u00a0\nCobicistat/\u00a0\nEmtricitabin\u00a0HIV\u00a0ZN\u00a0nicht\u00a0belegt\u00a0\n(6/6)\u00a0B\u00a0keine\u00a0 keine\u00a0 keine\u00a0\nTenofoviral\u2010\nafenamid/\u00a0\nEmtricitabin/\u00a0\nRilpivirin\u00a0HIV\u00a0ZN\u00a0nicht\u00a0belegt\u00a0\n(4/4)\u00a0B\u00a0keine\u00a0 keine\u00a0 keine\u00a0\nTenofoviral\u2010\nafenamid/\u00a0\nEmtricitabin\u00a0HIV\u00a0ZN\u00a0nicht\u00a0belegt\u00a0\n(4/4)\u00a0B\u00a0keine\u00a0 keine\u00a0 keine\u00a0\nTrifluridin/\u00a0\nTipiracil\u00a0Metastasiertes\u00a0\nKolorektalkarzinom\u00a0Anhaltspunkt\u00a0f\u00fcr\u00a0\ngeringen\u00a0ZN\u00a0(1/1)\u00a0B\u00a0 keine\u00a0 keine\u00a0Schritt\u2010\ninnovation\u00a0\nSofosbuvir/\u00a0\nVelpatasvir\u00a0cHCV\u00a0Anhaltspunkt\u00a0f\u00fcr\u00a0\nbetr\u00e4chtl.\u00a0ZN\u00a0(1/9)\u00a0\nAnhaltspunkt\u00a0f\u00fcr\u00a0\ngeringen\u00a0ZN\u00a0(1/9)\u00a0\nAnhaltspunkt\u00a0f\u00fcr\u00a0\nnicht\u00a0quantifizierb.\u00a0\nZN\u00a0(1/9)\u00a0\nZN\u00a0nicht\u00a0belegt\u00a0(6/9)\u00a0B\u00a0Mittel\u00a0der\u00a0\nWahl\u00a0in\u00a0best.\u00a0\nSituationen\u00a0\u00a0\njedoch\u00a0mit\u00a0\ngeringem\u00a0\nErfahrungs\u2010\u00a0\nhintergrund\u00a0Therapie\u00a0der\u00a0\nchronischen\u00a0\nHepatitis\u00a0C\u00a0\nist\u00a0wirksamer\u00a0\nund\u00a0einfacher\u00a0\ngeworden\u00a0Schritt\u2010\ninnovation\u00a0\nNBW=Nutzenbewertung,\u00a0a\u2010t=arznei\u2010telegramm,\u00a0atd=Arzneimitteldate nbank,\u00a0AMB=Der\u00a0Arzneimittelbrief,\u00a0PZ=Pharmazeutische\u00a0\nZeitung,\u00a0O= Orphan\u2010Arzneimittel,\u00a0CA=Carcinom,\u00a0cHCV= chronische\u00a0Hepatitis\u00a0C\u00a0Virus\u2010I nfektion,\u00a0GT=Genotyp,\u00a0ZN=Zusatznutzen,\u00a0\nQuotient\u00a0(x/y)=(Anzahl\u00a0Subgruppen\u00a0mit\u00a0entsprechender\u00a0Bewertung/ Gesamtzahl\u00a0bewerteter\u00a0Subgruppen)\u00a0\u00a0\n\u00a0\nDer\u00a0Umsatz\u00a0der\u00a0neuen\u00a0Arzneimittel\u00a0des\u00a0Jahres\u00a02016\u00a0lag\u00a0in\u00a0der\u00a0un tersuchten\u00a0Popu\u2010\nlation\u00a0der\u00a0TK\u2010Versicherten\u00a0im\u00a0Jahr\u00a02017\u00a0bei\u00a0rund\u00a0167\u00a0Mio.\u00a0\u20ac.\u00a0Di es\u00a0sind\u00a0rund\u00a04\u00a0%\u00a0\nder\u00a0gesamten\u00a0Arzneimittelausgabe n\u00a0der\u00a0TK\u00a0f\u00fcr\u00a0das\u00a0Jahr\u00a02017,\u00a0die \u00a0sich\u00a0auf\u00a0insge\u2010\nsamt\u00a04,25\u00a0Mrd.\u00a0\u20ac\u00a0beliefen.\u00a0Verglichen\u00a0mit\u00a0dem\u00a0Vorjahr\u00a0(145\u00a0Mio. \u00a0\u20ac\u00a0Ausgaben\u00a0im\u00a0\nJahr\u00a02016\u00a0f\u00fcr\u00a0die\u00a0neuen\u00a0Arzneimittel\u00a0des\u00a0Jahres\u00a02015)\u00a0waren\u00a0die \u00a0Ausgaben\u00a0der\u00a0TK\u00a048\u00a0f\u00fcr\u00a0die\u00a0neuen\u00a0Arzneimittel\u00a0um\u00a015\u00a0%\u00a0h\u00f6her.\u00a0Die\u00a0Menge\u00a0der\u00a0verordn eten\u00a0Packungen\u00a0\nlag\u00a0mit\u00a0128,5\u00a0Tausend\u00a0rund\u00a07\u00a0%\u00a0unterhalb\u00a0der\u00a0Packungsmenge\u00a0des\u00a0 Vorjahres\u00a0(n\u00a0=\u00a0\n138,1\u00a0Tsd.\u00a0f\u00fcr\u00a0das\u00a0Jahr\u00a02016).\u00a0Ergab\u00a0sich\u00a0damals\u00a0ein\u00a0durchschni ttlicher\u00a0Preis\u00a0pro\u00a0\nPackung\u00a0von\u00a01.048\u00a0\u20ac,\u00a0so\u00a0waren\u00a0es\u00a0nun\u00a01.298\u00a0\u20ac.\u00a0Das\u00a0umsatzst\u00e4rkst e\u00a0Arzneimittel\u00a0\nunter\u00a0den\u00a0Arzneimittelneuheiten\u00a0des\u00a0Jahres\u00a02016\u00a0war\u00a0im\u00a0Jahr\u00a0201 7\u00a0Palbociclib\u00a0\n(Tabelle\u00a03.2),\u00a0welches\u00a0zur\u00a0Beha ndlung\u00a0bestimmter\u00a0Brustkrebs\u2010Sub typen\u00a0angewen\u2010\ndet\u00a0wird\u00a0und\u00a01.006\u00a0TK\u2010Versicherten\u00a0verordnet\u00a0wurde\u00a0(Tabelle\u00a03.4 ).\u00a0Die\u00a0Kombinati\u2010\non\u00a0 der\u00a0 Wirkstoffe\u00a0 Elvitegravir/Cobicistat/Emtricitabin/Tenofovi ralafenamid\u00a0 zur\u00a0\nTherapie\u00a0von\u00a0HIV\u2010Infektionen\u00a0sowie\u00a0Daratumumab\u00a0zur\u00a0Behandlung\u00a0d es\u00a0multiplen\u00a0\nMyeloms\u00a0folgten\u00a0auf\u00a0Platz\u00a02\u00a0und\u00a0 3\u00a0der\u00a0umsatzst\u00e4rksten\u00a0Arzneimit tel\u00a0(Tabelle\u00a03.2).\u00a0\u00a0\nDas\u00a0im\u00a0Jahr\u00a02017\u00a0am\u00a0h\u00e4ufigsten\u00a0verschriebene\u00a0Arzneimittel\u00a0war\u00a0m it\u00a050,8\u00a0Tsd.\u00a0\nverordneten\u00a0Packungen\u00a0der\u00a0HPV\u2010Impfstoff\u00a0Gardasil\u00ae\u00a09,\u00a0mit\u00a0dem\u00a0ei ne\u00a0aktive\u00a0Im\u2010\nmunisierung\u00a0gegen\u00a0bestimmte\u00a0Viru stypen\u00a0erreicht\u00a0werden\u00a0kann,\u00a0di e\u00a0zu\u00a0durch\u00a0HPV\u2010\nErkrankungs\u00a0bedingten\u00a0Vorstufen\u00a0 wie\u00a0Zervix\u2010,\u00a0Vulva\u2010\u00a0und\u00a0Vaginal karzinomen\u00a0sowie\u00a0\nVorstufen\u00a0maligner\u00a0L\u00e4sionen\u00a0in\u00a0diesem\u00a0Bereich\u00a0und\u00a0Genitalwarzen \u00a0f\u00fchren\u00a0k\u00f6nnen.\u00a0\nAuf\u00a0Rang\u00a02\u00a0und\u00a03\u00a0der\u00a0h\u00e4ufigsten\u00a0Verordnungen\u00a0fanden\u00a0sich\u00a0Sacubi tril/Valsartan\u00a0\nzur\u00a0Therapie\u00a0der\u00a0chronischen\u00a0Her zinsuffizienz\u00a0und\u00a0Daratumumab\u00a0( Tabelle\u00a03.3).\u00a0\nInsgesamt\u00a0erhielten\u00a048.075\u00a0TK\u2010Versicherte\u00a0im\u00a0Jahr\u00a02017\u00a0ein\u00a0Arzn eimittel,\u00a0das\u00a0im\u00a0\nLaufe\u00a0des\u00a0Jahres\u00a02016\u00a0eingef\u00fchrt\u00a0worden\u00a0war\u00a0(Tabelle\u00a03.4).\u00a0Dies e\u00a0Anzahl\u00a0lag\u00a0im\u00a0\nVergleich\u00a0 zum\u00a0 Vorjahr\u00a0 um\u00a0 rund\u00a0 8\u00a0%\u00a0 h\u00f6her:\u00a0 2016\u00a0 bekamen\u00a0 noch\u00a0 44.3 15\u00a0 TK\u2010\nVersicherte\u00a0ein\u00a02015\u00a0neu\u00a0zugelasse nes\u00a0Arzneimittel\u00a0verordnet.\u00a0\nAuf\u00a0Bundeslandebene\u00a0zeigten\u00a0sich\u00a0hinsichtlich\u00a0der\u00a0Verordnungspr \u00e4valenz\u00a0bei\u00a0den\u00a0\nNeueinf\u00fchrungen\u00a0wie\u00a0auch\u00a0schon\u00a0 in\u00a0den\u00a0Jahren\u00a0zuvor\u00a0auff\u00e4llige\u00a0r egionale\u00a0Diffe\u2010\nrenzen.\u00a0Die\u00a0dargestellten\u00a0Zahlen\u00a0in\u00a0Abb.\u00a03.2\u00a0geben\u00a0den\u00a0Anteil\u00a0d er\u00a0TK\u2010Versicherten,\u00a0\ndie\u00a02017\u00a0mindestens\u00a0eine\u00a0Neueinf\u00fchrung\u00a0des\u00a0Jahres\u00a02016\u00a0erhielte n,\u00a0in\u00a0Relation\u00a0zur\u00a0\nGesamtzahl\u00a0der\u00a0TK\u2010Versicherten\u00a0(je\u00a01.000\u00a0Versicherte)\u00a0des\u00a0jewei ligen\u00a0Bundeslan\u2010\ndes\u00a0wieder.\u00a0Die\u00a0h\u00f6chsten\u00a0Anteile\u00a0fanden\u00a0sich\u00a0in\u00a0Sachsen\u2010Anhalt, \u00a0Hessen,\u00a0Nieder\u2010\nsachsen,\u00a0Baden\u2010W\u00fcrttemberg\u00a0und\u00a0Rh einland\u2010Pfalz\u00a0(zwischen\u00a07,23\u00a0u nd\u00a08,57\u00a0Promil\u2010\nle),\u00a0w\u00e4hrend\u00a0Bremen\u00a0(1,49\u00a0Promille)\u00a0die\u00a0niedrigste\u00a0Verordnungsp r\u00e4valenz\u00a0aufwies.\u00a0\nIm\u00a0Vorjahr\u00a0zeigte\u00a0sich\u00a0ein\u00a0anderes\u00a0Bild:\u00a0In\u00a0Sachsen,\u00a0Sachsen\u2010An halt,\u00a0Th\u00fcringen,\u00a0\nMecklenburg\u2010Vorpommern\u00a0und\u00a0dem\u00a0Saarland\u00a0waren\u00a0die\u00a0Verordnungspr \u00e4valenzen\u00a0\nbesonders\u00a0hoch,\u00a0w\u00e4hrend\u00a0der\u00a0niedrigste\u00a0Wert\u00a0ebenso\u00a0wie\u00a02017\u00a0in\u00a0 Bremen\u00a0zu\u00a0ver\u2010\nzeichnen\u00a0war.\u00a0Die\u00a0Gr\u00fcnde\u00a0f\u00fcr\u00a0solche\u00a0Differenzen\u00a0sind\u00a0im\u00a0Einzeln en\u00a0nicht\u00a0klar.\u00a0Zu\u00a0den\u00a0\nUnterschieden\u00a0tr\u00e4gt\u00a0unter\u00a0anderem\u00a0die\u00a0regionale\u00a0Altersstruktur\u00a0 bei,\u00a0aber\u00a0m\u00f6glich\u2010\nerweise\u00a0auch\u00a0der\u00a0unterschiedlich e\u00a0Informationsstand\u00a0der\u00a0verordn enden\u00a0\u00c4rzte.\u00a0\u00a0\nBei\u00a0sieben\u00a0Arzneimitteln\u00a0lag\u00a0die\u00a0Verordnungspr\u00e4valenz\u00a0bei\u00a0\u00fcber\u00a0 zehn\u00a0je\u00a0100.000\u00a0\nTK\u2010Versicherten.\u00a0Dies\u00a0waren\u00a0Gardasil\u00ae\u00a09\u00a0(345,8),\u00a0Sacubitril/Val sartan\u00a0(42,8),\u00a0drei\u00a0\nverschiedene\u00a0Tenofoviralafenamid \u2010haltige\u00a0Kombinationen\u00a0(10,3\u00a0bi s\u00a022,8),\u00a0Opica\u201049\u00a0pon\u00a0und\u00a0Palbociclib\u00a0(jeweils\u00a010,1).\u00a0Im\u00a0Mittel\u00a0waren\u00a0TK\u2010Versiche rte\u00a0mit\u00a0der\u00a0Verord\u2010\nnung\u00a0eines\u00a0neuen\u00a0Arzneimittels\u00a027,2\u00a0Jahre\u00a0alt\u00a0(Vorjahresinnovat ionen:\u00a058,1\u00a0Jahre).\u00a0\nDas\u00a0niedrige\u00a0Durchschnittsalter\u00a0ist\u00a0insbesondere\u00a0durch\u00a0die\u00a0gro\u00df e\u00a0junge\u00a0Population\u00a0\nbei\u00a0der\u00a0HPV\u2010Impfung\u00a0zu\u00a0erkl\u00e4ren.\u00a0Insgesamt\u00a0entfielen\u00a079,5\u00a0%\u00a0der \u00a0neuen\u00a0Arzneimit\u2010\ntel\u00a0auf\u00a0Frauen\u00a0und\u00a0nur\u00a020,5\u00a0%\u00a0auf\u00a0M\u00e4nner\u00a0(Tabelle\u00a03.4).\u00a0Auch\u00a0di es\u00a0ist\u00a0mit\u00a0Blick\u00a0auf\u00a0\ndie\u00a0HPV\u2010Impfung\u00a0nachvollziehbar, \u00a0die\u00a0zum\u00a0damaligen\u00a0Zeitpunkt\u00a0vo n\u00a0der\u00a0STIKO\u00a0nur\u00a0\nf\u00fcr\u00a0M\u00e4dchen\u00a0empfohlen\u00a0wurde.\u00a0\nTabelle\u00a03.2:\u00a0Top\u2010Liste\u00a0der\u00a0neuen \u00a0Arzneimittel\u00a0des\u00a0Jahres\u00a02016\u00a0n ach\u00a0Bruttoumsatz\u00a0\nim\u00a0Jahr\u00a02017\u00a0(TK\u00a0und\u00a0GKV)\u00a0\nRang\u00a0Wirkstoff\u00a0\n(Handelsname)\u00a0Techniker\u00a0Krankenkasse\u00a0 GKV\u00a0gesamt*\u00a0\nUmsatz\u00a0\u00a0\n2017\u00a0\n[in\u00a0Tsd.\u00a0\u20ac]\u00a0Umsatz\u2010\u00a0\n\u00e4nd.\u00a0\nzum\u00a0\nVorjahr\u00a0Verordnete\u00a0\nPackg.\u00a02017\u00a0\n[in\u00a0Tsd.]\u00a0Umsatz\u00a02017\u00a0\n[in\u00a0Tsd.\u00a0\u20ac]\u00a0Absatz\u00a0\n2017\u00a0\n[in\u00a0Tsd.]\u00a0\n\u00a0\u00a0\u00a01\u00a0Palbociclib\u00a0\n(Ibrance\u00ae)\u00a028.696,6\u00a0 +>999\u00a0%\u00a0 5,3\u00a0 232.198,6\u00a0 42,8\u00a0\n\u00a0\u00a0\u00a02\u00a0Tenofoviralafenamid/\u00a0\nElvitegravir/Cobicistat/\u00a0\nEmtricitabin\u00a0\u00a0\n(Genvoya\u00ae)\u00a021.348,5\u00a0 +58\u00a0%\u00a0 7,2\u00a0 113.586,7\u00a0 38,5\u00a0\n\u00a0\u00a0\u00a03\u00a0Daratumumab\u00a0\n(Darzalex\u00ae)\u00a018.364,7\u00a0 +204\u00a0%\u00a0 10,2\u00a0 885,7\u00a0 0,5\u00a0\n\u00a0\u00a0\u00a04\u00a0Tenofoviralafenamid/\u00a0\nEmtricitabin\u00a0\n(Descovy\u00ae)\u00a015.644,7\u00a0 +101\u00a0%\u00a0 8,5\u00a0 87.514,8\u00a0 48,7\u00a0\n\u00a0\u00a0\u00a05\u00a0Velpatasvir/Sofosbuvir\u00a0\n(Epclusa\u00ae)\u00a014.158,6\u00a0 +32\u00a0%\u00a0 0,7\u00a0 193.435,5\u00a0 9,8\u00a0\n\u00a0\u00a0\u00a06\u00a0Tenofoviralafenamid/\u00a0\nEmtricitabin/Rilpivirin\u00a0\n(Odefsey\u00ae)\u00a011.930,9\u00a0 +273\u00a0%\u00a0 3,8\u00a0 62.239,4\u00a0 19,8\u00a0\n\u00a0\u00a0\u00a07\u00a0Elbasvir/Grazoprevir\u00a0\u00a0\n(Zepatier\u00ae)\u00a09.144,1\u00a0 +>999\u00a0%\u00a0 0,8\u00a0 100.226,6\u00a0 8,6\u00a0\n\u00a0\u00a0\u00a08\u00a0HPV\u2010St\u00e4mme\u00a0\n(Gardasil\u00ae\u00a09)\u00a08.270,7\u00a0 +169\u00a0%\u00a0 50,8\u00a0 91.036,8\u00a0 348,9\u00a0\n\u00a0\u00a0\u00a09\u00a0Albutrepenonacog\u00a0alfa\u00a0\n(Idelvion\u00ae)\u00a07.019,8\u00a0 +243\u00a0%\u00a0 2,2\u00a0 2.612,7\u00a0 0,8\u00a0\n\u00a0\u00a010\u00a0Mepolizumab\u00a0\n(Nucala\u00ae)\u00a05.676,6\u00a0 +90\u00a0%\u00a0 1,8\u00a0 27.493,7\u00a0 9,5\u00a0\n\u00a0\u00a011\u00a0Sacubitril/Valsartan\u00a0\u00a0\n(Entresto\u00ae)\u00a05.345,1\u00a0 +142\u00a0%\u00a0 22,8\u00a0 63.300,4\u00a0 286,1\u00a0\n\u00a0\u00a012\u00a0Efmoroctocog\u00a0alfa\u00a0\n(Elocta\u00ae)\u00a03.758,3\u00a0 +289\u00a0%\u00a0 2,8\u00a0 8.198,0\u00a0 3,2\u00a0\n\u00a0\u00a013\u00a0Trifluridin/Tipiracil\u00a0\n(Lonsurf\u00ae)\u00a03.288,5\u00a0 +331\u00a0%\u00a0 1,1\u00a0 28.055,1\u00a0 10,1\u00a0\n\u00a0\u00a014\u00a0Migalastat\u00a0\n(Galafold\u00ae)\u00a03.197,8\u00a0 +434\u00a0%\u00a0 0,2\u00a0 17.499,0\u00a0 0,9\u00a0\n\u00a0\u00a015\u00a0Elotuzumab\u00a0\u00a0\n(Empliciti\u00ae)\u00a02.524,1\u00a0 +83\u00a0%\u00a0 1,6\u00a0 643,8\u00a0 0,4\u00a0\n\u00a0\u00a016\u00a0Olaratumab\u00a0\u00a0\n(Lartruvo\u00ae)\u00a02.274,4\u00a0 +>999\u00a0%\u00a0 1,3\u00a0 101,5\u00a0 0,1\u00a050\u00a0Rang\u00a0Wirkstoff\u00a0\n(Handelsname)\u00a0Techniker\u00a0Krankenkasse\u00a0 GKV\u00a0gesamt*\u00a0\nUmsatz\u00a0\u00a0\n2017\u00a0\n[in\u00a0Tsd.\u00a0\u20ac]\u00a0Umsatz\u2010\u00a0\n\u00e4nd.\u00a0\nzum\u00a0\nVorjahr\u00a0Verordnete\u00a0\nPackg.\u00a02017\u00a0\n[in\u00a0Tsd.]\u00a0Umsatz\u00a02017\u00a0\n[in\u00a0Tsd.\u00a0\u20ac]\u00a0Absatz\u00a0\n2017\u00a0\n[in\u00a0Tsd.]\u00a0\n\u00a0\u00a017\u00a0Selexipag\u00a0\n(Uptravi\u00ae)\u00a01.788,3\u00a0 +158\u00a0%\u00a0 0,3\u00a0 14.190,8\u00a0 2,7\u00a0\n\u00a0\u00a018\u00a0Brivaracetam\u00a0\n(Briviact\u00ae)\u00a01.077,5\u00a0 +25\u00a0%\u00a0 3,0\u00a0 8.347,7\u00a0 23,7\u00a0\n\u00a0\u00a019\u00a0Opicapon\u00a0\n(Ongentys\u00ae)\u00a01.075,9\u00a0 +>999\u00a0%\u00a0 2,7\u00a0 7.622,2\u00a0 19,5\u00a0\n\u00a0\u00a020\u00a0Osimertinib\u00a0\n(Tagrisso\u00ae)\u00a0859,2\u00a0 +62\u00a0%\u00a0 0,1\u00a0 5.560,1\u00a0 0,7\u00a0\n\u00a0\u00a021\u00a0Eftrenonacog\u00a0alfa\u00a0\n(Alprolix\u00ae)\u00a0733,1\u00a0 +320\u00a0%\u00a0 0,4\u00a0 2.256,1\u00a0 0,5\u00a0\n\u00a0\u00a022\u00a0Pitolisant\u00a0\n(Wakix\u00ae)\u00a0402,8\u00a0 +421\u00a0%\u00a0 0,7\u00a0 1.951,5\u00a0 3,6\u00a0\n\u00a0\u00a023\u00a0Talimogen\u00a0\u00a0\nlaherparepvec\u00a0\n(Imlygic\u00ae)\u00a0224,4\u00a0 +148\u00a0%\u00a0 0,1\u00a0 1.846,0\u00a0 0,8\u00a0\n1\u201023\u00a0Gesamt\u00a0 166.804,6\u00a0 175\u00a0%\u00a0 128,5\u00a0 1.070.802,8\u00a0 880,0\u00a0\n*GKV\u2010Zahlen\u00a0sind\u00a0nicht\u00a0vollst\u00e4ndig\u00a0abbildbar\u00a0\nTabelle\u00a03.3:\u00a0Top\u2010Liste\u00a0der\u00a0neuen\u00a0Arzneimittel\u00a0des\u00a0Jahres\u00a02016\u00a0\u2013 \u00a0nach\u00a0Anzahl\u00a0\nverordneter\u00a0Packungen\u00a0im\u00a0Jahr\u00a02017\u00a0(TK\u00a0und\u00a0GKV)\u00a0\nRang\u00a0Wirkstoff\u00a0\n(Handelsname)\u00a0Techniker\u00a0Krankenkasse\u00a0 GKV\u00a0gesamt*\u00a0\nVerordnete\u00a0\nPackg.\u00a02017\u00a0\n[in\u00a0Tsd.]\u00a0Packg.\u00a0\n\u00c4nderung\u00a0\u00a0\nzum\u00a0\u00a0\nVorjahr\u00a0Umsatz\u00a0\u00a0\n2017\u00a0\n[in\u00a0Tsd.\u00a0\u20ac]\u00a0Absatz\u00a0\u00a0\n2017\u00a0\u00a0\n[in\u00a0Tsd.]\u00a0Umsatz\u00a0\u00a0\n2017\u00a0\n[in\u00a0Tsd.\u00a0\u20ac]\u00a0\n\u00a0\u00a0\u00a01\u00a0HPV\u2010St\u00e4mme\u00a0\n(Gardasil\u00ae\u00a09)\u00a050,8\u00a0 +169\u00a0%\u00a0 8.270,7\u00a0 348,9\u00a0 91.036,8\u00a0\n\u00a0\u00a0\u00a02\u00a0Sacubitril/Valsartan\u00a0\u00a0\n(Entresto\u00ae)\u00a022,8\u00a0 +147\u00a0%\u00a0 5.345,1\u00a0 286,1\u00a0 63.300,4\u00a0\n\u00a0\u00a0\u00a03\u00a0Daratumumab\u00a0\n(Darzalex\u00ae)\u00a010,2\u00a0 +285\u00a0%\u00a0 18.364,7\u00a0 0,5\u00a0 885,7\u00a0\n\u00a0\u00a0\u00a04\u00a0Tenofoviralafenamid/\u00a0\nEmtricitabin\u00a0\n(Descovy\u00ae)\u00a08,5\u00a0 +113\u00a0%\u00a0 15.644,7\u00a0 48,7\u00a0 87.514,8\u00a0\n\u00a0\u00a0\u00a05\u00a0Tenofoviralafenamid\u00a0\nElvitegravir/Cobicistat/\u00a0\nEmtricitabin\u00a0\n(Genvoya\u00ae)\u00a07,2\u00a0 +35\u00a0%\u00a0 21.348,5\u00a0 38,5\u00a0 113.586,7\u00a0\n\u00a0\u00a0\u00a06\u00a0Palbociclib\u00a0\n(Ibrance\u00ae)\u00a05,3\u00a0 +>999\u00a0%\u00a0 28.696,6\u00a0 42,8\u00a0 232.198,6\u00a0\n\u00a0\u00a0\u00a07\u00a0Tenofoviralafenamid/\u00a0\nEmtricitabin/Rilpivirin\u00a0\n(Odefsey\u00ae)\u00a03,8\u00a0 +221\u00a0%\u00a0 11.930,9\u00a0 19,8\u00a0 62.239,4\u00a0\n\u00a0\u00a0\u00a08\u00a0Brivaracetam\u00a0\n(Briviact\u00ae)\u00a03,0\u00a0 +65\u00a0%\u00a0 1.077,5\u00a0 23,7\u00a0 8.347,7\u00a051\u00a0Rang\u00a0Wirkstoff\u00a0\n(Handelsname)\u00a0Techniker\u00a0Krankenkasse\u00a0 GKV\u00a0gesamt*\u00a0\nVerordnete\u00a0\nPackg.\u00a02017\u00a0\n[in\u00a0Tsd.]\u00a0Packg.\u00a0\n\u00c4nderung\u00a0\u00a0\nzum\u00a0\u00a0\nVorjahr\u00a0Umsatz\u00a0\u00a0\n2017\u00a0\n[in\u00a0Tsd.\u00a0\u20ac]\u00a0Absatz\u00a0\u00a0\n2017\u00a0\u00a0\n[in\u00a0Tsd.]\u00a0Umsatz\u00a0\u00a0\n2017\u00a0\n[in\u00a0Tsd.\u00a0\u20ac]\u00a0\n\u00a0\u00a0\u00a09\u00a0Efmoroctocog\u00a0alfa\u00a0\n(Elocta\u00ae)\u00a02,8\u00a0 +304\u00a0%\u00a0 3.758,3\u00a0 3,2\u00a0 8.198,0\u00a0\n\u00a0\u00a010\u00a0Opicapon\u00a0\n(Ongentys\u00ae)\u00a02,7\u00a0 +>999\u00a0%\u00a0 1.075,9\u00a0 19,5\u00a0 7.622,2\u00a0\n\u00a0\u00a011\u00a0Albutrepenonacog\u00a0alfa\u00a0\n(Idelvion\u00ae)\u00a02,2\u00a0 +242\u00a0%\u00a0 7.019,8\u00a0 0,8\u00a0 2.612,7\u00a0\n\u00a0\u00a012\u00a0Mepolizumab\u00a0\u00a0\n(Nucala\u00ae)\u00a01,8\u00a0 +110\u00a0%\u00a0 5.676,6\u00a0 9,5\u00a0 27.493,7\u00a0\n\u00a0\u00a013\u00a0Elotuzumab\u00a0\u00a0\n(Empliciti\u00ae)\u00a01,6\u00a0 +109\u00a0%\u00a0 2.524,1\u00a0 0,4\u00a0 643,8\u00a0\n\u00a0\u00a014\u00a0Olaratumab\u00a0\u00a0\n(Lartruvo\u00ae)\u00a01,3\u00a0 +>999\u00a0%\u00a0 2.274,4\u00a0 0,1\u00a0 101,5\u00a0\n\u00a0\u00a015\u00a0Trifluridin/Tipiracil\u00a0\n(Lonsurf\u00ae)\u00a01,1\u00a0 +337%\u00a0 3.288,5\u00a0 10,1\u00a0 28.055,1\u00a0\n\u00a0\u00a016\u00a0Elbasvir/Grazoprevir\u00a0\n(Zepatier\u00ae)\u00a00,8\u00a0 +>999\u00a0%\u00a0 9.144,1\u00a0 8,6\u00a0 100.226,6\u00a0\n\u00a0\u00a017\u00a0Pitolisant\u00a0\n(Wakix\u00ae)\u00a00,7\u00a0 +474\u00a0%\u00a0 402,8\u00a0 3,6\u00a0 1.951,5\u00a0\n\u00a0\u00a018\u00a0Velpatasvir/Sofosbuvir\u00a0\n(Epclusa\u00ae)\u00a00,7\u00a0 +48\u00a0%\u00a0 14.158,6\u00a0 9,8\u00a0 193.435,5\u00a0\n\u00a0\u00a019\u00a0Eftrenonacog\u00a0alfa\u00a0\n(Alprolix\u00ae)\u00a00,4\u00a0 +380\u00a0%\u00a0 733,1\u00a0 0,5\u00a0 2.256,1\u00a0\n\u00a0\u00a020\u00a0Selexipag\u00a0\n(Uptravi\u00ae)\u00a00,3\u00a0 +271\u00a0%\u00a0 1.788,3\u00a0 2,7\u00a0 14.190,8\u00a0\n\u00a0\u00a021\u00a0Migalastat\u00a0\n(Galafold\u00ae)\u00a00,2\u00a0 +481\u00a0%\u00a0 3.197,8\u00a0 0,9\u00a0 17.499,0\u00a0\n\u00a0\u00a022\u00a0Osimertinib\u00a0\n(Tagrisso\u00ae)\u00a00,1\u00a0 +62\u00a0%\u00a0 859,2\u00a0 0,7\u00a0 5.560,1\u00a0\n\u00a0\u00a023\u00a0Talimogen\u00a0\u00a0\nlaherparepvec\u00a0\u00a0\n(Imlygic\u00ae)\u00a00,1\u00a0 +203\u00a0%\u00a0 224,4\u00a0 0,8\u00a0 1.846,0\u00a0\n1\u201023\u00a0Gesamt\u00a0 128,5\u00a0 +169\u00a0%\u00a0 166.804,6\u00a0 880,0\u00a0 1.070.802,8\u00a0\n*GKV\u2010Zahlen\u00a0sind\u00a0nicht\u00a0vollst\u00e4ndig\u00a0abbildbar\u00a0\n\u00a0 \u00a052\u00a0Tabelle\u00a03.4:\u00a0Anzahl,\u00a0Alter\u00a0und\u00a0Geschlecht\u00a0der\u00a0Versicherten\u00a0mit\u00a0 mindestens\u00a0einer\u00a0\nVerordnung\u00a0der\u00a0neuen\u00a0Wirkstoffe\u00a0des\u00a0Jahres\u00a02016\u00a0(Daten\u00a0aus\u00a0dem\u00a0 Jahr\u00a02017)\u00a0\nWirkstoff\u00a0Anzahl\u00a0\nVersicherte\u00a0Pr\u00e4valenz\u00a0\nje\u00a0100.000\u00a0\nVersicherte\u00a0Alter\u00a0\nMittelwert\u00a0Anteil\u00a0weiblich\u00a0\nAlbutrepenonacog\u00a0alfa\u00a0 30\u00a0 0,3\u00a0 23,2\u00a0 0,00\u00a0%\u00a0\nBrivaracetam\u00a0 629\u00a0 6,3\u00a0 39,9\u00a0 50,08\u00a0%\u00a0\nDaratumumab\u00a0 260\u00a0 2,6\u00a0 68,1\u00a0 37,31\u00a0%\u00a0\nEfmoroctocog\u00a0alfa\u00a0 28\u00a0 0,3\u00a0 21,0\u00a0 7,14\u00a0%\u00a0\nEftrenonacog\u00a0alfa\u00a0 10\u00a0 0,1\u00a0 18,9\u00a0 0,00\u00a0%\u00a0\nElotuzumab\u00a0 73\u00a0 0,7\u00a0 69,7\u00a0 39,73\u00a0%\u00a0\nGrazoprevir/Elbasvir\u00a0 277\u00a0 2,8\u00a0 54,7\u00a0 47,29\u00a0%\u00a0\nHPV\u2010St\u00e4mme\u00a0 34.344\u00a0 345,8\u00a0 15,3\u00a0 99,79\u00a0%\u00a0\nMepolizumab\u00a0 422\u00a0 4,2\u00a0 54,6\u00a0 57,35\u00a0%\u00a0\nMigalastat\u00a0 16\u00a0 0,2\u00a0 45,3\u00a0 50,00\u00a0%\u00a0\nOlaratumab\u00a0 63\u00a0 0,6\u00a0 60,2\u00a0 49,21\u00a0%\u00a0\nOpicapon\u00a0 1.005\u00a0 10,1\u00a0 70,9\u00a0 33,33\u00a0%\u00a0\nOsimertinib\u00a0 46\u00a0 0,5\u00a0 63,6\u00a0 63,04\u00a0%\u00a0\nPalbociclib\u00a0 1.006\u00a0 10,1\u00a0 61,6\u00a0 99,20\u00a0%\u00a0\nPitolisant\u00a0 104\u00a0 1,0\u00a0 37,5\u00a0 56,73\u00a0%\u00a0\nSacubitril/Valsartan\u00a0 4.251\u00a0 42,8\u00a0 69,5\u00a0 19,74\u00a0%\u00a0\nSelexipag\u00a0 38\u00a0 0,4\u00a0 53,6\u00a0 65,79\u00a0%\u00a0\nTalimogen\u00a0\nlaherparepvec\u00a015\u00a0 0,2\u00a0 64,5\u00a0 86,67\u00a0%\u00a0\nTAF/Elvitegravir/\u00a0\nCobicistat/Emtricitabin\u00a01.870\u00a0 18,8\u00a0 43,7\u00a0 10,32\u00a0%\u00a0\nTAF/Emtricitabin\u00a0 2.265\u00a0 22,8\u00a0 46,7\u00a0 13,64\u00a0%\u00a0\nTAF/Emtricitabin/\u00a0\nRilpivirin\u00a01.019\u00a0 10,3\u00a0 43,9\u00a0 12,56\u00a0%\u00a0\nTrifluridin/Tipiracil\u00a0 246\u00a0 2,5\u00a0 65,2\u00a0 36,99\u00a0%\u00a0\nVelpatasvir/Sofosbuvir\u00a0 270\u00a0 2,7\u00a0 50,2\u00a0 38,15\u00a0%\u00a0\nGesamt\u00a0 48.287*\u00a0 484,0\u00a0 27,2\u00a0 79,49\u00a0%\u00a0\n*Mehrfachz\u00e4hlung\u00a0von\u00a0Versicherten\u00a0mit\u00a0Verordnung\u00a0in\u00a02017\u00a0(Einfa chz\u00e4hlung:\u00a0n\u00a0=\u00a048.075\u00a0in\u00a02017)\u00a053\u00a0Abbildung\u00a03.2:\u00a0Verordnungspr\u00e4valenz\u00a0neuer\u00a0Wirkstoffe\u00a0des\u00a0Jahres \u00a02016\u00a0in\u00a0\nPromille\u00a0nach\u00a0Bundesl\u00e4ndern\u00a0(Ve rordnungen\u00a0im\u00a0Jahr\u00a02017),\u00a0TK\u2010Ver sicherte\u00a0\n\u00a0\n54\u00a0Quellen\u00a0\na\u2010t\u00a0\u2013\u00a0arznei\u2010telegramm\u00a0(2019).\u00a0ht tps://www.arznei \u2010telegramm.de/ db/01pin.php3,\u00a0letzter\u00a0Zugriff:\u00a011.04.19.\u00a0\nLudwig\u00a0W\u2010D,\u00a0Schuler\u00a0J\u00a0(2019).\u00a0AMB\u00a0\u2013\u00a0Der\u00a0Arzneimittelbrief.\u00a0Berl in.\u00a0Westkreuz\u2010Verlag.\u00a0\nPZ\u00a0\u2013\u00a0Pharmazeutische\u00a0Zeitung\u00a0online\u00a0(2016).\u00a0Arzneistoffe\u00a0Jahrga ng\u00a02016.\u00a0https://www.pharmazeutische\u2010\nzeitung.de/arzneistoffe/arzneistoff\u2010jahrgang/jahr/2016/,\u00a0letzte r\u00a0Zugriff:\u00a011.04.19.\u00a0\nSchwabe\u00a0U,\u00a0Paffrath\u00a0D\u00a0(2016).\u00a0Arzneiverordnungs\u2010Report\u00a02016.\u00a0Be rlin,\u00a0Heidelberg:\u00a0Springer.\u00a0\nSchwabe\u00a0U,\u00a0Paffrath\u00a0D,\u00a0Ludwig\u00a0W\u2010D,\u00a0Klauber\u00a0J\u00a0(2017).\u00a0Arzneivero rdnungs\u2010Report\u00a02017.\u00a0Berlin,\u00a0Heidelberg:\u00a0Springer.\u00a0\n\u00a0\n\u00a0 \u00a055\u00a04 Bewertungen\u00a0der\u00a0neuen\u00a0Wirkstoffe\u00a0\n Albutrepenonacog\u00a0alfa\u00a04.1\nHandelsname:\u00a0Idelvion\u00ae\u00a0 \u00a0 \u00a0 Pharmazeutischer\u00a0Unternehmer:\u00a0\u00a0\nIndikation:\u00a0H\u00e4mophilie\u00a0B\u00a0 \u00a0 \u00a0 CSL\u00a0Behring\u00a0\nATC\u2010Code:\u00a0B02BD33\u00a0 \u00a0 \u00a0 Markteinf\u00fchrung:\u00a0Juni\u00a02016\u00a0\nDarreichungsform:\u00a0Pulve r\u00a0und\u00a0L\u00f6sungsmittel\u00a0\u00a0\nzur\u00a0Herstellung\u00a0einer\u00a0Injektionssuspension\u00a0 DDD:\u00a0400\u00a0E\u00a0P\u00a0 \u00a0 \u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 \u00a0\u00a0\u00a0O,\u25bc\u00a0\nBewertung \u00a0\nAlbutrepenonacog\u00a0 alfa\u00a0 (Idelvion\u00ae) \u00a0 wurde\u00a0 im\u00a0 Mai\u00a0 2016\u00a0 von\u00a0 der\u00a0 Eur op\u00e4ischen\u00a0\nKommission\u00a0zentral\u00a0als\u00a0 Orphan\u2010Arzneimittel\u00a0f\u00fcr\u00a0die\u00a0Behandlung\u00a0von\u00a0Patienten\u00a0mit\u00a0\nH\u00e4mophilie\u00a0 B\u00a0 zugelassen.\u00a0 Der\u00a0 Wirkstoff\u00a0 ist\u00a0 ein\u00a0 weiterer\u00a0rekombi nanter\u00a0 Gerin\u2010\nnungsfaktor\u00a0IX,\u00a0dessen\u00a0Halbwertzeit\u00a0durch\u00a0Fusion\u00a0mit\u00a0rekombinan tem\u00a0Albumin\u00a0\nverl\u00e4ngert\u00a0wurde.\u00a0Daten\u00a0f\u00fcr\u00a0Wirk samkeit\u00a0und\u00a0Sicherheit\u00a0bei\u00a0zuvo r\u00a0unbehandelten\u00a0\nPatienten\u00a0sowie\u00a0bei\u00a0\u00e4lteren\u00a0Mens chen\u00a0ab\u00a065\u00a0Jahren\u00a0liegen\u00a0bisher \u00a0nicht\u00a0vor.\u00a0\nDas\u00a0Pr\u00e4parat\u00a0steht\u00a0als\u00a0Lyophilisat\u00a0in\u00a0verschiedenen\u00a0Dosierungen \u00a0zur\u00a0Verf\u00fcgung,\u00a0\ndas\u00a0vor\u00a0der\u00a0langsamen\u00a0intraven\u00f6s en\u00a0Injektion\u00a0mit\u00a0Wasser\u00a0f\u00fcr\u00a0Inj ektionszwecke\u00a0\nrekonstituiert\u00a0werden\u00a0muss.\u00a0Die\u00a0Dosis\u00a0und\u00a0die\u00a0Dosierungsinterva lle\u00a0richten\u00a0sich\u00a0\nnach\u00a0dem\u00a0Schweregrad\u00a0des\u00a0Faktor\u2010IX\u2010Mangels,\u00a0dem\u00a0Ort\u00a0und\u00a0Ausma\u00df\u00a0 der\u00a0Blutung,\u00a0\ndem\u00a0klinischen\u00a0Zustand\u00a0und\u00a0Alter\u00a0des\u00a0Patienten\u00a0sowie\u00a0weiteren\u00a0p atientenindivi\u2010\nduellen\u00a0Charakteristika\u00a0im\u00a0Hinblick\u00a0auf\u00a0die\u00a0Pharmakokinetik.\u00a0Di e\u00a0Fachinformation\u00a0\nenth\u00e4lt\u00a0eine\u00a0detaillierte\u00a0Anleitung,\u00a0wie\u00a0sich\u00a0die\u00a0notwendigen\u00a0D osen\u00a0f\u00fcr\u00a0die\u00a0Be\u2010\ndarfsbehandlung\u00a0berechnen\u00a0lassen.\u00a0Die\u00a0\u00fcbliche\u00a0Dosierung\u00a0f\u00fcr\u00a0die \u00a0Prophylaxe\u00a0liegt\u00a0\nbei\u00a035\u00a0bis\u00a050\u00a0I.E./kg\u00a0KG\u00a0einmal\u00a0w\u00f6chentlich.\u00a0Eine\u00a0individuelle\u00a0 Anpassung\u00a0der\u00a0Dosen\u00a0\nund\u00a0Dosierungsintervalle\u00a0ist\u00a0jewe ils\u00a0erforderlich\u00a0(Fachinformat ion\u00a0Idelvion\u00ae,\u00a02019).\u00a0\nDer\u00a0Zulassung\u00a0liegen\u00a0drei\u00a0pivotale,\u00a0offene\u00a0Studien\u00a0zugrunde\u00a0(EM A,\u00a02016).\u00a0Dem\u00a0\nKrankheitsbild\u00a0 entsprechend\u00a0 wurden\u00a0 jeweils\u00a0 nur\u00a0 m\u00e4nnliche\u00a0 Teilne hmer\u00a0 einge\u2010\nschlossen.\u00a0Zu\u00a0den\u00a0Einschlusskriterien\u00a0geh\u00f6rte\u00a0eine\u00a0schwere\u00a0H\u00e4mo philie\u00a0B\u00a0mit\u00a0einer\u00a0\nFaktor\u2010IX\u2010Aktivit\u00e4t\u00a0\u2264\u00a02\u00a0%,\u00a0die\u00a0T eilnehmer\u00a0mussten\u00a0bereits\u00a0vorhe r\u00a0Faktor\u2010IX\u2010Pr\u00e4pa\u2010\nrate\u00a0erhalten\u00a0haben\u00a0und\u00a0durften\u00a0k eine\u00a0Inhibitoren\u00a0gegen\u00a0Faktor\u00a0 IX\u00a0aufweisen.\u00a0\u00a0\nDie\u00a017\u00a0Teilnehmer\u00a0zwischen\u00a013\u00a0und\u00a046\u00a0Jahren\u00a0in\u00a0der\u00a0Phase\u00a0I/II\u2010S tudie\u00a0\u201eStudy\u00a02004\u201c\u00a0\n(Martinowitz\u00a0et\u00a0al.,\u00a02015)\u00a0wurden\u00a0je\u00a0nach\u00a0Vorbehandlung\u00a0dem\u00a0Pro phylaxe\u2010Arm\u00a0\n(n\u00a0=\u00a013,\u00a0einmal\u00a0w\u00f6chentlich\u00a015\u00a0bis\u00a035\u00a0I.E./kg\u00a0KG\u00a0mit\u00a0individuel ler\u00a0Dosisanpassung,\u00a0\nBehandlung\u00a0\u00fcber\u00a0neun\u00a0bis\u00a0elf\u00a0Monate)\u00a0oder\u00a0dem\u00a0 On\u2010demand \u2010Arm\u00a0der\u00a0Studie\u00a0\n(individuelle\u00a0Dosis,\u00a0mindestens\u00a025\u00a0I.E./kg\u00a0KG,\u00a0\u00fcber\u00a0vier\u00a0bis\u00a0se chs\u00a0Monate)\u00a0zugeord\u2010\nnet.\u00a0Im\u00a0Prophylaxe\u2010Arm\u00a0lag\u00a0die\u00a0annualisierte\u00a0Blutungsrate\u00a0nach\u00a0 einer\u00a0Behand\u201056\u00a0lungsdauer\u00a0von\u00a0neun\u00a0bis\u00a0elf\u00a0Monaten\u00a0im\u00a0arithmetischen\u00a0Mittel\u00a0be i\u00a01,25,\u00a0im\u00a0Medi\u2010\nan\u00a0bei\u00a01,13.\u00a0In\u00a0beiden\u00a0Studienarmen\u00a0traten\u00a0insgesamt\u00a085\u00a0Blutung sepisoden\u00a0auf,\u00a0\nvon\u00a0denen\u00a089,4\u00a0%\u00a0mit\u00a0einer\u00a0Dosis \u00a0und\u00a010,6\u00a0%\u00a0mit\u00a0zwei\u00a0Dosen\u00a0erfo lgreich\u00a0behandelt\u00a0\nwurden.\u00a0Das\u00a0Ansprechen\u00a0wurde\u00a0in\u00a062,4\u00a0%\u00a0der\u00a0F\u00e4lle\u00a0als\u00a0ausgezeich net,\u00a0in\u00a034,1\u00a0%\u00a0als\u00a0\ngut\u00a0bewertet.\u00a0\nAn\u00a0der\u00a0Phase\u00a0II/III\u2010Studie\u00a0\u201eStudy\u00a03001\u201c\u00a0(Santagostino\u00a0et\u00a0al.,\u00a02 016)\u00a0nahmen\u00a0insge\u2010\nsamt\u00a063\u00a0Patienten\u00a0zwischen\u00a012\u00a0und\u00a061\u00a0Jahren\u00a0teil,\u00a0sieben\u00a0von\u00a0ih nen\u00a0waren\u00a0unter\u00a0\n18\u00a0Jahre\u00a0alt.\u00a0Je\u00a0nach\u00a0Vorbehandlung\u00a0wurden\u00a0sie\u00a0entweder\u00a0dem\u00a0Pro phylaxe\u2010Arm\u00a0\n(n\u00a0=\u00a040)\u00a0oder\u00a0dem\u00a0 on\u2010demand \u2010Arm\u00a0(n\u00a0=\u00a023)\u00a0zugeteilt.\u00a0\nIm\u00a0Prophylaxe\u2010Arm\u00a0erhielten\u00a040\u00a0Teilnehmer\u00a026\u00a0Wochen\u00a0lang\u00a0einmal \u00a0w\u00f6chentlich\u00a0\neine\u00a0Dosis\u00a0von\u00a035\u00a0bis\u00a050\u00a0I.E./kg\u00a0KG,\u00a0die\u00a0individuell\u00a0angepasst\u00a0 werden\u00a0konnte.\u00a0Danach\u00a0\nhatten\u00a0Patienten,\u00a0die\u00a0bestimmte\u00a0 Kriterien\u00a0erf\u00fcllten,\u00a0die\u00a0M\u00f6glic hkeit,\u00a0die\u00a0Dosisin\u2010\ntervalle\u00a0auf\u00a0alle\u00a0zehn\u00a0Tage\u00a0(n\u00a0=\u00a07)\u00a0bzw.\u00a0alle\u00a014\u00a0Tage\u00a0(n\u00a0=\u00a021)\u00a0 zu\u00a0verl\u00e4ngern.\u00a0Die\u00a0\nannualisierte\u00a0Blutungsrate\u00a0in\u00a0die sem\u00a0Studienarm\u00a0lag\u00a0bei\u00a0einem\u00a0D osierungsintervall\u00a0\nvon\u00a0sieben\u00a0Tagen\u00a0im\u00a0Mittel\u00a0bei\u00a01,24\u00a0(Median\u00a00),\u00a0bei\u00a0einem\u00a0Absta nd\u00a0von\u00a0zehn\u00a0Ta\u2010\ngen\u00a0im\u00a0Mittel\u00a0bei\u00a00,82\u00a0(Median\u00a00)\u00a0und\u00a0bei\u00a0einem\u00a0Abstand\u00a0von\u00a014\u00a0 Tagen\u00a0im\u00a0Mittel\u00a0\nbei\u00a01,96\u00a0(Median\u00a01,08).\u00a0Im\u00a0 on\u2010demand \u2010Arm\u00a0erhielten\u00a0die\u00a023\u00a0Teilnehmer\u00a026\u00a0Wo\u2010\nchen\u00a0lang\u00a0bei\u00a0Bedarf\u00a035\u00a0bis\u00a050\u00a0I.E./kg\u00a0KG.\u00a0Danach\u00a0wechselten\u00a0si e\u00a0zu\u00a0einer\u00a0prophy\u2010\nlaktischen\u00a0Behandlung,\u00a0bei\u00a0der\u00a0sie\u00a026\u00a0Wochen\u00a0lang\u00a0einmal\u00a0w\u00f6chen tlich\u00a0mit\u00a035\u00a0bis\u00a0\n50\u00a0I.E./kg\u00a0KG\u00a0behandelt\u00a0wurden.\u00a0W\u00e4hrend\u00a0der\u00a0 on\u2010demand \u2010Phase\u00a0lag\u00a0die\u00a0annuali\u2010\nsierte\u00a0Blutungsrate\u00a0in\u00a0diesem\u00a0Studienarm\u00a0im\u00a0Median\u00a0bei\u00a020,28,\u00a0n ach\u00a0dem\u00a0Wechsel\u00a0\nauf\u00a0die\u00a0prophylaktische\u00a0Behandlung\u00a0im\u00a0Median\u00a0bei\u00a02,87.\u00a0\u00a0\nInsgesamt\u00a0traten\u00a0in\u00a0der\u00a0Studie\u00a0358\u00a0behandlungsbed\u00fcrftige\u00a0Blutun gsepisoden\u00a0auf.\u00a0\n93,6\u00a0%\u00a0konnten\u00a0mit\u00a0einer\u00a0Einzeldosis\u00a0von\u00a0Albutrepenonacog\u00a0alfa\u00a0 behandelt\u00a0wer\u2010\nden.\u00a0Der\u00a0Erfolg\u00a0der\u00a0Behandlung\u00a0wurde\u00a0bei\u00a083,0\u00a0%\u00a0der\u00a0Blutungsepi soden\u00a0mit\u00a0ausge\u2010\nzeichnet,\u00a0bei\u00a011,2\u00a0%\u00a0mit\u00a0gut\u00a0bewertet.\u00a0\nAn\u00a0der\u00a0Phase\u2010III\u2010Studie\u00a0\u201eStudy\u00a03002\u201c\u00a0(Kenet\u00a0et\u00a0al.,\u00a02016)\u00a0nahme n\u00a027\u00a0Jungen\u00a0unter\u00a0\nzw\u00f6lf\u00a0Jahren\u00a0teil,\u00a0davon\u00a0waren\u00a0zw\u00f6lf\u00a0j\u00fcnger\u00a0als\u00a0sechs\u00a0Jahre.\u00a0Di e\u00a0Teilnehmer\u00a0erhiel\u2010\nten\u00a0f\u00fcr\u00a0insgesamt\u00a0zw\u00f6lf\u00a0Monate\u00a0einmal\u00a0w\u00f6chentlich\u00a0eine\u00a0prophyla ktische\u00a0Gabe\u00a0\nvon\u00a035\u00a0bis\u00a050\u00a0I.E./kg\u00a0KG,\u00a0zus\u00e4tzlich\u00a0war\u00a0eine\u00a0 on\u2010demand \u2010Behandlung\u00a0in\u00a0der\u00a0glei\u2010\nchen\u00a0Dosierung\u00a0m\u00f6glich.\u00a0Alle\u00a0Dosierungsschemata\u00a0konnten\u00a0je\u00a0nach \u00a0Ansprechen\u00a0\nindividuell\u00a0angepasst\u00a0werden.\u00a0\nDie\u00a0annualisierte\u00a0Blutungsrate\u00a0lag\u00a0im\u00a0Median\u00a0bei\u00a03,12\u00a0(arithmet isches\u00a0Mittel\u00a03,78).\u00a0\nInsgesamt\u00a0traten\u00a0106\u00a0behandlungsbed\u00fcrftige\u00a0Blutungsepisoden\u00a0auf ,\u00a0von\u00a0denen\u00a0\n88,7\u00a0%\u00a0erfolgreich\u00a0mit\u00a0nur\u00a0einer\u00a0Gabe\u00a0behandelt\u00a0werden\u00a0konnten. \u00a0Der\u00a0Behand\u2010\nlungserfolg\u00a0wurde\u00a0bei\u00a075\u00a0%\u00a0der\u00a0F\u00e4lle\u00a0als\u00a0ausgezeichnet,\u00a0bei\u00a021, 2\u00a0%\u00a0als\u00a0gut\u00a0einge\u2010\nstuft.\u00a057\u00a0Eine\u00a0noch\u00a0laufende\u00a0Unterstudie\u00a0untersucht\u00a0die\u00a0Wirksamkeit\u00a0von\u00a0A lbutrepenona\u2010\ncog\u00a0alfa\u00a0bei\u00a0chirurgischen\u00a0Patie nten.\u00a0Eine\u00a0Publikation\u00a0(N\u00e9grier \u00a0et\u00a0al.,\u00a02016)\u00a0berich\u2010\ntet\u00a0die\u00a0Ergebnisse\u00a0aus\u00a021\u00a0operat iven\u00a0Eingriffen\u00a0an\u00a019\u00a0Teilnehme rn,\u00a0die\u00a0perioperativ\u00a0\nnach\u00a0den\u00a0Empfehlungen\u00a0der\u00a0 World\u00a0Federation\u00a0of\u00a0Hemophilia \u00a0mit\u00a0Albutrepenona\u2010\ncog\u00a0alfa\u00a0behandelt\u00a0wurden.\u00a0Bei\u00a017\u00a0Eingriffen\u00a0wurde\u00a0das\u00a0Ansprech en\u00a0auf\u00a0die\u00a0Be\u2010\nhandlung\u00a0als\u00a0ausgezeichnet\u00a0(h\u00f6chstens\u00a020\u00a0%\u00a0mehr\u00a0Blutverlust\u00a0als \u00a0vorherzusehen),\u00a0\nbei\u00a0vier\u00a0Eingriffen\u00a0als\u00a0gut\u00a0(zwischen\u00a020\u00a0und\u00a030\u00a0%\u00a0mehr\u00a0Blutverl ust\u00a0als\u00a0vorherzuse\u2010\nhen)\u00a0bewertet.\u00a0\u00a0\nIn\u00a0den\u00a0Zulassungsstudien\u00a0berichteten\u00a0acht\u00a0von\u00a0107\u00a0mit\u00a0Albutrepe nonacog\u00a0alfa\u00a0\nbehandelten\u00a0 Patienten\u00a0 \u00fcber\u00a0 Nebenwirkungen\u00a0 wie\u00a0 Kopfschmerzen,\u00a0 Sc hwindel,\u00a0\nR\u00f6tungen\u00a0oder\u00a0H\u00e4matome\u00a0an\u00a0der\u00a0In jektionsstelle,\u00a0Ausschlag,\u00a0Vers topfung\u00a0und\u00a0\nInjektionsreaktionen.\u00a0Die\u00a0Bildung\u00a0von\u00a0hemmenden\u00a0Antik\u00f6rpern,\u00a0Th romboembo\u2010\nlien\u00a0oder\u00a0renale\u00a0Komplikationen\u00a0traten\u00a0nicht\u00a0auf.\u00a0\u00a0\nHinsichtlich\u00a0Nutzen\u00a0und\u00a0Schaden\u00a0fehlen\u00a0Daten\u00a0zu\u00a0bisher\u00a0mit\u00a0Fakt or\u2010IX\u2010Produkten\u00a0\nunbehandelten\u00a0Patienten\u00a0sowie\u00a0f\u00fcr\u00a0Patienten\u00a0ab\u00a065\u00a0Jahre\u00a0(EMA,\u00a02 016).\u00a0\nF\u00fcr\u00a0Arzneimittel\u00a0zur\u00a0Behandlung\u00a0eines\u00a0seltenen\u00a0Leidens\u00a0gilt\u00a0der \u00a0medizinische\u00a0Zu\u2010\nsatznutzen\u00a0durch\u00a0die\u00a0Zulassung\u00a0als\u00a0belegt,\u00a0lediglich\u00a0das\u00a0Ausma\u00df \u00a0des\u00a0Zusatznutzens\u00a0\nist\u00a0durch\u00a0den\u00a0pU\u00a0nachzuweisen.\u00a0Auf\u00a0der\u00a0Basis\u00a0der\u00a0drei\u00a0pivotalen \u00a0Zulassungsstudien\u00a0\nsowie\u00a0der\u00a0Zwischenergebnisse\u00a0einer\u00a0noch\u00a0laufenden\u00a0Studie\u00a0kam\u00a0de r\u00a0G\u2010BA\u00a0im\u00a0De\u2010\nzember\u00a02016\u00a0zu\u00a0dem\u00a0Schluss,\u00a0dass\u00a0der\u00a0 Zusatznutzen \u00a0f\u00fcr\u00a0Albutrepenonacog\u00a0alfa\u00a0\nnicht\u00a0quantifizierbar \u00a0ist.\u00a0Tragender\u00a0Grund\u00a0daf\u00fcr:\u00a0In\u00a0keiner\u00a0der\u00a0Studien\u00a0erfolgte\u00a0ein \u00a0\ndirekter\u00a0Vergleich\u00a0gegen\u00fcber\u00a0ein em\u00a0Arzneimittel,\u00a0das\u00a0den\u00a0derzei tigen\u00a0Behand\u2010\nlungsstandard\u00a0bei\u00a0H\u00e4mophilie\u00a0B\u00a0darstellt\u00a0(z.B.\u00a0rekombinanter\u00a0od er\u00a0aus\u00a0humanem\u00a0\nPlasma\u00a0gewonnener\u00a0Faktor\u00a0IX).\u00a0Der\u00a0durch\u00a0den\u00a0pU\u00a0vorgelegte\u00a0indir ekte\u00a0Vergleich\u00a0\nwies\u00a0nach\u00a0Einsch\u00e4tzung\u00a0des\u00a0G\u2010BA\u00a0aufgrund\u00a0methodischer\u00a0Schw\u00e4chen \u00a0ein\u00a0hohes\u00a0\nVerzerrungspotential\u00a0auf\u00a0und\u00a0war\u00a0deshalb\u00a0nicht\u00a0geeignet,\u00a0um\u00a0bel astbare\u00a0Aussagen\u00a0\ndaraus\u00a0abzuleiten\u00a0(G\u2010BA,\u00a02016).\u00a0\u00a0\nVerf\u00fcgbare\u00a0Therapien \u00a0 (Zusatz\u2010)Nutzen \u00a0 Kosten\u00a0\n\u00a0\nweiteres\u00a0rekombinantes\u00a0\nFaktor\u2010IX\u2010Pr\u00e4parat\u00a0\u00a0Zusatznutzen\u00a0wegen\u00a0\nOrphan\u2010Status\u00a0anerkannt,\u00a0\naber\u00a0nicht\u00a0quantifizierbar\u00a0\u00a0\nkein\u00a0Preisvergleich,\u00a0da\u00a0\nOrphan\u2010Arzneimittel\u00a0\nErl\u00e4uterung\u00a0der\u00a0Farben:\u00a0Verf\u00fcgbare\u00a0Therapien:\u00a0rot\u00a0=\u00a0weitere\u00a0The rapieoption,\u00a0gelb\u00a0=\u00a0Subgruppen\u2010Novit\u00e4t,\u00a0gr\u00fcn\u00a0=\u00a0Solist;\u00a0(Zusatz\u2010 )\u00a0\nNutzen:\u00a0rot\u00a0=\u00a0keine\u00a0Verbesserung\u00a0oder\u00a0schlechte\u00a0Nutzen/Schaden\u2010 Relation,\u00a0gelb\u00a0=\u00a0teilweise\u00a0Verbesserungen,\u00a0gr\u00fcn\u00a0=\u00a0Verbesserung\u00a0\nharter\u00a0Endpunkte;\u00a0Kosten:\u00a0rot\u00a0=\u00a0teurer\u00a0als\u00a0bestehende\u00a0Therapien ,\u00a0gelb\u00a0=\u00a0ungef\u00e4hr\u00a0gleich\u00a0bzw.\u00a0teils/teils,\u00a0gr\u00fcn\u00a0=\u00a0g\u00fcnstiger\u00a0als \u00a0\nbestehende\u00a0Therapien\u00a0\n58\u00a0Wie\u00a0bewerten\u00a0andere?\u00a0\nBewertung\u00a0nach\u00a0\nFricke\u00a0et\u00a0al.\u00a0a\u2010t\u2010Bewertung\u00a0 AMB\u00a0 Prescrire\u00a0 PZ\u00a0\nC\u00a0 \u2013\u00a0 \u2013\u00a0 \u2013\u00a0 Schrittinnovation\u00a0\nKosten\u00a0\nWirkstoff\u00a0 Behandlungsmodus\u00a0 Behandlungstage\u00a0 Jahrestherapiekosten\u00a0\nzu\u00a0bewertendes\u00a0Arzneimittel \u00a0\u00a0 \u00a0 \u00a0\nAlbutrepenonacog\u00a0alfa\u00a0 35\u00a0\u2013\u00a075\u00a0I.E./kg\u00a0KG\u00a0\u00a0\nalle\u00a07\u00a0\u2013\u00a014\u00a0Tage\u00a026\u00a0\u2013\u00a052\u00a0 92.820,00\u00a0\u2013\u00a0572.390,00\u00a0\u20ac*\u00a0\n*\u00a0Berechnung\u00a0f\u00fcr\u00a0Kleinkinder\u00a0bis\u00a0Erwachsene,\u00a0K\u00f6rpergewicht\u00a0f\u00fcr\u00a0 m\u00e4nnliche\u00a0Patienten\u00a0nach\u00a0Mikrozensus\u00a02013.\u00a0Ber\u00fccksichtigung\u00a0\nvon\u00a0Verwurf\u00a0je\u00a0Applikation.\u00a0Berechnung\u00a0anhand\u00a0Herstellerabgabep reis\u00a0plus\u00a0Umsatzsteuer\u00a0bei\u00a0Direktbezug\u00a0gem\u00e4\u00df\u00a0AMG\u00a0\u00a7\u00a047\u00a0(1)\u00a02a)\u00a0\nbzw.\u00a0BSG\u2010Urteil\u00a0Az:\u00a0B6KA\u00a018/14\u00a0R\u00a0f\u00fcr\u00a0die\u00a0Langzeitprophylaxe.\u00a0\nVersorgungsanalysen\u00a0\nSeit\u00a0der\u00a0Markteinf\u00fchrung\u00a0im\u00a0Juni\u00a02016\u00a0nehmen\u00a0die\u00a0verordneten\u00a0DD D\u00a0und\u00a0parallel\u00a0\nder\u00a0Bruttoumsatz\u00a0kontinuierlich\u00a0zu.\u00a0Zeitgleich\u00a0mit\u00a0dem\u00a0G\u2010BA\u2010Bes chluss\u00a0zur\u00a0fr\u00fchen\u00a0\nNutzenbewertung\u00a0im\u00a0Dezember\u00a02016\u00a0brechen\u00a0beide\u00a0Werte\u00a0kurz\u00a0ein\u00a0u nd\u00a0bleiben\u00a0\nzun\u00e4chst\u00a0auf\u00a0einem\u00a0niedrigeren\u00a0Niveau.\u00a0Ab\u00a0Mitte\u00a02017\u00a0sind\u00a0jedoc h\u00a0wieder\u00a0die\u00a0\nZahlen\u00a0vor\u00a0der\u00a0G\u2010BA\u2010Ver\u00f6ffentlic hung\u00a0erreicht\u00a0und\u00a0nehmen\u00a0seitde m\u00a0wieder\u00a0zu.\u00a0Am\u00a0\nEnde\u00a0des\u00a0betrachteten\u00a0Zeitraums\u00a0werden\u00a0800\u00a0DDD\u00a0verordnet,\u00a0der\u00a0z ugeh\u00f6rige\u00a0\nBruttoumsatz\u00a0liegt\u00a0bei\u00a0knapp\u00a0800.000\u00a0\u20ac\u00a0im\u00a0letzten\u00a0dokumentierte n\u00a0Monat.\u00a0\u00a0\n\u00a0 \u00a059\u00a0Abbildung\u00a04.1:\u00a0Verordnete\u00a0Tagesdosen\u00a0(DDD)\u00a0und\u00a0Bruttoums\u00e4tze\u00a0vo n\u00a0\u00a0\nAlbutrepenonacog\u00a0alfa\u00a0nach\u00a0Monaten\u00a0(2016\u00a0\u2013\u00a02017)\u00a0\n\u00a0\n\u00a0\nQuellen\u00a0\nAHCDO\u00a0\u2013\u00a0Australian\u00a0Haem ophilia\u00a0Centre\u00a0Directors\u2019\u00a0Organisation\u00a0( 2016).\u00a0Guidelines\u00a0for\u00a0the\u00a0management\u00a0of\u00a0haemophilia\u00a0in\u00a0\nAustralia\u00a0|\u00a0National\u00a0Blood\u00a0Authority.\u00a0https://www.blood.gov.au/ haemophilia\u2010guidelines,\u00a0letzter\u00a0Zugriff:\u00a010.07.2019.\u00a0\nB\u00c4K\u00a0\u2013\u00a0Bundes\u00e4rztekammer\u00a0(2014).\u00a0Querschnitts\u2010Leitlinien\u00a0zur\u00a0The rapie\u00a0mit\u00a0Blutkomponenten\u00a0und\u00a0Plasmaderivaten.\u00a0\nwww.bundesaerztekammer.de/aerzte/medizin\u2010ethik/wissenschaftlich er\u2010\nbeirat/veroeffentlichungen/haemotherapie\u2010transfusionsmedizin/qu erschnitt\u2010leitlinie/,\u00a0letzter\u00a0Zugriff:\u00a010.07.2019.\u00a0\nEMA\u00a0\u2013\u00a0European\u00a0medicines\u00a0agency\u00a0 (2016).\u00a0EPAR\u00a0(Public\u00a0Assessment \u00a0Report):\u00a0Idelvion.\u00a0\nhttps://www.ema.europa.eu/en/medicines/human/EPAR/idelvion,\u00a0let zter\u00a0Zugriff:\u00a010.07.2019.\u00a0\nFachinformation\u00a0Idelvion\u00ae\u00a0(2019) .\u00a0Fachinformation\u00a0Idelvion\u00ae.\u00a0St and\u00a0der\u00a0Information:\u00a0Januar\u00a02019.\u00a0\nhttps://www.ema.europa.eu/documents/product\u2010information/idelvio n\u2010epar\u2010product\u2010information_en.pdf,\u00a0letzter\u00a0\nZugriff:\u00a010.07.2019.\u00a0\nFricke\u00a0U,\u00a0Hein\u00a0L,\u00a0Schwabe\u00a0U\u00a0(2017).\u00a0Neue\u00a0Arzneimittel\u00a02016.\u00a0In: \u00a0Schwabe\u00a0U,\u00a0Paffrath\u00a0D,\u00a0Ludwig\u00a0W\u2010D,\u00a0Klauber\u00a0J\u00a0(Hrsg.)\u00a0(2017).\u00a0\nArzneiverordnungs\u2010Report\u00a02017.\u00a0Berlin,\u00a0Heidelberg.\u00a0Springer:\u00a055 \u2010135.\u00a0\nG\u2010BA\u00a0\u2013\u00a0Gemeinsamer\u00a0Bundesausschuss\u00a0(2016).\u00a0Nutzenbewertungsverf ahren\u00a0zum\u00a0Wirkstoff\u00a0Albutrepenonacog\u00a0alfa.\u00a0https://www.g\u2010\nba.de/informationen/nutzenbewertung/236/,\u00a0letzter\u00a0Zugriff:\u00a010.0 7.2019.\u00a0\n60\u00a0IQWiG\u00a0\u2013\u00a0Institut\u00a0f\u00fcr\u00a0Qualit\u00e4t\u00a0und\u00a0Wirtschaftlichkeit\u00a0im\u00a0Gesundh eitswesen\u00a0(2015).\u00a0[A13\u201007]\u00a0Therapie\u00a0von\u00a0H\u00e4mophilie\u2010Patienten\u00a0\u2010\u00a0\nRapid\u00a0Report.\u00a0https://www.iqwig.de/de/projekte\u2010ergebnisse/proje kte/arzneimittelbewertung/2013/a13\u201007\u2010\ntherapie\u2010von\u2010haemophilie\u2010patienten\u2010rapid\u2010report.3253.html,\u00a0letz ter\u00a0Zugriff:\u00a010.07.2019.\u00a0\nKenet\u00a0G,\u00a0Chambost\u00a0H,\u00a0Male\u00a0C,\u00a0Lambert\u00a0T,\u00a0Halimeh\u00a0S,\u00a0Chernova\u00a0T\u00a0e t\u00a0al.\u00a0(2016).\u00a0Long\u2010acting\u00a0recomb inant\u00a0fusion\u00a0protein\u00a0linking\u00a0\ncoagulation\u00a0factor\u00a0IX\u00a0with\u00a0albumin\u00a0(rIX\u2010FP)\u00a0in\u00a0children.\u00a0Thromb osis\u00a0and\u00a0Haemostasis\u00a0116(10):\u00a0659\u2013668.\u00a0\u00a0\nMartinowitz\u00a0U,\u00a0Lissitchkov\u00a0T,\u00a0Lubetsky\u00a0A,\u00a0Jotov\u00a0G,\u00a0Barazani\u2010Bru tman\u00a0T,\u00a0Voigt\u00a0C\u00a0et\u00a0al.\u00a0(2015).\u00a0Results\u00a0of\u00a0a\u00a0phase\u00a0I/II\u00a0open\u2010lab el,\u00a0\nsafety\u00a0and\u00a0efficacy\u00a0trial\u00a0of\u00a0coagulation\u00a0factor\u00a0IX\u00a0(recombinant ),\u00a0albumin\u00a0fusion\u00a0protein\u00a0in\u00a0haemophilia\u00a0B\u00a0patients.\u00a0\nHaemophilia\u00a021(6):\u00a0784\u2013790.\u00a0\u00a0\nN\u00e9grier\u00a0C,\u00a0Abdul\u00a0Karim\u00a0F,\u00a0Lepatan\u00a0LM,\u00a0Lienhart\u00a0A,\u00a0L\u00f3pez\u2010Fern\u00e1nd ez\u00a0MF,\u00a0Mahlangu\u00a0J\u00a0et\u00a0al.\u00a0(2016).\u00a0Efficacy\u00a0and\u00a0safety\u00a0of\u00a0long\u2010ac ting\u00a0\nrecombinant\u00a0fusion\u00a0protein\u00a0linking\u00a0factor\u00a0IX\u00a0with\u00a0albumin\u00a0in\u00a0ha emophilia\u00a0B\u00a0patients\u00a0undergoing\u00a0surgery.\u00a0\nHaemophilia\u00a022\u00a0(4):\u00a0e259\u2013e266.\u00a0\nPeyvandi\u00a0F,\u00a0Garagiola\u00a0I,\u00a0Young\u00a0G\u00a0(2016).\u00a0The\u00a0past\u00a0and\u00a0future\u00a0of \u00a0haemophilia:\u00a0diagnosis,\u00a0treatments,\u00a0and\u00a0its\u00a0complications.\u00a0Lan cet\u00a0\n388(10040):\u00a0187\u2013197.\u00a0\u00a0\nPZ\u00a0\u2013\u00a0Pharmazeutische\u00a0Zeitung\u00a0(2016).\u00a0Albutrepenonacog\u00a0alfa|Idel vion|16|2016.\u00a0https://www.pharmazeutische\u2010\nzeitung.de/arzneistoffe/daten/2016/albutrepenonacog\u2010alfaidelvio nr162016/,\u00a0letzter\u00a0Zugriff:\u00a027.02.2019.\u00a0\nSantagostino\u00a0E,\u00a0Martinowitz\u00a0U,\u00a0Lissitchkov\u00a0T,\u00a0Pan\u2010Petesch\u00a0B,\u00a0Ha nabusa\u00a0H,\u00a0Oldenburg\u00a0J\u00a0et\u00a0al.\u00a0(2016).\u00a0Long\u2010acting\u00a0recombinant\u00a0\ncoagulation\u00a0factor\u00a0IX\u00a0albumin\u00a0fu sion\u00a0protein\u00a0(rIX\u2010FP)\u00a0in\u00a0hemoph ilia\u00a0B:\u00a0results\u00a0of\u00a0a\u00a0phase\u00a03\u00a0trial.\u00a0Blood\u00a0127(14):\u00a01761\u2013\n1769.\u00a0\nvon\u00a0Mackensen\u00a0S,\u00a0Shah\u00a0J,\u00a0Seifert\u00a0W,\u00a0Kenet\u00a0G\u00a0(2019).\u00a0Health\u2010rela ted\u00a0quality\u00a0of\u00a0life\u00a0in\u00a0paediatric\u00a0haemophilia\u00a0B\u00a0patients\u00a0treate d\u00a0with\u00a0\nrIX\u2010FP.\u00a0Haemophili a\u00a025(1):\u00a045\u201353.\u00a0\u00a0\nWFH\u00a0\u2013\u00a0World\u00a0Federation\u00a0of\u00a0Hemophilia\u00a0(2013).\u00a0The\u00a0World\u00a0Federati on\u00a0of\u00a0Hemophilia\u00a0guideline\u00a0on \u00a0management\u00a0of\u00a0haemophilia.\u00a0\nhttps://www.wfh.org/en/resources/wfh\u2010treatment\u2010guidelines,\u00a0letz ter\u00a0Zugriff:\u00a010.07.2019.\u00a0\n\u00a0 \u00a061\u00a0 Brivaracetam\u00a04.2\nHandelsname:\u00a0Briviact\u00ae\u00a0 \u00a0 \u00a0 Pha rmazeutischer\u00a0Unternehmer:\u00a0\u00a0\nIndikation:\u00a0Epilepsie\u00a0 \u00a0 \u00a0 UCB\u00a0Pharma\u00a0\u00a0\nATC\u2010Code:\u00a0N03AX23\u00a0 \u00a0 \u00a0 Markteinf\u00fchrung:\u00a0Februar\u00a02016\u00a0\nDarreichungsform:\u00a0Filmtablette,\u00a0L\u00f6sung\u00a0 \u00a0\nzum\u00a0Einnehmen,\u00a0Injektions\u2010/Infusions\u2010\u00a0\nsuspension\u00a0 \u00a0 \u00a0 \u00a0 DDD:\u00a00,1\u00a0g\u00a0 \u00a0 \u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 \u25bc\u00a0\nBewertung \u00a0\nDas\u00a0Antiepileptikum\u00a0Brivaracetam\u00a0ist\u00a0sowohl\u00a0strukturell\u00a0als\u00a0auc h\u00a0pharmakologisch\u00a0\neng\u00a0verwandt\u00a0mit\u00a0dem\u00a0bereits\u00a0lan gj\u00e4hrig\u00a0verf\u00fcgbaren\u00a0Levetiracet am.\u00a0Als\u00a0Wirkme\u2010\nchanismus\u00a0wird\u00a0die\u00a0Bindung\u00a0an\u00a0das\u00a0synaptische\u00a0Vesikelprotein\u00a02A \u00a0(SV2A)\u00a0ange\u2010\nnommen.\u00a0Die\u00a0genaue\u00a0Rolle\u00a0dieses\u00a0Proteins\u00a0ist\u00a0noch\u00a0nicht\u00a0gekl\u00e4rt ,\u00a0jedoch\u00a0konnte\u00a0\ngezeigt\u00a0werden,\u00a0dass\u00a0es\u00a0die\u00a0Freisetzung\u00a0von\u00a0Neurotransmittern\u00a0i n\u00a0den\u00a0synapti\u2010\nschen\u00a0Spalt\u00a0beeinflusst\u00a0(Fachinformation\u00a0Briviact\u00ae,\u00a02018a).\u00a0\u00a0\nBrivaracetam\u00a0wurde\u00a0im\u00a0Januar\u00a02016\u00a0nach\u00a0einem\u00a0positiven\u00a0Votum\u00a0de s\u00a0CHMP\u00a0zent\u2010\nral\u00a0durch\u00a0die\u00a0Europ\u00e4ische\u00a0Kommissi on\u00a0zugelassen\u00a0zur\u00a0Zusatzbehan dlung\u00a0fokaler\u00a0\nAnf\u00e4lle\u00a0mit\u00a0oder\u00a0ohne\u00a0sekund\u00e4re\u00a0Generalisierung\u00a0bei\u00a0Erwachsenen \u00a0und\u00a0Jugendli\u2010\nchen\u00a0ab\u00a016\u00a0Jahren\u00a0mit\u00a0Epilepsie\u00a0(CHMP,\u00a02015).\u00a0Im\u00a0Juli\u00a02018\u00a0erfo lgte\u00a0die\u00a0Zulas\u2010\nsungserweiterung\u00a0f\u00fcr\u00a0Jugendliche\u00a0und\u00a0Kinder\u00a0ab\u00a0vier\u00a0Jahren\u00a0(CHM P,\u00a02018).\u00a0Briva\u2010\nracetam\u00a0wurde\u00a0unter\u00a0dem\u00a0Namen\u00a0Briviact\u00ae\u00a0im\u00a0Februar\u00a02016\u00a0auf\u00a0dem \u00a0deutschen\u00a0\nMarkt\u00a0eingef\u00fchrt.\u00a0Derzeit\u00a0sind\u00a0drei\u00a0unterschiedliche\u00a0Darreichun gsformen\u00a0verf\u00fcg\u2010\nbar:\u00a0Filmtabletten\u00a0in\u00a0verschiede nen\u00a0St\u00e4rken\u00a0von\u00a010\u00a0mg\u00a0bis\u00a0100\u00a0m g,\u00a0eine\u00a0L\u00f6sung\u00a0\nzum\u00a0Einnehmen\u00a0mit\u00a010\u00a0mg/ml\u00a0und\u00a0eine\u00a0L\u00f6sung\u00a0zur\u00a0Infusion\u00a0oder\u00a0In jektion\u00a0mit\u00a0\n10\u00a0mg/ml\u00a0Brivaracetam.\u00a0Die\u00a0erford erliche\u00a0Dosis\u00a0wird\u00a0auf\u00a0zwei\u00a0gl eich\u00a0gro\u00dfe\u00a0Dosen\u00a0\nmorgens\u00a0und\u00a0abends\u00a0aufgeteilt.\u00a0F\u00fc r\u00a0Erwachsene\u00a0sowie\u00a0Kinder\u00a0und\u00a0 Jugendliche\u00a0\n>\u00a050\u00a0kg\u00a0liegt\u00a0die\u00a0Erhaltungsdosis\u00a0bei\u00a050\u00a0bis\u00a0200\u00a0mg/Tag.\u00a0Bei\u00a0Ki ndern\u00a0und\u00a0Jugendli\u2010\nchen\u00a0<\u00a050\u00a0kg\u00a0wird\u00a0gewichtsadaptiert\u00a0dosiert\u00a0(Fachinformation\u00a0Br iviact\u00ae,\u00a02018a;\u00a0\nFachinformation\u00a0Briviact\u00ae,\u00a02018b;\u00a0Fachinformation\u00a0Briviact\u00ae,\u00a020 18c).\u00a0\u00a0\nBrivaracetam\u00a0wurde\u00a0f\u00fcr\u00a0Erwachsene\u00a0und\u00a0Jugendliche\u00a0ab\u00a016\u00a0Jahren\u00a0 auf\u00a0Basis\u00a0der\u00a0\ndrei\u00a0multizentrischen,\u00a0doppelblinden,\u00a0randomisierten,\u00a0placeboko ntrollierten\u00a0Pha\u2010\nse\u2010III\u2010Studien\u00a0N01252,\u00a0N01253\u00a0und\u00a0N01358\u00a0(Sponsor:\u00a0UCB\u00a0Pharma,\u00a0 NCT00490035/\u00a0\nNCT00464269/\u00a0 NCT01261325)\u00a0 zugelassen.\u00a0 Insgesamt\u00a0 erhielten\u00a0 1.099 \u00a0P at i e n t e n \u00a0\nBrivaracetam\u00a0und\u00a0459\u00a0Placebo,\u00a0jeweils\u00a0zus\u00e4tzlich\u00a0zu\u00a0ihrer\u00a0beste henden\u00a0Medikation\u00a0\nmit\u00a0ein\u00a0oder\u00a0zwei\u00a0anderen\u00a0Antiepileptika.\u00a0In\u00a0den\u00a0Studien\u00a0N01252 \u00a0und\u00a0N01253\u00a0war\u00a0\ndie\u00a0parallele\u00a0Einnahme\u00a0von\u00a0Leve tiracetam\u00a0erlaubt.\u00a0Dies\u00a0stellte\u00a0 sich\u00a0in\u00a0Subgrup\u2010\npenanalysen\u00a0als\u00a0negativer\u00a0Einflussfaktor\u00a0f\u00fcr\u00a0die\u00a0Wirkung\u00a0von\u00a0Br ivaracetam\u00a0heraus.\u00a0\nIn\u00a0der\u00a0Studie\u00a0N01358\u00a0war\u00a0die\u00a0Einnahme\u00a0von\u00a0Levetiracetam\u00a0daher\u00a0e in\u00a0Ausschluss\u201062\u00a0kriterium.\u00a0Die\u00a0jeweilige\u00a0Brivaracetam\u2010Dosis\u00a0wurde\u00a0in\u00a0allen\u00a0drei \u00a0Studien\u00a0w\u00e4hrend\u00a0\nder\u00a012\u2010w\u00f6chigen\u00a0Behandlungsphase\u00a0konstant\u00a0gehalten.\u00a0Anschlie\u00dfen d\u00a0folgte\u00a0ent\u2010\nweder\u00a0eine\u00a0Ausschleichphase\u00a0oder\u00a0 der\u00a0\u00dcbergang\u00a0in\u00a0eine\u00a0Langzeit\u2010 follow\u2010up \u2010Studie.\u00a0\u00a0\nDie\u00a0auf\u00a0zwei\u00a0Gaben\u00a0aufgeteilte\u00a0Tagesdosis\u00a0von\u00a0Brivaracetam\u00a0lag\u00a0 in\u00a0der\u00a0Studie\u00a0\nN01252\u00a0entweder\u00a0bei\u00a020\u00a0mg,\u00a050\u00a0mg\u00a0oder\u00a0100\u00a0mg\u00a0pro\u00a0Tag.\u00a0In\u00a0der\u00a0St udie\u00a0N01253\u00a0\nbetrug\u00a0sie\u00a05\u00a0mg,\u00a020\u00a0mg\u00a0oder\u00a050\u00a0mg.\u00a0Als\u00a0prim\u00e4rer\u00a0Endpunkt\u00a0diente \u00a0jeweils\u00a0die\u00a0Diffe\u2010\nrenz\u00a0zwischen\u00a0Brivaracetam\u00a0und\u00a0Placebo\u00a0hinsichtlich\u00a0der\u00a0prozent ualen\u00a0Reduktion\u00a0\nder\u00a0w\u00f6chentlichen\u00a0Anfallsh\u00e4ufigkeit.\u00a0F\u00fcr\u00a0die\u00a0Dosierungen\u00a0bis\u00a020 \u00a0mg\u00a0ergab\u00a0sich\u00a0kein\u00a0\nstatistisch\u00a0signifikanter\u00a0Effekt,\u00a0bei\u00a050\u00a0mg\u00a0waren\u00a0die\u00a0Ergebniss e\u00a0der\u00a0beiden\u00a0Studien\u00a0\nnicht\u00a0konsistent.\u00a0In\u00a0der\u00a0100\u00a0mg\u2010Dosierung\u00a0ergab\u00a0sich\u00a0eine\u00a0um\u00a011 ,7\u00a0Prozentpunkte\u00a0\n(95\u00a0%\u00a0KI\u00a0[0,7;\u00a021,4],\u00a0p\u00a0=\u00a00,037)\u00a0h\u00f6here\u00a0Reduktion\u00a0der\u00a0w\u00f6chentli chen\u00a0Anfallsh\u00e4ufig\u2010\nkeit\u00a0im\u00a0Vergleich\u00a0zu\u00a0Placebo\u00a0(Ry vlin\u00a0et\u00a0al.,\u00a02014;\u00a0Biton\u00a0et\u00a0al. ,\u00a02014).\u00a0\u00a0\nIn\u00a0der\u00a0Studie\u00a0N01358\u00a0wurden\u00a0Tagesdosierungen\u00a0von\u00a0100\u00a0mg\u00a0und\u00a0200 \u00a0mg\u00a0Brivara\u2010\ncetam\u00a0untersucht\u00a0und\u00a0zwei\u00a0prim\u00e4re\u00a0Endpunkte\u00a0erfasst:\u00a0die\u00a0Differ enz\u00a0zwischen\u00a0\nBrivaracetam\u00a0und\u00a0Placebo\u00a0hinsicht lich\u00a0der\u00a0prozentualen\u00a0Reduktio n\u00a0der\u00a0auf\u00a028\u00a0Tage\u00a0\nadjustierten\u00a0 Anfallsh\u00e4ufigkeit\u00a0 und\u00a0 die\u00a0 Ansprechrate,\u00a0 definiert\u00a0 als\u00a0 mindestens\u00a0\n50\u00a0%ige\u00a0Reduktion\u00a0der\u00a0auf\u00a028\u00a0Tage \u00a0standardisierten\u00a0Anfallsh\u00e4ufi gkeit\u00a0im\u00a0Vergleich\u00a0\nzum\u00a0Ausgangswert.\u00a0F\u00fcr\u00a0die\u00a0gering ere\u00a0Dosierung\u00a0ergab\u00a0sich\u00a0eine\u00a0u m\u00a022,8\u00a0Prozent\u2010\npunkte\u00a0(95\u00a0%\u00a0KI\u00a0[13,3;\u00a031,2],\u00a0p\u00a0<\u00a00,001)\u00a0h\u00f6here\u00a0Reduktion\u00a0der\u00a0A nfallsh\u00e4ufigkeit\u00a0\ngegen\u00fcber\u00a0Placebo\u00a0und\u00a0eine\u00a0h\u00f6here\u00a0Ansprechrate\u00a0von\u00a038,9\u00a0%\u00a0unter \u00a0Brivaracetam\u00a0\nversus\u00a021,6\u00a0%\u00a0unter\u00a0Placebo\u00a0(OR\u00a02,39;\u00a095\u00a0%\u00a0KI\u00a0[1,6;\u00a03,6],\u00a0p\u00a0<\u00a00 ,001).\u00a0Bei\u00a0200\u00a0mg\u00a0\nBrivaracetam\u00a0 lagen\u00a0 die\u00a0 Ergebnisse\u00a0 in\u00a0 derselben\u00a0 Gr\u00f6\u00dfenordnung,\u00a0 e ine\u00a0 st\u00e4rkere\u00a0\nWirkung\u00a0dieser\u00a0h\u00f6heren\u00a0Dosis\u00a0war\u00a0 nicht\u00a0nachweisbar\u00a0(Klein\u00a0et\u00a0al .,\u00a02015).\u00a0\u00a0\nDaten\u00a0zur\u00a0gesundheitsbezogenen\u00a0Lebensqualit\u00e4t\u00a0aus\u00a0den\u00a0Studien\u00a0N 01252,\u00a0N01253\u00a0\nund\u00a0N01358\u00a0wurden\u00a0in\u00a0einer\u00a0 Post\u2010hoc\u2010Analyse\u00a0ausgewertet,\u00a0jedoch\u00a0ergaben\u00a0sich\u00a0\nkeine\u00a0statistisch\u00a0signifikanten\u00a0Vorteile\u00a0f\u00fcr\u00a0Brivaracetam\u00a0gegen \u00fcber\u00a0Placebo\u00a0beim\u00a0\nGesamtscore\u00a0des\u00a0verwendeten\u00a0Fragebogens\u00a0(Brandt\u00a0et\u00a0al.,\u00a02017).\u00a0 Direkte\u00a0Verglei\u2010\nche\u00a0mit\u00a0Levetiracetam\u00a0oder\u00a0andere n\u00a0Antiepileptika\u00a0liegen\u00a0nicht\u00a0 vor.\u00a0Aktuell\u00a0lau\u2010\nfende\u00a0Studien\u00a0nehmen\u00a0\u2013\u00a0bis\u00a0auf\u00a0eine\u00a0Ausnahme\u00a0\u2013\u00a0ebenfalls\u00a0keinen \u00a0derartigen\u00a0\nVergleich\u00a0vor.\u00a0Lediglich\u00a0die\u00a0noch\u00a0nicht\u00a0publizierte\u00a0Studie\u00a0SAIR B\u201018\u20100016\u00a0untersucht\u00a0\nBrivaracetam\u00a0versus\u00a0Levetiracetam\u00a0an\u00a016\u00a0Patienten\u00a0mit\u00a0photosens itiver\u00a0Epilepsie\u00a0\n(ClinicalTrials.gov,\u00a02019a).\u00a0Das\u00a0IQWiG\u00a0f\u00fchrte\u00a02016\u00a0einen\u00a0indire kten\u00a0Vergleich\u00a0mit\u00a0\nzwei\u00a0Lacosamid\u2010Studien\u00a0durch,\u00a0bei\u00a0welchem\u00a0Placebo\u00a0plus\u00a0Basisthe rapie\u00a0als\u00a0Br\u00fc\u2010\nckenkomparator\u00a0 diente.\u00a0 Hinsichtlich\u00a0 der\u00a0 Anfallsfrequenz\u00a0 war\u00a0 Bri varacetam\u00a0 im\u00a0\nVergleich\u00a0mit\u00a0einer\u00a0der\u00a0Lacosami d\u2010Studien\u00a0unterlegen.\u00a0Zwar\u00a0erga b\u00a0sich\u00a0aus\u00a0diesem\u00a0\nTeilergebnis\u00a0kein\u00a0nachgewiesener\u00a0Nachteil\u00a0f\u00fcr\u00a0Brivaracetam,\u00a0jed och\u00a0stellten\u00a0die\u00a0\nDaten\u00a0infrage,\u00a0dass\u00a0Brivaracetam\u00a0genauso\u00a0wirksam\u00a0ist\u00a0wie\u00a0Lacosa mid.\u00a0Der\u00a0f\u00fcr\u00a063\u00a0Brivaracetam\u00a0gefundene\u00a0Vorteil\u00a0bei\u00a0der\u00a0Anzahl\u00a0schwerer\u00a0unerw\u00fcns chter\u00a0Arznei\u2010\nmittelereignisse\u00a0wurde\u00a0dadurch\u00a0relativiert\u00a0(IQWiG,\u00a02016).\u00a0\nBei\u00a0Dosierungen\u00a0ab\u00a050\u00a0mg\u00a0pro\u00a0Tag\u00a0waren\u00a0die\u00a0h\u00e4ufigsten\u00a0UAE\u00a0in\u00a0de n\u00a0genannten\u00a0\nStudien\u00a0Kopfschmerzen\u00a0(8,0\u00a0bis\u00a018,2\u00a0%),\u00a0Somnolenz\u00a0(6,1\u00a0bis\u00a016,8 \u00a0%),\u00a0Schwindel\u00a0\n(5,0\u00a0bis\u00a015,8\u00a0%)\u00a0und\u00a0M\u00fcdigkeit\u00a0(4,0\u00a0bis\u00a011,6\u00a0%).\u00a0Schwerwiegende \u00a0UAE\u00a0traten\u00a0unter\u00a0\nBrivaracetam\u00a0bei\u00a02,0\u00a0bis\u00a04,0\u00a0%\u00a0der\u00a0Studienteilnehmer\u00a0auf,\u00a0unter \u00a0Placebo\u00a0bei\u00a0kei\u2010\nnem\u00a0bis\u00a06,0\u00a0%\u00a0der\u00a0Teilnehmer.\u00a0\nDie\u00a0Zulassungserweiterung\u00a0f\u00fcr\u00a0B rivaracetam\u00a0bei\u00a0Jugendlichen\u00a0und \u00a0Kindern\u00a0ab\u00a0vier\u00a0\nJahren\u00a0beruht\u00a0auf\u00a0der\u00a0Studie\u00a0N01263\u00a0(Sponsor:\u00a0UCB\u00a0Pharma,\u00a0NCT00 422422)\u00a0und\u00a0\nderen\u00a0 noch\u00a0 nicht\u00a0 abgeschlossenem\u00a0 Langzeit\u2010 follow\u2010up \u00a0 N01266\u00a0 (Sponsor:\u00a0 UCB\u00a0\nPharma,\u00a0NCT01364597).\u00a0Es\u00a0handelt\u00a0sich\u00a0bei\u00a0der\u00a0Studie\u00a0N01263\u00a0um\u00a0 eine\u00a0multizent\u2010\nrische,\u00a0offene,\u00a0einarmige\u00a0Phase\u00a0IIa\u2010Studie\u00a0an\u00a099\u00a0Kindern\u00a0im\u00a0Alt er\u00a0von\u00a0einem\u00a0Monat\u00a0\nbis\u00a0unter\u00a016\u00a0Jahren,\u00a0die\u00a0prim\u00e4r\u00a0die\u00a0Pharmakokinetik\u00a0untersuchte \u00a0und\u00a0daraus\u00a0Do\u2010\nsierempfehlungen\u00a0ableitete\u00a0(Sc hoemaker\u00a0et\u00a0al.,\u00a02017).\u00a0Die\u00a0Studi e\u00a0N01266\u00a0ist\u00a0eine\u00a0\nmultizentrische,\u00a0offene,\u00a0einarmige\u00a0Phase\u00a0III\u2010Studie\u00a0zur\u00a0Untersu chung\u00a0der\u00a0Sicher\u2010\nheit\u00a0bei\u00a0Langzeitanwendung,\u00a0we lche\u00a0urspr\u00fcnglich\u00a0als\u00a0reines\u00a0 follow\u2010up \u00a0von\u00a0N01263\u00a0\ngeplant\u00a0war,\u00a0jedoch\u00a0nun\u00a0auch\u00a0zus\u00e4tzliche\u00a0neue\u00a0Teilnehmer\u00a0ab\u00a0vie r\u00a0Jahren\u00a0und\u00a0<\u00a017\u00a0\nJahren\u00a0erlaubt.\u00a0Zum\u00a0Stichtag\u00a031.08.2016\u00a0wurden\u00a0206\u00a0Patienten\u00a0in \u00a0die\u00a0Interimsana\u2010\nlyse\u00a0eingeschlossen.\u00a0Zu\u00a0diesem\u00a0Zeitpunkt\u00a0hatten\u00a038,8\u00a0%\u00a0der\u00a0Pati enten\u00a0die\u00a0Teil\u2010\nnahme\u00a0an\u00a0der\u00a0Studie\u00a0abgebrochen,\u00a0der\u00a0h\u00e4ufigste\u00a0Grund\u00a0war\u00a0fehlen de\u00a0Wirksamkeit\u00a0\n(13,6\u00a0%).\u00a0Insgesamt\u00a0traten\u00a0UAE\u00a0v ergleichbar\u00a0h\u00e4ufig\u00a0wie\u00a0bei\u00a0Erwa chsenen\u00a0auf.\u00a0Auf\u2010\nf\u00e4llig\u00a0war\u00a0eine\u00a0erh\u00f6hte\u00a0Suizidali t\u00e4t\u00a0im\u00a0Vergleich\u00a0zu\u00a0Erwachsene n\u00a0(CHMP,\u00a02018).\u00a0Die\u00a0\nStudie\u00a0l\u00e4uft\u00a0noch\u00a0voraussichtlic h\u00a0bis\u00a0Januar\u00a02024\u00a0(ClinicalTria ls.gov,\u00a02019b).\u00a0\u00a0\nDer\u00a0G\u2010BA\u00a0stellte\u00a0in\u00a0seinem\u00a0Beschluss\u00a0vom\u00a0August\u00a02016\u00a0fest,\u00a0dass \u00a0ein\u00a0Zusatznutzen\u00a0\nf\u00fcr\u00a0Erwachsene\u00a0und\u00a0Jugendliche\u00a0ab\u00a016\u00a0Jahren\u00a0 nicht\u00a0belegt \u00a0ist.\u00a0Die\u00a0zVT\u00a0war\u00a0defi\u2010\nniert\u00a0als\u00a0die\u00a0individuelle\u00a0antiepileptische\u00a0Zusatztherapie\u00a0mit\u00a0 einem\u00a0der\u00a0folgenden\u00a0\nWirkstoffe,\u00a0sofern\u00a0medizinisch\u00a0indiziert\u00a0und\u00a0falls\u00a0noch\u00a0keine\u00a0P harmakoresistenz\u00a0\nbzw.\u00a0Unvertr\u00e4glichkeit\u00a0und\u00a0Kontraindikationen\u00a0daf\u00fcr\u00a0bekannt\u00a0ist :\u00a0Eslicarbazepin,\u00a0\nGabapentin,\u00a0 Lacosamid,\u00a0 Lamotrigi n,\u00a0 Levetiracetam ,\u00a0 Oxcarbazepin, \u00a0 Pregabalin,\u00a0\nTopiramat,\u00a0Valproins\u00e4ure\u00a0oder\u00a0Zonisamid\u00a0(G\u2010BA,\u00a02016).\u00a0Nach\u00a0der\u00a0 Zulassungserwei\u2010\nterung\u00a0f\u00fcr\u00a0Kinder\u00a0ab\u00a0vier\u00a0Jahren\u00a0und\u00a0Jugendliche\u00a0unter\u00a016\u00a0Jahre n\u00a0folgte\u00a0ein\u00a0weite\u2010\nrer\u00a0Beschluss\u00a0des\u00a0G\u2010BA.\u00a0Die\u00a0zVT\u00a0 war\u00a0identisch\u00a0bis\u00a0auf\u00a0die\u00a0zus\u00e4t zliche\u00a0Ber\u00fccksichti\u2010\ngung\u00a0 von\u00a0 Perampanel\u00a0 und\u00a0 den\u00a0 Ausschluss\u00a0 von\u00a0 Pregabalin\u00a0 aufgrund\u00a0 fehlender\u00a0\nZulassung\u00a0dieses\u00a0Wirkstoffs\u00a0bei\u00a0der\u00a0betrachteten\u00a0Altersgruppe.\u00a0 Der\u00a0G\u2010BA\u00a0stellte\u00a0\nfest,\u00a0dass\u00a0ein\u00a0 Zusatznutzen\u00a0 auch\u00a0f\u00fcr\u00a0Kinder\u00a0ab\u00a0vier\u00a0Jahren\u00a0und\u00a0Jugendliche\u00a0unter\u00a0\n16\u00a0Jahren\u00a0 nicht\u00a0belegt \u00a0ist\u00a0(G\u2010BA,\u00a02019).\u00a0\n\u00a064\u00a0Verf\u00fcgbare\u00a0Therapien \u00a0 (Zusatz\u2010)Nutzen \u00a0 Kosten\u00a0\n\u00a0\nLevetiracetam\u2010Analogon\u00a0\nmit\u00a0h\u00f6herer\u00a0Affinit\u00e4t\u00a0zu\u00a0\nSV2A,\u00a0aber\u00a0ohne\u00a0\nnachgewiesene\u00a0\ntherapeutische\u00a0\n\u00dcberlegenheit\u00a0\u00a0direkte\u00a0Vergleiche\u00a0fehlen;\u00a0\nweniger\u00a0UAE,\u00a0aber\u00a0keine\u00a0\ngesicherte\u00a0gleichwertige\u00a0\nWirksamkeit\u00a0im\u00a0indirekten\u00a0\nVergleich\u00a0mit\u00a0Lacosamid\u00a0\u00a0\u00a0\ndie\u00a0Mehrzahl\u00a0der\u00a0zVT\u00a0ist\u00a0\ndeutlich\u00a0g\u00fcnstiger,\u00a0einige\u00a0\njedoch\u00a0auch\u00a0teurer\u00a0als\u00a0\nBrivaracetam\u00a0\nErl\u00e4uterung\u00a0der\u00a0Farben:\u00a0Verf\u00fcgbare\u00a0Therapien:\u00a0rot\u00a0=\u00a0weitere\u00a0The rapieoption,\u00a0gelb\u00a0=\u00a0Subgruppen\u2010Novit\u00e4t,\u00a0gr\u00fcn\u00a0=\u00a0Solist;\u00a0(Zusatz\u2010 )\u00a0\nNutzen:\u00a0rot\u00a0=\u00a0keine\u00a0Verbesserung\u00a0oder\u00a0schlechte\u00a0Nutzen/Schaden\u2010 Relation,\u00a0gelb\u00a0=\u00a0teilweise\u00a0Verbesserungen,\u00a0gr\u00fcn\u00a0=\u00a0Verbesserung\u00a0\nharter\u00a0Endpunkte;\u00a0Kosten:\u00a0rot\u00a0=\u00a0teurer\u00a0als\u00a0bestehende\u00a0Therapien ,\u00a0gelb\u00a0=\u00a0ungef\u00e4hr\u00a0gleich\u00a0bzw.\u00a0teils/teils,\u00a0gr\u00fcn\u00a0=\u00a0g\u00fcnstiger\u00a0als \u00a0\nbestehende\u00a0Therapien\u00a0\nWie\u00a0bewerten\u00a0andere?\u00a0\nBewertung\u00a0nach\u00a0\nFricke\u00a0et\u00a0al.\u00a0atd\u2010Bewertung\u00a0 AMB\u00a0 Prescrire\u00a0 PZ\u00a0\nC\u00a0Variante\u00a0ohne\u00a0\nbesonderen\u00a0\nStellenwert\u00a0\u2013\u00a0 Nothing\u00a0new\u00a0 Analogpr\u00e4parat\u00a0\nKosten\u00a0\nWirkstoff\u00a0 Behandlungsmodus\u00a0 Behandlungstage\u00a0 Jahrestherapiekosten\u00a0\nzu\u00a0bewertendes\u00a0\nArzneimittel \u00a0\u00a0 \u00a0 \u00a0\nBrivaracetam\u00a0 25\u00a0\u2013\u00a0100\u00a0mg\u00a02x\u00a0tgl.\u00a0 365\u00a0 1.309,74\u00a0\u20ac\u00a0\nzVT\u00a0 \u00a0 \u00a0 \u00a0\nEslicarbazepin\u00a0 800\u00a0\u2013\u00a01.200\u00a0mg\u00a01x\u00a0tgl.\u00a0 365\u00a02.529,65\u00a0\u2013\u00a05.170,53\u00a0\u20ac\u00a0\nGabapentin\u00a0 300\u00a0\u2013\u00a01200\u00a0mg\u00a03x\u00a0tgl.\u00a0 365\u00a0 229,40\u00a0\u2013\u00a0809,53\u00a0\u20ac\u00a0\nLacosamid\u00a0 100\u00a0\u2013\u00a0200\u00a0mg\u00a02x\u00a0tgl.\u00a0 365\u00a01.981,21\u00a0\u2013\u00a03.253,06\u00a0\u20ac\u00a0\nLamotrigin\u00a0 Tagesdosis\u00a0100\u00a0\u2013\u00a0400\u00a0mg\u00a01\u00a0\u2013\u00a02x\u00a0tgl.\u00a0 365\u00a0 65,92\u00a0\u2013\u00a0294,48\u00a0\u20ac\u00a0\nLevetiracetam\u00a0 500\u00a0\u2013\u00a01.500\u00a0mg\u00a02x\u00a0tgl.\u00a0 365\u00a0 155,42\u00a0\u2013\u00a0449,24\u00a0\u20ac\u00a0\nOxcarbazepin\u00a0 300\u00a0\u2013\u00a01.200\u00a0mg\u00a02x\u00a0tgl.\u00a0 365\u00a0 335,07\u00a0\u2013\u00a01.252,17\u00a0\u20ac\u00a0\nPregabalin\u00a0 Tagesdosis\u00a0150\u00a0\u2013\u00a0600\u00a0mg\u00a02\u00a0\u2013\u00a03x\u00a0tgl.\u00a0 365\u00a0 354,50\u00a0\u2013\u00a0750,48 \u00a0\u20ac\u00a0\nTopiramat\u00a0 100\u00a0\u2013\u00a0200\u00a0mg\u00a02x\u00a0tgl.\u00a0 365\u00a0 386,13\u00a0\u2013\u00a0639,92\u00a0\u20ac\u00a0\nValproins\u00e4ure\u00a0\u00a0 600\u00a0\u2013\u00a01.050\u00a0mg\u00a02x\u00a0tgl.\u00a0 365\u00a0 212,50\u00a0\u20ac\u00a0\nZonisamid\u00a0 Tagesdosis\u00a0300\u00a0\u2013\u00a0500\u00a0mg\u00a01\u00a0\u2013\u00a02x\u00a0tgl.\u00a0 365\u00a01.283,83\u00a0\u2013\u00a02.510,60\u00a0\u20ac\u00a0\nAlle\u00a0Preisangaben\u00a0jeweils\u00a0bezogen\u00a0auf\u00a0die\u00a0Erhaltungsdosis.\u00a0In\u00a0A nlehnung\u00a0an\u00a0die\u00a0Berechnungen\u00a0des\u00a0G\u2010BA\u00a0fand\u00a0f\u00fcr\u00a0Pregabalin\u00a0die\u00a0\nzwei\u00a0Mal\u00a0t\u00e4gliche\u00a0Gabe\u00a0Ber\u00fccksichtigung.\u00a0Die\u00a0Kosten\u00a0f\u00fcr\u00a0Valproi ns\u00e4ure\u00a0beziehen\u00a0sich\u00a0auf\u00a0unretardierte\u00a0Darreichungsformen.\u00a0\n\u00a0 \u00a0\n65\u00a0Versorgungsanalysen\u00a0\nNach\u00a0der\u00a0Markteinf\u00fchrung\u00a0im\u00a0Februar\u00a02016\u00a0stiegen\u00a0die\u00a0Verordnung s\u2010\u00a0und\u00a0Umsatz\u2010\nzahlen\u00a0f\u00fcr\u00a0Brivaracetam\u00a0zun\u00e4chst \u00a0stetig\u00a0an.\u00a0Die\u00a0negative\u00a0Nutzen bewertung\u00a0durch\u00a0\nden\u00a0G\u2010BA\u00a0Anfang\u00a0August\u00a02016\u00a0ging\u00a0mit\u00a0einer\u00a0kurzzeitigen\u00a0Verring erung\u00a0der\u00a0Ab\u2010\nsatzzahlen\u00a0einher.\u00a0Im\u00a0November \u00a02016\u00a0kennzeichnete\u00a0der\u00a0pU\u00a0w\u00e4hren d\u00a0der\u00a0Ver\u2010\nhandlung\u00a0des\u00a0Erstattungsbetrags\u00a0die\u00a0Brivaracetam\u2010haltigen\u00a0Pr\u00e4pa rate\u00a0als\u00a0au\u00dfer\u00a0\nVertrieb.\u00a0In\u00a0den\u00a0darauffolgenden\u00a0Monaten\u00a0schwankten\u00a0die\u00a0Absatzz ahlen.\u00a0Im\u00a0Juni\u00a0\n2017\u00a0erfolgte\u00a0eine\u00a0Einigung\u00a0auf\u00a0den\u00a0Erstattungsbetrag\u00a0und\u00a0die\u00a0e ntsprechenden\u00a0\nPr\u00e4parate\u00a0kamen\u00a0unter\u00a0neuen\u00a0PZN\u00a0au f\u00a0den\u00a0Markt.\u00a0Der\u00a0Apothekenver kaufspreis\u00a0fiel\u00a0\num\u00a0fast\u00a048\u00a0%\u00a0(Lauer\u2010Fischer,\u00a02019).\u00a0Zugleich\u00a0sank\u00a0die\u00a0Zahl\u00a0der\u00a0 verordneten\u00a0DDD\u00a0\nauf\u00a0rund\u00a017.200.\u00a0Dies\u00a0spiegelt\u00a0sich\u00a0deutlich\u00a0im\u00a0Bruttoumsatz\u00a0wi der.\u00a0In\u00a0den\u00a0darauf\u2010\nfolgenden\u00a0Monaten\u00a0waren\u00a0die\u00a0Vero rdnungszahlen\u00a0tendenziell\u00a0wiede r\u00a0steigend\u00a0mit\u00a0\neinem\u00a0Peak\u00a0im\u00a0November\u00a02017\u00a0von\u00a0\u00fcber\u00a034.000\u00a0DDD.\u00a0\nAbbildung\u00a04.2:\u00a0Verordnete\u00a0Tagesdosen\u00a0(DDD)\u00a0und\u00a0Bruttoums\u00e4tze\u00a0vo n\u00a0Briva\u2010\nracetam\u00a0nach\u00a0Monaten\u00a0(2016\u00a0\u2013\u00a02017)\u00a0\n\u00a0\n\u00a0\n\u00a0 \u00a0\n66\u00a0Quellen\u00a0\u00a0\natd\u00a0\u2013\u00a0arznei\u2010telegramm\u00a0Arzneimitteldatenbank\u00a0(2017).\u00a0Wirkstoff: \u00a0Brivaracetam.\u00a0https://www.arznei\u2010telegramm.de/,\u00a0letzter\u00a0Zugrif f:\u00a0\n14.02.2019.\u00a0\nBiton\u00a0V,\u00a0Berkovic\u00a0SF,\u00a0Abou\u2010Khalil\u00a0 B,\u00a0Sperling\u00a0MR,\u00a0Johnson\u00a0ME,\u00a0L u\u00a0S\u00a0(2014).\u00a0Brivaracetam\u00a0as\u00a0adjunctive\u00a0treatment\u00a0for\u00a0uncontroll ed\u00a0\npartial\u00a0epilepsy\u00a0in\u00a0adults:\u00a0a\u00a0phase\u00a0III\u00a0randomized,\u00a0double\u2010blin d,\u00a0placebo\u2010controlled\u00a0trial.\u00a0Epilepsia\u00a055(1):\u00a057\u201366.\u00a0\nBrandt\u00a0C,\u00a0Borghs\u00a0S,\u00a0Elmoufti\u00a0S,\u00a0 Mueller\u00a0K,\u00a0Townsend\u00a0R,\u00a0La\u00a0Loge\u00a0 C\u00a0de\u00a0(2017).\u00a0Health\u2010related\u00a0quality\u00a0of\u00a0life\u00a0in\u00a0double\u2010blind\u00a0Pha se\u00a0III\u00a0studies\u00a0\nof\u00a0brivaracetam\u00a0as\u00a0adjunctive\u00a0therapy\u00a0of\u00a0focal\u00a0seizures:\u00a0A\u00a0pool ed,\u00a0post\u2010hoc\u00a0analysis.\u00a0Epilepsy\u00a0&\u00a0behavior\u00a069:\u00a080\u201385.\u00a0\nCHMP\u00a0\u2013\u00a0Committee\u00a0for\u00a0Medicinal\u00a0Products\u00a0for\u00a0Human\u00a0Use\u00a0(2015).\u00a0A ssessment\u00a0report\u00a0Briviact.\u00a0International\u00a0non\u2010proprietary\u00a0name:\u00a0\nbrivaracetam.\u00a0https://www.ema.eu ropa.eu/document s/assessment\u2010re port/briviact\u2010epar\u2010public\u2010assessment\u2010\nreport_en.pdf,\u00a0letzter\u00a0Zugriff:\u00a0\u00a018.02.2019.\u00a0\nCHMP\u00a0\u2013\u00a0Committee\u00a0for\u00a0Medicinal\u00a0Products\u00a0for\u00a0Human\u00a0Use\u00a0(2018).\u00a0A ssessment\u00a0report\u00a0Briviact.\u00a0International\u00a0non\u2010proprietary\u00a0name:\u00a0\nbrivaracetam.\u00a0https://www.ema.europa.eu/documents/variation\u2010rep ort/briviact\u2010italy\u2010nubriveo\u2010h\u2010c\u20103898\u2010ii\u20100010\u2010g\u2010\nepar\u2010assessment\u2010report\u2010variation_en.pdf,\u00a0letzter\u00a0Zugriff:\u00a018.02 .2019.\u00a0\nClinicalTrials.gov\u00a0(2019a).\u00a0Does\u00a0BRV\u00a0Have\u00a0Faster\u00a0Onset\u00a0Time\u00a0&\u00a0G reater\u00a0Effect\u00a0Than\u00a0LEV\u00a0in\u00a0Epilepsy\u00a0Pts\u00a0Using\u00a0PPR\u00a0Pharmacodynami c\u00a0\nEfficacy\u00a0Endpoint.\u00a0https://clinic altrials.gov/ct2/show/NCT03580 707,\u00a0letzter\u00a0Zugriff:\u00a020.03.2019.\u00a0\nClinicalTrials.gov\u00a0(201 9b).\u00a0Open\u2010label\u00a0Long\u2010term\u00a0Study\u00a0of\u00a0Adjun ctive\u00a0Brivaracetam\u00a0in\u00a0Pediatric\u00a0Subjects\u00a0With\u00a0Epilepsy.\u00a0\nhttps://clinicaltrials.gov/ct2/show/record/NCT01364597,\u00a0letzter \u00a0Zugriff:\u00a0\u00a014.03.2019.\u00a0\nFachinformation\u00a0Briviact\u00ae\u00a0(2018a ).\u00a0Fachinformation\u00a0Briviact\u00ae\u00a010 mg/ml\u00a0Injektions\u2010/Infusionsl\u00f6sung.\u00a0Stand\u00a0der\u00a0Information:\u00a0Juli\u00a0\n2018.\u00a0https://www.fachinfo.de/,\u00a0 letzter\u00a0Zugriff:\u00a0\u00a014.02.2019.\u00a0\nFachinformation\u00a0Briviact\u00ae\u00a0(2018b ).\u00a0Fachinformation\u00a0Briviact\u00ae\u00a010 mg/ml\u00a0L\u00f6sung\u00a0zum\u00a0Einnehmen.\u00a0Stand\u00a0der\u00a0Information:\u00a0Juli\u00a02018.\u00a0\nhttps://www.fachinfo.de/,\u00a0letzter\u00a0Zugriff:\u00a0\u00a014.02.2019.\u00a0\nFachinformation\u00a0Briviact\u00ae\u00a0(2018c ).\u00a0Fachinformation\u00a0Briviact\u00ae\u00a0Fi lmtabletten.\u00a0Stand\u00a0der\u00a0Information:\u00a0Juli\u00a02018.\u00a0\nhttps://www.fachinfo.de/,\u00a0letzter\u00a0Zugriff:\u00a0\u00a014.02.2019.\u00a0\nG\u2010BA\u00a0\u2013\u00a0Gemeinsamer\u00a0Bundesausschuss\u00a0(2016).\u00a0Tragende\u00a0Gr\u00fcnde\u00a0zum\u00a0 Beschluss\u00a0des\u00a0Gemeinsamen\u00a0 Bundesausschusses\u00a0\u00fcber\u00a0eine\u00a0\n\u00c4nderung\u00a0der\u00a0Arzneimittel\u2010Richtlinie\u00a0(AM\u2010RL):\u00a0Anlage\u00a0XII\u00a0\u2013\u00a0Besc hl\u00fcsse\u00a0\u00fcber\u00a0die\u00a0Nutzenbewertung\u00a0von\u00a0Arzneimitteln\u00a0\nmit\u00a0neuen\u00a0Wirkstoffen\u00a0nach\u00a0\u00a7\u00a035a\u00a0SGB\u00a0V\u00a0\u2013\u00a0Brivaracetam.\u00a0https:// www.g\u2010ba.de/downloads/40\u2010268\u20103924/2016\u201008\u2010\n04_AM\u2010RL\u2010XII_Brivaracetam_D\u2010208_TrG.pdf,\u00a0letzter\u00a0Zugriff:\u00a0\u00a014.0 2.2019.\u00a0\nG\u2010BA\u00a0\u2013\u00a0Gemeinsamer\u00a0Bundesausschuss\u00a0(2019).\u00a0Tragende\u00a0Gr\u00fcnde\u00a0zum\u00a0 Beschluss\u00a0des\u00a0Gemeinsamen\u00a0 Bundesausschusses\u00a0\u00fcber\u00a0eine\u00a0\n\u00c4nderung\u00a0der\u00a0Arzneimittel\u2010Richtlinie\u00a0(AM\u2010RL):\u00a0Anlage\u00a0XII\u00a0\u2010\u00a0Besc hl\u00fcsse\u00a0\u00fcber\u00a0die\u00a0Nutzenbewertung\u00a0von\u00a0Arzneimitteln\u00a0\nmit\u00a0neuen\u00a0Wirkstoffen\u00a0nach\u00a0\u00a7\u00a035a\u00a0SGB\u00a0V\u00a0\u2010\u00a0Brivaracetam\u00a0(neues\u00a0An wendungsgebiet:\u00a0Epilepsie,\u00a0Patienten\u00a0von\u00a04\u00a0bis\u00a0\n<16\u00a0Jahre).\u00a0https://www.g\u2010ba.de/ downloads/40\u2010268\u20105532/2019\u201001\u20101 7_AM\u2010RL\u2010XII_Brivaracetam_D\u2010371_TrG.pdf,\u00a0\nletzter\u00a0Zugriff:\u00a0\u00a014.02.2019.\u00a0\nIQWiG\u00a0\u2013\u00a0Institut\u00a0f\u00fcr\u00a0Qualit\u00e4t\u00a0und\u00a0Wirtschaftlichkeit\u00a0im\u00a0Gesundh eitswesen\u00a0(2016).\u00a0[A16\u201038]\u00a0Brivaracetam\u00a0\u2010\u00a0Addendum\u00a0zum\u00a0Auftrag\u00a0\nA16\u201008.\u00a0https://www.g\u2010ba.de/downloads/92\u2010975\u20101468/2016\u201008\u201004_AM \u2010RL\u2010XII_Brivaracetam_D\u2010\n208_Addendum.pdf,\u00a0letzter\u00a0Zugriff:\u00a0\u00a014.02.2019.\u00a0\nKlein\u00a0P,\u00a0Schiemann\u00a0J,\u00a0Sperling\u00a0MR ,\u00a0Whitesides\u00a0J,\u00a0Liang\u00a0W,\u00a0Stalv ey\u00a0T\u00a0et\u00a0al.\u00a0(2015).\u00a0A\u00a0randomized,\u00a0double\u2010blind,\u00a0placebo\u2010control led,\u00a0\nmulticenter,\u00a0parallel\u2010group\u00a0study\u00a0to\u00a0evaluate\u00a0the\u00a0efficacy\u00a0and\u00a0 safety\u00a0of\u00a0adjunctive\u00a0brivaracetam\u00a0in\u00a0adult\u00a0patients\u00a0\nwith\u00a0uncontrolled\u00a0partial\u2010onset\u00a0seizures.\u00a0Epilepsia\u00a056(12):\u00a0189 0\u20131898.\u00a0\nLauer\u2010Fischer\u00a0(2019).\u00a0WEBAPO\u00ae\u00a0Infosystem,\u00a0LAUER\u2010TAXE\u00a0online.\u00a0ht tps://www.lauer\u2010fischer.de/LF/Seiten/WEBAPO\u2010\nInfoSystem/WEBAPO\u2010Infosystem.aspx,\u00a0letzter\u00a0Zugriff:\u00a0\u00a015.01.19.\u00a067\u00a0Prescrire\u00a0Int.\u00a0(2017).\u00a0Brivaracetam\u00a0(Briviact\u00ae)\u00a0and\u00a0partial\u00a0sei zures.\u00a0A\u00a0commercial\u00a0ploy\u00a0with\u00a0a\u00a0levetiracetam\u00a0\"mee\u2010too\".\u00a0Prescr ire\u00a0\nInternational\u00a026(188):\u00a0292\u2013293.\u00a0\nPZ\u00a0\u2013\u00a0Pharmazeutische\u00a0Zeitung\u00a0online\u00a0(2016).\u00a0Arzneistoffe:\u00a0Briva racetam|Briviact\u00ae|15|2016.\u00a0https://www.pharmazeutische\u2010\nzeitung.de/arzneistoffe/daten/2016/brivaracetambriviactr152016/ ,\u00a0letzter\u00a0Zugriff:\u00a014.02.2019.\u00a0\nRyvlin\u00a0P,\u00a0Werhahn\u00a0KJ,\u00a0Blaszczyk\u00a0 B,\u00a0Johnson\u00a0ME,\u00a0Lu\u00a0S\u00a0(2014).\u00a0Adj unctive\u00a0brivaracetam\u00a0in\u00a0adults\u00a0with\u00a0uncontrolled\u00a0focal\u00a0epilepsy :\u00a0\nresults\u00a0from\u00a0a\u00a0double\u2010blind,\u00a0randomized,\u00a0placebo\u2010controlled\u00a0tri al.\u00a0Epilepsia\u00a055(1):\u00a047\u201356.\u00a0\nSchoemaker\u00a0R,\u00a0Wade\u00a0JR,\u00a0Stockis\u00a0A\u00a0(2017).\u00a0Brivaracetam\u00a0populatio n\u00a0pharmacokinetics\u00a0in\u00a0children\u00a0with\u00a0epilepsy\u00a0aged\u00a01\u00a0month\u00a0to\u00a016 \u00a0\nyears.\u00a0European\u00a0journal\u00a0of\u00a0clinical\u00a0pharmacology\u00a073(6):\u00a0727\u2013733 .\u00a0\nSchwabe\u00a0U,\u00a0Paffrath\u00a0D,\u00a0Ludwig\u00a0W\u2010D,\u00a0Klauber\u00a0J\u00a0(2017).\u00a0Arzneivero rdnungs\u2010Report\u00a02017.\u00a0Berlin,\u00a0Heidelberg.\u00a0Springer\u00a0Verlag.\u00a0\n\u00a0 \u00a068\u00a0 Daratumumab\u00a04.3\nHandelsname:\u00a0Darzalex\u00ae\u00a0 \u00a0 \u00a0 Pha rmazeutischer\u00a0Unternehmer:\u00a0\u00a0\nIndikation:\u00a0Multiples\u00a0Myelom\u00a0 \u00a0 Janssen\u2010Cilag\u00a0\nATC\u2010Code:\u00a0L01XC24\u00a0 \u00a0 \u00a0 Markteinf\u00fchrung:\u00a0Juni\u00a02016\u00a0\nDarreichungsform:\u00a0Konzentrat\u00a0zur\u00a0\u00a0\nHerstellung\u00a0einer\u00a0Infusionsl\u00f6sung\u00a0 \u00a0 DDD:\u00a040 \u00a0mg\u00a0\u00a0 \u00a0 \u00a0O,\u00a0C, \u25bc,\u00a0\nBewertung \u00a0\nDarzalex\u00ae\u00a0wurde\u00a0im\u00a0Mai\u00a02016\u00a0zentralisiert\u00a0in\u00a0Europa\u00a0auf\u00a0Basis\u00a0 nicht\u00a0vergleichender,\u00a0\nexploratorischer\u00a0Studien\u00a0 zugelassen\u00a0als\u00a0Monotherapie\u00a0zur\u00a0Behandlung\u00a0erwachsener\u00a0\nPatienten\u00a0mit\u00a0rezidiviertem\u00a0und\u00a0refrakt\u00e4rem\u00a0multiplen\u00a0Myelom\u00a0(R /R\u2010MM),\u00a0die\u00a0\nbereits\u00a0mit\u00a0einem\u00a0Proteasom\u2010Inhi bitor\u00a0(PI)\u00a0und\u00a0einem\u00a0Immunmodul ator\u00a0(Immu\u2010\nnomodulatory\u00a0drug ,\u00a0IMiD)\u00a0behandelt\u00a0wurden,\u00a0und\u00a0die\u00a0w\u00e4hrend\u00a0der\u00a0letzten\u00a0Thera\u2010\npie\u00a0eine\u00a0Krankheitsprogression\u00a0zeigten\u00a0(EMA,\u00a02016).\u00a0Die\u00a0Ausweis ung\u00a0(designation )\u00a0\nals\u00a0Orphan\u00a0Drug \u00a0erhielt\u00a0Daratumumab\u00a0bereits\u00a02013\u00a0durch\u00a0die\u00a0Europ\u00e4ische\u00a0Kom\u2010\nmission\u00a0 zur\u00a0 Behandlung\u00a0 des\u00a0 multiplen\u00a0 Myeloms\u00a0 (MM)\u00a0 erteilt\u00a0 (EU/3 /13/1153)\u00a0\n(EMA,\u00a02013;\u00a0EC,\u00a02013).\u00a0\u00a0\nIm\u00a0April\u00a02017\u00a0erfolgte\u00a0die\u00a0Indikationserweiterung\u00a0von\u00a0Darzalex\u00ae \u00a0in\u00a0Kombination\u00a0\nmit\u00a0Lenalidomid\u00a0und\u00a0Dexamethason \u00a0oder\u00a0Bortezomib\u00a0und\u00a0Dexamethas on\u00a0f\u00fcr\u00a0die\u00a0\nBehandlung\u00a0erwachsener\u00a0Patienten\u00a0 mit\u00a0MM,\u00a0die\u00a0bereits\u00a0mindestens \u00a0eine\u00a0Therapie\u00a0\nerhalten\u00a0haben\u00a0(EMA,\u00a02017).\u00a0Im\u00a0Juli\u00a02018\u00a0wurde\u00a0Daratumumab\u00a0auch \u00a0zugelassen\u00a0in\u00a0\nKombination\u00a0mit\u00a0Bortezomib,\u00a0Melphalan\u00a0und\u00a0Prednison\u00a0f\u00fcr\u00a0die\u00a0Beh andlung\u00a0er\u2010\nwachsener\u00a0Patienten\u00a0mit\u00a0neu\u00a0diagnostiziertem\u00a0MM,\u00a0die\u00a0f\u00fcr\u00a0eine\u00a0a utologe\u00a0Stamm\u2010\nzelltransplantation\u00a0(ASZT)\u00a0nicht\u00a0geeignet\u00a0sind\u00a0(EMA,\u00a02018).\u00a0\nDaratumumab\u00a0wurde\u00a0im\u00a0Rahmen\u00a0einer\u00a0bedingten\u00a0Zulassung\u00a0 (conditional\u00a0marke\u2010\nting\u00a0authorisation,\u00a0 CMA)\u00a0nach\u00a0einer\u00a0beschleunigten\u00a0Beurteilung\u00a0( accelerated\u00a0as\u2010\nsessment ,\u00a0AA)\u00a0zugelassen.\u00a0Die\u00a0bedingte\u00a0Zulassung\u00a0f\u00fcr\u00a0Darzalex\u00ae\u00a0erfolgte ,\u00a0da\u00a0der\u00a0\nmonoklonale\u00a0Antik\u00f6rper\u00a0zur\u00a0Beha ndlung\u00a0einer\u00a0lebensbedrohlichen\u00a0 Krankheit\u00a0ein\u2010\ngesetzt\u00a0wird\u00a0und\u00a0es\u00a0sich\u00a0um\u00a0ein\u00a0 Orphan\u2010Arzneimittel\u00a0handelt.\u00a0Die\u00a0CMA\u00a0von\u00a0Dara\u2010\ntumumab\u00a0war\u00a0mit\u00a0der\u00a0Anforderung\u00a0verbunden,\u00a0weitere\u00a0Daten\u00a0aus\u00a0be reits\u00a0laufen\u2010\nden\u00a0Phase\u2010III\u2010Studien\u00a0mit\u00a0Daratum umab\u00a0vorzulegen,\u00a0um\u00a0Wirksamkei t\u00a0und\u00a0Sicher\u2010\nheit\u00a0besser\u00a0beurteilen\u00a0zu\u00a0k\u00f6nnen\u00a0(EMA,\u00a02016).\u00a0Im\u00a0April\u00a02017\u00a0wur de\u00a0die\u00a0Zulassung\u00a0\nvon\u00a0Daratumumab\u00a0in\u00a0eine\u00a0regul\u00e4re\u00a0Marktzulassung\u00a0( Full\u00a0Marketing\u00a0Authorisation )\u00a0\numgewandelt.\u00a0In\u00a0den\u00a0USA\u00a0hatte\u00a0Daratumumab\u00a02013\u00a0von\u00a0der\u00a0 Food\u00a0and\u00a0Drug\u00a0Admi\u2010\nnistration\u00a0(FDA)\u00a0eine\u00a0 Breakthrough\u2010therapy\u00a0designation \u00a0erhalten\u00a0und\u00a0wurde\u00a02015\u00a0\nzugelassen\u00a0(AMB,\u00a02018).\u00a0\n69\u00a0Daratumumab\u00a0ist\u00a0ein\u00a0humaner\u00a0monoklonaler\u00a0IgG1\u03ba\u2010Antik\u00f6rper\u00a0gegen \u00a0das\u00a0CD38\u2010\nAntigen,\u00a0der\u00a0in\u00a0einer\u00a0S\u00e4ugetier\u2010Zelllinie\u00a0(Ovarzellen\u00a0des\u00a0chine sischen\u00a0Hamsters,\u00a0 Chi\u2010\nnese\u00a0Hamster\u00a0Ovary ,\u00a0CHO)\u00a0mittels\u00a0rekombinanter\u00a0DNA \u2010Technologie\u00a0hergestellt\u00a0wird.\u00a0\nDie\u00a0Markteinf\u00fchrung\u00a0von\u00a0Darzalex\u00ae\u00a0in\u00a0Deutschland\u00a0erfolgte\u00a0im\u00a0Ju ni\u00a02016\u00a0(Lauer\u2010\nTaxe,\u00a02019).\u00a0Der\u00a0monoklonale\u00a0Antik\u00f6rper\u00a0ist\u00a0als\u00a0Konzentrat\u00a0zur\u00a0 Herstellung\u00a0einer\u00a0\nInfusionsl\u00f6sung\u00a0verf\u00fcgbar.\u00a0CD38\u00a0ist\u00a0ein\u00a0Glykoprotein,\u00a0das\u00a0auf\u00a0d er\u00a0Oberfl\u00e4che\u00a0vieler\u00a0\nImmunzellen,\u00a0wie\u00a0beispielsweise\u00a0B\u2010Lymphozyten\u00a0und\u00a0nat\u00fcrlichen\u00a0K illerzellen\u00a0(NK\u2010\nZellen),\u00a0sowie\u00a0in\u00a0hoher\u00a0Konzentration\u00a0auch\u00a0auf\u00a0der\u00a0Oberfl\u00e4che\u00a0d er\u00a0Myelomzellen\u00a0\nexprimiert\u00a0wird.\u00a0CD38\u00a0hat\u00a0verschiedene\u00a0Funktionen,\u00a0u.a.\u00a0geh\u00f6ren \u00a0dazu\u00a0die\u00a0rezeptor\u2010\nvermittelte\u00a0Adh\u00e4sion,\u00a0Signal\u00fcbertragung\u00a0und\u00a0enzymatische\u00a0Aktivi t\u00e4t.\u00a0Daratumumab\u00a0\nhemmt\u00a0das\u00a0Wachstum\u00a0von\u00a0CD38\u2010exprimierenden\u00a0Myelomzellen,\u00a0indem\u00a0 es\u00a0komple\u2010\nmentabh\u00e4ngige\u00a0Zytotoxizit\u00e4t,\u00a0Antik\u00f6rper\u2010abh\u00e4ngige\u00a0zellvermittel te\u00a0Zytotoxizit\u00e4t\u00a0und\u00a0\nAntik\u00f6rper\u2010abh\u00e4ngige\u00a0zellul\u00e4re\u00a0P hagozytose\u00a0ausl\u00f6st\u00a0und\u00a0so\u00a0die\u00a0M yelomzellen\u00a0zer\u2010\nst\u00f6rt\u00a0(AMB,\u00a02018;\u00a0Fachinformation\u00a0Darzalex\u00ae,\u00a02018).\u00a0\nDie\u00a0initiale\u00a0Zulassung\u00a0von\u00a0Darzalex\u00ae\u00a0beruhte\u00a0auf\u00a0zwei\u00a0multizent rischen,\u00a0offenen\u00a0\nStudien:\u00a0die\u00a0Phase\u2010I/II\u2010Studie\u00a0GEN501\u00a0(Sponsor:\u00a0Janssen\u00a0Researc h\u00a0and\u00a0Develop\u2010\nment,\u00a0NCT01985126)\u00a0und\u00a0die\u00a0Phase\u2010II\u2010Studie\u00a0SIRIUS\u00a0(Sponsor:\u00a0Jan ssen\u00a0Research\u00a0\nand\u00a0Development,\u00a0MMY2002;\u00a0NCT01985126)\u00a0(EMA,\u00a02016).\u00a0\nDie\u00a0GEN501\u2010Studie\u00a0war\u00a0eine\u00a0Phase\u2010I/II\u2010Studie,\u00a0deren\u00a0erster\u00a0Teil \u00a0eine\u00a0Dosiseskalati\u2010\nonsstudie\u00a0war.\u00a0Nachfolgend\u00a0wurden\u00a072\u00a0Patienten\u00a0in\u00a0den\u00a0einarmige n\u00a0Teil\u00a0II\u00a0einge\u2010\nschlossen,\u00a0die\u00a0rezidiviert\u00a0oder\u00a0refrakt\u00e4r\u00a0auf\u00a0mindestens\u00a0zwei\u00a0V ortherapien\u00a0(IMiD,\u00a0\nPI,\u00a0Chemotherapie\u00a0oder\u00a0ASZT)\u00a0waren.\u00a0Verabreicht\u00a0wurden\u00a0entweder \u00a08\u00a0mg/kg\u00a0KG\u00a0\n(n\u00a0=\u00a030)\u00a0oder\u00a016\u00a0mg/kg\u00a0KG\u00a0(n\u00a0=\u00a042).\u00a0Prim\u00e4rer\u00a0Endpunkt\u00a0war\u00a0die\u00a0S icherheit\u00a0von\u00a0\nDaratumumab.\u00a0Sekund\u00e4re\u00a0Endpunkte\u00a0waren\u00a0u.a.\u00a0PFS\u00a0und\u00a0OS.\u00a0Zum\u00a0Dat enschnitt\u00a0\n30.06.2015\u00a0betrug\u00a0das\u00a0mediane\u00a0OS\u00a0unter\u00a08\u00a0mg/kg\u00a0KG\u00a0Daratumumab\u00a01 8,2\u00a0Monate,\u00a0\nwar\u00a0unter\u00a0der\u00a0h\u00f6heren\u00a0Dosierung\u00a0a ber\u00a0noch\u00a0nicht\u00a0erreicht\u00a0(Lokho rst\u00a0et\u00a0al.,\u00a02015).\u00a0\u00a0\nIn\u00a0die\u00a0SIRIUS\u2010Studie\u00a0wurden\u00a0Patienten\u00a0mit\u00a0R/R\u2010MM\u00a0eingeschlossen ,\u00a0die\u00a0mindestens\u00a0\ndrei\u00a0vorherige\u00a0Therapien\u00a0erhalten\u00a0hatten,\u00a0einschlie\u00dflich\u00a0eines\u00a0 PI\u00a0und\u00a0eines\u00a0IMiD,\u00a0\noder\u00a0die\u00a0unter\u00a0einem\u00a0PI\u00a0und\u00a0einem\u00a0IMiD\u00a0refrakt\u00e4r\u00a0waren.\u00a0Im\u00a0Teil \u00a0I\u00a0der\u00a0Studie\u00a0(Aus\u2010\nwahl\u00a0des\u00a0Dosierungsschemas)\u00a0erhielten\u00a059\u00a0Patienten\u00a0Daratumumab\u00a0 in\u00a0der\u00a0Dosierung\u00a0\nvon\u00a0entweder\u00a016\u00a0mg/kg\u00a0KG\u00a0(Gruppe\u00a0A)\u00a0oder\u00a08\u00a0mg/kg\u00a0KG\u00a0(Gruppe\u00a0B). \u00a0Nach\u00a0acht\u00a0Wo\u2010\nchen\u00a0konnten\u00a0die\u00a0Patienten\u00a0aus\u00a0Gruppe\u00a0B\u00a0in\u00a0Gruppe\u00a0A\u00a0wechseln.\u00a0I n\u00a0den\u00a0Teil\u00a0II\u00a0der\u00a0\nStudie\u00a0(Evaluierung\u00a0des\u00a0gew\u00e4hlten\u00a0Dosierungsschemas)\u00a0wurden\u00a065\u00a0 Patienten\u00a0einge\u2010\nschlossen.\u00a0Mit\u00a0der\u00a0sp\u00e4ter\u00a0zugelassenen\u00a0Dosierung\u00a0von\u00a016\u00a0mg/kg\u00a0K G\u00a0wurden\u00a0insge\u2010\nsamt\u00a0106\u00a0Patienten\u00a0behandelt.\u00a0Das\u00a0mediane\u00a0Alter\u00a0der\u00a0zu\u00a049\u00a0%\u00a0m\u00e4n nlichen\u00a0Patienten\u00a0\nbetrug\u00a063,5\u00a0Jahre\u00a0und\u00a011\u00a0%\u00a0der\u00a0Patienten\u00a0waren\u00a0\u00e4lter\u00a0als\u00a075\u00a0Jah re.\u00a0Die\u00a0Patienten\u00a0\nhatten\u00a0zuvor\u00a0im\u00a0Median\u00a0f\u00fcnf\u00a0Therapien\u00a0(Min\u00a0\u2013\u00a0Max:\u00a02\u00a0\u2013\u00a014)\u00a0erhal ten,\u00a0darunter\u00a0\n80\u00a0%\u00a0eine\u00a0ASZT.\u00a0Beim\u00a0Studienbeginn\u00a0waren\u00a097\u00a0%\u00a0der\u00a0Patienten\u00a0ref rakt\u00e4r\u00a0gegen\u00a0die\u00a070\u00a0letzte\u00a0vorausgegangene\u00a0Therapie,\u00a095\u00a0%\u00a0waren\u00a0sowohl\u00a0gegen\u00a0einen\u00a0 PI\u00a0als\u00a0auch\u00a0\ngegen\u00a0einen\u00a0IMiD\u00a0refrakt\u00e4r\u00a0(Lonial\u00a0et\u00a0al.,\u00a02016).\u00a0\nPrim\u00e4rer\u00a0 Endpunkt\u00a0 der\u00a0 Studie\u00a0 war\u00a0 die\u00a0 Gesamtansprechrate\u00a0 ( Overall\u00a0 Response\u00a0\nRate,\u00a0ORR).\u00a0Sekund\u00e4re\u00a0Endpunkte\u00a0waren\u00a0u.a.\u00a0das\u00a0Gesamt\u00fcberleben\u00a0( Overall\u00a0Survi\u2010\nval,\u00a0 OS),\u00a0 das\u00a0 progressionsfreie\u00a0 \u00dcberleben\u00a0 ( Progression\u2010free\u00a0 Survival ,\u00a0 PFS),\u00a0 die\u00a0\nDauer\u00a0des\u00a0Ansprechens\u00a0( Duration\u00a0of\u00a0Response ,\u00a0DoR),\u00a0die\u00a0Zeit\u00a0bis\u00a0zur\u00a0Progression\u00a0\n(Time\u00a0to\u00a0Disease\u00a0Progression ,\u00a0TTP)\u00a0sowie\u00a0die\u00a0Sicherheit\u00a0und\u00a0Immunogenit\u00e4t\u00a0von\u00a0\nDaratumumab\u00a0(Lonial\u00a0et\u00a0al.,\u00a02016).\u00a0\nZum\u00a0Zeitpunkt\u00a0des\u00a0f\u00fcr\u00a0die\u00a0Zulassung\u00a0vorgelegten\u00a0Datenschnitts\u00a0( 30.06.2015)\u00a0wur\u2010\nde\u00a0der\u00a0prim\u00e4re\u00a0Endpunkt\u00a0ORR\u00a0von\u00a031\u00a0(29,2\u00a0%)\u00a0Patienten\u00a0erreicht\u00a0 (95\u00a0%\u00a0KI\u00a0[20,8;\u00a0\n38,9]).\u00a0Die\u00a0mediane\u00a0DoR\u00a0betrug\u00a07,4\u00a0Monate\u00a0(95\u00a0%\u00a0KI\u00a0[5,5;\u00a0n.e.]) ,\u00a0das\u00a0mediane\u00a0OS\u00a0\n17,5\u00a0Monaten\u00a0(95\u00a0%\u00a0KI\u00a0[13,7;\u00a0n.e. ]).\u00a0Eine\u00a0Krankheitsprogression \u00a0trat\u00a0bei\u00a018\u00a0(17,0\u00a0%)\u00a0\nPatienten\u00a0auf.\u00a0Das\u00a0mediane\u00a0PFS\u00a0betrug\u00a03,7\u00a0Monate\u00a0(95\u00a0%\u00a0KI\u00a0[2,8; \u00a04,6])\u00a0(Lonial\u00a0et\u00a0\nal.,\u00a02016).\u00a0\nDie\u00a0Ergebnisse\u00a0zu\u00a0den\u00a0Sicherheitsendpunkten\u00a0aus\u00a0beiden\u00a0Studien\u00a0 wurden\u00a0f\u00fcr\u00a0die\u00a0\nZulassung\u00a0 ge pooled\u00a0dargestellt.\u00a0Unter\u00a0der\u00a0 zulassu ngsrelevanten\u00a0Dosierung\u00a0von\u00a0\n16\u00a0mg/kg\u00a0KG\u00a0traten\u00a0schwere\u00a0UAE\u00a0vom\u00a0Grad\u00a0\u2265\u00a03\u00a0CTCAE\u00a0( Common\u00a0Terminology\u00a0\nCriteria\u00a0for\u00a0Adverse\u00a0Events )\u00a0bei\u00a088\u00a0(56,4\u00a0%)\u00a0der\u00a0Patienten\u00a0auf,\u00a0schwerwiegende\u00a0\nUAE\u00a0bei\u00a050\u00a0(32,1\u00a0%).\u00a0Ein\u00a0Therapieabbruch\u00a0aufgrund\u00a0von\u00a0UAE\u00a0wurde \u00a0f\u00fcr\u00a0sechs\u00a0Pati\u2010\nenten\u00a0(3,8\u00a0%)\u00a0berichtet,\u00a0Tod\u00a0aufgrund\u00a0von\u00a0UAE\u00a0f\u00fcr\u00a0drei\u00a0(1,9\u00a0%). \u00a0Die\u00a0h\u00e4ufigsten\u00a0UAE\u00a0\nwaren\u00a0Fatigue\u00a0(38\u00a0%\u00a0der\u00a0Patiente n),\u00a0Nausea\u00a0(26\u00a0%),\u00a0An\u00e4mie\u00a0(25\u00a0% ),\u00a0Neutropenie\u00a0\n(22\u00a0%),\u00a0R\u00fcckenschmerzen\u00a0(21\u00a0%),\u00a0Husten\u00a0(20\u00a0%)\u00a0und\u00a0Thrombozytope nie\u00a0(20\u00a0%).\u00a0\nDie\u00a0h\u00e4ufigsten\u00a0schweren\u00a0UAE\u00a0(Grad\u00a0\u2265\u00a03\u00a0CTCAE)\u00a0waren\u00a0Pneumonie\u00a0(6 \u00a0%\u00a0der\u00a0Patien\u2010\nten),\u00a0allgemeine\u00a0Erkrankungen\u00a0und\u00a0Beschwerden\u00a0am\u00a0Verabreichungs ort\u00a0(8\u00a0%)\u00a0und\u00a0\nHyperkalz\u00e4mie\u00a0 (3\u00a0%).\u00a0 Berichtet\u00a0 wurden\u00a0 elf\u00a0 (5\u00a0%)\u00a0 Todesf\u00e4lle\u00a0 als\u00a0 UAE\u00a0 (Grad\u00a0 5\u00a0\nCTCAE):\u00a0f\u00fcnf\u00a0infolge\u00a0genereller\u00a0 Verschlechterung\u00a0des\u00a0k\u00f6rperlich en\u00a0Gesundheitszu\u2010\nstands\u00a0und\u00a0je\u00a0einer\u00a0infolge\u00a0von\u00a0r espiratorischer\u00a0Insuffizienz,\u00a0 Herz\u2010\u00a0und\u00a0Atemstill\u2010\nstand,\u00a0Pneumonie,\u00a0Leberversage n\u00a0und\u00a0Hyperkalz\u00e4mie\u00a0(EMA,\u00a02016).\u00a0\nF\u00fcr\u00a0die\u00a0erste\u00a0Indikationserweiterung\u00a0in\u00a0der\u00a0Kombinationstherapi e\u00a0reichte\u00a0der\u00a0pU\u00a0\nzwei\u00a0multizentrische,\u00a0 offene,\u00a0randomisierte ,\u00a0aktiv\u00a0kontrolliert e\u00a0Phase\u2010III\u2010Studien\u00a0\n(CASTOR\u00a0und\u00a0POLLUX)\u00a0ein,\u00a0in\u00a0die\u00a0P atienten\u00a0eingeschlossen\u00a0wurden ,\u00a0die\u00a0zuvor\u00a0\nmindestens\u00a0eine\u00a0Therapie\u00a0erhalten \u00a0hatten\u00a0und\u00a0eine\u00a0dokumentierte \u00a0Krankheitspro\u2010\ngression\u00a0nach\u00a0der\u00a0letzten\u00a0Therap ie\u00a0aufwiesen.\u00a0Beide\u00a0Studien\u00a0sin d\u00a0noch\u00a0nicht\u00a0abge\u2010\nschlossen\u00a0(ClinicalTrials.gov,\u00a0NIH,\u00a02019a;\u00a0NIH,\u00a02019b).\u00a0\nIn\u00a0 CASTOR\u00a0 (Sponsor:\u00a0 Janssen\u00a0 Rese arch\u00a0 and\u00a0 Development,\u00a0 MMY3004;\u00a0 NCT\u00a0\n02136134)\u00a0wurden\u00a0498\u00a0Patienten\u00a0mit\u00a0R/R\u2010MM\u00a0eingeschlossen,\u00a0die\u00a0e ntweder\u00a0Dara\u2010\ntumumab\u00a0 in\u00a0 Kombination\u00a0 mit\u00a0 Bortezomib\u00a0 und\u00a0 Dexamethason\u00a0 (Daratum umab\u201071\u00a0Arm;\u00a0n\u00a0=\u00a0251)\u00a0oder\u00a0nur\u00a0Bortezomib\u00a0und\u00a0Dexamethason\u00a0(Kontrollarm ;\u00a0n\u00a0=\u00a0247)\u00a0\nerhalten.\u00a0Die\u00a0Randomisierung\u00a0erfo lgte\u00a0stratifiziert\u00a0nach\u00a0ISS\u2010St adium\u00a0(International\u00a0\nStaging\u00a0System ),\u00a0Anzahl\u00a0der\u00a0vorangegangenen\u00a0Therapielinien\u00a0sowie\u00a0einer\u00a0voran\u2010\ngegangenen\u00a0Bortezomib\u2010Behandlung.\u00a0Die\u00a0Patienten\u00a0waren\u00a0bei\u00a0Rando misierung\u00a0im\u00a0\nMedian\u00a064\u00a0Jahre\u00a0alt,\u00a0etwa\u00a0die\u00a0H\u00e4lfte\u00a0hatte\u00a0mindestens\u00a0zwei\u00a0Vorb ehandlungen.\u00a0\nBortezomib\u00a0und\u00a0Dexamethason\u00a0wurden\u00a0in\u00a0beiden\u00a0Studienarmen\u00a0f\u00fcr\u00a0a cht\u00a021\u2010Tage\u2010\nZyklen\u00a0verabreicht.\u00a0Ab\u00a0dem\u00a0neunten\u00a0Zyklus\u00a0wird\u00a0im\u00a0Daratumumab\u2010A rm\u00a0eine\u00a0Mo\u2010\nnotherapie\u00a0mit\u00a0Daratumumab\u00a0bis\u00a0zu\u00a0einer\u00a0Krankheitsprogression\u00a0o der\u00a0inakzeptab\u2010\nler\u00a0Toxizit\u00e4t\u00a0verabreicht\u00a0(Palumbo\u00a0et\u00a0al.,\u00a02016).\u00a0\nPrim\u00e4rer\u00a0Endpunkt\u00a0der\u00a0Studie\u00a0ist\u00a0das\u00a0PFS.\u00a0Als\u00a0sekund\u00e4re\u00a0Endpunk te\u00a0sind\u00a0u.a.\u00a0die\u00a0\nORR,\u00a0das\u00a0OS,\u00a0die\u00a0HRQoL \u00a0und\u00a0die\u00a0Vertr\u00e4glichkeit\u00a0(oder\u00a0 Toxizit\u00e4t)\u00a0herangezogen.\u00a0Die\u00a0\nzuvor\u00a0festgelegte\u00a0Interimsanalys e\u00a0erfolgte\u00a0beim\u00a0Erreichen\u00a0von\u00a01 77\u00a0Ereignissen\u00a0im\u00a0\nprim\u00e4ren\u00a0Endpunkt\u00a0PFS\u00a0(Datenschnitt:\u00a011.01.2016).\u00a0Zu\u00a0diesem\u00a0Zei tpunkt\u00a0hatten\u00a0\nvon\u00a0den\u00a0Patienten,\u00a0die\u00a0mindestens\u00a0eine\u00a0Dosis\u00a0der\u00a0Studienmedikat ion\u00a0erhalten\u00a0\nhatten\u00a0(243\u00a0im\u00a0Daratumumab\u2010Arm\u00a0und\u00a0237\u00a0im\u00a0Kontrollarm),\u00a030,5\u00a0%\u00a0 (74\u00a0Patienten)\u00a0\nim\u00a0Daratumumab\u2010Arm\u00a0und\u00a043,9\u00a0%\u00a0(104\u00a0Patienten)\u00a0im\u00a0Kontrollarm\u00a0di e\u00a0Studie\u00a0be\u2010\nreits\u00a0abgebrochen,\u00a0vor\u00a0allem\u00a0au fgrund\u00a0von\u00a0Krankheitsprogression \u00a0(19,3\u00a0%\u00a0bzw.\u00a0\n25,3\u00a0%)\u00a0oder\u00a0von\u00a0UAE\u00a0(7,8\u00a0%\u00a0bzw.\u00a09,7\u00a0%).\u00a0Die\u00a0mediane\u00a0Beobachtun gszeit\u00a0betrug\u00a0\n7,4\u00a0Monate.\u00a0Nach\u00a012\u00a0Monaten\u00a0lag\u00a0 das\u00a0PFS\u00a0bei\u00a060,7\u00a0%\u00a0(95\u00a0%\u00a0KI\u00a0[51 ,2;\u00a069,0])\u00a0im\u00a0\nDaratumumab\u2010Arm\u00a0und\u00a0bei\u00a026,9\u00a0%\u00a0( 95\u00a0%\u00a0KI\u00a0[17,1;\u00a037,5])\u00a0im\u00a0Kontro llarm.\u00a0Das\u00a0me\u2010\ndiane\u00a0PFS\u00a0war\u00a0im\u00a0Darat umumab\u2010Arm\u00a0noch\u00a0nicht\u00a0erreicht,\u00a0im\u00a0Kontro llarm\u00a0betrug\u00a0es\u00a0\n7,2\u00a0Monate.\u00a0Das\u00a0 Hazard\u00a0Ratio \u00a0(HR)\u00a0f\u00fcr\u00a0Krankheitsprogression\u00a0oder\u00a0Tod\u00a0unter\u00a0Dara\u2010\ntumumab\u00a0im\u00a0Vergleich\u00a0zum\u00a0Kontrollarm\u00a0war\u00a00,39\u00a0(95\u00a0%\u00a0KI\u00a0[0,28;\u00a00 ,53];\u00a0p\u00a0<\u00a00,001)\u00a0\n(Palumbo\u00a0et\u00a0al.,\u00a02016).\u00a0\u00a0\nUAE\u00a0traten\u00a0in\u00a0beiden\u00a0Behandlungsarmen\u00a0nahezu\u00a0bei\u00a0jedem\u00a0Patiente n\u00a0mindestens\u00a0\neinmal\u00a0auf.\u00a0Die\u00a0h\u00e4ufigsten\u00a0UAE\u00a0i n\u00a0beiden\u00a0Armen\u00a0der\u00a0Sicherheitsp opulation\u00a0(alle\u00a0\nPatienten,\u00a0die\u00a0mindestens\u00a0eine\u00a0D osis\u00a0der\u00a0Studienmedikation\u00a0erha lten\u00a0haben)\u00a0wa\u2010\nren\u00a0Thrombozytopenie,\u00a0An\u00e4mie,\u00a0pe riphere\u00a0Neuropathie,\u00a0Diarrh\u00f6,\u00a0A temwegsinfek\u2010\ntionen\u00a0und\u00a0Fieber.\u00a0Schwere\u00a0UAE\u00a0vom\u00a0Grad\u00a03\u00a0\u2013\u00a04\u00a0CTCAE\u00a0traten\u00a0im\u00a0D aratumumab\u2010\nArm\u00a0h\u00e4ufiger\u00a0auf:\u00a076,1\u00a0%\u00a0vs.\u00a062,4\u00a0%.\u00a0H\u00e4matologische\u00a0UAE\u00a0waren\u00a0u nabh\u00e4ngig\u00a0vom\u00a0\nSchweregrad\u00a0unter\u00a0Daratumumab\u00a0h\u00e4ufiger\u00a0als\u00a0unter\u00a0der\u00a0Kontrolle: \u00a0Thrombozyto\u2010\npenie\u00a0 (58,8\u00a0%\u00a0 vs.\u00a0 43,9\u00a0%),\u00a0 Neutropenie\u00a0 (17,7\u00a0%\u00a0 vs.\u00a0 9,3\u00a0%)\u00a0 und\u00a0 L ymphopenie\u00a0\n(13,2\u00a0%\u00a0vs.\u00a03,8\u00a0%).\u00a0Ein\u00a0Therapieabbruch\u00a0aufgrund\u00a0von\u00a0UAE\u00a0erfolg te\u00a0bei\u00a07,4\u00a0%\u00a0der\u00a0\nPatienten\u00a0im\u00a0Daratumumab\u2010Arm\u00a0und\u00a0bei\u00a09,3\u00a0%\u00a0der\u00a0Patienten\u00a0im\u00a0Kon trollarm.\u00a0Die\u00a0\nh\u00e4ufigsten\u00a0UAE,\u00a0die\u00a0zum\u00a0Therapieabbruch\u00a0f\u00fchrten,\u00a0waren\u00a0peripher e\u00a0Neuropathie\u00a0\n(0,4\u00a0%\u00a0bzw.\u00a02,5\u00a0%)\u00a0und\u00a0Pneumonie\u00a0(1,2\u00a0%\u00a0bzw.\u00a00,4\u00a0%)\u00a0(Palumbo\u00a0et \u00a0al.,\u00a02016).\u00a0\nTodesf\u00e4lle\u00a0infolge\u00a0UAE\u00a0(Grad\u00a05\u00a0CTCAE)\u00a0wurden\u00a0f\u00fcr\u00a013\u00a0Patienten\u00a0( 5,3\u00a0%)\u00a0unter\u00a0Dara\u2010\ntumumab\u00a0und\u00a014\u00a0Patienten\u00a0(5,9\u00a0%)\u00a0im\u00a0Kontrollarm\u00a0berichtet.\u00a0Infu sionsbedingte\u00a072\u00a0Reaktionen\u00a0traten\u00a0unter\u00a0Daratumumab\u00a0bei\u00a045,3\u00a0%\u00a0der\u00a0Patienten\u00a0au f,\u00a0wobei\u00a0diese\u00a0\nReaktionen\u00a0bei\u00a098,2\u00a0%\u00a0der\u00a0Patien ten\u00a0sich\u00a0w\u00e4hrend\u00a0der\u00a0ersten\u00a0Inf usion\u00a0ereigneten\u00a0\n(Palumbo\u00a0et\u00a0al.,\u00a02016).\u00a0\nIn\u00a0POLLUX\u00a0(Sponsor:\u00a0Janssen\u00a0Research\u00a0and\u00a0Development,\u00a0NCT020760 09)\u00a0wurden\u00a0\n569\u00a0Patienten\u00a0mit\u00a0R/R\u2010MM\u00a0eingeschlossen,\u00a0die\u00a0entweder\u00a0Daratumum ab\u00a0in\u00a0Kombi\u2010\nnation\u00a0mit\u00a0Lenalidomid\u00a0und\u00a0Dexam ethason\u00a0(Daratumumab\u2010Arm;\u00a0n\u00a0=\u00a02 86)\u00a0oder\u00a0\nLenalidomid\u00a0und\u00a0Dexamethason\u00a0(K ontrollarm;\u00a0n\u00a0=\u00a0283)\u00a0bekommen.\u00a0D ie\u00a0Randomi\u2010\nsierung\u00a0erfolgte\u00a0stratifiziert\u00a0na ch\u00a0ISS\u2010Stadium,\u00a0Anzahl\u00a0der\u00a0vor angegangenen\u00a0The\u2010\nrapielinien\u00a0sowie\u00a0einer\u00a0vorangeg angenen\u00a0Lenalidomid\u2010Behandlung. \u00a0Die\u00a0Patienten\u00a0\nwaren\u00a0bei\u00a0Randomisierung\u00a0im\u00a0Median\u00a065\u00a0Jahre\u00a0alt\u00a0und\u00a0zu\u00a060\u00a0%\u00a0m\u00e4n nlich.\u00a0Etwa\u00a0die\u00a0\nH\u00e4lfte\u00a0der\u00a0Patienten\u00a0hatte\u00a0mindestens\u00a0zwei\u00a0Vorbehandlungen.\u00a0In\u00a0 beiden\u00a0Studien\u2010\narmen\u00a0 erfolgt\u00a0 die\u00a0 Gabe\u00a0 der\u00a0 Studi enmedikation\u00a0 in\u00a0 28\u2010Tage\u2010Zyklen\u00a0 bis\u00a0 zu\u00a0 einer\u00a0\nKrankheitsprogression\u00a0oder\u00a0dem\u00a0Au ftreten\u00a0inakzeptabler\u00a0Toxizit\u00e4 t\u00a0(Dimopoulos\u00a0et\u00a0\nal.,\u00a02016).\u00a0\nPrim\u00e4rer\u00a0Endpunkt\u00a0der\u00a0Studie\u00a0ist\u00a0das\u00a0PFS.\u00a0Als\u00a0sekund\u00e4re\u00a0Endpunk te\u00a0werden\u00a0u.a.\u00a0\ndie\u00a0ORR,\u00a0das\u00a0OS,\u00a0die\u00a0HRQoL\u00a0und\u00a0die\u00a0Sicherheit\u00a0herangezogen.\u00a0Die \u00a0pr\u00e4spezifizierte\u00a0\nInterimsanalyse\u00a0erfolgte\u00a0beim\u00a0Erreichen\u00a0von\u00a0177\u00a0Ereignissen\u00a0im\u00a0 prim\u00e4ren\u00a0End\u2010\npunkt\u00a0 PFS\u00a0 (Datenschnitt:\u00a0 07.03.2016).\u00a0 Zu\u00a0 diesem\u00a0 Zeitpunkt\u00a0 hatte n\u00a0 23,3\u00a0%\u00a0 (66\u00a0\nPatienten)\u00a0im\u00a0Daratumumab\u2010Arm\u00a0un d\u00a047,0\u00a0%\u00a0(132\u00a0Patienten)\u00a0im\u00a0Kon trollarm\u00a0die\u00a0\nStudie\u00a0 bereits\u00a0 abgebrochen,\u00a0 vor\u00a0 allem\u00a0 aufgrund\u00a0 einer\u00a0 Krankheits progression\u00a0\n(14,1\u00a0%\u00a0bzw.\u00a034,2\u00a0%)\u00a0oder\u00a0UAE\u00a0(6,7\u00a0%\u00a0bzw.\u00a08,2\u00a0%).\u00a0Das\u00a0HR\u00a0f\u00fcr\u00a0Kr ankheitsprogressi\u2010\non\u00a0oder\u00a0Tod\u00a0unter\u00a0Daratumumab\u00a0im\u00a0Vergleich\u00a0zum\u00a0Kontrollarm\u00a0war\u00a0 0,37\u00a0(95\u00a0%\u00a0KI\u00a0\n[0,27;\u00a00,52],\u00a0p\u00a0<\u00a00,001).\u00a0Das\u00a0mediane\u00a0PFS\u00a0war\u00a0im\u00a0Daratumumab\u2010Ar m\u00a0noch\u00a0nicht\u00a0\nerreicht,\u00a0im\u00a0Kontrollarm\u00a0betrug\u00a0 es\u00a018,4\u00a0Monate\u00a0(Dimopoulos\u00a0et\u00a0a l.,\u00a02016).\u00a0\nDie\u00a0h\u00e4ufigsten\u00a0UAE\u00a0in\u00a0beiden\u00a0Arm en\u00a0der\u00a0Sicherheitspopulation\u00a0wa ren\u00a0Neutrope\u2010\nnie,\u00a0 An\u00e4mie,\u00a0 Thrombozytopenie, \u00a0 Diarrh\u00f6\u00a0 und\u00a0 Atemwegsinfektionen. \u00a0S c h w e r e \u00a0\nNeutropenien\u00a0und\u00a0Lymphopenien\u00a0vom\u00a0Grad\u00a03\u00a0\u2013\u00a04\u00a0CTCAE\u00a0traten\u00a0im\u00a0Da ratumumab\u2010\nArm\u00a0h\u00e4ufiger\u00a0auf\u00a0als\u00a0unter\u00a0Kontrolle:\u00a051,9\u00a0%\u00a0vs.\u00a037,0\u00a0%\u00a0bzw.\u00a05, 3\u00a0%\u00a0vs.\u00a03,6\u00a0%.\u00a0Tiefe\u00a0\nVenenthrombosen\u00a0wurden\u00a0bei\u00a01,8\u00a0%\u00a0der\u00a0Patienten\u00a0im\u00a0Daratumumab\u2010A rm\u00a0und\u00a0\n3,9\u00a0%\u00a0der\u00a0Patienten\u00a0im\u00a0Kontrolla rm\u00a0berichtet.\u00a0Schwerwiegende\u00a0UA E\u00a0wurden\u00a0bei\u00a0\n48,8\u00a0%\u00a0der\u00a0Patienten\u00a0im\u00a0Daratumumab\u2010Arm\u00a0und\u00a042,0\u00a0%\u00a0der\u00a0Patiente n\u00a0im\u00a0Kontroll\u2010\narm\u00a0berichtet,\u00a0die\u00a0h\u00e4ufigste\u00a0darunter\u00a0war\u00a0Pneumonie\u00a0(8,1\u00a0%\u00a0vs.\u00a0 8,5\u00a0%).\u00a0Ein\u00a0Thera\u2010\npieabbruch\u00a0aufgrund\u00a0von\u00a0UAE\u00a0wurde\u00a0 f\u00fcr\u00a06,7\u00a0%\u00a0der\u00a0Patienten\u00a0im\u00a0Da ratumumab\u2010\nArm\u00a0und\u00a07,8\u00a0%\u00a0der\u00a0Patienten\u00a0im\u00a0Kontrollarm\u00a0berichtet.\u00a0Die\u00a0h\u00e4ufi gsten\u00a0UAE,\u00a0die\u00a0\nzum\u00a0Therapieabbruch\u00a0f\u00fchrten,\u00a0waren\u00a0Pneumonie\u00a0(1,1\u00a0%\u00a0bzw.\u00a00,7\u00a0%) ,\u00a0Lungenem\u2010\nbolie\u00a0(1,1\u00a0%\u00a0im\u00a0Kontrollarm)\u00a0und\u00a0generelle\u00a0Verschlechterung\u00a0des \u00a0physischen\u00a0Ge\u2010\nsundheitszustands\u00a0(1,1\u00a0%\u00a0im\u00a0Darat umumab\u2010Arm)\u00a0(Dimopoulos\u00a0et\u00a0al. ,\u00a02016).\u00a073\u00a0Todesf\u00e4lle\u00a0infolge\u00a0UAE\u00a0(Grad\u00a05\u00a0CTCAE)\u00a0wurden\u00a0f\u00fcr\u00a0elf\u00a0Patienten\u00a0 (3,9\u00a0%)\u00a0unter\u00a0Dara\u2010\ntumumab\u00a0und\u00a015\u00a0Patienten\u00a0(5,3\u00a0%)\u00a0im\u00a0Kontrollarm\u00a0berichtet.\u00a0Die\u00a0 meisten\u00a0dieser\u00a0\nTodesf\u00e4lle\u00a0ereigneten\u00a0sich\u00a0als\u00a0Folge\u00a0akuter\u00a0Nierensch\u00e4digung\u00a0(0 ,4\u00a0%\u00a0vs.\u00a01,1\u00a0%),\u00a0\nseptischen\u00a0Schocks\u00a0(1,1\u00a0%\u00a0vs.\u00a00,4\u00a0%)\u00a0oder\u00a0Pneumonie\u00a0(je\u00a00,7\u00a0%). \u00a0Infusionsbedingte\u00a0\nReaktionen\u00a0traten\u00a0unter\u00a0Daratumumab\u00a0bei\u00a047,7\u00a0%\u00a0der\u00a0Patienten\u00a0au f,\u00a0bei\u00a092,0\u00a0%\u00a0\nder\u00a0Patienten\u00a0ereigneten\u00a0sich\u00a0di ese\u00a0w\u00e4hrend\u00a0der\u00a0ersten\u00a0Infusion \u00a0(Dimopoulos\u00a0et\u00a0\nal.,\u00a02016).\u00a0\nDie\u00a0zweite\u00a0Indikationserweiterung \u00a0von\u00a0Daratumumab\u00a0beruhte\u00a0auf\u00a0d en\u00a0Ergebnissen\u00a0\nder\u00a0ALCYONE\u2010Studie\u00a0(Sponsor:\u00a0Janssen\u00a0Research\u00a0and\u00a0Development,\u00a0 NCT02195479).\u00a0\nIn\u00a0diese\u00a0multizentrische,\u00a0offene ,\u00a0randomisierte,\u00a0aktiv\u00a0kontroll ierte\u00a0Phase\u2010III\u2010Studie\u00a0\nwurden\u00a0706\u00a0Patienten\u00a0mit\u00a0neu\u00a0diagnostiziertem\u00a0MM\u00a0eingeschlossen ,\u00a0die\u00a0nicht\u00a0f\u00fcr\u00a0\neine\u00a0Hochdosischemotherapie\u00a0mit\u00a0nachfolgender\u00a0ASZT\u00a0infrage\u00a0kame n.\u00a0Sie\u00a0beka\u2010\nmen\u00a0entweder\u00a0Daratumumab\u00a0in\u00a0Kombination\u00a0mit\u00a0Bortezomib,\u00a0Melphal an\u00a0und\u00a0\nPrednison\u00a0(Daratumumab\u2010Arm;\u00a0n\u00a0=\u00a0350)\u00a0oder\u00a0Bortezomib,\u00a0Melphalan \u00a0und\u00a0Predni\u2010\nson\u00a0(Kontrollarm;\u00a0n\u00a0=\u00a0356).\u00a0Die\u00a0 Randomisierung\u00a0erfolgte\u00a0stratif iziert\u00a0nach\u00a0ISS\u2010\nStadium.\u00a0Die\u00a0Patienten\u00a0waren\u00a0bei\u00a0Randomisierung\u00a0im\u00a0Median\u00a071\u00a0Ja hre\u00a0alt\u00a0und\u00a0die\u00a0\nDiagnose\u00a0wurde\u00a0im\u00a0Median\u00a0vor\u00a00,8\u00a0Monaten\u00a0(Min\u00a0\u2013\u00a0Max:\u00a00,1\u00a0\u2013\u00a025,3 )\u00a0gestellt.\u00a0In\u00a0\nbeiden\u00a0Studienarmen\u00a0erfolgt\u00a0die\u00a0Gabe\u00a0der\u00a0Studienmedikation\u00a0in\u00a04 2\u2010Tage\u2010Zyklen.\u00a0\nDie\u00a0Gabe\u00a0von\u00a0Bortezomib,\u00a0Melpha lan\u00a0und\u00a0Prednison\u00a0mit\u00a0oder\u00a0ohne\u00a0 Daratumumab\u00a0\nerfolgt\u00a0f\u00fcr\u00a0maximal\u00a0neun\u00a0Zyklen.\u00a0Ab\u00a0dem\u00a010.\u00a0Zyklus\u00a0wird\u00a0im\u00a0Dara tumumab\u2010Arm\u00a0\neine\u00a0Monotherapie\u00a0mit\u00a0Daratumumab\u00a0bis\u00a0zu\u00a0einer\u00a0Krankheitsprogre ssion\u00a0oder\u00a0\ninakzeptabler\u00a0Toxizit\u00e4t\u00a0fort gef\u00fchrt\u00a0(Mateos\u00a0et\u00a0al.,\u00a02018).\u00a0\nPrim\u00e4rer\u00a0Endpunkt\u00a0der\u00a0Studie\u00a0ist\u00a0das\u00a0PFS.\u00a0Als\u00a0sekund\u00e4re\u00a0Endpunk te\u00a0werden\u00a0u.a.\u00a0\ndie\u00a0ORR,\u00a0das\u00a0OS\u00a0und\u00a0die\u00a0Sicherheit \u00a0herangezogen.\u00a0Die\u00a0pr\u00e4spezifi zierte\u00a0Interimsana\u2010\nlyse\u00a0erfolgte\u00a0beim\u00a0Erreichen\u00a0von\u00a0231\u00a0Ereignissen\u00a0im\u00a0prim\u00e4ren\u00a0En dpunkt\u00a0PFS\u00a0(Da\u2010\ntenschnitt:\u00a012.06.2017).\u00a0Zu\u00a0diesem\u00a0Zeitpunkt\u00a0hatten\u00a0276\u00a0Patient en\u00a0(79,8\u00a0%)\u00a0im\u00a0\nDaratumumab\u2010Arm\u00a0und\u00a0220\u00a0Patienten\u00a0(62,1\u00a0%)\u00a0im\u00a0Kontrollarm\u00a0die\u00a0n eun\u00a0Zyklen\u00a0\nmit\u00a0Bortezomib,\u00a0Melphalan\u00a0und\u00a0P rednison\u00a0abgeschlossen.\u00a0W\u00e4hrend\u00a0 der\u00a0Kombina\u2010\ntionstherapie\u00a0brachen\u00a019,4\u00a0%\u00a0der\u00a0Patienten\u00a0im\u00a0Daratumumab\u2010Arm\u00a0u nd\u00a033,1\u00a0%\u00a0der\u00a0\nPatienten\u00a0im\u00a0Kontrollarm\u00a0die\u00a0St udie\u00a0ab.\u00a0Der\u00a0Anteil\u00a0der\u00a0Patiente n,\u00a0die\u00a0die\u00a0Studie\u00a0\naufgrund\u00a0einer\u00a0Krankheitsprogression\u00a0(6,6\u00a0%\u00a0bzw.\u00a013,3\u00a0%)\u00a0oder\u00a0U AE\u00a0(4,9\u00a0%\u00a0bzw.\u00a0\n9,3\u00a0%)\u00a0abbrachen,\u00a0war\u00a0unter\u00a0Darat umumab\u00a0niedriger.\u00a0Die\u00a0mediane\u00a0 Behandlungs\u2010\nzeit\u00a0betrug\u00a014,7\u00a0Monate\u00a0im\u00a0Daratumumab\u2010Arm\u00a0und\u00a012,0\u00a0Monate\u00a0im\u00a0K ontrollarm.\u00a0\nKrankheitsprogression\u00a0oder\u00a0Tod\u00a0traten\u00a0bei\u00a088\u00a0(25,1\u00a0%)\u00a0der\u00a0Patie nten\u00a0im\u00a0Daratu\u2010\nmumab\u2010Arm\u00a0und\u00a0bei\u00a0143\u00a0(40,2\u00a0%)\u00a0der\u00a0Patienten\u00a0im\u00a0Kontrollarm\u00a0auf .\u00a0Das\u00a0HR\u00a0f\u00fcr\u00a0\neine\u00a0Krankheitsprogression\u00a0oder\u00a0Tod\u00a0unter\u00a0Daratumumab\u00a0im\u00a0Vergle ich\u00a0zum\u00a0Kon\u2010\ntrollarm\u00a0war\u00a00,50\u00a0(95\u00a0%\u00a0KI\u00a0[0,38;\u00a00,65],\u00a0p\u00a0<\u00a00,001).\u00a0Die\u00a012\u2010Mon ats\u2010Rate\u00a0des\u00a0PFS\u00a0\nbetrug\u00a083,7\u00a0%\u00a0(95\u00a0%\u00a0KI\u00a0[82,6;\u00a089,9])\u00a0im\u00a0Daratumumab\u2010Arm\u00a0und\u00a076, 0\u00a0%\u00a0(95\u00a0%\u00a0KI\u00a0\n[71,0;\u00a080,2])\u00a0im\u00a0Kontrollarm.\u00a0Das\u00a0mediane\u00a0PFS\u00a0war\u00a0im\u00a0Daratumuma b\u2010Arm\u00a0noch\u00a074\u00a0nicht\u00a0erreicht,\u00a0im\u00a0Kontrollarm\u00a0betrug\u00a0es\u00a018,1\u00a0Monate.\u00a0Das\u00a0media ne\u00a0OS\u00a0war\u00a0in\u00a0\nbeiden\u00a0Armen\u00a0noch\u00a0nicht\u00a0erreicht\u00a0(Mateos\u00a0et\u00a0al.,\u00a02018).\u00a0Die\u00a0Stu die\u00a0l\u00e4uft\u00a0noch\u00a0(NIH,\u00a0\n2019c).\u00a0\nDie\u00a0h\u00e4ufigsten\u00a0UAE\u00a0in\u00a0beiden\u00a0Arm en\u00a0der\u00a0Sicherheitspopulation\u00a0wa ren\u00a0Neutropenie\u00a0\n(49,7\u00a0%\u00a0vs.\u00a052,5\u00a0%),\u00a0Thrombozytopenie\u00a0(48,8\u00a0%\u00a0vs.\u00a053,7\u00a0%),\u00a0peri phere\u00a0Neuropathie\u00a0\n(28,3\u00a0%\u00a0vs.\u00a034,2\u00a0%),\u00a0An\u00e4mie\u00a0(28,0\u00a0%\u00a0vs.\u00a037,6\u00a0%)\u00a0und\u00a0Atemwegsinf ektionen\u00a0(26,3\u00a0%\u00a0\nvs.\u00a013,8\u00a0%)\u00a0(Mateos\u00a0et\u00a0al.,\u00a02018).\u00a0\nSchwere\u00a0Neutropenien\u00a0vom\u00a0Grad\u00a03\u00a0\u2013\u00a04\u00a0CTCAE\u00a0traten\u00a0im\u00a0Daratumumab \u2010Arm\u00a0h\u00e4ufi\u2010\nger\u00a0als\u00a0unter\u00a0der\u00a0Kontrolle\u00a0auf:\u00a039,9\u00a0%\u00a0vs.\u00a038,7\u00a0%.\u00a0Schwere\u00a0Inf ektionen\u00a0vom\u00a0Grad\u00a0\u00a0\n3\u00a0\u2013\u00a04\u00a0CTCAE\u00a0wurden\u00a0bei\u00a023,1\u00a0%\u00a0der\u00a0Patienten\u00a0im\u00a0Daratumumab\u2010Arm\u00a0 und\u00a014,7\u00a0%\u00a0\nder\u00a0Patienten\u00a0im\u00a0Kontrollarm\u00a0ber ichtet,\u00a0darunter\u00a0als\u00a0h\u00e4ufigste\u00a0 Pneumonie\u00a0(11,3\u00a0%\u00a0\nvs.\u00a04,0\u00a0%).\u00a0Ein\u00a0Therapieabbruch\u00a0aufgrund\u00a0von\u00a0Infektionen\u00a0erfolg te\u00a0bei\u00a00,9\u00a0%\u00a0der\u00a0\nP a t i e n t e n \u00a0i m \u00a0D a r a t u m um a b \u2010 A r m \u00a0u nd \u00a0b e i \u00a01 , 4 \u00a0 % \u00a0d e r \u00a0P a t i e n t e n \u00a0i m \u00a0K o n trollarm.\u00a0\nTodesf\u00e4lle\u00a0aufgrund\u00a0von\u00a0Infektionen\u00a0traten\u00a0bei\u00a0f\u00fcnf\u00a0Patienten\u00a0( 1,4\u00a0%)\u00a0im\u00a0Daratu\u2010\nmumab\u2010Arm\u00a0auf\u00a0(zwei\u00a0Pneumonien,\u00a0 Peritonitis,\u00a0septischer\u00a0Schock\u00a0 und\u00a0eine\u00a0obere\u00a0\nAtemwegsinfektion)\u00a0 und\u00a0 bei\u00a0 vier\u00a0 Patienten\u00a0 (1,1\u00a0%)\u00a0 im\u00a0 Kontrollar m\u00a0 (septischer\u00a0\nSchock,\u00a0Candidasepsis,\u00a0Pneumon ie,\u00a0Sepsis)\u00a0(Mateos\u00a0et\u00a0al.,\u00a02018) .\u00a0\nSchwerwiegende\u00a0UAE \u00a0wurden\u00a0bei\u00a041,6\u00a0%\u00a0der\u00a0Patienten\u00a0im\u00a0Daratumumab\u2010Arm\u00a0und\u00a0\n32,5\u00a0%\u00a0der\u00a0Patienten\u00a0im\u00a0Kontrollarm\u00a0berichtet.\u00a0Ein\u00a0Therapieabbr uch\u00a0aufgrund\u00a0von\u00a0\nUAE\u00a0wurde\u00a0f\u00fcr\u00a04,9\u00a0%\u00a0der\u00a0Patienten\u00a0im\u00a0Daratumumab\u2010Arm\u00a0und\u00a09,0\u00a0%\u00a0 der\u00a0Patienten\u00a0\nim\u00a0Kontrollarm\u00a0berichtet.\u00a0Infusionsbedingte\u00a0Reaktionen,\u00a0meist\u00a0w \u00e4hrend\u00a0der\u00a0ersten\u00a0\nInfusion,\u00a0traten\u00a0unter\u00a0Daratumumab\u00a0bei\u00a027,7\u00a0%\u00a0der\u00a0Patienten\u00a0auf .\u00a0Ein\u00a0Tumorlyse\u2010\nsyndrom\u00a0wurde\u00a0f\u00fcr\u00a0je\u00a0zwei\u00a0Patienten\u00a0(0,6\u00a0%)\u00a0in\u00a0jedem\u00a0Behandlung sarm\u00a0berichtet\u00a0\n(Mateos\u00a0et\u00a0al.,\u00a02018).\u00a0\nDie\u00a0initiale\u00a0Nutzenbewertung\u00a0nach\u00a0\u00a7\u00a035a\u00a0SGB\u00a0V\u00a0von\u00a0Darzalex\u00ae\u00a0erf olgte\u00a0im\u00a0Dezem\u2010\nber\u00a02016.\u00a0Durch\u00a0die\u00a0Zulassung\u00a0als\u00a0 Orphan\u2010Arzneimittel\u00a0galt\u00a0der\u00a0 Zusatznutzen \u00a0au\u2010\ntomatisch\u00a0als\u00a0 belegt.\u00a0In\u00a0seinem\u00a0Beschluss\u00a0vom\u00a01.\u00a0Dezember\u00a02016\u00a0betonte\u00a0der\u00a0\u00a0\nG\u2010BA,\u00a0dass\u00a0das\u00a0Ausma\u00df\u00a0\u201edes\u00a0allein\u00a0aus\u00a0rechtlicher\u00a0Sicht\u00a0nach\u00a0\u00a7\u00a0 35a\u00a0[\u2026]\u00a0zu\u00a0unter\u2010\nstellenden\u00a0Zusatznutzens\u201c\u00a0(G\u2010BA,\u00a02016,\u00a0S.\u00a05)\u00a0von\u00a0Daratumumab\u00a0 nicht\u00a0quantifizier\u2010\nbar\u00a0ist.\u00a0Die\u00a0Entscheidung\u00a0basierte\u00a0auf\u00a0der\u00a0Zulassungsstudie\u00a0SIRIUS ,\u00a0wobei\u00a0durch\u00a0\ndie\u00a0 fehlende\u00a0 Kontrollgruppe\u00a0 keine\u00a0 quantitative\u00a0 vergleichende\u00a0 Be urteilung\u00a0 des\u00a0\nAusma\u00dfes\u00a0des\u00a0Zusatznutzens\u00a0v on\u00a0Daratumumab\u00a0m\u00f6glich\u00a0war.\u00a0\nDes\u00a0Weiteren\u00a0legte\u00a0der\u00a0pU\u00a0einen\u00a0nicht\u2010adjustierten\u00a0indirekten\u00a0V ergleich\u00a0in\u00a0den\u00a0\nEndpunktkategorien\u00a0Mortalit\u00e4t\u00a0und\u00a0UAE\u00a0vor\u00a0sowie\u00a0einen\u00a0 Matching \u2010adjustierten\u00a0\nindirekten\u00a0Vergleich\u00a0zwischen\u00a0der\u00a0Therapie\u00a0mit\u00a0Daratumumab\u00a0und\u00a0 der\u00a0Kombinati\u2010\nonstherapie\u00a0mit\u00a0Pomalidomid\u00a0und\u00a0ni edrig\u00a0dosiertem\u00a0Dexamethason\u00a0 in\u00a0der\u00a0End\u2010\npunktkategorie\u00a0Mortalit\u00e4t.\u00a0Diese\u00a0wurden\u00a0vom\u00a0G\u2010BA\u00a0aufgrund\u00a0von\u00a0m ethodischen\u00a075\u00a0Limitationen\u00a0nicht\u00a0herangezogen.\u00a0Der\u00a0Beschluss\u00a0wurde\u00a0vom\u00a0G\u2010BA\u00a0b is\u00a0zum\u00a030.\u00a0\nNovember\u00a02019\u00a0 befristet\u00a0und\u00a0mit\u00a0der\u00a0Forderung\u00a0der\u00a0Vorlage\u00a0weiterer\u00a0Studienda\u2010\nten\u00a0zu\u00a0Daratumumab\u00a0in\u00a0der\u00a0Mono therapie\u00a0verbunden\u00a0(G\u2010BA,\u00a02016). \u00a0\u00a0\nDie\u00a0Indikationserweiterung\u00a0f\u00fcr\u00a0Daratumumab\u00a0im\u00a0April\u00a02017\u00a0in\u00a0Kom bination\u00a0mit\u00a0\nLenalidomid\u00a0und\u00a0Dexamethason\u00a0oder\u00a0Bortezomib\u00a0und\u00a0Dexamethason\u00a0f \u00fcr\u00a0die\u00a0Be\u2010\nhandlung\u00a0erwachsener\u00a0Patienten\u00a0mit\u00a0MM\u00a0veranlasste\u00a0eine\u00a0neue\u00a0Nut zenbewertung\u00a0\nnach\u00a0\u00a7\u00a035a\u00a0SGB\u00a0V,\u00a0die\u00a0im\u00a0Juni\u00a02017\u00a0jedoch\u00a0vom\u00a0G\u2010BA\u00a0vorl\u00e4ufig\u00a0ei ngestellt\u00a0wurde.\u00a0\nGrund\u00a0daf\u00fcr\u00a0war\u00a0die\u00a0\u00dcberschreitung\u00a0der\u00a0Umsatzgrenze\u00a0von\u00a050\u00a0Mio. \u00a0\u20ac\u00a0f\u00fcr\u00a0Daratu\u2010\nmumab\u00a0in\u00a0der\u00a0GKV\u00a0in\u00a0den\u00a0letzten\u00a0 zw\u00f6lf\u00a0Kalendermonaten\u00a0(G\u2010BA,\u00a020 17).\u00a0Im\u00a0August\u00a0\n2017\u00a0begann\u00a0dann\u00a0eine\u00a0neue\u00a0Nutzenbewertung\u00a0des\u00a0 Orphan\u2010Arzneimittels\u00a0nach\u00a0\n\u00a7\u00a035a\u00a0SGB\u00a0V\u00a0f\u00fcr\u00a0die\u00a0beiden\u00a0zu gelassenen\u00a0Anwendungsgebiete.\u00a0\nAm\u00a015.\u00a0Februar\u00a02018\u00a0entschied\u00a0der\u00a0G\u2010BA,\u00a0dass\u00a0der\u00a0 Zusatznutzen \u00a0von\u00a0Daratumum\u2010\nab\u00a0 in\u00a0 der\u00a0 Monotherapie\u00a0 nicht\u00a0 belegt \u00a0 ist.\u00a0 F\u00fcr\u00a0 die\u00a0 Kombinationstherapie\u00a0 mit\u00a0\nLenalidomid\u00a0und\u00a0Dexamethason\u00a0od er\u00a0Bortezomib\u00a0und\u00a0Dexamethason\u00a0b estand\u00a0aus\u00a0\nSicht\u00a0des\u00a0G\u2010BA\u00a0ein\u00a0 Hinweis\u00a0auf\u00a0einen\u00a0betr\u00e4chtlichen\u00a0Zusatznutzen \u00a0(G\u2010BA,\u00a02018).\u00a0\nF\u00fcr\u00a0die\u00a0Bewertung\u00a0der\u00a0Monotherapie\u00a0mit\u00a0Daratumumab\u00a0wurde\u00a0vom\u00a0pU \u00a0ein\u00a0nicht\u2010\nadjustierter\u00a0indirekter\u00a0Vergleich\u00a0der\u00a0einarmigen\u00a0Zulassungsstud ie\u00a0SIRIUS\u00a0mit\u00a0einer\u00a0\nretrospektiven\u00a0Beobachtungsstudie.\u00a0F\u00fcr\u00a0die\u00a0Beobachtungsstudie\u00a0w urden\u00a0die\u00a0Da\u2010\nten\u00a0von\u00a0543\u00a0Patienten\u00a0herangezogen,\u00a0die\u00a0retrospektiv\u00a0aus\u00a0Kranke nakten\u00a0identifi\u2010\nziert\u00a0wurden.\u00a0Dieser\u00a0Vergleich\u00a0w ar\u00a0aus\u00a0Sicht\u00a0des\u00a0G\u2010BA\u00a0nicht\u00a0gee ignet\u00a0(G\u2010BA,\u00a02018).\u00a0\nF\u00fcr\u00a0die\u00a0Nutzenbewertung\u00a0in\u00a0der\u00a0Ko mbinationstherapie\u00a0legte\u00a0der\u00a0p U\u00a0die\u00a0Ergebnisse\u00a0\nder\u00a0beiden\u00a0f\u00fcr\u00a0die\u00a0Zulassung\u00a0rel evanten\u00a0(pivotalen)\u00a0Phase\u2010III\u2010S tudien\u00a0POLLUX\u00a0und\u00a0\nCASTOR\u00a0mit\u00a0dem\u00a0Datenschnitt\u00a030.06.2016\u00a0vor.\u00a0F\u00fcr\u00a0die\u00a0Bewertung\u00a0d es\u00a0Zusatznut\u2010\nzens\u00a0wurden\u00a0vom\u00a0G\u2010BA\u00a0beide\u00a0St udien\u00a0gemeinsam\u00a0ausgewertet.\u00a0\nD e r \u00a0G \u2010 B A \u00a0b e w e r t e t e \u00a0d e n \u00a0s t a t i s t i s c h \u00a0s i g n i f i k a n t e n \u00a0V o r t e i l \u00a0d e r \u00a0D a ratumumab \u2010\nKombinationstherapien\u00a0im\u00a0Endpunkt\u00a0OS\u00a0als\u00a0eine\u00a0moderate\u00a0Verl\u00e4nge rung\u00a0der\u00a0Le\u2010\nbensdauer.\u00a0Hinsichtlich\u00a0des\u00a0Ge sundheitsstatus\u00a0und\u00a0der\u00a0Symptomat ik\u00a0lagen\u00a0keine\u00a0\nstatistisch\u00a0signifikanten\u00a0Unterschiede\u00a0zwischen\u00a0den\u00a0Daratumumab \u2010Kombinations\u2010\ntherapien\u00a0und\u00a0der\u00a0zVT\u00a0vor.\u00a0Es\u00a0zeigten\u00a0sich\u00a0aber\u00a0Nachteile\u00a0der\u00a0D aratumumab\u2010\nKombinationstherapien\u00a0aufgrund\u00a0der\u00a0Zunahme\u00a0schwerer\u00a0UAE\u00a0(CTCAE\u00a0 Grad\u00a0\u2265\u00a03)\u00a0\nund\u00a0 spezifischer\u00a0 UAE\u00a0 (febrile\u00a0 Neutropenie,\u00a0 Erkrankungen\u00a0 des\u00a0 Gas trointestinal\u2010\ntrakts\u00a0und\u00a0Erkrankungen\u00a0der\u00a0Atemwege,\u00a0des\u00a0Brustraums\u00a0und\u00a0Medias tinums).\u00a0Die\u00a0\nRate\u00a0der\u00a0Therapieabbr\u00fcche\u00a0aufgrun d\u00a0von\u00a0UAE\u00a0war\u00a0in\u00a0beiden\u00a0Armen\u00a0 vergleichbar,\u00a0\nsodass\u00a0die\u00a0im\u00a0Daratumumab\u2010Arm\u00a0beobachteten\u00a0UAE\u00a0als\u00a0f\u00fcr\u00a0die\u00a0Pati enten\u00a0relevant,\u00a0\naber\u00a0als\u00a0\u00fcberwiegend\u00a0kontrollierbar\u00a0und\u00a0behandelbar\u00a0eingestuft\u00a0 wurden.\u00a0Vom\u00a0G\u2010\nBA\u00a0wurden\u00a0die\u00a0Ergebnisse\u00a0zu\u00a0den\u00a0Schadensendpunkten\u00a0vor\u00a0dem\u00a0Hint ergrund,\u00a0dass\u00a076\u00a0keine\u00a0Verschlechterung\u00a0der\u00a0Lebensqualit\u00e4t\u00a0auftrat\u00a0und\u00a0es\u00a0sich\u00a0u m\u00a0eine\u00a0schwere\u00a0\nErkrankung\u00a0handelt,\u00a0als\u00a0nicht\u00a0schwerwiegend\u00a0eingestuft\u00a0(G\u2010BA,\u00a02 018).\u00a0\nDer\u00a0Beschluss \u00a0wurde\u00a0vom\u00a0G\u2010BA\u00a0bis\u00a0zum\u00a001.10.2021\u00a0 befristet,\u00a0um\u00a0die\u00a0Endergebnis\u2010\nse\u00a0der\u00a0noch\u00a0laufenden\u00a0Studien\u00a0POLLUX\u00a0und\u00a0CASTOR\u00a0zum\u00a0OS\u00a0abzuwart en,\u00a0die\u00a0als\u00a0\nrelevant\u00a0f\u00fcr\u00a0die\u00a0Bewertung\u00a0erachtet\u00a0wurden\u00a0(G\u2010BA,\u00a02018).\u00a0\nF\u00fcr\u00a0 die\u00a0 Nutzenbewertung\u00a0 von\u00a0 Daratumumab\u00a0 in\u00a0 Kombination\u00a0 mit\u00a0 Bort ezomib,\u00a0\nMelphalan\u00a0 und\u00a0 Prednison\u00a0 f\u00fcr\u00a0 die\u00a0 Behandlung\u00a0 erwachsener\u00a0 Patiente n\u00a0 mit\u00a0 neu\u00a0\ndiagnostiziertem\u00a0MM,\u00a0die\u00a0f\u00fcr\u00a0eine\u00a0ASZT\u00a0nicht\u00a0geeignet\u00a0sind,\u00a0leg te\u00a0der\u00a0pU\u00a0die\u00a0Daten\u00a0\nder\u00a0Zulassungsstudie\u00a0ALCYONE\u00a0mi t\u00a0dem\u00a0Datenschnitt\u00a0vom\u00a012.06.201 8\u00a0vor.\u00a0Hin\u2010\nsichtlich\u00a0des\u00a0OS\u00a0lag\u00a0ein\u00a0statistisch\u00a0signifikanter\u00a0Vorteil\u00a0zugu nsten\u00a0der\u00a0Daratumum\u2010\nab\u2010Kombinationstherapie\u00a0vor,\u00a0der\u00a0vom\u00a0G\u2010BA\u00a0als\u00a0moderate\u00a0Verl\u00e4nge rung\u00a0der\u00a0Le\u2010\nbenszeit\u00a0gewertet\u00a0wurde.\u00a0Zudem\u00a0zeigten\u00a0sich\u00a0ein\u00a0statistisch\u00a0sig nifikanter,\u00a0gering\u2010\nf\u00fcgiger\u00a0Unterschied\u00a0hinsichtlich\u00a0 des\u00a0Symptoms\u00a0Fatigue\u00a0und\u00a0ein\u00a0V orteil\u00a0hinsichtlich\u00a0\nder\u00a0 Therapieabbr\u00fcche\u00a0 aufgrund\u00a0 von\u00a0 UAE\u00a0 zugunsten\u00a0 der\u00a0 Daratumumab \u2010\nKombinationstherapie\u00a0(G\u2010BA,\u00a02019).\u00a0\nDie\u00a0Ergebnisse\u00a0der\u00a0ALCYONE\u2010Studi e\u00a0waren\u00a0mit\u00a0Unsicherheiten\u00a0bez\u00fc glich\u00a0der\u00a0Studi\u2010\nenpopulation\u00a0 behaftet.\u00a0 So\u00a0 wurden\u00a0 auch\u00a0 Patienten\u00a0 eingeschlossen, \u00a0d i e \u00a0g e m \u00e4 \u00df \u00a0\naktueller\u00a0medizinischen\u00a0Kriterien\u00a0f\u00fcr\u00a0eine\u00a0ASZT\u00a0geeignet\u00a0waren. \u00a0Zudem\u00a0wurde\u00a0\nBortezomib\u00a0im\u00a0Vergleichsarm\u00a0in\u00a0einer\u00a0im\u00a0Vergleich\u00a0zur\u00a0Fachinfor mation\u00a0reduzier\u2010\nten\u00a0Dosierung\u00a0verabreicht.\u00a0Unter\u00a0Ber\u00fccksichtigung\u00a0dieser\u00a0Unsich erheiten\u00a0leitete\u00a0\nder\u00a0G\u2010BA\u00a0einen\u00a0Anhaltspunkt\u00a0f\u00fcr\u00a0einen\u00a0betr\u00e4chtlichen\u00a0Zusatznutz en\u00a0von\u00a0Daratu\u2010\nmumab\u00a0ab.\u00a0Da\u00a0der\u00a0finale\u00a0Datenschnitt\u00a0der\u00a0Studie\u00a0ALCYONE\u00a0f\u00fcr\u00a0End e\u00a02021\u00a0geplant\u00a0\nist,\u00a0befristete \u00a0der\u00a0G\u2010BA\u00a0den\u00a0Beschluss\u00a0bis\u00a0zum\u00a01.\u00a0M\u00e4rz\u00a02022\u00a0(G\u2010BA,\u00a02019).\u00a0\nVerf\u00fcgbare\u00a0Therapien \u00a0 (Zusatz\u2010)Nutzen \u00a0 Kosten\u00a0\n\u00a0\nerster\u00a0CD38\u2010\nAntik\u00f6rper\u00a0zur\u00a0\nBehandlung\u00a0des\u00a0MM\u00a0\u00a0G\u2010BA\u2010Beschluss:\u00a0kein\u00a0ZN\u00a0\n(Monotherapie)\u00a0bzw.\u00a0\nbetr\u00e4chtl.\u00a0ZN\u00a0\n(Kombinationstherapien)\u00a0b.\u00a0\nfortgeschr.\u00a0MM\u00a0und\u00a0\nbetr\u00e4chtlicher\u00a0ZN\u00a0bei\u00a0\nneudiagnostiziertem\u00a0MM;\u00a0\nSignifikante\u00a0Ergebnisse\u00a0\nbez\u00fcglich\u00a0PFS\u00a0in\u00a0den\u00a0\nKombinationstherapien\u00a0\u00a0\nKostenvergleich\u00a0beim\u00a0\u00a0\nOrphan\u2010Arzneimittel\u00a0\nwegen\u00a0\u00dcberschreitens\u00a0der\u00a0\u00a0\n50\u2010Mio.\u00a0\u20ac\u2010Umsatzgrenze\u00a0und\u00a0\nIndikationsweiterung:\u00a0\u00a0\nteils\u00a0teurer\u00a0als\u00a0zVT \u00a0\nErl\u00e4uterung\u00a0der\u00a0Farben:\u00a0Verf\u00fcgbare\u00a0Therapien:\u00a0rot\u00a0=\u00a0weitere\u00a0The rapieoption,\u00a0gelb\u00a0=\u00a0Subgruppen\u2010Novit\u00e4t,\u00a0gr\u00fcn\u00a0=\u00a0Solist;\u00a0(Zusatz\u2010 )\u00a0\nNutzen:\u00a0rot\u00a0=\u00a0keine\u00a0Verbesserung\u00a0oder\u00a0schlechte\u00a0Nutzen/Schaden\u2010 Relation,\u00a0gelb\u00a0=\u00a0teilweise\u00a0Verbesserungen,\u00a0gr\u00fcn\u00a0=\u00a0Verbesserung\u00a0\nharter\u00a0Endpunkte;\u00a0Kosten:\u00a0rot\u00a0=\u00a0teurer\u00a0als\u00a0bestehende\u00a0Therapien ,\u00a0gelb\u00a0=\u00a0ungef\u00e4hr\u00a0gleich\u00a0bzw.\u00a0teils/teils,\u00a0gr\u00fcn\u00a0=\u00a0g\u00fcnstiger\u00a0als \u00a0\nbestehende\u00a0Therapien\u00a0\n\u00a0\u00a0\n77\u00a0Wie\u00a0bewerten\u00a0andere?*\u00a0\nBewertung\u00a0nach\u00a0\nFricke\u00a0et\u00a0al.\u00a0a\u2010t\u2010Bewertung\u00a0 AMB\u00a0 Prescrire\u00a0 PZ\u00a0\nA\u00a0 \u2013\u00a0Weitere\u00a0vergl.\u00a0\nStudien\u00a0zur\u00a0Wirk\u2010\nsamkeit\u00a0und\u00a0Sicher\u2010\nheit\u00a0der\u00a0neuen\u00a0\nTherapieoptionen\u00a0\nf\u00fcr\u00a0das\u00a0MM\u00a0erfor\u2010\nderl.,\u00a0auch\u00a0wgn.\u00a0der\u00a0\nsehr\u00a0hohen\u00a0Jahres\u2010\ntherapiekosten\u00a0Nothing\u00a0new\u00a0 Sprunginnovation\u00a0\n*Nur\u00a0Bewertung\u00a0der\u00a0initialen\u00a0Zulassung\u00a0f.d.\u00a0Monotherapie\u00a0\nKosten\u00a0\nWirkstoff\u00a0 Behandlungsmodus\u00a0 Behandlungstage\u00a0 Jahrestherapiekosten\u00a0\nzu\u00a0bewertendes\u00a0Arzneimittel \u00a0\u00a0 \u00a0 \u00a0\nDaratumumab\u00a0(Monotherapie)\u00a0 Woche\u00a01\u00a0\u2013\u00a08:\u00a01.232\u00a0mg\u00a0\n1x\u00a0w\u00f6ch.\u00a0\u00a0\nWoche\u00a09\u00a0\u2013\u00a024:\u00a01.232\u00a0mg\u00a0\nalle\u00a02\u00a0Wochen\u00a0\u00a0\nab\u00a0Woche\u00a025:\u00a0\u00a0\n1.232\u00a0mg\u00a0alle\u00a04\u00a0Wochen\u00a0\u00a0\n(Folgejahr:\u00a01.232\u00a0mg\u00a0alle\u00a0\n4\u00a0Wochen)\u00a023\u00a0\n(13)\u00a0148.239,60\u00a0\u20ac\u00a0\n(83.787,60\u00a0\u20ac)\u00a0\nDaratumumab\u00a0 s.o.\u00a0 s.o.\u00a0 s.o.\u00a0\n+\u00a0Lenalidomid\u00a0 25\u00a0mg\u00a0an\u00a0Tag\u00a01\u00a0\u2013\u00a0211+2\u00a0 273\u00a0 104.707,98\u00a0\u20ac\u00a0\n+\u00a0Dexamethason\u00a0 40\u00a0mg\u00a0Tag\u00a01,\u00a08,\u00a015,\u00a0221+2\u00a0\u00a0\n\u00a029\u00a0\n(39)\u00a0108,87\u00a0\u20ac\u00a0\n(146,41\u00a0\u20ac)\u00a0\n\u00a0 \u00a0 \u00a0 253.056,45\u00a0\u20ac\u00a0\n(188.641,99\u00a0\u20ac) \u00a0\noder\u00a0 \u00a0 \u00a0 \u00a0\nDaratumumab \u00a0 Woche\u00a01\u00a0\u2013\u00a09:\u00a0\u00a0\n1.232\u00a0mg\u00a01x\u00a0w\u00f6ch.\u00a0\u00a0\nWoche\u00a010\u00a0\u2013\u00a024:\u00a0\n1.232\u00a0\u00a0mg\u00a0alle\u00a03\u00a0Wochen\u00a0\u00a0\nab\u00a0Woche\u00a025:\u00a01.232\u00a0mg\u00a0\nalle\u00a04\u00a0Wochen\u00a0\n(Folgejahr:\u00a01.232\u00a0mg\u00a0alle\u00a0\n4\u00a0Wochen)\u00a021\u00a0\n(13)\u00a0135.349,20\u00a0\u20ac\u00a0\n(83.787,60\u00a0\u20ac) \u00a0\n+\u00a0Bortezomib\u00a0 2,47\u00a0mg\u00a0an\u00a0Tag\u00a01,\u00a04,\u00a08,\u00a0113+4\u00a0 32\u00a0 52.584,00\u00a0\u20ac\u00a0\n+\u00a0Dexamethason\u00a0 20\u00a0mg\u00a0an\u00a0Tag\u00a01,\u00a02,\u00a04,\u00a05,\u00a0\n8,\u00a09,\u00a011,\u00a0123+4\u00a053\u00a0 125,66\u00a0\u20ac\u00a0\n\u00a0 \u00a0 \u00a0 188.058,86\u00a0\u20ac\u00a0\n(136.497,26\u00a0\u20ac)\u00a0\n\u00a0\n\u00a0\u00a078\u00a0Wirkstoff \u00a0 Behandlungsmodus \u00a0Behandlungstage \u00a0Jahrestherapiekosten \u00a0\nzVT\u00a0a)\u00a0Kombinationstherapie \u00a0\u00a0 \u00a0 \u00a0\nBortezomib\u00a0 2,47\u00a0mg\u00a0an\u00a0Tag\u00a01,\u00a04,\u00a08,\u00a0113+4\u00a0 32\u00a0 \u00a0\n+\u00a0Doxorubicin\u00a0 30\u00a0mg/m\u00b2\u00a0KOF\u00a0an\u00a0Tag\u00a043+4\u00a0 8\u00a0 73.529,04\u00a0\u20ac\u00a0\nLenalidomid\u00a0 25\u00a0mg\u00a0an\u00a0Tag\u00a01\u00a0\u2013\u00a0211+2\u00a0\u00a0\n\u00a0273\u00a0 \u00a0\n+\u00a0Dexamethason\u00a0 Zyklus\u00a01\u00a0\u2013\u00a041+2:\u00a0\n40\u00a0mg\u00a0an\u00a0Tag\u00a01\u00a0\u2013\u00a04,\u00a09\u00a0\u2013\u00a012,\u00a0\u00a0\n17\u00a0\u2013\u00a020\u00a0\u00a0\nab\u00a05.\u00a0Zyklus:\u00a040\u00a0mg\u00a0an\u00a0Tag\u00a0\n1\u00a0\u2013\u00a04\u00a084\u00a0\n(52)\u00a0105.023,32\u00a0\u20ac\u00a0\n(104.903,19\u00a0\u20ac) \u00a0\nBortezomib\u00a0 2,47\u00a0mg\u00a0an\u00a0Tag\u00a01,\u00a04,\u00a08,\u00a0113+5\u00a0 16\u00a0\u2013\u00a032\u00a0 \u00a0\n+\u00a0Dexamethason\u00a0 20\u00a0mg\u00a0an\u00a0Tag\u00a01,\u00a02,\u00a04,\u00a05,\u00a0\n8,\u00a09,\u00a011,\u00a0123+5\u00a032\u00a0\u2013\u00a064\u00a0 26.367,87\u00a0\u2013\u00a052.735,74\u00a0\u20ac\u00a0\nElotuzumab\u00a0 Zyklus\u00a01\u00a0\u2013\u00a021+2:\u00a010\u00a0mg/kg\u00a0\nKG\u00a0an\u00a0Tag\u00a01,\u00a08,\u00a015,\u00a022\u00a0\nab\u00a0Zyklus\u00a031+2:\u00a010\u00a0mg/kg\u00a0\nKG\u00a0an\u00a0Tag\u00a01,\u00a015\u00a030\u00a0\n(26)\u00a0\u00a0\n+\u00a0Lenalidomid\u00a0 25\u00a0mg\u00a0an\u00a0Tag\u00a01\u00a0\u2013\u00a0211+2\u00a0 273\u00a0 \u00a0\n+\u00a0Dexamethason\u00a0 Zyklus\u00a01\u00a0\u2013\u00a021+2:\u00a028\u00a0mg\u00a0an\u00a0\nTag\u00a01,\u00a08,\u00a015,\u00a022\u00a0\nab\u00a03.\u00a0Zyklus1+2:\u00a028\u00a0mg\u00a0an\u00a0\nTag\u00a01,\u00a015\u00a0+\u00a040\u00a0mg\u00a0an\u00a0Tag\u00a0\n8,\u00a022\u00a028\u00a0mg:\u00a0\n30\u00a0\n(26)\u00a0\n40\u00a0mg:\u00a0\n22\u00a0\n(26)\u00a0198.353,42\u00a0\u20ac\u00a0\n(185.893,39\u00a0\u20ac)\u00a0\nzVT\u00a0b)\u00a0Monotherapie \u00a0 \u00a0 \u00a0 \u00a0\nCyclophosphamid \u00a0 1.900\u00a0mg\u00a0an\u00a0Tag\u00a016\u00a0\u00a0 17\u00a0 \u00a0\n+\u00a0Prednison\u00a0 154\u00a0mg\u00a0an\u00a0Tag\u00a01\u00a0\u2013\u00a046\u00a0 52\u00a0 1.229,75\u00a0\u20ac\u00a0\nMelphalan\u00a0 20\u00a0mg\u00a0an\u00a0Tag\u00a01\u00a0\u2013\u00a041+2\u00a0 52\u00a0 \u00a0\n+\u00a0Prednison\u00a0 154\u00a0mg\u00a0an\u00a0Tag\u00a01\u00a0\u2013\u00a041+2\u00a0 52\u00a0 1.858,71\u00a0\u20ac\u00a0\nBortezomib\u00a0 siehe\u00a0zVT\u00a0a)\u00a0 \u00a0 \u00a0\n+\u00a0Dexamethason\u00a0 siehe\u00a0zVT\u00a0a)\u00a0 \u00a026.367,87\u00a0\u2013\u00a052.735,74\u00a0\u20ac\u00a0\nLenalidomid\u00a0 siehe\u00a0zVT\u00a0a)\u00a0 \u00a0 \u00a0\n+\u00a0Dexamethason\u00a0 siehe\u00a0zVT\u00a0a)\u00a0 \u00a0 105.023,32\u00a0\u20ac\u00a0\n(104.903,19\u00a0\u20ac) \u00a0\nElotuzumab\u00a0 siehe\u00a0zVT\u00a0a)\u00a0 \u00a0 \u00a0\n+\u00a0Lenalidomid\u00a0 siehe\u00a0zVT\u00a0a)\u00a0 \u00a0 \u00a0\n+\u00a0Dexamethason\u00a0 siehe\u00a0zVT\u00a0a)\u00a0 \u00a0198.353,42\u00a0\u2013\u00a0185.893,39\u00a0\u20ac \u00a0\nBSC\u00a0 \u00a0 \u00a0Patientenindividuell\u00a0\n1\u00a028\u2010Tage\u2010Zyklus\u00a0\n2\u00a0Insgesamt\u00a013\u00a0Zyklen\u00a0pro\u00a0Behandlung\u00a0\n3\u00a021\u2010Tage\u2010Zyklus\u00a0\n4\u00a0Insgesamt\u00a08\u00a0Zyklen\u00a0pro\u00a0Behandlung\u00a0\n5\u00a0Insgesamt\u00a04\u00a0\u2013\u00a08\u00a0Zyklen\u00a0pro\u00a0Behandlung\u00a0\n6\u00a0Insgesamt\u00a017\u00a0Zyklen\u00a0pro\u00a0Behandlung\u00a079\u00a0Versorgungsanalysen\u00a0\nNach\u00a0der\u00a0Markteinf\u00fchrung\u00a0von\u00a0Daratumumab\u00a0im\u00a0Juni\u00a02016\u00a0erreichte \u00a0das\u00a0Verord\u2010\nnungsvolumen\u00a0bereits\u00a0im\u00a0November\u00a02016\u00a0ein\u00a0Niveau\u00a0von\u00a0\u00fcber\u00a04.000 \u00a0DDD\u00a0pro\u00a0Mo\u2010\nnat.\u00a0Ab\u00a0Mai\u00a02017\u00a0stieg\u00a0das\u00a0Verordnungsvolumen\u00a0noch\u00a0weiter\u00a0an\u00a0un d\u00a0verdoppelte\u00a0\nsich\u00a0nahezu\u00a0innerhalb\u00a0von\u00a0sechs\u00a0Monaten\u00a0bis\u00a0November\u00a02017.\u00a0Dies e\u00a0deutliche\u00a0Stei\u2010\ngerung\u00a0der\u00a0Verordnungen\u00a0ist\u00a0vermutlich\u00a0auf\u00a0die\u00a0im\u00a0April\u00a02017\u00a0er folgte\u00a0Indikations\u2010\nerweiterung\u00a0von\u00a0Daratumumab\u00a0zur\u00fcckzuf\u00fchren.\u00a0Insgesamt\u00a0wurden\u00a020 17\u00a0weniger\u00a0als\u00a0\n300\u00a0Patienten\u00a0mit\u00a0Daratumumab\u00a0behandelt.\u00a0\nNach\u00a0der\u00a0Beschlussfassung\u00a0des\u00a0G\u2010BA\u00a0im\u00a0Dezember\u00a02016\u00a0und\u00a0der\u00a0Ane rkennung\u00a0\neines\u00a0nicht\u00a0quantifizierbaren\u00a0Zusatznutzens\u00a0des\u00a0 Orphan\u2010Arzneimittels\u00a0zeigte\u00a0sich\u00a0\nein\u00a0geringer\u00a0R\u00fcckgang\u00a0des\u00a0Verordnungsvolumens\u00a0im\u00a0Vergleich\u00a0zum\u00a0 hohen\u00a0Niveau\u00a0\nim\u00a0November\u00a02016.\u00a0Der\u00a0Einfluss\u00a0des\u00a0Erstattungsbetrages\u00a0von\u00a0Darz alex\u00ae,\u00a0der\u00a0ab\u00a0\ndem\u00a001.08.2017\u00a0galt,\u00a0zeigte\u00a0sich\u00a0sofort:\u00a0Obwohl\u00a0das\u00a0Verordnungs volumen\u00a0weiter\u2010\nhin\u00a0steil\u00a0anstieg,\u00a0fiel\u00a0der\u00a0Umsatz\u00a0deutlich\u00a0ab.\u00a0Im\u00a0Juli\u00a02017\u00a0se tzten\u00a0etwa\u00a06.300\u00a0DDD\u00a0\ngenauso\u00a0viel\u00a0um\u00a0wie\u00a0im\u00a0Oktober\u00a02017\u00a0mehr\u00a0als\u00a08.500\u00a0DDD.\u00a0Dies\u00a0en tspricht\u00a0etwa\u00a0\nder\u00a0Preisreduktion,\u00a0die\u00a0durch\u00a0die\u00a0Verhandlung\u00a0des\u00a0Erstattungsbe trags\u00a0erzielt\u00a0wur\u2010\nde.\u00a0Aufgrund\u00a0der\u00a0erneuten\u00a0Nutzenbewertung\u00a0im\u00a0Jahr\u00a02017/2018\u00a0erf olgte\u00a0eine\u00a0\nNeuverhandlung,\u00a0die\u00a0ab\u00a0Oktober\u00a02018\u00a0zu\u00a0einer\u00a0weiteren\u00a0Absenkung \u00a0des\u00a0Erstat\u2010\ntungsbetrags\u00a0von\u00a0Darzalex\u00ae\u00a0f\u00fchrte.\u00a0Ihr\u00a0Einfluss\u00a0ist\u00a0anhand\u00a0der\u00a0 vorliegenden\u00a0Daten\u00a0\nnoch\u00a0nicht\u00a0darstellbar.\u00a0\n\u00a0\u00a080\u00a0Abbildung\u00a04.3:\u00a0Verordnete\u00a0Tagesdosen\u00a0(DDD)\u00a0und\u00a0Bruttoums\u00e4tze\u00a0vo n\u00a0\u00a0\nDaratumumab\u00a0nach\u00a0Monaten\u00a0(2016\u00a0\u2013\u00a02017)\u00a0\n\u00a0\n\u00a0\nQuellen\u00a0\u00a0\nAMB\u00a0\u2013\u00a0Der\u00a0Arzneimittelbrief\u00a0(2018).\u00a0Multiples\u00a0Myelom:\u00a0Das\u00a0Zeita lter\u00a0des\u00a0Immuntherapie\u00a0hat\u00a0begonnen.\u00a0Arzneimittelbrief\u00a052\u00a0(09). \u00a0\nDimopoulos\u00a0MA,\u00a0Oriol\u00a0A,\u00a0Nahi\u00a0H,\u00a0San\u2010Miguel\u00a0J,\u00a0Bahlis\u00a0NJ\u00a0et\u00a0al.\u00a0 (2016).\u00a0Daratumumab,\u00a0Lenalidomide,\u00a0and\u00a0Dexamethasone\u00a0for\u00a0\nMultiple\u00a0Myeloma.\u00a0NEJM\u00a0375(14):\u00a01319\u20101331.\u00a0\nEC\u00a0\u2013\u00a0European\u00a0Commission\u00a0(2013).\u00a0Durchf\u00fchrungsbeschluss\u00a0der\u00a0Kom mission\u00a0vom\u00a017.7.2013\u00a0\u00fcber\u00a0die\u00a0Ausweisung\u00a0des\u00a0Arzneimittels\u00a0\n\"Daratumumab\"\u00a0als\u00a0Arzneimittel\u00a0f\u00fcr\u00a0seltene\u00a0Leiden\u00a0gem\u00e4\u00df\u00a0Verordn ung\u00a0(EG)\u00a0Nr.\u00a0141/2000\u00a0des\u00a0Europ\u00e4ischen\u00a0\nParlaments\u00a0und\u00a0des\u00a0Rates.\u00a0Stand\u00a0 der\u00a0Information:\u00a0Juli\u00a02013.\u00a0htt p://ec.europa.eu/health/documents/community\u2010\nregister/html/o1153.htm,\u00a0letzter\u00a0Zugriff:\u00a028.02.2019.\u00a0\nEMA\u00a0\u2013\u00a0European\u00a0Medicines\u00a0Agency\u00a0(2013).\u00a0Committee\u00a0for\u00a0Orphan\u00a0Me dicinal\u00a0Products.\u00a0Public\u00a0summary\u00a0of\u00a0opinion\u00a0on\u00a0orphan\u00a0\ndesignation.\u00a0Daratumumab\u00a0for\u00a0the\u00a0treatment\u00a0of\u00a0plasma\u00a0cell\u00a0myelo ma.\u00a0Stand\u00a0der\u00a0Information:\u00a0M\u00e4rz\u00a02013.\u00a0\nhttps://www.ema.europa.eu/documents/orphan\u2010designation/eu/3/13/ 1153\u2010public\u2010summary\u2010opinion\u2010orphan\u2010\ndesignation\u2010daratumumab\u2010treatment\u2010plasma\u2010cell\u2010myeloma_en.pdf,\u00a0l etzter\u00a0Zugriff:\u00a028.02.2019.\u00a0\nEMA\u00a0\u2013\u00a0European\u00a0Medicines\u00a0Agency\u00a0 (2016).\u00a0Assessment\u00a0report.\u00a0Darz alex.\u00a0Stand\u00a0der\u00a0Information:\u00a0April\u00a02016.\u00a0\nhttps://www.ema.europa.eu/documents/assessment\u2010report/darzalex\u2010 epar\u2010public\u2010assessment\u2010report_en.pdf,\u00a0\nletzter\u00a0Zugriff:\u00a028.02.2019.\u00a0\nEMA\u00a0\u2013\u00a0European\u00a0Medicines\u00a0Agency\u00a0 (2017).\u00a0Assessment\u00a0report.\u00a0Darz alex.\u00a0Stand\u00a0der\u00a0Information:\u00a0Februar\u00a02017.\u00a0\nhttps://www.ema.europa.eu/documents/variation\u2010report/darzalex\u2010h \u2010c\u20104077\u2010ii\u20100002\u2010epar\u2010assessment\u2010report\u2010\nvariation_en.pdf,\u00a0letzter\u00a0Zugriff:\u00a028.02.2019.\u00a0\n81\u00a0EMA\u00a0\u2013\u00a0European\u00a0Medicines\u00a0Agency\u00a0(2018).\u00a0CHMP\u00a0extension\u00a0of\u00a0indic ation\u00a0variation\u00a0assessment\u00a0report.\u00a0Darzalex.\u00a0Stand\u00a0der\u00a0\nInformation:\u00a0Juli\u00a02018.\u00a0https://www.ema.europa.eu/documents/var iation\u2010report/darzalex\u2010h\u2010c\u20104077\u2010ii\u20100011\u2010epar\u2010\nassessment\u2010report\u2010variation_en.pdf,\u00a0letzter\u00a0Zugriff:\u00a028.02.2019 .\u00a0\nFachinformation\u00a0Darzalex\u00ae\u00a0(2018).\u00a0Fachinformation\u00a0DARZALEX\u00ae\u00a020\u00a0 mg/ml\u00a0Konzentrat\u00a0zur\u00a0Herstellung\u00a0einer\u00a0Infusionsl\u00f6sung.\u00a0Stand\u00a0\nder\u00a0Information:\u00a0Dezember\u00a02018.\u00a0\nFricke\u00a0U,\u00a0Hein\u00a0L,\u00a0Schwabe\u00a0U\u00a0(2017).\u00a0Neue\u00a0Arzneimittel\u00a02016.\u00a0In: \u00a0Schwabe\u00a0U,\u00a0Paffrath\u00a0D,\u00a0Ludwig\u00a0W\u2010D,\u00a0Klauber\u00a0J\u00a0(Hrsg.)\u00a0(2017).\u00a0\nArzneiverordnungs\u2010Report\u00a02017.\u00a0Berlin,\u00a0Heidelberg.\u00a0Springer:\u00a055 \u2010135.\u00a0\nG\u2010BA\u00a0\u2013\u00a0Gemeinsamer\u00a0Bundesausschuss\u00a0(2016).\u00a0Tragende\u00a0Gr\u00fcnde\u00a0zum\u00a0 Beschluss\u00a0des\u00a0Gemeinsamen\u00a0 Bundesausschuss\u00a0\u00fcber\u00a0eine\u00a0\n\u00c4nderung\u00a0des\u00a0Arzneimittelrichtlinie\u00a0(AMRL):\u00a0Anlage\u00a0XII\u00a0\u2013\u00a0Beschl \u00fcsse\u00a0\u00fcber\u00a0die\u00a0Nutzenbewertung\u00a0von\u00a0Arzneimitteln\u00a0\nmit\u00a0neuen\u00a0Wirkstoffen\u00a0nach\u00a0\u00a7\u00a035a\u00a0SGB\u00a0V\u00a0\u2013\u00a0Daratumumab.\u00a0Stand\u00a0der \u00a0Information:\u00a0Dezember\u00a02016.\u00a0https://www.g\u2010\nba.de/downloads/40\u2010268\u20104071/2016\u201012\u201001_AM\u2010RL\u2010XII_Daratumumab_D\u2010 238_TrG.pdf,\u00a0letzter\u00a0Zugriff:\u00a028.02.2019.\u00a0\nG\u2010BA\u00a0\u2013\u00a0Gemeinsamer\u00a0Bundesausschuss\u00a0(2017).\u00a0Tragende\u00a0Gr\u00fcnde\u00a0zum\u00a0 Beschluss\u00a0des\u00a0Gemeinsamen\u00a0 Bundesausschuss\u00a0\u00fcber\u00a0die\u00a0\nvorl\u00e4ufige\u00a0Einstellung\u00a0der\u00a0Nutzenbewertung\u00a0nach\u00a0\u00a7\u00a035a\u00a0SGB\u00a0V\u00a0von \u00a0Daratumumab\u00a0mit\u00a0der\u00a0Indikation\u00a0\u201aDaratumumab\u00a0\nin\u00a0Kombination\u00a0mit\u00a0Lenalidomid\u00a0und\u00a0Dexamethason\u00a0oder\u00a0in\u00a0Kombina tion\u00a0mit\u00a0Bortezomib\u00a0und\u00a0Dexamethason\u00a0zur\u00a0\nBehandlung\u00a0erwachsener\u00a0Patienten\u00a0mit\u00a0Multiplem\u00a0Myelom,\u00a0die\u00a0bere its\u00a0mindestens\u00a0eine\u00a0Therapie\u00a0erhalten\u00a0haben.\u2018.\u00a0\nStand\u00a0der\u00a0Information:\u00a0Juni\u00a02017.\u00a0https://www.g\u2010ba.de/downloads /40\u2010268\u20104427/2017\u201006\u201015_AM\u2010RL\u2010\nXII_Daratumumab_D\u2010286_TrG.pdf,\u00a0letzter\u00a0Zugriff:\u00a028.02.2019\u00a0\nG\u2010BA\u00a0\u2013\u00a0Gemeinsamer\u00a0Bundesausschuss\u00a0(2018).\u00a0Tragende\u00a0Gr\u00fcnde\u00a0zum\u00a0 Beschluss\u00a0des\u00a0Gemeinsamen\u00a0 Bundesausschuss\u00a0\u00fcber\u00a0eine\u00a0\n\u00c4nderung\u00a0des\u00a0Arzneimittelrichtlinie\u00a0(AMRL):\u00a0Anlage\u00a0XII\u00a0\u2013\u00a0Beschl \u00fcsse\u00a0\u00fcber\u00a0die\u00a0Nutzenbewertung\u00a0von\u00a0Arzneimitteln\u00a0\nmit\u00a0neuen\u00a0Wirkstoffen\u00a0nach\u00a0\u00a7\u00a035a\u00a0SGB\u00a0V\u00a0\u2013\u00a0Daratumumab\u00a0(neues\u00a0Anw endungsgebiet;\u00a0Neubewertung\u00a0eines\u00a0Orphan\u00a0\nDrugs\u00a0nach\u00a0\u00dcberschreitung\u00a0der\u00a050\u00a0Mio.\u00a0Euro\u00a0Grenze).\u00a0Stand\u00a0der\u00a0I nformation:\u00a0Februar\u00a02018.\u00a0https://www.g\u2010\nba.de/downloads/40\u2010268\u20104804/2018\u201002\u201015_AM\u2010RL_XII_Daratumumab_D\u2010 310_TrG.pdf,\u00a0letzter\u00a0Zugriff:\u00a028.02.2019.\u00a0\nG\u2010BA\u00a0\u2013\u00a0Gemeinsamer\u00a0Bundesausschuss\u00a0(2019).\u00a0Tragende\u00a0Gr\u00fcnde\u00a0zum\u00a0 Beschluss\u00a0des\u00a0Gemeinsamen\u00a0 Bundesausschuss\u00a0\u00fcber\u00a0eine\u00a0\n\u00c4nderung\u00a0des\u00a0Arzneimittelrichtlinie\u00a0(AMRL):\u00a0Anlage\u00a0XII\u00a0\u2013\u00a0Beschl \u00fcsse\u00a0\u00fcber\u00a0die\u00a0Nutzenbewertung\u00a0von\u00a0Arzneimitteln\u00a0\nmit\u00a0neuen\u00a0Wirkstoffen\u00a0nach\u00a0\u00a7\u00a035a\u00a0SGB\u00a0V\u00a0\u2013\u00a0Daratumumab\u00a0(neues\u00a0Anw endungsgebiet:\u00a0neu\u00a0diagnostiziertes\u00a0Multiples\u00a0\nMyelom).\u00a0Stand\u00a0der\u00a0Information:\u00a0M\u00e4rz\u00a02019.\u00a0https://www.g\u2010ba.de/ downloads/40\u2010268\u20105653/2019\u201003\u201022_AM\u2010RL\u2010\nXII_Daratumumab_TrG.pdf,\u00a0letzter\u00a0Zugriff:\u00a001.05.2019.\u00a0\nLauer\u2010Fischer\u00a0(2019).\u00a0WEBAPO\u00ae\u00a0Infosystem,\u00a0LAUER\u2010TAXE\u00a0online,\u00a0St and\u00a0der\u00a0Information:\u00a015.\u00a0Februar\u00a02019.\u00a0\nhttp://www2.lauerfischer.de/produkte/lauer\u2010taxe/webapo\u2010infosyst em/,\u00a0letzter\u00a0Zugriff:\u00a028.02.2019.\u00a0\nLokhorst\u00a0HM,\u00a0Plesner\u00a0T,\u00a0Laubach\u00a0JP,\u00a0Nahi\u00a0H,\u00a0Gimsing\u00a0P,\u00a0Hansson\u00a0 M\u00a0et\u00a0al.\u00a0(2015).\u00a0Targeting\u00a0CD38\u00a0with\u00a0daratumumab\u00a0monotherapy\u00a0\nin\u00a0multiple\u00a0myeloma.\u00a0NEJM\u00a0373(13):\u00a01207\u201019.\u00a0\u00a0\nLonial\u00a0S,\u00a0Weiss\u00a0BM,\u00a0Usmani\u00a0SZ,\u00a0Singhal\u00a0S,\u00a0Chari\u00a0A,\u00a0Bahlis\u00a0NJ\u00a0et \u00a0al.\u00a0(2016).\u00a0Daratumumab\u00a0monotherapy\u00a0in\u00a0patients\u00a0with\u00a0treatment \u2010\nrefractory\u00a0multiple\u00a0myeloma\u00a0(SIRIUS):\u00a0an\u00a0open\u2010label,\u00a0randomised ,\u00a0phase\u00a02\u00a0trial.\u00a0Lancet\u00a0387(10027):\u00a01551\u201060.\u00a0\u00a0\nMateos\u00a0MV,\u00a0Dimopoulos\u00a0MA,\u00a0Cavo\u00a0M,\u00a0Suzuki\u00a0K,\u00a0Jakubowiak\u00a0A,\u00a0Knop\u00a0 S\u00a0et\u00a0al.\u00a0(2018).\u00a0Daratumumab\u00a0plus\u00a0Bortezomib,\u00a0Melphalan,\u00a0\nand\u00a0Prednisone\u00a0for\u00a0Untreated\u00a0Myeloma.\u00a0N\u00a0Engl\u00a0J\u00a0Med\u00a0378(6):\u00a0518\u2010 528.\u00a0\nNIH\u00a0\u2013\u00a0National\u00a0Institutes\u00a0of\u00a0Health\u00a0(2019a).\u00a0U.S.\u00a0National\u00a0Libr ary\u00a0of\u00a0Medicine.\u00a0Addition\u00a0of\u00a0Daratumumab\u00a0to\u00a0Combination\u00a0of\u00a0\nBortezomib\u00a0and\u00a0Dexamethasone\u00a0in\u00a0Participants\u00a0with\u00a0Relapsed\u00a0or\u00a0R efractory\u00a0Multiple\u00a0Myeloma.\u00a0Stand:\u00a0April\u00a02019.\u00a0\nhttps://clinicaltrials.gov/ct2/show/NCT02136134?cond=NCT0213613 4&rank=1,\u00a0letzter\u00a0Zugriff:\u00a001.05.2019.\u00a0\nNIH\u00a0\u2013\u00a0National\u00a0Institutes\u00a0of\u00a0Health\u00a0(2019b).\u00a0U.S.\u00a0National\u00a0Libr ary\u00a0of\u00a0Medicine.\u00a0A\u00a0Study\u00a0Comparing\u00a0Daratumumab,\u00a0Lenalidomide,\u00a0\nand\u00a0Dexamethasone\u00a0with\u00a0Lenalidomide\u00a0and\u00a0Dexamethasone\u00a0in\u00a0Relaps ed\u00a0or\u00a0Refractory\u00a0Multiple\u00a0Myeloma.\u00a0Stand:\u00a0\nFebruar\u00a02019.\u00a0https://clinicaltrials.gov/ct2/show/NCT02076009?c ond=NCT02076009&rank=1,\u00a0letzter\u00a0Zugriff:\u00a0\n28.02.2019.\u00a0\n\u00a082\u00a0NIH\u00a0\u2013\u00a0National\u00a0Institutes\u00a0of\u00a0Health\u00a0(2019c).\u00a0U.S.\u00a0National\u00a0Libr ary\u00a0of\u00a0Medicine.\u00a0A\u00a0Study\u00a0of\u00a0Combination\u00a0of\u00a0Daratumumab\u00a0and\u00a0\nVelcade\u00a0(Bortezomib)\u00a0Melphalan\u2010Prednisone\u00a0(DVMP)\u00a0Compared\u00a0to\u00a0Ve lcade\u00a0Melphalan\u2010Prednisone\u00a0(VMP)\u00a0in\u00a0\nParticipants\u00a0with\u00a0Previously\u00a0Unt reated\u00a0Multiple\u00a0Myeloma.\u00a0Stand: \u00a0Dezember\u00a02018.\u00a0\nhttps://clinicaltrials.gov/ct2/show/NCT02195479?cond=NCT0219547 9&rank=1,\u00a0letzter\u00a0Zugriff:\u00a028.02.2019.\u00a0\nPalumbo\u00a0A,\u00a0Chanan\u2010Khan\u00a0A,\u00a0Weisel\u00a0K,\u00a0Nooka\u00a0AK,\u00a0Masszi\u00a0T,\u00a0Beksac\u00a0 M\u00a0et\u00a0al.\u00a0(2016).\u00a0Daratumumab,\u00a0bortezomib,\u00a0and\u00a0dexamethasone\u00a0\nfor\u00a0multiple\u00a0myeloma.\u00a0NEJM\u00a0375(8):\u00a0754\u201066.\u00a0\u00a0\nPZ\u00a0\u2013\u00a0Pharmazeutische\u00a0Zeitung\u00a0online\u00a0(2019).\u00a0Neue\u00a0Arzneistoffe,\u00a0 Dartumumab|Darzalex\u00ae|86|2016.\u00a0https://www.pharmazeutische\u2010\nzeitung.de/arzneistoffe/daten/2016/daratumumabdarzalexr862016/, \u00a0letzter\u00a0Zugriff:\u00a028.02.2019.\u00a0\nPrescrire\u00a0Int.\u00a0(2017).\u00a0Daratumumab\u00a0(Darzalex\u00ae)\u00a0monotherapy\u00a0in\u00a0r elapsed\u00a0and\u00a0refractory\u00a0multiple\u00a0myeloma.\u00a0No\u00a0evidence\u00a0of\u00a0\nefficacy.\u00a0Prescrire\u00a0Int.\u00a026\u00a0(188):\u00a0290\u2010291.\u00a0\n\u00a0 \u00a083\u00a0 Efmoroctocog\u00a0alfa\u00a04.4\nHandelsname:\u00a0Elocta\u00ae\u00a0 \u00a0 \u00a0 Pharm azeutischer\u00a0Unternehmer:\u00a0\u00a0\nIndikation:\u00a0H\u00e4mophilie\u00a0A\u00a0 \u00a0 \u00a0 Swedish\u00a0Orphan\u00a0Biovitrum\u00a0\nATC\u2010Code:\u00a0B02BD32\u00a0 \u00a0 \u00a0 Markteinf\u00fchrung:\u00a0Januar\u00a02016\u00a0\nDarreichungsform:\u00a0Pulver\u00a0und\u00a0\nL\u00f6sungsmittel\u00a0zur\u00a0Herstellung\u00a0\u00a0\neiner\u00a0Injektionssuspension\u00a0 \u00a0 DDD:\u00a01\u00a0TSD\u00a0E\u00a0P\u00a0 \u00a0 \u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 \u25bc\u00a0\nBewertung \u00a0\nEfmoroctocog\u00a0 alfa\u00a0 (Elocta\u00ae)\u00a0 wurde\u00a0 im\u00a0 November\u00a0 2015\u00a0 von\u00a0 der\u00a0 Euro p\u00e4ischen\u00a0\nKommission\u00a0zentral\u00a0f\u00fcr\u00a0die\u00a0Behandlung\u00a0von\u00a0Patienten\u00a0mit\u00a0H\u00e4mophi lie\u00a0A\u00a0zugelas\u2010\nsen.\u00a0Der\u00a0Wirkstoff\u00a0ist\u00a0ein\u00a0weiterer\u00a0rekombinanter\u00a0Gerinnungsfak tor\u00a0VIII,\u00a0dessen\u00a0\nHalbwertzeit\u00a0nach\u00a0K\u00fcrzen\u00a0der\u00a0B\u2010Dom\u00e4ne\u00a0durch\u00a0Kopplung\u00a0an\u00a0die\u00a0Fc\u2010 Dom\u00e4ne\u00a0von\u00a0\nhumanem\u00a0Immunglobulin\u00a0G\u00a0verl\u00e4ngert\u00a0wurde.\u00a0\nDas\u00a0Pr\u00e4parat\u00a0steht\u00a0als\u00a0Lyophilisat\u00a0in\u00a0verschiedenen\u00a0Dosierungen \u00a0zur\u00a0Verf\u00fcgung,\u00a0\ndas\u00a0vor\u00a0der\u00a0langsamen\u00a0intraven\u00f6s en\u00a0Injektion\u00a0mit\u00a0Wasser\u00a0f\u00fcr\u00a0Inj ektionszwecke\u00a0\nrekonstituert\u00a0werden\u00a0muss.\u00a0\u00a0\nDie\u00a0Dosis\u00a0und\u00a0die\u00a0Dosierungsintervalle\u00a0richten\u00a0sich\u00a0nach\u00a0dem\u00a0Sc hweregrad\u00a0des\u00a0\nFaktor\u2010VIII\u2010Mangels,\u00a0dem\u00a0Ort\u00a0und\u00a0Ausma\u00df\u00a0der\u00a0Blutung,\u00a0dem\u00a0klinis chen\u00a0Zustand\u00a0\nund\u00a0Alter\u00a0des\u00a0Patienten\u00a0sowie\u00a0weiteren\u00a0patientenindividuellen\u00a0C harakteristika\u00a0im\u00a0\nHinblick\u00a0auf\u00a0die\u00a0Pharmakokinetik.\u00a0Die\u00a0Fachinformation\u00a0enth\u00e4lt\u00a0e ine\u00a0detaillierte\u00a0\nAnleitung,\u00a0wie\u00a0sich\u00a0die\u00a0notwendigen\u00a0Dosen\u00a0f\u00fcr\u00a0die\u00a0Bedarfsbehand lung\u00a0berechnen\u00a0\nlassen.\u00a0Die\u00a0\u00fcbliche\u00a0Dosierung\u00a0f\u00fcr \u00a0die\u00a0Prophylaxe\u00a0liegt\u00a0bei\u00a050\u00a0I .E./kg\u00a0KG\u00a0alle\u00a0drei\u00a0bis\u00a0\nf\u00fcnf\u00a0Tage.\u00a0Eine\u00a0individuelle\u00a0Anpassung\u00a0der\u00a0Dosen\u00a0und\u00a0Dosierungs intervalle\u00a0ist\u00a0\njeweils\u00a0erforderlich\u00a0(EMA,\u00a02019).\u00a0\nDie\u00a0 Zulassung\u00a0 beruht\u00a0 auf\u00a0 zwei\u00a0 pivotalen\u00a0 offenen\u00a0 multizentrische n\u00a0 Phase\u2010III\u2010\nStudien:\u00a0A\u2010LONG\u00a0mit\u00a0Patienten\u00a0ab\u00a0 zw\u00f6lf\u00a0Jahren\u00a0sowie\u00a0Kids\u00a0A\u2010LONG \u00a0mit\u00a0Patienten\u00a0\nunter\u00a0 zw\u00f6lf\u00a0 Jahren.\u00a0 Bei\u00a0 den\u00a0 ausschlie\u00dflich\u00a0 m\u00e4nnlichen\u00a0 Teilnehme rn\u00a0 in\u00a0 beiden\u00a0\nStudien\u00a0lag\u00a0eine\u00a0schwere\u00a0H\u00e4mophilie\u00a0A\u00a0mit\u00a0einer\u00a0Rest\u2010Faktor\u2010VII I\u2010Aktivit\u00e4t\u00a0<\u00a01\u00a0%\u00a0\nvor.\u00a0Sie\u00a0waren\u00a0au\u00dferdem\u00a0bereits\u00a0mit\u00a0anderen\u00a0Faktor\u2010VIII\u2010Pr\u00e4para ten\u00a0vorbehandelt\u00a0\nund\u00a0es\u00a0waren\u00a0keine\u00a0Inhibitoren\u00a0nachweisbar\u00a0(EMA,\u00a02015).\u00a0\nDie\u00a0165\u00a0Teilnehmer\u00a0der\u00a0A\u2010LONG\u2010Studie\u00a0waren\u00a0zwischen\u00a0zw\u00f6lf\u00a0und\u00a06 5\u00a0Jahren\u00a0alt\u00a0\n(Mahlangu\u00a0et\u00a0al.,\u00a02014).\u00a0In\u00a0der\u00a0Studie\u00a0wurden\u00a0drei\u00a0Behandlungsa rme\u00a0angeboten.\u00a0\nDie\u00a0Behandlungsarme\u00a01\u00a0und\u00a02\u00a0beinhalteten\u00a0eine\u00a0prophylaktische\u00a0G abe\u00a0von\u00a0Ef\u2010\nmoroctocog\u00a0alfa,\u00a0in\u00a0Behandlungsarm\u00a03\u00a0erfolgte\u00a0eine\u00a0 on\u2010demand \u2010Therapie.\u00a0Teil\u2010\nnehmer,\u00a0 die\u00a0 zuvor\u00a0 eine\u00a0 prophylaktische\u00a0 Behandlung\u00a0 erhalten\u00a0 hatt en,\u00a0 wurden\u00a084\u00a0Behandlungsarm\u00a01\u00a0zugete ilt.\u00a0Bei\u00a0vorhergehender\u00a0 on\u2010demand \u2010Behandlung\u00a0hatten\u00a0\ndie\u00a0Teilnehmer\u00a0die\u00a0Option,\u00a0an\u00a0Behandlungsarm\u00a01\u00a0teilzunehmen\u00a0ode r\u00a0in\u00a0die\u00a0Be\u2010\nhandlungsarme\u00a02\u00a0bzw.\u00a03\u00a0randomisiert\u00a0zu\u00a0werden\u00a0(jeweils\u00a0stratifi ziert\u00a0nach\u00a0Anzahl\u00a0\nder\u00a0Blutungsepisoden\u00a0in\u00a0den\u00a0vorhergehenden\u00a0zw\u00f6lf\u00a0Monaten).\u00a0Die\u00a0 Behandlungs\u2010\ndauer\u00a0lag\u00a0bei\u00a0bis\u00a0zu\u00a054\u00a0Wochen,\u00a0 etwa\u00a0zwei\u00a0Drittel\u00a0der\u00a0Teilnehme r\u00a0hatten\u00a0mindes\u2010\ntens\u00a050\u00a0Expositionstage.\u00a0\nIm\u00a0Behandlungsarm\u00a01\u00a0erhielten\u00a0die\u00a0118\u00a0Teilnehmer\u00a0zweimal\u00a0w\u00f6chen tlich\u00a0eine\u00a0\nprophylaktische\u00a0Behandlung\u00a0mit\u00a025\u00a0bis\u00a050\u00a0I.E./kg\u00a0KG.\u00a0Dosis\u00a0und\u00a0 Dosierungsinter\u2010\nvalle\u00a0wurden\u00a0individuell\u00a0anhand\u00a0de r\u00a0Faktor\u2010VIII\u2010Aktivit\u00e4t\u00a0angep asst.\u00a0Die\u00a0annuali\u2010\nsierte\u00a0Blutungsrate\u00a0in\u00a0dieser\u00a0Gruppe\u00a0lag\u00a0im\u00a0arithmetischen\u00a0Mitt el\u00a0bei\u00a02,91.\u00a0Im\u00a0\nBehandlungsarm\u00a02\u00a0waren\u00a0die\u00a0Dosis\u00a0und\u00a0das\u00a0Dosierungsintervall\u00a0f\u00fc r\u00a0die\u00a024\u00a0Teil\u2010\nnehmer\u00a0fix.\u00a0Sie\u00a0erhielten\u00a0alle\u00a0sieben\u00a0Tage\u00a065\u00a0I.E./kg\u00a0KG.\u00a0Die\u00a0a nnualisierte\u00a0Blutungs\u2010\nrate\u00a0in\u00a0dieser\u00a0Gruppe\u00a0lag\u00a0im\u00a0arithmetischen\u00a0Mittel\u00a0bei\u00a08,92.\u00a0Di e\u00a023\u00a0Teilnehmer\u00a0in\u00a0\nBehandlungsarm\u00a0 3\u00a0 wurden\u00a0 im\u00a0 Fall\u00a0 von\u00a0 Blutungen\u00a0 mit\u00a0 einer\u00a0 Startdo sis\u00a0 von\u00a0\n50\u00a0I.E./kg\u00a0 KG\u00a0 behandelt,\u00a0 bei\u00a0 Bedarf\u00a0 waren\u00a0 weitere\u00a0 Dosen\u00a0 zwische n\u00a0 10\u00a0 und\u00a0\n50\u00a0I.E./kg\u00a0KG\u00a0m\u00f6glich.\u00a0Die\u00a0annualisierte\u00a0Blutungsrate\u00a0in\u00a0dieser \u00a0Gruppe\u00a0lag\u00a0im\u00a0arith\u2010\nmetischen\u00a0Mittel\u00a0bei\u00a08,92.\u00a0\nInsgesamt\u00a0wurden\u00a0757\u00a0Blutungsepi soden\u00a0mit\u00a0Efmoroctocog\u00a0alfa\u00a0beh andelt.\u00a087,3\u00a0%\u00a0\ndavon\u00a0lie\u00dfen\u00a0sich\u00a0mit\u00a0einer\u00a0 Injektion\u00a0kontrollieren.\u00a0\nDie\u00a0Teilnehmer\u00a0aller\u00a0Behandlungsa rme\u00a0konnten\u00a0an\u00a0der\u00a0chirurgisch en\u00a0Substudie\u00a0\nvon\u00a0A\u2010LONG\u00a0teilnehmen.\u00a0Bei\u00a0neun\u00a0Patienten\u00a0wurden\u00a0neun\u00a0gr\u00f6\u00dfere\u00a0O perationen\u00a0\ndurchgef\u00fchrt.\u00a0In\u00a0acht\u00a0F\u00e4llen\u00a0wurde\u00a0die\u00a0H\u00e4mostase\u00a0als\u00a0ausgezeich net,\u00a0in\u00a0einem\u00a0Fall\u00a0\nals\u00a0gut\u00a0bewertet.\u00a0Au\u00dferdem\u00a0wurden\u00a0an\u00a015\u00a0Patienten\u00a017\u00a0kleinere\u00a0O perationen\u00a0\ndurchgef\u00fchrt.\u00a0Daten\u00a0liegen\u00a0f\u00fcr\u00a0zw\u00f6lf\u00a0der\u00a0Operationen\u00a0vor.\u00a0Bei\u00a0e lf\u00a0wurde\u00a0die\u00a0H\u00e4\u2010\nmostase\u00a0 als\u00a0 ausgezeichnet,\u00a0 bei\u00a0 e i n e r \u00a0k l e i n e r e n \u00a0O p e r a t i o n \u00a0a l s \u00a0g u t\u00a0 bewertet\u00a0\n(Mahlangu\u00a0et\u00a0al.,\u00a02014).\u00a0\u00a0\nAn\u00a0der\u00a0einarmigen\u00a0Studie\u00a0Kids\u00a0A\u2010LONG\u00a0nahmen\u00a0insgesamt\u00a071\u00a0Jungen \u00a0im\u00a0Alter\u00a0\nzwischen\u00a0einem\u00a0und\u00a0elf\u00a0Jahren\u00a0teil,\u00a0von\u00a0denen\u00a069\u00a0behandelt\u00a0wurd en.\u00a036\u00a0Kinder\u00a0\nwaren\u00a0j\u00fcnger\u00a0als\u00a0sechs\u00a0Jahre\u00a0(Young\u00a0et\u00a0al.,\u00a02015).\u00a0Die\u00a0Teilnehm er\u00a0erhielten\u00a0eine\u00a0\nprophylaktische\u00a0Behandlung\u00a0mit\u00a0Efmoroctocog\u00a0alfa.\u00a0Die\u00a0Dosis\u00a0lag \u00a0zu\u00a0Beginn\u00a0bei\u00a025\u00a0\nbis\u00a050\u00a0I.E./kg\u00a0KG\u00a0zweimal\u00a0w\u00f6chentlich.\u00a0Dosis\u00a0und\u00a0Dosierungsinte rvalle\u00a0konnten\u00a0\nindividuell\u00a0angepasst\u00a0werden.\u00a0\u00a0\nDie\u00a0annualisierte\u00a0Blutungsrate\u00a0lag\u00a0median\u00a0bei\u00a01,96.\u00a0Insgesamt\u00a0t raten\u00a086\u00a0Blutungs\u2010\nepisoden\u00a0auf,\u00a0von\u00a0denen\u00a081,4\u00a0%\u00a0mit\u00a0einer\u00a0Injektion\u00a0kontrolliert \u00a0werden\u00a0konnten.\u00a0\nAn\u00a0insgesamt\u00a0sieben\u00a0Patienten\u00a0wu rden\u00a0sieben\u00a0kleinere\u00a0Operatione n\u00a0durchgef\u00fchrt.\u00a0\nBei\u00a0f\u00fcnf\u00a0der\u00a0Operationen\u00a0wurde\u00a0die\u00a0H\u00e4mostase\u00a0als\u00a0ausgezeichnet, \u00a0bei\u00a0zwei\u00a0als\u00a0gut\u00a0\neingestuft.\u00a0\u00a085\u00a0Die\u00a0nicht\u2010verblindete,\u00a0nicht\u2010ra ndomisierte\u00a0Erweiterungsstudie\u00a0A SPIRE\u00a0wurde\u00a0im\u00a0\nOktober\u00a02017\u00a0abgeschlossen.\u00a0Eine\u00a0Interim\u2010Auswertung\u00a0mit\u00a0Datensc hnitt\u00a0Januar\u00a0\n2014\u00a0ging\u00a0in\u00a0den\u00a0europ\u00e4ischen\u00a0Beurteilungsbericht\u00a0ein\u00a0und\u00a0wurde \u00a02016\u00a0publiziert\u00a0\n(Nolan\u00a0et\u00a0al.,\u00a02016).\u00a0Die\u00a0vollst\u00e4ndigen\u00a0Daten\u00a0finden\u00a0sich\u00a0bishe r\u00a0jedoch\u00a0nur\u00a0im\u00a0Stu\u2010\ndienregister\u00a0(NCT01454739,\u00a0ClinicalTrials.gov,\u00a02011).\u00a0\u00a0\nAn\u00a0der\u00a0Studie\u00a0nahmen\u00a0insgesamt\u00a0240\u00a0Patienten\u00a0teil,\u00a0die\u00a0zuvor\u00a0be reits\u00a0an\u00a0einer\u00a0der\u00a0\nanderen\u00a0Studien\u00a0mit\u00a0Efmoroctocog\u00a0alfa\u00a0beteiligt\u00a0waren.\u00a061\u00a0davon \u00a0stammten\u00a0aus\u00a0\nder\u00a0p\u00e4diatrischen\u00a0Studie:\u00a030\u00a0waren\u00a0j\u00fcnger\u00a0als\u00a0sechs\u00a0Jahre,\u00a031\u00a0j \u00fcnger\u00a0als\u00a0zw\u00f6lf\u00a0\nJahre.\u00a0\nDie\u00a0Behandlung\u00a0erfolgte\u00a0\u00fcber\u00a0einen\u00a0Zeitraum\u00a0von\u00a0ungef\u00e4hr\u00a0f\u00fcnf\u00a0J ahren\u00a0in\u00a0vier\u00a0\nStudienarmen.\u00a0Eine\u00a0Gruppe\u00a0erhielt\u00a0eine\u00a0 on\u2010demand \u2010Behandlung,\u00a0in\u00a0den\u00a0anderen\u00a0\nGruppen\u00a0 erfolgte\u00a0 eine\u00a0 prophylaktische\u00a0 Gabe\u00a0 mit\u00a0 einem\u00a0 der\u00a0 drei\u00a0 P rophylaxe\u2010\nRegime:\u00a0Bei\u00a0individueller\u00a0Prophy laxe\u00a0erhielten\u00a0die\u00a0Teilnehmer\u00a02 5\u00a0bis\u00a065\u00a0I.E./kg\u00a0KG\u00a0\nalle\u00a0drei\u00a0bis\u00a0f\u00fcnf\u00a0Tage\u00a0bzw.\u00a020\u00a0bis\u00a065\u00a0I.E./kg\u00a0KG.\u00a0Im\u00a0zweiten\u00a0R egime\u00a0(w\u00f6chentliche\u00a0\nProphylaxe)\u00a0wurde\u00a0eine\u00a0fixe\u00a0Dosis\u00a0von\u00a065\u00a0I.E./kg\u00a0KG\u00a0alle\u00a0sieben \u00a0Tage\u00a0verabreicht.\u00a0\nWenn\u00a0diese\u00a0beiden\u00a0Regime\u00a0zu\u00a0keinem\u00a0ausreichend\u00a0guten\u00a0Behandlung sergebnis\u00a0\nf\u00fchrten,\u00a0war\u00a0die\u00a0Nutzung\u00a0des\u00a0dritten\u00a0Regimes\u00a0m\u00f6glich,\u00a0bei\u00a0dem\u00a0d ie\u00a0Dosierungen\u00a0\nund\u00a0Dosierungsintervalle\u00a0weiter\u00a0modifiziert\u00a0werden\u00a0konnten\u00a0(mod ifizierte\u00a0Prophy\u2010\nlaxe).\u00a0 Die\u00a0 Studienteilnehmer\u00a0 konnten\u00a0 die\u00a0 Studienarme\u00a0 w\u00e4hrend\u00a0 de r\u00a0 Laufzeit\u00a0\nwechseln.\u00a0F\u00fcr\u00a0p\u00e4diatrische\u00a0Patienten\u00a0standen\u00a0nur\u00a0die\u00a0Studienarm e\u00a0individuelle\u00a0\nProphylaxe\u00a0und\u00a0modifizierte\u00a0Prophylaxe\u00a0zur\u00a0Verf\u00fcgung.\u00a0Bei\u00a0Errei chen\u00a0des\u00a0zw\u00f6lften\u00a0\nLebensjahrs\u00a0war\u00a0aber\u00a0ein\u00a0Wechsel \u00a0in\u00a0einen\u00a0der\u00a0anderen\u00a0Studienar me\u00a0m\u00f6glich.\u00a0\nBei\u00a0den\u00a0p\u00e4diatrischen\u00a0Patienten\u00a0unter\u00a0sechs\u00a0Jahren\u00a0lag\u00a0die\u00a0annu alisierte\u00a0Blutungs\u2010\nrate\u00a0im\u00a0Median\u00a0in\u00a0der\u00a0Gruppe\u00a0mit \u00a0individueller\u00a0Prophylaxe\u00a0bei\u00a01 ,18,\u00a0bei\u00a0modifizier\u2010\nter\u00a0Prophylaxe\u00a0bei\u00a03,72.\u00a0P\u00e4diatrische\u00a0Patienten\u00a0ab\u00a0sechs\u00a0Jahren \u00a0erreichten\u00a0mit\u00a0\nindividueller\u00a0 Prophylaxe\u00a0 eine\u00a0 a nnualisierte\u00a0 Blutungsrate\u00a0 von\u00a0 me d i a n \u00a01 , 5 9 , \u00a0m i t \u00a0\nmodifizierter\u00a0Pro phylaxe\u00a0von\u00a01,01.\u00a0\nBei\u00a0den\u00a0erwachsenen\u00a0Studienteilnehmern\u00a0lag\u00a0die\u00a0annualisierte\u00a0Bl utungsrate\u00a0im\u00a0\nMedian\u00a0bei\u00a00,64\u00a0mit\u00a0individueller \u00a0Prophylaxe,\u00a0bei \u00a01,90\u00a0mit\u00a0w\u00f6ch entlicher\u00a0Prophy\u2010\nl a x e \u00a0u n d \u00a0b e i \u00a04 , 1 1 \u00a0m i t \u00a0m o d i f i z i e r ter\u00a0 Prophylaxe.\u00a0 Bei\u00a0 den\u00a0 Teilneh mern\u00a0 mit\u00a0 on\u2010\ndemand\u2010Behandlung\u00a0betrug\u00a0die\u00a0annualisie rte\u00a0Blutungsrate\u00a0im\u00a0Median\u00a019, 10.\u00a0\nIm\u00a0Rahmen\u00a0von\u00a0ASPIRE\u00a0wurde\u00a0ebenfalls\u00a0eine\u00a0chirurgische\u00a0Substudi e\u00a0durchgef\u00fchrt.\u00a0\nDaten\u00a0liegen\u00a0jedoch\u00a0nur\u00a0f\u00fcr\u00a0die\u00a0Interim\u2010Auswertung\u00a0mit\u00a0Datensch nitt\u00a0Januar\u00a02014\u00a0\nvor\u00a0(Mahlangu\u00a0et\u00a0al.,\u00a02016;\u00a0Nolan\u00a0et\u00a0al.,\u00a02016).\u00a0An\u00a013\u00a0Teilnehm ern\u00a0wurden\u00a015\u00a0\ngr\u00f6\u00dfere\u00a0Operationen\u00a0durchgef\u00fchrt,\u00a0eine\u00a0Beurteilung\u00a0liegt\u00a0jedoch \u00a0nur\u00a0f\u00fcr\u00a0elf\u00a0Teil\u2010\nnehmer\u00a0und\u00a013\u00a0Operationen\u00a0vor.\u00a0Bei\u00a0elf\u00a0der\u00a0gr\u00f6\u00dferen\u00a0Operationen \u00a0wurde\u00a0die\u00a0\nH\u00e4mostase\u00a0als\u00a0ausgezeichnet\u00a0eing estuft,\u00a0bei\u00a0zwei\u00a0als\u00a0gut.\u00a0Drei\u00a0 kleinere\u00a0Operatio\u201086\u00a0nen\u00a0wurden\u00a0an\u00a0drei\u00a0Teilnehmern\u00a0unter\u00a0zw\u00f6lf\u00a0Jahren\u00a0durchgef\u00fchrt, \u00a0die\u00a0H\u00e4mostase\u00a0\nwurde\u00a0in\u00a0zwei\u00a0F\u00e4llen\u00a0als\u00a0ausgezeichnet,\u00a0in\u00a0einem\u00a0Fall\u00a0als\u00a0gut\u00a0b ewertet.\u00a0In\u00a0dieser\u00a0\nAltersgruppe\u00a0liegen\u00a0keine\u00a0Erfahr ungen\u00a0mit\u00a0gr\u00f6\u00dferen\u00a0Operationen\u00a0 vor.\u00a0\u00a0\nZum\u00a0Zeitpunkt\u00a0der\u00a0Zulassung\u00a0beruhten\u00a0Erkenntnisse\u00a0\u00fcber\u00a0unerw\u00fcns chte\u00a0Wirkun\u2010\ngen\u00a0auf\u00a0der\u00a0Datenbasis\u00a0von\u00a0233\u00a0Patienten\u00a0und\u00a0knapp\u00a035.000\u00a0Expos itionstagen.\u00a0In\u00a0\nden\u00a0Zulassungsstudien\u00a0waren\u00a0unerw\u00fcnschte\u00a0Arzneimittelereignisse \u00a0selten,\u00a0traten\u00a0\noft\u00a0nur\u00a0bei\u00a0einem\u00a0einzelnen\u00a0Patienten\u00a0auf\u00a0und\u00a0zeigten\u00a0sich\u00a0etwa \u00a0in\u00a0Form\u00a0von\u00a0Kopf\u2010\nschmerzen,\u00a0Schwindel,\u00a0Bauch\u2010\u00a0oder \u00a0Gelenkschmerzen.\u00a0\u00dcberempfindl ichkeitsreak\u2010\ntionen\u00a0bis\u00a0hin\u00a0zum\u00a0anaphylaktischen\u00a0Schock\u00a0und\u00a0die\u00a0Entwicklung\u00a0 von\u00a0Inhibitoren\u00a0\nmit\u00a0Verlust\u00a0der\u00a0klinischen\u00a0Wirksamkeit\u00a0sind\u00a0wie\u00a0bei\u00a0allen\u00a0Fakto r\u2010VIII\u2010Pr\u00e4paraten\u00a0\nm\u00f6glich\u00a0(EMA,\u00a02015\u00a0und\u00a02019).\u00a0\n2017\u00a0wurde\u00a0eine\u00a0europ\u00e4ische\u00a0Risikobewertung\u00a0f\u00fcr\u00a0alle\u00a0Faktor\u2010VII I\u2010Pr\u00e4parate\u00a0ver\u00f6f\u2010\nfentlicht.\u00a0Darin\u00a0wurde\u00a0untersucht,\u00a0ob\u00a0sich\u00a0das\u00a0Risiko\u00a0f\u00fcr\u00a0eine\u00a0 Inhibitor\u2010Bildung\u00a0bei\u00a0\nhumanplasmatischen\u00a0und\u00a0rekombinan ten\u00a0Produkten\u00a0unterscheidet.\u00a0A uf\u00a0der\u00a0Basis\u00a0\nmehrerer\u00a0klinischer\u00a0und\u00a0epidemiologischer\u00a0Studien\u00a0lie\u00df\u00a0sich\u00a0jed och\u00a0kein\u00a0klarer\u00a0\nHinweis\u00a0auf\u00a0eine\u00a0eventuelle\u00a0Risikoerh\u00f6hung\u00a0bei\u00a0rekombinanten\u00a0Pr \u00e4paraten\u00a0finden\u00a0\n(EMA,\u00a02017).\u00a0\u00a0\nDie\u00a0Datengrundlage\u00a0f\u00fcr\u00a0Nutzen\u00a0und\u00a0Sicherheit\u00a0bei\u00a0Patienten\u00a0\u00fcber \u00a065\u00a0Jahren\u00a0ist\u00a0\nsehr\u00a0eingeschr\u00e4nkt,\u00a0bei\u00a0bisher\u00a0unbehandelten\u00a0Patienten\u00a0fehlen\u00a0s olche\u00a0Erkenntnis\u2010\nse\u00a0derzeit\u00a0ganz\u00a0(EMA,\u00a02015).\u00a0\nIm\u00a0Juni\u00a02016\u00a0fasste\u00a0der\u00a0G\u2010BA\u00a0den\u00a0Beschluss,\u00a0dass\u00a0der\u00a0 Zusatznutzen \u00a0von\u00a0Efmoroc\u2010\ntocog\u00a0alfa\u00a0gegen\u00fcber\u00a0der\u00a0zVT\u00a0(rek ombinante\u00a0oder\u00a0aus\u00a0humanem\u00a0Pla sma\u00a0gewon\u2010\nnene\u00a0 Blutgerinnungsfaktor\u2010VIII\u2010Pr\u00e4parate)\u00a0 nicht\u00a0 belegt\u00a0 ist.\u00a0 Grundlage\u00a0 war\u00a0 ein\u00a0\ngleichlautendes\u00a0Gutachten\u00a0des\u00a0IQWiG\u00a0aus\u00a0dem\u00a0M\u00e4rz\u00a02016,\u00a0das\u00a0das\u00a0 Fehlen\u00a0von\u00a0\nDaten\u00a0f\u00fcr\u00a0einen\u00a0direkten\u00a0Vergleich\u00a0konstatierte\u00a0und\u00a0den\u00a0vom\u00a0 pU\u00a0 vorgelegten\u00a0\nnicht\u2010adjustierten\u00a0 historischen\u00a0 Vergleich\u00a0 als\u00a0 ungeeignet\u00a0 einstu fte\u00a0 (G\u2010BA,\u00a0 2016;\u00a0\nIQWiG,\u00a02016).\u00a0\u00a0\n\u00a0 \u00a087\u00a0Verf\u00fcgbare\u00a0Therapien \u00a0 (Zusatz\u2010)Nutzen \u00a0 Kosten\u00a0\n\u00a0\nweiteres\u00a0rekombinantes\u00a0\nFaktor\u2010VIII\u2010Pr\u00e4parat\u00a0\u00a0ZN\u00a0nicht\u00a0belegt\u00a0\u00a0\nkomplexes\u00a0Dosierungs\u2010\nregime,\u00a0teils\u00a0g\u00fcnstiger\u00a0als\u00a0\nzVT,\u00a0da\u00a0bereits\u00a0Erstat\u2010\ntungsbetrag\u00a0verhandelt\u00a0\nwurde\u00a0\nErl\u00e4uterung\u00a0der\u00a0Farben:\u00a0Verf\u00fcgbare\u00a0Therapien:\u00a0rot\u00a0=\u00a0weitere\u00a0The rapieoption,\u00a0gelb\u00a0=\u00a0Subgruppen\u2010Novit\u00e4t,\u00a0gr\u00fcn\u00a0=\u00a0Solist;\u00a0(Zusatz\u2010 )\u00a0\nNutzen:\u00a0rot\u00a0=\u00a0keine\u00a0Verbesserung\u00a0oder\u00a0schlechte\u00a0Nutzen/Schaden\u2010 Relation,\u00a0gelb\u00a0=\u00a0teilweise\u00a0Verbesserungen,\u00a0gr\u00fcn\u00a0=\u00a0Verbesserung\u00a0\nharter\u00a0Endpunkte;\u00a0Kosten:\u00a0rot\u00a0=\u00a0teurer\u00a0als\u00a0bestehende\u00a0Therapien ,\u00a0gelb\u00a0=\u00a0ungef\u00e4hr\u00a0gleich\u00a0bzw.\u00a0teils/teils,\u00a0gr\u00fcn\u00a0=\u00a0g\u00fcnstiger\u00a0als \u00a0\nbestehende\u00a0Therapien\u00a0\nWie\u00a0bewerten\u00a0andere?\u00a0\nBewertung\u00a0nach\u00a0\nFricke\u00a0et\u00a0al.\u00a0a\u2010t\u2010Bewertung\u00a0 AMB\u00a0 Prescrire\u00a0 PZ\u00a0\nC\u00a0 \u2013\u00a0 \u2013\u00a0 \u2013\u00a0 Schrittinnovation\u00a0\nKosten\u00a0\nWirkstoff\u00a0 Behandlungsmodus\u00a0 Behandlungstage\u00a0 Jahrestherapiekosten\u00a0\nzu\u00a0bewertendes\u00a0Arzneimittel \u00a0\u00a0 \u00a0 \u00a0\nEfmoroctocog\u00a0alfa\u00a0 \u00a0 \u00a0 \u00a0\nErwachsene\u00a025\u00a0\u2013\u00a065\u00a0I.E./kg\u00a0KG\u00a0\nalle\u00a03\u00a0\u2013\u00a05\u00a0Tage\u00a073\u00a0\u2013\u00a0122\u00a0 184.120,97\u00a0\u2013\u00a0752.177,58\u00a0\u20ac\u00a0\nJugendliche\u00a025\u00a0\u2013\u00a065\u00a0I.E./kg\u00a0KG\u00a0\nalle\u00a03\u00a0\u2013\u00a05\u00a0Tage\u00a073\u00a0\u2013\u00a0122\u00a0 143.205,20\u00a0\u2013\u00a0581.228,13\u00a0\u20ac\u00a0\nKinder\u00a025\u00a0\u2013\u00a065\u00a0I.E./kg\u00a0KG\u00a0\nalle\u00a03\u00a0\u2013\u00a05\u00a0Tage\u00a073\u00a0\u2013\u00a0122\u00a0 81.831,54\u00a0\u2013\u00a0307.709,01\u00a0\u20ac\u00a0\nKleinkinder\u00a025\u00a0\u2013\u00a065\u00a0I.E./kg\u00a0KG\u00a0\nalle\u00a03\u00a0\u2013\u00a05\u00a0Tage\u00a073\u00a0\u2013\u00a0122\u00a0 40.915,77\u00a0\u2013\u00a0136.759,56\u00a0\u20ac\u00a0\nzVT\u00a0 \u00a0 \u00a0 \u00a0\nSimoctocog\u00a0alfa\u00a0 \u00a0 \u00a0 \u00a0\nErwachsene\u00a020\u00a0\u2013\u00a040\u00a0I.E./kg\u00a0KG\u00a0\u00a0\nalle\u00a02\u00a0\u2013\u00a03\u00a0Tage\u00a0122\u00a0\u2013\u00a0183\u00a0 254.065,00\u00a0\u2013\u00a0666.920,63\u00a0\u20ac\u00a0\nJugendliche\u00a020\u00a0\u2013\u00a040\u00a0I.E./kg\u00a0KG\u00a0\u00a0\nalle\u00a02\u00a0\u2013\u00a03\u00a0Tage\u00a0122\u00a0\u2013\u00a0183\u00a0 158.790,63\u00a0\u2013\u00a0476.371,88\u00a0\u20ac\u00a0\nKinder\u00a020\u00a0\u2013\u00a040\u00a0I.E./kg\u00a0KG\u00a0\u00a0\nalle\u00a02\u00a0\u2013\u00a03\u00a0Tage\u00a0122\u00a0\u2013\u00a0183\u00a0 95.274,38\u00a0\u2013\u00a0285.823,13\u00a0\u20ac\u00a0\nKleinkinder\u00a020\u00a0\u2013\u00a040\u00a0I.E./kg\u00a0KG\u00a0\u00a0\nalle\u00a02\u00a0\u2013\u00a03\u00a0Tage\u00a0122\u00a0\u2013\u00a0183\u00a0 63.516,25\u00a0\u2013\u00a0142.911,56\u00a0\u20ac\u00a0\nTuroctocog\u00a0alfa\u00a0 \u00a0 \u00a0 \u00a0\nErwachsene\u00a020\u00a0\u2013\u00a040\u00a0I.E./kg\u00a0KG\u00a0alle\u00a0\n2\u00a0Tage\u00a0bzw.\u00a020\u00a0\u2013\u00a050\u00a0\nI.E./kg\u00a0KG\u00a03x\u00a0w\u00f6ch.*\u00a0\u00a0104\u00a0\u2013\u00a0183\u00a0 269.642,10\u00a0\u2013\u00a0654.845,10\u00a0\u20ac\u00a0\nJugendliche\u00a020\u00a0\u2013\u00a040\u00a0I.E./kg\u00a0KG\u00a0alle\u00a0\n2\u00a0Tage\u00a0bzw.\u00a020\u00a0\u2013\u00a050\u00a0\nI.E./kg\u00a0KG\u00a03x\u00a0w\u00f6ch.*\u00a0\u00a0104\u00a0\u2013\u00a0183\u00a0 192.601,50\u00a0\u2013\u00a0500.763,90\u00a0\u20ac\u00a0\n*oder\u00a0>12Lj\u00a040\u00a0\u2013\u00a060\u00a0I.E./kg\u00a0KG\u00a0jeden\u00a03.\u00a0Tag\u00a0bzw.\u00a02x\u00a0w\u00f6ch. \u00a0 \u00a0\u00a0\n88\u00a0Wirkstoff\u00a0 Behandlungsmodus\u00a0 Behandlungstage\u00a0 Jahrestherapiekosten\u00a0\nKinder\u00a020\u00a0\u2013\u00a040\u00a0I.E./kg\u00a0KG\u00a0alle\u00a0\n2\u00a0Tage\u00a0bzw.\u00a020\u00a0\u2013\u00a050\u00a0\nI.E./kg\u00a0KG\u00a03x\u00a0w\u00f6ch.\u00a0156\u00a0\u2013\u00a0183\u00a0 115.560,90\u00a0\u2013\u00a0271.123,56\u00a0\u20ac\u00a0\nKleinkinder\u00a020\u00a0\u2013\u00a040\u00a0I.E./kg\u00a0KG\u00a0alle\u00a0\n2\u00a0Tage\u00a0bzw.\u00a020\u00a0\u2013\u00a050\u00a0\nI.E./kg\u00a0KG\u00a03x\u00a0w\u00f6ch.\u00a0156\u00a0\u2013\u00a0183\u00a0 77.040,60\u00a0\u2013\u00a0135.561,83\u00a0\u20ac\u00a0\nMoroctocog\u00a0alfa\u00a0 \u00a0 \u00a0 \u00a0\nErwachsene\u00a020\u00a0\u2013\u00a040\u00a0I.E./kg\u00a0KG\u00a0alle\u00a0\n2\u00a0\u2013\u00a03\u00a0Tage\u00a0122\u00a0\u2013\u00a0183\u00a0 246.443,05\u00a0\u2013\u00a0739.329,15\u00a0\u20ac\u00a0\nJugendliche\u00a020\u00a0\u2013\u00a040\u00a0I.E./kg\u00a0KG\u00a0alle\u00a0\n2\u00a0\u2013\u00a03\u00a0Tage\u00a0122\u00a0\u2013\u00a0183\u00a0 176.030,75\u00a0\u2013\u00a0528.092,25\u00a0\u20ac\u00a0\nKinder\u00a020\u00a0\u2013\u00a040\u00a0I.E./kg\u00a0KG\u00a0alle\u00a0\n2\u00a0\u2013\u00a03\u00a0Tage\u00a0122\u00a0\u2013\u00a0183\u00a0 105.618,45\u00a0\u2013\u00a0316.855,35\u00a0\u20ac\u00a0\nKleinkinder\u00a020\u00a0\u2013\u00a040\u00a0I.E./kg\u00a0KG\u00a0alle\u00a0\n2\u00a0\u2013\u00a03\u00a0Tage\u00a0122\u00a0\u2013\u00a0183\u00a0 70.412,30\u00a0\u2013\u00a0158.427,68\u00a0\u20ac\u00a0\nOctocog\u00a0alfa\u00a0 \u00a0 \u00a0 \u00a0\nErwachsene\u00a020\u00a0\u2013\u00a040\u00a0I.E./kg\u00a0KG\u00a0\n2\u00a0\u2013\u00a03x\u00a0w\u00f6ch.\u00a0104\u00a0\u2013\u00a0156\u00a0 229.574,80\u00a0\u2013\u00a0688.724,40\u00a0\u20ac\u00a0\nJugendliche\u00a020\u00a0\u2013\u00a040\u00a0I.E./kg\u00a0KG\u00a0\u00a0\n2\u00a0\u2013\u00a03x\u00a0w\u00f6ch.\u00a0104\u00a0\u2013\u00a0156\u00a0 163.982,00\u00a0\u2013\u00a0491.946,00\u00a0\u20ac\u00a0\nKinder\u00a020\u00a0\u2013\u00a040\u00a0(<12\u00a0Lj.:\u00a050)\u00a0\nI.E./kg\u00a0KG\u00a02\u00a0\u2013\u00a03x\u00a0w\u00f6ch.\u00a0\n(<12\u00a0Lj.\u00a0bis\u00a0zu\u00a0jd.\u00a02.\u00a0Tag)\u00a0104\u00a0\u2013\u00a0183\u00a0 98.389,20\u00a0\u2013\u00a0403.963,35\u00a0\u20ac\u00a0\nKleinkinder\u00a020\u00a0\u2013\u00a040\u00a0(<12\u00a0Lj.:\u00a050)\u00a0\nI.E./kg\u00a0KG\u00a02\u00a0\u2013\u00a03x\u00a0w\u00f6ch.\u00a0\n(<12\u00a0Lj.\u00a0bis\u00a0zu\u00a0jd.\u00a02.\u00a0Tag)\u00a0104\u00a0\u2013\u00a0183\u00a0 65.592,80\u00a0\u2013\u00a0173.127,15\u00a0\u20ac\u00a0\nHumanplasmatischer\u00a0Faktor\u00a0VIII\u00a0 \u00a0 \u00a0 \u00a0\nErwachsene\u00a020\u00a0\u2013\u00a040\u00a0I.E./kg\u00a0KG\u00a0\u00a0\nalle\u00a02\u00a0\u2013\u00a03\u00a0Tage\u00a0122\u00a0\u2013\u00a0183\u00a0 213.414,60\u00a0\u2013\u00a0640.243,80\u00a0\u20ac\u00a0\nJugendliche\u00a020\u00a0\u2013\u00a040\u00a0I.E./kg\u00a0KG\u00a0\nalle\u00a02\u00a0\u2013\u00a03\u00a0Tage\u00a0122\u00a0\u2013\u00a0183\u00a0 152.439,00\u00a0\u2013\u00a0457.317,00\u00a0\u20ac\u00a0\nKinder\u00a020\u00a0\u2013\u00a040\u00a0I.E./kg\u00a0KG\u00a0\nalle\u00a02\u00a0\u2013\u00a03\u00a0Tage\u00a0122\u00a0\u2013\u00a0183\u00a0 91.463,00\u00a0\u2013\u00a0274.390,20\u00a0\u20ac\u00a0\nKleinkinder\u00a020\u00a0\u2013\u00a040\u00a0I.E./kg\u00a0KG\u00a0alle\u00a0\n2\u00a0\u2013\u00a03\u00a0Tage\u00a0o.\u00a017\u00a0\u2013\u00a030\u00a0\nI.E./kg\u00a0KG\u00a02x\u00a0w\u00f6ch.\u00a0122\u00a0\u2013\u00a0183\u00a0 60.975,60\u00a0\u2013\u00a0137.195,10\u00a0\u20ac\u00a0\nHumanplasmatischer\u00a0Faktor\u00a0VIII\u00a0\nplus\u00a0von\u2010Willebrand\u2010Faktor\u00a0vWF\u00a0\u00a0 \u00a0 \u00a0\nErwachsene\u00a020\u00a0\u2013\u00a040\u00a0I.E./kg\u00a0KG\u00a0\nalle\u00a02\u00a0\u2013\u00a03\u00a0Tage\u00a0122\u00a0\u2013\u00a0183\u00a0 210.873,95\u00a0\u2013\u00a0632.621,85\u00a0\u20ac\u00a0\nJugendliche\u00a020\u00a0\u2013\u00a040\u00a0I.E./kg\u00a0KG\u00a0\nalle\u00a02\u00a0\u2013\u00a03\u00a0Tage\u00a0122\u00a0\u2013\u00a0183\u00a0 150.624,25\u00a0\u2013\u00a0451.872,75\u00a0\u20ac\u00a0\nKinder\u00a020\u00a0\u2013\u00a040\u00a0I.E./kg\u00a0KG\u00a0\nalle\u00a02\u00a0\u2013\u00a03\u00a0Tage\u00a0122\u00a0\u2013\u00a0183\u00a0 90.374,55\u00a0\u2013\u00a0271.123,65\u00a0\u20ac\u00a0\nKleinkinder\u00a020\u00a0\u2013\u00a040\u00a0I.E./kg\u00a0KG\u00a0\nalle\u00a02\u00a0\u2013\u00a03\u00a0Tage\u00a0o.\u00a017\u00a0\u2013\u00a0\n30\u00a0I.E./kg\u00a0KG\u00a02x\u00a0w\u00f6ch.\u00a0122\u00a0\u2013\u00a0183\u00a0 60.249,70\u00a0\u2013\u00a0135.561,83\u00a0\u20ac\u00a0\nAngaben\u00a0zu\u00a0I.E.\u00a0jeweils\u00a0je\u00a0Kilogramm\u00a0kg\u00a0K\u00f6rpergewicht\u00a0KG\u00a0abweic hend\u00a0nach\u00a0Mikrozensus\u00a02013\u00a0f\u00fcr\u00a0m\u00e4nnliche\u00a0Patienten\u00a0>18\u00a0Jahre\u00a0mi t\u00a0\n84,3\u00a0kg\u00a0KG,\u00a012\u2010<18LJ\u00a0mit\u00a061,7\u00a0kg\u00a0KG,\u00a06\u2010<12LJ\u00a0mit\u00a032,4\u00a0kg\u00a0KG\u00a0sow ie\u00a0<\u00a06LJ\u00a0mit\u00a015\u00a0kg\u00a0KG\u00a0berechnet\u00a0unter\u00a0Ber\u00fccksichtigung\u00a0von\u00a0Verw urf\u00a0je\u00a0\nApplikation\u00a0anhand\u00a0Herstellerabgabepreis\u00a0plus\u00a0Umsatzsteuer\u00a0bei\u00a0 Direktvertrieb\u00a0gem\u00e4\u00df\u00a0AMG\u00a0\u00a7\u00a047\u00a0(1)\u00a02a)\u00a0bzw.\u00a0BSG\u2010Urteil\u00a0Az:\u00a0B6KA\u00a0 18/14\u00a0\nR\u00a0f\u00fcr\u00a0die\u00a0Langzeitprophylaxe.\u00a0Erwachsene\u00a0>18\u00a0Lj.,\u00a0Jugendliche\u00a01 2\u00a0<18Lj.,\u00a0Kinder\u00a06\u00a0<12\u00a0Lj.\u00a0sowie\u00a0Kleinkinder\u00a0<6\u00a0Lj.\u00a089\u00a0Versorgungsanalysen\u00a0\nSeit\u00a0 der\u00a0 Markteinf\u00fchrung\u00a0 im\u00a0 Januar\u00a0 2016\u00a0 l\u00e4sst\u00a0 sich\u00a0 kein\u00a0 konsist entes\u00a0 Verord\u2010\nnungsmuster\u00a0von\u00a0Efmoroctocog\u00a0alfa\u00a0ausmachen.\u00a0Auch\u00a0die\u00a0Ver\u00f6ffent lichung\u00a0der\u00a0\nfr\u00fchen\u00a0Nutzenbewertung\u00a0im\u00a0Juni\u00a02016\u00a0schl\u00e4gt\u00a0sich\u00a0nicht\u00a0offensic htlich\u00a0in\u00a0den\u00a0Ver\u2010\nordnungszahlen\u00a0nieder.\u00a0Seit\u00a0etwa\u00a0August\u00a02017\u00a0geht\u00a0der\u00a0Trend\u00a0hin \u00a0zu\u00a0h\u00f6heren\u00a0\nVerordnungszahlen,\u00a0der\u00a0h\u00f6chste\u00a0Wert\u00a0im\u00a0betrachteten\u00a0Zeitraum\u00a0wi rd\u00a0im\u00a0Novem\u2010\nber\u00a02017\u00a0mit\u00a0knapp\u00a0570\u00a0DDD\u00a0und\u00a0einem\u00a0Bruttoumsatz\u00a0von\u00a0600.000\u00a0\u20ac \u00a0erreicht.\u00a0\nVerordnete\u00a0DDD\u00a0und\u00a0Bruttoums\u00e4tz e\u00a0laufen\u00a0weitestgehend\u00a0parallel. \u00a0\nAbbildung\u00a04.4:\u00a0Verordnete\u00a0Tagesdosen\u00a0(DDD)\u00a0und\u00a0Bruttoums\u00e4tze\u00a0vo n\u00a0Ef\u2010\nmoroctocog\u00a0alfa\u00a0nach\u00a0Monaten\u00a0(2016\u00a0\u2013\u00a02017)\u00a0\n\u00a0\n\u00a0\nQuellen\u00a0\u00a0\nClinicalTrials.gov\u00a0(2011).\u00a0NCT01454739\u00a0Long\u2010Term\u00a0Safety\u00a0and\u00a0Eff icacy\u00a0of\u00a0rFVIIIFc\u00a0in\u00a0the\u00a0Prevention\u00a0and\u00a0Treatment\u00a0of\u00a0Bleeding\u00a0\nEpisodes\u00a0in\u00a0Previously\u00a0Treated\u00a0Participants\u00a0With\u00a0Hemophilia\u00a0A\u00a0( ASPIRE).\u00a0\nhttps://clinicaltrials.gov/ct2/show/NCT01454739,\u00a0letzter\u00a0Zugrif f:\u00a010.07.2019.\u00a0\nEMA\u00a0\u2013\u00a0European\u00a0Medicines\u00a0Agency\u00a0(2015).\u00a0EPAR\u00a0(Public\u00a0Assessment \u00a0Report)\u00a0Elocta.\u00a0\nhttps://www.ema.europa.eu/en/medicines/human/EPAR/elocta,\u00a0letzt er\u00a0Zugriff:\u00a010.07.2019.\u00a0\nEMA\u00a0\u2013\u00a0European\u00a0Medicines\u00a0Agency\u00a0(2017).\u00a0Factor\u00a0VIII.\u00a0https://ww w.ema.europa.eu/en/medicines /human/referrals/factor\u2010viii,\u00a0\nletzter\u00a0Zugriff:\u00a010.07.2019.\u00a0\n90\u00a0EMA\u00a0\u2013\u00a0European\u00a0Medicines\u00a0Agency\u00a0 (2019).\u00a0Fachinformation\u00a0Elocta. \u00a0Stand\u00a0der\u00a0Information:\u00a0Februar\u00a02019.\u00a0\nhttps://www.ema.europa.eu/en/documents/product\u2010information/eloc ta\u2010epar\u2010product\u2010information_en.pdf,\u00a0letzter\u00a0\nZugriff:\u00a010.07.2019.\u00a0\nFricke\u00a0U,\u00a0Hein\u00a0L,\u00a0Schwabe\u00a0U\u00a0(2017).\u00a0Neue\u00a0Arzneimittel\u00a02016.\u00a0In: \u00a0Schwabe\u00a0U,\u00a0Paffrath\u00a0D,\u00a0Ludwig\u00a0W\u2010D,\u00a0Klauber\u00a0J\u00a0(Hrsg.)\u00a0(2017).\u00a0\nArzneiverordnungs\u2010Report\u00a02017.\u00a0Berlin,\u00a0Heidelberg.\u00a0Springer:\u00a055 \u2010135.\u00a0\nG\u2010BA\u00a0\u2013\u00a0Gemeinsamer\u00a0Bundesausschuss\u00a0(2016).\u00a0Nutzenbewertungsverf ahren\u00a0zum\u00a0Wirkstoff\u00a0Efmoroctocog\u00a0alfa.\u00a0https://www.g\u2010\nba.de/informationen/nutzenbewertung/210/,\u00a0letzter\u00a0Zugriff:\u00a010.0 7.2019.\u00a0\nIQWiG\u00a0\u2013\u00a0Institut\u00a0f\u00fcr\u00a0Qualit\u00e4t\u00a0und\u00a0Wirtschaftlichkeit\u00a0im\u00a0Gesundh eitswesen\u00a0(2016).\u00a0[A15\u201054]\u00a0Efmoroctocog\u00a0alfa\u00a0\u2010\u00a0Nutzenbewertung\u00a0\ngem\u00e4\u00df\u00a0\u00a7\u00a035a\u00a0SGB\u00a0V.\u00a0https://www.iqwig.de/de/projekte\u2010ergebnisse/ projekte/arzneimittelbewertung/2015/a15\u201054\u2010\nefmoroctocog\u2010alfa\u2010nutzenbewertung\u2010gemaess\u201035a\u2010sgb\u2010v.7226.html,\u00a0 letzter\u00a0Zugriff:\u00a010.07.2019.\u00a0\nMahlangu\u00a0J,\u00a0Powell\u00a0JS,\u00a0Ragni\u00a0MV,\u00a0 Chowdary\u00a0P,\u00a0Josephson\u00a0NC,\u00a0Pabi nger\u00a0I\u00a0et\u00a0al.\u00a0(2014).\u00a0Phase\u00a03\u00a0st udy\u00a0of\u00a0recombinant\u00a0factor\u00a0VIII\u00a0 Fc\u00a0\nfusion\u00a0protein\u00a0in\u00a0severe\u00a0hemophilia\u00a0A.\u00a0Blood\u00a0123(3):\u00a0317\u2013325.\u00a0\u00a0\nNolan\u00a0B,\u00a0Mahlangu\u00a0J,\u00a0Perry\u00a0D,\u00a0Young\u00a0G,\u00a0Liesner\u00a0R,\u00a0Konkle\u00a0B\u00a0et\u00a0a l.\u00a0(2016).\u00a0Long\u2010term\u00a0safety\u00a0and\u00a0efficacy\u00a0of\u00a0recombinant\u00a0factor\u00a0 VIII\u00a0Fc\u00a0\nfusion\u00a0protein\u00a0(rFVIIIFc)\u00a0in\u00a0subj ects\u00a0with\u00a0haemophilia\u00a0A.\u00a0Haemo philia\u00a022\u00a0(1):\u00a072\u201380.\u00a0\u00a0\nPZ\u00a0\u2013\u00a0Pharmazeutische\u00a0Zeitung\u00a0(2016).\u00a0Efmoroctocog\u00a0alfa|Elocta|1 6|2016.\u00a0https://www.pharmazeutische\u2010\nzeitung.de/arzneistoffe/daten/2016/efmoroctocog\u2010alfaeloctar1620 16/,\u00a0letzter\u00a0Zugriff:\u00a010.07.2019.\u00a0\nYoung\u00a0G,\u00a0Mahlangu\u00a0J,\u00a0Kulkarni\u00a0R,\u00a0 Nolan\u00a0B,\u00a0Liesner\u00a0R,\u00a0Pasi\u00a0J\u00a0et\u00a0 al.\u00a0(2015).\u00a0Recombinant\u00a0factor\u00a0V III\u00a0Fc\u00a0fusion\u00a0protein\u00a0for\u00a0the\u00a0\nprevention\u00a0and\u00a0treatment\u00a0of\u00a0bleeding\u00a0in\u00a0children\u00a0with\u00a0severe\u00a0he mophilia\u00a0A.\u00a0Journal\u00a0of\u00a0Thrombosis\u00a0and\u00a0\nHaemostasis\u202f:\u00a0JTH\u00a013(6):\u00a0967\u201377.\u00a0\u00a0\n\u00a0\u00a091\u00a0 Eftrenonacog\u00a0alfa\u00a04.5\nHandelsname:\u00a0Alprolix\u00ae\u00a0 \u00a0 \u00a0 Pharm azeutischer\u00a0Unternehmer:\u00a0\u00a0\nIndikation:\u00a0H\u00e4mophilie\u00a0B\u00a0 \u00a0 \u00a0 Swedish\u00a0Orphan\u00a0Biovitrum\u00a0\nATC\u2010Code:\u00a0B02BD34\u00a0 \u00a0 \u00a0 Markteinf\u00fchrung:\u00a0Juni\u00a02016\u00a0\nDarreichungsform:\u00a0Pulver\u00a0und\u00a0L\u00f6sungs\u2010\u00a0\nmittel\u00a0zur\u00a0Herstellung\u00a0einer\u00a0Injektions\u2010\u00a0\nsuspension\u00a0 \u00a0 \u00a0 \u00a0 DDD:\u00a0400\u00a0E\u00a0P\u00a0 \u00a0 \u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0O, \u25bc\u00a0\nBewertung \u00a0\nEftrenonacog\u00a0alfa\u00a0(Alprolix\u00ae)\u00a0wurde\u00a0im\u00a0Mai\u00a02016\u00a0von\u00a0der\u00a0Europ\u00e4i schen\u00a0Kommissi\u2010\non\u00a0zentral\u00a0als\u00a0 Orphan\u2010Arzneimittel\u00a0f\u00fcr\u00a0die\u00a0Behandlung \u00a0von\u00a0Patienten\u00a0mit\u00a0H\u00e4mophi\u2010\nlie\u00a0B\u00a0zugelassen.\u00a0Der\u00a0Wirkstoff\u00a0ist\u00a0ein\u00a0weiterer\u00a0rekombinanter\u00a0 Gerinnungsfaktor\u00a0IX,\u00a0\ndessen\u00a0Halbwertzeit\u00a0durch\u00a0Fusion\u00a0mit\u00a0der\u00a0Fc\u2010Dom\u00e4ne\u00a0des\u00a0humanen\u00a0 Immunglobu\u2010\nlins\u00a0G1\u00a0verl\u00e4ngert\u00a0wurde.\u00a0\u00a0\nDas\u00a0Pr\u00e4parat\u00a0steht\u00a0als\u00a0Lyophilisat\u00a0in\u00a0verschiedenen\u00a0Dosierungen \u00a0zur\u00a0Verf\u00fcgung,\u00a0\ndas\u00a0vor\u00a0der\u00a0langsamen\u00a0intraven\u00f6s en\u00a0Injektion\u00a0mit\u00a0Wasser\u00a0f\u00fcr\u00a0Inj ektionszwecke\u00a0\nrekonstituiert\u00a0werden\u00a0muss.\u00a0Die\u00a0Dosis\u00a0und\u00a0die\u00a0Dosierungsinterva lle\u00a0richten\u00a0sich\u00a0\nnach\u00a0dem\u00a0Schweregrad\u00a0des\u00a0Faktor\u2010IX\u2010Mangels,\u00a0dem\u00a0Ort\u00a0und\u00a0Ausma\u00df\u00a0 der\u00a0Blutung,\u00a0\ndem\u00a0klinischen\u00a0Zustand\u00a0und\u00a0Alter\u00a0des\u00a0Patienten\u00a0sowie\u00a0weiteren\u00a0p atientenindivi\u2010\nduellen\u00a0Charakteristika\u00a0im\u00a0Hinblick\u00a0auf\u00a0die\u00a0Pharmakokinetik.\u00a0Di e\u00a0Fachinformation\u00a0\nenth\u00e4lt\u00a0eine\u00a0detaillierte\u00a0Anleitung,\u00a0wie\u00a0sich\u00a0die\u00a0notwendigen\u00a0D osen\u00a0f\u00fcr\u00a0die\u00a0Be\u2010\ndarfsbehandlung\u00a0berechnen\u00a0lassen.\u00a0Die\u00a0\u00fcbliche\u00a0Dosierung\u00a0f\u00fcr\u00a0die \u00a0Prophylaxe\u00a0liegt\u00a0\nbei\u00a050\u00a0I.E./kg\u00a0KG\u00a0einmal\u00a0w\u00f6chentlich\u00a0bzw.\u00a0100 \u00a0I.E./kg\u00a0KG\u00a0einmal\u00a0alle\u00a0zehn\u00a0Tage.\u00a0\nEine\u00a0individuelle\u00a0Anpassung\u00a0der\u00a0Dos en\u00a0und\u00a0Dosierungsintervalle\u00a0 ist\u00a0jeweils\u00a0erfor\u2010\nderlich\u00a0(EMA,\u00a02018).\u00a0\nDie\u00a0Zulassung\u00a0st\u00fctzt\u00a0sich\u00a0im\u00a0Wesentlichen\u00a0auf\u00a0die\u00a0pivotalen\u00a0mul tizentrischen\u00a0Pha\u2010\nse\u2010III\u2010Studien\u00a0B\u2010LONG\u00a0und\u00a0Kids\u00a0B\u2010LONG.\u00a0Beide\u00a0Studien\u00a0wurden\u00a0im\u00a0 Open\u2010label\u2010\nDesign\u00a0 durchgef\u00fchrt\u00a0 und\u00a0 umfassten\u00a0 entsprechend\u00a0 des\u00a0 Krankheitsbildes\u00a0 a us\u2010\nschlie\u00dflich\u00a0m\u00e4nnliche\u00a0Teilnehmer\u00a0mit\u00a0schwerer\u00a0H\u00e4mophilie\u00a0B\u00a0und\u00a0 einer\u00a0Faktor\u2010IX\u2010\nAktivit\u00e4t\u00a0 von\u00a0 maximal\u00a0 2\u00a0%.\u00a0 Alle\u00a0 P atienten\u00a0 hatten\u00a0 bereits\u00a0 vorher \u00a0F a k t o r \u2010 I X \u2010\nPr\u00e4parate\u00a0erhalten\u00a0und\u00a0es\u00a0lie\u00dfen\u00a0sich\u00a0bei\u00a0ihnen\u00a0keine\u00a0Inhibitor en\u00a0gegen\u00a0diesen\u00a0\nFaktor\u00a0nachweisen.\u00a0Es\u00a0fehlen\u00a0Erfahrungen\u00a0mit\u00a0bisher\u00a0unbehandelt en\u00a0Patienten,\u00a0\nder\u00a0Erfahrungsumfang\u00a0mit\u00a0Mensche n\u00a0ab\u00a065\u00a0Jahren\u00a0ist\u00a0gering\u00a0(EMA, \u00a02016).\u00a0\nAn\u00a0der\u00a0Studie\u00a0B\u2010LONG\u00a0(Powell\u00a0et\u00a0al.,\u00a02013)\u00a0nahmen\u00a0123\u00a0Patienten \u00a0zwischen\u00a0zw\u00f6lf\u00a0\nund\u00a071\u00a0Jahren\u00a0teil.\u00a0Die\u00a0Studie\u00a0umfasste\u00a0vier\u00a0Behandlungsarme,\u00a0d enen\u00a0die\u00a0Patien\u2010\nten\u00a0je\u00a0nach\u00a0\u00fcblichen\u00a0Modalit\u00e4ten\u00a0in\u00a0den\u00a0Zentren\u00a0bzw.\u00a0vorhergehe nder\u00a0Behandlung\u00a0\nzugeordnet\u00a0wurden.\u00a0\u00a092\u00a0In\u00a0Behandlungsarm\u00a01\u00a0erhielten\u00a063\u00a0Studienteilnehmer\u00a0\u00fcber\u00a052\u00a0Woch en\u00a0eine\u00a0w\u00f6\u2010\nchentliche\u00a0prophylaktische\u00a0Gabe\u00a0von\u00a0Eftrenonacog\u00a0alfa.\u00a0Die\u00a0Dosi s\u00a0lag\u00a0zu\u00a0Beginn\u00a0bei\u00a0\n50\u00a0I.E./kg\u00a0KG,\u00a0eine\u00a0individuelle\u00a0Anpa ssung\u00a0war\u00a0m\u00f6glich.\u00a0Die\u00a0annual isierte\u00a0Blutungs\u2010\nrate\u00a0in\u00a0diesem\u00a0Behandlungsarm\u00a0lag\u00a0median\u00a0bei\u00a02,95.\u00a0In\u00a0Behandlun gsarm\u00a02\u00a0wurden\u00a0\ndie\u00a029\u00a0Teilnehmer\u00a0zu\u00a0Beginn\u00a0prophylaktisch\u00a0alle\u00a0zehn\u00a0Tage\u00a0mit\u00a0e iner\u00a0Dosis\u00a0von\u00a0\n100\u00a0I.E./kg\u00a0KG\u00a0behandelt,\u00a0danach\u00a0konnte\u00a0das\u00a0Dosierungsintervall \u00a0je\u00a0nach\u00a0Faktor\u2010IX\u2010\nAktivit\u00e4t\u00a0angepasst\u00a0werden.\u00a0Im\u00a0Median\u00a0lag\u00a0die\u00a0annualisierte\u00a0Blu tungsrate\u00a0in\u00a0die\u2010\nsem\u00a0Behandlungsarm\u00a0bei\u00a01,38.\u00a0\nIm\u00a0Behandlungsarm\u00a03\u00a0erfolgte\u00a0eine\u00a0Bedarfsbehandlung\u00a0\u00fcber\u00a0einen\u00a0 Zeitraum\u00a0von\u00a0\n52\u00a0Wochen.\u00a0Blutungen\u00a0bei\u00a0den\u00a027\u00a0Studienteilnehmern\u00a0wurden\u00a0je\u00a0na ch\u00a0Schwere\u2010\ngrad\u00a0mit\u00a020\u00a0bis\u00a0100 \u00a0I.E./kg\u00a0KG\u00a0behandelt.\u00a0Im\u00a0Median\u00a0lag\u00a0die\u00a0annualisierte\u00a0Blutungs\u2010\nrate\u00a0in\u00a0diesem\u00a0Behandlungsarm\u00a0bei\u00a017,69.\u00a0In\u00a0den\u00a0Behandlungsarme n\u00a01\u00a0bis\u00a03\u00a0traten\u00a0\ninsgesamt\u00a0636\u00a0Blutungsepisoden\u00a0auf,\u00a090,4\u00a0%\u00a0davon\u00a0waren\u00a0mit\u00a0eine r\u00a0Injektion\u00a0zu\u00a0\nbehandeln.\u00a0\u00a0\nBehandlungsarm\u00a04\u00a0evaluierte\u00a0das\u00a0perioperative\u00a0Management\u00a0mit\u00a0Ef trenonacog\u00a0\nalfa.\u00a0Bei\u00a0zw\u00f6lf\u00a0Patienten\u00a0wurden \u00a0insgesamt\u00a014\u00a0gr\u00f6\u00dfere\u00a0Operation en\u00a0durchgef\u00fchrt.\u00a0\nDer\u00a0Behandlungserfolg\u00a0wurde\u00a0in\u00a0 13\u00a0F\u00e4llen\u00a0mit\u00a0ausgezeichnet,\u00a0in\u00a0 einem\u00a0Fall\u00a0mit\u00a0gut\u00a0\nbewertet\u00a0(Powell\u00a0et\u00a0al.,\u00a02015).\u00a0 Daten\u00a0zur\u00a0gesundheitsbezogenen\u00a0 Lebensqualit\u00e4t\u00a0\nliegen\u00a0nur\u00a0f\u00fcr\u00a0einige\u00a0Teilnehmer\u00a0aus\u00a0den\u00a0Behandlungsarmen\u00a01\u00a0und \u00a02\u00a0vor\u00a0und\u00a0zei\u2010\ngen\u00a0keine\u00a0konsistenten\u00a0Verbesserungen\u00a0durch\u00a0die\u00a0Therapie\u00a0mit\u00a0Ef trenonacog\u00a0alfa\u00a0\n(Wyrwich\u00a0et\u00a0al.,\u00a02016).\u00a0\nAn\u00a0der\u00a0einarmigen\u00a0Studie\u00a0Kids\u00a0B\u2010LONG\u00a0(Fischer\u00a0et\u00a0al.,\u00a02017)\u00a0nah men\u00a030\u00a0Jungen\u00a0vor\u00a0\ndem\u00a0vollendeten\u00a0zw\u00f6lften\u00a0Lebensjahr\u00a0teil.\u00a015\u00a0von\u00a0ihnen\u00a0waren\u00a0j\u00fc nger\u00a0als\u00a0sechs\u00a0\nJahre.\u00a0Behandelt\u00a0wurden\u00a0die\u00a0Patienten\u00a0prophylaktisch\u00a0mit\u00a0einer\u00a0 Dosierung\u00a0von\u00a050\u00a0\nbis\u00a0 60\u00a0I.E./kg\u00a0 KG\u00a0 Eftrenonacog\u00a0 alfa\u00a0 ein mal\u00a0 w\u00f6chentlich.\u00a0 Die\u00a0 Dosierung\u00a0 konnte\u00a0\nindividuell\u00a0bis\u00a0maximal\u00a0100 \u00a0I.E./kg\u00a0KG\u00a0angepasst\u00a0werden,\u00a0das\u00a0Dosierungsintervall\u00a0\nauf\u00a0maximal\u00a0zweimal\u00a0pro\u00a0Woche.\u00a0D ie\u00a0Behandlung\u00a0erfolgte\u00a0\u00fcber\u00a050\u00a0 Expositionsta\u2010\nge,\u00a0entsprechend\u00a0etwa\u00a050\u00a0Wochen.\u00dcber\u00a0alle\u00a0Altersgruppen\u00a0lag\u00a0die \u00a0annualisierte\u00a0\nBlutungsrate\u00a0im\u00a0Median\u00a0bei\u00a01,97,\u00a0im\u00a0arithmetischen\u00a0Mittel\u00a0bei\u00a02 ,26.\u00a0Bei\u00a0den\u00a0unter\u00a0\nSechsj\u00e4hrigen\u00a0traten\u00a0pro\u00a0Jahr\u00a0im\u00a0Median\u00a01,09\u00a0(arithmetisches\u00a0Mi ttel\u00a01,72)\u00a0Blutun\u2010\ngen\u00a0auf,\u00a0bei\u00a0den\u00a0\u00e4lteren\u00a0Kindern\u00a0im\u00a0Median\u00a02,13\u00a0Blutungen\u00a0(arit hmetisches\u00a0Mittel\u00a0\n2,80).Von\u00a0den\u00a0insgesamt\u00a060\u00a0Blutungsepisoden\u00a0konnten\u00a075\u00a0%\u00a0mit\u00a0ei ner\u00a0Injektion\u00a0\nbehandelt\u00a0werden.\u00a0Im\u00a0Rahmen\u00a0der\u00a0Studie\u00a0wurden\u00a0keine\u00a0gr\u00f6\u00dferen\u00a0Op erationen\u00a0\ndurchgef\u00fchrt,\u00a0lediglich\u00a0drei\u00a0kle inere\u00a0Eingriffe\u00a0an\u00a0zwei\u00a0Teilneh mern.\u00a0In\u00a0allen\u00a0F\u00e4llen\u00a0\nwurde\u00a0das\u00a0Ansprechen\u00a0durch\u00a0die\u00a0B ehandler\u00a0als\u00a0ausgezeichnet\u00a0bewe rtet.\u00a0\nDie\u00a0Zwischenergebnisse\u00a0der\u00a0noch\u00a0laufenden\u00a0Erweiterungsstudie\u00a0B\u2010 YOND\u00a0mit\u00a0116\u00a0\nPatienten\u00a0sind\u00a0mit\u00a0den\u00a0pivotalen\u00a0 Studien\u00a0vergleichbar\u00a0(Pasi\u00a0et\u00a0 al.,\u00a02017).\u00a0\u00a093\u00a0In\u00a0den\u00a0Zulassungsstudien\u00a0traten\u00a0als\u00a0wichtigste\u00a0unerw\u00fcnschte\u00a0Arz neimittelereignis\u2010\nse\u00a0h\u00e4ufig\u00a0(jeweils\u00a0zwei\u00a0F\u00e4lle)\u00a0Kopfschmerzen,\u00a0orale\u00a0Par\u00e4sthesie \u00a0und\u00a0obstruktive\u00a0\nUropathie\u00a0auf.\u00a0Als\u00a0gelegentlich\u00a0 wurden\u00a0klassifiziert\u00a0(jeweils\u00a0e in\u00a0Fall):\u00a0Palpitationen,\u00a0\nFatigue,\u00a0Schmerzen\u00a0an\u00a0der\u00a0Injektionsstelle,\u00a0verminderter\u00a0Appeti t,\u00a0Schwindel,\u00a0Ge\u2010\nschmacksst\u00f6rung,\u00a0Hypotonie,\u00a0Mundgeruch,\u00a0H\u00e4maturie,\u00a0Nierenkolik\u00a0 (EMA,\u00a02016).\u00a0\nF\u00fcr\u00a0Arzneimittel\u00a0zur\u00a0Behandlung\u00a0eines\u00a0seltenen\u00a0Leidens\u00a0gilt\u00a0der \u00a0medizinische\u00a0Zu\u2010\nsatznutzen\u00a0durch\u00a0die\u00a0Zulassung\u00a0als\u00a0belegt,\u00a0lediglich\u00a0das\u00a0Ausma\u00df \u00a0des\u00a0Zusatznutzens\u00a0\nist\u00a0durch\u00a0den\u00a0pU\u00a0nachzuweisen.\u00a0\u00a0\nF\u00fcr\u00a0die\u00a0Bewertung\u00a0zog\u00a0der\u00a0G\u2010BA\u00a0di e\u00a0zwei\u00a0pivotalen\u00a0Zulassungsstu dien\u00a0sowie\u00a0Zwi\u2010\nschenergebnisse\u00a0der\u00a0noch\u00a0laufenden\u00a0Studie\u00a0B\u2010YOND\u00a0heran.\u00a0Auf\u00a0die ser\u00a0Basis\u00a0kam\u00a0\nder\u00a0G\u2010BA\u00a0im\u00a0Dezember\u00a02016\u00a0zu\u00a0dem\u00a0Schluss,\u00a0dass\u00a0der\u00a0 Zusatznutzen \u00a0f\u00fcr\u00a0Eftrenona\u2010\ncog\u00a0alfa\u00a0nicht\u00a0quantifizierbar \u00a0ist.\u00a0\u00a0\nBegr\u00fcndet\u00a0wurde\u00a0der\u00a0Beschluss\u00a0damit,\u00a0dass\u00a0die\u00a0im\u00a0Vergleich\u00a0zu\u00a0a nderen\u00a0Faktor\u2010IX\u2010\nPr\u00e4paraten\u00a0verl\u00e4ngerte\u00a0Halbwer tzeit\u00a0und\u00a0ein\u00a0dadurch\u00a0verl\u00e4ngerte s\u00a0Dosierungs\u2010\nintervall\u00a0an\u00a0sich\u00a0kein\u00a0patientenrelevanter\u00a0Endpunkt\u00a0ist\u00a0und\u00a0sic h\u00a0m\u00f6gliche\u00a0dadurch\u00a0\nbedingte\u00a0Vorteile\u00a0in\u00a0den\u00a0vorgelegten\u00a0Daten\u00a0nicht\u00a0in\u00a0den\u00a0Endpunk ten\u00a0Sicherheit,\u00a0\nLebensqualit\u00e4t\u00a0oder\u00a0Blutungsrate\u00a0niedergeschlagen\u00a0haben.\u00a0Andere \u00a0aussagekr\u00e4fti\u2010\nge\u00a0Daten,\u00a0anhand\u00a0derer\u00a0sich\u00a0ein\u00a0Zusatznutzen\u00a0h\u00e4tte\u00a0quantifizier en\u00a0lassen,\u00a0hatte\u00a0\nder\u00a0pU\u00a0nicht\u00a0vorgelegt\u00a0(G\u2010BA,\u00a02016).\u00a0\u00a0\n\u00a0\nVerf\u00fcgbare\u00a0Therapien \u00a0 (Zusatz\u2010)Nutzen \u00a0 Kosten\u00a0\n\u00a0\nweiteres\u00a0rekombinantes\u00a0\nFaktor\u2010IX\u2010Pr\u00e4parat\u00a0\u00a0nicht\u00a0quantifizierbarer\u00a0\nZusatznutzen\u00a0\u00a0\nkein\u00a0Kostenvergleich,\u00a0da\u00a0\nOrphan\u2010Arzneimittel\u00a0\nErl\u00e4uterung\u00a0der\u00a0Farben:\u00a0Verf\u00fcgbare\u00a0Therapien:\u00a0rot\u00a0=\u00a0weitere\u00a0The rapieoption,\u00a0gelb\u00a0=\u00a0Subgruppen\u2010Novit\u00e4t,\u00a0gr\u00fcn\u00a0=\u00a0Solist;\u00a0(Zusatz\u2010 )\u00a0\nNutzen:\u00a0rot\u00a0=\u00a0keine\u00a0Verbesserung\u00a0oder\u00a0schlechte\u00a0Nutzen/Schaden\u2010 Relation,\u00a0gelb\u00a0=\u00a0teilweise\u00a0Verbesserungen,\u00a0gr\u00fcn\u00a0=\u00a0Verbesserung\u00a0\nharter\u00a0Endpunkte;\u00a0Kosten:\u00a0rot\u00a0=\u00a0teurer\u00a0als\u00a0bestehende\u00a0Therapien ,\u00a0gelb\u00a0=\u00a0ungef\u00e4hr\u00a0gleich\u00a0bzw.\u00a0teils/teils,\u00a0gr\u00fcn\u00a0=\u00a0g\u00fcnstiger\u00a0als \u00a0\nbestehende\u00a0Therapien\u00a0\nWie\u00a0bewerten\u00a0andere?\u00a0\nBewertung\u00a0nach\u00a0\nFricke\u00a0et\u00a0al.\u00a0a\u2010t\u2010Bewertung\u00a0 AMB\u00a0 Prescrire\u00a0 PZ\u00a0\nC\u00a0 \u2013\u00a0 \u2013\u00a0 \u2013\u00a0 Schrittinnovation\u00a0\n94\u00a0Kosten\u00a0\nWirkstoff\u00a0 Behandlungsmodus\u00a0 Behandlungstage\u00a0 Jahrestherapiekosten\u00a0\nzu\u00a0bewertendes\u00a0Arzneimittel \u00a0\u00a0 \u00a0 \u00a0\nEftrenonacog\u00a0alfa\u00a0 \u00a0 \u00a0 \u00a0\nErwachsene\u00a084,3\u00a0kg\u00a0 50\u00a0I.E./kg\u00a0KG\u00a01x\u00a0w\u00f6ch.\u00a0\u00a0 52\u00a0 385.280,35\u00a0\u20ac\u00a0\n\u00a0oder\u00a0100\u00a0I.E./kg\u00a0KG\u00a0\nalle\u00a010\u00a0Tage\u00a0\u00a0\n\u00a037\u00a0 548.238,58\u00a0\u20ac\u00a0\nJugendliche\u00a0(12\u00a0bis\u00a0<18\u00a0Jahre)\u00a0\n61,7\u00a0kg\u00a050\u00a0I.E./kg\u00a0KG\u00a01x\u00a0w\u00f6ch.\u00a0\u00a0\n\u00a052\u00a0 294.626,15\u00a0\u20ac\u00a0\n\u00a0oder\u00a0100\u00a0I.E./kg\u00a0KG\u00a0\nalle\u00a010\u00a0Tage\u00a0\u00a0\n\u00a037\u00a0 403.149,69\u00a0\u20ac\u00a0\nKinder\u00a0(6\u00a0bis\u00a0<12\u00a0Jahre)\u00a0\n32,4\u00a0kg\u00a050\u00a0I.E./kg\u00a0KG\u00a01x\u00a0w\u00f6ch.\u00a0 52\u00a0 158.644,85\u00a0\u20ac\u00a0\n\u00a0oder\u00a060\u00a0I.E./kg\u00a0KG\u00a01x\u00a0\nw\u00f6ch.\u00a0\u00a0\n\u00a052\u00a0 181.308,40\u00a0\u20ac\u00a0\nKleinkinder\u00a0(<6\u00a0Jahre)\u00a0\n15\u00a0kg\u00a050\u00a0I.E./kg\u00a0KG\u00a01x\u00a0w\u00f6ch.\u00a0 52\u00a0 67.990,65\u00a0\u20ac\u00a0\n\u00a0oder\u00a060\u00a0I.E./kg\u00a0KG\u00a01x\u00a0\nw\u00f6ch.\u00a0\u00a0\n\u00a052\u00a0 90.654,20\u00a0\u20ac\u00a0\nK\u00f6rpergewicht\u00a0 abweichend\u00a0 nach\u00a0 Mikrozensus\u00a0 2013\u00a0 f\u00fcr\u00a0 m\u00e4nnliche\u00a0 Pa tienten.\u00a0 Ber\u00fccksichtigung\u00a0 von\u00a0 Verwurf\u00a0 je\u00a0 Applikation.\u00a0\nBerechnung\u00a0anhand\u00a0Herstellerabgabepreis\u00a0plus\u00a0Umsatzsteuer\u00a0bei\u00a0D irektvertrieb\u00a0gem\u00e4\u00df\u00a0AMG\u00a0\u00a7\u00a047\u00a0(1)\u00a02a)\u00a0bzw.\u00a0BSG\u2010Urteil\u00a0Az:\u00a0B6KA\u00a0\n18/14\u00a0R\u00a0f\u00fcr\u00a0die\u00a0Langzeitprophylaxe.\u00a0\nVersorgungsanalysen\u00a0\nAufgrund\u00a0 der\u00a0 geringen\u00a0 Anzahl\u00a0 an\u00a0 Patienten\u00a0 konnten\u00a0 aus\u00a0 Datenschu tzgr\u00fcnden\u00a0\nkeine\u00a0Versorgungsanalysen\u00a0von\u00a0Ef trenonacog\u00a0alfa\u00a0erstellt\u00a0werden .\u00a0\n\u00a0\u00a095\u00a0Quellen\u00a0\u00a0\nEMA\u00a0\u2013\u00a0European\u00a0Medicines\u00a0Agency\u00a0(2016).\u00a0EPAR\u00a0(Public\u00a0Assessment \u00a0Report)\u00a0Alprolix.\u00a0\nhttps://www.ema.europa.eu/en/medicines/human/EPAR/alprolix,\u00a0let zter\u00a0Zugriff:\u00a010.07.2019.\u00a0\nEMA\u00a0\u2013\u00a0European\u00a0Medicines\u00a0Agency\u00a0 (2018).\u00a0Fachinformation\u00a0Alproli x.\u00a0Stand\u00a0der\u00a0Information:\u00a0Juli\u00a02018.\u00a0\nhttps://www.ema.europa.eu/en/documents/product\u2010information/alpr olix\u2010epar\u2010product\u2010information_en.pdf,\u00a0letzter\u00a0\nZugriff:\u00a010.07.2019.\u00a0\nFischer\u00a0K,\u00a0Kulkarni\u00a0R,\u00a0Nolan\u00a0B,\u00a0M ahlangu\u00a0J,\u00a0Rangarajan\u00a0S,\u00a0Gambi no\u00a0G\u00a0et\u00a0al.\u00a0(2017).\u00a0Recombinant\u00a0factor\u00a0IX\u00a0Fc\u00a0fusion\u00a0protein\u00a0in\u00a0\nchildren\u00a0with\u00a0haemophili a\u00a0B\u00a0(Kids\u00a0B\u2010LONG):\u00a0r esults\u00a0from\u00a0a\u00a0multi centre,\u00a0non\u2010randomised\u00a0phase\u00a03\u00a0study.\u00a0Lancet\u00a0\nHaematol\u00a04(2):\u00a0e75\u2013e82.\u00a0\u00a0\nFricke\u00a0U,\u00a0Hein\u00a0L,\u00a0Schwabe\u00a0U\u00a0(2017).\u00a0Neue\u00a0Arzneimittel\u00a02016.\u00a0In: \u00a0Schwabe\u00a0U,\u00a0Paffrath\u00a0D,\u00a0Ludwig\u00a0W\u2010D,\u00a0Klauber\u00a0J\u00a0(Hrsg.)\u00a0(2017).\u00a0\nArzneiverordnungs\u2010Report\u00a02017.\u00a0Berlin,\u00a0Heidelberg.\u00a0Springer:\u00a055 \u2010135.\u00a0\nG\u2010BA\u00a0\u2013\u00a0Gemeinsamer\u00a0Bundesausschuss\u00a0(2016).\u00a0Nutzenbewertungsverf ahren\u00a0zum\u00a0Wirkstoff\u00a0Eftrenonacog\u00a0alfa.\u00a0https://www.g\u2010\nba.de/informationen/nutzenbewertung/242/,\u00a0letzter\u00a0Zugriff:\u00a010.0 7.2019.\u00a0\nPasi\u00a0KJ,\u00a0Fischer\u00a0K,\u00a0Ragni\u00a0M,\u00a0Nolan\u00a0B,\u00a0Perr\u00a0DJ,\u00a0Kulkarni\u00a0R\u00a0et\u00a0al .\u00a0(2017).\u00a0Long\u2010term\u00a0safety\u00a0and\u00a0efficacy\u00a0of\u00a0extended\u2010interval\u00a0pr ophylaxis\u00a0\nwith\u00a0recombinant\u00a0factor\u00a0IX\u00a0Fc\u00a0fusion\u00a0protein\u00a0(rFIXFc)\u00a0in\u00a0subjec ts\u00a0with\u00a0haemophilia\u00a0B.\u00a0Thromb\u00a0and\u00a0Haemost\u00a0117(03):\u00a0\n508\u2013518.\u00a0\u00a0\nPowell\u00a0JS,\u00a0Pasi\u00a0KJ,\u00a0Ragni\u00a0MV,\u00a0Ozelo\u00a0MC,\u00a0Valentino\u00a0LA,\u00a0Mahlangu\u00a0 JN\u00a0et\u00a0al.\u00a0(2013).\u00a0Phase\u00a03\u00a0Study\u00a0of\u00a0Recombinant\u00a0Factor\u00a0IX\u00a0Fc\u00a0Fus ion\u00a0\nProtein\u00a0in\u00a0Hemophilia\u00a0B.\u00a0NE JM\u00a0369(24):\u00a02313\u20132323.\u00a0\u00a0\nPowell\u00a0JS,\u00a0Apte\u00a0S,\u00a0Chambost\u00a0H,\u00a0He rmans\u00a0C,\u00a0Jackson\u00a0S,\u00a0Josephson\u00a0 NC\u00a0et\u00a0al.\u00a0(2015).\u00a0Long\u2010acting\u00a0recombinant\u00a0factor\u00a0IX\u00a0Fc\u00a0fusion\u00a0\nprotein\u00a0(rFIXFc)\u00a0for\u00a0perioperative\u00a0management\u00a0of\u00a0subjects\u00a0with\u00a0 haemophilia\u00a0B\u00a0in\u00a0the\u00a0phase\u00a03\u00a0B\u2010LONG\u00a0study.\u00a0B\u00a0J\u00a0\nHaematol\u00a0168(1):\u00a0124\u2013134.\u00a0\u00a0\nPZ\u00a0\u2013\u00a0Pharmazeutische\u00a0Zeitung\u00a0(2016).\u00a0Eftrenonacog\u00a0alfa|Alprolix |16|2016.\u00a0https://www.pharmazeutische\u2010\nzeitung.de/arzneistoffe/daten/2016/eftrenonacog\u2010alfaalprolixr16 2016/,\u00a0letzter\u00a0Zugriff:\u00a010.07.2019.\u00a0\nWyrwich\u00a0KW,\u00a0Krishnan\u00a0S,\u00a0Auguste\u00a0 P,\u00a0Poon\u00a0JL,\u00a0von\u00a0Maltzahn\u00a0R,\u00a0Yu\u00a0 R\u00a0et\u00a0al.\u00a0(2016).\u00a0Changes\u00a0in\u00a0health\u2010related\u00a0quality\u00a0of\u00a0life\u00a0with \u00a0\ntreatment\u00a0of\u00a0longer\u2010acting\u00a0clotting\u00a0factors:\u00a0results\u00a0in\u00a0the\u00a0A\u2010L ONG\u00a0and\u00a0B\u2010LONG\u00a0clinical\u00a0stu dies.\u00a0Haemophilia\u00a022(6):\u00a0\n866\u2013872.\u00a0\u00a0\n\u00a0 \u00a096\u00a0 Elbasvir/Grazoprevir\u00a04.6\nHandelsname:\u00a0Zepatier\u00ae\u00a0 \u00a0 \u00a0 Pharmazeutischer\u00a0Unternehmer:\u00a0\u00a0\nIndikation:\u00a0Chronische\u00a0Hepatitis\u00a0C\u00a0 \u00a0 MSD\u00a0\nATC\u2010Code:\u00a0J05AP54\u00a0 \u00a0 \u00a0 Markte inf\u00fchrung:\u00a0Dezember\u00a02016\u00a0\nDarreichungsform:\u00a0Filmtabletten\u00a0 \u00a0 DDD:\u00a01\u00a0DE\u00a0O\u00a0\u00a0 \u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 \u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 \u25bc,\u00a0\nBewertung\u00a0 \u00a0\nDie\u00a0fixe\u00a0Kombination\u00a0aus\u00a0Elbasvir\u00a0und\u00a0Grazoprevir\u00a0wurde\u00a0im\u00a0Juli \u00a02016\u00a0unter\u00a0dem\u00a0\nHandelsnamen\u00a0Zepatier\u00ae\u00a0zentral\u00a0 durch\u00a0die\u00a0Europ\u00e4ische\u00a0Kommission \u00a0f\u00fcr\u00a0die\u00a0Be\u2010\nhandlung\u00a0 der\u00a0 chronischen\u00a0 Hepatiti s\u00a0 C\u00a0 bei\u00a0 Erwachsenen\u00a0 zugelassen .\u00a0 Elbasvir\u00a0\nhemmt\u00a0das\u00a0Protein\u00a0NS5A,\u00a0Grazoprevir\u00a0ist\u00a0ein\u00a0Inhibitor\u00a0des\u00a0Enzym s\u00a0NS3/4A\u2010Prote\u2010\nase.\u00a0Die\u00a0Wirkstoffe\u00a0greifen\u00a0an\u00a0unterschiedlichen,\u00a0f\u00fcr\u00a0die\u00a0Virus replikation\u00a0essentiel\u2010\nlen\u00a0Abschnitten\u00a0in\u00a0den\u00a0Lebenszyklu s\u00a0des\u00a0Hepatitis\u2010C\u2010Virus\u00a0(HCV) \u00a0ein\u00a0und\u00a0wirken\u00a0\ndirekt\u00a0antiviral\u00a0(Fachinformation\u00a0Zepatier\u00ae,\u00a02018).\u00a0\nDie\u00a0Dosierung\u00a0liegt\u00a0bei\u00a0einmal\u00a0t \u00e4glich\u00a0einer\u00a0Filmtablette\u00a0mit\u00a05 0\u00a0mg\u00a0Elbasvir\u00a0und\u00a0\n100\u00a0mg\u00a0Grazoprevir,\u00a0die\u00a0unabh\u00e4ngig\u00a0von\u00a0einer\u00a0Mahlzeit\u00a0eingenomm en\u00a0werden\u00a0\nkann.\u00a0Bei\u00a0HCV\u2010Genotyp\u00a01b\u00a0sollte\u00a0die\u00a0Behandlung\u00a0\u00fcber\u00a0zw\u00f6lf\u00a0Woche n\u00a0erfolgen.\u00a0Bei\u00a0\nHCV\u2010Genotyp\u00a01a\u00a0und\u00a04\u00a0gilt\u00a0die\u00a0gle iche\u00a0Behandlungsdauer,\u00a0jedoch\u00a0 kann\u00a0bei\u00a0be\u2010\nstimmten\u00a0Patientengruppen\u00a0eine\u00a0Behandlung\u00a0\u00fcber\u00a016\u00a0Wochen\u00a0in\u00a0Kom bination\u00a0mit\u00a0\nRibavirin\u00a0erwogen\u00a0werden.\u00a0Bei\u00a0de n\u00a0HCV\u2010Genotypen\u00a02,\u00a03,\u00a05\u00a0und\u00a06\u00a0w ird\u00a0die\u00a0Anwen\u2010\ndung\u00a0nicht\u00a0empfohlen,\u00a0da\u00a0die\u00a0Wirksamkeit\u00a0nicht\u00a0belegt\u00a0wurde.\u00a0Er fahrungen\u00a0fehlen\u00a0\nbislang\u00a0bei\u00a0Patienten\u00a0nach\u00a0einer\u00a0Lebertransplantation.\u00a0Bei\u00a0mitt elschwerer\u00a0oder\u00a0\nschwerer\u00a0Leberfunktionsst\u00f6rung\u00a0(C hild\u2010Pugh\u00a0B\u00a0oder\u00a0C)\u00a0ist\u00a0die\u00a0An wendung\u00a0kontra\u2010\nindiziert.\u00a0Zepatier\u00ae\u00a0kann\u00a0zahlre iche\u00a0Wechselwirkungen\u00a0eingehen\u00a0 (Fachinformation\u00a0\nZepatier\u00ae,\u00a02018).\u00a0\nDie\u00a0Zulassung\u00a0beruht\u00a0auf\u00a0sechs\u00a0klinischen\u00a0Hauptstudien\u00a0mit\u00a0Elba svir/Grazoprevir,\u00a0\nvon\u00a0denen\u00a0vier\u00a0Phase\u2010II\u2010Studien\u00a0und\u00a0zwei\u00a0Phase\u2010III\u2010\u00a0bzw.\u00a0Phase\u00a0 II/III\u2010Studien\u00a0sind.\u00a0\nZwei\u00a0Phase\u2010II\u2010Studien\u00a0vergleichen\u00a0Elbasvir/Grazoprevir\u00a0und\u00a0Elba svir/Grazoprevir\u00a0\nkombiniert\u00a0mit\u00a0Ribavirin,\u00a0eine\u00a0weitere\u00a0Elbasvir/Grazoprevir\u00a0mit \u00a0Elbasvir/Grazo\u2010\nprevir\u00a0in\u00a0Kombination\u00a0mit\u00a0Sofosbuvir.\u00a0Eine\u00a0Phase\u2010II\u2010Studie\u00a0ist\u00a0 lediglich\u00a0einarmig.\u00a0In\u00a0\nden\u00a0 beiden\u00a0 multizentrischen\u00a0 doppelblinden\u00a0 Phase\u2010III\u2010\u00a0 bzw.\u00a0 Phase \u2010II/III\u2010Studien\u00a0\nwurden\u00a0die\u00a0Teilnehmer\u00a0randomisier t\u00a0entweder\u00a0der\u00a0sofortigen\u00a0Beha ndlung\u00a0(zw\u00f6lf\u2010\nw\u00f6chige\u00a0Behandlung\u00a0mit\u00a0Elbasvir/Grazoprevir\u00a050/100\u00a0mg)\u00a0oder\u00a0der \u00a0verz\u00f6gerten\u00a0\nBehandlung\u00a0(zw\u00f6lfw\u00f6chige\u00a0Behandl ung\u00a0mit\u00a0Placebo,\u00a0danach\u00a0Behandl ung\u00a0mit\u00a0El\u2010\nbasvir/Grazoprevir)\u00a0zugeteilt.\u00a0Prim\u00e4rer\u00a0Endpunkt\u00a0in\u00a0den\u00a0Studien \u00a0war\u00a0das\u00a0dauerhaf\u2010\nte\u00a0virologische\u00a0Ansprechen\u00a0zw\u00f6lf\u00a0Wochen\u00a0nach\u00a0dem\u00a0Ende\u00a0der\u00a0Behan dlung\u00a0(SVR12)\u00a0\n(EMA,\u00a02016).\u00a0\u00a0\n97\u00a0An\u00a0 der\u00a0 Studie\u00a0 C\u2010SURFER\u00a0 nahmen\u00a0 224\u00a0 Patienten\u00a0 mit\u00a0 chronischer\u00a0 Hep atitis\u2010C\u2010\nInfektion\u00a0vom\u00a0Genotyp\u00a01\u00a0(GT1)\u00a0und\u00a0einer\u00a0chronischen\u00a0Nierenerkra nkung\u00a0im\u00a0Stadi\u2010\num\u00a04\u00a0bis\u00a05\u00a0teil.\u00a0Bei\u00a06\u00a0%\u00a0von\u00a0ihnen\u00a0war\u00a0eine\u00a0Zirrhose\u00a0nachweisba r.\u00a0Rund\u00a080\u00a0%\u00a0hat\u2010\nten\u00a0zuvor\u00a0noch\u00a0keine\u00a0Behandlung\u00a0gegen\u00a0die\u00a0HCV\u2010Infektion\u00a0erhalte n.\u00a0Sie\u00a0wurden\u00a0im\u00a0\nVerh\u00e4ltnis\u00a01:1\u00a0der\u00a0sofortigen\u00a0bzw.\u00a0verz\u00f6gerten\u00a0Behandlung\u00a0zuget eilt.\u00a0In\u00a0der\u00a0Grup\u2010\npe\u00a0mit\u00a0sofortiger\u00a0Behandlung\u00a0erre ichten\u00a099\u00a0%\u00a0der\u00a0Teilnehmer\u00a0den \u00a0prim\u00e4ren\u00a0End\u2010\npunkt\u00a0(Roth\u00a0et\u00a0al.,\u00a02015).\u00a0\nAn\u00a0der\u00a0Studie\u00a0C\u2010EDGE\u00a0TN\u00a0nahmen\u00a0421\u00a0Teilnehmer\u00a0mit\u00a0chronischer\u00a0H CV\u2010Infektion\u00a0\nvom\u00a0Genotyp\u00a01,\u00a04\u00a0bzw.\u00a06\u00a0teil,\u00a0di e\u00a0zuvor\u00a0noch\u00a0keine\u00a0Behandlung\u00a0g egen\u00a0die\u00a0HCV\u2010\nInfektion\u00a0erhalten\u00a0hatten.\u00a0Bei\u00a0 22\u00a0%\u00a0lag\u00a0eine\u00a0Zirrhose\u00a0vor.\u00a0Sie\u00a0 wurden\u00a0im\u00a0Verh\u00e4ltnis\u00a0\n3:1\u00a0der\u00a0sofortigen\u00a0bzw.\u00a0verz\u00f6ger ten\u00a0Behandlung\u00a0zugeteilt.\u00a0In\u00a0de r\u00a0Gruppe\u00a0mit\u00a0sofor\u2010\ntiger\u00a0Behandlung\u00a0erreichten\u00a095\u00a0%\u00a0 der\u00a0Teilnehmer\u00a0den\u00a0prim\u00e4ren\u00a0En dpunkt\u00a0(Zeuzem\u00a0\net\u00a0al.,\u00a02015).\u00a0In\u00a0beiden\u00a0Studien\u00a0wurde\u00a0kein\u00a0statistischer\u00a0Test\u00a0 zum\u00a0Vergleich\u00a0der\u00a0\nbeiden\u00a0Gruppen\u00a0durchgef\u00fchrt.\u00a0In\u00a0der\u00a0Zusammenfassung\u00a0aller\u00a0zulas sungsrelevan\u2010\nten\u00a0Studien\u00a0wird\u00a0im\u00a0EPAR\u00a0die\u00a0SVR12,\u00a0jeweils\u00a0nach\u00a0zw\u00f6lfw\u00f6chiger\u00a0 Behandlung,\u00a0bei\u00a0\nGT1a\u00a0mit\u00a093\u00a0%\u00a0(n\u00a0=\u00a0519),\u00a0bei\u00a0GT1b\u00a0mit\u00a096\u00a0%\u00a0(n\u00a0=\u00a0312)\u00a0und\u00a0bei\u00a0GT 4\u00a0mit\u00a094\u00a0%\u00a0(n\u00a0=\u00a065)\u00a0\nangegeben\u00a0(EMA,\u00a02016).\u00a0\u00a0\nZum\u00a0Zeitpunkt\u00a0der\u00a0Zulassung\u00a0beruhte\u00a0die\u00a0Bewertung\u00a0der\u00a0Sicherhei t\u00a0auf\u00a0den\u00a0Daten\u00a0\nvon\u00a0rund\u00a02.000\u00a0mit\u00a0Elbasvir/Grazoprevir\u00a0behandelten\u00a0Patienten.\u00a0 In\u00a0den\u00a0Zulas\u2010\nsungsstudien\u00a0 traten\u00a0 als\u00a0 h\u00e4ufigst e\u00a0 unerw\u00fcnschte\u00a0 Arzneimittelerei gnisse\u00a0 Kopf\u2010\nschmerzen\u00a0und\u00a0Erm\u00fcdung\u00a0auf.\u00a0Als\u00a0weitere\u00a0h\u00e4ufige\u00a0Nebenwirkungen\u00a0 werden\u00a0in\u00a0der\u00a0\nFachinformation\u00a0verminderter\u00a0Appetit,\u00a0Schlaflosigkeit,\u00a0Angst,\u00a0D epression,\u00a0Schwin\u2010\ndel,\u00a0 gastrointestinale\u00a0 Beschwerden,\u00a0 Juckreiz,\u00a0 Haarausfall,\u00a0 Musk el\u2010\u00a0 und\u00a0 Gelenk\u2010\nschmerzen\u00a0sowie\u00a0Reizbarkeit\u00a0und\u00a0Kraftlosigkeit\u00a0genannt\u00a0(EMA,\u00a020 16).\u00a0Nach\u00a0der\u00a0\nZulassung\u00a0wurde\u00a0nach\u00a0einem\u00a0im\u00a0Mai\u00a02017\u00a0abgeschlossenen\u00a0Risikobe wertungsver\u2010\nfahren\u00a0der\u00a0EMA\u00a0die\u00a0Empfehlung\u00a0in\u00a0die\u00a0Fachinformation\u00a0aufgenomme n,\u00a0alle\u00a0Patien\u2010\nten\u00a0vor\u00a0Behandlung\u00a0mit\u00a0direkt\u00a0wi rkenden\u00a0antiviralen\u00a0Arzneimitte ln\u00a0(DAA)\u00a0auf\u00a0eine\u00a0\nInfektion\u00a0mit\u00a0Hepatitis\u00a0B\u00a0zu\u00a0screenen\u00a0(Akd\u00c4,\u00a02017).\u00a0Im\u00a0Oktober\u00a0 2018\u00a0wurde\u00a0ein\u00a0\nHinweis\u00a0erg\u00e4nzt,\u00a0dass\u00a0DAA\u00a0bei\u00a0Pa tienten\u00a0mit\u00a0Diabetes\u00a0mellitus\u00a0d as\u00a0Risiko\u00a0f\u00fcr\u00a0Hy\u2010\npoglyk\u00e4mien\u00a0erh\u00f6hen\u00a0k\u00f6nnen\u00a0(Akd\u00c4,\u00a02019).\u00a0\nF\u00fcr\u00a0die\u00a0fr\u00fche\u00a0Nutzenbewertung\u00a0wurde\u00a0die\u00a0zVT\u00a0f\u00fcr\u00a0zwei\u00a0Fragestell ungen\u00a0festgelegt.\u00a0\nIn\u00a0der\u00a0ersten\u00a0Fragestellung\u00a0bei\u00a0Infektionen\u00a0mit\u00a0HCV\u2010GT1\u00a0gelten\u00a0 die\u00a0Kombination\u00a0\naus\u00a0Ledipasvir\u00a0und\u00a0Sofosbuvir\u00a0oder\u00a0die\u00a0Kombination\u00a0aus\u00a0Ombitasv ir/Paritaprevir/\u00a0\nRitonavir\u00a0und\u00a0Dasabuvir,\u00a0ggf.\u00a0mit\u00a0Ribavirin,\u00a0als\u00a0zVT.\u00a0In\u00a0der\u00a0zw eiten\u00a0Fragestellung\u00a0\nbei\u00a0Infektionen\u00a0mit\u00a0HCV\u2010GT4\u00a0bild en\u00a0die\u00a0Kombination\u00a0aus\u00a0Ledipasv ir\u00a0und\u00a0Sofosbuvir\u00a0\noder\u00a0die\u00a0Kombination\u00a0aus\u00a0Ombitasvir/Paritaprevir/Ritonavir\u00a0plus \u00a0Ribavirin\u00a0die\u00a0zVT.\u00a0\nDas\u00a0IQWiG\u00a0kam\u00a0in\u00a0seinem\u00a0Gutachten\u00a0vom\u00a0M\u00e4rz\u00a02017\u00a0zu\u00a0dem\u00a0Urteil,\u00a0 dass\u00a0die\u00a0durch\u00a0\nden\u00a0pU\u00a0 vorgelegten\u00a0Daten\u00a0aus\u00a0direkten\u00a0Vergleichen\u00a0f\u00fcr\u00a0die\u00a0Nutze nbewertung\u00a098\u00a0nicht\u00a0geeignet\u00a0sind,\u00a0weil\u00a0die\u00a0Kontrollgruppen\u00a0nicht\u00a0die\u00a0zVT\u00a0erh alten\u00a0haben.\u00a0Die\u00a0\nvorgelegten\u00a0indirekten\u00a0Vergleiche\u00a0auf\u00a0der\u00a0Basis\u00a0von\u00a0Behandlungs armen\u00a0aus\u00a0ver\u2010\nschiedenen\u00a0Studien\u00a0waren\u00a0wegen\u00a0d es\u00a0hohen\u00a0Verzerrungspotentials\u00a0 und\u00a0dem\u00a0Feh\u2010\nlen\u00a0 dramatischer\u00a0 Effekte\u00a0 nicht\u00a0 aussagekr\u00e4ftig.\u00a0 Aus\u00a0 diesen\u00a0 Gr\u00fcnd en\u00a0 stellte\u00a0 das\u00a0\nIQWiG\u2010Gutachten\u00a0 fest,\u00a0 dass\u00a0 f\u00fcr\u00a0 beide\u00a0 Fragestellungen\u00a0 ein\u00a0 Zusatznutzen\u00a0 nicht\u00a0\nbelegt\u00a0ist\u00a0(IQWiG,\u00a02017).\u00a0Der\u00a0G\u2010BA\u00a0folgte\u00a0dieser\u00a0Bewertung\u00a0in\u00a0seinem\u00a0 Beschluss\u00a0\nvom\u00a0Juni\u00a02017\u00a0(G\u2010BA,\u00a02017).\u00a0\u00a0\n\u00a0\nVerf\u00fcgbare\u00a0Therapien \u00a0 (Zusatz\u2010)Nutzen \u00a0 Kosten\u00a0\n\u00a0\nweitere\u00a0Therapieoption\u00a0\nf\u00fcr\u00a0GT1\u00a0und\u00a0GT4\u00a0\u00a0ZN\u00a0nicht\u00a0belegt\u00a0wegen\u00a0\nfehlendem\u00a0validen\u00a0\nVergleich\u00a0mit\u00a0zVT\u00a0\u00a0\u00a0\ng\u00fcnstiger\u00a0als\u00a0zVT\u00a0\nErl\u00e4uterung\u00a0der\u00a0Farben:\u00a0Verf\u00fcgbare\u00a0Therapien:\u00a0rot\u00a0=\u00a0weitere\u00a0The rapieoption,\u00a0gelb\u00a0=\u00a0Subgruppen\u2010Novit\u00e4t,\u00a0gr\u00fcn\u00a0=\u00a0Solist;\u00a0(Zusatz\u2010 )\u00a0\nNutzen:\u00a0rot\u00a0=\u00a0keine\u00a0Verbesserung\u00a0oder\u00a0schlechte\u00a0Nutzen/Schaden\u2010 Relation,\u00a0gelb\u00a0=\u00a0teilweise\u00a0Verbesserungen,\u00a0gr\u00fcn\u00a0=\u00a0Verbesserung\u00a0\nharter\u00a0Endpunkte;\u00a0Kosten:\u00a0rot\u00a0=\u00a0teurer\u00a0als\u00a0bestehende\u00a0Therapien ,\u00a0gelb\u00a0=\u00a0ungef\u00e4hr\u00a0gleich\u00a0bzw.\u00a0teils/teils,\u00a0gr\u00fcn\u00a0=\u00a0g\u00fcnstiger\u00a0als \u00a0\nbestehende\u00a0Therapien\u00a0\n\u00a0\nWie\u00a0bewerten\u00a0andere?\u00a0\nBewertung\u00a0nach\u00a0\nFricke\u00a0et\u00a0al.\u00a0\u00a0atd\u2010Bewertung\u00a0 AMB\u00a0 Prescrire\u00a0 PZ\u00a0\nC\u00a0Mittel\u00a0der\u00a0Wahl\u00a0bei\u00a0\nHepatitis\u00a0C\u00a0GT1\u00a0+\u00a0GT4\u00a0\nmit\u00a0schwerer\u00a0oder\u00a0\ndialysepflichtiger\u00a0\nNiereninsuffizienz,\u00a0\nsonst\u00a0Variante\u00a0ohne\u00a0\nbes.\u00a0Stellenwert\u00a0mit\u00a0\nm\u00f6gl.\u00a0Preisvorteil\u00a0\u2013\u00a0 Nothing\u00a0new\u00a0 Analogpr\u00e4parat\u00a0\n\u00a0\n\u00a0 \u00a0\n99\u00a0Kosten\u00a0\nWirkstoff\u00a0 Behandlungsmodus\u00a0 Behandlungstage\u00a0 Jahrestherapiekosten\u00a0\nzu\u00a0bewertendes\u00a0Arzneimittel \u00a0\u00a0 \u00a0 \u00a0\nElbasvir/Grazoprevir\u00a0 50/100\u00a0mg\u00a01x\u00a0tgl.\u00a0\u00a0 84\u00a0 26.000,01\u00a0\u20ac\u00a0\noder\u00a0 \u00a0 \u00a0 \u00a0\nElbasvir/Grazoprevir\u00a0 50/100\u00a0mg\u00a01x\u00a0tgl.\u00a0\u00a0 112\u00a0 \u00a0\n+\u00a0Ribavirin\u00a0 200\u00a0\u2013\u00a0400\u00a0mg\u00a04\u00a0\u2013\u00a07x\u00a0\ntgl.\u00a0\n\u00a0112\u00a036.651,45\u00a0\u2013\u00a038.140,03\u00a0\u20ac\u00a0\nzVT\u00a0a)\u00a0Patienten\u00a0ohne\u00a0Zirrhose\u00a0o der\u00a0mit\u00a0kompensi erter\u00a0Zirrhose, \u00a0Genotyp\u00a01 \u00a0 \u00a0\nLedipasvir/Sofosbuvir\u00a0 90/400\u00a0mg\u00a01x\u00a0tgl.\u00a0\u00a0 56\u00a0\u2013\u00a0168\u00a0 29.990,00\u00a0\u2013\u00a089.970,00\u00a0\u20ac\u00a0\nOmbitasvir/Paritaprevir/Ritonavir*\u00a0 12,5/75/50\u00a0mg\u00a02x\u00a0tgl.\u00a0\u00a0 84\u00a0 \u00a0\n+\u00a0Dasabuvir*\u00a0 250\u00a0mg\u00a02x\u00a0tgl.\u00a0\u00a0 84\u00a0 52.034,73\u00a0\u20ac\u00a0\n\u00b1\u00a0Ribavirin\u00a0 200\u00a0\u2013\u00a0400\u00a0mg\u00a04\u00a0\u2013\u00a07x\u00a0\ntgl.\u00a0\n\u00a084\u00a053.523,31\u00a0\u2013\u00a054.639,75\u00a0\u20ac\u00a0\nzVT\u00a0b)\u00a0Patienten\u00a0ohne\u00a0Zirrhose\u00a0o der\u00a0mit\u00a0kompensi erter\u00a0Zirrhose, \u00a0Genotyp\u00a04\u00a0\nLedipasvir/Sofosbuvir\u00a0 90/400\u00a0mg\u00a01x\u00a0tgl.\u00a0\u00a0 84\u00a0\u2013\u00a0168\u00a0 44.985,00\u00a0\u2013\u00a089.970,00\u00a0\u20ac\u00a0\nOmbitasvir/Paritaprevir/Ritonavir*\u00a0 12,5/75/50\u00a0mg\u00a02x\u00a0tgl.\u00a0\u00a0\n\u00a084\u00a0 \u00a0\n+\u00a0Ribavirin\u00a0 200\u00a0\u2013\u00a0400\u00a0mg\u00a04\u00a0\u2013\u00a07x\u00a0\ntgl.\u00a0\n\u00a084\u00a048.914,95\u00a0\u2013\u00a050.031,39\u00a0\u20ac\u00a0\n*\u00a0g\u00fcnstigste\u00a0Variante\u00a0ist\u00a0als\u00a0Re\u2010Import\u00a0verf\u00fcgbar\u00a0\n\u00a0\nVersorgungsanalysen\u00a0\nIm\u00a0 betrachteten\u00a0 Zeitraum\u00a0 nehmen\u00a0 die\u00a0 verordneten\u00a0 Tagesdosen\u00a0 nach \u00a0d e r \u00a0\nMarkteinf\u00fchrung\u00a0im\u00a0Dezember\u00a02016\u00a0zun\u00e4chst\u00a0stark\u00a0zu.\u00a0Sie\u00a0erreich en\u00a0mit\u00a0rund\u00a0\n2.800\u00a0DDD\u00a0im\u00a0M\u00e4rz\u00a02017\u00a0ein\u00a0Maximum,\u00a0ein\u00a0zweiter\u00a0Verordnungsgipf el\u00a0wird\u00a0im\u00a0\nJuni\u00a02017\u00a0mit\u00a0rund\u00a02.400\u00a0DDD\u00a0sichtbar.\u00a0Danach\u00a0nehmen\u00a0die\u00a0Verord nungszahlen\u00a0\nkontinuierlich\u00a0bis\u00a0auf\u00a0rund\u00a01.000\u00a0DDD\u00a0im\u00a0Dezember\u00a02017\u00a0ab.\u00a0Ob\u00a0d iese\u00a0Entwicklung\u00a0\nmit\u00a0dem\u00a0Beschluss\u00a0des\u00a0G\u2010BA\u00a0zusa mmenh\u00e4ngt,\u00a0in\u00a0dem\u00a0f\u00fcr\u00a0Elbasvir/G razoprevir\u00a0kein\u00a0\nZusatznutzen\u00a0festgestellt\u00a0wurde ,\u00a0ist\u00a0unklar.\u00a0Die\u00a0Bruttoums\u00e4tze\u00a0 entwickeln\u00a0sich\u00a0im\u00a0\nWesentlichen\u00a0parallel\u00a0zu\u00a0den\u00a0verordneten\u00a0Tagesdosen.\u00a0Die\u00a0h\u00f6chst en\u00a0monatlichen\u00a0\nUms\u00e4tze\u00a0finden\u00a0sich\u00a0mit\u00a0rund\u00a01,2\u00a0Mio.\u00a0\u20ac\u00a0im\u00a0M\u00e4rz\u00a02017.\u00a0\n\u00a0 \u00a0100\u00a0Abbildung\u00a04.5:\u00a0Verordnete\u00a0Tagesdosen\u00a0(DDD)\u00a0und\u00a0Bruttoums\u00e4tze\u00a0vo n\u00a0\u00a0\nElbasvir/Grazoprevir\u00a0nach\u00a0Monaten\u00a0(2016\u00a0\u2013\u00a02017)\u00a0\n\u00a0\n\u00a0\nQuellen\u00a0\u00a0\nAKd\u00c4\u2013\u00a0Arzneimittelkommission\u00a0der\u00a0deutschen\u00a0\u00c4rzteschaft\u00a0(2017).\u00a0 Drug\u00a0Safety\u00a0Mail\u00a02017\u201016:\u00a0Direkt\u00a0wirkende\u00a0antivirale\u00a0\nArzneimittel\u00a0(DAA):\u00a0EMA\u00a0best\u00e4tigt\u00a0 die\u00a0Empfehlung\u00a0zum\u00a0Hepatitis\u2010 B\u2010Screening.\u00a0\nhttps://www.akdae.de/Arzneimittelsicherheit/DSM/Archiv/2017\u201016. html,\u00a0letzter\u00a0Zugriff:\u00a010.07.2019.\u00a0\nAKd\u00c4\u2013\u00a0Arzneimittelkommission\u00a0der\u00a0deutschen\u00a0\u00c4rzteschaft.\u00a0(2019). \u00a0Drug\u00a0Safety\u00a0Mail\u00a02019\u201006:\u00a0Direkt\u00a0wirkende\u00a0antivirale\u00a0\nArzneimittel\u00a0(DAAV)\u00a0zur\u00a0Behandlung\u00a0der\u00a0Hepatitis\u00a0C:\u00a0Hypoglyk\u00e4mi erisiko\u00a0bei\u00a0Patienten\u00a0mit\u00a0Diabetes\u00a0mellitus.\u00a0\nhttps://www.akdae.de/Arzneimittelsicherheit/DSM/Archiv/2019\u201006. html,\u00a0letzter\u00a0Zugriff:\u00a010.07.2019.\u00a0\natd\u00a0\u2013\u00a0arznei\u2010telegramm\u00a0Arzneimitteldatenbank\u00a0(2019).\u00a0Elbasvir\u00a0+ \u00a0Grazoprevir.\u00a0https://www.arznei\u2010\ntelegramm.de/db/0kombiwkstxt.php3?&knr=&art=kombi&kombinr=11452 &ah=,\u00a0letzter\u00a0Zugriff:\u00a010.07.2019.\u00a0\nEMA\u00a0\u2013\u00a0European\u00a0Medicines\u00a0Agency\u00a0(2016).\u00a0EPAR\u00a0(Public\u00a0Assessment \u00a0Report):\u00a0Zepatier.\u00a0\nhttps://www.ema.europa.eu/en/medicines/human/EPAR/zepatier,\u00a0let zter\u00a0Zugriff:\u00a010.07.2019.\u00a0\nFachinformation\u00a0Zepatier\u00ae\u00a0(2018).\u00a0Fachinformation\u00a0Zepatier\u00ae.\u00a0St and\u00a0der\u00a0Information:\u00a0Dezember\u00a02018.\u00a0\nFricke\u00a0U,\u00a0Hein\u00a0L,\u00a0Schwabe\u00a0U\u00a0(2017).\u00a0Neue\u00a0Arzneimittel\u00a02016.\u00a0In: \u00a0Schwabe\u00a0U,\u00a0Paffrath\u00a0D,\u00a0Ludwig\u00a0W\u2010D,\u00a0Klauber\u00a0J\u00a0(Hrsg.)\u00a0(2017).\u00a0\nArzneiverordnungs\u2010Report\u00a02017.\u00a0Berlin,\u00a0Heidelberg.\u00a0Springer:\u00a055 \u2010135.\u00a0\nG\u2010BA\u00a0\u2013\u00a0Gemeinsamer\u00a0Bundesausschuss\u00a0(2017).\u00a0Nutzenbewertungsverf ahren\u00a0zum\u00a0Wirkstoff\u00a0Elbasvir/Grazoprevir.\u00a0https://www.g\u2010\nba.de/bewertungsverfahren/nutzenbewertung/270/,\u00a0letzter\u00a0Zugriff :\u00a010.07.2019.\u00a0\n101\u00a0IQWiG\u00a0\u2013\u00a0Institut\u00a0f\u00fcr\u00a0Qualit\u00e4t\u00a0und\u00a0Wirtschaftlichkeit\u00a0im\u00a0Gesundh eitswesen\u00a0(2017).\u00a0[A16\u201075]\u00a0Elbasvir/Grazoprevir\u00a0(chronische\u00a0\nHepatitis\u00a0C)\u00a0\u2010\u00a0Nutzenbewertung\u00a0gem\u00e4\u00df\u00a0\u00a7\u00a035a\u00a0SGB\u00a0V.\u00a0https://www.i qwig.de/de/projekte\u2010ergebnisse/projekte\u2010\n301/arzneimittelbewertung/2016/a16\u201075\u2010elbasvir\u2010grazoprevir\u2010chro nische\u2010hepatitis\u2010c\u2010nutzenbewertung\u2010gemaess\u2010\n35a\u2010sgb\u2010v.7773.html,\u00a0letzter\u00a0Zugriff:\u00a010.07.2019.\u00a0\nPrescrire\u00a0Int.\u00a0(2018).\u00a0Elbasvir\u00a0+ \u00a0grazoprevir\u00a0and\u00a0hepatitis\u00a0C.\u00a0 Prescrire\u00a0Int\u00a027:\u00a092.\u00a0\nPZ\u00a0\u2013\u00a0Pharmazeutische\u00a0Zeitung\u00a0(2017).\u00a0Elbasvir|Zepatier|83|2016. \u00a0https://www.pharmazeutische\u2010\nzeitung.de/arzneistoffe/daten/2016/elbasvirzepatierr832016/,\u00a0le tzter\u00a0Zugriff:\u00a010.07.2019.\u00a0\nRoth\u00a0D,\u00a0Nelson\u00a0DR,\u00a0Bruchfeld\u00a0A,\u00a0 Liapakis\u00a0A,\u00a0Silva\u00a0M,\u00a0Monsour\u00a0H\u00a0 et\u00a0al.\u00a0(2015).\u00a0Grazoprevir\u00a0plus\u00a0 elbasvir\u00a0in\u00a0treatment\u2010naive\u00a0and \u00a0\ntreatment\u2010experienced\u00a0patients\u00a0with\u00a0hepatitis\u00a0C\u00a0virus\u00a0genotype\u00a0 1\u00a0infection\u00a0and\u00a0stage\u00a04\u20135\u00a0chronic\u00a0kidney\u00a0disease\u00a0\n(the\u00a0C\u2010SURFER\u00a0study):\u00a0a\u00a0combination\u00a0phase\u00a03\u00a0study.\u00a0Lancet\u00a0386(1 0003):\u00a01537\u20131545.\u00a0\u00a0\nZeuzem\u00a0S,\u00a0Ghalib\u00a0R,\u00a0Reddy\u00a0KR,\u00a0Po ckros\u00a0PJ,\u00a0Ari\u00a0ZB,\u00a0Zhao\u00a0Y\u00a0et\u00a0al. \u00a0(2015).\u00a0Grazoprevir\u2013Elbasvir\u00a0Combination\u00a0Therapy\u00a0for\u00a0Treatment \u2010\nNaive\u00a0Cirrhotic\u00a0and\u00a0Noncirrhotic \u00a0Patients\u00a0With\u00a0Chronic\u00a0Hepatiti s\u00a0C\u00a0Virus\u00a0Genotype\u00a01,\u00a04,\u00a0or\u00a06\u00a0Infection.\u00a0Ann\u00a0Intern\u00a0\nMed\u00a0163(1):\u00a01.\u00a0\u00a0\n\u00a0\n\u00a0 \u00a0102\u00a0 Elotuzumab\u00a04.7\nHandelsname:\u00a0Empliciti\u00ae\u00a0 \u00a0 \u00a0 Pha rmazeutischer\u00a0Unternehmer:\u00a0\u00a0\nIndikation:\u00a0Multiples\u00a0Myelom\u00a0 \u00a0 Bristol\u00a0Myers\u00a0Squibb\u00a0\nATC\u2010Code:\u00a0L01XC23\u00a0 \u00a0 \u00a0 Markteinf\u00fchrung:\u00a0Juni\u00a02016\u00a0\nDarreichungsform:\u00a0Pulver\u00a0f\u00fcr\u00a0ein\u00a0\u00a0\nKonzentrat\u00a0zur\u00a0Herstellung\u00a0\u00a0\neiner\u00a0Infusionsl\u00f6sung\u00a0 \u00a0 \u00a0 DDD:\u00a050\u00a0mg\u00a0\u00a0 \u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 \u00a0\u00a0\u00a0\u00a0\u25bc\u00a0\nBewertung \u00a0\nEmpliciti\u00ae\u00a0wurde\u00a0im\u00a0Mai\u00a02016\u00a0zentralisiert\u00a0in\u00a0Europa\u00a0zugelassen \u00a0in\u00a0Kombination\u00a0\nmit\u00a0Lenalidomid\u00a0und\u00a0Dexa methason\u00a0zur\u00a0Behandlung\u00a0des\u00a0multiplen\u00a0M yeloms\u00a0(MM)\u00a0\nbei\u00a0 Erwachsenen,\u00a0 welche\u00a0 mindestens\u00a0 eine\u00a0 vorangegangene\u00a0 Therapie \u00a0e r h a l t e n \u00a0\nhaben\u00a0(EMA,\u00a02016a).\u00a0F\u00fcr\u00a0Elotuzumab\u00a0wurde\u00a02012\u00a0eine\u00a0 Orphan\u2010Designation\u00a0durch\u00a0\ndie\u00a0 Europ\u00e4ische\u00a0 Kommission\u00a0 zur\u00a0 Behandlung\u00a0 des\u00a0 MM\u00a0 erteilt\u00a0 (EU/3/ 12/1037)\u00a0\n(EMA,\u00a02012;\u00a0EC,\u00a02012).\u00a0Im\u00a0Rahmen\u00a0der\u00a0Marktzulassung\u00a02016\u00a0erfolg te\u00a0eine\u00a0erneute\u00a0\nBewertung\u00a0durch\u00a0das\u00a0 Committee\u00a0for\u00a0Orphan\u00a0Medicinal\u00a0Products \u00a0(COMP)\u00a0der\u00a0EMA.\u00a0\nDas\u00a0COMP\u00a0kam\u00a0zum\u00a0Schluss,\u00a0dass\u00a0die\u00a0Bedingungen\u00a0f\u00fcr\u00a0eine\u00a0 Orphan\u2010Designation \u00a0\nnicht\u00a0mehr\u00a0gegeben\u00a0waren,\u00a0weil\u00a0der\u00a0signifikante\u00a0Nutzen\u00a0von\u00a0Elot uzumab\u00a0nach\u00a0der\u00a0\nzwischenzeitlichen\u00a0 Zulassung\u00a0 von\u00a0 Carfilzomib\u00a0 nicht\u00a0 mehr\u00a0 gegeben \u00a0w a r \u00a0( E M A , \u00a0\n2016b).\u00a0\nDie\u00a0Markteinf\u00fchrung\u00a0von\u00a0Empliciti\u00ae\u00a0in\u00a0Deutschland\u00a0erfolgte\u00a0im\u00a0J uni\u00a02016\u00a0(Lauer\u2010\nTaxe,\u00a02019).\u00a0Empliciti\u00ae\u00a0wird\u00a0intraven\u00f6s\u00a0appliziert.\u00a0Die\u00a0Behandl ung\u00a0erfolgt\u00a0in\u00a028\u2010\nTage\u2010Zyklen,\u00a0die\u00a0Dosis\u00a0betr\u00e4gt\u00a0 10\u00a0mg/kg\u00a0KG\u00a0(Fachinformation\u00a0Emp liciti\u00ae,\u00a02019).\u00a0\nElotuzumab\u00a0ist\u00a0ein\u00a0humanisierter,\u00a0monoklonaler\u00a0IgG1 \u03ba\u2010Antik\u00f6rper,\u00a0der\u00a0mittels\u00a0re\u2010\nkombinanter\u00a0DNA\u2010Technologie\u00a0aus\u00a0 Mausmyelomazellen\u00a0(NS0)\u00a0gewonne n\u00a0wird.\u00a0Elo\u2010\ntuzumab\u00a0bindet\u00a0spezifisch\u00a0an\u00a0die\u00a0extrazellul\u00e4re\u00a0Dom\u00e4ne\u00a0eines\u00a0Gl ykoproteins\u00a0( Sig\u2010\nnaling\u00a0Lymphocyte\u00a0Activation\u00a0Molecule\u00a0Family\u00a0Member\u00a07 ,\u00a0SLAMF7),\u00a0das\u00a0als\u00a0Lym\u2010\nphozytenaktivierungsmolek\u00fcl\u00a0 fungiert.\u00a0 SLAMF7\u00a0 wird\u00a0 auf\u00a0 der\u00a0 Oberf l\u00e4che\u00a0 von\u00a0\nMyelomzellen\u00a0und\u00a0nat\u00fcrlichen\u00a0Kille r\u00a0(NK)\u2010Zellen,\u00a0aber\u00a0auch\u00a0von\u00a0 normalen\u00a0Plasma\u2010\nzellen\u00a0und\u00a0anderen\u00a0Immunzellen\u00a0exprimiert.\u00a0Mit\u00a0seinem\u00a0Fc\u2010Anteil \u00a0bindet\u00a0Elotuzu\u2010\nmab\u00a0an\u00a0den\u00a0Fc\u2010Rezeptor\u00a0(CD16)\u00a0von\u00a0NK\u2010Zellen,\u00a0aktiviert\u00a0sie\u00a0und\u00a0 f\u00fchrt\u00a0zur\u00a0Freiset\u2010\nzung\u00a0von\u00a0zytotoxischen\u00a0Granula\u00a0und\u00a0Induktion\u00a0der\u00a0Anti\u2010Myelom\u2010Ak tivit\u00e4t.\u00a0Gleich\u2010\nzeitig\u00a0bindet\u00a0es\u00a0mit\u00a0dem\u00a0Fab\u2010Anteil\u00a0an\u00a0den\u00a0SLAMF7\u2010Rezeptor\u00a0der\u00a0 Myelomzellen,\u00a0\ndie\u00a0dadurch\u00a0von\u00a0den\u00a0NK\u2010Zellen\u00a0leichter\u00a0erkannt\u00a0und\u00a0\u00fcber\u00a0Antik\u00f6r per\u2010abh\u00e4ngige\u00a0\nzellvermittelte\u00a0Zytotoxizit\u00e4t\u00a0elim iniert\u00a0werden\u00a0(Fachinformatio n\u00a0Empliciti\u00ae,\u00a02019).\u00a0103\u00a0Die\u00a0Zulassung\u00a0von\u00a0Empliciti\u00ae\u00a0beruhte\u00a0auf\u00a0der\u00a0multizentrischen,\u00a0 offenen,\u00a0randomi\u2010\nsierten,\u00a0aktiv\u00a0kontrollierten\u00a0Phase\u2010III\u2010Studie\u00a0ELOQUENT\u20102\u00a0(Spon sor:\u00a0Bristol\u2010Myers\u00a0\nSquibb,\u00a0NCT01239797),\u00a0die\u00a0noch\u00a0nicht\u00a0abgeschlossen\u00a0ist\u00a0(NIH,\u00a020 19).\u00a0\nIn\u00a0die\u00a0Studie\u00a0ELOQUENT\u20102\u00a0wurden\u00a0erwachsene\u00a0Patienten\u00a0mit\u00a0MM\u00a0ein geschlossen,\u00a0\ndie\u00a0eine\u00a0bis\u00a0drei\u00a0vorherige\u00a0Therapien\u00a0erhalten\u00a0hatten\u00a0und\u00a0bei\u00a0d enen\u00a0nach\u00a0der\u00a0\nletzten\u00a0Therapie\u00a0eine\u00a0Progressio n\u00a0aufgetreten\u00a0war.\u00a0Die\u00a0Randomis ierung\u00a0erfolgte\u00a0\nstratifiziert\u00a0nach\u00a0\u03b22\u2010Mikroglobulin\u2010Spiegel\u00a0(<\u00a03,5\u00a0mg/l\u00a0vs.\u00a0\u2265\u00a03 ,5\u00a0mg/l),\u00a0Anzahl\u00a0der\u00a0\nvorangegangenen\u00a0Therapielinien\u00a0sowie\u00a0einer\u00a0vorangegangenen\u00a0Beha ndlung\u00a0mit\u00a0\neinem\u00a0Immunmodulator\u00a0(Lenalidomid,\u00a0Thalidomid).\u00a0Verglichen\u00a0wurd en\u00a0Elotuzum\u2010\nab\u00a0in\u00a0Kombination\u00a0mit\u00a0Lenalidomid\u00a0und\u00a0Dexamethason\u00a0(n\u00a0=\u00a0321\u00a0Pat ienten;\u00a0Elotu\u2010\nzumab\u2010Arm)\u00a0und\u00a0Lenalidomid\u00a0in\u00a0Kombination\u00a0mit\u00a0Dexamethason\u00a0(n\u00a0= \u00a0325\u00a0Patien\u2010\nten;\u00a0Kontrollarm).\u00a0Die\u00a0Behandlung \u00a0erfolgte\u00a0bis\u00a0zu\u00a0einer\u00a0Krankhe itsprogression,\u00a0\ninakzeptabler\u00a0Toxizit\u00e4t\u00a0oder\u00a0Widerruf\u00a0der\u00a0Einwilligung\u00a0der\u00a0Pati enten.\u00a0Die\u00a0Patienten\u00a0\nhatten\u00a0zuvor\u00a0im\u00a0Median\u00a0zwei\u00a0Therapielinien\u00a0(Min\u00a0\u2013\u00a0Max:\u00a01\u00a0\u2013\u00a04)\u00a0e rhalten\u00a0(Lonial\u00a0et\u00a0\nal.,\u00a02015).\u00a0\nPrim\u00e4re\u00a0Endpunkte\u00a0der\u00a0Studie\u00a0sind\u00a0die\u00a0Gesamtansprechrate\u00a0( Overall\u00a0Response\u00a0\nRate,\u00a0ORR)\u00a0und\u00a0das\u00a0progressionsfreie\u00a0\u00dcberleben\u00a0( Progression\u2010free\u00a0Survival ,\u00a0PFS).\u00a0\nSekund\u00e4re\u00a0Endpunkte\u00a0sind\u00a0u.a.\u00a0das\u00a0Gesamt\u00fcberleben\u00a0( Overall\u00a0Survival ,\u00a0OS)\u00a0sowie\u00a0\ngesundheitsbezogene\u00a0Lebensqualit\u00e4t\u00a0und\u00a0Sicherheit\u00a0(Lonial\u00a0et\u00a0al .,\u00a02015).\u00a0\nDie\u00a0Studiendauer\u00a0ist\u00a0definiert\u00a0bis\u00a0zum\u00a0Auftreten\u00a0von\u00a0466\u00a0Ereign issen\u00a0im\u00a0Endpunkt\u00a0\nPFS.\u00a0Eine\u00a0zuvor\u00a0festgelegte\u00a0Interimsanalyse\u00a0zum\u00a0Endpunkt\u00a0PFS\u00a0wu rde\u00a0durchge\u2010\nf\u00fchrt,\u00a0nachdem\u00a070\u00a0%\u00a0der\u00a0geplanten\u00a0Ereignisse\u00a0aufgetreten\u00a0waren\u00a0 und\u00a0mindestens\u00a0\nzwei\u00a0Jahre,\u00a0nachdem\u00a0der\u00a0erste\u00a0Pa tient\u00a0in\u00a0die\u00a0Studie\u00a0eingeschlos sen\u00a0wurde\u00a0(Daten\u2010\nschnitt\u00a0vom\u00a029.10.2014).\u00a0Die\u00a0mediane\u00a0Beobachtungszeit\u00a0betrug\u00a024 ,5\u00a0Monate.\u00a0Im\u00a0\nElotuzumab\u2010Arm\u00a0wurden\u00a0179\u00a0Ereignisse\u00a0(165\u00a0Krankheitsprogression en,\u00a014\u00a0Todes\u2010\nf\u00e4lle)\u00a0berichtet,\u00a0im\u00a0Kontrollar m\u00a0205\u00a0(183\u00a0Krankheitsprogression en,\u00a022\u00a0Todesf\u00e4lle).\u00a0\nDie\u00a0ORR\u00a0betrug\u00a079\u00a0%\u00a0(95\u00a0%\u00a0KI\u00a0[74;\u00a083])\u00a0im\u00a0Elotuzumab\u2010Arm\u00a0und\u00a066 \u00a0%\u00a0(95\u00a0%\u00a0KI\u00a0[60;\u00a0\n71])\u00a0im\u00a0Kontrollarm\u00a0mit\u00a0einer\u00a0 Odds\u00a0Ratio \u00a0von\u00a01,9\u00a0f\u00fcr\u00a0Elotuzumab\u00a0vs.\u00a0Kontrolle\u00a0\n(95\u00a0%\u00a0KI\u00a0[1,4;\u00a02,8],\u00a0p\u00a0<\u00a00,001).\u00a0Das\u00a0mediane\u00a0PFS\u00a0betrug\u00a019,4\u00a0Mo nate\u00a0(95\u00a0%\u00a0KI\u00a0[16,6;\u00a0\n22,2])\u00a0im\u00a0Elotuzumab\u2010Arm\u00a0vs.\u00a014,9\u00a0Monate\u00a0(95\u00a0%\u00a0KI\u00a0[12,1;\u00a017,2]) \u00a0im\u00a0Kontrollarm\u00a0\nmit\u00a0einem\u00a0 Hazard\u00a0Ratio \u00a0(HR)\u00a0f\u00fcr\u00a0Progression\u00a0von\u00a00,70\u00a0(95\u00a0%\u00a0KI\u00a0[0,57;\u00a00,85],\u00a0p\u00a0<\u00a0\n0,001).\u00a0Der\u00a0Effekt\u00a0im\u00a0PFS\u00a0war\u00a0ko nsistent\u00a0in\u00a0allen\u00a0bei\u00a0Studienbe ginn\u00a0festgelegten\u00a0\nSubgruppen.\u00a0Zum\u00a0Datenschnitt\u00a0vom\u00a029.10.2015\u00a0zeigte\u00a0sich\u00a0auch\u00a0im \u00a0sekund\u00e4ren\u00a0\nEndpunkt\u00a0OS\u00a0ein\u00a0Vorteil\u00a0f\u00fcr\u00a0Elotu zumab\u00a0gegen\u00fcber\u00a0dem\u00a0Kontrollar m\u00a0(43,6\u00a0Monate\u00a0\nim\u00a0Median\u00a0vs.\u00a039,6\u00a0Monate\u00a0im\u00a0Median;\u00a0HR\u00a00,77,\u00a095\u00a0%\u00a0KI\u00a0[0,61;\u00a00, 97],\u00a0p\u00a0=\u00a00,026).\u00a0\nBez\u00fcglich\u00a0der\u00a0gesundheitsbezogen en\u00a0Lebensqualit\u00e4t\u00a0bzw.\u00a0Symptoma tik\u00a0ergaben\u00a0\nsich\u00a0keine\u00a0statistisch\u00a0signifikanten\u00a0Unterschiede\u00a0zwischen\u00a0den\u00a0 beiden\u00a0Studienar\u2010\nmen\u00a0(Lonial\u00a0et\u00a0al.,\u00a02015;\u00a0EMA,\u00a02016a).\u00a0\u00a0104\u00a0Die\u00a0Studie\u00a0abgebrochen\u00a0haben\u00a065\u00a0%\u00a0der\u00a0Patienten\u00a0(206)\u00a0im\u00a0Elotuz umab\u2010Arm\u00a0und\u00a0\n79\u00a0%\u00a0(250)\u00a0im\u00a0Kontrollarm,\u00a0die\u00a0me isten\u00a0aufgrund\u00a0einer\u00a0Krankheit sprogression:\u00a0135\u00a0\nunter\u00a0Elotuzumab\u00a0und\u00a0149\u00a0unter\u00a0der\u00a0Kontrolle.\u00a0UAE\u00a0traten\u00a0in\u00a0bei den\u00a0Behand\u2010\nlungsarmen\u00a0nahezu\u00a0bei\u00a0jedem\u00a0Patienten\u00a0mindestens\u00a0einmal\u00a0auf.\u00a0Di e\u00a0h\u00e4ufigsten\u00a0\nUAE\u00a0in\u00a0beiden\u00a0Armen\u00a0der\u00a0Sicherheitspopulation\u00a0(alle\u00a0Patienten,\u00a0 die\u00a0mindestens\u00a0\neine\u00a0Dosis\u00a0der\u00a0Studienmedikation\u00a0erhalten\u00a0haben)\u00a0waren\u00a0Fatigue, \u00a0Diarrh\u00f6,\u00a0Ver\u2010\nstopfung,\u00a0Thrombozytopenie,\u00a0Neutropenie,\u00a0An\u00e4mie,\u00a0Fieber\u00a0und\u00a0obe re\u00a0Atemwegs\u2010\ninfektionen.\u00a0Schwerwiegende\u00a0UAE\u00a0w urden\u00a0zu\u00a065\u00a0%\u00a0im\u00a0Elotuzumab\u2010Ar m\u00a0und\u00a057\u00a0%\u00a0\nim\u00a0Kontrollarm\u00a0berichtet.\u00a0Schwere\u00a0UAE\u00a0vom\u00a0Grad\u00a0\u2265\u00a03\u00a0entsprechend \u00a0CTCAE\u00a0(Com\u2010\nmon\u00a0Terminology\u00a0Criteria\u00a0for\u00a0Adverse\u00a0Events )\u00a0traten\u00a0im\u00a0Elotuzumab\u2010Arm\u00a0h\u00e4ufiger\u00a0\nauf\u00a0(57,8\u00a0%\u00a0vs.\u00a048,9\u00a0%).\u00a0\u00a0\nSchwere\u00a0h\u00e4matologische\u00a0UAE\u00a0vom\u00a0Grad\u00a0\u2265\u00a03\u00a0entsprechend\u00a0CTCAE\u00a0trat en\u00a0in\u00a0beiden\u00a0\nArmen\u00a0auf:\u00a0Neutropenie\u00a0(33,6\u00a0%\u00a0vs.\u00a043,7\u00a0%),\u00a0Lymphopenie\u00a0(76,7\u00a0% \u00a0vs.\u00a048,7\u00a0%)\u00a0und\u00a0\nThrombozytopenie\u00a0(19,2\u00a0%\u00a0vs.\u00a020,3\u00a0%).\u00a0Ein\u00a0Therapieabbruch\u00a0aufgr und\u00a0von\u00a0UAE\u00a0\nwurde\u00a0f\u00fcr\u00a026,1\u00a0%\u00a0der\u00a0Patienten\u00a0im\u00a0Elotuzumab\u2010Arm\u00a0und\u00a026,8\u00a0%\u00a0der \u00a0Patienten\u00a0im\u00a0\nKontrollarm\u00a0berichtet.\u00a0Darunter\u00a0waren\u00a016,0\u00a0%\u00a0im\u00a0Elotuzumab\u2010Arm\u00a0 bzw.\u00a015,8\u00a0%\u00a0im\u00a0\nKontrollarm\u00a0von\u00a0schweren\u00a0UAE\u00a0vom\u00a0Grad\u00a03\u00a0\u2013\u00a04\u00a0CTCAE\u00a0betroffen\u00a0(EM A,\u00a02016a;\u00a0\nLonial\u00a0et\u00a0al.,\u00a02015).\u00a0T\u00f6dliche\u00a0UAE\u00a0(Grad\u00a05\u00a0CTCAE)\u00a0wurden\u00a0f\u00fcr\u00a0je \u00a02\u00a0%\u00a0der\u00a0Patienten\u00a0\nim\u00a0Elotuzumab\u2010Arm\u00a0und\u00a0im\u00a0Kontrollarm\u00a0berichtet.\u00a0Unter\u00a0Elotuzuma b\u00a0verstarben\u00a0\nzwei\u00a0Patienten\u00a0an\u00a0Infektionen\u00a0und\u00a0je\u00a0einer\u00a0an\u00a0Lungenembolie,\u00a0Da rmkrebs\u00a0und\u00a0\nmyelodysplastischem\u00a0Syndrom.\u00a0Im\u00a0Kontrollarm\u00a0verstarben\u00a0f\u00fcnf\u00a0Pat ienten\u00a0an\u00a0Infek\u2010\ntionen\u00a0und\u00a0einer\u00a0an\u00a0Lungenembo lie\u00a0(Lonial\u00a0et\u00a0al.,\u00a02015).\u00a0\u00a0\nInfektionen\u00a0traten\u00a0unter\u00a0Elotuzumab\u00a0bei\u00a081,4\u00a0%\u00a0der\u00a0Patienten\u00a0un d\u00a0im\u00a0Kontrollarm\u00a0\nbei\u00a074,4\u00a0%\u00a0der\u00a0Patienten\u00a0auf.\u00a0Schwere\u00a0Infektionen\u00a0vom\u00a0Grad\u00a03\u00a0\u2013\u00a0 4\u00a0CTCAE\u00a0traten\u00a0\nbei\u00a023,9\u00a0%\u00a0bzw.\u00a019,9\u00a0%,\u00a0fatale\u00a0Infektionen\u00a0vom\u00a0Grad\u00a05\u00a0CTCAE\u00a0bei \u00a02,5\u00a0%\u00a0bzw.\u00a02,2\u00a0%\u00a0\nauf.\u00a0Infusionsbedingte\u00a0Reaktionen\u00a0traten\u00a0unter\u00a0Elotuzumab\u00a0bei\u00a01 0\u00a0%\u00a0der\u00a0Patienten\u00a0\nauf,\u00a0bei\u00a070\u00a0%\u00a0der\u00a0Patienten\u00a0ereigneten\u00a0sich\u00a0diese\u00a0w\u00e4hrend\u00a0der\u00a0e rsten\u00a0Infusion.\u00a0\nKeine\u00a0der\u00a0infusionsbedingten\u00a0Reaktionen\u00a0war\u00a0vom\u00a0Grad\u00a04\u00a0oder\u00a05\u00a0n ach\u00a0CTCAE,\u00a0\njedoch\u00a0musste\u00a0die\u00a0Infusion\u00a0 bei\u00a015\u00a0Patienten\u00a0(5\u00a0%)\u00a0f\u00fcr\u00a0im\u00a0Median \u00a025\u00a0Minuten\u00a0\n[Min\u00a0\u2013\u00a0Max:\u00a05\u00a0\u2013\u00a070]\u00a0abgebrochen\u00a0werden,\u00a0zwei\u00a0Patienten\u00a0(1\u00a0%)\u00a0br achen\u00a0sogar\u00a0die\u00a0\nBehandlung\u00a0ab.\u00a0Die\u00a0h\u00e4ufigsten\u00a0UAE,\u00a0die\u00a0als\u00a0infusionsbedingt\u00a0von \u00a0den\u00a0Pr\u00fcf\u00e4rzten\u00a0\ngemeldet\u00a0 wurden,\u00a0 waren\u00a0 Fieber,\u00a0 Sch\u00fcttelfrost\u00a0 und\u00a0 Hypertonie.\u00a0 Ti efe\u00a0 Ve\u2010\nnenthrombosen\u00a0(TVT)\u00a0wurden\u00a0f\u00fcr\u00a07,2\u00a0%\u00a0der\u00a0Patienten\u00a0im\u00a0Elotuzuma b\u2010Arm\u00a0und\u00a0\n3,8\u00a0%\u00a0der\u00a0Patienten\u00a0im\u00a0Kontrolla rm\u00a0berichtet\u00a0(EMA,\u00a02016a;\u00a0Lonia l\u00a0et\u00a0al.,\u00a02015).\u00a0\nDie\u00a0Nutzenbewertung\u00a0nach\u00a0\u00a7\u00a035a\u00a0SGB\u00a0V\u00a0von\u00a0Empliciti\u00ae\u00a0erfolgte\u00a0im \u00a0Jahr\u00a02016.\u00a0Am\u00a0\n1.\u00a0Dezember\u00a02016\u00a0beschloss\u00a0der\u00a0G\u2010BA,\u00a0dass\u00a0ein\u00a0 Anhaltspunkt\u00a0 f\u00fcr\u00a0einen \u00a0geringen\u00a0\nZusatznutzen\u00a0 vorliegt.\u00a0Die\u00a0Entscheidung\u00a0erfolgte\u00a0auf\u00a0der\u00a0Basis\u00a0der\u00a0Zulassung sstu\u2010\ndie\u00a0ELOQUENT\u00a02\u00a0(G\u2010BA,\u00a02016).\u00a0105\u00a0In\u00a0der\u00a0ELOQUENT\u20102\u2010Studie\u00a0wurde\u00a0Dexamethason\u00a0in\u00a0einem\u00a0von\u00a0der\u00a0in \u00a0der\u00a0Fachin\u2010\nformation\u00a0von\u00a0Lenalidomid\u00a0abwei chenden\u00a0Dosierungsschema\u00a0mit\u00a040\u00a0 mg\u00a0oral\u00a0ein\u2010\nmal\u00a0w\u00f6chentlich\u00a0verabreicht.\u00a0Der\u00a0G\u2010BA\u00a0ber\u00fccksichtigte\u00a0diesbez\u00fcg lich\u00a0die\u00a0Stellung\u2010\nnahmen\u00a0medizinischer\u00a0Sachverst\u00e4ndiger\u00a0und\u00a0stellte\u00a0fest,\u00a0dass\u00a0\u201ed ie\u00a0laut\u00a0Fachinfor\u2010\nmation\u00a0vorgeschriebene\u00a0Dexametha son\u2010Dosierung\u00a0im\u00a0deutschen\u00a0Vers orgungsall\u2010\ntag\u00a0nicht\u00a0mehr\u00a0regelhaft\u00a0angewendet\u00a0wird\u201c\u00a0(G\u2010BA,\u00a02016,\u00a0S.\u00a06).\u00a0Z udem\u00a0wies\u00a0der\u00a0\u00a0\nG\u2010BA\u00a0auf\u00a0die\u00a0besondere\u00a0Therapie\u2010 \u00a0und\u00a0Versorgungssituation\u00a0im\u00a0vo rliegenden\u00a0An\u2010\nwendungsgebiet\u00a0hin\u00a0und\u00a0hielt\u00a0es\u00a0deshalb\u00a0aus\u00a0medizinischer\u00a0Sicht \u00a0f\u00fcr\u00a0gerechtfer\u2010\ntigt,\u00a0die\u00a0Daten\u00a0aus\u00a0der\u00a0ELOQUENT\u20102\u2010Studie\u00a0f\u00fcr\u00a0die\u00a0 Nutzenbewertung \u00a0von\u00a0Elotu\u2010\nzumab\u00a0heranzuziehen.\u00a0\u00a0\nDer\u00a0G\u2010BA\u00a0sah\u00a0einen\u00a0Vorteil\u00a0von\u00a0Elotuzumab\u00a0in\u00a0Kombination\u00a0mit\u00a0Le nalidomid\u00a0und\u00a0\nDexamethason\u00a0hinsichtlich\u00a0des\u00a0OS\u00a0(HR\u00a00,77,\u00a095\u00a0%\u00a0KI\u00a0[0,61;\u00a00,97] ,\u00a0p\u00a0=\u00a00,0257)\u00a0sowie\u00a0\neinen\u00a0Nachteil\u00a0f\u00fcr\u00a0Elotuzumab\u00a0be z\u00fcglich\u00a0des\u00a0Auftretens\u00a0schwerer \u00a0UAE\u00a0(CTCAE\u00a0\nGrad\u00a0 3\u00a0 oder\u00a0 4).\u00a0 Der\u00a0 \u00dcberlebensvo rteil\u00a0 von\u00a0 Elotuzumab\u00a0 in\u00a0 Kombina tion\u00a0 mit\u00a0\nLenalidomid\u00a0 und\u00a0 Dexamethason\u00a0 geg en\u00fcber\u00a0 Lenalidomid\u00a0 in\u00a0 Kombinati on\u00a0 mit\u00a0\nDexamethason\u00a0wurde\u00a0jedoch\u00a0als\u00a0so\u00a0relevant\u00a0bewertet,\u00a0dass\u00a0er\u00a0dur ch\u00a0die\u00a0beobach\u2010\nteten\u00a0schweren\u00a0UAE\u00a0(CTCAE\u00a0Grad\u00a03 \u00a0oder\u00a04)\u00a0nicht\u00a0infrage\u00a0gestellt \u00a0wurde.\u00a0\nUnter\u00a0Ber\u00fccksichtigung\u00a0des\u00a0therapeutischen\u00a0Ziels\u00a0(in\u00a0dieser\u00a0spe ziellen\u00a0Situation\u00a0\ndes\u00a0MM:\u00a0Palliation,\u00a0Verl\u00e4ngerung\u00a0des\u00a0OS\u00a0bzw.\u00a0PFS\u00a0und\u00a0vor\u00a0allem\u00a0 der\u00a0HRQoL)\u00a0wur\u2010\nde\u00a0das\u00a0Ausma\u00df\u00a0des\u00a0Zusatznutzens \u00a0von\u00a0Elotuzumab\u00a0in\u00a0Kombination\u00a0mit\u00a0Lenalido\u2010\nmid\u00a0und\u00a0Dexamethason\u00a0als\u00a0 gering\u00a0eingestuft,\u00a0da\u00a0es\u00a0sich\u00a0um\u00a0eine\u00a0bisher\u00a0nicht\u00a0er\u2010\nreichte\u00a0moderate\u00a0und\u00a0nicht\u00a0nur\u00a0ge ringf\u00fcgige\u00a0Verbesserung\u00a0des\u00a0th erapierelevanten\u00a0\nNutzens\u00a0 handelte\u00a0 (verl\u00e4ngertes\u00a0 OS ,\u00a0 HR\u00a0 0,77).\u00a0 Bez\u00fcglich\u00a0 der\u00a0 Auss agesicherheit\u00a0\nbestand\u00a0aus\u00a0Sicht\u00a0des\u00a0G\u2010BA\u00a0nur\u00a0ein\u00a0 Anhaltspunkt .\u00a0Das\u00a0offene\u00a0Studiendesign\u00a0und\u00a0\ndie\u00a0Effektmodifikation\u00a0bez\u00fcglic h\u00a0des\u00a0ECOG\u2010PS\u00a0begr\u00fcndeten\u00a0die\u00a0Ei nschr\u00e4nkung,\u00a0die\u00a0\nvor\u00a0allem\u00a0die\u00a0mangelnde\u00a0\u00dcbertragbarkeit\u00a0der\u00a0Ergebnisse\u00a0auf\u00a0die\u00a0 Gesamtpopulati\u2010\non\u00a0im\u00a0Anwendungsgebiet\u00a0betraf.\u00a0\u00a0\nVerf\u00fcgbare\u00a0Therapien \u00a0 (Zusatz\u2010)Nutzen \u00a0 Kosten\u00a0\n\u00a0\nerster\u00a0monoklonaler\u00a0\nAntik\u00f6rper\u00a0gegen\u00a0das\u00a0\nSLAMF7\u2010Protein\u00a0\u00a0G\u2010BA\u2010Beschluss:\u00a0\nAnhaltspunkt\u00a0f\u00fcr\u00a0einen\u00a0\ngeringen\u00a0ZN;\u00a0signifikante\u00a0\nErgebnisse\u00a0bez\u00fcglich\u00a0OS\u00a0\nund\u00a0PFS\u00a0\n\u00a0teurer\u00a0als\u00a0zVT\u00a0trotz\u00a0\nErstattungsbetrag\u00a0\nErl\u00e4uterung\u00a0der\u00a0Farben:\u00a0Verf\u00fcgbare\u00a0Therapien:\u00a0rot\u00a0=\u00a0weitere\u00a0The rapieoption,\u00a0gelb\u00a0=\u00a0Subgruppen\u2010Novit\u00e4t,\u00a0gr\u00fcn\u00a0=\u00a0Solist;\u00a0(Zusatz\u2010 )\u00a0\nNutzen:\u00a0rot\u00a0=\u00a0keine\u00a0Verbesserung\u00a0oder\u00a0schlechte\u00a0Nutzen/Schaden\u2010 Relation,\u00a0gelb\u00a0=\u00a0teilweise\u00a0Verbesserungen,\u00a0gr\u00fcn\u00a0=\u00a0Verbesserung\u00a0\nharter\u00a0Endpunkte;\u00a0Kosten:\u00a0rot\u00a0=\u00a0teurer\u00a0als\u00a0bestehende\u00a0Therapien ,\u00a0gelb\u00a0=\u00a0ungef\u00e4hr\u00a0gleich\u00a0bzw.\u00a0teils/teils,\u00a0gr\u00fcn\u00a0=\u00a0g\u00fcnstiger\u00a0als \u00a0\nbestehende\u00a0Therapien\u00a0\n\u00a0\n106\u00a0Wie\u00a0bewerten\u00a0andere?\u00a0\nBewertung\u00a0nach\u00a0\nFricke\u00a0et\u00a0al.\u00a0a\u2010t\u2010Bewertung\u00a0 AMB\u00a0 Prescrire\u00a0 PZ\u00a0\nA\u00a0 \u2013\u00a0Weitere\u00a0vergl.\u00a0\nStudien\u00a0zur\u00a0Wirk\u2010\nsamkeit\u00a0und\u00a0Sicher\u2010\nheit\u00a0der\u00a0neuen\u00a0\nTherapieoptionen\u00a0\nf\u00fcr\u00a0das\u00a0MM\u00a0erfor\u2010\nderl.\u00a0auch\u00a0wgn.\u00a0der\u00a0\nsehr\u00a0hohen\u00a0Jahres\u2010\ntherapiekosten\u00a0Nothing\u00a0new\u00a0 Sprunginnovation\u00a0\nKosten\u00a0\nWirkstoff\u00a0 Behandlungsmodus\u00a0 Behandlungstage\u00a0 Jahrestherapiekosten\u00a0\nzu\u00a0bewertendes\u00a0Arzneimittel \u00a0\u00a0 \u00a0 \u00a0\nElotuzumab\u00a0 1.\u00a0\u2013\u00a02.\u00a0Zyklus1\u00a0+\u00a02:\u00a0\n10\u00a0mg/kg\u00a0KG\u00a0an\u00a0Tag\u00a01,\u00a0\n8,\u00a015,\u00a022\u00a0(ab\u00a03.\u00a0Zyklus:\u00a0\nTag\u00a01,\u00a015)\u00a030\u00a0\n(26)3\u00a093.454,80\u00a0\u20ac\u00a0\n(80.994,16\u00a0\u20ac)3\u00a0\n+\u00a0Lenalidomid\u00a0 25\u00a0mg\u00a0an\u00a0Tag\u00a01\u00a0\u2013\u00a0211+2\u00a0 273\u00a0 104.707,98\u00a0\u20ac\u00a0\n+\u00a0Dexamethason\u00a0 1.\u00a0\u2013\u00a02.\u00a0Zyklus1+2:\u00a028\u00a0mg\u00a0\nan\u00a0Tag\u00a01,\u00a08,\u00a015,\u00a022\u00a0\u00a0\n(ab\u00a0dem\u00a03.\u00a0Zyklus:\u00a0\n28\u00a0mg\u00a0an\u00a0Tag\u00a01,\u00a015\u00a0\u00a0\n\u00a0\n+\u00a040\u00a0mg\u00a0an\u00a0Tag\u00a08,\u00a022) \u00a0\u00a0\n\u00a0\n\u00a0\n30\u00a0(26)3\u00a0\n\u00a0\n22\u00a0(26)3\u00a0\u00a0\n\u00a0\n\u00a0\n108,05\u00a0\u20ac\u00a0\n(93,64\u00a0\u20ac)3\u00a0\n82,59\u00a0\u20ac\u00a0\n(97,60\u00a0\u20ac)3\u00a0\n\u00a0 \u00a0 \u00a0 198.353,42\u00a0\u20ac\u00a0\n(185.893,39\u00a0\u20ac)3\u00a0\nzVT\u00a0 \u00a0 \u00a0 \u00a0\nBortezomib\u00a0 1,3\u00a0mg/m\u00b2\u00a0KOF\u00a0an\u00a0Tag\u00a0\n1,\u00a04,\u00a08,\u00a0114+5\u00a032\u00a0 52.584,00\u00a0\u20ac\u00a0\nBortezomib\u00a0 s.o.\u00a0 s.o.\u00a0 \u00a0\n+\u00a0Doxorubicin\u00a0 30\u00a0mg/m\u00b2\u00a0KOF\u00a0an\u00a0Tag\u00a0\n44+5\u00a0\u00a08\u00a0 73.529,04\u00a0\u20ac\u00a0\nBortezomib\u00a0 4\u00a0\u2013\u00a08\u00a0Zyklen4:\u00a0s.o.\u00a0 16\u00a0\u2013\u00a032\u00a0 \u00a0\n+\u00a0Dexamethason\u00a0 4\u00a0\u2013\u00a08\u00a0Zyklen4:\u00a020\u00a0mg\u00a0\nan\u00a0Tag\u00a01,\u00a02,\u00a04,\u00a05,\u00a08,\u00a09,\u00a0\n11,\u00a012\u00a032\u00a0\u2013\u00a064\u00a0 26.367,87\u00a0\u2013\u00a052.735,74\u00a0\u20ac\u00a0\nLenalidomid\u00a0 25\u00a0mg\u00a0an\u00a0Tag\u00a01\u00a0\u2013\u00a0211+2\u00a0 273\u00a0 \u00a0\n+\u00a0Dexamethason\u00a0 Zyklus\u00a01\u00a0\u2013\u00a041+2:\u00a0\u00a0\n40\u00a0mg\u00a0an\u00a0Tag\u00a01\u00a0\u2013\u00a04,\u00a09\u00a0\u2013\u00a0\n12,\u00a017\u00a0\u2013\u00a020\u00a0\nab\u00a05.\u00a0Zyklus1+2:\u00a0\u00a0\n40\u00a0mg\u00a0an\u00a0Tag\u00a01\u00a0\u2013\u00a04\u00a084\u00a0 105.023,32\u00a0\u20ac\u00a0\n1\u00a028\u2010Tage\u2010Zyklus\u00a0\n2\u00a0Insgesamt\u00a013\u00a0Zyklen\u00a0pro\u00a0Behandlung\u00a0\n3\u00a0Folgejahre\u00a0\n4\u00a021\u2010Tage\u2010Zyklus\u00a0\n5\u00a0Insgesamt\u00a08\u00a0Zyklen\u00a0pro\u00a0Behandlung\u00a0107\u00a0Versorgungsanalysen\u00a0\nNach\u00a0der\u00a0Markteinf\u00fchrung\u00a0von\u00a0Elotuzumab\u00a0im\u00a0Juni\u00a02016\u00a0erreichte\u00a0 das\u00a0Verord\u2010\nnungsvolumen\u00a0bereits\u00a0im\u00a0Dezember\u00a02016\u00a0ein\u00a0Niveau\u00a0von\u00a0\u00fcber\u00a01.000 \u00a0DDD\u00a0pro\u00a0\nMonat.\u00a0Ab\u00a0Juli\u00a02017\u00a0zeigte\u00a0sich\u00a0ein\u00a0R\u00fcckgang\u00a0auf\u00a0unter\u00a0800\u00a0DDD\u00a0 pro\u00a0Monat.\u00a0Dabei\u00a0\nmuss\u00a0ber\u00fccksichtigt\u00a0werden,\u00a0dass\u00a0es\u00a0sich\u00a0beim\u00a0MM\u00a0um\u00a0ein\u00a0seltene s\u00a0Leiden\u00a0( or\u2010\nphan\u00a0disease )\u00a0handelt\u00a0und\u00a02017\u00a0weniger\u00a0als\u00a080\u00a0Patienten\u00a0mit\u00a0Elotuzumab\u00a0beha n\u2010\ndelt\u00a0wurden.\u00a0\nDer\u00a0Beschluss\u00a0des\u00a0G\u2010BA\u00a0im\u00a0Dezember\u00a02016\u00a0und\u00a0die\u00a0Anerkennung\u00a0ein es\u00a0geringen\u00a0\nZusatznutzens\u00a0k\u00f6nnten\u00a0das\u00a0Verordnungsvolumen\u00a0beeinflusst\u00a0haben. \u00a0Ab\u00a0Februar\u00a0\n2017\u00a0zeigte\u00a0sich\u00a0n\u00e4mlich\u00a0ein\u00a0R\u00fcckgang\u00a0des\u00a0Verordnungsvolumens\u00a0i m\u00a0Vergleich\u00a0\nzum\u00a0hohen\u00a0Niveau\u00a0im\u00a0Dezember\u00a02016.\u00a0Der\u00a0Einfluss\u00a0des\u00a0Erstattungs betrages\u00a0von\u00a0\nEmpliciti\u00ae,\u00a0der\u00a0ab\u00a0dem\u00a001.07.2017\u00a0galt,\u00a0f\u00fchrte\u00a0rasch\u00a0zu\u00a0einem\u00a0U msatzr\u00fcckgang\u00a0von\u00a0\nElotuzumab.\u00a0Im\u00a0Oktober\u00a02016\u00a0setzten\u00a0etwa\u00a0800\u00a0DDD\u00a0genauso\u00a0viel\u00a0u m\u00a0wie\u00a0im\u00a0Juli\u00a0\n2017\u00a0\u00fcber\u00a01.000\u00a0DDD.\u00a0Dies\u00a0entspricht\u00a0etwa\u00a0der\u00a0durchschnittliche n\u00a0Preisreduktion\u00a0\nin\u00a0der\u00a0H\u00f6he\u00a0von\u00a0etwa\u00a022\u00a0%,\u00a0die\u00a0durch\u00a0den\u00a0Erstattungsbetrag\u00a0erzi elt\u00a0wurde.\u00a0\u00a0\nAbbildung\u00a04.6:\u00a0Verordnete\u00a0Tagesdosen\u00a0(DDD)\u00a0und\u00a0Bruttoums\u00e4tze\u00a0vo n\u00a0\u00a0\nElotuzumab\u00a0nach\u00a0Monaten\u00a0(2016\u00a0\u2013\u00a02017)\u00a0\n\u00a0\n\u00a0\n108\u00a0Quellen\u00a0\u00a0\nAMB\u00a0\u2013\u00a0Der\u00a0Arzneimittelbrief\u00a0(2018).\u00a0Multiples\u00a0Myelom:\u00a0Das\u00a0Zeita lter\u00a0des\u00a0Immuntherapie\u00a0hat\u00a0begonnen.\u00a0Arzneimittelbrief\u00a052(09).\u00a0\nEC\u00a0\u2013\u00a0European\u00a0Commission\u00a0(2012).\u00a0Durchf\u00fchrungsbeschluss\u00a0der\u00a0Kom mission\u00a0vom\u00a09.8.2012\u00a0\u00fcber\u00a0die\u00a0Ausweisung\u00a0des\u00a0Arzneimittels\u00a0\n\"Elotuzumab\"\u00a0als\u00a0Arzneimittel\u00a0f\u00fcr\u00a0seltene\u00a0Leiden\u00a0gem\u00e4\u00df\u00a0Verordnu ng\u00a0(EG)\u00a0Nr.\u00a0141/2000\u00a0des\u00a0Europ\u00e4ischen\u00a0\nParlaments\u00a0und\u00a0des\u00a0Rates.\u00a0Stand\u00a0der\u00a0Information:\u00a0August\u00a02012.\u00a0h ttp://ec.europa.eu/health/documents/community\u2010\nregister/html/o1037.htm,\u00a0letzter\u00a0Zugriff:\u00a028.02.2019.\u00a0\nEMA\u00a0\u2013\u00a0European\u00a0Medicines\u00a0Agency\u00a0(2012).\u00a0Public\u00a0summary\u00a0of\u00a0opini on\u00a0on\u00a0orphan\u00a0designation\u00a0Elotuzumab\u00a0for\u00a0the\u00a0treatment\u00a0of\u00a0\nmultiple\u00a0myeloma.\u00a0Stand\u00a0der\u00a0Information:\u00a0September\u00a02012.\u00a0https: //www.ema.europa.eu/documents/orphan\u2010\ndesignation/eu/3/12/1037\u2010public\u2010summary\u2010opinion\u2010orphan\u2010designat ion\u2010elotuzumab\u2010treatment\u2010multiple\u2010\nmyeloma_en.pdf,\u00a0letzter\u00a0Zugriff:\u00a028.02.2019.\u00a0\nEMA\u00a0\u2013\u00a0European\u00a0Medicines\u00a0Agency\u00a0(2016a).\u00a0Assessment\u00a0report\u00a0Empl iciti.\u00a0Stand\u00a0der\u00a0Information:\u00a0Januar\u00a02016.\u00a0\nhttps://www.ema.europa.eu/documents/assessment\u2010report/empliciti \u2010epar\u2010public\u2010assessment\u2010report_en.pdf,\u00a0\nletzter\u00a0Zugriff:\u00a028.02.2019.\u00a0\nEMA\u00a0\u2013\u00a0European\u00a0Medicines\u00a0Agency\u00a0(2016b).\u00a0Recommendation\u00a0for\u00a0rem oval\u00a0of\u00a0orphan\u00a0designation\u00a0at\u00a0the\u00a0time\u00a0of\u00a0marketing\u00a0\nauthorisation.\u00a0Empliciti\u00a0(elotuzumab)\u00a0for\u00a0the\u00a0treatment\u00a0of\u00a0mult iple\u00a0myeloma.\u00a0Stand\u00a0der\u00a0Information:\u00a0Mai\u00a02016.\u00a0\nhttps://www.ema.europa.eu/documents/orphan\u2010review/recommendatio n\u2010removal\u2010orphan\u2010designation\u2010time\u2010\nmarketing\u2010authorisation\u2010empliciti\u2010elotuzumab_en.pdf,\u00a0letzter\u00a0Zu griff:\u00a028.02.2019.\u00a0\nFachinformation\u00a0Empliciti\u00ae\u00a0(2019) .\u00a0Empliciti\u00ae\u00a0300\u00a0mg/400\u00a0mg\u00a0Pul ver\u00a0f\u00fcr\u00a0ein\u00a0Konzentrat\u00a0zur\u00a0Herstellung\u00a0einer\u00a0Infusionsl\u00f6sung.\u00a0\nStand\u00a0der\u00a0Information:\u00a0Februar\u00a02019.\u00a0\nFricke\u00a0U,\u00a0Hein\u00a0L,\u00a0Schwabe\u00a0U\u00a0(20 17).\u00a0Neue\u00a0Wirkstoffe\u00a0des\u00a0Jahres\u00a0 2016.\u00a0In:\u00a0Schwabe\u00a0U,\u00a0Paffrath\u00a0D,\u00a0Ludwig\u00a0W.\u2010D,\u00a0Klauber\u00a0J\u00a0(Hrsg.) .\u00a0\nArzneiverordnungs\u2010Report\u00a02017.\u00a0Berlin,\u00a0Heidelberg:\u00a0Springer:\u00a055 \u2010135.\u00a0\nG\u2010BA\u00a0\u2013\u00a0Gemeinsamer\u00a0Bundesausschuss\u00a0(2016).\u00a0Tragende\u00a0Gr\u00fcnde\u00a0zum\u00a0 Beschluss\u00a0des\u00a0Gemeinsamen\u00a0 Bundesausschuss\u00a0\u00fcber\u00a0eine\u00a0\n\u00c4nderung\u00a0des\u00a0Arzneimittelrichtlinie\u00a0(AMRL):\u00a0Anlage\u00a0XII\u00a0\u2013\u00a0Beschl \u00fcsse\u00a0\u00fcber\u00a0die\u00a0Nutzenbewertung\u00a0von\u00a0Arzneimitteln\u00a0\nmit\u00a0neuen\u00a0Wirkstoffen\u00a0nach\u00a0\u00a7\u00a035a\u00a0SGB\u00a0V\u00a0\u2013\u00a0Elotuzumab.\u00a0Stand\u00a0der\u00a0 Information:\u00a0Dezember\u00a02016.\u00a0https://www.g\u2010\nba.de/downloads/40\u2010268\u20104073/2016\u201012\u201001_AM\u2010RL\u2010XII_Elotuzumab_D\u20102 32_TrG.pdf,\u00a0letzter\u00a0Zugriff:\u00a028.02.2019.\u00a0\nLauer\u2010Fischer\u00a0(2019).\u00a0WEBAPO\u00ae\u00a0Infosystem,\u00a0LAUER\u2010TAXE\u00a0online,\u00a0St and\u00a0der\u00a0Information:\u00a015.\u00a0Februar\u00a02019.\u00a0\nhttp://www2.lauerfischer.de/produkte/lauer\u2010taxe/webapo\u2010infosyst em/,\u00a0letzter\u00a0Zugriff:\u00a028.02.2019.\u00a0\nLonial\u00a0S,\u00a0Dimopoulos\u00a0M,\u00a0Palumbo\u00a0 A,\u00a0White\u00a0D,\u00a0Grosicki\u00a0S,\u00a0Spicka\u00a0 I\u00a0et\u00a0al.\u00a0(2015).\u00a0Elotuzumab\u00a0Therapy\u00a0for\u00a0Relapsed\u00a0or\u00a0Refractory\u00a0\nMultiple\u00a0Myeloma.\u00a0N\u00a0Engl\u00a0J\u00a0Med\u00a0373(7):\u00a0621\u201031.\u00a0\nNIH\u00a0\u2013\u00a0National\u00a0Institutes\u00a0of\u00a0Health\u00a0(2019).\u00a0U.S.\u00a0National\u00a0Libra ry\u00a0of\u00a0Medicine.\u00a0Phase\u00a0III\u00a0Study\u00a0of\u00a0Lenalidomide\u00a0and\u00a0Dexamethaso ne\u00a0\nwith\u00a0or\u00a0Without\u00a0Elotuzumab\u00a0to\u00a0Treat\u00a0Relapsed\u00a0or\u00a0Refractory\u00a0Mult iple\u00a0Myeloma\u00a0(ELOQUENT\u00a0\u2010\u00a02).\u00a0Stand:\u00a0November\u00a0\n2018.\u00a0https://clinicaltrials.gov/ct2/show/NCT01239797,\u00a0letzter\u00a0 Zugriff:\u00a001.05.2019.\u00a0\nPZ\u00a0\u2013\u00a0Pharmazeutischen\u00a0Zeitung\u00a0online\u00a0(2016).\u00a0Neue\u00a0Arzneistoffe, \u00a0Elotuzumab|Empliciti\u00ae|86|2016.\u00a0https://www.pharmazeutische\u2010\nzeitung.de/arzneistoffe/daten/2016/elotuzumabemplicitir862016/, \u00a0letzter\u00a0Zugriff:\u00a028.02.2019.\u00a0\nPrescrire\u00a0Int.\u00a0(2018).\u00a0Elotuzumab\u00a0(Empliciti\u00ae)\u00a0combination\u00a0ther apy\u00a0for\u00a0relapsed\u00a0and\u00a0refractor y\u00a0multiple\u00a0myeloma.\u00a0No\u00a0proven\u00a0\ntherapeutic\u00a0advance\u00a0at\u00a0this\u00a0point.\u00a0Prescrire\u00a0Int.\u00a027\u00a0(193):\u00a0119 \u2010120.\u00a0\n\u00a0\n\u00a0\u00a0109\u00a0 HPV\u2010Impfstoff\u00a04.8\nHandelsname:\u00a0Gardasil\u00ae\u00a09\u00a0\u00a0 \u00a0 Pharmazeutischer\u00a0Unternehmer:\u00a0\u00a0\nIndikation:\u00a0aktive\u00a0Immunisierung\u00a0 \u00a0 MSD\u00a0VACCINS\u00a0\ngegen\u00a0HPV\u2010Erkrankungen\u00a0\u00a0 \u00a0 \u00a0\nATC\u2010Code:\u00a0J07BM03\u00a0 \u00a0 \u00a0 Markteinf\u00fchrung:\u00a0April\u00a02016\u00a0\nDarreichungsform:\u00a0Injektionssuspension\u00a0 DDD:\u00a01\u00a0DE\u00a0P\u00a00,27 \u00a0mg\u00a0\u00a0\u00a0 \u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u25bc\u00a0\nBewertung \u00a0\nGardasil\u00ae\u00a09\u00a0ist\u00a0ein\u00a0adjuvantierter,\u00a0nicht\u2010infekti\u00f6ser,\u00a0rekombin anter,\u00a0neunvalenter\u00a0\nImpfstoff\u00a0gegen\u00a0Humane\u00a0Papillomviren\u00a0(HPV).\u00a0Er\u00a0ist\u00a0aus\u00a0hochgere inigten\u00a0virus\u00e4hn\u2010\nlichen\u00a0Partikeln\u00a0des\u00a0Hauptkapsidproteins\u00a0L1\u00a0der\u00a0gleichen\u00a0vier\u00a0H PV\u2010Typen\u00a0(6,\u00a011,\u00a016\u00a0\nund\u00a018)\u00a0wie\u00a0der\u00a0viervalente\u00a0HPV\u2010Impfstoff\u00a0Gardasil/Silgard\u00a0herg estellt\u00a0sowie\u00a0f\u00fcnf\u00a0\nzus\u00e4tzlichen\u00a0HPV\u2010Typen\u00a0(31,\u00a033,\u00a045,\u00a052,\u00a058).\u00a0Es\u00a0wird\u00a0das\u00a0gleich e\u00a0amorphe\u00a0Alumini\u2010\numhydroxyphosphatsulfat\u2010Adjuvans \u00a0 wie\u00a0 beim\u00a0 viervalenten\u00a0 HPV\u2010Impf stoff\u00a0 ver\u2010\nwendet\u00a0(EMA,\u00a02018).\u00a0\nDie\u00a0HPV\u2010Typen\u00a016\u00a0und\u00a018\u00a0verursachen\u00a0ca.\u00a070\u00a0%\u00a0der\u00a0Zervikalkarzin ome\u00a0weltweit.\u00a0\nDa\u00a0die\u00a0mit\u00a0dem\u00a0neunvalenten\u00a0Impf stoff\u00a0abgedeckten\u00a0HPV\u2010Typen\u00a031, \u00a033,\u00a045,\u00a052\u00a0\nund\u00a058\u00a0zus\u00e4tzlich\u00a0rund\u00a020\u00a0%\u00a0der\u00a0Karzinome\u00a0verursachen,\u00a0wird\u00a0ang enommen,\u00a0dass\u00a0\nGardasil\u00ae\u00a09\u00a0sogar\u00a090\u00a0%\u00a0der\u00a0Zervix karzinome\u00a0verhindern\u00a0kann\u00a0(Ser rano\u00a0et\u00a0al.,\u00a02012).\u00a0\u00a0\nDas\u00a0im\u00a0April\u00a02016\u00a0von\u00a0der\u00a0Europ\u00e4ischen\u00a0Kommission\u00a0bei\u00a0Kindern\u00a0a b\u00a0neun\u00a0Jahren\u00a0\nzur\u00a0Impfung\u00a0gegen\u00a0HPV\u00a0zugelassene\u00a0Gardasil\u00ae\u00a09\u00a0(CHMP,\u00a02015a)\u00a0lie gt\u00a0als\u00a0Injektions\u2010\nsuspension\u00a0oder\u00a0als\u00a0solche\u00a0in\u00a0ei ner\u00a0Fertigspritze\u00a0vor.\u00a0Es\u00a0wird\u00a0 intramuskul\u00e4r\u00a0inji\u2010\nziert,\u00a0vorzugsweise\u00a0in\u00a0den\u00a0Delto ideusbereich\u00a0des\u00a0Oberarms\u00a0oder\u00a0 in\u00a0den\u00a0oberen\u00a0\nanterolateralen\u00a0Bereich\u00a0des\u00a0Ober schenkels\u00a0(Fachinformation\u00a0Gard asil\u00ae\u00a09,\u00a02018).\u00a0\nGardasil\u00ae\u00a09\u00a0kann\u00a0nach\u00a0einem\u00a0Zwei\u2010Dosen\u2010Impfschema\u00a0(\u201e0,\u00a0dann\u00a06\u00a0b is\u00a012\u00a0Monate\u201c)\u00a0\nverabreicht\u00a0werden,\u00a0d.h.\u00a0die\u00a0zweite\u00a0Dosis\u00a0sollte\u00a0der\u00a0ersten\u00a0nac h\u00a0f\u00fcnf\u00a0bis\u00a013\u00a0Mona\u2010\nten\u00a0folgen.\u00a0Wird\u00a0die\u00a0zweite\u00a0Impfdosis\u00a0fr\u00fcher\u00a0als\u00a0f\u00fcnf\u00a0Monate\u00a0na ch\u00a0der\u00a0ersten\u00a0ver\u2010\nabreicht,\u00a0sollte\u00a0eine\u00a0dritte\u00a0Dosis\u00a0geimpft\u00a0werden.\u00a0Personen\u00a0im\u00a0 Alter\u00a0von\u00a015\u00a0Jahren\u00a0\noder\u00a0\u00e4lter\u00a0sollten\u00a0nach\u00a0einem\u00a0Dr ei\u2010Dosen\u2010Schema\u00a0(\u201e0,\u00a02,\u00a06\u00a0Monat e\u201c)\u00a0geimpft\u00a0wer\u2010\nden.\u00a0Dabei\u00a0wird\u00a0die\u00a0zweite\u00a0Dosis\u00a0fr\u00fchestens\u00a0einen\u00a0Monat\u00a0nach\u00a0de r\u00a0ersten\u00a0und\u00a0die\u00a0\ndritte\u00a0fr\u00fchestens\u00a0drei\u00a0Monate\u00a0nach\u00a0der\u00a0zweiten\u00a0Dosis\u00a0verabreich t.\u00a0Alle\u00a0drei\u00a0Dosen\u00a0\nsollten\u00a0innerhalb\u00a0eines\u00a0Jahres\u00a0ve rabreicht\u00a0werden\u00a0(Fachinformat ion\u00a0Gardasil\u00ae\u00a09,\u00a0\n2018).\u00a0\u00a0\nDie\u00a0Zulassungsstudie\u00a0ist\u00a0eine\u00a0multizentrische,\u00a0doppelblinde,\u00a0ra ndomisierte,\u00a0mit\u00a0\ndem\u00a0 viervalenten\u00a0 Impfstoff\u00a0 Gardasil\u00a0 kontrollierte\u00a0 Phase\u2010IIb\u2010III \u2010Studie\u00a0 mit\u00a0 rund\u00a0110\u00a014.000\u00a0Frauen\u00a0im\u00a0Alter\u00a0zwischen\u00a016\u00a0und\u00a026\u00a0Jahren\u00a0(Sponsor:\u00a0Merc k\u00a0Sharp\u00a0&\u00a0Doh\u2010\nme,\u00a0NCT00543543).\u00a0\u00a0\nIn\u00a0der\u00a0Studie\u00a0wurde\u00a0insbesondere\u00a0untersucht,\u00a0bei\u00a0wie\u00a0vielen\u00a0Fra uen\u00a0zwischen\u00a016\u00a0\nund\u00a026\u00a0Jahren,\u00a0denen\u00a0Gardasil\u00ae\u00a09\u00a0verabreicht\u00a0worden\u00a0war,\u00a0eine\u00a0E rkrankung\u00a0(Wu\u2010\ncherungen\u00a0oder\u00a0Karzinome)\u00a0aufgrund\u00a0einer\u00a0durch\u00a0die\u00a0HPV\u2010Typen\u00a031 ,\u00a033,\u00a045,\u00a052\u00a0\nund\u00a058\u00a0verursachten\u00a0HPV\u2010Infektion\u00a0auftrat\u00a0und\u00a0mit\u00a0denen\u00a0verglic hen,\u00a0die\u00a0den\u00a0\nviervalenten\u00a0Impfstoff\u00a0Gardasil\u00ae\u00a0(gegen\u00a0die\u00a0HPV\u2010Typen\u00a06,\u00a011,\u00a016 \u00a0und\u00a018)\u00a0erhalten\u00a0\nhatten.\u00a0Zu\u00a0den\u00a0Endpunkten\u00a0geh\u00f6rten\u00a0hochgradige\u00a0intraepitheliale \u00a0Neoplasien\u00a0am\u00a0\nGeb\u00e4rmutterhals,\u00a0Adenokarzinom\u00a0i n\u00a0situ,\u00a0invasive s\u00a0Zervikalkarzi nom,\u00a0hochgradige\u00a0\nintraepitheliale\u00a0Neoplasien\u00a0der\u00a0 Vulva\u00a0und\u00a0Vagina\u00a0sowie\u00a0Vulva\u2010\u00a0u nd\u00a0Vaginakarzi\u2010\nnom.\u00a0In\u00a0der\u00a0Studie\u00a0wurde\u00a0gezeigt,\u00a0dass\u00a0die\u00a0Wirksamkeit\u00a0des\u00a0neun valenten\u00a0Impf\u2010\nstoffs\u00a0in\u00a0der\u00a0HPV\u2010naiven\u00a0Population\u00a0bei\u00a097\u00a0%\u00a0lag.\u00a0Dies\u00a0galt\u00a0f\u00fcr \u00a0die\u00a0Pr\u00e4vention\u00a0von\u00a0\nmittelgradigen\u00a0Dysplasien\u00a0am\u00a0Geb\u00e4 rmutterhals\u00a0(zervikale\u00a0intraep itheliale\u00a0Neopla\u2010\nsie,\u00a0Cervical\u00a0Intraepithelial\u00a0Neoplasia ,\u00a0CIN2)\u00a0oder\u00a0weniger\u00a0ernsten\u00a0Erkrankungen\u00a0\nwie\u00a0 hochgradigen\u00a0 intraepitheliale\u00a0 Neoplasien\u00a0 der\u00a0 Vulva\u00a0 ( Vulval\u00a0 Intraepithelial\u00a0\nNeoplasia ,\u00a0VIN2\u00a0oder\u00a03)\u00a0sowie\u00a0der\u00a0hochgra digen\u00a0intraepithelialen\u00a0Neoplas ien\u00a0der\u00a0\nVagina\u00a0(Vaginal\u00a0Intraepithelial\u00a0Neoplasia ,\u00a0VaIN2\u00a0oder\u00a03),\u00a0die\u00a0mit\u00a0den\u00a0HPV\u2010Typen\u00a0\n31,\u00a033,\u00a045,\u00a052\u00a0und\u00a058\u00a0in\u00a0Zusammenhang\u00a0stehen\u00a0(diese\u00a0Typen\u00a0sind\u00a0 nicht\u00a0im\u00a0vierva\u2010\nlenten\u00a0Impfstoff\u00a0enthalten).\u00a0In\u00a0 der\u00a0Gesamtpopulation\u00a0waren\u00a0die\u00a0 Raten\u00a0der\u00a0hoch\u2010\ngradigen\u00a0Erkankungen\u00a0von\u00a0Zervix,\u00a0Vagina\u00a0und\u00a0Vulva\u00a0mit\u00a014\u00a0F\u00e4llen \u00a0in\u00a01.000\u00a0Perso\u2010\nnenjahren\u00a0in\u00a0beiden\u00a0Impfstoffgruppen\u00a0gleich\u00a0hoch.\u00a0Die\u00a0Antik\u00f6rpe rreaktionen\u00a0auf\u00a0\ndie\u00a0HPV\u2010Typen\u00a06,\u00a011,\u00a016,\u00a0und\u00a018\u00a0waren\u00a0der\u00a0viervalenten\u00a0Impfung\u00a0 nicht\u00a0unterlegen\u00a0\n(Joura\u00a0et\u00a0al.,\u00a02015).\u00a0\nDie\u00a0Immunogenit\u00e4t\u00a0von\u00a0Gardasil\u00ae\u00a09\u00a0wurde\u00a0au\u00dferdem\u00a0in\u00a0einer\u00a0multi zentrischen,\u00a0\ndoppelblinden,\u00a0 randomisierten\u00a0 Ph ase\u2010III\u2010Studie\u00a0 im\u00a0 Parallelgrupp endesign\u00a0 bei\u00a0\n1.932\u00a0M\u00e4dchen\u00a0und\u00a0666\u00a0Jungen\u00a0im\u00a0Alter\u00a0von\u00a0neun\u00a0bis\u00a015\u00a0Jahren\u00a0so wie\u00a0bei\u00a0468\u00a0\nFrauen\u00a0im\u00a0Alter\u00a0von\u00a016\u00a0und\u00a026\u00a0Jahren\u00a0beurteilt\u00a0(Sponsor:\u00a0Merck\u00a0 Sharp\u00a0&\u00a0Dohme,\u00a0\nNCT00943722).\u00a0Nach\u00a0vier\u00a0Wochen\u00a0und\u00a0der\u00a0dritten\u00a0Dosis\u00a0des\u00a0Impfst offs,\u00a0zeigten\u00a0\n\u00fcber\u00a099\u00a0%\u00a0der\u00a0M\u00e4dchen,\u00a0Jungen\u00a0und\u00a0Frauen\u00a0eine\u00a0Serokonversion\u00a0f\u00fc r\u00a0jeden\u00a0der\u00a0\ngeimpften\u00a0HPV\u2010Typen.\u00a0Die\u00a0Ergebni sse\u00a0best\u00e4tigen\u00a0die\u00a0Wirksamkeit\u00a0 der\u00a0neunvalen\u2010\nten\u00a0HPV\u2010Impfung\u00a0bei\u00a0jungen\u00a0Frauen\u00a0zwischen\u00a016\u00a0und\u00a026\u00a0Jahren\u00a0sow ie\u00a0bei\u00a0M\u00e4d\u2010\nchen\u00a0und\u00a0Jungen\u00a0zwischen\u00a0neun\u00a0 und\u00a015\u00a0Jahren\u00a0(Van\u00a0Damme\u00a0et\u00a0al.,\u00a0 2015).\u00a0\u00a0\nIn\u00a0einer\u00a0open\u00a0label ,\u00a0nicht\u2010randomisierten\u00a0Phase\u2010III\u2010Studie\u00a0im\u00a0Parallelgruppende\u2010\nsign\u00a0wurde\u00a0die\u00a0Immunogenit\u00e4t\u00a0vo n\u00a0Gardasil\u00ae\u00a09\u00a0bei\u00a0M\u00e4nnern\u00a0und\u00a0Fr auen\u00a0im\u00a0Alter\u00a0\nvon\u00a016\u00a0bis\u00a026\u00a0Jahren\u00a0untersucht.\u00a0In\u00a0dieser\u00a0Studie\u00a0erhielten\u00a01.1 03\u00a0heterosexuelle\u00a0\nM\u00e4nner,\u00a0313\u00a0M\u00e4nner,\u00a0die\u00a0Sex\u00a0mit\u00a0M\u00e4nnern\u00a0haben,\u00a0und\u00a01.099\u00a0Frauen \u00a0Gardasil\u00ae\u00a09\u00a0\n(Sponsor:\u00a0Merck\u00a0Sharp\u00a0&\u00a0Dohme,\u00a0NCT01651949).\u00a099,5\u00a0%\u00a0der\u00a0Studien teilnehmer\u00a0111\u00a0waren\u00a0nach\u00a0sieben\u00a0Monaten\u00a0f\u00fcr\u00a0je den\u00a0der\u00a0geimpften\u00a0HPV\u2010Typen\u00a0ser opositiv\u00a0(Cas\u2010\ntellagu\u00e9\u00a0et\u00a0al.,\u00a02015).\u00a0\nDie\u00a0Immunogenit\u00e4t\u00a0und\u00a0Sicherheit\u00a0von\u00a0Gardasil\u00ae\u00a09\u00a0wurde\u00a0weiterhi n\u00a0an\u00a0600\u00a0M\u00e4d\u2010\nchen\u00a0im\u00a0Alter\u00a0zwischen\u00a0neun\u00a0und\u00a015\u00a0Jahren\u00a0in\u00a0einer\u00a0doppelblinde n,\u00a0randomisier\u2010\nten\u00a0Phase\u2010III\u2010Studie\u00a0im\u00a0Parallelgruppendesign\u00a0beurteilt.\u00a0Auch\u00a0h ier\u00a0wurde\u00a0Gardasil\u00ae\u00a09\u00a0\nmit\u00a0dem\u00a0viervalenten\u00a0Gardasil\u00ae\u00a0verglichen.\u00a0Die\u00a0Studie\u00a0zeigte\u00a0ei ne\u00a0vergleichbare\u00a0\nImmunogenit\u00e4t\u00a0f\u00fcr\u00a0die\u00a0HPV\u2010Typen\u00a0 6,\u00a011,\u00a016\u00a0und\u00a018\u00a0und\u00a0Sicherheit \u00a0(Sponsor:\u00a0Merck\u00a0\nSharp\u00a0&\u00a0Dohme,\u00a0NCT01304498;\u00a0Vesikari\u00a0et\u00a0al.,\u00a02015).\u00a0\u00a0\nDer\u00a0Vergleich\u00a0der\u00a0Immunogenit\u00e4t\u00a0 von\u00a0Gardasil\u00ae\u00a09\u00a0mit\u00a0dem\u00a0vierval enten\u00a0Gardasil\u00ae\u00a0\nbei\u00a0M\u00e4nnern\u00a0wurde\u00a0in\u00a0einer\u00a0weiteren\u00a0doppelblinden,\u00a0randomisiert en\u00a0Phase\u2010III\u2010\nStudie\u00a0im\u00a0Parallelgruppendesign\u00a0unternommen\u00a0(Sponsor:\u00a0Merck\u00a0Sha rp\u00a0&\u00a0Dohme,\u00a0\nNCT02114385).\u00a0In\u00a0diese\u00a0Studie\u00a0wurden\u00a0insgesamt\u00a0500\u00a0junge\u00a0M\u00e4nner \u00a0im\u00a0Alter\u00a0von\u00a0\n16\u00a0und\u00a026\u00a0Jahren\u00a0eingeschlossen. \u00a0Immunogenit\u00e4t\u00a0f\u00fcr\u00a0die\u00a0HPV\u2010Type n\u00a06,\u00a011,\u00a016\u00a0und\u00a0\n18\u00a0und\u00a0Sicherheit\u00a0der\u00a0beiden\u00a0Impfstoffe\u00a0waren\u00a0auch\u00a0hier\u00a0verglei chbar\u00a0(Van\u00a0Dam\u2010\nme\u00a0et\u00a0al.,\u00a02016).\u00a0\u00a0\nIn\u00a0zwei\u00a0weiteren\u00a0 open\u00a0label ,\u00a0randomisierten\u00a0Phase\u2010III\u2010Studien\u00a0im\u00a0Parallelgruppen\u2010\ndesign\u00a0wurde\u00a0die\u00a0gleichzeitige\u00a0G abe\u00a0von\u00a0Gardasil\u00ae\u00a09\u00a0und\u00a0anderen \u00a0Impfstoffen\u00a0\n(Menactra\u2122,\u00a0Adacel\u2122,\u00a0REPEVAX\u2122)\u00a0f\u00fcr\u00a0M\u00e4dchen\u00a0und\u00a0Jungen\u00a0im\u00a0Alter\u00a0 von\u00a0elf\u00a0bis\u00a015\u00a0\nJahren\u00a0beurteilt\u00a0(Sponsor:\u00a0Merck\u00a0Sharp\u00a0&\u00a0Dohme,\u00a0NCT00988884\u00a0und \u00a0NCT01073293).\u00a0\nIn\u00a0der\u00a0Studie,\u00a0welche\u00a0die\u00a0Immuno genit\u00e4t\u00a0und\u00a0Sicherheit\u00a0bei\u00a0glei chzeitiger\u00a0Gabe\u00a0mit\u00a0\nMenactra\u2122\u00a0oder\u00a0Adacel\u2122\u00a0(gegen\u00a0Me ningokokken\u00a0bzw.\u00a0Diphterie,\u00a0Tet anus\u00a0und\u00a0\nPertussis)\u00a0an\u00a0insgesamt\u00a01.241\u00a0elf\u2010\u00a0bis\u00a015\u2010j\u00e4hrigen\u00a0M\u00e4dchen\u00a0und\u00a0 Jungen\u00a0bewertete,\u00a0\nwurden\u00a0 621\u00a0 M\u00e4dchen\u00a0 und\u00a0 Jungen\u00a0 gleichzeitig\u00a0 geimpft.\u00a0 Die\u00a0 gleichz eitige\u00a0Gabe\u00a0\nwurde\u00a0insgesamt\u00a0gut\u00a0vertragen\u00a0und\u00a0es\u00a0zeigten\u00a0sich\u00a0keine\u00a0Beeintr \u00e4chtigungen\u00a0in\u00a0\nder\u00a0Immunogenit\u00e4t\u00a0(Schilling\u00a0et\u00a0a l.,\u00a02015).\u00a0In\u00a0der\u00a0Studie,\u00a0in\u00a0d er\u00a0die\u00a0gleichzeitige\u00a0\nGabe\u00a0von\u00a0REPEVAX\u2122\u00a0gegen\u00a0Tetanus ,\u00a0Pertussis\u00a0und\u00a0Poliomyelitis\u00a0an \u00a01.054\u00a0M\u00e4d\u2010\nchen\u00a0und\u00a0Jungen\u00a0im\u00a0Alter\u00a0von\u00a0elf\u00a0bis\u00a015\u00a0Jahren\u00a0untersucht\u00a0wurde ,\u00a0zeigten\u00a0sich\u00a0in\u00a0\nbeiden\u00a0Gruppen\u00a0Serokonversionsraten\u00a0f\u00fcr\u00a0die\u00a0geimpften\u00a0neunvalen ten\u00a0HPV\u2010Typen\u00a0\nvon\u00a0\u00fcber\u00a099,8\u00a0%\u00a0(Kosalaraksa\u00a0et\u00a0al.,\u00a02015).\u00a0\u00a0\nStudienergebnissen\u00a0an\u00a0921\u00a0M\u00e4dchen\u00a0und\u00a0Frauen\u00a0im\u00a0Alter\u00a0von\u00a0zw\u00f6lf \u00a0bis\u00a026\u00a0Jahren\u00a0\nzufolge,\u00a0ist\u00a0eine\u00a0Impfung\u00a0mit\u00a0Gardasil\u00ae\u00a09\u00a0ebenfalls\u00a0wirksam,\u00a0we nn\u00a0vorher\u00a0der\u00a0vier\u2010\nvalente\u00a0HPV\u2010Impfstoff\u00a0verabreicht\u00a0worden\u00a0ist.\u00a098\u00a0%\u00a0der\u00a0Studient eilnehmerinnen\u00a0\nwaren\u00a0seropositiv\u00a0f\u00fcr\u00a0die\u00a0geimpften\u00a0HPV\u2010Typen\u00a031,\u00a033,\u00a045,\u00a052\u00a0un d\u00a058\u00a0aus\u00a0Gardasil\u00ae\u00a09\u00a0\n(Garland\u00a0et\u00a0al.,\u00a02015).\u00a0Diesen\u00a0Ergebnissen\u00a0liegt\u00a0eine\u00a0doppelbli nde,\u00a0randomisierte\u00a0\nPhase\u2010III\u2010Studie\u00a0 im\u00a0 Parallelgruppe ndesign\u00a0 zugrunde\u00a0 (Sponsor:\u00a0 Me rck\u00a0 Sharp\u00a0 &\u00a0\nDohme,\u00a0NCT01047345).\u00a0\u00a0112\u00a0Eine\u00a0 aktuelle\u00a0 und\u00a0 vom\u00a0 pU\u00a0 unabh\u00e4ngige\u00a0 Metaanalyse\u00a0 von\u00a0 Costa\u00a0 und\u00a0 Kollegen\u00a0\n(2017)\u00a0schloss\u00a0drei\u00a0der\u00a0hier\u00a0aufgef\u00fchrten\u00a0RCTs\u00a0zur\u00a0Sicherheit\u00a0d es\u00a0neunvalenten\u00a0\nund\u00a0viervalenten\u00a0Impfstoffs\u00a0ein\u00a0(Joura\u00a0et\u00a0al.,\u00a02015;\u00a0Vesikari\u00a0e t\u00a0al.,\u00a02015;\u00a0Moreira\u00a0et\u00a0\nal.,\u00a02016)\u00a0und\u00a0verglich\u00a0die\u00a0Ergebnisse\u00a0auf\u00a0Unterschiede\u00a0hinsich tlich\u00a0des\u00a0Sicher\u2010\nheitsprofils.\u00a0Die\u00a0Studien\u00a0umfassten\u00a0insgesamt\u00a027.465\u00a0Frauen.\u00a0Sc hmerz\u00a0(OR\u00a01,72;\u00a0\n[95\u00a0%\u00a0KI\u00a01,62;\u00a01,82]\u00a0und\u00a0Erythem\u00a0(OR\u00a01,29;\u00a095\u00a0%\u00a0[KI\u00a01,21;\u00a01,36] \u00a0traten\u00a0signifikant\u00a0\nh\u00e4ufiger\u00a0 in\u00a0 der\u00a0 Gardasil\u00ae\u00a0 9\u2010Gruppe\u00a0 auf.\u00a0 Weitere\u00a0 Nebenwirkungen\u00a0 wie\u00a0 Kopf\u2010\nschmerzen\u00a0(OR\u00a01,07;\u00a095\u00a0%\u00a0[KI\u00a00,99; \u00a01,15],\u00a0Schwindel\u00a0(OR\u00a01,09;\u00a09 5\u00a0%\u00a0[KI\u00a00,93;\u00a01,27],\u00a0\nM\u00fcdigkeit\u00a0(OR\u00a01,09;\u00a095\u00a0%\u00a0[KI\u00a00,91;\u00a01,30]\u00a0und\u00a0schwere\u00a0unerw\u00fcnsch te\u00a0Ereignisse\u00a0\nwaren\u00a0selten\u00a0und\u00a0unterschieden\u00a0sich\u00a0in\u00a0der\u00a0H\u00e4ufigkeit\u00a0nicht\u00a0zwi schen\u00a0den\u00a0Gruppen\u00a0\n(Costa\u00a0et\u00a0al.,\u00a02017).\u00a0\nEin\u00a0Review\u00a0der\u00a0 Canadian\u00a0Agency\u00a0for\u00a0Drugs\u00a0and\u00a0Technologies\u00a0in\u00a0Health \u00a0(CADTH)\u00a0zur\u00a0\nkritischen\u00a0Bewertung\u00a0der\u00a0Wirksamkeit\u00a0und\u00a0Kosteneffektivit\u00e4t\u00a0der \u00a0HPV\u2010Impfung\u00a0f\u00fcr\u00a0\nM\u00e4nner\u00a0untersuchte\u00a0die\u00a0bestehende \u00a0Evidenz\u00a0zur\u00a0Pr\u00e4vention\u00a0von\u00a0HP V\u2010assoziierten\u00a0\nGenitalwarzen\u00a0und\u00a0Karzinomen\u00a0des\u00a0 Penis,\u00a0Anus\u00a0oder\u00a0Oropharynx\u00a0(2 017).\u00a0Zum\u00a0\nneunvalenten\u00a0Impfstoff\u00a0identifizierte\u00a0die\u00a0\u00dcbersichtsarbeit\u00a0vier \u00a0Studien\u00a0(ein\u00a0RCT\u00a0\nund\u00a0drei\u00a0prospektive\u00a0Kohortenstudien).\u00a0Hiervon\u00a0untersuchten\u00a0zwe i\u00a0Studien\u00a0Kinder\u00a0\nvon\u00a0neun\u00a0bis\u00a015\u00a0Jahren\u00a0und\u00a0zwei\u00a0Studien\u00a0Erwachsene.\u00a0Laut\u00a0CADTH\u00a0 unterst\u00fctzt\u00a0die\u00a0\nwachsende\u00a0Studienlage\u00a0den\u00a0Einschluss\u00a0von\u00a0Jungen\u00a0und\u00a0M\u00e4nnern\u00a0bis \u00a026\u00a0Jahre\u00a0in\u00a0\nHPV\u2010Immunisierungsprogramme.\u00a0Allerdings\u00a0schlussfolgerten\u00a0die\u00a0Au toren,\u00a0dass\u00a0der\u00a0\ngr\u00f6\u00dfte\u00a0Teil\u00a0der\u00a0Evidenz\u00a0Aussagen\u00a0 zum\u00a0\u201eZwischenergebnis\u201c\u00a0Serokon version\u00a0vor\u2010\nnimmt\u00a0und\u00a0Patienten\u00a0nicht\u00a0lange\u00a0genug\u00a0beobachtet\u00a0werden,\u00a0um\u00a0kli nisch\u00a0bedeu\u2010\ntungsvolle\u00a0Endpunkte\u00a0zu\u00a0messen.\u00a0Au\u00dferdem\u00a0st\u00fctzt\u00a0sich\u00a0ein\u00a0Gro\u00dfte il\u00a0der\u00a0Evidenz\u00a0\nauf\u00a0Studien\u00a0zum\u00a0viervalenten\u00a0Ga rdasil\u00ae,\u00a0sodass\u00a0es\u00a0schwierig\u00a0sei ,\u00a0den\u00a0Einfluss\u00a0der\u00a0\nImpfung\u00a0von\u00a0Jungen\u00a0und\u00a0M\u00e4nnern\u00a0auf\u00a0HPV\u2010assoziierte\u00a0Erkrankungen ,\u00a0auch\u00a0bezo\u2010\ngen\u00a0auf\u00a0das\u00a0beste\u00a0Impfalter,\u00a0u mfassend\u00a0zu\u00a0beurteilen\u00a0(CADTH,\u00a020 17).\u00a0\nEin\u00a0systematischer\u00a0Review\u00a0des\u00a0 Norwegian\u00a0Knowledge\u00a0Centre\u00a0for\u00a0the\u00a0Health\u00a0Ser\u2010\nvices\u00a0aus\u00a0dem\u00a0Jahr\u00a02015\u00a0fasste\u00a0Studien\u00a0zur\u00a0Wirkung\u00a0der\u00a0viervalenten\u00a0 Impfung\u00a0\nhinsichtlich\u00a0der\u00a0Pr\u00e4vention\u00a0externer\u00a0genitaler\u00a0L\u00e4sionen\u00a0aufgrun d\u00a0einer\u00a0Infektion\u00a0\nmit\u00a0den\u00a0HPV\u2010Typen\u00a06,\u00a011,\u00a016\u00a0oder\u00a018\u00a0bei\u00a0M\u00e4nnern\u00a0im\u00a0Alter\u00a0von\u00a016 \u00a0und\u00a026\u00a0Jahren\u00a0\nzusammen.\u00a0Die\u00a0Qualit\u00e4t\u00a0der\u00a0zugr undeliegenden\u00a0Evidenz\u00a0wurde\u00a0dabe i\u00a0als\u00a0mittel\u2010\nm\u00e4\u00dfig\u00a0eingestuft.\u00a0Haupts\u00e4chlich\u00a0sind\u00a0es\u00a0bei\u00a0den\u00a0genitalen\u00a0L\u00e4sio nen\u00a0Genitalwarzen,\u00a0\ndie\u00a0mit\u00a0der\u00a0Impfung\u00a0verhindert\u00a0werden\u00a0k\u00f6nnen.\u00a0Daten\u00a0zu\u00a0pr\u00e4malig nen\u00a0L\u00e4sionen\u00a0\nwie\u00a0solche,\u00a0die\u00a0zum\u00a0Peniskarzinom \u00a0geh\u00f6ren,\u00a0sind\u00a0stark\u00a0limitiert \u00a0und\u00a0nicht\u00a0eindeutig\u00a0\n(niedriger\u00a0Evidenzgrad).\u00a0Hier\u00a0si nd\u00a0l\u00e4ngere\u00a0Nachbeobachtungszeit en\u00a0erforderlich.\u00a0In\u00a0\nder\u00a0Subpopulation\u00a0der\u00a0M\u00e4nner,\u00a0die \u00a0Sex\u00a0mit\u00a0M\u00e4nnern\u00a0haben,\u00a0reduzi ert\u00a0die\u00a0Impfung\u00a0\ndas\u00a0Risiko\u00a0auf\u00a0ein\u00a0Analkarzinom\u00a0(niedriger\u00a0Evidenzgrad).\u00a0Daten\u00a0 aus\u00a0drei\u00a0Jahren\u00a0\nNachbeobachtungszeit\u00a0 zeigten\u00a0 kaum\u00a0 Unterschiede\u00a0 hinsichtlich\u00a0 sch werer\u00a0 uner\u2010\nw\u00fcnschter\u00a0Ereignisse\u00a0in\u00a0der\u00a0Im pf\u2010\u00a0gegen\u00fcber\u00a0der\u00a0Kontrollgruppe\u00a0 (mittlerer\u00a0Evi\u2010113\u00a0denzgrad).\u00a0 Weitere\u00a0 Forschung\u00a0 ist\u00a0 e rforderlich,\u00a0 um\u00a0 zu\u00a0 belegen,\u00a0 d ass\u00a0 die\u00a0 HPV\u2010\nImpfung\u00a0das\u00a0Risiko\u00a0auf\u00a0HPV\u2010assoz iierte\u00a0Karzinome\u00a0und\u00a0die\u00a0krebsb edingte\u00a0Mortali\u2010\nt\u00e4t\u00a0verringert\u00a0(NKCH,\u00a02015).\u00a0\u00a0\nDie\u00a0EMA\u00a0bewertet\u00a0das\u00a0Kosten\u2010Nutz en\u2010Verh\u00e4ltnis\u00a0f\u00fcr\u00a0Gardasil\u00ae\u00a09\u00a0a ls\u00a0insgesamt\u00a0\npositiv.\u00a0Auf\u00a0Basis\u00a0der\u00a0Daten\u00a0zu\u00a0Qualit\u00e4t,\u00a0Sicherheit\u00a0und\u00a0Wirksa mkeit\u00a0besteht\u00a0dem\u2010\nnach\u00a0ein\u00a0positives\u00a0Kosten\u2010Nutzen\u2010Verh\u00e4ltnis\u00a0f\u00fcr\u00a0pr\u00e4maligne\u00a0L\u00e4si onen\u00a0und\u00a0Karzi\u2010\nnome\u00a0der\u00a0Zervix,\u00a0Vulva,\u00a0Vagina\u00a0und\u00a0des\u00a0Anus,\u00a0die\u00a0durch\u00a0HPV\u2010Type n\u00a0der\u00a0Impfstoffe\u00a0\nverursacht\u00a0worden\u00a0sind.\u00a0Ebenso\u00a0be wertet\u00a0sie\u00a0das\u00a0Kosten\u2010Nutzen\u2010V erh\u00e4ltnis\u00a0f\u00fcr\u00a0\nGenitalwarzen\u00a0als\u00a0positiv\u00a0(CHMP,\u00a02015b;\u00a02016).\u00a0\u00a0\nZur\u00a0Impfung\u00a0von\u00a0Jungen\u00a0bewertet\u00a0das\u00a0arznei\u2010telegramm\u00a0Gardasil\u00ae\u00a0 9\u00a0als\u00a0wirksam,\u00a0\ninsbesondere\u00a0sei\u00a0die\u00a0Impfung\u00a0f\u00fcr\u00a0homosexuelle\u00a0M\u00e4nner\u00a0sinnvoll,\u00a0 die\u00a0von\u00a0einer\u00a0\ndurch\u00a0 die\u00a0 Immunisierung\u00a0 der\u00a0 M\u00e4dche n\u00a0 ausgehenden\u00a0 Herdenprotektio n\u00a0 ausge\u2010\nschlossen\u00a0 sind.\u00a0 Umgekehrt\u00a0 profitieren\u00a0 ungeimpfte\u00a0 M\u00e4dchen\u00a0 ebenfa lls\u00a0 von\u00a0 der\u00a0\nImmunisierung\u00a0der\u00a0Jungen.\u00a0Den\u00a0Schutz\u00a0vor\u00a0Penis\u2010\u00a0oder\u00a0Oropharynx karzinomen\u00a0\nbewertet\u00a0das\u00a0a\u2010t\u00a0derzeit\u00a0als\u00a0\u201enicht\u00a0belegt\u201c.\u00a0Bei\u00a0der\u00a0Immunisier ung\u00a0der\u00a0Jungen\u00a0\ngegen\u00a0HPV\u00a0wird\u00a0Gardasil\u00ae\u00a09\u00a0der\u00a0bivalenten\u00a0Alternative\u00a0Cervarix\u00ae \u00a0vorgezogen,\u00a0da\u00a0es\u00a0\ndie\u00a0beiden\u00a0Niedrigrisiko\u2010HPV\u2010Typen\u00a06\u00a0und\u00a011\u00a0zum\u00a0Schutz\u00a0vor\u00a0Geni talwarzen\u00a0ent\u2010\nh\u00e4lt.\u00a0F\u00fcr\u00a0das\u00a0bivalente\u00a0Cervarix\u00ae\u00a0liegt\u00a0kein\u00a0nachweisbarer\u00a0Nutz en\u00a0zum\u00a0Schutz\u00a0vor\u00a0\nGenitalwarzen\u00a0vor,\u00a0die\u00a0den\u00a0Haup tteil\u00a0der\u00a0HPV\u2010assoziierten\u00a0Erkra nkungen\u00a0ausma\u2010\nchen,\u00a0f\u00fcr\u00a0die\u00a0bei\u00a0Jungen\u00a0ein\u00a0Nut zen\u00a0der\u00a0Impfung\u00a0belegt\u00a0ist\u00a0(a\u2010t ,\u00a02018).\u00a0\u00a0\nDie\u00a0St\u00e4ndige\u00a0Impfkommission\u00a0(STIKO)\u00a0empfiehlt\u00a0die\u00a0Impfung\u00a0in\u00a0zw ei\u00a0Dosen\u00a0gegen\u00a0\nHPV\u00a0f\u00fcr\u00a0M\u00e4dchen\u00a0und\u00a0Jungen\u00a0im\u00a0Alter\u00a0von\u00a0neun\u00a0bis\u00a014\u00a0Jahren\u00a0vor\u00a0 dem\u00a0ersten\u00a0\nSexualkontakt.\u00a0Findet\u00a0die\u00a0erste\u00a0 HPV\u2010Impfung\u00a0nach\u00a0dem\u00a014.\u00a0Lebens jahr\u00a0statt,\u00a0sind\u00a0\ninsgesamt\u00a0drei\u00a0Impfungen\u00a0notwendig.\u00a0Laut\u00a0STIKO\u00a0kann\u00a0die\u00a0Impfung \u00a0bis\u00a0zu\u00a0einem\u00a0\nAlter\u00a0von\u00a017\u00a0Jahren\u00a0nachgeholt\u00a0 werden\u00a0(STIKO,\u00a02017;\u00a0AG\u00a0HPV,\u00a0201 8).\u00a0\nDie\u00a0Empfehlung\u00a0der\u00a0STIKO\u00a0zur\u00a0Impfung\u00a0von\u00a0Jungen\u00a0ab\u00a0neun\u00a0Jahren\u00a0 (STIKO,\u00a02017;\u00a0\nAG\u00a0HPV,\u00a02018),\u00a0beruht\u00a0auf\u00a0dem\u00a0o.g.\u00a0systematischen\u00a0Review\u00a0zur\u00a0Wi rksamkeit\u00a0und\u00a0\nSicherheit\u00a0der\u00a0HPV\u2010Impfung\u00a0bei\u00a0M\u00e4nnern\u00a0von\u00a0Harder\u00a0und\u00a0Kollegen\u00a0 (2018).\u00a0Harder\u00a0\nund\u00a0Kollegen\u00a0schlossen\u00a0sieben\u00a0Studien\u00a0zum\u00a0viervalenten\u00a0Gardasil \u00ae\u00a0bei\u00a0Jungen\u00a0ab\u00a0\nzw\u00f6lf\u00a0Jahren\u00a0ein\u00a0(2018).\u00a0Die\u00a0Impfempfehlung\u00a0der\u00a0STIKO\u00a0f\u00fcr\u00a0Garda sil\u00ae\u00a09\u00a0gilt\u00a0jedoch\u00a0\nf\u00fcr\u00a0Jungen\u00a0ab\u00a0neun\u00a0Jahren\u00a0(AG\u00a0HPV,\u00a02018).\u00a0\nZusammenfassend\u00a0ist\u00a0festzustellen,\u00a0dass\u00a0die\u00a0vorliegenden\u00a0Studie n\u00a0zur\u00a0Impfung\u00a0von\u00a0\nJungen\u00a0und\u00a0M\u00e4nnern\u00a0unverh\u00e4ltnism \u00e4\u00dfig\u00a0kleinere\u00a0Studienpopulation en\u00a0einschlie\u2010\n\u00dfen\u00a0als\u00a0die\u00a0Studien\u00a0zur\u00a0Impfung\u00a0von\u00a0Frauen.\u00a0Daten\u00a0zu\u00a0klinischen \u00a0Endpunkten\u00a0feh\u2010\nlen\u00a0bei\u00a0den\u00a0Studien\u00a0zu\u00a0M\u00e4nnern\u00a0weitgehend.\u00a0Es\u00a0muss\u00a0davon\u00a0ausgeg angen\u00a0werden,\u00a0\ndass\u00a0die\u00a0Datenlage\u00a0f\u00fcr\u00a0andere\u00a0Zie lgruppen,\u00a0z.B.\u00a0f\u00fcr\u00a0\u00e4ltere\u00a0Frau en,\u00a0unzureichend\u00a0ist.\u00a0\u00a0114\u00a0Verf\u00fcgbare\u00a0Impfungen\u00a0 (Zusatz\u2010)Nutzen\u00a0 Kosten\u00a0\n \neinziger\u00a0Impfstoff\u00a0gegen\u00a0\ndie\u00a0HPV\u2010Typen\u00a06,\u00a011\u00a0\nsowie\u00a031,\u00a033,\u00a045,\u00a052\u00a0und\u00a0\n58\u00a0 pot.\u00a0Verhinderung\u00a0von\u00a0\n90\u00a0%\u00a0(gg\u00fc.\u00a070\u00a0%)\u00a0aller\u00a0\nZervixkarzinome\u00a0 \nteils\u00a0g\u00fcnstiger\u00a0als\u00a0\nCervarix\u00ae\u00a0\nErl\u00e4uterung\u00a0der\u00a0Farben:\u00a0Verf\u00fcgbare\u00a0Therapien:\u00a0rot\u00a0=\u00a0weitere\u00a0The rapieoption,\u00a0gelb\u00a0=\u00a0Subgruppen\u2010Novit\u00e4t,\u00a0gr\u00fcn\u00a0=\u00a0Solist;\u00a0(Zusatz\u2010 )\u00a0\nNutzen:\u00a0rot\u00a0=\u00a0keine\u00a0Verbesserung\u00a0oder\u00a0schlechte\u00a0Nutzen/Schaden\u2010 Relation,\u00a0gelb\u00a0=\u00a0teilweise\u00a0Verbesserungen,\u00a0gr\u00fcn\u00a0=\u00a0Verbesserung\u00a0\nharter\u00a0Endpunkte;\u00a0Kosten:\u00a0rot\u00a0=\u00a0teurer\u00a0als\u00a0bestehende\u00a0Therapien ,\u00a0gelb\u00a0=\u00a0ungef\u00e4hr\u00a0gleich\u00a0bzw.\u00a0teils/teils,\u00a0gr\u00fcn\u00a0=\u00a0g\u00fcnstiger\u00a0als \u00a0\nbestehende\u00a0Therapien\u00a0\nWie\u00a0bewerten\u00a0andere?\u00a0\nBewertung\u00a0nach\u00a0\nFricke\u00a0et\u00a0al.\u00a0a\u2010t\u2010Bewertung\u00a0 AMB\u00a0 Prescrire\u00a0 PZ\u00a0\nB\u00a0Mittel\u00a0der\u00a0Wahl\u00a0\nNoch\u00a0offene\u00a0Fragen\u00a0\nBei\u00a0Jungen\u00a0\nCervarix\u00ae\u00a0\nvorzuziehen\u00a0Wirksam\u00a0zur\u00a0\nVerhinderung\u00a0von\u00a0\nGenitalwarzen\u00a0und\u00a0\nVorstufen\u00a0des\u00a0\nCervixkarzinoms\u00a0\u2013\u00a0 \u2013\u00a0\nKosten\u00a0\nWirkstoff\u00a0 Behandlungsmodus\u00a0 Therapiekosten\u00a0\nzu\u00a0bewertender\u00a0Impfstoff    \nGardasil\u00ae\u00a09  2\u00a0(3)\u00a0Dosen\u00a0innerhalb\u00a01\u00a0Jahr:\u00a00,\u00a06\u00a0\u2013\u00a012\u00a0(0,\u00a02,\u00a06)\u00a0\nMonate  325,40\u00a0\u2013\u00a0488,10\u00a0\u20ac*\u00a0\nweiterer\u00a0Impfstoff \u00a0 \u00a0 \u00a0\nCervarix\u00ae\u00a0 2\u00a0(3)\u00a0Dosen\u00a0innerhalb\u00a01\u00a0Jahr:\u00a00,\u00a05\u00a0\u2013\u00a013\u00a0(0,\u00a01,\u00a06)\u00a0\nMonate\u00a0312,76\u00a0\u2013\u00a0469,14\u00a0\u20ac*\u00a0\n*\u00a0Preise\u00a0gem\u00e4\u00df\u00a0Empfehlungen\u00a0f\u00fcr\u00a0die\u00a0Impfh\u00e4ufigkeit,\u00a0je\u00a0nach\u00a0KV\u2010 Regelung\u00a0Abrechnung\u00a0\u00fcber\u00a0Sprechstundenbedarf\u00a0(Zehnerpa\u2010\nckung)\u00a0m\u00f6glich\u00a0\nVersorgungsanalysen\u00a0\nDie\u00a0Verordnung\u00a0von\u00a0Gardasil\u00ae\u00a09\u00a0nimmt\u00a0ab\u00a0Listung\u00a0in\u00a0der\u00a0Lauer\u2010Ta xe\u00a0zu\u00a0bis\u00a0im\u00a0\nDezember\u00a02016\u00a0ein\u00a0erster\u00a0R\u00fcckgang\u00a0auf\u00a0das\u00a0Niveau\u00a0des\u00a0Vormonats\u00a0 von\u00a02.755\u00a0DDD\u00a0\nerreicht\u00a0wird.\u00a0Danach\u00a0wird\u00a0die\u00a0steigende\u00a0Tendenz\u00a0bis\u00a0zum\u00a0Maximu m\u00a0von\u00a05.162\u00a0\nDDD\u00a0im\u00a0November\u00a02017\u00a0deutlich\u00a0(Abbildung\u00a04.7).\u00a0Die\u00a0unregelm\u00e4\u00dfig e,\u00a0aber\u00a0insge\u2010\nsamt\u00a0deutliche\u00a0Steigerung\u00a0der\u00a0Bruttoums\u00e4tze\u00a0und\u00a0DDDs\u00a0bis\u00a0zum\u00a0Ja hresende\u00a02017\u00a0\nist\u00a0vermutlich\u00a0darauf\u00a0zur\u00fcckzuf\u00fchren,\u00a0dass\u00a0vor\u00a0August\u00a02017\u00a0para llel\u00a0noch\u00a0der\u00a0vier\u2010\nvalente\u00a0Impfstoff\u00a0Gardasil\u00ae\u00a0und\u00a0 seitdem\u00a0nur\u00a0noch\u00a0der\u00a0neunvalent e\u00a0Impfstoff\u00a0Gar\u2010\ndasil\u00ae\u00a09\u00a0sowie\u00a0die\u00a0bivalente\u00a0Alternative\u00a0Cervarix\u00ae\u00a0auf\u00a0dem\u00a0Mark t\u00a0sind\u00a0(STIKO,\u00a0\n2017).\u00a0Dass\u00a0es\u00a0im\u00a0Dezember\u00a0zu\u00a0einem\u00a0deutlichen\u00a0R\u00fcckgang\u00a0der\u00a0ver ordneten\u00a0Ta\u2010\ngesdosen\u00a0kommt,\u00a0ist\u00a0eher\u00a0ein\u00a0org anisatorisches\u00a0Problem:\u00a0Aufgrun d\u00a0der\u00a0Feiertage\u00a0\nfinden\u00a0weniger\u00a0Impfungen\u00a0sta tt\u00a0oder\u00a0werden\u00a0vorgezogen.\u00a0\n115\u00a0Abbildung\u00a04.7:\u00a0Verordnete\u00a0Tagesdosen\u00a0(DDD)\u00a0und\u00a0Bruttoums\u00e4tze\u00a0vo n\u00a0\u00a0\nGardasil\u00ae\u00a09\u00a0nach\u00a0Monaten\u00a0(2016\u00a0\u2013\u00a02017)\u00a0\n\u00a0\n\u00a0\nQuellen\u00a0\u00a0\nAG\u00a0HPV\u00a0der\u00a0STIKO\u00a0(2018).\u00a0Wissenschaftliche\u00a0Begr\u00fcndung\u00a0f\u00fcr\u00a0die\u00a0E mpfehlung\u00a0der\u00a0HPV\u2010Impfung\u00a0f\u00fcr\u00a0Jungen\u00a0im\u00a0Alter\u00a0von\u00a09\u00a0bis\u00a014\u00a0\nJahren.\u00a0Epid\u00a0Bull\u00a026:\u00a0233\u2010250.\u00a0\na\u2010t\u00a0\u2013\u00a0arznei\u2010telegramm\u00a0(2018).\u00a0STIKO\u00a0empfiehlt\u00a0HPV\u2010Impfung\u00a0f\u00fcr\u00a0 Jungen.\u00a0arznei\u2010telegramm\u00a049:\u00a067\u201068.\u00a0\nAMB\u00a0\u2013\u00a0Arzneimittelbrief\u00a0(2007).\u00a0Gardasil\u00ae\u00a0und\u00a0Cervarix\u00ae:\u00a0Wie\u00a0ka nn\u00a0man\u00a0den\u00a0langfristigen\u00a0Nutzen\u00a0dieser\u00a0Impfstoffe\u00a0gegen\u00a0humane\u00a0\nPapillom\u2010Viren\u00a0beurteilen?\u00a0AMB\u00a041,\u00a092.\u00a0\nCADTH\u00a0\u2013\u00a0Canadian\u00a0Agency\u00a0for\u00a0Drugs\u00a0and\u00a0Technologies\u00a0in\u00a0Health\u00a0(2 017).\u00a0CADTH\u00a0RAPID\u00a0RESPONSE\u00a0REPORT:\u00a0SUMMARY\u00a0WITH\u00a0\nCRITICAL\u00a0APPRAISAL\u00a0HPV\u00a0Vaccinatio n\u00a0in\u00a0Men:\u00a0A\u00a0Review\u00a0of\u00a0Clinical \u00a0Effectiveness,\u00a0CostEffectiveness,\u00a0and\u00a0Guidelines.\u00a0\nhttps://www.cadth.ca/sites/default/files/pdf/htis/2017/RC0862%2 0%20Gardasil%20for%20men%20Final.pdf,\u00a0\nletzter\u00a0Zugriff:\u00a023.01.2019.\u00a0\nCHMP\u00a0\u2013\u00a0Committee\u00a0for\u00a0Medicinal\u00a0Products\u00a0for\u00a0Human\u00a0Use\u00a0(2015a)\u00a0. \u00a0Positive\u00a0opinion,\u00a0initial\u00a0authorization:\u00a0Gardasil\u00a09\u00a0human\u00a0\npapillomavirus\u00a09\u2010valent\u00a0vaccine\u00a0(recombinant,\u00a0adsorbed).\u00a0EMA/CH MP/76588/2015,\u00a0London:\u00a026.\u00a0M\u00e4rz.\u00a0\u00a0\nCHMP\u00a0\u2013\u00a0Committee\u00a0for\u00a0Medicinal\u00a0Products\u00a0for\u00a0Human\u00a0Use\u00a0(2015b).\u00a0 Assessment\u00a0report\u00a0Gardasil\u00a09\u00a0International\u00a0non\u2010proprietary\u00a0\nname:\u00a0human\u00a0papillomavirus\u00a09\u2010vale nt\u00a0vaccine\u00a0(RECOMBINANT,\u00a0ADSOR BED)\u00a0Procedure\u00a0No.\u00a0\nEMEA/H/C/003852/0000. \u00a0https://www.ema.europa.eu/en/documents/assessment\u2010report/gardas il\u20109\u2010epar\u2010public\u2010\nassessment\u2010report_en.pdf,\u00a0letzter\u00a0Zugriff:\u00a011.07.2019. \u00a0\u00a0\n116\u00a0CHMP\u00a0\u2013\u00a0Committee\u00a0for\u00a0Medicinal\u00a0Products\u00a0for\u00a0Human\u00a0Use\u00a0(2016).\u00a0P rocedure\u00a0Management\u00a0and\u00a0Committees\u00a0Support\u00a0Division\u00a0\nAssessment\u00a0report\u00a0for\u00a0paediatric\u00a0studies\u00a0submitted\u00a0according\u00a0to \u00a0Article\u00a046\u00a0of\u00a0the\u00a0Regulation\u00a0(EC)\u00a0No\u00a01901/2006\u00a0\nGardasil\u00a09\u00a0human\u00a0papillomavirus\u00a0 vaccine\u00a0[types\u00a06,\u00a011,\u00a016,\u00a018,\u00a03 1,\u00a033,\u00a045,\u00a052,\u00a058]\u00a0(recombinant,\u00a0adsorbed)\u00a0Procedure\u00a0\nno:\u00a0EMEA/H/C/003852/P46/002. \u00a0https://www.ema.europa.eu/en/documents/variation\u2010report/gardasi l\u20109\u2010h\u2010c\u20103852\u2010\np46\u2010epar\u2010assessment\u2010report\u2010variation_en.pdf,\u00a0letzter\u00a0Zugriff:\u00a01 1.07.2019.\u00a0\nCosta\u00a0APF,\u00a0Cobucci\u00a0RNO,\u00a0da\u00a0Silva\u00a0JM,\u00a0da\u00a0Costa\u00a0Lima\u00a0PH,\u00a0Giraldo\u00a0 PC\u00a0et\u00a0al.\u00a0(2017).\u00a0Safety\u00a0of\u00a0Human\u00a0Papillomavirus\u00a09\u2010Valent\u00a0Vacci ne:\u00a0\nA\u00a0Meta\u2010Analysis\u00a0of\u00a0Randomized\u00a0Trials.\u00a0Journal\u00a0of\u00a0Immunology\u00a0Res earch\u00a02017:\u00a03736201.\u00a0\nEMA\u00a0\u2013\u00a0European\u00a0Medicines\u00a0Agency\u00a0 (2018)\u00a0Produktinformation\u00a0Garda sil\u00ae9,\u00a0Anhang\u00a0I:\u00a0Zusammenfassung\u00a0der\u00a0Merkmale\u00a0des\u00a0\nArzneimittels.\u00a0https://www.ema.europa.eu/en/medicines/human/EPA R/gardasil\u20109#product\u2010information\u2010section,\u00a0\nletzter\u00a0Zugriff:\u00a023.01.2019.\u00a0\u00a0\u00a0\nFachinformation\u00a0Gardasil\u00ae9\u00a0(2018) .\u00a0Fachinformation\u00a0Gardasil\u00ae9.\u00a0\nhttps://www.msd.de/fileadmin/files/fachinformationen/gardasil_9 .pdf,\u00a0letzter\u00a0Zugriff:\u00a023.01.2019.\u00a0\nFricke\u00a0U,\u00a0Hein\u00a0L,\u00a0Schwabe\u00a0U\u00a0(2017).\u00a0Neue\u00a0Arzneimittel\u00a02016.\u00a0In: \u00a0Schwabe\u00a0U,\u00a0Paffrath\u00a0D,\u00a0Ludwig\u00a0W\u2010D,\u00a0Klauber\u00a0J\u00a0(Hrsg.)\u00a0(2017).\u00a0\nArzneiverordnungs\u2010Report\u00a02017.\u00a0Berlin,\u00a0Heidelberg.\u00a0Springer:\u00a055 \u2010135.\u00a0\nGarland\u00a0SM,\u00a0Cheung\u00a0TH,\u00a0McNeill\u00a0S,\u00a0Petersen\u00a0LK,\u00a0Romaguera\u00a0J,\u00a0Vaz quez\u2010Narvaez\u00a0J\u00a0et\u00a0al.\u00a0(2015).\u00a0Safety\u00a0and\u00a0immunogenicity\u00a0of\u00a0a\u00a09\u2010\nvalent\u00a0HPV\u00a0vaccine\u00a0in\u00a0females\u00a012\u201026\u00a0years\u00a0of\u00a0age\u00a0who\u00a0previously \u00a0received\u00a0the\u00a0quadrivalent\u00a0HPV\u00a0vaccine.\u00a0Vaccine\u00a0\n33(48):\u00a06855\u201064.\u00a0\u00a0\nGiuliano\u00a0AR,\u00a0Palefsky\u00a0JM,\u00a0Goldst one\u00a0S,\u00a0Moreira\u00a0ED,\u00a0Penny\u00a0M.\u00a0E,\u00a0 Aranda\u00a0C\u00a0et\u00a0al.\u00a0(2011).\u00a0Efficacy\u00a0of\u00a0Quadrivalent\u00a0HPV\u00a0Vaccine\u00a0ag ainst\u00a0\nHPV\u00a0Infection\u00a0and\u00a0Disease\u00a0in\u00a0Mal es.\u00a0New\u00a0England\u00a0Journal\u00a0of\u00a0Medi cine\u00a0364(5):\u00a0401\u2013411.\u00a0\nHarder\u00a0T,\u00a0Wichmann\u00a0O,\u00a0Klug\u00a0SJ,\u00a0van\u00a0der\u00a0Sande\u00a0MAB,\u00a0Wiese\u2010Posselt \u00a0M\u00a0(2018).\u00a0Efficacy,\u00a0effectiveness\u00a0and\u00a0safety\u00a0of\u00a0vaccination\u00a0\nagainst\u00a0human\u00a0papillomavirus\u00a0in\u00a0m ales:\u00a0a\u00a0systematic\u00a0review.\u00a0BMC \u00a0Medicine\u00a016(1):\u00a0110.\u00a0\nHorn\u00a0J,\u00a0Damm\u00a0O,\u00a0Kretzschmar\u00a0M,  Deler\u00e9\u00a0Y,\u00a0Wichmann\u00a0O,\u00a0Kaufmann\u00a0AM\u00a0et\u00a0al.\u00a0(2012).\u00a0Langfristige\u00a0e pidemiologische\u00a0und\u00a0\n\u00f6konomische\u00a0Auswirkungen\u00a0der\u00a0HPV\u2010Impfung\u00a0in\u00a0Deutschland\u00a0\u2010\u00a0\u00dcbera rbeiteter\u00a0Abschlussbericht\u00a0im\u00a0Auftrag\u00a0des\u00a0RKI.\u00a0\nhttps://www.rki.de /DE/Content/Infekt/Impfen/Forschungsprojekte/ abgeschlossene_Projekte/HPV\u2010\nImpfung/Abschlussbericht.pdf?__b lob=publicationFile,\u00a0letzter\u00a0Zu griff:\u00a023.01.2019.\u00a0\u00a0\u00a0\nJoura\u00a0EA,\u00a0Giuliano\u00a0AR,\u00a0Iversen\u00a0O\u2010E,\u00a0Bouchard\u00a0C,\u00a0Mao\u00a0C,\u00a0Mehlsen\u00a0 J\u00a0et\u00a0al.\u00a0(2015).\u00a0A\u00a09\u2010valent\u00a0HPV\u00a0vaccine\u00a0against\u00a0infection\u00a0and\u00a0\nintraepithelial\u00a0neoplasia\u00a0in\u00a0women.\u00a0NEJM\u00a0372(8):\u00a0711\u2013723.\u00a0\nKosalaraksa\u00a0P,\u00a0Mehlsen\u00a0J,\u00a0Vesikari\u00a0T,\u00a0Forst\u00e9n\u00a0A,\u00a0Helm\u00a0K,\u00a0Van\u00a0Da mme\u00a0P\u00a0et\u00a0al.\u00a0(2015).\u00a0An\u00a0open\u2010label,\u00a0randomized\u00a0study\u00a0of\u00a0a\u00a09\u2010val ent\u00a0\nhuman\u00a0papillomavirus\u00a0vaccine\u00a0give n\u00a0concomitantly\u00a0with\u00a0diphtheri a,\u00a0tetanus,\u00a0pertussis\u00a0and\u00a0poliomyelitis\u00a0vaccines\u00a0to\u00a0\nhealthy\u00a0adolescents\u00a011\u201015\u00a0years\u00a0of\u00a0age.\u00a0Pediatr\u00a0Infect\u00a0Dis\u00a0J.\u00a03 4(6):\u00a0627\u201034.\u00a0\u00a0\nMoreira\u00a0ED,\u00a0Block\u00a0SL,\u00a0Ferris\u00a0D,\u00a0 Giuliano\u00a0AR,\u00a0Iversen\u00a0OE,\u00a0Joura\u00a0 EA\u00a0et\u00a0al.\u00a0(2016).\u00a0Safety\u00a0Profile\u00a0of\u00a0the\u00a09\u2010Valent\u00a0HPV\u00a0Vaccine:\u00a0A \u00a0\nCombined\u00a0Analysis\u00a0of\u00a07\u00a0Phase\u00a0III\u00a0Clinical\u00a0Trials.\u00a0Pediatrics.\u00a01 38(2):\u00a0e20154387.\u00a0\nNKCH\u00a0\u2013\u00a0Norwegian\u00a0Knowledge\u00a0Centre\u00a0for\u00a0the\u00a0Health\u00a0Services;\u00a0Kunn skapssenteret\u00a0(2015).\u00a0Effect\u00a0of\u00a0HPV\u2010vaccination\u00a0of\u00a0boys,\u00a0No\u00a01\u2013\n2015\u00a0Systematic\u00a0review\u00a0Report. \u00a0\nhttps://www.fhi.no/globalassets/dokumenterfiler/rapporter/2015/ rapport_2015_01_hpv_gutter.pdf,\u00a0letzter\u00a0\nZugriff:\u00a011.07.2019.\u00a0\u00a0\nSchilling\u00a0A,\u00a0Parra\u00a0MM,\u00a0Gutierrez \u00a0M,\u00a0Restrepo\u00a0J,\u00a0Ucros\u00a0S,\u00a0Herrer a\u00a0T\u00a0et\u00a0al.\u00a0(2015).\u00a0Coadministration\u00a0of\u00a0a\u00a09\u2010Valent\u00a0Human\u00a0\nPapillomavirus\u00a0Vaccine\u00a0With\u00a0Menin gococcal\u00a0and\u00a0Tdap\u00a0Vaccines.\u00a0Pe diatrics\u00a0136(3):\u00a0e563\u201072.\u00a0\u00a0\nSTIKO\u00a0\u2013\u00a0St\u00e4ndige\u00a0Impfkommission\u00a0(2017).\u00a0Empfehlungen\u00a0der\u00a0St\u00e4ndi gen\u00a0Impfkommission\u00a0(STIKO)\u00a0am\u00a0Robert\u00a0Koch\u2010Institut.\u00a0Epid\u00a0Bull\u00a0\n34:\u00a0333\u2010\u00a0380.\u00a0\u00a0117\u00a0Van\u00a0Damme\u00a0P,\u00a0Olsson\u00a0SE,\u00a0Block\u00a0S,\u00a0 Castellsague\u00a0X,\u00a0Gray\u00a0GE,\u00a0Herre ra\u00a0T\u00a0et\u00a0al.\u00a0(2015).\u00a0Immunogenicity\u00a0and\u00a0Safety\u00a0of\u00a0a\u00a09\u2010Valent\u00a0HPV \u00a0\nVaccine.\u00a0Pediatrics\u00a0136(1):\u00a0e28\u2013e39.\u00a0\nVan\u00a0Damme\u00a0P,\u00a0Meijer\u00a0CJLM,\u00a0Kieninger\u00a0D,\u00a0Schuyleman\u00a0A,\u00a0Thomas\u00a0S,\u00a0 Luxembourg\u00a0A\u00a0et\u00a0al.\u00a0(2016).\u00a0A\u00a0phase\u00a0III\u00a0clinical\u00a0study\u00a0to\u00a0\ncompare\u00a0the\u00a0immunogenicity\u00a0and\u00a0safety\u00a0of\u00a0the\u00a09\u2010valent\u00a0and\u00a0quadr ivalent\u00a0HPV\u00a0vaccines\u00a0in\u00a0men.\u00a0Vaccine\u00a034(35):\u00a0\n4205\u20104212.\u00a0\u00a0\nVesikari\u00a0T,\u00a0Brodszki\u00a0N,\u00a0van\u00a0Damme\u00a0P,\u00a0Diez\u2010Domingo\u00a0J,\u00a0Icardi\u00a0G,\u00a0 Petersen\u00a0LK\u00a0et\u00a0al.(2015).\u00a0A\u00a0Randomized,\u00a0Double\u2010Blind,\u00a0Phase\u00a0III \u00a0\nStudy\u00a0of\u00a0the\u00a0Immunogenicity\u00a0and\u00a0Safety\u00a0of\u00a0a\u00a09\u2010Valent\u00a0Human\u00a0Papi llomavirus\u00a0L1\u00a0Virus\u2010Like\u00a0 Particle\u00a0Vaccine\u00a0(V503)\u00a0\nVersus\u00a0Gardasil\u00ae\u00a0in\u00a09\u201015\u2010Year\u2010Old \u00a0Girls.\u00a0Pediatr\u00a0Infect\u00a0Dis\u00a0J\u00a03 4(9):\u00a0992\u20108.\u00a0\n\u00a0 \u00a0118\u00a0 Mepolizumab\u00a04.9\nHandelsname:\u00a0Nucala\u00ae\u00a0 \u00a0 \u00a0 Pharm azeutischer\u00a0Unternehmer:\u00a0\u00a0\nIndikation:\u00a0Asthma\u00a0bronchiale\u00a0 \u00a0 GSK\u00a0\nATC\u2010Code:\u00a0R03DX09\u00a0 \u00a0 \u00a0 Markte inf\u00fchrung:\u00a0Februar\u00a02016\u00a0\nDarreichungsform:\u00a0Pul ver\u00a0z.\u00a0Herstellung\u00a0\neiner\u00a0Injektionssuspension\u00a0 \u00a0 DDD:\u00a00,37 \u00a0mg\u00a0P\u00a0s.c.\u00a0 \u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 \u25bc\u00a0\nBewertung \u00a0\nIn\u00a0Deutschland\u00a0steht\u00a0mit\u00a0Mepolizumab\u00a0(Nucala\u00ae)\u00a0seit\u00a0Februar\u00a0201 6\u00a0der\u00a0erste\u00a0Inter\u2010\nleukin\u20105\u2010Inhibitor\u00a0f\u00fcr\u00a0die\u00a0Behandlung\u00a0von\u00a0Patienten\u00a0mit\u00a0schwere m\u00a0Asthma,\u00a0die\u00a0mit\u00a0\nStandardtherapeutika\u00a0nicht\u00a0ausre ichend\u00a0kontrolliert\u00a0werden\u00a0k\u00f6nn en,\u00a0zur\u00a0Verf\u00fc\u2010\ngung.\u00a0Der\u00a0humanisierte\u00a0monoklonale\u00a0Antik\u00f6rper\u00a0bindet\u00a0mit\u00a0hoher\u00a0 Affinit\u00e4t\u00a0und\u00a0\nSpezifit\u00e4t\u00a0an\u00a0Interleukin\u20105\u00a0(IL\u2010 5),\u00a0ein\u00a0Zytokin,\u00a0das\u00a0ma\u00dfgeblich \u00a0die\u00a0Aktivit\u00e4t\u00a0eosino\u2010\nphiler\u00a0Granulozyten\u00a0reguliert.\u00a0Be i\u00a0etwa\u00a050\u00a0%\u00a0der\u00a0Patienten\u00a0mit\u00a0 schwerem\u00a0Asthma\u00a0\nist\u00a0die\u00a0Anzahl\u00a0der\u00a0Eosinophilen\u00a0in\u00a0Blut\u00a0und\u00a0Gewebe\u00a0erh\u00f6ht\u00a0und\u00a0d ient\u00a0daher\u00a0als\u00a0\nBiomarker\u00a0zur\u00a0Ph\u00e4notypisierung\u00a0der\u00a0Erkrankung\u00a0(Fajt\u00a0&\u00a0Wenzel,\u00a02 017).\u00a0Der\u00a0Wirk\u2010\nstoff\u00a0Mepolizumab\u00a0soll\u00a0die\u00a0Bindung \u00a0von\u00a0IL\u20105\u00a0an\u00a0seinen\u00a0Rezeptor\u00a0 verhindern,\u00a0um\u00a0\ndie\u00a0Aktivit\u00e4t\u00a0der\u00a0Eosinophilen\u00a0 zu\u00a0vermindern\u00a0und\u00a0somit\u00a0eine\u00a0bes sere\u00a0Kontrolle\u00a0des\u00a0\nAsthmas\u00a0zu\u00a0erreichen\u00a0(GSK,\u00a02018).\u00a0Mepolizumab\u00a0wird\u00a0im\u00a0Abstand\u00a0v on\u00a0vier\u00a0Wo\u2010\nchen\u00a0subkutan\u00a0in\u00a0den\u00a0Oberarm,\u00a0den\u00a0Oberschenkel\u00a0oder\u00a0die\u00a0Bauchde cke\u00a0injiziert.\u00a0\nDaf\u00fcr\u00a0werden\u00a0100\u00a0mg\u00a0Pulver\u00a0in\u00a01\u00a0ml\u00a0Kochsalzl\u00f6sung\u00a0rekonstituier t.\u00a0Erwachsenen\u00a0\nund\u00a0Kindern\u00a0ab\u00a0zw\u00f6lf\u00a0Jahren\u00a0werden\u00a0100\u00a0mg\u00a0verabreicht.\u00a0Kinder\u00a0a b\u00a0sechs\u00a0Jahren\u00a0\nerhalten\u00a040\u00a0mg\u00a0bzw.\u00a00,4\u00a0ml\u00a0der\u00a0L\u00f6sung,\u00a0was\u00a0einen\u00a0erheblichen\u00a0Ve rwurf\u00a0bedingt.\u00a0\nDas\u00a0Arzneimittel\u00a0ist\u00a0f\u00fcr\u00a0die\u00a0Lan gzeitbehandlung\u00a0bestimmt.\u00a0Die\u00a0N otwendigkeit\u00a0einer\u00a0\nFortsetzung\u00a0der\u00a0Therapie\u00a0sollte\u00a0 mindestens\u00a0einmal\u00a0j\u00e4hrlich,\u00a0auf \u00a0Basis\u00a0der\u00a0\u00e4rztlichen\u00a0\nBeurteilung\u00a0des\u00a0Schweregrades\u00a0der\u00a0Erkrankung\u00a0und\u00a0des\u00a0Ausma\u00dfes\u00a0d er\u00a0Exazerbati\u2010\nonskontrolle\u00a0des\u00a0Patienten,\u00a0\u00fcberpr\u00fcft\u00a0werden\u00a0(GSK,\u00a02018).\u00a0\nDer\u00a0 Wirkstoff\u00a0 durchlief\u00a0 ein\u00a0 zent ralisiertes\u00a0 Zulassungsverfahren \u00a0 und\u00a0 wurde\u00a0 im\u00a0\u00a0\nDezember\u00a02015\u00a0von\u00a0der\u00a0Europ\u00e4ischen\u00a0Kommission\u00a0f\u00fcr\u00a0die\u00a0Zusatzthe rapie\u00a0erwach\u2010\nsener\u00a0Patienten\u00a0mit\u00a0schwerem\u00a0ref rakt\u00e4rem\u00a0eosinophilem\u00a0Asthma\u00a0br onchiale\u00a0zuge\u2010\nlassen\u00a0 (EMA,\u00a0 2015).\u00a0 In\u00a0 einem\u00a0 zweiten\u00a0 Verfahren\u00a0 genehmigte\u00a0 die\u00a0 E urop\u00e4ische\u00a0\nKommission\u00a0die\u00a0Indikationserweite rung\u00a0auf\u00a0Jugendliche\u00a0und\u00a0Kinde r\u00a0ab\u00a0sechs\u00a0Jah\u2010\nren\u00a0(EMA,\u00a02018).\u00a0\u00a0\nF\u00fcr\u00a0das\u00a0erste\u00a0Zulassungsverfahren\u00a0untersuchte\u00a0die\u00a0multizentrisc he,\u00a0doppelblinde,\u00a0\n1:1:1:1\u2010randomisierte,\u00a0placebokontrollierte\u00a0Phase\u2010IIb/IIIa\u2010Stud ie\u00a0DREAM\u00a0(Sponsor:\u00a0\nGSK,\u00a0NCT01000506)\u00a0den\u00a0Effekt\u00a0von\u00a0Mepolizumab\u00a0auf\u00a0die\u00a0H\u00e4ufigkeit \u00a0von\u00a0Exazerba\u2010\ntionen\u00a0bei\u00a0Patienten\u00a0ab\u00a0zw\u00f6lf\u00a0Jahren\u00a0mit\u00a0schwerem\u00a0refrakt\u00e4rem\u00a0A sthma\u00a0und\u00a0dien\u2010\nte\u00a0der\u00a0Dosisfindung.\u00a0616\u00a0Patienten\u00a0wurden\u00a0in\u00a0vier\u00a0Studienarme\u00a0g ruppiert\u00a0und\u00a0119\u00a0erhielten\u00a0alle\u00a0vier\u00a0Wochen\u00a0i.v .\u00a075\u00a0mg,\u00a0250\u00a0mg\u00a0oder\u00a0750\u00a0mg\u00a0Mepol izumab\u00a0oder\u00a0\nPlacebo.\u00a0Als\u00a0Exazerbation\u00a0wurde\u00a0 die\u00a0Verschlimmerung\u00a0des\u00a0Asthmas \u00a0definiert,\u00a0die\u00a0\neine\u00a0mindestens\u00a0dreit\u00e4gige\u00a0Gabe\u00a0von\u00a0systemischen\u00a0oder\u00a0oralen\u00a0Co rticosteroiden\u00a0\n(OCS),\u00a0einen\u00a0Krankenhausaufentha lt\u00a0oder\u00a0eine\u00a0Vorstellung\u00a0in\u00a0der \u00a0Notaufnahme\u00a0\nerforderte.\u00a0Bei\u00a0Patienten,\u00a0die\u00a0bereits\u00a0regelm\u00e4\u00dfig\u00a0mit\u00a0OCS\u00a0behan delt\u00a0werden,\u00a0ent\u2010\nspricht\u00a0die\u00a0Exazerbation\u00a0mindestens\u00a0der\u00a0Verdopplung\u00a0der\u00a0\u00fcbliche n\u00a0OCS\u2010Dosis\u00a0\u00fcber\u00a0\nwenigstens\u00a0 drei\u00a0 Tage\u00a0 (Pavord\u00a0 et\u00a0 al.,\u00a0 2012).\u00a0 Die\u00a0 multizentrische ,\u00a0 doppelblinde,\u00a0\n1:1:1\u2010randomisierte,\u00a0placebokontrollierte\u00a0Phase\u2010III\u2010Studie\u00a0MENS A\u00a0(Sponsor:\u00a0GSK,\u00a0\nNCT\u00a001691521)\u00a0untersuchte\u00a0ebenfalls\u00a0die\u00a0H\u00e4ufigkeit\u00a0von\u00a0Exazerba tionen\u00a0unter\u00a0\nMepolizumab\u00a0im\u00a0Vergleich\u00a0zu\u00a0Placebo.\u00a0Dazu\u00a0wurden\u00a0580\u00a0Patienten\u00a0 ab\u00a0zw\u00f6lf\u00a0Jah\u2010\nren\u00a0mit\u00a0schwerem\u00a0refrakt\u00e4rem\u00a0eosinophilem\u00a0Asthma\u00a0drei\u00a0Gruppen\u00a0z ugewiesen\u00a0\nund\u00a0erhielten\u00a075\u00a0mg\u00a0i.v.\u00a0oder\u00a0100\u00a0mg\u00a0s.c.\u00a0Mepolizumab\u00a0oder\u00a0Plac ebo\u00a0(Ortega\u00a0et\u00a0\nal.,\u00a02014).\u00a0Die\u00a0zusammengefasste\u00a0Analyse\u00a0von\u00a0DREAM\u00a0und\u00a0MENSA\u00a0er gab\u00a0im\u00a0Ver\u2010\ngleich\u00a0zu\u00a0Placebo\u00a0weniger\u00a0Exazerbationen:\u00a01,24\u00a0vs.\u00a02,40\u00a0(RR:\u00a00, 52\u00a0[0,39;\u00a00,69],\u00a0\np\u00a0<\u00a00,001)\u00a0in\u00a0DREAM\u00a0und\u00a00,83\u00a0vs.\u00a01,74\u00a0(RR:\u00a00,39\u00a0[0,18;\u00a00,83],\u00a0p \u00a0<\u00a00,001)\u00a0in\u00a0MENSA\u00a0\n(EMA,\u00a02015).\u00a0Schwerpunkt\u00a0der\u00a0multizentrischen,\u00a0doppelblinden,\u00a01 :1\u2010randomisier\u2010\nten,\u00a0placebokontrollierten\u00a0Phase \u2010III\u2010Studie\u00a0SIRIUS\u00a0(Sponsor:\u00a0GS K,\u00a0NCT01691521)\u00a0\n(Bel\u00a0et\u00a0al.,\u00a02014)\u00a0war\u00a0die\u00a0OCS\u2010Dosisreduktion\u00a0unter\u00a0Mepolizumab \u00a0im\u00a0Vergleich\u00a0zu\u00a0\nPlacebo.\u00a0135\u00a0Patienten\u00a0wurden\u00a0in\u00a0zwei\u00a0Studienarme\u00a0randomisiert\u00a0 und\u00a0erhielten\u00a0\n\u00fcber\u00a020\u00a0Wochen\u00a0s.c.\u00a0100\u00a0mg\u00a0Mepolizumab\u00a0oder\u00a0Placebo.\u00a0Vor\u00a0Behand lungsbeginn\u00a0\nwurden\u00a0die\u00a0Patienten\u00a0innerhalb\u00a0einer\u00a0drei\u2010\u00a0bis\u00a0achtw\u00f6chigen\u00a0Opt imierungsphase\u00a0\nauf\u00a0die\u00a0minimal\u00a0erforderliche\u00a0OCS\u2010Dosis\u00a0eingestellt,\u00a0die\u00a0ausrei chte,\u00a0um\u00a0die\u00a0Erkran\u2010\nkung\u00a0zu\u00a0kontrollieren.\u00a064\u00a0%\u00a0der\u00a0 mit\u00a0Mepolizumab\u00a0behandelten\u00a0Pat ienten\u00a0konnten\u00a0\ndie\u00a0OCS\u2010Einnahme\u00a0reduzieren\u00a0gege n\u00fcber\u00a044\u00a0%\u00a0im\u00a0Placebo\u2010Arm\u00a0(OR:\u00a0 2,39\u00a0[1,25,\u00a0\n4,56],\u00a0p\u00a0=\u00a00,08).\u00a0Als\u00a0besonders\u00a0r elevant\u00a0stufte\u00a0der\u00a0CHMP\u00a0ein,\u00a0d ass\u00a0unter\u00a0Mepoli\u2010\nzumab\u00a0mehr\u00a0Patienten\u00a0eine\u00a0OCS\u2010Reduktion\u00a0auf\u00a0h\u00f6chstens\u00a05\u00a0mg\u00a0t\u00e4gl ich\u00a0erreichten\u00a0\nals\u00a0unter\u00a0Placebo\u00a0(54\u00a0%\u00a0vs.\u00a032\u00a0%).\u00a0Mit\u00a0dem\u00a0Unterschreiten\u00a0der\u00a0r elativen\u00a0Cushing\u2010\nSchwelle\u00a0(7,5\u00a0mg\u00a0Prednisolon\u00a0pro\u00a0Tag)\u00a0wird\u00a0f\u00fcr\u00a0die\u00a0OCS\u2010Therapie \u00a0eine\u00a0bessere\u00a0\nLangzeitvertr\u00e4glichkei t\u00a0angenommen.\u00a0Die\u00a0Analyse\u00a0des\u00a0Sicherheits profils\u00a0erfolgte\u00a0\nim\u00a0 Europ\u00e4ischen\u00a0 Beurteilungsbericht\u00a0 auf\u00a0 Basis\u00a0 der\u00a0 zusammengefas sten\u00a0 Daten\u00a0\nrelevanter\u00a0Phase\u00a0III\u2010Studien.\u00a0Uner w\u00fcnschte\u00a0Arzneimittelereignis se\u00a0(UAE)\u00a0waren\u00a0\nunter\u00a0Mepolizumab\u00a0\u00e4hnlich\u00a0h\u00e4ufig\u00a0wie\u00a0unter\u00a0Placebo,\u00a082\u00a0%\u00a0gegen\u00fc ber\u00a079\u00a0%\u00a0unter\u00a0\n100\u00a0mg\u00a0 s.c.\u00a0 Mepolizumab.\u00a0 Am\u00a0 h\u00e4ufigsten\u00a0 traten\u00a0 Kopfschmerzen\u00a0 (20 \u00a0%)\u00a0 und\u00a0\nNasopharyngitis\u00a0(16\u00a0%)\u00a0auf.\u00a0Die\u00a0In zidenz\u00a0von\u00a0schwerwiegenden\u00a0UA E\u00a0war\u00a0bei\u00a0Pati\u2010\nenten,\u00a0die\u00a0100\u00a0mg\u00a0s.c.\u00a0Mepolizumab\u00a0erhielten,\u00a0mit\u00a06\u00a0%\u00a0geringer\u00a0 als\u00a0unter\u00a0Placebo\u00a0\nmit\u00a015\u00a0%.\u00a0\nF\u00fcr\u00a0 den\u00a0 Wirksamkeitsnachweis\u00a0 bei\u00a0 Kindern\u00a0 und\u00a0 Jugendlichen\u00a0 ab\u00a0 se chs\u00a0 Jahren\u00a0\nwurden\u00a0im\u00a0Wesentlichen\u00a0extrapolierte\u00a0Daten\u00a0von\u00a0erwachsenen\u00a0Pati enten\u00a0heran\u2010\ngezogen.\u00a0Der\u00a0CHMP\u00a0stimmte\u00a0diesem\u00a0Vorgehen\u00a0vor\u00a0dem\u00a0Hintergrund\u00a0d er\u00a0geringen\u00a0\nInzidenz\u00a0von\u00a0schwerem\u00a0refrakt\u00e4rem\u00a0eosinophilem\u00a0Asthma\u00a0in\u00a0dieser \u00a0Patientenpo\u2010120\u00a0pulation\u00a0von\u00a0weniger\u00a0als\u00a01\u00a0%\u00a0zu.\u00a0Der\u00a0pU\u00a0legte\u00a0die\u00a0Daten\u00a0der\u00a0Tei lnehmer\u00a0zwischen\u00a0\nsechs\u00a0und\u00a017\u00a0Jahren\u00a0aus\u00a0den\u00a0Studien\u00a0MENSA\u00a0(n\u00a0=\u00a025)\u00a0und\u00a0MUSCA\u00a0(n \u00a0=\u00a09)\u00a0vor.\u00a0Die\u00a0\nplacebokontrollierte,\u00a0 1:1\u2010randomisierte,\u00a0 doppelblinde\u00a0 Phase\u2010III \u2010Studie\u00a0 MUSCA\u00a0\n(Sponsor:\u00a0 GSK,\u00a0 NCT02281318)\u00a0 adre ssierte\u00a0 551\u00a0 Patienten\u00a0 ab\u00a0 zw\u00f6lf\u00a0 Jahren\u00a0 mit\u00a0\nschwerem\u00a0refrakt\u00e4rem\u00a0eosinophilem\u00a0Asthma,\u00a0die\u00a0alle\u00a0vier\u00a0Wochen\u00a0 100\u00a0mg\u00a0Mepo\u2010\nlizumab\u00a0s.c.\u00a0erhielten.\u00a0Gem\u00e4\u00df\u00a0Studienprotokoll\u00a0erhielten\u00a0die\u00a0Pa tienten\u00a0hochdo\u2010\nsierte\u00a0inhalative\u00a0Corticosteroide\u00a0( Inhaled\u00a0Corticosteroids ,\u00a0ICS)\u00a0und\u00a0mindestens\u00a0eine\u00a0\nweitere\u00a0Kontrollmedikation\u00a0(Chupp\u00a0et\u00a0al.,\u00a02017).\u00a0Prim\u00e4rer\u00a0Endpu nkt\u00a0der\u00a0Studie\u00a0\nwar\u00a0der\u00a0Effekt\u00a0auf\u00a0die\u00a0HRQoL ,\u00a0der\u00a0mittels\u00a0Fragebogen\u00a0( St.\u00a0George's\u00a0Respiratory\u00a0\nQuestionnaire ,\u00a0SGRQ)\u00a0erfasst\u00a0wurde.\u00a0Die\u00a0differ enzierte\u00a0Analyse\u00a0zeigte\u00a0f\u00fcr\u00a0Pa tien\u2010\nten\u00a0zwischen\u00a0zw\u00f6lf\u00a0und\u00a017\u00a0Jahren\u00a0eine\u00a040\u00a0%ige\u00a0Reduktion\u00a0(RR:\u00a00, 6\u00a0[0,17;\u00a02,10])\u00a0\nklinisch\u00a0 relevanter\u00a0Exazerbation en\u00a0gegen\u00fcber\u00a050\u00a0%\u00a0bei\u00a0Erwachsen en\u00a0(RR: \u00a00,46\u00a0\n[0,38;\u00a00,56]).\u00a0F\u00fcr\u00a0die\u00a0Altersgruppe\u00a0sechs\u00a0bis\u00a0elf\u00a0Jahre\u00a0beschr\u00e4 nkt\u00a0sich\u00a0die\u00a0Evidenz\u00a0\nauf\u00a0die\u00a0Studie\u00a0200363\u00a0(Sponsor:\u00a0GSK,\u00a0NCT\u00a002377427),\u00a0eine\u00a0einarm ige,\u00a0offene\u00a0Pha\u2010\nse\u2010II\u2010Studie\u00a0mit\u00a040\u00a0mg\u00a0oder\u00a0100\u00a0mg\u00a0s.c.\u00a0Mepolizumab,\u00a0die\u00a036\u00a0Kin der\u00a0mit\u00a0schwerem\u00a0\neosinophilem\u00a0Asthma\u00a0im\u00a0Alter\u00a0von\u00a0sechs\u00a0bis\u00a0elf\u00a0Jahren\u00a0untersuch te.\u00a0Die\u00a0Kinder\u00a0\nerhielten\u00a0zu\u00a0Studienbeginn\u00a0mitte l\u2010\u00a0oder\u00a0hochdosierte\u00a0ICS\u00a0und\u00a0mi ndestens\u00a0eine\u00a0\nBegleitmedikation\u00a0 (ClinicalTrails.gov,\u00a0 2018).\u00a0 Die\u00a0 Studie\u00a0 zielte \u00a0 jedoch\u00a0 nicht\u00a0 auf\u00a0\neinen\u00a0Wirksamkeitsvergleich,\u00a0sondern\u00a0fokussierte\u00a0pharmakokineti sche\u00a0und\u00a0phar\u2010\nmakodynamische\u00a0Aspekte\u00a0sowie\u00a0die \u00a0Vertr\u00e4glichkeit\u00a0von\u00a0Mepolizuma b.\u00a0Sekund\u00e4rer\u00a0\nEndpunkt\u00a0 war\u00a0 die\u00a0 Asthmakontrolle,\u00a0 die\u00a0 mit\u00a0 den\u00a0 Fragenb\u00f6gen\u00a0 ACQ\u20107 \u00a0(Asthma\u00a0\nControl\u00a0Questionnaire\u20107 )\u00a0und\u00a0ACQ\u20105\u00a0bestimmt\u00a0wurde.\u00a0Die\u00a0Auswertung\u00a0zeigte\u00a0zum\u00a0\nEnde\u00a0der\u00a0zw\u00f6lfw\u00f6chigen\u00a0Behandlun gsphase\u00a0bei\u00a048\u00a0%\u00a0(ACQ\u20107)\u00a0bzw.\u00a05 5\u00a0%\u00a0(ACQ\u20105)\u00a0\nder\u00a0Kinder\u00a0die\u00a0als\u00a0minimal\u00a0klinis ch\u00a0relevant\u00a0definierte\u00a0Verbess erung\u00a0um\u00a0mindes\u2010\ntens\u00a00,5\u00a0Punkte.\u00a0Dieses\u00a0Ergebnis\u00a0entspricht\u00a0den\u00a0Effekten,\u00a0die\u00a0b ei\u00a0den\u00a0erwachsenen\u00a0\nStudienteilnehmern\u00a0beobachtet\u00a0wurden.\u00a0In\u00a0MENSA\u00a0verbesserten\u00a063\u00a0 %\u00a0der\u00a0Patien\u2010\nten\u00a0unter\u00a0Mepolizumab\u00a0zwischen\u00a012\u00a0und\u00a017\u00a0Jahren\u00a0und\u00a052\u00a0%\u00a0der\u00a0Er wachsenen\u00a0\nden\u00a0ACQ\u20105\u2010 Score\u00a0um\u00a0mindestens\u00a00,5\u00a0Punkte.\u00a0Bei\u00a0den\u00a0Teilnehmern,\u00a0die\u00a0Placebo\u00a0\nerhielten,\u00a0betrug\u00a0der\u00a0Anteil\u00a044\u00a0%\u00a0bei\u00a0den\u00a0jugendlichen\u00a0und\u00a046\u00a0% \u00a0bei\u00a0den\u00a0erwach\u2010\nsenen\u00a0Patienten.\u00a0Die\u00a0differenzierte\u00a0Auswertung\u00a0nach\u00a0eingesetzte r\u00a0Dosis\u00a0zeigt,\u00a0dass\u00a0\nPatienten\u00a0mit\u00a040\u00a0mg\u00a0Mepolizumab\u00a0 in\u00a0gr\u00f6\u00dferem\u00a0Ausma\u00df\u00a0profitierten \u00a0als\u00a0Patienten\u00a0\nmit\u00a0100\u00a0mg\u00a0Mepolizumab.\u00a061\u00a0%\u00a0der\u00a0Teilnehmer\u00a0unter\u00a040\u00a0kg\u00a0KG\u00a0verb esserten\u00a0den\u00a0\nACQ\u20105\u2010Score\u00a0um\u00a0mindestens\u00a00,5\u00a0Punkte,\u00a0bei\u00a0Teilnehmern\u00a0mit\u00a0mindestens\u00a040\u00a0kg \u00a0KG\u00a0\nhingegen\u00a0nur\u00a040\u00a0%,\u00a0\u00e4hnlich\u00a0wie\u00a0in\u00a0der\u00a0Placebo\u2010Gruppe.\u00a0Die\u00a0Studi e\u00a0200363\u00a0war\u00a0\nnicht\u00a0geeignet,\u00a0den\u00a0Endpunkt\u00a0Exazerbationen\u00a0zu\u00a0bestimmen.\u00a0Im\u00a0EP AR\u00a0wird\u00a0der\u00a0\nbesondere\u00a0therapeutische\u00a0Bedarf\u00a0betont,\u00a0Strategien\u00a0zu\u00a0entwickel n,\u00a0um\u00a0die\u00a0Ein\u2010\nnahme\u00a0der\u00a0OCS\u00a0zu\u00a0reduzieren.\u00a0Aktuell\u00a0ist\u00a0die\u00a0Datenlage\u00a0zur\u00a0Wirk samkeit\u00a0von\u00a0Me\u2010\npolizumab\u00a0bei\u00a0Kindern\u00a0als\u00a0unz ureichend\u00a0zu\u00a0bezeichnen.\u00a0\nDen\u00a0therapeutischen\u00a0Stellenwert\u00a0von\u00a0Mepolizumab\u00a0und\u00a0anderen\u00a0IL\u2010 5\u2010Antik\u00f6rpern\u00a0\nsieht\u00a0die\u00a0aktuelle\u00a0NVL\u00a0Asthma\u00a0in \u00a0der\u00a0Behandlung\u00a0von\u00a0erwachsenen \u00a0Patienten\u00a0mit\u00a0121\u00a0schwerem\u00a0eosinophilem\u00a0Asthma\u00a0der\u00a0Stufe\u00a05.\u00a0Nach\u00a0den\u00a0Ergebnissen\u00a0 von\u00a0Corren\u00a0\nund\u00a0Kollegen\u00a0fordern\u00a0die\u00a0Autoren\u00a0eine\u00a0Eosinophilen\u2010Konzentratio n\u00a0von\u00a0mindes\u2010\ntens\u00a0300/\u00b5l\u00a0Blut\u00a0(AWMF,\u00a02018).\u00a0\nAm\u00a021.\u00a0Juli\u00a02016\u00a0schloss\u00a0der\u00a0G\u2010BA\u00a0das\u00a0erste\u00a0Nutzenbewertungsver fahren\u00a0nach\u00a0\u00a7\u00a035\u00a0a\u00a0\nSGB\u00a0V\u00a0\u00fcber\u00a0Mepolizumab\u00a0ab.\u00a0Als\u00a0zVT\u00a0wurde\u00a0f\u00fcr\u00a0die\u00a0Anwendung\u00a0bei\u00a0 Erwachsenen\u00a0mit\u00a0\nschwerem\u00a0refrakt\u00e4rem\u00a0eosinophilem\u00a0Asthma\u00a0eine\u00a0patientenindividu elle\u00a0Therapie\u2010\neskalation\u00a0mit\u00a0mittel\u2010\u00a0bis\u00a0hochdosierten\u00a0ICS\u00a0und\u00a0langwirksamen\u00a0 Bronchodilatatoren\u00a0\n(LABA)\u00a0definiert.\u00a0Auch\u00a0die\u00a0zus\u00e4tzliche\u00a0Behandlung\u00a0mit\u00a0Tiotropiu m\u00a0oder\u00a0mit\u00a0m\u00f6glichst\u00a0\nniedrig\u00a0dosierten\u00a0OCS,\u00a0auch\u00a0in\u00a0Kombination\u00a0mit\u00a0Omalizumab,\u00a0war\u00a0 vorgesehen.\u00a0Einen\u00a0\nAnhaltspunkt\u00a0f\u00fcr\u00a0einen\u00a0geringen\u00a0Zusatznutzen \u00a0stellte\u00a0der\u00a0G\u2010BA\u00a0f\u00fcr\u00a0Patienten\u00a0fest,\u00a0\ndie\u00a0OCS\u00a0als\u00a0regelm\u00e4\u00dfige\u00a0Zusatztherapie\u00a0erhalten.\u00a0Ausschlaggeben d\u00a0waren\u00a0die\u00a0Ergeb\u2010\nnisse\u00a0der\u00a0OCS\u2010Reduktions\u2010Studie\u00a0SIRIUS,\u00a0die\u00a0zeigte,\u00a0dass\u00a0mehr\u00a0P atienten\u00a0unter\u00a0Me\u2010\npolizumab\u00a0als\u00a0unter\u00a0Placebo\u00a0die\u00a0t\u00e4gliche\u00a0Einnahme\u00a0auf\u00a0maximal\u00a05 \u00a0mg/Tag\u00a0Predniso\u2010\nlon\u00a0reduzieren\u00a0konnten.\u00a0Patienten,\u00a0die\u00a0nicht\u00a0oder\u00a0nur\u00a0im\u00a0Rahmen \u00a0akuter\u00a0Exazerbati\u2010\nonen\u00a0mit\u00a0OCS\u00a0behandelt\u00a0werden,\u00a0wurden\u00a0in\u00a0SIRIUS\u00a0nicht\u00a0ber\u00fccksic htigt.\u00a0Da\u00a0der\u00a0pU\u00a0\nf\u00fcr\u00a0diese\u00a0Patienten\u00a0keine\u00a0geeigneten\u00a0Studien\u00a0vorlegte,\u00a0gilt\u00a0der \u00a0Zusatznutzen \u00a0als\u00a0nicht\u00a0\nbelegt\u00a0(G\u2010BA,\u00a02016b).\u00a0In\u00a0einem\u00a0zweiten\u00a0Verfahren\u00a0beurteilte\u00a0der\u00a0G\u2010BA\u00a0 den\u00a0Zusatz\u2010\nnutzen\u00a0f\u00fcr\u00a0die\u00a0Behandlung\u00a0von\u00a0 Kindern\u00a0und\u00a0Jugendlichen\u00a0ab\u00a0sechs\u00a0Jahren .\u00a0Der\u00a0pU\u00a0\nlegte\u00a0in\u00a0diesem\u00a0Zusammenhang\u00a0keine\u00a0geeigneten\u00a0Daten\u00a0vor,\u00a0so\u00a0das s\u00a0der\u00a0G\u2010BA\u00a0 kei\u2010\nnen\u00a0Beleg\u00a0f\u00fcr\u00a0einen\u00a0Zusatznutzen\u00a0 identifizierte\u00a0(G\u2010BA,\u00a02019).\u00a0\nVerf\u00fcgbare\u00a0Therapien \u00a0 (Zusatz\u2010)Nutzen \u00a0 Kosten\u00a0\n\u00a0\nerster\u00a0zielgerichteter\u00a0\nimmunologischer\u00a0\nBehandlungsansatz\u00a0bei\u00a0\neosinophilem\u00a0Asthma\u00a0\u00a0Anhaltspunkt\u00a0f\u00fcr\u00a0geringen\u00a0\nZusatznutzen\u00a0nur\u00a0belegt\u00a0\nf\u00fcr\u00a0erwachsene\u00a0Patienten,\u00a0\ndie\u00a0regelm\u00e4\u00dfig\u00a0OCS\u00a0\nanwenden,\u00a0direkt\u00a0\nvergleichende\u00a0Studien\u00a0\nfehlen,\u00a0insbes.\u00a0bei\u00a0Kindern\u00a0\nlimitierte\u00a0Evidenz\u00a0\u00a0\nteurer\u00a0als\u00a0zVT\u00a0mit\u00a0\nICS/LABA/LAMA,teils\u00a0\ng\u00fcnstiger\u00a0als\u00a0Omalizumab,\u00a0\ndas\u00a0f\u00fcr\u00a0etwa\u00a0ein\u00a0Drittel\u00a0\nder\u00a0Patienten\u00a0im\u00a0 label\u00a0\ninfrage\u00a0kommt,\u00a0bei\u00a0\nBehandlung\u00a0von\u00a0Kindern\u00a0\n\u22656\u00a0\u2013\u00a0<12\u00a0Jahre\u00a0hoher\u00a0\nVerwurf\u00a0von\u00a060\u00a0%\u00a0\u00a0\n\u00a0\nErl\u00e4uterung\u00a0der\u00a0Farben:\u00a0Verf\u00fcgbare\u00a0Therapien:\u00a0rot\u00a0=\u00a0weitere\u00a0The rapieoption,\u00a0gelb\u00a0=\u00a0Subgruppen\u2010Novit\u00e4t,\u00a0gr\u00fcn\u00a0=\u00a0Solist;\u00a0(Zusatz\u2010 )\u00a0\nNutzen:\u00a0rot\u00a0=\u00a0keine\u00a0Verbesserung\u00a0oder\u00a0schlechte\u00a0Nutzen/Schaden\u2010 Relation,\u00a0gelb\u00a0=\u00a0teilweise\u00a0Verbesserungen,\u00a0gr\u00fcn\u00a0=\u00a0Verbesserung\u00a0\nharter\u00a0Endpunkte;\u00a0Kosten:\u00a0rot\u00a0=\u00a0teurer\u00a0als\u00a0bestehende\u00a0Therapien ,\u00a0gelb\u00a0=\u00a0ungef\u00e4hr\u00a0gleich\u00a0bzw.\u00a0teils/teils,\u00a0gr\u00fcn\u00a0=\u00a0g\u00fcnstiger\u00a0als \u00a0\nbestehende\u00a0Therapien\u00a0\nWie\u00a0bewerten\u00a0andere?\u00a0\nBewertung\u00a0nach\u00a0\nFricke\u00a0et\u00a0al.\u00a0a\u2010t\u2010Bewertung\u00a0 AMB\u00a0 Prescrire\u00a0 PZ\u00a0\nA\u00a0Mittel\u00a0der\u00a0Reserve\u00a0\nmit\u00a0\nEinschr\u00e4nkungen\u00a0\u00a0Nach\u00a0der\u00a0NVL\u00a0\nAsthma:\u00a0\u00a0\nerst\u00a0in\u00a0letzter\u00a0\nTherapiestufe\u00a0\u00a0\nempfohlen\u00a0Not\u00a0acceptable\u00a0\nnow\u00a0under\u00a0re\u2010\nexamination\u00a0Sprunginnovation\u00a0\n122\u00a0Kosten\u00a0\nWirkstoff\u00a0 Behandlungsmodus\u00a0 Behandlungstage\u00a0 Jahrestherapiekosten\u00a0\nzu\u00a0bewertendes\u00a0Arzneimittel \u00a0 \u00a0 \u00a0\nMepolizumab\u00a0 100\u00a0mg\u00a01x\u00a0alle\u00a04\u00a0Wochen\u00a0\n1x\u00a040\u00a0mg\u00a0\u22656\u00a0\u2013\u00a0<12\u00a0Jahre/\u00a0\n100\u00a0mg\u00a0\u226512\u00a0\u2013\u00a0\n<18\u00a0Jahre\u00a0alle\u00a04\u00a0Wochen\u00a013\u00a0 16.264,99\u00a0\u20ac\u00a0\nICS\u00a0+\u00a0LABA\u00a0 \u00a0 \u00a0 \u00a0\nMittel\u2010\u00a0bis\u00a0hoch\u00a0dosierte\u00a0ICS\u00a0 \u00a0 \u00a0 \u00a0\nBudesonid\u00a0 400\u00a0\u2013\u00a0800\u00a0\u00b5g\u00a01x\u00a0tgl.\u00a0 365\u00a0 67,45\u00a0\u2013\u00a0134,90\u00a0\u20ac\u00a0\nLABA\u00a0 \u00a0 \u00a0 \u00a0\nFormoterol\u00a0 24\u00a0\u2013\u00a048\u00a0\u00b5g1\u00a01x\u00a0tgl.\u00a0\n12\u00a0\u00b5g2\u00a02x\u00a0tgl.\u00a0365\u00a0 250,92\u00a0\u2013\u00a0501,83\u00a0\u20ac\u00a0\n250,\u00a092\u00a0\u20ac\u00a0\nICS+LABA\u00a0Fixkombination\u00a0\u00a0 \u00a0 \u00a0 \u00a0\nFluticason/Vilanterol1\u00a092/22\u00a0\u00b5g\u00a01x\u00a0tgl.\u00a0oder\u00a0\n184/22\u00a0\u00b5g\u00a0365\u00a0 425,79\u00a0\u2013\u00a0555,98\u00a0\u20ac\u00a0\nFluticason/Salmeterol2\u00a050/100\u00a0\u00b5g\u00a02x\u00a0tgl.\u00a0oder\u00a0\n50/250\u00a0\u00b5g\u00a0oder\u00a050/500\u00a0\u00b5g\u00a0365\u00a0 318,24\u00a0\u2013\u00a0502,08\u00a0\u20ac\u00a0\nOCS1\u00a0\u00a0 \u00a0 \u00a0\nPrednison\u00a0 5\u00a0\u2013\u00a015\u00a0mg1\u00a01x\u00a0tgl.\u00a0patientenindividuell\u00a0 59,53\u00a0\u2013\u00a0144,43\u00a0\u20ac\u00a0\nPrednisolon\u00a0 5\u00a0\u2013\u00a015\u00a0mg1\u00a01x\u00a0tgl.\u00a0 patientenindividuell\u00a0 50,92\u00a0\u2013\u00a0111,69\u00a0\u20ac\u00a0\nLAMA\u00a0 \u00a0 \u00a0 \u00a0\nTiotropium\u00a0\u00a0 5\u00a0\u00b5g\u00a01x\u00a0tgl.\u00a0 365\u00a0 727,00\u00a0\u20ac\u00a0\nzVT\u00a0 \u00a0 \u00a0 \u00a0\nICS\u00a0+\u00a0LABA\u00a0 \u00a0 \u00a0 \u00a0\nMittel\u2010\u00a0bis\u00a0hoch\u00a0dosierte\u00a0ICS\u00a0 \u00a0 \u00a0 \u00a0\nBudesonid\u00a0 400\u00a0\u2013\u00a0800\u00a0\u00b5g\u00a0tgl.\u00a0 365\u00a0 67,45\u00a0\u2013\u00a0134,90\u00a0\u20ac\u00a0\nLABA\u00a0 \u00a0 \u00a0 \u00a0\nFormoterol\u00a0 24\u00a0\u2013\u00a048\u00a0\u00b5g1\u00a0tgl.\u00a0\n12\u00a0\u00b5g2\u00a02x\u00a0tgl.\u00a0365\u00a0 250,92\u00a0\u2013\u00a0501,83\u00a0\u20ac\u00a0\n250,\u00a092\u00a0\u20ac\u00a0\nICS+LABA\u00a0Fixkombination\u00a0\u00a0 \u00a0 \u00a0 \u00a0\nFluticason/Vilanterol1\u00a092/22\u00a0\u00b5g\u00a0oder\u00a0184/22\u00a0\u00b5g\u00a0\n1x\u00a0tgl.\u00a0365\u00a0 425,79\u00a0\u2013\u00a0555,98\u00a0\u20ac\u00a0\nFluticason/Salmeterol2\u00a050/100\u00a0\u00b5g\u00a0oder\u00a050/250\u00a0\u00b5g\u00a0\noder\u00a050/500\u00a0\u00b5g\u00a02x\u00a0tgl.\u00a0365\u00a0 318,24\u00a0\u2013\u00a0502,08\u00a0\u20ac\u00a0\nOCS1\u00a0\u00a0 \u00a0 \u00a0\nPrednison\u00a0 5\u00a0\u2013\u00a015\u00a0mg1\u00a01x\u00a0tgl.\u00a0 patientenindividuell\u00a0 59,53\u00a0\u2013\u00a0144,43\u00a0\u20ac\u00a0\nPrednisolon\u00a0 5\u00a0\u2013\u00a015\u00a0mg1\u00a01x\u00a0tgl.\u00a0 patientenindividuell\u00a0 50,92\u00a0\u2013\u00a0111,69\u00a0\u20ac\u00a0\nLAMA\u00a0 \u00a0 \u00a0 \u00a0\nTiotropium\u00a0\u00a0 5\u00a0\u00b5g\u00a01x\u00a0tgl.\u00a0 365\u00a0 727,00\u00a0\u20ac\u00a0\nIgE\u2010Antik\u00f6rper\u00a0 \u00a0 \u00a0 \u00a0\nOmalizumab3\u00a0 75\u00a0\u2013\u00a0600\u00a0mg\u00a01x\u00a0alle\u00a02\u00a0oder\u00a0\n4\u00a0Wochen\u00a013\u00a0\u2013\u00a026\u00a0 3.486,73\u00a0\u2013\u00a051.2314,34\u00a0\u20ac\u00a0\n1\u00a0Erwachsene\u00a0\n2\u00a0Kinder\u00a0\n3\u00a0Lt.\u00a0Fachinformation\u00a0sollte\u00a0Omal izumab\u00a0nur\u00a0bei\u00a0Patienten\u00a0mit\u00a0Ig E\u2010vermittelten\u00a0Asthma\u00a0eingesetzt\u00a0werden\u00a0\n\u00a0\u00a0123\u00a0Versorgungsanalysen\u00a0\nInnerhalb\u00a0des\u00a0ersten\u00a0Halbjahres\u00a0nach\u00a0Markteintritt\u00a0im\u00a0Februar\u00a02 016\u00a0steigen\u00a0die\u00a0\nVerordnungen\u00a0auf\u00a03.976\u00a0DDD\u00a0im\u00a0Juni\u00a02016\u00a0an.\u00a0Im\u00a0darauffolgenden\u00a0 Monat\u00a0\u00e4ndert\u00a0\nsich\u00a0diese\u00a0Tendenz\u00a0und\u00a0die\u00a0DDD\u00a0sinken\u00a0auf\u00a02.966.\u00a0Historisch\u00a0ist \u00a0diese\u00a0Entwicklung\u00a0\nmit\u00a0dem\u00a0Abschluss\u00a0des\u00a0ersten\u00a0Nutzenbewertungsverfahrens\u00a0des\u00a0G\u2010B A\u00a0assoziiert,\u00a0in\u00a0\ndem\u00a0Mepolizumab\u00a0f\u00fcr\u00a0die\u00a0Anwendung \u00a0bei\u00a0Erwachsenen\u00a0kein\u00a0Zusatznu tzen\u00a0zuer\u2010\nkannt\u00a0wurde\u00a0(G\u2010BA,\u00a02016a).\u00a0Im\u00a0weiteren\u00a0Verlauf\u00a0nehmen\u00a0die\u00a0Veror dnungsvolumi\u2010\nna\u00a0tendenziell\u00a0zu\u00a0und\u00a0erreichen\u00a0 im\u00a0November\u00a02017\u00a0den\u00a0Maximalwer t\u00a0von\u00a010.777\u00a0\nDDD.\u00a0Zum\u00a0Abschluss\u00a0des\u00a0dargestellten\u00a0Zeitraums\u00a0sind\u00a0die\u00a0Verordn ungen\u00a0wieder\u00a0\nr\u00fcckl\u00e4ufig.\u00a0Die\u00a0Bruttoums\u00e4tze\u00a0e rreichen\u00a0im\u00a0November\u00a02016\u00a0das\u00a0Ma ximum\u00a0von\u00a0\n545.472\u00a0\u20ac.\u00a0Die\u00a0Einf\u00fchrung\u00a0des\u00a0Erstattungsbetrages\u00a0zum\u00a015.\u00a0Mai\u00a02 017\u00a0f\u00fchrt\u00a0zu\u00a0\neiner\u00a0Preisreduktion\u00a0von \u00a0im\u00a0Mittel\u00a028\u00a0%\u00a0pro\u00a0DDD.\u00a0\u00a0\nAbbildung\u00a04.8:\u00a0Verordnete\u00a0Tagesdosen\u00a0(DDD)\u00a0und\u00a0Bruttoums\u00e4tze\u00a0vo n\u00a0\u00a0\nMepolizumab\u00a0nach\u00a0Monaten\u00a0(2016\u00a0\u2013\u00a02017)\u00a0\n\u00a0\n\u00a0\u00a0\n124\u00a0Quellen\u00a0\u00a0\nAWMF\u00a0\u2013\u00a0Arbeitsgemeinschaft\u00a0der\u00a0W issenschaftlichen\u00a0Medizinischen \u00a0Fachgesellschaften\u00a0(2018).\u00a0Na tionale\u00a0VersorgungsLeitlinie\u00a0\nAsthma\u00a0.\u00a0https://www.awmf.org/uploads/tx_szleitlinien/nvl\u2010002l_ S3_Asthma_2018\u201009.pdf,\u00a0letzter\u00a0Zugriff:\u00a0\n11.07.2019.\u00a0\nat\u00a0\u2013\u00a0arznei\u2010telegramm\u00a0(2016).\u00a0Neu\u00a0auf\u00a0dem\u00a0Markt:\u00a0Mepolizumab\u00a0(N ucala\u00ae)\u00a0bei\u00a0schwerem\u00a0refrakt\u00e4ren \u00a0eosinophilen\u00a0Asthma.\u00a0arznei\u2010\ntelegramm\u00a047(34).\u00a0\natd\u00a0\u2013\u00a0arznei\u2010telegramm\u00a0(2019).\u00a0Arzneimitteldatenbank\u00a0Wirkstoff: \u00a0Mepolizumab.\u00a0Bewertung.\u00a02019.\u00a0https://www.arznei\u2010\ntelegramm.de/db/0codewkstxt.php3?&knr=&art=mono&nummer=ADBG&ord =uaw,\u00a0letzter\u00a0Zugriff:\u00a027.02.2019.\u00a0\nBel\u00a0EH,\u00a0Wenzel\u00a0SE,\u00a0Thompson\u00a0PJ,\u00a0Prazma\u00a0CM,\u00a0Keene\u00a0O,\u00a0Yancey\u00a0M\u00a0et \u00a0al.\u00a0(2014).\u00a0Oral\u00a0glucocorticoid\u2010 sparing\u00a0effect\u00a0of\u00a0mepolizumab\u00a0\nin\u00a0eosinophilic\u00a0asthma.\u00a0The\u00a0New\u00a0England\u00a0journal\u00a0of\u00a0medicine\u00a0371 (13):\u00a01189\u201097.\u00a0\nChupp\u00a0GL,\u00a0Bradford\u00a0E,\u00a0Albers\u00a0F,\u00a0Bratton\u00a0DJ,\u00a0Wang\u2010Jairaj\u00a0J,\u00a0Nels en\u00a0L\u00a0et\u00a0al.\u00a0(2017).\u00a0Efficacy\u00a0of\u00a0mepolizumab\u00a0add\u2010on\u00a0therapy\u00a0on\u00a0h ealth\u2010\nrelated\u00a0quality\u00a0of\u00a0life\u00a0and\u00a0markers\u00a0of\u00a0asthma\u00a0control\u00a0in\u00a0severe \u00a0eosinophilic\u00a0asthma\u00a0(MUSCA):\u00a0a\u00a0randomised,\u00a0double\u2010\nblind,\u00a0placebo\u2010controlled,\u00a0parallel\u2010group,\u00a0multicentre,\u00a0phase\u00a03 b\u00a0trial.\u00a0The\u00a0Lancet\u00a0Respiratory\u00a0Medicine\u00a05(5).\u00a0\nClinicalTrails.gov\u00a0(201 8).\u00a0Pharmacokinetics\u00a0and\u00a0Pharmacodynamic s\u00a0of\u00a0Mepolizumab\u00a0Administered\u00a0Subcutaneously\u00a0in\u00a0Children\u00a0\u2010\u00a0\nStudy\u00a0Results\u00a0\u2010\u00a0ClinicalTrials.g ov.\u00a02018.\u00a0https://clinicaltrial s.gov/ct2/show/results/NCT02377427,\u00a0letzter\u00a0Zugriff:\u00a0\n11.04.2019.\u00a0\nCorren\u00a0J,\u00a0Weinstein\u00a0S,\u00a0Janka\u00a0L,\u00a0Zangrilli\u00a0J,\u00a0Garin\u00a0M\u00a0(2016).\u00a0Ph ase\u00a03\u00a0Study\u00a0of\u00a0Reslizumab\u00a0in\u00a0Pati ents\u00a0With\u00a0Poorly\u00a0Controlled\u00a0As thma:\u00a0\nEffects\u00a0Across\u00a0a\u00a0Broad\u00a0Range\u00a0of\u00a0Eosinophil\u00a0Counts.\u00a0Chest\u00a0150(4) .\u00a0\nEMA\u00a0\u2013\u00a0European\u00a0Medicines\u00a0Agency\u00a0 (2015).\u00a0European\u00a0Assessment\u00a0Rep ort\u00a0Mepolizumab\u00a0\n(Nucala\u00ae)https://www.ema.europa.eu/documents/assessment\u2010report/ nucala\u2010epar\u2010public\u2010assessment\u2010\nreport_en.pdf,\u00a0letzter\u00a0Zugriff:\u00a011.07.2019.\u00a0\nEMA\u2013\u00a0European\u00a0Medicines\u00a0Agency \u00a0(2018).\u00a0European\u00a0Assessment\u00a0Repo rt\u00a0Mepolozumab\u00a0(Nucala\u00ae)\u00a0Varation.\u00a0\nhttps://www.ema.europa.eu/documents/variation\u2010report/nucala\u2010h\u2010c \u20103860\u2010ii\u20100013\u2010g\u2010epar\u2010assessment\u2010report\u2010\nvariation_en.pdf,\u00a0letzter\u00a0Zugriff:\u00a011.07.2019.\u00a0\nFajt\u00a0ML\u00a0,\u00a0Wenzel\u00a0SE\u00a0(2017).\u00a0Development\u00a0of\u00a0New\u00a0Therapies\u00a0for\u00a0Se vere\u00a0Asthma.\u00a0Allergy,\u00a0asthma\u00a0&\u00a0immunology\u00a0research\u00a09(1).\u00a0\nFDA\u00a0\u2013\u00a0Food\u00a0and\u00a0Drug\u00a0Administration\u00a0(2015).\u00a0Drugs@FDA:\u00a0FDA\u00a0Appro ved\u00a0Drug\u00a0Products.\u00a02015.\u00a0\nhttps://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event =BasicSearch.process,\u00a0letzter\u00a0Zugriff:\u00a015.03.2019.\u00a0\nG\u2010BA\u00a0\u2013\u00a0Gemeinsamer\u00a0Bundesausschuss\u00a0(2016a).\u00a0Beschluss\u00a0des\u00a0Gemei nsamen\u00a0Bundesausschusses\u00a0\u00fcber\u00a0eine\u00a0\u00c4nderung\u00a0der\u00a0\nArzneimittel\u2010Richtlinie\u00a0(AM\u2010RL):\u00a0 Anlage\u00a0XII\u00a0\u2010\u00a0Beschl\u00fcsse\u00a0\u00fcber\u00a0d ie\u00a0Nutzenbewertung\u00a0von\u00a0Arzneimitteln\u00a0mit\u00a0neuen\u00a0\nWirkstoffen\u00a0nach\u00a0\u00a7\u00a035a\u00a0SGB\u00a0V\u00a0\u2013\u00a0Mepolizumab.\u00a0https://www.g\u2010ba.de /downloads/39\u2010261\u20102653/2016\u201007\u201021_AM\u2010RL\u2010\nXII_Mepolizumab_D\u2010211_BAnz.pdf,\u00a0letzter\u00a0Zugriff:\u00a011.07.2019.\u00a0\nG\u2010BA\u00a0\u2013\u00a0Gemeinsamer\u00a0Bundesausschuss\u00a0(2016b).\u00a0Tragende\u00a0Gr\u00fcnde\u00a0zum \u00a0Beschluss\u00a0des\u00a0Gemeinsamen\u00a0 Bundesausschusses\u00a0\u00fcber\u00a0eine\u00a0\n\u00c4nderung\u00a0der\u00a0Arzneimittel\u2010Richtlinie\u00a0(AM\u2010RL):\u00a0Anlage\u00a0XII\u00a0\u2010\u00a0Besc hl\u00fcsse\u00a0\u00fcber\u00a0die\u00a0Nutzenbewertung\u00a0von\u00a0Arzneimitteln\u00a0\nmit\u00a0neuen\u00a0Wirkstoffen\u00a0nach\u00a0\u00a7\u00a035a\u00a0SGB\u00a0V\u00a0\u2010\u00a0Mepolizumab.\u00a0https://w ww.g\u2010ba.de/downloads/40\u2010268\u20103894/2016\u201007\u2010\n21_AM\u2010RL\u2010XII_Mepolizumab_D\u2010211_TrG.pdf,\u00a0letzter\u00a0Zugriff:\u00a027.02. 2019.\u00a0\nG\u2010BA\u00a0\u2013\u00a0Gemeinsamer\u00a0Bundesausschuss\u00a0(2019).\u00a0Tragende\u00a0Gr\u00fcnde\u00a0zum\u00a0 Beschluss\u00a0des\u00a0Gemeinsamen\u00a0 Bundesausschusses\u00a0\u00fcber\u00a0eine\u00a0\n\u00c4nderung\u00a0der\u00a0Arzneimittel\u2010Richtlinie\u00a0(AM\u2010RL):\u00a0Anlage\u00a0XII\u00a0\u2013\u00a0Besc hl\u00fcsse\u00a0\u00fcber\u00a0die\u00a0Nutzenbewertung\u00a0von\u00a0Arzneimitteln\u00a0\nmit\u00a0neuen\u00a0Wirkstoffen\u00a0nach\u00a0\u00a7\u00a035a\u00a0SGB\u00a0V\u00a0\u2013\u00a0Mepolizumab\u00a0(neues\u00a0Anw endungsgebiet:\u00a0Zusatzbehandlung\u00a0bei\u00a0\nschwerem\u00a0refrakt\u00e4rem\u00a0eosinophilem\u00a0Asthma\u00a0bei\u00a0Kindern\u00a0und\u00a0Jugend lichen\u00a0im\u00a0Alter\u00a0von\u00a0\u2265\u00a06\u00a0bis\u00a0<\u00a018\u00a0Jahren).\u00a0\nhttps://www.g\u2010ba.de/downloads/ 39\u2010261\u20103722/2019\u201003\u201022_AM\u2010RL\u2010XII_ Mepolizumab_D\u2010390_BAnz.pdf\u00a0,\u00a0letzter\u00a0\nZugriff:\u00a011.07.2019.\u00a0125\u00a0Fachinformation\u00a0Nucala\u00ae\u00a0(2018).\u00a0Fachinformation\u00a0Nucala\u00ae\u00a0100\u00a0mg\u00a0 Pulver\u00a0zur\u00a0Herstellung\u00a0einer\u00a0Inj ektionsl\u00f6sung,\u00a0letzter\u00a0Zugriff: \u00a0\n27.02.2018.\u00a0\nOrtega\u00a0HG,\u00a0Mark\u00a0C,\u00a0Pavord\u00a0I,\u00a0Brusselle\u00a0GG,\u00a0FitzGerald\u00a0M,\u00a0Chetta \u00a0A\u00a0et\u00a0al.(2014).\u00a0Mepolizumab\u00a0treatment\u00a0in\u00a0patients\u00a0with\u00a0severe\u00a0\neosinophilic\u00a0asthma.\u00a0The\u00a0New\u00a0Engla nd\u00a0journal\u00a0of\u00a0medicine\u00a0371(13 ),\u00a01198\u2010207.\u00a0\nPavord\u00a0ID,\u00a0Korn\u00a0S,\u00a0Howarth\u00a0P,\u00a0Bleecker\u00a0E,\u00a0Buhl\u00a0R,\u00a0Keene\u00a0O\u00a0et\u00a0al .\u00a0(2012).\u00a0Mepolizumab\u00a0for\u00a0severe\u00a0eosinophilic\u00a0asthma\u00a0(DREAM):\u00a0a \u00a0\nmulticentre,\u00a0double\u2010blind,\u00a0place bo\u2010controlled\u00a0trial.\u00a0The\u00a0Lancet \u00a0380(9842),\u00a0651\u20109.\u00a0\nPrescrire\u00a0Int.\u00a0(2017).\u00a0Mepolizumab\u00a0in\u00a0asthma.\u00a0Another\u00a0poorly\u00a0ef fective\u00a0immunosuppressant.\u00a0Prescrire\u00a0International\u00a026(179).\u00a0\nPrescrire\u00a0Int.\u00a0(2018).\u00a0Notable\u00a0changes\u00a0in\u00a0the\u00a02018\u00a0update.\u00a0Pres crire\u00a0International\u00a027(192).\u00a0\nPZ\u00a0\u2013\u00a0Pharmazeutische\u00a0Zeitung\u00a0(2016).\u00a0Arzneistoffe.\u00a0Mepolizumab\u00a0 Nucala\u00ae.\u00a02016.\u00a0https://www.pharmazeutische\u2010\nzeitung.de/arzneistoffe/daten/2016/mepolizumabnucalar282016/,\u00a0l etzter\u00a0Zugriff:\u00a028.02.2019.\u00a0\nSchwabe\u00a0U,\u00a0Paffrath\u00a0D,\u00a0Ludwig\u00a0W\u2010D,\u00a0Klauber\u00a0J\u00a0(2017).\u00a0Arzneivero rdnungs\u2010Report\u00a02017.\u00a0Berlin,\u00a0Heidelberg:\u00a0Springer\u00a0Berlin\u00a0Heidel berg:\u00a0\n55\u2010136.\u00a0\n\u00a0 \u00a0126\u00a0 Migalastat\u00a04.10\nHandelsname:\u00a0Galafold\u00ae\u00a0 \u00a0 \u00a0 Pha rmazeutischer\u00a0Unternehmer:\u00a0\u00a0\nIndikation:\u00a0Morbus\u00a0Fabry\u00a0 \u00a0 \u00a0 Amicus\u00a0Therapeutics\u00a0\nATC\u2010Code:\u00a0A16AX14\u00a0 \u00a0 \u00a0 Markteinf\u00fchrung:\u00a0Juni\u00a02016\u00a0\nDarreichungsform:\u00a0Hartkapseln\u00a0 \u00a0 DDD:\u00a061,5 \u00a0mg\u00a0O\u00a0 \u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0O,\u00a0 \u25bc\u00a0\nBewertung \u00a0\nMigalastat\u00a0 (Galafold\u00ae)\u00a0 wurde\u00a0 im\u00a0 Mai\u00a0 2016\u00a0 von\u00a0 der\u00a0 Europ\u00e4ischen\u00a0 K ommission\u00a0\nzentral\u00a0als\u00a0 Orphan\u2010Arzneimittel\u00a0f\u00fcr\u00a0die\u00a0Dauerbehandlung\u00a0von\u00a0Erwachsenen\u00a0und\u00a0\nJugendlichen\u00a0ab\u00a016\u00a0Jahren\u00a0mit\u00a0gesicherter\u00a0Morbus\u2010Fabry\u2010Diagnose \u00a0zugelassen,\u00a0bei\u00a0\ndenen\u00a0eine\u00a0Mutation\u00a0vorliegt,\u00a0die\u00a0auf\u00a0die\u00a0Behandlung\u00a0mit\u00a0Migala stat\u00a0anspricht.\u00a0F\u00fcr\u00a0\ndiese\u00a0Indikation\u00a0ist\u00a0Migalastat\u00a0 die\u00a0erste\u00a0orale\u00a0Therapieoption. \u00a0\nDie\u00a0Symptome\u00a0bei\u00a0Menschen\u00a0mit\u00a0Morbus\u00a0Fabry\u00a0entstehen\u00a0durch\u00a0eine n\u00a0Mangel\u00a0\nbzw.\u00a0unzureichende\u00a0Aktivit\u00e4t\u00a0des\u00a0Enzyms\u00a0\u03b1\u2010Galaktosidase\u00a0A\u00a0(GLA) ,\u00a0das\u00a0f\u00fcr\u00a0den\u00a0\nAbbau\u00a0von\u00a0Globotriaosylzeramid\u00a0(GL\u20103)\u00a0verantwortlich\u00a0ist.\u00a0Migal astat\u00a0stabilisiert\u00a0\nGLA\u00a0und\u00a0erh\u00f6ht\u00a0so\u00a0dessen\u00a0Aktivit\u00e4t.\u00a0\u00a0\nDie\u00a0Dosierung\u00a0liegt\u00a0bei\u00a0123\u00a0mg\u00a0Wirkstoff\u00a0in\u00a0einer\u00a0Hartkapsel,\u00a0d ie\u00a0die\u00a0Patienten\u00a0\njeden\u00a0zweiten\u00a0Tag\u00a0im\u00a0Ganzen\u00a0einnehmen.\u00a0Da\u00a0die\u00a0Resorption\u00a0durch\u00a0 gleichzeitige\u00a0\nNahrungsaufnahme\u00a0verringert\u00a0wird,\u00a0sollte\u00a0die\u00a0Einnahme\u00a0zwei\u00a0Stun den\u00a0vor\u00a0und\u00a0\nzwei\u00a0Stunden\u00a0nach\u00a0einer\u00a0Mahlzeit\u00a0erfolgen\u00a0(EMA,\u00a02016;\u00a02018).\u00a0\u00a0\nDer\u00a0Zulassung\u00a0liegen\u00a0zwei\u00a0pivotal e,\u00a0randomisierte\u00a0Phase\u2010III\u2010Stu dien\u00a0zugrunde,\u00a0an\u00a0\ndenen\u00a0Patienten\u00a0\u00fcber\u00a016\u00a0Jahre\u00a0mit \u00a0best\u00e4tigter\u00a0Morbus\u2010Fabry\u2010Diag nose\u00a0teilnah\u2010\nmen,\u00a0deren\u00a0Mutationen\u00a0im\u00a0GLA\u2010Gen\u00a0auf\u00a0eine\u00a0Behandlung\u00a0mit\u00a0Migala stat\u00a0anspre\u2010\nchen\u00a0(EMA,\u00a02016).\u00a0\nDie\u00a067\u00a0Patienten\u00a0in\u00a0der\u00a0doppelblinden\u00a0FACETS\u2010Studie\u00a0hatten\u00a0zuvo r\u00a0mindestens\u00a0\nsechs\u00a0Monate\u00a0lang\u00a0keine\u00a0Enzymers atztherapie\u00a0erhalten\u00a0(Germain\u00a0e t\u00a0al.,\u00a02016).\u00a0Die\u00a0\nInterventionsgruppe\u00a0mit\u00a034\u00a0Teilnehmern\u00a0erhielt\u00a0150\u00a0mg\u00a0Migalasta t\u00a0peroral\u00a0jeden\u00a0\nzweiten\u00a0Tag,\u00a0die\u00a0Kontrollgrupp e\u00a0mit\u00a033\u00a0Teilnehmern\u00a0Placebo.\u00a0\u00a0\nPrim\u00e4rer\u00a0Endpunkt\u00a0der\u00a0Studie\u00a0war\u00a0der\u00a0Anteil\u00a0der\u00a0Patienten\u00a0mit\u00a0A nsprechen\u00a0auf\u00a0die\u00a0\nTherapie\u00a0nach\u00a0sechs\u00a0Monaten,\u00a0definiert\u00a0als\u00a0eine\u00a0mindestens\u00a050\u2010% \u2010ige\u00a0Reduktion\u00a0der\u00a0\nGL\u20103\u2010Inklusionen\u00a0 in\u00a0 den\u00a0 interstitiellen\u00a0 Nierenkapillaren\u00a0 im\u00a0 Ver g l e i c h \u00a0z u m \u00a0A u s \u2010\ngangswert.\u00a0Der\u00a0Unterschied\u00a0war\u00a0nicht\u00a0statistisch\u00a0signifikant,\u00a0g leiches\u00a0galt\u00a0auch\u00a0f\u00fcr\u00a0\nden\u00a0Endpunkt\u00a0gesundheitsbezogene\u00a0Lebensqualit\u00e4t.\u00a0127\u00a0Die\u00a060\u00a0Patienten\u00a0in\u00a0der\u00a0offenen\u00a0ATTRACT\u2010Studie\u00a0hatten\u00a0zuvor\u00a0ein e\u00a0intraven\u00f6se\u00a0\nEnzymersatztherapie\u00a0mit\u00a0Agalsida se\u00a0alfa\u00a0oder\u00a0Agalsidase\u00a0beta\u00a0er halten\u00a0(Hughes\u00a0et\u00a0\nal.,\u00a02017).\u00a0Die\u00a0Interventionsgruppe\u00a0mit\u00a035\u00a0Teilnehmern\u00a0erhielt\u00a0 jeden\u00a0zweiten\u00a0Tag\u00a0\n150\u00a0mg\u00a0Migalastat\u00a0peroral,\u00a0die\u00a0Kontrollgruppe\u00a0mit\u00a024\u00a0Teilnehmern\u00a0f\u00fc hrte\u00a0die\u00a0bis\u2010\nherige\u00a0intraven\u00f6se\u00a0Enzym ersatztherapie\u00a0weiter.\u00a0\u00a0\nPrim\u00e4rer\u00a0Endpunkt\u00a0war\u00a0die\u00a0annualisierte\u00a0Ver\u00e4nderung\u00a0der\u00a0glomeru l\u00e4ren\u00a0Filtrati\u2010\nonsrate,\u00a0die\u00a0mit\u00a0zwei\u00a0Verfahren\u00a0ermittelt\u00a0wurde\u00a0(mGFR iohexol\u00a0und\u00a0eGFR CDK\u2010EPI).\u00a0We\u2010\ngen\u00a0 der\u00a0 geringen\u00a0 verf\u00fcgbaren\u00a0 Teilnehmerzahl\u00a0 war\u00a0 die\u00a0 Studie\u00a0 form a l \u00a0n i c h t \u00a0a l s \u00a0\nNicht\u2010Unterlegenheitsstudie\u00a0angele gt.\u00a0Als\u00a0Ma\u00df\u00a0f\u00fcr\u00a0\u201eVergleichbar keit\u201c\u00a0wurde\u00a0eine\u00a0\n\u00dcberlappung\u00a0der\u00a095\u00a0%\u2010Konfidenzintervalle\u00a0von\u00a0mindestens\u00a050\u00a0%\u00a0so wie\u00a0ein\u00a0Unter\u2010\nschied\u00a0 der\u00a0 annualisierten\u00a0 Ver\u00e4nderung\u00a0 der\u00a0 glomerul\u00e4ren\u00a0 Filtrati onsrate\u00a0 von\u00a0\nh\u00f6chstens\u00a02,2\u00a0ml/min/1,73\u00a0m2\u00a0definiert.\u00a0\u00a0\nNach\u00a018\u00a0Monaten\u00a0betrug\u00a0der\u00a0Unterschied\u00a0zwischen\u00a0den\u00a0Gruppen\u00a0bei \u00a0mGFR iohexol\u00a0\u00a0\n\u20101,11,\u00a0bei\u00a0eGFR CDK\u2010EPI\u00a0+0,63,\u00a0jeweils\u00a0mit\u00a0sehr\u00a0weiten\u00a0Konfidenzintervallen.\u00a0\u00a0\nDie\u00a0gesundheitsbezogene\u00a0Lebensqualit\u00e4t\u00a0wurde\u00a0mit\u00a0Hilfe\u00a0des\u00a0SF\u20103 6\u2010Fragebogens\u00a0\nerfasst.\u00a0In\u00a0beiden\u00a0Gruppen\u00a0fanden\u00a0sich\u00a0am\u00a0Ende\u00a0der\u00a0Studie\u00a0aber\u00a0 keine\u00a0wesentli\u2010\nchen\u00a0Ver\u00e4nderungen\u00a0zum\u00a0Ausgangswert.\u00a0\nNach\u00a0der\u00a0Bewertung\u00a0des\u00a0europ\u00e4ischen\u00a0Beurteilungsberichts\u00a0wird\u00a0d ie\u00a0\u201eVergleich\u2010\nbarkeit\u201c\u00a0der\u00a0beiden\u00a0Intervention en\u00a0auf\u00a0dieser\u00a0Basis\u00a0akzeptiert. \u00a0Gleichzeitig\u00a0wird\u00a0\naber\u00a0auch\u00a0darauf\u00a0hingewiesen,\u00a0dass\u00a0sich\u00a0aus\u00a0diesen\u00a0Ergebnissen\u00a0 keine\u00a0definitiven\u00a0\nSchlussfolgerungen\u00a0im\u00a0Hinblick\u00a0au f\u00a0die\u00a0Vergleichbarkeit\u00a0von\u00a0Mig alastat\u00a0und\u00a0der\u00a0\nintraven\u00f6sen\u00a0Enzymersatztherapie\u00a0ziehen\u00a0lassen.\u00a0Eingeschr\u00e4nkt\u00a0w ird\u00a0die\u00a0Aussage\u2010\nkraft\u00a0auch\u00a0dadurch,\u00a0dass\u00a0in\u00a0der\u00a0Studie\u00a0ein\u00a0Placebo\u2010Arm\u00a0fehlt\u00a0un d\u00a0Informationen\u00a0\nzum\u00a0Krankheitsverlauf\u00a0der\u00a0Patienten\u00a0vor\u00a0Einschluss\u00a0in\u00a0die\u00a0Studi e\u00a0fehlen.\u00a0Nicht\u2010\nUnterlegenheit\u00a0ist\u00a0also\u00a0formal\u00a0nicht\u00a0belegt\u00a0(EMA,\u00a02016).\u00a0\nDerzeit\u00a0l\u00e4uft\u00a0noch\u00a0eine\u00a0offene\u00a0einarmige\u00a0Studie\u00a0an\u00a0p\u00e4diatrische n\u00a0Patienten\u00a0zwi\u2010\nschen\u00a0zw\u00f6lf\u00a0und\u00a018\u00a0Jahren\u00a0(NCT03500094).\u00a0\nZum\u00a0Zeitpunkt\u00a0der\u00a0Zulassung\u00a0lagen\u00a0f\u00fcr\u00a0die\u00a0Sicherheit\u00a0von\u00a0Migala stat\u00a0Erfahrungs\u2010\nwerte\u00a0an\u00a0168\u00a0Patienten\u00a0mit\u00a0Morbus\u00a0Fabry\u00a0vor,\u00a0davon\u00a0119\u00a0mit\u00a0eine r\u00a0Behandlungs\u2010\ndauer\u00a0von\u00a0mindestens\u00a0einem\u00a0Jahr.\u00a0H\u00e4ufige\u00a0unerw\u00fcnschte\u00a0Arzneimit telereignisse\u00a0in\u00a0\nden\u00a0pivotalen\u00a0Studien\u00a0waren\u00a0Kopfs chmerzen,\u00a0Nasopharyngitis,\u00a0M\u00fcd igkeit,\u00a0Fatigue,\u00a0\nFieber\u00a0und\u00a0Par\u00e4sthesien.\u00a0Die\u00a0Reak tionen\u00a0waren\u00a0meist\u00a0leicht\u00a0bis\u00a0 moderat.\u00a0Insge\u2010\nsamt\u00a0 sind\u00a0 die\u00a0 Erkenntnisse\u00a0 zu\u00a0 Nebenwirkungen\u00a0 aufgrund\u00a0 der\u00a0 relat iv\u00a0 geringen\u00a0\nAnzahl\u00a0an\u00a0behandelten\u00a0Patienten\u00a0und\u00a0der\u00a0relativ\u00a0kurzen\u00a0Behandlu ngsdauer\u00a0einge\u2010\nschr\u00e4nkt\u00a0(EMA,\u00a02016).\u00a0128\u00a0F\u00fcr\u00a0Arzneimittel\u00a0zur\u00a0Behandlung\u00a0eines\u00a0seltenen\u00a0Leidens\u00a0gilt\u00a0der \u00a0medizinische\u00a0Zu\u2010\nsatznutzen\u00a0durch\u00a0die\u00a0Zulassung\u00a0als\u00a0belegt,\u00a0lediglich\u00a0das\u00a0Ausma\u00df \u00a0des\u00a0Zusatznutzens\u00a0\nist\u00a0durch\u00a0den\u00a0pU\u00a0nachzuweisen.\u00a0F\u00fcr\u00a0die\u00a0Bewertung\u00a0zog\u00a0der\u00a0G\u2010BA\u00a0d ie\u00a0pivotale\u00a0Zu\u2010\nlassungsstudie\u00a0ATTRACT\u00a0heran.\u00a0Auf\u00a0dieser\u00a0Basis\u00a0kam\u00a0der\u00a0G\u2010BA\u00a0im\u00a0 Dezember\u00a02016\u00a0\nzu\u00a0dem\u00a0Schluss,\u00a0dass\u00a0der\u00a0Zusatznutzen\u00a0f\u00fcr\u00a0Migalastat\u00a0 nicht\u00a0quantifizierbar \u00a0ist,\u00a0da\u00a0\ndie\u00a0Ergebnisse\u00a0der\u00a0patientenrelevanten\u00a0Endpunkte\u00a0der\u00a0Studie\u00a0kei ne\u00a0statistisch\u00a0\nsignifikanten\u00a0Vorteile\u00a0von\u00a0Migalastat\u00a0gegen\u00fcber\u00a0der\u00a0im\u00a0deutsche n\u00a0Versorgungsall\u2010\ntag\u00a0verwendeten\u00a0Enzymersatzthe rapie\u00a0aufzeigen\u00a0(G\u2010BA,\u00a02016).\u00a0 \u00a0\nVerf\u00fcgbare\u00a0Therapien \u00a0 (Zusatz\u2010)Nutzen \u00a0 Kosten\u00a0\n\u00a0\nerste\u00a0orale\u00a0\nTherapieoption,\u00a0aber\u00a0\nGleichwertigkeit\u00a0zu\u00a0einer\u00a0\nintraven\u00f6sen\u00a0\nEnzymersatztherapie\u00a0\nnicht\u00a0belegt\u00a0\u00a0Zusatznutzen\u00a0nicht\u00a0\nquantifizierbar\u00a0\u00a0\nkein\u00a0Kostenvergleich,\u00a0da\u00a0\nOrphan\u2010Arzneimittel\u00a0\nErl\u00e4uterung\u00a0der\u00a0Farben:\u00a0Verf\u00fcgbare\u00a0Therapien:\u00a0rot\u00a0=\u00a0weitere\u00a0The rapieoption,\u00a0gelb\u00a0=\u00a0Subgruppen\u2010Novit\u00e4t,\u00a0gr\u00fcn\u00a0=\u00a0Solist;\u00a0(Zusatz\u2010 )\u00a0\nNutzen:\u00a0rot\u00a0=\u00a0keine\u00a0Verbesserung\u00a0oder\u00a0schlechte\u00a0Nutzen/Schaden\u2010 Relation,\u00a0gelb\u00a0=\u00a0teilweise\u00a0Verbesserungen,\u00a0gr\u00fcn\u00a0=\u00a0Verbesserung\u00a0\nharter\u00a0Endpunkte;\u00a0Kosten:\u00a0rot\u00a0=\u00a0teurer\u00a0als\u00a0bestehende\u00a0Therapien ,\u00a0gelb\u00a0=\u00a0ungef\u00e4hr\u00a0gleich\u00a0bzw.\u00a0teils/teils,\u00a0gr\u00fcn\u00a0=\u00a0g\u00fcnstiger\u00a0als \u00a0\nbestehende\u00a0Therapien\u00a0\nWie\u00a0bewerten\u00a0andere?\u00a0\nBewertung\u00a0nach\u00a0\nFricke\u00a0et\u00a0al.\u00a0a\u2010t\u2010Bewertung\u00a0 AMB\u00a0 Prescrire\u00a0 PZ\u00a0\nA\u00a0 \u2013\u00a0 \u2013\u00a0 Nothing\u00a0new\u00a0 Schrittinnovation\u00a0\nKosten\u00a0\nWirkstoff\u00a0 Behandlungsmodus\u00a0 Behandlungstage\u00a0 Jahrestherapiekosten\u00a0\nzu\u00a0bewertendes\u00a0Arzneimittel \u00a0\u00a0 \u00a0 \u00a0\nMigalastat\u00a0 alle\u00a02\u00a0Tage\u00a0123\u00a0mg\u00a0 183\u00a0 247.789,84\u00a0\u20ac\u00a0\n\u00a0\nVersorgungsanalysen\u00a0\nAufgrund\u00a0 der\u00a0 geringen\u00a0 Anzahl\u00a0 an\u00a0 Patienten\u00a0 konnten\u00a0 aus\u00a0 Datenschu tzgr\u00fcnden\u00a0\nkeine\u00a0Versorgungsanalysen\u00a0von\u00a0 Migalastat\u00a0erstellt\u00a0werden.\u00a0\n\u00a0\u00a0\n129\u00a0Quellen\u00a0\nEMA\u00a0\u2013\u00a0European\u00a0Medicines\u00a0Agency\u00a0(2016).\u00a0EPAR\u00a0(Public\u00a0Assessment \u00a0Report)\u00a0Galafold.\u00a0\nhttps://www.ema.europa.eu/en/medicines/human/EPAR/galafold,\u00a0let zter\u00a0Zugriff:\u00a001.04.2019.\u00a0\nEMA\u00a0\u2013\u00a0European\u00a0Medicines\u00a0Agency\u00a0 (2018).\u00a0Fachinformation\u00a0Galasta d\u00a0(Stand\u00a012.11.2018).\u00a0\nhttps://www.ema.europa.eu/en/documents/product\u2010information/gala fold\u2010epar\u2010product\u2010information_en.pdf,\u00a0\nletzter\u00a0Zugriff:\u00a001.04.2019.\u00a0\nFricke\u00a0U,\u00a0Hein\u00a0L,\u00a0Schwabe\u00a0U\u00a0(2017).\u00a0Neue\u00a0Arzneimittel\u00a02016.\u00a0In: \u00a0Schwabe\u00a0U,\u00a0Paffrath\u00a0D,\u00a0Ludwig\u00a0W\u2010D,\u00a0Klauber\u00a0J\u00a0(Hrsg.)\u00a0(2017).\u00a0\nArzneiverordnungs\u2010Report\u00a02017.\u00a0Berlin,\u00a0Heidelberg.\u00a0Springer:\u00a055 \u2010135.\u00a0\nG\u2010BA\u00a0\u2013\u00a0Gemeinsamer\u00a0Bundesausschuss\u00a0(2016).\u00a0Nutzenbewertungsverf ahren\u00a0zum\u00a0Wirkstoff\u00a0Migalastat.\u00a0\u00a0\nhttps://www.g\u2010ba.de/informationen/nutzenbewertung/237/,\u00a0letzter \u00a0Zugriff:\u00a001.04.2019.\u00a0\nGermain\u00a0D\u00a0P,\u00a0Hughes\u00a0D\u00a0A,\u00a0Nicholls \u00a0K,\u00a0Bichet\u00a0D\u00a0G,\u00a0Giugliani\u00a0R,\u00a0W ilcox\u00a0W\u00a0R\u00a0et\u00a0al.\u00a0(2016).\u00a0Treatment\u00a0of\u00a0Fabry\u2019s\u00a0Disease\u00a0with\u00a0the\u00a0\nPharmacologic\u00a0Chaperone\u00a0Migalastat.\u00a0NEJM\u00a0375(6):\u00a0545\u2010555.\u00a0\u00a0\nHughes\u00a0DA,\u00a0Nicholls\u00a0K,\u00a0Shankar\u00a0SP ,\u00a0Sunder\u2010Plassmann\u00a0G,\u00a0Koeller\u00a0 D,\u00a0Nedd\u00a0K\u00a0et\u00a0al.\u00a0(2017).\u00a0Oral\u00a0pharmacological\u00a0chaperone\u00a0\nmigalastat\u00a0compared\u00a0with\u00a0enzyme\u00a0 replacement\u00a0therapy\u00a0in\u00a0Fabry\u00a0di sease:\u00a018\u2010month\u00a0results\u00a0from\u00a0the\u00a0randomised\u00a0\nphase\u00a0III\u00a0ATTRACT\u00a0study.\u00a0J\u00a0M ed\u00a0Genet\u00a054(4):\u00a0288\u2010296.\u00a0\u00a0\nPrescrire\u00a0Int.\u00a0(2018).\u00a0Migalastat\u00a0and\u00a0Fabry\u00a0disease.\u00a0No\u00a0proof\u00a0o f\u00a0efficacy\u00a0and\u00a0adverse\u00a0effects\u00a0s till\u00a0insufficiently\u00a0known.\u00a0Pres crire\u00a0Int\u00a0\n27(195),\u00a0176.\u00a0\nPZ\u00a0\u2013\u00a0Pharmazeutische\u00a0Zeitung\u00a0(2016).\u00a0Migalastat|Galafold|40|201 6.\u00a0https://www.pharmazeutische\u2010\nzeitung.de/arzneistoffe/daten/2016/migalastatgalafoldr402016/,\u00a0 letzter\u00a0Zugriff:\u00a001.04.2019.\u00a0\n\u00a0 \u00a0130\u00a0 Olaratumab\u00a04.11\nHandelsname:\u00a0Lartruvo\u00ae\u00a0 \u00a0 \u00a0 Pharmazeutischer\u00a0Unternehmer:\u00a0\u00a0\nIndikation:\u00a0Weichgewebesarkom\u00a0 \u00a0 Eli\u00a0Lilly\u00a0\nATC\u2010Code:\u00a0L01XC27\u00a0 \u00a0 \u00a0 Markte inf\u00fchrung:\u00a0Dezember\u00a02016\u00a0\nDarreichungsform:\u00a0Konzentrat\u00a0\u00a0\nzur\u00a0Herstellung\u00a0einer\u00a0Infusionsl\u00f6sung\u00a0 DDD:\u00a00,1\u00a0g\u00a0\u00a0 \u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 \u00a0\u00a0\u00a0\u00a0O,\u00a0C, \u25bc,\u00a0\nBewertung \u00a0\nLartruvo\u00ae\u00a0wurde\u00a0im\u00a0November\u00a02016\u00a0in\u00a0Europa\u00a0in\u00a0Kombination\u00a0mit\u00a0D oxorubicin\u00a0zur\u00a0\nBehandlung\u00a0von\u00a0fortgeschrittenem\u00a0Weichgewebesarkom\u00a0in\u00a0einem\u00a0zen tralisierten\u00a0\nVerfahren\u00a0zugelassen,\u00a0f\u00fcr\u00a0Patienten,\u00a0die\u00a0nicht\u00a0f\u00fcr\u00a0eine\u00a0kurativ e\u00a0Behandlung\u00a0(Ope\u2010\nration\u00a0oder\u00a0Strahlentherapie)\u00a0geeignet\u00a0sind,\u00a0und\u00a0die\u00a0zuvor\u00a0nich t\u00a0mit\u00a0Doxorubicin\u00a0\nbehandelt\u00a0wurden\u00a0(EMA,\u00a02016).\u00a0F\u00fcr\u00a0Olaratumab\u00a0wurde\u00a0bereits\u00a02015 \u00a0eine\u00a0Orphan\u2010\nDesignation \u00a0durch\u00a0die\u00a0Europ\u00e4ische\u00a0Kommission \u00a0zur\u00a0Behandlung\u00a0von\u00a0Weichgewe\u2010\nbesarkomen\u00a0erteilt\u00a0(EU/3/15/1447)\u00a0(EMA,\u00a0 2015;\u00a0 EC,\u00a02015).\u00a0Die\u00a0Zu lassung\u00a0von\u00a0\nOlaratumab\u00a0erfolgte\u00a0im\u00a0Rahmen\u00a0einer\u00a0bedingten\u00a0Zulassung\u00a0 (Conditional\u00a0Marketing\u00a0\nAuthorisation,\u00a0 CMA).\u00a0F\u00fcr\u00a0die\u00a0Erteilung\u00a0einer\u00a0solchen\u00a0Zulassung\u00a0auf\u00a0der\u00a0Grundla ge\u00a0\nweniger\u00a0umfangreicher\u00a0Daten,\u00a0als \u00a0dies\u00a0normalerweise\u00a0der\u00a0Fall\u00a0is t,\u00a0wurde\u00a0mit\u00a0der\u00a0\nVerordnung\u00a0(EG)\u00a0Nr.\u00a0507/2006\u00a0ein\u00a0Verfahren\u00a0etabliert,\u00a0das\u00a0an\u00a0be stimmte\u00a0Auflagen\u00a0\ngekn\u00fcpft\u00a0ist.\u00a0Diese\u00a0bedingte\u00a0Zulassung\u00a0wird\u00a0f\u00fcr\u00a0Arzneimittel\u00a0mi t\u00a0noch\u00a0unvollst\u00e4n\u2010\ndigen\u00a0klinischen\u00a0Daten\u00a0erteilt,\u00a0die\u00a0zur\u00a0Behandlung,\u00a0Vorbeugung\u00a0 oder\u00a0\u00e4rztlichen\u00a0\nDiagnose\u00a0von\u00a0zu\u00a0schwerer\u00a0Invalidit\u00e4t\u00a0f\u00fchrenden\u00a0oder\u00a0lebensbedro hlichen\u00a0Krank\u2010\nheiten\u00a0bestimmt\u00a0sind,\u00a0f\u00fcr\u00a0 Orphan\u2010Arzneimittel\u00a0oder\u00a0f\u00fcr\u00a0Arzneimittel,\u00a0die\u00a0in\u00a0Krisen\u2010\nsituationen\u00a0gegen\u00a0eine\u00a0Bedrohung\u00a0der\u00a0\u00f6ffentlichen\u00a0Gesundheit\u00a0ei ngesetzt\u00a0werden\u00a0\nsollen.\u00a0Bedingungen\u00a0sind\u00a0weiterhin,\u00a0dass\u00a0umfangreiche\u00a0Daten\u00a0zu\u00a0 Wirksamkeit\u00a0und\u00a0\nSicherheit\u00a0sp\u00e4ter\u00a0nach\u00a0der\u00a0Zulassung\u00a0eingereicht\u00a0werden\u00a0und\u00a0ein \u00a0ungedeckter\u00a0\nmedizinischer\u00a0Bedarf\u00a0( unmet\u00a0medical\u00a0need )\u00a0besteht.\u00a0Zudem\u00a0erfolgte\u00a0die\u00a0Zulassung\u00a0\nanhand\u00a0einer\u00a0beschleunigten\u00a0Beurteilung\u00a0( Accelerated\u00a0Assessment )\u00a0f\u00fcr\u00a0Arzneimit\u2010\ntel,\u00a0die\u00a0von\u00a0besonderer\u00a0Bedeutung \u00a0f\u00fcr\u00a0die\u00a0\u00f6ffentliche\u00a0Gesundhei t\u00a0sind,\u00a0insbeson\u2010\ndere\u00a0f\u00fcr\u00a0therapeutische\u00a0Innova tionen\u00a0(EMA,\u00a02016).\u00a0Aufgrund\u00a0des\u00a0 gezeigten\u00a0Vor\u2010\nteils\u00a0im\u00a0Gesamt\u00fcberleben\u00a0( Overall\u00a0Survival ,\u00a0OS)\u00a0und\u00a0der\u00a0vom\u00a0pU\u00a0bereits\u00a0geplanten\u00a0\nPhase\u2010III\u2010Studie\u00a0mit\u00a0Olaratumab\u00a0s timmte\u00a0die\u00a0EMA\u00a0einer\u00a0bedingten \u00a0Zulassung\u00a0zu\u00a0\nmit\u00a0der\u00a0Auflage\u00a0f\u00fcr\u00a0den\u00a0pU,\u00a0die\u00a0Daten\u00a0aus\u00a0der\u00a0Phase\u2010III\u2010Studie\u00a0 nachzureichen\u00a0\n(EMA,\u00a02016).\u00a0Die\u00a0Zulassung\u00a0von\u00a0Olaratumab\u00a0ist\u00a0noch\u00a0nicht\u00a0in\u00a0ein e\u00a0regul\u00e4re\u00a0Markt\u2010\nzulassung\u00a0( Full\u00a0Marketing\u00a0Authorisation )\u00a0umgewandelt\u00a0worden.\u00a0In\u00a0den\u00a0USA\u00a0hatte\u00a0\nOlaratumab\u00a0 von\u00a0 der\u00a0 Food\u00a0 and\u00a0 Drug\u00a0 Administrati on\u00a0 (FDA)\u00a0 eine\u00a0 Breakthrough\u2010\ntherapy\u00a0designation \u00a0erhalten\u00a0und\u00a0wurde\u00a0im\u00a0Rahmen\u00a0des\u00a0 Accelerated\u00a0Approval\u00a0\nProgram\u00a0im\u00a0Oktober\u00a02016\u00a0zugelassen\u00a0(FDA,\u00a02019).\u00a0\n131\u00a0Die\u00a0Markteinf\u00fchrung\u00a0von\u00a0Olaratumab\u00a0in\u00a0Deutschland\u00a0erfolgte\u00a0im\u00a0D ezember\u00a02016\u00a0\n(Lauer\u2010Taxe,\u00a02019).\u00a0Olaratumab\u00a0w ird\u00a0intraven\u00f6s\u00a0appliziert.\u00a0Die\u00a0 empfohlene\u00a0Dosie\u2010\nrung\u00a0ist\u00a015\u00a0mg/kg\u00a0KG,\u00a0die\u00a0an\u00a0Tag\u00a01\u00a0und\u00a08\u00a0eines\u00a0jeden\u00a0dreiw\u00f6chig en\u00a0Zyklus\u00a0bis\u00a0zum\u00a0\nT u m o r p r o g r e s s \u00a0o d e r \u00a0b i s \u00a0z u m \u00a0A u f t r eten\u00a0 nicht\u00a0 akzeptabler\u00a0 Toxizit\u00e4 t\u00a0 verabreicht\u00a0\nwird.\u00a0Die\u00a0Gabe\u00a0von\u00a0Olaratumab\u00a0in\u00a0Kombination\u00a0mit\u00a0Doxorubicin\u00a0(A nthrazyklin)\u00a0\nerfolgt\u00a0f\u00fcr\u00a0bis\u00a0zu\u00a0acht\u00a0Zyklen,\u00a0dabei\u00a0wird\u00a0Doxorubicin\u00a0am\u00a0Tag\u00a01 \u00a0jedes\u00a0Zyklus\u00a0im\u00a0\nAnschluss\u00a0an\u00a0die\u00a0Olaratumab\u2010Infusion\u00a0verabreicht.\u00a0Anschlie\u00dfend\u00a0 erfolgt\u00a0eine\u00a0Mo\u2010\nnotherapie\u00a0mit\u00a0Olaratumab\u00a0bei\u00a0Patienten,\u00a0deren\u00a0Erkrankung\u00a0nicht \u00a0weiter\u00a0fortge\u2010\nschritten\u00a0ist.\u00a0Zur\u00a0Vorbeugung\u00a0infusionsbedingter\u00a0Reaktionen\u00a0sol lten\u00a0alle\u00a0Patienten\u00a0\neine\u00a0 Pr\u00e4medikation\u00a0 mit\u00a0 einem\u00a0 H1\u2010Antagonisten\u00a0 und\u00a0 Dexamethason\u00a0 e rhalten\u00a0\n(Fachinformation\u00a0Lartruvo\u00ae,\u00a02018).\u00a0\u00a0\nOlaratumab\u00a0ist\u00a0ein\u00a0monoklonaler, \u00a0humaner\u00a0IgG1\u2010Antik\u00f6rper,\u00a0der\u00a0i n\u00a0einer\u00a0murinen\u00a0\nZelllinie\u00a0(NSO)\u00a0mittels\u00a0rekombinanter\u00a0DNA\u2010Technologie\u00a0hergestel lt\u00a0wird.\u00a0Olara\u2010\ntumab\u00a0ist\u00a0ein\u00a0Antagonist\u00a0am\u00a0Thrombozyten\u2010Wachstumsfaktor\u2010Rezept or\u00a0\u03b1\u00a0(Platelet\u00a0\nDerived\u00a0Growth\u00a0Factor\u00a0Receptor\u00a0\u0391,\u00a0 PDGFR\u03b1).\u00a0PDGFR\u03b1\u00a0wird\u00a0auf\u00a0Tumor\u2010\u00a0und\u00a0Stro\u2010\nmazellen\u00a0exprimiert\u00a0und\u00a0reguliert \u00a0unter\u00a0anderem\u00a0das\u00a0Tumorwachst um,\u00a0die\u00a0Prolife\u2010\nration\u00a0und\u00a0Metastasierung.\u00a0Olarat umab\u00a0bindet\u00a0spezifisch\u00a0an\u00a0PDGF R\u03b1\u00a0und\u00a0blockiert\u00a0\ndadurch\u00a0 die\u00a0 Rezeptoraktivierung\u00a0 durch\u00a0 PDGF\u2010AA,\u00a0 PDGF\u2010BB\u00a0 und\u00a0 PDGF \u2010CC.\u00a0 Die\u00a0\nUnterbrechung\u00a0der\u00a0PDGFR\u03b1\u2010Signal \u00fcbertragung\u00a0in\u00a0den\u00a0Tumorzellen\u00a0i nduziert\u00a0eine\u00a0\nHemmung\u00a0des\u00a0Tumorwachstums\u00a0(EMA,\u00a0 2016;\u00a0Fachinformation\u00a0Lartruvo \u00ae,\u00a02018).\u00a0\nDie\u00a0Zulassung\u00a0von\u00a0Lartruvo\u00ae\u00a0ber uhte\u00a0auf\u00a0einer\u00a0Phase\u2010Ib/II\u2010Studi e\u00a0(Sponsor:\u00a0Eli\u00a0Lilly,\u00a0\nJGDG,\u00a0NCT01185964),\u00a0die\u00a0an\u00a016\u00a0Zentren\u00a0in\u00a0den\u00a0USA\u00a0im\u00a0Zeitraum\u00a0Ok tober\u00a02010\u00a0bis\u00a0\nMai\u00a02015\u00a0stattfand.\u00a0In\u00a0die\u00a0Studie\u00a0wurden\u00a0Anthrazyklin\u2010naive\u00a0Pat ienten\u00a0mit\u00a0histolo\u2010\ngisch\u00a0oder\u00a0zytologisch\u00a0best\u00e4tigt em\u00a0fortgeschrittenem\u00a0Weichgeweb esarkom\u00a0einge\u2010\nschlossen,\u00a0die\u00a0nicht\u00a0f\u00fcr\u00a0eine\u00a0kurative\u00a0Behandlung\u00a0(Operation\u00a0od er\u00a0Strahlenthera\u2010\npie)\u00a0geeignet\u00a0waren.\u00a0Patienten\u00a0mit\u00a0gastrointestinalen\u00a0Stromatum oren\u00a0(GIST)\u00a0oder\u00a0\nKaposi\u2010Sarkom\u00a0wurden\u00a0ausgeschlossen.\u00a0\u00a0\nIn\u00a0der\u00a0Phase\u2010Ib\u2010Studie\u00a0wurden\u00a015\u00a0 Patienten\u00a0eingeschlossen,\u00a0um\u00a0d ie\u00a0Sicherheit\u00a0und\u00a0\ndie\u00a0Pharmakokinetik\u00a0von\u00a0Olaratum ab\u00a0zu\u00a0evaluieren.\u00a0Die\u00a0Phase\u00a0II\u00a0 war\u00a0eine\u00a0offene,\u00a0\nrandomisierte,\u00a0aktiv\u00a0kontrollierte\u00a0Studie,\u00a0in\u00a0die\u00a0133\u00a0Patienten \u00a0eingeschlossen\u00a0wur\u2010\nden.\u00a0Die\u00a0Patienten\u00a0wurden\u00a01:1\u2010randomisiert\u00a0und\u00a0erhielten\u00a0entwed er\u00a0Olaratumab\u00a0\n(15\u00a0mg/kg\u00a0KG)\u00a0an\u00a0Tag\u00a01\u00a0und\u00a08\u00a0in\u00a0Kombination\u00a0mit\u00a0Doxorubicin\u00a0(75 \u00a0mg/m2\u00a0KOF)\u00a0an\u00a0\nTag\u00a01\u00a0eines\u00a0jeden\u00a021\u2010Tage\u2010Zyklus\u00a0f\u00fcr\u00a0insgesamt\u00a0bis\u00a0zu\u00a0acht\u00a0Zykl en\u00a0(Olaratumab\u2010\nArm,\u00a0n\u00a0=\u00a066)\u00a0oder\u00a0Doxorubicin\u00a0 allein\u00a0in\u00a0der\u00a0Dosierung\u00a075\u00a0mg/m2\u00a0KOF\u00a0(Kontrollarm,\u00a0\nn\u00a0=\u00a067).\u00a0Die\u00a0Randomisierung\u00a0erfolgte\u00a0stratifiziert\u00a0nach\u00a0PDGFR\u03b1\u2010 Status\u00a0(positiv\u00a0vs.\u00a0\nnegativ),\u00a0Anzahl\u00a0systemischer\u00a0Vortherapien\u00a0(0\u00a0vs.\u00a0\u2265\u00a01),\u00a0histolo gischem\u00a0Tumortyp\u00a0\n(Leiomyosarkom\u00a0vs.\u00a0Synovialsarkom\u00a0vs.\u00a0andere)\u00a0und\u00a0ECOG\u2010PS\u00a0(0\u00a0bi s\u00a01\u00a0vs.\u00a02).\u00a0Ab\u00a0\ndem\u00a0f\u00fcnften\u00a0Zyklus\u00a0war\u00a0die\u00a0Gabe\u00a0von\u00a0Dexrazoxan\u00a0zur\u00a0Risikoredukt ion\u00a0einer\u00a0Anth\u2010132\u00a0razyklin\u2010induzierten\u00a0Kardiotoxizi t\u00e4t\u00a0in\u00a0beiden\u00a0Armen\u00a0nach\u00a0Ermes sen\u00a0des\u00a0Pr\u00fcfarztes\u00a0\nerlaubt.\u00a0Die\u00a0Patienten\u00a0im\u00a0Olaratumab\u2010Arm\u00a0erhielten\u00a0nach\u00a0acht\u00a0Zy klen\u00a0Kombinati\u2010\nonstherapie\u00a0eine\u00a0Monotherapie\u00a0mit\u00a0Olaratumab\u00a0bis\u00a0Krankheitsprog ression,\u00a0Tod\u00a0\noder\u00a0nicht\u00a0akzeptabler\u00a0Toxizit\u00e4t.\u00a0Die\u00a0Patienten\u00a0im\u00a0Kontrollarm\u00a0 sollten\u00a0laut\u00a0Studi\u2010\nenprotokoll\u00a0nach\u00a0Abschluss\u00a0der\u00a0acht\u00a0Zyklen\u00a0Doxorubicin\u00a0keine\u00a0we itere\u00a0medika\u2010\nment\u00f6se\u00a0Therapie\u00a0erhalten\u00a0(Tap\u00a0et\u00a0al.,\u00a02016).\u00a0Durch\u00a0eine\u00a0nachtr \u00e4gliche\u00a0\u00c4nderung\u00a0\ndes\u00a0Studienprotokolls\u00a0(Version\u00a03.0\u00a0vom\u00a002.02.2012)\u00a0wurde\u00a0Patien ten,\u00a0die\u00a0im\u00a0Kon\u2010\ntrollarm\u00a0die\u00a0Behandlung\u00a0aufgrund\u00a0 von\u00a0nicht\u00a0akzeptabler\u00a0Toxizit\u00e4 t\u00a0abbrachen,\u00a0er\u2010\nlaubt,\u00a0zur\u00a0Olaratumab\u2010Monotherapie\u00a0zu\u00a0wechseln.\u00a0Zudem\u00a0konnten\u00a0a uch\u00a0Patien\u2010\nten,\u00a0die\u00a0unter\u00a0Doxorubicin\u00a0eine\u00a0 Krankheitsprogression\u00a0hatten,\u00a0e ine\u00a0Olaratumab\u2010\nMonotherapie\u00a0erhalten\u00a0(EMA,\u00a02016).\u00a0\nDas\u00a0mediane\u00a0Alter\u00a0war\u00a058\u00a0Jahre\u00a0bei\u00a0Randomisierung,\u00a042\u00a0Patienten \u00a0waren\u00a065\u00a0Jahre\u00a0alt\u00a0\noder\u00a0\u00e4lter.\u00a0Eingeschlossen\u00a0wurden \u00a0mehr\u00a0als\u00a025\u00a0verschiedene\u00a0Subt ypen\u00a0von\u00a0Weich\u2010\ngewebesarkomen.\u00a0Die\u00a0h\u00e4ufigsten\u00a0d arunter\u00a0waren\u00a0Leiomyosarkome\u00a0(3 8,4\u00a0%),\u00a0undif\u2010\nferenzierte\u00a0pleomorphe\u00a0Sarkome\u00a0(18,1\u00a0%)\u00a0und\u00a0Liposarkome\u00a0(17,3\u00a0% )\u00a0(Tap\u00a0 et\u00a0al.,\u00a0\n2016).\u00a0\nDer\u00a0prim\u00e4re\u00a0Endpunkt\u00a0der\u00a0Studie\u00a0war\u00a0das\u00a0progressionsfreie\u00a0\u00dcberl eben\u00a0(Progressi\u2010\non\u2010free\u00a0 Survival ,\u00a0 PFS).\u00a0 Sekund\u00e4re\u00a0 Endpunkte\u00a0 waren\u00a0 u.a.\u00a0 das\u00a0 Gesamt\u00fcberleben\u00a0\n(Overall\u00a0Survival ,\u00a0OS)\u00a0sowie\u00a0die\u00a0objektive\u00a0Ansprechrate\u00a0 (Objective\u00a0Response\u00a0Rate,\u00a0\nORR).\u00a0Die\u00a0Studiendauer\u00a0war\u00a0ereignisgesteuert\u00a0und\u00a0die\u00a0Analyse\u00a0zu m\u00a0prim\u00e4ren\u00a0End\u2010\npunkt\u00a0PFS\u00a0sollte\u00a0nach\u00a0Auftreten\u00a0von\u00a0mindestens\u00a0110\u00a0Ereignissen\u00a0 erfolgen.\u00a0Auf\u2010\ngrund\u00a0 einer\u00a0 nachtr\u00e4glichen\u00a0 \u00c4nderu ng\u00a0 des\u00a0 Studienprotokolls\u00a0 (Vers ion\u00a0 5.0\u00a0 vom\u00a0\n19.08.2014)\u00a0und\u00a0ge\u00e4nderter\u00a0Zensierung\u00a0bez\u00fcglich\u00a0des\u00a0Endpunkts\u00a0P FS\u00a0konnte\u00a0diese\u00a0\npr\u00e4definierte\u00a0Ereignisanzahl\u00a0nicht\u00a0erreicht\u00a0werden,\u00a0sodass\u00a0die\u00a0 finale\u00a0Analyse\u00a0zum\u00a0\nPFS\u00a0mit\u00a0dem\u00a0Datenschnitt\u00a0vom\u00a015.08.2014\u00a0durchgef\u00fchrt\u00a0wurde.\u00a0Auf grund\u00a0nach\u2010\ntr\u00e4glicher\u00a0\u00c4nderungen\u00a0der\u00a0statistischen\u00a0Auswertung\u00a0erfolgte\u00a0ein e\u00a0Intention\u2010to\u2010\ntreat\u00a0(ITT)\u2010Auswertung\u00a0und\u00a0eine\u00a0verblindete\u00a0radiologische\u00a0Bewertung\u00a0d er\u00a0Krank\u2010\nheitsprogression\u00a0(Tap\u00a0et\u00a0al.,\u00a02016;\u00a0EMA,\u00a02016).\u00a0\nIn\u00a0der\u00a0pr\u00e4definierten\u00a0Bewertung\u00a0durch\u00a0die\u00a0Pr\u00fcf\u00e4rzte\u00a0( Investigator\u00a0Review )\u00a0wurden\u00a0\nf\u00fcr\u00a0die\u00a0ITT\u2010Population\u00a0im\u00a0Olaratumab\u2010Arm\u00a055\u00a0(83,3\u00a0%)\u00a0Ereignisse \u00a0und\u00a0im\u00a0Kontroll\u2010\narm\u00a048\u00a0(71,6\u00a0%)\u00a0Ereignisse\u00a0beric htet.\u00a0Das\u00a0mediane\u00a0PFS\u00a0betrug\u00a06, 6\u00a0Monate\u00a0im\u00a0Ola\u2010\nratumab\u2010Arm\u00a0vs.\u00a04,1\u00a0Monate\u00a0im\u00a0Kontrollarm.\u00a0Der\u00a0Unterschied\u00a0zwis chen\u00a0den\u00a0Be\u2010\nhandlungsarmen\u00a0war\u00a0nicht\u00a0statistisch\u00a0signifikant.\u00a0Die\u00a0verblinde te,\u00a0post\u2010hoc\u00a0Bewer\u2010\ntung\u00a0ergab\u00a0f\u00fcr\u00a0die\u00a0ITT\u2010Population\u00a0im\u00a0Olaratumab\u2010Arm\u00a037\u00a0(56,1\u00a0%) \u00a0und\u00a0im\u00a0Kontroll\u2010\narm\u00a034\u00a0(50,7\u00a0%)\u00a0Ereignisse.\u00a0Hierbei\u00a0betrug\u00a0das\u00a0mediane\u00a0PFS\u00a08,2\u00a0 Monate\u00a0im\u00a0Olara\u2010\ntumab\u2010Arm\u00a0vs.\u00a04,4\u00a0Monate\u00a0im\u00a0Kontrollarm.\u00a0Die\u00a0ORR\u00a0war\u00a0in\u00a0beiden\u00a0 Bewertungen\u00a0\nunter\u00a0Olaratumab\u00a0numerisch\u00a0h\u00f6her,\u00a0der\u00a0Unterschied\u00a0zwischen\u00a0den\u00a0 Behandlungs\u2010\narmen\u00a0war\u00a0aber\u00a0nicht\u00a0statistisch\u00a0signifikant\u00a0(Tap\u00a0et\u00a0al.,\u00a02016) .\u00a0133\u00a0Zum\u00a0Datenschnitt\u00a0vom\u00a016.05.2015\u00a0zeigte\u00a0sich\u00a0im\u00a0sekund\u00e4ren\u00a0Endpu nkt\u00a0OS\u00a0ein\u00a0\nVorteil\u00a0f\u00fcr\u00a0Olaratumab\u00a0gegen\u00fcber \u00a0der\u00a0Kontrolle:\u00a026,5\u00a0Monate\u00a0im\u00a0 Median\u00a0vs.\u00a014,7\u00a0\nMonate\u00a0im\u00a0Median\u00a0( Hazard\u00a0Ratio \u00a0(HR)\u00a00,46,\u00a095\u00a0%\u00a0KI\u00a0[0,30;\u00a00,71],\u00a0p\u00a0=\u00a00,0003).\u00a0Zu\u00a0\ndiesem\u00a0Zeitpunkt\u00a0waren\u00a0noch\u00a023\u00a0Pa tienten\u00a0im\u00a0Olaratumab\u2010Arm\u00a0sowi e\u00a0acht\u00a0Patien\u2010\nten\u00a0im\u00a0Kontrollarm\u00a0(drei\u00a0davon\u00a0waren\u00a0Patienten,\u00a0die\u00a0eine\u00a0Monoth erapie\u00a0mit\u00a0Olara\u2010\ntumab\u00a0erhielten,\u00a0nachdem\u00a0sie\u00a0die\u00a0Behandlung\u00a0mit\u00a0Doxorubicin\u00a0abg ebrochen\u00a0hat\u2010\nten)\u00a0(Tap\u00a0et\u00a0al.,\u00a02016).\u00a0\nUnerw\u00fcnschte\u00a0Arzneimittelereigni sse\u00a0(UAE)\u00a0traten\u00a0in\u00a0beiden\u00a0Beha ndlungsarmen\u00a0\nnahezu\u00a0bei\u00a0jedem\u00a0Patienten\u00a0minde stens\u00a0einmal\u00a0auf.\u00a0Schwerwiegend e\u00a0UAE\u00a0traten\u00a0\nbei\u00a027\u00a0(42,2\u00a0%)\u00a0der\u00a0Patienten\u00a0im\u00a0Olaratumab\u2010Arm\u00a0und\u00a0bei\u00a025\u00a0(38, 5\u00a0%)\u00a0der\u00a0Patien\u2010\nten\u00a0im\u00a0Kontrollarm\u00a0w\u00e4hrend\u00a0der\u00a0Be handlung\u00a0mit\u00a0der\u00a0Kombinationst herapie\u00a0auf.\u00a0\nUnter\u00a0der\u00a0Monotherapie\u00a0mit\u00a0Olaratumab\u00a0bei\u00a0Patienten,\u00a0die\u00a0initia l\u00a0in\u00a0den\u00a0Kontroll\u2010\narm\u00a0randomisiert\u00a0wurden\u00a0und\u00a0nach\u00a0Abbruch\u00a0der\u00a0Therapie\u00a0mit\u00a0Doxor ubicin\u00a0eine\u00a0\nOlaratumab\u2010Monotherapi e\u00a0erhielten\u00a0(n\u00a0=\u00a030,\u00a0 Crossover \u2010Arm),\u00a0hatten\u00a0neun\u00a0(30\u00a0%)\u00a0\nder\u00a0Patienten\u00a0mindestens\u00a0ein\u00a0schwerwiegendes\u00a0UAE.\u00a0\nSchwere\u00a0UAE\u00a0vom\u00a0Grad\u00a0\u2265\u00a03\u00a0CTCAE\u00a0( Common\u00a0Terminology\u00a0Criteria\u00a0for\u00a0Adverse\u00a0\nEvents)\u00a0traten\u00a0im\u00a0Olaratumab\u2010Arm\u00a0h\u00e4ufiger\u00a0auf:\u00a079,7\u00a0%\u00a0vs.\u00a069,2\u00a0%\u00a0sowi e\u00a036,7\u00a0%\u00a0im\u00a0\nCrossover \u2010Arm.\u00a0Ein\u00a0Therapieabbruch\u00a0aufgrund\u00a0von\u00a0UAE\u00a0wurde\u00a0f\u00fcr\u00a012,5\u00a0%\u00a0der \u00a0Pati\u2010\nenten\u00a0im\u00a0Olaratumab\u2010Arm\u00a0und\u00a018,5\u00a0%\u00a0der\u00a0Patienten\u00a0im\u00a0Kontrollarm \u00a0sowie\u00a0f\u00fcr\u00a0\n6,7\u00a0%\u00a0der\u00a0Patienten\u00a0im\u00a0 Crossover \u2010Arm\u00a0berichtet.\u00a0Die\u00a0h\u00e4uf igsten\u00a0Nebenwirkungen,\u00a0\ndie\u00a0zum\u00a0dauerhaften\u00a0Behandlungsa bbruch\u00a0f\u00fchrten,\u00a0waren\u00a0reduziert e\u00a0Auswurfs\u2010\nfraktion\u00a0des\u00a0Herzens\u00a0(4,7\u00a0%\u00a0vs.\u00a06,2\u00a0%),\u00a0infusionsbedingte\u00a0Reakt ionen\u00a0(3,1\u00a0%\u00a0vs.\u00a0\n0\u00a0%),\u00a0respiratorische\u00a0Insuffizienz\u00a0(1,6\u00a0%\u00a0vs.\u00a01,5\u00a0%),\u00a0Pneumonie \u00a0und\u00a0Mukositis\u00a0(je\u00a0\n1,6\u00a0%\u00a0im\u00a0Olaratumab\u2010Arm,\u00a0keine\u00a0i m\u00a0Kontrollarm).\u00a0T\u00f6dliche\u00a0(schwe re)\u00a0UAE\u00a0(Grad\u00a05\u00a0\nCTCAE)\u00a0wurden\u00a0f\u00fcr\u00a0keinen\u00a0Patient en\u00a0im\u00a0Olaratumab\u2010Arm\u00a0berichtet, \u00a0jedoch\u00a0f\u00fcr\u00a0f\u00fcnf\u00a0\n(7,7\u00a0%)\u00a0der\u00a0Patienten\u00a0im\u00a0Kontrollarm\u00a0und\u00a0f\u00fcr\u00a0zwei\u00a0(6,7\u00a0%)\u00a0der\u00a0P atienten\u00a0im\u00a0 Cross\u2010\nover\u2010Arm\u00a0(Tap\u00a0et\u00a0al.,\u00a02016;\u00a0EMA,\u00a02016).\u00a0\nDie\u00a0h\u00e4ufigsten\u00a0UAE\u00a0in\u00a0beiden\u00a0Arm en\u00a0der\u00a0Sicherheitspopulation\u00a0(a lle\u00a0Patienten,\u00a0die\u00a0\nmindestens\u00a0 eine\u00a0 Dosis\u00a0 der\u00a0 Studienmedikation\u00a0 erhalten\u00a0 haben)\u00a0 war en\u00a0 Nausea,\u00a0\nFatigue,\u00a0muskeloskelettale\u00a0Schme rzen,\u00a0Neutropenie,\u00a0Mukositis,\u00a0D iarrh\u00f6,\u00a0Fieber,\u00a0\nThrombozytopenie,\u00a0Neuropathie,\u00a0Husten\u00a0und\u00a0Dyspnoe.\u00a0Die\u00a0meisten\u00a0 gastrointesti\u2010\nnalen\u00a0UAE\u00a0waren\u00a0nicht\u00a0schwer\u00a0und\u00a0traten\u00a0unter\u00a0Olaratumab\u00a0h\u00e4ufig er\u00a0auf:\u00a0\u00dcbelkeit\u00a0\n(73,4\u00a0%\u00a0vs.\u00a052,3\u00a0%),\u00a0Mukositis\u00a0(52,3\u00a0%\u00a0vs.\u00a035,4\u00a0%),\u00a0Erbrechen\u00a0( 45,3\u00a0%\u00a0vs.\u00a018,5\u00a0%)\u00a0\nund\u00a0Diarrh\u00f6\u00a0(34,4\u00a0%\u00a0vs.\u00a023,1\u00a0%).\u00a0Schwere\u00a0Neutropenien\u00a0vom\u00a0Grad\u00a0 \u2265\u00a03\u00a0CTCAE\u00a0tra\u2010\nten\u00a0unter\u00a0Olaratumab\u00a0h\u00e4ufiger\u00a0auf:\u00a054,7\u00a0%\u00a0vs.\u00a033,8\u00a0%.\u00a0Schwere\u00a0I nfektionen\u00a0(20,3\u00a0%\u00a0\nvs.\u00a021,5\u00a0%)\u00a0und\u00a0febrile\u00a0Neutropenien\u00a0(12,5\u00a0%\u00a0vs.\u00a013,8\u00a0%)\u00a0traten \u00a0in\u00a0beiden\u00a0Armen\u00a0\nvergleichbar\u00a0h\u00e4ufig\u00a0auf.\u00a0Infusionsbedingte\u00a0Reaktionen\u00a0im\u00a0Olarat umab\u2010Arm\u00a0wurden\u00a0\nbei\u00a012,5\u00a0%\u00a0der\u00a0Patienten\u00a0berich tet,\u00a0haupts\u00e4chlich\u00a0als\u00a0Sch\u00fcttelf rost,\u00a0Fieber\u00a0oder\u00a0134\u00a0Atemnot.\u00a0Schwere\u00a0infusionsbedingte\u00a0Reaktionen,\u00a0inklusive\u00a0eines\u00a0 Todesfalls,\u00a0wur\u2010\nden\u00a0f\u00fcr\u00a03,1\u00a0%\u00a0der\u00a0Patienten\u00a0berichtet\u00a0und\u00a0zeigten\u00a0sich\u00a0haupts\u00e4c hlich\u00a0als\u00a0Kurzat\u2010\nmigkeit,\u00a0Bewusstlosigkeit\u00a0und\u00a0Hypotonie.\u00a0Alle\u00a0schweren\u00a0infusion sbedingten\u00a0Reak\u2010\ntionen\u00a0traten\u00a0w\u00e4hrend\u00a0oder\u00a0unverz\u00fcglich\u00a0nach\u00a0der\u00a0ersten\u00a0Gabe\u00a0vo n\u00a0Olaratumab\u00a0\nauf\u00a0(Tap\u00a0et\u00a0al.,\u00a02016;\u00a0EMA,\u00a02016).\u00a0\nMuskuloskelettale\u00a0Schmerzen\u00a0traten\u00a0im\u00a0Olaratumab\u2010Arm\u00a0bei\u00a064,1\u00a0% \u00a0der\u00a0Patienten\u00a0\nund\u00a0 im\u00a0 Kontrollarm\u00a0 bei\u00a0 24,6\u00a0%\u00a0 der\u00a0 Patienten\u00a0 auf.\u00a0 Schwere\u00a0 muskul oskelettale\u00a0\nSchmerzen\u00a0(Grad\u00a0\u2265\u00a03\u00a0CTCAE)\u00a0wurden\u00a0f\u00fcr\u00a07,8\u00a0%\u00a0bzw.\u00a01,5\u00a0%\u00a0berichte t.\u00a0Bei\u00a0der\u00a0Mehr\u2010\nheit\u00a0der\u00a0Patienten\u00a0wurden\u00a0die\u00a0Schmerzen\u00a0auf\u00a0die\u00a0Krebserkrankung \u00a0bzw.\u00a0die\u00a0Meta\u2010\nstasen\u00a0sowie\u00a0auf\u00a0vorherigen\u00a0oder\u00a0aktuell\u00a0vorliegenden\u00a0Erkrankun gen\u00a0zur\u00fcckge\u2010\nf\u00fchrt.\u00a0Bez\u00fcglich\u00a0der\u00a0Kardiotoxizit\u00e4t\u00a0wurden\u00a0keine\u00a0klinisch\u00a0rele vanten\u00a0Unterschiede\u00a0\nzwischen\u00a0den\u00a0beiden\u00a0Behandlungsarmen\u00a0berichtet.\u00a0Die\u00a0Inzidenz\u00a0vo n\u00a0Herzrhyth\u2010\nmusst\u00f6rungen\u00a0(15,6\u00a0%\u00a0vs.\u00a015,4\u00a0%)\u00a0s owie\u00a0von\u00a0auftretenden\u00a0kardial en\u00a0Funktionsst\u00f6\u2010\nrungen\u00a0w\u00e4hrend\u00a0der\u00a0Behandlungszeit\u00a0(7,8\u00a0%\u00a0vs.\u00a06,2\u00a0%)\u00a0war\u00a0zwisch en\u00a0beiden\u00a0Be\u2010\nhandlungsarmen\u00a0vergleichbar\u00a0(Tap\u00a0et\u00a0al.,\u00a02016).\u00a0\nDie\u00a0Phase\u2010III\u2010Studie\u00a0ANNOUNCE\u00a0(Sponsor:\u00a0Eli\u00a0Lilly,\u00a0NCT02451943) \u00a0ist\u00a0eine\u00a0multi\u2010\nzentrische,\u00a0doppelblinde,\u00a0randomisierte,\u00a0aktiv\u00a0kontrollierte\u00a0St udie,\u00a0in\u00a0die\u00a0seit\u00a02015\u00a0\n460\u00a0 Anthrazyklin\u2010naive\u00a0 Patienten\u00a0 mit\u00a0 fortgeschrittenem\u00a0 oder\u00a0 met astasiertem\u00a0\nWeichgewebesarkom\u00a0eingeschlossen\u00a0 wurden,\u00a0die\u00a0nicht\u00a0f\u00fcr\u00a0eine\u00a0kur ative\u00a0Behand\u2010\nlung\u00a0(Operation\u00a0oder\u00a0Strahlenthe rapie)\u00a0geeignet\u00a0waren.\u00a0Die\u00a0Pati enten\u00a0werden\u00a0mit\u00a0\nOlaratumab\u00a0in\u00a0Kombination\u00a0mit\u00a0Doxorubicin\u00a0bzw.\u00a0mit\u00a0einer\u00a0Doxoru bicin\u2010Monothe\u2010\nrapie\u00a0behandelt.\u00a0Der\u00a0prim\u00e4re\u00a0Endpunkt\u00a0der\u00a0Studie\u00a0ist\u00a0die\u00a0Verl\u00e4n gerung\u00a0des\u00a0OS\u00a0\n(Moroncini\u00a0et\u00a0al.,\u00a02018;\u00a0NIH,\u00a02019).\u00a0\nI m \u00a0J a n u a r \u00a02 0 1 9 \u00a0w i e s \u00a0d i e \u00a0E M A \u00a0d a r a u f \u00a0h i n , \u00a0d a s s \u00a0d i e \u00a0e r s t e n \u00a0E r g e b n i sse\u00a0 der\u00a0\nANNOUNCE\u2010Studie\u00a0keinen\u00a0\u00dcberlebensvorteil\u00a0f\u00fcr\u00a0Olaratumab\u00a0in\u00a0Komb ination\u00a0mit\u00a0\nDoxorubicin\u00a0im\u00a0Vergleich\u00a0zu\u00a0Doxo rubicin\u00a0allein\u00a0zeigen.\u00a0Bis\u00a0zur\u00a0 Vorlage\u00a0der\u00a0voll\u2010\nst\u00e4ndigen\u00a0Ergebnisse\u00a0der\u00a0Studie\u00a0empfahl\u00a0die\u00a0EMA,\u00a0dass\u00a0keine\u00a0neu en\u00a0Patienten\u00a0\neine\u00a0Behandlung\u00a0mit\u00a0Olaratumab\u00a0beginnen\u00a0sollten.\u00a0Basierend\u00a0auf\u00a0 den\u00a0bisher\u00a0ver\u2010\nf\u00fcgbaren\u00a0Informationen\u00a0gab\u00a0es\u00a0au s\u00a0Sicht\u00a0der\u00a0EMA\u00a0keine\u00a0neuen\u00a0Ris ikosignale\u00a0be\u2010\nz\u00fcglich\u00a0der\u00a0Sicherheit\u00a0von\u00a0Olaratumab.\u00a0Das\u00a0Sicherheitsprofil\u00a0de r\u00a0beiden\u00a0Studien\u2010\narme\u00a0wurde\u00a0als\u00a0vergleichbar\u00a0eingestuft,\u00a0da\u00a0die\u00a0UAE,\u00a0die\u00a0unter\u00a0d er\u00a0Kombinations\u2010\ntherapie\u00a0auftraten,\u00a0vergleichbar \u00a0mit\u00a0denen\u00a0unter\u00a0der\u00a0Monotherap ie\u00a0mit\u00a0Doxorubi\u2010\ncin\u00a0waren\u00a0(EMA,\u00a02019a).\u00a0Am\u00a026.04.2019\u00a0empfahl\u00a0die\u00a0EMA,\u00a0die\u00a0Zula ssung\u00a0des\u00a0Arz\u2010\nneimittels\u00a0 zu\u00a0 widerrufen.\u00a0 Die\u00a0 zwi schenzeitlich\u00a0 abgeschlossene\u00a0 B ewertung\u00a0 der\u00a0\nStudienergebnisse\u00a0belegte,\u00a0dass\u00a0Olaratumab\u00a0in\u00a0Kombination\u00a0mit\u00a0D oxorubicin\u00a0das\u00a0\nGesamt\u00fcberleben\u00a0 der\u00a0 Patienten\u00a0 mit\u00a0 fortgeschrittenen\u00a0 Weichgewebe sarkomen\u00a0\nnicht\u00a0verl\u00e4ngert,\u00a0sodass\u00a0ein\u00a0Nutz en\u00a0der\u00a0Kombinationsbehandlung\u00a0 nicht\u00a0besteht\u00a0\n(EMA,\u00a02019b).\u00a0Der\u00a0Widerruf\u00a0der\u00a0EU\u2010Zulassung\u00a0wegen\u00a0fehlender\u00a0the rapeutischer\u00a0135\u00a0Wirksamkeit\u00a0erfolgte\u00a0am\u00a06.\u00a0Mai\u00a02019;\u00a0in\u00a0Deutschland\u00a0wurden\u00a0\u00c4rzt e\u00a0mit\u00a0einem\u00a0\nRote\u2010Hand\u2010Brief\u00a0informiert\u00a0(Lilly,\u00a02019a).\u00a0\nIn\u00a0der\u00a0ANNOUNCE\u2010Studie\u00a0betrug\u00a0das\u00a0mediane\u00a0OR\u00a020,4\u00a0Monate\u00a0im\u00a0Ola ratumab\u2010\nArm\u00a0vs.\u00a019,7\u00a0Monate\u00a0im\u00a0Kontrollarm\u00a0mit\u00a0einem\u00a0HR\u00a0f\u00fcr\u00a0Tod\u00a0von\u00a01,0 5\u00a0in\u00a0der\u00a0Ge\u2010\nsamtpopulation\u00a0(alle\u00a0Weichgewebesarkome).\u00a0In\u00a0der\u00a0Subpopulation\u00a0 der\u00a0Patienten\u00a0\nmit\u00a0Leiomyosarkomen\u00a0betrug\u00a0das\u00a0mediane\u00a0OS\u00a021,6\u00a0Monate\u00a0im\u00a0Olarat umab\u2010Arm\u00a0\nvs.\u00a021,9\u00a0Monate\u00a0im\u00a0Kontrollarm\u00a0mit\u00a0einem\u00a0HR\u00a0f\u00fcr\u00a0Tod\u00a0von\u00a00,95.\u00a0D as\u00a0mediane\u00a0PFS\u00a0\nbetrug\u00a0in\u00a0der\u00a0Gesamtpopulation\u00a05,42\u00a0Monate\u00a0im\u00a0Olaratumab\u2010Arm\u00a0vs .\u00a06,77\u00a0Monate\u00a0\nim\u00a0Kontrollarm\u00a0(HR\u00a0f\u00fcr\u00a0Progression\u00a01,23,\u00a0p\u00a0=\u00a00,042).\u00a0In\u00a0Deutsch land\u00a0wurden\u00a0\u00c4rzte\u00a0\nmit\u00a0einem\u00a0Rote\u2010Hand\u2010Brief\u00a0dar\u00fcbe r\u00a0informiert\u00a0(Eli\u00a0Lilly,\u00a02019). \u00a0\nDie\u00a0Nutzenbewertung\u00a0nach\u00a0\u00a7\u00a035a\u00a0SGB\u00a0V\u00a0von\u00a0Lartruvo\u00ae\u00a0erfolgte\u00a0201 7.\u00a0Durch\u00a0die\u00a0\nZulassung\u00a0als\u00a0 Orphan\u2010Arzneimittel\u00a0gilt\u00a0der\u00a0 Zusatznutzen \u00a0als\u00a0belegt.\u00a0Am\u00a018.\u00a0Mai\u00a0\n2017\u00a0beschloss\u00a0der\u00a0G\u2010BA,\u00a0dass\u00a0das\u00a0Ausma\u00df\u00a0des\u00a0Zusatznutzens\u00a0von\u00a0 Olaratumab\u00a0\nbetr\u00e4chtlich \u00a0ist.\u00a0Die\u00a0Entscheidung\u00a0erfolgte\u00a0auf\u00a0der\u00a0Basis\u00a0der\u00a0Zulassungsstu die\u00a0JGDG\u00a0\n(G\u2010BA,\u00a02017).\u00a0\nF\u00fcr\u00a0die\u00a0Bewertung\u00a0des\u00a0Ausma\u00dfes\u00a0des\u00a0Zusatznutzens\u00a0von\u00a0Olaratumab \u00a0in\u00a0Kombina\u2010\ntion\u00a0mit\u00a0Doxorubicin\u00a0wurden\u00a0insbesondere\u00a0die\u00a0Ergebnisse\u00a0zum\u00a0End punkt\u00a0OS\u00a0her\u2010\na n g e z o g e n . \u00a0D i e \u00a0s t a t i s t i s c h \u00a0s i g n i f i k a n t e \u00a0V e r l \u00e4 n g e r u n g \u00a0d e r \u00a0\u00dc b e r l e benszeit\u00a0 von\u00a0\n11,8\u00a0Monaten\u00a0im\u00a0Median\u00a0entsprach\u00a0aus\u00a0Sicht\u00a0des\u00a0G\u2010BA\u00a0einer\u00a0deutl ichen\u00a0Verbesse\u2010\nrung,\u00a0die\u00a0deshalb\u00a0mit\u00a0einem\u00a0betr\u00e4chtlichen\u00a0Ausma\u00df\u00a0bewertet\u00a0wurd e.\u00a0Die\u00a0Scha\u2010\ndensendpunkte\u00a0(Nebenwirkungen)\u00a0zeigten\u00a0aus\u00a0Sicht\u00a0des\u00a0G\u2010BA\u00a0weder \u00a0einen\u00a0Vorteil\u00a0\nnoch\u00a0einen\u00a0eindeutigen\u00a0Nachteil,\u00a0da\u00a0die\u00a0Zunahme\u00a0von\u00a0schweren\u00a0Ne utropenien\u00a0\n(Grad\u00a0\u2265\u00a03\u00a0CTCAE)\u00a0unter\u00a0Olaratumab\u00a0in\u00a0der\u00a0Studie\u00a0nicht\u00a0mit\u00a0einem \u00a0verst\u00e4rkten\u00a0\nAuftreten\u00a0von\u00a0febrilen\u00a0Neutropenien\u00a0oder\u00a0schweren\u00a0Infektionen\u00a0v erbunden\u00a0war.\u00a0\nEs\u00a0lagen\u00a0keine\u00a0Daten\u00a0f\u00fcr\u00a0eine\u00a0Bewertung\u00a0der\u00a0gesundheitsbezogene n\u00a0Lebensquali\u2010\nt\u00e4t\u00a0oder\u00a0der\u00a0krankheitsspezifischen\u00a0Symptomatik\u00a0vor.\u00a0In\u00a0der\u00a0Ges amtschau\u00a0der\u00a0\nErgebnisse\u00a0zu\u00a0patientenrelevanten\u00a0Endpunkten\u00a0stellte\u00a0der\u00a0G\u2010BA\u00a0f \u00fcr\u00a0Olaratumab\u00a0in\u00a0\nKombination\u00a0 mit\u00a0 Doxorubicin\u00a0 eine n\u00a0 Zusatznutzen\u00a0 gegen\u00fcber\u00a0 der\u00a0 Do xorubicin\u2010\nMonotherapie\u00a0aufgrund\u00a0der\u00a0erziel ten\u00a0Verl\u00e4ngerung\u00a0im\u00a0OS\u00a0fest\u00a0(G\u2010 BA,\u00a02017).\u00a0\nDer\u00a0G\u2010BA\u00a0wies\u00a0auf\u00a0einige\u00a0Limitationen\u00a0der\u00a0Daten\u00a0hin,\u00a0die\u00a0die\u00a0Au ssagekraft\u00a0der\u00a0\nStudienergebnisse\u00a0beeinflussen\u00a0bzw.\u00a0vermindern.\u00a0Dazu\u00a0z\u00e4hlten\u00a0vo r\u00a0allem\u00a0die\u00a0ge\u2010\nringe\u00a0Stichprobengr\u00f6\u00dfe\u00a0der\u00a0Studi e\u00a0mit\u00a0nur\u00a0133\u00a0eingeschlossenen\u00a0 Patienten,\u00a0aber\u00a0\nauch,\u00a0dass\u00a0statistische\u00a0Kriterien\u00a0der\u00a0durchgef\u00fchrten\u00a0Analysen\u00a0t eilweise\u00a0nicht\u00a0ad\u00e4\u2010\nquat\u00a0a\u00a0priori\u00a0definiert\u00a0wurden.\u00a0Zudem\u00a0bestand\u00a0eine\u00a0Imbalance\u00a0zwischen\u00a0Interv en\u2010\ntions\u2010\u00a0und\u00a0Kontrollgruppe\u00a0bez\u00fcglic h\u00a0verschiedener\u00a0Patientenchar akteristika.\u00a0Auch\u00a0\nwurde\u00a0post\u00a0hoc\u00a0ein\u00a0 Crossover \u00a0von\u00a0Patienten\u00a0mit\u00a0einer\u00a0Progression\u00a0w\u00e4hrend\u00a0oder\u00a0\nnach\u00a0der\u00a0Doxorubicin\u2010Monotherapie \u00a0zu\u00a0einer\u00a0Olaratumab\u2010Monothera pie\u00a0erlaubt.\u00a0\nDies\u00a0erschwerte\u00a0aus\u00a0Sicht\u00a0des\u00a0G\u2010 BA\u00a0eine\u00a0valide\u00a0Einsch\u00e4tzung\u00a0des \u00a0Behandlungsef\u2010136\u00a0fektes\u00a0 von\u00a0 Olaratumab\u00a0 in\u00a0 Kombination\u00a0 mit\u00a0 Doxorubicin\u00a0 zus\u00e4tzlich .\u00a0Aus\u00a0 diesen\u00a0\nLimitationen\u00a0resultierten\u00a0zwar\u00a0relevante\u00a0Unsicherheiten\u00a0in\u00a0der\u00a0 Interpretation\u00a0der\u00a0\nErgebnisse,\u00a0deren\u00a0Ausma\u00df\u00a0jedoch\u00a0nicht\u00a0derart\u00a0eingesch\u00e4tzt\u00a0wurde ,\u00a0als\u00a0dass\u00a0diese\u00a0\neine\u00a0Quantifizierung\u00a0des\u00a0Zusatznutzens\u00a0nicht\u00a0erlauben\u00a0w\u00fcrden\u00a0(G \u2010BA,\u00a02017).\u00a0\u00a0\nDer\u00a0Beschluss\u00a0wurde\u00a0vom\u00a0G\u2010BA\u00a0bis\u00a0zum\u00a01.\u00a0Mai\u00a02020\u00a0 befristet,\u00a0 um\u00a0die\u00a0Vorlage\u00a0der\u00a0\nErgebnisse\u00a0der\u00a0bereits\u00a0laufenden\u00a0Phase\u20103\u2010Studie\u00a0ANNOUNCE\u00a0abzuwa rten,\u00a0die\u00a0als\u00a0\npotenziell\u00a0relevant\u00a0f\u00fcr\u00a0die\u00a0Nut zenbewertung\u00a0eingestuft\u00a0wurden \u00a0(G\u2010BA,\u00a02017).\u00a0\nVerf\u00fcgbare\u00a0Therapien \u00a0 (Zusatz\u2010)Nutzen \u00a0 Kosten\u00a0\n\u00a0erster\u00a0gegen\u00a0PDGFR\u03b1\u00a0\ngerichteter\u00a0Antik\u00f6rper,\u00a0\naber\u00a02019\u00a0Widerruf\u00a0der\u00a0\nZulassung,\u00a0bezogen\u00a0auf\u00a0\ntherapeutische\u00a0\nWirksamkeit\u00a0\u00a0\u00a0G\u2010BA\u2010Bewertung:\u00a0\nbetr\u00e4chtlicher\u00a0ZN\u00a0mit\u00a0\nbefristetem\u00a0Beschluss,\u00a0\nneueste\u00a0Studienergeb\u2010\nnisse\u00a0zeigen\u00a0keinen\u00a0\n\u00dcberlebensvorteil\u00a0und\u00a0\ndaher\u00a0keinen\u00a0Nutzen\u00a0\u00a0\nkein\u00a0Kostenvergleich,\u00a0da\u00a0\nOrphan\u2010Arzneimittel\u00a0\nErl\u00e4uterung\u00a0der\u00a0Farben:\u00a0Verf\u00fcgbare\u00a0Therapien:\u00a0rot\u00a0=\u00a0weitere\u00a0The rapieoption,\u00a0gelb\u00a0=\u00a0Subgruppen\u2010Novit\u00e4t,\u00a0gr\u00fcn\u00a0=\u00a0Solist;\u00a0(Zusatz\u2010 )\u00a0\nNutzen:\u00a0rot\u00a0=\u00a0keine\u00a0Verbesserung\u00a0oder\u00a0schlechte\u00a0Nutzen/Schaden\u2010 Relation,\u00a0gelb\u00a0=\u00a0teilweise\u00a0Verbesserungen,\u00a0gr\u00fcn\u00a0=\u00a0Verbesserung\u00a0\nharter\u00a0Endpunkte;\u00a0Kosten:\u00a0rot\u00a0=\u00a0teurer\u00a0als\u00a0bestehende\u00a0Therapien ,\u00a0gelb\u00a0=\u00a0ungef\u00e4hr\u00a0gleich\u00a0bzw.\u00a0teils/teils,\u00a0gr\u00fcn\u00a0=\u00a0g\u00fcnstiger\u00a0als \u00a0\nbestehende\u00a0Therapien\u00a0\nWie\u00a0bewerten\u00a0andere?\u00a0\nBewertung\u00a0nach\u00a0\nFricke\u00a0et\u00a0al.\u00a0atd\u2010Bewertung\u00a0 AMB\u00a0 Prescrire\u00a0 PZ\u00a0\nA\u00a0Zweifelhaftes\u00a0\nTherapieprinzip,\u00a0\ndessen\u00a0Zulassung\u00a0\nwegen\u00a0fehlender\u00a0\nWirksamkeit\u00a0\nwiderrufen\u00a0wurde\u00a0\u2013\u00a0 \u2013\u00a0 Sprunginnovation\u00a0\nKosten\u00a0\nWirkstoff\u00a0 Behandlungsmodus\u00a0 Behandlungstage\u00a0 Jahrestherapiekosten\u00a0\nzu\u00a0bewertendes\u00a0Arzneimittel \u00a0\u00a0 \u00a0 \u00a0\nOlaratumab\u00a0 17\u00a0Zyklen*:\u00a0\n15\u00a0mg/kg\u00a0KG\u00a0an\u00a0Tag\u00a01,\u00a08\u00a034\u00a0 130.838,12\u00a0\u20ac\u00a0\n+\u00a0Doxorubicin\u00a0(nur\u00a0im\u00a01.\u00a0Jahr)\u00a0 8\u00a0Zyklen*:\u00a0\n75\u00a0mg/m\u00b2\u00a0KOF\u00a0an\u00a0Tag\u00a01\u00a08\u00a0 2.515,36\u00a0\u20ac\u00a0\n\u00a0 \u00a0 \u00a0 133.353,48\u00a0\u20ac\u00a0\n(Folgejahr\u00a0130.838,12\u00a0\u20ac)\u00a0\n*\u00a021\u2010Tage\u2010Zyklen\u00a0\n\u00a0\n\u00a0\n137\u00a0Versorgungsanalysen\u00a0\nNach\u00a0der\u00a0Markteinf\u00fchrung\u00a0von\u00a0Olaratumab\u00a0im\u00a0Dezember\u00a02016\u00a0stieg\u00a0 das\u00a0Verord\u2010\nnungsvolumen\u00a0kontinuierlich\u00a0an\u00a0und\u00a0erreichte\u00a0im\u00a0Mai\u00a02017\u00a0einen\u00a0 Wert\u00a0von\u00a0\u00fcber\u00a0\n500\u00a0DDD\u00a0pro\u00a0Monat.\u00a0Im\u00a0Juni\u00a02017\u00a0zeigte\u00a0sich\u00a0ein\u00a0starker\u00a0Abfall\u00a0 der\u00a0verordneten\u00a0\nDDD\u00a0pro\u00a0Monat,\u00a0danach\u00a0stieg\u00a0das\u00a0Verordnungsvolumen\u00a0aber\u00a0wieder\u00a0 steil\u00a0an,\u00a0ver\u2010\nmutlich\u00a0unter\u00a0dem\u00a0Einfluss\u00a0der\u00a0positiven\u00a0Beschlussfassung\u00a0des\u00a0G \u2010BA\u00a0im\u00a0Mai\u00a02017\u00a0\nund\u00a0der\u00a0Zuerkennung\u00a0eines\u00a0betr\u00e4chtlichen\u00a0Zusatznutzens\u00a0f\u00fcr\u00a0das\u00a0 Orphan\u2010Arznei\u2010\nmittel.\u00a0Es\u00a0muss\u00a0dazu\u00a0ber\u00fccksichtigt\u00a0werden,\u00a0dass\u00a0sich\u00a0das\u00a0zu\u00a0be handelnde\u00a0Patien\u2010\ntenkollektiv\u00a0aus\u00a0einigen\u00a0wenigen\u00a0Patienten\u00a0zusammensetzt,\u00a0da\u00a0es \u00a0sich\u00a0bei\u00a0Weich\u2010\ngewebesarkomen\u00a0um\u00a0eine\u00a0seltene\u00a0E rkrankung\u00a0handelt.\u00a02017\u00a0wurden\u00a0 insgesamt\u00a0\nweniger\u00a0als\u00a070\u00a0Patienten\u00a0mit\u00a0Olaratumab\u00a0behandelt.\u00a0\u00a0\nDer\u00a0Erstattungsbetrag\u00a0trat\u00a0erst\u00a0zum\u00a015.01.2018\u00a0in\u00a0Kraft,\u00a0sodass \u00a0die\u00a0durchschnittli\u2010\nche\u00a0Preisreduktion\u00a0von\u00a0etwa\u00a017\u00a0%\u00a0in\u00a0diesen\u00a0Daten\u00a0noch\u00a0nicht\u00a0ber \u00fccksichtigt\u00a0wer\u2010\nden\u00a0konnte.\u00a0Auch\u00a0der\u00a0Einfluss\u00a0des\u00a0Rote\u2010Hand\u2010Briefs\u00a0zu\u00a0Lartruvo\u00ae ,\u00a0mit\u00a0dem\u00a0im\u00a0\nJanuar\u00a02019\u00a0darauf\u00a0hingewiesen\u00a0wurde,\u00a0dass\u00a0keine\u00a0neuen\u00a0Patiente n\u00a0Olaratumab\u00a0\nbekommen\u00a0sollen,\u00a0kann\u00a0anhand\u00a0dieser\u00a0Daten\u00a0nicht\u00a0beurteilt\u00a0werde n\u00a0(Lilly,\u00a02019b).\u00a0\nEr\u00a0d\u00fcrfte\u00a0aber\u00a0gravierende\u00a0Folgen\u00a0f\u00fcr\u00a0das\u00a0Verordnungsvolumen\u00a0vo n\u00a0Olaratumab\u00a0\ngehabt\u00a0haben.\u00a0\nAbbildung\u00a04.9:\u00a0Verordnete\u00a0Tagesdosen\u00a0(DDD)\u00a0und\u00a0Bruttoums\u00e4tze\u00a0vo n\u00a0\u00a0\nOlaratumab\u00a0nach\u00a0Monaten\u00a0(2016\u00a0\u2013\u00a02017)\u00a0\n\u00a0\n138\u00a0Quellen\u00a0\natd\u00a0\u2013\u00a0Arzneimitteldatenbank\u00a0(2019).\u00a0Olaratumab,\u00a0Bewertung.\u00a0Stan d\u00a0der\u00a0Information:\u00a0Juni\u00a0 2019,\u00a0https: //www.arznei\u2010\ntelegramm.de/db/01pin.php3,\u00a0letzter\u00a0Zugriff:\u00a001.05.2019.\u00a0\na\u2010t\u00a0\u2013\u00a0arznei\u2010telegramm\u00a0(2019).\u00a0Kurz\u00a0und\u00a0b\u00fcndig.\u00a040\u00a0Millionen\u00a0Eu ro\u00a0f\u00fcr\u00a0unwirksames\u00a0Medikament.\u00a0arznei\u2010telegramm\u00a050:\u00a055.\u00a0\nEC\u00a0\u2013\u00a0European\u00a0Commission\u00a0(2015).\u00a0Durchf\u00fchrungsbeschluss\u00a0der\u00a0Kom mission\u00a0vom\u00a012.02.2015\u00a0\u00fcber\u00a0die\u00a0Ausweisung\u00a0des\u00a0\nArzneimittels\u00a0\"Olaratumab\"\u00a0als\u00a0Arzneimittel\u00a0f\u00fcr\u00a0seltene\u00a0Leiden\u00a0 gem\u00e4\u00df\u00a0Verordnung\u00a0(EG)\u00a0Nr.\u00a0141/2000\u00a0des\u00a0\nEurop\u00e4ischen\u00a0Parlaments\u00a0und\u00a0des\u00a0Rates.\u00a0Stand\u00a0der\u00a0Information:\u00a0F ebruar\u00a02015.\u00a0\nhttp://ec.europa.eu/health/documents/community\u2010register/html/o1 447.htm,\u00a0letzter\u00a0Zugriff:\u00a028.02.2019.\u00a0\nEMA\u00a0\u2013\u00a0European\u00a0Medicines\u00a0Agency\u00a0(2015).\u00a0Public\u00a0summary\u00a0of\u00a0opini on\u00a0on\u00a0orphan\u00a0designation.\u00a0Olaratumab\u00a0for\u00a0the\u00a0treatment\u00a0of\u00a0\nsoft\u00a0tissue\u00a0sarcoma.\u00a0Stand\u00a0der\u00a0Information:\u00a0M\u00e4rz\u00a02015.\u00a0https:// www.ema.europa.eu/en/documents/orphan\u2010\ndesignation/eu/3/15/1447\u2010public\u2010summary\u2010opinion\u2010orphan\u2010designat ion\u2010olaratumab\u2010treatment\u2010soft\u2010tissue\u2010\nsarcoma_en.pdf,\u00a0letzter\u00a0Zugriff:\u00a028.02.2019.\u00a0\nEMA\u00a0\u2013\u00a0European\u00a0Medicines\u00a0Agency\u00a0 (2016).\u00a0Assessment\u00a0report\u00a0Lartr uvo.\u00a0Stand\u00a0der\u00a0Information:\u00a0September\u00a02016.\u00a0\nhttps://www.ema.europa.eu/en/documents/assessment\u2010report/lartru vo\u2010epar\u2010public\u2010assessment\u2010report_en.pdf,\u00a0\nletzter\u00a0Zugriff:\u00a028.02.2019.\u00a0\nEMA\u00a0\u2013\u00a0European\u00a0Medicines\u00a0Agency\u00a0(2019a).\u00a0No\u00a0new\u00a0patients\u00a0should \u00a0start\u00a0treatment\u00a0with\u00a0Lartruvo\u00a0after\u00a0study\u00a0shows\u00a0cancer\u00a0\nmedicine\u00a0does\u00a0not\u00a0prolong\u00a0life.\u00a0Stand\u00a0der\u00a0Information:\u00a0Januar\u00a02 019.\u00a0https://www.ema.europa.eu/en/news/no\u2010new\u2010\npatients\u2010should\u2010start\u2010treatment\u2010lartruvo\u2010after\u2010study\u2010shows\u2010canc er\u2010medicine\u2010does\u2010not\u2010prolong,\u00a0letzter\u00a0Zugriff:\u00a0\n28.02.2019.\u00a0\nEMA\u00a0\u2013\u00a0European\u00a0Medicines\u00a0Agency\u00a0(2019b).\u00a0EMA\u00a0recommends\u00a0withdra wal\u00a0of\u00a0marketing\u00a0authorisation\u00a0for\u00a0cancer\u00a0medicine\u00a0\nLartruvo.\u00a0Stand\u00a0der\u00a0Information:\u00a0April\u00a02019.\u00a0https://www.ema.eu ropa.eu/documents/referral/lartruvo\u2010article\u201020\u2010\nreferral\u2010ema\u2010recommends\u2010withdrawal\u2010marketing\u2010authorisation\u2010canc er\u2010medicine_en.pdf,\u00a0letzter\u00a0Zugriff:\u00a001.05.2019.\u00a0\nFachinformation\u00a0Lartruvo\u00ae\u00a0(2019) .\u00a0Lartruvo\u00ae.\u00a0Stand\u00a0der\u00a0Informat ion:\u00a0Januar\u00a02018.\u00a0\nFricke\u00a0U,\u00a0Hein\u00a0L,\u00a0Schwabe\u00a0U\u00a0(2017).\u00a0Neue\u00a0Arzneimittel\u00a02016.\u00a0In: \u00a0Schwabe\u00a0U,\u00a0Paffrath\u00a0D,\u00a0Ludwig\u00a0W\u2010D,\u00a0Klauber\u00a0J\u00a0(Hrsg.)\u00a0(2017).\u00a0\nArzneiverordnungs\u2010Report\u00a02017.\u00a0Berlin,\u00a0Heidelberg.\u00a0Springer:\u00a055 \u2010135.\u00a0\nFDA\u00a0\u2013\u00a0Food\u00a0and\u00a0Drug\u00a0Administatio n\u00a0(2019).\u00a0Olaratumab\u00a0(LARTRUVO) .\u00a0Stand\u00a0der\u00a0Information:\u00a0Januar\u00a02019.\u00a0\nhttps://www.fda.gov/drugs/informationondrugs/approveddrugs/ucm5 26087.htm,\u00a0letzter\u00a0Zugriff:\u00a028.02.2019.\u00a0\nG\u2010BA\u00a0\u2013\u00a0Gemeinsamer\u00a0Bundesausschuss\u00a0(2017).\u00a0Tragende\u00a0Gr\u00fcnde\u00a0zum\u00a0 Beschluss\u00a0des\u00a0Gemeinsamen\u00a0 Bundesausschuss\u00a0\u00fcber\u00a0eine\u00a0\n\u00c4nderung\u00a0des\u00a0Arzneimittelrichtlinie\u00a0(AMRL):\u00a0Anlage\u00a0XII\u00a0\u2013\u00a0Beschl \u00fcsse\u00a0\u00fcber\u00a0die\u00a0Nutzenbewertung\u00a0von\u00a0Arzneimitteln\u00a0\nmit\u00a0neuen\u00a0Wirkstoffen\u00a0nach\u00a0\u00a7\u00a035a\u00a0SGB\u00a0V\u00a0\u2013\u00a0Olaratumab.\u00a0Stand\u00a0der\u00a0 Information:\u00a0Mai\u00a02017.\u00a0https://www.g\u2010\nba.de/downloads/40\u2010268\u20104391/2017\u201005\u201018_AM\u2010RL\u2010XII_Olaratumab_D\u20102 65\u2010TrG.pdf,\u00a0letzter\u00a0Zugriff:\u00a028.02.2019.\u00a0\nLauer\u2010Fischer\u00a0(2019).\u00a0WEBAPO\u00ae\u00a0Infosystem,\u00a0LAUER\u2010TAXE\u00a0online,\u00a0St and\u00a0der\u00a0Information:\u00a0Februar\u00a02019.\u00a0\nhttp://www2.lauerfischer.de/produkte/lauer\u2010taxe/webapo\u2010infosyst em/,\u00a0letzter\u00a0Zugriff:\u00a028.02.2019.\u00a0\nLilly\u00a0Deutschland\u00a0(2019a).\u00a0Rote \u2010Hand\u2010Brief\u00a0zu\u00a0Latruvo\u00ae.\u00a0\nhttps://www.akdae.de/Arzneimittelsicherheit/RHB/Archiv/2019/201 90507.pdf\u00a0,\u00a0letzter\u00a0Zugriff:\u00a007.05.2019.\u00a0\nLilly\u00a0Deutschland\u00a0(2019b).\u00a0Rote\u2010H and\u2010Brief\u00a0zu\u00a0Latruvo\u00ae.\u00a0https:/ /www.akdae.de/Arzneimittelsiche rheit/RHB/20190128.pdf,\u00a0letzter\u00a0\nZugriff:\u00a007.05.2019\u00a0\nMoroncini\u00a0G,\u00a0Maccaroni\u00a0E,\u00a0Fiordo liva\u00a0I,\u00a0Pellei\u00a0C,\u00a0Gabrielli\u00a0A,\u00a0 Berardi\u00a0R\u00a0(2018).\u00a0Developments\u00a0in\u00a0the\u00a0management\u00a0of\u00a0advanced\u00a0so ft\u2010\ntissue\u00a0sarcoma\u00a0\u2010\u00a0olaratumab\u00a0in\u00a0context.\u00a0Onco\u00a0Targets\u00a0Ther\u00a011:\u00a08 33\u2010842.\u00a0\u00a0139\u00a0NIH\u00a0\u2013\u00a0U.S.\u00a0National\u00a0Library\u00a0of\u00a0M edicine\u00a0(2019).\u00a0A\u00a0Study\u00a0of\u00a0Doxo rubicin\u00a0Plus\u00a0Olaratumab\u00a0(LY3012207)\u00a0in\u00a0Participants\u00a0With\u00a0Advanc ed\u00a0\nor\u00a0Metastatic\u00a0Soft\u00a0Tissue\u00a0Sarcoma\u00a0(ANNOUNCE).\u00a0Stand\u00a0der\u00a0Informa tion:\u00a0Februar\u00a02019.\u00a0\nhttps://clinicaltrials.gov/ct2/show/NCT02451943,\u00a0letzter\u00a0Zugrif f:\u00a028.02.2019.\u00a0\nPZ\u00a0\u2013\u00a0Pharmazeutische\u00a0Zeitung\u00a0online\u00a0(2016).\u00a0Neue\u00a0Arzneistoffe,\u00a0 Olaratumab|Lartruvo\u00ae|86|2016.\u00a0https://www.pharmazeutische\u2010\nzeitung.de/arzneistoffe/daten/2016/olaratumablartruvo8482862016 /,\u00a0letzter\u00a0Zugriff:\u00a028.02.2019.\u00a0\nTap\u00a0WD,\u00a0Jones\u00a0RL,\u00a0Van\u00a0Tine\u00a0BA,\u00a0C hmielowski\u00a0B,\u00a0Elias\u00a0AD,\u00a0Adkins\u00a0 D\u00a0et\u00a0al.\u00a0(2016).\u00a0Olaratumab\u00a0and\u00a0doxorubicin\u00a0vs.\u00a0doxorubicin\u00a0alo ne\u00a0\nfor\u00a0treatment\u00a0of\u00a0soft\u2010tissue\u00a0sarcoma:\u00a0an\u00a0open\u2010label\u00a0phase\u00a01b\u00a0an d\u00a0randomised\u00a0phase\u00a02\u00a0trial.\u00a0Lancet\u00a0\u00a0388\u00a0(10043):\u00a0\n488\u2010497.\u00a0\n\u00a0\u00a0140\u00a0 Opicapon\u00a04.12\nHandelsname:\u00a0Ongentys\u00ae\u00a0\u00a0 \u00a0 Pharmazeutischer\u00a0Unternehmer:\u00a0\u00a0\nIndikation:\u00a0Morbus\u00a0Parkinson\u00a0 \u00a0 Bial\u2010Portela\u00a0\nATC\u2010Code:\u00a0N04BX04\u00a0 \u00a0 \u00a0 Markteinf\u00fchrung:\u00a0Februar\u00a02014\u00a0\nDarreichungsform:\u00a0Hartkapseln\u00a0 \u00a0 DDD:\u00a050 \u00a0mg\u00a0O\u00a0 \u00a0 \u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 \u25bc\u00a0\nBewertung\u00a0\nO p i c a p o n \u00a0w u r d e \u00a0i m \u00a0J u n i \u00a02 0 1 6 \u00a0a l s \u00a0d r i t t e r \u00a0H e m m s t o f f \u00a0d e r \u00a0C a t c h e o l \u2010 O\u2010Methyl\u2010\ntransferase\u00a0(COMT)\u00a0von\u00a0der\u00a0Europ \u00e4ischen\u00a0Kommission\u00a0zentral\u00a0f\u00fcr\u00a0 die\u00a0Behandlung\u00a0\nvon\u00a0erwachsenen\u00a0Patienten\u00a0mit\u00a0Parkinson\u2010Erkrankung\u00a0zugelassen,\u00a0 die\u00a0bereits\u00a0eine\u00a0\nKombination\u00a0aus\u00a0Levodopa\u00a0und\u00a0eine m\u00a0Dopa\u2010Decarboxylase\u2010Hemmer\u00a0ei nnehmen\u00a0\nund\u00a0deren\u00a0 End\u2010of\u2010dose \u2010Wirkungsfluktuationen\u00a0nicht\u00a0ausreichend\u00a0auf\u00a0diese\u00a0Behand\u2010\nlung\u00a0ansprechen.\u00a0Opicapon\u00a0hemmt\u00a0den\u00a0Abbau\u00a0von\u00a0Levodopa\u00a0und\u00a0erh\u00f6 ht\u00a0so\u00a0die\u00a0\nPlasmaspiegel.\u00a0F\u00fcr\u00a0Erwachsene\u00a0ab\u00a085\u00a0Jahren\u00a0liegen\u00a0nur\u00a0begrenzte \u00a0Erfahrungen\u00a0vor.\u00a0\u00a0\nOpicapon\u00a0wird\u00a0in\u00a0einer\u00a0Dosis\u00a0von\u00a050\u00a0mg\u00a0(entspricht\u00a0zwei\u00a0Hartkap seln)\u00a0einmal\u00a0t\u00e4g\u2010\nlich\u00a0abends\u00a0vor\u00a0dem\u00a0Schlafengehen \u00a0eingenommen,\u00a0mindestens\u00a0eine\u00a0 Stunde\u00a0vor\u00a0\noder\u00a0nach\u00a0der\u00a0Levodopa/Dopa\u2010Deca rboxylase\u2010Hemmer\u2010Einnahme\u00a0(EMA, \u00a02017).\u00a0\u00a0\nDie\u00a0Zulassung\u00a0beruht\u00a0auf\u00a0zwei\u00a0pivotalen\u00a0randomisierten,\u00a0kontrol lierten,\u00a0doppel\u2010\nblinden,\u00a0 multizentrischen\u00a0 Phase\u2010III\u2010Studien\u00a0 an\u00a0 Patientinnen\u00a0 und \u00a0P a t i e n t e n \u00a0m i t \u00a0\nidiopathischem\u00a0 Parkinson\u2010Syndrom\u00a0 und\u00a0 motorischen\u00a0 End\u2010of\u2010Dose \u2010Fluktuationen\u00a0\ntrotz\u00a0optimierter\u00a0Therapie\u00a0mit\u00a0L\u2010Dopa\u00a0und\u00a0einem\u00a0Dopa\u2010Decarboxyl ase\u2010Hemmer.\u00a0In\u00a0\nbeiden\u00a0Studien\u00a0wurde\u00a0diese\u00a0Medikation\u00a0in\u00a0stabiler\u00a0Dosis\u00a0weiterg ef\u00fchrt\u00a0und\u00a0die\u00a0\nStudiendauer\u00a0lag\u00a0bei\u00a014\u00a0bis\u00a015\u00a0Wochen\u00a0(EMA,\u00a02016).\u00a0\nAn\u00a0der\u00a0BIPARK\u20101\u2010Studie\u00a0(Ferreira\u00a0et\u00a0al.,\u00a02016)\u00a0nahmen\u00a0600\u00a0Patie nten\u00a0im\u00a0mittleren\u00a0\nAlter\u00a0von\u00a0etwa\u00a064\u00a0Jahren\u00a0teil,\u00a0d ie\u00a0seit\u00a0etwa\u00a0sieben\u00a0bis\u00a0acht\u00a0Ja hren\u00a0an\u00a0Morbus\u00a0Par\u2010\nkinson\u00a0litten\u00a0und\u00a0bei\u00a0denen\u00a0seit\u00a0etwa\u00a0zwei\u00a0Jahren\u00a0motorische\u00a0Fl uktuationen\u00a0be\u2010\nstanden.\u00a0Als\u00a0Studienmedikation\u00a0diente\u00a0in\u00a0den\u00a0f\u00fcnf\u00a0Behandlungsar men\u00a0Opicapon\u00a0in\u00a0\neiner\u00a0von\u00a0drei\u00a0Dosierungen\u00a0(5\u00a0mg,\u00a025\u00a0mg\u00a0bzw.\u00a050\u00a0mg),\u00a0Placebo\u00a0od er\u00a0(als\u00a0aktive\u00a0\nKontrolle)\u00a0Entacapon\u00a0200\u00a0mg.\u00a0\nPrim\u00e4rer\u00a0Endpunkt\u00a0der\u00a0Studie\u00a0war\u00a0die\u00a0mittlere\u00a0Ver\u00e4nderung\u00a0der\u00a0 off\u2010Zeit\u00a0im\u00a0Ver\u2010\ngleich\u00a0zum\u00a0Ausgangswert.\u00a0Dabei\u00a0war\u00a0Opicapon\u00a050\u00a0mg,\u00a0aber\u00a0nicht\u00a0d ie\u00a0anderen\u00a0\nDosierungen,\u00a0 Placebo\u00a0 signifikant \u00a0 \u00fcberlegen.\u00a0 Gegen\u00fcber\u00a0 Entacapon \u00a0k o n n t e \u00a0f \u00fc r \u00a0\nOpicapon\u00a050\u00a0mg\u00a0Nicht\u2010Unterlegenheit\u00a0belegt\u00a0werden:\u00a0Die\u00a0 off\u2010Zeit\u00a0nahm\u00a0mit\u00a0Opi\u2010\ncapon\u00a050\u00a0mg\u00a0um\u00a0etwa\u00a0117\u00a0Minuten\u00a0ab,\u00a0mit\u00a0Placebo\u00a0um\u00a056\u00a0Minuten\u00a0u nd\u00a0mit\u00a0En\u2010\ntacapon\u00a0um\u00a0rund\u00a096\u00a0Minuten.\u00a0\u00a0141\u00a0An\u00a0der\u00a0BIPARK\u20102\u2010Studie\u00a0(Lees\u00a0et\u00a0al.,\u00a02017)\u00a0nahmen\u00a0427\u00a0Patienten \u00a0im\u00a0mittleren\u00a0\nAlter\u00a0von\u00a0etwa\u00a062\u00a0bis\u00a066\u00a0Jahren\u00a0 teil,\u00a0die\u00a0seit\u00a0etwa\u00a0acht\u00a0Jahren \u00a0an\u00a0Morbus\u00a0Parkinson\u00a0\nlitten\u00a0und\u00a0bei\u00a0denen\u00a0seit\u00a0etwa\u00a0dr ei\u00a0Jahren\u00a0motorische\u00a0Fluktuati onen\u00a0bestanden.\u00a0\nAls\u00a0Studienmedikation\u00a0diente\u00a0in\u00a0den\u00a0drei\u00a0Behandlungsarmen\u00a0Opica pon\u00a025\u00a0mg,\u00a0\nOpicapon\u00a050\u00a0mg\u00a0bzw.\u00a0Placebo.\u00a0\nPrim\u00e4rer\u00a0Endpunkt\u00a0der\u00a0Studie\u00a0war\u00a0die\u00a0mittlere\u00a0Ver\u00e4nderung\u00a0der\u00a0 off\u2010Zeit\u00a0im\u00a0Ver\u2010\ngleich\u00a0zum\u00a0Ausgangswert.\u00a0Nur\u00a0f\u00fcr\u00a0die\u00a0Dosierung\u00a0mit\u00a050\u00a0mg\u00a0zeigte \u00a0sich\u00a0ein\u00a0signifi\u2010\nkanter\u00a0Unterschied\u00a0zu\u00a0Placebo:\u00a0Die\u00a0 off\u2010Zeit\u00a0nahm\u00a0mit\u00a0Opicapon\u00a050\u00a0mg\u00a0um\u00a0etwa\u00a0\n124\u00a0Minuten\u00a0und\u00a0mit\u00a0Placebo\u00a0um\u00a0etwa\u00a065\u00a0Minuten\u00a0ab.\u00a0\u00a0\nIn\u00a0beiden\u00a0Studien\u00a0war\u00a0im\u00a0Hinblick\u00a0auf\u00a0die\u00a0gesundheitsbezogene\u00a0L ebensqualit\u00e4t\u00a0\nkein\u00a0Unterschied\u00a0zwischen\u00a0den\u00a0 Behandlungsgruppen\u00a0nachweisbar.\u00a0\nZum\u00a0Zeitpunkt\u00a0der\u00a0Zulassung\u00a0beruhte\u00a0der\u00a0Erfahrungsumfang\u00a0im\u00a0Hin blick\u00a0auf\u00a0die\u00a0\nSicherheit\u00a0auf\u00a0der\u00a0Behandlung\u00a0von\u00a0knapp\u00a0800\u00a0Patienten\u00a0mit\u00a0Parki nson\u2010Erkrankung.\u00a0\nIn\u00a0 den\u00a0 Zulassungsstudien\u00a0 traten\u00a0 als\u00a0 unerw\u00fcnschte\u00a0 Arzneimitteler eignisse\u00a0 sehr\u00a0\nh\u00e4ufig\u00a0 Dyskinesien\u00a0 auf,\u00a0 h\u00e4ufig\u00a0 Verstopfung,\u00a0 Schlafst\u00f6rungen,\u00a0 tr ockener\u00a0 Mund,\u00a0\nSchwindel\u00a0und\u00a0eine\u00a0Erh\u00f6hung\u00a0der\u00a0 Creatinphosphokinase\u00a0im\u00a0Blut\u00a0(E MA,\u00a02016).\u00a0Die\u00a0\nFachinformation\u00a0enth\u00e4lt\u00a0den\u00a0Hinweis,\u00a0dass\u00a0unter\u00a0Opicapon\u00a0wie\u00a0be i\u00a0allen\u00a0dopami\u2010\nnergen\u00a0Arzneimitteln\u00a0Impulskontrollst\u00f6rungen\u00a0auftreten\u00a0k\u00f6nnen\u00a0( EMA,\u00a02017).\u00a0\nAls\u00a0zweckm\u00e4\u00dfige\u00a0Vergleichstherapie\u00a0f\u00fcr\u00a0die\u00a0fr\u00fche\u00a0Nutzenbewertun g\u00a0wurde\u00a0die\u00a0\nZusatztherapie\u00a0 mit\u00a0 einem\u00a0 Non\u2010Ergot\u2010Dopaminagonisten,\u00a0 einem\u00a0 COMT \u2010Hemmer\u00a0\noder\u00a0einem\u00a0MAO\u2010B\u2010Hemmer\u00a0herangez ogen.\u00a0Basis\u00a0des\u00a0vom\u00a0pU\u00a0vorgeleg ten\u00a0Dos\u2010\nsiers\u00a0bildete\u00a0die\u00a0Studie\u00a0BIPARK\u20101,\u00a0bei\u00a0der\u00a0die\u00a0Wirksamkeit\u00a0von\u00a0 Opicapon\u00a0mit\u00a0der\u00a0\nvon\u00a0Entacapon\u00a0verglichen\u00a0wurde.\u00a0Da\u00a0der\u00a0G\u2010BA\u00a0bereits\u00a0im\u00a0Rahmen\u00a0e ines\u00a0anderen\u00a0\nVerfahrens\u00a0in\u00a0der\u00a0Indikation\u00a0Morbus\u00a0Parkinson\u00a0entschieden\u00a0hatte ,\u00a0dass\u00a0eine\u00a0Stu\u2010\ndiendauer\u00a0von\u00a014\u00a0bis\u00a015\u00a0Wochen\u00a0f\u00fcr\u00a0die\u00a0Nutzenbewertung\u00a0in\u00a0diese r\u00a0Indikation\u00a0\nnicht\u00a0ausreichend\u00a0ist,\u00a0kam\u00a0das\u00a0IQWiG\u2010Gutachten\u00a0im\u00a0Januar\u00a02017\u00a0z u\u00a0dem\u00a0Schluss,\u00a0\ndass\u00a0 keine\u00a0 geeigneten\u00a0 Daten\u00a0 vorlie gen\u00a0 und\u00a0 ein\u00a0 Zusatznutzen\u00a0 nich t\u00a0 belegt\u00a0 ist\u00a0\n(IQWiG,\u00a02017a).\u00a0\nNach\u00a0dem\u00a0Stellungnahmeverfahren\u00a0e ntschied\u00a0der\u00a0G\u2010BA,\u00a0dass\u00a0f\u00fcr\u00a0ei nzelne\u00a0Morbidi\u2010\nt\u00e4tsendpunkte\u00a0 die\u00a0 kurze\u00a0 Studienda uer\u00a0 m\u00f6glicherweise\u00a0 doch\u00a0 ausrei chend\u00a0 sein\u00a0\nk\u00f6nnte\u00a0und\u00a0beauftragte\u00a0das\u00a0IQWiG\u00a0daher,\u00a0die\u00a0Studie\u00a0BIPARK\u20101\u00a0als \u00a0Basis\u00a0der\u00a0Nut\u2010\nzenbewertung\u00a0heranzuziehen.\u00a0In\u00a0de m\u00a0erg\u00e4nzenden\u00a0Gutachten,\u00a0ver\u00f6f fentlicht\u00a0im\u00a0\nM\u00e4rz\u00a02017,\u00a0wurde\u00a0festgestellt,\u00a0da ss\u00a0sich\u00a0bei\u00a0den\u00a0parkinsonspezi fischen\u00a0Endpunk\u2010\nten\u00a0und\u00a0den\u00a0Nebenwirkungen\u00a0keine\u00a0wesentlichen\u00a0Unterschiede\u00a0zwis chen\u00a0Opica\u2010\npon\u00a0und\u00a0Entacapon\u00a0als\u00a0Zusatztherapie\u00a0zeigen.\u00a0Ein\u00a0 Zusatznutzen \u00a0gegen\u00fcber\u00a0der\u00a0\nzweckm\u00e4\u00dfigen\u00a0Vergleichstherapie\u00a0ist\u00a0entsprechend\u00a0 nicht\u00a0belegt \u00a0(IQWiG,\u00a02017b).\u00a0\nDieser\u00a0Einsch\u00e4tzung\u00a0schloss\u00a0sich \u00a0der\u00a0G\u2010BA\u00a0im\u00a0M\u00e4rz\u00a02017\u00a0an\u00a0(G\u2010BA ,\u00a02017).\u00a0\u00a0142\u00a0Verf\u00fcgbare\u00a0Therapien \u00a0 (Zusatz\u2010)Nutzen \u00a0 Kosten\u00a0\n\u00a0\ndritter\u00a0COMT\u2010Hemmer\u00a0\nohne\u00a0nachgewiesene\u00a0\ntherapeutische\u00a0Vorteile\u00a0\u00a0\nZusatznutzen\u00a0nicht\u00a0belegt\u00a0\u00a0\nteils\u00a0g\u00fcnstiger,\u00a0teils\u00a0teurer\u00a0\nals\u00a0zVT\u00a0\nErl\u00e4uterung\u00a0der\u00a0Farben:\u00a0Verf\u00fcgbare\u00a0Therapien:\u00a0rot\u00a0=\u00a0weitere\u00a0The rapieoption,\u00a0gelb\u00a0=\u00a0Subgruppen\u2010Novit\u00e4t,\u00a0gr\u00fcn\u00a0=\u00a0Solist;\u00a0(Zusatz\u2010 )\u00a0\nNutzen:\u00a0rot\u00a0=\u00a0keine\u00a0Verbesserung\u00a0oder\u00a0schlechte\u00a0Nutzen/Schaden\u2010 Relation,\u00a0gelb\u00a0=\u00a0teilweise\u00a0Verbesserungen,\u00a0gr\u00fcn\u00a0=\u00a0Verbesserung\u00a0\nharter\u00a0Endpunkte;\u00a0Kosten:\u00a0rot\u00a0=\u00a0teurer\u00a0als\u00a0bestehende\u00a0Therapien ,\u00a0gelb\u00a0=\u00a0ungef\u00e4hr\u00a0gleich\u00a0bzw.\u00a0teils/teils,\u00a0gr\u00fcn\u00a0=\u00a0g\u00fcnstiger\u00a0als \u00a0\nbestehende\u00a0Therapien\u00a0\nWie\u00a0bewerten\u00a0andere?\u00a0\nBewertung\u00a0nach\u00a0\nFricke\u00a0et\u00a0al.\u00a0atd\u2010Bewertung\u00a0 AMB\u00a0 Prescrire\u00a0 PZ\u00a0\nC\u00a0Variante\u00a0ohne\u00a0\nbesonderen\u00a0\nStellenwert\u00a0\u00a0\u2013\u00a0 \u2013\u00a0 Schrittinnovation\u00a0\nKosten\u00a0\nWirkstoff\u00a0 Behandlungsmodus\u00a0 Behandlungstage\u00a0 Jahrestherapiekosten\u00a0\nzu\u00a0bewertendes\u00a0Arzneimittel \u00a0\u00a0 \u00a0 \u00a0\nOpicapon\u00a0 1x\u00a0tgl.\u00a050\u00a0mg\u00a0 365\u00a0 1.306,70\u00a0\u20ac\u00a0\n\u00a0 \u00a0 \u00a0 \u00a0\nzVT\u00a0Non\u2010Ergot\u2010Dopaminagonisten\u00a0 \u00a0 \u00a0 \u00a0\nPiribedil\u00a0 3x\u00a0tgl.\u00a0150\u00a0\u2013\u00a0250\u00a0mg\u00a0 365\u00a0 3.261,95\u00a0\u2013\u00a05.436,58\u00a0\u20ac\u00a0\nPramipexol\u00a0 3x\u00a0tgl.\u00a00,26\u2013\u00a03,30\u00a0mg\u00a0 365\u00a0 252,95\u00a0\u2013\u00a01.024,37\u00a0\u20ac\u00a0\nPramipexol\u00a0retardiert\u00a0 1x\u00a0tgl.\u00a00,26\u00a0\u2013\u00a03,15\u00a0mg\u00a0 365\u00a0 168,96\u00a0\u2013\u00a01.505,55\u00a0\u20ac\u00a0\nRopinirol\u00a0 3x\u00a0tgl.\u00a03\u00a0\u2013\u00a024\u00a0mg\u00a0 365\u00a0 591,43\u00a0\u2013\u00a05.065,68\u00a0\u20ac\u00a0\nRopinirol\u00a0retardiert\u00a0 1x\u00a0tgl.\u00a04\u00a0\u2013\u00a024\u00a0mg\u00a0 365\u00a0 594,21\u00a0\u2013\u00a03.505,17\u00a0\u20ac\u00a0\nRotigotion\u00a0 1x\u00a0tgl.\u00a04\u00a0\u2013\u00a016\u00a0mg\u00a0 365\u00a0 3.245,28\u00a0\u2013\u00a08.217,98\u00a0\u20ac\u00a0\nzVT\u00a0COMT\u2010Hemmer\u00a0 \u00a0 \u00a0 \u00a0\nEntacapon\u00a03\u00a0\u2013\u00a010x\u00a0tgl.\u00a0600\u00a0\u2013\u00a0\u00a0\n2.000\u00a0mg*\u00a0365\u00a0 717,44\u00a0\u2013\u00a02.391,48\u00a0\u20ac\u00a0\nzVT\u00a0MAO\u2010B\u2010Hemmer\u00a0 \u00a0 \u00a0 \u00a0\nRasagilin\u00a0 1x\u00a0tgl.\u00a01\u00a0mg\u00a0 365\u00a0 853,63\u00a0\u20ac\u00a0\nSafinamid\u00a0 1x\u00a0tgl.\u00a050\u00a0\u2013\u00a0100\u00a0mg\u00a0 365\u00a0 1.045,21\u00a0\u20ac\u00a0\nSelegilin\u00a0 1x\u00a0tgl.\u00a05\u00a0\u2013\u00a010\u00a0mg\u00a0 365\u00a0 153,99\u00a0\u2013\u00a0277,77\u00a0\u20ac\u00a0\n\u00a0\n\u00a0 \u00a0\n143\u00a0Versorgungsanalysen\u00a0\nSeit\u00a0der\u00a0Markteinf\u00fchrung\u00a0im\u00a0Oktober\u00a02016\u00a0nehmen\u00a0die\u00a0Verordnunge n\u00a0von\u00a0Opica\u2010\npon\u00a0nahezu\u00a0kontinuierlich\u00a0zu,\u00a0dabei\u00a0laufen\u00a0verordnete\u00a0DDD\u00a0und\u00a0B ruttoums\u00e4tze\u00a0\nweitestgehend\u00a0 parallel.\u00a0 Weder\u00a0 d ie\u00a0 Ver\u00f6ffentlichung\u00a0 des\u00a0 IQWiG\u2010Gu tachtens\u00a0 im\u00a0\nJanuar\u00a02017\u00a0noch\u00a0der\u00a0G\u2010BA\u2010Beschluss\u00a0im\u00a0M\u00e4rz\u00a02017\u00a0spiegeln\u00a0sich\u00a0 in\u00a0den\u00a0Verord\u2010\nnungszahlen\u00a0wider.\u00a0\u00a0\nAbbildung\u00a04.10:\u00a0Verordnete\u00a0Tages dosen\u00a0(DDD)\u00a0und\u00a0Bruttoums\u00e4tze\u00a0v on\u00a0Opi\u2010\ncapon\u00a0nach\u00a0Monaten\u00a0(2016\u00a0\u2013\u00a02017)\u00a0\n\u00a0\n\u00a0\nQuellen\u00a0\natd\u00a0\u2013\u00a0\u00a0arznei\u2010telegramm\u00a0Arzneimitteldatenbank\u00a0(2016).\u00a0Wirkstoff :\u00a0Opicapon.\u00a0https://www.arznei\u2010\ntelegramm.de/db/0codewkstxt.php3?&knr=&art=mono&nummer=BGDT&ord =uaw,\u00a0letzter\u00a0Zugriff:\u00a006.03.2019.\u00a0\nEMA\u00a0\u2013\u00a0European\u00a0Medicines\u00a0Agency\u00a0(2016).\u00a0EPAR\u00a0(Public\u00a0Assessment \u00a0Report)\u00a0Ongentys.\u00a0\nhttps://www.ema.europa.eu/en/medicines/human/EPAR/ongentys,\u00a0let zter\u00a0Zugriff:\u00a006.03.2019.\u00a0\nEMA\u00a0\u2013\u00a0European\u00a0Medicines\u00a0Agency\u00a0 (2017).\u00a0Fachinformation\u00a0Ongenty s\u00a0(Stand\u00a002.02.2017).\u00a0\nhttps://www.ema.europa.eu/en/documents/product\u2010information/onge ntys\u2010epar\u2010product\u2010information_en.pdf,\u00a0\nletzter\u00a0Zugriff:\u00a006.03.2019.\u00a0\n144\u00a0Ferreira\u00a0JJ,\u00a0Lees\u00a0A,\u00a0Rocha\u00a0J\u2010F,\u00a0Po ewe\u00a0W,\u00a0Rascol\u00a0O,\u00a0Soares\u2010da\u2010Si lva\u00a0\u00a0P\u00a0et\u00a0al.\u00a0(2016).\u00a0Opicapone\u00a0as\u00a0an\u00a0adjunct\u00a0to\u00a0levodopa\u00a0in\u00a0pa tients\u00a0\nwith\u00a0Parkinson\u2019s\u00a0disease\u00a0and\u00a0end\u2010of\u2010dose\u00a0motor\u00a0fluctuations:\u00a0a\u00a0 randomised,\u00a0double\u2010blind,\u00a0controlled\u00a0trial.\u00a0The\u00a0\nLancet\u00a0Neurology\u00a015(2):\u00a0154\u2013165.\u00a0\u00a0\nFricke\u00a0U,\u00a0Hein\u00a0L,\u00a0Schwabe\u00a0U\u00a0(2017).\u00a0Neue\u00a0Arzneimittel\u00a02016.\u00a0In: \u00a0Schwabe\u00a0U,\u00a0Paffrath\u00a0D,\u00a0Ludwig\u00a0W\u2010D,\u00a0Klauber\u00a0J\u00a0(Hrsg.)\u00a0(2017).\u00a0\nArzneiverordnungs\u2010Report\u00a02017.\u00a0Berlin,\u00a0Heidelberg.\u00a0Springer:\u00a055 \u2010135.\u00a0\nG\u2010BA\u00a0\u2013\u00a0Gemeinsamer\u00a0Bundesausschuss\u00a0(2017).\u00a0Nutzenbewertungsverf ahren\u00a0zum\u00a0Wirkstoff\u00a0Opicapon.\u00a0https://www.g\u2010\nba.de/informationen/nutzenbewertung/260/,\u00a0letzter\u00a0Zugriff:\u00a006.0 3.2019.\u00a0\nIQWiG\u00a0\u2013\u00a0Institut\u00a0f\u00fcr\u00a0Qualit\u00e4t\u00a0und\u00a0Wirtschaftlichkeit\u00a0im\u00a0Gesundh eitswesen\u00a0(2017a).\u00a0[A16\u201061]\u00a0Opicapon\u00a0(Morbus\u00a0Parkinson)\u00a0\u2010\u00a0\nNutzenbewertung\u00a0gem\u00e4\u00df\u00a0\u00a7\u00a035a\u00a0SGB\u00a0V.\u00a0https://www.iqwig.de/de/proj ekte\u2010\nergebnisse/projekte/arzneimittelbewertung/2016/a16\u201061\u2010opicapon\u2010 morbus\u2010parkinson\u2010nutzenbewertung\u2010gemaess\u2010\n35a\u2010sgb\u2010v.7706.html,\u00a0letzter\u00a0Zugriff:\u00a006.03.2019.\u00a0\nIQWiG\u00a0\u2013\u00a0Institut\u00a0f\u00fcr\u00a0Qualit\u00e4t\u00a0und\u00a0Wirtschaftlichkeit\u00a0im\u00a0Gesundh eitswesen\u00a0(2017b).\u00a0[A17\u201004]\u00a0Opicapon\u00a0(Morbus\u00a0Parkinson)\u00a0\u2010\u00a0\nAddendum\u00a0zum\u00a0Auftrag\u00a0A16\u201061.\u00a0https://www.iqwig.de/de/projekte\u2010e rgebnisse/projekte\u2010\n301/arzneimittelbewertung/2017/a17\u201004\u2010opicapon\u2010morbus\u2010parkinson \u2010addendum\u2010zum\u2010auftrag\u2010a16\u201061.7795.html,\u00a0\nletzter\u00a0Zugriff:\u00a006.03.2019.\u00a0\nLees\u00a0AJ,\u00a0Ferreira\u00a0J,\u00a0Rascol\u00a0O,\u00a0Poewe\u00a0W,\u00a0Rocha\u00a0JF,\u00a0McCrory\u00a0M\u00a0et\u00a0 al.\u00a0(2017).\u00a0Opicapone\u00a0as\u00a0Adjunct\u00a0to\u00a0Levodopa\u00a0Therapy\u00a0in\u00a0Patient s\u00a0\nWith\u00a0Parkinson\u00a0Disease\u00a0and\u00a0Motor\u00a0Fluctuations.\u00a0JAMA\u00a0Neurology\u00a07 4(2):\u00a0197.\u00a0\u00a0\nPZ\u00a0\u2013\u00a0Pharmazeutische\u00a0Zeitung\u00a0(2016).\u00a0Opicapon|Ongentys|70|2016. \u00a0https://www.pharmazeutische\u2010\nzeitung.de/arzneistoffe/daten/2016/opicaponongentysr702016/,\u00a0le tzter\u00a0Zugriff:\u00a006.03.2019.\u00a0\n\u00a0 \u00a0145\u00a0 Osimertinib\u00a04.13\nHandelsname:\u00a0Tagrisso\u00ae\u00a0 \u00a0 \u00a0 Pharm azeutischer\u00a0Unternehmer:\u00a0\u00a0\nIndikation:\u00a0nicht\u2010kleinzell.\u00a0Lungenkarzinom\u00a0 AstraZeneca\u00a0\nATC\u2010Code:\u00a0L01XE35\u00a0 \u00a0 \u00a0 Mar kteinf\u00fchrung:\u00a0M\u00e4rz\u00a02016\u00a0\nDarreichungsform:\u00a0Filmtabletten\u00a0 \u00a0 DDD:\u00a080 \u00a0mg\u00a0\u00a0 \u00a0 \u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 \u25bc\u00a0\nBewertung\u00a0\nOsimertinib\u00a0ist\u00a0ein\u00a0Tyrosinkinas e\u2010Inhibitor\u00a0(TKI),\u00a0der\u00a0selektiv \u00a0und\u00a0irreversibel\u00a0epi\u2010\ndermale\u00a0Wachstumsfaktor\u2010Rezeptor \u00a0(EGFR)\u2010Varianten\u00a0mit\u00a0aktiviere nden\u00a0Mutatio\u2010\nnen\u00a0(EGFRm)\u00a0und\u00a0mit\u00a0der\u00a0Mutation\u00a0T790M\u00a0hemmt,\u00a0die\u00a0ma\u00dfgeblich\u00a0f\u00fc r\u00a0die\u00a0Resis\u2010\ntenz\u00a0gegen\u00fcber\u00a0TKI\u00a0verantwortlich\u00a0ist.\u00a0Dadurch\u00a0wirkt\u00a0Osimertini b\u00a0antitumoral\u00a0und\u00a0\nantiproliferativ\u00a0(Fachinformation\u00a0Tagrisso\u00ae,\u00a02018).\u00a0 \u00a0\nDer\u00a0EGFR\u00a0geh\u00f6rt\u00a0zur\u00a0sogenannten\u00a0 ErbB\u2010Familie,\u00a0die\u00a0aus\u00a0den\u00a0vier\u00a0 eng\u00a0verwandten\u00a0\nRezeptor\u2010Tyrosinkinasen\u00a0EGFR\u00a0(ErbB1),\u00a0HER2\u00a0(ErbB2),\u00a0ErbB3\u00a0und\u00a0E rbB4\u00a0besteht\u00a0\n(Sharma\u00a0et\u00a0al.,\u00a02007). \u00a0Eine\u00a0verst\u00e4rkte\u00a0Aktivierung\u00a0oder\u00a0Mutation\u00a0dieser\u00a0Tyrosin\u2010\nkinasen\u00a0kann\u00a0zu\u00a0einer\u00a0abnormen\u00a0Stimulation\u00a0intrazellul\u00e4rer\u00a0Sign alwege\u00a0mit\u00a0der\u00a0\nFolge\u00a0unkontrollierter\u00a0Zellproliferation\u00a0und\u00a0Hemmung\u00a0der\u00a0Apopto se\u00a0f\u00fchren. \u00a0\nBeim\u00a0 nicht\u2010kleinzelligen\u00a0 Lungenkarzinom\u00a0 ( Non\u2010Small\u00a0 Cell\u00a0 Lung\u00a0 Cancer ,\u00a0 NSCLC),\u00a0\ninsbesondere\u00a0bei\u00a0der\u00a0Progression \u00a0der\u00a0Erkrankung,\u00a0spielen\u00a0onkoge ne\u00a0Treibermuta\u2010\ntionen\u00a0des\u00a0EGFR\u00a0eine\u00a0gro\u00dfe\u00a0Rolle\u00a0(Bansal\u00a0et\u00a0al.,\u00a02016).\u00a0Sie\u00a0lie gen\u00a0bei\u00a010\u00a0bis\u00a015\u00a0%\u00a0\nder\u00a0NSCLC\u2010Patienten\u00a0kaukasischer \u00a0Herkunft\u00a0und\u00a0bei\u00a0etwa\u00a040\u00a0%\u00a0der \u00a0Patienten\u00a0asia\u2010\ntischer\u00a0Herkunft\u00a0vor.\u00a0Infolge\u00a0einer\u00a0ligandenunabh\u00e4ngigen\u00a0Aktivi erung\u00a0des\u00a0Rezep\u2010\ntors\u00a0ist\u00a0das\u00a0Gleichgewicht\u00a0zwischen\u00a0Apoptose\u00a0und\u00a0Proliferation\u00a0 gest\u00f6rt,\u00a0wodurch\u00a0\nTumorwachstum\u00a0und\u00a0\u2010ausbreitung\u00a0b eg\u00fcnstigt\u00a0werden.\u00a0\u00dcber\u00a080\u00a0%\u00a0der \u00a0aktivieren\u2010\nden\u00a0 EGFR\u2010Aberrationen\u00a0 sind\u00a0 Deletionen\u00a0 in\u00a0 Exon\u00a0 19\u00a0 (del19)\u00a0 und\u00a0 L8 58R\u2010\nPunktmutationen\u00a0in\u00a0Exon\u00a021\u00a0(Michels\u00a0&\u00a0Wolf,\u00a02018).\u00a0Bei\u00a0den\u00a0wese ntlich\u00a0seltene\u2010\nren\u00a0EGFR\u2010Mutationen\u00a0(UC,\u00a0 Uncommon\u00a0Mutations )\u00a0wird\u00a0zwischen\u00a0TKI\u2010sensitiven\u00a0\n(UC\u00a0I\u00a0und\u00a0UC\u00a0II)\u00a0und\u00a0TKI\u2010resistenten\u00a0Mutationen\u00a0(UC\u00a0III,\u00a0z.B.\u00a0E xon\u00a020\u00a0Insertionsmu\u2010\ntation)\u00a0unterschieden\u00a0(Griesinger\u00a0et\u00a0al.,\u00a02018).\u00a0Die\u00a0ersten\u00a0bei m\u00a0NSCLC\u00a0eingesetz\u2010\nten\u00a0TKI\u00a0gegen\u00a0den\u00a0in\u00a0den\u00a0Tumorze llen\u00a0verst\u00e4rkt\u00a0aktivierten\u00a0EGFR \u2010Signalweg\u00a0waren\u00a0\nGefitinib,\u00a0 Erlotinib\u00a0 und\u00a0 Afatinib,\u00a0 die\u00a0 bei\u00a0 nachgewiesener\u00a0 aktiv ierender\u00a0 EGFR\u2010\nMutation\u00a0 der\u00a0 Chemotherapie\u00a0 \u00fcberl egen\u00a0 waren\u00a0 (Griesinger\u00a0 et\u00a0 al.,\u00a0 2018).\u00a0 Nach\u00a0\ninitialem\u00a0Ansprechen\u00a0trat\u00a0bei\u00a0den\u00a0meisten\u00a0Patienten\u00a0jedoch\u00a0scho n\u00a0innerhalb\u00a0eines\u00a0\nJahres\u00a0eine\u00a0Krankheitsprogression \u00a0infolge\u00a0einer\u00a0erworbenen\u00a0EGFR \u2010TKI\u2010Resistenz\u00a0\nauf,\u00a0die\u00a0in\u00a0etwa\u00a063\u00a0%\u00a0der\u00a0F\u00e4lle\u00a0auf\u00a0einer\u00a0zur\u00a0Kategorie\u00a0UC\u00a0II\u00a0z \u00e4hlenden\u00a0T790M\u2010\nMutation\u00a0beruht,\u00a0bei\u00a0der\u00a0im\u00a0Exon\u00a020\u00a0des\u00a0EGFR\u2010Gens\u00a0an\u00a0Position\u00a07 90\u00a0Threonin\u00a0\ndurch\u00a0Methionin\u00a0ausgetauscht\u00a0ist.\u00a0Hierdurch\u00a0kommt\u00a0es\u00a0zu\u00a0einer\u00a0r \u00e4umlichen\u00a0Be\u2010\nhinderung\u00a0der\u00a0TKI\u2010Bindung\u00a0an\u00a0die\u00a0ATP\u2010Bindungsdom\u00e4ne,\u00a0wodurch\u00a0di e\u00a0Inhibierung\u00a0146\u00a0des\u00a0Rezeptors\u00a0nicht\u00a0mehr\u00a0m\u00f6glich\u00a0 ist\u00a0und\u00a0sein\u00a0onkogenes\u00a0Potenzi al\u00a0wiederherge\u2010\nstellt\u00a0wird\u00a0(Michels\u00a0&\u00a0Wolf,\u00a02018).\u00a0Osimertinib\u00a0inhibiert\u00a0auch\u00a0 EGFR\u00a0mit\u00a0 einer\u00a0derar\u2010\ntigen\u00a0T790M\u2010Mutation\u00a0und\u00a0zeigt\u00a0au\u00dferdem\u00a0in\u00a0vitro\u00a0eine\u00a0nahezu\u00a0200fach\u00a0 geringere\u00a0\nAktivit\u00e4t\u00a0gegen\u00a0den\u00a0EGFR\u2010Wildtyp\u00a0als\u00a0gegen\u00a0die\u00a0EGFR\u2010L858R/T790M \u2010Mutationen,\u00a0\nwodurch\u00a0im\u00a0Vergleich\u00a0zu\u00a0den\u00a0bislang\u00a0zugelassenen\u00a0nicht\u2010selektiv en\u00a0EGFR\u2010TKI\u00a0die\u00a0\nf\u00fcr\u00a0diese\u00a0Wirkstoffklasse\u00a0typischen\u00a0Nebenwirkungen,\u00a0vor\u00a0allem\u00a0D iarrh\u00f6,\u00a0Hautaus\u2010\nschlag\u00a0und\u00a0trockene\u00a0Haut,\u00a0milder\u00a0ausfallen\u00a0(Bollinger\u00a0et\u00a0al.,\u00a02 018).\u00a0Da\u00a0Osimertinib\u00a0\nauch\u00a0den\u00a0f\u00fcr\u00a0die\u00a0Zellproliferation\u00a0bedeutsamen\u00a0HER2\u2010Rezeptor\u00a0an tagonisiert,\u00a0der\u00a0\nauf\u00a0der\u00a0Oberfl\u00e4che\u00a0vieler\u00a0Zellen \u00a0exprimiert\u00a0wird\u00a0und\u00a0dessen\u00a0Blo ckade\u00a0an\u00a0den\u00a0\nHerzmuskelzellen\u00a0zu\u00a0kardiotoxischen\u00a0Effekten\u00a0f\u00fchren\u00a0kann,\u00a0beste ht\u00a0ein\u00a0erh\u00f6htes\u00a0\nRisiko\u00a0f\u00fcr\u00a0kardiale\u00a0Nebenwirkungen,\u00a0insbesondere\u00a0f\u00fcr\u00a0eine\u00a0Verri ngerung\u00a0der\u00a0links\u2010\nventrikul\u00e4ren\u00a0 Ejektionsfraktion\u00a0 (FDA,\u00a0 2017).\u00a0 Zudem\u00a0 verl\u00e4ngert\u00a0 O simertinib\u00a0 das\u00a0\nQTc\u2010Intervall. \u00a0\nOsimertinib\u00a0wurde\u00a0im\u00a0Februar\u00a02016\u00a0durch\u00a0die\u00a0Europ\u00e4ische\u00a0Kommiss ion\u00a0zugelassen\u00a0\nf\u00fcr\u00a0die\u00a0Behandlung\u00a0des\u00a0lokal\u00a0for tgeschrittenen\u00a0oder\u00a0metastasier ten\u00a0EGFR\u2010T790M\u2010\nmutationspositiven\u00a0NSCLC\u00a0(EMA,\u00a02016).\u00a0Die\u00a0Zulassung\u00a0erfolgte\u00a0na ch\u00a0einem\u00a0be\u2010\nschleunigten\u00a0Verfahren,\u00a0zun\u00e4chst\u00a0unter\u00a0\u201ebesonderen\u00a0Bedingungen\u201c \u00a0(Conditional\u00a0\nApproval,\u00a0CA ).\u00a0Im\u00a0April\u00a02017,\u00a0nach\u00a0Vorlage\u00a0von\u00a0Ergebnissen\u00a0aus\u00a0der\u00a0AURA3\u2010St udie\u00a0\ndurch\u00a0den\u00a0pU,\u00a0wurde\u00a0diese\u00a0Einschr\u00e4nkung\u00a0aufgehoben\u00a0und\u00a0eine\u00a0une ingeschr\u00e4nkte\u00a0\nGenehmigung\u00a0ausgesprochen\u00a0(EMA,\u00a0 2017).\u00a0Am\u00a007.07.2018\u00a0wurde\u00a0die\u00a0 Zulassung\u00a0\nvon\u00a0 Osimertinib\u00a0 erweitert\u00a0 auf\u00a0 das\u00a0 Anwendungsgebiet\u00a0 \u201eErstlinient herapie\u00a0 von\u00a0\nerwachsenen\u00a0Patienten\u00a0mit\u00a0lokal\u00a0 fortgeschrittenem\u00a0oder\u00a0metastas iertem\u00a0NSCLC\u00a0\nmit\u00a0aktivierenden\u00a0Mutationen\u00a0des\u00a0EGFR\u201c.\u00a0\u00a0\nVoraussetzung\u00a0f\u00fcr\u00a0den\u00a0Beginn\u00a0der\u00a0Behandlung\u00a0mit\u00a0Osimertinib\u00a0ist \u00a0ein\u00a0positiver\u00a0\nEGFR\u2010Mutationsstatus,\u00a0 der\u00a0 mit\u00a0 einem\u00a0 validierten\u00a0 Test\u00a0 unter\u00a0 Verw endung\u00a0 von\u00a0\nTumor\u2010DNA\u00a0aus\u00a0einer\u00a0Gewebebiopsie\u00a0oder\u00a0aus\u00a0Blutplasma\u00a0( Liquid\u00a0Biopsy )\u00a0festge\u2010\nstellt\u00a0wurde\u00a0(Fachinformation\u00a0Tagrisso\u00ae,\u00a02018). \u00a0\nDie\u00a0 empfohlene\u00a0 Tagesdosis\u00a0 f\u00fcr\u00a0 Os imertinib\u00a0 betr\u00e4gt\u00a0 80\u00a0mg\u00a0 einmal\u00a0 t\u00e4glich\u00a0 oral.\u00a0\nAufgrund\u00a0individueller\u00a0Sicherheits\u2010\u00a0und\u00a0Vertr\u00e4glichkeitsaspekte \u00a0kann\u00a0eine\u00a0Dosisun\u2010\nterbrechung\u00a0und/oder\u00a0\u2010reduktion\u00a0auf\u00a040\u00a0mg\u00a0einmal\u00a0t\u00e4glich\u00a0erfolg en.\u00a0Im\u00a0Handel\u00a0\nsind\u00a0N1\u2010Packungen\u00a0\u00e0\u00a030\u00a0Filmtabletten\u00a0von\u00a0Tagrisso\u00ae\u00a080\u00a0mg\u00a0und\u00a040 \u00a0mg,\u00a0beide\u00a0St\u00e4r\u2010\nken\u00a0zum\u00a0gleichen\u00a0Preis.\u00a0Die\u00a0Behandlung\u00a0wird\u00a0bis\u00a0zu\u00a0einer\u00a0Krankh eitsprogression\u00a0\noder\u00a0bis\u00a0zum\u00a0Auftreten\u00a0unzumutbarer\u00a0Nebenwirkungen\u00a0fortgef\u00fchrt. \u00a0\nDa\u00a0der\u00a0Phase\u2010I\u2010Metabolismus\u00a0von\u00a0 Osimertinib\u00a0haupts\u00e4chlich\u00a0\u00fcber\u00a0 CYP3A4\u00a0und\u00a0\nCYP3A5\u00a0erfolgt,\u00a0ist\u00a0die\u00a0gleichzeitige\u00a0Anwendung\u00a0anderer\u00a0starker \u00a0oder\u00a0m\u00e4\u00dfiger\u00a0\nCYP3A\u2010Induktoren\u00a0(z.B.\u00a0Carbamazepin,\u00a0Rifampicin)\u00a0zu\u00a0vermeiden.\u00a0 Die\u00a0Anwendung\u00a0\nzusammen\u00a0mit\u00a0Johanniskraut\u00a0ist\u00a0kontraindiziert.\u00a0\u00a0147\u00a0Die\u00a0 Verl\u00e4ngerung\u00a0 des\u00a0 QTc\u2010Intervalls\u00a0 durch\u00a0 Osimertinib\u00a0 muss\u00a0 bei\u00a0 gleichzeitiger\u00a0\nAnwendung\u00a0anderer\u00a0QT\u2010Zeit\u2010verl\u00e4n gernder\u00a0Arzneimittel\u00a0ber\u00fccksich tigt\u00a0werden. \u00a0\nDa\u00a0in\u00a0den\u00a0klinischen\u00a0Studien\u00a0unter\u00a0Osimertinib\u00a0ein\u00a0erh\u00f6htes\u00a0Ris iko\u00a0f\u00fcr\u00a0eine\u00a0lebens\u2010\nbedrohliche\u00a0interstitielle\u00a0Lungenerkrankung\u00a0(ILD)\u00a0bzw.\u00a0ILD\u2010\u00e4hnl iche\u00a0Nebenwirkun\u2010\ngen,\u00a0z.B.\u00a0Pneumonitis,\u00a0beobachte t\u00a0wurde,\u00a0werden\u00a0entsprechende\u00a0W arnhinweise\u00a0\nund\u00a0 Vorsichtsma\u00dfnahmen\u00a0 in\u00a0 der\u00a0 Fach\u2010\u00a0 und\u00a0 Gebrauchsinformation\u00a0 au fgef\u00fchrt.\u00a0\nGleiches\u00a0gilt\u00a0f\u00fcr\u00a0die\u00a0unerw\u00fcnschten\u00a0Effekte\u00a0auf\u00a0das\u00a0QTc\u2010Interva ll\u00a0und\u00a0auf\u00a0die\u00a0Herz\u2010\nkontraktilit\u00e4t. \u00a0\nIn\u00a0Deutschland\u00a0nahm\u00a0der\u00a0pU\u00a0Anfang\u00a0November\u00a02016\u00a0nach\u00a0dem\u00a0negati ven\u00a0Ergebnis\u00a0\nder\u00a0ersten\u00a0fr\u00fchen\u00a0Nutzenbewertung\u00a0durch\u00a0den\u00a0G\u2010BA\u00a0Tagrisso\u00ae\u00a0aufg rund\u00a0der\u00a0feh\u2010\nlenden\u00a0Aussicht,\u00a0sich\u00a0mit\u00a0dem\u00a0GKV\u2010Spitzenverband\u00a0auf\u00a0einen\u00a0akze ptablen\u00a0Erstat\u2010\ntungsbetrag\u00a0zu\u00a0einigen,\u00a0vom\u00a0Markt\u00a0(DAZ,\u00a02016).\u00a0Seit\u00a0dem\u00a01.\u00a0Nove mber\u00a02017\u00a0ist\u00a0\nTagrisso\u00ae\u00a0wieder\u00a0in\u00a0Deutschland\u00a0 verf\u00fcgbar,\u00a0nachdem\u00a0der\u00a0G\u2010BA\u00a0Osi mertinib\u00a0im\u00a0\nRahmen\u00a0 der\u00a0 erneuten\u00a0 Nutzenbewertung\u00a0 am\u00a0 19.10.2017\u00a0 einen\u00a0 betr\u00e4ch tlichen\u00a0\nZusatznutzen\u00a0f\u00fcr\u00a0die\u00a0Zweitlinie\u00a0der\u00a0mit\u00a0einem\u00a0EGFR\u2010TKI\u00a0vorbehan delten\u00a0Patienten\u00a0\nkonstatiert\u00a0hatte\u00a0(DAZ,\u00a02017).\u00a0\nIn\u00a0den\u00a0zwei\u00a0f\u00fcr\u00a0die\u00a0Zulassung\u00a0relevanten\u00a0kombinierten\u00a0einarmige n,\u00a0unverblindeten\u00a0\nPhase\u2010II\u2010Studien\u00a0AURAex\u00a0und\u00a0AURA2\u00a0(Sponsor:\u00a0AstraZeneca,\u00a0NCT018 02632\u00a0und\u00a0\nNCT02094261 )\u00a0wurde\u00a0die\u00a0Wirksamkeit\u00a0von\u00a0Osmertinib\u00a0als\u00a0Monotherapie\u00a0an\u00a0insg e\u2010\nsamt\u00a0411\u00a0TKI\u2010vorbehandelten\u00a0NSCLC\u2010Patienten\u00a0mit\u00a0nachgewiesener\u00a0 EGFR\u2010T790M\u2010\nMutation,\u00a0die\u00a0w\u00e4hrend\u00a0einer\u00a0oder\u00a0mehrerer\u00a0vorhergehender\u00a0system ischer\u00a0Thera\u2010\npie(n)\u00a0 progredient\u00a0 waren,\u00a0 untersucht.\u00a0 Alle\u00a0 Patienten\u00a0 erhielten\u00a0 einmal\u00a0 t\u00e4glich\u00a0\n80\u00a0mg\u00a0Osimertinib\u00a0bis\u00a0zum\u00a0Fortschreiten\u00a0der\u00a0Erkrankung.\u00a0Die\u00a0Ges amtansprechrate\u00a0\nORR\u00a0(Objective\u00a0Response\u00a0Rate )\u00a0als\u00a0prim\u00e4rer\u00a0Endpunkt\u00a0lag\u00a0bei\u00a066\u00a0%,\u00a0die\u00a0mediane\u00a0\nAnsprechdauer\u00a0DoR\u00a0( Duration\u00a0of\u00a0Response )\u00a0bei\u00a012,5\u00a0Monaten\u00a0und\u00a0der\u00a0Medianwert\u00a0\ndes\u00a0progressionsfreien\u00a0\u00dcberlebens\u00a0PFS\u00a0( Progression\u2010Free\u00a0Survival )\u00a0bei\u00a0elf\u00a0Monaten\u00a0\n(EMA,\u00a02016).\u00a0\u00a0\nIn\u00a0der\u00a0im\u00a0August\u00a02014\u00a0begonnenen\u00a0und\u00a0f\u00fcr\u00a0die\u00a0Zulassung\u00a0in\u00a0der\u00a0Z weitlinie\u00a0heran\u2010\ngezogenen\u00a0multizentrischen,\u00a0unve rblindeten,\u00a02:1\u2010randomisierten\u00a0 Phase\u2010III\u2010Studie\u00a0\nAURA3\u00a0(Sponsor:\u00a0AstraZeneca,\u00a0NCT02151981)\u00a0an\u00a0419\u00a0Patienten\u00a0mit\u00a0 EGFR\u2010T790M\u2010\nMutation\u00a0und\u00a0Progression\u00a0nach\u00a0EGFR\u2010TKI\u2010Vorbehandlung\u00a0wurde\u00a0die\u00a0 Wirksamkeit\u00a0\nvon\u00a0Osimertinib\u00a0verglichen\u00a0mit\u00a0e iner\u00a0Platin\u2010basierten\u00a0Chemother apie\u00a0(Mok\u00a0et\u00a0al.,\u00a0\n2017).\u00a0Im\u00a0Osimertinib\u2010Arm\u00a0erhielten\u00a0279\u00a0Patienten\u00a0einmal\u00a0t\u00e4glic h\u00a080\u00a0mg\u00a0Osimerti\u2010\nnib;\u00a0im\u00a0Vergleichsarm\u00a0bekamen\u00a014 0\u00a0Patienten\u00a0eine\u00a0Kombinationsch emotherapie\u00a0aus\u00a0\nentweder\u00a0Cisplatin\u00a075\u00a0mg/m\u00b2\u00a0oder\u00a0Carboplatin\u00a0AUC5\u00a0( Area\u00a0under\u00a0the\u00a0curve ,\u00a0Dosie\u2010\nrung\u00a0nach\u00a0Zielfl\u00e4che\u00a0unter\u00a0der\u00a0Plasmakonzentrations\u2010Zeit\u2010Kurve) \u00a0plus\u00a0Pemetrexed\u00a0\n500\u00a0mg/m\u00b2\u00a0an\u00a0Tag\u00a01\u00a0jedes\u00a021\u2010t\u00e4gigen\u00a0Zyklus\u00a0f\u00fcr\u00a0maximal\u00a0sechs\u00a0Zy klen\u00a0und\u00a0optional\u00a0\nanschlie\u00dfend\u00a0eine\u00a0Erhaltungstherapie\u00a0mit\u00a0Pemetrexed.\u00a0Patienten\u00a0 mit\u00a0best\u00e4tigter\u00a0148\u00a0Krankheitsprogression\u00a0 konnten\u00a0 aus\u00a0 dem\u00a0 Vergleichs\u2010\u00a0 in\u00a0 den\u00a0 Interv entionsarm\u00a0\nwechseln.\u00a0Prim\u00e4rer\u00a0Endpunkt\u00a0war\u00a0das\u00a0PFS\u00a0gem\u00e4\u00df\u00a0Bewertung\u00a0durch\u00a0d en\u00a0Pr\u00fcfarzt,\u00a0\nweitere\u00a0Endpunkte\u00a0u.a.\u00a0das\u00a0Gesamt\u00fcberleben\u00a0( Overall\u00a0Survival ,\u00a0OS),\u00a0die\u00a0gesund\u2010\nheitsbezogene\u00a0Lebensqualit\u00e4t\u00a0(HRQoL)\u00a0und\u00a0unerw\u00fcnschte\u00a0Ereigniss e\u00a0(UAE).\u00a0Die\u00a0in\u00a0\nder\u00a0Mehrzahl\u00a0asiatischen\u00a0Patienten\u00a0waren\u00a0im\u00a0Mittel\u00a062\u00a0Jahre\u00a0alt ,\u00a0in\u00a0gutem\u00a0oder\u00a0\nnur\u00a0gering\u00a0reduziertem\u00a0Allgemeinzustand\u00a0(ECOG\u2010Performance\u00a0Statu s\u00a00\u00a0oder\u00a01)\u00a0und\u00a0\nzu\u00a0etwa\u00a0zwei\u00a0Dritteln\u00a0weiblich.\u00a0Fast\u00a0alle\u00a0hatten\u00a0eine\u00a0metastasi erte\u00a0Erkankung,\u00a0bei\u00a0\n\u00fcber\u00a0einem\u00a0Drittel\u00a0lagen\u00a0Hirnmeta stasen\u00a0vor.\u00a0Das\u00a0mediane\u00a0PFS\u00a0la g\u00a0unter\u00a0Osimerti\u2010\nnib\u00a0bei\u00a010,1\u00a0Monaten\u00a0und\u00a0war\u00a05,7\u00a0 Monate\u00a0l\u00e4nger\u00a0als\u00a0im\u00a0Kontrolla rm.\u00a0In\u00a0der\u00a0Sub\u2010\ngruppe\u00a0der\u00a0Patienten\u00a0mit\u00a0ZNS\u2010Metastasen\u00a0(28\u00a0%\u00a0des\u00a0Gesamtkollekt ivs)\u00a0erzielte\u00a0\nOsimertinib\u00a0eine\u00a0Verl\u00e4ngerung\u00a0des\u00a0PFS\u00a0von\u00a04,2\u00a0auf\u00a08,5\u00a0Monate.\u00a0B ez\u00fcglich\u00a0der\u00a0\nGesamt\u00fcberlebenszeit\u00a0 ergab\u00a0 sich\u00a0 zum\u00a0 Zeitpunkt\u00a0 des\u00a0 zweiten\u00a0 Daten schnittes\u00a0\n(02.09.2016)\u00a0kein\u00a0signifikanter\u00a0Unterschied\u00a0zwischen\u00a0beiden\u00a0Beh andlungsarmen.\u00a0\nBei\u00a0der\u00a0mittels\u00a0der\u00a0Frageb\u00f6gen\u00a0EO RTC\u00a0QLQ\u2010C30\u00a0und\u00a0dessen\u00a0lungenk rebsspezifi\u2010\nschen\u00a0Erg\u00e4nzungsmoduls\u00a0EORTC\u00a0QLQ\u2010C13\u00a0erfassten\u00a0und\u00a0zum\u00a0ersten\u00a0D atenschnitt\u00a0\n(15.04.2016)\u00a0 ausgewerteten\u00a0 HRQoL\u00a0 zeigten\u00a0 sich\u00a0 insgesamt\u00a0 signifi kante\u00a0 Unter\u2010\nschiede\u00a0zugunsten\u00a0von\u00a0Osimertinib.\u00a0Schwere\u00a0UAE\u00a0im\u00a0CTCAE\u2010Grad\u00a03/ 4\u00a0traten\u00a0bei\u00a0\n23\u00a0%\u00a0der\u00a0Patienten\u00a0unter\u00a0Osimertinib\u00a0auf\u00a0und\u00a0bei\u00a047\u00a0%\u00a0unter\u00a0Che motherapie.\u00a0\nH\u00e4ufigste\u00a0UAE\u00a0waren\u00a0Diarrh\u00f6,\u00a0Hau tausschlag,\u00a0trockene\u00a0Haut,\u00a0Nage lver\u00e4nderungen\u00a0\nund\u00a0Appetitlosigkeit.\u00a0Negative\u00a0Wir kungen\u00a0von\u00a0Osimertinib\u00a0gegen\u00fc ber\u00a0der\u00a0Ver\u2010\ngleichstherapie\u00a0zeigten\u00a0sich\u00a0bei \u00a0Diarrh\u00f6,\u00a0Nagelver\u00e4nderungen\u00a0un d\u00a0Nebenwirkun\u2010\ngen\u00a0an\u00a0der\u00a0Haut.\u00a0Bei\u00a03,6\u00a0%\u00a0der\u00a0Patienten\u00a0im\u00a0Osimertinib\u2010Arm\u00a0tra t\u00a0eine\u00a0interstitielle\u00a0\nLungenerkrankung\u00a0auf,\u00a0die\u00a0\u00fcberwi egend\u00a0leichteren\u00a0Grades\u00a0war,\u00a0in \u00a0einem\u00a0Fall\u00a0aber\u00a0\nzum\u00a0Tod\u00a0infolge\u00a0Pneumonitis\u00a0f\u00fchrte.\u00a0Bei\u00a04\u00a0%\u00a0der\u00a0Patienten\u00a0im\u00a0Os imertinib\u2010Arm\u00a0\nkam\u00a0es\u00a0zu\u00a0einer\u00a0Verl\u00e4ngerung\u00a0des \u00a0QTc\u2010Intervalls\u00a0ohne\u00a0Auftreten\u00a0 von\u00a0Arrhythmien\u00a0\nund\u00a0bei\u00a05\u00a0%\u00a0zu\u00a0einer\u00a0Verringerung\u00a0der\u00a0linksventrikul\u00e4ren\u00a0Ejekti onsfraktion.\u00a0\nIn\u00a0die\u00a0ebenfalls\u00a0vom\u00a0p U\u00a0gesponserte,\u00a0noch\u00a0laufende\u00a0multizentris che,\u00a0doppelblinde,\u00a0\nrandomisierte\u00a0kontrollierte\u00a0Phase\u2010III\u2010Studie\u00a0FLAURA\u00a0(NCT0229612 5),\u00a0die\u00a0im\u00a0Febru\u2010\nar\u00a02015\u00a0startete\u00a0und\u00a0auf\u00a0der\u00a0die\u00a0Zulassung\u00a0in\u00a0der\u00a0Erstlinie\u00a0gr\u00fc ndet,\u00a0wurden\u00a0556\u00a0\nunbehandelte\u00a0Patienten\u00a0mit\u00a0fortgeschrittenem\u00a0oder\u00a0metastasierte m\u00a0NSCLC\u00a0und\u00a0\nden\u00a0 EGFR\u2010Aberrationen\u00a0 Exon\u00a0 21\u00a0 Substitutionsmutation\u00a0 (L858R)\u00a0 und \u00a0 Exon\u00a0 19\u2010\nDeletion\u00a0(del\u00a019)\u00a0eingeschlossen\u00a0(Soria\u00a0et\u00a0al.,\u00a02018).\u00a0Nach\u00a01:1 \u2010Randomisierung\u00a0\nwurden\u00a0die\u00a0Patienten\u00a0entweder\u00a0im\u00a0Osimertinib\u2010Arm\u00a0(n\u00a0=\u00a0279,\u00a080\u00a0m g\u00a0einmal\u00a0t\u00e4glich\u00a0\noral)\u00a0oder\u00a0im\u00a0Vergleichsarm\u00a0(n\u00a0=\u00a0277,\u00a0150\u00a0mg\u00a0Erlotinib\u00a0bzw.\u00a0250 \u00a0mg\u00a0Gefitinib\u00a0ein\u2010\nmal\u00a0t\u00e4glich\u00a0oral)\u00a0behandelt,\u00a0wobe i\u00a0sich\u00a0die\u00a0Studienzentren\u00a0vor\u00a0 der\u00a0Studienteilnah\u2010\nme\u00a0f\u00fcr\u00a0Erlotinib\u00a0oder\u00a0Gefitinib\u00a0entschieden\u00a0und\u00a034\u00a0%\u00a0der\u00a0Patien ten\u00a0Erlotinib\u00a0und\u00a0\n66\u00a0%\u00a0 der\u00a0 Patienten\u00a0 Gefitinib\u00a0 erhi elten.\u00a0 Die\u00a0 \u00fcberwiegend\u00a0 in\u00a0 Asie n\u00a0 rekrutierten\u00a0\nPatienten\u00a0waren\u00a0im\u00a0Mittel\u00a0etwa\u00a063\u00a0Jahre\u00a0alt,\u00a0in\u00a0gutem\u00a0oder\u00a0nur\u00a0 gering\u00a0reduziertem\u00a0\nAllgemeinzustand\u00a0(ECOG\u00a0PS\u00a00\u00a0oder\u00a0 1),\u00a0in\u00a0der\u00a0Mehrzahl\u00a0weiblich\u00a0u nd\u00a0Nie\u2010Raucher\u00a0\nsowie\u00a0fast\u00a0alle\u00a0in\u00a0einem\u00a0metastasierten\u00a0Stadium\u00a0des\u00a0NSCLC.\u00a0Bei\u00a0 etwa\u00a0einem\u00a0F\u00fcnf\u2010149\u00a0tel\u00a0lagen\u00a0zu\u00a0Studienbeginn\u00a0zentr alnerv\u00f6se\u00a0Metastasen\u00a0vor.\u00a0Die\u00a0B ehandlung\u00a0erfolg\u2010\nte,\u00a0bis\u00a0der\u00a0Pr\u00fcfarzt\u00a0entschied,\u00a0dass\u00a0der\u00a0Patient\u00a0nicht\u00a0mehr\u00a0l\u00e4n ger\u00a0klinisch\u00a0profitier\u2010\nte,\u00a0oder\u00a0bis\u00a0zum\u00a0Therapieabbruch,\u00a0z.B.\u00a0aufgrund\u00a0von\u00a0UAE.\u00a0Bei\u00a0Pr ogress\u00a0mit\u00a0Nach\u2010\nweis\u00a0einer\u00a0T790M\u2010Mutation\u00a0konnten\u00a0Patienten\u00a0aus\u00a0dem\u00a0Kontrollarm \u00a0unverblindet\u00a0\neine\u00a0Folgetherapie\u00a0mit\u00a0Osimertinib\u00a0bekommen,\u00a0was\u00a0zum\u00a0Zeitpunkt\u00a0 des\u00a0ersten\u00a0\nDatenschnittes\u00a0im\u00a0Juni\u00a02017\u00a0bei\u00a022,4\u00a0%\u00a0der\u00a0Patienten\u00a0der\u00a0Fall\u00a0w ar.\u00a0Beim\u00a0PFS\u00a0als\u00a0\nprim\u00e4rem\u00a0Endpunkt\u00a0lag\u00a0der\u00a0Median\u00a0unter\u00a0Osimertinib\u00a0bei\u00a018,9\u00a0Mon aten\u00a0gegen\u2010\n\u00fcber\u00a010,2\u00a0Monaten\u00a0unter\u00a0Erlotinib/Gefitinib\u00a0bei\u00a0einer\u00a0vergleich baren\u00a0Ansprechrate\u00a0\n(80\u00a0%\u00a0vs.\u00a076\u00a0%).\u00a0Der\u00a0Median\u00a0der\u00a0Gesamt\u00fcberlebenszeit\u00a0war\u00a0zum\u00a0Ze itpunkt\u00a0der\u00a0\nAuswertung\u00a0im\u00a0Juni\u00a02017\u00a0in\u00a0beiden\u00a0Armen\u00a0nicht\u00a0erreicht,\u00a0jedoch\u00a0 zeigte\u00a0sich\u00a0ein\u00a0\nstatistisch\u00a0signifikanter\u00a0Effekt\u00a0zugunsten\u00a0von\u00a0Osimertinib\u00a0(HR: \u00a00,63,\u00a095\u00a0%\u00a0KI\u00a0[0,45;\u00a0\n0,88],\u00a0p\u00a0=\u00a00,0068).\u00a0Die\u00a0\u00dcberlebe nsrate\u00a0im\u00a0Osimertinib\u2010Arm\u00a0lag\u00a0n ach\u00a012\u00a0Monaten\u00a0\nabsolut\u00a0um\u00a06,6\u00a0%,\u00a0nach\u00a024\u00a0Monaten\u00a0absolut\u00a0um\u00a09\u00a0%\u00a0oberhalb\u00a0des\u00a0K ontrollarms.\u00a0\nBei\u00a0den\u00a0Endpunktkategorien\u00a0Morbidit\u00e4t\u00a0und\u00a0HRQoL,\u00a0die\u00a0\u00fcber\u00a0die\u00a0S kalen\u00a0der\u00a0Fra\u2010\ngeb\u00f6gen\u00a0EORTC\u00a0QLQ\u2010C30\u00a0und\u00a0des\u00a0l ungenkrebsspezifischen\u00a0Zusatzmod uls\u00a0EORTC\u00a0\nQLQ\u2010LC13\u00a0 erfasst\u00a0 wurden,\u00a0 ergaben\u00a0 sich,\u00a0 mit\u00a0 Ausnahme\u00a0 der\u00a0 unter\u00a0 O simertinib\u00a0\nseltener\u00a0auftretenden\u00a0Alopezie,\u00a0keine\u00a0relevanten\u00a0Unterschiede.\u00a0 F\u00fcr\u00a0den\u00a0Endpunkt\u00a0\nschwere\u00a0UAE\u00a0im\u00a0CTCAE\u2010Grad\u00a0\u2265\u00a03\u00a0ze igte\u00a0sich\u00a0ein\u00a0statistisch\u00a0signi fikanter\u00a0Vorteil\u00a0von\u00a0\nOsimertinib\u00a0vs.\u00a0Erlotinib/Gefiti nib\u00a0(34\u00a0%\u00a0vs.\u00a045\u00a0%),\u00a0ebenso\u00a0f\u00fcr \u00a0den\u00a0Endpunkt\u00a0Ab\u2010\nbruch\u00a0wegen\u00a0UAE.\u00a0H\u00e4ufiger\u00a0im\u00a0Osimertinib\u2010\u00a0als\u00a0im\u00a0Kontrollarm\u00a0tr aten\u00a0Ver\u00e4nderun\u2010\ngen\u00a0der\u00a0QT\u2010Zeit\u00a0(11,5\u00a0%\u00a0vs.\u00a05,4\u00a0 %)\u00a0und\u00a0Herzversagen\u00a0(4,7\u00a0%\u00a0vs.\u00a0 2,2\u00a0%)\u00a0auf.\u00a0Zudem\u00a0\nkam\u00a0es\u00a0bei\u00a04,3\u00a0%\u00a0der\u00a0Patienten\u00a0im\u00a0Osimertinib\u2010Arm\u00a0versus\u00a02,2\u00a0%\u00a0 im\u00a0Kontrollarm\u00a0zu\u00a0\neiner\u00a0interstitiellen\u00a0Lungenerkrankung.\u00a0\nZu\u00a0Osimertinib\u00a0liegen\u00a0drei\u00a0Nutzenbewertungsverfahren\u00a0durch\u00a0den\u00a0 G\u2010BA\u00a0vor.\u00a0In\u00a0der\u00a0\nfr\u00fchen\u00a0 Nutzenbewertung\u00a0 auf\u00a0 Basis\u00a0 der\u00a0 Zulassungsstudien\u00a0 AURAex/A URA2\u00a0 und\u00a0\nAURA3\u00a0mit\u00a0Beschluss\u00a0vom\u00a015.09.2016\u00a0und\u00a0Befristung\u00a0bis\u00a0zum\u00a030.06 .2017\u00a0wurde\u00a0\nkein\u00a0Zusatznutzen \u00a0festgestellt\u00a0(G\u2010BA,\u00a02016).\u00a0Begr\u00fcndet\u00a0wurde\u00a0dies\u00a0mit\u00a0den\u00a0feh\u2010\nlenden\u00a0 aussagekr\u00e4ftigen\u00a0 Daten\u00a0 (nie drige\u00a0 Evidenzstufe\u00a0 der\u00a0 Phase\u2010 II\u2010Studien\u00a0\nAURAex\u00a0und\u00a0AURA2,\u00a0Verwendung\u00a0von\u00a0Daten\u00a0aus\u00a0historischen\u00a0Verglei chen,\u00a0noch\u00a0\nkeine\u00a0verf\u00fcgbaren\u00a0Ergebnisse\u00a0aus \u00a0der\u00a0Phase\u2010III\u2010Studie\u00a0AURA3).\u00a0\u00a0\nNach\u00a0Fristablauf\u00a0und\u00a0Einreichung\u00a0von\u00a0Analysen\u00a0der\u00a0AURA3\u2010Studie\u00a0 durch\u00a0den\u00a0pU\u00a0\nf\u00fchrte\u00a0der\u00a0G\u2010BA\u00a0erneut\u00a0eine\u00a0Nutzenbewertung\u00a0durch,\u00a0allerdings\u00a0n ur\u00a0f\u00fcr\u00a0die\u00a0Sub\u2010\ngruppe\u00a0der\u00a0Patienten,\u00a0die\u00a0mit\u00a0einem\u00a0EGFR\u2010TKI\u00a0vorbehandelt\u00a0sind\u00a0 und\u00a0f\u00fcr\u00a0die\u00a0eine\u00a0\nzytotoxische\u00a0Chemotherapie\u00a0infrage\u00a0kommt.\u00a0Der\u00a0G\u2010BA\u00a0kam\u00a0am\u00a019.10 .2017\u00a0zu\u00a0dem\u00a0\nErgebnis,\u00a0dass\u00a0bei\u00a0diesen\u00a0Patienten\u00a0ein\u00a0 Anhaltspunkt\u00a0f\u00fcr\u00a0einen\u00a0betr\u00e4chtlichen\u00a0\nZusatznutzen \u00a0 f\u00fcr\u00a0 Osimertinib\u00a0 im\u00a0 Vergleich\u00a0 zur\u00a0 Platin\u2010basierten\u00a0 Chemotherapi e\u00a0\nvorliegt\u00a0(G\u2010BA,\u00a02017).\u00a0Entgegen\u00a0der\u00a0Empfehlung\u00a0des\u00a0IQWiG,\u00a0f\u00fcr\u00a0d ie\u00a0Nutzenbewer\u2010\ntung\u00a0nur\u00a0das\u00a0Drittel\u00a0der\u00a0Patiente n\u00a0der\u00a0AURA3\u2010Studie\u00a0heranzuzieh en,\u00a0f\u00fcr\u00a0das\u00a0vor\u00a0\nder\u00a0Randomisierung\u00a0eine\u00a0Vergleichstherapie\u00a0mit\u00a0Cisplatin\u00a0+\u00a0Peme trexed\u00a0festgelegt\u00a0150\u00a0wurde,\u00a0bewertete\u00a0der\u00a0G\u2010BA\u00a0das\u00a0Gesamtkollektiv\u00a0der\u00a0Studie,\u00a0obwoh l\u00a0nicht\u00a0ersicht\u2010\nlich\u00a0ist,\u00a0nach\u00a0welchen\u00a0Kriterien\u00a0d ie\u00a0Auswahl\u00a0von\u00a0entweder\u00a0Carbo platin\u00a0oder\u00a0Cispla\u2010\ntin\u00a0als\u00a0Bestandteil\u00a0der\u00a0Vergle ichstherapie\u00a0stattgefunden\u00a0hat\u00a0(I QWiG,\u00a02017).\u00a0Car\u2010\nboplatin\u00a0ist\u00a0nicht\u00a0zur\u00a0Behandlung\u00a0des\u00a0NSCLC\u00a0zugelassen\u00a0und\u00a0kann \u00a0nur\u00a0eingesetzt\u00a0\nwerden,\u00a0wenn\u00a0ein\u00a0erh\u00f6htes\u00a0Risiko\u00a0f\u00fcr\u00a0Cisplatin\u2010induzierte\u00a0Neben wirkungen\u00a0be\u2010\nsteht.\u00a0W\u00e4hrend\u00a0sich\u00a0f\u00fcr\u00a0den\u00a0Endpunkt\u00a0OS\u00a0gegen\u00fcber\u00a0dem\u00a0Kontrolla rm\u00a0kein\u00a0statis\u2010\ntisch\u00a0signifikanter\u00a0Unterschied\u00a0 ergab,\u00a0zeigten\u00a0sich\u00a0bez\u00fcglich\u00a0d er\u00a0krankheitsassozi\u2010\nierten\u00a0Symptomatik\u00a0und\u00a0der\u00a0UAE\u00a0bei\u00a0vielen\u00a0Endpunkten\u00a0und\u00a0bez\u00fcgl ich\u00a0der\u00a0ge\u2010\nsundheitsbezogenen\u00a0Lebensqualit\u00e4t\u00a0bei\u00a0allen\u00a0Endpunkten\u00a0relevant e\u00a0Effekte\u00a0zu\u2010\ngunsten\u00a0von\u00a0Osimertinib.\u00a0Da\u00a0das\u00a0 Verzerrungspotential\u00a0vor\u00a0allem\u00a0 aufgrund\u00a0der\u00a0\nfehlenden\u00a0Verblindung\u00a0und\u00a0wegen\u00a0de s\u00a0hohen\u00a0Anteils\u00a0an\u00a0Patienten\u00a0 im\u00a0Vergleichs\u2010\narm,\u00a0die\u00a0bei\u00a0Progress\u00a0auf\u00a0Osimertinib\u00a0wechselten\u00a0(zum\u00a0Zeitpunkt \u00a0des\u00a0zweiten\u00a0\nDatenschnittes\u00a0 waren\u00a0 67\u00a0%  aus\u00a0 dem\u00a0 Chemotherapie\u2010\u00a0 in\u00a0 den\u00a0 Osimertinib\u2010Arm\u00a0\ngewechselt),\u00a0als\u00a0\u201ehoch\u201c\u00a0eingestuft\u00a0wird,\u00a0konnten\u00a0f\u00fcr\u00a0alle\u00a0Endpu nkte\u00a0nur\u00a0maximal\u00a0\nAnhaltspunkte\u00a0f\u00fcr\u00a0das\u00a0Ausma\u00df\u00a0des\u00a0Zusatznutzens\u00a0festgestellt\u00a0wer den.\u00a0\nDie\u00a0dritte\u00a0Nutzenbewertung\u00a0von\u00a0Osimertinib\u00a0erfolgte\u00a0in\u00a0dem\u00a0seit \u00a0Juli\u00a02018\u00a0neu\u00a0\nzugelassenen\u00a0Anwendungsgebiet\u00a0\u201eErs tlinientherapie\u00a0bei\u00a0lokal\u00a0for tgeschrittenem\u00a0\noder\u00a0metastasiertem\u00a0NSCLC\u00a0mit\u00a0aktivierenden\u00a0EGFR\u2010Mutationen\u201c\u00a0au f\u00a0der\u00a0Basis\u00a0der\u00a0\nErgebnisse\u00a0der\u00a0FLAURA\u2010Studie\u00a0(G\u2010BA,\u00a02019).\u00a0Im\u00a0Gegensatz\u00a0zum\u00a0pU\u00a0 und\u00a0zur\u00a0Zulas\u2010\nsung,\u00a0die\u00a0bei\u00a0den\u00a0aktivierenden\u00a0EGFR\u2010Mutationen\u00a0nicht\u00a0differenz iert,\u00a0unterschei\u2010\ndet\u00a0der\u00a0G\u2010BA\u00a0zwei\u00a0Patientengruppen,\u00a0n\u00e4mlich\u00a0a)\u00a0Patienten\u00a0mit\u00a0de n\u00a0h\u00e4ufigen\u00a0EGFR\u2010\nMutationen\u00a0L858R\u00a0und\u00a0del19\u00a0und\u00a0der\u00a0zVT\u00a0Afatinib,\u00a0Erlotinib\u00a0oder \u00a0Gefitinib\u00a0und\u00a0b)\u00a0\nPatienten\u00a0mit\u00a0den\u00a0wesentlich\u00a0selteneren\u00a0anderen\u00a0EGFR\u2010Mutationen ,\u00a0f\u00fcr\u00a0die\u00a0er\u00a0als\u00a0\nm \u00f6 g l i c h e \u00a0z V T \u00a0n e b e n \u00a0E G F R \u2010 T K I \u00a0a u c h \u00a0 verschiedene,\u00a0 \u00fcberwiegend\u00a0 Plat in\u2010basierte\u00a0\nChemotherapien\u00a0bestimmt.\u00a0Da\u00a0in\u00a0der\u00a0FLAURA\u2010Studie\u00a0nur\u00a0Patienten\u00a0 mit\u00a0L858R\u00a0oder\u00a0\ndel\u00a019\u00a0eingeschlossen\u00a0wurden,\u00a0ist\u00a0aufgrund\u00a0fehlender\u00a0Daten\u00a0f\u00fcr\u00a0 die\u00a0Gruppe\u00a0b)\u00a0kein\u00a0\nZusatznutzen\u00a0belegt.\u00a0F\u00fcr\u00a0die\u00a0Gruppe\u00a0a)\u00a0sieht\u00a0der\u00a0G\u2010BA\u00a0einen\u00a0 Anhaltspunkt\u00a0f\u00fcr\u00a0\neinen\u00a0betr\u00e4chtlichen\u00a0Zusatznutzen \u00a0von\u00a0Osimertinib\u00a0gegen\u00fcber\u00a0Erlotinib\u00a0und\u00a0Gefi\u2010\ntinib.\u00a0Auch\u00a0wenn\u00a0die\u00a0finalen\u00a0Analysen\u00a0zum\u00a0Endpunkt\u00a0Gesamt\u00fcberle benszeit\u00a0noch\u00a0\nausstehen,\u00a0der\u00a0Median\u00a0aufgrund\u00a0der\u00a0geringen\u00a0Anzahl\u00a0an\u00a0Todeserei gnissen\u00a0noch\u00a0\nnicht\u00a0erreicht\u00a0war\u00a0und\u00a0das\u00a0Wechseln\u00a0einer\u00a0gr\u00f6\u00dferen\u00a0Zahl\u00a0von\u00a0Pat ienten\u00a0bei\u00a0Pro\u2010\ngress\u00a0aus\u00a0dem\u00a0Kontroll\u2010\u00a0in\u00a0den\u00a0O simertinib\u2010Arm\u00a0den\u00a0Nachweis\u00a0ers chwerten,\u00a0zeigte\u00a0\nsich\u00a0im\u00a0OS\u00a0ein\u00a0statistisch\u00a0signifikanter\u00a0Vorteil\u00a0von\u00a0Osimertini b.\u00a0In\u00a0der\u00a0Endpunktka\u2010\ntegorie\u00a0Morbidit\u00e4t\u00a0gab\u00a0es\u00a0hinsichtlich\u00a0des\u00a0Endpunktes\u00a0Alopezie\u00a0 einen\u00a0relevanten\u00a0\nUnterschied\u00a0zugunsten\u00a0von\u00a0Osimertinib.\u00a0Bei\u00a0den\u00a0UAE\u2010Endpunkten\u00a0u nterschiedli\u2010\nchen\u00a0 Schweregrads\u00a0 ergaben\u00a0 sich\u00a0 insgesamt\u00a0 ausschlie\u00dflich\u00a0 positiv e\u00a0 Effekte\u00a0 f\u00fcr\u00a0\nOsimertinib.\u00a0Im\u00a0Vergleich\u00a0zu\u00a0Erlotinib\u00a0und\u00a0Gefitinib\u00a0f\u00fchrte\u00a0der \u00a0neue\u00a0Wirkstoff\u00a0zu\u00a0\neiner\u00a0deutlichen\u00a0Verringerung\u00a0von\u00a0schweren\u00a0UAE\u00a0(CTCAE\u2010Grad\u00a0\u2265\u00a03) ,\u00a0weniger\u00a0Ab\u2010\nbr\u00fcchen\u00a0wegen\u00a0UAE\u00a0und\u00a0einem\u00a0verringerten\u00a0Risiko\u00a0f\u00fcr\u00a0Erkrankunge n\u00a0der\u00a0Haut\u00a0und\u00a0\ndes\u00a0Unterhautgewebes\u00a0einschlie\u00dflich\u00a0der\u00a0akneiformen\u00a0Dermatitis. \u00a0Die\u00a0Aussage\u2010151\u00a0sicherheit\u00a0f\u00fcr\u00a0einen\u00a0betr\u00e4chtlichen\u00a0Zusatznutzen\u00a0von\u00a0Osimertini b\u00a0wird\u00a0vom\u00a0G\u2010BA\u00a0\nals\u00a0nur\u00a0eingeschr\u00e4nkt\u00a0beurteilbar\u00a0bewertet\u00a0\u2013\u00a0vor\u00a0allem\u00a0durch\u00a0da s\u00a0hohe\u00a0Verzer\u2010\nrungspotential\u00a0infolge\u00a0unterschi edlicher\u00a0Beobachtungszeiten\u00a0in\u00a0 den\u00a0Behandlungs\u2010\narmen\u00a0(16\u00a0Monate\u00a0im\u00a0Osimertinib\u2010Arm\u00a0vs.\u00a0zw\u00f6lf\u00a0Monate\u00a0im\u00a0Kontrol larm)\u00a0und\u00a0\naufgrund\u00a0der\u00a0unvollst\u00e4ndigen\u00a0Ausw ertung\u00a0erhobener\u00a0Daten\u00a0hinsich tlich\u00a0der\u00a0pati\u2010\nentenberichteten\u00a0Endpunkte\u00a0Symptomatik\u00a0und\u00a0gesundheitsbezogene\u00a0 Lebensquali\u2010\nt\u00e4t.\u00a0Das\u00a0IQWiG\u00a0sieht\u00a0die\u00a0Aussagekraft\u00a0der\u00a0FLAURA\u2010Studie\u00a0zus\u00e4tzl ich\u00a0vermindert\u00a0\ndurch\u00a0 die\u00a0 fragliche\u00a0 zulassungsk onforme\u00a0 Behandlung\u00a0 im\u00a0 Vergleichs arm\u00a0 \u2013\u00a0 nicht\u00a0\nsichergestellte\u00a0N\u00fcchterneinnahme\u00a0von\u00a0Erlotinib\u00a0\u2013\u00a0bei\u00a0ungef\u00e4hr\u00a0e inem\u00a0Drittel\u00a0die\u2010\nser\u00a0Patienten.\u00a0\nVerf\u00fcgbare\u00a0Therapien \u00a0 (Zusatz\u2010)Nutzen \u00a0 Kosten\u00a0\nEGFR\u2010TKI\u00a0der\u00a03 .\u00a0Gene\u2010\nration\u00a0mit\u00a0Wirksamkeit\u00a0\nbei\u00a0T790M\u2010mutiertem\u00a0\nEGFR\u00a0\u00a0Patienten\u00a0profitieren\u00a0\nbzgl.\u00a0Ansprechen\u00a0und\u00a0\nVertr\u00e4glichkeit;\u00a0\nUnsicherheiten\u00a0bzgl.\u00a0\nschwerer\u00a0pulmonaler\u00a0und\u00a0\nkardialer\u00a0UAE\u00a0\u00a02\u00a0bis\u00a02,6fach\u00a0teurer\u00a0als\u00a0\u00a0\nzVT\u00a0Gefitinib,\u00a0Erlotinib\u00a0\u00a0\noder\u00a0Afatinib,\u00a0aber\u00a0etwas\u00a0\ng\u00fcnstiger\u00a0als\u00a0zVT\u00a0\nPemetrexed\u00a0+\u00a0Cis\u2010\u00a0bzw.\u00a0\nCarboplatin\u00a0\nErl\u00e4uterung\u00a0der\u00a0Farben:\u00a0Verf\u00fcgbare\u00a0Therapien:\u00a0rot\u00a0=\u00a0weitere\u00a0The rapieoption,\u00a0gelb\u00a0=\u00a0Subgruppen\u2010Novit\u00e4t,\u00a0gr\u00fcn\u00a0=\u00a0Solist;\u00a0(Zusatz\u2010 )\u00a0\nNutzen:\u00a0rot\u00a0=\u00a0keine\u00a0Verbesserung\u00a0oder\u00a0schlechte\u00a0Nutzen/Schaden\u2010 Relation,\u00a0gelb\u00a0=\u00a0teilweise\u00a0Verbesserungen,\u00a0gr\u00fcn\u00a0=\u00a0Verbesserung\u00a0\nharter\u00a0Endpunkte;\u00a0Kosten:\u00a0rot\u00a0=\u00a0teurer\u00a0als\u00a0bestehende\u00a0Therapien ,\u00a0gelb\u00a0=\u00a0ungef\u00e4hr\u00a0gleich\u00a0bzw.\u00a0teils/teils,\u00a0gr\u00fcn\u00a0=\u00a0g\u00fcnstiger\u00a0als \u00a0\nbestehende\u00a0Therapien\u00a0\nWie\u00a0bewerten\u00a0andere?\u00a0\u00a0\nBewertung\u00a0nach\u00a0\nFricke\u00a0et\u00a0al.\u00a0a\u2010t\u2010Bewertung\u00a0 AMB\u00a0 Prescrire\u00a0 PZ\u00a0\nB\u00a0 \u2013\u00a0 \u2013\u00a0 Nothing\u00a0new*\u00a0 Schrittinnovation\u00a0\n*Bewertung\u00a0der\u00a0Erstzulassung\u00a0durch\u00a0einarmige\u00a0Phase\u2010II\u2010Studien\u00a0A URAex\u00a0und\u00a0AURA2\u00a0\n\u00a0\u00a0\n152\u00a0Kosten\u00a0\nWirkstoff\u00a0 Behandlungsmodus\u00a0 Behandlungstage\u00a0 Jahrestherapiekosten\u00a0\nzu\u00a0bewertendes\u00a0Arzneimittel \u00a0\u00a0 \u00a0 \u00a0\nOsimertinib\u00a0 80\u00a0mg\u00a01x\u00a0tgl.\u00a0\u00a0 365\u00a0 86.649,66\u00a0\u20ac\u00a0\nzVT\u00a0Erwachsene\u00a0Patienten\u00a0mit\u00a0lok al\u00a0fortgeschrittenem\u00a0oder\u00a0metas tasiertem\u00a0NSCLC\u00a0mit\u00a0den\u00a0aktivierenden\u00a0\nEGFR\u2010Mutationen\u00a0L858R\u00a0oder\u00a0del\u00a019 \u00a0\nAfatinib\u00a0 40\u00a0mg\u00a01x\u00a0tgl.\u00a0\u00a0 365\u00a0 32.784,30\u00a0\u20ac\u00a0\nErlotinib\u00a0 150\u00a0mg\u00a01x\u00a0tgl.\u00a0\u00a0 365\u00a0 35.133,32\u00a0\u20ac\u00a0\nGefitinib\u00a0 250\u00a0mg\u00a01x\u00a0tgl.\u00a0\u00a0 365\u00a0 42.080,85\u00a0\u20ac\u00a0\nzVT\u00a0Erwachsene\u00a0Patienten\u00a0mit\u00a0lok al\u00a0fortgeschrittenem\u00a0oder\u00a0metas tasiertem\u00a0NSCLC\u00a0mit\u00a0seltenen\u00a0\naktivierenden\u00a0EGFR\u2010Mutationen\u00a0 (au\u00dfer\u00a0de\u00a0novo\u00a0T790M\u2010Mutationen) \u00a0\nAfatinib\u00a0 s.o.\u00a0 s.o.\u00a0 s.o.\u00a0\nErlotinib\u00a0 s.o.\u00a0 s.o.\u00a0 s.o.\u00a0\nGefitinib\u00a0 s.o.\u00a0 s.o.\u00a0 s.o.\u00a0\nGemcitabin\u00a0 1.000\u00a0mg/m\u00b2\u00a0KOF\u00a0\n3x\u00a0pro\u00a028\u2010Tage\u2010Zyklus\u00a039\u00a0 5.788,38\u00a0\u20ac\u00a0\nVinorelbin\u00a0 25\u00a0\u2013\u00a030\u00a0mg/m\u00b2\u00a0KOF\u00a0\u00a0\n1x\u00a0w\u00f6ch.\u00a0\u00a052\u00a0 7.920,12\u00a0\u2013\u00a09.925,76\u00a0\u20ac\u00a0\nCisplatin\u00a0in\u00a0Kombination\u00a0mit\u00a0 75\u00a0\u2013\u00a0100\u00a0mg/m\u00b2\u00a0KOF\u00a0\u00a0\n1x\u00a0pro\u00a021\u2010Tage\u2010Zyklus\u00a017\u00a0 \u00a0\nVinorelbin\u00a0 25\u00a0\u2013\u00a030\u00a0mg/m\u00b2\u00a0KOF\u00a0\u00a0\n2x\u00a0pro\u00a021\u2010Tage\u2010Zyklus\u00a034\u00a0 7.280,25\u00a0\u2013\u00a09.082,76\u00a0\u20ac\u00a0\noder\u00a0Gemcitabin\u00a0 1.250\u00a0mg/m\u00b2\u00a0KOF\u00a0\u00a0\n2x\u00a0pro\u00a021\u2010Tage\u2010Zyklus\u00a034\u00a0 9.086,67\u00a0\u2013\u00a09.577,80\u00a0\u20ac\u00a0\noder\u00a0Docetaxel\u00a0 75\u00a0mg/m\u00b2\u00a0KOF\u00a0\u00a0\n1x\u00a0pro\u00a021\u2010Tage\u2010Zyklus\u00a017\u00a0 24.335,84\u00a0\u20ac\u00a0\noder\u00a0Paclitaxel\u00a0 175\u00a0mg/m\u00b2\u00a0KOF\u00a0\u00a0\n1x\u00a0pro\u00a021\u2010Tage\u2010Zyklus\u00a017\u00a0 24.078,97\u00a0\u20ac\u00a0\noder\u00a0Pemetrexed\u00a0 500\u00a0mg/m\u00b2\u00a0KOF\u00a0\u00a0\n1x\u00a0pro\u00a021\u2010Tage\u2010Zyklus\u00a017\u00a0 87.101,71\u00a0\u20ac\u00a0\nCarboplatin\u00a0in\u00a0Kombination\u00a0mit\u00a0 500\u00a0mg/m\u00b2\u00a0KOF\u00a0\u00a0\n1x\u00a0pro\u00a021\u2010Tage\u2010Zyklus\u00a017\u00a0 \u00a0\nVinorelbin\u00a0 25\u00a0\u2013\u00a030\u00a0mg/m\u00b2\u00a0KOF\u00a0\u00a0\n2x\u00a0pro\u00a021\u2010Tage\u2010Zyklus\u00a034\u00a013.683,64\u00a0\u2013\u00a014.995,02\u00a0\u20ac\u00a0\noder\u00a0Gemcitabin\u00a0 1.250\u00a0mg/m\u00b2\u00a0KOF\u00a0\u00a0\n2x\u00a0pro\u00a021\u2010Tage\u2010Zyklus\u00a034\u00a0 15.490,06\u00a0\u20ac\u00a0\noder\u00a0Docetaxel\u00a0 75\u00a0mg/m\u00b2\u00a0KOF\u00a0\u00a0\n1x\u00a0pro\u00a021\u2010Tage\u2010Zyklus\u00a017\u00a0 30.739,23\u00a0\u20ac\u00a0\noder\u00a0Paclitaxel\u00a0 175\u00a0mg/m\u00b2\u00a0KOF\u00a0\u00a0\n1x\u00a0pro\u00a021\u2010Tage\u2010Zyklus\u00a017\u00a0 30.189,96\u00a0\u20ac\u00a0\noder\u00a0Pemetrexed\u00a0 500\u00a0mg/m\u00b2\u00a0KOF\u00a0\u00a0\n1x\u00a0pro\u00a021\u2010Tage\u2010Zyklus\u00a017\u00a0 93.505,10\u00a0\u20ac\u00a0\noder\u00a0nab\u2010Paclitaxel\u00a0 100\u00a0mg/m\u00b2\u00a0KOF\u00a0\u00a0\n3x\u00a0pro\u00a021\u2010Tage\u2010Zyklus\u00a051\u00a0 51.634,78\u00a0\u20ac\u00a0\n\u00a0\nVersorgungsanalysen\u00a0\nMit\u00a0Markteintritt\u00a0im\u00a0M\u00e4rz\u00a02016\u00a0steigen\u00a0Verbrauch\u00a0und\u00a0Kosten\u00a0von \u00a0Osimertinib\u00a0in\u00a0\nden\u00a0ersten\u00a0vier\u00a0Monaten\u00a0schnell\u00a0und\u00a0kontinuierlich\u00a0auf\u00a0\u00fcber\u00a01.0 00\u00a0DDD\u00a0an\u00a0mit\u00a0\neinem\u00a0Bruttoumsatz\u00a0von\u00a0\u00fcber\u00a0310.000\u00a0\u20ac.\u00a0Sie\u00a0pendeln\u00a0sich\u00a0in\u00a0den\u00a0 Folgemonaten\u00a0\nauf\u00a0einem\u00a0etwas\u00a0niedrigeren\u00a0Nive au\u00a0ein,\u00a0bevor\u00a0der\u00a0Verbrauch\u00a0im\u00a0 November\u00a02016\u00a0153\u00a0auf\u00a0\u00fcber\u00a01.400\u00a0DDD\u00a0entsprechend\u00a0nahezu\u00a050\u00a0behandelten\u00a0Patienten \u00a0anw\u00e4chst\u00a0mit\u00a0\neinem\u00a0Bruttoumsatz\u00a0von\u00a0\u00fcber\u00a0400.000\u00a0\u20ac.\u00a0Unmittelbar\u00a0danach\u00a0gibt\u00a0 es\u00a0infolge\u00a0der\u00a0\nMarktr\u00fccknahme\u00a0von\u00a0Tagrisso\u00ae\u00a0fast\u00a0ein\u00a0Jahr\u00a0lang\u00a0keine\u00a0Verordnun gen.\u00a0Mit\u00a0der\u00a0\nzweiten,\u00a0nun\u00a0positiven\u00a0Nutzenbe wertung\u00a0im\u00a0Oktober\u00a02017\u00a0und\u00a0der\u00a0 unmittelbar\u00a0\nsich\u00a0 anschlie\u00dfenden\u00a0 Marktwiedereinf\u00fchrung\u00a0 von\u00a0 Tagrisso\u00ae\u00a0 steigt\u00a0 das\u00a0 Verord\u2010\nnungsvolumen\u00a0im\u00a0November\u00a02017\u00a0sofort\u00a0auf\u00a0fast\u00a01.500\u00a0DDD\u00a0bzw.\u00a044 0.000\u00a0\u20ac\u00a0und\u00a0\n\u00fcberschreitet\u00a0damit\u00a0noch\u00a0die\u00a0H\u00f6chstwerte\u00a0im\u00a0Vorjahr.\u00a0\nAbbildung\u00a04.11:\u00a0Verordnete\u00a0Tages dosen\u00a0(DDD)\u00a0und\u00a0Bruttoums\u00e4tze\u00a0v on\u00a0\u00a0\nOsimertinib\u00a0nach\u00a0Monaten\u00a0(2016\u00a0\u2013\u00a02017)\u00a0\n\u00a0\n\u00a0\nQuellen\u00a0\nBansal\u00a0P,\u00a0Osman\u00a0D,\u00a0Gan\u00a0GN,\u00a0Simon\u00a0GR,\u00a0Boumber\u00a0Y\u00a0(2016).\u00a0Recent\u00a0A dvances\u00a0in\u00a0Targetable\u00a0Therapeutics\u00a0in\u00a0Metastatic\u00a0Non\u2010\nSquamous\u00a0NSCLC.\u00a0Frontier s\u00a0in\u00a0Oncology\u00a06:\u00a0112.\u00a0\u00a0\nBollinger\u00a0MK,\u00a0Agnew\u00a0AS,\u00a0Mascara\u00a0 GP\u00a0(2018).\u00a0Osimertinib:\u00a0A\u00a0third \u2010generation\u00a0tyrosine\u00a0kinase\u00a0inhibitor\u00a0for\u00a0treatment\u00a0of\u00a0epiderma l\u00a0\ngrowth\u00a0factor\u00a0receptor\u2010mutated\u00a0non\u2010small\u00a0cell\u00a0lung\u00a0cancer\u00a0with\u00a0 the\u00a0acquired\u00a0Thr790Met\u00a0mutation.\u00a0J\u00a0Oncol\u00a0Pharm\u00a0\nPract\u00a024(5):\u00a0379\u2013388.\u00a0\u00a0\nDAZ\u00a0\u2013\u00a0Deutsche\u00a0Apotheker\u00a0Zeitung\u00a0(2016).\u00a0Nach\u00a0negativer\u00a0Nutzenb ewertung:\u00a0AstraZeneca\u00a0nimmt\u00a0Tagrisso\u00a0vom\u00a0Markt.\u00a0\nhttps://www.deutsche\u2010apotheker\u2010zeitung.de/news/artikel/2016/11/ 02/astrazeneca\u2010nimmt\u2010tagrisso\u2010vom\u2010markt,\u00a0\nletzter\u00a0Zugriff:\u00a021.02.2019.\u00a0\n154\u00a0DAZ\u00a0\u2013\u00a0Deutsche\u00a0Apotheker\u00a0Zeitung\u00a0(2017).\u00a0Ab\u00a01.\u00a0November:\u00a0Tagris so\u00a0kommt\u00a0zur\u00fcck.\u00a0https://www.deutsche\u2010apotheker\u2010\nzeitung.de/news/artikel/2017/10/20/tagrisso\u2010kommt\u2010zurueck,\u00a0letz ter\u00a0Zugriff:\u00a028.02.2019.\u00a0\nEMA\u00a0\u2013\u00a0European\u00a0Medicines\u00a0Agency\u00a0(2016).\u00a0Tagrisso\u00a0|\u00a0European\u00a0Med icines\u00a0Agency.\u00a0\nhttps://www.ema.europa.eu/en/medicines/human/EPAR/tagrisso,\u00a0let zter\u00a0Zugriff:\u00a006.12.2019.\u00a0\nFachinformation\u00a0Tagrisso\u00ae\u00a0(2018) .\u00a0Stand\u00a0der\u00a0Information:\u00a0August \u00a02018.\u00a0https://www.fachinfo.de/,\u00a0 letzter\u00a0Zugriff:\u00a006.12.2018\u00a0\nG\u2010BA\u00a0\u2013\u00a0Gemeinsamer\u00a0Bundesausschuss\u00a0(2016).\u00a0Nutzenbewertungsverf ahren\u00a0zum\u00a0Wirkstoff\u00a0Osimertinib\u00a0\u2010\u00a0Gemeinsamer\u00a0\nBundesausschuss.\u00a0https ://www.g\u2010 ba.de/informationen/nutzenbewert ung/224/#tab/beschluesse,\u00a0letzter\u00a0Zugriff:\u00a0\n21.02.2019.\u00a0\nG\u2010BA\u00a0\u2013\u00a0Gemeinsamer\u00a0Bundesausschuss\u00a0(2017).\u00a0Nutzenbewertungsverf ahren\u00a0zum\u00a0Wirkstoff\u00a0Osimertinib\u00a0(Neubewertung\u00a0nach\u00a0\nFristablauf)\u00a0\u2010\u00a0Gemeinsamer\u00a0Bundesausschuss.\u00a0https://www.g\u2010ba.de /informationen/nutzenbewertung/286/,\u00a0letzter\u00a0\nZugriff:\u00a028.02.2019.\u00a0\nG\u2010BA\u00a0\u2013\u00a0Gemeinsamer\u00a0Bundesausschuss\u00a0(2019).\u00a0Nutzenbewertungsverf ahren\u00a0zum\u00a0Wirkstoff\u00a0Osimertinib\u00a0(neues\u00a0Anwendungsgebiet:\u00a0\nnicht\u2010kleinzelliges\u00a0Lungenkarzin om,\u00a0Erstlinientherapie)\u00a0\u2010\u00a0Gemei nsamer\u00a0Bundesausschuss.\u00a0\u00a0https://www.g\u2010\nba.de/informationen/nutzenbewertung/377/,\u00a0letzter\u00a0Zugriff:\u00a028.0 2.2019.\u00a0\nGriesinger\u00a0F,\u00a0Eberhardt\u00a0W,\u00a0Fr\u00fch\u00a0M,\u00a0Gautschi\u00a0O,\u00a0Hilbe\u00a0W,\u00a0Hoffman n\u00a0H\u00a0et\u00a0al.\u00a0(2018).\u00a0Onkopedia\u00a0Leitlinie\u00a0NSCLC.\u00a0\nhttps://www.onkopedia.com/de/onkopedia/guidelines/lungenkarzino m\u2010nicht\u2010kleinzellig\u2010\nnsclc/@@guideline/html/index.html,\u00a0letzter\u00a0Zugriff:\u00a006.12.2019. \u00a0\nIQWiG\u00a0\u2013\u00a0Institut\u00a0f\u00fcr\u00a0Qualit\u00e4t\u00a0und\u00a0Wirtschaftlichkeit\u00a0im\u00a0Gesundh eitswesen\u00a0(2017).\u00a0Nutzenbewertungsverfahren\u00a0zum\u00a0Wirkstoff\u00a0\nOsimertinib\u00a0(Neubewertung\u00a0nach\u00a0Fristablauf)\u00a0\u2010\u00a0Gemeinsamer\u00a0Bunde sausschuss.\u00a0https://www.g\u2010\nba.de/informationen/nutzenbewertung/286/#tab/nutzenbewertung,\u00a0l etzter\u00a0Zugriff:\u00a028.02.2019.\u00a0\nLauer\u2010Fischer\u00a0(2018).\u00a0WEBAPO\u00ae\u00a0Infosystem,\u00a0LAUER\u2010TAXE\u00a0online,\u00a0St and\u00a0der\u00a0Information:\u00a0Dezember\u00a02017.\u00a0https://www.lauer\u2010\nfischer.de/LF/Seiten/WEBAPO\u2010Info System/WEBAPO\u2010Infosystem.aspx,\u00a0 letzter\u00a0Zugriff:\u00a004.01.2018.\u00a0\nMichels\u00a0S,\u00a0Wolf\u00a0J\u00a0(2018).\u00a0Therapie\u00a0im\u00a0Stadium\u00a0IV\u00a0des\u00a0nichtklein zelligen\u00a0Lungenkarzinoms\u00a0mit\u00a0Treibermutation.\u00a0Der\u00a0Onkologe\u00a0\n24(12),\u00a0983\u2013991.\u00a0\nMok\u00a0TS,\u00a0Wu\u00a0YL,\u00a0Ahn\u00a0MJ,\u00a0Garassino\u00a0MC,\u00a0Kim\u00a0HR,\u00a0Ramalingam\u00a0SS\u00a0et\u00a0a l.\u00a0(2017).\u00a0Osimertinib\u00a0or\u00a0Pl atinum\u2013Pemetrexed\u00a0in\u00a0EGFR\u00a0\nT790M\u2013Positive\u00a0Lung\u00a0Cancer.\u00a0NEJM\u00a0376(7):\u00a0629\u2013640.\u00a0\nPZ\u00a0\u2013\u00a0Pharmazeutische\u00a0Zeitung\u00a0(2016).\u00a0Osimertinib|Tagrisso|86|20 16\u00a0|\u00a0Pharmazeutische\u00a0Zeitung.\u00a0https://www.pharmazeutische\u2010\nzeitung.de/arzneistoffe/daten/2016/osimertinibtagrissor862016/, \u00a0letzter\u00a0Zugriff:\u00a011.07.2019.\u00a0\nPrescrire\u00a0Int.\u00a0(2017).\u00a0Osimertinib\u00a0in\u00a0T790M\u00a0mutation\u2010positive\u00a0l ung\u00a0cancer.\u00a0Preliminary\u00a0evaluation.\u00a0Prescrire\u00a0International\u00a026( 183):\u00a0\n147\u2010148.\u00a0\nFDA\u00a0\u2013\u00a0Food\u00a0and\u00a0Drug\u00a0Administration\u00a0(2017).\u00a0Approved\u00a0Drugs\u00a0\u2010\u00a0Osi mertinib\u00a0(TAGRISSO).\u00a0\nhttps://www.fda.gov/drugs/informationondrugs/approveddrugs/ucm5 49683.html,\u00a0letzter\u00a0Zugriff:\u00a011.07.2019.\u00a0\nSharma\u00a0SV,\u00a0Bell\u00a0DW,\u00a0Settleman\u00a0J,\u00a0Haber\u00a0DA\u00a0(2007).\u00a0Epidermal\u00a0gro wth\u00a0factor\u00a0receptor\u00a0mutations\u00a0in\u00a0lung\u00a0cancer.\u00a0Nat\u00a0Rev\u00a0Cancer\u00a07\u00a0\n(3):\u00a0169\u2013181.\u00a0\nSoria\u00a0JC,\u00a0Ohe\u00a0Y,\u00a0Vansteenkiste\u00a0J,\u00a0Reungwetwattana\u00a0T,\u00a0Chewaskuly ong\u00a0B,\u00a0Lee\u00a0KH\u00a0et\u00a0al.\u00a0(2018).\u00a0Osimertinib\u00a0in\u00a0Untreated\u00a0EGFR\u00a0\u2010\nMutated\u00a0Advanced\u00a0Non\u2013Small\u2010Cell\u00a0Lung\u00a0Cancer.\u00a0NEJM\u00a0378(2):\u00a0113\u20131 25.\u00a0\n\u00a0\u00a0155\u00a0 Palbociclib\u00a04.14\nHandelsname:\u00a0Ibrance\u00ae\u00a0 \u00a0 \u00a0 Pharmazeutischer\u00a0Unternehmer:\u00a0\u00a0\nIndikation:\u00a0HR\u2010positiver,\u00a0 HER2\u2010negativer\u00a0\u00a0 Pfizer\u00a0\nfortgeschrittener\u00a0Brustkrebs\u00a0 \u00a0\nATC\u2010Code:\u00a0L01XE33\u00a0 \u00a0 \u00a0 Markteinf\u00fchrung:\u00a0Februar\u00a02014\u00a0\nDarreichungsform:\u00a0Hartkapseln\u00a0 \u00a0 DDD:\u00a094 \u00a0mg\u00a0O\u00a0\u00a0 \u00a0 \u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 \u25bc\u00a0\nBewertung \u00a0\nPalbociclib\u00a0(Ibrance\u00ae)\u00a0wurde\u00a0im\u00a0November\u00a02016\u00a0in\u00a0Kombination\u00a0mi t\u00a0einem\u00a0Aroma\u2010\ntasehemmer\u00a0 oder\u00a0 Fulvestrant\u00a0 zur\u00a0 B ehandlung\u00a0 von\u00a0 Hormonrezeptor\u2010p ositivem,\u00a0\nhumanem,\u00a0epidermalem\u00a0Wachstumsfaktor\u2010Rezeptor\u20102\u00a0(HER2)\u2010negative m\u00a0fortge\u2010\nschrittenem\u00a0Brustkrebs\u00a0zentral\u00a0von\u00a0der\u00a0Europ\u00e4ischen\u00a0Kommission\u00a0 zugelassen.\u00a0Der\u00a0\nWirkstoff\u00a0inhibiert\u00a0als\u00a0erster\u00a0V ertreter\u00a0seiner\u00a0Wirkstoffklasse \u00a0die\u00a0Cyclin\u2010abh\u00e4n\u2010\ngigen\u00a0Kinasen\u00a0(CDK)\u00a04\u00a0und\u00a06.\u00a0Werde n\u00a0diese\u00a0Kinasen\u00a0gehemmt,\u00a0nimm t\u00a0die\u00a0Prolifera\u2010\ntion\u00a0der\u00a0Tumorzellen\u00a0ab\u00a0(Fachinformation\u00a0Ibrance\u00ae,\u00a02019;\u00a0Turner \u00a0et\u00a0al.,\u00a02017).\u00a0\nDie\u00a0Patientinnen\u00a0nehmen\u00a0die\u00a0Hartkapseln\u00a0mit\u00a0Palbociclib\u00a0zyklisc h\u00a0ein:\u00a0Die\u00a0empfoh\u2010\nlene\u00a0Dosierung\u00a0in\u00a0den\u00a0ersten\u00a0drei\u00a0Wochen\u00a0betr\u00e4gt\u00a0125\u00a0mg\u00a0einmal\u00a0 t\u00e4glich\u00a0zu\u00a0einer\u00a0\nMahlzeit,\u00a0gefolgt\u00a0von\u00a0einer\u00a0Einn ahmepause\u00a0von\u00a0sieben\u00a0Tagen\u00a0(3/1 \u00a0Schema;\u00a0Fachin\u2010\nformation\u00a0Ibrance\u00ae,\u00a02019).\u00a0Eine\u00a0Dosisanpassung\u00a0kann\u00a0aufgrund\u00a0vo n\u00a0Nebenwirkun\u2010\ngen\u00a0erforderlich\u00a0werden.\u00a0Die\u00a0Begleittherapie\u00a0mit\u00a0Aromatasehemme rn\u00a0erfolgt\u00a0laut\u00a0\nFachinformation.\u00a0Bei\u00a0Fulvestrant\u00a0werden\u00a0zu\u00a0Beginn\u00a0alle\u00a0zwei\u00a0Woc hen,\u00a0nach\u00a0dem\u00a0\nersten\u00a0Behandlungsmonat\u00a0einmal\u00a0monatlich,\u00a0500\u00a0mg\u00a0intramuskul\u00e4r\u00a0 injiziert.\u00a0Bei\u00a0pr\u00e4\u2010\u00a0\nund\u00a0perimenopausalen\u00a0Frauen\u00a0soll\u00a0die\u00a0endokrine\u00a0Therapie\u00a0au\u00dferde m\u00a0mit\u00a0einem\u00a0\nAgonisten\u00a0des\u00a0 Luteinizing\u00a0Hormone \u00a0Releasing\u00a0Hormone \u00a0(LHRH,\u00a0Luteinisierungshor\u2010\nmon\u2010Releasinghormon)\u00a0kombiniert\u00a0werden\u00a0(Fachinformation\u00a0Ibrance \u00ae,\u00a02019).\u00a0\u00a0\nDie\u00a0Zulassung\u00a0von\u00a0Palbociclib\u00a0basiert\u00a0auf\u00a0zwei\u00a0f\u00fcr\u00a0die\u00a0Zulassun g\u00a0relevanten\u00a0(pivota\u2010\nlen)\u00a0 multizentrischen,\u00a0 doppelbli nden,\u00a0 randomisierten\u00a0 kontrollie rten\u00a0 Phase\u2010III\u2010\nStudien\u00a0(PALOMA\u20102\u00a0und\u00a0\u20103).\u00a0In\u00a0beiden\u00a0klinischen\u00a0Studien\u00a0wurden\u00a0 Frauen\u00a0mit\u00a0Hor\u2010\nmonrezeptor\u2010positivem,\u00a0HER2\u2010nega tivem\u00a0Brustkrebs\u00a0im\u00a0fortgeschri ttenen\u00a0Stadium\u00a0\neingeschlossen.\u00a0Dazu\u00a0geh\u00f6rten\u00a0sow ohl\u00a0lokoregionale\u00a0rezidivieren de\u00a0Erkrankungen,\u00a0\ndie\u00a0 einer\u00a0 kurativen\u00a0 Therapie\u00a0 nicht\u00a0 zug\u00e4nglich\u00a0 waren,\u00a0 als\u00a0 auch\u00a0 m etastasierter\u00a0\nBrustkrebs.\u00a0Die\u00a0Patientinnen\u00a0durften\u00a0zuvor\u00a0noch\u00a0keine\u00a0Behandlun g\u00a0f\u00fcr\u00a0die\u00a0fortge\u2010\nschrittene\u00a0Erkrankung\u00a0erhalten\u00a0haben\u00a0und\u00a0wurden\u00a0im\u00a0Verh\u00e4ltnis\u00a02 :1\u00a0der\u00a0Behand\u2010\nlungsgruppe\u00a0mit\u00a0Palbociclib\u00a0bzw.\u00a0der\u00a0Kontrollgruppe\u00a0mit\u00a0Placebo \u00a0zugeteilt,\u00a0jeweils\u00a0\nzus\u00e4tzlich\u00a0zu\u00a0einer\u00a0endokrinen\u00a0Therapie.\u00a0Die\u00a0Dosierung\u00a0von\u00a0Palb ociclib\u00a0erfolgte\u00a0\nzyklisch\u00a0(3/1\u2010Schema):\u00a0Drei\u00a0Woch en\u00a0lang\u00a0erhielten\u00a0die\u00a0Teilnehme rinnen\u00a0t\u00e4glich\u00a0\n125\u00a0mg\u00a0Palbociclib,\u00a0gefolgt\u00a0von\u00a0 einem\u00a0einw\u00f6chigen\u00a0behandlungsfr eien\u00a0Intervall\u00a0\n(EMA,\u00a02016).\u00a0156\u00a0An\u00a0der\u00a0Studie\u00a0PALOMA\u20102\u00a0(Finn\u00a0et\u00a0al.,\u00a02016)\u00a0nahmen\u00a0666\u00a0postmenop ausale\u00a0Frauen\u00a0\nim\u00a0mittleren\u00a0Alter\u00a0von\u00a062\u00a0Jahren\u00a0teil.\u00a0Die\u00a0Teilnehmerinnen\u00a0in\u00a0b eiden\u00a0Gruppen\u00a0\nerhielten\u00a0au\u00dfer\u00a0Palbociclib\u00a0bzw.\u00a0Placebo\u00a0zus\u00e4tzlich\u00a0kontinuierl ich\u00a0t\u00e4glich\u00a02,5\u00a0mg\u00a0\nLetrozol.\u00a0 Nach\u00a0 einer\u00a0 medianen\u00a0 Beobachtungszeit\u00a0 von\u00a0 38\u00a0 Monaten\u00a0 b etrug\u00a0 das\u00a0\nprogressionsfreie\u00a0\u00dcberleben\u00a0(PFS,\u00a0prim\u00e4rer\u00a0Endpunkt)\u00a0mit\u00a0Palboc iclib\u00a0im\u00a0Median\u00a0\n27,6\u00a0Monate,\u00a0mit\u00a0Placebo\u00a014,5\u00a0Monate\u00a0(EMA,\u00a02016;\u00a0Fachinformatio n\u00a0Ibrance\u00ae,\u00a0\n2019).\u00a0Der\u00a0Unterschied\u00a0zwischen\u00a0den\u00a0Gruppen\u00a0war\u00a0statistisch\u00a0sig nifikant.\u00a0Bisher\u00a0\nliegen\u00a0 keine\u00a0 ausreichenden\u00a0 Daten\u00a0 f\u00fcr\u00a0 das\u00a0 Gesamt\u00fcberleben\u00a0 (sekun d\u00e4rer\u00a0 End\u2010\npunkt)\u00a0vor.\u00a0F\u00fcr\u00a0die\u00a0gesundheitsbezogene\u00a0Lebensqualit\u00e4t,\u00a0erhoben \u00a0mit\u00a0den\u00a0Frage\u2010\nb\u00f6gen\u00a0EuroQOL\u00a05\u00a0 Dimensions \u00a0(EQ\u20105D)\u00a0und\u00a0 Functional\u00a0Assessment\u00a0of\u00a0Cancer\u00a0Ther\u2010\napy\u2010Breast \u00a0(FACT\u2010B),\u00a0zeigte\u00a0sich\u00a0am\u00a0Ende\u00a0der\u00a0Therapie\u00a0mit\u00a0beiden\u00a0Messinst rumen\u2010\nten\u00a0kein\u00a0signifikanter\u00a0Unterschi ed\u00a0zwischen\u00a0den\u00a0Gruppen\u00a0(Rugo\u00a0e t\u00a0al.,\u00a02018).\u00a0\nAn\u00a0der\u00a0Studie\u00a0PALOMA\u20103\u00a0(Cristofanilli\u00a0et\u00a0al.,\u00a02016)\u00a0nahmen\u00a0521\u00a0 Patientinnen\u00a0im\u00a0\nmedianen\u00a0Alter\u00a0von\u00a057\u00a0Jahren\u00a0teil.\u00a0Die\u00a0Teilnehmerinnen\u00a0in\u00a0beide n\u00a0Gruppen\u00a0erhiel\u2010\nten\u00a0au\u00dfer\u00a0Palbociclib\u00a0bzw.\u00a0Place bo\u00a0zus\u00e4tzlich\u00a0eine\u00a0Therapie\u00a0mit \u00a0Fulvestrant\u00a0500\u00a0mg\u00a0\nals\u00a0intramuskul\u00e4re\u00a0Injektion.\u00a0Zu\u00a0Beginn\u00a0erfolgte\u00a0die\u00a0Injektion\u00a0 alle\u00a0zwei\u00a0Wochen,\u00a0\nnach\u00a0 dem\u00a0 ersten\u00a0 Behandlungsmonat\u00a0 einmal\u00a0 alle\u00a0 vier\u00a0 Wochen.\u00a0 Pr\u00e4\u2010\u00a0 und\u00a0 peri\u2010\nmenopausale\u00a0Frauen\u00a0wurden\u00a0au\u00dferd em\u00a0mit\u00a0dem\u00a0LHRH\u2010Agonisten\u00a0Goser elin\u00a0be\u2010\nhandelt.\u00a0\nNach\u00a0einer\u00a0medianen\u00a0Beobachtungszeit\u00a0von\u00a0neun\u00a0Monaten\u00a0lag\u00a0das\u00a0P FS\u00a0(prim\u00e4rer\u00a0\nEndpunkt)\u00a0in\u00a0der\u00a0Palbociclib\u2010Gruppe\u00a0im\u00a0Median\u00a0bei\u00a011,2\u00a0Monaten, \u00a0in\u00a0der\u00a0Placebo\u2010\nGruppe\u00a0im\u00a0Median\u00a0bei\u00a04,6\u00a0Monaten.\u00a0Der\u00a0Unterschied\u00a0zwischen\u00a0den\u00a0 Gruppen\u00a0war\u00a0\nstatistisch\u00a0signifikant\u00a0(EMA,\u00a02016).\u00a0Nach\u00a0einer\u00a0medianen\u00a0Beobac htungszeit\u00a0von\u00a0\n44,8\u00a0Monaten\u00a0betrug\u00a0das\u00a0Gesamt\u00fcberleben\u00a0in\u00a0der\u00a0Palbociclib\u2010Grup pe\u00a0im\u00a0Median\u00a0\u00a0\n34,9\u00a0Monate,\u00a0in\u00a0der\u00a0Placebo\u2010Gruppe\u00a0im\u00a0Median\u00a028,0\u00a0Monate.\u00a0Der\u00a0U nterschied\u00a0\nwar\u00a0jedoch\u00a0nicht\u00a0statistisch\u00a0signifikant\u00a0(Turner\u00a0et\u00a0al.,\u00a02018). \u00a0\nDie\u00a0gesundheitsbezogene\u00a0Lebensqua lit\u00e4t\u00a0(HRQoL)\u00a0wurde\u00a0als\u00a0sekund \u00e4rer\u00a0Endpunkt\u00a0\nmithilfe\u00a0verschiedener\u00a0Frageb\u00f6gen\u00a0erfasst:\u00a0 European\u00a0Organization\u00a0for\u00a0Research\u00a0\nand\u00a0Treatment\u00a0of\u00a0Cancer\u00a0Quality\u00a0of\u00a0Life\u00a0Questionnaire \u00a0(EORTC\u00a0QLQ\u2010C30)\u00a0sowie\u00a0\ndem\u00a0begleitenden\u00a0 European\u00a0Organization\u00a0for\u00a0Resea rch\u00a0and\u00a0Treatment\u00a0of\u00a0Cancer\u00a0\nBreast\u00a0Cancer\u00a0Module \u00a0(EORTC\u00a0QLQ\u00a0BR23).\u00a0Dabei\u00a0zeigten\u00a0sich\u00a0signifikante\u00a0Unter\u2010\nschiede\u00a0nur\u00a0f\u00fcr\u00a0zwei\u00a0von\u00a0sechs\u00a0Subskalen\u00a0der\u00a0QLQ\u2010C30\u00a0 Functional\u00a0Scale ,\u00a0f\u00fcr\u00a0zwei\u00a0\nvon\u00a0neun\u00a0Subskalen\u00a0der\u00a0QLQ\u2010C30\u00a0 Symptom\u00a0Scale \u00a0(beide\u00a0zugunsten\u00a0von\u00a0Palboci\u2010\nclib)\u00a0sowie\u00a0eine\u00a0von\u00a0vier\u00a0Subskalen\u00a0der\u00a0QLQ\u00a0BR23\u00a0 Symptom\u00a0Scale \u00a0(zugunsten\u00a0von\u00a0\nPlacebo)\u00a0(Harbeck\u00a0et\u00a0al.,\u00a02016).\u00a0\nIn\u00a0den\u00a0Zulassungsstudien\u00a0trat\u00a0als\u00a0h\u00e4ufigstes\u00a0UAE\u00a0Neutropenie\u00a0au f,\u00a0die\u00a0bei\u00a0rund\u00a0\neinem\u00a0Drittel\u00a0der\u00a0behandelten\u00a0Patientinnen\u00a0eine\u00a0Dosisreduktion\u00a0 oder\u00a0vor\u00fcberge\u2010\nhende\u00a0Therapieunterbrechung\u00a0notwe ndig\u00a0machte.\u00a0Au\u00dferdem\u00a0kam\u00a0es\u00a0h \u00e4ufig\u00a0zu\u00a0157\u00a0Fatigue,\u00a0Infektionen,\u00a0anderen\u00a0Leukopenien,\u00a0\u00dcbelkeit\u00a0und\u00a0Erbrech en,\u00a0Gelenkschmer\u2010\nzen,\u00a0Entz\u00fcndungen\u00a0der\u00a0Mundschleimhaut,\u00a0Durchfall\u00a0und\u00a0Haarausfal l.\u00a0In\u00a0den\u00a0meisten\u00a0\nF\u00e4llen\u00a0handelte\u00a0es\u00a0sich\u00a0um\u00a0einen\u00a0leichten\u00a0oder\u00a0moderaten\u00a0Schwer egrad\u00a0(CTCAE\u00a0\nGrade\u00a0 1\u00a0 bzw.\u00a0 2),\u00a0 Neutropenien\u00a0 und\u00a0 andere\u00a0 Leukopenien\u00a0 waren\u00a0 dage gen\u00a0 meist\u00a0\nschwerwiegend\u00a0(CTCAE\u00a0Grade\u00a03)\u00a0(EMA,\u00a02016;\u00a0Fachinformation\u00a0Ibran ce\u00ae,\u00a02019).\u00a0\nDie\u00a0fr\u00fche\u00a0Nutzenbewertung\u00a0von\u00a0Palbociclib\u00a0wurde\u00a0f\u00fcr\u00a0vier\u00a0Subgru ppen\u00a0von\u00a0Frauen\u00a0\nmit\u00a0HR\u2010positivem,\u00a0HER2\u2010negativem,\u00a0fortgeschrittenem\u00a0bzw.\u00a0metast asiertem\u00a0Brust\u2010\nkrebs\u00a0vorgenommen.\u00a0\u00a0\nF\u00fcr\u00a0die\u00a0endokrine\u00a0Erstlinienther apie\u00a0von\u00a0postmenopausalen\u00a0Fraue n\u00a0(Gruppe\u00a0A1)\u00a0\nwurden\u00a0Anastrozol\u00a0oder\u00a0Letrozol\u00a0 als\u00a0zVT\u00a0festgelegt\u00a0bzw.\u00a0Tamoxif en,\u00a0wenn\u00a0Aroma\u2010\ntasehemmer\u00a0nicht\u00a0geeignet\u00a0sind.\u00a0F \u00fcr\u00a0die\u00a0endokrine\u00a0Erstlinienthe rapie\u00a0von\u00a0pr\u00e4\u2010\u00a0und\u00a0\nperimenopausalen\u00a0Frauen\u00a0(Gruppe\u00a0A2)\u00a0wurde\u00a0Tamoxifen\u00a0in\u00a0Kombinat ion\u00a0mit\u00a0einer\u00a0\nAusschaltung\u00a0der\u00a0Ovarialfunktion\u00a0als\u00a0zVT\u00a0festgesetzt.\u00a0\u00a0\nF\u00fcr\u00a0die\u00a0Zweit\u2010\u00a0und\u00a0Folgelinienthe rapie\u00a0bei\u00a0postmenopausalen\u00a0Fra uen\u00a0mit\u00a0Progres\u2010\nsion\u00a0unter\u00a0endokriner\u00a0Therapie\u00a0(Gruppe\u00a0B1)\u00a0gilt\u00a0als\u00a0zVT\u00a0je\u00a0nach \u00a0Vorbehandlung\u00a0\nund/oder\u00a0 unter\u00a0 bestimmten\u00a0 Bedingungen\u00a0 Tamoxifen,\u00a0 Anastrozol,\u00a0 Fu lvestrant,\u00a0\nLetrozol,\u00a0Exemestan\u00a0oder\u00a0Everolimus\u00a0in\u00a0Kombination\u00a0mit\u00a0Exemesta n.\u00a0Dabei\u00a0gelten\u00a0\nFulvestrant,\u00a0Letrozol\u00a0und\u00a0Exemestan\u00a0nur\u00a0f\u00fcr\u00a0Patientinnen\u00a0mit\u00a0Re zidiv\u00a0oder\u00a0Pro\u2010\ngress\u00a0nach\u00a0einer\u00a0Anti\u00f6strogenbehandlung\u00a0als\u00a0zVT,\u00a0Everolimus/Exe mestan\u00a0nur\u00a0f\u00fcr\u00a0\nPatientinnen\u00a0ohne\u00a0symptomatische\u00a0viszerale\u00a0Metastasierung,\u00a0nach dem\u00a0es\u00a0zu\u00a0einer\u00a0\nProgression\u00a0unter\u00a0einem\u00a0nicht\u00a0steroidalen\u00a0Aromataseinhibitor\u00a0ge kommen\u00a0ist.\u00a0F\u00fcr\u00a0\ndie\u00a0Zweit\u2010\u00a0und\u00a0Folgelinientherapie\u00a0bei\u00a0pr\u00e4\u2010\u00a0und\u00a0perimenopausale n\u00a0Frauen\u00a0mit\u00a0\nProgression\u00a0unter\u00a0endokriner\u00a0Therapie\u00a0(Gruppe\u00a0B2)\u00a0wurde\u00a0als\u00a0zVT \u00a0eine\u00a0endokrine\u00a0\nTherapie\u00a0nach\u00a0\u00e4rztlicher\u00a0Ma\u00dfgabe\u00a0unter\u00a0Beachtung\u00a0der\u00a0Zulassung\u00a0 festgelegt.\u00a0\u00a0\nDas\u00a0IQWiG\u00a0konnte\u00a0in\u00a0seinem\u00a0urspr\u00fcnglichen\u00a0Gutachten\u00a0f\u00fcr\u00a0die\u00a0Gru ppen\u00a0B1\u00a0und\u00a0B2\u00a0\nkeinen\u00a0Zusatznutzen\u00a0feststellen,\u00a0da\u00a0in\u00a0den\u00a0vorgelegten\u00a0Daten\u00a0de s\u00a0pU\u00a0der\u00a0Vergleich\u00a0\nnicht\u00a0der\u00a0festgelegten\u00a0zVT\u00a0entsprach.\u00a0F\u00fcr\u00a0Gruppe\u00a0A2\u00a0hatte\u00a0der\u00a0p U\u00a0gar\u00a0keine\u00a0Daten\u00a0\nvorgelegt.\u00a0F\u00fcr\u00a0 die\u00a0Gruppe\u00a0A1\u00a0konnte\u00a0das\u00a0Gutachten\u00a0keinen\u00a0Zusatz nutzen\u00a0von\u00a0\nPalbociclib\u00a0gegen\u00fcber\u00a0der\u00a0zVT\u00a0fe ststellen\u00a0(IQWiG,\u00a02017a).\u00a0Auch\u00a0 eine\u00a0Erweiterung\u00a0\ndes\u00a0Auftrags\u00a0durch\u00a0den\u00a0G\u2010BA\u00a0ver\u00e4 nderte\u00a0das\u00a0Ergebnis\u00a0nicht\u00a0(IQWi G,\u00a02017b).\u00a0\u00a0\nDer\u00a0G\u2010BA\u00a0schloss\u00a0sich\u00a0im\u00a0Mai\u00a02017\u00a0dem\u00a0Urteil\u00a0des\u00a0IQWiG\u00a0an\u00a0( Zusatznutzen\u00a0nicht\u00a0\nbelegt).\u00a0F\u00fcr\u00a0die\u00a0 Gruppen\u00a0A1,\u00a0B1\u00a0und\u00a0B2 \u00a0wurde\u00a0der\u00a0Beschluss\u00a0jedoch\u00a0 befristet\u00a0\u00a0\n(G\u2010BA,\u00a02017).\u00a0\u00a0\nNach\u00a0Ablauf\u00a0der\u00a0Befristung\u00a0f\u00fcr\u00a0die\u00a0Gruppen\u00a0B1\u00a0und\u00a0B2\u00a0kam\u00a0ein\u00a0Gu tachten\u00a0des\u00a0\nIQWiG\u00a0erneut\u00a0zu\u00a0dem\u00a0Ergebnis,\u00a0dass\u00a0die\u00a0Daten\u00a0im\u00a0Dossier\u00a0des\u00a0pU\u00a0 nicht\u00a0f\u00fcr\u00a0die\u00a0\nBewertung\u00a0des\u00a0Zusatznutzens\u00a0geeignet\u00a0sind,\u00a0da\u00a0die\u00a0zVT\u00a0nicht\u00a0umg esetzt\u00a0wurde,\u00a0158\u00a0und\u00a0damit\u00a0ein\u00a0Zusatznutzen\u00a0nicht\u00a0belegt\u00a0ist\u00a0(IQWiG,\u00a02019).\u00a0Der\u00a0 G\u2010BA\u00a0schloss\u00a0sich\u00a0\ntrotz\u00a0abweichender\u00a0Einsch\u00e4tzung\u00a0zur\u00a0zVT\u00a0Ende\u00a0M\u00e4rz\u00a02019\u00a0der\u00a0Eins ch\u00e4tzung\u00a0an,\u00a0\ndass\u00a0ein\u00a0Zusatznutzen\u00a0 nicht\u00a0belegt \u00a0ist\u00a0(G\u2010BA,\u00a02019).\u00a0Die\u00a0Befristung\u00a0des\u00a0Beschlusses\u00a0\nzur\u00a0Gruppe\u00a0A1\u00a0 wurde\u00a0bis\u00a0Anfang\u00a02021 \u00a0verl\u00e4ngert,\u00a0da\u00a0erst\u00a0dann\u00a0Daten\u00a0zum\u00a0Ge\u2010\nsamt\u00fcberleben\u00a0zur\u00a0Verf\u00fcgung\u00a0stehen\u00a0werden\u00a0(G\u2010BA,\u00a02018).\u00a0\u00a0\n\u00a0\nVerf\u00fcgbare\u00a0Therapien \u00a0 (Zusatz\u2010)Nutzen \u00a0 Kosten\u00a0\n\u00a0\nweitere\u00a0Therapieoption\u00a0\nbei\u00a0fortgeschrittenem\u00a0\nBrustkrebs\u00a0\u00a01.\u00a0Bewertung:\u00a0ZN\u00a0nicht\u00a0\nbelegt,\u00a0Beschluss\u00a0teilweise\u00a0\nbefristet.\u00a02.\u00a0Bewertung:\u00a0\nZN\u00a0nicht\u00a0belegt.\u00a0Teilweise\u00a0\nweiter\u00a0befristet\u00a0\u00a0\nin\u00a0Erstlinientherapie\u00a0\nteurer\u00a0als\u00a0zVT,\u00a0in\u00a0Zweit\u2010/\u00a0\nFolgelinientherapie\u00a0teils\u00a0\ng\u00fcnstiger\u00a0als\u00a0zVT\u00a0\nErl\u00e4uterung\u00a0der\u00a0Farben:\u00a0Verf\u00fcgbare\u00a0Therapien:\u00a0rot\u00a0=\u00a0weitere\u00a0The rapieoption,\u00a0gelb\u00a0=\u00a0Subgruppen\u2010Novit\u00e4t,\u00a0gr\u00fcn\u00a0=\u00a0Solist;\u00a0(Zusatz\u2010 )\u00a0\nNutzen:\u00a0rot\u00a0=\u00a0keine\u00a0Verbesserung\u00a0oder\u00a0schlechte\u00a0Nutzen/Schaden\u2010 Relation,\u00a0gelb\u00a0=\u00a0teilweise\u00a0Verbesserungen,\u00a0gr\u00fcn\u00a0=\u00a0Verbesserung\u00a0\nharter\u00a0Endpunkte;\u00a0Kosten:\u00a0rot\u00a0=\u00a0teurer\u00a0als\u00a0bestehende\u00a0Therapien ,\u00a0gelb\u00a0=\u00a0ungef\u00e4hr\u00a0gleich\u00a0bzw.\u00a0teils/teils,\u00a0gr\u00fcn\u00a0=\u00a0g\u00fcnstiger\u00a0als \u00a0\nbestehende\u00a0Therapien\u00a0\nWie\u00a0bewerten\u00a0andere?\u00a0\nBewertung\u00a0nach\u00a0\nFricke\u00a0et\u00a0al.\u00a0a\u2010t\u2010Bewertung\u00a0 AMB\u00a0 Prescrire\u00a0 PZ\u00a0\nA\u00a0 \u2013\u00a0 \u2013\u00a0 Not\u00a0acceptable\u00a0 Sprunginnovation\u00a0\u00a0\n\u00a0\n\u00a0\u00a0\n159\u00a0Kosten\u00a0\nWirkstoff\u00a0 Behandlungsmodus\u00a0 Behandlungstage\u00a0 Jahrestherapiekosten\u00a0\nzu\u00a0bewertendes\u00a0Arzneimittel \u00a0\u00a0 \u00a0 \u00a0\nPalbociclib\u00a0 125\u00a0mg\u00a01x\u00a0tgl.\u00a0 273\u00a0 35.640,93\u00a0\u20ac\u00a0\n+\u00a0Aromatasehemmer\u00a0\n\u00a0\u00a0\u00a0(Anastrazol,\u00a0Letrozol\u00a0oder\u00a0\n\u00a0\u00a0\u00a0Exemestan)\u00a01\u00a0\u2013\u00a025\u00a0mg\u00a01x\u00a0tgl.\u00a0 365\u00a0 146,22\u00a0\u2013\u00a0376,50\u00a0\u20ac\u00a0\n\u00a0 \u00a0 \u00a035.787,15\u00a0\u2013\u00a036.017,43\u00a0\u20ac\u00a0\noder\u00a0 \u00a0 \u00a0\u00a0\n+\u00a0Fulvestrant\u00a0500\u00a0mg\u00a01x\u00a0mtl.\u00a0(2x\u00a0mtl.\u00a0in\u00a0\nMonat\u00a01)\u00a013\u00a0im\u00a01.\u00a0Jahr,\u00a0\u00a0\n(dann\u00a012)\u00a010.399,74\u00a0\u20ac\u00a0\n(9.599,76\u00a0\u20ac)\u00a0\n\u00a0 \u00a0 \u00a046.040,67\u00a0\u20ac\u00a0\n(45.240,69\u00a0\u20ac)\u00a0\nLHRH\u2010Analogon\u00a0als\u00a0Basistherapie1:\u00a0\u00a0 \u00a0 \u00a0\nLeuprorelin\u00a0 11,25\u00a0mg\u00a01x\u00a0alle\u00a03\u00a0Monate\u00a0\u00a0 4\u00a0 1.897,78\u00a0\u20ac\u00a0\noder\u00a0 \u00a0 \u00a0 \u00a0\nGoserelin\u00a0 3,6\u00a0mg\u00a01x\u00a0alle\u00a028\u00a0Tage\u00a0\u00a0 13\u00a0 2.372,33\u00a0\u20ac\u00a0\nzVT\u00a0Postmenopausale\u00a0Pat.\u00a0in\u00a0Erstlinientherapie \u00a0\nAnastrozol\u00a0 1\u00a0mg\u00a01x\u00a0tgl.\u00a0\u00a0 365\u00a0 178,05\u00a0\u20ac\u00a0\nLetrozol\u00a0 2,5\u00a0mg\u00a01x\u00a0tgl.\u00a0\u00a0 365\u00a0 146,22\u00a0\u20ac\u00a0\nTamoxifen\u00a0 20\u00a0\u2013\u00a040\u00a0mg\u00a01x\u00a0tgl.\u00a0 365\u00a0 76,80\u00a0\u2013\u00a0310,98\u00a0\u20ac\u00a0\nzVT\u00a0Pr\u00e4\u2010/Perimenopausale\u00a0Pat.\u00a0in\u00a0Erstlinientherapie \u00a0\nTamoxifen\u00a0 s.o.\u00a0 s.o.\u00a0 \u00a0\n+\u00a0LHRH\u2010Analogon \u00a0 s.o.\u00a0 s.o.\u00a0 1.974,58\u00a0\u2013\u00a02.683,31\u00a0\u20ac\u00a0\nzVT\u00a0Postmenopausale\u00a0Pat.\u00a0mit\u00a0Progression\u00a0nach\u00a0einer\u00a0vorangegang enen\u00a0endokrinen\u00a0Therapie \u00a0\nTamoxifen \u00a0 s.o.\u00a0 s.o.\u00a0 s.o.\u00a0\nAnastrozol\u00a0 s.o.\u00a0 s.o.\u00a0 s.o.\u00a0\nFulvestrant\u00a0 s.o.\u00a0 s.o.\u00a0 s.o.\u00a0\nLetrozol\u00a0 s.o.\u00a0 s.o.\u00a0 s.o.\u00a0\nExemestan\u00a0 25\u00a0mg\u00a01x\u00a0tgl.\u00a0\u00a0 365\u00a0 376,50\u00a0\u20ac\u00a0\nEverolimus\u00a0+\u00a0Exemestan\u00a0 10/25\u00a0mg\u00a01x\u00a0tgl.\u00a0\u00a0 365\u00a0 49.718,82\u00a0\u20ac\u00a0\nzVT\u00a0Pr\u00e4\u2010/Perimenopausal e\u00a0Pat.\u00a0mit\u00a0Progression\u00a0nach\u00a0einer\u00a0vorang egangenen\u00a0endokrinen\u00a0Therapie \u00a0\nTamoxifen\u00a0 s.o.\u00a0 s.o.\u00a0 s.o.\u00a0\nMedroxyprogesteronacetat\u00a0 500\u00a0mg*\u00a01\u00a0\u2013\u00a02x\u00a0tgl.\u00a0\u00a0 365\u00a0 1.261,66\u00a0\u2013\u00a02.523,32\u00a0\u20ac\u00a0\nMegestrolacetat\u00a0 160\u00a0mg\u00a01x\u00a0tgl.\u00a0\u00a0 365\u00a0 5.741,33\u00a0\u20ac\u00a0\nExemestan\u00a0\u00a0 s.o.\u00a0 s.o.\u00a0 s.o.\u00a0\nLetrozol\u00a0 s.o.\u00a0 s.o.\u00a0 s.o.\u00a0\u00a0\nLHRH\u2010Analogon\u00a0 s.o.\u00a0 s.o.\u00a0 s.o.\u00a0\n*G\u2010BA\u2010Therapie\u00a0von\u00a0300\u00a0mg\u00a0nicht\u00a0im\u00a0Handel\u00a0\n1\u00a0nur\u00a0bei\u00a0pr\u00e4\u2010/perimenopausalen\u00a0Patientinnen\u00a0in\u00a0Erstlinientherap ie\u00a0und\u00a0bei\u00a0pr\u00e4\u2010/perimenopausalen\u00a0Patientinnen\u00a0mit\u00a0Progression\u00a0\nnach\u00a0einer\u00a0vorangegangenen\u00a0endokrinen\u00a0Therapie\u00a0160\u00a0Versorgungsanalysen\u00a0\nSeit\u00a0der\u00a0Markteinf\u00fchrung\u00a0Anfang\u00a0Dezember\u00a02016\u00a0steigt\u00a0die\u00a0Anzahl \u00a0der\u00a0verordne\u2010\nten\u00a0Tagesdosen\u00a0Palbociclib\u00a0nahezu\u00a0kontinuierlich\u00a0an.\u00a0Parallel\u00a0e ntwickeln\u00a0sich\u00a0die\u00a0\nBruttoums\u00e4tze.\u00a0Die\u00a0jeweils\u00a0h\u00f6chs ten\u00a0Werte\u00a0werden\u00a0mit\u00a0mehr\u00a0als\u00a01 4.000\u00a0DDD\u00a0und\u00a0\neinem\u00a0Bruttoumsatz\u00a0von\u00a0mehr\u00a0als\u00a03\u00a0Mio.\u00a0\u20ac\u00a0im\u00a0November\u00a02017\u00a0errei cht.\u00a0Der\u00a0G\u2010BA\u2010\nBeschluss\u00a0zur\u00a0fr\u00fchen\u00a0Nutzenbewertung\u00a0im\u00a0Mai\u00a02017,\u00a0der\u00a0f\u00fcr\u00a0Palbo ciclib\u00a0keinen\u00a0\nZusatznutzen\u00a0anerkannte,\u00a0schl\u00e4gt\u00a0sich\u00a0in\u00a0den\u00a0Verordnungszahlen\u00a0 nicht\u00a0nieder.\u00a0\nAbbildung\u00a04.12:\u00a0Verordnete\u00a0Tages dosen\u00a0(DDD)\u00a0und\u00a0Bruttoums\u00e4tze\u00a0v on\u00a0\nPalbociclib\u00a0nach\u00a0Monaten\u00a0(2016\u00a0\u2013\u00a02017)\u00a0\n\u00a0\n\u00a0\nQuellen\u00a0\u00a0\nAWMF\u00a0\u2013\u00a0Arbeitsgemeinschaft\u00a0der\u00a0W issenschaftlichen\u00a0Medizinischen \u00a0Fachgesellschaften\u00a0(2017).\u00a0Fr\u00fcherkennung,\u00a0Diagnostik,\u00a0\nTherapie\u00a0und\u00a0Nachsorge\u00a0des\u00a0Mammakarzinoms.\u00a0https://www.awmf.org /leitlinien/detail/ll/032\u2010045OL.html,\u00a0letzter\u00a0\nZugriff:\u00a011.07.2019.\u00a0\nCardoso\u00a0F,\u00a0Senkus\u00a0E,\u00a0Costa\u00a0A,\u00a0Papadopoulos\u00a0E,\u00a0Aapro\u00a0M,\u00a0Andr\u00e9\u00a0F\u00a0 et\u00a0al.\u00a0(2018).\u00a04th\u00a0ESO\u2010ESMO\u00a0International\u00a0Consensus\u00a0Guidelines\u00a0\nfor\u00a0Advanced\u00a0Breast\u00a0Cancer\u00a0(ABC\u00a04)\u2020.\u00a0Ann\u00a0Oncol\u00a029(8):\u00a01634\u20101657 .\u00a0\u00a0\nCristofanilli\u00a0M,\u00a0Turner\u00a0NC,\u00a0Bonda renko\u00a0I,\u00a0Ro\u00a0J,\u00a0Im\u00a0S\u2010A,\u00a0Masuda\u00a0 N\u00a0et\u00a0al.\u00a0(2016).\u00a0Fulvestrant\u00a0plus \u00a0palbociclib\u00a0versus\u00a0fulvestran t\u00a0plus\u00a0\nplacebo\u00a0for\u00a0treatment\u00a0of\u00a0hormone\u2010receptor\u2010positive,\u00a0HER2\u2010negati ve\u00a0metastatic\u00a0breast\u00a0cancer\u00a0that\u00a0progressed\u00a0on\u00a0\nprevious\u00a0endocrine\u00a0therapy\u00a0(PALOMA\u20103):\u00a0final\u00a0analysis\u00a0of\u00a0the\u00a0mu lticentre,\u00a0double\u2010blind,\u00a0phase\u00a03\u00a0randomised\u00a0\ncontrolled\u00a0trial.\u00a0Lancet\u00a0Oncol\u00a017(4):\u00a0425\u2010439.\u00a0\u00a0\n161\u00a0EMA\u00a0\u2013\u00a0European\u00a0Medicines\u00a0Agency\u00a0(2016).\u00a0European\u00a0public\u00a0assessm ent\u00a0report\u00a0(EPAR)\u00a0Ibrance.\u00a0\nhttps://www.ema.europa.eu/en/medicines/human/EPAR/ibrance,\u00a0letz ter\u00a0Zugriff:\u00a011.07.2019.\u00a0\nFachinformation\u00a0Ibrance\u00a0(2018).\u00a0Fachinformation\u00a0Ibrance.\u00a0Stand\u00a0 der\u00a0Information:\u00a0\u00a0November\u00a02017.\u00a0\nFinn\u00a0RS,\u00a0Martin\u00a0M,\u00a0Rugo\u00a0HS,\u00a0Jone s\u00a0S,\u00a0Im\u00a0S\u2010A,\u00a0Gelmon\u00a0K\u00a0et\u00a0al.\u00a0(2 016).\u00a0Palbociclib\u00a0and\u00a0Letrozole\u00a0in\u00a0Advanced\u00a0Breast\u00a0Cancer.\u00a0NEJM \u00a0\n375(20):\u00a01925\u20101936.\u00a0\u00a0\nFricke\u00a0U,\u00a0Hein\u00a0L,\u00a0Schwabe\u00a0U\u00a0(2017).\u00a0Neue\u00a0Arzneimittel\u00a02016.\u00a0In: \u00a0Schwabe\u00a0U,\u00a0Paffrath\u00a0D,\u00a0Ludwig\u00a0W\u2010D,\u00a0Klauber\u00a0J\u00a0(Hrsg.)\u00a0(2017).\u00a0\nArzneiverordnungs\u2010Report\u00a02017.\u00a0Berlin,\u00a0Heidelberg.\u00a0Springer:\u00a055 \u2010135.\u00a0\nG\u2010BA\u00a0\u2013\u00a0Gemeinsamer\u00a0Bundesausschuss\u00a0(2017).\u00a0Nutzenbewertungsverf ahren\u00a0zum\u00a0Wirkstoff\u00a0Palbociclib.\u00a0https://www.g\u2010\nba.de/informationen/nutzenbewertung/269/,\u00a0letzter\u00a0Zugriff:\u00a011.0 7.2019.\u00a0\nG\u2010BA\u00a0\u2013\u00a0Gemeinsamer\u00a0Bundesausschuss\u00a0(2018).\u00a0Arzneimittel\u2010Richtli nie/Anlage\u00a0XII:\u00a0Palbociclib\u00a0\u2013\u00a0Verl\u00e4ngerung\u00a0der\u00a0Befristung\u00a0der\u00a0\nGeltungsdauer.\u00a0https://www.g\u2010ba.de/informationen/beschluesse/34 79/,\u00a0letzter\u00a0Zugriff:\u00a011.07.2019.\u00a0\nG\u2010BA\u00a0\u2013\u00a0Gemeinsamer\u00a0Bundesausschuss\u00a0(2019).\u00a0Nutzenbewertungsverf ahren\u00a0zum\u00a0Wirkstoff\u00a0Palboc iclib\u00a0(Neubewertung\u00a0nach\u00a0\nFristablauf\u00a0\u2013\u00a0Patientenpopulation\u00a0b1\u00a0und\u00a0b2).\u00a0https://www.g\u2010ba. de/informationen/nutzenbewertung/394/,\u00a0letzter\u00a0\nZugriff:\u00a011.07.2019.\u00a0\nHarbeck\u00a0N,\u00a0Iyer\u00a0S,\u00a0Turner\u00a0N,\u00a0Cristofanilli\u00a0M,\u00a0Ro\u00a0J,\u00a0Andr\u00e9\u00a0F\u00a0et\u00a0 al.\u00a0(2016).\u00a0Quality\u00a0of\u00a0life\u00a0with \u00a0palbociclib\u00a0plus\u00a0fulvestrant\u00a0i n\u00a0previously\u00a0\ntreated\u00a0hormone\u00a0receptor\u2010positive,\u00a0HER2\u2010negative\u00a0metastatic\u00a0bre ast\u00a0cancer:\u00a0patient\u2010reported\u00a0outcomes\u00a0from\u00a0the\u00a0\nPALOMA\u20103\u00a0trial.\u00a0Ann\u00a0Oncol\u00a027(6):\u00a01047\u20101054.\u00a0\u00a0\nIQWiG\u00a0\u2013\u00a0Institut\u00a0f\u00fcr\u00a0Qualit\u00e4t\u00a0und\u00a0Wirtschaftlichkeit\u00a0im\u00a0Gesundh eitswesen\u00a0(2017a).\u00a0[A16\u201074]\u00a0Palbociclib\u00a0(Mammakarzinom)\u00a0\u2010\u00a0\nNutzenbewertung\u00a0gem\u00e4\u00df\u00a0\u00a7\u00a035a\u00a0SGB\u00a0V.\u00a0https://www.iqwig.de/de/proj ekte\u2010\nergebnisse/projekte/arzneimittelbewertung/2016/a16\u201074\u2010palbocicl ib\u2010mammakarzinom\u2010nutzenbewertung\u2010gemaess\u2010\n35a\u2010sgb\u2010v.7749.html,\u00a0letzter\u00a0Zugriff:\u00a011.07.2019.\u00a0\nIQWiG\u00a0\u2013\u00a0Institut\u00a0f\u00fcr\u00a0Qualit\u00e4t\u00a0und\u00a0Wirtschaftlichkeit\u00a0im\u00a0Gesundh eitswesen\u00a0(2017b).\u00a0[A17\u201015]\u00a0Palbociclib\u00a0(Mammakarzinom)\u00a0\u2010\u00a0\nAddendum\u00a0zum\u00a0Auftrag\u00a0A16\u201074.\u00a0Retrieved\u00a0from\u00a0https://www.iqwig.d e/de/projekte\u2010ergebnisse/projekte\u2010\n301/arzneimittelbewertung/2017/a17\u201015\u2010palbociclib\u2010mammakarzinom \u2010addendum\u2010zum\u2010auftrag\u2010a16\u201074.7908.html,\u00a0\nletzter\u00a0Zugriff:\u00a011.07.2019.\u00a0\nIQWiG\u00a0\u2013\u00a0Institut\u00a0f\u00fcr\u00a0Qualit\u00e4t\u00a0und\u00a0Wirtschaftlichkeit\u00a0im\u00a0Gesundh eitswesen\u00a0(2019).\u00a0[A18\u201063]\u00a0Palbociclib\u00a0(Mammakarzinom)\u00a0\u2010\u00a0\nNutzenbewertung\u00a0gem\u00e4\u00df\u00a0\u00a7\u00a035a\u00a0SGB\u00a0V\u00a0(Ablauf\u00a0Befristung).\u00a0https:// www.iqwig.de/de/projekte\u2010\nergebnisse/projekte/arzneimittelbewertung/2018/a18\u201063\u2010palbocicl ib\u2010mammakarzinom\u2010nutzenbewertung\u2010gemaess\u2010\n35a\u2010sgb\u2010v\u2010ablauf\u2010befristung.10624.html,\u00a0letzter\u00a0Zugriff:\u00a011.07. 2019.\u00a0\nNICE\u00a0\u2013\u00a0National\u00a0Institute\u00a0for\u00a0Health\u00a0and\u00a0Care\u00a0Excellence\u00a0(2017) .\u00a0Palbociclib\u00a0with\u00a0an\u00a0aromatase\u00a0inhibitor\u00a0for\u00a0previously\u00a0untrea ted\u00a0\nhormone\u00a0receptor\u2010positie,\u00a0HER\u2010negative\u00a0locally\u00a0advanced\u00a0or\u00a0meta static\u00a0breast\u00a0cancer.\u00a0\nhttps://www.nice.org.uk/guidance/ta495/resources/palbociclib\u2010wi th\u2010an\u2010aromatase\u2010inhibitor\u2010for\u2010previously\u2010\nuntreated\u2010hormone\u2010receptorpositive\u2010her2negative\u2010locally\u2010advance d\u2010or\u2010metastatic\u2010breast\u2010cancer\u2010pdf\u2010\n82605088634821,\u00a0letzter\u00a0Zugriff:\u00a011.07.2019.\u00a0\nPrescrire\u00a0Int.\u00a0(2018).\u00a0Palbociclib\u00a0(ibrance\u00ae)\u00a0and\u00a0inoperable\u00a0or \u00a0metastatic\u00a0breast\u00a0cancer.\u00a0Prescrire\u00a0International\u00a0(27)\u00a040.\u00a0\nPZ\u00a0\u2013\u00a0Pharmazeutische\u00a0Zeitung\u00a0on line\u00a0(2017).\u00a0Palbociclib|Ibrance |86|2016.\u00a0https://www.pharmazeutische\u2010\nzeitung.de/arzneistoffe/daten/2016/palbociclibibrancer862016/,\u00a0 letzter\u00a0Zugriff:\u00a016.07.2019.\u00a0\nRKI\u00a0\u2013\u00a0Robert\u00a0Koch\u00a0Institut\u00a0(2017) .\u00a0Krebs\u00a0in\u00a0Deutschland\u00a0f\u00fcr\u00a0201 3/2014.\u00a0\nhttps://www.rki.de/DE/Content/Gesundheitsmonitoring/Krebsregist erdaten/krebs_node.html,\u00a0letzter\u00a0Zugriff:\u00a0\n11.07.2019.\u00a0162\u00a0Rugo\u00a0HS,\u00a0Di\u00e9ras\u00a0V,\u00a0Gelmon\u00a0KA,\u00a0Finn\u00a0RS,\u00a0Slamon\u00a0DJ,\u00a0Martin\u00a0M\u00a0et\u00a0a l.\u00a0(2018).\u00a0Impact\u00a0of\u00a0pa lbociclib\u00a0plus\u00a0letrozole\u00a0on\u00a0patient\u2010repo rted\u00a0\nhealth\u2010related\u00a0quality\u00a0of\u00a0life:\u00a0results\u00a0from\u00a0the\u00a0PALOMA\u20102\u00a0trial .\u00a0Ann\u00a0Oncol\u00a029(4):\u00a0888\u2013894.\u00a0\u00a0\nRugo\u00a0HS,\u00a0Rumble\u00a0RB,\u00a0Macrae\u00a0E,\u00a0Bar ton\u00a0DL,\u00a0Connolly\u00a0HK,\u00a0Dickler\u00a0M N\u00a0et\u00a0al.\u00a0(2016).\u00a0Endocrine\u00a0Therapy\u00a0for\u00a0Hormone\u00a0Receptor\u2010\nPositive\u00a0Metastatic\u00a0Breast\u00a0Cancer:\u00a0American\u00a0Society\u00a0of\u00a0Clinical \u00a0Oncology\u00a0Guideline.\u00a0J\u00a0Clin\u00a0Oncol\u00a034(25):\u00a03069\u2013103.\u00a0\u00a0\nTurner\u00a0NC,\u00a0Neven\u00a0P,\u00a0Loibl\u00a0S,\u00a0Andre\u00a0F\u00a0(2017).\u00a0Advances\u00a0in\u00a0the\u00a0tr eatment\u00a0of\u00a0advanced\u00a0oestrogen\u2010receptor\u2010positive\u00a0breast\u00a0cancer.\u00a0\nLancet\u00a0389(10087):\u00a02403\u20132414.\u00a0\u00a0\nTurner\u00a0NC,\u00a0Slamon\u00a0DJ,\u00a0Ro\u00a0J,\u00a0Bondarenko\u00a0I,\u00a0Im\u00a0S\u2010A,\u00a0Masuda\u00a0N\u00a0et\u00a0a l.\u00a0(2018).\u00a0Overall\u00a0Surv ival\u00a0with\u00a0Palbociclib\u00a0and\u00a0Fulvestrant\u00a0in \u00a0\nAdvanced\u00a0Breast\u00a0Cancer.\u00a0NEJM\u00a0379(20):\u00a01926\u20131936.\u00a0\u00a0\nWaks\u00a0AG,\u00a0Winer\u00a0EP\u00a0(2019).\u00a0Breast\u00a0Cancer\u00a0Treatment.\u00a0JAMA\u00a0321(3): \u00a0288.\u00a0\u00a0 \u00a0163\u00a0 Pitolisant\u00a04.15\nHandelsname:\u00a0Wakix\u00ae\u00a0 \u00a0 \u00a0 Pharm azeutischer\u00a0Unternehmer:\u00a0\u00a0\nIndikation:\u00a0Narkolepsie\u00a0mit\u00a0oder\u00a0 \u00a0 Bioprojet\u00a0Pharma\u00a0\nohne\u00a0Kataplexie\u00a0\nATC\u2010Code:\u00a0N07XX11\u00a0 \u00a0 \u00a0 Markte inf\u00fchrung:\u00a0August\u00a02016\u00a0\nDarreichungsform:\u00a0Filmtabletten\u00a0 \u00a0 DDD:\u00a018 \u00a0mg\u00a0O\u00a0 \u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0O, \u25bc\u00a0\nBewertung\u00a0 \u00a0\nPitolisant\u00a0wurde\u00a0im\u00a0M\u00e4rz\u00a02016\u00a0zentral\u00a0von\u00a0der\u00a0Europ\u00e4ischen\u00a0Komm ission\u00a0als\u00a0 Or\u2010\nphan\u2010Arzneimittel\u00a0f\u00fcr\u00a0die\u00a0Behandlung\u00a0der\u00a0Narkolepsie\u00a0mit\u00a0oder\u00a0ohne\u00a0 Kataplexie\u00a0bei\u00a0\nErwachsenen\u00a0zugelassen.\u00a0Der\u00a0Wirkstoff\u00a0verst\u00e4rkt\u00a0die\u00a0Aktivit\u00e4t\u00a0v on\u00a0histaminergen\u00a0\nNeuronen\u00a0im\u00a0Gehirn,\u00a0die\u00a0eine\u00a0wic htige\u00a0Rolle\u00a0f\u00fcr\u00a0den\u00a0Wachheitszu stand\u00a0spielen.\u00a0\u00a0\nDie\u00a0Dosierung\u00a0erfolgt\u00a0individuell, \u00a0beginnend\u00a0mit\u00a0einer\u00a0Anfangsd osis\u00a0von\u00a09\u00a0mg\u00a0t\u00e4glich,\u00a0\ndie\u00a0je\u00a0nach\u00a0Ansprechen\u00a0auf\u00a04,5\u00a0mg\u00a0gesenkt\u00a0oder\u00a0bis\u00a0zu\u00a0einer\u00a0max imalen\u00a0Tagesdosis\u00a0\nvon\u00a036\u00a0mg\u00a0erh\u00f6ht\u00a0werden\u00a0kann.\u00a0Die\u00a0Filmtabletten\u00a0werden\u00a0morgens\u00a0 als\u00a0Einzeldosis\u00a0\nw\u00e4hrend\u00a0des\u00a0Fr\u00fchst\u00fccks\u00a0eingenommen\u00a0(Fachinformation\u00a0Wakix\u00ae,\u00a0201 8).\u00a0\nDie\u00a0Zulassung\u00a0von\u00a0Pitolisant\u00a0ber uht\u00a0auf\u00a0zwei\u00a0pivotalen\u00a0randomis iert\u2010kontrollierten\u00a0\ndoppelblinden\u00a0Studien\u00a0an\u00a0Erwachsenen\u00a0mit\u00a0Narkolepsie\u00a0mit\u00a0und\u00a0oh ne\u00a0Kataplexie.\u00a0\nIn\u00a0beiden\u00a0dreiarmigen\u00a0Studien\u00a0wurde\u00a0Pitolisant\u00a0jeweils\u00a0mit\u00a0Plac ebo\u00a0und\u00a0mit\u00a0Mo\u2010\ndafinil\u00a0in\u00a0individueller\u00a0Dosierun g\u00a0verglichen\u00a0und\u00a0die\u00a0Auswirkun gen\u00a0auf\u00a0die\u00a0Tages\u2010\nschl\u00e4frigkeit\u00a0mithilfe\u00a0der\u00a0 Epworth\u00a0Sleepiness\u00a0Scale \u00a0(ESS)\u00a0beurteilt.\u00a0\u00a0\nAn\u00a0der\u00a0HARMONY\u00a0I\u2010Studie\u00a0nahmen\u00a095\u00a0Patienten\u00a0teil.\u00a0Die\u00a0Dosierung en\u00a0lagen\u00a0f\u00fcr\u00a0\nPitolisant\u00a0zwischen\u00a010\u00a0mg\u00a0und\u00a040\u00a0mg,\u00a0f\u00fcr\u00a0Modafinil\u00a0zwischen\u00a0100 \u00a0und\u00a0400\u00a0mg.\u00a0\nNach\u00a0acht\u00a0Wochen\u00a0verbesserte\u00a0Pi tolisant\u00a0die\u00a0Tagesschl\u00e4frigkeit\u00a0 signifikant\u00a0besser\u00a0\nals\u00a0Placebo.\u00a0Allerdings\u00a0konnte\u00a0die\u00a0Nicht\u2010Unterlegenheit\u00a0gegen\u00fcb er\u00a0Modafinil\u00a0nicht\u00a0\nbelegt\u00a0werden\u00a0(Dauvilliers\u00a0et\u00a0al.,\u00a02013).\u00a0\nIn\u00a0der\u00a0bisher\u00a0nicht\u00a0publizierten\u00a0HARMONY\u00a0Ibis\u2010Studie\u00a0nahmen\u00a0166 \u00a0Patienten\u00a0teil.\u00a0\nDie\u00a0Dosierungen\u00a0f\u00fcr\u00a0Pitolisant\u00a0la gen\u00a0zwischen\u00a05\u00a0und\u00a020\u00a0mg,\u00a0die\u00a0 f\u00fcr\u00a0Modafinil\u00a0zwi\u2010\nschen\u00a0100\u00a0und\u00a0400\u00a0mg.\u00a0Nach\u00a0acht\u00a0Wochen\u00a0lie\u00df\u00a0sich\u00a0kein\u00a0statistis ch\u00a0signifikanter\u00a0\nUnterschied\u00a0zwischen\u00a0Placebo\u00a0und\u00a0Pitolisant\u00a0nachweisen,\u00a0die\u00a0Nic ht\u2010Unterlegen\u2010\nheit\u00a0gegen\u00fcber\u00a0Modafinil\u00a0wurde\u00a0da raufhin\u00a0nicht\u00a0mehr\u00a0getestet\u00a0(E MA,\u00a02016).\u00a0\u00a0\nIn\u00a0den\u00a0Zulassungsstudien\u00a0traten\u00a0als\u00a0h\u00e4ufigste\u00a0unerw\u00fcnschte\u00a0Arzn eimittelereignisse\u00a0\nneuropsychiatrische\u00a0 und\u00a0 gastrointestinale\u00a0 Beschwerden\u00a0 auf.\u00a0 Bei\u00a0 Narkolepsie\u2010\nPatienten\u00a0traten\u00a0mit\u00a0Pitolisant\u00a0im\u00a0Vergleich\u00a0zu\u00a0Modafinil\u00a0h\u00e4ufi ger\u00a0psychiatrische\u00a0164\u00a0Beschwerden\u00a0auf\u00a0(21,9 \u00a0%\u00a0vs.\u00a013,3 \u00a0%),\u00a0unerw\u00fcnschte\u00a0neuro logische\u00a0Effekte\u00a0dage\u2010\ngen\u00a0etwas\u00a0seltener\u00a0(22,8 \u00a0%\u00a0vs.\u00a023,5 \u00a0%)\u00a0(EMA,\u00a02016).\u00a0\nF\u00fcr\u00a0Arzneimittel\u00a0zur\u00a0Behandlung\u00a0eines\u00a0seltenen\u00a0Leidens\u00a0gilt\u00a0der \u00a0medizinische\u00a0Zu\u2010\nsatznutzen\u00a0durch\u00a0die\u00a0Zulassung\u00a0als\u00a0belegt,\u00a0lediglich\u00a0das\u00a0Ausma\u00df \u00a0des\u00a0Zusatznutzens\u00a0\nist\u00a0durch\u00a0den\u00a0pU\u00a0nachzuweisen.\u00a0Im\u00a0Januar\u00a02017\u00a0fasste\u00a0der\u00a0G\u2010BA\u00a0a ufgrund\u00a0der\u00a0\nmethodischen\u00a0Limitationen\u00a0der\u00a0vo rgelegten\u00a0Studien\u00a0den\u00a0Beschluss ,\u00a0dass\u00a0der \u00a0Zu\u2010\nsatznutzen \u00a0von\u00a0Pitolisant\u00a0 nicht\u00a0quantifizierbar \u00a0ist\u00a0(G\u2010BA,\u00a02017).\u00a0 \u00a0\nVerf\u00fcgbare\u00a0Therapien \u00a0 (Zusatz\u2010)Nutzen \u00a0 Kosten\u00a0\n\u00a0\nweitere\u00a0Therapieoption\u00a0\nbei\u00a0Narkolepsie\u00a0\u00a0ZN\u00a0nicht\u00a0quantifizierbar\u00a0\u00a0\nkeine\u00a0Kostenbewertung,\u00a0\nda\u00a0Orphan\u2010Arzneimittel\u00a0\nErl\u00e4uterung\u00a0der\u00a0Farben:\u00a0Verf\u00fcgbare\u00a0Therapien:\u00a0rot\u00a0=\u00a0weitere\u00a0The rapieoption,\u00a0gelb\u00a0=\u00a0Subgruppen\u2010Novit\u00e4t,\u00a0gr\u00fcn\u00a0=\u00a0Solist;\u00a0(Zusatz\u2010 )\u00a0\nNutzen:\u00a0rot\u00a0=\u00a0keine\u00a0Verbesserung\u00a0oder\u00a0schlechte\u00a0Nutzen/Schaden\u2010 Relation,\u00a0gelb\u00a0=\u00a0teilweise\u00a0Verbesserungen,\u00a0gr\u00fcn\u00a0=\u00a0Verbesserung\u00a0\nharter\u00a0Endpunkte;\u00a0Kosten:\u00a0rot\u00a0=\u00a0teurer\u00a0als\u00a0bestehende\u00a0Therapien ,\u00a0gelb\u00a0=\u00a0ungef\u00e4hr\u00a0gleich\u00a0bzw.\u00a0teils/teils,\u00a0gr\u00fcn\u00a0=\u00a0g\u00fcnstiger\u00a0als \u00a0\nbestehende\u00a0Therapien\u00a0\nWie\u00a0bewerten\u00a0andere?\u00a0\nBewertung\u00a0nach\u00a0\nFricke\u00a0et\u00a0al.\u00a0a\u2010t\u2010Bewertung\u00a0 AMB\u00a0 Prescrire\u00a0 PZ\u00a0\nA/C\u00a0 \u2013\u00a0 \u2013\u00a0 Nothing\u00a0new\u00a0 Sprunginnovation\u00a0\nKosten\u00a0\nWirkstoff\u00a0 Behandlungsmodus\u00a0 Behandlungstage\u00a0 Jahrestherapiekosten\u00a0\nzu\u00a0bewertendes\u00a0Arzneimittel \u00a0\u00a0 \u00a0 \u00a0\nPitolisant\u00a0 1x\u00a0tgl.\u00a04,5\u00a0\u2013\u00a036\u00a0mg\u00a0 365\u00a0 4.901,95\u00a0\u2013\u00a09.803,90\u00a0\u20ac\u00a0\n\u00a0\n\u00a0\u00a0\n165\u00a0Versorgungsanalysen\u00a0\nNach\u00a0der\u00a0Markteinf\u00fchrung\u00a0im\u00a0August\u00a02016\u00a0nehmen\u00a0die\u00a0verordneten\u00a0 Tagesdosen\u00a0\nzun\u00e4chst\u00a0zu\u00a0und\u00a0erreichen\u00a0im\u00a0Juli\u00a02017\u00a0im\u00a0betrachteten\u00a0Zeitraum \u00a0den\u00a0h\u00f6chsten\u00a0\nWert\u00a0von\u00a0rund\u00a02.200\u00a0DDD.\u00a0Danach\u00a0gehen\u00a0die\u00a0Zahlen\u00a0zun\u00e4chst\u00a0bis\u00a0a uf\u00a0rund\u00a01.300\u00a0\nDDD\u00a0zur\u00fcck,\u00a0steigen\u00a0dann\u00a0aber\u00a0wieder\u00a0leicht\u00a0an.\u00a0Die\u00a0Ver\u00f6ffentli chung\u00a0der\u00a0fr\u00fchen\u00a0\nNutzenbewertung\u00a0im\u00a0Januar\u00a02017\u00a0spiegelt\u00a0sich\u00a0nicht\u00a0in\u00a0den\u00a0Veror dnungszahlen\u00a0\nwider.\u00a0Die\u00a0Bruttoums\u00e4tze\u00a0entwickeln\u00a0sich\u00a0zun\u00e4chst\u00a0parallel\u00a0zu\u00a0d en\u00a0verordneten\u00a0\nDDD.\u00a0Ein\u00a0relativer\u00a0R\u00fcckgang\u00a0des\u00a0Bruttoumsatzes\u00a0pro\u00a0DDD\u00a0ist\u00a0ab\u00a0O ktober\u00a02017\u00a0zu\u00a0\nbeobachten\u00a0und\u00a0h\u00e4ngt\u00a0vermutlich\u00a0mit\u00a0dem\u00a0verhandelten\u00a0Erstattung sbetrag\u00a0zu\u2010\nsammen.\u00a0\nAbbildung\u00a04.13:\u00a0Verordnete\u00a0Tages dosen\u00a0(DDD)\u00a0und\u00a0Bruttoums\u00e4tze\u00a0v on\u00a0Pito\u2010\nlisant\u00a0nach\u00a0Monaten\u00a0(2016\u00a0\u2013\u00a02017)\u00a0\n\u00a0\n\u00a0\n\u00a0\u00a0\n166\u00a0Quellen\u00a0\u00a0\nDauvilliers\u00a0Y,\u00a0Bassetti\u00a0C,\u00a0Lammers\u00a0GJ,\u00a0Arnulf\u00a0I,\u00a0Mayer\u00a0G,\u00a0Roden beck\u00a0A\u00a0et\u00a0al.\u00a0(2013).\u00a0Pitolisant\u00a0versus\u00a0placebo\u00a0or\u00a0modafinil\u00a0in \u00a0patients\u00a0\nwith\u00a0narcolepsy:\u00a0a\u00a0double\u2010blind,\u00a0randomised\u00a0trial.\u00a0Lancet\u00a0Neuro logy\u00a012(11):\u00a01068\u20131075.\u00a0\u00a0\nEMA\u00a0\u2013\u00a0European\u00a0Medicines\u00a0Agency\u00a0(2016).\u00a0European\u00a0public\u00a0assessm ent\u00a0report\u00a0(EPAR)\u00a0Wakix.\u00a0\nhttps://www.ema.europa.eu/en/medicines/human/EPAR/wakix,\u00a0letzte r\u00a0Zugriff:\u00a010.07.2019.\u00a0\nFachinformation\u00a0Wakix\u00a0(2018).\u00a0Fachinformation\u00a0Wakix.\u00a0Stand\u00a0der\u00a0 Information:\u00a0August\u00a02018.\u00a0\nFricke\u00a0U,\u00a0Hein\u00a0L,\u00a0Schwabe\u00a0U\u00a0(2017).\u00a0Neue\u00a0Arzneimittel\u00a02016.\u00a0In: \u00a0Schwabe\u00a0U,\u00a0Paffrath\u00a0D,\u00a0Ludwig\u00a0W\u2010D,\u00a0Klauber\u00a0J\u00a0(Hrsg.)\u00a0(2017).\u00a0\nArzneiverordnungs\u2010Report\u00a02017.\u00a0Berlin,\u00a0Heidelberg.\u00a0Springer:\u00a055 \u2010135.\u00a0\nG\u2010BA\u00a0\u2013\u00a0Gemeinsamer\u00a0Bundesausschuss\u00a0(2017).\u00a0Nutzenbewertungsverf ahren\u00a0zum\u00a0Wirkstoff\u00a0Pitolisant.\u00a0https://www.g\u2010\nba.de/informationen/nutzenbewertung/255/,\u00a0letzter\u00a0Zugriff:\u00a010.0 7.2019.\u00a0\nPrescrire\u00a0Int.\u00a0(2017).\u00a0Pitolisant\u00a0(Wakix)\u00a0and\u00a0narcolepsy.\u00a0Presc rire\u00a0International\u00a026:\u00a0236\u2013237.\u00a0\nPZ\u00a0\u2013\u00a0Pharmazeutische\u00a0Zeitung\u00a0(2016).\u00a0Pitolisant|Wakix|71|2016.\u00a0 https://www.pharmazeutische\u2010\nzeitung.de/arzneistoffe/daten/2016/pitolisantwakixr712016/,\u00a0let zter\u00a0Zugriff:\u00a010.07.2019.\u00a0\n\u00a0\u00a0167\u00a0 Sacubitril/Valsartan\u00a04.16\nHandelsname:\u00a0Entresto\u00ae\u00a0 \u00a0 \u00a0 Pharmazeutischer\u00a0Unternehmer:\u00a0\u00a0\nIndikation:\u00a0chronische\u00a0Herzinsuffizienz\u00a0mit\u00a0\u00a0 Novartis\u00a0Pharma\u00a0\nreduzierter\u00a0Ejektionsfraktion\u00a0 \u00a0 \u00a0\u00a0\nATC\u2010Code:\u00a0C09DX04\u00a0 \u00a0 \u00a0 Markteinf\u00fchrung:\u00a0Januar\u00a02016\u00a0\nDarreichungsform:\u00a0Filmtablette\u00a0 \u00a0 DDD:\u00a02\u00a0DE\u00a0\u00a0 \u00a0 \u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 \u25bc\u00a0\nBewertung \u00a0\nEntresto\u00ae\u00a0ist\u00a0der\u00a0erste\u00a0Angioten sin\u2010Rezeptor\u2010Neprilysin\u2010Inhibit or\u00a0(ARNI).\u00a0Die\u00a0Fix\u2010\nkombination\u00a0enth\u00e4lt\u00a0den\u00a0bereits\u00a0seit\u00a01996\u00a0zugelassenen\u00a0AT 1\u2010Rezeptor\u2010Antagonis\u2010\nten\u00a0Valsartan\u00a0und\u00a0den\u00a0neuen\u00a0Wirk stoff\u00a0Sacubitril,\u00a0einen\u00a0Neprily sin\u2010Inhibitor\u00a0(EMA,\u00a0\n2010;\u00a0EMA,\u00a02015).\u00a0Es\u00a0handelt\u00a0sich\u00a0bei\u00a0Sacubitril\u00a0um\u00a0ein\u00a0 Prodrug,\u00a0dessen\u00a0aktiver\u00a0\nMetabolit\u00a0LBQ657\u00a0das\u00a0Enzym\u00a0Neprilysin\u00a0(Neutrale\u00a0Endopeptidase)\u00a0 hemmt.\u00a0Dies\u00a0\nf\u00fchrt\u00a0zu\u00a0einer\u00a0Anreicherung\u00a0von\u00a0natriuretischen\u00a0Peptiden,\u00a0welch e\u00a0eine\u00a0Gef\u00e4\u00dfer\u2010\nweiterung,\u00a0verst\u00e4rkte\u00a0Natrium\u2010\u00a0und\u00a0Harnausscheidung,\u00a0erh\u00f6hte\u00a0GF R\u00a0und\u00a0erh\u00f6hten\u00a0\nBlutfluss\u00a0in\u00a0der\u00a0Niere\u00a0sowie\u00a0eine\u00a0verringerte\u00a0Freisetzung\u00a0von\u00a0R enin\u00a0und\u00a0Aldosteron\u00a0\nvermitteln.\u00a0Zudem\u00a0wird\u00a0die\u00a0Aktivit\u00e4t\u00a0des\u00a0Sympathikus\u00a0vermindert \u00a0und\u00a0es\u00a0k\u00f6nnen\u00a0\nsich\u00a0antihypertrophe\u00a0und\u00a0antifibrotische\u00a0Effekte\u00a0am\u00a0Herzen\u00a0zeig en\u00a0(Fachinformati\u2010\non\u00a0Entresto\u00ae,\u00a02018).\u00a0\u00a0\nSacubitril/Valsartan\u00a0wurde\u00a0im\u00a0November\u00a02015\u00a0nach\u00a0einer\u00a0beschleu nigten\u00a0Beurtei\u2010\nlung\u00a0 (AA,\u00a0 accelerated\u00a0 assessment )\u00a0 zentral\u00a0 durch\u00a0 die\u00a0 Europ\u00e4ische\u00a0 Kommission\u00a0\nzugelassen\u00a0zur\u00a0Behandlung\u00a0einer\u00a0sy mptomatischen,\u00a0chronischen\u00a0He rzinsuffizienz\u00a0\nmit\u00a0reduzierter\u00a0Ejektionsfraktion\u00a0bei\u00a0erwachsenen\u00a0Patienten\u00a0(CH MP,\u00a02015).\u00a0Die\u00a0\nMarkteinf\u00fchrung\u00a0 in\u00a0 Deutschland\u00a0 erfolgte\u00a0 im\u00a0 Januar\u00a0 2016.\u00a0 Sacubit ril/Valsartan\u00a0\nsteht\u00a0als\u00a0Filmtablette\u00a0in\u00a0den\u00a0drei\u00a0Dosierungen\u00a024\u00a0mg/26\u00a0mg,\u00a049\u00a0 mg/51\u00a0mg\u00a0und\u00a0\n97\u00a0mg/103\u00a0mg\u00a0zur\u00a0Verf\u00fcgung.\u00a0Die\u00a0Zieldosis\u00a0liegt\u00a0bei\u00a0zweimal\u00a0t\u00e4g lich\u00a097\u00a0mg/103\u00a0mg\u00a0\nund\u00a0wird\u00a0unabh\u00e4ngig\u00a0von\u00a0den\u00a0Mahlze iten\u00a0eingenommen.\u00a0Wegen\u00a0erh\u00f6h ter\u00a0Biover\u2010\nf\u00fcgbarkeit\u00a0entsprechen\u00a0hier\u00a0103\u00a0mg\u00a0Valsartan\u00a0160\u00a0mg\u00a0in\u00a0anderen\u00a0 Tablettenformu\u2010\nlierungen\u00a0(Fachinformation\u00a0Entresto\u00ae,\u00a02018).\u00a0\nDie\u00a0Zulassung\u00a0von\u00a0Sacubitril/Valsartan\u00a0beruht\u00a0auf\u00a0der\u00a0PARADIGM\u2010 HF\u2010Studie\u00a0(Spon\u2010\nsor:\u00a0Novartis,\u00a0NCT01035255),\u00a0einer\u00a0multizentrischen,\u00a0doppelblin den,\u00a01:1\u2010randomi\u2010\nsierten,\u00a0 kontrollierten\u00a0 Phase\u2010III\u2010Studie.\u00a0 Untersucht\u00a0 wurde\u00a0 Sacu bitril/Valsartan\u00a0\nzweimal\u00a0t\u00e4glich\u00a0200\u00a0mg\u00a0(97\u00a0mg/103\u00a0 mg)\u00a0versus\u00a0Enalapril\u00a0zweimal\u00a0 t\u00e4glich\u00a010\u00a0mg\u00a0\njeweils\u00a0zus\u00e4tzlich\u00a0zur\u00a0empfohlenen\u00a0Therapie.\u00a0Aufgrund\u00a0zweier\u00a0 run\u2010in\u2010Phasen,\u00a0die\u00a0\nnacheinander\u00a0zun\u00e4chst\u00a0mit\u00a0 Enala pril\u00a0und\u00a0anschlie\u00dfend\u00a0 mit\u00a0Sacubi tril/Valsartan\u00a0\nstattfanden,\u00a0schieden\u00a0rund\u00a020\u00a0%\u00a0 der\u00a0anf\u00e4nglich\u00a010.513\u00a0Teilnehme r\u00a0bereits\u00a0vor\u00a0der\u00a0\nRandomisierung\u00a0 aus.\u00a0 Die\u00a0 Aussagekraft\u00a0 der\u00a0 Studie\u00a0 f\u00fcr\u00a0 Patienten\u00a0 i m\u00a0 NYHA\u2010Sta\u2010\ndium\u00a0IV\u00a0(<\u00a01\u00a0%\u00a0der\u00a0Teilnehmer)\u00a0und\u00a0Frauen\u00a0(\u2248\u00a020\u00a0%\u00a0im\u00a0Sacubitril /Valsartan\u2010Arm)\u00a0ist\u00a0168\u00a0zudem\u00a0begrenzt.\u00a0Die\u00a0Studie\u00a0wurde\u00a0nach\u00a027\u00a0Monaten\u00a0vorzeitig\u00a0been det,\u00a0da\u00a0bei\u00a0der\u00a0\nletzten\u00a0Interimsanalyse\u00a0vordefinierte\u00a0\u00dcberlegenheitskriterien\u00a0f \u00fcr\u00a0Sacubitril/Valsar\u2010\ntan\u00a0erf\u00fcllt\u00a0wurden.\u00a0Die\u00a0zu\u00a0diesem\u00a0Zeitpunkt\u00a0eingenommenen\u00a0Tages dosen\u00a0betru\u2010\ngen\u00a0im\u00a0Mittel\u00a0rund\u00a0375\u00a0mg\u00a0Sacubitril/Valsartan\u00a0und\u00a019\u00a0mg\u00a0Enalap ril,\u00a0verteilt\u00a0auf\u00a0\njeweils\u00a0zwei\u00a0Dosen.\u00a0Der\u00a0prim\u00e4re\u00a0Endpunkt\u00a0\u2013\u00a0ein\u00a0kombinierter\u00a0End punkt\u00a0aus\u00a0kardi\u2010\novaskul\u00e4rem\u00a0Tod\u00a0oder\u00a0herzinsuffi zienzbedingter\u00a0Hospitalisierung \u00a0\u2013\u00a0trat\u00a0bei\u00a021,8\u00a0%\u00a0\nder\u00a0Patienten\u00a0unter\u00a0Sacubitril/Valsartan\u00a0ein\u00a0und\u00a0bei\u00a026,5\u00a0%\u00a0der \u00a0Enalapril\u2010Gruppe\u00a0\n(HR:\u00a00,80;\u00a095\u00a0%\u00a0KI\u00a0[0,73;\u00a00,87], \u00a0p\u00a0<\u00a00,001).\u00a0Auch\u00a0bei\u00a0der\u00a0geson derten\u00a0Analyse\u00a0der\u00a0\nGesamtmortalit\u00e4t,\u00a0der\u00a0kardiovask ul\u00e4ren\u00a0Mortalit\u00e4t\u00a0und\u00a0der\u00a0herzi nsuffizienzbeding\u2010\nten\u00a0Hospitalisierung\u00a0war\u00a0Sacubitril/Valsartan\u00a0jeweils\u00a0\u00fcberlegen .\u00a0Subgruppenanaly\u2010\nsen\u00a0zum\u00a0prim\u00e4ren\u00a0Endpunkt\u00a0ergaben\u00a0eine\u00a0Interaktion\u00a0(p\u00a0=\u00a00,03)\u00a0b ei\u00a0den\u00a0Schwere\u2010\ngraden\u00a0 der\u00a0 Herzinsuffizienz.\u00a0 Sacubitril/Valsartan\u00a0 war\u00a0 bei\u00a0 Patie nten\u00a0 im\u00a0 NYHA\u2010\nStadium\u00a0I\u00a0oder\u00a0II\u00a0Enalapril\u00a0\u00fcberlegen,\u00a0bei\u00a0jenen\u00a0im\u00a0Stadium\u00a0III \u00a0oder\u00a0IV\u00a0dagegen\u00a0\nnicht.\u00a0Deskriptiv\u00a0auff\u00e4llig\u00a0ist\u00a0eine\u00a0fehlende\u00a0\u00dcberlegenheit\u00a0bei \u00a0der\u00a0westeurop\u00e4i\u2010\nschen\u00a0 Studienpopulation,\u00a0 die\u00a0 rund\u00a0 24\u00a0%\u00a0 des\u00a0 Gesamtkollektivs\u00a0 aus machte.\u00a0 Die\u00a0\nkardiovaskul\u00e4re\u00a0Mortalit\u00e4t\u00a0wurde\u00a0zudem\u00a0bei\u00a0Diabetikern\u00a0im\u00a0Gegen satz\u00a0zu\u00a0Nichtdi\u2010\nabetikern\u00a0 durch\u00a0 Sacubitril/Valsartan\u00a0 nicht\u00a0 st\u00e4rker\u00a0 gesenkt\u00a0 als\u00a0 durch\u00a0 Enalapril\u00a0\n(p\u00a0<\u00a00,05\u00a0f\u00fcr\u00a0die\u00a0Interaktion).\u00a0 Die\u00a0gesundheitsbezogene\u00a0Lebensq ualit\u00e4t\u00a0wurde\u00a0unter\u00a0\nanderem\u00a0anhand\u00a0des\u00a0 Kansas\u00a0City\u00a0Cardiomyopathy\u00a0Questionnaire \u00a0(KCCQ)\u00a0ermittelt.\u00a0\nNach\u00a0acht\u00a0Monaten\u00a0hatte\u00a0sich\u00a0der\u00a0Wert\u00a0unter\u00a0Sacubitril/Valsarta n\u00a0um\u00a02,99\u00a0\u00b1\u00a00,36\u00a0\nPunkte\u00a0verschlechtert,\u00a0unter\u00a0Enalapril\u00a0um\u00a04,63\u00a0\u00b1\u00a00,36\u00a0Punkte\u00a0(p \u00a0=\u00a00,001).\u00a0Als\u00a0klinisch\u00a0\nrelevant\u00a0wurden\u00a0Ver\u00e4nderungen\u00a0ab\u00a05\u00a0Punkten\u00a0definiert\u00a0(McMurray\u00a0 et\u00a0al.,\u00a02014).\u00a0\u00a0\nBisher\u00a0fehlen\u00a0 head\u2010to\u2010head \u2010Vergleiche\u00a0mit\u00a0Valsartan.\u00a0Die\u00a0derzeit\u00a0laufende\u00a0PARA\u2010\nGON\u2010HF\u2010Studie\u00a0geht\u00a0dieser\u00a0Frages tellung\u00a0bei\u00a0Herzinsuffizienz\u2010Pa tienten\u00a0mit\u00a0erhal\u2010\ntener\u00a0Ejektionsfraktion\u00a0nach.\u00a0Der\u00a0Abschluss\u00a0der\u00a0Studie\u00a0ist\u00a0f\u00fcr\u00a0 Mai\u00a02019\u00a0geplant\u00a0\n(ClinicalTrials.gov,\u00a02019a).\u00a0 Weitere\u00a0Informationen\u00a0dazu\u00a0finden\u00a0sich\u00a0in\u00a0der\u00a0Lang\u2010\nfassung.\u00a0 Die\u00a0voraussichtlich\u00a0bis\u00a0September\u00a02019\u00a0laufende\u00a0LIFE\u2010Studie\u00a0ver gleicht\u00a0\nebenfalls\u00a0Sacubitril/Valsartan\u00a0gegen\u00a0Valsartan.\u00a0Im\u00a0Fokus\u00a0stehen \u00a0die\u00a0in\u00a0der\u00a0Zulas\u2010\nsungsstudie\u00a0 unterrepr\u00e4sentierten\u00a0 Patienten\u00a0 mit\u00a0 NYHA\u2010Stadium\u00a0 IV\u00a0 (ClinicalTri\u2010\nals.gov,\u00a02019b).\u00a0Des\u00a0Weiteren\u00a0soll\u00a0die\u00a0Studie\u00a0PERSPECTIVE\u00a0kl\u00e4re n,\u00a0ob\u00a0Sacubit\u2010\nril/Valsartan\u00a0einen\u00a0negativen\u00a0Einfluss\u00a0auf\u00a0die\u00a0kognitive\u00a0Funkti on\u00a0hat\u00a0(ClinicalTri\u2010\nals.gov,\u00a02019c).\u00a0Die\u00a0FDA\u00a0hat\u00a0im\u00a0Rahmen\u00a0der\u00a0Zulassung\u00a0die\u00a0Durchf \u00fchrung\u00a0einer\u00a0\nsolchen\u00a0klinischen\u00a0Studie\u00a0zum\u00a0m\u00f6 glichen\u00a0Risiko\u00a0f\u00fcr\u00a0kognitive\u00a0Dy sfunktionen\u00a0beauf\u2010\nlagt\u00a0 (FDA,\u00a0 2015).\u00a0 Hintergrund\u00a0 der\u00a0 Untersuchung\u00a0 ist,\u00a0 dass\u00a0 Nepril ysin\u00a0 an\u00a0 der\u00a0\nClearance \u00a0von\u00a0Beta\u2010Amyloid\u00a0aus\u00a0dem\u00a0Gehirn\u00a0und\u00a0Liquor\u00a0beteiligt\u00a0ist\u00a0(Fach informa\u2010\ntion\u00a0Entresto\u00ae,\u00a02018).\u00a0Die\u00a0Studie\u00a0wird\u00a0voraussichtlich\u00a0im\u00a0Mai\u00a02 022\u00a0abgeschlossen.\u00a0\u00a0\nZu\u00a0den\u00a0sehr\u00a0h\u00e4ufigen\u00a0UAE\u00a0unter\u00a0Sacubitril/Valsartan\u00a0z\u00e4hlten\u00a0bei \u00a0den\u00a0selektierten\u00a0\nPatienten\u00a0der\u00a0PARADIGM\u2010HF\u2010Studie\u00a0 Hypotonien,\u00a0Hyperkali\u00e4mien\u00a0und \u00a0Nierenfunk\u2010\ntionsst\u00f6rungen.\u00a0Hypotonien\u00a0traten\u00a0unter\u00a0Sacubitril/Valsartan\u00a0si gnifikant\u00a0h\u00e4ufiger\u00a0169\u00a0auf\u00a0als\u00a0unter\u00a0Enalapril.\u00a0Hyperkali\u00e4mien\u00a0und\u00a0Nierenfunktionsst\u00f6r ungen\u00a0waren\u00a0unter\u00a0\nEnalapril\u00a0numerisch\u00a0h\u00e4ufiger,\u00a0A ngio\u00f6deme\u00a0hingeg en\u00a0seltener.\u00a0\u00a0\nDer\u00a0G\u2010BA\u00a0bewertete\u00a0den\u00a0Zusatznutzen\u00a0f\u00fcr\u00a0zwei\u00a0Subgruppen.\u00a0F\u00fcr\u00a0Pa tienten\u00a0ohne\u00a0\nDiabetes\u00a0mellitus\u00a0stellte\u00a0er\u00a0einen\u00a0 Anhaltspunkt\u00a0f\u00fcr\u00a0einen\u00a0betr\u00e4chtlichen\u00a0Zusatz\u2010\nnutzen\u00a0von\u00a0Sacubitril/Valsartan\u00a0gegen\u00fcber\u00a0einem\u00a0ACE\u2010Hemmer\u00a0(Enalapril ),\u00a0jeweils\u00a0\nin\u00a0Kombination\u00a0mit\u00a0einem\u00a0Betablo cker,\u00a0fest.\u00a0F\u00fcr\u00a0Patienten\u00a0mit\u00a0D iabetes\u00a0mellitus\u00a0\nsah\u00a0der\u00a0G\u2010BA\u00a0einen\u00a0 Anhaltspunkt\u00a0f\u00fcr\u00a0einen\u00a0geringen\u00a0Zusatznutzen \u00a0(G\u2010BA,\u00a02016).\u00a0\u00a0\n\u00a0\nVerf\u00fcgbare\u00a0Therapien \u00a0 (Zusatz\u2010)Nutzen \u00a0 Kosten\u00a0\n\u00a0\nneuer\u00a0Wirkmechanismus\u00a0\u00a0\nder\u00a0Neprilysin\u2010Inhibition\u00a0\nerweitert\u00a0die\u00a0\nvorhandenen\u00a0\nTherapieoptionen\u00a0\u00a0\u00a0Mortalit\u00e4tssenkung\u00a0f\u00fcr\u00a0\nPatienten\u00a0ohne\u00a0Diabetes\u00a0\nmellitus\u00a0in\u00a0stark\u00a0\nselektiertem\u00a0Kollektiv\u00a0\u00a0\nwesentlich\u00a0teurer\u00a0als\u00a0zVT\u00a0\ntrotz\u00a0Verhandlung\u00a0eines\u00a0\nErstattungsbetrags\u00a0\nErl\u00e4uterung\u00a0der\u00a0Farben:\u00a0Verf\u00fcgbare\u00a0Therapien:\u00a0rot\u00a0=\u00a0weitere\u00a0The rapieoption,\u00a0gelb\u00a0=\u00a0Subgruppen\u2010Novit\u00e4t,\u00a0gr\u00fcn\u00a0=\u00a0Solist;\u00a0(Zusatz\u2010 )\u00a0\nNutzen:\u00a0rot\u00a0=\u00a0keine\u00a0Verbesserung\u00a0oder\u00a0schlechte\u00a0Nutzen/Schaden\u2010 Relation,\u00a0gelb\u00a0=\u00a0teilweise\u00a0Verbesserungen,\u00a0gr\u00fcn\u00a0=\u00a0Verbesserung\u00a0\nharter\u00a0Endpunkte;\u00a0Kosten:\u00a0rot\u00a0=\u00a0teurer\u00a0als\u00a0bestehende\u00a0Therapien ,\u00a0gelb\u00a0=\u00a0ungef\u00e4hr\u00a0gleich\u00a0bzw.\u00a0teils/teils,\u00a0gr\u00fcn\u00a0=\u00a0g\u00fcnstiger\u00a0als \u00a0\nbestehende\u00a0Therapien\u00a0\nWie\u00a0bewerten\u00a0andere?\u00a0\nBewertung\u00a0nach\u00a0\u00a0\nFricke\u00a0et\u00a0al.\u00a0atd\u2010Bewertung\u00a0 AMB\u00a0 Prescrire\u00a0 PZ\u00a0\nA\u00a0 Mittel\u00a0der\u00a0Reserve\u00a0Trotz\u00a0insgesamt\u00a0\npositiver\u00a0Bewertung\u00a0\n(noch)\u00a0kein\u00a0neuer\u00a0\nStandard\u00a0in\u00a0der\u00a0\nHerzinsuffizienz\u2010\ntherapie\u00a0\u00a0\u00a0Possibly\u00a0helpful\u00a0 Sprunginnovation\u00a0\nKosten\u00a0\nWirkstoff\u00a0 Behandlungsmodus\u00a0 Behandlungstage\u00a0 Jahrestherapiekosten\u00a0\nzu\u00a0bewertendes\u00a0Arzneimittel \u00a0 \u00a0 \u00a0 \u00a0\nSacubitril/Valsartan\u00a0 2x\u00a0tgl.\u00a097\u00a0mg/103\u00a0mg\u00a0 365\u00a0 2.063,52\u00a0\u20ac\u00a0\n+\u00a0Betablocker\u00a0 gem\u00e4\u00df\u00a0Fachinformation\u00a0 \u00a02.120,35\u00a0\u2013\u00a02.254,92\u00a0\u20ac\u00a0\nzVT\u00a0 \u00a0 \u00a0 \u00a0\nACE\u2010Hemmer\u00a0 gem\u00e4\u00df\u00a0Fachinformation\u00a0 \u00a044,79\u00a0\u2013\u00a0301,49\u00a0\u20ac\u00a0\nACE\u2010Hemmer\u00a0\u00a0 gem\u00e4\u00df\u00a0Fachinformation\u00a0 \u00a0 \u00a0\n+\u00a0Betablocker\u00a0 \u00a0 \u00a0101,62\u00a0\u2013\u00a0492,90\u00a0\u20ac\u00a0\nAlle\u00a0Angaben\u00a0beziehen\u00a0sich\u00a0auf\u00a0die\u00a0jeweilige\u00a0Erhaltungsdosis.\u00a0C ave:\u00a0ACE\u2010Hemmer\u00a0Trandolapril\u00a0und\u00a0Zofenopril\u00a0nur\u00a0nach\u00a0Myokardin\u2010\nfarkt\u00a0zugelassen.\u00a0\u00a0\n170\u00a0Versorgungsanalysen\u00a0\nDie\u00a0Verordnungszahlen\u00a0von\u00a0Sacubitril/Valsartan\u00a0stiegen\u00a0im\u00a0erste n\u00a0Jahr\u00a0nach\u00a0der\u00a0\nMarkteinf\u00fchrung\u00a0kontinuierlich\u00a0an.\u00a0Die\u00a0fr\u00fche\u00a0Nutzenbewertung\u00a0du rch\u00a0den\u00a0G\u2010BA\u00a0\nim\u00a0Juni\u00a02016\u00a0hatte\u00a0keinen\u00a0erkennbaren\u00a0Effekt\u00a0auf\u00a0die\u00a0Verordnung sh\u00e4ufigkeit.\u00a0Im\u00a0\nzweiten\u00a0Jahr\u00a0schwankten\u00a0die\u00a0Verordnungszahlen,\u00a0nahmen\u00a0jedoch\u00a0in sgesamt\u00a0be\u2010\ntrachtet\u00a0auch\u00a0in\u00a0diesem\u00a0Zeitraum\u00a0stark\u00a0zu.\u00a0Im\u00a0Dezember\u00a02017\u00a0war \u00a0die\u00a0Anzahl\u00a0der\u00a0\nverordneten\u00a0DDD\u00a0rund\u00a0doppelt\u00a0so\u00a0hoch\u00a0wie\u00a0im\u00a0Dezember\u00a0des\u00a0Vorjah res.\u00a0Im\u00a0No\u2010\nvember\u00a0 2017\u00a0 erreichten\u00a0 Ab\u2010\u00a0 und\u00a0 Umsatz\u00a0 mit\u00a0 \u00fcber\u00a0 105.000\u00a0 DDD\u00a0 und\u00a0 knapp\u00a0\n612.000\u00a0\u20ac\u00a0ihr\u00a0Maximum.\u00a0Deutlich\u00a0erkennbar\u00a0ist\u00a0die\u00a0Festsetzung\u00a0e ines\u00a0Erstattungs\u2010\nbetrages\u00a0im\u00a0April\u00a02017,\u00a0welche\u00a0zu \u00a0einer\u00a0Reduktion\u00a0des\u00a0Apotheken verkaufspreises\u00a0\num\u00a0rund\u00a024\u00a0%\u00a0f\u00fchrte\u00a0(Lauer\u2010Fischer,\u00a02018).\u00a0Die\u00a0Analyse\u00a0eines\u00a0Ma rktforschungs\u2010\ninstituts\u00a0zeigt,\u00a0dass\u00a0Sacubitril/Valsartan\u00a0sehr\u00a0h\u00e4ufig\u00a0nicht\u00a0fa chgerecht\u00a0angewendet\u00a0\nwird.\u00a0Nur\u00a0bei\u00a0jedem\u00a0F\u00fcnften\u00a0wird\u00a0die\u00a0Zieldosis\u00a0von\u00a0zweimal\u00a0200\u00a0 mg/Tag\u00a0erreicht\u00a0\n(AMB,\u00a02019).\u00a0\u00a0\nAbbildung\u00a04.14:\u00a0Verordnete\u00a0Tages dosen\u00a0(DDD)\u00a0und\u00a0Bruttoums\u00e4tze\u00a0v on\u00a0\u00a0\nSacubitril/Valsartan\u00a0nach\u00a0Monaten\u00a0(2016\u00a0\u2013\u00a02017)\u00a0\n\u00a0\n\u00a0\u00a0\n171\u00a0Quellen\u00a0\u00a0\nAMB\u00a0\u2013\u00a0Der\u00a0Arzneimittelbrief\u00a0(2016 ).\u00a0Behandlung\u00a0der\u00a0Herzinsuffiz ienz:\u00a0Aktuelles\u00a0zu\u00a0Sacubitril/Valsartan.\u00a0Der\u00a0Arzneimittelbrief. \u00a050(33).\u00a0\nAMB\u00a0\u2013\u00a0\u00a0Der\u00a0Arzneimittelbrief\u00a0(2019).\u00a0Nicht\u00a0fachgerechte\u00a0Anwendu ng\u00a0von\u00a0Sacubitril/Valsartan.\u00a0Der \u00a0Arzneimittelbrief.\u00a053(34).\u00a0\natd\u00a0\u2013\u00a0arznei\u2010telegramm\u00a0Arzneimitteldatenbank\u00a0(2018).\u00a0Wirkstoff: \u00a0Sacubitril\u2010Natrium\u2010Valsartan\u2010Dinatrium.\u00a0https://www.arznei\u2010\ntelegramm.de/,\u00a0letzter\u00a0Zugriff:\u00a012.12.2018.\u00a0\nCHMP\u00a0\u2013\u00a0Committee\u00a0for\u00a0Medicinal\u00a0Products\u00a0for\u00a0Human\u00a0Use\u00a0(2015).\u00a0A ssessment\u00a0report\u00a0Entresto.\u00a0International\u00a0non\u2010proprietary\u00a0\nname:\u00a0sacubitril/valsartan.\u00a0https://www.ema.europa.eu/documents /assessment\u2010report/entresto\u2010epar\u2010public\u2010\nassessment\u2010report_en.pdf,\u00a0letzter\u00a0Zugriff:\u00a014.02.2019.\u00a0\nClinicalTrials.gov\u00a0(2019a).\u00a0Efficacy\u00a0and\u00a0Safety\u00a0of\u00a0LCZ696\u00a0Compa red\u00a0to\u00a0Valsartan,\u00a0on\u00a0Morbidity\u00a0and\u00a0Mortality\u00a0in\u00a0Heart\u00a0Failure\u00a0\nPatients\u00a0With\u00a0Preserved\u00a0Ejection \u00a0Fraction.\u00a0https://clinicaltria ls.gov/ct2/show/NCT01920711,\u00a0letzter\u00a0Zugriff:\u00a0\n01.02.2019.\u00a0\nClinicalTrials.gov\u00a0(2019b).\u00a0EntrestoTM\u00a0(LCZ696)\u00a0In\u00a0Advanced\u00a0Hea rt\u00a0Failure\u00a0(LIFE\u00a0Study)\u00a0(HFN\u2010LIFE).\u00a0\nhttps://clinicaltrials.gov/ct2/show/record/NCT02816736,\u00a0letzter \u00a0Zugriff:\u00a013.03.2019.\u00a0\nClinicalTrials.gov\u00a0(2019c).\u00a0Efficacy\u00a0and\u00a0Safety\u00a0of\u00a0LCZ696\u00a0Compa red\u00a0to\u00a0Valsartan\u00a0on\u00a0Cognitive\u00a0Function\u00a0in\u00a0Patients\u00a0With\u00a0Chronic \u00a0\nHeart\u00a0Failure\u00a0and\u00a0Preserved\u00a0Ejection\u00a0Fraction.\u00a0https://clinical trials.gov/ct2/show/NCT02884206,\u00a0letzter\u00a0Zugriff:\u00a0\n01.02.2019.\u00a0\nEMA\u00a0\u2013\u00a0European\u00a0Medicines\u00a0Agency\u00a0(2010).\u00a0Diovan.\u00a0https://www.ema .europa.eu/en/medicines/human/referrals/diovan\u20101,\u00a0letzter\u00a0\nZugriff:\u00a010.12.2018.\u00a0\nEMA\u00a0\u2013\u00a0European\u00a0Medicines\u00a0Agency\u00a0(2015).\u00a0Entresto.\u00a0https://www.e ma.europa.eu/en/medicines/human/EPAR/entresto,\u00a0letzter\u00a0\nZugriff:\u00a010.12.2018.\u00a0\nFachinformation\u00a0Entresto\u00ae\u00a0(2018).\u00a0Fachinformation\u00a0Entresto\u00ae.\u00a0St and\u00a0der\u00a0Information:\u00a0Juni\u00a02018. \u00a0https://www.fachinfo.de/,\u00a0letzt er\u00a0\nZugriff:\u00a012.12.2018.\u00a0\nFDA\u00a0\u2013\u00a0Food\u00a0and\u00a0Drug\u00a0Administration\u00a0(2015).\u00a0Approval\u00a0package\u00a0for \u00a0Entresto.\u00a0https://www.accessdata.fda.gov/drugsatfda_docs/\u00a0\nnda/2015/207620Orig1s000Approv.pdf,\u00a0letzter\u00a0Zugriff:\u00a030.01.2019 .\u00a0\nG\u2010BA\u00a0\u2013\u00a0Gemeinsamer\u00a0Bundesausschuss\u00a0(2016).\u00a0Tragende\u00a0Gr\u00fcnde\u00a0zum\u00a0 Beschluss\u00a0des\u00a0Gemeinsamen\u00a0 Bundesausschusses\u00a0\u00fcber\u00a0eine\u00a0\n\u00c4nderung\u00a0der\u00a0Arzneimittel\u2010Richtlinie\u00a0(AM\u2010RL):\u00a0Anlage\u00a0XII\u00a0\u2013\u00a0Besc hl\u00fcsse\u00a0\u00fcber\u00a0die\u00a0Nutzenbewertung\u00a0von\u00a0Arzneimitteln\u00a0\nmit\u00a0neuen\u00a0Wirkstoffen\u00a0nach\u00a0\u00a7\u00a035a\u00a0SGB\u00a0V\u00a0\u2013\u00a0Sacubitril/Valsartan.\u00a0 https://www.g\u2010ba.de/downloads/40\u2010268\u2010\n3823/2016\u201006\u201016_AM\u2010RL\u2010XII_Sacubutril_Valsartan_D\u2010207_TrG.pdf,\u00a0l etzter\u00a0Zugriff:\u00a017.01.2019.\u00a0\nLauer\u2010Fischer\u00a0(2018).\u00a0WEBAPO\u00ae\u00a0Infosystem,\u00a0LAUER\u2010TAXE\u00a0online.\u00a0ht tps://www.lauer\u2010fischer.de/LF/Seiten/WEBAPO\u2010\nInfoSystem/WEBAPO\u2010Infosystem.aspx,\u00a0letzter\u00a0Zugriff:\u00a010.12.2018. \u00a0\nMcMurray\u00a0JJV,\u00a0Packer\u00a0M,\u00a0Desai\u00a0AS,\u00a0Gong\u00a0J,\u00a0Lefkowitz\u00a0MP,\u00a0Rizkala \u00a0AR\u00a0et\u00a0al.\u00a0(2014).\u00a0Angiotensin\u2010neprilysin\u00a0inhibition\u00a0versus\u00a0ena lapril\u00a0\nin\u00a0heart\u00a0failure.\u00a0The\u00a0New\u00a0England\u00a0journal\u00a0of\u00a0medicine.\u00a0371(11): \u00a0993\u20131004.\u00a0\nPrescrire\u00a0Int.\u00a0(2017).\u00a0Sacubitril\u00a0+\u00a0valsartan\u00a0(Entresto\u00ae)\u00a0in\u00a0ch ronic\u00a0heart\u00a0failure.\u00a0Favourable\u00a0results\u00a0in\u00a0highly\u00a0selected\u00a0pati ents.\u00a0\nPrescrire\u00a0International.\u00a026(179):\u00a033\u201337.\u00a0\nPZ\u00a0\u2013\u00a0Pharmazeutische\u00a0Zeitung\u00a0online\u00a0(2016).\u00a0Arzneistoffe:\u00a0Sacub itril/Valsartan|Entresto\u00ae| 53|2016.\u00a0https: //www.pharmaz\u00a0\neutische\u2010zeitung.de/arzneistoffe/daten/2016/sacubitrilvalsartan entrestor532016/,\u00a0letzter\u00a0Zugriff:\u00a012.12.2018.\u00a0\nSchwabe\u00a0U,\u00a0Paffrath\u00a0D,\u00a0Ludwig\u00a0W\u2010D,\u00a0Klauber\u00a0J\u00a0(2017).\u00a0Arzneivero rdnungs\u2010Report\u00a02017.\u00a0Berlin,\u00a0Heidelberg:\u00a0Springer\u00a0Verlag.\u00a0172\u00a0 Selexipag\u00a04.17\nHandelsname:\u00a0Uptravi\u00ae\u00a0 \u00a0 \u00a0 Pharmazeutischer\u00a0Unternehmer:\u00a0\u00a0\nIndikation:\u00a0Pulmonal\u00a0arter ielle\u00a0Hypertonie\u00a0 Actelion\u00a0\nWHO\u2010Funktionsklasse\u00a0II\u00a0bis\u00a0III\u00a0\nATC\u2010Code:\u00a0C02KX09\u00a0 \u00a0 \u00a0 Markteinf\u00fchrung:\u00a0Juni\u00a02016\u00a0\nDarreichungsform:\u00a0Filmtabletten\u00a0 \u00a0 DDD:\u00a01,8 \u00a0mg\u00a0O\u00a0 \u00a0 \u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u25bc,\u00a0\nBewertung \u00a0\nSelexipag\u00a0wurde\u00a0im\u00a0Mai\u00a02016\u00a0zentral\u00a0durch\u00a0die\u00a0Europ\u00e4ische\u00a0Kommi ssion\u00a0zur\u00a0Lang\u2010\nzeitbehandlung\u00a0der\u00a0pulmonal\u00a0arteri ellen\u00a0Hypertonie\u00a0(PAH)\u00a0bei\u00a0er wachsenen\u00a0Pati\u2010\nenten\u00a0der\u00a0WHO\u2010Funktionsklasse\u00a0II\u00a0bis\u00a0III\u00a0zugelassen.\u00a0Selexipag\u00a0 kann\u00a0in\u00a0Kombinati\u2010\nonstherapie\u00a0eingesetzt\u00a0werden\u00a0bei\u00a0unzureichender\u00a0Wirksamkeit\u00a0vo n\u00a0Endothelin\u2010\nRezeptor\u2010Antagonisten\u00a0oder\u00a0Phos phodiesterase\u00a0(PDE)\u20105\u2010Hemmern\u00a0bz w.\u00a0als\u00a0Mono\u2010\ntherapie,\u00a0wenn\u00a0diese\u00a0Wirkstoffk lassen\u00a0nicht\u00a0infrage\u00a0kommen.\u00a0\nDer\u00a0Wirkstoff\u00a0ist\u00a0ein\u00a0oral\u00a0wirks amer,\u00a0selektiver\u00a0Agonist\u00a0an\u00a0Pro stacyclin\u00a0(PGI 2)\u2010\nRezeptoren,\u00a0 durch\u00a0 deren\u00a0 Stimulation\u00a0 es\u00a0 zu\u00a0 Vasodilation\u00a0 der\u00a0 Pulm onalarterien\u00a0\nsowie\u00a0einer\u00a0Hemmung\u00a0von\u00a0Zellproliferation\u00a0und\u00a0Fibrose\u00a0kommt.\u00a0Da mit\u00a0greift\u00a0Sele\u2010\nxipag\u00a0in\u00a0wichtige\u00a0Pathomechanismen\u00a0der\u00a0PAH\u00a0ein.\u00a0\u00a0\nPatienten\u00a0nehmen\u00a0die\u00a0Filmtabletten\u00a0mit\u00a0Selexipag\u00a0morgens\u00a0und\u00a0ab ends\u00a0jeweils\u00a0zu\u00a0\neiner\u00a0Mahlzeit\u00a0ein.\u00a0Die\u00a0Dosis\u00a0wi rd\u00a0je\u00a0nach\u00a0Vertr\u00e4glichkeit\u00a0pati entenindividuell\u00a0festge\u2010\nlegt\u00a0und\u00a0bis\u00a0zur\u00a0h\u00f6chsten\u00a0vertr\u00e4glichen\u00a0Menge\u00a0auftitriert\u00a0(zwis chen\u00a0200\u00a0und\u00a01.600\u00a0\u00b5g\u00a0\nzweimal\u00a0t\u00e4glich).\u00a0F\u00fcr\u00a0die\u00a0Dosisfindung\u00a0liegen\u00a0Schulungsmaterial ien\u00a0f\u00fcr\u00a0\u00c4rzte,\u00a0Apo\u2010\ntheker\u00a0und\u00a0Patienten\u00a0vor\u00a0(EMA,\u00a02016;\u00a0Fachinformation\u00a0Uptravi\u00ae,\u00a0 2018).\u00a0\nDie\u00a0Zulassung\u00a0beruht\u00a0auf\u00a0der\u00a0randomisierten,\u00a0placebo\u2010kontrollie rten,\u00a0doppelblin\u2010\nden\u00a0Phase\u2010III\u2010Studie\u00a0GRIPHON,\u00a0an\u00a0 der\u00a01.156\u00a0Patienten\u00a0mit\u00a0PAH,\u00a0g r\u00f6\u00dftenteils\u00a0WHO\u2010\nFunktionsklasse\u00a0II\u00a0oder\u00a0III\u00a0teiln ahmen.\u00a020,4\u00a0%\u00a0aller\u00a0Patienten\u00a0 waren\u00a0ohne\u00a0spezifi\u2010\nsche\u00a0 Begleittherapie,\u00a0 die\u00a0 \u00fcbrigen\u00a0 erhielten\u00a0 einen\u00a0 Endothelin\u2010Re zeptor\u2010Antago\u2010\nnisten\u00a0und/oder\u00a0einen\u00a0Phosphodiesterase\u20105\u2010Inhibitor\u00a0jeweils\u00a0in\u00a0 stabiler\u00a0Dosierung.\u00a0\nDie\u00a0Selexipag\u2010Dosis\u00a0wurde\u00a0zwischen\u00a0200\u00a0und\u00a01.600\u00a0Mikrogramm\u00a0bis \u00a0zur\u00a0h\u00f6chsten\u00a0\nvertr\u00e4glichen\u00a0 Menge\u00a0 patientenindi viduell\u00a0 auftitriert.\u00a0 Nach\u00a0 eine r\u00a0 medianen\u00a0 Be\u2010\nhandlungszeit\u00a0von\u00a064\u00a0(Placebo\u2010Gruppe)\u00a0und\u00a071\u00a0Wochen\u00a0(Selexipag\u2010 Gruppe)\u00a0trat\u00a0\nder\u00a0prim\u00e4re\u00a0Endpunkt\u00a0(Komposit\u00a0aus\u00a0Tod\u00a0oder\u00a0PAH\u2010bedingter\u00a0Kompl ikation)\u00a0bei\u00a0\n27\u00a0%\u00a0der\u00a0Patienten\u00a0in\u00a0der\u00a0Selexipag\u2010Gruppe\u00a0und\u00a0bei\u00a041,6\u00a0%\u00a0in\u00a0de r\u00a0Placebo\u2010Gruppe\u00a0\nauf.\u00a0Der\u00a0statistisch\u00a0signifikante\u00a0Unterschied\u00a0zwischen\u00a0den\u00a0Grup pen\u00a0war\u00a0haupts\u00e4ch\u2010\nlich\u00a0durch\u00a0Fortschreiten\u00a0der\u00a0Erkrankung\u00a0und\u00a0Hospitalisierung\u00a0be dingt\u00a0(EMA,\u00a02016;\u00a0\nSitbon\u00a0et\u00a0al.,\u00a02015).\u00a0\n173\u00a0In\u00a0der\u00a0GRIPHON\u2010Studie\u00a0traten\u00a0als\u00a0h\u00e4ufigste\u00a0unerw\u00fcnschte\u00a0Arzneim ittelereignisse\u00a0\n(Placebo\u00a0vs.\u00a0Selexipag)\u00a0Kopfschmerzen\u00a0(32,8\u00a0%\u00a0vs.\u00a065,2\u00a0%),\u00a0Durc hfall\u00a0(19,1\u00a0%\u00a0vs.\u00a0\n42,4\u00a0%),\u00a0\u00dcbelkeit\u00a0(18,5\u00a0%\u00a0vs.\u00a033,6\u00a0%),\u00a0Kieferschmerzen\u00a0(6,2\u00a0%\u00a0v s.\u00a025,7\u00a0%).\u00a0Auch\u00a0\nErbrechen,\u00a0Schmerzen\u00a0in\u00a0den\u00a0Extremit\u00e4ten,\u00a0Muskelschmerzen\u00a0und\u00a0F lush\u00a0waren\u00a0\nunter\u00a0Selexipag\u00a0h\u00e4ufiger\u00a0als\u00a0unter\u00a0Placebo.\u00a0Im\u00a0Juni\u00a02017\u00a0wurde\u00a0 ein\u00a0Rote\u2010Hand\u2010\nBrief\u00a0zu\u00a0m\u00f6glichen\u00a0Interaktionen\u00a0 mit\u00a0starken\u00a0CYP2C8\u2010Inhibitoren \u00a0wie\u00a0Gemfibrozil\u00a0\nver\u00f6ffentlicht,\u00a0die\u00a0gleichzeitig e\u00a0Anwendung\u00a0ist\u00a0kontraindiziert \u00a0(Actelion,\u00a02017).\u00a0\u00a0\nF\u00fcr\u00a0die\u00a0fr\u00fche\u00a0Nutzenbewertung\u00a0von\u00a0Selexipag\u00a0wurde\u00a0als\u00a0zweckm\u00e4\u00dfi ge\u00a0Vergleichs\u2010\ntherapie\u00a0eine\u00a0patientenindividue ll\u00a0optimierte\u00a0medikament\u00f6se\u00a0The rapie\u00a0nach\u00a0Ma\u00df\u2010\ngabe\u00a0des\u00a0Arztes\u00a0unter\u00a0Ber\u00fccksichtigung\u00a0des\u00a0jeweiligen\u00a0Zulassung sstatus\u00a0festgelegt.\u00a0\nDa\u00a0in\u00a0den\u00a0vom\u00a0pU\u00a0vorgelegten\u00a0Daten\u00a0die\u00a0zVT\u00a0nicht\u00a0sachgerecht\u00a0um gesetzt\u00a0wurde,\u00a0\nbeschloss\u00a0der\u00a0G\u2010BA\u00a0im\u00a0Dezember\u00a02016,\u00a0dass\u00a0ein\u00a0Zusatznutzen\u00a0von\u00a0 Selexipag\u00a0nicht\u00a0\nbelegt\u00a0ist\u00a0(G\u2010BA,\u00a02016).\u00a0\u00a0\nVerf\u00fcgbare\u00a0Therapien \u00a0 (Zusatz\u2010)Nutzen \u00a0 Kosten\u00a0\n\u00a0\nWeitere\u00a0Therapieoption\u00a0\nbei\u00a0PAH\u00a0\u00a0ZN\u00a0nicht\u00a0belegt\u00a0\u00a0\nteils\u00a0teurer,\u00a0teils\u00a0g\u00fcnstiger\u00a0\nals\u00a0zVT\u00a0\nErl\u00e4uterung\u00a0der\u00a0Farben:\u00a0Verf\u00fcgbare\u00a0Therapien:\u00a0rot\u00a0=\u00a0weitere\u00a0The rapieoption,\u00a0gelb\u00a0=\u00a0Subgruppen\u2010Novit\u00e4t,\u00a0gr\u00fcn\u00a0=\u00a0Solist;\u00a0(Zusatz\u2010 )\u00a0\nNutzen:\u00a0rot\u00a0=\u00a0keine\u00a0Verbesserung\u00a0oder\u00a0schlechte\u00a0Nutzen/Schaden\u2010 Relation,\u00a0gelb\u00a0=\u00a0teilweise\u00a0Verbesserungen,\u00a0gr\u00fcn\u00a0=\u00a0Verbesserung\u00a0\nharter\u00a0Endpunkte;\u00a0Kosten:\u00a0rot\u00a0=\u00a0teurer\u00a0als\u00a0bestehende\u00a0Therapien ,\u00a0gelb\u00a0=\u00a0ungef\u00e4hr\u00a0gleich\u00a0bzw.\u00a0teils/teils,\u00a0gr\u00fcn\u00a0=\u00a0g\u00fcnstiger\u00a0als \u00a0\nbestehende\u00a0Therapien\u00a0\nWie\u00a0bewerten\u00a0andere?\u00a0\nBewertung\u00a0nach\u00a0\nFricke\u00a0et\u00a0al.\u00a0a\u2010t\u2010Bewertung\u00a0 AMB\u00a0 Prescrire\u00a0 PZ\u00a0\nC\u00a0 \u2013\u00a0 \u2013\u00a0 Not\u00a0acceptable\u00a0 Schrittinnovation\u00a0\n\u00a0\n\u00a0\u00a0\n174\u00a0Kosten\u00a0\nWirkstoff\u00a0 Behandlungsmodus\u00a0 Behandlungstage\u00a0 Jahrestherapiekosten\u00a0\nzu\u00a0bewertendes\u00a0Arzneimittel \u00a0\u00a0 \u00a0 \u00a0\nSelexipag\u00a0 2x\u00a0tgl.\u00a0200\u00a0\u2013\u00a01.600\u00a0\u00b5g\u00a0 365\u00a0 38.119,99\u00a0\u20ac*\u00a0\nzVT\u00a0 \u00a0 \u00a0 \u00a0\nIloprost\u00a0 6\u00a0\u2013\u00a09x\u00a0tgl.\u00a0Inhalation\u00a0 365\u00a0 76.321,35\u00a0\u2013\u00a0114.482,03\u00a0\u20ac\u00a0\nRiociguat\u00a0 3x\u00a0tgl.\u00a02,5\u00a0mg\u00a0 365\u00a0 33.525,44\u00a0\u20ac\u00a0\nTadalafil\u00a0 1x\u00a0tgl.\u00a040\u00a0mg\u00a0 365\u00a0 4.406,85\u00a0\u20ac\u00a0\nSildenafil\u00a0 3x\u00a0tgl.\u00a020\u00a0mg\u00a0 365\u00a0 6.204,64\u00a0\u20ac\u00a0\nAmbrisentan\u00a0 1x\u00a0tgl.\u00a05\u00a0\u2013\u00a010\u00a0mg\u00a0 365\u00a0 45.030,42\u00a0\u20ac\u00a0\nBosentan\u00a0 2x\u00a0tgl.\u00a0125\u00a0mg\u00a0 365\u00a0 19.392,45\u00a0\u20ac\u00a0\nMacitentan\u00a0 1x\u00a0tgl.\u00a010\u00a0mg\u00a0 365\u00a0 26.414,44\u00a0\u20ac\u00a0\n*Die\u00a0Kosten\u00a0pro\u00a0Packung\u00a0sind\u00a0trotz\u00a0unterschiedlicher\u00a0Wirkstoffm engen\u00a0je\u00a0Filmtablette\u00a0gleich\u00a0\nVersorgungsanalysen\u00a0\nNach\u00a0Markteinf\u00fchrung\u00a0im\u00a0Juni\u00a02016\u00a0bewegen\u00a0sich\u00a0die\u00a0verordneten\u00a0 DDD\u00a0zun\u00e4chst\u00a0\nauf\u00a0einem\u00a0relativ\u00a0niedrigen\u00a0Niveau,\u00a0bevor\u00a0sie\u00a0ab\u00a0Januar\u00a02017\u00a0le icht\u00a0ansteigen.\u00a0Die\u00a0\nVer\u00f6ffentlichung\u00a0der\u00a0fr\u00fchen\u00a0Nutz enbewertung\u00a0im\u00a0Dezember\u00a02016\u00a0sp iegelt\u00a0sich\u00a0in\u00a0\nden\u00a0verordneten\u00a0DDD\u00a0nicht\u00a0wider. \u00a0Die\u00a0h\u00f6chsten\u00a0Verordnungszahlen \u00a0finden\u00a0sich\u00a0im\u00a0\nbetrachteten\u00a0Zeitraum\u00a0mit\u00a0etwas\u00a0mehr\u00a0als\u00a0900\u00a0DDD\u00a0im\u00a0November\u00a020 17.\u00a0Die\u00a0Brut\u2010\ntoums\u00e4tze\u00a0entwickeln\u00a0sich\u00a0zun\u00e4chst\u00a0weitestgehend\u00a0parallel\u00a0zu\u00a0de n\u00a0verordneten\u00a0\nDDD.\u00a0Ab\u00a0September\u00a02016\u00a0sinken\u00a0die\u00a0Bruttoums\u00e4tze\u00a0pro\u00a0DDD\u00a0jedoch\u00a0 deutlich,\u00a0was\u00a0\nvermutlich\u00a0auf\u00a0die\u00a0Vereinbarung\u00a0des\u00a0Erstattungsbetrags\u00a0zur\u00fcckge ht.\u00a0Den\u00a0h\u00f6chsten\u00a0\nWert\u00a0im\u00a0betrachteten\u00a0Zeitraum\u00a0erreichen\u00a0die\u00a0Bruttoums\u00e4tze\u00a0mit\u00a0r und\u00a0183.000\u00a0\u20ac\u00a0\nim\u00a0Juni\u00a02017.\u00a0\n\u00a0\u00a0\u00a0175\u00a0Abbildung\u00a04.15:\u00a0Verordnete\u00a0Tages dosen\u00a0(DDD)\u00a0und\u00a0Bruttoums\u00e4tze\u00a0v on\u00a0\u00a0\nSelexipag\u00a0nach\u00a0Monaten\u00a0(2016\u00a0\u2013\u00a02017)\u00a0\n\u00a0\n\u00a0\nQuellen\u00a0\u00a0\nActelion\u00a0(2017).\u00a0Rote\u2010Hand\u2010Brief\u00a0Selexipag\u00a0vom\u00a009.06.2017.\u00a0http s://www.akdae.de/Arzneimittelsicherheit/DSM/Archiv/2019\u2010\n12.html,\u00a0letzter\u00a0Zugriff:\u00a011.07.2019.\u00a0\nEMA\u00a0\u2013\u00a0European\u00a0Medicines\u00a0Agency\u00a0(2016).\u00a0European\u00a0public\u00a0assessm ent\u00a0report\u00a0Uptravi.\u00a0\u00a0\nhttps://www.ema.europa.eu/en/medicines/human/EPAR/uptravi\u00a0\nFachinformation\u00a0Uptravi\u00a0(2018).\u00a0Fachinformation\u00a0Uptravi.\u00a0Stand\u00a0 der\u00a0Information:\u00a0November\u00a02018.\u00a0\nFricke\u00a0U,\u00a0Hein\u00a0L,\u00a0Schwabe\u00a0U\u00a0(2017).\u00a0Neue\u00a0Arzneimittel\u00a02016.\u00a0In: \u00a0Schwabe\u00a0U,\u00a0Paffrath\u00a0D,\u00a0Ludwig\u00a0W\u2010D,\u00a0Klauber\u00a0J\u00a0(Hrsg.)\u00a0(2017).\u00a0\nArzneiverordnungs\u2010Report\u00a02017.\u00a0Berlin,\u00a0Heidelberg.\u00a0Springer:\u00a055 \u2010135.\u00a0\nG\u2010BA\u00a0\u2013\u00a0Gemeinsamer\u00a0Bundesausschuss\u00a0(2016).\u00a0Nutzenbewertungsverf ahren\u00a0zum\u00a0Wirkstoff\u00a0Selexipag.\u00a0https://www.g\u2010\nba.de/bewertungsverfahren/nutzenbewertung/241/,\u00a0letzter\u00a0Zugriff :\u00a011.07.2019.\u00a0\nPrescrire\u00a0Int.\u00a0(2017).\u00a0Selexipag\u00a0(\u00a0Uptravi\u00a0\u00b0)\u00a0and\u00a0pulmonary\u00a0art erial\u00a0hypertension.\u00a0Prescrire\u00a0International\u00a026:\u00a0237\u2013238.\u00a0\nPZ\u00a0\u2013\u00a0Pharmazeutische\u00a0Zeitung\u00a0(2016).\u00a0Selexipag|Uptravi|17|2016\u00a0 |.\u00a0https://www.pharmazeutische\u2010\nzeitung.de/arzneistoffe/daten/2016/selexipaguptravir172016/,\u00a0le tzter\u00a0Zugriff:\u00a011.07.2019.\u00a0\nSitbon\u00a0O,\u00a0Channick\u00a0R,\u00a0Chin\u00a0KM,\u00a0Fr ey\u00a0A,\u00a0Gaine\u00a0S,\u00a0Gali\u00e8\u00a0N\u00a0et\u00a0al.\u00a0 (2015).\u00a0Selexipag\u00a0for\u00a0the\u00a0Treatment\u00a0of\u00a0Pulmonary\u00a0Arterial\u00a0\nHypertension.\u00a0New\u00a0England\u00a0Journal\u00a0of\u00a0Medicine\u00a0373(26):\u00a02522\u2013253 3.\u00a0\u00a0 \u00a0\n176\u00a0 Sofosbuvir/Velpatasvir\u00a04.18\nHandelsname:\u00a0Epclusa\u00ae\u00a0 \u00a0 \u00a0 Pharmazeutischer\u00a0Unternehmer:\u00a0\u00a0\nIndikation:\u00a0Chronische\u00a0Hepatitis\u00a0C\u00a0 \u00a0 Gilead\u00a0\nATC\u2010Code:\u00a0J05AP55\u00a0 \u00a0 \u00a0 Markte inf\u00fchrung:\u00a0August\u00a02016\u00a0\nDarreichungsform:\u00a0Filmtabletten\u00a0 \u00a0 DDD:\u00a01\u00a0DE\u00a0O\u00a0\u00a0 \u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 \u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 \u25bc,\u00a0\nBewertung\u00a0 \u00a0\nDie\u00a0fixe\u00a0Kombination\u00a0aus\u00a0Sofosbuvir\u00a0und\u00a0Velpatasvir\u00a0wurde\u00a0im\u00a0Ju li\u00a02016\u00a0unter\u00a0dem\u00a0\nHandelsnamen\u00a0Epclusa\u00ae\u00a0zentral\u00a0von\u00a0der\u00a0Europ\u00e4ischen\u00a0Kommission\u00a0z ur\u00a0Behandlung\u00a0\nder\u00a0chronischen\u00a0Hepatitis\u00a0C\u00a0(HCV )\u00a0bei\u00a0Erwachsenen\u00a0zugelassen.\u00a0V elpatasvir\u00a0ist\u00a0ein\u00a0\nHCV\u2010Inhibitor,\u00a0 der\u00a0 auf\u00a0 das\u00a0 HCV\u2010NS5A\u2010Protein\u00a0 gerichtet\u00a0 ist,\u00a0 das\u00a0 f\u00fcr\u00a0 die\u00a0 RNA\u2010\nReplikation\u00a0und\u00a0auch\u00a0den\u00a0Zusamme nbau\u00a0von\u00a0HCV\u2010Virionen\u00a0essentiel l\u00a0ist.\u00a0Sofosbu\u2010\nvir\u00a0ist\u00a0ein\u00a0bereits\u00a02014\u00a0zugelassener\u00a0pangenotypischer\u00a0Inhibito r\u00a0der\u00a0ebenfalls\u00a0f\u00fcr\u00a0\ndie\u00a0HCV\u2010Replikation\u00a0erforderlich en\u00a0RNA\u2010Polymerase\u00a0NS5B.\u00a0Die\u00a0Wir kstoffe\u00a0greifen\u00a0\nsomit\u00a0auf\u00a0zwei\u00a0verschiedenen\u00a0Sch ienen\u00a0in\u00a0die\u00a0HCV\u2010Vermehrung\u00a0ein \u00a0und\u00a0wirken\u00a0\ndirekt\u00a0antiviral\u00a0(Fachinformation\u00a0Epclusa\u00ae,\u00a02018).\u00a0\u00a0\nDie\u00a0Dosierung\u00a0liegt\u00a0bei\u00a0einmal\u00a0t\u00e4 glich\u00a0einer\u00a0Filmtablette\u00a0mit\u00a04 00\u00a0mg\u00a0Sofosbuvir\u00a0\nund\u00a0100\u00a0mg\u00a0Velpatasvir,\u00a0die\u00a0unabh\u00e4 ngig\u00a0von\u00a0einer\u00a0Mahlzeit\u00a0einge nommen\u00a0werden\u00a0\nkann.\u00a0Bei\u00a0Patienten\u00a0ohne\u00a0Zirrhose\u00a0bzw.\u00a0mit\u00a0kompensierter\u00a0Zirrho se\u00a0wird\u00a0in\u00a0der\u00a0\nRegel\u00a0eine\u00a0Behandlung\u00a0\u00fcber\u00a0zw\u00f6lf\u00a0Wochen\u00a0empfohlen.\u00a0Bei\u00a0dekompen sierter\u00a0Zir\u2010\nrhose\u00a0sowie\u00a0bei\u00a0Infektion\u00a0mit\u00a0HCV\u00a0vom\u00a0Genotyp\u00a0(GT)\u00a03\u00a0und\u00a0kompen sierter\u00a0Zirrho\u2010\nse\u00a0wird\u00a0die\u00a0Kombination\u00a0mit\u00a0Ribavirin\u00a0empfohlen.\u00a0Bei\u00a0Patienten, \u00a0bei\u00a0denen\u00a0zuvor\u00a0\neine\u00a0Therapie\u00a0mit\u00a0einem\u00a0NS5A\u2010hal tigen\u00a0Regime\u00a0versagt\u00a0hat,\u00a0kann\u00a0 die\u00a0Kombination\u00a0\nmit\u00a0Ribavirin\u00a0\u00fcber\u00a0einen\u00a0Zeitrau m\u00a0von\u00a024\u00a0Wochen\u00a0erwogen\u00a0werden. \u00a0F\u00fcr\u00a0Patienten\u00a0\nmit\u00a0schwerer\u00a0oder\u00a0terminaler\u00a0Niereninsuffizienz\u00a0und\u00a0f\u00fcr\u00a0Patient en\u00a0mit\u00a0einer\u00a0Zir\u2010\nrhose\u00a0der\u00a0Child\u2010Pugh\u2010Turcotte\u00a0(C PT)\u2010Klasse\u00a0C\u00a0liegen\u00a0keine\u00a0ausre ichenden\u00a0Erfah\u2010\nrungen\u00a0vor,\u00a0ebenso\u00a0wenig\u00a0f\u00fcr\u00a0die\u00a0Anwendung\u00a0bei\u00a0Kindern\u00a0und\u00a0Juge ndlichen\u00a0sowie\u00a0\nf\u00fcr\u00a0Patienten\u00a0nach\u00a0einer\u00a0Lebertransplantation.\u00a0Epclusa\u00ae\u00a0kann\u00a0za hlreiche\u00a0Wechsel\u2010\nwirkungen\u00a0eingehen\u00a0(Fachinformation\u00a0Epclusa\u00ae,\u00a02018).\u00a0\u00a0\nDie\u00a0Zulassung\u00a0beruht\u00a0auf\u00a0vier\u00a0multizentrischen\u00a0randomisiert\u2010kon trollierten\u00a0Phase\u2010\nIII\u2010Studien\u00a0(ASTRAL\u20101,\u00a0ASTRAL\u20102,\u00a0 ASTRAL\u20103,\u00a0ASTRAL\u20104)\u00a0mit\u00a0erwach senen\u00a0Patienten\u00a0\nmit\u00a0chronischer\u00a0HCV\u2010Infektion.\u00a0In\u00a0den\u00a0Studien\u00a0wurde\u00a0Sofosbuvir/ Velpatasvir\u00a0in\u00a0\neiner\u00a0Dosis\u00a0von\u00a0400\u00a0mg/100\u00a0mg\u00a0einmal\u00a0t\u00e4glich\u00a0verordnet.\u00a0Prim\u00e4re r\u00a0Endpunkt\u00a0in\u00a0\nallen\u00a0Studien\u00a0war\u00a0das\u00a0dauerhafte\u00a0virologische\u00a0Ansprechen\u00a0zw\u00f6lf\u00a0 Wochen\u00a0nach\u00a0\nAbschluss\u00a0der\u00a0Behandlung\u00a0(SVR12)\u00a0(EMA,\u00a02016).\u00a0\nEine\u00a0der\u00a0Studien\u00a0(ASTRAL\u20101)\u00a0war\u00a0doppelblind\u00a0angelegt,\u00a0die\u00a0ander en\u00a0unverblindet.\u00a0\nIn\u00a0den\u00a0Studien\u00a0ASTRAL\u20101\u00a0bis\u00a0\u20103\u00a0wiesen\u00a0zwischen\u00a019\u00a0und\u00a030\u00a0%\u00a0der\u00a0 Teilnehmer\u00a0eine\u00a0\n177\u00a0kompensierte\u00a0Zirrhose\u00a0auf,\u00a0der\u00a0A nteil\u00a0der\u00a0vorbehandelten\u00a0Patien ten\u00a0lag\u00a0zwischen\u00a0\n15\u00a0und\u00a032\u00a0%.\u00a0\nAn\u00a0der\u00a0zweiarmigen\u00a0ASTRAL\u20101\u2010Studie\u00a0nahmen\u00a0625\u00a0Patienten\u00a0mit\u00a0ver schiedenen\u00a0\nHCV\u2010Genotypen\u00a0teil.\u00a0Die\u00a0Teilnehmer\u00a0wurden\u00a0im\u00a0Verh\u00e4ltnis\u00a05:1\u00a0der \u00a0Behandlung\u00a0mit\u00a0\nSofosbuvir/Velpatasvir\u00a0oder\u00a0Plac ebo\u00a0\u00fcber\u00a0eine\u00a0Dauer\u00a0von\u00a0zw\u00f6lf\u00a0W ochen\u00a0zugeteilt.\u00a0\nDen\u00a0prim\u00e4ren\u00a0Endpunkt\u00a0SVR12\u00a0erreichte\u00a0kein\u00a0Patient\u00a0in\u00a0der\u00a0Place bo\u2010Gruppe,\u00a0aber\u00a0\n99\u00a0%\u00a0der\u00a0Patienten\u00a0in\u00a0der\u00a0Sofosbuv ir/Velpatasvir\u2010Gruppe\u00a0(Feld\u00a0e t\u00a0al.,\u00a02015).\u00a0\nAn\u00a0der\u00a0zweiarmigen\u00a0ASTRAL\u20102\u2010Studie\u00a0nahmen\u00a0269\u00a0Patienten\u00a0mit\u00a0HCV \u2010GT\u00a02\u00a0teil.\u00a0Sie\u00a0\nwurden\u00a0im\u00a0Verh\u00e4ltnis\u00a01:1\u00a0entweder\u00a0einer\u00a0Behandlung\u00a0mit\u00a0Sofosbuv ir/Velpatasvir\u00a0\noder\u00a0einer\u00a0Therapie\u00a0mit\u00a0Sofosbuvir\u00a0400\u00a0mg\u00a0einmal\u00a0t\u00e4glich\u00a0in\u00a0Kom bination\u00a0mit\u00a0\nRibavirin\u00a01.000\u00a0oder\u00a01.200\u00a0mg\u00a0pro\u00a0Tag\u00a0\u00fcber\u00a0zw\u00f6lf\u00a0Wochen\u00a0zugetei lt.\u00a0Den\u00a0prim\u00e4ren\u00a0\nEndpunkt\u00a0SVR12\u00a0erreichten\u00a0in\u00a0der\u00a0 Sofosbuvir/Velpatasvir\u2010Gruppe\u00a0 99\u00a0%\u00a0der\u00a0Patien\u2010\nten\u00a0und\u00a0damit\u00a0statistisch\u00a0signifikant\u00a0mehr\u00a0als\u00a094\u00a0%\u00a0mit\u00a0Sofosbu vir/Ribavirin\u00a0(Foster\u00a0\net\u00a0al.,\u00a02015).\u00a0\nAn\u00a0der\u00a0zweiarmigen\u00a0ASTRAL\u20103\u2010Studie\u00a0nahmen\u00a0552\u00a0Patienten\u00a0mit\u00a0HCV \u2010GT\u00a03\u00a0teil.\u00a0Sie\u00a0\nwurden\u00a0im\u00a0Verh\u00e4ltnis\u00a01:1\u00a0entweder\u00a0einer\u00a0Behandlung\u00a0mit\u00a0Sofosbuv ir/Velpatasvir\u00a0\n\u00fcber\u00a0einen\u00a0Zeitraum\u00a0von\u00a0zw\u00f6lf\u00a0Woc hen\u00a0oder\u00a0einer\u00a0Therapie\u00a0mit\u00a0So fosbuvir\u00a0400\u00a0mg\u00a0\neinmal\u00a0t\u00e4glich\u00a0in\u00a0Kombination\u00a0mit\u00a0Ribavirin\u00a01.000\u00a0oder\u00a01.200\u00a0mg \u00a0pro\u00a0Tag\u00a0\u00fcber\u00a024\u00a0\nWochen\u00a0zugeteilt.\u00a0In\u00a0der\u00a0Gruppe\u00a0mit\u00a0Sofosbuvir/Velpatasvir\u00a0erre ichten\u00a095\u00a0%\u00a0der\u00a0\nTeilnehmer\u00a0den\u00a0prim\u00e4ren\u00a0Endpunkt\u00a0und\u00a0damit\u00a0statistisch\u00a0signifik ant\u00a0mehr\u00a0als\u00a0in\u00a0\nder\u00a0Sofosbuvir/Ribavirin\u2010Gr uppe\u00a080\u00a0%\u00a0(Foster\u00a0et\u00a0al.,\u00a02015).\u00a0\nAn\u00a0der\u00a0dreiarmigen\u00a0ASTRAL\u20104\u2010Studie\u00a0nahmen\u00a0267\u00a0Patienten\u00a0mit\u00a0ver schiedenen\u00a0\nHCV\u2010GT\u00a0mit\u00a0Leberzirrhose\u00a0im\u00a0Stadium\u00a0CPT\u00a0B\u00a0teil.\u00a055\u00a0%\u00a0hatten\u00a0ber eits\u00a0zuvor\u00a0eine\u00a0\nBehandlung\u00a0gegen\u00a0die\u00a0HCV\u2010Infektion\u00a0erhalten.\u00a0Die\u00a0Teilnehmer\u00a0wur den\u00a0im\u00a0Verh\u00e4lt\u2010\nnis\u00a01:1:1\u00a0auf\u00a0die\u00a0Behandlungsarme\u00a0verteilt:\u00a0Gruppe\u00a01\u00a0erhielt\u00a0So fosbuvir/Velpatas\u2010\nvir\u00a0\u00fcber\u00a0zw\u00f6lf\u00a0Wochen,\u00a0Gruppe\u00a02\u00a0So fosbuvir/Velpatasvir\u00a0plus\u00a0Rib avirin\u00a01.000\u00a0oder\u00a0\n1.200\u00a0mg\u00a0pro\u00a0Tag\u00a0\u00fcber\u00a0zw\u00f6lf\u00a0Wochen,\u00a0Gruppe\u00a03\u00a0Sofosbuvir/Velpata svir\u00a0f\u00fcr\u00a024\u00a0\nWochen.\u00a0Den\u00a0prim\u00e4ren\u00a0Endpunkt\u00a0erreichten\u00a0in\u00a0Gruppe\u00a01\u00a083\u00a0%\u00a0der\u00a0P atienten,\u00a0in\u00a0\nGruppe\u00a02\u00a094\u00a0%\u00a0und\u00a0in\u00a0Gruppe\u00a03\u00a086\u00a0%\u00a0(Curry\u00a0et\u00a0al.,\u00a02015).\u00a0\nZum\u00a0Zeitpunkt\u00a0der\u00a0Zulassung\u00a0beruhte\u00a0der\u00a0Erfahrungsumfang\u00a0zu\u00a0une rw\u00fcnschten\u00a0\nWirkungen\u00a0auf\u00a0rund\u00a01.300\u00a0Patienten,\u00a0die\u00a0f\u00fcr\u00a0mindestens\u00a0zw\u00f6lf\u00a0Wo chen\u00a0Sofosbu\u2010\nvir/Velpatasvir\u00a0 erhalten\u00a0 hatten.\u00a0 In\u00a0 den\u00a0 Zulassungsstudien\u00a0 trate n\u00a0 als\u00a0 h\u00e4ufigste\u00a0\nunerw\u00fcnschte\u00a0Arzneimittelereigni sse\u00a0Kopfschmerzen,\u00a0Ersch\u00f6pfung\u00a0 und\u00a0\u00dcbelkeit\u00a0\nauf\u00a0(EMA,\u00a02016).\u00a0Nach\u00a0der\u00a0Zulassung\u00a0wurde\u00a0nach\u00a0einem\u00a0im\u00a0Mai\u00a0201 7\u00a0abgeschlos\u2010\nsenen\u00a0Risikobewertungsverfahren\u00a0der\u00a0EMA\u00a0die\u00a0Empfehlung\u00a0in\u00a0die\u00a0F achinformation\u00a0\naufgenommen,\u00a0alle\u00a0Patienten\u00a0vor\u00a0Behandlung\u00a0mit\u00a0direkt\u00a0wirkenden \u00a0antiviralen\u00a0\nArzneimitteln\u00a0(DAA)\u00a0auf\u00a0eine\u00a0Infektion\u00a0mit\u00a0Hepatitis\u00a0B\u00a0zu\u00a0scree nen\u00a0(Akd\u00c4,\u00a02017).\u00a0178\u00a0Im\u00a0Oktober\u00a02018\u00a0wurde\u00a0ein\u00a0Hinwei s\u00a0erg\u00e4nzt,\u00a0dass\u00a0DAA\u00a0bei\u00a0Patient en\u00a0mit\u00a0Diabetes\u00a0\nmellitus\u00a0das\u00a0Risiko\u00a0f\u00fcr\u00a0Hypoglyk \u00e4mien\u00a0erh\u00f6hen\u00a0k\u00f6nnen\u00a0(Akd\u00c4,\u00a0201 9).\u00a0\nF\u00fcr\u00a0die\u00a0fr\u00fche\u00a0Nutzenbewertung\u00a0wurden\u00a0je\u00a0nach\u00a0Genotyp\u00a0und\u00a0Zirrho se\u2010Stadium\u00a0\nzehn\u00a0Fragestellungen\u00a0identifiziert,\u00a0f\u00fcr\u00a0die\u00a0jeweils\u00a0die\u00a0zVT\u00a0fes tgelegt\u00a0und\u00a0der\u00a0Zu\u2010\nsatznutzen\u00a0bewertet\u00a0wurde\u00a0(s.\u00a0Tabelle).\u00a0Das\u00a0Gutachten\u00a0des\u00a0IQWiG \u00a0kam\u00a0auf\u00a0der\u00a0\nBasis\u00a0der\u00a0vom\u00a0pU\u00a0vorgelegten\u00a0Daten\u00a0im\u00a0Oktober\u00a02016\u00a0zu\u00a0dem\u00a0Ergeb nis,\u00a0dass\u00a0bei\u00a0\nGT2\u00a0ohne\u00a0Zirrhose\u00a0oder\u00a0mit\u00a0kompensierter\u00a0Zirrhose\u00a0ein\u00a0Anhaltspu nkt\u00a0f\u00fcr\u00a0einen\u00a0\nbetr\u00e4chtlichen\u00a0Zusatznutzen\u00a0vorliegt,\u00a0bei\u00a0GT3\u00a0ohne\u00a0Zirrhose\u00a0ode r\u00a0mit\u00a0kompensier\u2010\nter\u00a0 Zirrhose\u00a0 ein\u00a0 Anhaltspunkt\u00a0 f\u00fcr\u00a0 einen\u00a0 nicht\u00a0 quantifizierbaren \u00a0 Zusatznutzen\u00a0\n(IQWiG,\u00a02016).\u00a0Im\u00a0Laufe\u00a0der\u00a0Nutze nbewertung\u00a0legte\u00a0der\u00a0pU\u00a0weiter e\u00a0Daten\u00a0f\u00fcr\u00a0\nPatienten\u00a0mit\u00a0HIV\u2010Koinfektion\u00a0vor.\u00a0Ein\u00a0im\u00a0Januar\u00a02017\u00a0ver\u00f6ffent liches\u00a0Addendum\u00a0\nzum\u00a0IQWiG\u2010Gutachten\u00a0konnte\u00a0auf\u00a0der\u00a0Basis\u00a0der\u00a0vorgelegten\u00a0Daten\u00a0 f\u00fcr\u00a0diese\u00a0Pati\u2010\nentengruppe\u00a0jedoch\u00a0keinen\u00a0Zusat znutzen\u00a0feststellen\u00a0(IQWiG,\u00a02017 ).\u00a0\nDer\u00a0Beschluss\u00a0des\u00a0G\u2010BA\u00a0im\u00a0Januar\u00a02017\u00a0weicht\u00a0in\u00a0drei\u00a0Fragestell ungen\u00a0von\u00a0der\u00a0\nEinsch\u00e4tzung\u00a0des\u00a0IQWiG\u00a0ab.\u00a0Dadurch\u00a0ergibt\u00a0sich\u00a0f\u00fcr\u00a0Patienten\u00a0mi t\u00a0GT2\u00a0ohne\u00a0Zir\u2010\nrhose\u00a0oder\u00a0mit\u00a0kompensierter\u00a0Zirrhose\u00a0ein\u00a0 Anhaltspunkt\u00a0f\u00fcr\u00a0einen\u00a0geringen\u00a0Zu\u2010\nsatznutzen ,\u00a0f\u00fcr\u00a0Patienten\u00a0mit\u00a0GT3\u00a0ohne\u00a0Zirrhose\u00a0oder\u00a0mit\u00a0kompensierter\u00a0Zi rrhose\u00a0\nein\u00a0Anhaltspunkt\u00a0f\u00fcr\u00a0einen\u00a0betr\u00e4chtlichen\u00a0Zusatznutzen \u00a0sowie\u00a0f\u00fcr\u00a0Patienten\u00a0mit\u00a0\ndekompensierter\u00a0Zirrhose\u00a0und\u00a0GT2\u20106\u00a0ein\u00a0 Anhaltspunkt\u00a0f\u00fcr\u00a0einen\u00a0nicht\u00a0quantifi\u2010\nzierbaren\u00a0Zusatznutzen\u00a0 (G\u2010BA,\u00a02017).\u00a0\n\u00a0\u00a0179\u00a0Fr\u00fche\u00a0Nutzenbewertung\u00a0nach\u00a0Genotyp\u00a0und\u00a0Zirrhose\u2010Stadium\u00a0\nPatientengruppe\u00a0 zVT\u00a0 Zusatznutzen\u00a0\n(IQWIG)\u00a0Zusatznutzen\u00a0(G\u2010BA)\u00a0\nGT1\u00a0 \u00a0 \u00a0 \u00a0\nohne\u00a0Zirrhose\u00a0 Ledipasvir/Sofosbuvir\u00a0oder\u00a0\nOmbitasvir/Paritaprevir/Ritonavir\u00a0\nplus\u00a0Dasabuvir\u00a0(ggf.\u00a0plus\u00a0\nRibavirin)\u00a0ZN\u00a0nicht\u00a0belegt\u00a0 ZN\u00a0nicht\u00a0belegt\u00a0\nmit\u00a0kompensierter\u00a0\nZirrhose\u00a0Ledipasvir/Sofosbuvir\u00a0 ZN\u00a0nicht\u00a0belegt\u00a0 ZN\u00a0nicht\u00a0belegt\u00a0\nmit\u00a0dekompensierter\u00a0\nZirrhose\u00a0Ledipasvir/Sofosbuvir\u00a0\u00a0\nplus\u00a0Ribavirin\u00a0ZN\u00a0nicht\u00a0belegt\u00a0 ZN\u00a0nicht\u00a0belegt\u00a0\nGT2\u00a0 \u00a0 \u00a0 \u00a0\nohne\u00a0Zirrhose\u00a0oder\u00a0mit\u00a0\nkompensierter\u00a0Zirrhose\u00a0Sofosbuvir\u00a0\u00a0\nplus\u00a0Ribavirin\u00a0Anhaltspkt.\u00a0f\u00fcr\u00a0\nbetr\u00e4chtlichen\u00a0ZN\u00a0\n(Patienten\u00a0mit\u00a0HIV\u2010\nKoinfektion:\u00a0ZN\u00a0\nnicht\u00a0belegt)\u00a0Anhaltspunkt\u00a0f\u00fcr\u00a0einen\u00a0\ngeringen\u00a0Zusatznutzen\u00a0\nGT3\u00a0 \u00a0 \u00a0 \u00a0\nohne\u00a0Zirrhose\u00a0oder\u00a0mit\u00a0\nkompensierter\u00a0Zirrhose\u00a0Sofosbuvir\u00a0\u00a0\nplus\u00a0Ribavirin\u00a0Anhaltspunkt\u00a0f\u00fcr\u00a0\nnicht\u00a0quantifizierb.\u00a0\nZN\u00a0(Patienten\u00a0mit\u00a0\nHIV\u2010Koinfektion:\u00a0ZN\u00a0\nnicht\u00a0belegt)\u00a0Anhaltspunkt\u00a0f\u00fcr\u00a0einen\u00a0\nbetr\u00e4chtlichen\u00a0\nZusatznutzen\u00a0\nGT4\u00a0 \u00a0 \u00a0 \u00a0\nohne\u00a0Zirrhose\u00a0 Ledipasvir/Sofosbuvir\u00a0oder\u00a0\nOmbitasvir/Paritaprevir/Ritonavir\u00a0\nplus\u00a0Ribavirin\u00a0ZN\u00a0nicht\u00a0belegt\u00a0 ZN\u00a0nicht\u00a0belegt\u00a0\nmit\u00a0kompensierter\u00a0\nZirrhose\u00a0Ledipasvir/Sofosbuvir\u00a0 ZN\u00a0nicht\u00a0belegt\u00a0 ZN\u00a0nicht\u00a0belegt\u00a0\nGT5\u00a0 \u00a0 \u00a0 \u00a0\nohne\u00a0Zirrhose\u00a0oder\u00a0mit\u00a0\nkompensierter\u00a0Zirrhose\u00a0Peginterferon\u00a0alfa\u00a0und\u00a0Ribavirin\u00a0 ZN\u00a0nicht\u00a0belegt\u00a0 ZN\u00a0nicht\u00a0belegt\u00a0\nGT6\u00a0 \u00a0 \u00a0 \u00a0\nohne\u00a0Zirrhose\u00a0oder\u00a0mit\u00a0\nkompensierter\u00a0Zirrhose\u00a0Peginterferon\u00a0alfa\u00a0und\u00a0Ribavirin\u00a0 ZN\u00a0nicht\u00a0belegt\u00a0 ZN\u00a0nicht\u00a0belegt\u00a0\nGT2\u00a0\u2013\u00a06\u00a0\u00a0 \u00a0 \u00a0 \u00a0\nmit\u00a0dekompensierter\u00a0\nZirrhose\u00a0Best\u00a0supportive\u00a0Care\u00a0 ZN\u00a0nicht\u00a0belegt\u00a0 Anhaltspunkt\u00a0f\u00fcr\u00a0einen\u00a0\nnicht\u00a0quantifizierbaren\u00a0\nZusatznutzen\u00a0\n\u00a0180\u00a0Verf\u00fcgbare\u00a0Therapien \u00a0 (Zusatz\u2010)Nutzen \u00a0 Kosten\u00a0\n\u00a0\nVelpatasvir\u00a0erster\u00a0\npangenotypischer\u00a0NS5A\u2010\nInhibitor\u00a0in\u00a0Kombination\u00a0\nmit\u00a0bekanntem\u00a0Wirkstoff\u00a0\u00a0Anhaltspunkte\u00a0f\u00fcr\u00a0\nZusatznutzen\u00a0in\u00a0zwei\u00a0von\u00a0\nacht\u00a0Fragestellungen\u00a0\u00a0\ng\u00fcnstiger\u00a0als\u00a0zVT\u00a0\nErl\u00e4uterung\u00a0der\u00a0Farben:\u00a0Verf\u00fcgbare\u00a0Therapien:\u00a0rot\u00a0=\u00a0weitere\u00a0The rapieoption,\u00a0gelb\u00a0=\u00a0Subgruppen\u2010Novit\u00e4t,\u00a0gr\u00fcn\u00a0=\u00a0Solist;\u00a0(Zusatz\u2010 )\u00a0\nNutzen:\u00a0rot\u00a0=\u00a0keine\u00a0Verbesserung\u00a0oder\u00a0schlechte\u00a0Nutzen/Schaden\u2010 Relation,\u00a0gelb\u00a0=\u00a0teilweise\u00a0Verbesserungen,\u00a0gr\u00fcn\u00a0=\u00a0Verbesserung\u00a0\nharter\u00a0Endpunkte;\u00a0Kosten:\u00a0rot\u00a0=\u00a0teurer\u00a0als\u00a0bestehende\u00a0Therapien ,\u00a0gelb\u00a0=\u00a0ungef\u00e4hr\u00a0gleich\u00a0bzw.\u00a0teils/teils,\u00a0gr\u00fcn\u00a0=\u00a0g\u00fcnstiger\u00a0als \u00a0\nbestehende\u00a0Therapien\u00a0\nWie\u00a0bewerten\u00a0andere?\u00a0\nBewertung\u00a0nach\u00a0\nFricke\u00a0et\u00a0al.\u00a0atd\u2010Bewertung\u00a0 AMB\u00a0 Prescrire\u00a0 PZ\u00a0\nB\u00a0Mittel\u00a0der\u00a0Wahl\u00a0in\u00a0\nbestimmten\u00a0\nSituationen,\u00a0jedoch\u00a0\nmit\u00a0noch\u00a0geringem\u00a0\nErfahrungs\u2010\nhintergrund\u00a0Therapie\u00a0der\u00a0\nchronischen\u00a0\nHepatitis\u00a0C\u00a0ist\u00a0\nwirksamer\u00a0und\u00a0\neinfacher\u00a0geworden\u00a0Offers\u00a0an\u00a0advantage\u00a0 Schrittinnovation\u00a0\nKosten\u00a0\nWirkstoff\u00a0 Behandlungsmodus\u00a0 Behandlungstage\u00a0 Jahrestherapiekosten\u00a0\nzu\u00a0bewertendes\u00a0Arzneimittel \u00a0\u00a0 \u00a0 \u00a0\nSofosbuvir/Velpatasvir\u00a0 400/100\u00a0mg\u00a01x\u00a0tgl.\u00a0\u00a0 84\u00a0 29.989,95\u00a0\u20ac\u00a0\noder\u00a0 \u00a0 \u00a0 \u00a0\n+\u00a0Ribavirin*\u00a0 1.000\u00a0\u2013\u00a01.200\u00a0mg\u00a01x\u00a0tgl.\u00a0\u00a0 84\u00a01.860,73\u00a0\u2013\u00a02.232,87\u00a0\u20ac\u00a0\n\u00a0 \u00a0 \u00a031.850,68\u00a0\u2013\u00a032.222,82\u00a0\u20ac\u00a0\nzVT\u00a0Patienten\u00a0ohne\u00a0Zirrhose,\u00a0Genotyp\u00a01 \u00a0 \u00a0 \u00a0\nLedipasvir/Sofosbuvir\u00a0 90/400\u00a0mg\u00a01x\u00a0tgl.\u00a0\u00a0 84\u00a0 44.985,00\u00a0\u20ac\u00a0\nOmbitasvir/Paritaprevir/Ritonavir\u00a0 12,5/75/50\u00a0mg\u00a02x\u00a0tgl.\u00a0\u00a0 84\u00a0 \u00a0\n+\u00a0Dasabuvir\u00a0 2x\u00a0tgl.\u00a0250\u00a0mg\u00a0 84\u00a0 52.034,73\u00a0\u20ac\u00a0\nzVT\u00a0Patienten\u00a0mit\u00a0kompensierter\u00a0Zirrhose,\u00a0Genotyp\u00a01;\u00a0Patienten\u00a0 ohne\u00a0Zirrhose,\u00a0Genotyp\u00a04;\u00a0\u00a0Patienten\u00a0mit\u00a0\nkompensierter\u00a0Zirrhose,\u00a0Genotyp\u00a04,\u00a0\u00a0Patienten\u00a0ohne\u00a0Zirrhose\u00a0ode r\u00a0mit\u00a0kompensierter\u00a0Zirrhose,\u00a0Genotyp\u00a05\u00a0\noder\u00a06\u00a0\nLedipasvir/Sofosbuvir\u00a0 90/400\u00a0mg\u00a01x\u00a0tgl.\u00a0\u00a0 84\u00a0 44.985,00\u00a0\u20ac\u00a0\nzVT\u00a0Patienten\u00a0ohne\u00a0Zirrhose\u00a0oder\u00a0mit\u00a0kompensierter\u00a0Zirrhose,\u00a0Ge notyp\u00a02\u00a0 \u00a0\nSofosbuvir\u00a0 400\u00a0mg\u00a01x\u00a0tgl.\u00a0\u00a0 84\u00a0 \u00a0\n+\u00a0Ribavirin\u00a0 1.000\u00a0\u2013\u00a01.200\u00a0mg\u00a01x\u00a0tgl.\u00a0 84\u00a0 44.907,67\u00a0\u20ac\u00a0\nzVT\u00a0Patienten\u00a0ohne\u00a0Zirrhose\u00a0oder\u00a0mit\u00a0kompensierter\u00a0Zirrhose,\u00a0Ge notyp\u00a03\u00a0 \u00a0\nSofosbuvir \u00a0 400\u00a0mg\u00a01x\u00a0tgl.\u00a0\u00a0 168\u00a0 \u00a0\n+\u00a0Ribavirin \u00a0 1.000\u00a0\u2013\u00a01.200\u00a0mg\u00a01x\u00a0tgl.\u00a0 168\u00a089.815,33\u00a0\u2013\u00a090.559,62\u00a0\u20ac\u00a0\n\u00a0\u00a0 \u00a0 \u00a0\n181\u00a0zVT\u00a0Patienten\u00a0mit\u00a0dekompensierter\u00a0Zirrhose,\u00a0Genotyp\u00a01\u00a0 \u00a0\nLedipasvir/Sofosbuvir\u00a0 90/400\u00a0mg\u00a01x\u00a0tgl.\u00a0\u00a0 84\u00a0 \u00a0\n+\u00a0Ribavirin\u00a0 1.000\u00a0\u2013\u00a01.200\u00a0mg\u00a01x\u00a0tgl.\u00a0 84\u00a046.845,73\u00a0\u2013\u00a047.217,87\u00a0\u20ac\u00a0\nzVT\u00a0Patienten\u00a0mit\u00a0dekompensierter\u00a0Zirrhose,\u00a0Genotyp\u00a02/3/4/5\u00a0ode r\u00a06\u00a0 \u00a0\nBSC\u00a0 Patientenindividuell\u00a0 \u00a0Patientenindividuell\u00a0\n*\u00a0Kombination\u00a0nur\u00a0bei\u00a0Patienten\u00a0ohne\u00a0Zirrhose\u00a0oder\u00a0mit\u00a0kompensi erter\u00a0Zirrhose,\u00a0Genotyp\u00a03,\u00a0bei\u00a0Patienten\u00a0mit\u00a0dekompensierter\u00a0\nZirrhose,\u00a0Genotyp\u00a01\u00a0und\u00a0Patienten\u00a0mit\u00a0dekompensierter\u00a0Zirrhose, \u00a0Genotyp\u00a02/3/4/5\u00a0oder\u00a06\u00a0\nVersorgungsanalysen\u00a0\nSeit\u00a0der\u00a0Markteinf\u00fchrung\u00a0im\u00a0August\u00a02016\u00a0nehmen\u00a0die\u00a0verordneten\u00a0 Tagesdosen\u00a0\nrasch\u00a0zu\u00a0und\u00a0erreichen\u00a0von\u00a0September\u00a0bis\u00a0November\u00a02016\u00a0mit\u00a0rund \u00a03.000\u00a0DDD\u00a0\nden\u00a0h\u00f6chsten\u00a0Stand\u00a0im\u00a0betrachteten\u00a0Zeitraum.\u00a0Danach\u00a0sinken\u00a0die\u00a0 Verordnungs\u2010\nzahlen\u00a0leicht,\u00a0erreichen\u00a0im\u00a0M\u00e4rz\u00a02017\u00a0aber\u00a0fast\u00a0noch\u00a0einmal\u00a0das \u00a0vorherige\u00a0Niveau.\u00a0\nAb\u00a0April\u00a02017\u00a0gehen\u00a0die\u00a0verordneten\u00a0DDD\u00a0deutlich\u00a0zur\u00fcck.\u00a0Die\u00a0Br uttoums\u00e4tze\u00a0\nentwickeln\u00a0sich\u00a0parallel\u00a0zu\u00a0den\u00a0verordneten\u00a0Tagesdosen.\u00a0Die\u00a0h\u00f6c hsten\u00a0monatli\u2010\nchen\u00a0Ums\u00e4tze\u00a0mit\u00a0rund\u00a02,5\u00a0Mio.\u00a0\u20ac\u00a0werden\u00a0im\u00a0September\u00a02016\u00a0erzie lt.\u00a0\nAbbildung\u00a04.16:\u00a0Verordnete\u00a0Tages dosen\u00a0(DDD)\u00a0und\u00a0Bruttoums\u00e4tze\u00a0v on\u00a0So\u2010\nfosbuvir/Velpatasvir\u00a0nach\u00a0Monaten\u00a0(2016\u00a0\u2013\u00a02017)\u00a0\n\u00a0\n\u00a0\n182\u00a0Quellen\u00a0\nAKd\u00c4\u2013\u00a0Arzneimittelkommission\u00a0der\u00a0deutschen\u00a0\u00c4rzteschaft\u00a0(2017).\u00a0 Drug\u00a0Safety\u00a0Mail\u00a02017\u201016:\u00a0Direkt\u00a0wirkende\u00a0antivirale\u00a0\nArzneimittel\u00a0(DAA):\u00a0EMA\u00a0best\u00e4tigt\u00a0 die\u00a0Empfehlung\u00a0zum\u00a0Hepatitis\u2010 B\u2010Screening.\u00a0\nhttps://www.akdae.de/Arzneimittelsicherheit/DSM/Archiv/2017\u201016. html,\u00a0letzter\u00a0Zugriff:\u00a010.07.2019.\u00a0\nAKd\u00c4\u00a0\u2013\u00a0Arzneimittelkommission\u00a0der\u00a0deutschen\u00a0\u00c4rzteschaft\u00a0(2019). \u00a0Drug\u00a0Safety\u00a0Mail\u00a02019\u201006:\u00a0Direkt\u00a0wirkende\u00a0antivirale\u00a0\nArzneimittel\u00a0(DAAV)\u00a0zur\u00a0Behandlung\u00a0der\u00a0Hepatitis\u00a0C:\u00a0Hypoglyk\u00e4mi erisiko\u00a0bei\u00a0Patienten\u00a0mit\u00a0Diabetes\u00a0mellitus.\u00a0\nhttps://www.akdae.de/Arzneimittelsicherheit/DSM/Archiv/2019\u201006. html,\u00a0letzter\u00a0Zugriff:\u00a010.07.2019.\u00a0\nAMB\u00a0\u2013\u00a0Der\u00a0Arzneimittelbrief\u00a0(2015).\u00a0Therapie\u00a0der\u00a0chronischen\u00a0He patitis\u00a0C\u00a0ist\u00a0wirksamer\u00a0und\u00a0einfacher\u00a0geworden.\u00a0AMB\u00a049:\u00a091.\u00a0\natd\u00a0\u2013\u00a0arznei\u2010telegramm\u00a0Arzneimitteldatenbank\u00a0(2019).\u00a0Sofosbuvir \u00a0+\u00a0Velpatasvir.\u00a0https://www.arznei\u2010\ntelegramm.de/db/0kombiwkstxt.php3?&knr=&art=kombi&kombinr=11465 &ah=,\u00a0letzter\u00a0Zugriff:\u00a010.07.2019.\u00a0\nCurry\u00a0MP,\u00a0O\u2019Leary\u00a0JG,\u00a0Bzowej\u00a0N,\u00a0Muir\u00a0AJ,\u00a0Korenblat\u00a0KM,\u00a0Fenkel\u00a0J M\u00a0et\u00a0al.\u00a0(2015).\u00a0Sofosbuvir\u00a0and\u00a0Velpatasvir\u00a0for\u00a0HCV\u00a0in\u00a0Patients \u00a0with\u00a0\nDecompensated\u00a0Cirrhosis.\u00a0NEJM\u00a0373(27):\u00a02618\u20132628.\u00a0\u00a0\nEMA\u00a0\u2013\u00a0European\u00a0Medicines\u00a0Agency\u00a0(2016).\u00a0EPAR\u00a0(Public\u00a0Assessment \u00a0Report):\u00a0Epclusa.\u00a0\nhttps://www.ema.europa.eu/en/medicines/human/EPAR/epclusa,\u00a0letz ter\u00a0Zugriff:\u00a010.07.2019.\u00a0\nFachinformation\u00a0Epclusa\u00a0(2018).\u00a0Fachinformation\u00a0Epclusa.\u00a0Stand\u00a0 der\u00a0Information:\u00a0Dezember\u00a02018.\u00a0\nFeld\u00a0JJ,\u00a0Jacobson\u00a0IM,\u00a0H\u00e9zode\u00a0C,\u00a0Asselah\u00a0T,\u00a0Ruane\u00a0PJ,\u00a0Gruener\u00a0N\u00a0 et\u00a0al.\u00a0(2015).\u00a0Sofosbuvir\u00a0and\u00a0Velpatasvir\u00a0for\u00a0HCV\u00a0Genotype\u00a01,\u00a02 ,\u00a04,\u00a0\n5,\u00a0and\u00a06\u00a0Infection.\u00a0NEJM\u00a0373(27):\u00a02599\u20132607.\u00a0\u00a0\nFoster\u00a0GR,\u00a0Afdhal\u00a0N,\u00a0Roberts\u00a0SK, \u00a0Br\u00e4u\u00a0N,\u00a0Gane\u00a0EJ,\u00a0Pianko\u00a0S\u00a0et\u00a0a l.\u00a0(2015).\u00a0Sofosbuvir\u00a0and\u00a0Velpatasvir\u00a0for\u00a0HCV\u00a0Genotype\u00a02\u00a0and\u00a03\u00a0\nInfection.\u00a0NEJM\u00a0373(27):\u00a02608\u20132617.\u00a0\u00a0\nFricke\u00a0U,\u00a0Hein\u00a0L,\u00a0Schwabe\u00a0U\u00a0(2017).\u00a0Neue\u00a0Arzneimittel\u00a02016.\u00a0In: \u00a0Schwabe\u00a0U,\u00a0Paffrath\u00a0D,\u00a0Ludwig\u00a0W\u2010D,\u00a0Klauber\u00a0J\u00a0(Hrsg.)\u00a0(2017).\u00a0\nArzneiverordnungs\u2010Report\u00a02017.\u00a0Berlin,\u00a0Heidelberg.\u00a0Springer:\u00a055 \u2010135.\u00a0\nG\u2010BA\u00a0\u2013\u00a0Gemeinsamer\u00a0Bundesausschuss\u00a0(2017).\u00a0Nutzenbewertungsverf ahren\u00a0zum\u00a0Wirkstoff\u00a0Sofosbuvir/Velpatasvir.\u00a0https://www.g\u2010\nba.de/bewertungsverfahren/nutzenbewertung/251/,\u00a0letzter\u00a0Zugriff :\u00a010.07.2019.\u00a0\nIQWiG\u00a0\u2013\u00a0Institut\u00a0f\u00fcr\u00a0Qualit\u00e4t\u00a0und\u00a0Wirtschaftlichkeit\u00a0im\u00a0Gesundh eitswesen\u00a0(2016).\u00a0[A16\u201048]\u00a0Sofosbuvir/Velpatasvir\u00a0(chronische\u00a0\nHepatitis\u00a0C)\u00a0\u2010\u00a0Nutzenbewertung\u00a0gem\u00e4\u00df\u00a0\u00a735a\u00a0SGB\u00a0V.\u00a0https://www.iq wig.de/de/projekte\u2010\nergebnisse/projekte/arzneimittelbewertung/2016/a16\u201048\u2010sofosbuvi r\u2010velpatasvir\u2010chronische\u2010hepatitis\u2010c\u2010\nnutzenbewertung\u2010gemaess\u201035a\u2010sgb\u2010v .7604.html,\u00a0letzter\u00a0Zugriff:\u00a01 0.07.2019.\u00a0\nIQWiG\u00a0\u2013\u00a0Institut\u00a0f\u00fcr\u00a0Qualit\u00e4t\u00a0und\u00a0Wirtschaftlichkeit\u00a0im\u00a0Gesundh eitswesen\u00a0(2017).\u00a0[A16\u201073]\u00a0Sofosbuvir/Velpatasvir\u00a0(chronische\u00a0\nHepatitis\u00a0C)\u00a0\u2010\u00a0Addendum\u00a0zum\u00a0Auftrag\u00a0A16\u201048.\u00a0https://www.iqwig.d e/de/projekte\u2010\nergebnisse/projekte/arzneimittelbewertung/2016/a16\u201073\u2010sofosbuvi r\u2010velpatasvir\u2010chronische\u2010hepatitis\u2010c\u2010addendum\u2010\nzum\u2010auftrag\u2010a16\u201048.7739.html,\u00a0letzter\u00a0Zugriff:\u00a010.07.2019.\u00a0\nPrescrire\u00a0Int.\u00a0(2018).\u00a0Sofosbuvir \u00a0+\u00a0velpatasvir\u00a0(Epclusa)\u00a0in\u00a0ch ronic\u00a0hepatitis\u00a0C.\u00a0Prescrire\u00a0International\u00a027:\u00a089.\u00a0\nPZ\u00a0\u2013\u00a0Pharmazeutische\u00a0Zeitung\u00a0(2016).\u00a0Velpatasvir|Epclusa|83|201 6.\u00a0https://www.pharmazeutische\u2010\nzeitung.de/arzneistoffe/daten/2 016/velpatasvirepclusar832016/,\u00a0 letzter\u00a0Zugriff:\u00a010.07.2019.\u00a0\n\u00a0\u00a0183\u00a0 Talimogen\u00a0laherparepvec\u00a04.19\nHandelsname:\u00a0Imlygic\u00ae\u00a0 \u00a0 \u00a0 Pharm azeutischer\u00a0Unternehmer:\u00a0\u00a0\nIndikation:\u00a0Melanom\u00a0 \u00a0 \u00a0 Amgen\u00a0Europe\u00a0B.V.\u00a0\nATC\u2010Code:\u00a0L01XX51\u00a0 \u00a0 \u00a0 Markteinf\u00fchrung:\u00a0Juni\u00a02016\u00a0\nDarreichungsform:\u00a0Injektionssuspension\u00a0 DDD:\u00a00,14\u00a0DE\u00a0(entspr.\u00a014 \u00a0Mio.\u00a0PFU)\u00a0 \u25bc\u00a0\nBewertung \u00a0\nMit\u00a0Talimogen\u00a0laherparepvec\u00a0(kurz\u00a0T\u2010Vec,\u00a0Imlygic\u00ae)\u00a0erhielt\u00a0am\u00a01 6.\u00a0Dezember\u00a02015\u00a0\ndas\u00a0zweite\u00a0Gentherapeutikum\u00a0in\u00a0Europa\u00a0eine\u00a0Zulassung\u00a0(Fachinfor mation\u00a0Imlygic\u00ae,\u00a0\n2018),\u00a0zwei\u00a0Monate\u00a0nachdem\u00a0die\u00a0FDA\u00a0der\u00a0Zulassung\u00a0zugestimmt\u00a0hat te.\u00a0Das\u00a0Zulas\u2010\nsungsverfahren\u00a0folgte\u00a0den\u00a0regulatorischen\u00a0Anforderungen\u00a0f\u00fcr\u00a0Arz neimittel\u00a0der\u00a0neu\u2010\nartigen\u00a0Therapierichtungen\u00a0( Advanced\u00a0Therapy\u00a0Medicinal\u00a0Products ,\u00a0ATMP)\u00a0nach\u00a0EG\u00a0\nNr.\u00a01394/2007,\u00a0so\u00a0dass\u00a0sowohl\u00a0der \u00a0CHMP\u00a0als\u00a0auch\u00a0der\u00a0Ausschuss\u00a0f \u00fcr\u00a0neuartige\u00a0The\u2010\nrapien\u00a0(Committee\u00a0for\u00a0Advanced\u00a0Therapies ,\u00a0CAT)\u00a0am\u00a0Bewertungsprozess\u00a0beteiligt\u00a0\nwaren.\u00a0 Das\u00a0 Anwendungsgebiet\u00a0 umfasst\u00a0 die\u00a0 Behandlung\u00a0 des\u00a0 nicht\u2010re sezierbaren,\u00a0\nlokal\u00a0oder\u00a0entfernt\u00a0metastasierten\u00a0Melanoms\u00a0im\u00a0Stadium\u00a0IIIB,\u00a0II IC\u00a0und\u00a0IVM1a\u00a0ohne\u00a0\nKnochen\u2010,\u00a0Hirn\u2010,\u00a0Lungen\u2010\u00a0oder\u00a0andere\u00a0viszerale\u00a0Beteiligung\u00a0(EMA ,\u00a02016).\u00a0T\u2010Vec\u00a0ist\u00a0ein\u00a0\ngentechnologisch\u00a0ver\u00e4ndertes,\u00a0abgeschw\u00e4chtes\u00a0Herpes\u2010simplex\u2010Vir us\u00a0Typ\u00a01\u00a0(HSV\u20101),\u00a0\ndas\u00a0die\u00a0codierende\u00a0Sequenz\u00a0f\u00fcr\u00a0den\u00a0humanen\u00a0Granulozyten\u2010\u00a0und\u00a0Ma krophagen\u2010ko\u2010\nloniestimulierenden\u00a0Faktor\u00a0(GM\u2010CSF)\u00a0in\u00a0sich\u00a0tr\u00e4gt\u00a0(Grigg\u00a0et\u00a0al. ,\u00a02016;\u00a0Fachinformati\u2010\non\u00a0Imlygic\u00ae,\u00a02018).\u00a0Angenommen\u00a0wird\u00a0ein\u00a0dualer\u00a0Wirkmechanismus. \u00a0Er\u00a0besteht\u00a0zum\u00a0\neinen\u00a0aus\u00a0einer\u00a0lokalen\u00a0Wirkung\u00a0durch\u00a0Lyse\u00a0der\u00a0Tumorzellen.\u00a0Zum \u00a0anderen\u00a0wird\u00a0die\u00a0\nImmunantwort\u00a0durch\u00a0die\u00a0vermehrte\u00a0Freisetzung\u00a0von\u00a0Tumorantigenen \u00a0forciert.\u00a0Die\u00a0\nExpression\u00a0von\u00a0GM\u2010CSF\u00a0durch\u00a0die\u00a0genetische\u00a0Modifikation\u00a0des\u00a0Vir us\u00a0stimuliert\u00a0zu\u2010\ns\u00e4tzlich\u00a0die\u00a0Reifung\u00a0von\u00a0dendritischen\u00a0Zellen\u00a0und\u00a0induziert\u00a0die \u00a0Immuninfiltration\u00a0des\u00a0\nTumorgewebes\u00a0mit\u00a0CD8\u2010Lymphozyten\u00a0(Ribas\u00a0et\u00a0al.,\u00a02017).\u00a0\nDer\u00a0Wirkstoff\u00a0wird\u00a0in\u00a0Form\u00a0einer\u00a0Injektionssuspension\u00a0in\u00a0den\u00a0Ko nzentrationen\u00a0106\u00a0\nPFU\u00a0(Plaque\u00a0Forming\u00a0Unit ,\u00a0Plaque\u2010bildende\u00a0Einheit)/ml\u00a0und\u00a0108\u00a0PFU/ml\u00a0vertrieben.\u00a0\nDie\u00a0L\u00f6sung\u00a0wird\u00a0f\u00e4cherf\u00f6rmig\u00a0direkt\u00a0in\u00a0die\u00a0L\u00e4sionen\u00a0injiziert,\u00a0 wobei\u00a0pro\u00a0Behand\u2010\nlung\u00a0maximal\u00a04\u00a0ml\u00a0verabreicht\u00a0we rden.\u00a0F\u00fcr\u00a0die\u00a0erste\u00a0Behandlung\u00a0 wird\u00a0die\u00a0Kon\u2010\nzentration\u00a0106\u00a0PFU/ml\u00a0verwendet,\u00a0ab\u00a0der\u00a0zweiten,\u00a0die\u00a0im\u00a0Abstand\u00a0von\u00a0drei\u00a0Wo\u2010\nchen\u00a0folgt,\u00a0werden\u00a0108\u00a0PFU/ml\u00a0verabreicht.\u00a0Anschlie\u00dfende\u00a0Behandlungen\u00a0finden\u00a0\nalle\u00a0zwei\u00a0Wochen\u00a0statt.\u00a0T\u2010Vec\u00a0ist\u00a0trotz\u00a0Modifikationen\u00a0infekti\u00f6 s,\u00a0sodass\u00a0medizini\u2010\nsches\u00a0 Fachpersonal\u00a0 und\u00a0 enge\u00a0 Kontaktpersonen\u00a0 den\u00a0 direkten\u00a0 Kontak t\u00a0 mit\u00a0 den\u00a0\nbehandelten\u00a0L\u00e4sionen\u00a0oder\u00a0K\u00f6rperf l\u00fcssigkeiten\u00a0w\u00e4hrend\u00a0der\u00a0gesam ten\u00a0Behand\u2010\nlungszeit\u00a0und\u00a0bis\u00a0zu\u00a030\u00a0Tage\u00a0nach\u00a0der\u00a0letzten\u00a0Anwendung\u00a0meiden\u00a0 sollten.\u00a0Im\u00a0Rah\u2010\nmen\u00a0des\u00a0Risikomanagements\u00a0stellt \u00a0der\u00a0pU\u00a0Lehrmaterialen\u00a0f\u00fcr\u00a0\u00c4rzt e\u00a0und\u00a0Patienten\u00a0184\u00a0zur\u00a0 Verf\u00fcgung,\u00a0 auch\u00a0 ein\u00a0 Patientenausweis\u00a0 ist\u00a0 in\u00a0 der\u00a0 Zulassung\u00a0 v orgesehen\u00a0\n(AMGEN,\u00a02016a;\u00a0AMGEN,\u00a02016b;\u00a0AMGEN,\u00a02016c;\u00a0EMA,\u00a02016).\u00a0\nHauptevidenz\u00a0zum\u00a0Wirksamkeitsnachweis\u00a0im\u00a0Zulassungsverfahren\u00a0wa r\u00a0die\u00a0multi\u2010\nzentrische,\u00a0 offene,\u00a0 2:1\u2010randomisierte\u00a0 Phase\u2010III\u2010Studie\u00a0 OPTiM\u00a0 (S ponsor:\u00a0 AMGEN,\u00a0\nNCT00769704)\u00a0(EMA,\u00a02016;\u00a0Andtbacka\u00a0et\u00a0al.,\u00a02015).\u00a0Die\u00a0Studie\u00a0fo kussierte\u00a0die\u00a0Effek\u2010\nte\u00a0der\u00a0intral\u00e4sionalen\u00a0Behandlung\u00a0mit\u00a0T\u2010Vec\u00a0und\u00a0subkutan\u00a0angewe ndetem\u00a0GM\u2010CSF\u00a0\nauf\u00a0die\u00a0Ansprechrate\u00a0von\u00a0Patient en\u00a0mit\u00a0nicht\u2010resektablem\u00a0Melano m\u00a0in\u00a0Stadium\u00a0IIIB,\u00a0\nIIIC,\u00a0IVM1a,\u00a0IVM1b,\u00a0IM1c.\u00a0Prim\u00e4rer \u00a0Endpunkt\u00a0war\u00a0die\u00a0dauerhafte\u00a0 Ansprechrate\u00a0( Du\u2010\nrable\u00a0Response\u00a0Rate ,\u00a0DRR),\u00a0definiert\u00a0als\u00a0der\u00a0Anteil\u00a0der\u00a0Patienten\u00a0mit\u00a0einem\u00a0R\u00fcckga ng\u00a0\nder\u00a0Tumorgr\u00f6\u00dfe\u00a0innerhalb\u00a0von\u00a0zw\u00f6lf\u00a0Monaten\u00a0um\u00a0mindestens\u00a050\u00a0%\u00a0u nd\u00a0einem\u00a0\nFortbestehen\u00a0des\u00a0Effekts\u00a0\u00fcber\u00a0mindestens\u00a0sechs\u00a0Monate.\u00a0Die\u00a0Anal yse\u00a0zeigte\u00a0f\u00fcr\u00a0T\u2010\nVec\u00a0mit\u00a016,3\u00a0%\u00a0(KI\u00a0[12,1\u00a0%;\u00a020,5 \u00a0%],\u00a0p\u00a0<\u00a00,05)\u00a0eine\u00a0vielfach\u00a0h\u00f6 here\u00a0DRR\u00a0als\u00a0im\u00a0Ver\u2010\ngleichsarm\u00a0mit\u00a0GM\u2010CSF,\u00a0in\u00a0dem\u00a0der\u00a0Anteil\u00a02,1\u00a0%\u00a0([0\u00a0%;\u00a04,5\u00a0%],\u00a0p \u00a0<\u00a00,05)\u00a0betrug.\u00a0Das\u00a0\nOS\u00a0wurde\u00a0als\u00a0sekund\u00e4rer\u00a0Endpunkt\u00a0erhoben\u00a0und\u00a0betrug\u00a023,3\u00a0Monate \u00a0in\u00a0der\u00a0T\u2010Vec\u2010\nGruppe\u00a0und\u00a018,9\u00a0Monate\u00a0in\u00a0der\u00a0GM\u2010CSF\u2010Gruppe.\u00a0Das\u00a0Ergebnis\u00a0war\u00a0j edoch\u00a0nicht\u00a0\nsignifikant\u00a0(HR:\u00a00,79,\u00a0KI\u00a0[0,62;\u00a01,00],\u00a0p\u00a0=\u00a00,0511).\u00a0Erst\u00a0die\u00a0n achtr\u00e4glich\u00a0durchgef\u00fchrte\u00a0\nSubgruppenanalyse\u00a0f\u00fcr\u00a0die\u00a0Stadien\u00a0IIIA,\u00a0IIIB\u00a0und\u00a0IVM1a\u00a0erreicht e\u00a0statistische\u00a0Rele\u2010\nvanz\u00a0mit\u00a0p\u00a0=\u00a00,0494\u00a0(EMA,\u00a02016).\u00a0Der\u00a0CAT\u00a0\u00e4u\u00dferte\u00a0Bedenken\u00a0zur\u00a0W ahl\u00a0des\u00a0Kompara\u2010\ntors\u00a0GM\u2010CSF,\u00a0der\u00a0bis\u00a0heute\u00a0keine\u00a0zugelassene\u00a0Behandlungsoption\u00a0 im\u00a0Anwendungs\u2010\ngebiet\u00a0darstellt.\u00a0Es\u00a0fehlten\u00a0vergleichende\u00a0Untersuchungen\u00a0mit\u00a0e tablierten\u00a0Therapien,\u00a0\nwas\u00a0die\u00a0Einstufung\u00a0der\u00a0beobachteten\u00a0Effekte\u00a0der\u00a0OPTiM\u2010Studie\u00a0er schwere.\u00a0Auch\u00a0die\u00a0\nRelevanz\u00a0des\u00a0Endpunktes\u00a0DRR\u00a0wurde\u00a0diskutiert.\u00a0Am\u00a0h\u00e4ufigsten\u00a0wur den\u00a0M\u00fcdigkeit\u00a0\n(50,3\u00a0%\u00a0vs.\u00a036,2\u00a0%),\u00a0Sch\u00fcttelfrost\u00a0(48,6\u00a0%\u00a0vs.\u00a08,7\u00a0%),\u00a0Fieber\u00a0( 42,8\u00a0%\u00a0vs.\u00a08,7\u00a0%),\u00a0\u00dcbel\u2010\nkeit\u00a0(35,6\u00a0%\u00a0vs.\u00a019,7\u00a0%),\u00a0grippe\u00e4hnliche\u00a0Symptome\u00a0(30,5\u00a0%\u00a0vs.\u00a01 5,0\u00a0%)\u00a0und\u00a0Erbrechen\u00a0\n(21,2\u00a0%\u00a0vs.\u00a09,4\u00a0%)\u00a0beobachtet.\u00a0Zu\u00a0den\u00a0h\u00e4ufigsten\u00a0UAE\u00a0Grad\u00a03\u00a0ode r\u00a04\u00a0geh\u00f6rten\u00a0Celluli\u2010\ntis\u00a0an\u00a0der\u00a0Einstichstelle\u00a0(2,1\u00a0%\u00a0vs.\u00a00,8\u00a0%),\u00a0Erbrechen\u00a0(1,7\u00a0%\u00a0v s.\u00a00\u00a0%)\u00a0und\u00a0M\u00fcdigkeit\u00a0\n(1,7\u00a0%\u00a0vs.\u00a00\u00a0%)\u00a0(Andtbacka\u00a0et\u00a0al.,\u00a02015).\u00a0Zur\u00a0Evaluation\u00a0der\u00a0Ef fekte\u00a0der\u00a0Behandlung\u00a0\nmit\u00a0T\u2010Vec\u00a0fordert\u00a0der\u00a0europ\u00e4ische\u00a0Beurteilungsbericht,\u00a0dass\u00a0wei tere\u00a0Studien\u00a0durch\u2010\ngef\u00fchrt\u00a0werden\u00a0m\u00fcssen.\u00a0Die\u00a0Europ\u00e4ische\u00a0Kommission\u00a0kn\u00fcpfte\u00a0entsp rechende\u00a0Auf\u2010\nlagen\u00a0an\u00a0die\u00a0Zulassung.\u00a0Dazu\u00a0geh\u00f6ren\u00a0die\u00a0Durchf\u00fchrung\u00a0einer\u00a0Reg isterstudie\u00a0sowie\u00a0\neiner\u00a0Sicherheitsstudie\u00a0( Post\u00a0Authorization\u00a0Safety\u00a0Study,\u00a0 PASS).\u00a0Der\u00a0pU\u00a0wurde\u00a0dazu\u00a0\nverpflichtet,\u00a0 die\u00a0 Ergebnisse\u00a0 der\u00a0 m ultizentrischen,\u00a0 offenen,\u00a0 ein armigen\u00a0 Phase\u2010II\u2010\nStudie\u00a0(Sponsor:\u00a0AMGEN,\u00a0NCT20120325)\u00a0(ClinicalTrials.gov,\u00a02019) \u00a0vorzulegen.\u00a0Hier\u00a0\nwird\u00a0gepr\u00fcft,\u00a0ob\u00a0die\u00a0objektive\u00a0Ansprechrate\u00a0mit\u00a0dem\u00a0Ausgangswer t\u00a0der\u00a0intratumora\u2010\nlen\u00a0CD8+\u2010T\u2010Lymphozyten\u2010Zelldichte\u00a0bei\u00a0Patienten\u00a0mit\u00a0nicht\u2010resez iertem\u00a0Melanom\u00a0im\u00a0\nStadium\u00a0IIIB\u00a0bis\u00a0IVM1c,\u00a0die\u00a0mit\u00a0T\u2010Vec\u00a0behandelt\u00a0wurden,\u00a0korreli eren.\u00a0Auch\u00a0die\u00a0vor\u2010\nl\u00e4ufigen\u00a0Ergebnisse\u00a0der\u00a0multizentrischen,\u00a0randomisierten,\u00a0offen en\u00a0Phase\u2010II\u2010Studie\u00a0\n(Sponsor:\u00a0 AMGEN,\u00a0 NCT20110266)\u00a0 (ClinicalTrials.gov,\u00a0 2018a)\u00a0 zur\u00a0 B eurteilung\u00a0 der\u00a0\nWirksamkeit\u00a0und\u00a0Sicherheit\u00a0der\u00a0neoadjuvanten\u00a0Behandlung\u00a0mit\u00a0T\u2010V ec\u00a0mit\u00a0chirurgi\u2010\nschem\u00a0Eingriff\u00a0vs.\u00a0alleinigem\u00a0chirurgischem\u00a0Eingriff\u00a0bei\u00a0resekt ablem\u00a0Melanom\u00a0im\u00a0185\u00a0Stadium\u00a0IIIB\u00a0bis\u00a0IVM1a\u00a0werden\u00a0ein gefordert.\u00a0Ferner\u00a0sollen\u00a0auch\u00a0 vorl\u00e4ufige\u00a0Resultate\u00a0\nzur\u00a0Wirksamkeit\u00a0der\u00a0multizentrischen\u00a0Phase\u2010III\u2010Studie\u00a0(Sponsor: \u00a0AMGEN\u00a0&\u00a0Merck\u00a0\nSharp\u00a0Dohme,\u00a0NCT20110265)\u00a0(ClinicalTrials.gov,\u00a02018b)\u00a0zur\u00a0Kombi nation\u00a0von\u00a0T\u2010Vec\u00a0\nmit\u00a0Pembrolizumab\u00a0vorgelegt\u00a0werden\u00a0(EMA,\u00a02016).\u00a0\nDie\u00a0Bedeutung\u00a0von\u00a0T\u2010Vec\u00a0f\u00fcr\u00a0die\u00a0deutsche\u00a0Versorgungssituation\u00a0i st\u00a0nicht\u00a0eindeutig\u00a0\nzu\u00a0beurteilen,\u00a0da\u00a0die\u00a0Anzahl\u00a0der\u00a0f\u00fcr\u00a0die\u00a0Therapie\u00a0infrage\u00a0komme nden\u00a0Patienten\u00a0mit\u00a0\netwa\u00a0400\u00a0bis\u00a0700\u00a0vergleichsweise\u00a0klein\u00a0ist\u00a0(G\u2010BA,\u00a02016c).\u00a0Insbe sondere\u00a0die\u00a0Quantifi\u2010\nzierung\u00a0der\u00a0Behandlungseffekte\u00a0ist\u00a0vor\u00a0dem\u00a0Hintergrund\u00a0der\u00a0\u00fcber schaubaren\u00a0Evi\u2010\ndenz\u00a0 eher\u00a0 schwierig.\u00a0 Verschiedene\u00a0 Gremien\u00a0 kritisieren\u00a0 insbesond ere\u00a0 das\u00a0 Fehlen\u00a0\nvergleichender\u00a0Studien\u00a0mit\u00a0etablierten\u00a0Therapien\u00a0des\u00a0Anwendungs gebiets\u00a0(G\u2010BA,\u00a0\n2016c;\u00a0EMA,\u00a02016).\u00a0Allerdings\u00a0warnten\u00a0die\u00a0Experten\u00a0der\u00a0Arbeitsg ruppe\u00a0der\u00a0EMA\u00a0zu\u00a0\nonkologischen\u00a0Themen\u00a0( Scientific\u00a0Advisory\u00a0Group\u00a0Oncology, \u00a0SAG\u2010O)\u00a0explizit\u00a0davor,\u00a0\ndass\u00a0f\u00fcr\u00a0Patienten\u00a0Nachteile\u00a0entstehen\u00a0k\u00f6nnten,\u00a0wenn\u00a0ihnen\u00a0die\u00a0 m\u00f6glicherweise\u00a0\neffektiveren\u00a0Behandlungsm\u00f6glichkeiten\u00a0nicht\u00a0angeboten\u00a0w\u00fcrden\u00a0(E MA,\u00a02016).\u00a0Pati\u2010\nenten\u00a0mit\u00a0schlechtem\u00a0Gesundheitsstatus\u00a0k\u00f6nnten\u00a0hingegen\u00a0eventue ll\u00a0profitieren:\u00a0Im\u00a0\nRahmen\u00a0der\u00a0m\u00fcndlichen\u00a0Anh\u00f6rung\u00a0betonte\u00a0Herr\u00a0Prof.\u00a0Michael\u00a0Weich enthal,\u00a0Vertre\u2010\nter\u00a0der\u00a0Arbeitsgemeinschaft\u00a0Derm atologische\u00a0Onkologie\u00a0(ADO),\u00a0ei ne\u00a0im\u00a0Vergleich\u00a0zur\u00a0\nBRAF\u2010\u00a0und\u00a0Checkpoint\u2010Inhibitoren\u00a0bessere\u00a0Vertr\u00e4glichkeit,\u00a0bedin gt\u00a0durch\u00a0den\u00a0\u00fcber\u2010\nwiegend\u00a0lokalen\u00a0Wirkmechanismus\u00a0(G\u2010BA,\u00a02016b).\u00a0Ein\u00a0Mitglied\u00a0des \u00a0CHMP\u00a0sprach\u00a0\nsich\u00a0ausdr\u00fccklich\u00a0gegen\u00a0die\u00a0Zulassung\u00a0von\u00a0T\u2010Vec\u00a0aus,\u00a0da\u00a0die\u00a0im\u00a0 Zulassungsverfahren\u00a0\nzusammengetragene\u00a0Evidenz\u00a0keinen\u00a0Beleg\u00a0f\u00fcr\u00a0klinisch\u00a0relevante\u00a0E ffekte\u00a0ergebe.\u00a0Der\u00a0\nbeobachtete\u00a0Vorteil\u00a0hinsichtlich\u00a0des\u00a0OS\u00a0beruhe\u00a0auf\u00a0einer\u00a0im\u00a0Stu dienprotokoll\u00a0nicht\u00a0\nvorgesehenen\u00a0 post\u2010hoc\u00a0durchgef\u00fchrten\u00a0Subgruppenanalyse\u00a0(EMA,\u00a02016).\u00a0\nDer\u00a0G\u2010BA\u00a0beendete\u00a0am\u00a015.\u00a0Dezember\u00a02016\u00a0das\u00a0Nutzenbewertungsverf ahren\u00a0nach\u00a0\n\u00a7\u00a035a\u00a0SGB\u00a0V\u00a0zu\u00a0T\u2010Vec\u00a0(G\u2010BA,\u00a02016a).\u00a0Grundlage\u00a0f\u00fcr\u00a0die\u00a0Beurteilu ng\u00a0waren\u00a0die\u00a0Ergeb\u2010\nnisse\u00a0der\u00a0zulassungsrelevanten,\u00a0randomisierten,\u00a0offenen\u00a0Phase\u2010I II\u2010Studie\u00a0OPTiM,\u00a0die\u00a0\nden\u00a0Vergleich\u00a0der\u00a0Wirksamkeit\u00a0von\u00a0T\u2010Vec\u00a0und\u00a0GM\u2010CSF\u00a0untersuchte. \u00a0Der\u00a0G\u2010BA\u00a0hatte\u00a0\nZweifel\u00a0an\u00a0der\u00a0Eignung\u00a0des\u00a0Komparators\u00a0GM\u2010CSF,\u00a0der\u00a0nicht\u00a0Teil\u00a0d er\u00a0definierten\u00a0zVT\u00a0\nwar.\u00a0Somit\u00a0stellte\u00a0der\u00a0G\u2010BA\u00a0 keinen\u00a0Zusatznutzen \u00a0f\u00fcr\u00a0T\u2010Vec\u00a0fest\u00a0(G\u2010BA,\u00a02016c).\u00a0\u00a0\n\u00a0 \u00a0186\u00a0Verf\u00fcgbare\u00a0Therapien \u00a0 (Zusatz\u2010)Nutzen \u00a0 Kosten\u00a0\n\u00a0neuartiger\u00a0\nWirkmechanismus,\u00a0\nausreichende\u00a0Belege\u00a0\nzur\u00a0Effektrelation\u00a0\nfehlen\u00a0\u00a0\u00a0fehlende\u00a0Evidenz:\u00a0kein\u00a0\nVergleich\u00a0mit\u00a0\netablierten\u00a0Therapien\u00a0\noder\u00a0Quantifizierung\u00a0\nder\u00a0Effekte\u00a0m\u00f6glich\u00a0\n\u00a0teilweise\u00a0teurer\u00a0als\u00a0die\u00a0\nzVT\u00a0\nErl\u00e4uterung\u00a0der\u00a0Farben:\u00a0Verf\u00fcgbare\u00a0Therapien:\u00a0rot\u00a0=\u00a0weitere\u00a0The rapieoption,\u00a0gelb\u00a0=\u00a0Subgruppen\u2010Novit\u00e4t,\u00a0gr\u00fcn\u00a0=\u00a0Solist;\u00a0(Zusatz\u2010 )\u00a0\nNutzen:\u00a0rot\u00a0=\u00a0keine\u00a0Verbesserung\u00a0oder\u00a0schlechte\u00a0Nutzen/Schaden\u2010 Relation,\u00a0gelb\u00a0=\u00a0teilweise\u00a0Verbesserungen,\u00a0gr\u00fcn\u00a0=\u00a0Verbesserung\u00a0\nharter\u00a0Endpunkte;\u00a0Kosten:\u00a0rot\u00a0=\u00a0teurer\u00a0als\u00a0bestehende\u00a0Therapien ,\u00a0gelb\u00a0=\u00a0ungef\u00e4hr\u00a0gleich\u00a0bzw.\u00a0teils/teils,\u00a0gr\u00fcn\u00a0=\u00a0g\u00fcnstiger\u00a0als \u00a0\nbestehende\u00a0Therapien\u00a0\nWie\u00a0bewerten\u00a0andere?\u00a0\nBewertung\u00a0nach\u00a0\nFricke\u00a0et\u00a0al.\u00a0atd\u2010Bewertung\u00a0 AMB\u00a0 Prescrire\u00a0 PZ\u00a0\nA\u00a0Umstrittenes\u00a0\nTherapieprinzip\u00a0\u2013\u00a0 \u2013\u00a0 Sprunginnovation\u00a0\nKosten\u00a0\nWirkstoff\u00a0 Behandlungsmodus\u00a0 Behandlungstage\u00a0 Jahrestherapiekosten\u00a0\nzu\u00a0bewertendes\u00a0Arzneimittel \u00a0\u00a0 \u00a0 \u00a0\nTalimogen\u00a0laherparepvec\u00a0 max.\u00a0106\u00a0PFU/mla\u00a0bzw.\u00a0\n108\u00a0PFU/mlb\u00a0\u00a0\n1x\u00a0pro\u00a014\u2010Tage\u2010Zyklusc\u00a0\u00a026\u00a039.159,12\u00a0\u2013\u00a0156.636,48\u00a0\u20ac\u00a0\nzVT\u00a0f\u00fcr\u00a0nicht\u00a0vorbeh andelte\u00a0Patienten\u00a0mi t\u00a0BRAF\u2010V600\u2010Mutation \u00a0 \u00a0\nVemurafenib\u00a0960\u00a0mg\u00a02x\u00a0tgl.\u00a0\u00a0 365\u00a0 77.814,35\u00a0\u20ac\u00a0\n\u00b1\u00a0Cobimetinib\u00a060\u00a0mg\u00a0an\u00a0Tag\u00a01\u00a0\u2013\u00a021d\u00a0\u00a0\n1x\u00a0tgl.\u00a0\u00a0273\u00a0 75.627,76\u00a0\u20ac\u00a0\nDabrafenib\u00a0\u00a0 2\u00a0mg\u00a01x\u00a0tgl.\u00a0\u00a0 365\u00a0 \u00a0\n+\u00a0Trametinib\u00a0 150\u00a0mg\u00a02x\u00a0tgl.\u00a0\u00a0 365\u00a0 131.612,31\u00a0\u20ac\u00a0\nzVT\u00a0f\u00fcr\u00a0nicht\u00a0vorbeh andelte\u00a0Patienten\u00a0mi t\u00a0BRAF\u2010V600\u2010Wildtyp \u00a0 \u00a0\nPembrolizumab\u00a02\u00a0mg/kg\u00a0KG\u00a0alle\u00a03\u00a0Wochen\u00a0\u00a0 17\u00a0 109.987,96\u00a0\u20ac\u00a0\nNivolumab\u00a0 240\u00a0mg\u00a0alle\u00a02\u00a0Wochen\u00a0\u00a0\n1x\u00a0tgl.\u00a0oder\u00a0\u00a0\n480\u00a0mg\u00a0alle\u00a04\u00a0Wochen\u00a01x\u00a0tgl.\u00a026\u00a0\n\u00a0\n13\u00a080.740,40\u00a0\u20ac\u00a0\nzVT\u00a0f\u00fcr\u00a0vorbehandelte\u00a0Patienten \u00a0 \u00a0 \u00a0\nNivolumab\u00a0s.o.\u00a0 s.o.\u00a0 80.740,40\u00a0\u20ac\u00a0\nVemurafenib\u00a0 s.o.\u00a0 s.o.\u00a0 77.814,35\u00a0\u20ac\u00a0\n\u00b1\u00a0Cobimetinib\u00a0 s.o.\u00a0 s.o.\u00a0 75.627,76\u00a0\u20ac\u00a0\nDabrafenib\u00a0\u00a0 150\u00a0mg\u00a02x\u00a0tgl.\u00a0\u00a0 365\u00a0 75.260,81\u00a0\u20ac\u00a0\nDacarbazin\u00a0 200\u00a0\u2013\u00a0250\u00a0mg/m\u00b2\u00a0KOF\u00a0an\u00a0\nTag\u00a01\u00a0\u2013\u00a05d\u00a0oder\u00a0\u00a0\n850\u00a0mg/m\u00b2\u00a0KOF\u00a0an\u00a0Tag\u00a01d\u00a0\u00a085\u00a0\n\u00a0\n17\u00a05.262,69\u00a0\u2013\u00a08.096,25\u00a0\u20ac\u00a0\n\u00a0\n\u00a0\n\u00a0\u00a0 \u00a0 \u00a0\n187\u00a0Wirkstoff\u00a0 Behandlungsmodus\u00a0 Behandlungstage\u00a0 Jahrestherapiekosten\u00a0\nLomustin\u00a0 70\u00a0\u2013\u00a0100\u00a0mg/m\u00b2\u00a0KOF\u00a0alle\u00a0\n6\u00a0Wochen\u00a01x\u00a0tgl.\u00a0\u00a08\u00a0 841,58\u00a0\u2013\u00a0935,09\u00a0\u20ac\u00a0\nIpilimumab\u00a0 3\u00a0mg/kg\u00a0KG\u00a0alle\u00a03\u00a0Wochen\u00a0\u00a0 4\u00a0 78.466,72\u00a0\u20ac\u00a0\nPembrolizumab\u00a0 s.o.\u00a0 s.o.\u00a0 109.987,96\u00a0\u20ac\u00a0\nTrametinib\u00a0 2\u00a0mg\u00a01x\u00a0tgl.\u00a0\u00a0 365\u00a0 56.351,50\u00a0\u20ac\u00a0\nTrametinib\u00a0\u00a0 s.o.\u00a0 s.o.\u00a0 \u00a0\n+\u00a0Dabrafenib\u00a0 s.o.\u00a0 s.o.\u00a0 131.612,31\u00a0\u20ac\u00a0\nNivolumab\u00a0s.o.\u00a0 s.o.\u00a0 \u00a0\n+\u00a0Ipilimumab\u00a0 s.o.\u00a0 s.o.\u00a0 144.759,20\u00a0\u20ac\u00a0\na\u00a0Dosis\u00a0bei\u00a0Erstbehandlung\u00a0\u00a0\nb\u00a0Dosis\u00a0f\u00fcr\u00a0Folgebehandlungen\u00a0\nc\u00a0Der\u00a0zweite\u00a0Zyklus\u00a0beginnt\u00a0abweichend\u00a021\u00a0Tage\u00a0nach\u00a0dem\u00a0ersten\u00a0\nd\u00a028\u2010Tage\u2010Zyklus\u00a0\ne\u00a0Beispielhaft\u00a0f\u00fcr\u00a0eine\u00a0patientenindividuelle\u00a0Therapie\u00a0nach\u00a0Ma\u00dfg abe\u00a0des\u00a0behandelnden\u00a0Arztes\u00a0unter\u00a0Ber\u00fccksichtigung\u00a0des\u00a0Zulas\u2010\nsungsstatus\u00a0der\u00a0jeweiligen\u00a0Vortherapie\u00a0\nVersorgungsanalysen\u00a0\nAus\u00a0datenschutzrechtlichen\u00a0Gr\u00fcnden\u00a0wurde\u00a0bei\u00a0geringer\u00a0Verordnun gspr\u00e4valenz\u00a0\nauf\u00a0eine\u00a0differenzierte\u00a0graphisc he\u00a0Auswertung\u00a0verzichtet.\u00a0Zur\u00a0M arkteinf\u00fchrung\u00a0am\u00a0\n15.\u00a0Juni\u00a02016\u00a0war\u00a0T\u2010Vec\u00a0in\u00a0zwei\u00a0Dosisst\u00e4rken\u00a0106\u00a0PFU/ml\u00a0und\u00a0108\u00a0PFU/ml\u00a0in\u00a0der\u00a0\ndeutschen\u00a0Spezialit\u00e4tentaxe\u00a0gelis tet.\u00a0Der\u00a0damalige\u00a0Apothekenver kaufspreis\u00a0beider\u00a0\nFertigarzneimittel\u00a0betrug\u00a02.949,97\u00a0\u20ac.\u00a0Die\u00a0Preisverhandlungen\u00a0zu m\u00a0Erstattungsbe\u2010\ntrag\u00a0nach\u00a0\u00a7\u00a0130b\u00a0SGB\u00a0V\u00a0wurden\u00a0ma\u00dfgeblich\u00a0durch\u00a0die\u00a0Bewertung\u00a0de s\u00a0G\u2010BA\u00a0ge\u2010\npr\u00e4gt,\u00a0der\u00a0T\u2010Vec\u00a0keinen\u00a0Zusatznutzen\u00a0zuerkannte\u00a0(G\u2010BA,\u00a02016a).\u00a0 Die\u00a0Umsetzung\u00a0\ndes\u00a0ab\u00a013.\u00a0Mai\u00a02017\u00a0g\u00fcltigen\u00a0neu\u00a0formulierten\u00a0\u00a7\u00a0130b\u00a0Abs.\u00a03\u00a0SGB \u00a0V\u00a0stellte\u00a0dabei\u00a0\neinen\u00a0 Streitpunkt\u00a0 zwischen\u00a0 pU\u00a0 und\u00a0 GKV\u2010Spitzenverband\u00a0 dar.\u00a0 Der\u00a0 P aragraph\u00a0\nschreibt\u00a0vor,\u00a0dass\u00a0der\u00a0Erstattungsbetrag\u00a0bei\u00a0einem\u00a0Arzneimittel \u00a0ohne\u00a0Zusatznutzen\u00a0\nnicht\u00a0zu\u00a0h\u00f6heren\u00a0Therapiekosten\u00a0als\u00a0eine\u00a0vom\u00a0G\u2010BA\u00a0definierte\u00a0zV T\u00a0bzw.\u00a0der\u00a0wirt\u2010\nschaftlichsten\u00a0zVT\u00a0f\u00fchren\u00a0\u201esoll\u201c. \u00a0Letztlich\u00a0legte\u00a0die\u00a0zust\u00e4ndig e\u00a0Schiedsstelle\u00a0einen\u00a0\nBetrag\u00a0fest,\u00a0der\u00a0zum\u00a015.\u00a0Oktober\u00a02017\u00a0wirksam\u00a0wurde.\u00a0In\u00a0der\u00a0Fol ge\u00a0sank\u00a0der\u00a0Apo\u2010\nthekenverkaufspreis\u00a0um\u00a0etwa\u00a049\u00a0%\u00a0 (Preise\u00a0aus\u00a0Lauer\u2010Fischer,\u00a0201 9).\u00a0\n\u00a0\nQuellen\u00a0\nAMGEN\u00a0(2016a).\u00a0Imlygic\u00ae\u00a0Lehrmaterial\u00a0f\u00fcr\u00a0\u00c4rzte\u00a02016.\u00a0https://ww w.imlygic\u2010rm.de/x_download.php?id=639,\u00a0letzter\u00a0Zugriff:\u00a0\n20.02.2019.\u00a0\nAMGEN\u00a0(2016b).\u00a0Imlygic\u00ae\u00a0Lehrmaterial\u00a0f\u00fcr\u00a0Patienten\u00a02016.\u00a0https: //www.imlygic\u2010rm.de/x_download.php?id=640,\u00a0letzter\u00a0Zugriff:\u00a0\n20.02.2019.\u00a0\nAMGEN\u00a0(2016c).\u00a0Patientenausweis\u00a0Imlygic\u00ae\u00a02016.\u00a0https://www.imly gic\u2010rm.de/x_download.php?id=638,\u00a0letzter\u00a0Zugriff:\u00a020.2.2019.\u00a0188\u00a0Andtbacka\u00a0RHI,\u00a0Kaufman\u00a0HL,\u00a0Collichio\u00a0F,\u00a0Amatruda,\u00a0T,\u00a0Senzer\u00a0N,\u00a0 Chesney\u00a0\u00a0J\u00a0et\u00a0al.\u00a0(2015).\u00a0Talimogene\u00a0Laherparepvec\u00a0Improves\u00a0\nDurable\u00a0Response\u00a0Rate\u00a0in\u00a0Patients\u00a0With\u00a0Advanced\u00a0Melanoma.\u00a0Journ al\u00a0of\u00a0clinical\u00a0oncology\u00a0:\u00a0official\u00a0journal\u00a0of\u00a0the\u00a0\nAmerican\u00a0Society\u00a0of\u00a0Clinical\u00a0Oncology\u00a033(25).\u00a0\natd\u00a0\u2013\u00a0Arzneimitteldatenbank\u00a0(2016).\u00a0Wirkstoff:\u00a0Talimogen\u00a0laherp arepvec.\u00a0Bewertung.\u00a02016.\u00a0https://www.arznei\u2010telegramm.de/,\u00a0\nletzter\u00a0Zugriff:\u00a028.11.2018.\u00a0\nClinicalTrials.gov\u00a0( 2018a).\u00a0Efficacy\u00a0and\u00a0Safety\u00a0of\u00a0Talimogene\u00a0L aherparepvec\u00a0Neoadjuvant\u00a0Treatment\u00a0Plus\u00a0Surgery\u00a0Versus\u00a0Surgery\u00a0\nAlone\u00a0for\u00a0Melanoma.\u00a0https://clini caltrials.gov/ct2/show/NCT0221 1131,\u00a0letzter\u00a0Zugriff:\u00a021.02.2019.\u00a0\nClinicalTrials.gov\u00a0(201 8b).\u00a0Pembrolizumab\u00a0With\u00a0or\u00a0Without\u00a0Talim ogene\u00a0Laherparepvec\u00a0or\u00a0Talimogene\u00a0Laherparepvec\u00a0Placebo\u00a0in\u00a0\nUnresected\u00a0Melanoma.\u00a0https://clin icaltrials.gov/ct2/show/NCT022 63508,\u00a0letzter\u00a0Zugriff:\u00a021.02.2019.\u00a0\nClinicalTrials.gov\u00a0(201 9).\u00a0Single\u2010arm\u00a0Trial\u00a0to\u00a0Evaluate\u00a0the\u00a0Rol e\u00a0of\u00a0the\u00a0Immune\u00a0Response\u00a0to\u00a0Talimogene\u00a0Laherparepvec\u00a0in\u00a0\nUnresected\u00a0Melanoma\u00a0(TVEC\u2010325).\u00a0https://clinicaltrials.gov/ct2/ show/NCT02366195,\u00a0letzter\u00a0Zugriff:\u00a021.02.2019.\u00a0\nEMA\u00a0\u2013\u00a0European\u00a0Medicines\u00a0Agency\u00a0(2016).\u00a0European\u00a0Public\u00a0Assesse ment\u00a0Report:\u00a0Imlygic\u00ae.\u00a0\nhttps://www.ema.europa.eu/documents/assessment\u2010report/imlygic\u2010e par\u2010public\u2010assessment\u2010report_en.pdf,\u00a0letzter\u00a0\nZugriff:\u00a029.11.2018.\u00a0\nFachinformation\u00a0Imlygic\u00ae\u00a0(2018).\u00a0 Fachinforamtion\u00a0IMLYGIC\u00ae\u00a0106\u00a0/ \u00a0108\u00a0Plaque\u2010bildende\u00a0Einheiten\u00a0(PFU)/ml\u00a0Injektionsl\u00f6sung.\u00a0Stand \u00a0\nder\u00a0Information:\u00a0Juli\u00a02018.\u00a0https://www.fachinfo.de/suche/imlyg ic,\u00a0letzter\u00a0Zugriff:\u00a029.11.2018.\u00a0\nG\u2010BA\u00a0\u2013\u00a0Gemeinsamer\u00a0Bundesausschuss\u00a0(2016a).\u00a0Beschluss\u00a0\u00fcber\u00a0eine \u00a0\u00c4nderung\u00a0der\u00a0Arzneimittel\u2010Richtlinie\u00a0(AM\u2010RL):\u00a0Anlage\u00a0XII\u00a0\u2010\u00a0\nBeschl\u00fcsse\u00a0\u00fcber\u00a0die\u00a0Nutzenbewertung\u00a0von\u00a0Arzneimitteln\u00a0mit\u00a0neuen \u00a0Wirkstoffen\u00a0nach\u00a0\u00a7\u00a035a\u00a0SGB\u00a0V\u00a0\u2013\u00a0Talimogen\u00a0\nlaherparepvec.\u00a02016.\u00a0https://www.g\u2010ba.de/downloads/39\u2010261\u20102799/ 2016\u201012\u201015_AM\u2010RL\u2010XII_Talimogen\u2010\nlaherparepvec_D\u2010237_BAnz.pdf,\u00a0letzter\u00a0Zugriff:\u00a028.11.2018.\u00a0\nG\u2010BA\u00a0\u2013\u00a0Gemeinsamer\u00a0Bundesausschuss\u00a0(2016b).\u00a0M\u00fcndlichen\u00a0Anh\u00f6rung \u00a0gem\u00e4\u00df\u00a05.\u00a0Kapitel\u00a0\u00a7\u00a019\u00a0Abs.\u00a02\u00a0Verfahrensordnung\u00a0des\u00a0\nGemeinsamen\u00a0Bundesausschusses\u00a0zu m\u00a0Wirkstoff\u00a0Talimogen\u00a0laherpare pvec.\u00a02016.\u00a0https://www.g\u2010\nba.de/downloads/91\u20101031\u2010243/2016\u201010\u201024_Wortprotokoll_Talimogen\u2010 laherparepvec.pdf,\u00a0letzter\u00a0Zugriff:\u00a0\n19.12.2018.\u00a0\nG\u2010BA\u00a0\u2013\u00a0Gemeinsamer\u00a0Bundesausschuss\u00a0(2016c).\u00a0Tragende\u00a0Gr\u00fcnde\u00a0zum \u00a0Beschluss\u00a0\u00fcber\u00a0eine\u00a0\u00c4nderung\u00a0d er\u00a0Arzneimittel\u2010Richtlinie\u00a0\n(AM\u2010RL):\u00a0Anlage\u00a0XII\u00a0\u2010\u00a0Beschl\u00fcsse\u00a0\u00fcber\u00a0die\u00a0Nutzenbewertung\u00a0von\u00a0A rzneimitteln\u00a0mit\u00a0neuen\u00a0Wirkstoffen\u00a0nach\u00a0\u00a7\u00a035a\u00a0\nSGB\u00a0V\u00a0\u2013\u00a0Talimogen\u00a0laherparepvec.\u00a02016.\u00a0https://www.g\u2010ba.de/down loads/40\u2010268\u20104103/2016\u201012\u201015_AM\u2010RL\u2010\nXII_Talimogen\u2010laherparepvec_D\u2010237_TrG.pdf,\u00a0letzter\u00a0Zugriff:\u00a028. 11.2018.\u00a0\nGrigg\u00a0C,\u00a0Blake\u00a0Z,\u00a0Gartrell\u00a0R,\u00a0Sa cher\u00a0A,\u00a0Taback\u00a0B,\u00a0Saenger\u00a0Y\u00a0(20 16).\u00a0Talimogene\u00a0laherparepvec\u00a0(T\u2010Vec)\u00a0for\u00a0the\u00a0treatment\u00a0of\u00a0\nmelanoma\u00a0and\u00a0other\u00a0cancers.\u00a0Seminars\u00a0in\u00a0oncology\u00a043(6):\u00a02.\u00a0\nLauer\u2010Fischer\u00a0(2019).\u00a0WEBAPO\u00ae\u00a0Infosystem,\u00a0Lauer\u2010Taxe\u00a0online.\u00a020 19.\u00a0https://webapo\u2010info.lauer\u2010fischer.de/Infosystem/,\u00a0letzter\u00a0\nZugriff:\u00a011.07.2019.\u00a0\nPZ\u00a0\u2013\u00a0Pharmazeutische\u00a0Zeitung\u00a0(2016).\u00a0Arzneistoffe.\u00a0Talimogen\u00a0la herparepvec\u00a0(Imlygic\u00ae).\u00a02016.\u00a0h ttps://www.pharmazeutische\u2010\nzeitung.de/arzneistoffe/daten/2016 /talimogen\u2010laherparepvecimlyg icr862016/,\u00a0letzter\u00a0Zugriff:\u00a028.11.2018.\u00a0\nRibas\u00a0A,\u00a0Dummer\u00a0R,\u00a0Puzanow\u00a0I,\u00a0VaderWalde\u00a0A,\u00a0Andtbacka\u00a0RHI,\u00a0Mich ielin\u00a0O\u00a0et\u00a0al.\u00a0(2017).\u00a0Oncolytic\u00a0Virotherapy\u00a0Promotes\u00a0\nIntratumoral\u00a0T\u00a0Cell\u00a0Infiltration\u00a0and\u00a0Improves\u00a0Anti\u2010PD\u20101\u00a0Immunot herapy.\u00a0Cell\u00a0170(6).\u00a0\nSchwabe\u00a0U,\u00a0Paffrath\u00a0D,\u00a0Ludwig\u00a0W\u2010D,\u00a0Klauber\u00a0J\u00a0(2017).\u00a0Arzneivero rdnungs\u2010Report\u00a02017.\u00a0Berlin,\u00a0Heidelberg:\u00a0Springer.\u00a0\n\u00a0 \u00a0189\u00a0 Tenofoviralafenamid\u00a0(TAF)\u00a04.20\nTAF,\u00a0Elvitegravir,\u00a0Cobicistat\u00a0und\u00a0Emtricitabin\u00a0\nHandelsname:\u00a0Genvoya\u00ae\u00a0 \u00a0 \u00a0 Pharm azeutischer\u00a0Unternehmer:\u00a0\u00a0\nIndikation:\u00a0HIV\u2010Infektion\u00a0 \u00a0 \u00a0 Gilead\u00a0Sciences\u00a0\nATC\u2010Code:\u00a0J05AR18\u00a0 \u00a0 \u00a0 Markteinf\u00fchrung:\u00a0Januar\u00a02016\u00a0\nDarreichungsform:\u00a0Filmtabletten\u00a0 \u00a0 DDD:\u00a01\u00a0Filmtablette\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 \u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 \u25bc \u00a0\n\u00a0\nTAF\u00a0und\u00a0Emtricitabin\u00a0\nHandelsname:\u00a0Descovy\u00ae\u00a0 \u00a0 \u00a0 Pharmazeutischer\u00a0Unternehmer:\u00a0\u00a0\nIndikation:\u00a0HIV\u2010Infektion\u00a0 \u00a0 \u00a0 Gilead\u00a0Sciences\u00a0\nATC\u2010Code:\u00a0J05AR17\u00a0 \u00a0 \u00a0 Markteinf\u00fchrung:\u00a0Mai\u00a02016\u00a0\nDarreichungsform:\u00a0Filmtabletten\u00a0 \u00a0 DDD:\u00a01\u00a0Filmtablette\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 \u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 \u25bc  \n\u00a0\nTAF,\u00a0Emtricitabin\u00a0und\u00a0Rilpivirin\u00a0\u00a0\nHandelsname:\u00a0Odefsey\u00ae\u00a0 \u00a0 \u00a0 Pharmazeutischer\u00a0Unternehmer:\u00a0\u00a0\nIndikation:\u00a0HIV\u2010Infektion\u00a0 \u00a0 \u00a0 Gilead\u00a0Sciences\u00a0\nATC\u2010Code:\u00a0J05AR19\u00a0 \u00a0 \u00a0 Markteinf\u00fchrung:\u00a0Juli\u00a02016\u00a0\nDarreichungsform:\u00a0Filmtabletten\u00a0 \u00a0 DDD:\u00a01\u00a0Filmtablette\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 \u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 \u25bc  \nBewertung \u00a0\nTenofoviralafenamid\u00a0(TAF)\u00a0ist\u00a0ein\u00a0nukleotidischer\u00a0Hemmstoff\u00a0der \u00a0Reversen\u00a0Tran\u2010\nskriptase\u00a0(NRTI,\u00a0Nukleosidischer/Nukleotidischer\u00a0Reverse\u00a0Transk riptase\u00a0Inhibitor)\u00a0\ndes\u00a0HI\u2010Virus\u00a0( Human\u00a0Immunodeficiency\u00a0Virus ,\u00a0HIV)\u00a0und\u00a0zur\u00a0Behandlung\u00a0der\u00a0HIV\u2010\nInfektion\u00a0europaweit\u00a0zugelassen.\u00a0In\u00a0Deutschland\u00a0ist\u00a0TAF\u00a0in\u00a0Form \u00a0verschiedener\u00a0\nKombinationspr\u00e4parate\u00a0erh\u00e4ltlich:\u00a0als\u00a0Genvoya \u00ae\u00a0mit\u00a0Elvitegravir,\u00a0Cobicistat\u00a0und\u00a0\nEmtricitabin\u00a0seit\u00a0Januar\u00a02016,\u00a0als\u00a0Descovy \u00ae\u00a0zusammen\u00a0mit\u00a0Emtricitabin\u00a0seit\u00a0Mai\u00a0\n2016\u00a0und\u00a0als\u00a0Odefsey \u00ae\u00a0mit\u00a0Rilpivirin\u00a0und\u00a0Emtricitabin\u00a0seit\u00a0Juli\u00a02016.\u00a0TAF\u00a0stellt\u00a0ein e\u00a0\nWeiterentwicklung\u00a0des\u00a0bereits\u00a0bekannten\u00a0antiretroviralen\u00a0Wirkst offs\u00a0Tenofovir\u2010\ndisoproxil\u00a0(TDF)\u00a0dar.\u00a0Beide\u00a0sind\u00a0 Prodrugs\u00a0von\u00a0Tenofovir,\u00a0das\u00a0nach\u00a0intrazellul\u00e4rer\u00a0\nPhosphorylierung\u00a0als\u00a0Antimetabolit\u00a0ins\u00a0virale\u00a0Erbgut\u00a0eingebaut\u00a0 wird\u00a0und\u00a0die\u00a0Syn\u2010\nthese\u00a0neuer\u00a0Viren\u00a0verhindert\u00a0(Ray\u00a0et\u00a0al.,\u00a02016).\u00a0Aufgrund\u00a0seine r\u00a0h\u00f6heren\u00a0Estersta\u2010\nbilit\u00e4t\u00a0unterliegt\u00a0TAF\u00a0einer\u00a0anderen\u00a0Pharmakokinetik\u00a0als\u00a0TDF\u00a0un d\u00a0wird\u00a0deutlich\u00a0\nniedriger\u00a0dosiert\u00a0als\u00a0sein\u00a0Vorg\u00e4nger.\u00a0\nDie\u00a0HIV\u2010Infektion\u00a0wird\u00a0\u00fcblicherweise\u00a0mit\u00a0drei\u00a0verschiedenen\u00a0Wir kstoffen\u00a0thera\u2010\npiert,\u00a0wobei\u00a0zwei\u00a0NRTI\u00a0als\u00a0 backbone \u00a0des\u00a0Therapieregimes\u00a0mit\u00a0einem\u00a0dritten\u00a0Part\u2010\nner\u00a0aus\u00a0einer\u00a0anderen\u00a0Gruppe,\u00a0z.B.\u00a0einem\u00a0Integraseinhibitor\u00a0ode r\u00a0einem\u00a0Nicht\u2010\nnukleosidischen\u00a0Reverse\u2010Transkriptase\u2010Inhibitor\u00a0(NNRTI),\u00a0kombin iert\u00a0werden.\u00a0190\u00a0Die\u00a0drei\u00a0Kombinationspr\u00e4parate\u00a0mit\u00a0TAF\u00a0d\u00fcrfen\u00a0nur\u00a0bei\u00a0Erwachsen en\u00a0oder\u00a0Jugend\u2010\nlichen\u00a0ab\u00a0einem\u00a0Alter\u00a0von\u00a0zw\u00f6lf\u00a0Jahren\u00a0und\u00a0mindestens\u00a035\u00a0kg\u00a0KG\u00a0 angewendet\u00a0\nwerden.\u00a0Lediglich\u00a0Genvoya \u00ae\u00a0darf\u00a0im\u00a0Einzelfall\u00a0bereits\u00a0Kindern\u00a0ab\u00a0einem\u00a0Alter\u00a0von\u00a0\nsechs\u00a0Jahren\u00a0und\u00a0mindestens\u00a025\u00a0kg\u00a0KG\u00a0verabreicht\u00a0werden,\u00a0sofern \u00a0andere\u00a0Arznei\u2010\nmittel\u00a0zur\u00a0Behandlung\u00a0ungeeignet\u00a0sind.\u00a0Descovy\u00ae\u00a0als\u00a0reines\u00a0 backbone \u00a0aus\u00a0TAF/\u00a0\nEmtricitabin\u00a0muss\u00a0mit\u00a0einem\u00a0weiteren\u00a0antiretroviral\u00a0wirksamen\u00a0A rzneimittel\u00a0kom\u2010\nbiniert\u00a0werden.\u00a0Da\u00a0in\u00a0Abh\u00e4ngigkeit\u00a0von\u00a0der\u00a0Art\u00a0des\u00a0dritten\u00a0Wirk stoffs\u00a0die\u00a0Dosie\u2010\nrung\u00a0von\u00a0TAF\u00a0anzupassen\u00a0ist,\u00a0exist ieren\u00a0zwei\u00a0Descovy\u00ae\u2010Pr\u00e4parate \u00a0mit\u00a0entweder\u00a0\n10\u00a0mg\u00a0oder\u00a025\u00a0mg\u00a0TAF\u00a0und\u00a0200\u00a0mg\u00a0Emtricitabin.\u00a0Die\u00a0Einnahme\u00a0der\u00a0 Filmtabletten\u00a0\nerfolgt\u00a0 einmal\u00a0 t\u00e4glich\u00a0 zur\u00a0 gleichen\u00a0 Uhrzeit.\u00a0 Die\u00a0 Einnahme\u00a0 zusam men\u00a0 mit\u00a0 einer\u00a0\nMahlzeit\u00a0ist\u00a0erforderlich,\u00a0falls\u00a0das\u00a0Arzneimittel\u00a0mehr\u00a0als\u00a0nur\u00a0 zwei\u00a0Wirkstoffe\u00a0enth\u00e4lt.\u00a0\nOdefsey\u00ae\u00a0darf\u00a0ebenso\u00a0wie\u00a0andere\u00a0Rilpivirin\u2010haltige\u00a0Arzneimittel \u00a0nur\u00a0angewendet\u00a0\nwerden,\u00a0wenn\u00a0die\u00a0Viruslast\u00a0bei\u00a0Therapiebeginn\u00a0den\u00a0Wert\u00a0von\u00a0100. 000\u00a0Kopien/ml\u00a0\nnicht\u00a0\u00fcberschreitet.\u00a0Eventuell\u00a0vorliegende\u00a0Resistenzen\u00a0gegen\u00a0ei nzelne\u00a0Wirkstoffe\u00a0\nsind\u00a0 vor\u00a0 Therapiebeginn\u00a0 zu\u00a0 ber\u00fccksichtigen\u00a0 (Fachinformation\u00a0 Des covy\u00ae,\u00a0 2017;\u00a0\nFachinformation\u00a0Genvoya\u00ae,\u00a02017; \u00a0Fachinformation\u00a0Odefsey\u00ae,\u00a02018) .\u00a0\nDie\u00a0Zulassung\u00a0von\u00a0TAF\u00a0in\u00a0Form\u00a0unterschiedlicher\u00a0Kombinationsarz neimittel\u00a0basiert\u00a0\nauf\u00a0mehreren\u00a0klinischen\u00a0Studien,\u00a0die\u00a0alle\u00a0herstellerfinanziert\u00a0 durchgef\u00fchrt\u00a0worden\u00a0\nsind.\u00a0 Insbesondere\u00a0 die\u00a0 multizentrischen,\u00a0 doppelblinden,\u00a0 1:1\u2010ran domisierten\u00a0 und\u00a0\naktiv\u00a0kontrollierten\u00a0Phase\u2010III\u2010Z ulassungsstudien\u00a0GS\u2010US\u2010292\u20100104 \u00a0und\u00a0\u20100111\u00a0(Sponsor:\u00a0\nGilead\u00a0Sciences)\u00a0sind\u00a0von\u00a0Interesse,\u00a0da\u00a0hier\u00a0TAF\u00a0direkt\u00a0gegen\u00fcb er\u00a0einer\u00a0Kontroll\u2010\ngruppe\u00a0getestet\u00a0wurde,\u00a0die\u00a0stattdessen\u00a0TDF\u00a0bekam,\u00a0w\u00e4hrend\u00a0die\u00a0\u00fc brigen\u00a0drei\u00a0\nBestandteile\u00a0der\u00a0antiretroviralen\u00a0Therapie\u00a0identisch\u00a0waren.\u00a0Das \u00a0Ergebnis\u00a0dieser\u00a0\nStudien\u00a0 an\u00a0 1.744\u00a0 therapienaiven\u00a0 Erwachsenen,\u00a0 deren\u00a0 prim\u00e4rer\u00a0 End punkt\u00a0 das\u00a0\nvirologische\u00a0Ansprechen\u00a0nach\u00a0einer\u00a0Anwendungsdauer\u00a0von\u00a048\u00a0Woche n\u00a0war,\u00a0ist\u00a0die\u00a0\nDemonstration\u00a0der\u00a0Nicht\u2010Unterlegenheit\u00a0(92\u00a0%\u00a0vs.\u00a090\u00a0%\u00a0in\u00a0der\u00a0Ko ntrollgruppe).\u00a0\nEine\u00a0\u00dcberlegenheit\u00a0der\u00a0neuen\u00a0Subs tanz\u00a0ist\u00a0nicht\u00a0belegt\u00a0(Sax\u00a0et\u00a0 al.,\u00a02015).\u00a0\nDer\u00a0G\u2010BA\u00a0sieht\u00a0f\u00fcr\u00a0keine\u00a0der\u00a0Patientengruppen\u00a0Vorteile\u00a0in\u00a0der\u00a0A nwendung\u00a0der\u00a0neuen\u00a0\nArzneimittel.\u00a0Alle\u00a0drei\u00a0TAF\u2010haltigen\u00a0Arzneimittel\u00a0weisen\u00a0nach\u00a0A uffassung\u00a0der\u00a0Beh\u00f6r\u2010\nde\u00a0keinen\u00a0Zusatznutzen\u00a0 auf.\u00a0Insbesondere\u00a0durch\u00a0die\u00a0mangelnde\u00a0Umsetzung\u00a0der\u00a0zVT\u00a0\nin\u00a0den\u00a0klinischen\u00a0Studien\u00a0sei\u00a0eine\u00a0Bewertung\u00a0nur\u00a0auf\u00a0relativ\u00a0ge ringer\u00a0Datenlage\u00a0m\u00f6g\u2010\nlich.\u00a0Die\u00a0Studien,\u00a0die\u00a0als\u00a0Komparator\u00a0eine\u00a0Kombination\u00a0aus\u00a0Elvi tegravir,\u00a0Cobicistat,\u00a0\nEmtricitabin\u00a0und\u00a0TDF\u00a0enthalten,\u00a0sind\u00a0nach\u00a0Auffassung\u00a0des\u00a0G\u2010BA\u00a0n icht\u00a0geeignet,\u00a0einen\u00a0\nZusatznutzen\u00a0abzuleiten,\u00a0da\u00a0ther apienaiven\u00a0Erwachsenen\u00a0in\u00a0der\u00a0v ollst\u00e4ndigen\u00a0zVT\u00a0\nauch\u00a0Efavirenz,\u00a0Rilpivirin\u00a0oder\u00a0 Dolutegravir\u00a0h\u00e4tte\u00a0angeboten\u00a0we rden\u00a0m\u00fcssen.\u00a0Es\u00a0sei\u00a0\nnicht\u00a0ausreichend,\u00a0TDF\u00a0gegen\u00a0TAF\u00a0auszutauschen\u00a0und\u00a0daraus\u00a0einen \u00a0etwaigen\u00a0Zusatz\u2010\nnutzen\u00a0abzuleiten\u00a0(G\u2010BA,\u00a02016a;\u00a0G\u2010BA,\u00a02016b;\u00a0G\u2010BA,\u00a02017).\u00a0\n\u00a0\u00a0191\u00a0TAF\u00a0mit\u00a0Elvitegravir,\u00a0Cobicistat\u00a0und\u00a0Emtricitabin\u00a0\u00a0\nVerf\u00fcgbare\u00a0Therapien \u00a0 (Zusatz\u2010)Nutzen \u00a0 Kosten\u00a0\n\u00a0\nweiterer\u00a0NRTI\u00a0zur\u00a0\nBehandlung\u00a0von\u00a0HIV\u2010\nInfektionen\u00a0\u00a0f\u00fcr\u00a0keine\u00a0TAF\u2010Kombination\u00a0\nbelegt\u00a0\u00a0\u00a0\nu.U.\u00a0teurer\u00a0als\u00a0zVT,\u00a0die\u00a0\nteilweise\u00a0generisch\u00a0\nerh\u00e4ltlich\u00a0ist\u00a0\nErl\u00e4uterung\u00a0der\u00a0Farben:\u00a0Verf\u00fcgbare\u00a0Therapien:\u00a0rot\u00a0=\u00a0weitere\u00a0The rapieoption,\u00a0gelb\u00a0=\u00a0Subgruppen\u2010Novit\u00e4t,\u00a0gr\u00fcn\u00a0=\u00a0Solist;\u00a0(Zusatz\u2010 )\u00a0\nNutzen:\u00a0rot\u00a0=\u00a0keine\u00a0Verbesserung\u00a0oder\u00a0schlechte\u00a0Nutzen/Schaden\u2010 Relation,\u00a0gelb\u00a0=\u00a0teilweise\u00a0Verbesserungen,\u00a0gr\u00fcn\u00a0=\u00a0Verbesserung\u00a0\nharter\u00a0Endpunkte;\u00a0Kosten:\u00a0rot\u00a0=\u00a0teurer\u00a0als\u00a0bestehende\u00a0Therapien ,\u00a0gelb\u00a0=\u00a0ungef\u00e4hr\u00a0gleich\u00a0bzw.\u00a0teils/teils,\u00a0gr\u00fcn\u00a0=\u00a0g\u00fcnstiger\u00a0als \u00a0\nbestehende\u00a0Therapien\u00a0\nTAF\u00a0mit\u00a0Emtricitabin\u00a0\nVerf\u00fcgbare\u00a0Therapien \u00a0 (Zusatz\u2010)Nutzen \u00a0 Kosten\u00a0\n\u00a0\nweiterer\u00a0NRTI\u00a0zur\u00a0\nBehandlung\u00a0von\u00a0HIV\u2010\nInfektionen\u00a0\u00a0f\u00fcr\u00a0keine\u00a0TAF\u2010Kombination\u00a0\nbelegt\u00a0\u00a0\u00a0\nteurer\u00a0als\u00a0zVT\u00a0\nTAF\u00a0mit\u00a0Emtricitabin\u00a0und\u00a0Rilpivirin\u00a0\nVerf\u00fcgbare\u00a0Therapien \u00a0 (Zusatz\u2010)Nutzen \u00a0 Kosten\u00a0\n\u00a0\nweiterer\u00a0NRTI\u00a0zur\u00a0\nBehandlung\u00a0von\u00a0HIV\u2010\nInfektionen\u00a0\u00a0f\u00fcr\u00a0keine\u00a0TAF\u2010Kombination\u00a0\nbelegt\u00a0\u00a0\u00a0\nu.U.\u00a0teurer\u00a0als\u00a0zVT,\u00a0die\u00a0\nteilweise\u00a0generisch\u00a0\nerh\u00e4ltlich\u00a0ist\u00a0\n\u00a0\nWie\u00a0bewerten\u00a0andere?\u00a0\nBewertung\u00a0nach\u00a0\nFricke\u00a0et\u00a0al.\u00a0a\u2010t\u2010Bewertung\u00a0 AMB\u00a0 Prescrire\u00a0 PZ\u00a0\nB\u00a0 \u2013\u00a0 \u2013\u00a0 Nothing\u00a0new\u00a0 \u2013\u00a0\n\u00a0\n\u00a0\u00a0\n192\u00a0Kosten\u00a0\nWirkstoff\u00a0 Behandlungsmodus\u00a0 Behandlungstage\u00a0 Jahrestherapiekosten\u00a0\nzu\u00a0bewertende\u00a0TAF\u2010haltige\u00a0Arzneimittel \u00a0\na)\u00a0Elvitegravir/Cobicistat/Em\u2010\u00a0\ntricitabin/TAF\u00a0150/150/200/10\u00a0mg\u00a0\n1x\u00a0tgl.\u00a0\u00a0365\u00a0 13.950,30\u00a0\u20ac\u00a0\nund\u00a0 \u00a0 \u00a0 \u00a0\nb)\u00a0Emtricitabin/Rilpivirin/TAF1\u00a0200/25/25\u00a0mg\u00a01x\u00a0tgl.\u00a0 365\u00a0 14.293,40\u00a0\u20ac\u00a0\nund\u00a0 \u00a0 \u00a0 \u00a0\nc)\u00a0Emtricitabin/TAF2\u00a0 200/10\u00a0mg\u00a0oder\u00a0\n200/25\u00a0mg\u00a01x\u00a0tgl.\u00a0365\u00a0 7.821,95\u00a0\u20ac\u00a0\nzu\u00a0a)\u00a0zVT\u00a0nicht\u00a0vorbehandelte\u00a0HIV\u20101\u00a0infizierte\u00a0Kinder\u00a0im\u00a0Alter\u00a0 von\u00a0>=6\u00a0bis\u00a0<12\u00a0Jahren \u00a0\nDolutegravir\u00a0 35\u00a0mg\u00a01x\u00a0tgl.\u00a0 365\u00a0 \u00a0\n\u00a0\u00a0\u00a0+\u00a0Abacavir/Lamivudin\u00a0 300/600\u00a0mg\u00a01x\u00a0tgl.\u00a0 365\u00a0 8.362,15\u00a0\u20ac\u00a0\nDolutegravir\u00a0 s.o.\u00a0 s.o.\u00a0\u00a0\n\u00a0\u00a0\u00a0+\u00a0Abacavir\u00a0 300\u00a0mg\u00a02x\u00a0tgl.\u00a0 365\u00a0\u00a0\n\u00a0\u00a0\u00a0+\u00a0Emtricitabin\u00a0 200\u00a0mg\u00a01x\u00a0tgl.\u00a0 365\u00a0 14.099,95\u00a0\u20ac\u00a0\nAtazanavir\u00a0 200\u00a0mg\u00a01x\u00a0tgl.\u00a0 365\u00a0 \u00a0\n\u00a0\u00a0\u00a0+\u00a0Ritonavir\u00a0 100\u00a0mg\u00a01x\u00a0tgl.\u00a0 365\u00a0 \u00a0\n\u00a0\u00a0\u00a0+\u00a0Abacavir\u00a0 s.o.\u00a0 s.o.\u00a0 \u00a0\n\u00a0\u00a0\u00a0+\u00a0Lamivudin\u00a0 300\u00a0mg\u00a01x\u00a0tgl.\u00a0 365\u00a0 12.858,95\u00a0\u20ac\u00a0\nAtazanavir\u00a0 s.o.\u00a0 s.o.\u00a0 \u00a0\n\u00a0\u00a0\u00a0+\u00a0Ritonavir\u00a0 s.o.\u00a0 s.o.\u00a0 \u00a0\n\u00a0\u00a0\u00a0+\u00a0Abacavir\u00a0 s.o.\u00a0 s.o.\u00a0 \u00a0\n\u00a0\u00a0\u00a0+\u00a0Emtricitabin\u00a0 s.o.\u00a0 s.o.\u00a0 13.990,45\u00a0\u20ac\u00a0\nzu\u00a0a)\u00a0zVT\u00a0vorbehandelte\u00a0HIV\u20101\u00a0infizierte\u00a0Kinder\u00a0im\u00a0Alter\u00a0von\u00a0>= 6\u00a0bis\u00a0<12\u00a0Jahren \u00a0\nEfavirenz\u00a0 350\u00a0mg\u00a01x\u00a0tgl.\u00a0 365\u00a0 \u00a0\n\u00a0\u00a0\u00a0+\u00a0Lamivudin/Zidovudin\u00a0 150/300\u00a0mg\u00a02x\u00a0tgl.\u00a0 365\u00a0 7.650,40\u00a0\u20ac\u00a0\nRaltegravir\u00a0 400\u00a0mg\u00a02x\u00a0tgl.\u00a0 365\u00a0 \u00a0\n\u00a0\u00a0\u00a0+\u00a0Abacavir\u00a0 s.o.\u00a0 s.o.\u00a0 \u00a0\n\u00a0\u00a0\u00a0+\u00a0TDF\u00a0 204\u00a0mg\u00a01x\u00a0tgl.\u00a0 365\u00a0 20.144,35\u00a0\u20ac\u00a0\nzu\u00a0a+b)\u00a0zVT\u00a0weitere\u00a0Patientengruppen3\u00a0\nAbacavir\u00a0 s.o.\u00a0 s.o.\u00a0 4.241,30\u00a0\u20ac\u00a0\nAbacavir/Lamivudin\u00a0 600/300\u00a0mg\u00a01x\u00a0tgl.\u00a0 365\u00a0 6.905,80\u00a0\u20ac\u00a0\n\u00b1\u00a0Efavirenz\u00a0 600\u00a0mg\u00a01x\u00a0tgl.\u00a0 365\u00a0 9.511,90\u00a0\u20ac\u00a0\nDolutegravir\u00a0 50\u00a0mg\u00a01x\u00a0tgl.\u00a0 365\u00a0 8.657,80\u00a0\u20ac\u00a0\nDolutegravir/Abacavir/\u00a0\nLamivudin\u00a050/600/300\u00a0mg\u00a0\u00a0\n1x\u00a0tgl.\u00a0365\u00a0 14.326,25\u00a0\u20ac\u00a0\nEfavirenz\u00a0 600\u00a0mg\u00a01x\u00a0tgl.\u00a0 365\u00a0 2.606,10\u00a0\u20ac\u00a0193\u00a0Efavirenz/Emtricitabin/TDF\u00a0600/200/245\u00a0mg\u00a0\u00a0\n1x\u00a0tgl.\u00a0365\u00a0 8.862,20\u00a0\u20ac\u00a0\nElvitegravir/Cobicistat/Emtrici\u2010\ntabin/TDF\u00a0150/150/200/245\u00a0mg\u00a0\n1x\u00a0tgl.\u00a0365\u00a0 13.950,30\u00a0\u20ac\u00a0\nEmtricitabin\u00a0 200\u00a0mg\u00a01x\u00a0tgl.\u00a0 365\u00a0 3.679,20\u00a0\u20ac\u00a0\nEmtricitabin/TDF\u00a0 200/245\u00a0mg\u00a01x\u00a0tgl.\u00a0 365\u00a0 609,55\u00a0\u20ac\u00a0\nLamivudin\u00a0 300\u00a0mg\u00a01x\u00a0tgl.\u00a0 365\u00a0 2.547,70\u00a0\u20ac\u00a0\nMaraviroc\u00a0 300\u00a0mg\u00a02x\u00a0tgl.\u00a0 365\u00a0 13.052,40\u00a0\u20ac\u00a0\nRaltegravir\u00a0 400\u00a0mg\u00a02x\u00a0tgl.\u00a0 365\u00a0 10.519,30\u00a0\u20ac\u00a0\nRilpivirin/Emtricitabin/TDF\u00a0200/25/245\u00a0mg\u00a0\u00a0\n1x\u00a0tgl.\u00a0365\u00a0 14.636,50\u00a0\u20ac\u00a0\nRilpivirin\u00a0 25\u00a0mg\u00a01x\u00a0tgl.\u00a0 365\u00a0 4.551,55\u00a0\u20ac\u00a0\nTDF\u00a0 245\u00a0mg\u00a01x\u00a0tgl.\u00a0 365\u00a0 547,50\u00a0\u20ac\u00a0\nzu\u00a0c)\u00a0zVT\u00a0 \u00a0 \u00a0 \u00a0\nEmtricitabin/TDF\u00a0 s.o.\u00a0 s.o.\u00a0 s.o.\u00a0\nAbacavir/Lamivudin\u00a0 s.o.\u00a0 s.o.\u00a0 s.o.\u00a0\n1\u00a0zVT\u00a0weitere\u00a0Patientengruppen\u00a0zu\u00a0b)\u00a0\n2\u00a0zVT\u00a0weitere\u00a0Patientengruppen\u00a0zu\u00a0a)\u00a0und\u00a0b)\u00a0\n3\u00a0Der\u00a0\u00dcbersichtlichkeit\u00a0halber\u00a0werden\u00a0die\u00a0Kosten,\u00a0die\u00a0Behandlungs dauer\u00a0und\u00a0der\u00a0Verbrauch\u00a0f\u00fcr\u00a0das\u00a0zu\u00a0bewertende\u00a0Arzneimittel\u00a0\n\u00a0\u00a0\u00a0und\u00a0die\u00a0Wirkstoffe\u00a0der\u00a0zVT\u00a0nicht\u00a0nach\u00a0den\u00a0weiteren\u00a0vier\u00a0Pati entengruppen\u00a0unterschieden,\u00a0sondern\u00a0zusammenfassend\u00a0aufgelistet .\u00a0\n\u00a0\u00a0\u00a0\u2010\u00a0nicht\u00a0antiretroviral\u00a0vorbehandelte\u00a0(therapienaive)\u00a0Erwachs ene\u00a0\n\u00a0\u00a0\u00a0\u2010\u00a0nicht\u00a0antiretroviral\u00a0vorbehandelte\u00a0(therapienaive)\u00a0Jugendl iche\u00a0ab\u00a012\u00a0Jahren\u00a0\n\u00a0\u00a0\u00a0\u2010\u00a0antiretroviral\u00a0vorbehandelte\u00a0(therapieerfahrene)\u00a0Erwachsen e\u00a0\n\u00a0\u00a0\u00a0\u2010\u00a0antiretroviral\u00a0vorbehandelte\u00a0(therapieerfahrene)\u00a0Jugendlic he\u00a0ab\u00a012\u00a0Jahren\u00a0 \u00a0194\u00a0Versorgungsanalysen\u00a0\nDie\u00a0 Viererkombination\u00a0 Tenofovira lafenamid/Elvitegravir/Cobicist at/Emtricitabin\u00a0 wird\u00a0\nseit\u00a0ihrer\u00a0Markteinf\u00fchrung\u00a0Anfang\u00a02016\u00a0immer\u00a0h\u00e4ufiger\u00a0verordnet .\u00a0Die\u00a0Anzahl\u00a0an\u00a0\nDDD\u00a0lag\u00a0Mitte\u00a02016\u00a0noch\u00a0bei\u00a0rund\u00a030.000\u00a0und\u00a0hat\u00a0sich\u00a0bis\u00a0Ende\u00a02 017\u00a0auf\u00a0mehr\u00a0als\u00a0\n50.000\u00a0pro\u00a0Monat\u00a0gesteigert.\u00a0Die\u00a0Kosten\u00a0f\u00fcr\u00a0das\u00a0Kombinationspr\u00e4 parat\u00a0liegen\u00a0\ninzwischen\u00a0bei\u00a0rund\u00a02.000.000 \u00a0\u20ac\u00a0monatlich.\u00a0\nAbbildung\u00a04.17:\u00a0Verordnete\u00a0Tagesdosen\u00a0(DDD)\u00a0und\u00a0Bruttoums\u00e4tze\u00a0v on\u00a0Tenofo\u2010\nviralafenamid/Elvitegravir/Cobicistat/Emtricitabin\u00a0nach\u00a0Monaten \u00a0(2016\u00a0\u2013\u00a02017)\u00a0\n\u00a0\n\u00a0 \u00a0\n195\u00a0Die\u00a0Kombination\u00a0aus\u00a0TAF\u00a0und\u00a0Emtricitabin\u00a0konnte\u00a0seit\u00a0ihrer\u00a0Einf \u00fchrung\u00a0Anfang\u00a0\n2016\u00a0schnell\u00a0Marktanteile\u00a0gewinnen\u00a0und\u00a0lag\u00a0Ende\u00a02016\u00a0bei\u00a0rund\u00a05 0.000\u00a0DDD\u00a0mo\u2010\nnatlich.\u00a0 Im\u00a0 Januar\u00a0 2017\u00a0 wurde\u00a0 mit\u00a0 66.120\u00a0 DDD\u00a0 ein\u00a0 Spitzenwert\u00a0 vo n\u00a0 \u00fcber\u00a0\n1.800.000\u00a0\u20ac\u00a0erreicht.\u00a0Monatlich\u00a0werden\u00a0inzwischen\u00a0regelhaft\u00a0zwi schen\u00a050.000\u00a0und\u00a0\n70.000\u00a0DDD\u00a0verschrieben.\u00a0\nAbbildung\u00a04.18:\u00a0Verordnete\u00a0Tages dosen\u00a0(DDD)\u00a0und\u00a0Bruttoums\u00e4tze\u00a0v on\u00a0\u00a0\nTenofoviralafenamid/Emtricitabin\u00a0nach\u00a0Monaten\u00a0(2016\u00a0\u2013\u00a02017)\u00a0\n\u00a0\n\u00a0\u00a0\n196\u00a0Die\u00a0 erst\u00a0 seit\u00a0 Mitte\u00a0 2016\u00a0 verf\u00fcgbare\u00a0 Kombination\u00a0 aus\u00a0 Tenofoviral afena\u2010\nmid/Emtricitabin/Rilpivirin\u00a0verzeichnete\u00a0seit\u00a0ihrer\u00a0Einf\u00fchrung\u00a0 gro\u00dfe\u00a0Zuw\u00e4chse\u00a0in\u00a0\nder\u00a0Verordnungsh\u00e4ufigkeit.\u00a0Ende\u00a02017\u00a0wurde\u00a0der\u00a0H\u00f6chstwert\u00a0von\u00a03 0.000\u00a0DDD\u00a0pro\u00a0\nMonat\u00a0mit\u00a0Kosten\u00a0von\u00a0etwa\u00a01.200.000\u00a0\u20ac\u00a0\u00fcberschritten.\u00a0\u00a0\nAbbildung\u00a04.19:\u00a0Verordnete\u00a0Tages dosen\u00a0(DDD)\u00a0und\u00a0Bruttoums\u00e4tze\u00a0v on\u00a0Teno\u2010\nfoviralafenamid/Emtricitabin/Rilpivirin\u00a0nach\u00a0Monaten\u00a0(2016\u00a0\u2013\u00a020 17)\u00a0\n\u00a0\n\u00a0\nQuellen\u00a0\u00a0\nFachinformation\u00a0Descovy\u00ae\u00a0(2018).\u00a0Fachinformation\u00a0Descovy\u00ae\u00a0200\u00a0m g/10\u00a0mg/\u2010200\u00a0mg/25\u00a0mg\u00a0Filmtablet ten.\u00a0Stand\u00a0der\u00a0Information:\u00a0\nSeptember\u00a02018.\u00a0https://www.fachinfo.de/suche/fi/021052,\u00a0letzte r\u00a0Zugriff:\u00a014.02.2019\u00a0\nFachinformation\u00a0Genvoya\u00ae\u00a0(2018).\u00a0 Fachinformation\u00a0Genvoya\u00a0150\u00a0mg /150\u00a0mg/200\u00a0mg/10\u00a0mg\u00a0Filmtablet ten.\u00a0Stand\u00a0der\u00a0Information:\u00a0\nSeptember\u00a02018.\u00a0https://www.fachinfo.de/pdf/020875,\u00a0letzter\u00a0Zug riff:\u00a014.02.2019\u00a0\nFachinformation\u00a0Odefsey\u00ae\u00a0(2018).\u00a0Fachinformation\u00a0Odefsey\u00ae\u00a0200mg /25mg/25mg\u00a0Filmtabletten.\u00a0Stand\u00a0der\u00a0Information:\u00a0November\u00a0\n2018.\u00a0https://www.fachinfo.de/such e/fi/021120,\u00a0letzter\u00a0Zugriff: \u00a014.02.2019\u00a0\nFricke\u00a0U,\u00a0Hein\u00a0L,\u00a0Schwabe\u00a0U\u00a0(2017).\u00a0Neue\u00a0Arzneimittel\u00a02016.\u00a0In: \u00a0Schwabe\u00a0U,\u00a0Paffrath\u00a0D,\u00a0Ludwig\u00a0W\u2010D,\u00a0Klauber\u00a0J\u00a0(Hrsg.)\u00a0(2017).\u00a0\nArzneiverordnungs\u2010Report\u00a02017.\u00a0Berlin,\u00a0Heidelberg.\u00a0Springer:\u00a055 \u2010135.\u00a0\nG\u2010BA\u00a0\u2013\u00a0Gemeinsamer\u00a0Bundeausschuss\u00a0(2016a).\u00a0Tragende\u00a0Gr\u00fcnde\u00a0zum\u00a0 Beschluss\u00a0des\u00a0Geme insamen\u00a0Bundesausschusses\u00a0\u00fcber\u00a0eine\u00a0\n\u00c4nderung\u00a0der\u00a0Arzneimittel\u2010Richtlinie\u00a0(AM\u2010RL):\u00a0Anlage\u00a0XII\u00a0\u2010\u00a0Besc hl\u00fcsse\u00a0\u00fcber\u00a0die\u00a0Nutzenbewertung\u00a0von\u00a0Arzneimitteln\u00a0\nmit\u00a0neuen\u00a0Wirkstoffen\u00a0nach\u00a0\u00a7\u00a035a\u00a0SGB\u00a0V\u00a0\u2013\u00a0Emtricitabin/Tenofovir alafenamid.\u00a0https://www.g\u2010ba.de/downloads/40\u2010\n268\u20104043/2016\u201011\u201003_AM\u2010RL\u2010XII_Emtricitabin_Tenofoviralafenamid_ D\u2010228_TrG.pdf,\u00a0letzter\u00a0Zugriff:\u00a011.07.2019.\u00a0\n197\u00a0G\u2010BA\u00a0\u2013\u00a0Gemeinsamer\u00a0Bundeausschuss\u00a0(2016b).\u00a0Tragende\u00a0Gr\u00fcnde\u00a0zum\u00a0 Beschluss\u00a0des\u00a0Geme insamen\u00a0Bundesausschusses\u00a0\u00fcber\u00a0eine\u00a0\n\u00c4nderung\u00a0der\u00a0Arzneimittel\u2010Richtlinie\u00a0(AM\u2010RL):\u00a0Anlage\u00a0XII\u00a0\u2010\u00a0Besc hl\u00fcsse\u00a0\u00fcber\u00a0die\u00a0Nutzenbewertung\u00a0von\u00a0Arzneimitteln\u00a0\nmit\u00a0neuen\u00a0Wirkstoffen\u00a0nach\u00a0\u00a7\u00a035a\u00a0SGB\u00a0V\u00a0\u2010\u00a0Elvitegravir/Cobicista t/Emtricitabin/Tenofoviralafenamid.\u00a0https://www.g\u2010\nba.de/downloads/40\u2010268\u20103828/2016\u201006\u201016_AM\u2010RL\u2010XII_Elvitagravir\u2010C obicistat\u2010Emtricitabin\u2010Tenofoviralafenamid_D\u2010\n206_TrG.pdf,\u00a0letzter\u00a0Zugriff:\u00a011.07.2019.\u00a0\nG\u2010BA\u00a0\u2013\u00a0Gemeinsamer\u00a0Bundesausschuss\u00a0(2017).\u00a0Tragende\u00a0Gr\u00fcnde\u00a0zum\u00a0 Beschlussentwurf\u00a0des\u00a0Gemeinsamen\u00a0Bundesausschusses\u00a0\n\u00fcber\u00a0eine\u00a0\u00c4nderung\u00a0der\u00a0Arzneimittel\u2010Richtlinie\u00a0(AM\u2010RL):\u00a0Anlage\u00a0 XII\u00a0\u2010\u00a0Beschl\u00fcsse\u00a0\u00fcber\u00a0die\u00a0Nutzenbewertung\u00a0von\u00a0\nArzneimitteln\u00a0mit\u00a0neuen\u00a0Wirkstoffen\u00a0nach\u00a0\u00a7\u00a035a\u00a0SGB\u00a0V\u00a0\u2013\u00a0Emtricit abin/Rilpivirin/Tenofoviralafenamid.\u00a0\nhttps://www.g\u2010ba.de/downloads/ 40\u2010268\u20101980/2012\u201007\u201005_AM\u2010RL\u2010XII_ Emtricitabin\u2010Rilpivirin\u2010Tenofovir_TrG.pdf,\u00a0\nletzter\u00a0Zugriff:\u00a011.07.2019.\u00a0\nPrescrire\u00a0Int.\u00a0(2017).\u00a0Tenofovir\u00a0alafenamide\u00a0+\u00a0emtricitabine\u00a0+\u00a0 elvitegravir\u00a0+\u00a0cobicista t\u00a0(Genvoya\u00b0)\u00a0and\u00a0HIV.\u00a0\nhttp://english.prescrire.org/en/81/168/53083/0/NewsDetails.aspx ,\u00a0letzer\u00a0Zugriff:\u00a014.02.2019\u00a0\nRay\u00a0AS,\u00a0Fordyce\u00a0MW,\u00a0Hitchcock\u00a0MJM\u00a0(2016).\u00a0Tenofovir\u00a0alafenamide :\u00a0A\u00a0novel\u00a0prodrug\u00a0of\u00a0tenofovir\u00a0for\u00a0the\u00a0treatment\u00a0of\u00a0Human\u00a0\nImmunodeficiency\u00a0Virus.\u00a0Antiviral\u00a0Res\u00a0125:\u00a063\u201370.\u00a0\u00a0\nSax\u00a0PE,\u00a0Wohl\u00a0D,\u00a0Yin\u00a0MT\u00a0et\u00a0al.\u00a0(2015).\u00a0Tenofovir\u00a0alafenamide\u00a0ver sus\u00a0tenofovir\u00a0disoproxil\u00a0fumarate,\u00a0coformulated\u00a0with\u00a0elvitegrav ir,\u00a0\ncobicistat,\u00a0and\u00a0emtricitabine,\u00a0f or\u00a0initial\u00a0treatment\u00a0of\u00a0HIV\u20101\u00a0i nfection:\u00a0Two\u00a0randomised,\u00a0double\u2010blind,\u00a0phase\u00a03,\u00a0non\u2010\ninferiority\u00a0trials.\u00a0Lancet\u00a0385(9987):\u00a02606\u20132615.\u00a0\n\u00a0 \u00a0198\u00a0 Trifluridin/Tipiracil\u00a04.21\nHandelsname:\u00a0Lonsurf\u00ae\u00a0 \u00a0 \u00a0 Pharmazeutischer\u00a0Unternehmer:\u00a0\u00a0\nIndikation:\u00a0Metastasiertes\u00a0Kolorektal\u2010\u00a0 Servier/Taiho\u00a0Oncology\u00a0\nkarzinom\u00a0 \u00a0\nATC\u2010Code:\u00a0L01BC59\u00a0 \u00a0 \u00a0 Markte inf\u00fchrung:\u00a0August\u00a02016\u00a0\nDarreichungsform:\u00a0Filmtabletten\u00a0 \u00a0 DDD:\u00a045 \u00a0mg\u00a0(bez.\u00a0auf\u00a0Trifluridin)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 \u25bc\u00a0\nBewertung \u00a0\nDas\u00a0Pyrimidinderivat\u00a0Trifluridin\u00a0war\u00a0seit\u00a0der\u00a0Markteinf\u00fchrung\u00a01 975\u00a0bis\u00a0Ende\u00a02012\u00a0\nals\u00a0 Ophthalmikum\u00a0 (u.a.\u00a0 Triflumann\u00ae)\u00a0 mit\u00a0 der\u00a0 Indikation\u00a0 Herpes\u2010K eratitis\u00a0 in\u00a0\nDeutschland\u00a0im\u00a0Handel\u00a0(atd,\u00a02019) .\u00a0Als\u00a0Nukleosid\u2010Analogon\u00a0wirkt \u00a0es\u00a0nach\u00a0Einbau\u00a0\nin\u00a0die\u00a0Desoxyribonukleins\u00e4ure\u00a0(DNS)\u00a0hemmend\u00a0auf\u00a0die\u00a0Zellteilung .\u00a0Es\u00a0unterliegt\u00a0\neinem\u00a0 hohen\u00a0 First\u2010Pass \u2010Effekt\u00a0 und\u00a0 wird\u00a0 rasch\u00a0 durch\u00a0 das\u00a0 Enzym\u00a0 Thymidin\u2010\nPhosphorylase\u00a0(TPase)\u00a0abgebaut.\u00a0In\u00a0Kombination\u00a0mit\u00a0dem\u00a0TPase\u2010In hibitor\u00a0Tipiracil\u00a0\nsteht\u00a0es\u00a0seit\u00a0August\u00a02016\u00a0im\u00a0molaren\u00a0Verh\u00e4ltnis\u00a01\u00a0zu\u00a00,5\u00a0als\u00a0or ales\u00a0Zytostatikum\u00a0\nzur\u00a0Verf\u00fcgung.\u00a0\nDie\u00a0Zulassung\u00a0durch\u00a0die\u00a0europ\u00e4ische\u00a0Kommission\u00a0erfolgte\u00a0im\u00a0Apri l\u00a02016\u00a0f\u00fcr\u00a0er\u2010\nwachsene\u00a0Patienten\u00a0mit\u00a0metastasiertem\u00a0kolorektalem\u00a0Karzinom\u00a0(mK RK),\u00a0die\u00a0zuvor\u00a0\nmit\u00a0verf\u00fcgbaren\u00a0Therapien\u00a0behande lt\u00a0wurden\u00a0oder\u00a0hierf\u00fcr\u00a0nicht\u00a0g eeignet\u00a0sind,\u00a0d.h.\u00a0\nmit\u00a0Fluoropyrimidin\u2010,\u00a0 Oxaliplatin\u2010,\u00a0Irinotecan\u2010,\u00a0Anti\u2010VEGF\u2010\u00a0bzw .\u00a0Anti\u2010EGFR\u2010haltigen\u00a0\nArzneimitteln\u00a0(CHMP,\u00a02016a).\u00a0\nDie\u00a0Kombination\u00a0Trifluridin/Tipiracil\u00a0liegt\u00a0als\u00a0Filmtablette\u00a0mi t\u00a015\u00a0bzw.\u00a020\u00a0mg\u00a0bezo\u2010\ngen\u00a0auf\u00a0Trifluridin\u00a0vor.\u00a0Das\u00a0Dosierungsregime\u00a0gestaltet\u00a0sich\u00a0ko mplex,\u00a0da\u00a0je\u00a0Quad\u2010\nratmeter\u00a0K\u00f6rperoberfl\u00e4che\u00a0(KOF)\u00a0jeweils\u00a035\u00a0mg\u00a0Trifluridin\u00a0an\u00a0de n\u00a0Tagen\u00a01\u00a0bis\u00a05\u00a0\nsowie\u00a08\u00a0bis\u00a012\u00a0des\u00a028\u2010Tage\u2010Zyklus\u00a0bis\u00a0eine\u00a0Stunde\u00a0nach\u00a0Fr\u00fchst\u00fcc k\u00a0sowie\u00a0Abendes\u2010\nsen\u00a0gegeben\u00a0werden,\u00a0und\u00a0zwar\u00a0sol ange,\u00a0bis\u00a0eine\u00a0Tumorprogression \u00a0oder\u00a0eine\u00a0\ninakzeptable\u00a0Toxizit\u00e4t\u00a0auftritt.\u00a0Durch\u00a0Blutbildkontrollen\u00a0vor\u00a0j edem\u00a0neuen\u00a0Zyklus\u00a0\nund\u00a0ggf.\u00a0nachfolgender\u00a0Dosisreduktion\u00a0(30/25/20\u00a0mg/m\u00b2\u00a0KOF)\u00a0kann \u00a0das\u00a0Auftreten\u00a0\nvon\u00a0UAW\u00a0reduziert\u00a0werden.\u00a0Pr\u00e4klinische\u00a0Daten\u00a0weisen\u00a0auf\u00a0eine\u00a0Ge notoxizit\u00e4t\u00a0hin,\u00a0\nsodass\u00a0vor\u00a0Therapiebeginn\u00a0ein\u00a0Schwangerschaftstest\u00a0sowie\u00a0w\u00e4hren ddessen\u00a0eine\u00a0\nsichere\u00a0Barrieremethode\u00a0zur\u00a0Empf\u00e4 ngnisverh\u00fctung\u00a0obligat\u00a0ist\u00a0(EM A,\u00a02016).\u00a0\nDie\u00a0Zulassung\u00a0der\u00a0Kombination\u00a0beruht\u00a0ma\u00dfgeblich\u00a0auf\u00a0der\u00a0interna tionalen,\u00a0multi\u2010\nzentrischen,\u00a0 doppelblinden,\u00a0 place bokontrollierten,\u00a0 2:1\u2010randomis ierten\u00a0 Phase\u2010III\u2010\nStudie\u00a0RECOURSE\u00a0(Sponsor:\u00a0Taiho\u00a0Oncology,\u00a0NCT01607957),\u00a0welche\u00a0 die\u00a0Gaben\u00a0\nvon\u00a035\u00a0mg/m\u00b2\u00a0KOF\u00a0Trifluridin/Tipiracil\u00a0(Synonym:\u00a0TAS\u2010102)\u00a0vs.\u00a0P lacebo\u00a0zus\u00e4tzlich\u00a0\nzu\u00a0bester\u00a0unterst\u00fctzender\u00a0Behandlung,\u00a0 Best\u00a0Supportive\u00a0Care \u00a0(BSC),\u00a0an\u00a0800\u00a0Patien\u2010\nten\u00a0untersuchte\u00a0(ClinicalTrials.gov,\u00a02017).\u00a0Es\u00a0wurden\u00a0erwachsen e\u00a0Patienten\u00a0mit\u00a0199\u00a0metastasiertem\u00a0Adenokarzinom\u00a0des\u00a0Kolons\u00a0bzw.\u00a0Rektums\u00a0mit\u00a0Tumorp rogression\u00a0\nunter\u00a0bzw.\u00a0toxizit\u00e4tsbedingtem\u00a0A bbruch\u00a0von\u00a0mindestens\u00a0zwei\u00a0Vort herapien\u00a0mit\u00a0\nFluoropyrimidin,\u00a0 Oxaliplatin,\u00a0 Iri notecan,\u00a0 Anti\u2010VEGF\u2010\u00a0 bzw.\u00a0 Anti\u2010 EGFR\u2010Wirkstoff\u00a0\neingeschlossen,\u00a0welche\u00a0hiernach\u00a0i n\u00a0gutem\u00a0Allgemeinzustand\u00a0nach\u00a0 Eastern\u00a0Coope\u2010\nrative\u00a0Oncology\u00a0Group\u2010Performance\u00a0Status ,\u00a0ECOG\u2010PS\u00a00\u00a0bzw.\u00a01\u00a0waren.\u00a0Stratifiziert\u00a0\nwurden\u00a0die\u00a0Teilnehmer\u00a0nach\u00a0geographischer\u00a0Region\u00a0(1:\u00a0Japan\u00a0vs.\u00a0 2:\u00a0Westen\u00a0(USA,\u00a0\nEU,\u00a0Australien)),\u00a0Zeit\u00a0seit\u00a0erster\u00a0Diagnose\u00a0von\u00a0Metastasen\u00a0(<\u00a01 8\u00a0bzw.\u00a0\u2265\u00a018\u00a0Monaten)\u00a0\nund\u00a0KRAS\u00a0( Kirsten\u00a0RAt\u00a0Sarcoma\u00a0viral\u00a0oncogene\u00a0homolog )\u2010Gen\u2010Status\u00a0(Wildtyp\u00a0oder\u00a0\nmutiert).\u00a0Das\u00a0mediane\u00a0Alter\u00a0der\u00a0eingeschlossenen\u00a0Patienten\u00a0lag\u00a0 bei\u00a063\u00a0Jahren\u00a0(27\u00a0\nbis\u00a082),\u00a033\u00a0%\u00a0kamen\u00a0aus\u00a0Japan.\u00a0Als\u00a0Anzahl\u00a0der\u00a0Vortherapien\u00a0ware n\u00a0zwei,\u00a0drei\u00a0oder\u00a0\n\u2265\u00a0vier\u00a0unter\u00a0Verum\u00a018/22/60\u00a0%\u00a0vs.\u00a017/20/63\u00a0%\u00a0unter\u00a0Placebo\u00a0doku mentiert\u00a0(Ma\u2010\nyer\u00a0et\u00a0al.,\u00a02015).\u00a0\nIm\u00a0prim\u00e4ren\u00a0Endpunkt\u00a0Gesamt\u00fcberleben\u00a0( Overall\u00a0Survival ,\u00a0OS)\u00a0konnte\u00a0eine\u00a0statis\u2010\ntisch\u00a0signifikante\u00a0Verl\u00e4ngerung\u00a0um\u00a0absolut\u00a02,0\u00a0Monate\u00a0zum\u00a0zweit en\u00a0Datenschnitt\u00a0\nam\u00a008.10.2014\u00a0gezeigt\u00a0werden\u00a0(Verum:\u00a07,2\u00a0[6,6;\u00a07,8]\u00a0vs.\u00a05,2\u00a0[4, 6;\u00a05,9]\u00a0Monate;\u00a0HR:\u00a0\n0,69\u00a0[0,59;\u00a00,81];\u00a0p\u00a0<\u00a00,001)\u00a0(G\u2010BA,\u00a02017a).\u00a0Auch\u00a0im\u00a0sekund\u00e4ren \u00a0Endpunkt\u00a0progres\u2010\nsionsfreies\u00a0\u00dcberleben\u00a0( Progression\u00a0Free\u00a0Survival ,\u00a0PFS)\u00a0konnte\u00a0eine\u00a0absolute\u00a0Ver\u2010\nl\u00e4ngerung\u00a0um\u00a00,3\u00a0Monate\u00a0berichtet\u00a0werden\u00a0(Verum:\u00a02,0\u00a0[1,9;\u00a02,1] \u00a0vs.\u00a01,7\u00a0[1,7;\u00a01,8]\u00a0\nMonate\u00a0(HR:\u00a00,49\u00a0[0,42;\u00a00,58];\u00a0p\u00a0<\u00a00,001).\u00a0Umfassende\u00a0Daten\u00a0zur \u00a0Morbidit\u00e4t\u00a0oder\u00a0\ngesundheitsbezogenen\u00a0Lebensqualit\u00e4t\u00a0( Health\u00a0related\u00a0Quality\u00a0of\u00a0life ,\u00a0HRQoL)\u00a0wur\u2010\nden\u00a0in\u00a0der\u00a0Studie\u00a0RECOURSE\u00a0nicht\u00a0erhoben\u00a0(Mayer\u00a0et\u00a0al.,\u00a02015).\u00a0\nF\u00fcr\u00a0die\u00a0Zulassungsbeh\u00f6rden\u00a0waren\u00a0im\u00a0Kontext\u00a0der\u00a0Studie\u00a0RECOURSE \u00a0die\u00a0uner\u2010\nw\u00fcnschten\u00a0Ereignisse\u00a0(UE)\u00a0Myelos uppression,\u00a0gastrointestinale\u00a0S t\u00f6rungen\u00a0sowie\u00a0\nInfektionen\u00a0von\u00a0besonderem\u00a0Interesse\u00a0( Adverse\u00a0Events\u00a0of\u00a0Special\u00a0Interest ,\u00a0AESI).\u00a0\n(CHMP,\u00a02016b).\u00a0Es\u00a0wurden\u00a0unter\u00a0Verum\u00a0vs.\u00a0Placebo\u00a0geh\u00e4uft\u00a0Neutro penie\u00a0(67\u00a0vs.\u00a0\n38\u00a0%),\u00a0Leukopenie\u00a0(77\u00a0vs.\u00a021\u00a0%),\u00a0An\u00e4mie\u00a0(77\u00a0vs.\u00a018\u00a0%)\u00a0bzw.\u00a0Thro mbozytopenie\u00a0(42\u00a0\nvs.\u00a05\u00a0%)\u00a0berichtet\u00a0(Mayer\u00a0et\u00a0al.,\u00a02015).\u00a0Das\u00a0 Committee\u00a0for\u00a0Medicinal\u00a0Products\u00a0for\u00a0\nHuman\u00a0Use \u00a0(CHMP)\u00a0der\u00a0EMA\u00a0erachtet\u00a0das\u00a0UE\u2010Profil\u00a0von\u00a0Trifluridin/Tipiraci l\u00a0im\u00a0\nRahmen\u00a0einer\u00a0palliativen\u00a0Therapie\u00a0durch\u00a0die\u00a0Verordnung\u00a0nur\u00a0von\u00a0 erfahrenen\u00a0On\u2010\nkologen\u00a0sowie\u00a0einer\u00a0anschlie\u00dfenden\u00a0engmaschigen\u00a0\u00dcberwachung\u00a0(Bl utbilder\u00a0vor\u00a0\njedem\u00a0 Zyklus)\u00a0 als\u00a0 beherrschbar.\u00a0 Im\u00a0 europ\u00e4ischen\u00a0 Zulassungsberic ht\u00a0 (European\u00a0\nPublic\u00a0Assessment\u00a0Report ,\u00a0EPAR)\u00a0werden\u00a0zu\u00a0RECOURSE\u00a0erg\u00e4nzend\u00a0bei\u00a00,3\u00a0%\u00a0der\u00a0\nVerum\u2010Patienten\u00a0Behandlungsabbr\u00fcche\u00a0in\u00a0Folge\u00a0von\u00a0An\u00e4mie\u00a0bericht et,\u00a0bei\u00a016,9\u00a0%\u00a0\nder\u00a0Patienten\u00a0wurden\u00a0Bluttransfusionen\u00a0notwendig.\u00a0Weiterhin\u00a0war \u00a0bei\u00a09,4\u00a0%\u00a0der\u00a0\nmit\u00a0TAS\u2010102\u00a0behandelten\u00a0Patientenen\u00a0die\u00a0Gabe\u00a0granulocytenstimul ierender\u00a0Fak\u2010\ntorpr\u00e4parate\u00a0(G\u2010CSF)\u00a0erforderlich.\u00a0Daneben\u00a0wurde\u00a0\u00fcber\u00a0drei\u00a0Tode sf\u00e4lle\u00a0im\u00a0Zu\u2010\nsammenhang\u00a0mit\u00a0der\u00a0Therapie\u00a0in\u00a0Fol ge\u00a0von\u00a0Infektionen\u00a0berichtet\u00a0 (CHMP,\u00a02016b).\u00a0200\u00a0Zur\u00a0Studie\u00a0RECOURSE\u00a0liegen\u00a0mehrere\u00a0Sekund\u00e4rpublikationen\u00a0vor,\u00a0h ierunter\u00a0zwei\u00a0\nSubgruppen\u2010Analysen,\u00a0welche\u00a0im\u00a0Kontext\u00a0der\u00a0Studienpopulation\u00a0mi t\u00a0ECOG\u2010PS\u00a00\u00a0\nbis\u00a01\u00a0sowie\u00a0dem\u00a0medianem\u00a0Alter\u00a0von\u00a063\u00a0Lebensjahren\u00a0zu\u00a0interpret ieren\u00a0sind.\u00a0Die\u00a0\nspanische\u00a0Kohorte\u00a0stellt\u00a0mit\u00a0112\u00a0Patienten\u00a028\u00a0%\u00a0der\u00a0403\u00a0Teilneh mer\u00a0der\u00a0Region\u00a0EU\u00a0\ndar\u00a0und\u00a0weist\u00a0tendenziell\u00a0im\u00a0Vergleich\u00a0zur\u00a0Region\u00a01\u00a0(Japan)\u00a0ein en\u00a0h\u00f6heren\u00a0ECOG\u2010\nPS\u00a0und\u00a0median\u00a0k\u00fcrzeres\u00a0OS\u00a0(6,8\u00a0vs .\u00a04,6\u00a0Monate\u00a0[0,28;\u00a00,78];\u00a0p\u00a0= \u00a00,0032)\u00a0bei\u00a0abso\u2010\nluter\u00a0Verl\u00e4ngerung\u00a0des\u00a0OS\u00a0um\u00a02,2\u00a0Monate\u00a0auf\u00a0(Longo\u2010Mu\u00f1oz\u00a0et\u00a0al. ,\u00a02017).\u00a0Die\u00a0\nzweite\u00a0Subgruppenanalyse\u00a0st\u00fctzt\u00a0diese\u00a0Erkenntnis,\u00a0ber\u00fccksichtig t\u00a0aber\u00a0alle\u00a0Regio\u2010\nnen\u00a0au\u00dfer\u00a0Australien\u00a0(van\u00a0Cutsem\u00a0et\u00a0al.,\u00a02018).\u00a0Sowohl\u00a0das\u00a0 Center\u00a0for\u00a0Drug\u00a0Evalua\u2010\ntion\u00a0and\u00a0Research\u00a0 (CDER)\u00a0der\u00a0U.S.\u00a0amerikanis chen\u00a0Zulassungsbeh\u00f6rde\u00a0 Food\u00a0and\u00a0\nDrug\u00a0Administrations \u00a0(FDA)\u00a0als\u00a0auch\u00a0das\u00a0Institut\u00a0f\u00fcr\u00a0Qualit\u00e4t\u00a0und\u00a0Wirtschaftlichkei t\u00a0\nim\u00a0Gesundheitswesen\u00a0(IQWiG)\u00a0weisen\u00a0auf\u00a0unterschiedliche\u00a0Effekte \u00a0in\u00a0Folge\u00a0Anzahl\u00a0\nder\u00a0Vortherapien\u00a02\u00a0bzw.\u00a0\u2265\u00a04\u00a0hin\u00a0(CDER,\u00a02015;\u00a0IQWiG,\u00a02016).\u00a0\nDer\u00a0G\u2010BA\u00a0hat\u00a0den\u00a0 Beschluss \u00a0zur\u00a0Nutzenbewertung\u00a0der\u00a0Kombination\u00a0von\u00a0Trifluri\u2010\ndin/Tipiracil\u00a0vom\u00a002.02.2017\u00a0aufgru nd\u00a0unvollst\u00e4ndiger\u00a0Daten\u00a0bis \u00a031.01.2019\u00a0 be\u2010\nfristet\u00a0und\u00a0diese\u00a0auf\u00a0Antrag\u00a0des\u00a0pU\u00a0 bis\u00a001.04.2020 \u00a0verl\u00e4ngert\u00a0(G\u2010BA,\u00a02017a;\u00a0G\u2010BA,\u00a0\n2018a;\u00a0G\u2010BA,\u00a02018b).\u00a0Auf\u00a0Basis\u00a0des\u00a0Dossiers\u00a0bzw.\u00a0von\u00a0nachgereic hten\u00a0Auswertun\u2010\ngen\u00a0des\u00a0pU\u00a0stellt\u00a0der\u00a0G\u2010BA\u00a0einen \u00a0Anhaltspunkt\u00a0 f\u00fcr\u00a0einen \u00a0geringen\u00a0Zusatznutzen \u00a0\nfest\u00a0und\u00a0begr\u00fcndet\u00a0dies\u00a0einerseits\u00a0mit\u00a0einer\u00a0relevanten\u00a0Verl\u00e4ng erung\u00a0des\u00a0OS\u00a0bei\u00a0\ngleichzeitig\u00a0vorliegenden\u00a0Schadensaspekten,\u00a0insbesondere\u00a0aber\u00a0a uch\u00a0wegen\u00a0feh\u2010\nlender\u00a0Daten\u00a0zur\u00a0Morbidit\u00e4t\u00a0bzw.\u00a0 HRQoL\u00a0im\u00a0palliativen\u00a0Kontext.\u00a0 In\u00a0den\u00a0tragenden\u00a0\nGr\u00fcnden\u00a0werden\u00a0explizit\u00a0Angaben\u00a0zu \u00a0weiterhin\u00a0erforderlichen\u00a0Dat en\u00a0dargelegt\u00a0\nund\u00a0eine\u00a0\u00dcbertragbarkeit\u00a0der\u00a0Erkenntnisse\u00a0der\u00a0Studie\u00a0RECOURSE\u00a0a uf\u00a0den\u00a0klini\u2010\nschen\u00a0Versorgungskontext\u00a0in\u00a0Deut schland\u00a0angezweifelt,\u00a0da\u00a0in\u00a0der \u00a0Beobachtungs\u2010\nphase\u00a0der\u00a0Studie\u00a0weder\u00a0palliative \u00a0Radiotherapie\u00a0noch\u00a0medikament \u00f6se\u00a0Krebsthe\u2010\nrapien\u00a0gem\u00e4\u00df\u00a0dem\u00a0Studienprotokoll\u00a0erlaubt\u00a0waren,\u00a0jedoch\u00a0in\u00a0der\u00a0 Nachbeobach\u2010\ntungsphase\u00a0>40\u00a0%\u00a0der\u00a0Patienten\u00a0im\u00a0Verum\u2010\u00a0und\u00a0Placebo\u2010Arm\u00a0ebendi ese\u00a0Therapien\u00a0\nerhielten\u00a0(G\u2010BA,\u00a02016;\u00a0G\u2010BA,\u00a02017b).\u00a0\nDie\u00a0australische\u00a0Zulassungsbeh\u00f6rde\u00a0 Therapeutic\u00a0Goods\u00a0Administration\u00a0 (TGA)\u00a0ging\u00a0\nin\u00a0diesem\u00a0Zusammenhang\u00a0sogar\u00a0weiter\u00a0und\u00a0verlangte\u00a0f\u00fcr\u00a0die\u00a0Kombi nation\u00a0Trifluri\u2010\ndin/Tipiracil\u00a0einen\u00a0besonderen\u00a0Hi nweis\u00a0auf\u00a0das\u00a0Fehlen\u00a0von\u00a0Daten \u00a0zur\u00a0Behandlung\u00a0\nvon\u00a0Patienten\u00a0mit\u00a0ECOG\u2010PS\u00a0\u2265\u00a02\u00a0(T GA,\u00a02017).\u00a0Gleichzeitig\u00a0wird\u00a0zu r\u00a0Verbesserung\u00a0der\u00a0\nArzneimittelsicherheit\u00a0und\u00a0des\u00a0Patientenschutzes\u00a0in\u00a0Bezug\u00a0auf\u00a0d as\u00a0komplizierte\u00a0\nDosierungsschema,\u00a0das\u00a0eine\u00a0Gabe\u00a0von\u00a035\u00a0mg/m\u00b2\u00a0KOF\u00a0vorsieht,\u00a0die\u00a0 teilweise\u00a0nur\u00a0\ndurch\u00a0Kombination\u00a0der\u00a0beiden\u00a0Wirkst\u00e4rken\u00a0erreicht\u00a0werden\u00a0kann,\u00a0 die\u00a0Aush\u00e4ndi\u2010\ngung\u00a0einer\u00a0individuellen\u00a0Patient enkarte\u00a0vorgeschlagen\u00a0(TGA,\u00a0201 8).\u00a0\nIn\u00a0der\u00a0asiatischen\u00a0Phase\u2010III\u2010St udie\u00a0TERRA\u00a0(Sponsor:\u00a0Taiho\u00a0Oncol ogy,\u00a0NCT01955837)\u00a0\nmit\u00a0Studienzentren\u00a0in\u00a0China,\u00a0de r\u00a0Republik\u00a0Korea\u00a0sowie\u00a0Thailand, \u00a0die\u00a0der\u00a0Studie\u00a0201\u00a0RECOURSE\u00a0sehr\u00a0\u00e4hnlich\u00a0ist,\u00a0wurde\u00a0f\u00fcr\u00a0den\u00a0prim\u00e4ren\u00a0Endpunkt\u00a0OS\u00a0e ine\u00a0absolute\u00a0\nVerl\u00e4ngerung\u00a0von\u00a00,7\u00a0Monaten,\u00a0d.h.\u00a07,8\u00a0vs.\u00a07,1\u00a0Monate\u00a0(HR:\u00a00,79 \u00a0[0,62;\u00a00,99];\u00a0\u00a0\np\u00a0=\u00a00,035)\u00a0berichtet\u00a0(Xu\u00a0et\u00a0al.,\u00a02018).\u00a0\nIm\u00a0Februar\u00a02019\u00a0erfolgte\u00a0eine\u00a0Indikationserweiterung\u00a0der\u00a0FDA\u00a0f\u00fc r\u00a0Patienten\u00a0mit\u00a0\nTumorprogression\u00a0und\u00a0Metastasen\u00a0b ei\u00a0Adenokarzinomen\u00a0des\u00a0Magens\u00a0 und\u00a0des\u00a0\ngastro\u2010oesophagealen\u00a0 \u00dcbergangs\u00a0 ( gastro\u2010esophageal\u00a0 junction ,\u00a0 GEJ)\u00a0 nach\u00a0 zwei\u00a0\nerfolgten\u00a0Therapielinien\u00a0(FDA,\u00a02019).\u00a0Ein\u00a0Antrag\u00a0auf\u00a0Indikation serweiterung\u00a0wird\u00a0\nderzeit\u00a0von\u00a0der\u00a0EMA\u00a0gepr\u00fcft\u00a0(Taiho\u00a0&\u00a0Servier,\u00a02018).\u00a0\nVerf\u00fcgbare\u00a0Therapien \u00a0 (Zusatz\u2010)Nutzen \u00a0 Kosten\u00a0\n\u00a0\nweitere\u00a0palliative\u00a0Thera\u2010\npieoption\u00a0bei\u00a0mKRK\u00a0\nneben\u00a0Regorafenib\u00a0\u00a0befristeter\u00a0G\u2010BA\u00a0Beschluss\u00a0\n(04/2020):\u00a0Anhaltspunkt\u00a0\nf\u00fcr\u00a0geringen\u00a0ZN\u00a0\nkeine\u00a0Daten\u00a0zu\u00a0Morbidit\u00e4t/\u00a0\nHRQoL;\u00a0limitierte\u00a0Daten\u00a0zu\u00a0\nECOG\u2010PS\u00a0\u22652\u00a0\u00a0patientenindividuell   \n\u00a0\nErl\u00e4uterung\u00a0der\u00a0Farben:\u00a0Verf\u00fcgbare\u00a0Therapien:\u00a0rot\u00a0=\u00a0weitere\u00a0The rapieoption,\u00a0gelb\u00a0=\u00a0Subgruppen\u2010Novit\u00e4t,\u00a0gr\u00fcn\u00a0=\u00a0Solist;\u00a0(Zusatz\u2010 )\u00a0\nNutzen:\u00a0rot\u00a0=\u00a0keine\u00a0Verbesserung\u00a0oder\u00a0schlechte\u00a0Nutzen/Schaden\u2010 Relation,\u00a0gelb\u00a0=\u00a0teilweise\u00a0Verbesserungen,\u00a0gr\u00fcn\u00a0=\u00a0Verbesserung\u00a0\nharter\u00a0Endpunkte;\u00a0Kosten:\u00a0rot\u00a0=\u00a0teurer\u00a0als\u00a0bestehende\u00a0Therapien ,\u00a0gelb\u00a0=\u00a0ungef\u00e4hr\u00a0gleich\u00a0bzw.\u00a0teils/teils,\u00a0gr\u00fcn\u00a0=\u00a0g\u00fcnstiger\u00a0als \u00a0\nbestehende\u00a0Therapien\u00a0\nWie\u00a0bewerten\u00a0andere?\u00a0\nBewertung\u00a0nach\u00a0\nFricke\u00a0et\u00a0al.\u00a0a\u2010t\u2010Bewertung\u00a0 AMB\u00a0 Prescrire\u00a0 PZ\u00a0\nB\u00a0 \u2013\u00a0 \u2013\u00a0 Possibly\u00a0helpful\u00a0 Schrittinnovation\u00a0\nKosten\u00a0\nWirkstoff\u00a0 Behandlungsmodus\u00a0 Behandlungstage\u00a0 Jahrestherapiekosten\u00a0\nzu\u00a0bewertendes\u00a0Arzneimittel \u00a0\u00a0 \u00a0 \u00a0\nTrifluridin/Tipiracil\u00a0 2x\u00a0tgl.\u00a035\u00a0mg/m\u00b2\u00a0KOF\u00a0\nan\u00a0den\u00a0Tagen\u00a01\u00a0bis\u00a05\u00a0\nund\u00a08\u00a0bis\u00a012\u00a0des\u00a028\u2010\nTage\u00a0Zyklus\u00a0130\u00a0 44.015,44\u00a0\u20ac\u00a0\nzVT\u00a0 \u00a0 \u00a0 \u00a0\nBest\u00a0Supportive\u00a0Care\u00a0\u00a0365\u00a0 patientenindividuell\u00a0\n\u00a0\n\u00a0\u00a0\n202\u00a0Versorgungsanalysen\u00a0\nDie\u00a0Verordnung\u00a0der\u00a0Kombination\u00a0Tr ifluridin/Tipiracil\u00a0nimmt\u00a0ab\u00a0L istung\u00a0in\u00a0der\u00a0Lau\u2010\ner\u2010Taxe\u00a0im\u00a0August\u00a02016\u00a0stetig\u00a0zu\u00a0und\u00a0erreicht\u00a0ein\u00a0erstes\u00a0Platea u\u00a0mit\u00a0ca.\u00a01.000\u00a0DDD\u00a0\nmonatlich\u00a0im\u00a0vierten\u00a0Quartal\u00a02016\u00a0bei\u00a0Kosten\u00a0um\u00a0180.000\u00a0\u20ac.\u00a0Hier nach\u00a0steigen\u00a0Ab\u2010\u00a0\nund\u00a0Umsatz\u00a0der\u00a0Kombinationstherapie\u00a0weiter\u00a0an\u00a0bis\u00a0zum\u00a0Maximum\u00a0d es\u00a0Auswer\u2010\ntungszeitraumes\u00a0im\u00a0Monat\u00a0Juli\u00a02017\u00a0mit\u00a02.260\u00a0DDD\u00a0bzw.\u00a0406.847\u00a0\u20ac .\u00a0Ab\u00a0August\u00a0\n2017\u00a0wird\u00a0der\u00a0Einfluss\u00a0des\u00a0Erstattungsbetrags\u00a0deutlich\u00a0sichtbar ,\u00a0der\u00a0zu\u00a0einer\u00a0Preis\u2010\nsenkung\u00a0des\u00a0Apothekenverkaufspreises\u00a0um\u00a035\u00a0%\u00a0f\u00fchrt\u00a0(Lauer\u2010Fisch er,\u00a02016).\u00a0Im\u00a0\nDezember\u00a0 2017\u00a0 lag\u00a0 der\u00a0 Verbrauch\u00a0 von\u00a0 Trifluridin/Tipiracil\u00a0 bei\u00a0 1 .420\u00a0DDD\u00a0 und\u00a0\nKosten\u00a0in\u00a0H\u00f6he\u00a0von\u00a0166.620\u00a0\u20ac.\u00a0\nAbbildung\u00a04.20:\u00a0Verordnete\u00a0Tages dosen\u00a0(DDD)\u00a0und\u00a0Bruttoums\u00e4tze\u00a0v on\u00a0\u00a0\nTrifluridin/Tipiracil\u00a0nach\u00a0Monaten\u00a0(2016\u00a0\u2013\u00a02017)\u00a0\n\u00a0\n\u00a0\u00a0\n203\u00a0Quellen\u00a0\natd\u00a0\u2013\u00a0arznei\u2010telegramm\u00a0Datenbank\u00a0(2019).\u00a0Wirkstoff:\u00a0Trifluridin /Auge.\u00a02019.\u00a0https://www.arznei\u2010\ntelegramm.de/db/0codewkstxt.php3?art=mono&nummer=57211&ord=uaw& ah=ah,\u00a0letzter\u00a0Zugriff:\u00a002.04.2019.\u00a0\nCDER\u00a0\u2013\u00a0Center\u00a0for\u00a0Drug\u00a0Evaluation\u00a0and\u00a0Research\u00a0(2015).\u00a0Statisti cal\u00a0Review(s).\u00a0\nhttps://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/207981O rig1s000StatR.pdf,\u00a0letzter\u00a0Zugriff:\u00a004.04.2019.\u00a0\nCHMP\u00a0\u2013\u00a0Committee\u00a0for\u00a0Medicinal\u00a0Products\u00a0for\u00a0Human\u00a0Use\u00a0(2016a).\u00a0 CHMP\u00a0summary\u00a0of\u00a0positive\u00a0opinion\u00a0for\u00a0Lonsurf\u00a0(initial\u00a0\nauthorisation)\u00a0Lonsurf\u00a0(trifluri dine/tipiracil).\u00a02016.\u00a0https:// www.ema.europa.eu/documents/smop\u2010initial/chmp\u2010\nsummary\u2010positive\u2010opinion\u2010lonsurf_ en.pdf,\u00a0letzter\u00a0Zugriff:\u00a004.04 .2019.\u00a0\nCHMP\u00a0\u2013\u00a0Committee\u00a0for\u00a0Medicinal\u00a0Products\u00a0for\u00a0Human\u00a0Use\u00a0(2016b).\u00a0 Lonsurf:\u00a0EPAR\u00a0\u2010\u00a0Public\u00a0assessment\u00a0report.\u00a02016.\u00a0\nhttps://www.ema.europa.eu/documents/assessment\u2010report/lonsurf\u2010e par\u2010public\u2010assessment\u2010report_en.pdf,\u00a0letzter\u00a0\nZugriff:\u00a004.04.2019.\u00a0\nClinicalTrials.gov\u00a0(201 7).\u00a0Study\u00a0of\u00a0TAS\u2010102\u00a0in\u00a0Patients\u00a0With\u00a0Me tastatic\u00a0Colorectal\u00a0Cancer\u00a0Refractory\u00a0to\u00a0Standard\u00a0Chemotherapy\u00a0\n(RECOURSE).\u00a02017.\u00a0https://www.clin icaltrials.gov/ct2/show/study /NCT01607957?term=tas102&phase=2&rank=4,\u00a0\nletzter\u00a0Zugriff:\u00a003.04.2019.\u00a0\nEMA\u00a0\u2013\u00a0European\u00a0Medicines\u00a0Agency\u00a0(2016).\u00a0Lonsuf:\u00a0EPAR\u00a0\u2013\u00a0Product\u00a0 Information\u00a0[SPC].\u00a0\nhttps://www.ema.europa.eu/documents/product\u2010information/lonsurf \u2010epar\u2010product\u2010information_de.pdf,\u00a0letzter\u00a0\nZugriff:\u00a004.04.2019.\u00a0\nFDA\u00a0\u2013\u00a0Food\u00a0and\u00a0Drug\u00a0Administration\u00a0(2019).\u00a0FDA\u00a0approves\u00a0Lonsurf \u00a0for\u00a0recurrent,\u00a0metastatic\u00a0gastr ic\u00a0and\u00a0gastroesophageal\u00a0junctio n\u00a0\nadenocarcinoma.\u00a02019.\u00a0https://www.fda.gov/Drugs/InformationOnDr ugs/ApprovedDrugs/ucm632032.htm,\u00a0letzter\u00a0\nZugriff:\u00a004.04.2019.\u00a0\nFricke\u00a0U,\u00a0Hein\u00a0L,\u00a0Schwabe\u00a0U\u00a0(2017).\u00a0Neue\u00a0Arzneimittel\u00a02016.\u00a0In: \u00a0Schwabe\u00a0U,\u00a0Paffrath\u00a0D,\u00a0Ludwig\u00a0W\u2010D,\u00a0Klauber\u00a0J\u00a0(Hrsg.)\u00a0(2017).\u00a0\nArzneiverordnungs\u2010Report\u00a02017.\u00a0Berlin,\u00a0Heidelberg.\u00a0Springer:\u00a055 \u2010135.\u00a0\nG\u2010BA\u00a0\u2013\u00a0Gemeinsamer\u00a0Bundesausschuss\u00a0(2016).\u00a0M\u00fcndliche\u00a0Anh\u00f6rung\u00a0\u2013 \u00a0hier:\u00a0Trifluridin/Tipiracil.\u00a02016.\u00a0https://www.g\u2010\nba.de/downloads/91\u20101031\u2010258/2016\u201012\u201020_Wortprotokoll_Trifluridi n\u2010Tipiracil_D\u2010252.pdf,\u00a0letzter\u00a0Zugriff:\u00a0\n09.04.2019.\u00a0\nG\u2010BA\u00a0\u2013\u00a0Gemeinsamer\u00a0Bundesausschuss\u00a0(2017a).\u00a0Beschluss\u00a0\u2013\u00a0Triflur idin/Tipiracil.\u00a02017.\u00a0https://www.g\u2010ba.de/downloads/39\u2010261\u2010\n2852/2017\u201002\u201002_AM\u2010RL\u2010XII_Trifluridin\u2010Tipiracil_D\u2010252_BAnz.pdf, \u00a0letzter\u00a0Zugriff:\u00a004.04.2019.\u00a0\nG\u2010BA\u00a0\u2013\u00a0Gemeinsamer\u00a0Bundesausschuss\u00a0(2017b).\u00a0Tragende\u00a0Gr\u00fcnde\u00a0\u2013\u00a0T rifluridin/Tipiracil.\u00a02017.\u00a0https://www.g\u2010\nba.de/downloads/40\u2010268\u20104189/2017\u201002\u201002_AM\u2010RL\u2010XII_Trifluridin\u2010Ti piracil_D\u2010252_TrG.pdf,\u00a0letzter\u00a0Zugriff:\u00a0\n04.04.2019.\u00a0\nG\u2010BA\u00a0\u2013\u00a0Gemeinsamer\u00a0Bundesausschuss\u00a0(2018a).\u00a0Beschluss\u00a0\u2013\u00a0Triflur idin/Tipiracil\u00a0[Verl\u00e4ngerung\u00a0\u2010\u00a0Be fristung].\u00a02018.\u00a0https://www.g \u2010\nba.de/downloads/39\u2010261\u20103399/2018\u201007\u201005_AM\u2010RL\u2010XII_Trifluridin\u2010Ti piracil_Verlaengerung\u2010Befristung_D\u2010\n252_BAnz.pdf,\u00a0letzter\u00a0Zugriff:\u00a004.04.2019.\u00a0\nG\u2010BA\u00a0\u2013\u00a0Gemeinsamer\u00a0Bundesausschuss\u00a0(2018b).\u00a0Geltende\u00a0Fassung\u00a0de r\u00a0Arzneimittel\u2010Richtlinie/Anlage\u00a0 XII:\u00a0Trifluridin/Tipiracil.\u00a020 18.\u00a0\nhttps://www.g\u2010ba.de/downloads/ 91\u20101385\u2010258/2018\u201007\u201005_Geltende\u2010F assung_Trifluridin_Tipiracil_D\u2010252.pdf,\u00a0\nletzter\u00a0Zugriff:\u00a004.04.2019.\u00a0\nGrothey\u00a0A,\u00a0van\u00a0Cutsem\u00a0E,\u00a0Sobrero\u00a0A,\u00a0Siena\u00a0S,\u00a0Falcone\u00a0A,\u00a0Ychou\u00a0M \u00a0et\u00a0al.\u00a0(2013).\u00a0Regorafenib\u00a0monotherapy\u00a0for\u00a0previously\u00a0treated\u00a0\nmetastatic\u00a0colorectal\u00a0cancer\u00a0(CORRECT).\u00a0The\u00a0Lancet\u00a0381(9863):\u00a03 03\u201012.\u00a0\nIQWiG\u00a0\u2013\u00a0Institut\u00a0f\u00fcr\u00a0Qualit\u00e4t\u00a0und\u00a0Wirtschaftlichkeit\u00a0im\u00a0Gesundh eitswesen\u00a0(2016).\u00a0Trifluridin/Tipiracil\u00a0(Kolorektalkarzinom)\u00a0\nAddendum\u00a0zum\u00a0Auftrag\u00a0A16\u201054.\u00a0https://www.g\u2010ba.de/downloads/92\u20109 75\u20101733/2017\u201002\u201002_AM\u2010RL\u2010XII_Trifluridin\u2010\nTipiracil_D\u2010252_Addendum.pdf,\u00a0letzter\u00a0Zugriff:\u00a009.04.2019.\u00a0204\u00a0Lauer\u2010Fischer\u00a0(2016).\u00a0Lauer\u2010Taxe \u00a0online.\u00a02016.\u00a0h ttps://www.cgm. com/lauer\u2010fischer/impressum_lf /impressum~1.de.jsp,\u00a0letzter\u00a0\nZugriff:\u00a001.04.2019.\u00a0\nLongo\u2010Mu\u00f1oz\u00a0F,\u00a0Argiles\u00a0G,\u00a0Tabernero\u00a0J,\u00a0Cervantes\u00a0A,\u00a0Gravalos\u00a0C, \u00a0Pericay\u00a0C\u00a0et\u00a0al.\u00a0(2017).\u00a0Efficacy\u00a0of\u00a0trifluridine\u00a0and\u00a0tipiraci l\u00a0(TAS\u2010\n102)\u00a0versus\u00a0placebo,\u00a0with\u00a0supportive\u00a0care,\u00a0in\u00a0a\u00a0randomized,\u00a0con trolled\u00a0trial\u00a0of\u00a0patients\u00a0with\u00a0metastatic\u00a0colorectal\u00a0\ncancer\u00a0from\u00a0Spain.\u00a0Clinical\u00a0and\u00a0Translational\u00a0Oncology\u00a019(2):\u00a02 27\u2010235.\u00a0\nMayer\u00a0RJ,\u00a0van\u00a0Cutsem\u00a0E,\u00a0Falcone\u00a0A,\u00a0Yoshino\u00a0T,\u00a0Garcia\u2010Carbonero\u00a0 R,\u00a0Mizunuma\u00a0N\u00a0et\u00a0al.\u00a0(2015).\u00a0Randomized\u00a0trial\u00a0of\u00a0TAS\u2010102\u00a0for\u00a0\nrefractory\u00a0metastatic\u00a0colorectal\u00a0cancer.\u00a0NEJM\u00a0372(20):\u00a01909\u2010191 9.\u00a0\nPrescrire\u00a0Int.\u00a0(2018).\u00a0trifluridine\u00a0+\u00a0tipiracil\u00a0(LONSURF\u00ae)\u00a0in\u00a0m etastatic\u00a0colorectal\u00a0cancer.\u00a0Prescrire\u00a0Int\u00a027(189).\u00a0\nPZ\u00a0\u2013\u00a0Pharmazeutische\u00a0Zeitung\u00a0online\u00a0(2016).\u00a0Arzneistoffe\u00a0\u2013\u00a0Tipi racil\u00a0Lonsurf.\u00a02016.\u00a0https://www.pharmazeutische\u2010\nzeitung.de/arzneistoffe/daten/2016/tipiracillonsurfr862016/,\u00a0le tzter\u00a0Zugriff:\u00a001.04.2019.\u00a0\nTabernero\u00a0J,\u00a0Yoshino\u00a0T,\u00a0Cohn\u00a0AL,\u00a0Obermannova\u00a0R,\u00a0Bodoky\u00a0G,\u00a0Garci a\u2010Carbonero\u00a0R\u00a0et\u00a0al.\u00a0(2015).\u00a0Ramucirumab\u00a0versus\u00a0placebo\u00a0in\u00a0\ncombination\u00a0with\u00a0second\u2010line\u00a0FOLF IRI\u00a0in\u00a0patients\u00a0with\u00a0metastati c\u00a0colorectal\u00a0carcinoma\u00a0that\u00a0progressed\u00a0during\u00a0or\u00a0\nafter\u00a0first\u2010line\u00a0therapy\u00a0with\u00a0bevacizumab,\u00a0oxaliplatin,\u00a0and\u00a0a\u00a0f luoropyrimidine\u00a0(RAISE).\u00a0T he\u00a0Lancet\u00a0Oncology\u00a016(5).\u00a0\nTaiho\u00a0&\u00a0Servier\u00a0(2018).\u00a0Taiho\u00a0an d\u00a0Servier\u00a0Announce\u00a0Positive\u00a0Res ults\u00a0from\u00a0Lonsurf\u00ae\u00a0(trifluridine/tipiracil).\u00a0\nhttps://www.taiho.co.jp/en/release/files/pdf/20181022.pdf,\u00a0letz ter\u00a0Zugriff:\u00a003.04.2019.\u00a0\nTGA\u00a0\u2013\u00a0Therapeutic\u00a0Goods\u00a0Administ ration\u00a0(2017).\u00a0Australian\u00a0Produ ct\u00a0Information\u00a0\u2010\u00a0Lonsurf\u00a0(trifluridin/tipiracil).\u00a02017.\u00a0\nhttps://www.ebs.tga.gov.au/ebs/picmi/picmirepository.nsf/pdf?Op enAgent&id=CP\u20102017\u2010PI\u201001847\u20101,\u00a0letzter\u00a0Zugriff:\u00a0\n11.04.2019.\u00a0\nTGA\u00a0\u2013\u00a0Therapeutic\u00a0Goods\u00a0Administ ration\u00a0(2018).\u00a0AUSPAR\u00a0\u2010\u00a0triflur idine/tipiracil.\u00a02018.\u00a0\nhttps://www.tga.gov.au/sites/default/files/auspar\u2010trifluridine\u2010 tipiracil\u2010180612.pdf,\u00a0letzter\u00a0Zugriff:\u00a004.04.2019.\u00a0\nvan\u00a0Cutsem\u00a0E,\u00a0Mayer\u00a0RJ,\u00a0Laurent\u00a0S,\u00a0Winkler\u00a0R,\u00a0Gr\u00e1valos\u00a0C,\u00a0Benav ides\u00a0M\u00a0et\u00a0al.\u00a0(2018).\u00a0The\u00a0subgro ups\u00a0of\u00a0the\u00a0phase\u00a0III\u00a0RECOURSE\u00a0t rial\u00a0\nof\u00a0trifluridine/tipiracil\u00a0(TAS\u20101 02)\u00a0versus\u00a0placebo\u00a0with\u00a0best\u00a0su pportive\u00a0care\u00a0in\u00a0patients\u00a0with\u00a0metastatic\u00a0colorectal\u00a0\ncancer.\u00a0Eur\u00a0J\u00a0Cancer\u00a090:\u00a063\u201072.\u00a0\nXu\u00a0J,\u00a0Kim\u00a0TW,\u00a0Shen\u00a0L,\u00a0Sriuranpong\u00a0V,\u00a0Pan\u00a0H,\u00a0Xu\u00a0R\u00a0et\u00a0al.\u00a0(2018). \u00a0Results\u00a0of\u00a0a\u00a0Randomized,\u00a0Double\u2010 Blind,\u00a0Placebo\u2010Controlled,\u00a0Pha se\u00a0III\u00a0\nTrial\u00a0of\u00a0Trifluridine/Tipiracil\u00a0(TAS\u2010102)\u00a0Monotherapy\u00a0in\u00a0Asian\u00a0 Patients\u00a0With\u00a0Previously\u00a0Treated\u00a0Metastatic\u00a0Colorectal\u00a0\nCancer.\u00a0J\u00a0Clin\u00a0Oncol\u00a036(4):\u00a0350\u2010358.\u00a0\n\u00a0\u00a0205\u00a05 Diskussion\u00a0\nIm\u00a0Innovationsreport\u00a02019\u00a0wurden\u00a0insgesamt\u00a022\u00a0neue\u00a0Fertigarznei mittel\u00a0in\u00a017\u00a0\nAnwendungsgebieten\u00a0des\u00a0Jahres\u00a02016\u00a0und\u00a0ein\u00a0HPV\u2010Impfstoff\u00a0aufgen ommen.\u00a0Nach\u00a0\nden\u00a0Daten\u00a0des\u00a0Arzneiverordnungs\u2010Reportes\u00a02017\u00a0(Fricke\u00a0et\u00a0al.,\u00a02 017,\u00a0S.\u00a056)\u00a0wur\u2010\nden\u00a0im\u00a0Jahre\u00a02016\u00a0insgesamt\u00a031\u00a0neue\u00a0Arzneistoffe\u00a0angeboten.\u00a0Das s\u00a0in\u00a0diesem\u00a0\nInnovationsreport\u00a0nur\u00a021\u00a0der\u00a0neuen\u00a0Arzneistoffe\u00a0(hiermit\u00a0werden \u00a0ausschlie\u00dflich\u00a0\ndie\u00a0unterschiedlichen\u00a0Wirkstoffe\u00a0angesprochen)\u00a0genannt\u00a0und\u00a0bewe rtet\u00a0werden,\u00a0\nhat\u00a0damit\u00a0zu\u00a0tun,\u00a0dass\u00a0es\u00a0sich\u00a0be i\u00a0zwei\u00a0der\u00a0Arzneimittel\u00a0um\u00a0ber eits\u00a0l\u00e4nger\u00a0bekannte\u00a0\nArzneistoffe\u00a0ohne\u00a0Unterlagenschutz\u00a0handelt,\u00a0die\u00a0mit\u00a0neuen\u00a0Indik ationen\u00a0auf\u00a0den\u00a0\ndeutschen\u00a0Markt\u00a0kamen\u00a0und\u00a0f\u00fcr\u00a0die\u00a0vom\u00a0G\u2010BA\u00a0auch\u00a0deshalb\u00a0keine\u00a0B ewertung\u00a0\nvorliegt\u00a0(Eisen(III)\u2010Maltol\u00a0(Fer accru\u00ae),\u00a0Milnacipran\u00a0(Milnaneur ax\u00ae)).\u00a0F\u00fcnf\u00a0der\u00a0Arz\u2010\nneistoffe\u00a0(Dalbavancin\u00a0(Xydalba\u00ae) ,\u00a0Dinutuximab\u00a0(Unituxin\u00ae),\u00a0Ida rucizumab\u00a0(Prax\u2010\nbind\u00ae),\u00a0Necitumumab\u00a0(Portrazza\u00ae),\u00a0Susoctocog\u00a0alfa\u00a0(Obizur\u00ae))\u00a0si nd\u00a0oder\u00a0waren\u00a0\nvor\u00fcbergehend\u00a0nur\u00a0von\u00a0krankenhaus versorgenden\u00a0Apotheken\u00a0direkt\u00a0 vom\u00a0Herstel\u2010\nler\u00a0zu\u00a0beziehen\u00a0und\u00a0spielen\u00a0somi t\u00a0keine\u00a0Rolle\u00a0in\u00a0der\u00a0ambulanten \u00a0Versorgung.\u00a0Zwei\u00a0\nder\u00a0Arzneimittel,\u00a0n\u00e4mlich\u00a0Afamelanotid\u00a0(Scenesse\u00ae)\u00a0und\u00a0Tasimelt eon\u00a0(Hetlioz\u00ae)\u00a0\nwurden\u00a0aufgrund\u00a0ihrer\u00a0speziellen\u00a0und\u00a0seltenen\u00a0Indikation\u00a0nicht\u00a0 in\u00a0unsere\u00a0Bewer\u2010\ntung\u00a0einbezogen.\u00a0Das\u00a0Arzneimittel\u00a0Ospemifem\u00a0(Senshio\u00ae)\u00a0ist\u00a0seit \u00a0April\u00a02017\u00a0nicht\u00a0\nmehr\u00a0 im\u00a0 Handel.\u00a0 Der\u00a0 Arzneistoff\u00a0 Tenofovir\u00a0 wurde\u00a0 neu\u00a0 als\u00a0 prodrug\u00a0T e n o f o v i r \u2010\nalafenamid\u00a0in\u00a0drei\u00a0Produkten\u00a0(Des covy\u00ae,\u00a0Genvoya\u00ae,\u00a0Odefsey\u00ae)\u00a0ein bezogen.\u00a0Insge\u2010\nsamt\u00a0wurden\u00a0daher\u00a0in\u00a0diesem\u00a0vor liegenden\u00a0Innovationsreport\u00a0letz tlich\u00a0also\u00a021\u00a0\nWirkstoffe\u00a0in\u00a023\u00a0Arzneimitteln\u00a0bewertet.\u00a0Alle\u00a0in\u00a0den\u00a0Report\u00a0auf genommenen\u00a0Arz\u2010\nneimittel\u00a0wurden\u00a0im\u00a0Rahmen\u00a0des\u00a0zentralen\u00a0Zulassungsverfahrens\u00a0d er\u00a0EMA\u00a0zuge\u2010\nlassen.\u00a0Sechs\u00a0der\u00a0neuen\u00a0Arzneimi ttel\u00a0entfielen\u00a0auf\u00a0die\u00a0Gruppe\u00a0d er\u00a0Arzneimittel\u00a0zur\u00a0\nBehandlung\u00a0seltener\u00a0Krankheiten\u00a0(Waisenarzneimittel/ Orphan\u00a0Drugs \u00a0zur\u00a0Anwen\u2010\ndung\u00a0bei\u00a0 Orphan\u00a0Diseases ).\u00a0\u00a0\nNachdem\u00a0im\u00a0letzten\u00a0Innovationsreport\u00a02018\u00a0ein\u00a0positiver\u00a0Trend\u00a0e rkennbar\u00a0war\u00a0\nund\u00a0sieben\u00a0Arzneimittel\u00a0mit\u00a0einer\u00a0\u201egr\u00fcnen\u201c\u00a0Ampel\u00a0bewertet\u00a0worde n\u00a0sind,\u00a0die\u00a0\nsowohl\u00a0f\u00fcr\u00a0den\u00a0Patientennutzen\u00a0wie\u00a0auch\u00a0f\u00fcr\u00a0die\u00a0Effektivit\u00e4t\u00a0un d\u00a0f\u00fcr\u00a0Effizienz\u00a0eine\u00a0\npositive\u00a0Gesamtbewertung\u00a0signalis iert,\u00a0hat\u00a0sich\u00a0in\u00a0diesem\u00a0Innov ationsreport\u00a0diese\u00a0\nseinerzeit\u00a0optimistisch\u00a0stimmende\u00a0positive\u00a0Entwicklung\u00a0nicht\u00a0we iter\u00a0fortgesetzt.\u00a0\nSo\u00a0wurden\u00a0nur\u00a0drei\u00a0der\u00a016\u00a0Nicht\u2010 Orphan\u2010Arzneimittel,\u00a0die\u00a0HPV\u2010Impfung\u00a0und\u00a0nur\u00a0\neines\u00a0der\u00a0sechs\u00a0 Orphan\u2010Arzneimittel\u00a0mit\u00a0einer\u00a0\u201egr\u00fcnen\u201c\u00a0Gesamtampel\u00a0bewertet\u00a0\nund\u00a0damit\u00a0zwei\u00a0weniger\u00a0als\u00a0im\u00a0Jahr\u00a0zuvor\u00a0erreicht.\u00a0Insgesamt\u00a0do minieren\u00a0weiter\u2010\nhin\u00a0die\u00a0\u201eroten\u201c\u00a0Ampeln\u00a0in\u00a0der\u00a0Bewertung\u00a0der\u00a0neuen\u00a0Arzneimittel\u00a0 hinsichtlich\u00a0der\u00a0\nverf\u00fcgbaren\u00a0Therapien,\u00a0des\u00a0(Zu satz\u2010)\u00a0Nutzens\u00a0und\u00a0der\u00a0Kosten.\u00a0\nAuch\u00a0der\u00a0Aspekt\u00a0des\u00a0Auftretens\u00a0von\u00a0unerw\u00fcnschten\u00a0Wirkungen\u00a0und\u00a0 Ereignissen\u00a0\nhat\u00a0 die\u00a0 Vermarktung\u00a0 der\u00a0 neuen\u00a0 Arzneimittel\u00a0 begleitet.\u00a0 F\u00fcr\u00a0 vier\u00a0 Medikamente\u00a0\nmussten\u00a0\u201eRote\u2010Hand\u2010Briefe\u201c\u00a0verschickt\u00a0werden,\u00a0im\u00a0Fall\u00a0der\u00a0Wirks toffe\u00a0Sofosbuvir/\u00a0206\u00a0Velpatasvir\u00a0sowie\u00a0Elbasvir/Grazo previr\u00a0sogar\u00a0je\u00a0zwei\u00a0Rote\u2010Hand\u2010 Briefe,\u00a0die\u00a0sich\u00a0an\u00a0\nalle\u00a0direkt\u00a0antiviral\u00a0wirkende\u00a0Arzneimittel\u00a0richteten.\u00a0Nur\u00a0zu\u00a0z wei\u00a0Wirkstoffen\u00a0(Da\u2010\nratumumab\u00a0und\u00a0Selexipag)\u00a0wurde\u00a0ein\u00a0\u201eBlauer\u2010Hand\u2010Brief\u201c\u00a0mit\u00a0neue n\u00a0Informatio\u2010\nnen\u00a0f\u00fcr\u00a0\u00c4rzte\u00a0und\u00a0Patienten\u00a0verfasst.\u00a0\nEine\u00a0Besonderheit\u00a0ist\u00a0in\u00a0diesem\u00a0Jahr\u00a0die\u00a0Bewertung\u00a0des\u00a0HPV\u2010Impf stoffes\u00a0Gardasil\u00ae\u00a09.\u00a0\nDieser\u00a0wurde\u00a0mit\u00a0derselben\u00a0Methodik\u00a0wie\u00a0alle\u00a0anderen\u00a0Arzneimitt el\u00a0bewertet\u00a0und\u00a0\nhat\u00a0daher\u00a0eine\u00a0\u201egr\u00fcne\u201c\u00a0Ampel\u00a0in\u00a0der\u00a0Gesamtbewertung\u00a0erhalten.\u00a0D er\u00a0Impfstoffhat\u00a0\nsich\u00a0aufgrund\u00a0der\u00a0vorliegenden\u00a0epidemiologischen\u00a0und\u00a0klinischen \u00a0Daten\u00a0als\u00a0wert\u2010\nvolle\u00a0Pr\u00e4vention\u00a0f\u00fcr\u00a0M\u00e4dchen\u00a0und\u00a0 Jungen\u00a0vor\u00a0dem\u00a0ersten\u00a0Geschlec htsverkehr\u00a0\nbew\u00e4hrt.\u00a0Er\u00a0verhindert\u00a0Infektionen\u00a0durch\u00a0Papillomviren,\u00a0die\u00a0als \u00a0Vorstufe\u00a0f\u00fcr\u00a0Krebs\u2010\nerkrankungen\u00a0gelten\u00a0\nIn\u00a0Tabelle\u00a05.1\u00a0wurden\u00a0die\u00a0Ergebnisse\u00a0des\u00a0Innovationsreportes\u00a020 19\u00a0mit\u00a0den\u00a0ein\u2010\nzelnen\u00a0Bewertungskategorien,\u00a0dem \u00a0Eingang\u00a0in\u00a0Leitlinien\u00a0und\u00a0weit eren\u00a0Besonder\u2010\nheiten\u00a0zusammengefasst.\u00a0Die\u00a0Gesamt\u2010Scores\u00a0der\u00a0bewerteten\u00a0Arznei mittel\u00a0k\u00f6nnen\u00a0\nden\u00a0Tabellen\u00a05.4,\u00a05.5\u00a0sowie\u00a0der\u00a0T abelle\u00a05.6\u00a0entnommen\u00a0werden.\u00a0\n\u00a0 \u00a0207\u00a0Tabelle\u00a05.1:\u00a0Zusammenfassung\u00a0der\u00a0Wirkstoffbewertungen\u00a0(neue\u00a0Wir kstoffe\u00a0des\u00a0\nJahres\u00a02016)\u00a0nach\u00a0dem\u00a0im\u00a0Report\u00a0genutzten\u00a0Ampelschema\u00a0\nWirkstoff \u00a0 pU\u00a0 Bewertung \u00a0 Eingang\u00a0in\u00a0Leitlinien\u00a0\n(nur\u00a0bei\u00a0mind.\u00a0einer\u00a0\npositiven\u00a0\u00a0\nEmpfehlung)\u00a0Besonderheiten\u00a0 \u00a0\nVerf\u00fcgbare\u00a0\nTherapien\u00a0(Zusatz\u2010)\u00a0\nNutzen\u00a0Kosten\u00a0\nAlbutrepenonacog\u00a0alfa\u00a0\n(O)\u00a0CSL\u00a0Behring\u00a0\u00a0\u00a0 \u00a0nicht\u00a0explizit\u00a0erw\u00e4hnt\u00a0\u00a0\nBrivaracetam\u00a0 UCB\u00a0Pharma\u00a0\u00a0\u00a0\u00a0 \u00a0nicht\u00a0explizit\u00a0erw\u00e4hnt\u00a0Zulassungserw.\u00a0\nKinder\u00a0ab\u00a001/2019\u00a0\nDaratumumab\u00a0(O)\u00a0 Janssen\u2010Cilag\u00a0\u00a0\u00a0\u00a0ESMO,\u00a0NCCN,\u00a0DGHO\u00a0 Blaue\u00a0Hand,\u00a0\u00dcber\u2010\nschreitung\u00a0der\u00a0\u00a0\n50\u00a0Mio.\u00a0\u20ac\u2010Grenze,\u00a0\u00a0\n2\u00a0neue\u00a0Anwendungs\u2010\ngebiete,\u00a03\u00a0G\u2010BA\u2010\nBeschl\u00fcsse,\u00a02\u00a0befr.\u00a0\nEfmoroctocog\u00a0alfa\u00a0 Swedish\u00a0\nOrphan\u00a0Biovitrum\u00a0\u00a0\u00a0 \u00a0nicht\u00a0explizit\u00a0erw\u00e4hnt\u00a0 Europ\u00e4isches\u00a0\nRisikobewertungs\u2010\nverfahren\u00a0f\u00fcr\u00a0alle\u00a0\nFaktor\u2010VIII\u2010Pr\u00e4para\u2010\nte:\u00a0Kein\u00a0erh\u00f6htes\u00a0\nRisiko\u00a0f\u00fcr\u00a0Inhibitor\u2010\nbildung\u00a0bei\u00a0rekombi\u2010\nnanten\u00a0im\u00a0Vergleich\u00a0\nzu\u00a0humanplasmati\u2010\nschen\u00a0Pr\u00e4paraten\u00a0\nnachweisbar\u00a0\nEftrenonacog\u00a0alfa\u00a0(O)\u00a0 Swedish\u00a0\nOrphan\u00a0\nBiovitrum\u00a0\u00a0\u00a0 \u00a0nicht\u00a0explizit\u00a0erw\u00e4hnt\u00a0 \u00a0\nElbasvir/Grazoprevir\u00a0 MSD\u00a0\n\u00a0\u00a0 \u00a0Therapieoption\u00a0bei\u00a0\nGT1/GT4\u00a0ohne\u00a0oder\u00a0\nmit\u00a0kompensierter\u00a0\nZirrhose\u00a0(DGVS,\u00a0EASL,\u00a0\nNICE)\u00a02\u00a0RHB\u00a0f\u00fcr\u00a0alle\u00a0DAA \u00a0\nElotuzumab\u00a0Bristol\u2010Myers\u00a0\nSquibb\u00a0\u00a0\u00a0 \u00a0ESMO,\u00a0NCCN,\u00a0DGHO\u00a0\u00a0\nHPV\u2010Impfstoff\u00a0\n(Gardasil\u00ae\u00a09)\u00a0MSD\u00a0\u00a0\u00a0 \u00a0\n\u00a0 \u00a0\nMepolizumab\u00a0 GSK\u00a0\u00a0\u00a0 \u00a0\u00a0Zulassungserw.\u00a0\nKinder\u00a0ab\u00a003/2019\u00a0\nMigalastat\u00a0(O)\u00a0 Amicus\u00a0\nTherapeutics\u00a0\u00a0\u00a0 \u00a0Weitere\u00a0Therapie\u2010\noption\u00a0bei\u00a0sonst\u00a0\nindizierter\u00a0Enzymer\u2010\nsatztherapie\u00a0(NICE)\u00a0\u00a0\nOlaratumab\u00a0(O)\u00a0 Eli\u00a0Lilly\u00a0\u00a0\u00a0 \u00a0ESMO,\u00a0DGHO;\u00a0NCCN:\u00a0\nentfernt\u00a0im\u00a0Februar\u00a0\n2019\u00a0RHB,\u00a0\u00a0\nbefr.\u00a0G\u2010BA\u2010Beschluss\u00a0\nWiderruf\u00a0der\u00a0\nZulassung\u00a0\nOpicapon\u00a0 Bial\u2010Portela\u00a0\u00a0\u00a0 \u00a0Therapieoption\u00a0bei\u00a0\nDyskinesien/\u00a0\nWirkungsfluktua\u2010\ntionen,\u00a0wenn\u00a0\nEntacapon\u00a0nicht\u00a0\nvertragen\u00a0wird\u00a0\n(NICE),\u00a0Therapieopti\u2010\non\u00a0bei\u00a0Wirkungsfluk\u2010\ntuationen\u00a0(MDS)\u00a0\u00a0208\u00a0Wirkstoff \u00a0 pU\u00a0 Bewertung \u00a0 Eingang\u00a0in\u00a0Leitlinien\u00a0\n(nur\u00a0bei\u00a0mind.\u00a0einer\u00a0\npositiven\u00a0\u00a0\nEmpfehlung)\u00a0Besonderheiten\u00a0 \u00a0\nVerf\u00fcgbare\u00a0\nTherapien\u00a0(Zusatz\u2010)\u00a0\nNutzen\u00a0Kosten\u00a0\nOsimertinib\u00a0 AstraZeneca\u00a0\u00a0\u00a0 \u00a0 ESMO,\u00a0NCCN,\u00a0DGHO,\u00a0\nAWMF\u2010S3\u2010Leitlinie\u00a0\nLungenkarzinom\u00a03\u00a0G\u2010BA\u2010Beschl.;\u00a0\u00a0\nIn\u00a0Deutschland\u00a0\nvor\u00fcbergehend\u00a0\nau\u00dfer\u00a0Vertrieb\u00a0\nPalbociclib\u00a0 Pfizer\u00a0\u00a0\u00a0 \u00a0Therapieoption\u00a0(als\u00a0\nKombination\u00a0in\u00a0\nbestimmten\u00a0Situatio\u2010\nnen)\u00a0bei\u00a0fortgeschrit\u2010\ntenem\u00a0Mammakarzi\u2010\nnom\u00a0(DKG,\u00a0NICE,\u00a0\nESMO,\u00a0ASCO)\u00a02\u00a0G\u2010BA\u2010Beschl\u00fcsse,\u00a0\u00a0\n1\u00a0davon\u00a0noch\u00a0\nbefristet\u00a0\nPitolisant\u00a0(O)\u00a0 Bioprojet\u00a0\nPharma\u00a0\u00a0\u00a0 \u00a0nicht\u00a0erw\u00e4hnt\u00a0(DGN),\u00a0\nkeine\u00a0explizite\u00a0\nEmpfehlung\u00a0(NICE)\u00a0\u00a0\nSacubitril/Valsartan\u00a0 Novartis\u00a0\nPharma\u00a0\u00a0\u00a0 \u00a0 NVL,\u00a0ESC,\u00a0NICE,\u00a0\nACC/AHA/HFSA\u00a0\u00a0\nSelexipag\u00a0 Actelion\u00a0\u00a0\u00a0 \u00a0Therapieoption\u00a0(ESC),\u00a0\nDrittlinien\u2010Therapie\u00a0\n(CADTH,\u00a0NICE)\u00a0Blaue\u00a0Hand\u00a0\nSofosbuvir/Velpatasvir\u00a0 Gilead\u00a0\u00a0\u00a0 \u00a0Therapieoption\u00a0bei\u00a0\nallen\u00a0GT\u00a0(DGSV,\u00a0\nWHO,\u00a0EASL,\u00a0NICE)\u00a02\u00a0RHB\u00a0f\u00fcr\u00a0alle\u00a0DAA\u00a0\nTalimogen\u00a0\u00a0laherparepvec\u00a0Amgen\u00a0\nEurope\u00a0B.V.\u00a0\u00a0\u00a0 \u00a0\u00a0\n\u00a0\nTenofoviralafenamid/\u00a0\nElvitegravir/\u00a0\nCobicistat/\u00a0\nEmtricitabin\u00a0Gilead\u00a0\nSciences\u00a0\u00a0\u00a0 \u00a0\nTAF:\u00a0Deutsch\u2010\n\u00d6sterreichische\u00a0\nLeitlinien\u00a0zur\u00a0\nantiretroviralen\u00a0\nTherapie\u00a0\nder\u00a0HIV\u2010Infektion\u00a0RHB,\u00a0Zulassungserw.\u00a0\nKinder\u00a0ab\u00a007/2018,\u00a0\u00a0\n2\u00a0G\u2010BA\u2010Beschl.\u00a0\nTenofoviralafenamid/\u00a0Emtricitabin\u00a0\u00a0\u00a0\u00a0\n\u00a0 \u00a0\nTenofoviralafenamid/\u00a0\nEmtricitabin/\u00a0Rilpivirin\u00a0\u00a0\u00a0\u00a0 \u00a0\n\u00a0\nTrifluridin/Tipiracil\u00a0 Servier/Taiho\u00a0\nOncology\u00a0\u00a0\u00a0\u00a0 \u00a0AWMF\u00a0S3\u2010Leitlinie\u00a0\nKolorektalkarzinom\u00a0\u00a0\u00a0G\u2010BA:\u00a0Befristeter\u00a0\nBeschluss\u00a0\u00a0\nFDA:\u00a0Indikationser\u2010\nweiterung\u00a0f\u00fcr\u00a0Adeno\u2010\nCA\u00a0des\u00a0Magens\u00a0und\u00a0\nGEJ\u00a0als\u00a0Orphan\u2010\nArzneimittel\u00a0im\u00a0\nPriority\u00a0Review \u00a0\u00a0\u00a0\n\u00a0\n\u00a0 \u00a0209\u00a0Auch\u00a0in\u00a0diesem\u00a0Jahr\u00a0waren\u00a0wieder\u00a0vor\u00a0allem\u00a0Arzneimittel\u00a0zur\u00a0Beh andlung\u00a0von\u00a0\nKrebserkrankungen\u00a0die\u00a0h\u00e4ufigsten\u00a0 bewerteten\u00a0Medikamente\u00a0(30\u00a0%). \u00a0F\u00fcnf\u00a0Wirk\u2010\nstoffe\u00a0entfielen\u00a0auf\u00a0die\u00a0ATC\u20103\u2010G ruppe\u00a0\u201eAntivirale\u00a0Mittel\u00a0zur\u00a0sy stemischen\u00a0Anwen\u2010\ndung\u201c\u00a0zur\u00a0Behandlung\u00a0von\u00a0Hepatitis\u00a0C\u00a0oder\u00a0HIV.\u00a0Die\u00a0restlichen\u00a0z ehn\u00a0Arzneimittel\u00a0\nund\u00a0 der\u00a0 HPV\u2010Impfstoff\u00a0 entfallen\u00a0 auf\u00a0 zehn\u00a0 weitere\u00a0 ATC\u2010Indikation sgruppen\u00a0 (s.\u00a0\nTabelle\u00a05.2).\u00a0\nTabelle\u00a05.2:\u00a0Untersuchte\u00a0ATC\u2010Gruppen\u00a0nach\u00a0H\u00e4ufigkeit\u00a0\nUntersuchte\u00a0ATC\u20103\u2010Gruppen\u00a0Anzahl\u00a0Wirkstoffe\u00a0\u00a0\nnach\u00a0H\u00e4ufigkeit\u00a0\nL01\u00a0Antineoplastische\u00a0Mittel\u00a0 7\u00a0\nJ05\u00a0Antivirale\u00a0Mittel\u00a0zur\u00a0 systemischen\u00a0Anwendung\u00a0 5\u00a0\nB02\u00a0 Antih\u00e4morrhagika\u00a0 3\u00a0\nA16\u00a0Andere\u00a0Mittel\u00a0f\u00fcr\u00a0das\u00a0aliment\u00e4re\u00a0System\u00a0und\u00a0den\u00a0Stoffwechsel\u00a0 1\u00a0\nB01*\u00a0Antithrombotische\u00a0Mittel\u00a0 1\u00a0\nC09\u00a0Mittel\u00a0mit\u00a0Wirkung\u00a0auf\u00a0das\u00a0Renin\u2010Angiotensin\u2010System\u00a0\u00a0 1\u00a0\nJ07\u00a0Impfstoffe\u00a0 1\u00a0\nN03\u00a0Antiepileptika\u00a0 1\u00a0\nN04\u00a0Antiparkinsonmittel\u00a0 1\u00a0\nN07\u00a0Andere\u00a0Mittel\u00a0f\u00fcr\u00a0den\u00a0Respirationstrakt\u00a0 1\u00a0\nR03*\u00a0Mittel\u00a0bei\u00a0obstruktiven\u00a0 Atemwegserkrankungen\u00a0 1\u00a0\n\u00a0Gesamt\u00a0 23\u00a0\n*\u00a0weitere\u00a0ATC\u20103\u2010Gruppe\u00a0nach\u00a0WIdO\u00a0\n\u00a0 \u00a0210\u00a0Von\u00a0sechs\u00a0 Orphan\u2010Arzneimitteln\u00a0haben\u00a0insgesamt\u00a0f\u00fcnf\u00a0Arzneimittel\u00a0eine\u00a0 \u201erote\u00a0\nAmpel\u201c\u00a0im\u00a0Gesamt\u2010Score\u00a0erhalten\u00a0(Tabelle\u00a05.3).\u00a0Eine\u00a0\u201egelbe\u00a0Ampe l\u201c\u00a0konnte\u00a0f\u00fcr\u00a0\nkeines\u00a0der\u00a0 Orphan\u2010Arzneimittel\u00a0vergeben\u00a0werden.\u00a0Lediglich\u00a0ein\u00a0Wirkstoff\u00a0bekam\u00a0\neine\u00a0\u201egr\u00fcne\u201c\u00a0Ampel.\u00a0Darzalex \u00ae\u00a0(Daratumumab)\u00a0wurde\u00a0als\u00a0 Orphan\u00a0zugelassen,\u00a0hat\u00a0\naber\u00a0mittlerweile\u00a0die\u00a050\u00a0Mio.\u00a0\u20ac\u2010Grenze\u00a0\u00fcberschritten\u00a0und\u00a0wurde\u00a0 somit\u00a0erneut\u00a0\ndurch\u00a0den\u00a0G\u2010BA\u00a0bewertet.\u00a0Auch\u00a0bei\u00a0den\u00a017\u00a0Nicht\u2010 Orphan\u2010Arzneimitteln\u00a0erhielten\u00a0\ndie\u00a0meisten,\u00a0insgesamt\u00a0neun\u00a0Mittel,\u00a0eine\u00a0\u201erote\u201c\u00a0Ampel\u00a0im\u00a0Gesamt \u2010Score.\u00a0Immer\u2010\nhin\u00a0vier\u00a0Arzneimittel\u00a0konnten\u00a0aber\u00a0mit\u00a0einer\u00a0\u201egr\u00fcnen\u201c\u00a0und\u00a0vier\u00a0 mit\u00a0einer\u00a0\u201egelben\u201c\u00a0\nGesamtampel\u00a0bewertet\u00a0werden.\u00a0\nTabelle\u00a05.3:\u00a0Gesamt\u00fcberblick\u00a0der\u00a0Ampeln\u00a0\u00a0\n\u00a0 Gr\u00fcn\u00a0 Gelb\u00a0 Rot\u00a0\nWirkstoffe\u00a0mit\u00a0 Orphan\u2010\nZulassung\u00a0\nn\u00a0=\u00a06\u00a0\n(erneut\u00a0bewertet\u00a0n \u00a0=\u00a01)\u00a01\u00a0(16,7\u00a0%)\u00a0 0\u00a0(0\u00a0%)\u00a0 5\u00a0(83,3\u00a0%)\u00a0\n\u00a0 \u00a0 \u00a0 \u00a0\nNicht\u2010Orphan\u2010Wirkstoffe\u00a0\n(davon\u00a0ein\u00a0Impfstoff)\u00a0\nn\u00a0=\u00a017\u00a04\u00a0(23,5\u00a0%)\u00a0 4\u00a0(23,5\u00a0%)\u00a0 9\u00a0(52,9\u00a0%)\u00a0\n\u00a0 \u00a0 \u00a0 \u00a0\nGesamt\u00a0\u00a0\nn\u00a0=\u00a023\u00a05\u00a0(21,7\u00a0%)\u00a0 4\u00a0(17,4\u00a0%)\u00a0 14\u00a0(60,9\u00a0%)\u00a0\n\u00a0\n\u00a0\u00a0211\u00a0Tabelle\u00a05.4:\u00a0Gesamt\u2010Score\u00a0Innovationsbewertung\u00a0\nVerf\u00fcgbare\u00a0\nTherapien\u00a0\u00a0 (Zusatz\u2010)Nutzen\u00a0 \u00a0 Kosten\u00a0 \u00a0 Gesamt\u2010Score\u00a0\n\u00a0\nBrivaracetam\u00a0\nEfmoroctocog\u00a0alfa\u00a0\nElbasvir/Grazoprevir\u00a0\nOpicapon\u00a0\nPalbociclib\u00a0\nTenofoviralafenamid/\u00a0\nElvitegravir/Cobicistat/\nEmtricitabin\u00a0\nTenofoviralafenamid/\u00a0\nEmtricitabin\u00a0\nTenofoviralafenamid/\u00a0\nEmtricitabin/Rilpivirin\u00a0\nSelexipag\u00a0\n\u00a0\u00a0Brivaracetam\u00a0\nEfmoroctocog\u00a0alfa\u00a0\nElbasvir/Grazoprevir\u00a0\nOpicapon\u00a0\nPalbociclib\u00a0\nSelexipag\u00a0\nTalimogen\u00a0laherpa\u2010\nrepvec\u00a0\nTenofoviralafenamid/\u00a0\nElvitegravir/Cobicistat/\u00a0\nEmtricitabin\u00a0\nTenofoviralafenamid/\u00a0\nEmtricitabin\u00a0\nTenofoviralafenamid/\u00a0\nEmtricitabin/Rilpivirin\u00a0\n\u00a0\u00a0Elotuzumab\u00a0\nPalbociclib\u00a0\nSacubitril/Valsartan\u00a0\nTenofoviralafenamid/\u00a0\nEmtricitabin\u00a0\n\u00a0\u00a0Brivaracetam\u00a0(1)\u00a0\nEfmoroctocog\u00a0alfa\u00a0(1)\u00a0\nElbasvir/Grazoprevir\u00a0(2)\u00a0\nTenofoviralafenamid/\u00a0\nElvitegravir/Cobicistat/\u00a0\nEmtricitabin\u00a0(1)\u00a0\nTenofoviralafenamid/\u00a0\nEmtricitabin/Rilpivirin\u00a0(1)\u00a0\nTenofoviralafenamid/\u00a0\nEmtricitabin\u00a0(0)\u00a0\nOpicapon\u00a0(1)\u00a0\nPalbociclib\u00a0(0)\u00a0\nSelexipag\u00a0(1)\u00a0\n\u00a0\n\u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nOsimertinib\u00a0\nSacubitril/Valsartan\u00a0\nSofosbuvir/Velpatasvir\u00a0\nTrifluridin/Tipiracil\u00a0\n\u00a0\u00a0Mepolizumab\u00a0\nOsimertinib\u00a0\nSofosbuvir/Velpatas\u2010\nvir\u00a0\nTrifluridin/Tipiracil\u00a0\n\u00a0\u00a0Brivaracetam\u00a0\nEfmoroctocog\u00a0alfa\u00a0\nHPV\u2010Impfstoff\u00a0(Gar\u2010\ndasil\u00ae\u00a09)\u00a0\nMepolizumab\u00a0\nOpicapon\u00a0\nOsimertinib\u00a0\nSelexipag\u00a0\nSofosbuvir/Velpatasvir\u00a0\nTalimogen\u00a0laherpa\u2010\nrepvec\u00a0\nTenofoviralafenamid/\u00a0\nElvitegravir/Cobicistat/\u00a0\nEmtricitabin\u00a0\u00a0\nTenofoviralafenamid/\u00a0\nEmtricitabin/Rilpivirin\u00a0\n\u00a0\u00a0Osimertinib\u00a0(4)\u00a0\nTrifluridin/Tipiracil\u00a0(3)\u00a0\nSofosbuvir/Velpatas\u2010\nvir\u00a0(4)\u00a0\nTalimogen\u00a0laherpa\u2010\nrepvec\u00a0(3)\u00a0\n\u00a0\n\u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nElotuzumab\u00a0\nHPV\u2010Impfstoff\u00a0\n(Gardasil\u00ae\u00a09)\u00a0\nMepolizumab\u00a0\nTalimogen\u00a0laherpa\u2010\nrepvec\u00a0\n\u00a0\u00a0Elotuzumab\u00a0\nHPV\u2010Impfstoff\u00a0\n(Gardasil\u00ae\u00a09)\u00a0\nSacubitril/Valsartan\u00a0\n\u00a0\u00a0Elbasvir/Grazoprevir\u00a0 \u00a0 Elotuzumab\u00a0(6)\u00a0\nHPV\u2010Impfstoff\u00a0\n(Gardasil\u00ae\u00a09)\u00a0(7)\u00a0\nMepolizumab\u00a0(5)\u00a0\nSacubitril/Valsar\u2010\u00a0\ntan\u00a0(5)\u00a0\n\u00a0\nScore\u2010Erl\u00e4uterung :\u00a0Bei\u00a0den\u00a0Wirkstoffportr\u00e4ts\u00a0wurden\u00a0die\u00a0einzelnen\u00a0Punkte\u00a0der\u00a0Inn ovationsbewertung\u00a0separat\u00a0betrachtet,\u00a0der\u00a0\npatientenrelevante\u00a0Zusatznutzen\u00a0erhielt\u00a0das\u00a0gr\u00f6\u00dfte\u00a0Gewicht.\u00a0Die \u00a0Vergabe\u00a0der\u00a0Punkte\u00a0wurde\u00a0wie\u00a0folgt\u00a0vorgenommen: \u00a0Verf\u00fcgbare \u00a0\nTherapien: \u00a0rote\u00a0Ampel\u00a0=\u00a00\u00a0Punkte,\u00a0gelbe\u00a0Ampel\u00a0=\u00a01\u00a0Punkt,\u00a0gr\u00fcne\u00a0Ampel\u00a0=\u00a02\u00a0P unkte;\u00a0(Zusatz\u2010)Nutzen :\u00a0rote\u00a0Ampel\u00a0=\u00a00\u00a0Punkte,\u00a0gelbe\u00a0\nAmpel\u00a0=\u00a02\u00a0Punkte,\u00a0gr\u00fcne\u00a0Ampel\u00a0=\u00a04\u00a0Punkte; \u00a0Kosten:\u00a0rote\u00a0Ampel\u00a0=\u00a00\u00a0Punkte,\u00a0gelbe\u00a0Ampel\u00a0=\u00a01\u00a0Punkt,\u00a0gr\u00fcne\u00a0Ampel\u00a0=\u00a02 \u00a0Punkte;\u00a0\nGesamt:\u00a0rote\u00a0Ampel\u00a0=\u00a0h\u00f6chstens\u00a02\u00a0Punkte,\u00a0gelbe\u00a0Ampel\u00a0=\u00a03\u00a0oder\u00a04\u00a0Punkt e,\u00a0gr\u00fcne\u00a0Ampel\u00a0=\u00a05\u00a0Punkte\u00a0und\u00a0mehr.\u00a0Wirkstoffe\u00a0ohne\u00a0\nKostenbewertung\u00a0erhalten\u00a0einen\u00a0Gesamt\u2010Score\u00a0aus\u00a0Verf\u00fcgbaren\u00a0The rapien\u00a0und\u00a0(Zusatz\u2010)Nutzen.\u00a0212\u00a0Tabelle\u00a0 5.5:\u00a0 Gesamt\u2010Score\u00a0 Innovationsbewertung\u00a0 Arzneimittel\u00a0 mit \u00a0Orphan\u2010\nZulassung\u00a0\nVerf\u00fcgbare\u00a0\nTherapien\u00a0\u00a0 (Zusatz\u2010)Nutzen\u00a0 \u00a0 Kosten\u00a0 \u00a0 Gesamt\u2010Score\u00a0\n\u00a0\nAlbutrepenonacog\u00a0alfa\u00a0\nEftrenonacog\u00a0alfa\u00a0\nMigalastat\u00a0\nOlaratumab\u00a0\nPitolisant\u00a0\u00a0Olaratumab\u00a0\n\u00a0\u00a0\u00a0\u00a0 Albutrepenonacog\u00a0alfa\u00a0\n(2)\u00a0\nEftrenonacog\u00a0alfa\u00a0(2)\u00a0\nMigalastat\u00a0(2)\u00a0\nOlaratumab\u00a0(0)\u00a0\nPitolisant\u00a0(2)\u00a0\n\u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\n\u00a0\n\u00a0\u00a0Albutrepenonacog\u00a0alfa\u00a0\nEftrenonacog\u00a0alfa\u00a0\nMigalastat\u00a0\nPitolisant\u00a0\u00a0Daratumumab\u00a0\n\u00a0\u00a0\u00a0\n\u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nDaratumumab\u00a0\n\u00a0\u00a0Daratumumab\u00a0\n\u00a0\u00a0\u00a0\u00a0 Daratumumab\u00a0(7)\u00a0\n\u00a0\nScore\u2010Erl\u00e4uterung :\u00a0Bei\u00a0den\u00a0Wirkstoffportr\u00e4ts\u00a0wurden\u00a0die\u00a0einzelnen\u00a0Punkte\u00a0der\u00a0Inn ovationsbewertung\u00a0separat\u00a0betrachtet,\u00a0der\u00a0\npatientenrelevante\u00a0Zusatznutzen\u00a0erhielt\u00a0das\u00a0gr\u00f6\u00dfte\u00a0Gewicht.\u00a0Die \u00a0Vergabe\u00a0der\u00a0Punkte\u00a0wurde\u00a0wie\u00a0folgt\u00a0vorgenommen: \u00a0Verf\u00fcgbare \u00a0\nTherapien: \u00a0rote\u00a0Ampel\u00a0=\u00a00\u00a0Punkte,\u00a0gelbe\u00a0Ampel\u00a0=\u00a01\u00a0Punkt,\u00a0gr\u00fcne\u00a0Ampel\u00a0=\u00a02\u00a0P unkte;\u00a0(Zusatz\u2010)Nutzen :\u00a0rote\u00a0Ampel\u00a0=\u00a00\u00a0Punkte,\u00a0gelbe\u00a0\nAmpel\u00a0=\u00a02\u00a0Punkte,\u00a0gr\u00fcne\u00a0Ampel\u00a0=\u00a04\u00a0Punkte\u00a0 Kosten:\u00a0rote\u00a0Ampel\u00a0=\u00a00\u00a0Punkte,\u00a0gelbe\u00a0Ampel\u00a0=\u00a01\u00a0Punkt,\u00a0gr\u00fcne\u00a0Ampel\u00a0=\u00a02 \u00a0Punkte;\u00a0\nGesamt:\u00a0rote\u00a0Ampel\u00a0=\u00a0h\u00f6chstens\u00a02\u00a0Punkte,\u00a0gelbe\u00a0Ampel\u00a0=\u00a03\u00a0oder\u00a04\u00a0Punkt e,\u00a0gr\u00fcne\u00a0Ampel\u00a0=\u00a05\u00a0Punkte\u00a0und\u00a0mehr.\u00a0Wirkstoffe\u00a0ohne\u00a0Kosten\u2010\nbewertung\u00a0erhalten\u00a0einen\u00a0Gesamt\u2010Score\u00a0aus\u00a0Verf\u00fcgbaren\u00a0Therapien \u00a0und\u00a0(Zusatz\u2010)Nutzen.\u00a0O ex:\u00a0aufgehobener\u00a0 Orphan\u2010Status.\u00a0\n\u00a0\u00a0213\u00a0Tabelle\u00a05.6:\u00a0Zusammenfassung\u00a0Ges amt\u2010Score\u00a0und\u00a0G\u2010BA\u2010Nutzenbewert ung\u00a0\nWirkstoff\u00a0 Indikation \u00a0 Gesamt\u2010Score \u00a0G\u2010BA\u00a0Nutzenbewertung \u00a0\nAlbutrepenonacog\u00a0alfa\u00a0(O) \u00a0H\u00e4mophilie\u00a0B\u00a0\u00a0ZN\u00a0nicht\u00a0quantifizierbar\u00a0(1/1)\u00a0\nBrivaracetam \u00a0 Epilepsie\u00a0\u00a0ZN\u00a0nicht\u00a0belegt\u00a0(2/2)\u00a0\nDaratumumab\u00a0(O) \u00a0 Multiples\u00a0Myelom\u00a0\u00a0Hinweis\u00a0auf\u00a0betr\u00e4chtl.\u00a0ZN\u00a0(1/3)\u00a0\nZN\u00a0nicht\u00a0belegt\u00a0(1/3)\u00a0\nAnhaltspunkt\u00a0f.\u00a0betr\u00e4chtl.\u00a0ZN\u00a0(1/3)\u00a0\nEfmoroctocog\u00a0alfa \u00a0 H\u00e4mophilie\u00a0A\u00a0\u00a0ZN\u00a0nicht\u00a0belegt\u00a0(1/1)\u00a0\nEftrenonacog\u00a0alfa\u00a0(O) \u00a0H\u00e4mophilie\u00a0B\u00a0\u00a0ZN\u00a0nicht\u00a0quantifizierbar\u00a0(1/1)\u00a0\nElbasvir/Grazoprevir\u00a0 Chronische\u00a0Hepatitis\u00a0C\u00a0\u00a0\u00a0ZN\u00a0nicht\u00a0belegt\u00a0(2/2)\u00a0\nElotuzumab \u00a0 Multiples\u00a0Myelom\u00a0\u00a0\nAnhaltspunkt\u00a0f.\u00a0geringen\u00a0ZN\u00a0(1/1)\u00a0\nHPV\u2010Impfstoff\u00a0(Gardasil\u00ae\u00a09) \u00a0HPV\u2010Impfstoff\u00a0\u00a0keine\u00a0Nutzenbewertung\u00a0\nMepolizumab \u00a0 Asthma\u00a0bronchiale\u00a0\u00a0\nAnhaltspunkt\u00a0f.\u00a0geringen\u00a0ZN\u00a0(1/3)\u00a0\nZN\u00a0nicht\u00a0belelgt\u00a0(2/3)\u00a0\nMigalastat\u00a0(O) \u00a0 Morbus\u00a0Fabry\u00a0\u00a0\nZN\u00a0nicht\u00a0quantifizierbar\u00a0(1/1)\u00a0\nOlaratumab\u00a0(O) \u00a0 Weichgewebesarkom\u00a0\u00a0\nZN\u00a0betr\u00e4chtlich\u00a0(1/1)\u00a0\nOpicapon \u00a0 Morbus\u00a0Parkinson\u00a0\u00a0\nZN\u00a0nicht\u00a0belegt\u00a0(1/1)\u00a0\nOsimertinib \u00a0 nicht\u2010kleinzell.\u00a0Lungenkarzinom\u00a0\u00a0\nAnhaltspunkt\u00a0f.\u00a0betr\u00e4chtl.\u00a0ZN\u00a0(2/6)\u00a0\nZN\u00a0nicht\u00a0belegt\u00a0(4/6)\u00a0\nPalbociclib \u00a0 HR\u2010positiver,\u00a0HER2\u2010negativer\u00a0\nfortgeschrittener\u00a0Brustkrebs\u00a0\u00a0\nZN\u00a0nicht\u00a0belegt\u00a0(4/4)\u00a0\nPitolisant\u00a0(O) \u00a0 Narkolepsie\u00a0mit\u00a0oder\u00a0ohne\u00a0\nKataplexie\u00a0\u00a0\nZN\u00a0nicht\u00a0quantifizierbar\u00a0(1/1)\u00a0\nSacubitril/Valsartan \u00a0 chronische\u00a0Herzinsuffizienz\u00a0mit\u00a0\nreduzierter\u00a0Ejektionsfraktion\u00a0\u00a0\u00a0\nAnhaltspunkt\u00a0f.\u00a0betr\u00e4chtl.\u00a0ZN\u00a0(1/2)\u00a0\nAnhaltspunkt\u00a0f.\u00a0geringen\u00a0ZN\u00a0(1/2)\u00a0\nSelexipag \u00a0 Pulmonal\u00a0arterielle\u00a0Hypertonie\u00a0\u00a0\nZN\u00a0nicht\u00a0belegt\u00a0(1/1)\u00a0\nSofosbuvir/Velpatasvir\u00a0 Chronische\u00a0Hepatitis\u00a0C\u00a0\u00a0\u00a0\nAnhaltspunkt\u00a0f.\u00a0betr\u00e4chtl.\u00a0ZN\u00a0(1/9)\u00a0\nAnhaltspunkt\u00a0f.\u00a0geringen\u00a0ZN\u00a0(1/9)\u00a0\nAnhaltspunkt\u00a0f.\u00a0nicht\u00a0\nquantifizierbaren\u00a0ZN\u00a0(1/9)\u00a0\nZN\u00a0nicht\u00a0belelgt\u00a0(6/9)\u00a0\nTalimogen\u00a0laherparepvec \u00a0Melanom\u00a0\u00a0\nZN\u00a0nicht\u00a0belegt\u00a0(3/3)\u00a0\nTenofoviralafenamid/\u00a0\nElvitegravir/Cobicistat/\u00a0\nEmtricitabin \u00a0HIV\u00a0\u00a0ZN\u00a0nicht\u00a0belegt\u00a0(6/6)\u00a0\nTenofoviralafenamid/\u00a0\nEmtricitabin\u00a0HIV\u00a0\u00a0ZN\u00a0nicht\u00a0belegt\u00a0(4/4)\u00a0\nTenofoviralafenamid/\u00a0\nEmtricitabin/Rilpivirin\u00a0HIV\u00a0\u00a0ZN\u00a0nicht\u00a0belegt\u00a0(4/4)\u00a0\nTrifluridin/Tipiracil \u00a0 Metastasiertes\u00a0Kolorektal\u2010CA\u00a0\u00a0\nAnhaltspunkt\u00a0f\u00fcr\u00a0geringen\u00a0ZN\u00a0(1/1)\u00a0\n\u00a0214\u00a0Insgesamt\u00a0wurden\u00a0in\u00a0diesem\u00a0Jahr\u00a0f\u00fcr\u00a061 \u00a0%\u00a0der\u00a0im\u00a0Jahre\u00a02016\u00a0neu\u00a0eingef\u00fchrten\u00a0\nMittel\u00a0eine\u00a0\u201erote\u201c\u00a0Ampel\u00a0f\u00fcr\u00a0die\u00a0 Gesamtbewertung\u00a0vergeben.\u00a0F\u00fcr\u00a0 knapp\u00a022 \u00a0%\u00a0der\u00a0\nMedikamente\u00a0w\u00fcrde\u00a0eine\u00a0\u201egr\u00fcne\u201c,\u00a0f\u00fcr\u00a0rund\u00a017 \u00a0%\u00a0eine\u00a0\u201egelbe\u201c\u00a0Ampel\u00a0vergeben.\u00a0\nDie\u00a0positive\u00a0Entwicklung\u00a0aus\u00a0dem\u00a0Innovationsreport\u00a02018\u00a0hat\u00a0sic h\u00a0also\u00a0leider\u00a0nicht\u00a0\nfortgesetzt.\u00a0Letztlich\u00a0erh\u00e4lt\u00a0dam it\u00a0mehr\u00a0als\u00a0die\u00a0H\u00e4lfte\u00a0der\u00a0neu en\u00a0Arzneimittel\u00a0eine\u00a0\nschlechte\u00a0Bewertung,\u00a0\u201eneu\u201c\u00a0ist\u00a0bekannterma\u00dfen\u00a0auch\u00a0grunds\u00e4tzlic h\u00a0nicht\u00a0in\u00a0jedem\u00a0\nFall\u00a0gleichbedeutend\u00a0mit\u00a0therapeutischem\u00a0Fortschritt.\u00a0Auch\u00a0die\u00a0 Zwischenkategorie\u00a0\n\u201egelb\u201c\u00a0war\u00a0nur\u00a0relativ\u00a0selten\u00a0vertreten.\u00a0Auff\u00e4llig\u00a0ist\u00a0erneut,\u00a0 dass\u00a0f\u00fcr\u00a0die\u00a0 Orphan\u2010\nArzneimittel\u00a0des\u00a0Jahres\u00a02016\u00a0nur\u00a0einmal\u00a0eine\u00a0\u201egr\u00fcne\u201c\u00a0Ampel\u00a0verg eben\u00a0werden\u00a0\nkonnte,\u00a0f\u00fcnfmal\u00a0kam\u00a0es\u00a0zu\u00a0einer\u00a0\u201eroten\u201c\u00a0Ampel.\u00a0Dies\u00a0ist\u00a0ein\u00a0wei terer\u00a0Hinweis\u00a0da\u2010\nf\u00fcr,\u00a0dass\u00a0auch\u00a0 Orphan\u2010Arzneimittel\u00a0nicht\u00a0schon\u00a0allein\u00a0durch\u00a0die\u00a0Zulassung\u00a0als\u00a0\u201ege\u2010\nadelt\u201c\u00a0im\u00a0Sinne\u00a0eines\u00a0nachgewiesenen\u00a0Patientennutzens\u00a0gelten\u00a0so llten,\u00a0sondern\u00a0\nauch\u00a0durch\u00a0das\u00a0gesamte\u00a0AMNOG\u2010Verfahren\u00a0hindurchm\u00fcssen\u00a0\u2013\u00a0zum\u00a0Sch utz\u00a0und\u00a0zur\u00a0\nSicherheit\u00a0der\u00a0Patienten.\u00a0\u00a0\n\u00a0\u00a0215\u00a0Abbildung\u00a05.1:\u00a0Verordnungspr\u00e4valenz\u00a0der\u00a0neuen\u00a0Wirkstoffe\u00a0des\u00a0Ja hres\u00a02016\u00a0\nohne\u00a0Zusatznutzen\u00a0(\u201erote\u00a0Ampel\u201c)\u00a0f\u00fcr\u00a0TK\u2010Versicherte\u00a0in\u00a0Promille \u00a0nach\u00a0Bundes\u2010\nl\u00e4ndern\u00a0(nur\u00a0Verordnungen\u00a0im\u00a0Jahr\u00a02017)\u00a0\n\u00a0\n\u00a0\u00a0\n216\u00a0Quellen\u00a0\nFricke\u00a0U,\u00a0Hein\u00a0L,\u00a0Schwabe\u00a0U\u00a0(2017).\u00a0Neue\u00a0Arzneimittel\u00a02016.\u00a0In: \u00a0Schwabe\u00a0U,\u00a0Paffrath\u00a0D,\u00a0Ludwig\u00a0W\u2010D,\u00a0Klauber\u00a0J\u00a0(Hrsg.)\u00a0(2017).\u00a0\nArzneiverordnungs\u2010Report\u00a02017.\u00a0Berlin,\u00a0Heidelberg.\u00a0Springer:\u00a055 \u2010135..\u00a0\n\u00a0\n\u00a0 \u00a0217\u00a06 Impfen\u00a0und \u00a0Impfpflicht\u00a0\nGerd\u00a0Glaeske,\u00a0Winfried\u00a0V.\u00a0Kern,\u00a0Chantal\u00a0Mei\u00dfner\u00a0\nDie\u00a0medizinische\u00a0Pr\u00e4vention\u00a0f\u00fcr\u00a0Kinder\u00a0ist\u00a0in\u00a0Bezug\u00a0auf\u00a0Impfung en\u00a0strukturell\u00a0und\u00a0\norganisatorisch\u00a0in\u00a0Deutschland\u00a0z war\u00a0gut\u00a0ausgebaut.\u00a0Es\u00a0bestehen\u00a0 allerdings\u00a0oftmals\u00a0\nDefizite\u00a0 hinsichtlich\u00a0 der\u00a0 Darstellung\u00a0 von\u00a0 Wirksamkeit\u00a0 und\u00a0 Nutze n\u00a0 f\u00fcr\u00a0 einzelne\u00a0\nMenschen\u00a0und\u00a0die\u00a0gesamte\u00a0Bev\u00f6lkerung\u00a0sowie\u00a0von\u00a0Qualit\u00e4tssicheru ng\u00a0in\u00a0der\u00a0Um\u2010\nsetzung\u00a0von\u00a0Impfempfehlungen.\u00a0Die\u00a0\u00f6ffentlich\u00a0ausgetragenen\u00a0Ause inandersetzun\u2010\ngen\u00a0von\u00a0Impfbef\u00fcrwortern\u00a0und\u00a0Impfgegnern,\u00a0die\u00a0auch\u00a0bis\u00a0in\u00a0das\u00a0\u00e4 rztliche\u00a0Umfeld\u00a0\nhineinreichen,\u00a0f\u00fchren\u00a0insbesondere \u00a0auch\u00a0bei\u00a0Eltern\u00a0oder\u00a0Erziehu ngsberechtigten\u00a0\nzur\u00a0Verunsicherung\u00a0dar\u00fcber,\u00a0ob\u00a0die\u00a0Kinder\u00a0nun\u00a0geimpft\u00a0werden\u00a0so llen\u00a0oder\u00a0nicht.\u00a0\nNicht\u00a0selten\u00a0stehen\u00a0die\u00a0Argument e\u00a0f\u00fcr\u00a0oder\u00a0gegen\u00a0eine\u00a0Impfung\u00a0g eradezu\u00a0unver\u2010\ns\u00f6hnlich\u00a0gegen\u00fcber.\u00a0Die\u00a0Folge:\u00a0die\u00a0erw\u00fcnschten\u00a0und\u00a0f\u00fcr\u00a0eine\u00a0aus reichende\u00a0Immu\u2010\nnit\u00e4t\u00a0in\u00a0der\u00a0Gesellschaft\u00a0notwendigen\u00a0Impfquoten\u00a0werden\u00a0bei\u00a0ein er\u00a0Reihe\u00a0von\u00a0\nImpfungen\u00a0nicht\u00a0erreicht.\u00a0Zwei\u00a0denkbare\u00a0Gr\u00fcnde:\u00a0Zwar\u00a0wird\u00a0im\u00a0\u00a7\u00a0 25\u00a0des\u00a0SGB\u00a0V\u00a0im\u00a0\nZusammenhang\u00a0mit\u00a0den\u00a0Gesundheitsuntersuchungen\u00a0ab\u00a0dem\u00a018.\u00a0Leben sjahr\u00a0auch\u00a0\ndie\u00a0\u00dcberpr\u00fcfung\u00a0des\u00a0Impfstatus\u00a0im\u00a0Hinblick\u00a0auf\u00a0die\u00a0Empfehlungen \u00a0der\u00a0St\u00e4ndigen\u00a0\nImpfkommission\u00a0(STIKO)\u00a0nach\u00a0\u00a7\u00a020\u00a0Absatz\u00a02\u00a0des\u00a0Infektionsschutzg esetzes\u00a0(s.\u00a0nach\u2010\nfolgender\u00a0Kasten)\u00a0angesprochen.\u00a0Es\u00a0fehlen\u00a0jedoch\u00a0\u00e4hnliche\u00a0Regel ungen\u00a0f\u00fcr\u00a0die\u00a0\nebenso\u00a0wichtige\u00a0\u00dcberpr\u00fcfung\u00a0des\u00a0Impfstatus\u00a0bei\u00a0Kindern\u00a0 sowie\u00a0ei ne\u00a0rechtlich\u00a0\nabgesicherte\u00a0Empfehlung\u00a0zum\u00a0Umgang\u00a0mit\u00a0Impfl\u00fccken,\u00a0die\u00a0bei\u00a0der\u00a0 \u00dcberpr\u00fcfung\u00a0\ndes\u00a0Impfstatus\u00a0festgestellt\u00a0werden.\u00a0Denkbar\u00a0w\u00e4re\u00a0z.B.\u00a0eine\u00a0verp flichtende\u00a0\u00dcber\u2010\nweisung\u00a0zu\u00a0einer\u00a0Impfberatung\u00a0bei\u00a0besonders\u00a0fachkundigen\u00a0und\u00a0ko mmunikativ\u00a0\ngeschulten\u00a0\u00c4rzten.\u00a0Im\u00a0\u00a7\u00a026\u00a0Abs. \u00a01,\u00a0Satz\u00a02\u00a0zum\u00a0Thema\u00a0\u201eGesundheit suntersuchun\u2010\ngen\u00a0f\u00fcr\u00a0Kinder\u00a0und\u00a0Jugendliche\u201c\u00a0he i\u00dft\u00a0es\u00a0zwar:\u00a0\u201eDie\u00a0Untersuchun gen\u00a0beinhalten\u00a0\nauch\u00a0eine\u00a0Erfassung\u00a0und\u00a0Bewertung\u00a0gesundheitlicher\u00a0Risiken\u00a0eins chlie\u00dflich\u00a0einer\u00a0\n\u00dcberpr\u00fcfung\u00a0der\u00a0Vollst\u00e4ndigkeit\u00a0d es\u00a0Impfstatus\u00a0sowie\u00a0eine\u00a0darau f\u00a0abgestimmte\u00a0\npr\u00e4ventionsorientierte\u00a0Beratung\u00a0 einschlie\u00dflich\u00a0Informationen\u00a0zu \u00a0regionalen\u00a0Unter\u2010\nst\u00fctzungsangeboten\u00a0f\u00fcr\u00a0Eltern\u00a0und\u00a0Kind.\u201c\u00a0Jedoch\u00a0ist\u00a0nur\u00a0in\u00a0weni gen\u00a0Bundesl\u00e4n\u2010\ndern\u00a0gesetzlich\u00a0geregelt,\u00a0dass\u00a0 die\u00a0Gesundheitsuntersuchungen\u00a0wa hrgenommen\u00a0\nwerden\u00a0m\u00fcssen,\u00a0und\u00a0es\u00a0gibt\u00a0auch\u00a0keine\u00a0klare\u00a0Verpflichtung\u00a0zu\u00a0ei ner\u00a0inhaltlich\u00a0und\u00a0\nkommunikativ\u00a0kompetenten\u00a0Impfberatung\u00a0durch\u00a0die\u00a0\u00c4rzte.\u00a0Hinzu\u00a0ko mmt\u00a0als\u00a0zwei\u2010\nter\u00a0Grund\u00a0die\u00a0oft\u00a0intransparent e\u00a0und\u00a0auch\u00a0wenig\u00a0verst\u00e4ndliche\u00a0D arstellung\u00a0der\u00a0\nPr\u00fcfung\u00a0von\u00a0Impfstoffen\u00a0im\u00a0Zulassungsverfahren\u00a0beim\u00a0Paul\u2010Ehrlic h\u2010Institut\u00a0(PEI),\u00a0\nvor\u00a0allem\u00a0mit\u00a0Blick\u00a0auf\u00a0die\u00a0viel\u00a0diskutierten\u00a0Begleitstoffe\u00a0zur \u00a0Wirkverst\u00e4rkung\u00a0oder\u00a0\nKonservierung.\u00a0Aluminium\u2010\u00a0und\u00a0Quecksilberanteile\u00a0f\u00fchren\u00a0bei\u00a0vie len\u00a0Menschen\u00a0zu\u00a0\n\u00c4ngsten\u00a0\u00fcber\u00a0m\u00f6gliche\u00a0unerw\u00fcnschte \u00a0Folgen,\u00a0wie\u00a0z.B.\u00a0Autismus\u00a0be i\u00a0Kindern,\u00a0die\u00a0\nallerdings\u00a0 l\u00e4ngst\u00a0 im\u00a0 Rahmen\u00a0 von\u00a0 qualitativ\u00a0 hochwertigen\u00a0 Studien \u00a0 ausger\u00e4umt\u00a0\nwerden\u00a0konnten.\u00a0Zur\u00a0Erh\u00f6hung\u00a0der\u00a0Teilnahmeraten\u00a0von\u00a0sozial\u00a0bena chteiligten\u00a0\nKindern\u00a0an\u00a0Fr\u00fcherkennungsuntersuchungen\u00a0und\u00a0Impfprogrammen\u00a0soll ten\u00a0daher\u00a0218\u00a0auch\u00a0 international\u00a0 erfolgreiche\u00a0 Interventionen\u00a0 wie\u00a0 Einladungen, \u00a0 Erinnerungen,\u00a0\nAnreize\u00a0oder\u00a0aufsuchende\u00a0Program me\u00a0(zugehende\u00a0Arbeit\u00a0wie\u00a0in\u00a0der \u00a0Drogen\u2010\u00a0und\u00a0\nHIV/AIDS\u2010Pr\u00e4vention)\u00a0genutzt\u00a0wer den.\u00a0In\u00a0den\u00a0U3\u2010\u00a0und\u00a0U9\u2010Kinderun tersuchungen\u00a0\nsind\u00a0z.B.\u00a0schon\u00a0jetzt\u00a0eine\u00a0Impfberatung\u00a0und\u00a0\u00dcberpr\u00fcfung\u00a0der\u00a0Vol lst\u00e4ndigkeit\u00a0des\u00a0\nImpfstatus\u00a0vorgesehen.\u00a0\nTabelle\u00a06.1:\u00a0Verkaufte\u00a0Impfst offe\u00a0in\u00a0Deutschland\u00a0im\u00a0Jahr\u00a02016\u00a0\nImpfstoff\u00a0 Packungen\u00a0in\u00a0\n1.000\u00a0gegen\u00fcber\u00a02015\u00a0\n+/\u2010\u00a0in\u00a0%\u00a0Umsatz\u00a0in\u00a01.000\u00a0\u20ac\u00a0 gegen\u00fcber\u00a02015\u00a0\n+/\u2010\u00a0in\u00a0%\u00a0\nMehrfach\u2010Impfung\u00a0\nMasern/Mumps \u00a0426,7\u00a0 \u201030\u00a0 69.916,9\u00a0 \u201019\u00a0\nMehrfach\u2010Impfung\u00a0\nTetanus\u00a01.295,7\u00a0 \u20105\u00a0 196.180,5\u00a0 \u20102\u00a0\nSonstige\u00a0Mehrfach\u2010Impfstoffe\u00a07,4\u00a0 \u201073\u00a0 396,1\u00a0 \u201076\u00a0\nPneumokokken\u2010\nImpfstoff\u00a0585,6\u00a0 +14\u00a0 117.737,0\u00a0 2\u00a0\nMeningokokken\u2010\nImpfstoff\u00a0443,8\u00a0 +11\u00a0 34.617,2\u00a0 +12\u00a0\nHib\u2010Impfstoff\u00a0 11,3\u00a0 +18\u00a0 215,8\u00a0 +18\u00a0\nTyphus\u2010Impfstoff\u00a0 \u00a0 214,4\u00a0 +76\u00a0 2.002,3\u00a0 +74\u00a0\nTetanus\u2010Impfstoff \u00a0 77,2\u00a0 \u20109\u00a0 795,0\u00a0 \u20106\u00a0\nCholera\u2010Impfstoff \u00a0 62,5\u00a0 +30\u00a0 2.259,1\u00a0 +33\u00a0\nAlle\u00a0\u00fcbr.\u00a0bakteriellen\u00a0\nImpfstoffe\u00a03\u00a0 \u201099\u00a0 2,4\u00a0 \u201099\u00a0\nInfluenza\u2010Impfstoff \u00a0 1.984,3\u00a0 +9\u00a0 136.167,6\u00a0 +33\u00a0\nVarizellen\u2010Impfstoff \u00a0 137,9\u00a0 \u20103\u00a0 18.425,4\u00a0 \u20102\u00a0\nHPV\u2010Impfstoff\u00a0 564,8\u00a0 \u20101\u00a0 91.489,4\u00a0 +5\u00a0\nHepatitis\u2010Impfstoff\u00a0(A\u00a0\nund\u00a0B)\u00a01.543,8\u00a0 +6\u00a0 90.299,5\u00a0 +7\u00a0\nRotaviren\u2010Impfstoff \u00a0 167,8\u00a0 \u20108\u00a0 31.106,0\u00a0 +3\u00a0\nAlle\u00a0\u00fcbr.\u00a0viralen\u00a0\nImpfstoffe\u00a01.349,9\u00a0 +10\u00a0 111.383,6\u00a0 +9\u00a0\nQuelle:\u00a0IMS,\u00a02017\u00a0\nDas\u00a0Gesetz\u00a0zur\u00a0Verh\u00fctung\u00a0und\u00a0Bek\u00e4mpfung\u00a0von\u00a0Infektionskrankheit en\u00a0beim\u00a0\nMenschen\u00a0(Infektionsschutzgesetz\u00a0\u2013\u00a0IfSG)\u00a0\nVor\u00a0der\u00a0Einf\u00fchrung\u00a0des\u00a0IfSG\u00a0im\u00a0Januar\u00a02001\u00a0galten\u00a0viele\u00a0Infekti onskrankheiten\u00a0wie\u00a0\nz.B.\u00a0Cholera,\u00a0Diphtherie\u00a0und\u00a0Pocken\u00a0in\u00a0Deutschland\u00a0als\u00a0besiegt. \u00a0Die\u00a0hygienischen\u00a0\nVerh\u00e4ltnisse\u00a0wurden\u00a0auch\u00a0durch\u00a0den\u00a0erh\u00f6hten\u00a0Lebensstandard\u00a0kont inuierlich\u00a0ver\u2010\nbessert,\u00a0 es\u00a0 wurden\u00a0 landesweit\u00a0 Schutzimpfungen\u00a0 in\u00a0 allen\u00a0 Bev\u00f6lker ungsgruppen\u00a0\ndurchgef\u00fchrt\u00a0 und\u00a0 f\u00fcr\u00a0 die\u00a0 Behandlung\u00a0 von\u00a0 vielen\u00a0 Infektionskrankh eiten\u00a0 standen\u00a0\nwirksame\u00a0Antibiotika\u00a0zur\u00a0Verf\u00fcgu ng.\u00a0Mittlerweile\u00a0erh\u00f6hen\u00a0sich\u00a0d ie\u00a0Morbidit\u00e4tsraten\u00a0219\u00a0von\u00a0 einigen\u00a0 Infektionskrankheiten\u00a0 wie\u00a0 z.B.\u00a0 verschiedenen\u00a0 Grippe erkrankungen\u00a0\u00a0\n(Vogel\u2010\u00a0und\u00a0Schweinegrippe)\u00a0oder\u00a0auch\u00a0Tuberkulose.\u00a0Dies\u00a0h\u00e4ngt\u00a0a uch\u00a0damit\u00a0zusam\u2010\nmen,\u00a0dass\u00a0die\u00a0internationale\u00a0Mobilit\u00e4t\u00a0der\u00a0Menschen\u00a0und\u00a0die\u00a0Bev \u00f6lkerungsdichte\u00a0\nansteigen\u00a0und\u00a0dass\u00a0sich\u00a0dadurch\u00a0die\u00a0\u00dcbertragungsgefahr\u00a0von\u00a0Infe ktionskrankheiten\u00a0\nerh\u00f6ht.\u00a0Die\u00a0Entwicklung\u00a0von\u00a0Antibiotikaresistenzen\u00a0erschwert\u00a0es \u00a0mehr\u00a0und\u00a0mehr,\u00a0\nInfektionen\u00a0zu\u00a0beherrschen\u00a0und\u00a0der\u00a0\u201eKlimawandel\u00a0beg\u00fcnstigt\u00a0die\u00a0 geografische\u00a0Aus\u2010\nweitung\u00a0der\u00a0Siedlungsgebiete\u00a0von\u00a0Keimen\u00a0oder\u00a0Keimtr\u00e4gern\u201c\u00a0(BAD, \u00a02019).\u00a0\u00a0\nDiese\u00a0Entwicklungen\u00a0er forderten\u00a0u.a.\u00a0neue\u00a0ge setzliche\u00a0Regelunge n\u00a0f\u00fcr\u00a0den\u00a0Impf\u2010\nschutz,\u00a0die\u00a0am\u00a001.01.2001\u00a0in\u00a0Kraft\u00a0traten.\u00a0Der\u00a0schon\u00a0erw\u00e4hnte\u00a0\u00a7 \u00a020\u00a0IfSG\u00a0hat\u00a0folgen\u2010\nden\u00a0Wortlaut: \u00a0\n\u00a7\u00a020\u00a0IfSG\u00a0\u2013\u00a0Schutzimpfungen\u00a0und\u00a0a ndere\u00a0Ma\u00dfnahmen\u00a0der\u00a0spezifisch en\u00a0Prophylaxe\u00a0\n\u00a0\n(1)\u00a0Die\u00a0zust\u00e4ndige\u00a0obere\u00a0Bundesbe h\u00f6rde,\u00a0die\u00a0obersten\u00a0Landesgesu ndheitsbeh\u00f6rden\u00a0und\u00a0die\u00a0von\u00a0\nihnen\u00a0beauftragten\u00a0Stellen\u00a0sowi e\u00a0die\u00a0Gesundheits\u00e4mter\u00a0informier en\u00a0die\u00a0Bev\u00f6lkerung\u00a0\u00fcber\u00a0die\u00a0\nBedeutung\u00a0von\u00a0Schutzimpfungen\u00a0und\u00a0 anderen\u00a0Ma\u00dfnahmen\u00a0der\u00a0spezifi schen\u00a0Prophylaxe\u00a0\u00fcber\u2010\ntragbarer\u00a0Krankheiten.\u00a0\n\u00a0\n(2)\u00a0Beim\u00a0Robert\u00a0Koch\u2010Institut\u00a0wi rd\u00a0eine\u00a0St\u00e4ndige\u00a0Impfkommission \u00a0eingerichtet.\u00a0Die\u00a0Kommission\u00a0\ngibt\u00a0sich\u00a0eine\u00a0Gesch\u00e4ftsordnung,\u00a0 die\u00a0der\u00a0Zustimmung\u00a0des\u00a0Bundesm inisteriums\u00a0f\u00fcr\u00a0Gesundheit\u00a0\nbedarf.\u00a0Die\u00a0Kommission\u00a0gibt\u00a0Empf ehlungen\u00a0zur\u00a0Durchf\u00fchrung\u00a0von\u00a0S chutzimpfungen\u00a0und\u00a0zur\u00a0\nDurchf\u00fchrung\u00a0anderer\u00a0Ma\u00dfnahmen\u00a0der \u00a0spezifischen\u00a0Prophylaxe\u00a0\u00fcber tragbarer\u00a0Krankheiten\u00a0und\u00a0\nentwickelt\u00a0Kriterien\u00a0zur\u00a0Abgrenz ung\u00a0einer\u00a0\u00fcblichen\u00a0Impfreaktion \u00a0und\u00a0einer\u00a0\u00fcber\u00a0das\u00a0\u00fcbliche\u00a0\nAusma\u00df\u00a0einer\u00a0Impfreaktion\u00a0hinaus gehenden\u00a0gesundheitlichen\u00a0Sch\u00e4d igung.\u00a0Die\u00a0Mitglieder\u00a0der\u00a0\nKommission\u00a0werden\u00a0vom\u00a0Bundesmini sterium\u00a0f\u00fcr\u00a0Gesundheit\u00a0im\u00a0Beneh men\u00a0mit\u00a0den\u00a0obersten\u00a0\nLandesgesundheitsbeh\u00f6rden\u00a0berufen. \u00a0Vertreter\u00a0des\u00a0Bundesminister iums\u00a0f\u00fcr\u00a0Gesundheit,\u00a0der\u00a0\nobersten\u00a0Landesgesundheitsbeh\u00f6rden,\u00a0des\u00a0Robert\u00a0Koch\u2010Institutes\u00a0 und\u00a0des\u00a0Paul\u2010Ehrlich\u2010Institutes\u00a0\nnehmen\u00a0mit\u00a0beratender\u00a0Stimme\u00a0an\u00a0 den\u00a0Sitzungen\u00a0teil.\u00a0Weitere\u00a0Ver treter\u00a0von\u00a0Bundesbeh\u00f6rden\u00a0\nk\u00f6nnen\u00a0daran\u00a0teilnehmen.\u00a0Die\u00a0Emp fehlungen\u00a0der\u00a0Kommission\u00a0werden \u00a0von\u00a0dem\u00a0Robert\u00a0Koch\u2010\nInstitut\u00a0den\u00a0obersten\u00a0Landesges undheitsbeh\u00f6rden\u00a0\u00fcbermittelt\u00a0und \u00a0anschlie\u00dfend\u00a0ver\u00f6ffentlicht.\u00a0\n\u00a0\n(3)\u00a0Die\u00a0obersten\u00a0Landesgesundheit sbeh\u00f6rden\u00a0sollen\u00a0\u00f6ffentliche\u00a0E mpfehlungen\u00a0f\u00fcr\u00a0Schutzimpfun\u2010\ngen\u00a0oder\u00a0andere\u00a0Ma\u00dfnahmen\u00a0der\u00a0spe zifischen\u00a0Prophylaxe\u00a0auf\u00a0der\u00a0G rundlage\u00a0der\u00a0jeweiligen\u00a0\nEmpfehlungen\u00a0der\u00a0St\u00e4ndigen\u00a0 Impfkommission\u00a0aussprechen.\u00a0\n\u00a0\n(4)\u00a0Das\u00a0Bundesministerium\u00a0f\u00fcr\u00a0Ge sundheit\u00a0wird\u00a0erm\u00e4chtigt,\u00a0nach\u00a0 Anh\u00f6rung\u00a0der\u00a0St\u00e4ndigen\u00a0Impf\u2010\nkommission\u00a0und\u00a0der\u00a0Spitzenverb\u00e4nd e\u00a0der\u00a0gesetzlichen\u00a0Krankenkass en\u00a0durch\u00a0Rechtsverordnung\u00a0\nohne\u00a0Zustimmung\u00a0des\u00a0Bundesrates\u00a0 zu\u00a0bestimmen,\u00a0dass\u00a0die\u00a0Kosten\u00a0f \u00fcr\u00a0bestimmte\u00a0Schutzimpfun\u2010\ngen\u00a0von\u00a0den\u00a0Tr\u00e4gern\u00a0der\u00a0Krankenv ersicherung\u00a0nach\u00a0dem\u00a0dritten\u00a0Ab schnitt\u00a0des\u00a0dritten\u00a0Kapitels\u00a0des\u00a0\nF\u00fcnften\u00a0Buches\u00a0Sozialgesetzbuch\u00a0 getragen\u00a0werden,\u00a0falls\u00a0die\u00a0Pers on\u00a0bei\u00a0einer\u00a0Krankenkasse\u00a0nach\u00a0\n\u00a7\u00a04\u00a0des\u00a0F\u00fcnften\u00a0Buches\u00a0Sozialges etzbuch\u00a0versichert\u00a0ist.\u00a0In\u00a0der\u00a0 Rechtsverordnung\u00a0k\u00f6nnen\u00a0auch\u00a0\nRegelungen\u00a0zur\u00a0Erfassung\u00a0und\u00a0\u00dcber mittlung\u00a0von\u00a0anonymisierten\u00a0Da ten\u00a0\u00fcber\u00a0durchgef\u00fchrte\u00a0\nSchutzimpfungen\u00a0getroffen\u00a0werden.\u00a0\n\u00a0\n(5)\u00a0Die\u00a0obersten\u00a0Landesgesundheit sbeh\u00f6rden\u00a0k\u00f6nnen\u00a0bestimmen,\u00a0da ss\u00a0die\u00a0Gesundheits\u00e4mter\u00a0\nunentgeltlich\u00a0Schutzimpfungen\u00a0ode r\u00a0andere\u00a0Ma\u00dfnahmen\u00a0der\u00a0spezifi schen\u00a0Prophylaxe\u00a0gegen\u00a0\nbestimmte\u00a0\u00fcbertragbare\u00a0Krankheite n\u00a0durchf\u00fchren.\u00a0Die\u00a0zust\u00e4ndigen \u00a0Beh\u00f6rden\u00a0k\u00f6nnen\u00a0mit\u00a0den\u00a0220\u00a0Ma\u00dfnahmen\u00a0nach\u00a0Satz\u00a01\u00a0Dritte\u00a0beauf tragen.\u00a0Soweit\u00a0die\u00a0von\u00a0der\u00a0Ma \u00dfnahme\u00a0betroffene\u00a0Person\u00a0\ngegen\u00a0einen\u00a0anderen\u00a0Kostentr\u00e4ger \u00a0einen\u00a0Anspruch\u00a0auf\u00a0entsprechen de\u00a0Leistungen\u00a0hat\u00a0oder\u00a0einen\u00a0\nAnspruch\u00a0auf\u00a0Erstattung\u00a0der\u00a0Aufwe ndungen\u00a0f\u00fcr\u00a0entsprechende\u00a0Leis tungen\u00a0h\u00e4tte,\u00a0ist\u00a0dieser\u00a0zur\u00a0\nTragung\u00a0der\u00a0Sachkosten\u00a0verpflicht et.\u00a0Wenn\u00a0Dritte\u00a0nach\u00a0Satz\u00a02\u00a0be auftragt\u00a0wurden,\u00a0ist\u00a0der\u00a0andere\u00a0\nKostentr\u00e4ger\u00a0auch\u00a0zur\u00a0Tragung\u00a0die ser\u00a0Kosten\u00a0verpflichtet,\u00a0sowei t\u00a0diese\u00a0angemessen\u00a0sind.\u00a0\n\u00a0\n(6)\u00a0Das\u00a0Bundesministerium\u00a0f\u00fcr\u00a0Ge sundheit\u00a0wird\u00a0erm\u00e4chtigt,\u00a0durch \u00a0Rechtsverordnung\u00a0mit\u00a0Zustim\u2010\nmung\u00a0des\u00a0Bundesrates\u00a0anzuordnen,\u00a0d ass\u00a0bedrohte\u00a0Teile\u00a0der\u00a0Bev\u00f6lk erung\u00a0an\u00a0Schutzimpfungen\u00a0\noder\u00a0anderen\u00a0Ma\u00dfnahmen\u00a0der\u00a0spezi fischen\u00a0Prophylaxe\u00a0teilzunehmen \u00a0haben,\u00a0wenn\u00a0eine\u00a0\u00fcber\u2010\ntragbare\u00a0Krankheit\u00a0mit\u00a0klinisch\u00a0s chweren\u00a0Verlaufsformen\u00a0auftrit t\u00a0und\u00a0mit\u00a0ihrer\u00a0epidemischen\u00a0\u00a0\nVerbreitung\u00a0zu\u00a0rechnen\u00a0ist.\u00a0Das\u00a0G rundrecht\u00a0der\u00a0k\u00f6rperlichen\u00a0Unv ersehrtheit\u00a0(Artikel\u00a02\u00a0Abs.\u00a02\u00a0\nSatz\u00a01\u00a0Grundgesetz)\u00a0kann\u00a0insoweit \u00a0eingeschr\u00e4nkt\u00a0werden.\u00a0Ein\u00a0nac h\u00a0dieser\u00a0Rechtsverordnung\u00a0\nImpfpflichtiger,\u00a0der\u00a0nach\u00a0\u00e4rztlic hem\u00a0Zeugnis\u00a0ohne\u00a0Gefahr\u00a0f\u00fcr\u00a0se in\u00a0Leben\u00a0oder\u00a0seine\u00a0Gesundheit\u00a0\nnicht\u00a0geimpft\u00a0werden\u00a0kann,\u00a0ist \u00a0von\u00a0der\u00a0Impfpflicht\u00a0freizustelle n;\u00a0dies\u00a0gilt\u00a0auch\u00a0bei\u00a0anderen\u00a0Ma\u00df\u2010\nnahmen\u00a0der\u00a0spezifischen\u00a0Prophylaxe.\u00a0\u00a0\n\u00a0\n(7)\u00a0Solange\u00a0das\u00a0Bundesministeri um\u00a0f\u00fcr\u00a0Gesundheit\u00a0von\u00a0der\u00a0Erm\u00e4ch tigung\u00a0nach\u00a0Absatz\u00a06\u00a0keinen\u00a0\nGebrauch\u00a0macht,\u00a0sind\u00a0die\u00a0Landesreg ierungen\u00a0zum\u00a0Erlass\u00a0einer\u00a0Rec htsverordnung\u00a0nach\u00a0Absatz\u00a06\u00a0\nerm\u00e4chtigt.\u00a0Die\u00a0Landesregierungen \u00a0k\u00f6nnen\u00a0die\u00a0Erm\u00e4chtigung\u00a0durch \u00a0Rechtsverordnung\u00a0auf\u00a0die\u00a0\nobersten\u00a0Landesgesundheitsbeh\u00f6rden\u00a0\u00fcbertragen.\u00a0Das\u00a0Grundrecht\u00a0d er\u00a0k\u00f6rperlichen\u00a0Unversehrt\u2010\nheit\u00a0(Artikel\u00a02\u00a0Abs.\u00a02\u00a0Satz\u00a01\u00a0Gr undgesetz)\u00a0kann\u00a0insoweit\u00a0einges chr\u00e4nkt\u00a0werden.\u00a0\u00a0\n\u00a0\nSchutzimpfungen\u00a0als\u00a0wirksame\u00a0Prim\u00e4rpr\u00e4vention\u00a0\nSchutzimpfungen\u00a0z\u00e4hlen\u00a0zu\u00a0den\u00a0wirkungsvollsten\u00a0und\u00a0kosteng\u00fcnsti gsten\u00a0pr\u00e4ventiven\u00a0\nMa\u00dfnahmen\u00a0der\u00a0modernen\u00a0Medizin.\u00a0Sie\u00a0sch\u00fctzen\u00a0nicht\u00a0nur\u00a0individu ell,\u00a0sondern\u00a0\nf\u00fchren\u00a0auch\u00a0zu\u00a0einem\u00a0Kollektivschutz\u00a0der\u00a0Bev\u00f6lkerung.\u00a0Ist\u00a0der\u00a0A nteil\u00a0geimpfter\u00a0Per\u2010\nsonen\u00a0hoch,\u00a0so\u00a0findet\u00a0der\u00a0Erreger\u00a0nicht\u00a0mehr\u00a0genug\u00a0empf\u00e4ngliche \u00a0Personen,\u00a0die\u00a0\nKrankheit\u00a0kann\u00a0sich\u00a0nicht\u00a0ausbreiten.\u00a0Dieser\u00a0Nutzen\u00a0f\u00fcr\u00a0den\u00a0Ges undheitsschutz\u00a0der\u00a0\nAllgemeinbev\u00f6lkerung\u00a0setzt\u00a0jedoch\u00a0erst\u00a0ein,\u00a0wenn\u00a0ausreichende\u00a0I mpfquoten\u00a0erzielt\u00a0\nwerden.\u00a0Der\u00a0Prozentsatz\u00a0an\u00a0Personen,\u00a0die\u00a0in\u00a0einer\u00a0Bev\u00f6lkerung\u00a0g eimpft\u00a0sein\u00a0m\u00fcssen,\u00a0\num\u00a0einen\u00a0sicheren\u00a0Kollektivschutz\u00a0zu\u00a0gew\u00e4hrleisten,\u00a0ist\u00a0dabei\u00a0f \u00fcr\u00a0jede\u00a0Infektions\u2010\nkrankheit\u00a0unterschiedlich\u00a0hoch.\u00a0F\u00fcr\u00a0die\u00a0Diphtherie\u00a0liegt\u00a0der\u00a0er forderliche\u00a0Anteil\u00a0Ge\u2010\nimpfter\u00a0bei\u00a0mindestens\u00a080\u00a0%,\u00a0f\u00fcr\u00a0Mumps\u00a0bei\u00a0ca.\u00a090\u00a0%\u00a0und\u00a0f\u00fcr\u00a0Mas ern\u00a0bei\u00a095\u00a0%.\u00a0\nEmpfehlungen\u00a0f\u00fcr\u00a0die\u00a0Durchf\u00fchrung\u00a0von\u00a0Impfungen\u00a0in\u00a0Deutschland\u00a0 werden\u00a0j\u00e4hrlich\u00a0\nvon\u00a0der\u00a0STIKO\u00a0am\u00a0Robert\u00a0Koch\u2010Institut\u00a0(RKI)\u00a0herausgegeben\u00a0und\u00a0k ontinuierlich\u00a0an\u00a0\nden\u00a0aktuellen\u00a0Wissensstand\u00a0und\u00a0den\u00a0konkreten\u00a0Bedarf\u00a0angepasst\u00a0( RKI,\u00a02007).\u00a0\nDer\u00a0Impfstatus\u00a0aus\u00a0dem\u00a0KiGGS\u2010Survey\u00a0\nDer\u00a0Impfstatus\u00a0der\u00a0Bev\u00f6lkerung\u00a0als\u00a0wichtiger\u00a0Indikator\u00a0f\u00fcr\u00a0gesu ndheitliche\u00a0Pr\u00e4ven\u2010\ntion\u00a0wurde\u00a0auch\u00a0bei\u00a093,3\u00a0%\u00a0(16.460)\u00a0der\u00a0untersuchten\u00a0Kinder\u00a0und \u00a0Jugendlichen\u00a0im\u00a0\nAlter\u00a0von\u00a00\u00a0bis\u00a017\u00a0Jahren\u00a0im\u00a0bundesweiten\u00a0Kinder\u2010\u00a0und\u00a0Jugendges undheitssurvey\u00a0\n(KiGGS)\u00a0erfasst\u00a0(zuletzt\u00a0Poethko\u2010M\u00fcller\u00a0et\u00a0al.,\u00a02007).\u00a0Grundlag e\u00a0waren\u00a0die\u00a0vorge\u2010\nlegten\u00a0 Impfausweise.\u00a0 Beurteilt\u00a0 wurden\u00a0 Impfungen\u00a0 gegen\u00a0 Tetanus\u00a0 ( Wundstarr\u2010221\u00a0krampf),\u00a0Diphtherie\u00a0(lebensgef\u00e4hrliche,\u00a0bakterielle\u00a0Erkrankung\u00a0 der\u00a0oberen\u00a0Atem\u2010\nwege),\u00a0Poliomyelitis\u00a0(Kinderl\u00e4hmung),\u00a0Pertussis\u00a0(Keuchhusten),\u00a0 Hepatitis\u00a0B\u00a0(Leber\u2010\nentz\u00fcndung),\u00a0Haemophilus\u00a0influenz ae\u00a0Typ\u00a0B\u00a0(lebensgef\u00e4hrliche,\u00a0e ntz\u00fcndliche\u00a0Er\u2010\nkrankung\u00a0im\u00a0Hals\u2010Nasen\u2010Ohren\u2010Bereich;\u00a0Hib)\u00a0sowie\u00a0Masern,\u00a0Mumps\u00a0 und\u00a0R\u00f6teln\u00a0\n(MMR).\u00a0Die\u00a0nachfolgend\u00a0dargestellten\u00a0Angaben\u00a0von\u00a0Impfquoten\u00a0f\u00fcr \u00a0die\u00a0gesamte\u00a0\nGruppe\u00a0der\u00a0Kinder\u00a0und\u00a0Jugendlichen\u00a0beziehen\u00a0sich\u00a0auf\u00a0Zwei\u2010\u00a0bis\u00a0 17\u2010J\u00e4hrige.\u00a0Sie\u00a0\nstellen\u00a0weder\u00a0die\u00a0niedrigeren\u00a0Im pfquoten\u00a0bei\u00a0Kindern\u00a0bis\u00a0zum\u00a015 .\u00a0Lebensmonat\u00a0\ndar\u00a0(erst\u00a0zu\u00a0diesem\u00a0Zeitpunkt\u00a0muss\u00a0nach\u00a0Empfehlungen\u00a0der\u00a0STIKO\u00a0 eine\u00a0zeitgerech\u2010\nte\u00a0Grundimmunisierung\u00a0abgeschlosse n\u00a0sein),\u00a0noch\u00a0den\u00a0hohen\u00a0Antei l\u00a0versp\u00e4tet\u00a0\ngegebener\u00a0Impfungen\u00a0in\u00a0den\u00a0ersten\u00a0beiden\u00a0Lebensjahren.\u00a0Beeinflu sst\u00a0sind\u00a0die\u00a0\nImpfquoten\u00a0jedoch\u00a0zum\u00a0Teil\u00a0dadurch,\u00a0dass\u00a0f\u00fcr\u00a0die\u00a0KiGGS\u2010Teilnehm er\u00a0aus\u00a0den\u00a0Ge\u2010\nburtsjahrg\u00e4ngen\u00a01985\u00a0bis\u00a02006\u00a0f\u00fcr\u00a0einige\u00a0Impfungen\u00a0deutlich\u00a0unt erschiedliche\u00a0\nImpfempfehlungen\u00a0bestanden.\u00a0So\u00a0wu rden\u00a0die\u00a0allgemeinen\u00a0Impfempfe hlungen\u00a0f\u00fcr\u00a0\ndie\u00a0Pertussis\u2010Impfung,\u00a0die\u00a0Hib\u2010Impfung\u00a0und\u00a0eine\u00a0zweite\u00a0Maserndo sis\u00a0erst\u00a0im\u00a0Jahr\u00a0\n1991\u00a0durch\u00a0die\u00a0STIKO\u00a0ausgesprochen\u00a0und\u00a0erst\u00a0seit\u00a01995\u00a0wird\u00a0die\u00a0 Hepatitis\u00a0B\u2010\nImpfung\u00a0f\u00fcr\u00a0alle\u00a0Kinder\u00a0 und\u00a0S\u00e4uglinge\u00a0empfohlen.\u00a0\nDie\u00a0Grundimmunisierung\u00a0gegen\u00a0Te tanus,\u00a0Diphtherie,\u00a0Polio\u00a0und\u00a0Hib \u00a0wird\u00a0bei\u00a0Kin\u2010\ndern\u00a0in\u00a0Deutschland\u00a0weitgehend\u00a0durchgef\u00fchrt.\u00a093\u00a0%\u00a0aller\u00a0untersu chten\u00a0Kinder\u00a0im\u00a0\nAlter\u00a0von\u00a0\u00fcber\u00a0zwei\u00a0Jahren\u00a0in\u00a0D eutschland\u00a0haben\u00a0eine\u00a0vollst\u00e4ndi ge\u00a0Grundimmuni\u2010\nsierung\u00a0 gegen\u00a0 Tetanus\u00a0 erhalten.\u00a0 Die\u00a0 Quoten\u00a0 der\u00a0 Impfungen\u00a0 gegen\u00a0 Diphtherie\u00a0\nliegen\u00a0mit\u00a092,6\u00a0%\u00a0nur\u00a0geringf\u00fcgig\u00a0unter\u00a0denen\u00a0f\u00fcr\u00a0Tetanus.\u00a0Denn och\u00a0k\u00f6nnen\u00a0aktu\u2010\nell\u00a0nur\u00a077,6\u00a0%\u00a0der\u00a0Kinder\u00a0im\u00a0Alter\u00a0von\u00a0mindestens\u00a0zwei\u00a0Jahren\u00a0a ls\u00a0altersgerecht\u00a0\ngegen\u00a0Tetanus\u00a0geimpft\u00a0gelten.\u00a0Nic ht\u00a0oder\u00a0versp\u00e4tet\u00a0gegebene\u00a0Auf frischungsimp\u2010\nfungen\u00a0bedingen\u00a0den\u00a0niedrigen\u00a0Anteil\u00a0ausreichend\u00a0gegen\u00a0Tetanus\u00a0 und\u00a0Diphtherie\u00a0\ngeimpfter\u00a0Kinder.\u00a090,8\u00a0%\u00a0der\u00a0Kinde r\u00a0haben\u00a0eine\u00a0vollst\u00e4ndige\u00a0Gru ndimmunisierung\u00a0\ngegen\u00a0Poliomyelitis\u00a0und\u00a065,8\u00a0%\u00a0gegen\u00a0Hepatitis\u00a0B\u00a0erhalten.\u00a077,1 \u00a0%\u00a0der\u00a0Kinder\u00a0im\u00a0\nAlter\u00a0von\u00a0\u00fcber\u00a024\u00a0Monaten\u00a0sind\u00a0vollst\u00e4ndig\u00a0gegen\u00a0Hib\u00a0grundimmun isiert,\u00a0und\u00a0\n69,5\u00a0%\u00a0haben\u00a0eine\u00a0vollst\u00e4ndige\u00a0 Grundimmunisierung\u00a0gegen\u00a0Pertuss is\u00a0erhalten.\u00a0\nGegen\u00a0Masern\u00a0sind\u00a093,6\u00a0%\u00a0der\u00a0Kinde r\u00a0mindestens\u00a0einmal\u00a0geimpft,\u00a0 bei\u00a0drei\u00a0Vierteln\u00a0\ndieser\u00a0Kinder\u00a0wurde\u00a0auch\u00a0eine\u00a0zw eite\u00a0Masernimpfung\u00a0durchgef\u00fchrt .\u00a0Die\u00a0Quoten\u00a0\nsowohl\u00a0f\u00fcr\u00a0die\u00a0erste\u00a0als\u00a0auch\u00a0zweite\u00a0Mumpsimpfdosis\u00a0liegen\u00a0nur\u00a0 geringf\u00fcgig\u00a0unter\u00a0\ndenen\u00a0der\u00a0Masernimpfungen\u00a0und\u00a0weisen\u00a0ebenso\u00a0f\u00fcr\u00a0die\u00a0zweite\u00a0Impf dosis\u00a0beson\u2010\ndere\u00a0Defizite\u00a0auf.\u00a0Im\u00a0Vergleich\u00a0zur\u00a0Masernimpfung\u00a0haben\u00a0noch\u00a0we niger\u00a0Kinder\u00a0und\u00a0\nJugendliche\u00a0eine\u00a0erste\u00a0und\u00a0zweite\u00a0R\u00f6teln\u2010Impfung\u00a0erhalten.\u00a0Auch \u00a0in\u00a0Bezug\u00a0auf\u00a0\nR\u00f6teln\u00a0besteht\u00a0das\u00a0Ziel,\u00a0f\u00fcr\u00a0die\u00a0erste\u00a0und\u00a0zweite\u00a0Impfung\u00a0jewei ls\u00a0eine\u00a0Durchimp\u2010\nfung\u00a0von\u00a095\u00a0%\u00a0zu\u00a0erreichen.\u00a0W\u00e4hrend\u00a0die\u00a0Impfquoten\u00a0in\u00a0Deutschla nd\u00a0f\u00fcr\u00a0die\u00a0al\u2010\nlermeisten\u00a0Impfungen\u00a0keine\u00a0Geschlechtsunterschiede\u00a0aufweisen,\u00a0z eigen\u00a0doch\u00a0die\u00a0\nDaten\u00a0der\u00a0R\u00f6teln\u2010Impfquoten,\u00a0dass\u00a0die\u00a014\u2010\u00a0bis\u00a017\u2010j\u00e4hrigen\u00a0Junge n\u00a0in\u00a0dieser\u00a0Alters\u2010\ngruppe\u00a0noch\u00a0seltener\u00a0gegen\u00a0R\u00f6teln\u00a0geimpft\u00a0sind\u00a0als\u00a0M\u00e4dchen.\u00a0In\u00a0 den\u00a0j\u00fcngeren\u00a0222\u00a0Altersgruppen\u00a0 sind\u00a0 diese\u00a0 Geschlechtsunterschiede\u00a0 auch\u00a0 bei\u00a0 der\u00a0 R \u00f6teln\u2010\nImmunisierung\u00a0nicht\u00a0vorhanden.\u00a0Dies\u00a0mag\u00a0damit\u00a0zusammenh\u00e4ngen,\u00a0d ass\u00a0M\u00e4d\u2010\nchen\u00a0durch\u00a0h\u00e4ufigere\u00a0Arztkontakte,\u00a0v.a.\u00a0bei\u00a0ihren\u00a0Gyn\u00e4kologen,\u00a0 h\u00e4ufiger\u00a0auf\u00a0diese\u00a0\nImpfung\u00a0 hingewiesen\u00a0 werden.\u00a0 Im\u00a0 f r\u00fcheren\u00a0 Lebensalter\u00a0 \u00fcbernehmen\u00a0 dagegen\u00a0\nKinder\u00e4rzte\u00a0im\u00a0Rahmen\u00a0der\u00a0U3\u2010U9\u2010Untersuchungen\u00a0die\u00a0Beratung\u00a0und \u00a0\u00dcberpr\u00fc\u2010\nfung\u00a0des\u00a0Impfstatus\u00a0bei\u00a0allen\u00a0 Kindern,\u00a0unabh\u00e4ngig\u00a0vom\u00a0Geschlech t.\u00a0\nDefizite\u00a0bestehen\u00a0also\u00a0bei\u00a0der\u00a0z eitgerechten\u00a0und\u00a0vollst\u00e4ndigen\u00a0 Inanspruchnahme\u00a0\nvon\u00a0Impfungen.\u00a0Insbesondere\u00a0die\u00a0im\u00a0sechsten\u00a0bis\u00a0siebten\u00a0Lebensj ahr\u00a0f\u00e4lligen\u00a0Auf\u2010\nfrischimpfungen\u00a0gegen\u00a0Tetanus\u00a0und\u00a0Diphtherie\u00a0werden\u00a0sehr\u00a0h\u00e4ufig \u00a0zu\u00a0sp\u00e4t\u00a0oder\u00a0\ngar\u00a0nicht\u00a0verabreicht,\u00a0die\u00a0zweit en\u00a0Masernimpfungen\u00a0fehlen\u00a0bei\u00a0e inem\u00a0Viertel\u00a0der\u00a0\nKinder\u00a0und\u00a0Jugendlichen.\u00a0\nIm\u00a0Vergleich\u00a0zwischen\u00a0den\u00a0alten\u00a0und\u00a0neuen\u00a0Bundesl\u00e4ndern\u00a0differi eren\u00a0die\u00a0Impf\u2010\nquoten\u00a0der\u00a0vollst\u00e4ndigen\u00a0Grundi mmunisierungen\u00a0gegen\u00a0Tetanus,\u00a0Di phtherie,\u00a0Polio\u00a0\nund\u00a0Hepatitis\u00a0B\u00a0kaum\u00a0noch.\u00a0Sehr\u00a0deutliche\u00a0Ost\u2010West\u2010Unterschiede \u00a0zeigen\u00a0sich\u00a0\njedoch\u00a0(bedingt\u00a0vorrangig\u00a0durch\u00a0\u00e4ltere\u00a0Kinder\u00a0und\u00a0Jugendliche)\u00a0 bei\u00a0der\u00a0Durchimp\u2010\nfung\u00a0gegen\u00a0Pertussis,\u00a0Masern\u00a0und\u00a0R\u00f6teln\u00a0(vor\u00a0allem\u00a0hinsichtlich \u00a0der\u00a0zweiten\u00a0Impf\u2010\ndosis)\u00a0sowie\u00a0bei\u00a0der\u00a0Inanspruchnahme\u00a0von\u00a0Auffrischimpfungen.\u00a0So \u00a0haben\u00a0fast\u00a0drei\u00a0\nViertel\u00a0der\u00a0Sieben\u2010\u00a0bis\u00a0Zehnj\u00e4hrigen\u00a0in\u00a0den\u00a0neuen\u00a0Bundesl\u00e4ndern \u00a0bereits\u00a0die\u00a0Teta\u2010\nnusauffrischimpfung\u00a0erhalten,\u00a0jedoch\u00a0nur\u00a0etwas\u00a0mehr\u00a0als\u00a0die\u00a0H\u00e4l fte\u00a0der\u00a0gleichaltri\u2010\ngen\u00a0Kinder\u00a0in\u00a0den\u00a0alten\u00a0Bundesl\u00e4ndern.\u00a0\u00a0\nDie\u00a0Impfquoten\u00a0sind\u00a0bei\u00a0Kindern\u00a0und\u00a0Jugendlichen\u00a0aus\u00a0Familien\u00a0m it\u00a0mittlerem\u00a0\nsozio\u00f6konomischem\u00a0Status\u00a0h\u00f6her\u00a0als\u00a0in\u00a0Familien\u00a0mit\u00a0niedrigem\u00a0un d\u00a0hohem\u00a0Sozial\u2010\nstatus.\u00a0Diese\u00a0Unterschiede\u00a0sind\u00a0bei\u00a0den\u00a0meisten\u00a0Impfungen\u00a0kaum\u00a0 bedeutsam.\u00a0Ein\u00a0\ndeutlicher\u00a0Unterschied\u00a0zwischen\u00a0den\u00a0Sozialstatusgruppen\u00a0besteht \u00a0jedoch\u00a0bei\u00a0der\u00a0\nMaserndurchimpfung:\u00a0Kinder\u00a0und\u00a0Jugendliche\u00a0aus\u00a0Familien\u00a0mit\u00a0hoh em\u00a0Sozialsta\u2010\ntus\u00a0werden\u00a0seltener\u00a0gegen\u00a0Masern\u00a0geimpft\u00a0als\u00a0Kinder\u00a0und\u00a0Jugendl iche\u00a0aus\u00a0Fami\u2010\nlien\u00a0mit\u00a0niedrigem\u00a0oder\u00a0mittlerem\u00a0sozialen\u00a0Status.\u00a0\nDie\u00a0differenzierte\u00a0Betrachtung\u00a0der\u00a0Durchimpfung\u00a0von\u00a0Kindern\u00a0und \u00a0Jugendlichen\u00a0mit\u00a0\nMigrationshintergrund\u00a0zeigt,\u00a0dass\u00a0das\u00a0wichtigste\u00a0Differenzierun gsmerkmal\u00a0im\u00a0Hin\u2010\nblick\u00a0auf\u00a0die\u00a0im\u00a0KiGGS\u00a0erfassten\u00a0Impfungen\u00a0ist,\u00a0ob\u00a0die\u00a0Geburt\u00a0d es\u00a0Kindes\u00a0in\u00a0Deutsch\u2010\nland\u00a0stattgefunden\u00a0hat\u00a0oder\u00a0das\u00a0Kind\u00a0erst\u00a0nach\u00a0der\u00a0Geburt\u00a0zugew andert\u00a0ist:\u00a0W\u00e4h\u2010\nrend\u00a0in\u00a0Deutschland\u00a0geborene\u00a0Kinder\u00a0mit\u00a0Migrationshintergrund\u00a0n icht\u00a0schlechter\u00a0\ngeimpft\u00a0sind\u00a0als\u00a0Kinder\u00a0ohne\u00a0Migrationshintergrund,\u00a0haben\u00a0die\u00a0K inder\u00a0und\u00a0Jugendli\u2010\nchen,\u00a0die\u00a0nach\u00a0der\u00a0Geburt\u00a0zugewa ndert\u00a0sind,\u00a0einen\u00a0deutlich\u00a0schl echteren\u00a0Impfstatus,\u00a0\nwobei\u00a0hier\u00a0auch\u00a0Dokumentationsdefizite\u00a0eine\u00a0Rolle\u00a0spielen\u00a0d\u00fcrft en.\u00a0\nZusammenfassend\u00a0 betrachtet,\u00a0 bestehen\u00a0 in\u00a0 Deutschland\u00a0 trotz\u00a0 insge samt\u00a0 hoher\u00a0\nImpfquoten\u00a0noch\u00a0immer\u00a0deutliche\u00a0Defizite\u00a0bei\u00a0der\u00a0Immunisierung\u00a0 gegen\u00a0Pertussis\u00a0223\u00a0und\u00a0Hepatitis\u00a0B,\u00a0den\u00a0zweiten\u00a0Impfungen\u00a0gegen\u00a0Masern,\u00a0Mumps\u00a0und\u00a0 R\u00f6teln\u00a0sowie\u00a0\nbei\u00a0den\u00a0Auffrischimpfungen\u00a0gegen\u00a0Tetanus\u00a0und\u00a0Diphtherie.\u00a0Dar\u00fcbe r\u00a0hinaus\u00a0beste\u2010\nhen\u00a0bei\u00a0einigen\u00a0Impfungen\u00a0(wie\u00a0z.B.\u00a0Masern\u00a0und\u00a0Pertussis)\u00a0teilw eise\u00a0deutliche\u00a0\nUnterschiede\u00a0in\u00a0der\u00a0Durchimpfung \u00a0zwischen\u00a0den\u00a0Alters\u2010\u00a0und\u00a0Sozia lstatusgruppen,\u00a0\nzwischen\u00a0Kindern\u00a0aus\u00a0den\u00a0neuen\u00a0bzw.\u00a0alten\u00a0Bundesl\u00e4ndern\u00a0und\u00a0zwi schen\u00a0zuge\u2010\nwanderten\u00a0 bzw.\u00a0 in\u00a0 Deutschland\u00a0 geborenen\u00a0 Kindern\u00a0 mit\u00a0 Migrationsh intergrund\u00a0\nund\u00a0Kindern\u00a0ohne\u00a0Migrationshintergrund.\u00a0Diese\u00a0Defizite\u00a0k\u00f6nnen\u00a0n icht\u00a0nur\u00a0zu\u00a0indi\u2010\nviduellen\u00a0Gesundheitsgef\u00e4hrdungen\u00a0f\u00fchren,\u00a0sondern\u00a0sind\u00a0auch\u00a0f\u00fcr \u00a0den\u00a0umfassen\u2010\nden\u00a0Gesundheitsschutz\u00a0der\u00a0 Bev\u00f6lkerung\u00a0relevant.\u00a0\nWie\u00a0wirken\u00a0Impfungen?\u00a0\nBei\u00a0einer\u00a0Impfung\u00a0wird\u00a0der\u00a0K\u00f6rper\u00a0einem\u00a0abgeschw\u00e4chten\u00a0Krankhei tserreger\u00a0oder\u00a0\nTeilen\u00a0davon\u00a0ausgesetzt\u00a0und\u00a0so\u00a0zu\u00a0einer\u00a0immunologischen\u00a0Abwehrr eaktion\u00a0ange\u2010\nregt.\u00a0Diese\u00a0hat\u00a0zur\u00a0Folge,\u00a0dass\u00a0 bei\u00a0einem\u00a0Kontakt\u00a0mit\u00a0dem\u00a0wirkl ichen\u00a0Erreger\u00a0die\u2010\nser\u00a0abgewehrt\u00a0wird\u00a0und\u00a0die\u00a0Krankheit\u00a0sich\u00a0nicht\u00a0oder\u00a0nur\u00a0sehr\u00a0a bgeschw\u00e4cht\u00a0ent\u2010\nwickelt.\u00a0\nBei\u00a0den\u00a0Impfungen\u00a0gegen\u00a0die\u00a0im\u00a0K indesalter\u00a0auftretenden\u00a0Infekti onskrankheiten\u00a0\nist\u00a0es\u00a0generell\u00a0ratsam,\u00a0dass\u00a0so\u00a0fr\u00fch\u00a0wie\u00a0m\u00f6glich\u00a0mit\u00a0der\u00a0Impfun g\u00a0begonnen\u00a0wird,\u00a0\num\u00a0eine\u00a0Krankheit\u00a0m\u00f6glichst\u00a0zuverl\u00e4ssig\u00a0zu\u00a0verhindern.\u00a0Das\u00a0Kind \u00a0sollte\u00a0zum\u00a0Zeit\u2010\npunkt\u00a0der\u00a0Impfung\u00a0aber\u00a0schon\u00a0ein\u00a0ausreichend\u00a0leistungsf\u00e4higes\u00a0i mmunologisches\u00a0\nSystem\u00a0entwickelt\u00a0haben.\u00a0Daher\u00a0impft\u00a0man\u00a0in\u00a0der\u00a0Regel\u00a0erst\u00a0ab\u00a0d em\u00a0dritten\u00a0Le\u2010\nbensmonat,\u00a0denn\u00a0nicht\u00a0alle\u00a0Impfstoffe\u00a0sind\u00a0in\u00a0jedem\u00a0Alter\u00a0vertr \u00e4glich.\u00a0\nImpfungen\u00a0 k\u00f6nnen\u00a0 mittelschwere\u00a0 und\u00a0 schwere\u00a0 Nebenwirkungen\u00a0 haben .\u00a0 Nur,\u00a0\nwenn\u00a0sie\u00a0nicht\u00a0h\u00e4ufiger\u00a0als\u00a0\u201esehr\u00a0selten\u201c\u00a0sind\u00a0(weniger\u00a0als\u00a0ein \u00a0Behandelter\u00a0von\u00a0\n10.000;\u00a0<\u00a00,01\u00a0%),\u00a0werden\u00a0Impfungen\u00a0zugelassen.\u00a0Dabei\u00a0wird\u00a0eine \u00a0Schadensh\u00e4u\u2010\nfigkeit\u00a0der\u00a0Impfung\u00a0gegen\u00a0die\u00a0H\u00e4ufigkeit\u00a0eines\u00a0Schadens\u00a0aufgrun d\u00a0der\u00a0Infektion,\u00a0\ngegen\u00a0die\u00a0geimpft\u00a0werden\u00a0soll,\u00a0a bgewogen.\u00a0Die\u00a0Schadensh\u00e4ufigkei t\u00a0einer\u00a0Impfung\u00a0\nist\u00a0also\u00a0bereits\u00a0aufgrund\u00a0der\u00a0Zulassungsbedingungen\u00a0nahezu\u00a0kons tant.\u00a0Hingegen\u00a0\nsind\u00a0die\u00a0H\u00e4ufigkeit\u00a0der\u00a0Infektion,\u00a0die\u00a0verhindert\u00a0werden\u00a0soll,\u00a0 sowie\u00a0die\u00a0Schwere\u00a0\ndes\u00a0Verlaufs\u00a0einer\u00a0Infektion\u00a0erheblich\u00a0variabel\u00a0und\u00a0vom\u00a0Alter\u00a0e iner\u00a0Person,\u00a0von\u00a0\nihren\u00a0Ern\u00e4hrungsbedingungen\u00a0sowi e\u00a0von\u00a0ihren\u00a0Lebensbedingungen\u00a0g enerell\u00a0ab\u2010\nh\u00e4ngig.\u00a0Dies\u00a0f\u00fchrt\u00a0dazu,\u00a0dass\u00a0das\u00a0Verh\u00e4ltnis\u00a0von\u00a0Nutzen\u00a0zu\u00a0Scha den\u00a0von\u00a0Staat\u00a0zu\u00a0\nStaat\u00a0unterschiedlich\u00a0sein\u00a0und\u00a0sich\u00a0au\u00dferdem\u00a0\u00fcber\u00a0die\u00a0Zeit\u00a0\u00e4nde rn\u00a0kann.\u00a0\u00a0\nDass\u00a0durch\u00a0Impfungen\u00a0bestimmte\u00a0Unterarten\u00a0des\u00a0jeweiligen\u00a0Infekt ionserregers\u00a0\nselektiert\u00a0werden,\u00a0kann\u00a0als\u00a0Nebe nwirkung\u00a0auf\u00a0Bev\u00f6lkerungsebene\u00a0 gesehen\u00a0wer\u2010\nden.\u00a0Impfungen\u00a0treffen\u00a0nie\u00a0alle\u00a0Typen\u00a0eines\u00a0Erregers,\u00a0sodass\u00a0Un terarten,\u00a0manch\u2010\nmal\u00a0auch\u00a0im\u00a0Sinne\u00a0von\u00a0so\u00a0genannten \u00a0\u201eProblemkeimen\u201c,\u00a0\u00fcbrig\u00a0bleib en,\u00a0gegen\u00a0die\u00a0\ndie\u00a0Impfung\u00a0ohne\u00a0Wirkung\u00a0bleibt.\u00a0Dies\u00a0konnte\u00a0z.B.\u00a0bei\u00a0der\u00a0Polio \u2010Impfung\u00a0nachge\u2010224\u00a0wiesen\u00a0werden\u00a0(Dowdle\u00a0et\u00a0al.,\u00a02003).\u00a0Klassisch\u00a0ist\u00a0es\u00a0relevant\u00a0 f\u00fcr\u00a0Pneumokokken,\u00a0\naber\u00a0auch\u00a0bei\u00a0der\u00a0Varizellen\u2010Imp fung\u00a0gibt\u00a0es\u00a0Hinweise\u00a0auf\u00a0selek tierte\u00a0Infektionskei\u2010\nme\u00a0(Chaves\u00a0et\u00a0al.,\u00a02007).\u00a0Dies\u00a0kann\u00a0vor\u00a0allem\u00a0im\u00a0Rahmen\u00a0einer\u00a0s teigenden\u00a0Mobilit\u00e4t\u00a0\neine\u00a0Rolle\u00a0spielen,\u00a0da\u00a0trotz\u00a0einer\u00a0Impfung\u00a0im\u00a0Heimatland\u00a0eine\u00a0I nfektion\u00a0im\u00a0Reiseland\u00a0\nmit\u00a0anderen\u00a0Erreger\u2010Subtypen\u00a0durchaus\u00a0in\u00a0einzelnen\u00a0F\u00e4llen\u00a0m\u00f6gli ch\u00a0ist.\u00a0\nWas\u00a0ist\u00a0das\u00a0Ziel\u00a0von\u00a0Impfungen?\u00a0\nImpfungen\u00a0sind\u00a0Schutzma\u00dfnahmen,\u00a0die\u00a0unterschiedliche\u00a0Schutzbed\u00fc rftige\u00a0im\u00a0Blick\u00a0\nhaben.\u00a0Sie\u00a0stehen\u00a0damit\u00a0zwischen \u00a0den\u00a0Elementen\u00a0der\u00a0individual\u2010\u00a0 und\u00a0bev\u00f6lke\u2010\nrungsmedizinischen\u00a0Pr\u00e4vention\u00a0(Nuffield\u00a0Council\u00a0of\u00a0Bioethics,\u00a02 007).\u00a0\nZielsetzungen\u00a0einer\u00a0Impfung\u00a0k\u00f6nnen\u00a0sein:\u00a0\n\uf0b7 Der\u00a0individuelle\u00a0Schutz\u00a0\nDie\u00a0Impfung\u00a0dient\u00a0dem\u00a0individuellen\u00a0Schutz\u00a0vor\u00a0einer\u00a0Infektions \u2010\nk r a n k h e i t . \u00a0D i e \u00a0I n f e k t i o n \u00a0w i r d \u00a0i m \u00a0F a l l e \u00a0d e s \u00a0A u f t r e t e n s \u00a0n i c h t \u00a0v o n \u00a0\nMensch\u00a0 zu\u00a0 Mensch\u00a0 weitergegeben.\u00a0 Ein\u00a0 Beispiel\u00a0 ist\u00a0 die\u00a0 Tetanus\u2010\nImpfung.\u00a0Bei\u00a0solchen\u00a0Impfungen\u00a0gibt\u00a0es\u00a0keinen\u00a0medizinischen\u00a0Gru nd\u00a0\nf\u00fcr\u00a0eine\u00a0Impfverpflichtung,\u00a0da\u00a0keine\u00a0Gef\u00e4hrdung\u00a0Dritter\u00a0durch\u00a0n icht\u00a0\ngeimpfte\u00a0Personen\u00a0besteht.\u00a0\n\uf0b7 Der\u00a0individuelle\u00a0Schutz\u00a0und\u00a0de r\u00a0Schutz\u00a0der\u00a0Bev\u00f6lkerung\u00a0\nDie\u00a0Impfung\u00a0dient\u00a0dazu,\u00a0dass\u00a0der\u00a0geimpfte\u00a0Einzelne\u00a0die\u00a0Erkranku ng\u00a0\nnicht\u00a0bekommen\u00a0wird\u00a0und\u00a0andere\u00a0nicht\u00a0infizieren\u00a0kann.\u00a0Das\u00a0Risik o\u00a0\nder\u00a0Ansteckung\u00a0besteht\u00a0dann\u00a0alle rdings\u00a0nur\u00a0f\u00fcr\u00a0diejenigen,\u00a0die\u00a0 sich\u00a0\nselbst\u00a0entschieden\u00a0haben,\u00a0sich\u00a0und/oder\u00a0ihre\u00a0Kinder\u00a0nicht\u00a0impfe n\u00a0zu\u00a0\nlassen.\u00a0Das\u00a0Argument\u00a0der\u00a0eigenen\u00a0Entscheidung\u00a0gilt\u00a0allerdings\u00a0n icht\u00a0\nf\u00fcr\u00a0Menschen,\u00a0die\u00a0sich\u00a0aufgrund\u00a0einer\u00a0Erkrankung,\u00a0Schwangerscha ft\u00a0\noder\u00a0immunologischen\u00a0Schw\u00e4che\u00a0(noch)\u00a0nicht\u00a0impfen\u00a0lassen\u00a0k\u00f6nnen \u00a0\n(z.B.\u00a0Pertussis,\u00a0R\u00f6teln).\u00a0\u00a0\n\uf0b7 Der\u00a0Schutz\u00a0der\u00a0Bev\u00f6lkerung\u00a0oder\u00a0 eines\u00a0definierten\u00a0Bev\u00f6lkerungsa nteils\u00a0\nDie\u00a0Impfung\u00a0dient\u00a0nicht\u00a0\u2013\u00a0oder\u00a0heute\u00a0nicht\u00a0mehr\u00a0\u2013\u00a0prim\u00e4r\u00a0dem\u00a0ei ge\u2010\nnen\u00a0Schutz\u00a0des\u00a0Geimpften,\u00a0sondern \u00a0der\u00a0Eradikation\u00a0(Ausrottung)\u00a0 ei\u2010\nnes\u00a0Keimes\u00a0und\u00a0damit\u00a0der\u00a0Erkrankung\u00a0auf\u00a0Bev\u00f6lkerungsebene.\u00a0Ein\u00a0\nBeispiel\u00a0f\u00fcr\u00a0ein\u00a0erfolgreiches\u00a0P rogramm\u00a0ist\u00a0die\u00a0Pockenimpfung,\u00a0 ein\u00a0\nBeispiel\u00a0 f\u00fcr\u00a0 ein\u00a0 bisher\u00a0 immer\u00a0 noch\u00a0 nicht\u00a0 ganz\u00a0 erfolgreiches\u00a0 Pro \u2010\ngramm\u00a0ist\u00a0die\u00a0Polio\u2010Impfung,\u00a0und\u00a0ein\u00a0Beispiel\u00a0f\u00fcr\u00a0einen\u00a0entspre \u2010\nchenden\u00a0 Versuch\u00a0 der\u00a0 Eradikation\u00a0 weltweit\u00a0 ist\u00a0 die\u00a0 Hepatitis\u00a0 B\u2010Impfung.\u00a0Will\u00a0man\u00a0die\u00a0Eradikation\u00a0eines\u00a0Erregers\u00a0erreichen,\u00a0mus s\u00a0225\u00a0man\u00a0die\u00a0Bev\u00f6lkerung\u00a0zu\u00a0einer\u00a0hohen\u00a0Impfbeteiligung\u00a0mit\u00a0Raten\u00a0um \u00a0\netwa\u00a085\u00a0%\u00a0und\u00a0h\u00f6her\u00a0bringen\u00a0(Silman\u00a0&\u00a0Allwright,\u00a01988).\u00a0Bei\u00a0Mas ern\u00a0\nwerden\u00a095\u00a0%\u00a0als\u00a0notwendige\u00a0Rate\u00a0 angegeben.\u00a0Auch\u00a0hier\u00a0k\u00f6nnen,\u00a0\nwie\u00a0bei\u00a0der\u00a0Fr\u00fcherkennung,\u00a0der\u00a0individuelle\u00a0Nutzen\u00a0und\u00a0der\u00a0bev\u00f6 l\u2010\nkerungsmedizinische\u00a0Nutzen\u00a0k onkurrierende\u00a0Ziele\u00a0sein.\u00a0\u00a0\n\u00a0\nDie\u00a0Impfempfehlungen\u00a0der\u00a0STIKO\u00a0\nImpfempfehlungen\u00a0werden\u00a0in\u00a0Deutschland\u00a0von\u00a0der\u00a0STIKO\u00a0ausgesproc hen.\u00a0Bei\u00a0der\u00a0\nSTIKO\u00a0handelt\u00a0es\u00a0sich\u00a0um\u00a0eine\u00a0\u00f6ffentlich\u2010rechtliche\u00a0Einrichtung ,\u00a0also\u00a0eine\u00a0Einrich\u2010\ntung\u00a0unter\u00a0staatlicher\u00a0Aufsicht,\u00a0aber\u00a0mit\u00a0freiem\u00a0Entscheidungsr aum.\u00a0Die\u00a0Mitglieder\u00a0\nder\u00a0STIKO\u00a0werden,\u00a0wie\u00a0gesetzlich \u00a0festgelegt,\u00a0berufen.\u00a0Ihre\u00a0Empf ehlungen\u00a0werden\u00a0\nnach\u00a0einer\u00a0Entscheidung\u00a0des\u00a0G\u2010BA\u00a0als\u00a0Regelleistung\u00a0von\u00a0der\u00a0GKV\u00a0 \u00fcbernommen.\u00a0\nAufgabe\u00a0der\u00a0STIKO\u00a0ist\u00a0es,\u00a0auf\u00a0Ba sis\u00a0von\u00a0vorliegenden\u00a0Daten\u00a0\u00fcber \u00a0den\u00a0Nutzen\u00a0und\u00a0\nden\u00a0Schaden\u00a0von\u00a0Impfungen,\u00a0insbesondere\u00a0solcher,\u00a0die\u00a0neu\u00a0eingef \u00fchrt\u00a0werden\u00a0\nsollen,\u00a0 diese\u00a0 Empfehlungen\u00a0 abzugeben.\u00a0 Der\u00a0 G\u2010BA\u00a0 und\u00a0 die\u00a0 ihm\u00a0 zuar beitenden\u00a0\nGremien\u00a0haben\u00a0bei\u00a0deren\u00a0Aufnahme \u00a0in\u00a0den\u00a0Leistungskatalog\u00a0der\u00a0GK V\u00a0neben\u00a0Nut\u2010\nzen\u00a0und\u00a0Schaden\u00a0auch\u00a0die\u00a0Wirtschaf tlichkeit\u00a0und\u00a0Notwendigkeit\u00a0z u\u00a0pr\u00fcfen.\u00a0\u00a0\nDie\u00a0derzeit\u00a0von\u00a0der\u00a0STIKO\u00a0empfohlenen\u00a0Impfungen\u00a0werden\u00a0im\u00a0Impfk alender\u00a0(Ab\u2010\nbildung\u00a06.1)\u00a0aufgelistet.\u00a0\n\u00a0 \u00a0226\u00a0Abbildung\u00a06.1:\u00a0Impfkalender\u00a0f\u00fcr\u00a0S\u00e4uglinge,\u00a0Kinder,\u00a0Jugendliche\u00a0 und\u00a0Erwachsene\u00a0\nImpfstoff\u00a0 \u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0Alter\u00a0in\u00a0\u00a0 Alter\u00a0in\u00a0\u00a0\nWochen\u00a0 Monaten\u00a0 Jahren\u00a0\n\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0S\u00e4uglinge\u00a0 \u00a0\u00a0\u00a0\u00a0\u00a0Kleinkinder\u00a0 Kinder\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0Jugendliche\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0Erwachsene\u00a0\n6\u00a02\u00a03\u00a04\u00a011\u201014\u00a015\u201023\u00a02\u20104\u00a05\u20106\u00a09\u201014\u00a015\u201016\u00a017\u00a0ab\u00a018\u00a0ab\u00a060\nTetanus\u00a0 \u00a0G1\u00a0G2\u00a0G3\u00a0G4\u00a0N\u00a0N\u00a0A1\u00a0 A2\u00a0 N\u00a0A\u00a0(ggf.\u00a0N)e\u00a0\nDiphtherie\u00a0 \u00a0G1\u00a0G2\u00a0G3\u00a0G4\u00a0 N\u00a0 N\u00a0 A1\u00a0 A2\u00a0 N\u00a0 A\u00a0(ggf.\u00a0N)e\u00a0\nPertussis\u00a0 \u00a0G1\u00a0G2\u00a0G3\u00a0G4\u00a0N\u00a0N\u00a0A1\u00a0 A2\u00a0 N\u00a0A\u00a0(ggf.\u00a0N)e\u00a0\nHib\u00a0\nH.\u00a0influenzae\u00a0Typ\u00a0b\u00a0\u00a0G1\u00a0G2c\u00a0G3\u00a0G4\u00a0 N\u00a0 N\u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0\nPoliomyelitis\u00a0 \u00a0G1\u00a0G2c\u00a0G3\u00a0G4\u00a0N\u00a0 N\u00a0 A1\u00a0 N\u00a0ggf.\u00a0N\u00a0\nHepatitis\u00a0B\u00a0 \u00a0G1\u00a0G2c\u00a0G3\u00a0G4\u00a0 N\u00a0 N\u00a0 \u00a0 \u00a0\nPneumokokkena\u00a0 \u00a0G1\u00a0\u00a0G2\u00a0G3\u00a0N\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0Sg\u00a0\nRotaviren\u00a0 G1b\u00a0G2\u00a0 (G3)\u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0\nMeningokokken\u00a0C\u00a0 \u00a0\u00a0\u00a0\u00a0G1\u00a0(ab\u00a012\u00a0\nMonaten)\u00a0N\u00a0 \u00a0\u00a0\nMasern\u00a0 \u00a0\u00a0 \u00a0\u00a0 G1\u00a0G2\u00a0 N\u00a0 Sf\u00a0\u00a0\nMumps,\u00a0R\u00f6teln\u00a0 \u00a0\u00a0\u00a0\u00a0G1\u00a0G2\u00a0 N\u00a0 \u00a0\u00a0\nVarizellen\u00a0 \u00a0\u00a0 \u00a0\u00a0 G1\u00a0G2\u00a0 N\u00a0 \u00a0 \u00a0\nInfluenza\u00a0 \u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0S*\u00a0\u00a0\nHPV\u00a0Humane\u00a0\nPapillomviren\u00a0\u00a0\u00a0 \u00a0\u00a0\u00a0\u00a0 \u00a0 G1d\u00a0G2d\u00a0Nd\u00a0\u00a0\u00a0\nHerpes\u00a0Zoster\u00a0 \u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 \u00a0 \u00a0S\u00a0\nG\u00a0=\u00a0Grundimmunisierung\u00a0(in\u00a0bis\u00a0zu\u00a04\u00a0Teilimpfungen\u00a0G1\u00a0\u2013\u00a0G4),\u00a0A\u00a0= \u00a0Auffrischimpfung,\u00a0S\u00a0=\u00a0Standardimpfung,\u00a0N\u00a0=\u00a0Nachholimpfung\u00a0\n(Grund\u2010\u00a0bzw.\u00a0Erstimmunisierung\u00a0aller\u00a0noch\u00a0nicht\u00a0Geimpften\u00a0bzw.\u00a0 Komplettierung\u00a0einer\u00a0unvollst\u00e4ndigen\u00a0Impfserie)\u00a0\n*j\u00e4hrlich\u00a0\na\u00a0Fr\u00fchgeborene\u00a0erhalten\u00a0eine\u00a0zus\u00e4tzliche\u00a0Impfstoffdosis\u00a0im\u00a0Alter \u00a0von\u00a0drei\u00a0Monaten,\u00a0d.\u00a0h.\u00a0insgesamt\u00a0vier\u00a0Impfstoffdosen\u00a0\nb\u00a0Die\u00a0erste\u00a0Impfung\u00a0sollte\u00a0bereits\u00a0ab\u00a0einem\u00a0Alter\u00a0von\u00a0sechs\u00a0Woch en\u00a0erfolgen,\u00a0je\u00a0nach\u00a0Impfstoff\u00a0sind\u00a0zwei\u00a0bzw.\u00a0drei\u00a0Impfstoffdos en\u00a0\nim\u00a0Abstand\u00a0von\u00a0mindestens\u00a04\u00a0Wochen\u00a0erforderlich\u00a0\nc\u00a0Bei\u00a0Anwendung\u00a0eines\u00a0monovalenten\u00a0Impfstoffes\u00a0kann\u00a0diese\u00a0Dosis\u00a0 entfallen\u00a0\nd\u00a0Standardimpfung\u00a0f\u00fcr\u00a0M\u00e4dchen\u00a0und\u00a0Jungen\u00a0im\u00a0Alter\u00a0von\u00a0neun\u00a0bis\u00a01 4\u00a0Jahren\u00a0mit\u00a0zwei\u00a0Impfstoffdosen\u00a0im\u00a0Abstand\u00a0von\u00a0mindestens\u00a0\nf\u00fcnf\u00a0Monaten,\u00a0bei\u00a0Nachholimpfung\u00a0beginnend\u00a0im\u00a0Alter\u00a0\u00fcber\u00a014\u00a0Jah ren\u00a0oder\u00a0bei\u00a0einem\u00a0Impfabstand\u00a0von\u00a0unter\u00a0f\u00fcnf\u00a0Monaten\u00a0\nzwischen\u00a0erster\u00a0und\u00a0zweiter\u00a0Dosis\u00a0ist\u00a0eine\u00a0dritte\u00a0Dosis\u00a0erforde rlich\u00a0(Fachinformation\u00a0beachten)\u00a0\ne\u00a0Td\u2010Auffrischimpfung\u00a0alle\u00a0zehn\u00a0Ja hre.\u00a0Die\u00a0n\u00e4chste\u00a0f\u00e4llige\u00a0Td\u2010Im pfung\u00a0einmalig\u00a0als\u00a0Tdap\u2010\u00a0bzw.\u00a0bei\u00a0entsprechender\u00a0Indikation\u00a0als \u00a0\nTdap\u2010IPV\u2010Kombinationsimpfung\u00a0\nf\u00a0Einmalige\u00a0Impfung\u00a0mit\u00a0einem\u00a0MMR\u2010Impfstoff\u00a0f\u00fcr\u00a0alle\u00a0nach\u00a01970\u00a0g eborenen\u00a0Personen\u00a0\u2265\u00a018\u00a0Jahre\u00a0mit\u00a0unklarem\u00a0Impfstatus,\u00a0ohne\u00a0\nImpfung\u00a0oder\u00a0mit\u00a0nur\u00a0einer\u00a0Impfung\u00a0in\u00a0der\u00a0Kindheit\u00a0\ng\u00a0Impfung\u00a0mit\u00a0dem\u00a023\u2010valenten\u00a0Polysaccharid\u2010Impfstoff\u00a0\n\u00a0Quelle:\u00a0nach\u00a0RKI,\u00a02018a\u00a0227\u00a0Die\u00a0ersten\u00a0sechs\u00a0in\u00a0der\u00a0Abbildung \u00a06.1\u00a0angef\u00fchrten\u00a0Impfstoffe\u00a0we rden\u00a0meist\u00a0in\u00a0\neiner\u00a0Kombinationsimpfung\u00a0verabreicht\u00a0(Sechsfachimpfung).\u00a0Maser n,\u00a0Mumps\u00a0und\u00a0\nR\u00f6teln\u00a0werden\u00a0ebenfalls\u00a0meist\u00a0kom biniert\u00a0in\u00a0einer\u00a0Spritze\u00a0geimp ft\u00a0(MMR),\u00a0die\u00a0\nKombinationsimpfung\u00a0 Masern,\u00a0 Mumps,\u00a0 R\u00f6teln\u00a0 und\u00a0 Varizellen\u00a0 (MMRV) \u00a0i s t \u00a0s e i t \u00a0\neiniger\u00a0Zeit\u00a0ebenfalls\u00a0m\u00f6glich.\u00a0Bei\u00a0der\u00a0Verwendung\u00a0von\u00a0Kombinat ionsimpfstoffen\u00a0\nsind\u00a0die\u00a0Angaben\u00a0des\u00a0Herstellers\u00a0zu\u00a0den\u00a0Impfabst\u00e4nden\u00a0zu\u00a0beacht en\u00a0sowie\u00a0zur\u00a0\ngleichzeitigen\u00a0 Gabe\u00a0 von\u00a0 anderen\u00a0 Impfstoffen.\u00a0 Der\u00a0 Zeitpunkt\u00a0 der\u00a0 empfohlenen\u00a0\nImpfungen\u00a0wird\u00a0in\u00a0Wochen,\u00a0Monaten\u00a0und\u00a0Jahren\u00a0angegeben.\u00a0Die\u00a0Imp fungen\u00a0soll\u2010\nten\u00a0zum\u00a0fr\u00fchestm\u00f6glichen\u00a0Zeitpunkt\u00a0erfolgen.\u00a0Die\u00a0untere\u00a0Grenze\u00a0 bezeichnet\u00a0voll\u2010\nendete\u00a0Lebensjahre\u00a0bzw.\u00a0Lebensmonate.\u00a0Die\u00a0obere\u00a0Grenze\u00a0ist\u00a0defi niert\u00a0durch\u00a0den\u00a0\nletzten\u00a0Tag\u00a0des\u00a0aufgef\u00fchrten\u00a0Alters\u00a0in\u00a0Jahren/Monaten;\u00a0am\u00a0Beisp iel\u00a0von\u00a0neun\u00a0bis\u00a0\n16\u00a0Jahren:\u00a0Vom\u00a0neunten\u00a0Geburtstag\u00a0bis\u00a0zum\u00a0Ende\u00a0des\u00a017.\u00a0Lebensja hres\u00a0(am\u00a0letz\u2010\nten\u00a0Tag\u00a0vor\u00a0dem\u00a017.\u00a0Geburtstag)\u00a0solte\u00a0geimpft\u00a0werden.\u00a0Daneben\u00a0g ibt\u00a0es\u00a0auch\u00a0\nEmpfehlungen,\u00a0 die\u00a0 sich\u00a0 aus\u00a0 medizinischen\u00a0 und\u00a0 beruflichen\u00a0 Aspekt en\u00a0 ableiten\u00a0\nlassen.\u00a0\nSpezielle\u00a0Aspekte\u00a0bei\u00a0HPV\u2010\u00a0und\u00a0Masernimpfungen\u00a0\n1. HPV\u2010Impfung\u00a0zur\u00a0Reduktion\u00a0von\u00a0Geb\u00e4rmutterhalskarzinomen\u00a0(vgl.\u00a0K apitel\u00a04.8)\u00a0\nBei\u00a0der\u00a0Entstehung\u00a0von\u00a0Geb\u00e4rmutterhalskrebs\u00a0spielt\u00a0die\u00a0Infektio n\u00a0mit\u00a0humanen\u00a0\nPapillomviren\u00a0(HPV)\u00a0eine\u00a0wesentliche\u00a0Rolle.\u00a0Diese\u00a0Viren\u00a0lassen\u00a0 sich\u00a0in\u00a0unterschied\u2010\nliche\u00a0Typen\u00a0unterteilen,\u00a0von\u00a0denen\u00a0einige\u00a0bei\u00a0der\u00a0Krebsentstehu ng\u00a0beteiligt\u00a0sind.\u00a0\nIm\u00a0Falle\u00a0eines\u00a0Kontaktes\u00a0mit\u00a0HPV\u00a0durch\u00a0sexuelle\u00a0Kontakte\u00a0kann\u00a0e s\u00a0zu\u00a0einer\u00a0anhal\u2010\ntenden\u00a0Ansiedlung\u00a0der\u00a0Viren\u00a0z.B.\u00a0 im\u00a0Bereich\u00a0des\u00a0Geb\u00e4rmutterhals es\u00a0kommen.\u00a0Bei\u00a0\nder\u00a0ganz\u00a0\u00fcberwiegenden\u00a0Mehrzahl\u00a0d er\u00a0Menschen,\u00a0die\u00a0Kontakt\u00a0mit\u00a0d em\u00a0Virus\u00a0\nhaben,\u00a0wird\u00a0dieses\u00a0aber\u00a0durch\u00a0k\u00f6rpereigene\u00a0Kr\u00e4fte\u00a0abgewehrt\u00a0bzw .\u00a0wieder\u00a0besei\u2010\ntigt.\u00a0Bei\u00a0einigen\u00a0Frauen\u00a0persist iert\u00a0das\u00a0Virus,\u00a0bei\u00a0wiederum\u00a0ei nem\u00a0Teil\u00a0dieser\u00a0Frau\u2010\nen\u00a0entwickelt\u00a0sich\u00a0ein\u00a0Geb\u00e4rmu tterhalskarzinom\u00a0(WHO,\u00a02018a).\u00a0\nDer\u00a0erste\u00a0HPV\u2010Impfstoff\u00a0kam\u00a02006\u00a0auf\u00a0den\u00a0Markt.\u00a0Seinerzeit\u00a0wurd e\u00a0von\u00a0der\u00a0STIKO\u00a0\ndie\u00a0Impfung\u00a0zun\u00e4chst\u00a0nur\u00a0f\u00fcr\u00a0M\u00e4dchen\u00a0und\u00a0junge\u00a0Frauen\u00a0im\u00a0Alter\u00a0 von\u00a012\u00a0bis\u00a017\u00a0\nJahren\u00a0empfohlen.\u00a0Bereits\u00a0im\u00a0Jahre\u00a02014\u00a0wurde\u00a0diese\u00a0Empfehlung\u00a0 ver\u00e4ndert:\u00a0Es\u00a0\nsollten\u00a0nun\u00a0die\u00a0neun\u00a0bis\u00a014\u2010j\u00e4hrigen\u00a0M\u00e4dchen\u00a0geimpft\u00a0werden,\u00a0di e\u00a0Impfung,\u00a0so\u00a0die\u00a0\nSTIKO,\u00a0k\u00f6nnte\u00a0auch\u00a0bis\u00a0zum\u00a018.\u00a0Lebensjahr\u00a0nachgeholt\u00a0werden.\u00a0Im \u00a0Jahre\u00a02018\u00a0\nweitete\u00a0sie\u00a0die\u00a0Empfehlung\u00a0auch\u00a0auf\u00a0Jungen\u00a0und\u00a0junge\u00a0M\u00e4nner\u00a0im\u00a0 Alter\u00a0von\u00a0neun\u00a0\nbis\u00a014\u00a0Jahren\u00a0aus,\u00a0auch\u00a0hier\u00a0kann\u00a0die\u00a0Impfung\u00a0bis\u00a0zum\u00a018.\u00a0Leben sjahr\u00a0nachgeholt\u00a0\nwerden.\u00a0Dies\u00a0betrifft\u00a0vor\u00a0allem\u00a0d ie\u00a0Anwendung\u00a0des\u00a0Impfstoffes\u00a0G ardasil\u00ae\u00a09.\u00a0Garda\u2010\nsil\u00ae\u00a09\u00a0sch\u00fctzt\u00a0gegen\u00a0insgesamt\u00a0neun\u00a0HPV\u2010Typen,\u00a0darunter\u00a0sieben\u00a0 Hochrisikotypen\u00a0\nf\u00fcr\u00a0Geb\u00e4rmutterhalskrebs\u00a0(16,\u00a018,\u00a031,\u00a033,\u00a045,\u00a052,\u00a058)\u00a0und\u00a0gegen \u00a0die\u00a0beiden\u00a0h\u00e4u\u2010\nfigsten\u00a0Genitalwarzen\u00a0ausl\u00f6sende n\u00a0HPV\u2010Typen\u00a06\u00a0und\u00a011.\u00a0Ein\u00a0ander er\u00a0Impfstoff,\u00a0\nCervarix\u00ae,\u00a0der\u00a0auf\u00a0dem\u00a0deutschen\u00a0Markt\u00a0angeboten\u00a0wird,\u00a0kann\u00a0ebe nfalls\u00a0ange\u2010228\u00a0wendet\u00a0werden,\u00a0wirkt\u00a0aber\u00a0weniger\u00a0breit\u00a0(er\u00a0sch\u00fctzt\u00a0als\u00a0zwei\u2010va lente\u00a0Impfung\u00a0\ngegen\u00a0die\u00a0Hochrisiko\u2010Typen\u00a016\u00a0und\u00a018).\u00a0Es\u00a0ist\u00a0wichtig,\u00a0sich\u00a0vor \u00a0dem\u00a0ersten\u00a0Ge\u2010\nschlechtsverkehr\u00a0impfen\u00a0zu\u00a0lassen,\u00a0die\u00a0Viren\u00a0k\u00f6nnen\u00a0aber\u00a0auch\u00a0\u00fc ber\u00a0Oralsex\u00a0in\u00a0den\u00a0\nMund\u2010\u00a0und\u00a0Rachenbereich\u00a0gelangen \u00a0und\u00a0dort\u00a0eine\u00a0Infektion\u00a0verurs achen.\u00a0Etwa\u00a0\n80\u00a0%\u00a0der\u00a0sexuell\u00a0aktiven\u00a0jungen \u00a0Frauen\u00a0und\u00a0M\u00e4nner\u00a0im\u00a0Alter\u00a0von\u00a0 15\u00a0bis\u00a025\u00a0Jahren\u00a0\ninfizieren\u00a0sich\u00a0mit\u00a0solchen\u00a0Viren,\u00a0bei\u00a0etwa\u00a010\u00a0%\u00a0von\u00a0ihnen\u00a0blei ben\u00a0sie\u00a0im\u00a0Genital\u2010,\u00a0\nAfter\u2010\u00a0oder\u00a0Mund\u2010Rachenbereich\u00a0na chweisbar.\u00a0Diese\u00a0Viren\u00a0k\u00f6nnen\u00a0 die\u00a0betroffenen\u00a0\nHautzellen\u00a0an\u00a0allen\u00a0Infektionsorten\u00a0zu\u00a0Krebsvorstufen\u00a0ver\u00e4ndern \u00a0und\u00a0in\u00a0etwa\u00a0zehn\u00a0\nbis\u00a030\u00a0Jahren\u00a0zu\u00a0Krebs\u00a0f\u00fchren.\u00a0Als\u00a0wichtigstes\u00a0Alter\u00a0f\u00fcr\u00a0eine\u00a0I mpfung\u00a0gilt\u00a0der\u00a0Zeitraum\u00a0\nvom\u00a0neunten\u00a0bis\u00a0zum\u00a014.\u00a0Lebensjahr,\u00a0weil\u00a0zu\u00a0diesem\u00a0Zeitpunkt\u00a094 \u00a0%\u00a0der\u00a0M\u00e4dchen\u00a0\nund\u00a097\u00a0%\u00a0der\u00a0Jungen\u00a0noch\u00a0keinen\u00a0Sex\u00a0hatten\u00a0und\u00a0damit\u00a0frei\u00a0von\u00a0H PV\u00a0sind.\u00a0Hinzu\u00a0\nkommt,\u00a0dass\u00a0in\u00a0diesem\u00a0Alter\u00a0das\u00a0Immunsystem\u00a0sehr\u00a0gut\u00a0auf\u00a0die\u00a0Im pfung\u00a0anspricht\u00a0\nund\u00a0nur\u00a0zwei\u00a0Impfdosen\u00a0erforderlich\u00a0sind\u00a0(RKI,\u00a02018b).\u00a0\nInsgesamt\u00a0gibt\u00a0es\u00a0mehr\u00a0als\u00a0200\u00a0HP V\u2010Typen,\u00a0davon\u00a0k\u00f6nnen\u00a040\u00a0Infek tionen\u00a0ausl\u00f6sen.\u00a0\nDa\u00a0aber\u00a0durch\u00a0alle\u00a0Impfstoffe\u00a0nur\u00a0Infektionen\u00a0eines\u00a0eingeschr\u00e4n kten,\u00a0wenn\u00a0auch\u00a0\nwichtigen\u00a0Anteils\u00a0von\u00a0HPV\u2010Typen\u00a0 verhindert\u00a0werden\u00a0k\u00f6nnen,\u00a0die\u00a0I nfektionen\u00a0sel\u2010\nber\u00a0aber\u00a0meist\u00a0symptomfrei\u00a0und\u00a0unbemerkt\u00a0verlaufen,\u00a0ist\u00a0ein\u00a0HPV \u2010Fr\u00fcherken\u2010\nnungstest\u00a0auch\u00a0f\u00fcr\u00a0geimpfte\u00a0M\u00e4dchen\u00a0und\u00a0junge\u00a0Frauen\u00a0notwendig, \u00a0der\u00a0sog.\u00a0Pap\u2010\nTest\u00a0(benannt\u00a0nach\u00a0dem\u00a0Erfinder\u00a0Papanicolaou).\u00a0Er\u00a0wurde\u00a0entwick elt,\u00a0um\u00a0Zervix\u2010\nkarzinome\u00a0und\u00a0deren\u00a0Vorstufen\u00a0im \u00a0Rahmen\u00a0einer\u00a0mikroskopischen\u00a0U ntersuchung\u00a0\nnach\u00a0einem\u00a0Zellabstrich\u00a0am\u00a0Geb\u00e4r mutterhals\u00a0rechtzeitig\u00a0erkennen \u00a0zu\u00a0k\u00f6nnen.\u00a0Der\u00a0\nPap\u2010Test\u00a0ist\u00a0aber\u00a0nicht\u00a0sehr\u00a0gut\u00a0geeignet,\u00a0um\u00a0Vorstufen\u00a0diagnos tizieren\u00a0zu\u00a0k\u00f6nnen\u00a0\n(Klug,\u00a02019\u00a0zit.\u00a0nach\u00a0Uhlmann,\u00a02019).\u00a0Neben\u00a0dem\u00a0Pap\u2010Test\u00a0dient\u00a0 daher\u00a0auch\u00a0der\u00a0\nsog.\u00a0HPV\u2010Test\u00a0zur\u00a0Fr\u00fcherkennung\u00a0von\u00a0Geb\u00e4rmutterhalskrebs.\u00a0Laut\u00a0 Studienergeb\u2010\nnissen\u00a0kann\u00a0der\u00a0HPV\u2010Test\u00a0hochgradi ge\u00a0Dysplasien\u00a0m\u00f6glicherweise\u00a0 besser\u00a0erkennen\u00a0\nals\u00a0der\u00a0Pap\u2010Test.\u00a0Der\u00a0HPV\u2010Test\u00a0w ird\u00a0nicht\u00a0routinem\u00e4\u00dfig\u00a0eingeset zt,\u00a0sondern\u00a0z\u00e4hlt\u00a0\naktuell\u00a0 zu\u00a0 den\u00a0 Angeboten\u00a0 im\u00a0 IGeL\u2010Katalog\u00a0 (IQWiG,\u00a0 2011\u00a0 und\u00a0 2014) .\u00a0 Ab\u00a0 dem\u00a0\n01.01.2020\u00a0haben\u00a0aber\u00a0alle\u00a0Frauen\u00a0ab\u00a0dem\u00a035.\u00a0Lebensjahr\u00a0alle\u00a0dr ei\u00a0Jahre\u00a0einen\u00a0\nAnspruch\u00a0auf\u00a0ein\u00a0kombiniertes\u00a0 Screening \u00a0im\u00a0Sinne\u00a0einer\u00a0sog.\u00a0Ko\u2010Testung.\u00a0Diese\u00a0\nbesteht\u00a0aus\u00a0einem\u00a0PAP\u2010Abstrich\u00a0und\u00a0einem\u00a0HPV\u2010Test.\u00a0Mit\u00a0den\u00a0scho n\u00a0verf\u00fcgbaren\u00a0\nHPV\u2010Tests\u00a0 k\u00f6nnen\u00a0 HPV\u2010DNA\u00a0 oder\u00a0 HP V\u2010Onkogen\u2010mRNA\u00a0 nachgewiesen\u00a0 wer den.\u00a0\nDaher\u00a0werden\u00a0diese\u00a0Tests\u00a0zur\u00a0Abk l\u00e4rung\u00a0unklarer\u00a0zytologischer\u00a0B efunde,\u00a0grenz\u2010\nwertiger\u00a0 zytologischer\u00a0 Auff\u00e4lligkeiten\u00a0 oder\u00a0 leichter\u00a0 Dysplasien \u00a0e i n g e s e t z t . \u00a0M i t \u00a0\nsolchen\u00a0Tests\u00a0ist\u00a0es\u00a0auch\u00a0m\u00f6glic h,\u00a0Hochrisiko\u2010HPV\u2010Typen,\u00a0die\u00a0ei n\u00a0besonders\u00a0hohes\u00a0\nonkogenes\u00a0Potenzial\u00a0haben,\u00a0als o\u00a0z.B.\u00a0HPV\u00a016\u00a0und\u00a018\u00a0sowie\u00a0dauerh aft\u00a0vorkommen\u2010\nde\u00a0Infektionen,\u00a0zu\u00a0diagnostizier en\u00a0(s.\u00a0auch\u00a0S3\u2010Leitlinie\u00a0\u201ePr\u00e4ve ntion\u00a0des\u00a0Zervixkarzi\u2010\nnoms\u201c\u00a0(AWMF\u2010Nr.\u00a0015/027OL)).\u00a0\nMit\u00a0dem\u00a0Pap\u2010Test\u00a0werden\u00a0ca.\u00a050\u00a0%\u00a0der\u00a0Vorstufen\u00a0entdeckt.\u00a0Der\u00a0HP V\u2010Test\u00a0erkennt\u00a0\nca.\u00a090\u00a0%\u00a0der\u00a0Vorstufen,\u00a0deswegen\u00a0ist\u00a0er\u00a0in\u00a0vielen\u00a0L\u00e4ndern\u00a0schon \u00a0seit\u00a0Jahren\u00a0Stan\u2010229\u00a0dard.\u00a0In\u00a0Deutschland\u00a0wird\u00a0der\u00a0Pap\u2010Test\u00a0h\u00e4ufiger\u00a0durchgef\u00fchrt\u00a0al s\u00a0in\u00a0anderen\u00a0L\u00e4n\u2010\nd e r n , \u00a0b i s h e r \u00a0s o l l t e n \u00a0s c h o n \u00a02 0 \u2010 j \u00e4 hrige\u00a0 Frauen\u00a0 an\u00a0 dieser\u00a0 Vorsorge untersuchung\u00a0\nj\u00e4hrlich\u00a0teilnehmen.\u00a0\u201eNach\u00a0den\u00a0Richtlinien\u00a0der\u00a0WHO\u00a0hingegen\u00a0sol l\u00a0sich\u00a0eine\u00a0Frau\u00a0\nohne\u00a0HPV\u2010Infektion\u00a0fr\u00fchestens\u00a0nach\u00a0f\u00fcnf\u00a0Jahren\u00a0erneut\u00a0testen\u00a0la ssen.\u201c\u00a0(Uhlmann,\u00a0\n2019).\u00a0\u201eFakt\u00a0ist,\u00a0man\u00a0muss\u00a0nicht\u00a0j\u00e4hrlich\u00a0zum\u00a0Pap\u2010Abstrich,\u00a0wen n\u00a0[...\u00a0die\u00a0Vorsorge\u2010\nuntersuchung]\u00a0mit\u00a0hoher\u00a0Qualit\u00e4t\u00a0durchgef\u00fchrt\u00a0wird\u201c\u00a0(Klug,\u00a02019 ,\u00a0zit.\u00a0nach\u00a0Uhl\u2010\nmann,\u00a02019,\u00a014),\u00a0d.h.\u00a0wenn\u00a0gleichzeitig\u00a0ein\u00a0HPV\u2010Test\u00a0gemacht\u00a0wi rd.\u00a0Fast\u00a0alle\u00a0Frau\u2010\nen\u00a0bevorzugen\u00a0nach\u00a0einer\u00a0Wolfsbur ger\u00a0Studie\u00a0einen\u00a0F\u00fcnf\u2010Jahresab stand\u00a0statt\u00a0einer\u00a0\nj\u00e4hrlichen\u00a0Untersuchung\u00a0(M\u00fcller,\u00a02019).\u00a0\nBest\u00e4tigt\u00a0sich\u00a0eine\u00a0HPV\u2010Infektion,\u00a0wird\u00a0die\u00a0Stelle\u00a0wegge\u00e4tzt,\u00a0g elasert\u00a0oder\u00a0operativ\u00a0\nkegelf\u00f6rmig\u00a0ausgeschnitten\u00a0(Konisation).\u00a0Pro\u00a0Jahr\u00a0wird\u00a0dieser\u00a0o perative\u00a0Eingriff\u00a0bei\u00a0\n56.000\u00a0Frauen\u00a0durchgef\u00fchrt\u00a0(RKI,\u00a02018c).\u00a0Die\u00a0Impfung\u00a0bietet\u00a0als o\u00a0keinen\u00a0hundert\u2010\nprozentigen\u00a0Schutz.\u00a0Bisher\u00a0ist\u00a0nur\u00a0belegt,\u00a0dass\u00a0Vorstufen\u00a0einig er\u00a0Krebsarten\u00a0ver\u2010\nhindert\u00a0werden.\u00a0Es\u00a0ist\u00a0also\u00a0keine\u00a0Impfung\u00a0gegen\u00a0Krebs,\u00a0wie\u00a0oftm als\u00a0leichthin\u00a0ge\u2010\nsagt\u00a0wird.\u00a0Denn\u00a0ob\u00a0sie\u00a0tats\u00e4chlich\u00a0zu\u00a0weniger\u00a0Krebsf\u00e4llen\u00a0f\u00fchrt ,\u00a0wird\u00a0sich\u00a0erst\u00a0in\u00a0\nZukunft\u00a0zeigen.\u00a0Derzeit\u00a0sind\u00a0nur\u00a0etwa\u00a0zwischen\u00a022,4\u00a0%\u00a0(in\u00a0Bayer n)\u00a0und\u00a052\u00a0%\u00a0(in\u00a0\nMecklenburg\u2010Vorpommern)\u00a0der\u00a015\u2010j\u00e4hrigen\u00a0M\u00e4dchen\u00a0geimpft,\u00a0obwohl \u00a0die\u00a0Imp\u2010\nfung\u00a0sinnvoll\u00a0zur\u00a0Vorbeugung\u00a0von\u00a0Vorstufen\u00a0von\u00a0Geb\u00e4rmutterhals\u2010 \u00a0und\u00a0Scheiden\u2010\nkrebs\u00a0sowie\u00a0von\u00a0Genitalwarzen\u00a0wirkt.\u00a0In\u00a0den\u00a0alten\u00a0Bundesl\u00e4ndern \u00a0sind\u00a0es\u00a0in\u00a0der\u00a0\ngenannten\u00a0Altersgruppe\u00a0der\u00a015\u2010j\u00e4hrigen\u00a0M\u00e4dchen\u00a0im\u00a0Durchschnitt\u00a0 nur\u00a029,1\u00a0%,\u00a0in\u00a0\nden\u00a0neuen\u00a046,2\u00a0%\u00a0(RKI,\u00a02018b).\u00a0Eine\u00a0aktuelle\u00a0deutsche\u00a0Analyse\u00a0z eigt,\u00a0dass\u00a0mittler\u2010\nweile\u00a0jeder\u00a0f\u00fcnfte\u00a0geimpfte\u00a0Jugendliche\u00a0m\u00e4nnlich\u00a0ist.\u00a0Etwa\u00a060\u00a0% \u00a0der\u00a0geimpften\u00a0Kin\u2010\nder\u00a0und\u00a0Jugendlichen\u00a0ist\u00a0zum\u00a0Zeitpunkt\u00a0der\u00a0Impfung\u00a0zwischen\u00a012\u00a0 und\u00a015\u00a0Jahre\u00a0alt\u00a0\n(Insight\u00a0Health,\u00a02019).\u00a0F\u00fcr\u00a0Jungen\u00a0wird\u00a0der\u00a0Impfstoff\u00a0Gardasil\u00ae \u00a09\u00a0empfohlen.\u00a0F\u00fcr\u00a0den\u00a0\nImpfstoff\u00a0Cervarix\u00ae\u00a0kann\u00a0eine\u00a0so lche\u00a0positive\u00a0Empfehlung\u00a0derzei t\u00a0trotz\u00a0einer\u00a0vorhan\u2010\ndenen\u00a0Zulassung\u00a0u.E.\u00a0noch\u00a0nicht\u00a0ausgesprochen\u00a0werden\u00a0(vgl.\u00a0Kap. \u00a04.8\u00a0und\u00a0Garland\u00a0et\u00a0\nal.,\u00a02016).\u00a0\nEine\u00a0gerade\u00a0erschienene\u00a0Metaanal yse\u00a0aus\u00a0Kanada,\u00a0in\u00a0der\u00a0die\u00a0Date n\u00a0von\u00a060\u00a0Mio.\u00a0\nHPV\u2010geimpften\u00a0M\u00e4dchen,\u00a0Frauen\u00a0und\u00a0 Jungen\u00a0ausgewertet\u00a0wurden,\u00a0ze igt\u00a0einen\u00a0\ndeutlichen\u00a0R\u00fcckgang\u00a0von\u00a0Genitalwa rzen,\u00a0Hochrisiko\u2010HPV\u2010Infektion en\u00a0und\u00a0zervika\u2010\nlen\u00a0intraepithelialen\u00a0Neoplasien \u00a0und\u00a0damit\u00a0den\u00a0Vorstufen\u00a0von\u00a0Ge b\u00e4rmutterhals\u2010\nkrebs\u00a0seit\u00a0Einf\u00fchrung\u00a0der\u00a0HPV\u2010Impfung\u00a0(Drolet\u00a0et\u00a0al.,\u00a02019).\u00a0Da her\u00a0sollte\u00a0die\u00a0For\u2010\nderung\u00a0der\u00a0WHO\u00a0umgesetzt\u00a0werden,\u00a0die\u00a0Impfquote\u00a0bei\u00a0m\u00f6glichst\u00a0vi elen\u00a0M\u00e4dchen,\u00a0\njungen\u00a0Frauen\u00a0und\u00a0auch\u00a0Jungen\u00a0noch \u00a0vor\u00a0dem\u00a0ersten\u00a0Sexualkontakt \u00a0zu\u00a0erh\u00f6hen.\u00a0\nAllerdings\u00a0sollte\u00a0bei\u00a0der\u00a0Durchf \u00fchrung\u00a0der\u00a0HPV\u2010Impfung\u00a0der\u00a0Hinw eis\u00a0auf\u00a0die\u00a0Teil\u2010\nnahme\u00a0an\u00a0der\u00a0Krebsfr\u00fcherkennung\u00a0zur\u00a0Pflicht\u00a0gemacht\u00a0werden.\u00a0Das \u00a0Problem\u00a0da\u2010\nbei\u00a0ist,\u00a0dass\u00a0man\u00a0Kinder\u00a0impft,\u00a0a ber\u00a0auf\u00a0etwas\u00a0hinweisen\u00a0muss,\u00a0 was\u00a0erst\u00a0im\u00a0Er\u2010\nwachsenenalter\u00a0Bedeutung\u00a0bekommt .\u00a0Dies\u00a0verringert\u00a0die\u00a0Akzeptanz \u00a0der\u00a0Impfung:\u00a0230\u00a0Kl\u00e4rt\u00a0der\u00a0Arzt\u00a0deutlich\u00a0\u00fcber\u00a0die\u00a0genannten\u00a0Zusammenh\u00e4nge\u00a0auf,\u00a0h \u00e4ngt\u00a0es\u00a0sehr\u00a0von\u00a0\neiner\u00a0sachgerechten\u00a0Kommunikation \u00a0ab,\u00a0damit\u00a0die\u00a0Jugendlichen\u00a0de n\u00a0perspektivi\u2010\nschen\u00a0Sinn\u00a0\u2013\u00a0berechtigt\u00a0oder\u00a0nicht\u00a0\u2013\u00a0und\u00a0Nutzen\u00a0der\u00a0Impfung\u00a0ver stehen.\u00a0Es\u00a0sollte\u00a0\nerreicht\u00a0werden,\u00a0dass\u00a0sich\u00a0die\u00a0Impfteilnahme\u00a0an\u00a0der\u00a0HPV\u2010Impfung \u00a0erh\u00f6ht,\u00a0weil\u00a0\ndadurch\u00a0die\u00a0individuelle\u00a0Vorbeugung\u00a0einerseits\u00a0und\u00a0das\u00a0bev\u00f6lker ungsorientierte\u00a0\nZiel\u00a0der\u00a0Verringerung\u00a0von\u00a0HPV\u2010Inf ektionen\u00a0andererseits\u00a0erreicht \u00a0werden\u00a0k\u00f6nnte.\u00a0\u00a0\n2. Zwischen\u00a0individueller\u00a0Pr\u00e4vention,\u00a0Gemeinschaftsschutz\u00a0und\u00a0Impf pflicht:\u00a0Die\u00a0\nDiskussion\u00a0um\u00a0die\u00a0Masernimpfung\u00a0\nKeine\u00a0Impfung\u00a0wird\u00a0in\u00a0der\u00a0\u00d6ffentlichkeit\u00a0mehr\u00a0diskutiert\u00a0als\u00a0di e\u00a0Impfung\u00a0gegen\u00a0\nMasern.\u00a0Die\u00a0meisten\u00a0Eltern\u00a0und\u00a0Experten\u00a0sind\u00a0sich\u00a0darin\u00a0einig,\u00a0 dass\u00a0kein\u00a0Kind\u00a0mehr\u00a0\nunter\u00a0dieser\u00a0Krankheit\u00a0leiden\u00a0m\u00fcsste\u00a0und\u00a0dass\u00a0sie\u00a0\u00e4hnlich\u00a0wie\u00a0d ie\u00a0Kinderl\u00e4hmung\u00a0\nbei\u00a0einer\u00a0konsequenten\u00a0Ber\u00fccksichtigung\u00a0der\u00a0Impfempfehlung\u00a0(s.\u00a0 Abbildung\u00a06.1)\u00a0\neradiziert\u00a0werden\u00a0k\u00f6nnte.\u00a0Bereits\u00a0seit\u00a0den\u00a01960er\u00a0Jahren\u00a0werden \u00a0effektive\u00a0und\u00a0\nauch\u00a0sichere,\u00a0dabei\u00a0noch\u00a0kosteng \u00fcnstige\u00a0Impfstoffe\u00a0gegen\u00a0diese\u00a0 hoch\u00a0ansteckende\u00a0\nErkrankung\u00a0angeboten,\u00a0trotzdem\u00a0nimmt\u00a0die\u00a0Anzahl\u00a0der\u00a0Erkrankten\u00a0 nach\u00a0Jahren\u00a0\ndes\u00a0R\u00fcckgangs\u00a0in\u00a0Europa\u00a0wieder\u00a0zu.\u00a0Im\u00a0Jahr\u00a02018\u00a0waren\u00a0es\u00a0mehr\u00a0a ls\u00a082.000\u00a0F\u00e4lle\u00a0\n(WHO,\u00a02019c).\u00a0Diese\u00a0Entwicklung\u00a0gilt\u00a0auch\u00a0f\u00fcr\u00a0Deutschland:\u00a0\u00a0\nZwar\u00a0gab\u00a0es\u00a0insgesamt\u00a0seit\u00a0Einf\u00fchrung\u00a0der\u00a0Meldepflicht\u00a0in\u00a0Deuts chland\u00a0im\u00a0Jahre\u00a0\n2001\u00a0einen\u00a0starken\u00a0R\u00fcckgang\u00a0der\u00a0Masern\u00a0von\u00a06.040\u00a0auf\u00a0543\u00a0F\u00e4lle\u00a0 in\u00a02018,\u00a0jedoch\u00a0\nstagniert\u00a0diese\u00a0Anzahl\u00a0seit\u00a02007\u00a0mit\u00a0Schwankungen\u00a0abh\u00e4ngig\u00a0vom\u00a0 Ausbruchsge\u2010\nschehen\u00a0(Matysiak\u2010Klose\u00a0&\u00a0Santibanez,\u00a02018,\u00a0325;\u00a0RKI,\u00a02019a).\u00a0S o\u00a0kommt\u00a0es\u00a0nach\u00a0\nJahren\u00a0mit\u00a0niedrigen\u00a0Inzidenzrat en\u00a0immer\u00a0wieder\u00a0zu\u00a0steigenden\u00a0N euerkrankungs\u2010\nzahlen\u00a0durch\u00a0endemische\u00a0Transmissionsketten,\u00a0wie\u00a0von\u00a0Oktober\u00a020 14\u00a0bis\u00a0Mai\u00a0\n2015\u00a0in\u00a0Berlin\u00a0beim\u00a0gr\u00f6\u00dften\u00a0Ausbruchsgeschehen\u00a0seit\u00a0Beginn\u00a0der\u00a0 Meldepflicht\u00a0\n(vgl.\u00a0Abbildung\u00a06.2)\u00a0(Razum\u00a0et\u00a0al.,\u00a02016).\u00a0Begr\u00fcnden\u00a0lassen\u00a0k\u00f6n nte\u00a0sich\u00a0diese\u00a0Ent\u2010\nwicklung\u00a0mit\u00a0der\u00a0vergleichsweise \u00a0hohen\u00a0Bev\u00f6lkerungsdichte\u00a0in\u00a0De utschland.\u00a0Au\u2010\n\u00dferdem\u00a0stellen\u00a0externe\u00a0Einfl\u00fcsse\u00a0w ie\u00a0eine\u00a0Einreise\u00a0oder\u00a0Einwand erung\u00a0aus\u00a0ande\u2010\nren\u00a0L\u00e4ndern\u00a0ein\u00a0Risiko\u00a0f\u00fcr\u00a0so\u00a0gen annte\u00a0\u201eimportierte\u00a0F\u00e4lle\u201c\u00a0dar\u00a0 (Razum\u00a0et\u00a0al.,\u00a02016,\u00a0\n329).\u00a0Die\u00a0am\u00a0RKI\u00a0angesiedelte\u00a0Nationale\u00a0Verifizierungskommissio n\u00a0Masern/R\u00f6teln\u00a0\n(NAVKO)\u00a0geht\u00a0nach\u00a0einer\u00a0kritischen\u00a0Pr\u00fcfung\u00a0der\u00a0Daten\u00a0davon\u00a0aus, \u00a0dass\u00a0es\u00a0sich\u00a0bei\u00a0\nAusbr\u00fcchen\u00a0von\u00a02011\u00a0bis\u00a02012\u00a0sowie\u00a02013\u00a0bis\u00a02015\u00a0um\u00a0eine\u00a0endemi sche\u00a0\u00dcbertra\u2010\ngung\u00a0importierter\u00a0Masernviren\u00a0handelt\u00a0(Razum\u00a0et\u00a0al.,\u00a02016);\u00a0die s\u00a0alles\u00a0vor\u00a0dem\u00a0\nHintergrund,\u00a0dass\u00a0die\u00a0WHO\u00a0als\u00a0Ziel \u00a0einer\u00a0erfolgreichen\u00a0Eliminat ion\u00a0der\u00a0Maserner\u2010\nkrankungen\u00a0eine\u00a0H\u00e4ufigkeit\u00a0von\u00a0unter\u00a0einem\u00a0Fall\u00a0pro\u00a0Million\u00a0Ein wohner\u00a0ausgeru\u2010\nfen\u00a0hat.\u00a0Deutschland\u00a0hat\u00a0diese\u00a0Marke\u00a0seit\u00a0Jahren\u00a0verfehlt\u00a0(s.\u00a0A bbildung\u00a06.2).\u00a0\n\u00a0 \u00a0231\u00a0Abbildung\u00a06.2:\u00a0Maserninzidenzraten\u00a02008\u00a0\u2013\u00a02018\u00a0in\u00a0Deutschland\u00a0i m\u00a0Vergleich\u00a0\nzum\u00a0Eliminationsziel\u00a0der\u00a0WHO\u00a0\n\u00a0\nQuelle:\u00a0Eigene\u00a0Darstellung\u00a0nach\u00a0RKI,\u00a02019a\u00a0\nInnerhalb\u00a0Deutschlands\u00a0divergiert\u00a0die\u00a0Anzahl\u00a0an\u00a0Maserninfektion en\u00a0stark\u00a0je\u00a0nach\u00a0\nBundesland\u00a0(vgl.\u00a0Tabelle\u00a06.2).\u00a0W\u00e4hrend\u00a0es\u00a0vor\u00a0einigen\u00a0Jahren\u00a0eh er\u00a0in\u00a0den\u00a0westli\u2010\nchen\u00a0L\u00e4ndern\u00a0hohe\u00a0Inzidenzraten\u00a0gab,\u00a0gleicht\u00a0sich\u00a0das\u00a0Verh\u00e4ltni s\u00a0zwischen\u00a0Ost\u00a0und\u00a0\nWest\u00a0inzwischen\u00a0an\u00a0(BMG,\u00a02015,\u00a017).\u00a0Die\u00a0h\u00f6chste\u00a0Neuerkrankungsr ate\u00a0in\u00a0den\u00a0\nJahren\u00a02017\u00a0und\u00a02018\u00a0gab\u00a0es\u00a0in\u00a0Nordrhein\u2010Westfalen.\u00a0Ebenfalls\u00a0h ohe\u00a0Neuerkrankungs\u2010\nraten\u00a0lagen\u00a02018\u00a0in\u00a0Bayern,\u00a0Baden\u2010W\u00fcrttemberg\u00a0und\u00a0Berlin\u00a0vor.\u00a0D ie\u00a0niedrigste\u00a0Rate\u00a0\nverzeichnete\u00a0in\u00a0beiden\u00a0Jahren\u00a0da s\u00a0Saarland,\u00a0gefolgt\u00a0von\u00a0Th\u00fcring en\u00a0und\u00a0Mecklen\u2010\nburg\u2010Vorpommern\u00a0mit\u00a0jeweils\u00a0einem\u00a0Masernfall\u00a0(RKI,\u00a02019a).\u00a0\u00a0\nIm\u00a0hohen\u00a0Alter\u00a0nimmt\u00a0die\u00a0Inzidenzrate\u00a0f\u00fcr\u00a0Masern\u00a0jedoch\u00a0wieder\u00a0 ab,\u00a0sodass\u00a0in\u00a0der\u00a0\nAltersgruppe\u00a0ab\u00a070\u00a0Jahre\u00a0fast\u00a0kei ne\u00a0F\u00e4lle\u00a0mehr\u00a0auftreten\u00a0(RKI,\u00a0 2018d,\u00a0164f).\u00a0Kon\u2010\nstant\u00a0hoch\u00a0ist\u00a0die\u00a0Neuerkrankungsrate\u00a0bei\u00a0Kindern\u00a0im\u00a0ersten\u00a0Leb ensjahr,\u00a0da\u00a0diese\u00a0\nnoch\u00a0nicht\u00a0gegen\u00a0die\u00a0Infektion\u00a0geimpft\u00a0werden\u00a0k\u00f6nnen\u00a0und\u00a0von\u00a0de r\u00a0Immunit\u00e4t\u00a0\ninnerhalb\u00a0der\u00a0Bev\u00f6lkerung\u00a0abh\u00e4ngig\u00a0sind.\u00a0Die\u00a0Inzidenz\u00a0in\u00a0dieser \u00a0Altersgruppe\u00a0be\u2010\nl\u00e4uft\u00a0sich\u00a0im\u00a0Jahr\u00a02017\u00a0auf\u00a01,6\u00a0F\u00e4lle\u00a0je\u00a0Million\u00a0Kinder\u00a0(RKI,\u00a02 018d,\u00a0S.\u00a0164).\u00a0Insge\u2010\nsamt\u00a0sprechen\u00a0Epidemiologen\u00a0von\u00a0 einer\u00a0heterogenen\u00a0Verteilung\u00a0de r\u00a0Masernf\u00e4lle\u00a0\nin\u00a0der\u00a0gesamten\u00a0Bundesrepublik\u00a0hinsichtlich\u00a0des\u00a0Ortes,\u00a0Alters\u00a0u nd\u00a0Geschlechts\u00a0\nsowie\u00a0der\u00a0ethnischen\u00a0und\u00a0sozialen\u00a0Gruppenzugeh\u00f6rigkeit.\u00a0Folglic h\u00a0ist\u00a0das\u00a0Risiko\u00a0f\u00fcr\u00a0\n232\u00a0gro\u00dfe\u00a0Ausbruchsgeschehen\u00a0und\u00a0endemische\u00a0\u00dcbertragungen\u00a0bisher\u00a0un kalkulierbar\u00a0\nund\u00a0hoch\u00a0(BMG,\u00a02015).\u00a0\nF\u00fcr\u00a0die\u00a0Grundimmunisierung\u00a0gegen\u00a0das\u00a0Masernvirus\u00a0sind\u00a0zwei\u00a0Impf dosen\u00a0vorge\u2010\nsehen.\u00a0Historisch\u00a0betrachtet\u00a0wird\u00a0die\u00a0einmalige\u00a0Masernimpfung\u00a0b ereits\u00a0seit\u00a01966\u00a0\nin\u00a0der\u00a0ehemaligen\u00a0DDR\u00a0und\u00a0seit\u00a01974\u00a0in\u00a0Westdeutschland\u00a0durchgef \u00fchrt.\u00a0In\u00a0der\u00a0\nehemaligen\u00a0DDR\u00a0bestand\u00a0ab\u00a01970\u00a0eine\u00a0Pflicht\u00a0f\u00fcr\u00a0die\u00a0einmalige\u00a0I mpfung\u00a0gegen\u00a0\nMasern\u00a0bei\u00a0Kindern,\u00a0w\u00e4hrend\u00a0in\u00a0den\u00a0alten\u00a0Bundesl\u00e4ndern\u00a0ab\u00a01974\u00a0 lediglich\u00a0eine\u00a0\nEmpfehlung\u00a0der\u00a0STIKO\u00a0vorlag\u00a0(Poethko\u2010M\u00fcller\u00a0&\u00a0Schmitz,\u00a02013).\u00a0D ie\u00a0Einf\u00fchrung\u00a0\nder\u00a0zweiten\u00a0Impfdosis\u00a0fand\u00a0erst\u00a0einige\u00a0Jahre\u00a0sp\u00e4ter\u00a0statt,\u00a01986 \u00a0f\u00fcr\u00a0alle\u00a0Kinder\u00a0in\u00a0\nder\u00a0ehemaligen\u00a0DDR\u00a0und\u00a01991\u00a0in\u00a0Westdeutschland.\u00a0Dabei\u00a0sollte\u00a0di e\u00a0zweite\u00a0Impf\u2010\ndosis\u00a0erst\u00a0ab\u00a0dem\u00a0sechsten\u00a0Lebensjahr\u00a0verabreicht\u00a0werden.\u00a0Im\u00a0Zu ge\u00a0der\u00a0Wieder\u2010\nvereinigung\u00a0wurde\u00a01990\u00a0die\u00a0Pflichtimpfung\u00a0aufgehoben\u00a0und\u00a0die\u00a0Em pfehlungen\u00a0der\u00a0\nSTIKO\u00a0f\u00fcr\u00a0die\u00a0gesamte\u00a0Bundesrepublik\u00a0geltend\u00a0gemacht.\u00a0Seit\u00a02001 \u00a0wird\u00a0zudem\u00a0\nempfohlen,\u00a0die\u00a0zweite\u00a0Impfdosis\u00a0bereits\u00a0im\u00a0zweiten\u00a0Lebensjahr\u00a0z u\u00a0verabreichen\u00a0\n(Klein\u00a0et\u00a0al.,\u00a02012).\u00a0\n\u00a0 \u00a0233\u00a0Tabelle\u00a0 6.2: \u00a0Masern\u2010Fallzahlen\u00a0 und\u00a0 Inzidenzraten\u00a0 f\u00fcr\u00a0 2017\u00a0 und\u00a0 2018\u00a0 nach\u00a0\u00a0\nBundesland\u00a0\nBundesland\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a02017\u00a0 \u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a02018\u00a0\nFallzahl\u00a0Inzidenz/1\u00a0Mio.\u00a0\nEinwohner\u00a0Fallzahl\u00a0Inzidenz/1\u00a0Mio.\u00a0\nEinwohner\u00a0\nBaden\u2010W\u00fcrttemberg\u00a0 53\u00a0 4,9\u00a0 89\u00a0 8,1\u00a0\nBayern\u00a0 59\u00a0 4,6\u00a0 108\u00a0 8,3\u00a0\nBerlin\u00a0 69\u00a0 20\u00a0 30\u00a0 8,1\u00a0\nBrandenburg\u00a0 8\u00a0 3,2\u00a0 12\u00a0 4,8\u00a0\nBremen\u00a0 3\u00a0 4,5\u00a0 2\u00a0 2,9\u00a0\nHamburg\u00a0 8\u00a0 4,5\u00a0 14\u00a0 7,6\u00a0\nHessen\u00a0 76\u00a0 12,5\u00a0 25\u00a0 4,0\u00a0\nMecklenburg\u2010\nVorpommern\u00a01\u00a0 0,6\u00a0 1\u00a0 0,6\u00a0\nNiedersachsen\u00a0 15\u00a0 1,9\u00a0 18\u00a0 2,3\u00a0\nNordrhein\u2010Westfalen\u00a0 520\u00a0 29,1\u00a0 211\u00a0 11,8\u00a0\nRheinland\u2010Pfalz\u00a0 21\u00a0 5,2\u00a0 9\u00a0 2,2\u00a0\nSaarland\u00a0 2\u00a0 2\u00a0 0\u00a0 0,0\u00a0\nSachsen\u00a0 69\u00a0 16,6\u00a0 8\u00a0 2,0\u00a0\nSachsen\u2010Anhalt\u00a0 9\u00a0 3,8\u00a0 10\u00a0 4,5\u00a0\nSchleswig\u2010Holstein\u00a0 10\u00a0 3,9\u00a0 5\u00a0 1,7\u00a0\nTh\u00fcringen\u00a0 6\u00a0 2,7\u00a0 1\u00a0 0,5\u00a0\nGesamt\u00a0 929\u00a0 11,4\u00a0 543\u00a0 6,6\u00a0\nQuelle:\u00a0RKI,\u00a02019a;\u00a0Destatis,\u00a02018\u00a0\nZudem\u00a0zeigt\u00a0sich\u00a0seit\u00a02003\u00a0eine\u00a0Altersverschiebung\u00a0der\u00a0Masernf\u00e4 lle\u00a0in\u00a0Deutsch\u2010\nland.\u00a0Waren\u00a0bis\u00a0dahin\u00a0eher\u00a0Kinder\u00a0unter\u00a0neun\u00a0Jahren\u00a0von\u00a0der\u00a0Erk rankung\u00a0betrof\u2010\nfen,\u00a0entfallen\u00a0nun\u00a0die\u00a0H\u00e4lfte\u00a0der\u00a0F\u00e4lle\u00a0auf\u00a0junge\u00a0Erwachsene\u00a0ab \u00a020\u00a0Jahren\u00a0(BMG,\u00a0\n2015,\u00a017;\u00a0RKI,\u00a0o.\u00a0J.).\u00a0\u00a0\n\u00a0234\u00a0Die\u00a0Hospitalisierungsraten\u00a0der\u00a0unterschiedlichen\u00a0Altersgruppen\u00a0 scheinen\u00a0auch\u00a0auf\u00a0\nunterschiedliche\u00a0 Schweregrade\u00a0 des\u00a0 Krankheitsverlaufs\u00a0 hinzudeute n.\u00a0 Menschen,\u00a0\ndie\u00a0\u00e4lter\u00a0als\u00a020\u00a0Jahre\u00a0sind,\u00a0werden\u00a0bei\u00a0einer\u00a0Maserninfektion\u00a0e her\u00a0im\u00a0Krankenhaus\u00a0\nbehandelt\u00a0(Abbildung\u00a06.3).\u00a0\nAbbildung\u00a06.3:\u00a0Hospitalisierungsraten\u00a0Masern\u00a0nach\u00a0Alter\u00a0im\u00a0Jahr \u00a02018\u00a0\n\u00a0\nQuelle:\u00a0Eigene\u00a0Darstellung\u00a0nach\u00a0RKI,\u00a02019a\u00a0\n\u00a0 \u00a0\n235\u00a0Nach\u00a0einem\u00a0massiven\u00a0Abfall\u00a0der\u00a0Kurve\u00a0(Abb.\u00a06.4)\u00a0nach\u00a02001\u00a0auf\u00a0d en\u00a0bisherigen\u00a0\nTiefstwert\u00a0von\u00a01,5\u00a0Masernf\u00e4llen\u00a0pro\u00a0Million\u00a0Einwohner\u00a0im\u00a0Jahr\u00a02 004\u00a0pendelt\u00a0sich\u00a0\ndie\u00a0Rate\u00a0der\u00a0gemeldeten\u00a0Masernf\u00e4 lle\u00a0pro\u00a0Million\u00a0Einwohner\u00a0auf\u00a0e inem\u00a0relativ\u00a0\nniedrigen\u00a0Niveau\u00a0ein.\u00a0Daher\u00a0ist\u00a0 es\u00a0auch\u00a0sehr\u00a0\u00fcberraschend,\u00a0dass \u00a0aufgrund\u00a0der\u00a0\nEntwicklung\u00a0der\u00a0Masern\u2010Inzidenzen\u00a0nun\u00a0\u2013\u00a0ohne\u00a0zun\u00e4chst\u00a0\u00fcber\u00a0ande re\u00a0Ma\u00dfnah\u2010\nmen\u00a0nachzudenken\u00a0(bessere\u00a0Informationen,\u00a0Erinnerungsma\u00dfnahmen,\u00a0 Impfkam\u2010\npagnen\u00a0etc.)\u00a0\u2013\u00a0eine\u00a0Impfpflicht\u00a0in\u00a0die\u00a0politische\u00a0Diskussion\u00a0ge bracht\u00a0wird\u00a0(BMG,\u00a0\n2019).\u00a0\u00a0\nAbbildung\u00a06.4:\u00a0Masern\u2010Inzidenzen\u00a0pro\u00a01\u00a0Mio.\u00a0Einwohner\u00a0nach\u00a0Jahr en\u00a0\n\u00a0\nQuelle:\u00a0nach\u00a0RKI,\u00a02019\u00a0\nGegenw\u00e4rtig\u00a0wird\u00a0die\u00a0erste\u00a0Gabe\u00a0 des\u00a0Masernimpfstoffes\u00a0von\u00a0der\u00a0S TIKO\u00a0zwischen\u00a0\ndem\u00a0elften\u00a0und\u00a014.\u00a0Lebensmonat\u00a0und\u00a0somit\u00a0zum\u00a0Zeitpunkt\u00a0der\u00a0Fr\u00fch erkennungsun\u2010\ntersuchung\u00a0U6\u00a0empfohlen\u00a0(STIKO,\u00a02018a).\u00a0Bei\u00a0einem\u00a0akuten\u00a0Ausbru chsgeschehen\u00a0\noder\u00a0einer\u00a0Unterbringung\u00a0in\u00a0einer\u00a0Gemeinschaftseinrichtung\u00a0k\u00f6nn en\u00a0S\u00e4uglinge\u00a0\nbereits\u00a0ab\u00a0dem\u00a0neunten\u00a0Lebensmonat\u00a0geimpft\u00a0werden.\u00a0In\u00a0Ausnahmef \u00e4llen\u00a0sind\u00a0\nnach\u00a0einer\u00a0individuellen\u00a0Risiko\u2010Nutzen\u2010Abw\u00e4gung\u00a0sogar\u00a0Impfungen \u00a0ab\u00a0dem\u00a0sechs\u2010\nten\u00a0Lebensmonat\u00a0m\u00f6glich.\u00a0Die\u00a0STI KO\u00a0merkt\u00a0jedoch\u00a0an,\u00a0dass\u00a0es\u00a0sic h\u00a0hierbei\u00a0um\u00a0\neinen\u00a0Off\u2010label\u2010use \u00a0handelt\u00a0und\u00a0keine\u00a0ausreichende n\u00a0Daten\u00a0zur\u00a0Wirksamkeit\u00a0und\u00a0\nSicherheit\u00a0in\u00a0diesem\u00a0Lebensalter \u00a0vorliegen.\u00a0Die\u00a0Konsequenz\u00a0eine r\u00a0derart\u00a0fr\u00fchen\u00a0\nErstimpfung\u00a0ist\u00a0aber,\u00a0dass\u00a0f\u00fcr\u00a0ei nen\u00a0vollst\u00e4ndigen\u00a0Schutz\u00a0denno ch\u00a0auch\u00a0die\u00a0beiden\u00a0\n236\u00a0empfohlenen\u00a0Grundimmunisierungen\u00a0in\u00a0den\u00a0\u00fcblichen\u00a0Zeitr\u00e4umen\u00a0geg eben\u00a0wer\u2010\nden\u00a0m\u00fcssen,\u00a0sodass\u00a0diese\u00a0Kinder\u00a0insgesamt\u00a0dreimal\u00a0gegen\u00a0Masern\u00a0 geimpft\u00a0wer\u2010\nden.\u00a0Im\u00a0fr\u00fchesten\u00a0Kindesalter\u00a0ist\u00a0die\u00a0Immunit\u00e4t\u00a0durch\u00a0die\u00a0Impfu ng\u00a0aber\u00a0noch\u00a0nicht\u00a0\nausreichend\u00a0(STIKO,\u00a02018b).\u00a0Dar\u00fcber\u00a0hinaus\u00a0sollte\u00a0darauf\u00a0geacht et\u00a0werden,\u00a0dass\u00a0\nsolche\u00a0besonders\u00a0jungen\u00a0S\u00e4uglinge\u00a0m\u00f6glichst\u00a0nur\u00a0Kontakt\u00a0mit\u00a0gei mpften\u00a0Personen\u00a0\nhaben\u00a0sollten,\u00a0um\u00a0sie\u00a0vor\u00a0einer\u00a0 Maserninfektion\u00a0zu\u00a0sch\u00fctzen.\u00a0Ih r\u00a0Immunsystem\u00a0ist\u00a0\nl\u00e4ngst\u00a0noch\u00a0nicht\u00a0so\u00a0\u201eabwehrbere it\u201c\u00a0wie\u00a0in\u00a0den\u00a0sp\u00e4teren\u00a0Monaten \u00a0(STIKO,\u00a02013).\u00a0\nDie\u00a0zweite\u00a0Impfdosis\u00a0der\u00a0Grundimmunisierung\u00a0gegen\u00a0Masern\u00a0sollte \u00a0nach\u00a0dem\u00a0\naktuellen\u00a0Impfschema\u00a0zwischen\u00a0dem\u00a015.\u00a0und\u00a023.\u00a0Lebensmonat,\u00a0sp\u00e4t estens\u00a0im\u00a0\nRahmen\u00a0der\u00a0Fr\u00fcherkennungsuntersuchung\u00a0U7\u00a0verabreicht\u00a0werden.\u00a0De r\u00a0Mindest\u2010\nabstand\u00a0zur\u00a0ersten\u00a0Impfdosis\u00a0betr\u00e4gt\u00a0demzufolge\u00a0vier\u00a0Wochen\u00a0(ST IKO,\u00a02018a).\u00a0\nGrunds\u00e4tzlich\u00a0sollte\u00a0die\u00a0Grundimmunisierung\u00a0schnellstm\u00f6glich,\u00a0j edoch\u00a0in\u00a0jedem\u00a0\nFall\u00a0 vor\u00a0 dem\u00a0 24.\u00a0 Lebensmonat,\u00a0 abgeschlossen\u00a0 werden,\u00a0 um\u00a0 einen\u00a0 fr \u00fchzeitigen\u00a0\nSchutz\u00a0der\u00a0Kleinkinder\u00a0und\u00a0S\u00e4ugli nge\u00a0zu\u00a0gew\u00e4hrleisten,\u00a0da\u00a0diese \u00a0Gruppe\u00a0besonders\u00a0\nanf\u00e4llig\u00a0f\u00fcr\u00a0Infektionen\u00a0ist\u00a0(STIKO,\u00a02018b).\u00a0Die\u00a0zweite\u00a0Impfdos is\u00a0ist\u00a0n\u00f6tig,\u00a0um\u00a0eine\u00a0\nausreichende\u00a0Immunit\u00e4t\u00a0aufzubauen,\u00a0denn\u00a0laut\u00a0einer\u00a0systematisch en\u00a0\u00dcbersichts\u2010\narbeit\u00a0betr\u00e4gt\u00a0die\u00a0Impfeffektivit\u00e4t\u00a0der\u00a0ersten\u00a0Masernimpfung\u00a0be i\u00a0Menschen\u00a0ab\u00a0\nneun\u00a0Monaten\u00a0im\u00a0Median\u00a0lediglich\u00a091\u00a0%\u00a0und\u00a0ist\u00a0somit\u00a0nicht\u00a0ausre ichend,\u00a0um\u00a0eine\u00a0\nHerdenimmunit\u00e4t\u00a0zu\u00a0erzielen\u00a0(Uzicanin\u00a0&\u00a0Zimmermann,\u00a02011).\u00a0Nach \u00a0der\u00a0zweimali\u2010\ngen\u00a0Impfung\u00a0kann\u00a0hingegen\u00a0eine\u00a0Impfeffektivit\u00e4t\u00a0von\u00a0bis\u00a0zu\u00a099\u00a0% \u00a0erreicht\u00a0werden\u00a0\n(RKI,\u00a02019b).\u00a0F\u00fcr\u00a0die\u00a0Immunisierung\u00a0gegen\u00a0Masern\u00a0bedarf\u00a0es\u00a0kein er\u00a0Auffrischimp\u2010\nfung,\u00a0da\u00a0der\u00a0Schutz\u00a0gegen\u00a0den\u00a0Erreger\u00a0in\u00a0der\u00a0Regel\u00a0ein\u00a0Leben\u00a0la ng\u00a0andauert.\u00a0Kin\u2010\ndern\u00a0und\u00a0Jugendlichen\u00a0mit\u00a0keiner \u00a0oder\u00a0einer\u00a0unvollst\u00e4ndigen\u00a0Gru ndimmunisierung\u00a0\ngegen\u00a0Masern\u00a0wird\u00a0zu\u00a0einer\u00a0Nachholimpfung\u00a0geraten\u00a0(STIKO,\u00a02018a ).\u00a0Zudem\u00a0hat\u00a0\nsich\u00a0die\u00a0STIKO\u00a0in\u00a0Folge\u00a0des\u00a0hohen\u00a0Anteils\u00a0an\u00a0Masernf\u00e4llen\u00a0bei\u00a0j ungen\u00a0Erwachsenen\u00a0\n2010\u00a0im\u00a0Jahr\u00a02013\u00a0f\u00fcr\u00a0eine\u00a0einmalige\u00a0Standardimpfung\u00a0(s.\u00a0Abb.\u00a06 .1)\u00a0f\u00fcr\u00a0nach\u00a01970\u00a0\nGeborene\u00a0mit\u00a0unklarem\u00a0oder\u00a0keinem\u00a0Impfstatus\u00a0ausgesprochen.\u00a0\u00a0\nDer\u00a0erste\u00a0Impfstoff\u00a0gegen\u00a0Masern\u00a0wurde\u00a0in\u00a0Deutschland\u00a0im\u00a0Jahre\u00a0 1966\u00a0zugelassen.\u00a0\nDabei\u00a0handelte\u00a0es\u00a0sich\u00a0um\u00a0einen\u00a0T ot\u2010Impfstoff,\u00a0der\u00a0aufgrund\u00a0man gelnder\u00a0Impf\u2010\neffektivit\u00e4t\u00a0lediglich\u00a0drei\u00a0Jahre \u00a0eingesetzt\u00a0wurde.\u00a0Bereits\u00a0196 7\u00a0kam\u00a0der\u00a0erste\u00a0Le\u2010\nbend\u2010Impfstoff\u00a0auf\u00a0den\u00a0Markt\u00a0(Klein\u00a0et\u00a0al.,\u00a02012).\u00a0Gegenw\u00e4rtig\u00a0 sind\u00a0in\u00a0der\u00a0Bundes\u2010\nrepublik\u00a0insgesamt\u00a021\u00a0Pr\u00e4parate\u00a0f\u00fcr\u00a0die\u00a0Immunisierung\u00a0gegen\u00a0Mas ern\u00a0zugelassen,\u00a0\nvon\u00a0denen\u00a0zwei\u00a0jedoch\u00a0aktuell\u00a0ni cht\u00a0auf\u00a0dem\u00a0deutschen\u00a0Markt\u00a0ver trieben\u00a0werden.\u00a0\nLediglich\u00a0eine\u00a0dieser\u00a021\u00a0Vakzine\u00a0ist\u00a0ein\u00a0monovalenter\u00a0Masernimp fstoff.\u00a0Der\u00a0Mono\u2010\nLebendvirus\u2010Impfstoff\u00a0 M\u00e9rieux\u00ae\u00a0 ka nn\u00a0 ab\u00a0 einem\u00a0 Lebensalter\u00a0 von\u00a0 el f\u00a0 Monaten\u00a0\neingesetzt\u00a0werden.\u00a0Bei\u00a0den\u00a0polyv alenten\u00a0Vakzinen\u00a0handelt\u00a0es\u00a0sic h\u00a0in\u00a0zw\u00f6lf\u00a0F\u00e4llen\u00a0\num\u00a0eine\u00a0Impfung\u00a0gegen\u00a0MMR\u00a0und\u00a0bei\u00a0acht\u00a0Stoffen\u00a0um\u00a0eine\u00a0Vakzinat ion\u00a0gegen\u00a0\nMMRV\u00a0(PEI,\u00a02019).\u00a0In\u00a0Deutschland\u00a0stehen\u00a0derzeit\u00a0ausschlie\u00dflich\u00a0 polyvalente\u00a0Impf\u2010\nstoffe\u00a0zur\u00a0Verf\u00fcgung,\u00a0da\u00a0der\u00a0Vertrieb\u00a0des\u00a0monovalenten\u00a0Pr\u00e4parat s\u00a0im\u00a0Mai\u00a02012\u00a0237\u00a0eingestellt\u00a0wurde.\u00a0F\u00fcr\u00a0das\u00a0Pr\u00e4parat\u00a0Priorix\u2010Tetra\u00ae\u00a0gibt\u00a0es\u00a0derz eit\u00a0(August\u00a02019)\u00a0\neinen\u00a0Lieferengpass\u00a0(D\u00c4,\u00a02019).\u00a0\nDie\u00a0Gabe\u00a0des\u00a0Kombinationsimpfsto ffes\u00a0ist\u00a0auch\u00a0m\u00f6glich,\u00a0wenn\u00a0ber eits\u00a0aufgrund\u00a0\neiner\u00a0Wildinfektion\u00a0eine\u00a0Immunit\u00e4 t\u00a0gegen\u00a0eine\u00a0oder\u00a0mehrere\u00a0der\u00a0 Erkrankungen\u00a0\nvorliegt\u00a0(PEI,\u00a02019).\u00a0F\u00fcr\u00a0die\u00a0Standardimpfung\u00a0ab\u00a018\u00a0Jahren\u00a0wird \u00a0die\u00a0Anwendung\u00a0\neines\u00a0MMR\u2010Impfstoffes\u00a0empfohlen\u00a0(STIKO,\u00a02018b).\u00a0Die\u00a0in\u00a0Tabelle\u00a0 6.3\u00a0genannten\u00a0\nVakzinen\u00a0werden\u00a0aktuell\u00a0f\u00fcr\u00a0die\u00a0Masernimpfungen\u00a0in\u00a0Deutschland\u00a0 eingesetzt:\u00a0\nTabelle\u00a06.3:\u00a0Handelsnamen\u00a0der\u00a0zugelassenen\u00a0und\u00a0derzeit\u00a0vertrieb enen\u00a0Masern\u2010\nimpfstoffe\u00a0in\u00a0Deutschland\u00a0\nAntigene\u00a0 Handelsname\u00a0 Zugelassen\u00a0ab\u00a0 Anwendung\u00a0bis\u00a0\nMMR\u00a0M\u2010M\u2010RVaxPro\u00ae\u00a0 12\u00a0Monaten*\u00a0 ohne\u00a0Altersgrenze\u00a0\nPriorix\u00ae\u00a0 9\u00a0Monaten\u00a0 ohne\u00a0Altersgrenze\u00a0\nMMR\u2010V\u00a0Priorix\u2010Tetra\u00ae\u00a0 11\u00a0Monaten*\u00a0 13.\u00a0Geburtstag\u00a0\nProQuad\u00ae\u00a0 12\u00a0Monaten*\u00a0 ohne\u00a0Altersgrenze\u00a0\nQuelle:\u00a0Eigene\u00a0Darstellung\u00a0nach\u00a0STIKO\u00a02018b,\u00a0376\u00a0\n*\u00a0Einsatz\u00a0ab\u00a0dem\u00a0neunten\u00a0Monat\u00a0m\u00f6glich,\u00a0sofern\u00a0fr\u00fcherer\u00a0Impfsch utz\u00a0medizinisch\u00a0notwendig\u00a0\nIm\u00a0Vergleich\u00a0zu\u00a0anderen\u00a0europ\u00e4ischen\u00a0L\u00e4ndern\u00a0erf\u00fcllt\u00a0Deutschlan d\u00a0bei\u00a0der\u00a0ersten\u00a0\nDosis\u00a0der\u00a0Masernimpfung\u00a0(MCV\u00a01,\u00a0 Measles\u00a0Containing\u00a0Vaccine\u00a01 )\u00a0bereits\u00a0die\u00a0von\u00a0\nder\u00a0WHO\u00a0geforderte\u00a0Impfabdeckung\u00a0von\u00a095\u00a0%\u00a0am\u00a0Ende\u00a0des\u00a0zweiten\u00a0L ebensjahres.\u00a0\nDie\u00a0Problematik\u00a0liegt\u00a0jedoch\u00a0in\u00a0der\u00a0Nichterreichung\u00a0der\u00a0Quote\u00a0b ei\u00a0der\u00a0zweiten\u00a0\nGabe\u00a0des\u00a0Impfstoffes\u00a0(MCV\u00a02)\u00a0(vgl.\u00a0Abbildung\u00a06.5).\u00a0Aktuellste\u00a0D aten\u00a0zur\u00a0europ\u00e4i\u2010\nschen\u00a0Impfabdeckung\u00a0bei\u00a0Masern\u00a0stammen\u00a0aus\u00a0dem\u00a0Jahre\u00a02017\u00a0und\u00a0z eigen,\u00a0dass\u00a0\nDeutschland\u00a0hierbei\u00a0lediglich\u00a0ei ne\u00a0Rate\u00a0von\u00a093\u00a0%\u00a0bei\u00a0der\u00a0zweite n\u00a0Impfstoffdosis\u00a0\nerreicht\u00a0(WHO/UNICEF,\u00a02018).\u00a0\n\u00a0 \u00a0238\u00a0Abbildung\u00a06.5:\u00a0Impfrate\u00a0der\u00a0zweit en\u00a0Dosis\u00a0des\u00a0Masernimpfstoffs\u00a0 in\u00a0Europa\u00a0im\u00a0\nJahre\u00a02017\u00a0\n\u00a0\nQuelle:\u00a0eigene\u00a0Darstellung\u00a0nach\u00a0ECDC,\u00a02019\u00a0\n\u00a0 \u00a0\n239\u00a0Die\u00a0j\u00fcngst\u00a0publizierten\u00a0Ergebnisse\u00a0der\u00a0zweiten\u00a0Welle\u00a0des\u00a0KiGGS\u00a0 erm\u00f6glichen\u00a0eine\u00a0\nBetrachtung\u00a0des\u00a0Impfstatus\u00a0von\u00a0insgesamt\u00a03.238\u00a0Kindern\u00a0und\u00a0Juge ndlichen\u00a0in\u00a0\nDeutschland\u00a0im\u00a0Zeitraum\u00a0von\u00a02014\u00a0bis\u00a02017\u00a0und\u00a0geben\u00a0somit\u00a0Aufsc hluss\u00a0\u00fcber\u00a0die\u00a0\nEntwicklung\u00a0der\u00a0Impfraten\u00a0(Poethko\u2010M\u00fcller\u00a0et\u00a0al.,\u00a02019,\u00a0411).\u00a09 6\u00a0%\u00a0dieser\u00a0Perso\u2010\nnengruppe\u00a0haben\u00a0laut\u00a0Angabe\u00a0der\u00a0Eltern\u00a0mindestens\u00a0eine\u00a0MMR\u2010Impf ung\u00a0erhalten.\u00a0\nDie\u00a0Rate\u00a0f\u00fcr\u00a0die\u00a0zweite\u00a0Impfdosis\u00a0liegt\u00a0bei\u00a0den\u00a0ber\u00fccksichtigte n\u00a0Kindern\u00a0und\u00a0Ju\u2010\ngendlichen\u00a0bei\u00a093,6\u00a0%\u00a0und\u00a0ist\u00a0signifikant\u00a0h\u00f6her\u00a0als\u00a0die\u00a0Rate\u00a0be i\u00a0Gleichaltrigen\u00a0in\u00a0\nder\u00a0Basisbefragung\u00a0von\u00a02003\u00a0bis\u00a02006\u00a0(Poethko\u2010M\u00fcller\u00a0et\u00a0al.,\u00a020 19,\u00a0416f).\u00a0Zwar\u00a0\nstiegen\u00a0die\u00a0Impfquoten\u00a0von\u00a0Kindern\u00a0zum\u00a0Ende\u00a0des\u00a0zweiten\u00a0Lebensj ahres\u00a0im\u00a0KiGGS\u00a0\nmit\u00a0den\u00a0fortlaufenden\u00a0Geburtsjahrg\u00e4ngen\u00a0kontinuierlich\u00a0an,\u00a0doch \u00a0blieben\u00a0sie\u00a0mit\u00a0\neiner\u00a0Rate\u00a0von\u00a064,4\u00a0%\u00a0f\u00fcr\u00a0die\u00a0zweite\u00a0Masernimpfdosis\u00a0in\u00a0den\u00a0Geb urtsjahrg\u00e4ngen\u00a0\n2010\u00a0bis\u00a02013\u00a0deutlich\u00a0unter\u00a0den\u00a0angestrebten\u00a095\u00a0%\u00a0(Poethko\u2010M\u00fcl ler\u00a0et\u00a0al.,\u00a02019,\u00a0\nS.\u00a0417f).\u00a0Diese\u00a0Ergebnisse\u00a0lassen\u00a0sich\u00a0durch\u00a0die\u00a0erhobenen\u00a0Date n\u00a0der\u00a0KV\u2010Impfsur\u2010\nveillance\u00a0best\u00e4tigen\u00a0und\u00a0fortf\u00fchren.\u00a0Insgesamt\u00a0zeigen\u00a0diese\u00a0abe r\u00a0eine\u00a0positive\u00a0\nEntwicklung\u00a0und\u00a0steigende\u00a0Durchf\u00fchrung\u00a0der\u00a0Masernimpfung\u00a0im\u00a0emp fohlenen\u00a0\nZeitraum\u00a0f\u00fcr\u00a0beide\u00a0Impfdosen\u00a0(vgl.\u00a0Abbildung\u00a06.6).\u00a0\nAbbildung\u00a06.6:\u00a0Impfquoten\u00a0von\u00a02009\u00a0bis\u00a02014\u00a0zum\u00a015.\u00a0Lebensmonat \u00a0f\u00fcr\u00a0die\u00a0\nerste\u00a0Impfdosis\u00a0(MCV1)\u00a0und\u00a0zum\u00a024.\u00a0Lebensmonat\u00a0f\u00fcr\u00a0die\u00a0zweite\u00a0I mpfdosis\u00a0\n(MCV2)\u00a0in\u00a0Prozent\u00a0\n\u00a0\nQuelle:\u00a0Eigene\u00a0Darstellung\u00a0nach\u00a0RKI,\u00a02017\u00a0\n240\u00a0Die\u00a0 KiGGS\u2010Daten\u00a0 bilden\u00a0 im\u00a0 Vergleich\u00a0 zur\u00a0 KV\u2010Impfsurveillance\u00a0 unt erschiedliche\u00a0\nQuoten\u00a0ab.\u00a0Dies\u00a0h\u00e4ngt\u00a0damit\u00a0zusammen,\u00a0dass\u00a0im\u00a0KiGGS\u00a0Befragungsd aten\u00a0als\u00a0Basis\u00a0\nherangezogen\u00a0werden,\u00a0die\u00a0mit\u00a0den\u00a0Impfausweisen\u00a0abgeglichen\u00a0wurd en.\u00a0Bei\u00a0den\u00a0\nKV\u2010Quoten\u00a0wurden\u00a0dagegen\u00a0Abrechnungsdaten\u00a0herangezogen,\u00a0die\u00a0let ztlich\u00a0nur\u00a0\nden\u00a0Querschnitt\u00a0der\u00a0verabreichten\u00a0Impfdosen\u00a0abbilden.\u00a0\nDie\u00a0aktuellsten\u00a0Auswertungen\u00a0der\u00a0Surveillance\u00a0f\u00fcr\u00a0die\u00a0Geburtsko horte\u00a0von\u00a02014\u00a0\nzeigen\u00a0jedoch\u00a0ebenfalls,\u00a0dass\u00a0di e\u00a0erforderlichen\u00a0Raten\u00a0trotz\u00a0st eigender\u00a0Impfquote\u00a0\nimmer\u00a0noch\u00a0verfehlt\u00a0werden.\u00a0Im\u00a0D urchschnitt\u00a0erhielten\u00a0entgegen\u00a0 der\u00a0Impfemp\u2010\nfehlungen\u00a0der\u00a0STIKO\u00a0(s.\u00a0Abbildung\u00a06.1)\u00a0nur\u00a089,5\u00a0%\u00a0der\u00a0Kinder\u00a0au s\u00a0dieser\u00a0Kohorte\u00a0\nihre\u00a0erste\u00a0Impfdosis\u00a0gegen\u00a0Maser n\u00a0bis\u00a0zum\u00a015.\u00a0Lebensmonat.\u00a0Bis\u00a0 zur\u00a0Vollendung\u00a0\ndes\u00a0zweiten\u00a0Lebensjahres\u00a0holten\u00a0 viele\u00a0Eltern\u00a0die\u00a0erste\u00a0Teilimpf ung\u00a0der\u00a0Grund\u2010\nimmunisierung\u00a0nach,\u00a0sodass\u00a0in\u00a0diesem\u00a0Lebensalter\u00a0im\u00a0Bundesdurch schnitt\u00a0eine\u00a0\nAbdeckung\u00a0von\u00a095,6\u00a0%\u00a0mit\u00a0der\u00a0ersten\u00a0Impfdosis\u00a0erzielt\u00a0werden\u00a0ko nnte.\u00a0Die\u00a0Rate\u00a0\nder\u00a0zweiten\u00a0Impfdosis\u00a0gegen\u00a0Masern\u00a0ist\u00a0zu\u00a0diesem\u00a0Zeitpunkt\u00a0mit\u00a0 73,9\u00a0%\u00a0jedoch\u00a0\nwie\u00a0bereits\u00a0in\u00a0den\u00a0Jahrg\u00e4ngen\u00a0des\u00a0KiGGS\u00a0deutlich\u00a0unzureichend.\u00a0 Vor\u00a0allem\u00a0in\u00a0Sach\u2010\nsen\u00a0sind\u00a0mit\u00a0einer\u00a0Quote\u00a0von\u00a024,9\u00a0%\u00a0am\u00a0Ende\u00a0des\u00a024.\u00a0Lebensmonat s\u00a0in\u00a0dieser\u00a0\nGeburtskohorte\u00a0deutlich\u00a0zu\u00a0wenig\u00a0K inder\u00a0zweimalig\u00a0gegen\u00a0den\u00a0Err eger\u00a0geimpft,\u00a0\num\u00a0eine\u00a0Herdenimmunit\u00e4t\u00a0herzustellen\u00a0(RKI,\u00a02017).\u00a0Als\u00a0einziges\u00a0 Bundesland\u00a0hat\u00a0\nSachsen\u00a0eine\u00a0landesspezifische\u00a0Im pfkommission,\u00a0deren\u00a0Empfehlung en\u00a0sich\u00a0zum\u00a0\nTeil\u00a0von\u00a0denen\u00a0der\u00a0STIKO\u00a0unterscheiden\u00a0und\u00a0urs\u00e4chlich\u00a0f\u00fcr\u00a0die\u00a0n iedrige\u00a0Impfquote\u00a0\nam\u00a0Ende\u00a0des\u00a0zweiten\u00a0Lebensjahres\u00a0auf\u00a0Landesebene\u00a0sein\u00a0k\u00f6nnten.\u00a0 Die\u00a0s\u00e4chsische\u00a0\nImpfkommission\u00a0(SIKO)\u00a0empfiehlt\u00a0im\u00a0Gegensatz\u00a0zur\u00a0STIKO\u00a0die\u00a0Gabe \u00a0der\u00a0ersten\u00a0\nImpfdosis\u00a0zwischen\u00a0dem\u00a013.\u00a0und\u00a024.\u00a0Lebensmonat\u00a0sowie\u00a0die\u00a0Verabr eichung\u00a0der\u00a0\nzweiten\u00a0Impfdosis\u00a0gegen\u00a0Masern\u00a0erst\u00a0im\u00a0f\u00fcnften\u00a0Lebensjahr\u00a0und\u00a0n icht\u00a0zwischen\u00a0\ndem\u00a015.\u00a0und\u00a023.\u00a0Lebensmonat\u00a0(SIKO,\u00a02019).\u00a0Nichtsdestotrotz\u00a0zeig t\u00a0sich\u00a0in\u00a0der\u00a0\ngesamten\u00a0 Bundesrepublik\u00a0 auf\u00a0 L\u00e4nder\u2010\u00a0 und\u00a0 Regionsebene\u00a0 eine\u00a0 Verfe hlung\u00a0 der\u00a0\nerforderlichen\u00a0Impfrate\u00a0von\u00a095\u00a0% \u00a0f\u00fcr\u00a0die\u00a0zweite\u00a0Impfdosis\u00a0am\u00a0En de\u00a0des\u00a0zweiten\u00a0\nLebensjahres\u00a0\u2013\u00a0mit\u00a0erheblichen\u00a0regionalen\u00a0Unterschieden\u00a0(vgl.\u00a0T abelle\u00a06.4).\u00a0\n\u00a0\u00a0241\u00a0Tabelle\u00a06.4:\u00a0Masernimpfung\u00a0in\u00a0der\u00a0Geburtskohorte\u00a02014\u00a0nach\u00a0Bund esland,\u00a0Impf\u2010\ndosis\u00a0und\u00a0Lebensalter\u00a0\nBundesland\u00a0Impfquote\u00a0in\u00a0Prozent\u00a0(%)\u00a0\n\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0MCV\u00a01\u00a0 \u00a0MCV\u00a02\u00a0\n15\u00a0Monate\u00a0 24\u00a0Monate\u00a0 24\u00a0Monate\u00a0\nBaden\u2010W\u00fcrttemberg\u00a0 83,6\u00a0 89,8\u00a0 68,9\u00a0\nBayern\u00a0 90,0\u00a0 96,2\u00a0 75,7\u00a0\nBerlin\u00a0 93,5\u00a0 97,3\u00a0 79,6\u00a0\nBrandenburg\u00a0 91,4\u00a0 96,8\u00a0 73,5\u00a0\nBremen\u00a0 91,3\u00a0 97,0\u00a0 77,2\u00a0\nHamburg\u00a0 93,5\u00a0 97,2\u00a0 80,5\u00a0\nHessen\u00a0 91,5\u00a0 97,3\u00a0 79,0\u00a0\nMecklenburg\u2010Vorpommern\u00a0 89,5\u00a0 96,2\u00a0 71,9\u00a0\nNiedersachsen\u00a0 90,7\u00a0 96,5\u00a0 79,1\u00a0\nNordrhein\u2010Westfalen\u00a0 91,2\u00a0 96,8\u00a0 79,2\u00a0\nRheinland\u2010Pfalz\u00a0 88,7\u00a0 95,8\u00a0 77,3\u00a0\nSaarland\u00a0 91,6\u00a0 96,9\u00a0 76,5\u00a0\nSachsen\u00a0 82,4\u00a0 93,5\u00a0 24,9\u00a0\nSachsen\u2010Anhalt\u00a0 91,3\u00a0 96,7\u00a0 74,4\u00a0\nSchleswig\u2010Holstein\u00a0 91,6\u00a0 96,7\u00a0 80,3\u00a0\nTh\u00fcringen\u00a0 88,4\u00a0 95,4\u00a0 70,6\u00a0\nBundesdurchschnitt\u00a0 89,5\u00a0 95,6\u00a0 73,9\u00a0\nQuelle:\u00a0Eigene\u00a0Darstellung\u00a0nach\u00a0RKI,\u00a02017\u00a0\nMithilfe\u00a0der\u00a0Daten\u00a0der\u00a0KV\u2010Impf surveillance\u00a0kann\u00a0die\u00a0Umsetzung\u00a0d er\u00a0Empfehlung\u00a0\neiner\u00a0Impfquote\u00a0von\u00a0\u00fcber\u00a095\u00a0%\u00a0bei\u00a0der\u00a0zweiten\u00a0Masernimpfung\u00a0\u00fcbe rpr\u00fcft\u00a0werden.\u00a0\nDie\u00a0Auswertung\u00a0der\u00a0Erhebungen\u00a0durch\u00a0das\u00a0RKI\u00a0zeigt\u00a0anhand\u00a0der\u00a0Im pfinzidenzen,\u00a0\nalso\u00a0 dem\u00a0 Anteil\u00a0 an\u00a0 neu\u00a0 durchgef\u00fchrten\u00a0 Impfungen\u00a0 in\u00a0 dieser\u00a0 Perso nengruppe,\u00a0\neinen\u00a0Anstieg\u00a0der\u00a0Neuimpfungen\u00a0von\u00a0Erwachsenen,\u00a0die\u00a0nach\u00a01970\u00a0g eboren\u00a0sind,\u00a0\nvon\u00a00,4\u00a0%\u00a0im\u00a0Jahre\u00a02009\u00a0vor\u00a0Einf\u00fchrung\u00a0der\u00a0entsprechenden\u00a0Impfe mpfehlung\u00a0auf\u00a0\n\u00fcber\u00a01,0\u00a0%\u00a0in\u00a02016\u00a0(Rieck\u00a0et\u00a0al.,\u00a02019,\u00a0426).\u00a0Die\u00a0h\u00f6chste\u00a0Impfi nzidenz\u00a0von\u00a01,5\u00a0%\u00a0\nwurde\u00a0im\u00a0Jahr\u00a02015\u00a0verzeichnet,\u00a0nachdem\u00a0aufgrund\u00a0eines\u00a0akuten\u00a0A usbruchsge\u2010\nschehens\u00a0viele\u00a0Masernf\u00e4lle\u00a0auftr aten.\u00a0In\u00a0allen\u00a0Jahren\u00a0zeigte\u00a0si ch\u00a0eine\u00a0h\u00f6here\u00a0Impf\u2010\ninzidenz\u00a0in\u00a0den\u00a0westlichen\u00a0Bundesl \u00e4ndern\u00a0sowie\u00a0unter\u00a0Frauen\u00a0(Ri eck\u00a0et\u00a0al.,\u00a02019,\u00a0\n246).\u00a0Jedoch\u00a0liegt\u00a0die\u00a0Vermutung\u00a0nahe,\u00a0dass\u00a0in\u00a0den\u00a0\u00f6stlichen\u00a0Bu ndesl\u00e4ndern,\u00a0auf\u2010\ngrund\u00a0einer\u00a0positiven\u00a0Impfeinstellung\u00a0und\u00a0der\u00a0ehemaligen\u00a0Impfpf licht,\u00a0die\u00a0Impf\u2010242\u00a0quoten\u00a0bereits\u00a0im\u00a0Vorhinein\u00a0h\u00f6herlagen\u00a0und\u00a0die\u00a0Notwendigkeit\u00a0ei ner\u00a0Standardimp\u2010\nfung\u00a0geringer\u00a0ist,\u00a0da\u00a0bereits\u00a0eine\u00a0ausreichende\u00a0Grundimmunisier ung\u00a0erfolgte.\u00a0Diese\u00a0\nAnnahme\u00a0best\u00e4tigen\u00a0die\u00a0Daten\u00a0der\u00a0Studie\u00a0zur\u00a0Gesundheit\u00a0Erwachse ner\u00a0in\u00a0Deutschland\u00a0\n(DEGS),\u00a0aus\u00a0denen\u00a0eine\u00a0weitaus\u00a0h \u00f6here\u00a0Impfrate\u00a0in\u00a0den\u00a0neuen\u00a0als \u00a0in\u00a0den\u00a0alten\u00a0\nBundesl\u00e4ndern\u00a0hervorgeht\u00a0(s.\u00a0Tabelle\u00a06.5).\u00a0Des\u00a0Weiteren\u00a0l\u00e4sst\u00a0s ich\u00a0feststellen,\u00a0dass\u00a0\nPersonen\u00a0mit\u00a0niedrigem\u00a0Sozialstatus\u00a0insgesamt\u00a0\u00f6fter\u00a0gegen\u00a0Maser n\u00a0geimpft\u00a0sind\u00a0\nals\u00a0Personen\u00a0mit\u00a0einem\u00a0hohen\u00a0Sozialstatus.\u00a0Gesamtwerte\u00a0sind\u00a0nic ht\u00a0f\u00fcr\u00a0alle\u00a0Unter\u2010\npunkte\u00a0vorhanden,\u00a0die\u00a0Daten\u00a0f\u00fcr\u00a0die\u00a0Sozialstruktur\u00a0konnten\u00a0nich t\u00a0f\u00fcr\u00a0alle\u00a0Beteilig\u2010\nten\u00a0ausgewertet\u00a0werden.\u00a0\nTabelle\u00a06.5:\u00a0Impfquoten\u00a0f\u00fcr\u00a0Masern\u00a0nach\u00a0Geschlecht,\u00a0Altersgrupp en,\u00a0Wohnort\u00a0\nund\u00a0sozio\u00f6konomischen\u00a0Status\u00a0in\u00a0Prozent\u00a0mit\u00a095\u00a0%\u2010Konfidenzinter vallen\u00a0\n\u00a0Frauen\u00a0\n18\u201064\u00a0Jahre\u00a0Impfquote\u00a0\nFrauen\u00a0in\u00a0%\u00a0M\u00e4nner\u00a0\n18\u201064\u00a0Jahre\u00a0Impfquote\u00a0\nM\u00e4nner\u00a0in\u00a0%\u00a0Gesamt\u00a0Impfquote\u00a0\nGesamt\u00a0in\u00a0%\u00a0\nGeschlecht\u00a0 2.791\u00a039,5\u00a0\n(37,0\u00a0\u2013\u00a042,1) \u00a02.322\u00a036,7\u00a0\n(33,9\u00a0\u2013\u00a039,5) \u00a05.113\u00a038,1\u00a0\n(36,0\u00a0\u2013\u00a040,3)\u00a0\nWohnort\u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0\nOst\u00a0 774\u00a053,4\u00a0\n(48,2\u00a0\u2013\u00a058,5)\u00a0656\u00a054,3\u00a0\n(50,1\u00a0\u2013\u00a058,5)\u00a0\u00a0 \u00a0\nWest\u00a0 2.017\u00a036,7\u00a0\n(34,0\u00a0\u2013\u00a039,5)\u00a01.666\u00a033,0\u00a0\n(30,1\u00a0\u2013\u00a036,0)\u00a0\u00a0 \u00a0\nSozialstatus\u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0\nNiedrig\u00a0 376\u00a045,5\u00a0\n(39,4\u00a0\u2013\u00a051,8)\u00a0356\u00a037,6\u00a0\n(31,6\u00a0\u2013\u00a044,0)\u00a0\u00a0 \u00a0\nMittel\u00a0 1.708\u00a039,3\u00a0\n(36,3\u00a0\u2013\u00a042,3)\u00a01.309\u00a037,4\u00a0\n(33,8\u00a0\u2013\u00a041,0)\u00a0\u00a0 \u00a0\nHoch\u00a0 674\u00a037,0\u00a0\n(32,2\u00a0\u2013\u00a042,2)\u00a0638\u00a034,4\u00a0\n(29,6\u00a0\u2013\u00a039,7)\u00a0\u00a0 \u00a0\nAlter\u00a0 \u00a0\u00a0\u00a0\u00a0 \u00a0 \u00a0\n18\u201029\u00a0Jahre\u00a0 \u00a082,2\u00a0\n(77,7\u00a0\u2013\u00a086,0)\u00a0\u00a077,2\u00a0\n(71,6\u00a0\u2013\u00a081,9)\u00a0\u00a079,8\u00a0\n(76,3\u00a0\u2013\u00a082,9)\u00a0\n30\u201039\u00a0Jahre\u00a0 \u00a047,2\u00a0\n(41,3\u00a0\u2013\u00a053,1)\u00a0\u00a046,2\u00a0\n(40,1\u00a0\u2013\u00a052,4)\u00a0\u00a046,7\u00a0\n(42,2\u00a0\u2013\u00a051,2)\u00a0\n40\u201049\u00a0Jahre\u00a0 \u00a027,3\u00a0\n(23,3\u00a0\u2013\u00a031,8)\u00a0\u00a022,8\u00a0\n(18,6\u00a0\u2013\u00a027,6)\u00a0\u00a025,1\u00a0\n(21,8\u00a0\u2013\u00a028,7)\u00a0\n50\u201059\u00a0Jahre\u00a0 \u00a016,6\u00a0\n(13,6\u00a0\u2013\u00a020,0)\u00a0\u00a016,1\u00a0\n(12,9\u00a0\u2013\u00a019,9)\u00a0\u00a016,3\u00a0\n(14,0\u00a0\u2013\u00a019,0)\u00a0\n60\u201064\u00a0Jahre\u00a0 \u00a04,1\u00a0\n(2,0\u00a0\u2013\u00a08,1)\u00a0\u00a03,4\u00a0\n(1,7\u00a0\u2013\u00a06,4)\u00a0\u00a03,8\u00a0\n(2,3\u00a0\u2013\u00a06,0)\u00a0\nQuelle:\u00a0Eigene\u00a0Darstellung\u00a0nach\u00a0Poethko\u2010M\u00fcller\u00a0&\u00a0Schmitz,\u00a02013, \u00a0846ff.\u00a0Datengrundlage:\u00a0DEGS\u00a0Welle\u00a01.\u00a0\nInsgesamt\u00a0 l\u00e4sst\u00a0 sich\u00a0 in\u00a0 Deutschland\u00a0 eine\u00a0 \u00fcberwiegend\u00a0 positive\u00a0 E instellung\u00a0 zur\u00a0\nMasernimpfung\u00a0verzeichnen.\u00a0Eine\u00a0Befragung\u00a0der\u00a0Bundeszentrale\u00a0f\u00fc r\u00a0gesundheitli\u2010\nche\u00a0Aufkl\u00e4rung\u00a0(BZgA)\u00a0in\u00a0einer\u00a0Stichprobe\u00a0von\u00a05.012\u00a0Personen\u00a0zw ischen\u00a016\u00a0und\u00a085\u00a0\nJahren\u00a0ergab,\u00a0dass\u00a0im\u00a0Jahr\u00a02016\u00a077\u00a0%\u00a0der\u00a0Erwachsenen\u00a0den\u00a0Impfsc hutz\u00a0gegen\u00a0den\u00a0\nErreger\u00a0als\u00a0(besonders)\u00a0wichtig\u00a0 ansehen\u00a0und\u00a0damit\u00a08\u00a0%\u00a0mehr\u00a0als\u00a0 im\u00a0Jahre\u00a02012\u00a0243\u00a0(Horstk\u00f6tter\u00a0et\u00a0al.,\u00a02017,\u00a039).\u00a0Dennoch\u00a0haben\u00a0die\u00a0bisherigen\u00a0Im pfquoten\u00a0nicht\u00a0den\u00a0\ngew\u00fcnschten\u00a0Wert\u00a0erreicht.\u00a0Ein\u00a0si gnifikanter\u00a0Unterschied\u00a0ist\u00a0\u00fcb rigens\u00a0in\u00a0der\u00a0Impf\u2010\neinstellung\u00a0zwischen\u00a0Frauen\u00a0und\u00a0M\u00e4nner\u00a0zu\u00a0sehen,\u00a0da\u00a0Frauen\u00a0die\u00a0 Impfung\u00a0h\u00e4ufi\u2010\nger\u00a0als\u00a0relevant\u00a0empfinden.\u00a0Zur\u00a0a llgemeinen\u00a0Inanspruchnahme\u00a0von \u00a0Impfungen\u00a0\ngaben\u00a028\u00a0%\u00a0der\u00a0befragten\u00a0Erwachsenen\u00a0an,\u00a0in\u00a0den\u00a0letzten\u00a0Jahren\u00a0 einmal\u00a0eine\u00a0Im\u2010\npfung\u00a0nicht\u00a0wahrgenommen\u00a0zu\u00a0haben\u00a0(Horstk\u00f6tter\u00a0et\u00a0al.,\u00a02017,\u00a043 f).\u00a0Die\u00a0Gr\u00fcnde\u00a0\nhierf\u00fcr,\u00a0aufgelistet\u00a0in\u00a0Abbil dung\u00a06.7,\u00a0waren\u00a0vielf\u00e4ltig:\u00a0\nAbbildung\u00a06.7:\u00a0Angegebene\u00a0Gr\u00fcnde\u00a0f\u00fcr\u00a0vers\u00e4umte\u00a0Impfungen\u00a0bei\u00a0\u00a0\nErwachsenen\u00a0\n\u00a0\nQuelle:\u00a0Eigene\u00a0Darstellung\u00a0nach\u00a0Horstk\u00f6tter\u00a0et\u00a0al.,\u00a02017,\u00a069\u00a0\n\u00a0 \u00a0\n244\u00a0Die\u00a0Grippeimpfung\u00a0\n6.1\u00a0\u00a0\u00a0Influenza\u00a0\nDie\u00a0Erreger\u00a0der\u00a0\u201eechten\u201c\u00a0Grippe,\u00a0 der\u00a0Influenza\u00a0(im\u00a0Unterschied\u00a0 zum\u00a0grippalen\u00a0\nInfekt),\u00a0geh\u00f6ren\u00a0zur\u00a0Klasse\u00a0Orthomyxoviren.\u00a0Sie\u00a0k\u00f6nnen\u00a0in\u00a0die\u00a0V irustypen\u00a0A,\u00a0B\u00a0und\u00a0\nC\u00a0eingeteilt\u00a0werden.\u00a0Als\u00a0Krankheitserreger\u00a0sind\u00a0vor\u00a0allem\u00a0die\u00a0s aisonal\u00a0auftretenden\u00a0\nInfluenza\u2010Virustypen\u00a0A\u00a0und\u00a0B\u00a0f\u00fcr\u00a0die\u00a0Infektion\u00a0von\u00a0Menschen\u00a0rel evant.\u00a0Als\u00a0Haupt\u2010\nerreger\u00a0der\u00a0Influenza\u00a0gelten\u00a0h ierzulande\u00a0folgende\u00a0Subtypen:\u00a0\u00a0\n\uf0b7 Influenza\u00a0A\u00a0(H1N1)\u00a0pdm09\u00a0\n\uf0b7 Influenza\u00a0A\u00a0(H3N2)\u00a0\n\uf0b7 Influenza\u00a0B\u00a0\nH3N2\u2010Subtypen\u00a0sind\u00a0zumeist\u00a0\u2013\u00a0gemessen\u00a0an\u00a0der\u00a0Gesamterkrankungsz ahl\u00a0\u2013\u00a0unter\u2010\nrepr\u00e4sentiert,\u00a0der\u00a0Anteil\u00a0an\u00a0H1N1\u2010Subtypen\u00a0dominiert.\u00a0Im\u00a0Laufe\u00a0 einer\u00a0Grippewelle\u00a0\nund\u00a0einer\u00a0steigenden\u00a0Erkrankungsh\u00e4ufigkeit\u00a0kann\u00a0aber\u00a0auch\u00a0der\u00a0I nfluenza\u00a0B\u00a0Typ\u00a0\nals\u00a0Krankheitsausl\u00f6ser\u00a0zunehm en\u00a0oder\u00a0sogar\u00a0\u00fcberwiegen.\u00a0\nF\u00fcr\u00a0den\u00a0Menschen\u00a0k\u00f6nnen\u00a0auch\u00a0nicht\u2010humane\u00a0Influenzaviren\u00a0anstec kend\u00a0sein,\u00a0wie\u00a0\nsie\u00a0beispielsweise\u00a0in\u00a0V\u00f6geln\u00a0oder\u00a0Schweinen\u00a0vorkommen.\u00a0Diese\u00a0Vi ren\u00a0werden\u00a0\n\u00fcblicherweise\u00a0nicht\u00a0von\u00a0Mensch\u00a0zu\u00a0Mensch\u00a0\u00fcbertragen,\u00a0k\u00f6nnen\u00a0sic h\u00a0aber\u00a0durch\u00a0\nAdaption\u00a0an\u00a0den\u00a0Menschen\u00a0oder\u00a0auch\u00a0durch\u00a0genetische\u00a0Mischung\u00a0au s\u00a0zootischen\u00a0\nund\u00a0humanen\u00a0Erregern\u00a0zu\u00a0\u00fcbertragbaren\u00a0Influenzaviren\u00a0umwandeln. \u00a0\nIn\u00a0gem\u00e4\u00dfigten\u00a0Zonen\u00a0der\u00a0n\u00f6rdlic hen\u00a0und\u00a0s\u00fcdlichen\u00a0Erdhalbkugel\u00a0t reten\u00a0Grippewel\u2010\nlen\u00a0in\u00a0den\u00a0jeweiligen\u00a0Wintermonaten\u00a0auf.\u00a0Das\u00a0Erkrankungsrisiko\u00a0 ist\u00a0in\u00a0Deutsch\u2010\nland,\u00a0 gemessen\u00a0 an\u00a0 der\u00a0 grippebezogenen\u00a0 Konsultationsfrequenz\u00a0 in\u00a0 Arztpraxen,\u00a0\ndaher\u00a0zu\u00a0Beginn\u00a0eines\u00a0jeden\u00a0Jahr es\u00a0besonders\u00a0hoch\u00a0und\u00a0erstreckt \u00a0sich\u00a0durch\u2010\nschnittlich\u00a0\u00fcber\u00a0acht\u00a0bis\u00a0zehn\u00a0Wochen,\u00a0in\u00a0einzelnen\u00a0Jahren\u00a0aber \u00a0auch\u00a0deutlich\u00a0\nl\u00e4nger.\u00a0Aus\u00a0diesem\u00a0Grund\u00a0schwanken\u00a0auch\u00a0Inzidenzzahlen\u00a0von\u00a0Jahr \u00a0zu\u00a0Jahr\u00a0und\u00a0\nwerden\u00a0mit\u00a05\u00a0%\u00a0bis\u00a020\u00a0%\u00a0der\u00a0Bev\u00f6lkerung\u00a0angegeben.\u00a0Die\u00a0Arbeitsg emeinschaft\u00a0\nInfluenza\u00a0(AGI)\u00a0des\u00a0RKI\u00a0sch\u00e4tzt\u00a0pro\u00a0Jahr\u00a0im\u00a0Allgemeinen\u00a0zwische n\u00a0einer\u00a0und\u00a0sieben\u00a0\nMio.\u00a0Influenza\u2010bedingte\u00a0Arztbesuche.\u00a0Als\u00a0Erkrankungsf\u00e4lle\u00a0gemel det\u00a0sind\u00a0davon\u00a0\naber\u00a0nur\u00a0sch\u00e4tzungsweise\u00a01\u00a0%\u00a0(AGI,\u00a0o.J.).\u00a0\nIm\u00a0Vergleich\u00a0zu\u00a0einer\u00a0\u201enormalen\u00a0Erk\u00e4ltung\u201c\u00a0oder\u00a0einem\u00a0\u201egrippale n\u00a0Infekt\u201c\u00a0entwi\u2010\nckelt\u00a0sich\u00a0eine\u00a0durch\u00a0Influenzavi ren\u00a0ausgel\u00f6ste\u00a0\u201eechte\u201c\u00a0Grippe\u00a0 meist\u00a0schneller,\u00a0\nverl\u00e4uft\u00a0schwerer\u00a0und\u00a0dauert\u00a0unter\u00a0Umst\u00e4nden\u00a0l\u00e4nger.\u00a0Die\u00a0Beschw erden\u00a0einer\u00a0\nInfluenzainfektion\u00a0stellen\u00a0sich\u00a0i n\u00a0der\u00a0Regel\u00a0pl\u00f6tzlich\u00a0und\u00a0glei ch\u00a0zu\u00a0Beginn\u00a0auch\u00a0\nheftig\u00a0ein.\u00a0H\u00e4ufige,\u00a0aber\u00a0nicht\u00a0zwingende\u00a0Kennzeichen\u00a0sind\u00a0ein\u00a0 gleich\u00a0zu\u00a0Beginn\u00a0\neinsetzendes\u00a0hohes\u00a0Fieber\u00a0(um\u00a039\u00a0bis\u00a040\u00a0\u00b0C),\u00a0heftige\u00a0Kopf\u2010,\u00a0Mus kel\u2010\u00a0und\u00a0Glieder\u2010245\u00a0schmerzen\u00a0mit\u00a0Reizhusten\u00a0sowie\u00a0ein\u00a0starkes\u00a0allgemeines\u00a0Krankhei tsgef\u00fchl.\u00a0Die\u00a0\nAugen\u00a0k\u00f6nnen\u00a0empfindlich\u00a0auf\u00a0Licht\u00a0reagieren.\u00a0Wenn\u00a0Husten\u00a0und\u00a0S chnupfen\u00a0nach\u2010\nfolgen,\u00a0dann\u00a0meist\u00a0sehr\u00a0viel\u00a0st\u00e4rker\u00a0als\u00a0sonst,\u00a0und\u00a0das\u00a0Bed\u00fcrfn is\u00a0nach\u00a0Ruhe\u00a0und\u00a0\nSchlaf\u00a0ist\u00a0gro\u00df.\u00a0Weitere\u00a0Symptome\u00a0k\u00f6nnen\u00a0auch\u00a0Schwei\u00dfausbr\u00fcche, \u00a0selten\u00a0auch\u00a0\n\u00dcbelkeit/Erbrechen\u00a0und\u00a0Durchfall\u00a0sein.\u00a0Eine\u00a0\u201eechte\u201c\u00a0Grippe\u00a0ist\u00a0 meist\u00a0erst\u00a0nach\u00a0\nzwei\u00a0bis\u00a0drei\u00a0Wochen\u00a0\u00fcberstanden.\u00a0Nach\u00a0einer\u00a0Infektion\u00a0mit\u00a0Infl uenzaviren\u00a0ist\u00a0eine\u00a0\nAnsteckungsgefahr\u00a0 gegeben,\u00a0 solange\u00a0 vermehrungsf\u00e4hige\u00a0 Viren\u00a0 ausg eschieden\u00a0\nwerden.\u00a0Dies\u00a0umfasst\u00a0einen\u00a0Zeitrau m\u00a0von\u00a0vier\u00a0bis\u00a0f\u00fcnf\u00a0Tagen\u00a0ab\u00a0 dem\u00a0Auftreten\u00a0der\u00a0\nersten\u00a0Symptome,\u00a0bei\u00a0schweren\u00a0Ve rl\u00e4ufen\u00a0auch\u00a0bis\u00a0zu\u00a0sieben\u00a0Tage n.\u00a0\nInfluenza\u2010Infektionen\u00a0k\u00f6nnen\u00a0zu\u00a0 gravierenden\u00a0Problemen\u00a0f\u00fchren:\u00a0\n\uf0b7 Zu\u00a0einem\u00a0schweren\u00a0Krankheitsverlauf\u00a0mit\u00a0pulmonalen\u00a0Komplikatio\u2010\nnen\u00a0wie\u00a0eine\u00a0Influenzavirus\u2010be dingte\u00a0Lungenentz\u00fcndung,\u00a0bakterie ll\u00a0\nbedingte\u00a0Lungenentz\u00fcndungen\u00a0nach\u00a0Superinfektion\u00a0u.a.\u00a0durch\u00a0Pneu \u2010\nmokokken,\u00a0Staphylokokken,\u00a0Haemophi lus\u00a0influenzae\u00a0oder\u00a0Exazerba\u2010\ntionen\u00a0bereits\u00a0vorhandener\u00a0chronischer\u00a0Lungenerkrankungen.\u00a0\n\uf0b7 In\u00a0sehr\u00a0seltenen\u00a0F\u00e4llen\u00a0kann\u00a0es\u00a0auch\u00a0zu\u00a0Entz\u00fcndungen\u00a0des\u00a0Herzmu s\u2010\nkels,\u00a0von\u00a0Hirnarealen\u00a0oder\u00a0Muskeln\u00a0kommen.\u00a0\u00a0\n\uf0b7 Zu\u00a0erh\u00f6hter\u00a0Sterblichkeit\u00a0in\u00a0Risikogruppen\u00a0wie\u00a0sehr\u00a0jungen\u00a0Kind ern,\u00a0\nSchwangeren,\u00a0\u00e4lteren\u00a0Personen,\u00a0Personen\u00a0mit\u00a0schweren\u00a0Grunder\u2010krankungen,\u00a0immungeschw\u00e4chten\u00a0Personen.\u00a0\n\uf0b7 Zu\u00a0einer\u00a0Pandemie:\u00a0Aufgrund\u00a0einer\u00a0Umwandlung\u00a0von\u00a0vormals\u00a0wenig\u00a0\npathogenen\u00a0zu\u00a0pathogenen\u00a0und\u00a0zugl eich\u00a0gut\u00a0\u00fcbertragbaren\u00a0neuen\u00a0\nhumanen\u00a0Influenzaviren,\u00a0die\u00a0von\u00a0Mensch\u00a0zu\u00a0Mensch\u00a0weitergegeben\u00a0werden\u00a0und\u00a0gegen\u00a0die\u00a0noch\u00a0keine\u00a0oder\u00a0nur\u00a0eine\u00a0geringe\u00a0Immunit\u00e4t \u00a0\nbesteht.\u00a0\u00a0\nAm\u00a0h\u00e4ufigsten\u00a0werden\u00a0in\u00a0der\u00a0typischen\u00a0Erkrankungssaison\u00a0Kleinki nder\u00a0(bis\u00a0zu\u00a0vier\u00a0\nJahren)\u00a0und\u00a0Kinder\u00a0(f\u00fcnf\u00a0bis\u00a014\u00a0Jahre)\u00a0wegen\u00a0akuter\u00a0Atemwegserk rankungen\u00a0\u00e4rzt\u2010\nlich\u00a0behandelt.\u00a0Mit\u00a0steigendem\u00a0Alter\u00a0sinkt\u00a0die\u00a0H\u00e4ufigkeit\u00a0der\u00a0E rkrankung.\u00a0Aller\u2010\ndings\u00a0 kommt\u00a0 es\u00a0 auch\u00a0 zu\u00a0 Krankenhauseinweisungen\u00a0 aufgrund\u00a0 einer\u00a0 I nfluenza\u2010\nInfektion,\u00a0am\u00a0h\u00e4ufigsten\u00a0in\u00a0der\u00a0Altersgruppe\u00a0der\u00a0Kleinkinder\u00a0so wie\u00a0bei\u00a0der\u00a0\u00e4lteren\u00a0\nBev\u00f6lkerung.\u00a0Die\u00a0Komplikationen\u00a0bei\u00a0Kindern\u00a0reichen\u00a0von\u00a0einer\u00a0M ittelohrentz\u00fcn\u2010\ndung\u00a0\u00fcber\u00a0Atemprobleme,\u00a0die\u00a0mit\u00a0einer\u00a0Beatmungspflicht\u00a0einherge hen,\u00a0bis\u00a0hin\u00a0zu\u00a0\nseltenen\u00a0Komplikationen\u00a0wie\u00a0z.B.\u00a0Myokarditis\u00a0oder\u00a0Enzephalopath ie.\u00a0Bei\u00a0\u00e4lteren\u00a0\nPersonen\u00a0kann\u00a0es\u00a0im\u00a0Rahmen\u00a0schwerer\u00a0Verl\u00e4ufe\u00a0zur\u00a0Exazerbation\u00a0c hronischer\u00a0\nHerzerkrankungen,\u00a0chronischer\u00a0Lu ngenerkrankungen,\u00a0von\u00a0Stoffwech selerkrankun\u2010\ngen\u00a0(z.B.\u00a0Diabetes\u00a0mellitus),\u00a0Immundefekten,\u00a0neurologischen\u00a0bzw .\u00a0neuromuskul\u00e4\u2010\nren\u00a0Erkrankungen\u00a0und\u00a0schwerer\u00a0Fettleibigkeit\u00a0(Adipositas)\u00a0komme n.\u00a0Eine\u00a0Schwan\u2010246\u00a0gerschaft,\u00a0v.a.\u00a0im\u00a0fortgeschritt enen\u00a0Stadium,\u00a0erh\u00f6ht\u00a0das\u00a0Risiko \u00a0f\u00fcr\u00a0einen\u00a0schweren\u00a0\nVerlauf.\u00a0\n6.2\u00a0\u00a0\u00a0Die\u00a0Impfung\u00a0gegen\u00a0Influenza\u00a0\nMit\u00a0einer\u00a0einzigen\u00a0Impfung\u00a0wird\u00a0 keine\u00a0ausreichende\u00a0lebenslange\u00a0 Immunit\u00e4t\u00a0gegen\u00a0\nInfluenzaviren\u00a0erreicht.\u00a0Die\u00a0Immunogenit\u00e4t\u00a0der\u00a0Impfung\u00a0ist\u00a0bei\u00a0 \u00e4lteren\u00a0Menschen\u00a0\nschlechter\u00a0als\u00a0bei\u00a0j\u00fcngeren.\u00a0Influenzaviren\u00a0sind\u00a0durch\u00a0ihre\u00a0ras che\u00a0Wandelbarkeit\u00a0\ngekennzeichnet,\u00a0was\u00a0es\u00a0dem\u00a0k\u00f6rpereigenen\u00a0System\u00a0erschwert,\u00a0eine \u00a0langanhalten\u2010\nde\u00a0Immunit\u00e4t\u00a0aufzubauen.\u00a0Im\u00a0Laufe\u00a0eines\u00a0Jahres\u00a0k\u00f6nnen\u00a0sich\u00a0stru kturell\u00a0geringf\u00fc\u2010\ngige\u00a0Abwandlungen\u00a0auf\u00a0der\u00a0Virusoberfl\u00e4che\u00a0ergeben\u00a0oder\u00a0es\u00a0entst ehen\u00a0ganz\u00a0neue\u00a0\nVirusvarianten.\u00a0Die\u00a0im\u00a0K\u00f6rper\u00a0bereits\u00a0vorhandenen\u00a0Antik\u00f6rper\u00a0er kennen\u00a0diese\u00a0\nver\u00e4nderten\u00a0Strukturen\u00a0aber\u00a0nicht\u00a0mehr.\u00a0Will\u00a0man\u00a0also\u00a0prophylak tisch\u00a0eine\u00a0Immu\u2010\nnit\u00e4t\u00a0gegen\u00a0die\u00a0\u00fcblichen\u00a0Influenzaviren\u00a0f\u00fcr\u00a0die\u00a0bevorstehende\u00a0S aison\u00a0erreichen,\u00a0\nmuss\u00a0jedes\u00a0Jahr\u00a0eine\u00a0Impfung\u00a0mit\u00a0dem\u00a0aktuell\u00a0verf\u00fcgbaren\u00a0Grippe impfstoff\u00a0vorge\u2010\nnommen\u00a0 werden.\u00a0 Die\u00a0 aktuell\u00a0 geltende\u00a0 empfohlene\u00a0 Zusammensetzung\u00a0 wird\u00a0 in\u00a0\njedem\u00a0Jahr\u00a0von\u00a0der\u00a0WHO\u00a0herausgeg eben,\u00a0und\u00a0zwar\u00a0zu\u00a0einem\u00a0Zeitpun kt\u00a0(z.B.\u00a0im\u00a0\nFebruar),\u00a0der\u00a0es\u00a0der\u00a0Industrie\u00a0e rm\u00f6glicht,\u00a0die\u00a0Impfstoffe\u00a0recht zeitig\u00a0zum\u00a0Herbst\u00a0zu\u00a0\nproduzieren.\u00a0Ein\u00a0Produktionslauf\u00a0 ben\u00f6tigt\u00a0etwa\u00a0sechs\u00a0Monate.\u00a0Di e\u00a0Genauigkeit\u00a0der\u00a0\nVorhersage,\u00a0 welche\u00a0 Influenzasubtypen\u00a0 in\u00a0 der\u00a0 kommenden\u00a0 Saison\u00a0 do minieren\u00a0\nwerden,\u00a0variiert.\u00a0Wie\u00a0schon\u00a0bei\u00a0der\u00a0Masernimpfung\u00a0zeigt\u00a0sich\u00a0be i\u00a0der\u00a0Impfung\u00a0\ngegen\u00a0Influenza\u00a0in\u00a0den\u00a0Daten\u00a0der\u00a0TK\u00a0ein\u00a0deutlicher\u00a0Unterschied\u00a0 zwischen\u00a0den\u00a0\nBundesl\u00e4ndern\u00a0 der\u00a0 ehemaligen\u00a0 DDR \u00a0 und\u00a0 denen\u00a0 der\u00a0 westlichen\u00a0 Bunde sl\u00e4nder.\u00a0\nOhne\u00a0Ausnahme\u00a0haben\u00a0die\u00a0westlichen\u00a0Bundesl\u00e4nder\u00a0geringere\u00a0Impfq uoten,\u00a0der\u00a0\nAbstand\u00a0zwischen\u00a0Ost\u00a0und\u00a0West\u00a0betr\u00e4gt\u00a0sogar\u00a0mindestens\u00a05\u00a0%,\u00a0wen n\u00a0man\u00a0das\u00a0\n\u201egemischte\u201c\u00a0Berlin\u00a0au\u00dfer\u00a0Acht\u00a0l\u00e4sst.\u00a0\u00a0\n\u00a0 \u00a0247\u00a0Abbildung\u00a06.8:\u00a0Anteil\u00a0der\u00a0Grippeimpfungen\u00a0f\u00fcr\u00a0TK\u2010Versicherte\u00a0je \u00a0KV\u00a0Region\u00a0\nim\u00a0Jahr\u00a02017\u00a0\n\u00a0\n\u00a0 \u00a0\n248\u00a06.3\u00a0\u00a0\u00a0STIKO\u2010Empfehlungen\u00a0zur\u00a0Grippeimpfung\u00a0\u2013\u00a0noch\u00a0aktuell?\u00a0\nDie\u00a0bisherige\u00a0Empfehlung\u00a0der\u00a0STI KO\u00a0bez\u00fcglich\u00a0der\u00a0Grippeimpfung\u00a0 lautet,\u00a0dass\u00a0\nm\u00f6glichst\u00a0alle\u00a0Personen\u00a0\u00fcber\u00a060\u00a0Ja hre\u00a0geimpft\u00a0werden\u00a0sollen.\u00a0Da gegen\u00a0sollen\u00a0\nKinder\u00a0und\u00a0Erwachsene\u00a0erst\u00a0dann\u00a0geimpft\u00a0werden,\u00a0wenn\u00a0bei\u00a0ihnen\u00a0 eine\u00a0erh\u00f6hte\u00a0\ngesundheitliche\u00a0Gef\u00e4hrdung\u00a0vorliegt.\u00a0Die\u00a0Evidenz\u00a0zu\u00a0Wirksamkeit \u00a0und\u00a0Sicherheit\u00a0\nder\u00a0Grippeimpfung\u00a0bei\u00a0Personen\u00a0ab\u00a065\u00a0Jahren\u00a0und\u00a0\u00e4lter\u00a0ist\u00a0aber\u00a0 als\u00a0eher\u00a0unzu\u2010\nreichend\u00a0zu\u00a0bezeichnen.\u00a0Eine\u00a0systematische\u00a0\u00dcbersicht\u00a0der\u00a0 Cochrane\u00a0Collaboration \u00a0\nl\u00e4sst\u00a0erkennen,\u00a0dass\u00a0die\u00a0Beleglage\u00a0f\u00fcr\u00a0die\u00a0Empfehlung\u00a0einer\u00a0gen erellen\u00a0Impfung\u00a0\n\u00e4lterer\u00a0Personen\u00a0\u00fcber\u00a065\u00a0Jahren\u00a0verbesserungsbed\u00fcrftig\u00a0ist\u00a0und\u00a0 dass\u00a0eine\u00a0Schutz\u2010\nwirkung\u00a0dieser\u00a0Gruppe\u00a0durch\u00a0die\u00a0Impfung\u00a0allenfalls\u00a0als\u00a0moderat\u00a0 anzusehen\u00a0ist\u00a0\n(Jefferson\u00a0et\u00a0al.,\u00a02010,\u00a0Osterholm\u00a0et\u00a0al.,\u00a02012).\u00a0Die\u00a0vorhanden e\u00a0Evidenz\u00a0ist\u00a0von\u00a0\nschlechter\u00a0Qualit\u00e4t\u00a0und\u00a0stellt\u00a0keine\u00a0brauchbare\u00a0Grundlage\u00a0f\u00fcr\u00a0d ie\u00a0Beurteilung\u00a0der\u00a0\nWirksamkeit\u00a0der\u00a0Impfung\u00a0bei\u00a0\u00e4lteren\u00a0Personen\u00a0dar.\u00a0Die\u00a0Immunogen it\u00e4t\u00a0der\u00a0Imp\u2010\nfung\u00a0bei\u00a0j\u00fcngeren\u00a0Personen\u00a0ist\u00a0besser\u00a0zu\u00a0bewerten,\u00a0damit\u00a0auch\u00a0d er\u00a0individuelle\u00a0\nSchutz\u00a0der\u00a0j\u00fcngeren\u00a0Personen.\u00a0Indirekt\u00a0bietet\u00a0die\u00a0Impfung\u00a0j\u00fcnge rer\u00a0Personen,\u00a0die\u00a0\noftmals\u00a0als\u00a0\u201eAnsteckungsherd\u201c\u00a0betrachtet\u00a0werden\u00a0(bedingt\u00a0durch\u00a0 den\u00a0h\u00e4ufigen\u00a0\nKontakt\u00a0zu\u00a0Kitas,\u00a0Kinderg\u00e4rten\u00a0und\u00a0Schulen\u00a0mit\u00a0erh\u00f6hten\u00a0Inziden zen),\u00a0den\u00a0Schutz\u00a0\nvon\u00a0Risikogruppen\u00a0in\u00a0h\u00f6herem\u00a0Alter.\u00a0Die\u00a0Stiftung\u00a0Warentest\u00a0empf iehlt\u00a0im\u00a0Jahr\u00a0\n2018\u00a0daher\u00a0eine\u00a0m\u00f6glichst\u00a0vollst\u00e4ndige\u00a0Impfung\u00a0junger\u00a0Kinder,\u00a0u m\u00a0\u00fcber\u00a0dieses\u00a0\nVorgehen\u00a0nicht\u00a0nur\u00a0die\u00a0Krankheitslast\u00a0in\u00a0der\u00a0Impfgruppe,\u00a0sonder n\u00a0auch\u00a0eine\u00a0Her\u2010\ndenimmunit\u00e4t\u00a0zu\u00a0erreichen.\u00a0So\u00a0sollen\u00a0durch\u00a0geimpfte\u00a0junge\u00a0Perso nen,\u00a0bei\u00a0denen\u00a0\nvon\u00a0einer\u00a0deutlichen\u00a0Immunit\u00e4t\u00a0nach\u00a0der\u00a0Impfung\u00a0auszugehen\u00a0ist\u00a0 (Jefferson\u00a0et\u00a0al.,\u00a0\n2012),\u00a0auch\u00a0andere\u00a0gef\u00e4hrdete\u00a0aber\u00a0nicht\u00a0immunisierte\u00a0Personen\u00a0 (z.B.\u00a0Schwange\u2010\nre,\u00a0ganz\u00a0junge\u00a0Kinder,\u00a0\u00e4ltere\u00a0Menschen,\u00a0Menschen\u00a0mit\u00a0schweren\u00a0E rkrankungen,\u00a0\nMenschen\u00a0mit\u00a0Immunschw\u00e4che)\u00a0vor\u00a0einer\u00a0Infektion\u00a0gesch\u00fctzt\u00a0werde n.\u00a0Dies\u00a0konn\u2010\nte\u00a0in\u00a0der\u00a0Zwischenzeit\u00a0in\u00a0mehreren\u00a0Studien\u00a0best\u00e4tigt\u00a0werden\u00a0(Lo eb\u00a0et\u00a0al.,\u00a02010;\u00a0\nJefferson\u00a0et\u00a0al.,\u00a02012;\u00a0McGuire\u00a0et\u00a0al.,\u00a02015).\u00a0Zus\u00e4tzlich\u00a0gibt\u00a0 es\u00a0Hinweise\u00a0darauf,\u00a0\ndass\u00a0diese\u00a0Risikogruppen\u00a0auch\u00a0von\u00a0der\u00a0Impfung\u00a0gesunder\u00a0Kinder\u00a0a b\u00a0zwei\u00a0Jahren\u00a0\nprofitieren.\u00a0Die\u00a0Auswertungen\u00a0de r\u00a0TK\u2010Daten\u00a0zeigen\u00a0allerdings\u00a0na ch\u00a0wie\u00a0vor\u00a0die\u00a0\nDominanz\u00a0der\u00a0Grippeimpfung\u00a0in\u00a0den\u00a0h\u00f6heren\u00a0Altersgruppen\u00a0(s.\u00a0Abb ildung\u00a06.9).\u00a0\n\u00a0 \u00a0249\u00a0Abbildung\u00a06.9:\u00a0Verordnungen\u00a0von\u00a0Grippeimpfungen\u00a0an\u00a0TK\u2010Versicher te\u00a0nach\u00a0Alter\u00a0\nund\u00a0Geschlecht\u00a0im\u00a0Jahr\u00a02017\u00a0\n\u00a0\nEine\u00a0Empfehlung\u00a0zur\u00a0Grippeimpfung\u00a0f\u00fcr\u00a0Kinder\u00a0zwischen\u00a0f\u00fcnf\u00a0und\u00a0 17\u00a0Jahren\u00a0wird\u00a0\nmittlerweile\u00a0von\u00a0verschiedenen\u00a0Staaten\u00a0gegeben,\u00a0z.B.\u00a0in\u00a0den\u00a0USA \u00a0und\u00a0Kanada.\u00a0In\u00a0\nEuropa\u00a0sind\u00a0es\u00a0\u00d6sterreich,\u00a0Finnl and,\u00a0Litauen,\u00a0Malta,\u00a0Polen,\u00a0Slo wenien\u00a0und\u00a0England.\u00a0\nDie\u00a0Kosten\u00a0werden\u00a0allerdings\u00a0nur\u00a0in\u00a0England,\u00a0Litauen\u00a0und\u00a0Finnla nd\u00a0vom\u00a0Gesund\u2010\nheitswesen\u00a0\u00fcbernommen\u00a0(McGuire\u00a0et\u00a0al.,\u00a02015;\u00a0f\u00fcr\u00a0Wales\u00a0und\u00a0Engl and:\u00a0Baguelin\u00a0\net\u00a0al.,\u00a02015).\u00a0Baguelin\u00a0und\u00a0Kollege n\u00a0beschreiben\u00a0den\u00a0h\u00f6chsten\u00a0N ettonutzen\u00a0bei\u00a0\nAusweitung\u00a0der\u00a0Impfung\u00a0auf\u00a0Kinder\u00a0ab\u00a0zwei\u00a0Jahre\u00a0\u2013\u00a0f\u00fcr\u00a0den\u00a0Schut z\u00a0der\u00a0geimpften\u00a0\nGruppe\u00a0und\u00a0das\u00a0Erreichen\u00a0der\u00a0Herd enimmunit\u00e4t\u00a0f\u00fcr\u00a0andere\u00a0nicht\u2010g eimpfte\u00a0Perso\u2010\nnengruppen.\u00a0Bei\u00a0diesem\u00a0Vorgehen\u00a0wird\u00a0\u2013\u00a0f\u00fcr\u00a0England\u00a0und\u00a0unter\u00a0de r\u00a0Vorausset\u2010\nzung,\u00a0dass\u00a0die\u00a0f\u00fcr\u00a0das\u00a0Modell\u00a0getroffenen\u00a0Annahmen\u00a0auch\u00a0in\u00a0Zuku nft\u00a0eintreffen\u00a0\u2013\u00a0\nauch\u00a0eine\u00a0Kosten\u2010Effektivit\u00e4t\u00a0konstatiert.\u00a0Thorrington\u00a0und\u00a0Koll egen\u00a0weisen\u00a02015\u00a0\ndarauf\u00a0hin,\u00a0dass\u00a0Kinder\u00a0ab\u00a0Eintritt\u00a0in\u00a0das\u00a0Schulalter\u00a0( primary\u00a0and\u00a0secondary\u00a0school\u00a0\nchildren)\u00a0geimpft\u00a0werden\u00a0sollten,\u00a0um\u00a0durch\u00a0die\u00a0erreichte\u00a0Herdenimmunit\u00e4 t\u00a0eine\u00a0\n\u00dcbertragung\u00a0der\u00a0Grippeviren\u00a0in\u00a0der\u00a0laufenden\u00a0Saison\u00a0zu\u00a0unterbre chen.\u00a0Durchimp\u2010\nfungsraten\u00a0von\u00a0nahezu\u00a050\u00a0%\u00a0in\u00a0der\u00a0 primary\u00a0school \u00a0sollten\u00a0dabei\u00a0erreicht\u00a0werden.\u00a0\u00a0\nF\u00fcr\u00a0eine\u00a0ge\u00e4nderte\u00a0Strategie,\u00a0ei ne\u00a0grunds\u00e4tzliche\u00a0Empfehlung\u00a0f\u00fc r\u00a0die\u00a0Grippeimp\u2010\nfung\u00a0von\u00a0Kindern\u00a0statt\u00a0f\u00fcr\u00a0\u00e4ltere\u00a0Menschen\u00a0auszusprechen,\u00a0stehe n\u00a0somit\u00a0in\u00a0der\u00a0\nHauptsache\u00a0folgende\u00a0Gr\u00fcnde:\u00a0\n250\u00a0\uf0b7 Verhinderung\u00a0von\u00a0Grippeinfektionen\u00a0in\u00a0der\u00a0Gruppe\u00a0der\u00a0Geimpften\u00a0\ndurch\u00a0direkte\u00a0Schutzma\u00dfnahmen\u00a0\n\uf0b7 Schutz\u00a0von\u00a0Risikogruppen,\u00a0bei\u00a0denen\u00a0eine\u00a0Impfung\u00a0nicht\u00a0m\u00f6glich\u00a0 ist\u00a0\noder\u00a0schlechte\u00a0Ergebnisse\u00a0zeigt\u00a0(aufgrund\u00a0fehlender\u00a0Erreichbark eit,\u00a0\nImmunogenit\u00e4t\u00a0etc.)\u00a0durch\u00a0indirekte\u00a0Schutzma\u00dfnahmen\u00a0\u00a0\nHinzu\u00a0kommen\u00a0praktische\u00a0und\u00a0messbare\u00a0Auswirkungen:\u00a0Es\u00a0geht\u00a0um\u00a0d ie\u00a0Reduktion\u00a0\nvon\u00a0Grippeinfektionen,\u00a0folglich\u00a0um\u00a0die\u00a0Reduktion\u00a0der\u00a0Inanspruch nahme\u00a0der\u00a0Ge\u2010\nsundheitssysteme\u00a0(Arztbesuch,\u00a0Hospitalisierung)\u00a0und\u00a0um\u00a0die\u00a0Redu ktion\u00a0indirekter\u00a0\nKrankheitskosten\u00a0(Arbeitsunf\u00e4higkeit\u00a0von\u00a0Arbeitnehmern\u00a0und\u00a0Elte rn).\u00a0Mit\u00a0einer\u00a0\nderartigen\u00a0Strategie\u00e4nderung\u00a0werden\u00a0vor\u00a0allem\u00a0altruistische\u00a0und \u00a0ethische\u00a0Beweg\u2010\ngr\u00fcnde\u00a0einer\u00a0Impfung\u00a0best\u00e4rkt,\u00a0d.h.\u00a0zum\u00a0Schutz\u00a0von\u00a0Anderen\u00a0sich \u00a0oder\u00a0sein\u00a0(ge\u2010\nsundes)\u00a0Kind\u00a0impfen\u00a0zu\u00a0lassen.\u00a0\u00c4hnliche\u00a0Argumente\u00a0wie\u00a0auch\u00a0bei\u00a0 der\u00a0Masernimp\u2010\nfung\u00a0kommen\u00a0hier\u00a0zum\u00a0Tragen\u00a0\u2013\u00a0allerdings\u00a0mit\u00a0dem\u00a0Unterschied,\u00a0d ass\u00a0die\u00a0Folgen\u00a0\neiner\u00a0Influenza\u2010Infektion\u00a0zumeist\u00a0deutlich\u00a0weniger\u00a0dramatisch\u00a0u nd\u00a0folgenschwer\u00a0\nausfallen\u00a0als\u00a0bei\u00a0einer\u00a0Masern infektion,\u00a0gesundheits\u00f6konomisch\u00a0 aber\u00a0von\u00a0gr\u00f6\u00dfe\u2010\nrem\u00a0Gewicht\u00a0sein\u00a0k\u00f6nnten.\u00a0Dennoch\u00a0ist\u00a0die\u00a0vorliegende\u00a0Evidenz\u00a0u .E.\u00a0ausreichend,\u00a0\num\u00a0 eine\u00a0 Ver\u00e4nderung\u00a0 oder\u00a0 zumindest \u00a0 eine\u00a0 Erg\u00e4nzung\u00a0 der\u00a0 derzeitig en\u00a0 STIKO\u2010\nImpfempfehlungen\u00a0zu\u00a0w\u00fcnschen\u00a0und\u00a0es\u00a0nicht\u00a0einzelnen\u00a0Krankenkass en\u00a0zu\u00a0\u00fcberlas\u2010\nsen,\u00a0die\u00a0Kosten\u00a0f\u00fcr\u00a0eine\u00a0Grippeimpfung\u00a0als\u00a0Satzungsleistungen\u00a0a uch\u00a0f\u00fcr\u00a0Kinder\u00a0und\u00a0\nJugendliche\u00a0zu\u00a0erstatten.\u00a0\u00a0\n\u00a0 \u00a0251\u00a06.4\u00a0\u00a0\u00a0Versorgungsdaten\u00a0der\u00a0Techni ker\u00a0Krankenkasse\u00a0(TK)\u00a0zur\u00a0Mase rnimpfung \u00a0\nAuswertungen\u00a0von\u00a0Jahresdaten\u00a0der \u00a0TK\u00a0lassen\u00a0wie\u00a0bei\u00a0den\u00a0Surveill ance\u2010Daten\u00a0keine\u00a0\nR\u00fcckschl\u00fcsse\u00a0auf\u00a0die\u00a0Impfquoten\u00a0zu,\u00a0sondern\u00a0bieten\u00a0allenfalls\u00a0Z ahlen\u00a0zu\u00a0den\u00a0Impf\u2010\naktivit\u00e4ten\u00a0bei\u00a0niedergelassenen\u00a0\u00c4rzten\u00a0in\u00a0den\u00a0jeweiligen\u00a0KV\u2010Re gionen\u00a0im\u00a0Unter\u2010\nsuchungsjahr\u00a02017.\u00a0\u00a0\nAbbildung\u00a06.10:\u00a0Anteil\u00a0der\u00a0TK\u2010Versicherten\u00a0mit\u00a0Masernimpfungen\u00a0 nach\u00a0Alter\u00a0\nund\u00a0Geschlecht\u00a0im\u00a0Jahr\u00a02017\u00a0\n\u00a0\n\u00a0 \u00a0\n252\u00a0In\u00a0der\u00a0Grafik\u00a06.10\u00a0sind\u00a0die\u00a0an\u00a0die\u00a0verschiedenen\u00a0Altersgruppen\u00a0 verabreichten\u00a0Imp\u2010\nfungen\u00a0abzulesen.\u00a0Entsprechend\u00a0den\u00a0Impfempfehlungen\u00a0bei\u00a0Kindern \u00a0sind\u00a0in\u00a0den\u00a0\nAltersgruppen\u00a0der\u00a00\u2010\u00a0bis\u00a017\u2010J\u00e4hrigen\u00a0die\u00a0meisten\u00a0Impfungen\u00a0zu\u00a0v erzeichnen.\u00a0Zu\u00a0\nbedenken\u00a0ist\u00a0in\u00a0diesem\u00a0Zusammenhang\u00a0die\u00a0bereits\u00a0erw\u00e4hnte\u00a0angest iegene\u00a0Masern\u2010\nInzidenz\u00a0bei\u00a0den\u00a0jungen\u00a0Erwachsenen\u00a0ab\u00a020\u00a0Jahren:\u00a0Rund\u00a050\u00a0%\u00a0all er\u00a0Masernerkran\u2010\nkungen\u00a0entfallen\u00a0auf\u00a0diese\u00a0Altersgruppe\u00a0(vgl.\u00a0S.\u00a0255).\u00a0Die\u00a0Impf daten\u00a0der\u00a0TK\u00a0zeigen\u00a0f\u00fcr\u00a0\ndiese\u00a0Altersgruppen\u00a0allerdings\u00a0(noch)\u00a0keine\u00a0entsprechenden\u00a0Impf h\u00e4ufigkeiten.\u00a0Bei\u00a0all\u00a0\ndiesen\u00a0Daten\u00a0muss\u00a0jedoch\u00a0ber\u00fccksichtigt\u00a0werden,\u00a0dass\u00a0diese\u00a0nur\u00a0 einen\u00a0Blick\u00a0auf\u00a0die\u00a0\nImpfsituation\u00a0im\u00a0Jahre\u00a02017\u00a0und\u00a0keine\u00a0Unterscheidung\u00a0in\u00a0die\u00a0Ers t\u2010\u00a0oder\u00a0Zweitimp\u2010\nfung\u00a0zulassen\u00a0\u2013\u00a0es\u00a0kann\u00a0also\u00a0nur\u00a0eine\u00a0Querschnittsauswertung\u00a0an geboten\u00a0werden.\u00a0\n6.5\u00a0\u00a0\u00a0W\u00fcrde\u00a0mit\u00a0einer\u00a0Impfpflicht\u00a0gegen\u00a0Masern\u00a0alles\u00a0besser?\u00a0Ei n\u00a0Blick\u00a0auf\u00a0Europa\u00a0\nDie\u00a0Daten\u00a0zu\u00a0den\u00a0Impfquoten\u00a0zeigen\u00a0f\u00fcr\u00a0Deutschland,\u00a0dass\u00a0zumind est\u00a0Handlungs\u2010\nbedarf\u00a0f\u00fcr\u00a0die\u00a0Zweitimpfung\u00a0besteht,\u00a0um\u00a0eine\u00a0Herdenimmunit\u00e4t\u00a0ge gen\u00a0Masern\u00a0zu\u00a0\nerreichen,\u00a0die\u00a0in\u00a0vielen\u00a0anderen\u00a0L\u00e4ndern\u00a0bereits\u00a0gegeben\u00a0ist\u00a0(v gl.\u00a0Abbildung\u00a06.5).\u00a0\nAls\u00a0eine\u00a0m\u00f6gliche\u00a0Ma\u00dfnahme\u00a0wird\u00a0die\u00a0Einf\u00fchrung\u00a0einer\u00a0Impfpflich t\u00a0diskutiert\u00a0und\u00a0\nvorgeschlagen.\u00a0Aber\u00a0l\u00e4sst\u00a0sich\u00a0damit\u00a0eine\u00a0Verbesserung\u00a0der\u00a0derz eitigen\u00a0Situation\u00a0\nerreichen,\u00a0die\u00a0sich\u00a0doch,\u00a0wie\u00a0be reits\u00a0gezeigt\u00a0werden\u00a0konnte\u00a0(s. \u00a0Abbildung\u00a06.4),\u00a0im\u00a0\nVerlauf\u00a0der\u00a0vergangenen\u00a0Jahre\u00a0bereits\u00a0deutlich\u00a0hin\u00a0zu\u00a0einer\u00a0Ver ringerung\u00a0der\u00a0In\u2010\nfektionen\u00a0ver\u00e4ndert\u00a0hat?\u00a0Eine\u00a0\u00dcbe rsicht\u00a0des\u00a0Europ\u00e4ischen\u00a0Zentru ms\u00a0f\u00fcr\u00a0die\u00a0Pr\u00e4\u2010\nvention\u00a0und\u00a0die\u00a0Kontrolle\u00a0von\u00a0Krankheiten\u00a0( European\u00a0Center\u00a0for\u00a0Disease\u00a0Preventi\u2010\non\u00a0and\u00a0Control ,\u00a0ECDC)\u00a0zeigt,\u00a0dass\u00a0die\u00a0Masernimpfung\u00a0bereits\u00a0in\u00a0zehn\u00a0von\u00a028\u00a0L\u00e4 n\u2010\ndern\u00a0der\u00a0EU\u00a0verpflichtend\u00a0ist\u00a0(vgl.\u00a0Tabelle\u00a06.6\u00a0und\u00a0Abbildung\u00a06 .11)\u00a0(ECDC,\u00a02019).\u00a0\nDie\u00a0Inzidenzraten\u00a0f\u00fcr\u00a0eine\u00a0Maser ninfektion\u00a0in\u00a0der\u00a0EU\u00a0divergiere n\u00a0jedoch\u00a0stark\u00a0und\u00a0\nsind\u00a0in\u00a0den\u00a0Staaten\u00a0mit\u00a0einer\u00a0verpflichtenden\u00a0Impfung\u00a0nicht\u00a0zwa ngsl\u00e4ufig\u00a0niedriger\u00a0\nals\u00a0in\u00a0L\u00e4ndern\u00a0ohne\u00a0Pflicht\u00a0(WHO,\u00a02019d).\u00a0\n\u00a0\n\u00a0 \u00a0253\u00a0Abbildung\u00a06.11:\u00a0Impfpflicht\u00a0gegen\u00a0Masern\u00a0in\u00a0Europa\u00a0\n\u00a0\nQuelle:\u00a0Eigene\u00a0Darstellung\u00a0nach\u00a0Berres,\u00a02019\u00a0\nSo\u00a0wies\u00a0z.B.\u00a0die\u00a0Slowakei\u00a0trotz\u00a0Impfpflicht\u00a0die\u00a0zweith\u00f6chste\u00a0Ma serninzidenzrate\u00a0\npro\u00a0eine\u00a0Million\u00a0Einwohner\u00a0im\u00a0Jah re\u00a02018\u00a0auf,\u00a0w\u00e4hrend\u00a0die\u00a0niedr igsten\u00a0Raten\u00a0auf\u00a0\ndie\u00a0Niederlande\u00a0und\u00a0D\u00e4nemark\u00a0entfielen,\u00a0wo\u00a0lediglich\u00a0eine\u00a0Impfe mpfehlung\u00a0exis\u2010\ntiert.\u00a0Ebenfalls\u00a0vergleichsweise\u00a0hohe\u00a0Neuerkrankungsraten\u00a0trotz \u00a0verpflichtender\u00a0\nMasernimpfung\u00a0zeigen\u00a0sich\u00a0in\u00a0Italien\u00a0und\u00a0Frankreich.\u00a0Hierbei\u00a0is t\u00a0jedoch\u00a0anzumer\u2010\nken,\u00a0dass\u00a0in\u00a0diesen\u00a0beiden\u00a0L\u00e4nde rn\u00a0die\u00a0Impfpflicht\u00a0erst\u00a0in\u00a02017 \u00a0eingef\u00fchrt\u00a0wurde.\u00a0\n\u00a0 \u00a0\n254\u00a0Tabelle\u00a06.6:\u00a0Maserninzidenzrate\u00a0im\u00a0Jahre\u00a02018\u00a0pro\u00a0eine\u00a0Million\u00a0 Einwohner\u00a0in\u00a0\nL\u00e4ndern\u00a0der\u00a0Europ\u00e4ischen\u00a0Union\u00a0 und\u00a0Angabe\u00a0zur\u00a0Impfpflicht\u00a0gegen \u00a0Masern\u00a0\nL\u00e4nder\u00a0der\u00a0Europ\u00e4ischen\u00a0Union\u00a0 Inzidenzrate\u00a0pro\u00a0eine\u00a0Mio.\nEinwohnerAbsolute\u00a0\nFallzahlenVerpflichtende\u00a0\nMasernimpfung\u00a0\nGriechenland\u00a0 196,82 2.193 Nein\u00a0\nSlowakei\u00a0 104,96 572 Ja\u00a0\nRum\u00e4nien\u00a0 55,51 1.087 Nein\u00a0\nFrankreich\u00a0 44,66 2.913 Ja\u00a0\nItalien\u00a0 42,45 2.517 Ja\u00a0\nIrland\u00a0 18,74 90 Nein\u00a0\nTschechische\u00a0Republik\u00a0 18,73 199 Ja\u00a0\nPortugal\u00a0 16,62 171 Nein\u00a0\nVereinigtes\u00a0K\u00f6nigreich\u00a0 14,32 953 Nein\u00a0\nZypern\u00a0 11,77 14 Nein\u00a0\nMalta\u00a0 11,57 5 Nein\u00a0\nBelgien\u00a0 10,44 120 Nein\u00a0\nLitauen\u00a0 10,43 30 Nein\u00a0\nLettland\u00a0 10,36 20 Ja\u00a0\n\u00d6sterreich\u00a0 8,8 77 Nein\u00a0\nPolen\u00a0 8,79 335 Ja\u00a0\nEstland\u00a0 7,65 10 Nein\u00a0\nLuxemburg\u00a0 6,78 4 Nein\u00a0\nDeutschland\u00a0 6,46 323 Nein\u00a0\nKroatien\u00a0 5,52 23 Ja\u00a0\nSpanien\u00a0 4,85 225 Nein\u00a0\nSlowenien\u00a0 4,32 9 Ja\u00a0\nSchweden\u00a0 3,81 38 Nein\u00a0\nFinnland\u00a0 2,71 15 Nein\u00a0\nBulgarien\u00a0 1,85 13 Ja\u00a0\nUngarn\u00a0 1,44 14 Ja\u00a0\nNiederlande\u00a0 1,4 24 Nein\u00a0\nD\u00e4nemark\u00a0 1,39 8 Nein\u00a0\nQuelle:\u00a0Eigene\u00a0Darstellung\u00a0nach\u00a0ECDC,\u00a02019;\u00a0WHO,\u00a02019d\u00a0255\u00a0Zur\u00a0Einf\u00fchrung\u00a0einer\u00a0Impfpflicht\u00a0in\u00a0Deutschland\u00a0sollten\u00a0auf\u00a0all e\u00a0F\u00e4lle\u00a0die\u00a0Rahmen\u2010\nbedingungen\u00a0und\u00a0die\u00a0Einstellungen\u00a0der\u00a0Bev\u00f6lkerung\u00a0eingehend\u00a0ana lysiert\u00a0werden.\u00a0\nIn\u00a0der\u00a0\u00fcberwiegenden\u00a0Anzahl\u00a0der\u00a0an\u00a0einer\u00a0Befragung\u00a0beteiligten\u00a0 28\u00a0EU\u2010L\u00e4nder\u00a0gibt\u00a0\nes\u00a0vor\u00a0allem\u00a0Impfempfehlungen,\u00a0se ltener\u00a0eine\u00a0Impfpflicht\u00a0bei\u00a0ei nigen\u00a0Impfungen.\u00a0\nBei\u00a0MMR\u00a0haben\u00a0von\u00a0den\u00a028\u00a0L\u00e4ndern\u00a0nur\u00a0acht\u00a0eine\u00a0Impfpflicht\u00a0eing ef\u00fchrt\u00a0(Haver\u2010\nkate\u00a0et\u00a0al.,\u00a02012).\u00a0\u00a0\nGrunds\u00e4tzlich\u00a0gelten\u00a0Masern\u00a0als\u00a0eliminiert,\u00a0wenn\u00a0eine\u00a0endemisch e\u00a0Ausbreitung\u00a0\nm\u00f6glichst\u00a0f\u00fcr\u00a036\u00a0Monate\u00a0vermieden\u00a0wurde.\u00a0Es\u00a0muss\u00a0auch\u00a0ber\u00fccksic htigt\u00a0werden,\u00a0\ndass\u00a0zwar\u00a0immer\u00a0von\u00a0Masern\u00a0als\u00a0\u201eKinderkrankheit\u201c\u00a0gesprochen\u00a0wir d,\u00a0dass\u00a0aber\u00a0\nauch\u00a0zunehmend\u00a0Erwachsene\u00a0zwischen\u00a0dem\u00a020.\u00a0und\u00a050.\u00a0Lebensjahr\u00a0e rkranken,\u00a0vor\u00a0\nallem,\u00a0wenn\u00a0bisher\u00a0keine\u00a0Impfung\u00a0in\u00a0Anspruch\u00a0genommen\u00a0wurde.\u00a0De r\u00a0Anteil\u00a0der\u00a0\nerkrankten\u00a0Erwachsenen\u00a0im\u00a0Alter\u00a0von\u00a0\u00fcber\u00a020\u00a0Jahren\u00a0schwankt,\u00a0je \u00a0nach\u00a0Alters\u2010\ngruppe,\u00a0zwischen\u00a0rund\u00a050\u00a0%\u00a0bei\u00a0den\u00a0j\u00fcngeren\u00a0und\u00a030\u00a0%\u00a0bei\u00a0den\u00a0\u00e4l teren\u00a0Menschen,\u00a0\nbei\u00a0denen\u00a0die\u00a0Inzidenz rate\u00a0wieder\u00a0abnimmt.\u00a0\u00a0\nAufgrund\u00a0der\u00a0hohen\u00a0Inzidenzrate\u00a0und\u00a0dem\u00a0akuten\u00a0Ausbruchsgescheh en\u00a0geh\u00f6rte\u00a0\nDeutschland\u00a0im\u00a0Jahre\u00a02017\u00a0zu\u00a0den\u00a019\u00a0%\u00a0der\u00a0L\u00e4nder\u00a0in\u00a0Europa,\u00a0in\u00a0 denen\u00a0keine\u00a0\nElimination,\u00a0also\u00a0keine\u00a0Unterbrechung\u00a0der\u00a0endemischen\u00a0Transmiss ion\u00a0der\u00a0Masern\u00a0\n\u00fcber\u00a0zw\u00f6lf\u00a0Monate,\u00a0nachgewiesen \u00a0wurde\u00a0(vgl.\u00a0Abbildung\u00a06.12).\u00a0Di eses\u00a0Ergebnis\u00a0\nzeigt\u00a0eine\u00a0Zunahme\u00a0der\u00a0endemisc hen\u00a0Masernf\u00e4lle,\u00a0denn\u00a0ein\u00a0Jahr\u00a0z uvor\u00a0wurde\u00a0die\u00a0\nentsprechende\u00a0Unterbrechung\u00a0der\u00a0\u00dcbertragung\u00a0verifiziert\u00a0(WHO,\u00a02 018,\u00a04).\u00a0Die\u00a0\nrestlichen\u00a0vier\u00a0F\u00fcnftel\u00a0der\u00a0euro p\u00e4ischen\u00a0WHO\u2010L\u00e4nder\u00a0hatten\u00a0Mase rn\u00a0eliminiert.\u00a0\n\u00a0 \u00a0256\u00a0Abbildung\u00a06.12:\u00a0Anteil\u00a0der\u00a0L\u00e4nder\u00a0der\u00a0europ\u00e4ischen\u00a0WHO\u00a0Region\u00a0m it\u00a0Unter\u2010\nbrechung\u00a0der\u00a0endemischen\u00a0Transmission\u00a0von\u00a0Masern\u00a0im\u00a0Jahre\u00a02017\u00a0\n\u00a0\nQuelle:\u00a0Eigene\u00a0Darstellung\u00a0nach\u00a0WHO,\u00a02018,\u00a04 \u00a0\nAufgrund\u00a0der\u00a0\u201eschwankenden\u201c\u00a0Entwicklung\u00a0der\u00a0H\u00e4ufigkeit\u00a0von\u00a0Mase rninfektionen\u00a0\nwurde\u00a0 vom\u00a0 Bundesministerium\u00a0 f\u00fcr\u00a0 Gesundheit\u00a0 im\u00a0 Jahre\u00a0 2015\u00a0 ein\u00a0 \u201eN ationaler\u00a0\nAktionsplan\u00a02015\u00a0\u2013\u00a02020\u201c\u00a0zur\u00a0Elimination\u00a0von\u00a0Masern\u00a0und\u00a0R\u00f6teln\u00a0 verabschiedet,\u00a0\nder\u00a0folgende\u00a0Ziele\u00a0vorsieht\u00a0(BMG ,\u00a02015;\u00a0folgende\u00a0Daten\u00a0aus\u00a0RKI, \u00a02018b):\u00a0\n\uf0b7 Eine\u00a0positive\u00a0Akzeptanz\u00a0der\u00a0MMR\u2010 Impfung\u00a0soll\u00a0verst\u00e4rkt\u00a0werden\u00a0u nd\u00a0ei\u2010\nne\u00a0Impfquote\u00a0von\u00a095\u00a0%\u00a0bei\u00a0Kindern\u00a0und\u00a0Jugendlichen\u00a0sowie\u00a0von\u00a080 \u00a0%\u00a0\nbei\u00a0Erwachsenen,\u00a0die\u00a0nach\u00a01970\u00a0ge boren\u00a0sind,\u00a0soll\u00a0erreicht\u00a0werd en.\u00a0\n\uf0b7 Bei\u00a0der\u00a0Impfung\u00a0der\u00a0maximal\u00a015\u00a0Mo nate\u00a0alten\u00a0Kinder\u00a0soll\u00a0eine\u00a0Qu ote\u00a0\nvon\u00a095\u00a0%\u00a0bei\u00a0der\u00a0Erstimpfung\u00a0mit\u00a0der\u00a0MMR\u2010Impfung\u00a0erreicht\u00a0werde n.\u00a0\n\u00c4rztliche\u00a0 Abrechnungsdaten\u00a0 zeigen\u00a0 bundesweit\u00a0 bei\u00a0 15\u00a0 Monate\u00a0 alte n\u00a0\nKindern,\u00a0die\u00a02014\u00a0geboren\u00a0waren,\u00a0eine\u00a0Quote\u00a0von\u00a0etwa\u00a090\u00a0%\u00a0(bei\u00a0 den\u00a0\n2013\u00a0geborenen\u00a0von\u00a087\u00a0%).\u00a0In\u00a0den\u00a0westlichen\u00a0Bundesl\u00e4ndern\u00a0lag\u00a0d ie\u00a0\nQuote\u00a0bei\u00a089,9\u00a0%,\u00a0in\u00a0den\u00a0\u00f6stlichen\u00a0bei\u00a087,5\u00a0%.\u00a0Die\u00a0Werte\u00a0in\u00a0unt erschied\u2010\nlichen\u00a0Landkreisen\u00a0lagen\u00a0zwischen\u00a072,4\u00a0und\u00a097,5\u00a0%.\u00a0\nBei\u00a0der\u00a0Schuleingangsuntersuchung\u00a0im\u00a0Jahre\u00a02016\u00a0lag\u00a0die\u00a0Impfquo te\u00a0gegen\u00a0MMR\u00a0\nbei\u00a092,9\u00a0%\u00a0(2015:\u00a092,8\u00a0%),\u00a0la ndesweit\u00a0zwischen\u00a090\u00a0und\u00a096\u00a0%.\u00a0\nNimmt\u00a0man\u00a0alle\u00a0Daten,\u00a0auch\u00a0die\u00a0f\u00fcr\u00a0die\u00a0Erwachsenen\u00a0zusammen,\u00a0wu rde\u00a0eine\u00a0\nKrankheitsquote\u00a0von\u00a0<\u00a01\u00a0pro\u00a0Million\u00a0Einwohner\u00a0bisher\u00a0nicht\u00a0erre icht.\u00a0Ein\u00a0ausrei\u2010\nchender\u00a0Bev\u00f6lkerungsschutz\u00a0gegen\u00a0eine\u00a0Verbreitung\u00a0von\u00a0Masernvir en\u00a0ist\u00a0demzu\u2010\n257\u00a0folge\u00a0nicht\u00a0gegeben.\u00a0Dies\u00a0ist\u00a0umso\u00a0problematischer,\u00a0weil\u00a0Masern infizierte\u00a0bereits\u00a0\nvier\u00a0Tage\u00a0vor\u00a0dem\u00a0und\u00a0auch\u00a0noch\u00a0vier\u00a0Tage\u00a0nach\u00a0dem\u00a0\u00e4u\u00dferlich\u00a0er kennbaren\u00a0Exan\u2010\nthembild\u00a0andere\u00a0Menschen\u00a0anstecken\u00a0k\u00f6nnen.\u00a0\n6.6\u00a0\u00a0\u00a0Impfskepsis\u00a0bei\u00a0Masern:\u00a0Emotionen\u00a0vs.\u00a0Evidenz\u00a0\nWarum\u00a0hinkt\u00a0Deutschland\u00a0bei\u00a0der\u00a0Prim\u00e4rpr\u00e4vention\u00a0der\u00a0Maserninfe ktion\u00a0schon\u00a0\nseit\u00a0Jahren\u00a0hinterher?\u00a0Verantwortlich\u00a0scheint\u00a0u.a.\u00a0die\u00a0steigend e\u00a0Impfskepsis\u00a0zu\u00a0\nsein,\u00a0die\u00a0von\u00a0einer\u00a0relativ\u00a0klei nen\u00a0Anzahl\u00a0von\u00a0Impfgegnern\u00a0mit\u00a0 relativ\u00a0gro\u00dfem\u00a0\nErfolg\u00a0verbreitet\u00a0wird.\u00a0Diese\u00a0h\u00e4 ufig\u00a0emotional\u00a0formulierten\u00a0Bot schaften,\u00a0bezogen\u00a0\nauf\u00a0 vermutete\u00a0 oder\u00a0 sehr\u00a0 selten\u00a0 a uftretende\u00a0 Impfsch\u00e4den,\u00a0 wie\u00a0 z.B .\u00a0 allergische\u00a0\nReaktionen,\u00a0l\u00e4nger\u00a0andauernde\u00a0Gel enksch\u00e4den\u00a0(BZgA,\u00a02019),\u00a0werde n\u00a0rasch\u00a0und\u00a0\nbreit\u00a0\u00fcber\u00a0die\u00a0sozialen\u00a0Medien\u00a0verbreitet.\u00a0Sie\u00a0k\u00f6nnen\u00a0eine\u00a0gro\u00df e\u00a0Wirkung\u00a0haben,\u00a0\nauch\u00a0wenn\u00a0sie\u00a0auf\u00a0falschen\u00a0Informationen\u00a0beruhen,\u00a0wie\u00a0z.B.\u00a0dem\u00a0 angeblichen\u00a0\nZusammenhang\u00a0von\u00a0Autismus\u00a0und\u00a0einer\u00a0MMR\u2010Impfung.\u00a0Dem\u00a0Autor\u00a0Andr ew\u00a0Wa\u2010\nkefield,\u00a0 der\u00a0 einen\u00a0 solchen\u00a0 Zusammenhang\u00a0 1998\u00a0 in\u00a0 der\u00a0 angesehenen \u00a0Z e i t s c h r i f t \u00a0\n\u201eLancet\u201c\u00a0beschrieben\u00a0hatte,\u00a0wurde\u00a0allerdings\u00a0nach\u00a0der\u00a0Publikati on\u00a0wegen\u00a0unethi\u2010\nscher\u00a0Untersuchungsmethoden\u00a0und\u00a0nicht\u00a0offen\u00a0gelegter\u00a0finanziell er\u00a0Abh\u00e4ngigkeit\u00a0die\u00a0\nErlaubnis\u00a0zur\u00a0Aus\u00fcbung\u00a0des\u00a0Arztberufes\u00a0entzogen,\u00a0die\u00a0\u201eLancet\u201c\u00a0z og\u00a0die\u00a0Publikation\u00a0\naus\u00a0den\u00a0gleichen\u00a0Gr\u00fcnden\u00a0zur\u00fcck\u00a0(Dominus,\u00a02011).\u00a0Eine\u00a0\u00e4hnliche\u00a0 Studie\u00a0von\u00a0Brian\u00a0\nHooker\u00a0aus\u00a0dem\u00a0Jahre\u00a02014\u00a0wurde\u00a0ebenfalls\u00a0zur\u00fcckgezogen,\u00a0u.a.\u00a0w egen\u00a0unkorrekter\u00a0\nNutzung\u00a0 und\u00a0 Interpretation\u00a0 der\u00a0 erhobenen\u00a0 Daten\u00a0 (Murch\u00a0 et\u00a0 al.,\u00a0 2 004;\u00a0 s.\u00a0 auch\u00a0\nBfArM/PEI,\u00a02017).\u00a0\nEine\u00a0so\u00a0entstandene\u00a0Skepsis\u00a0gegen\u00fcber\u00a0der\u00a0Impfung\u00a0auf\u00a0Seiten\u00a0de r\u00a0Eltern,\u00a0die\u00a0\u00fcber\u00a0\neine\u00a0Impfung\u00a0f\u00fcr\u00a0ihre\u00a0Kinder\u00a0entscheiden,\u00a0oder\u00a0von\u00a0Erwachsenen, \u00a0die\u00a0f\u00fcr\u00a0sich\u00a0selbst\u00a0\neine\u00a0Entscheidung\u00a0zu\u00a0treffen\u00a0haben,\u00a0schw\u00e4cht\u00a0aber\u00a0letztlich\u00a0die \u00a0Akzeptanz\u00a0von\u00a0Imp\u2010\nfungen\u00a0allgemein\u00a0und\u00a0speziell\u00a0auch\u00a0gegen\u00a0die\u00a0Masernimpfung,\u00a0obw ohl\u00a0deren\u00a0Nutzen\u00a0\nals\u00a0prim\u00e4rpr\u00e4ventive\u00a0Ma\u00dfnahme\u00a0wiederholt\u00a0nachgewiesen\u00a0wurde.\u00a0Al s\u00a0Konsequenz\u00a0\nkommt\u00a0es\u00a0dann\u00a0zu\u00a0einem\u00a0ungen\u00fcgend\u00a0wirksamen\u00a0\u201egesellschaftlichen \u00a0Schutzschirm\u201c\u00a0\ngegen\u00a0Infektionserkrankungen\u00a0wie\u00a0Masern,\u00a0die\u00a0durch\u00a0Impfungen\u00a0gr \u00f6\u00dftenteils\u00a0ver\u2010\nmieden\u00a0werden\u00a0k\u00f6nnten.\u00a0Und\u00a0die\u00a0Folgen\u00a0k\u00f6nnen\u00a0dramatisch,\u00a0oft\u00a0so gar\u00a0lebensbe\u2010\ndrohlich\u00a0oder\u00a0t\u00f6dlich\u00a0sein.\u00a0Gef\u00fcrchtet\u00a0ist\u00a0vor\u00a0allem\u00a0die\u00a0subaku te\u00a0sklerosierende\u00a0Pan\u2010\nenzephalitis\u00a0(SSPE)\u00a0als\u00a0die\u00a0am\u00a0meisten\u00a0gef\u00fcrchtete\u00a0Komplikation \u00a0einer\u00a0Maserninfek\u2010\ntion\u00a0(mit\u00a0Symptomen\u00a0wie\u00a0Ver\u00e4nderungen\u00a0der\u00a0Pers\u00f6nlichkeit,\u00a0Kramp fanf\u00e4llen,\u00a0Koma\u00a0\nund\u00a0Tod\u00a0nach\u00a0etwa\u00a0ein\u00a0bis\u00a0drei\u00a0Jahren).\u00a0An\u00a0der\u00a0Entstehung\u00a0diese r\u00a0Folgen\u00a0gibt\u00a0es\u00a0\noffenbar\u00a0keinen\u00a0Zweifel,\u00a0da\u00a0bisher\u00a0in\u00a0jedem\u00a0Fall\u00a0Bestandteile\u00a0v on\u00a0Masernviren\u00a0(vom\u00a0\nWildtyp,\u00a0aber\u00a0niemals\u00a0vom\u00a0Impfvi rus)\u00a0nachgewiesen\u00a0werden\u00a0konnte n.\u00a0Neben\u00a0der\u00a0\nSSPE\u00a0sind\u00a0auch\u00a0akute\u00a0Gehirnentz\u00fcndungen\u00a0denkbar,\u00a0die\u00a0zu\u00a0Behinde rungen\u00a0f\u00fchren\u00a0\nk\u00f6nnen\u00a0(z.B.\u00a0Taubheit).\u00a0\u00c4hnliche\u00a0unerw\u00fcnschte\u00a0Folgen\u00a0sind\u00a0zwar\u00a0 auch\u00a0nach\u00a0einer\u00a0\nImpfung\u00a0denkbar\u00a0\u2013\u00a0allerdings\u00a0in\u00a0 ganz\u00a0anderer\u00a0H\u00e4ufigkeit:\u00a0W\u00e4hren d\u00a0bei\u00a0ungeimpften\u00a0\nKindern\u00a0bei\u00a0einer\u00a0Maserninfektion\u00a0(z.B.\u00a0auf\u00a0sog.\u00a0Masernparties, \u00a0auf\u00a0denen\u00a0gesunde\u00a0258\u00a0Kinder\u00a0mit\u00a0infizierten\u00a0Masernkindern\u00a0in\u00a0Kontakt\u00a0gebracht\u00a0werden ,\u00a0damit\u00a0sie\u00a0auf\u00a0\nnat\u00fcrlichem\u00a0Wege\u00a0Abwehrstoffe\u00a0entwickeln)\u00a0das\u00a0Risiko\u00a0der\u00a0Folgek rankheiten\u00a0bei\u00a0\n1:1.000\u00a0liegt,\u00a0betr\u00e4gt\u00a0das\u00a0Risiko\u00a0nach\u00a0einer\u00a0Impfung\u00a01:1.000.00 0.\u00a0\nAbbildung\u00a06.13:\u00a0Einstellungen\u00a0zur\u00a0Frage\u00a0\u201eIst\u00a0Impfen\u00a0sicher?\u201c\u00a0\n\u00a0\nQuelle:\u00a0Eigene\u00a0Darstellung\u00a0nach\u00a0Wellcome\u00a0Trust,\u00a02019\u00a0\nEine\u00a0Umfrage\u00a0zeigt,\u00a0dass\u00a0die\u00a0Impfskepsis\u00a0in\u00a0Deutschland\u00a0gegen\u00fcb er\u00a0den\u00a0\u00fcbrigen\u00a0\neurop\u00e4ischen\u00a0L\u00e4ndern\u00a0noch\u00a0moderat\u00a0ausf\u00e4llt.\u00a0So\u00a0glauben\u00a0immerhin \u00a067\u00a0%\u00a0der\u00a0Befrag\u2010\nten,\u00a0dass\u00a0Impfen\u00a0sicher\u00a0sei,\u00a013\u00a0%\u00a0widersprechen\u00a0der\u00a0Aussage\u00a0\u201eIm pfen\u00a0ist\u00a0sicher\u201c\u00a0\nausdr\u00fccklich.\u00a0Im\u00a0Vergleich\u00a0dazu\u00a0stufen\u00a0nur\u00a059\u00a0%\u00a0der\u00a0befragten\u00a0W esteurop\u00e4er\u00a0Impfen\u00a0\nals\u00a0ungef\u00e4hrlich\u00a0ein\u00a0und\u00a0immerhin\u00a022\u00a0%\u00a0widersprechen\u00a0dieser\u00a0Aus sage\u00a0(s.\u00a0Abbildung\u00a0\n6.13).\u00a0Besonders\u00a0bedenklich\u00a0ist\u00a0die\u00a0Situation\u00a0in\u00a0Osteuropa.\u00a0Dor t\u00a0haben\u00a0nur\u00a040\u00a0%\u00a0der\u00a0\nBefragten\u00a0keine\u00a0Zweifel\u00a0an\u00a0der\u00a0Impfsicherheit\u00a0(Wellcome\u00a0Trust,\u00a0 2019).\u00a0\nDie\u00a0Reaktion\u00a0der\u00a0\u00c4rzte\u00a0auf\u00a0\u00c4ngste\u00a0und\u00a0Zweifel\u00a0der\u00a0Patienten\u00a0bez \u00fcglich\u00a0der\u00a0Impfung\u00a0\nist\u00a0insbesondere\u00a0bei\u00a0impfkritischen\u00a0Patienten\u00a0ein\u00a0zentraler\u00a0Fak tor\u00a0f\u00fcr\u00a0die\u00a0Impfakzep\u2010\ntanz\u00a0bei\u00a0Eltern\u00a0und\u00a0Erziehungsberechtigten,\u00a0wenn\u00a0es\u00a0um\u00a0die\u00a0Impf ung\u00a0von\u00a0Kindern\u00a0\ngeht,\u00a0oder\u00a0bei\u00a0den\u00a0Menschen,\u00a0die\u00a0f\u00fcr\u00a0sich\u00a0selber\u00a0eine\u00a0Impfentsc heidung\u00a0zu\u00a0treffen\u00a0\nhaben.\u00a0Dazu\u00a0haben\u00a0Betsch\u00a0und\u00a0Kollegen\u00a02019\u00a0die\u00a0wichtigsten\u00a0Prin zipien\u00a0f\u00fcr\u00a0ein\u00a0Pati\u2010\nentengespr\u00e4ch\u00a0zusammengestellt,\u00a0 dieses\u00a0Mal\u00a0mit\u00a0Blick\u00a0auf\u00a0die\u00a0Gr ippeimpfung:\u00a0\u00a0\n259\u00a0Einstieg:\u00a0Heute\u00a0ist\u00a0Ihre\u00a0Impfung\u00a0f\u00e4llig .\u00a0Dieser\u00a0Einstieg\u00a0f\u00fchrt\u00a0zu\u00a0einer \u00a0h\u00f6heren\u00a0Impfbereitschaft\u00a0als\u00a0\nwenn\u00a0Sie\u00a0fragen,\u00a0ob\u00a0der\u00a0Patient\u00a0h eute\u00a0eine\u00a0Impfung\u00a0m\u00f6chte\u00a0(Brew er\u00a0et\u00a0al,\u00a02017\u00a0zit .\u00a0nach\u00a0Betsch\u00a0et\u00a0\nal.,\u00a02019).\u00a0Sie\u00a0gehen\u00a0so\u00a0davon\u00a0a us,\u00a0dass\u00a0Impfen\u00a0der\u00a0Standard\u00a0is t.\u00a0Dies\u00a0gibt\u00a0den\u00a0Patienten\u00a0Sicherheit\u00a0\n\u2013\u00a0und\u00a0erlaubt\u00a0ihnen\u00a0immer\u00a0noch,\u00a0na chzufragen\u00a0oder\u00a0nein\u00a0zu\u00a0sagen .\u00a0\n\u00a0\nSchritt\u00a01:\u00a0Empathie\u00a0zeigen\u00a0und\u00a0Glaubw\u00fcrdigkeit\u00a0schaffen .\u00a0Hier\u00a0gilt\u00a0es,\u00a0gemeinsame\u00a0Werte\u00a0zu\u00a0\nbetonen\u00a0und\u00a0zu\u00a0zeigen,\u00a0dass\u00a0Sie\u00a0 zuh\u00f6ren.\u00a0Statt\u00a0zu\u00a0sagen:\u00a0\u201eIch\u00a0v erstehe,\u00a0dass\u00a0Sie\u00a0Bedenken\u00a0haben,\u00a0\ndass\u00a0die\u00a0Grippe\u2010Impfung\u00a0Grippe\u00a0a usl\u00f6sen\u00a0k\u00f6nnte\u201c\u00a0k\u00f6nnen\u00a0Sie\u00a0dara uf\u00a0aufbauen,\u00a0dass\u00a0Ihrem\u00a0Patien\u2010\nten\u00a0Gesundheit\u00a0wichtig\u00a0ist:\u00a0\u201eIch \u00a0nehme\u00a0wahr,\u00a0dass\u00a0es\u00a0Ihnen\u00a0wich tig\u00a0ist,\u00a0nicht\u00a0die\u00a0Grippe\u00a0zu\u00a0be\u2010\nkommen\u00a0und\u00a0gesund\u00a0zu\u00a0bleiben.\u201c\u00a0Werden\u00a0spezifische\u00a0Bedenken\u00a0ge\u00e4u \u00dfert,\u00a0sollte\u00a0man\u00a0um\u00a0die\u00a0\nErlaubnis\u00a0fragen,\u00a0Inform ationen\u00a0zu\u00a0teilen\u00a0\u2013\u00a0so\u00a0\u00fcberw\u00e4ltigen\u00a0Sie \u00a0den\u00a0Patienten\u00a0nicht\u00a0und\u00a0gehen\u00a0\nwertsch\u00e4tzend\u00a0mit\u00a0seinen\u00a0\u00c4ngsten \u00a0und\u00a0Zweifeln\u00a0um\u00a0(Gagneur\u00a0et\u00a0al .,\u00a02018\u00a0zit.\u00a0nach\u00a0 Betsch\u00a0et\u00a0al.,\u00a0\n2019):\u00a0\u201eIch\u00a0habe\u00a0mit\u00a0Influenza\u00a0vi el\u00a0Erfahrung.\u00a0Darf\u00a0ich\u00a0mit\u00a0Ihn en\u00a0teilen,\u00a0was\u00a0ich\u00a0daraus\u00a0gelernt\u00a0\nhabe?\u201c\u00a0\n\u00a0\nSchritt\u00a02:\u00a0Kurz\u00a0die\u00a0Bedenken\u00a0adressieren\u00a0\u2013\u00a0wenn\u00a0welche\u00a0ge\u00e4u\u00dfert \u00a0werden.\u00a0Hier\u00a0gilt\u00a0das\u00a0Prinzip\u00a0\nweniger\u00a0ist\u00a0mehr,\u00a0denn\u00a0kurze\u00a0und\u00a0 verst\u00e4ndliche\u00a0Erkl\u00e4rungen\u00a0wirk en\u00a0besser\u00a0als\u00a0lange\u00a0und\u00a0detail\u2010\nlierte\u00a0Ausf\u00fchrungen\u00a0(Lewandowsky\u00a0 et\u00a0al.,\u00a02012\u00a0zit.\u00a0nach\u00a0Betsch\u00a0 et\u00a0al.\u00a02019).\u00a0Adressieren\u00a0Sie\u00a0nur\u00a0\ndie\u00a0Bedenken,\u00a0die\u00a0aktiv\u00a0ge\u00e4u\u00dfert\u00a0 werden\u00a0und\u00a0bringen\u00a0Sie\u00a0keine\u00a0w eiteren\u00a0auf.\u00a0Streiten\u00a0Sie\u00a0nicht,\u00a0\nh\u00f6ren\u00a0Sie\u00a0zu\u00a0und\u00a0geben\u00a0Sie\u00a0kurze\u00a0Antworten.\u00a0\n\u00a0\nSchritt\u00a03:\u00a0Krankheitsrisiken\u00a0erkl\u00e4ren .\u00a0Impfpr\u00e4ventable\u00a0Erkrankungen \u00a0treten\u00a0heute\u00a0nur\u00a0noch\u00a0selten\u00a0\nauf,\u00a0daher\u00a0wissen\u00a0viele\u00a0Menschen\u00a0nicht\u00a0mehr,\u00a0wie\u00a0schwerwiegend\u00a0 sie\u00a0sein\u00a0k\u00f6nnen\u00a0(Chen,\u00a01999\u00a0zit.\u00a0\nnach\u00a0Betsch\u00a0et\u00a0al.,\u00a020 19).\u00a0Daher\u00a0m\u00fcssen\u00a0dies e\u00a0Risiken\u00a0auch\u00a0komm uniziert\u00a0werden.\u00a0Das\u00a0Ziel\u00a0ist\u00a0\nhierbei\u00a0nicht,\u00a0den\u00a0Patienten\u00a0zu \u00a0ver\u00e4ngstigen.\u00a0Es\u00a0geht\u00a0darum,\u00a0di e\u00a0Diskussion\u00a0weg\u00a0von\u00a0den\u00a0Mythen\u00a0\nzu\u00a0lenken\u00a0und\u00a0hin\u00a0zur\u00a0Diskussion\u00a0\u00fc ber\u00a0die\u00a0Krankheit,\u00a0die\u00a0man\u00a0ge meinsam\u00a0verhindern\u00a0will.\u00a0Hier\u00a0hilft\u00a0\nauch\u00a0ein\u00a0Hinweis\u00a0auf\u00a0m\u00f6gliche\u00a0Fol geerkrankungen\u00a0wie\u00a0Sepsis\u00a0(Eit ze\u00a0et\u00a0al.,\u00a02018\u00a0zit.\u00a0nach\u00a0Betsch\u00a0et\u00a0\nal.,\u00a02019;\u00a0Riley\u00a0&\u00a0Wheeler,\u00a02012\u00a0zit.\u00a0nach\u00a0Betsch\u00a0et\u00a0al.,\u00a02019) \u00a0oder\u00a0ein\u00a0erh\u00f6htes\u00a0H erzinfarktrisiko\u00a0\nnach\u00a0Influenza\u00a0(Caldeira\u00a0et\u00a0al., \u00a02018\u00a0zit.\u00a0nach\u00a0Betsch\u00a0et\u00a0al.,\u00a0 2019).\u00a0\n\u00a0\nSchritt\u00a04:\u00a0Effektivit\u00e4t\u00a0von\u00a0Impfungen\u00a0als\u00a0Schutz\u00a0vor\u00a0der\u00a0Erkran kung\u00a0vermitteln .\u00a0Wenn\u00a0Sie\u00a0\u00fcber\u00a0das\u00a0\nRisiko\u00a0durch\u00a0die\u00a0Erkrankung\u00a0aufge kl\u00e4rt\u00a0haben,\u00a0ist\u00a0es\u00a0wichtig,\u00a0e ine\u00a0effektive\u00a0Gegenma\u00dfnahme\u00a0zu\u00a0\npr\u00e4sentieren\u00a0\u2013\u00a0dies\u00a0st\u00e4rkt\u00a0die\u00a0H andlungsbereitschaft.\u00a0Daher\u00a0sol lte\u00a0nun\u00a0betont\u00a0werden,\u00a0dass\u00a0die\u00a0\nImpfung\u00a0die\u00a0Erkrankung\u00a0sehr\u00a0effe ktiv\u00a0und\u00a0sehr\u00a0sicher\u00a0verhindert .\u00a0An\u00a0dieser\u00a0Stelle\u00a0ist\u00a0es\u00a0auch\u00a0\nrelevant,\u00a0auf\u00a0den\u00a0sozialen\u00a0Nutze n\u00a0der\u00a0Impfung\u00a0hinzuweisen:\u00a0Denn \u00a0wenn\u00a0Personen\u00a0erfahren,\u00a0dass\u00a0\nsie\u00a0mit\u00a0ihrer\u00a0Impfung\u00a0auch\u00a0ande re\u00a0mitsch\u00fctzen\u00a0k\u00f6nnen,\u00a0die\u00a0dies\u00a0 selbst\u00a0nicht\u00a0k\u00f6nnen,\u00a0macht\u00a0sie\u00a0\ndies\u00a0impfbereiter\u00a0(Betsch\u00a0et\u00a0al. ,\u00a02017\u00a0zit.\u00a0nach \u00a0Betsch\u00a0et\u00a0al., \u00a02019).\u00a0\u00a0\n\u00a0\nSchritt\u00a05:\u00a0Eine\u00a0starke\u00a0pers\u00f6nliche\u00a0Empfehlung .\u00a0\u00c4rzte\u00a0sind\u00a0die\u00a0Vertrauen sperson\u00a0Nummer\u00a01\u00a0f\u00fcr\u00a0ihre\u00a0\nPatienten,\u00a0deren\u00a0Empfehlungen\u00a0ein en\u00a0gro\u00dfen\u00a0Effekt\u00a0haben\u00a0k\u00f6nnen. \u00a0Beschlie\u00dfen\u00a0Sie\u00a0daher\u00a0den\u00a0\nDialog\u00a0mit\u00a0einer\u00a0starken,\u00a0 pers\u00f6nlichen\u00a0Empfehlung.\u00a0\n\u00a0\nAusblick:\u00a0Den\u00a0Dialog\u00a0offen\u00a0halten .\u00a0Manche\u00a0Patienten\u00a0entscheiden \u00a0sich\u00a0m\u00f6glicherweise\u00a0nicht\u00a0\nunmittelbar\u00a0f\u00fcr\u00a0eine\u00a0Im pfung.\u00a0Best\u00e4rken\u00a0Sie\u00a0sie\u00a0darin,\u00a0sich\u00a0wei terhin\u00a0mit\u00a0dem\u00a0Impfen\u00a0auseinan\u2010\nderzusetzen\u00a0und\u00a0laden\u00a0Sie\u00a0zu\u00a0einem \u00a0erneuten\u00a0Gespr\u00e4ch\u00a0ein.\u00a0Geben \u00a0Sie\u00a0Hinweise,\u00a0wo\u00a0gute\u00a0Infor\u2010\nmationen\u00a0angeboten\u00a0werden.\u00a0\n\u00a0260\u00a06.7\u00a0\u00a0\u00a0Ist\u00a0in\u00a0Deutschland\u00a0eine\u00a0Impfpflicht\u00a0gegen\u00a0Masern\u00a0sinnvoll ?\u00a0\nUm\u00a0die\u00a0Einf\u00fchrung\u00a0einer\u00a0Impfpflicht\u00a0in\u00a0Deutschland\u00a0\u2013\u00a0auch\u00a0unter \u00a0dem\u00a0Eindruck\u00a0der\u00a0\nEntwicklungen\u00a0in\u00a0europ\u00e4ischen\u00a0L\u00e4 ndern\u00a0mit\u00a0und\u00a0ohne\u00a0verpflichten de\u00a0Masernimp\u2010\nfung\u00a0\u2013\u00a0besser\u00a0einordnen\u00a0zu\u00a0k\u00f6nnen,\u00a0sollen\u00a0als\u00a0Resum\u00e9\u00a0einige\u00a0Arg umente\u00a0gegen\u2010\n\u00fcbergestellt\u00a0werden:\u00a0\n\uf0b7 Der\u00a0Aspekt\u00a0des\u00a0individuellen\u00a0Schutzes\u00a0\nAbgesehen\u00a0von\u00a0dem\u00a0grunds\u00e4tzliche n\u00a0individuellen\u00a0Schutz\u00a0vor\u00a0den\u00a0 gravierenden\u00a0\nFolgen\u00a0einer\u00a0Maserninfektion\u00a0spr icht\u00a0das\u00a0\u00f6konomische\u00a0Argument\u00a0f \u00fcr\u00a0eine\u00a0Impf\u2010\npflicht,\u00a0weil\u00a0die\u00a0Gesellschaft,\u00a0die\u00a0Versichertengemeinschaft,\u00a0i m\u00a0Falle\u00a0des\u00a0Auftre\u2010\ntens\u00a0einer\u00a0solchen\u00a0Erkrankung\u00a0nicht\u00a0f\u00fcr\u00a0deren\u00a0Behandlung\u00a0finanz iell\u00a0zust\u00e4ndig\u00a0sein\u00a0\nsollte,\u00a0da\u00a0das\u00a0individuelle\u00a0Auftreten\u00a0durch\u00a0eine\u00a0Impfung\u00a0zu\u00a0ver hindern\u00a0gewesen\u00a0\nw\u00e4re.\u00a0Ein\u00a0solches\u00a0\u201eVerschuldensprinzip\u201c,\u00a0das\u00a0auch\u00a0in\u00a0anderen\u00a0Zu sammenh\u00e4ngen\u00a0\ndiskutiert\u00a0wird,\u00a0z.B.\u00a0f\u00fcr\u00a0Unf\u00e4lle\u00a0bei\u00a0Risikosportarten,\u00a0h\u00e4tte\u00a0a ber\u00a0weitreichende\u00a0\nKonsequenzen.\u00a0Neben\u00a0definitorisc hen\u00a0und\u00a0auch\u00a0sozialrechtlich\u00a0re levanten\u00a0Schwie\u2010\nrigkeiten\u00a0der\u00a0Abgrenzung\u00a0w\u00fcrde\u00a0ein\u00a0grunds\u00e4tzlicher\u00a0Konsens\u00a0in\u00a0d er\u00a0GKV\u00a0infrage\u00a0\ngestellt,\u00a0nach\u00a0dem\u00a0bei\u00a0Krankheit \u00a0unabh\u00e4ngig\u00a0von\u00a0der\u00a0Verschulden sfrage\u00a0die\u00a0Soli\u2010\ndargemeinschaft\u00a0helfend\u00a0verantwortlich\u00a0ist.\u00a0Ob\u00a0in\u00a0diesem\u00a0Zusamm enhang\u00a0der\u00a0\u00a7\u00a052\u00a0\nSGB\u00a0V\u00a0in\u00a0Ansatz\u00a0gebracht\u00a0werden\u00a0kann,\u00a0der\u00a0im\u00a0Satz\u00a01\u00a0lautet:\u00a0\u201eHa ben\u00a0sich\u00a0Versi\u2010\ncherte\u00a0eine\u00a0Krankheit\u00a0vors\u00e4tzlich\u00a0oder\u00a0bei\u00a0einem\u00a0von\u00a0ihnen\u00a0bega ngenen\u00a0Verbre\u2010\nchen\u00a0oder\u00a0vors\u00e4tzlichen\u00a0Vergehen \u00a0zugezogen,\u00a0kann\u00a0die\u00a0Krankenkas se\u00a0sie\u00a0an\u00a0den\u00a0\nKosten\u00a0der\u00a0Leistungen\u00a0in\u00a0angemessener\u00a0H\u00f6he\u00a0beteiligen\u00a0und\u00a0das\u00a0K rankengeld\u00a0ganz\u00a0\noder\u00a0teilweise\u00a0f\u00fcr\u00a0die\u00a0Dauer\u00a0dieser\u00a0Krankheit\u00a0versagen\u00a0und\u00a0zur\u00fc ckfordern.\u201c\u00a0ist\u00a0bei\u00a0\neiner\u00a0unterlassenen\u00a0Impfung\u00a0eher\u00a0 fraglich,\u00a0weil\u00a0in\u00a0diesem\u00a0Zusam menhang\u00a0auch\u00a0\ndas\u00a0im\u00a0Grundgesetzt\u00a0verankerte\u00a0Recht\u00a0auf\u00a0k\u00f6rperliche\u00a0Unversehrh eit\u00a0ber\u00fccksich\u2010\ntigt\u00a0werden\u00a0muss.\u00a0Darauf\u00a0hat\u00a0auch\u00a0der\u00a0wissenschaftliche\u00a0Dienst\u00a0 des\u00a0Bundestages\u00a0\nschon\u00a02016\u00a0hingewiesen.\u00a0Eine\u00a0Impfung\u00a0sei\u00a0ein\u00a0Eingriff\u00a0in\u00a0das\u00a0\u201eR echt\u00a0auf\u00a0Leben\u00a0und\u00a0\nk\u00f6rperliche\u00a0Unversehrtheit\u201c\u00a0und\u00a0sei\u00a0verfassungsrechtlich\u00a0nur\u00a0da nn\u00a0verh\u00e4ltnism\u00e4\u2010\n\u00dfig,\u00a0wenn\u00a0damit\u00a0ein\u00a0legitimes\u00a0Ziel\u00a0(also\u00a0der\u00a0Schutz\u00a0der\u00a0Bev\u00f6lke rung\u00a0vor\u00a0hochanste\u2010\nckenden\u00a0Infektionskrankheiten)\u00a0verfolgt\u00a0werde\u00a0und\u00a0der\u00a0Eingriff\u00a0 \u201egeeignet,\u00a0erfor\u2010\nderlich\u00a0und\u00a0angemessen\u00a0ist\u201c.\u00a0F\u00fcr\u00a0 eine\u00a0generelle\u00a0Impfpflicht\u00a0m\u00fcs ste\u00a0also\u00a0plausibel\u00a0\nsein,\u00a0dass\u00a0der\u00a0Schutz\u00a0der\u00a0Allgem einheit\u00a0vor\u00a0einer\u00a0ansteckenden\u00a0 Krankheit,\u00a0die\u00a0\nschon\u00a0seit\u00a02005\u00a0ausgerottet\u00a0sein\u00a0sollte,\u00a0einen\u00a0Eingriff\u00a0in\u00a0das\u00a0 Recht\u00a0auf\u00a0Unversehrt\u2010\nheit\u00a0rechtfertigt.\u00a0Daher\u00a0ist\u00a0ein\u00a0theoretisch\u00a0unter\u00a0bestimmten\u00a0B edingungen\u00a0denkba\u2010\nrer\u00a0R\u00fcckgriff\u00a0auf\u00a0den\u00a0\u00a7\u00a052\u00a0SGB\u00a0V\u00a0im\u00a0Sinne\u00a0einer\u00a0vors\u00e4tzlichen\u00a0E igenverschuldung\u00a0\nbei\u00a0der\u00a0Entwicklung\u00a0einer\u00a0Maserninfektion\u00a0wegen\u00a0einer\u00a0nicht\u00a0vor angegangenen\u00a0\nMasernimpfung\u00a0derzeit\u00a0wenig\u00a0realistisch.\u00a0\u00a0\n\u00a0 \u00a0261\u00a0\uf0b7 Der\u00a0Aspekt\u00a0des\u00a0individuellen\u00a0Sc hutzes\u00a0und\u00a0des\u00a0Schutzes\u00a0der\u00a0Bev\u00f6 lke\u2010\nrung\u00a0\nMan\u00a0kann\u00a0auch\u00a0hier\u00a0wieder,\u00a0neben\u00a0dem\u00a0Aspekt\u00a0der\u00a0verf\u00fcgbaren\u00a0ind ividuellen\u00a0\nPrim\u00e4rpr\u00e4vention\u00a0zur\u00a0Vermeidung\u00a0d er\u00a0Maserninfektion,\u00a0\u00f6konomisch \u00a0argumentie\u2010\nren\u00a0und\u00a0darauf\u00a0hinweisen,\u00a0dass\u00a0Krankheit\u00a0Kosten\u00a0verursacht\u00a0und\u00a0 diese\u00a0Kosten\u00a0\ndurch\u00a0Nicht\u2010Geimpfte\u00a0nicht\u00a0von\u00a0der\u00a0Gesellschaft,\u00a0der\u00a0Versichert engemeinschaft,\u00a0\ngetragen\u00a0werden\u00a0sollten.\u00a0Zudem\u00a0k\u00f6nnte\u00a0das\u00a0Nicht\u2010Impfen\u00a0eines\u00a0ei genen\u00a0Kindes\u00a0als\u00a0\nf\u00fcr\u00a0dessen\u00a0Wohl\u00a0unverantwortlic h\u00a0und\u00a0nicht\u00a0tolerabel\u00a0angesehen\u00a0 werden.\u00a0Auch\u00a0\ndie\u00a0Konsequenzen\u00a0dieser\u00a0Haltung\u00a0w\u00e4ren\u00a0sehr\u00a0weitreichend.\u00a0Wenn\u00a0d ie\u00a0Erkrankung\u00a0\nauch\u00a0ohne\u00a0Impfung\u00a0selten\u00a0bzw.\u00a0ihr\u00a0gesundheitliches\u00a0Schadenspote nzial\u00a0gering\u00a0ist,\u00a0\ndann\u00a0kann\u00a0es\u00a0sein,\u00a0dass\u00a0der\u00a0indi viduelle\u00a0Schutz\u00a0nicht\u00a0mehr\u00a0in\u00a0e inem\u00a0angemessenen\u00a0\nVerh\u00e4ltnis\u00a0zu\u00a0den\u00a0Nebenwirkungen\u00a0und\u00a0damit\u00a0auch\u00a0den\u00a0Kosten\u00a0eine r\u00a0Impfung\u00a0\nsteht.\u00a0\u00a0\nEine\u00a0 Impfpflicht\u00a0 ist\u00a0 dann\u00a0 weder\u00a0 medizinisch\u00a0 noch\u00a0 \u00f6konomisch\u00a0 aus reichend\u00a0 zu\u00a0\nbegr\u00fcnden.\u00a0Anders\u00a0k\u00f6nnte\u00a0es\u00a0bei\u00a0einigen\u00a0Infektionen\u00a0(z.B.\u00a0Hepat itis\u00a0B)\u00a0f\u00fcr\u00a0be\u2010\nstimmte\u00a0Berufsgruppen\u00a0\u2013\u00a0wie\u00a0z.B.\u00a0Chirurgen\u00a0\u2013\u00a0oder\u00a0andere\u00a0Risiko gruppen\u00a0ausse\u2010\nhen,\u00a0bei\u00a0denen\u00a0das\u00a0Risiko,\u00a0dass\u00a0sie\u00a0infiziert\u00a0sind,\u00a0erh\u00f6ht\u00a0ist\u00a0 und\u00a0die\u00a0daher\u00a0h\u00e4ufiger\u00a0\nInfektionen\u00a0weitergeben\u00a0k\u00f6nnen.\u00a0Dieser\u00a0Aspekt\u00a0trifft\u00a0auch\u00a0f\u00fcr\u00a0d ie\u00a0Masernimpfung\u00a0\nzu,\u00a0da\u00a0das\u00a0Schadenspotenzial\u00a0bei \u00a0einer\u00a0Infektion\u00a0von\u00a0nicht\u2010geim pften\u00a0Kindern\u00a0und\u00a0\nErwachsenen\u00a0erheblich,\u00a0aber\u00a0die\u00a0Nebenwirkungsh\u00e4ufigkeit\u00a0bei\u00a0der \u00a0Impfung\u00a0als\u00a0\n\u201esehr\u00a0selten\u201c\u00a0einzustufen\u00a0ist.\u00a0\n\uf0b7 Der\u00a0Aspekt\u00a0des\u00a0Schutzes\u00a0der\u00a0Bev\u00f6 lkerung\u00a0oder\u00a0eines\u00a0definierten\u00a0 Be\u2010\nv\u00f6lkerungsanteils\u00a0\nUm\u00a0die\u00a0Eradikation\u00a0eines\u00a0Erregers\u00a0zu\u00a0erreichen,\u00a0muss\u00a0die\u00a0Bev\u00f6lk erung\u00a0zu\u00a085\u00a0%\u00a0bis\u00a0\n95\u00a0%\u00a0geimpft\u00a0sein,\u00a0bei\u00a0Masern\u00a0zu\u00a0mindestens\u00a095\u00a0%.\u00a0Der\u00a0individue lle\u00a0Nutzen\u00a0und\u00a0\nder\u00a0bev\u00f6lkerungsmedizinische\u00a0Nut zen\u00a0k\u00f6nnen\u00a0hier\u00a0konkurrierende\u00a0 Ziele\u00a0sein.\u00a0In\u00a0\nZeiten,\u00a0in\u00a0denen\u00a0Autonomie\u00a0und\u00a0Partizipation\u00a0von\u00a0Patienten\u00a0und\u00a0 B\u00fcrgern\u00a0einen\u00a0\nhohen\u00a0ethischen\u00a0Wert\u00a0darstellen,\u00a0bedarf\u00a0das\u00a0Verschweigen\u00a0dieses \u00a0Zielkonfliktes\u00a0\nschwergewichtiger\u00a0ethischer\u00a0Argu mente\u00a0(Nuffield\u00a0Council\u00a0of\u00a0Bioe thics,\u00a02007).\u00a0\nZusammen\u00a0mit\u00a0einer\u00a0Impfpflicht\u00a0f\u00fcr\u00a0Kinder\u00a0gegen\u00a0eine\u00a0Maserninfe ktion\u00a0werden\u00a0\nbei\u00a0einer\u00a0Nichtbeachtung\u00a0dieser\u00a0Verpflichtung\u00a0auch\u00a0Sanktionen\u00a0f \u00fcr\u00a0die\u00a0Eltern\u00a0oder\u00a0\nErziehungsberechtigten\u00a0diskutiert.\u00a0Gedacht\u00a0ist\u00a0an\u00a0Geldstrafen\u00a0( im\u00a0Gespr\u00e4ch\u00a0sind\u00a0\n2.500\u00a0 Euro),\u00a0 der\u00a0 Ausschluss\u00a0 aus\u00a0 Kitas,\u00a0 Kinderg\u00e4rten\u00a0 und\u00a0 Schulen .\u00a0 Unabh\u00e4ngig\u00a0\ndavon,\u00a0ob\u00a0ein\u00a0Ausschluss\u00a0von\u00a0der\u00a0Schulpflicht\u00a0wegen\u00a0der\u00a0\u00fcbergeo rdnet\u00a0erschei\u2010\nnenden\u00a0 Impfpflicht\u00a0 rechtlich\u00a0 m\u00f6glich\u00a0 ist,\u00a0 wird\u00a0 derzeit\u00a0 aus\u00a0 poli tischen\u00a0 Kreisen\u00a0\ndurchaus\u00a0Zustimmung\u00a0mancher\u00a0L\u00e4ndervertreter\u00a0(z.B.\u00a0aus\u00a0Brandenbu rg\u00a0oder\u00a0aus\u00a0\nNordrhein\u2010Westfalen)\u00a0oder\u00a0auch\u00a0von\u00a0Mitgliedern\u00a0der\u00a0Bundesregier ung\u00a0(so\u00a0von\u00a0262\u00a0Gesundheitsminister\u00a0Jens\u00a0Spahn,\u00a0d er\u00a0diesen\u00a0Vorschlag\u00a0eingebrach t\u00a0hat,\u00a0oder\u00a0von\u00a0\nBundesfamilienministerin\u00a0Franziska\u00a0Giffey)\u00a0signalisiert.\u00a0Andere \u00a0Stimmen\u00a0sind\u00a0zu\u2010\nr\u00fcckhaltender\u00a0oder\u00a0schlagen\u00a0ande re\u00a0Verpflichtungen\u00a0vor:\u00a0So\u00a0ford ert\u00a0die\u00a0CDU\u00a0in\u00a0\nHamburg,\u00a0dass\u00a0sich\u00a0alle\u00a0st\u00e4dtischen\u00a0Mitarbeiter\u00a0impfen\u00a0lassen\u00a0m \u00fcssen,\u00a0die\u00a0mit\u00a0\nKindern\u00a0arbeiten.\u00a0Dieser\u00a0Vorschlag\u00a0ber\u00fccksichtigt\u00a0auch\u00a0das\u00a0Votu m\u00a0des\u00a0Deutschen\u00a0\nEthikrates,\u00a0der\u00a0eine\u00a0unzul\u00e4ssige\u00a0Verengung\u00a0der\u00a0aktuellen\u00a0Debatt e\u00a0auf\u00a0die\u00a0Kinder,\u00a0\neine\u00a0unzureichende\u00a0Ber\u00fccksichtigung\u00a0der\u00a0gesamten\u00a0Datenlage\u00a0und\u00a0 einen\u00a0unschar\u2010\nfen\u00a0Begriff\u00a0der\u00a0Impfpflicht\u00a0kritisiert\u00a0(Deutscher\u00a0Ethikrat,\u00a0201 9).\u00a0Schlie\u00dflich\u00a0sind\u00a0die\u00a0\nH\u00e4lfte\u00a0aller\u00a0an\u00a0Masern\u00a0Erkrankten\u00a0in\u00a0Deutschland\u00a0Erwachsene\u00a0\u2013\u00a0u nd\u00a0dies\u00a0mit\u00a0stei\u2010\ngender\u00a0Tendenz.\u00a0Ein\u00a0wirksamer\u00a0Gemeinschaftsschutz\u00a0k\u00f6nne\u00a0daher\u00a0n ur\u00a0dann\u00a0er\u2010\nreicht\u00a0werden,\u00a0wenn\u00a0auch\u00a0bei\u00a0Erwachsenen\u00a0die\u00a0Impfquoten\u00a0erh\u00f6ht\u00a0 werden.\u00a0Im\u00a0\n\u00dcbrigen\u00a0 st\u00fcnden\u00a0 insbesondere\u00a0 Menschen,\u00a0 die\u00a0 aufgrund\u00a0 ihrer\u00a0 beruf sbedingten\u00a0\nKontakte\u00a0ein\u00a0h\u00f6heres\u00a0Infektionsrisiko\u00a0haben\u00a0(z.B.\u00a0Gesundheitsbe rufe\u00a0oder\u00a0p\u00e4da\u2010\ngogisches\u00a0Personal),\u00a0in\u00a0einer\u00a0bes onderen\u00a0Verantwortung,\u00a0gegeben enfalls\u00a0durchzu\u2010\nsetzen\u00a0z.B.\u00a0mit\u00a0einem\u00a0T\u00e4tigkeitsverbot\u00a0f\u00fcr\u00a0ungeimpfte\u00a0\u00c4rzte\u00a0mit \u00a0Patientenkontakt\u00a0\n(Richter\u2010Kuhlmann,\u00a02019).\u00a0\nGerade\u00a0auch\u00a0das\u00a0Votum\u00a0des\u00a0Deutschen\u00a0Ethikrates\u00a0macht\u00a0deutlich,\u00a0 dass\u00a0die\u00a0Einf\u00fch\u2010\nrung\u00a0einer\u00a0Impfpflicht\u00a0zwar\u00a0eine \u00a0denkbare\u00a0Strategie\u00a0zur\u00a0m\u00f6glich en\u00a0Erh\u00f6hung\u00a0der\u00a0\nImpfquote\u00a0sein\u00a0k\u00f6nnte,\u00a0dass\u00a0zun\u00e4chst\u00a0aber\u00a0noch\u00a0weitere\u00a0Strategi en\u00a0zur\u00a0F\u00f6rderung\u00a0\neiner\u00a0h\u00f6heren\u00a0Durchimpfungsrate\u00a0ausgesch\u00f6pft\u00a0werden\u00a0sollten.\u00a0So \u00a0sollten\u00a0vor\u00a0\nallem\u00a0 Anstrengungen\u00a0 verst\u00e4rkt\u00a0 wer den,\u00a0 Informationsdefizite\u00a0 zu\u00a0 b eheben\u00a0 und\u00a0\nbesonders\u00a0Eltern,\u00a0Erziehungsberech tigte,\u00a0Jugendliche\u00a0und\u00a0Erwach sene\u00a0allgemein\u00a0\ngezielt\u00a0auf\u00a0die\u00a0Masernimmunisierung\u00a0anzusprechen,\u00a0Jugendliche\u00a0z .B.\u00a0im\u00a0Rahmen\u00a0\nder\u00a0Jugendgesundheitsuntersuchung\u00a0J1\u00a0und\u00a0der\u00a0erweiterten\u00a0Gesund heitsvorsorge\u2010\nUntersuchung\u00a0ab\u00a0dem\u00a018.\u00a0Lebensjahr.\u00a0Interessant\u00a0sind\u00a0in\u00a0diesem\u00a0 Zusammenhang\u00a0\nauch\u00a0Ergebnisse\u00a0einer\u00a0Untersuchung,\u00a0die\u00a0eine\u00a0h\u00f6here\u00a0Impfbereits chaft\u00a0bei\u00a0Men\u2010\nschen\u00a0zeigen,\u00a0denen\u00a0erkl\u00e4rt\u00a0wird,\u00a0dass\u00a0sie\u00a0durch\u00a0ihre\u00a0Immunisie rung\u00a0zum\u00a0Schutz\u00a0\nvon\u00a0Mitmenschen\u00a0beitragen\u00a0k\u00f6nnen,\u00a0die\u00a0aus\u00a0medizinischen\u00a0Gr\u00fcnden \u00a0nicht\u00a0selbst\u00a0\ngeimpft\u00a0werden\u00a0k\u00f6nnen.\u00a0Andererseits\u00a0k\u00f6nnte\u00a0es\u00a0auch\u00a0sein,\u00a0dass\u00a0I mpfgegner\u00a0we\u2010\ngen\u00a0der\u00a0Sanktionsandrohung\u00a0noch\u00a0verh\u00e4rteter\u00a0bei\u00a0ihrer\u00a0Meinung\u00a0b leiben\u00a0oder\u00a0\ndass\u00a0der\u00a0ein\u00a0oder\u00a0andere\u00a0denken\u00a0k\u00f6nnte,\u00a0dass\u00a0die\u00a0\u00dcberzeugungskr aft\u00a0des\u00a0Impfnut\u2010\nzens\u00a0wohl\u00a0doch\u00a0nicht\u00a0ausreiche nd\u00a0ist\u00a0und\u00a0man\u00a0daher\u00a0eine\u00a0Impfpfl icht\u00a0einf\u00fchren\u00a0\nm\u00fcsse\u00a0(Wieler,\u00a02019).\u00a0\nUnd\u00a0das\u00a0Fazit?\u00a0\nEine\u00a0Masern\u2010Impfpflicht\u00a0stellt\u00a0sich\u00a0daher\u00a0auf\u00a0Grund\u00a0der\u00a0vorlieg enden\u00a0internationa\u2010\nlen\u00a0Erfahrungen\u00a0und\u00a0Publikationen\u00a0 allenfalls\u00a0als\u00a0\u201eultima\u00a0ratio\u201c \u00a0dar,\u00a0alle\u00a0kommuni\u2010\nkativen\u00a0Strategien\u00a0sollten\u00a0ausgesch\u00f6pft\u00a0werden.\u00a0Denkbar\u00a0w\u00e4re\u00a0ei ne\u00a0Impfpflicht,\u00a0\nwenn\u00a0andere,\u00a0durch\u00a0Impfungen\u00a0verhi nderbare\u00a0schwere\u00a0Infektionser krankungen\u00a0\nwieder\u00a0h\u00e4ufiger\u00a0w\u00fcrden,\u00a0wie\u00a0z.B.\u00a0Polio.\u00a0Dies\u00a0zeigen\u00a0auch\u00a0Studie n,\u00a0die\u00a0sich\u00a0vor\u00a0263\u00a0allem\u00a0mit\u00a0psychologisch\u00a0basierten\u00a0Strategien\u00a0einer\u00a0Ver\u00e4nderung\u00a0 der\u00a0Impfskepsis\u00a0\nbesch\u00e4ftigt\u00a0haben\u00a0(Betsch\u00a0et\u00a0al.,\u00a02019).\u00a0Ein\u00a0Beispiel\u00a0ist\u00a0auch\u00a0 die\u00a0Brosch\u00fcre\u00a0\u201eInfor\u2010\nmationen\u00a0zur\u00a0Masernimpfung\u201c\u00a0des\u00a0Bundeskanzleramtes,\u00a0die\u00a0u.a.\u00a0in \u00a0Kooperation\u00a0\nmit\u00a0der\u00a0TK\u00a0im\u00a0November\u00a02018\u00a0ve r\u00f6ffentlicht\u00a0worden\u00a0ist\u00a0(Presse\u2010\u00a0 und\u00a0Informati\u2010\nonsamt\u00a0der\u00a0Bundesregierung,\u00a02018).\u00a0Solche\u00a0auf\u00a0psychologisch\u00a0bas ierten\u00a0Strategien\u00a0\naufgebauten\u00a0Interventionen\u00a0k\u00f6nnt en\u00a0sehr\u00a0gut\u00a0f\u00fcr\u00a0kommende\u00a0Kampag nen\u00a0in\u00a0Arzt\u2010\npraxen,\u00a0 Apotheken,\u00a0 Krankenh\u00e4usern,\u00a0 Kitas,\u00a0 Kinderg\u00e4rten\u00a0 oder\u00a0 Sch ulen\u00a0 genutzt\u00a0\nwerden,\u00a0um\u00a0Widerst\u00e4nde\u00a0vor\u00a0allem\u00a0gegen\u00a0die\u00a0Masernimpfung\u00a0zu\u00a0ver ringern\u00a0und\u00a0\ndamit\u00a0den\u00a0Bev\u00f6lkerungsschutz\u00a0vor\u00a0 vermeidbaren\u00a0Infektionen\u00a0zu\u00a0er h\u00f6hen.\u00a0\u00a0\nDie\u00a0generelle\u00a0Grippeimpfung\u00a0alle r\u00a0gesunden\u00a0Erwachsenen\u00a0\u00fcber\u00a060\u00a0 Jahre\u00a0ist\u00a0dahin\u2010\ngegen\u00a0wenig\u00a0sinnvoll.\u00a0Das\u00a0Immuns ystem\u00a0wird\u00a0mit\u00a0zunehmendem\u00a0Alte r\u00a0und\u00a0den\u00a0\nauftretenden\u00a0Begleiterkrankunge n\u00a0schw\u00e4cher\u00a0\u2013\u00a0und\u00a0reagiert\u00a0immer \u00a0schlechter\u00a0auf\u00a0\ndie\u00a0Impfung.\u00a0Sinnvoll\u00a0erscheint\u00a0 vielmehr\u00a0die\u00a0Impfung\u00a0m\u00f6glichst\u00a0 vieler\u00a0Kinder\u00a0und\u00a0\nJugendlicher,\u00a0da\u00a0ihre\u00a0Immunantwort\u00a0h\u00f6her\u00a0als\u00a0bei\u00a0den\u00a0\u00fcber\u00a060\u2010J\u00e4 hrigen\u00a0ist.\u00a0Zudem\u00a0\nverbreiten\u00a0Kinder\u00a0und\u00a0Jugendliche\u00a0die\u00a0Viren\u00a0aufgrund\u00a0ihrer\u00a0viel en\u00a0Sozialkontakte\u00a0\nbesonders\u00a0stark.\u00a0Die\u00a0j\u00e4hrliche\u00a0Impfung\u00a0von\u00a0Kindern\u00a0k\u00f6nnte\u00a0auch\u00a0 \u00e4ltere\u00a0Menschen\u00a0\nund\u00a0andere\u00a0Risikogruppen\u00a0wie\u00a0Kleinkinder,\u00a0Schwangere\u00a0und\u00a0schwer kranke\u00a0Perso\u2010\nnen\u00a0sch\u00fctzen.\u00a0Wichtig\u00a0w\u00e4ren\u00a0in\u00a0diesem\u00a0Zusammenhang\u00a0auch\u00a0die\u00a0Imp fung\u00a0von\u00a0\nmedizinischem\u00a0Personal\u00a0und\u00a0Pflege heimbewohnern\u00a0sowie\u00a0innerbetri ebliche\u00a0Impf\u2010\nprogramme,\u00a0wenn\u00a0eine\u00a0hohe\u00a0Durchi mpfung\u00a0erreicht\u00a0werden\u00a0kann.\u00a0Da mit\u00a0k\u00f6nnte\u00a0\neiner\u00a0Weiterverbreitung\u00a0entgegengewirkt\u00a0werden.\u00a0\u00a0\n\u00a0 \u00a0264\u00a0Folgende\u00a0Aspekte\u00a0sollten\u00a0bedacht\u00a0und\u00a0kommuniziert\u00a0werden:\u00a0\n1. Impfungen\u00a0geh\u00f6ren\u00a0zweifelsohne\u00a0z u\u00a0den\u00a0wirksamsten\u00a0\u2013\u00a0und\u00a0in\u00a0eini \u2010\ngen\u00a0F\u00e4llen\u00a0auch\u00a0einzig\u00a0m\u00f6gliche n\u00a0\u2013\u00a0vorbeugenden\u00a0Ma\u00dfnahmen\u00a0ge\u2010\ngen\u00a0teils\u00a0schwerwiegende\u00a0I nfektionserkrankungen.\u00a0\n2. Viele\u00a0der\u00a0vorgesehenen\u00a0Impfungen\u00a0richten\u00a0sich\u00a0gegen\u00a0Erkrankunge n\u00a0\noder\u00a0deren\u00a0Komplikationen,\u00a0die\u00a0\u2013\u00a0teils\u00a0als\u00a0Folge\u00a0eines\u00a0lang\u00a0eta blier\u2010\nten\u00a0Impfprogramms\u00a0\u2013\u00a0insgesamt\u00a0nur \u00a0selten\u00a0auftreten.\u00a0Vor\u00a0diesem\u00a0\nHintergrund\u00a0gewinnt\u00a0die\u00a0Sicherheit\u00a0der\u00a0Impfstoffe\u00a0eine\u00a0besonder e\u00a0\nBedeutung.\u00a0\n3. Ein\u00a0Teil\u00a0der\u00a0Bev\u00f6lkerung\u00a0steht\u00a0Impfungen\u00a0skeptisch\u00a0gegen\u00fcber.\u00a0D ies\u00a0\nbetrifft\u00a0derzeit\u00a0vor\u00a0allem\u00a0die\u00a0Masernimpfung,\u00a0bei\u00a0der\u00a0in\u00a0bestim mten\u00a0\nBev\u00f6lkerungskreisen\u00a0eine\u00a0hohe\u00a0Ablehnung\u00a0erkennbar\u00a0ist\u00a0und\u00a0f\u00fcr\u00a0d ie\u00a0\naus\u00a0Gr\u00fcnden\u00a0des\u00a0individuellen\u00a0Schutzes\u00a0f\u00fcr\u00a0die\u00a0Kinder,\u00a0aber\u00a0auc h\u00a0aus\u00a0\nGr\u00fcnden\u00a0des\u00a0Bev\u00f6lkerungsschutzes\u00a0eine\u00a0Erh\u00f6hung\u00a0der\u00a0Impfquote\u00a0\nauch\u00a0im\u00a0Rahmen\u00a0einer\u00a0Impfpflicht\u00a0angestrebt\u00a0wird.\u00a0Wegen\u00a0eines\u00a0a ll\u2010\ngemeinen\u00a0Rechtes\u00a0auf\u00a0ausreichende \u00a0Information\u00a0ist\u00a0Transparenz\u00a0b ei\u00a0\nEntscheidungen\u00a0und\u00a0Empfehlungen\u00a0zu\u00a0diesem\u00a0Thema\u00a0von\u00a0gro\u00dfer\u00a0Bedeutung.\u00a0Dies\u00a0betrifft\u00a0neben\u00a0objektiven\u00a0Informationen\u00a0zum\u00a0pat i\u2010\nentenrelevanten\u00a0Nutzen\u00a0und\u00a0Schaden\u00a0auch\u00a0die\u00a0Information,\u00a0ob\u00a0ehe r\u00a0\nder\u00a0individual\u2010\u00a0oder\u00a0der\u00a0bev\u00f6lker ungsmedizinische\u00a0Nutzen\u00a0bei\u00a0ei ner\u00a0\nspezifischen\u00a0Impfung\u00a0im\u00a0Vordergrund\u00a0steht\u00a0und\u00a0warum\u00a0dieser\u00a0Nut\u2010\nzen\u00a0aktuell\u00a0so\u00a0wichtig\u00a0erscheint.\u00a0Zwar\u00a0sind\u00a0in\u00a0Bezug\u00a0auf\u00a0die\u00a0Te ilnah\u2010\nme\u00a0an\u00a0Impfungen\u00a0die\u00a0sozialen\u00a0Unt erschiede\u00a0in\u00a0den\u00a0vergangenen\u00a0Ja h\u2010\nren\u00a0geringer\u00a0geworden\u00a0(Poethko\u2010M\u00fcller\u00a0et\u00a0al.,\u00a02007),\u00a0die\u00a0Durchi mp\u2010\nfungsrate\u00a0f\u00e4llt\u00a0aber\u00a0bei\u00a0einzelnen\u00a0Impfungen\u00a0durchaus\u00a0unterschi ed\u2010\nlich\u00a0aus,\u00a0in\u00a0diesem\u00a0Zusammenhang\u00a0sei\u00a0auch\u00a0die\u00a0HPV\u2010Impfung\u00a0als\u00a0d ie\u00a0\nzuletzt\u00a0eingef\u00fchrte\u00a0Impfung\u00a0genannt.\u00a0Hier\u00a0sollten\u00a0eindr\u00fcckliche \u00a0und\u00a0\nwi rksam e\u00a0Info rm ati o nskam pag nen\u00a0vo r\u00a0all em \u00a0bei \u00a0Masern\u00a0wi e\u00a0z .B.\u00a0fr\u00fcher\u00a0zur\u00a0Polio\u2010Impfung\u00a0genutzt\u00a0werden:\u00a0\u201eSchluckimpfung\u00a0ist\u00a0s\u00fc \u00df,\u00a0\nKinderl\u00e4hmung\u00a0ist\u00a0grausam.\u201c\u00a0Die\u00a0Auswirkungen\u00a0einer\u00a0Maserninfek\u2010\ntion\u00a0 beim\u00a0 einem\u00a0 ungeimpften\u00a0 Ki nd\u00a0 k\u00f6nnen\u00a0 ebenfalls\u00a0 \u201egrausam\u201c\u00a0\nsein:\u00a0Bei\u00a0einem\u00a0von\u00a01.000\u00a0Kindern\u00a0sind\u00a0bleibende\u00a0Sch\u00e4den\u00a0zu\u00a0be\u2010\nf\u00fcrchten,\u00a0als\u00a0Nebenwirkung\u00a0einer\u00a0Impfung\u00a0lediglich\u00a0bei\u00a0einem\u00a0Ki nd\u00a0\nvon\u00a01.000.000!\u00a0265\u00a0\u00a0\nQuelle:\u00a0\u00a0Stiftung\u00a0Deutsches\u00a0Hyg iene\u2010Museum\u00a0Dresden\u00a0(um\u00a01965)\u00a0\n4. Wichtig\u00a0ist\u00a0es,\u00a0mit\u00a0impff\u00f6rdernden\u00a0Ma\u00dfnahmen\u00a0auch\u00a0die\u00a0zu\u00a0errei\u2010\nchen,\u00a0die\u00a0davon\u00a0profitieren.\u00a0Die\u00a0Angabe\u00a0von\u00a0Termingr\u00fcnden\u00a0als\u00a0h \u00e4u\u2010\nfigsten\u00a0Hinderungsgrund\u00a0gegen\u00a0eine\u00a0Impfung\u00a0sollte\u00a0zum\u00a0Anlass\u00a0ge \u2010\nnommen\u00a0werden,\u00a0praxisferne\u00a0Gelegenheiten\u00a0f\u00fcr\u00a0Impfungen\u00a0in\u00a0Schu\u2010\nlen\u00a0oder\u00a0z.B.\u00a0bei\u00a0einem\u00a0Wahltermin,\u00a0bei\u00a0den\u00a0Beh\u00f6rden\u00a0zur\u00a0Verl\u00e4n ge\u2010\nrung\u00a0von\u00a0Personalausweisen\u00a0und\u00a0P\u00e4ssen\u00a0oder\u00a0in\u00a0der\u00a0KFZ\u2010Zulassung s\u2010\nstelle\u00a0anzubieten.\u00a0Insbesondere\u00a0vor\u00a0Aufnahme\u00a0in\u00a0eine\u00a0Kinderbetr eu\u2010\nungseinrichtung\u00a0(Kita,\u00a0Kindergarten)\u00a0und\u00a0in\u00a0die\u00a0Grundschule\u00a0sow ie\u00a0\nauch\u00a0sp\u00e4ter\u00a0in\u00a0Zusammenarbeit\u00a0mit\u00a0den\u00a0Schulen\u00a0bietet\u00a0sich\u00a0die\u00a0M \u00f6g\u2010\nlichkeit\u00a0der\u00a0\u00dcberpr\u00fcfung\u00a0des\u00a0Impfausweises\u00a0und\u00a0des\u00a0Nachholens\u00a0v on\u00a0\nfehlenden\u00a0Impfungen.\u00a0\n5. Die\u00a0in\u00a0Deutschland\u00a0f\u00fcr\u00a0die\u00a0Impfem pfehlungen\u00a0zentrale\u00a0Stelle,\u00a0di e\u00a0\nSTIKO,\u00a0muss\u00a0\u00fcber\u00a0jeden\u00a0Verdacht\u00a0 der\u00a0Befangenheit\u00a0erhaben\u00a0sein.\u00a0\n266\u00a06. Impfungen\u00a0 gegen\u00a0 bestimmte\u00a0 Erreger\u00a0 oder\u00a0 bestimmte\u00a0 Erreger\u2010\nSubgruppen\u00a0k\u00f6nnen\u00a0dazu\u00a0f\u00fchren,\u00a0dass\u00a0die\u00a0Zahl\u00a0der\u00a0betreffenden\u00a0E r\u2010\nkrankungen\u00a0sinkt,\u00a0Erkrankungen\u00a0durch\u00a0andere\u00a0Erreger(\u2010Subgruppen )\u00a0\ndagegen\u00a0zunehmen.\u00a0F\u00fcr\u00a0solche\u00a0Ver\u00e4nderungen\u00a0ist\u00a0ein\u00a0langfristige s\u00a0\nMonitoring\u00a0zu\u00a0fordern.\u00a0\nQuellen\u00a0\nAWMF\u00a0\u2013\u00a0Arbeitsgemeinschaft\u00a0der\u00a0W issenschaftlichen\u00a0Medizinischen \u00a0Fachgesellschaften.\u00a0S3\u2010Le itlinie\u00a0Pr\u00e4vention\u00a0des\u00a0\nZervixkarzinoms.\u00a0https://www.awm f.org/uploads/tx_szleitlinien/0 15\u2010027OLl_Praevention_Zervixkarzinom_2018\u2010\n01.pdf,\u00a0letzter\u00a0Zugriff:\u00a009.07.2019.\u00a0\nB\u2219A\u2219D\u00a0\u2013\u00a0Gesundheitsvorsorge\u00a0und\u00a0Sicherheitstechnik\u00a0GmbH\u00a0(2019). \u00a0https://www.bad\u2010gmbh.de/glossar/show\u2010\nterm/infektionsschutz\u20101797/,\u00a0letzter\u00a0Zugriff:\u00a020.06.2019.\u00a0\nBaguelin\u00a0M,\u00a0Camacho\u00a0A,\u00a0Flasche\u00a0S,\u00a0Edmunds\u00a0WJ\u00a0(2015).\u00a0Extending\u00a0 the\u00a0elderly\u2010\u00a0and\u00a0risk\u2010group\u00a0programme\u00a0of\u00a0vaccination\u00a0against\u00a0\nseasonal\u00a0influenza\u00a0in\u00a0England\u00a0and\u00a0Wales:\u00a0a\u00a0cost\u2010effectiveness\u00a0s tudy.\u00a0BMC\u00a0Med\u00a013\u00a0(1):236.\u00a0\u00a0\nBerres\u00a0I\u00a0(2019).\u00a0Wo\u00a0die\u00a0Impfpflic ht\u00a0gilt\u00a0\u2010\u00a0und\u00a0wie\u00a0sie\u00a0wirkt.\u00a0E rfahrungen\u00a0aus\u00a0zw\u00f6lf\u00a0EU\u2010L\u00e4ndern.\u00a0Spiegel\u00a0Online.\u00a0\nhttps://www.spiegel.de/gesundheit/diagnose/impfpflicht\u2010in\u2010diese n\u2010eu\u2010laendern\u2010funktioniert\u2010sie\u2010a\u20101259575.html,\u00a0\nletzter\u00a0Zugriff:\u00a020.06.2019.\u00a0\nBetsch\u00a0C,\u00a0B\u00f6hm\u00a0R,\u00a0Korn\u00a0L,\u00a0Holtmann\u00a0C\u00a0(2017).\u00a0On\u00a0the\u00a0benefits\u00a0of \u00a0explaining\u00a0herd\u00a0immunity\u00a0in\u00a0va ccine\u00a0advocacy.\u00a0Nature\u00a0Human\u00a0\nBehaviour.\u00a01\u00a0(3):\u00a00056.\u00a0\nBetsch\u00a0C,\u00a0von\u00a0Hirschhausen\u00a0E,\u00a0Zylka\u2010Menhorn\u00a0V\u00a0(2019a).\u00a0Professi onelle\u00a0Gespr\u00e4chsf\u00fchrung\u00a0\u2013\u00a0wenn\u00a0Reden\u00a0Gold\u00a0wert\u00a0ist.\u00a0Deutsches\u00a0\n\u00c4rzteblatt.\u00a0116(11):\u00a0A\u2010520\u00a0/\u00a0B\u2010427\u00a0/\u00a0C\u2010422.\u00a0\nBetsch\u00a0C,\u00a0Schmid\u00a0P,\u00a0Korn\u00a0L,\u00a0Stei nmeyer\u00a0L,\u00a0Heinemeier\u00a0D,\u00a0Eitze\u00a0S \u00a0et\u00a0al.\u00a0(2019b).\u00a0Impfverhalten\u00a0psychologisch\u00a0erkl\u00e4ren,\u00a0messen\u00a0u nd\u00a0\nver\u00e4ndern.\u00a0Bundesgesundheitsblatt.\u00a062:400.\u00a0\u00a0\nBfArM/PEI\u00a0\u2013\u00a0Bundesinstitut\u00a0f\u00fcr\u00a0Arzneimittel\u00a0und\u00a0Medizinprodukte /Paul\u2010Ehrlich\u2010Institut\u00a0(2017).\u00a0Bu lletin\u00a0zur\u00a0Arzneimittelsicherh eit.\u00a0\nInformationen\u00a0aus\u00a0BfArM\u00a0und\u00a0PEI.\u00a01:\u00a017\u201025.\u00a0\nBMG\u00a0\u2013\u00a0Bundesministerium\u00a0f\u00fcr\u00a0Gesundheit\u00a0(2015).\u00a0Nationaler\u00a0Aktio nsplan\u00a02015\u20132020\u00a0zur\u00a0Elimination\u00a0der\u00a0Masern\u00a0und\u00a0R\u00f6teln\u00a0in\u00a0\nDeutschland.\u00a0Hintergr\u00fcnde,\u00a0Ziele\u00a0und\u00a0Strategien.\u00a0https://www.gmkonline.de/documents/Aktionsplan_Masern_Roeteln_2 .pdf,\u00a0letzter\u00a0Zugriff:\u00a002.06.2019.\u00a0\nBMG\u00a0\u2013\u00a0Bundesministerium\u00a0f\u00fcr\u00a0Gesundheit\u00a0(2019).\u00a0Referentenentwur f\u00a0des\u00a0Bundesministeriums\u00a0f\u00fcr\u00a0Gesundheit\u00a0Entwurf\u00a0eines\u00a0\nGesetzes\u00a0f\u00fcr\u00a0den\u00a0Schutz\u00a0vor\u00a0Masern\u00a0und\u00a0zur\u00a0St\u00e4rkung\u00a0der\u00a0Impfpr\u00e4 vention\u00a0(Masernschutzgesetz).\u00a0\nhttps://www. bundesgesundheitsministerium.de/fileadmin/Dateien/3 _Downloads/Gesetze_und_Verordnungen/Gu\nV/M/Masernschutzgesetz\u2010RefE.pdf,\u00a0,\u00a0letzter\u00a0Zugriff:\u00a002.07.2019. \u00a0\nBrewer\u00a0NT,\u00a0Hall\u00a0ME,\u00a0Malo\u00a0TL,\u00a0Gilkey\u00a0MB,\u00a0Quinn\u00a0B,\u00a0Lathren\u00a0C\u00a0(201 7).\u00a0Announcements\u00a0versus\u00a0con versations\u00a0to\u00a0improve\u00a0HPV\u00a0\nvaccination\u00a0coverage:\u00a0a\u00a0randomized\u00a0trial.\u00a0Pediatrics.\u00a0139\u00a0(1):\u00a0 e20161764.\u00a0\nBZgA\u00a0\u2013\u00a0Bundeszentrale\u00a0f\u00fcr\u00a0gesundheitliche\u00a0Aufkl\u00e4rung\u00a0(2019).\u00a0Ma sern\u2010Impfung\u00a0bei\u00a0Kindern.\u00a0https://www.impfen\u2010\ninfo.de/impfempfehlungen/fuer\u2010kinder\u20100\u201012\u2010jahre/masern/,\u00a0letzte r\u00a0Zugriff:\u00a013.08.2019.\u00a0\nCaldeira\u00a0D,\u00a0Ferreira\u00a0JJ,\u00a0Costa\u00a0J \u00a0(2018).\u00a0Influenza\u00a0vaccination\u00a0 and\u00a0prevention\u00a0of\u00a0cardiovascular\u00a0disease\u00a0mortality.\u00a0Lancet.\u00a0391 :\u00a0426\u20137.\u00a0\u00a0\nChavez\u00a0LL,\u00a0Davenport\u00a0MP,\u00a0Shive r\u00a0JW,\u00a0Tussey\u00a0LG,\u00a0 Cox\u00a0KS,\u00a0Bachinsk y\u00a0M\u00a0et\u00a0al.\u00a0(2008).\u00a0The\u00a0effect\u00a0of\u00a0early\u00a0versus\u00a0delayed\u00a0challenge \u00a0\nafter\u00a0vaccination\u00a0in\u00a0controlling\u00a0 SHIV\u00a089.6P\u00a0infection\u00a0Virology\u00a0 381(1),\u00a075\u201380.\u00a0267\u00a0Chen\u00a0RT\u00a0(1999).\u00a0Vaccine\u00a0risks:\u00a0real,\u00a0perceived\u00a0and\u00a0unknown.\u00a0Vac cine\u00a017\u00a0(3):\u00a041\u20136.\u00a0\u00a0\nD\u00c4\u00a0\u2013\u00a0Deutsches\u00a0\u00c4rzteblatt\u00a0(2019).\u00a0Masern:\u00a0Lieferengpass\u00a0bei\u00a0Kom bipr\u00e4parat.\u00a0Dt\u00a0\u00c4rztebl\u00a0(116)31/32:\u00a0A1410.\u00a0\nDestatis\u00a0\u2013\u00a0Statistisches\u00a0Bundesamt\u00a0(2018).\u00a0Bundesl\u00e4nder\u00a0mit\u00a0Hau ptst\u00e4dten\u00a0nach\u00a0Fl\u00e4che,\u00a0Bev\u00f6lkerung\u00a0und\u00a0Bev\u00f6lkerungsdichte\u00a0am\u00a0\n31.12.2017.\u00a0https://www.destatis.de/DE/Themen/Laender\u2010\nRegionen/Regionales/Gemeindeverzeichnis/Administrativ/02\u2010bundes laender.html,\u00a0letzter\u00a0Zugriff:\u00a003.07.2019.\u00a0\nDeutscher\u00a0Ethikrat\u00a0(2019).\u00a0Ethikrat\u00a0fordert\u00a0differenziertere\u00a0De batte\u00a0zur\u00a0Impfpflicht.\u00a0Pressemitteilung\u00a0am\u00a002/2019.\u00a0\nhttps://www.ethikrat.org/mitteilungen/2019/ethikrat\u2010fordert\u2010dif ferenziertere\u2010debatte\u2010zur\u2010impfpflicht/,\u00a0letzter\u00a0\nZugriff:\u00a002.06.2019.\u00a0\nDominus\u00a0S\u00a0(2011).\u00a0The\u00a0Crash\u00a0and\u00a0Burn\u00a0of\u00a0an\u00a0Autism\u00a0Guru.\u00a0The\u00a0New \u00a0York\u00a0Times\u00a0Magazine.\u00a0\nhttps://www.nytimes.com/2011/04/24/magazine/mag\u201024Autism\u2010t.html ?pagewanted=all&_r=0,\u00a0letzter\u00a0Zugriff:\u00a0\n24.06.2019.\u00a0\nDowdle\u00a0WR,\u00a0De\u00a0Gourville\u00a0E,\u00a0Kew\u00a0OM,\u00a0Pallansch\u00a0MA,\u00a0Wood\u00a0DJ\u00a0(2003) .\u00a0Polio\u00a0eradication:\u00a0the\u00a0OPV\u00a0par adox\u00a0Rev.\u00a0Med.\u00a0Virol.,\u00a013(5),\u00a0\n277\u2013291.\u00a0\u00a0\nDrolet\u00a0M,\u00a0B\u00e9nard\u00a0E,\u00a0P\u00e9rez\u00a0N,\u00a0Bri sson\u00a0M,\u00a0Ali\u00a0H,\u00a0Boily\u00a0MC\u00a0et\u00a0al.\u00a0 (2019).\u00a0Population\u2010level\u00a0impact\u00a0and\u00a0herd\u00a0effects\u00a0following\u00a0the\u00a0\nintroduction\u00a0of\u00a0human\u00a0papillomavirus\u00a0vaccination\u00a0programmes:\u00a0up dated\u00a0systematic\u00a0review\u00a0and\u00a0meta\u2010analysis.\u00a0\nLancet,\u00a0https://www.thelancet.com/journals/lancet/article/PIIS0 140\u20106736(19)30298\u20103/fulltext,\u00a0letzter\u00a0Zugriff:\u00a0\n05.07.2019.\u00a0\nEitze\u00a0S,\u00a0Fleischmann\u2010Struzek\u00a0C, \u00a0Betsch\u00a0C,\u00a0Reinhart\u00a0K,\u00a0the\u00a0vacci nation60+\u00a0study\u00a0group\u00a0(2018).\u00a0Determinants\u00a0of\u00a0sepsis\u00a0knowledge: \u00a0a\u00a0\nrepresentative\u00a0survey\u00a0of\u00a0the\u00a0elderly\u00a0population\u00a0in\u00a0Germany.\u00a0Cri tical\u00a0Care.\u00a0\nhttps://ccforum.biomedcentral.com/articles/10.1186/s13054\u2013018\u20132 208\u20135,\u00a0letzter\u00a0Zugriff:\u00a021.06.2019.\u00a0\nECDC\u00a0\u2010\u00a0European\u00a0Centre\u00a0for\u00a0Disease\u00a0Prevention\u00a0and\u00a0Control.\u00a0(201 9).\u00a0Vaccination\u00a0coverage\u00a0for\u00a0 the\u00a0second\u00a0dose\u00a0of\u00a0measles\u2010\ncontaining\u00a0vaccine,\u00a0EU/EEA,\u00a02017.\u00a0https://ecdc.europa.eu/en/pub lications\u2010data/vaccinatio n\u2010coverage\u2010second\u2010dose\u2010\nmeasles\u2010containing\u2010vaccine\u2010eueea\u20102017,\u00a0letzter\u00a0Zugriff:\u00a019.04.2 019.\u00a0\nGagneur\u00a0A,\u00a0Lema\u00eetre\u00a0T,\u00a0Gosselin\u00a0V,\u00a0Farrands\u00a0A,\u00a0Carrier\u00a0N,\u00a0Petit \u00a0G,\u00a0et\u00a0al.\u00a0(2018).\u00a0A\u00a0postpartum\u00a0vaccination\u00a0promotion\u00a0intervent ion\u00a0\nusing\u00a0motivational\u00a0interviewing\u00a0techniques\u00a0improves\u00a0short\u2010term\u00a0 vaccine\u00a0coverage:\u00a0PromoVac\u00a0study.\u00a0BMC\u00a0Public\u00a0\nHealth.\u00a0https://bmcpublichealth.biomedcentral.com/articles/10.1 186/s12889\u2013018\u20135724\u2010y,\u00a0letzter\u00a0Zugriff\u00a0\n21.06.2019.\u00a0\nGarland\u00a0SM,\u00a0Paavonen\u00a0J,\u00a0Jaisamrarn\u00a0U,\u00a0Naud\u00a0P,\u00a0Salmeron\u00a0J,\u00a0Chow, \u00a0SN\u00a0et\u00a0al.\u00a0(2016).\u00a0Prior\u00a0human\u00a0papillomavirus\u201016/18\u00a0AS04\u2010\nadjuvanted\u00a0vaccination\u00a0prevents\u00a0recurrent\u00a0high\u00a0grade\u00a0cervical\u00a0i ntraepithelial\u00a0neoplasia\u00a0after\u00a0definitive\u00a0surgical\u00a0\ntherapy:\u00a0Post\u2010hoc\u00a0analysis\u00a0from\u00a0 a\u00a0randomized\u00a0controlled\u00a0trial.\u00a0 International\u00a0Journal\u00a0of\u00a0Cancer\u00a0139(12):\u00a02812\u20102826.\u00a0\nHaverkate\u00a0M,\u00a0D\u2019Ancona\u00a0F,\u00a0Giambi\u00a0C ,\u00a0Johansen\u00a0K,\u00a0Lopalco\u00a0PL,\u00a0Cozz a\u00a0A\u00a0et\u00a0al.\u00a0(2012).\u00a0Mandatory\u00a0and\u00a0recommended\u00a0vaccination\u00a0in\u00a0the \u00a0\nEU,\u00a0Iceland\u00a0and\u00a0Norway:\u00a0results\u00a0 of\u00a0the\u00a0VENICE\u00a02019\u00a0survey\u00a0in\u00a0th e\u00a0ways\u00a0implementing\u00a0national\u00a0vaccination\u00a0\nprogrammes.\u00a0Euro\u00a0Surve ill.\u00a017(22):pil=20183.\u00a0\nHorstk\u00f6tter\u00a0N,\u00a0M\u00fcller\u00a0U,\u00a0Ommen\u00a0 O,\u00a0Platte\u00a0A,\u00a0Reckendrees\u00a0B,\u00a0Stan der\u00a0V\u00a0et\u00a0al.\u00a0(2017).\u00a0Einstellungen,\u00a0Wissen\u00a0und\u00a0Verhalten\u00a0von\u00a0\nErwachsenen\u00a0und\u00a0Eltern\u00a0gegen\u00fcber\u00a0Impfungen\u00a0\u2013\u00a0Ergebnisse\u00a0der\u00a0Rep r\u00e4sentativbefragung\u00a02016\u00a0zum\u00a0Infektions\u2010\nschutz.\u00a0K\u00f6ln:\u00a0Bundeszentrale\u00a0f\u00fcr\u00a0gesundheitliche\u00a0Aufkl\u00e4rung.\u00a0\u00a0\nIMS\u00a0Health\u00a0\u2013\u00a0Institut\u00a0f\u00fcr\u00a0medi zinische\u00a0Statistik\u00a0(Hrsg.)\u00a0(2017) .\u00a0Der\u00a0pharmazeutische\u00a0Markt\u00a0in\u00a0Deutschland.\u00a0Stand\u00a0der\u00a0Informati on:\u00a0\nDezember\u00a02017,\u00a0Frankfurt\u00a0a.M.:\u00a0Im\u00a0Eigenverlag.\u00a0\nInsight\u00a0Health\u00a0(2019).\u00a0Jeder\u00a0f\u00fcnfte\u00a0gegen\u00a0HPV\u00a0geimpfte\u00a0Jugendli che\u00a0ist\u00a0m\u00e4nnlich.\u00a0www.insight\u2010health.de/sites/default/files/201 9\u2010\n08/IH\u2010Pressemitteilung_HPV\u2010Impfung.pdf,\u00a0letzter\u00a0Zugriff:\u00a001.08. 2019.\u00a0268\u00a0IQWiG\u00a0\u2013\u00a0Institut\u00a0f\u00fcr\u00a0Qualit\u00e4t\u00a0und\u00a0Wirtschaftlichkeit\u00a0im\u00a0Gesundh eitswesen\u00a0(2011).\u00a0IQWiG\u2010Berichte;\u00a0Band\u00a0106.\u00a0Nutzenbewertung\u00a0\neines\u00a0HPV\u2010Tests\u00a0im\u00a0Prim\u00e4rscreenin g\u00a0des\u00a0Zervixkarzinoms:\u00a0Abschlu ssbericht.\u00a0\nIQWiG\u00a0\u2013\u00a0Institut\u00a0f\u00fcr\u00a0Qualit\u00e4t\u00a0und\u00a0Wirtschaftlichkeit\u00a0im\u00a0Gesundh eitswesen\u00a0(2014).\u00a0IQWiG\u2010Berichte;\u00a0Band\u00a0222.\u00a0Nutzenbewertung\u00a0\neines\u00a0HPV\u2010Tests\u00a0im\u00a0Prim\u00e4rscreenin g\u00a0des\u00a0Zervixkarzinoms:\u00a0Aktuali sierung.\u00a0Rapid\u00a0Report.\u00a0\u00a0\nJefferson\u00a0T,\u00a0Di\u00a0Pietrantonj\u00a0C,\u00a0Al\u2010Ansary\u00a0LA,\u00a0Ferroni\u00a0E,\u00a0Thornin g\u00a0S,\u00a0Thomas\u00a0RE\u00a0(2010).\u00a0Vaccines\u00a0for\u00a0preventing\u00a0influenza\u00a0in\u00a0the \u00a0\nelderly.\u00a0Cochrane\u00a0Database\u00a0of\u00a0Systematic\u00a0Reviews\u00a02\u00a0(CD004876).\u00a0 \u00a0\nJefferson\u00a0T,\u00a0Rivetti\u00a0A,\u00a0Di\u00a0Pietr antonj\u00a0C,\u00a0Demicheli\u00a0V,\u00a0Ferroni\u00a0 E\u00a0(2012).\u00a0Vaccines\u00a0for\u00a0preventing\u00a0influenza\u00a0in\u00a0healthy\u00a0children .\u00a0\nCochrane\u00a0Database\u00a0of\u00a0Systematic\u00a0Reviews\u00a08.\u00a0(CD004879).\u00a0\nKlein\u00a0S,\u00a0Sch\u00f6neberg\u00a0I,\u00a0Krause\u00a0G\u00a0(2012).\u00a0Vom\u00a0Zwang\u00a0zur\u00a0Pockensch utzimpfung\u00a0zum\u00a0Nationalen\u00a0Impfplan.\u00a0Die\u00a0Entwicklung\u00a0des\u00a0\nImpfwesens\u00a0vom\u00a0Deutschen\u00a0Kaiserreich\u00a0bis\u00a0heute.\u00a0Bundesgesundhei tsblatt\u00a055:1512\u20131523.\u00a0\u00a0\nLewandowsky\u00a0S,\u00a0Ecker\u00a0UK,\u00a0Seifer t\u00a0CM,\u00a0Schwarz\u00a0N,\u00a0Cook\u00a0J\u00a0(2012).\u00a0 Misinformation\u00a0and\u00a0its\u00a0correction\u00a0continued\u00a0influence\u00a0and\u00a0\nsuccessful\u00a0debiasing.\u00a0Psychological\u00a0Science\u00a0in\u00a0the\u00a0Public\u00a0Inter est\u00a013\u00a0(3):\u00a0106\u201331.\u00a0\nLoeb\u00a0M,\u00a0Russell\u00a0ML,\u00a0Moss\u00a0L,\u00a0Fons eca\u00a0K,\u00a0Fox\u00a0J,\u00a0Earn\u00a0DJ\u00a0et\u00a0al.\u00a0(2 010).\u00a0Effect\u00a0of\u00a0influenza\u00a0vaccination\u00a0of\u00a0children\u00a0on\u00a0infection\u00a0 rates\u00a0in\u00a0\nHutterite\u00a0communities:\u00a0a\u00a0\u00a0randomized\u00a0trial.\u00a0JAMA\u00a0303(10):943\u201050 .\u00a0\u00a0\nNuffield\u00a0Council\u00a0of\u00a0Bioethics\u00a0(2007).\u00a0Public\u00a0health:\u00a0ethical\u00a0is sues.\u00a0Nuffield\u00a0Council\u00a0of\u00a0Bioethics,\u00a0London,\u00a0\nhttp://www.nuffieldbioethics.org/fileLibrary/pdf/Public_health_ \u2010_ethical_issues.pdf,\u00a0letzter\u00a0Zugriff:\u00a021.06.2019.\u00a0\nMatysiak\u2010Klose\u00a0D,\u00a0Santibanez\u00a0S\u00a0( 2018).\u00a0Aktuelle\u00a0Epidemiologie\u00a0d er\u00a0Masern\u00a0in\u00a0Deutschland.\u00a0Epidemiologisches\u00a0Bulletin.\u00a0\nhttps://www.rki.de/DE/Content/Infekt/EpidBull/Archiv/2018/Ausga ben/33_18.pdf?__blob=publicationFile,\u00a0letzter\u00a0\nZugriff\u00a021.06.2019.\u00a0\u00a0\u00a0\u00a0\nMcGuire\u00a0A,\u00a0Drummond\u00a0M,\u00a0Keeping\u00a0S\u00a0(2015).\u00a0Childhood\u00a0and\u00a0adolesce nt\u00a0influenza\u00a0vaccination\u00a0in\u00a0Europe:\u00a0A\u00a0review\u00a0of\u00a0the\u00a0evidence.\u00a0\nFINAL\u00a0Report\u00a0April\u00a02015.\u00a0LSE\u00a0enterprise.\u00a0http://blogs.lse.ac.uk/lseenterprise/files/2015/04/ChildhoodAnd AdolescentInfluenzaVaccination.pdf,\u00a0letzter\u00a0Zugriff:\u00a0\n09.07.2019.\u00a0\nM\u00fcller\u00a0T\u00a0(2019).\u00a0Humane\u00a0Papillomviren.\u00a0Erfolg\u00a0mit\u00a0HPV\u2010Screening :\u00a0Weniger\u00a0Zervixkarzinome.\u00a0CME\u00a0Premium\u2010Fortbildung\u00a0f\u00fcr\u00a0die\u00a0\nmedizinische\u00a0Praxis.\u00a016\u00a0(6):\u00a038\u201338.\u00a0\nMurch\u00a0SH,\u00a0Anthony\u00a0A,\u00a0Casson\u00a0DH ,\u00a0Malik\u00a0M,\u00a0Berelowitz\u00a0M,\u00a0Dhillon\u00a0 AP,\u00a0et\u00a0al.\u00a0(2004).\u00a0Retraction\u00a0of\u00a0an\u00a0interpretation.\u00a0Erratum\u00a0for \u00a0\nIleal\u2010lymphoid\u2010nodular\u00a0hyperplas ia,\u00a0non\u2010specific\u00a0colitis,\u00a0and\u00a0p ervasive\u00a0developmental\u00a0disorder\u00a0in\u00a0children.\u00a0Lancet.\u00a0\n363\u00a0(9411):\u00a0750.\u00a0\nOsterholm\u00a0MT,\u00a0Kelley\u00a0NS,\u00a0Sommer\u00a0A,\u00a0Belongia\u00a0EA\u00a0et\u00a0al.\u00a0(2012).\u00a0E fficacy\u00a0and\u00a0effectiveness\u00a0of\u00a0influenza\u00a0vaccines:\u00a0a\u00a0systematic\u00a0r eview\u00a0\nand\u00a0meta\u2010analysis.\u00a0Lancet\u00a0Infect\u00a0Dis\u00a012(1):\u00a036\u201344.\u00a0\nPEI\u00a0\u2013\u00a0Paul\u2010Ehrlich\u2010Institut\u00a0(2019).\u00a0Impfstoffe\u00a0gegen\u00a0Masern.\u00a0ht tps://www.pei.de/DE/arzneimittel/impfstoff\u2010impfstoffe\u2010fuer\u2010den\u2010\nmenschen/masern/masern\u2010node.html,\u00a0letzter\u00a0Zugriff:\u00a028.05.2019.\u00a0\nPoethko\u2010M\u00fcller\u00a0C,\u00a0Kuhnert\u00a0R,\u00a0Schlaud\u00a0M\u00a0(2007).\u00a0Durchimpfung\u00a0und \u00a0Determinanten\u00a0des\u00a0Impfstatus\u00a0 in\u00a0Deutschland.\u00a0Ergebnisse\u00a0des\u00a0\nKinder\u2010\u00a0und\u00a0Jugendgesundheitssurveys\u00a0(KiGGS).\u00a0Bundesgesundheits blatt\u00a0\u2013\u00a0Gesundheitsforsch\u00a0\u2013\u00a0Gesundheitsschutz.\u00a0\n50(5/6):\u00a0851\u2010862.\u00a0\nPoethko\u2010M\u00fcller\u00a0C,\u00a0Schmitz\u00a0R\u00a0(2013).\u00a0Impfstatus\u00a0von\u00a0Erwachsenen\u00a0 in\u00a0Deutschland:\u00a0Ergebnisse\u00a0der\u00a0Studie\u00a0zur\u00a0Gesundheit\u00a0\nErwachsener\u00a0in\u00a0Deutschland\u00a0(DEGS1).\u00a0Bundesgesundheitsblatt,\u00a0Ges undheitsforschung,\u00a0Gesundheitsschutz.\u00a056(5\u20106):\u00a0\n845\u2013857.\u00a0\u00a0\u00a0269\u00a0Poethko\u2010M\u00fcller\u00a0C,\u00a0Kuhnert\u00a0R,\u00a0Gillesberg\u00a0Lassen\u00a0S,\u00a0Siedler\u00a0A\u00a0(20 19).\u00a0Durchimpfung\u00a0von\u00a0Kindern\u00a0und\u00a0Jugendlichen\u00a0in\u00a0Deutschland:\u00a0\nAktuelle\u00a0Daten\u00a0aus\u00a0KiGGS\u00a0Welle\u00a02\u00a0und\u00a0Trends\u00a0aus\u00a0der\u00a0KiGGS\u2010Studi e.\u00a0Bundesgesundheitsblatt,\u00a0Gesundheitsfor\u2010\nschung,\u00a0Gesundheitsschutz.\u00a062(4):\u00a0410\u2013421.\u00a0\u00a0\u00a0\nPresse\u2010\u00a0und\u00a0Informationsamt\u00a0der\u00a0Bundesregierung\u00a0(2018).\u00a0Informa tionen\u00a0zur\u00a0Masernimpfung.\u00a0\nMaterialband.https:// www.bundesregierung.de/resource/blob/97527 2/1504716/889f782b1d2dae7f7a467c97ad81\ndf8c/2018\u201007\u201012\u2010masernimpfung\u2010materialband\u2010data.pdf?download=1, \u00a0letzter\u00a0Zugriff:\u00a014.08.2019.\u00a0\nRazum\u00a0O,\u00a0Matysiak\u2010Klose\u00a0D,\u00a0\u00a0Kouros\u00a0B\u00a0(2016).\u00a0Elimination\u00a0von\u00a0Ma sern\u00a0und\u00a0R\u00f6teln.\u00a0Keine\u00a0signifikante\u00a0Verbesserung.\u00a0Deutsches\u00a0\n\u00c4rzteblatt.\u00a014:\u00a0A646\u2010A651.\u00a0\u00a0\u00a0\nRichter\u2010Kuhlmann\u00a0E\u00a0(2019).\u00a0Ethikrat\u00a0gegen\u00a0generellen\u00a0Zwang.\u00a0Deu tsches\u00a0\u00c4rzteblatt\u00a0116(27\u201328):\u00a0A\u00a01306\u2010A\u00a01307.\u00a0\nRieck\u00a0T,\u00a0Matysiak\u2010Klose\u00a0D,\u00a0Helle nbrand\u00a0W,\u00a0Koch\u00a0J,\u00a0Feig\u00a0M,\u00a0Siedl er\u00a0A,\u00a0et\u00a0al.\u00a0(2019).\u00a0Umsetzung\u00a0der\u00a0Masern\u2010\u00a0und\u00a0\nPertussisimpfempfehlungen\u00a0f\u00fcr\u00a0Erwachsene:\u00a0Analyse\u00a0von\u00a0Daten\u00a0des \u00a0bundesweiten\u00a0Monitorings\u00a0der\u00a0KV\u2010\nImpfsurveillance.\u00a0Bundesgesundheitsblatt,\u00a0Gesundheitsforschung, \u00a0Gesundheitsschutz,\u00a062(4),\u00a0422\u2013432.\u00a0\u00a0\u00a0\nRiley\u00a0C,\u00a0Wheeler\u00a0DS\u00a0(2012).\u00a0Prevention\u00a0of\u00a0sepsis\u00a0in\u00a0children:\u00a0a \u00a0new\u00a0paradigm\u00a0for\u00a0public\u00a0policy. \u00a0Critical\u00a0Care\u00a0Research\u00a0and\u00a0Pra ctice.\u00a0\n2012:\u00a0437139.\u00a0\nAGI\u00a0\u2013\u00a0Robert\u00a0Koch\u2010Institut\u00a0Arbeitsgruppe\u00a0Influenza\u00a0(o.\u00a0J.).\u00a0RKI \u00a0:\u00a0https://influenza.rki.de/MapArchive.aspx,\u00a0letzter\u00a0Zugriff:\u00a0\n10.07.2019.\u00a0\u00a0\nRKI\u00a0\u2013\u00a0Robert\u00a0Koch\u2010Institut\u00a0(o.\u00a0J.).\u00a0SurvStat@RKI\u00a02.0.\u00a0https://s urvstat.rki.de,\u00a0letzter\u00a0Zugriff:\u00a002.06.2019.\u00a0\u00a0\nRKI\u00a0\u2013\u00a0Robert\u00a0Koch\u2010Institut\u00a0(2007).\u00a0Empfehlungen\u00a0der\u00a0St\u00e4ndigen\u00a0I mpfkommission\u00a0(STIKO)\u00a0am\u00a0Robert\u00a0Koch\u2010Institut.\u00a0\nEpidemiologisches\u00a0Bulletin.https://www.rki.de/DE/Content/Infekt/EpidBull/Archiv/2 007/Ausgabenlinks/30_07.pdf?__blob=publication\nFile,\u00a0letzter\u00a0Zugriff:\u00a009.07.2019.\u00a0\nRKI\u00a0\u2013\u00a0Robert\u00a0Koch\u2010Institut\u00a0(2017).\u00a0VacMap\u00a0\u2010\u00a0Measles\u00a0Vaccination \u00a0Coverage\u00a0in\u00a0Germany,\u00a0Robert\u00a0Koch\u2010Institut.\u00a0.\u00a0\nhttp://www.vacmap.de/,\u00a0letzter\u00a0Zugriff:\u00a019.04.2019.\u00a0\nRKI\u00a0\u2013\u00a0Robert\u00a0Koch\u2010Institut\u00a0(2018a).\u00a0Impfkalender.\u00a0Epidemiologis ches\u00a0Bulletin\u00a0\nhttps://www.rki.de/DE/Content/Kommissionen/STIKO/Empfehlungen/A ktuelles/Impfkalender.pdf;jsessionid=5E0D0\n665A927532BD064533E5251A8A4.1_cid390?__blob=publicationFile,\u00a0le tzter\u00a0Zugriff:\u00a003.06.2019.\u00a0\nRKI\u00a0\u2013\u00a0Robert\u00a0Koch\u2010Institut\u00a0(2018b).\u00a0Epidemiologisches\u00a0Bulletin\u00a0 1.\u00a0Aktuelles\u00a0aus\u00a0der\u00a0KV\u2010Impfsurveillance\u00a0\u2013\u00a0Impfquoten\u00a0ausgew\u00e4hl ter\u00a0\nSchutzimpfungen\u00a0in\u00a0Deutschland.\u00a0https://www.rki.de/DE/Content/Infekt/EpidBull/Archiv/2018/Ausga ben/01_18.pdf?__blob=publicationFile,\u00a0letzter\u00a0\nZugriff\u00a021.06.2019.\u00a0\u00a0\nRKI\u00a0\u2013\u00a0Robert\u00a0Koch\u2010Institut\u00a0(2018c).\u00a0Humane\u00a0Papillomviren,\u00a0RKI\u2010R atgeber\u00a02018.\u00a0\nhttps://www.rki.de/DE/Content/Infekt/EpidBull/Merkblaetter/Ratg eber_HPV.html#doc11064408bodyText2,\u00a0letzter\u00a0\nZugriff\u00a021.06.2019.\u00a0\u00a0\nRKI\u00a0\u2013\u00a0Robert\u00a0Koch\u2010Institut\u00a0(2018d).\u00a0Infektionsepidemiologisches \u00a0Jahrbuch\u00a0meldepflichtiger\u00a0Krankheiten\u00a0f\u00fcr\u00a02017.\u00a0\nhttps://edoc.rki.de/bitstream/handle/176904/5820/Jahrbuch_2017. pdf?sequence=1&isAllowed=y,\u00a0letzter\u00a0Zugriff\u00a0\n10.07.2019.\u00a0\u00a0\nRKI\u00a0\u2013\u00a0\u00a0Robert\u00a0Koch\u2010Institut.\u00a0(2019a).\u00a0Epidemiologische\u00a0Situatio n\u00a0der\u00a0Masern\u00a0und\u00a0R\u00f6teln\u00a0in\u00a0Deutschland\u00a0in\u00a02018.\u00a0\nhttps://www.rki.de/DE/Content/Infekt/Impfen/Praevention/elimina tion_04_01.html,\u00a0letzter\u00a0Zugriff:\u00a019.04.2019.\u00a0\nRKI\u00a0\u2013\u00a0\u00a0Robert\u00a0Koch\u2010Institut.\u00a0(2019b).\u00a0Schutzimpfung\u00a0gegen\u00a0Maser n:\u00a0H\u00e4ufig\u00a0gestellte\u00a0Fragen\u00a0und\u00a0Antworten,\u00a0letzter\u00a0Zugriff:\u00a0\n28.05.2019.\u00a0https://www.rki.de/SharedDocs/FAQ/Impfen/MMR/FAQ\u2010Li ste_Masern_Impfen.html\u00a0\u00a0270\u00a0SIKO\u00a0\u2013\u00a0S\u00e4chsische\u00a0Impfkommission\u00a0(2019).\u00a0Synopsis\u2010Impfkalender\u00a0 f\u00fcr\u00a0Kinder,\u00a0Jugendliche\u00a0und\u00a0Erwachsene\u00a0im\u00a0Freistaat\u00a0Sachsen.\u00a0\nZugriff\u00a0am\u00a028.05.2019.\u00a0https://www.slaek.de/media/dokumente/02m edien/Patienten/gesundheitsinformationen/\u00a0\nimpfen/Synopsis_2019.pdf,\u00a0letzter\u00a0Zugriff:\u00a024.06.2019.\u00a0\nSilman\u00a0AJ,\u00a0Allwright\u00a0SPA\u00a0(1988).\u00a0Elimination\u00a0or\u00a0reduction\u00a0of\u00a0di seases?\u00a0Opportunities\u00a0for\u00a0health\u00a0service\u00a0action\u00a0in\u00a0Europe.\u00a0Oxfo rd:\u00a0\nOxford\u00a0University\u00a0Press.\u00a0\nStiftung\u00a0Deutsches\u00a0Hygiene\u2010Museum\u00a0Dresden\u00a0(um\u00a01965).\u00a0Kinderl\u00e4hm ung\u00a0droht\u00a0wieder/Schluckimpfung\u00a0ist\u00a0s\u00fc\u00df/Kinderl\u00e4hmung\u00a0ist\u00a0\ngrausam.\u00a0Deutschland\u00a0um\u00a01965,\u00a0Herausgeber\u00a0unbekannt,\u00a0Inv\u2010Nr.\u00a020 10/410.\u00a0Dauerleihgabe\u00a0der\u00a0Novartis\u00a0Behring.\u00a0\nStiftung\u00a0Warentest\u00a0(2018).\u00a0Grippe:\u00a0F\u00fcr\u00a0wen\u00a0eine\u00a0Impfung\u00a0sinnvol l\u00a0ist.\u00a0https://www.test.de/Grippeschutzimpfung\u2010Fuer\u2010wen\u2010der\u2010\nGang\u2010zum\u2010Arzt\u2010sinnvoll\u2010ist\u20104624021\u20100/\u00a017.10.2918,\u00a0letzter\u00a0Zugri ff\u00a021.06.2019.\u00a0\u00a0\nSTIKO\u00a0\u2013\u00a0St\u00e4ndige\u00a0Impfkommission\u00a0(2013).\u00a0Mitteilung\u00a0der\u00a0St\u00e4ndige n\u00a0Impfkommission\u00a0(STIKO)\u00a0zur\u00a0konsequenten\u00a0Umsetzung\u00a0der\u00a0\nStandardimpfempfehlungen\u00a0gegen\u00a0Masern\u00a0im\u00a0S\u00e4uglings\u2010\u00a0und\u00a0Erwachs enenalter.\u00a0Epidemiologisches\u00a0Bulletin\u00a0Nr.\u00a016.\u00a0\u00a0\u00a0\nSTIKO\u00a0\u2013\u00a0St\u00e4ndige\u00a0Impfkommission.\u00a0(2018a).\u00a0Impfkalender\u00a02018.\u00a0\nhttps://www.rki.de/DE/Content/Kommissionen/STIKO/Empfehlungen/A ktuelles/Impfkalender.pdf?__blob=publicati\nonFile,\u00a0letzter\u00a0Zugriff:\u00a028.05.2019.\u00a0\u00a0\u00a0\nSTIKO\u00a0\u2013\u00a0St\u00e4ndige\u00a0Impfkommission\u00a0(2018b).\u00a0Empfehlungen\u00a0der\u00a0St\u00e4nd igen\u00a0Impfkommission\u00a0(STIKO)\u00a0beim\u00a0Robert\u00a0Koch\u2010Institut\u00a0\u2013\u00a0\n2018/2019.\u00a0Epidemiologisches\u00a0Bulletin\u00a0Nr.\u00a034.\u00a0\u00a0\nUhlmann,\u00a0B\u00a0(2019).\u00a0Bis\u00a0etwas\u00a0gefunden\u00a0wird.\u00a0SZ.\u00a0134:\u00a014.\u00a0\nUzicanin\u00a0A,\u00a0Zimmerman\u00a0L\u00a0(2011).\u00a0Field\u00a0effectiveness\u00a0of\u00a0live\u00a0att enuated\u00a0meas\u2010les\u2010containing\u00a0vaccines:\u00a0a\u00a0review\u00a0of\u00a0published\u00a0\nliterature.\u00a0The\u00a0Journal\u00a0of\u00a0Infectious\u00a0Diseases.\u00a0204\u00a0(1):\u00a0S133\u20104 8\u00a0\u00a0\nWellcome\u00a0(2019).\u00a0The\u00a0Wellcome\u00a0Global\u00a0Monitor\u00a02018.\u00a0How\u00a0does\u00a0the \u00a0world\u00a0feel\u00a0about\u00a0science\u00a0and\u00a0health?\u00a0\nhttps://wellcome.ac.uk/sites/default/files/wellcome\u2010global\u2010moni tor\u20102018.pdf,\u00a0letzter\u00a0Zugriff:\u00a024.06.2019\u00a0\nWHO\u00a0\u2013\u00a0World\u00a0Health\u00a0Organization\u00a0 (2017).\u00a0\u00a0Weekly\u00a0epidemiological \u00a0record.\u00a0Human\u00a0papillomavirus\u00a0vaccines:\u00a0WHO\u00a0position\u00a0paper,\u00a0\nMay\u00a02017.\u00a0http://apps.who.int/iris/bitstream/handle/10665/255353/WER9219. pdf;jsessionid=193F05D94016FDBBD9AF687F7\n1D6FA04?sequence=1,\u00a0letzter\u00a0Zugriff\u00a021.06.2019.\u00a0\nWHO\u00a0\u2013\u00a0World\u00a0Health\u00a0Organization\u00a0(2018a).\u00a0Measles.\u00a0https://www.w ho.int/immunization/diseases/measles/en/,\u00a0letzter\u00a0Zugriff:\u00a0\n28.05.2019.\u00a0\nWHO\u00a0\u2013\u00a0World\u00a0Health\u00a0Organization\u00a0(2018b).\u00a0Seventh\u00a0Meeting\u00a0of\u00a0the \u00a0European\u00a0Regional\u00a0Verification\u00a0Commission\u00a0for\u00a0Measles\u00a0and\u00a0\nRubella\u00a0Elimination\u00a0(RVC).\u00a0http://www.euro.who.int/en/health\u2010to pics/communicable\u2010diseases/measles\u2010and\u2010\nrubella/publications/2018/7th\u2010meeting\u2010of\u2010the\u2010european\u2010regional\u2010 verification\u2010commission\u2010for\u2010measles\u2010and\u2010rubella\u2010\nelimination\u2010rvc.\u2010report,\u00a0letzter\u00a0Zugriff:\u00a002.06.2019\u00a0\nWHO\u00a0\u2013\u00a0World\u00a0Health\u00a0Organization\u00a0 (2019a).\u00a0Measles:\u00a0Key\u00a0facts.\u00a0ht tps://www.who.int/en/news\u2010room/fact\u2010sheets/detail/measles,\u00a0\nletzter\u00a0Zugriff:\u00a028.05.2019.\u00a0\nWHO\u00a0\u2013\u00a0World\u00a0Health\u00a0Organization\u00a0 (2019b).\u00a0New\u00a0measles\u00a0surveillan ce\u00a0data\u00a0for\u00a02019.\u00a0\nhttps://www.who.int/immunization/newsroom/measles\u2010data\u20102019/en/ ,\u00a0letzter\u00a0Zugriff:\u00a002.06.2019.\u00a0\nWHO\u00a0\u2013\u00a0World\u00a0Health\u00a0Organization\u00a0(2019c).\u00a0WHO\u00a0EpiData.\u00a0January\u00a02 018\u00a0\u2010\u00a0December\u00a02018.\u00a0\nwww.euro.who.int/__data/assets/pdf_file/0004/394060/2019_01_Epi _Data_EN_Jan\u2010Dec\u20102018.pdf?ua=1,\u00a0letzter\u00a0\nZugriff:\u00a018.04.2019.\u00a0\u00a0271\u00a0WHO\u00a0\u2013\u00a0World\u00a0Health\u00a0Organization\u00a0(2019d).\u00a0WHO\u00a0EpiData.\u00a0January\u00a02 018\u00a0\u2013\u00a0December\u00a02018.\u00a0http://www.euro.who.int/\u00a0data/as\u2010\u00a0\nsets/pdf_file/0004/394060/2019_01_Epi_Data_EN_Jan\u2010Dec\u20102018.pdf? ua=1,\u00a0letzter\u00a0Zugriff:\u00a018.04.2019.\u00a0\nWHO\u00a0\u2013\u00a0World\u00a0Health\u00a0Organization\u00a0(2019c).\u00a0WHO\u00a0EpiData.\u00a0January\u00a02 018\u00a0\u2010\u00a0December\u00a02018.\u00a0\nwww.euro.who.int/__data/assets/pdf_file/0004/394060/2019_01_Epi _Data_EN_Jan\u2010Dec\u20102018.pdf?ua=1,\u00a0letzter\u00a0\nZugriff:\u00a018.04.2019.\u00a0\u00a0\nWHO\u00a0\u2013\u00a0World\u00a0Health\u00a0Organziation\u00a0 &\u00a0UNICEF.\u00a0(2018).\u00a0WHO\u2010UNICEF\u00a0es timates\u00a0of\u00a0MCV1\u00a0coverage.\u00a0\nhttps://apps.who.int/immunization_monitoring/globalsummary/time series/tswucoveragemcv1.html,\u00a0letzter\u00a0Zugriff:\u00a0\n28.05.2019.\u00a0\nWieler\u00a0LH\u00a0(2019).\u00a0zitiert\u00a0nach\u00a0Geissel\u00a0W\u00a0(2019).\u00a0Ungeimpfte\u00a0\u00c4rz te:\u00a0Gefahr\u00a0f\u00fcr\u00a0Patienten,\u00a0Risiko\u00a0f\u00fcr\u00a0Kliniken.\u00a0\u00c4rzte\u00a0Ztg\u00a0online .\u00a03.\u00a0Mai\u00a0\n2019,\u00a0https:// www.aerztezeitung.de/medizi n/krankheiten/infektio nskrankheiten/article/934935/ungeimpfte\u2010\naerzte\u2010gefahr\u2010patienten\u2010risiko\u2010k liniken.html,\u00a0letzter\u00a0Zugriff:\u00a0 24.06.2019.\u00a0\n\u00a0\n\u00a0 \u00a0272\u00a07 Keypoints\u00a0und\u00a0Fazit\u00a0\n\uf0b7 Im\u00a0Jahr\u00a02016\u00a0kamen\u00a0insgesamt\u00a050\u00a0neue\u00a0nicht\u2010generische\u00a0Arzneimit tel\u00a0\nauf\u00a0 den\u00a0 deutschen\u00a0 Markt.\u00a0 Neun\u00a0 davon\u00a0 enthielten\u00a0 bereits\u00a0 bekannte \u00a0\nWirkstoffe\u00a0in\u00a0neuen\u00a0Kombinatione n,\u00a0weitere\u00a0acht\u00a0Arzneistoffe\u00a0(C abo\u2010\nzantinib,\u00a0 Daclizumab,\u00a0 Guanfacin,\u00a0 Irinotecan,\u00a0 Ivermectin,\u00a0 Lenvat inib,\u00a0\nPivmecillinam\u00a0und\u00a0Umeclidinium)\u00a0waren\u00a0mit\u00a0einer\u00a0Zulassung\u00a0f\u00fcr\u00a0a ndere\u00a0\nIndikationen\u00a0schon\u00a0l\u00e4nger\u00a0auf\u00a0dem\u00a0Markt.\u00a0Von\u00a0den\u00a0verbleibenden\u00a0 33\u00a0\ntats\u00e4chlich\u00a0neuen\u00a0Arzneimitteln\u00a0enthielten\u00a0drei\u00a0unterschiedlich e\u00a0Kombi\u2010\nnationspr\u00e4parate\u00a0jeweils\u00a0denselben\u00a0neuen\u00a0Wirkstoff\u00a0(Tenefoviral afena\u2010\nmid),\u00a0so\u00a0dass\u00a0es\u00a0faktisch\u00a031\u00a0neu\u00a0eingef\u00fchrte\u00a0Arzneistoffe\u00a0gab.\u00a0 Weil\u00a0Pr\u00e4\u2010\nparate,\u00a0die\u00a0prim\u00e4r\u00a0im\u00a0Krankenhaus\u00a0eingesetzt\u00a0werden\u00a0oder\u00a0aufgru nd\u00a0ih\u2010\nrer\u00a0speziellen\u00a0und\u00a0seltenen\u00a0Indikation\u00a0in\u00a0der\u00a0ambulanten\u00a0Versor gung\u00a0\nkeine\u00a0Rolle\u00a0spielen,\u00a0und\u00a0(vor\u00fcbergehend)\u00a0vom\u00a0Markt\u00a0genommene\u00a0Ar z\u2010\nneimittel\u00a0nicht\u00a0ber\u00fccksichtigt\u00a0w urden,\u00a0bewertet\u00a0der\u00a0Innovations report\u00a0\n2019\u00a023\u00a0neue\u00a0Arzneimitte l\u00a0des\u00a0Jahres\u00a02016.\u00a0\n\uf0b7 Alle\u00a033\u00a0der\u00a0im\u00a0Jahr\u00a02016\u00a0in\u00a0Deutschland\u00a0neu\u00a0eingef\u00fchrten\u00a0Arznei mittel\u00a0\nwurden\u00a0nach\u00a0einer\u00a0zentralisierten\u00a0Zulassung\u00a0durch\u00a0die\u00a0EMA\u00a0auf\u00a0d en\u00a0\nMarkt\u00a0gebracht.\u00a0\n\uf0b7 Acht\u00a0dieser\u00a033\u00a0neuen\u00a0Ar zneimittel\u00a0(Daratumumab,\u00a0Elbasvir/Grazop revir,\u00a0\nElotuzumab,\u00a0Migalastat,\u00a0Olaratumab,\u00a0Osimertinib,\u00a0Selexipag\u00a0und\u00a0 Velpa\u2010\ntasvir/Sofosbuvir)\u00a0kamen\u00a0im\u00a0Rahmen\u00a0eines\u00a0beschleunigten\u00a0Zulassu ngs\u2010\nverfahrens\u00a0auf\u00a0den\u00a0Markt.\u00a0Die\u00a0On kologika\u00a0Daratumumab,\u00a0Olaratuma b\u00a0\nund\u00a0Osimertinib\u00a0erhielten\u00a0zun\u00e4chst\u00a0nur\u00a0eine\u00a0bedingte\u00a0Zulassung\u00a0 (Condi\u2010\ntional\u00a0Marketing\u00a0Authorisation ,\u00a0CMA),\u00a0die\u00a0bei\u00a0Daratumumab\u00a0und\u00a0Osi\u2010\nmertinib\u00a0nach\u00a0Einreichung\u00a0zus\u00e4tzlicher\u00a0Daten\u00a0in\u00a0eine\u00a0regul\u00e4re\u00a0Z ulassung\u00a0\numgewandelt\u00a0wurde.\u00a0Die\u00a0EU\u2010Zulassung\u00a0von\u00a0Olaratumab\u00a0wurde\u00a0wegen\u00a0\nfehlender\u00a0therapeutischer\u00a0Wirksamkeit\u00a0im\u00a0Mai\u00a02019\u00a0widerrufen.\u00a0\n\uf0b7 Wie\u00a0schon\u00a0im\u00a0Jahr\u00a02015\u00a0stellen\u00a0auch\u00a0in\u00a02016\u00a0die\u00a0antineoplastisc hen\u00a0\nWirkstoffe\u00a0die\u00a0gr\u00f6\u00dfte\u00a0Indikationsgruppe\u00a0der\u00a0neu\u00a0eingef\u00fchrten\u00a0Ar znei\u2010\nmittel.\u00a0Im\u00a0Innovationsreport\u00a02019\u00a0sind\u00a0sieben\u00a0der\u00a023\u00a0bewerteten \u00a0Arz\u2010\nneimittel\u00a0Onkologika\u00a0(ATC\u20103\u2010Gruppe\u00a0L01),\u00a0davon\u00a0drei\u00a0monoklonale \u00a0Anti\u2010\nk\u00f6rper,\u00a0zwei\u00a0Proteinkinaseinhibi toren,\u00a0ein\u00a0klassisches\u00a0Zytostat ikum\u00a0und\u00a0\nein\u00a0Gentherapeutikum.\u00a0Weitere\u00a0f\u00fcnf\u00a0Arzneimittel\u00a0enthalten\u00a0antiv irale\u00a0\nWirkstoffe\u00a0(ATC\u20103\u2010Gruppe\u00a0J05)\u00a0und\u00a0drei\u00a0rekombinante\u00a0Gerinnungsf akto\u2010\nren\u00a0(ATC\u20103\u2010Gruppe\u00a0B02).\u00a0Die\u00a0rest lichen\u00a0acht\u00a0Wirkstoffe\u00a0verteile n\u00a0sich\u00a0auf\u00a0\nunterschiedliche\u00a0andere\u00a0Indikationsbereiche.\u00a0\n\uf0b7 Dass\u00a0neun\u00a0der\u00a023\u00a0bewerteten\u00a0neuen\u00a0Arzneimittel\u00a0(knapp\u00a040\u00a0%)\u00a0\u2013\u00a0v ier\u00a0\nmonoklonale\u00a0Antik\u00f6rper,\u00a0drei\u00a0Gerinnungsfaktoren,\u00a0ein\u00a0Gentherape uti\u2010273\u00a0kum\u00a0und\u00a0ein\u00a0Impfstoff\u00a0\u2013\u00a0zu\u00a0den\u00a0Biologika\u00a0geh\u00f6ren,\u00a0unterstreicht \u00a0deren\u00a0\nzunehmende\u00a0Bedeutung\u00a0in\u00a0der\u00a0Arzneimitteltherapie.\u00a0\n\uf0b7 Unter\u00a0 den\u00a0 31\u00a0 Neueinf\u00fchrungen\u00a0 des\u00a0 Jahres\u00a0 2016\u00a0 sind\u00a0 neun\u00a0 Orphan\u2010\nArzneimittel.\u00a0Sechs\u00a0davon\u00a0wurden\u00a0im\u00a0Innovationsreport\u00a02019\u00a0ber\u00fc ck\u2010\nsichtigt,\u00a0ihr\u00a0Anteil\u00a0an\u00a0den\u00a023\u00a0insgesamt\u00a0bewerteten\u00a0Arzneimitte ln\u00a0liegt\u00a0\nmit\u00a026\u00a0%\u00a0niedriger\u00a0als\u00a0in\u00a0den \u00a0Jahren\u00a02018\u00a0(34\u00a0%)\u00a0und\u00a02017\u00a0(38\u00a0% ).\u00a0\u00a0\n\uf0b7 Von\u00a0den\u00a0in\u00a0den\u00a0Innovationsreport\u00a02019\u00a0aufgenommenen\u00a023\u00a0neuen\u00a0Ar z\u2010\nneimitteln\u00a0des\u00a0Jahres\u00a02016\u00a0wurden\u00a0im\u00a0Jahr\u00a02017,\u00a0d.h.\u00a0im\u00a0Jahr\u00a0na ch\u00a0ihrer\u00a0\nMarkteinf\u00fchrung,\u00a0128,5\u00a0Tausend\u00a0Packungen\u00a0mit\u00a0einem\u00a0Umsatz\u00a0von\u00a01 67\u00a0\nMio.\u00a0\u20ac\u00a0f\u00fcr\u00a0TK\u2010Versicherte\u00a0veror dnet.\u00a0Verglichen\u00a0mit\u00a0den\u00a0Ergebni ssen\u00a0des\u00a0\nInnovationsreports\u00a02018\u00a0lag\u00a0diese\u00a0Menge\u00a0rund\u00a07\u00a0%\u00a0unterhalb\u00a0der\u00a0 Men\u2010\nge\u00a0des\u00a0Vorjahres\u00a0(138,1\u00a0Tausend).\u00a0Die\u00a0Ausgaben\u00a0der\u00a0TK\u00a0f\u00fcr\u00a0die\u00a0n euen\u00a0\nArzneimittel\u00a0lagen\u00a0dagegen\u00a0um\u00a015\u00a0%\u00a0h\u00f6her,\u00a0weil\u00a0der\u00a0durchschnitt liche\u00a0\nPreis\u00a0pro\u00a0Packung\u00a0der\u00a0neuen\u00a0Wirkstoffe\u00a0von\u00a01.048\u00a0\u20ac\u00a0im\u00a0Jahr\u00a02016 \u00a0auf\u00a0\n1.298\u00a0\u20ac\u00a0im\u00a0Jahr\u00a02017\u00a0angestiegen\u00a0war.\u00a0\n\uf0b7 Im\u00a0Innovationsreport\u00a02018\u00a0hatte\u00a0sich\u00a0angedeutet,\u00a0dass\u00a0der\u00a0Antei l\u00a0der\u00a0\npositiv\u00a0mit\u00a0einer\u00a0\u201egr\u00fcnen\u201c\u00a0Gesam tampel\u00a0zu\u00a0bewertenden\u00a0Arzneimit tel\u00a0\nansteigen\u00a0w\u00fcrde.\u00a0Insgesamt\u00a0konnten\u00a0im\u00a0Jahr\u00a02018\u00a0sechs\u00a0der\u00a032\u00a0au fge\u2010\nnommenden\u00a0Mittel\u00a0diese\u00a0beste\u00a0Be wertung\u00a0erreichen\u00a0(knapp\u00a019\u00a0%).\u00a0 An\u2010\nhand\u00a0der\u00a0Ergebnisse\u00a0des\u00a0letzten\u00a0I nnovationsreportes\u00a0war\u00a0anzuneh men,\u00a0\ndass\u00a0sich\u00a0mit\u00a0dem\u00a0AMNOG\u2010Verfahren\u00a0auch\u00a0die\u00a0Studienlage\u00a0und\u00a0Evi\u2010denzbasierung\u00a0f\u00fcr\u00a0die\u00a0neuen\u00a0Arzn eimittel\u00a0verbessert\u00a0h\u00e4tte.\u00a0Im\u00a0I nnovati\u2010\nonsreport\u00a02019\u00a0haben\u00a0nun\u00a0f\u00fcnf\u00a0von\u00a023\u00a0neuen\u00a0Mitteln\u00a0eine\u00a0\u201egr\u00fcne\u201c \u00a0Am\u2010\npel\u00a0erreicht,\u00a0was\u00a0einem\u00a0Anteil\u00a0von\u00a0knapp\u00a022\u00a0%\u00a0entspricht.\u00a0Eine\u00a0 leichte\u00a0\nSteigerung\u00a0ist\u00a0also\u00a0zu\u00a0konstatieren.\u00a0Das\u00a0Gesamtergebnis\u00a0der\u00a0Bew ertun\u2010\ngen\u00a0f\u00e4llt\u00a0durch\u00a0die\u00a014\u00a0Arzneimittel\u00a0mit\u00a0einem\u00a0roten\u00a0Gesamt\u2010Scor e\u00a0aller\u2010\ndings\u00a0schlechter\u00a0aus\u00a0als\u00a0im\u00a0letz ten\u00a0Jahr:\u00a061\u00a0%\u00a0der\u00a0bewerteten\u00a0A rzneimit\u2010\ntel\u00a0 erhielten\u00a0 eine\u00a0 rote\u00a0 Gesamtampel,\u00a0 die\u00a0 Best\u00e4tigung\u00a0 des\u00a0 AMNOG\u2010Verfahrens\u00a0kann\u00a0also\u00a0nicht\u00a0aufrechterhalten\u00a0werden.\u00a0\n\uf0b7 Trotz\u00a0dieses\u00a0eher\u00a0\u201ebescheidenen\u201c\u00a0Gesamtergebnisses\u00a0wurden\u00a013\u00a0Ar z\u2010\nneimittel\u00a0\u2013\u00a0und\u00a0nicht\u00a0nur\u00a0die\u00a0positiv\u00a0bewerteten\u00a0Mittel\u00a0\u2013\u00a0in\u00a0Le itlinien\u00a0\noder\u00a0Therapieempfehlungen\u00a0aufge nommen.\u00a0 Solche\u00a0Ergebnisse\u00a0lassen \u00a0\nZweifel\u00a0daran\u00a0aufkommen,\u00a0ob\u00a0die\u00a0Auswertung\u00a0der\u00a0vorliegenden\u00a0Evi denz\u00a0\nimmer\u00a0unabh\u00e4ngig\u00a0und\u00a0neutral\u00a0durchgef\u00fchrt\u00a0wird\u00a0oder\u00a0ob\u00a0nicht\u00a0au ch\u00a0\n\u00f6konomische\u00a0 oder\u00a0 klinisch\u2010wettbewerbliche\u00a0 Interessen\u00a0 die\u00a0 Behand \u2010\nlungsempfehlungen\u00a0der\u00a0Fachge sellschaften\u00a0beeinflussen.\u00a0\n\uf0b7 In\u00a0diesem\u00a0Zusammenhang\u00a0sind\u00a0auch\u00a0neue\u00a0Erkenntnisse\u00a0bez\u00fcglich\u00a0de r\u00a0\nUnbedenklichkeit\u00a0neuer\u00a0Arzneimittel\u00a0zu\u00a0erw\u00e4hnen.\u00a0F\u00fcr\u00a0zwei\u00a0der\u00a02 3\u00a0be\u2010\nwerteten\u00a0Arzneimittel\u00a0liegen\u00a0Blaue\u2010Hand\u2010Informationen\u00a0vor.\u00a0Es\u00a0w urden\u00a0\ninsgesamt\u00a0 sechs\u00a0 Rote\u2010Hand\u2010Briefe \u00a0 verschickt,\u00a0 was\u00a0 darauf\u00a0 hindeut et,\u00a0274\u00a0dass\u00a0Zulassungsstudien\u00a0mit\u00a0selektierten\u00a0Patientengruppen\u00a0nur\u00a0ei n\u00a0ein\u2010\ngeschr\u00e4nktes\u00a0Bild\u00a0von\u00a0m\u00f6glichen\u00a0 unerw\u00fcnschten\u00a0Wirkungen\u00a0liefern .\u00a0Ge\u2010\nrade\u00a0 im\u00a0 Zusammenhang\u00a0 mit\u00a0 beschleunigten\u00a0 Zulassungen\u00a0 sind\u00a0 daher\u00a0Pharmakovigilanzstudien\u00a0 im\u00a0 \u201eNachmarkt\u201c,\u00a0 also\u00a0 w\u00e4hrend\u00a0 der\u00a0 Anwen\u2010dung\u00a0der\u00a0neuen\u00a0Arzneimittel\u00a0in\u00a0der\u00a0allt\u00e4glichen\u00a0Patientenversor gung,\u00a0\nund\u00a0eine\u00a0Sp\u00e4tbewertung\u00a0der\u00a0Erfahrungen\u00a0dringend\u00a0erforderlich.\u00a0N ur\u00a0so\u00a0\nk\u00f6nnen\u00a0potentielle\u00a0Risiken\u00a0und\u00a0die\u00a0Vertr\u00e4glichkeit,\u00a0insbesonder e\u00a0in\u00a0Be\u2010\nzug\u00a0auf\u00a0seltene\u00a0unerw\u00fcnschte\u00a0Wirkungen,\u00a0besser\u00a0eingesch\u00e4tzt\u00a0wer den.\u00a0\u00a0\n\uf0b7 Das\u00a0Thema\u00a0\u201eImpfen\u00a0und\u00a0Impfpflicht\u201c\u00a0wird\u00a0in\u00a0einem\u00a0eigenen\u00a0Kapite l\u00a0des\u00a0\nInnovationsreportes\u00a0 2019\u00a0 behandelt.\u00a0 Im\u00a0 Mittelpunkt\u00a0 steht\u00a0 dabei\u00a0 die\u00a0\nDiskussion\u00a0\u00fcber\u00a0die\u00a0notwendige\u00a0Erh\u00f6hung\u00a0der\u00a0Impfquote\u00a0bei\u00a0den\u00a0M a\u2010\nsernimpfungen,\u00a0es\u00a0werden\u00a0aber\u00a0auch\u00a0Daten\u00a0zur\u00a0HPV\u2010\u00a0und\u00a0Grippesch utz\u2010\nimpfung\u00a0vorgestellt.\u00a0Bez\u00fcglich\u00a0de r\u00a0HPV\u2010Impfung\u00a0haben\u00a0sich\u00a0die\u00a0E rkennt\u2010\nnisse\u00a0bei\u00a0der\u00a0Anwendung\u00a0dieser\u00a0Impfung\u00a0weltweit\u00a0verbessert\u00a0und\u00a0 die\u00a0\nEmpfehlungen\u00a0f\u00fcr\u00a0eine\u00a0Impfung\u00a0wurden\u00a0insofern\u00a0erweitert,\u00a0als\u00a0da ss\u00a0ne\u2010\nben\u00a0M\u00e4dchen\u00a0im\u00a0Alter\u00a0von\u00a0neun\u00a0bis\u00a014\u00a0Jahren\u00a0nun\u00a0auch\u00a0Jungen\u00a0im\u00a0 glei\u2010\nchen\u00a0Alter\u00a0geimpft\u00a0werden\u00a0sollen.\u00a0Zur\u00a0Grippeschutzimpfung\u00a0mehre n\u00a0sich\u00a0\ninternational\u00a0die\u00a0Hinweise,\u00a0be sser\u00a0Kinder\u00a0und\u00a0Jugendliche\u00a0zu\u00a0im pfen\u00a0\nstatt\u00a0grunds\u00e4tzlich\u00a0\u00e4ltere\u00a0Menschen\u00a0ab\u00a0dem\u00a060.\u00a0Lebensjahr.\u00a0Viel es\u00a0deu\u2010\ntet\u00a0darauf\u00a0hin,\u00a0dass\u00a0mit\u00a0gesteige rten\u00a0Impfraten\u00a0gegen\u00a0Grippe\u00a0be i\u00a0Kin\u2010\ndern\u00a0und\u00a0Jugendlichen\u00a0ein\u00a0st\u00e4rke r\u00a0wirksamer\u00a0\u201eHerdeneffekt\u201c\u00a0in\u00a0d er\u00a0Ge\u2010\nsellschaft\u00a0erreicht\u00a0werden\u00a0kann\u00a0a ls\u00a0mit\u00a0der\u00a0routinem\u00e4\u00dfigen\u00a0Impf ung\u00a0von\u00a0\n\u00e4lteren\u00a0Menschen,\u00a0deren\u00a0Immunsystem\u00a0weniger\u00a0gut\u00a0auf\u00a0die\u00a0Impfung \u00a0\nanspricht.\u00a0Es\u00a0sollten\u00a0daher\u00a0verme hrt\u00a0stratifizierte\u00a0Empfehlunge n\u00a0f\u00fcr\u00a0die\u00a0\nGrippeimpfung\u00a0bestimmter\u00a0Gruppen\u00a0\u00e4lterer\u00a0Menschen\u00a0formuliert\u00a0un d\u00a0\ngleichzeitig\u00a0hohe\u00a0Impfquoten\u00a0bei\u00a0 Kindern\u00a0und\u00a0Jugendlichen\u00a0anges trebt\u00a0\nwerden.\u00a0\n\uf0b7 Bei\u00a0der\u00a0Strategie,\u00a0die\u00a0Masernimpfquoten\u00a0zu\u00a0erh\u00f6hen,\u00a0insbesonder e\u00a0mit\u00a0\nBlick\u00a0auf\u00a0die\u00a0zweite\u00a0Impfung,\u00a0zeigen\u00a0europ\u00e4ische\u00a0Vergleichsdate n,\u00a0dass\u00a0\neine\u00a0 Impfpflicht\u00a0 keineswegs\u00a0 zwangsl\u00e4ufig\u00a0 die\u00a0 Impfquoten\u00a0 verbess ert\u00a0\nund\u00a0zum\u00a0angestrebten\u00a0und\u00a0f\u00fcr\u00a0den\u00a0Impfschutz\u00a0in\u00a0einer\u00a0 Gesellscha ft\u00a0\nwirksamen\u00a0Niveau\u00a0von\u00a0\u00fcber\u00a095\u00a0%\u00a0f\u00fchrt.\u00a0Insofern\u00a0sollte\u00a0auch\u00a0das\u00a0 Votum\u00a0\ndes\u00a0Deutschen\u00a0Ethikrates\u00a0beachtet\u00a0werden,\u00a0der\u00a0zum\u00a0einen\u00a0als\u00a0Str ategie\u00a0\nzu\u00a0 einem\u00a0 verbesserten\u00a0 Masernschutz\u00a0 nicht\u00a0 nur\u00a0 die\u00a0 Kinder,\u00a0 sonder n\u00a0\nebenso\u00a0die\u00a0Erwachsenen\u00a0ber\u00fccksichtigt\u00a0sehen\u00a0m\u00f6chte,\u00a0und\u00a0der\u00a0and erer\u2010\nseits\u00a0betont,\u00a0dass\u00a0auch\u00a0andere\u00a0Ma\u00dfnahmen\u00a0wie\u00a0verbesserte\u00a0Aufkl\u00e4 rungs\u2010\u00a0\nund\u00a0Informationskampagnen\u00a0verst\u00e4rkt\u00a0werden\u00a0sollten,\u00a0bevor\u00a0als\u00a0\u201e Ultima\u00a0\nRatio\u201c\u00a0die\u00a0gesetzlich\u00a0verbindlic he\u00a0und\u00a0von\u00a0Sanktionen\u00a0begleitet e\u00a0Impf\u2010\npflicht\u00a0eingef\u00fchrt\u00a0wird.\u00a0\n\u00a0275\u00a0Fazit\u00a0\nImmer\u00a0deutlicher\u00a0zeigt\u00a0sich\u00a0\u2013\u00a0und\u00a0dies\u00a0ist\u00a0sicherlich\u00a0auch\u00a0ein\u00a0 Erfolg\u00a0der\u00a0Diskussio\u2010\nnen,\u00a0die\u00a0durch\u00a0die\u00a0bisher\u00a0publiz ierten\u00a0Innovationsreporte\u00a0ausge l\u00f6st\u00a0wurden\u00a0\u2013,\u00a0dass\u00a0\nsowohl\u00a0f\u00fcr\u00a0den\u00a0G\u2010BA\u00a0als\u00a0auch\u00a0f\u00fcr\u00a0das\u00a0IQWiG\u00a0Erg\u00e4nzungen\u00a0des\u00a0AMNO G\u2010Bewer\u2010\ntungsprozesses\u00a0notwendig\u00a0erschein en.\u00a0So\u00a0beklagt\u00a0das\u00a0IQWiG,\u00a0\u201edas s\u00a0\u00fcber\u00a0die\u00a0H\u00e4lfte\u00a0\nder\u00a0Arzneimittel,\u00a0die\u00a0seit\u00a02011\u00a0in\u00a0Deutschland\u00a0auf\u00a0den\u00a0Markt\u00a0ka men,\u00a0ohne\u00a0beleg\u2010\nten\u00a0Zusatznutzen\u00a0aus\u00a0der\u00a0fr\u00fchen\u00a0Nutzenbewertung\u00a0hervorgegangen\u00a0 sind\u201c\u00a0(IQWiG,\u00a0\n2019).\u00a0Es\u00a0sei\u00a0daher\u00a0notwendig,\u00a0die\u00a0Vergleichstherapien\u00a0in\u00a0Zulas sungsstudien\u00a0dem\u00a0\naktuellen\u00a0Standard\u00a0anzupassen\u00a0und\u00a0 vor\u00a0allem\u00a0in\u00a0Zeiten\u00a0beschleun igter\u00a0Zulassun\u2010\ngen\u00a0aussagekr\u00e4ftige\u00a0Daten\u00a0f\u00fcr\u00a0die\u00a0Anwendung\u00a0der\u00a0Arzneimittel\u00a0zu \u00a0sammeln.\u00a0Damit\u00a0\ngreift\u00a0das\u00a0IQWiG\u00a0ebenso\u00a0wie\u00a0der\u00a0G\u2010BA\u00a0Forderungen\u00a0aus\u00a0den\u00a0bisher igen\u00a0Innovati\u2010\nonsreporten\u00a0nach\u00a0einer\u00a0kontrollierteren\u00a0Einf\u00fchrung\u00a0neuer\u00a0Arznei mittel\u00a0auf\u00a0(beglei\u2010\ntende\u00a0Versorgungsforschung\u00a0und\u00a0Sp \u00e4tbewertung).\u00a0Der\u00a0G\u2010BA\u00a0hat\u00a0im\u00a0 Entwurf\u00a0seiner\u00a0\nStellungnahme\u00a0zur\u00a0Verbesserung\u00a0der\u00a0Arzneimittelversorgung\u00a0den\u00a0B egriff\u00a0der\u00a0\u201ever\u2010\nsorgungsbegleitenden\u00a0Studien\u201c\u00a0in\u00a0die\u00a0Diskussion\u00a0gebracht,\u00a0die\u00a0h elfen\u00a0sollen,\u00a0den\u00a0\nPatientennutzen\u00a0genauer\u00a0als\u00a0bisher\u00a0klassifizieren\u00a0zu\u00a0k\u00f6nnen.\u00a0Di eser\u00a0Patientennut\u2010\nzen\u00a0(siehe\u00a0\u00a7\u00a035\u00a0b\u00a0SGB\u00a0V),\u00a0der\u00a0insbesondere\u00a0an\u00a0den\u00a0Indikatoren\u00a0V erbesserung\u00a0des\u00a0\nGesundheitszustandes,\u00a0Verk\u00fcrzung\u00a0der\u00a0Krankheitsdauer,\u00a0Verl\u00e4nger ung\u00a0der\u00a0Lebens\u2010\ndauer,\u00a0Verringerung\u00a0der\u00a0Nebenwirkungen\u00a0sowie\u00a0Verbesserung\u00a0der\u00a0L ebensqualit\u00e4t\u00a0\nbestimmt\u00a0wird,\u00a0ist\u00a0nur\u00a0sehr\u00a0eingeschr\u00e4nkt\u00a0auf\u00a0der\u00a0Basis\u00a0von\u00a0kli nischen\u00a0Zulassungs\u2010\nstudien\u00a0und\u00a0noch\u00a0weniger\u00a0von\u00a0solchen\u00a0Studien\u00a0zu\u00a0erkennen,\u00a0die\u00a0i m\u00a0Zusammen\u2010\nhang\u00a0mit\u00a0einer\u00a0beschleunigten\u00a0Zulassung\u00a0vorgelegt\u00a0werden.\u00a0Weite re\u00a0Studien\u00a0in\u00a0der\u00a0\nrealen\u00a0Patientenversorgung\u00a0sind\u00a0unabdingbar\u00a0\u2013\u00a0diese\u00a0Forderung\u00a0w ird\u00a0auch\u00a0wei\u2010\nterhin\u00a0Teil\u00a0der\u00a0Konsequenzen\u00a0der \u00a0Ergebnisse\u00a0des\u00a0Innovationsrepo rtes\u00a0bleiben.\u00a0\n\u00a0\nQuellen\u00a0\nIQWiG\u00a0\u2013\u00a0Institut\u00a0f\u00fcr\u00a0Qualit\u00e4t\u00a0und\u00a0Wirtschaftlichkeit\u00a0im\u00a0Gesundh eitswesen\u00a0(2019).\u00a0Fr\u00fche\u00a0Nutzenbewertung\u00a0zeigt\u00a0Schw\u00e4chen\u00a0in\u00a0der\u00a0\nEntwicklung\u00a0neuer\u00a0Arzneimittel\u00a0 auf.\u00a0Pressemitteilung\u00a011.07.2019 .\u00a0\nhttps://www.iqwig.de/de/presse/pressemitteilungen/2019/fruehe\u2010n utzenbewertung\u2010zeigt\u2010schwaechen\u2010in\u2010der\u2010\nentwicklung\u2010neuer\u2010arzneimittel\u2010auf.12351.html,\u00a0letzter\u00a0Zugriff: \u00a019.07.2019.\u00a0", "language": "PDF", "image": "PDF", "pagetype": "PDF", "links": "PDF"}